[[{"header": {"dataset": "BioASQ", "split": "dev"}}]]
{"context": "Processive versus distributive methyl group transfer was assessed for pea Rubisco large subunit methyltransferase, a SET domain protein lysine methyltransferase catalyzing the formation of trimethyllysine-14 in the large subunit of Rubisco. Catalytically competent complexes between an immobilized form of des(methyl) Rubisco and Rubisco large subunit methyltransferase were used to demonstrate enzyme release that was co-incident with and dependent on formation of trimethyllysine. Catalytic rate constants determined for formation of trimethyllysine were considerably lower ( approximately 10-fold) than rate constants determined for total radiolabel incorporation from [3H-methyl]-S-adenosylmethionine. Double-reciprocal velocity plots under catalytic conditions favoring monomethyllysine indicated a random or ordered reaction mechanism, while conditions favoring trimethyllysine suggested a hybrid ping-pong mechanism. These results were compared with double-reciprocal velocity plots and product analyses obtained for HsSET7/9 (a monomethyltransferase) and SpCLR4 (a dimethyltransferase) and suggest a predictive ability of double-reciprocal velocity plots for single versus multiple methyl group transfers by SET domain protein lysine methyltransferases. A model is proposed for SET domain protein lysine methyltransferases in which initial binding of polypeptide substrate and S-adenosylmethionine is random, with polypeptide binding followed by deprotonation of the epsilon-amine of the target lysyl residue and subsequent methylation. Following methyl group transfer, S-adenosylhomocysteine and monomethylated polypeptide dissociate from monomethyltransferases, but di- and trimethyltransferases begin a successive and catalytically obligatory deprotonation of enzyme-bound methylated lysyl intermediates, which along with binding and release of S-adenosylmethionine and S-adenosylhomocysteine is manifested as a hybrid ping-pong-like reaction mechanism.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "68b1c5deb7d64bd7862645b2ab55c4ff", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[16, 17], [185, 186], [174, 175]], "char_spans": [[117, 126], [1286, 1295], [1216, 1225]]}]}], "context_tokens": [["Processive", 0], ["versus", 11], ["distributive", 18], ["methyl", 31], ["group", 38], ["transfer", 44], ["was", 53], ["assessed", 57], ["for", 66], ["pea", 70], ["Rubisco", 74], ["large", 82], ["subunit", 88], ["methyltransferase", 96], [",", 113], ["a", 115], ["SET", 117], ["domain", 121], ["protein", 128], ["lysine", 136], ["methyltransferase", 143], ["catalyzing", 161], ["the", 172], ["formation", 176], ["of", 186], ["trimethyllysine-14", 189], ["in", 208], ["the", 211], ["large", 215], ["subunit", 221], ["of", 229], ["Rubisco", 232], [".", 239], ["Catalytically", 241], ["competent", 255], ["complexes", 265], ["between", 275], ["an", 283], ["immobilized", 286], ["form", 298], ["of", 303], ["des(methyl", 306], [")", 316], ["Rubisco", 318], ["and", 326], ["Rubisco", 330], ["large", 338], ["subunit", 344], ["methyltransferase", 352], ["were", 370], ["used", 375], ["to", 380], ["demonstrate", 383], ["enzyme", 395], ["release", 402], ["that", 410], ["was", 415], ["co", 419], ["-", 421], ["incident", 422], ["with", 431], ["and", 436], ["dependent", 440], ["on", 450], ["formation", 453], ["of", 463], ["trimethyllysine", 466], [".", 481], ["Catalytic", 483], ["rate", 493], ["constants", 498], ["determined", 508], ["for", 519], ["formation", 523], ["of", 533], ["trimethyllysine", 536], ["were", 552], ["considerably", 557], ["lower", 570], ["(", 576], ["approximately", 578], ["10-fold", 592], [")", 599], ["than", 601], ["rate", 606], ["constants", 611], ["determined", 621], ["for", 632], ["total", 636], ["radiolabel", 642], ["incorporation", 653], ["from", 667], ["[", 672], ["3H", 673], ["-", 675], ["methyl]-S", 676], ["-", 685], ["adenosylmethionine", 686], [".", 704], ["Double", 706], ["-", 712], ["reciprocal", 713], ["velocity", 724], ["plots", 733], ["under", 739], ["catalytic", 745], ["conditions", 755], ["favoring", 766], ["monomethyllysine", 775], ["indicated", 792], ["a", 802], ["random", 804], ["or", 811], ["ordered", 814], ["reaction", 822], ["mechanism", 831], [",", 840], ["while", 842], ["conditions", 848], ["favoring", 859], ["trimethyllysine", 868], ["suggested", 884], ["a", 894], ["hybrid", 896], ["ping", 903], ["-", 907], ["pong", 908], ["mechanism", 913], [".", 922], ["These", 924], ["results", 930], ["were", 938], ["compared", 943], ["with", 952], ["double", 957], ["-", 963], ["reciprocal", 964], ["velocity", 975], ["plots", 984], ["and", 990], ["product", 994], ["analyses", 1002], ["obtained", 1011], ["for", 1020], ["HsSET7/9", 1024], ["(", 1033], ["a", 1034], ["monomethyltransferase", 1036], [")", 1057], ["and", 1059], ["SpCLR4", 1063], ["(", 1070], ["a", 1071], ["dimethyltransferase", 1073], [")", 1092], ["and", 1094], ["suggest", 1098], ["a", 1106], ["predictive", 1108], ["ability", 1119], ["of", 1127], ["double", 1130], ["-", 1136], ["reciprocal", 1137], ["velocity", 1148], ["plots", 1157], ["for", 1163], ["single", 1167], ["versus", 1174], ["multiple", 1181], ["methyl", 1190], ["group", 1197], ["transfers", 1203], ["by", 1213], ["SET", 1216], ["domain", 1220], ["protein", 1227], ["lysine", 1235], ["methyltransferases", 1242], [".", 1260], ["A", 1262], ["model", 1264], ["is", 1270], ["proposed", 1273], ["for", 1282], ["SET", 1286], ["domain", 1290], ["protein", 1297], ["lysine", 1305], ["methyltransferases", 1312], ["in", 1331], ["which", 1334], ["initial", 1340], ["binding", 1348], ["of", 1356], ["polypeptide", 1359], ["substrate", 1371], ["and", 1381], ["S", 1385], ["-", 1386], ["adenosylmethionine", 1387], ["is", 1406], ["random", 1409], [",", 1415], ["with", 1417], ["polypeptide", 1422], ["binding", 1434], ["followed", 1442], ["by", 1451], ["deprotonation", 1454], ["of", 1468], ["the", 1471], ["epsilon", 1475], ["-", 1482], ["amine", 1483], ["of", 1489], ["the", 1492], ["target", 1496], ["lysyl", 1503], ["residue", 1509], ["and", 1517], ["subsequent", 1521], ["methylation", 1532], [".", 1543], ["Following", 1545], ["methyl", 1555], ["group", 1562], ["transfer", 1568], [",", 1576], ["S", 1578], ["-", 1579], ["adenosylhomocysteine", 1580], ["and", 1601], ["monomethylated", 1605], ["polypeptide", 1620], ["dissociate", 1632], ["from", 1643], ["monomethyltransferases", 1648], [",", 1670], ["but", 1672], ["di-", 1676], ["and", 1680], ["trimethyltransferases", 1684], ["begin", 1706], ["a", 1712], ["successive", 1714], ["and", 1725], ["catalytically", 1729], ["obligatory", 1743], ["deprotonation", 1754], ["of", 1768], ["enzyme", 1771], ["-", 1777], ["bound", 1778], ["methylated", 1784], ["lysyl", 1795], ["intermediates", 1801], [",", 1814], ["which", 1816], ["along", 1822], ["with", 1828], ["binding", 1833], ["and", 1841], ["release", 1845], ["of", 1853], ["S", 1856], ["-", 1857], ["adenosylmethionine", 1858], ["and", 1877], ["S", 1881], ["-", 1882], ["adenosylhomocysteine", 1883], ["is", 1904], ["manifested", 1907], ["as", 1918], ["a", 1921], ["hybrid", 1923], ["ping", 1930], ["-", 1934], ["pong", 1935], ["-", 1939], ["like", 1940], ["reaction", 1945], ["mechanism", 1954], [".", 1963]]}
{"context": "Previous studies in vivo reported that processing of primary microRNA (pri-miRNA) is coupled to transcription by RNA polymerase II (RNAP II) and can occur co-transcriptionally. Here we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts. We show that both the kinetics and efficiency of pri-miRNA processing are dramatically enhanced in this system compared to that of the corresponding naked pri-miRNA. Moreover, this enhancement is general as it occurs with multiple pri-miRNAs. We also show that nascent pri-miRNA is efficiently processed before it is released from the DNA template. Together, our work directly demonstrates that transcription and pri-miRNA processing are functionally coupled and establishes the first in vivo model systems for this functional coupling and for co-transcriptional processing.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "7e8e0ce5314a41af8717ec9140ab7049", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[20, 22]], "char_spans": [[113, 129]]}]}], "context_tokens": [["Previous", 0], ["studies", 9], ["in", 17], ["vivo", 20], ["reported", 25], ["that", 34], ["processing", 39], ["of", 50], ["primary", 53], ["microRNA", 61], ["(", 70], ["pri", 71], ["-", 74], ["miRNA", 75], [")", 80], ["is", 82], ["coupled", 85], ["to", 93], ["transcription", 96], ["by", 110], ["RNA", 113], ["polymerase", 117], ["II", 128], ["(", 131], ["RNAP", 132], ["II", 137], [")", 139], ["and", 141], ["can", 145], ["occur", 149], ["co", 155], ["-", 157], ["transcriptionally", 158], [".", 175], ["Here", 177], ["we", 182], ["have", 185], ["established", 190], ["a", 202], ["robust", 204], ["in", 211], ["vivo", 214], ["system", 219], ["in", 226], ["which", 229], ["pri", 235], ["-", 238], ["miRNA", 239], ["is", 245], ["transcribed", 248], ["by", 260], ["RNAP", 263], ["II", 268], ["and", 271], ["processed", 275], ["to", 285], ["pre", 288], ["-", 291], ["miRNA", 292], ["in", 298], ["HeLa", 301], ["cell", 306], ["nuclear", 311], ["extracts", 319], [".", 327], ["We", 329], ["show", 332], ["that", 337], ["both", 342], ["the", 347], ["kinetics", 351], ["and", 360], ["efficiency", 364], ["of", 375], ["pri", 378], ["-", 381], ["miRNA", 382], ["processing", 388], ["are", 399], ["dramatically", 403], ["enhanced", 416], ["in", 425], ["this", 428], ["system", 433], ["compared", 440], ["to", 449], ["that", 452], ["of", 457], ["the", 460], ["corresponding", 464], ["naked", 478], ["pri", 484], ["-", 487], ["miRNA", 488], [".", 493], ["Moreover", 495], [",", 503], ["this", 505], ["enhancement", 510], ["is", 522], ["general", 525], ["as", 533], ["it", 536], ["occurs", 539], ["with", 546], ["multiple", 551], ["pri", 560], ["-", 563], ["miRNAs", 564], [".", 570], ["We", 572], ["also", 575], ["show", 580], ["that", 585], ["nascent", 590], ["pri", 598], ["-", 601], ["miRNA", 602], ["is", 608], ["efficiently", 611], ["processed", 623], ["before", 633], ["it", 640], ["is", 643], ["released", 646], ["from", 655], ["the", 660], ["DNA", 664], ["template", 668], [".", 676], ["Together", 678], [",", 686], ["our", 688], ["work", 692], ["directly", 697], ["demonstrates", 706], ["that", 719], ["transcription", 724], ["and", 738], ["pri", 742], ["-", 745], ["miRNA", 746], ["processing", 752], ["are", 763], ["functionally", 767], ["coupled", 780], ["and", 788], ["establishes", 792], ["the", 804], ["first", 808], ["in", 814], ["vivo", 817], ["model", 822], ["systems", 828], ["for", 836], ["this", 840], ["functional", 845], ["coupling", 856], ["and", 865], ["for", 869], ["co", 873], ["-", 875], ["transcriptional", 876], ["processing", 892], [".", 902]]}
{"context": "Siltuximab is a chimeric, anti-interleukin-6 monoclonal antibody with potential therapeutic benefit in castration-resistant prostate cancer (CRPC) patients. We assessed the safety and tolerability of siltuximab in combination with docetaxel, the pharmacokinetics of docetaxel alone and with siltuximab, and the efficacy and pharmacodynamics of siltuximab plus docetaxel. In an open-label, dose-escalation, multicenter, phase 1 study, patients with metastatic, progressive CRPC received docetaxel 75 mg/m(2) q3w plus siltuximab 6 mg/kg q2w (n=12), 9 mg/kg q3w (n=12), or 12 mg/kg q3w (n=15). Dose-limiting toxicity (DLT), PSA, and radiologic response according to WHO criteria were evaluated. DLT was reported in 1 of 11 patients receiving 6 mg/kg, 1 of 12 receiving 9 mg/kg, and in 1 of 14 receiving 12 mg/kg. Common Grade \u2265 3 adverse events were neutropenia (73 %), leukopenia (60 %), lymphopenia (30 %), dyspnea (19 %), and fatigue (14 %). Toxicities were not dose dependent. Siltuximab did not affect docetaxel pharmacokinetics. The pharmacokinetic profile for siltuximab in combination was similar to single-agent siltuximab pharmacokinetics. Twenty-three (62 %; 95 % CI 45 %, 78 %) of 37 combination-treated patients achieved a confirmed \u2265 50 % PSA decline. Of 17 patients with measurable disease at baseline, 2 confirmed and 2 unconfirmed radiologic partial responses ranging 190 to 193 days were achieved with 9- and 12-mg/kg siltuximab. C-reactive protein concentrations were suppressed throughout treatment in all patients. These results suggest that siltuximab in combination with docetaxel is safe and shows preliminary efficacy in patients with CRPC, although alternative siltuximab schedules may be better tolerated for future studies.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "af8f3fdfac2141fb802e6f2ad31ed549", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[7, 7]], "char_spans": [[31, 43]]}]}], "context_tokens": [["Siltuximab", 0], ["is", 11], ["a", 14], ["chimeric", 16], [",", 24], ["anti", 26], ["-", 30], ["interleukin-6", 31], ["monoclonal", 45], ["antibody", 56], ["with", 65], ["potential", 70], ["therapeutic", 80], ["benefit", 92], ["in", 100], ["castration", 103], ["-", 113], ["resistant", 114], ["prostate", 124], ["cancer", 133], ["(", 140], ["CRPC", 141], [")", 145], ["patients", 147], [".", 155], ["We", 157], ["assessed", 160], ["the", 169], ["safety", 173], ["and", 180], ["tolerability", 184], ["of", 197], ["siltuximab", 200], ["in", 211], ["combination", 214], ["with", 226], ["docetaxel", 231], [",", 240], ["the", 242], ["pharmacokinetics", 246], ["of", 263], ["docetaxel", 266], ["alone", 276], ["and", 282], ["with", 286], ["siltuximab", 291], [",", 301], ["and", 303], ["the", 307], ["efficacy", 311], ["and", 320], ["pharmacodynamics", 324], ["of", 341], ["siltuximab", 344], ["plus", 355], ["docetaxel", 360], [".", 369], ["In", 371], ["an", 374], ["open", 377], ["-", 381], ["label", 382], [",", 387], ["dose", 389], ["-", 393], ["escalation", 394], [",", 404], ["multicenter", 406], [",", 417], ["phase", 419], ["1", 425], ["study", 427], [",", 432], ["patients", 434], ["with", 443], ["metastatic", 448], [",", 458], ["progressive", 460], ["CRPC", 472], ["received", 477], ["docetaxel", 486], ["75", 496], ["mg", 499], ["/", 501], ["m(2", 502], [")", 505], ["q3w", 507], ["plus", 511], ["siltuximab", 516], ["6", 527], ["mg", 529], ["/", 531], ["kg", 532], ["q2w", 535], ["(", 539], ["n=12", 540], [")", 544], [",", 545], ["9", 547], ["mg", 549], ["/", 551], ["kg", 552], ["q3w", 555], ["(", 559], ["n=12", 560], [")", 564], [",", 565], ["or", 567], ["12", 570], ["mg", 573], ["/", 575], ["kg", 576], ["q3w", 579], ["(", 583], ["n=15", 584], [")", 588], [".", 589], ["Dose", 591], ["-", 595], ["limiting", 596], ["toxicity", 605], ["(", 614], ["DLT", 615], [")", 618], [",", 619], ["PSA", 621], [",", 624], ["and", 626], ["radiologic", 630], ["response", 641], ["according", 650], ["to", 660], ["WHO", 663], ["criteria", 667], ["were", 676], ["evaluated", 681], [".", 690], ["DLT", 692], ["was", 696], ["reported", 700], ["in", 709], ["1", 712], ["of", 714], ["11", 717], ["patients", 720], ["receiving", 729], ["6", 739], ["mg", 741], ["/", 743], ["kg", 744], [",", 746], ["1", 748], ["of", 750], ["12", 753], ["receiving", 756], ["9", 766], ["mg", 768], ["/", 770], ["kg", 771], [",", 773], ["and", 775], ["in", 779], ["1", 782], ["of", 784], ["14", 787], ["receiving", 790], ["12", 800], ["mg", 803], ["/", 805], ["kg", 806], [".", 808], ["Common", 810], ["Grade", 817], ["\u2265", 823], ["3", 825], ["adverse", 827], ["events", 835], ["were", 842], ["neutropenia", 847], ["(", 859], ["73", 860], ["%", 863], [")", 864], [",", 865], ["leukopenia", 867], ["(", 878], ["60", 879], ["%", 882], [")", 883], [",", 884], ["lymphopenia", 886], ["(", 898], ["30", 899], ["%", 902], [")", 903], [",", 904], ["dyspnea", 906], ["(", 914], ["19", 915], ["%", 918], [")", 919], [",", 920], ["and", 922], ["fatigue", 926], ["(", 934], ["14", 935], ["%", 938], [")", 939], [".", 940], ["Toxicities", 942], ["were", 953], ["not", 958], ["dose", 962], ["dependent", 967], [".", 976], ["Siltuximab", 978], ["did", 989], ["not", 993], ["affect", 997], ["docetaxel", 1004], ["pharmacokinetics", 1014], [".", 1030], ["The", 1032], ["pharmacokinetic", 1036], ["profile", 1052], ["for", 1060], ["siltuximab", 1064], ["in", 1075], ["combination", 1078], ["was", 1090], ["similar", 1094], ["to", 1102], ["single", 1105], ["-", 1111], ["agent", 1112], ["siltuximab", 1118], ["pharmacokinetics", 1129], [".", 1145], ["Twenty", 1147], ["-", 1153], ["three", 1154], ["(", 1160], ["62", 1161], ["%", 1164], [";", 1165], ["95", 1167], ["%", 1170], ["CI", 1172], ["45", 1175], ["%", 1178], [",", 1179], ["78", 1181], ["%", 1184], [")", 1185], ["of", 1187], ["37", 1190], ["combination", 1193], ["-", 1204], ["treated", 1205], ["patients", 1213], ["achieved", 1222], ["a", 1231], ["confirmed", 1233], ["\u2265", 1243], ["50", 1245], ["%", 1248], ["PSA", 1250], ["decline", 1254], [".", 1261], ["Of", 1263], ["17", 1266], ["patients", 1269], ["with", 1278], ["measurable", 1283], ["disease", 1294], ["at", 1302], ["baseline", 1305], [",", 1313], ["2", 1315], ["confirmed", 1317], ["and", 1327], ["2", 1331], ["unconfirmed", 1333], ["radiologic", 1345], ["partial", 1356], ["responses", 1364], ["ranging", 1374], ["190", 1382], ["to", 1386], ["193", 1389], ["days", 1393], ["were", 1398], ["achieved", 1403], ["with", 1412], ["9-", 1417], ["and", 1420], ["12-mg", 1424], ["/", 1429], ["kg", 1430], ["siltuximab", 1433], [".", 1443], ["C", 1445], ["-", 1446], ["reactive", 1447], ["protein", 1456], ["concentrations", 1464], ["were", 1479], ["suppressed", 1484], ["throughout", 1495], ["treatment", 1506], ["in", 1516], ["all", 1519], ["patients", 1523], [".", 1531], ["These", 1533], ["results", 1539], ["suggest", 1547], ["that", 1555], ["siltuximab", 1560], ["in", 1571], ["combination", 1574], ["with", 1586], ["docetaxel", 1591], ["is", 1601], ["safe", 1604], ["and", 1609], ["shows", 1613], ["preliminary", 1619], ["efficacy", 1631], ["in", 1640], ["patients", 1643], ["with", 1652], ["CRPC", 1657], [",", 1661], ["although", 1663], ["alternative", 1672], ["siltuximab", 1684], ["schedules", 1695], ["may", 1705], ["be", 1709], ["better", 1712], ["tolerated", 1719], ["for", 1729], ["future", 1733], ["studies", 1740], [".", 1747]]}
{"context": "The influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (LLPS) on the dynamic spatial organization of FtsZ, the main component of the bacterial division machinery, has been studied using several LLPS systems. The GTP-dependent assembly cycle of FtsZ is thought to be crucial for the formation of the septal ring, which is highly regulated in time and space. We found that FtsZ accumulates in one of the phases and/or at the interface, depending on the system composition and on the oligomerization state of the protein. These results were observed both in bulk LLPS and in lipid-stabilized, phase-separated aqueous microdroplets. The visualization of the droplets revealed that both the location and structural arrangement of FtsZ filaments is determined by the nature of the LLPS. Relocation upon depolymerization of the dynamic filaments suggests the protein may shift among microenvironments in response to changes in its association state. The existence of these dynamic compartments driven by phase transitions can alter the local composition and reactivity of FtsZ during its life cycle acting as a nonspecific modulating factor of cell function.", "qas": [{"question": "What is liquid liquid phase transition?", "answers": ["membrane-free microcompartments"], "qid": "4ac4c382940b442db8c27a8b57de6f0e", "question_tokens": [["What", 0], ["is", 5], ["liquid", 8], ["liquid", 15], ["phase", 22], ["transition", 28], ["?", 38]], "detected_answers": [{"text": "membrane-free microcompartments", "token_spans": [[3, 6]], "char_spans": [[17, 47]]}]}], "context_tokens": [["The", 0], ["influence", 4], ["of", 14], ["membrane", 17], ["-", 25], ["free", 26], ["microcompartments", 31], ["resulting", 49], ["from", 59], ["crowding", 64], ["-", 72], ["induced", 73], ["liquid", 81], ["/", 87], ["liquid", 88], ["phase", 95], ["separation", 101], ["(", 112], ["LLPS", 113], [")", 117], ["on", 119], ["the", 122], ["dynamic", 126], ["spatial", 134], ["organization", 142], ["of", 155], ["FtsZ", 158], [",", 162], ["the", 164], ["main", 168], ["component", 173], ["of", 183], ["the", 186], ["bacterial", 190], ["division", 200], ["machinery", 209], [",", 218], ["has", 220], ["been", 224], ["studied", 229], ["using", 237], ["several", 243], ["LLPS", 251], ["systems", 256], [".", 263], ["The", 265], ["GTP", 269], ["-", 272], ["dependent", 273], ["assembly", 283], ["cycle", 292], ["of", 298], ["FtsZ", 301], ["is", 306], ["thought", 309], ["to", 317], ["be", 320], ["crucial", 323], ["for", 331], ["the", 335], ["formation", 339], ["of", 349], ["the", 352], ["septal", 356], ["ring", 363], [",", 367], ["which", 369], ["is", 375], ["highly", 378], ["regulated", 385], ["in", 395], ["time", 398], ["and", 403], ["space", 407], [".", 412], ["We", 414], ["found", 417], ["that", 423], ["FtsZ", 428], ["accumulates", 433], ["in", 445], ["one", 448], ["of", 452], ["the", 455], ["phases", 459], ["and/or", 466], ["at", 473], ["the", 476], ["interface", 480], [",", 489], ["depending", 491], ["on", 501], ["the", 504], ["system", 508], ["composition", 515], ["and", 527], ["on", 531], ["the", 534], ["oligomerization", 538], ["state", 554], ["of", 560], ["the", 563], ["protein", 567], [".", 574], ["These", 576], ["results", 582], ["were", 590], ["observed", 595], ["both", 604], ["in", 609], ["bulk", 612], ["LLPS", 617], ["and", 622], ["in", 626], ["lipid", 629], ["-", 634], ["stabilized", 635], [",", 645], ["phase", 647], ["-", 652], ["separated", 653], ["aqueous", 663], ["microdroplets", 671], [".", 684], ["The", 686], ["visualization", 690], ["of", 704], ["the", 707], ["droplets", 711], ["revealed", 720], ["that", 729], ["both", 734], ["the", 739], ["location", 743], ["and", 752], ["structural", 756], ["arrangement", 767], ["of", 779], ["FtsZ", 782], ["filaments", 787], ["is", 797], ["determined", 800], ["by", 811], ["the", 814], ["nature", 818], ["of", 825], ["the", 828], ["LLPS", 832], [".", 836], ["Relocation", 838], ["upon", 849], ["depolymerization", 854], ["of", 871], ["the", 874], ["dynamic", 878], ["filaments", 886], ["suggests", 896], ["the", 905], ["protein", 909], ["may", 917], ["shift", 921], ["among", 927], ["microenvironments", 933], ["in", 951], ["response", 954], ["to", 963], ["changes", 966], ["in", 974], ["its", 977], ["association", 981], ["state", 993], [".", 998], ["The", 1000], ["existence", 1004], ["of", 1014], ["these", 1017], ["dynamic", 1023], ["compartments", 1031], ["driven", 1044], ["by", 1051], ["phase", 1054], ["transitions", 1060], ["can", 1072], ["alter", 1076], ["the", 1082], ["local", 1086], ["composition", 1092], ["and", 1104], ["reactivity", 1108], ["of", 1119], ["FtsZ", 1122], ["during", 1127], ["its", 1134], ["life", 1138], ["cycle", 1143], ["acting", 1149], ["as", 1156], ["a", 1159], ["nonspecific", 1161], ["modulating", 1173], ["factor", 1184], ["of", 1191], ["cell", 1194], ["function", 1199], [".", 1207]]}
{"context": "The Bacillus anthracis toxin genes, cya, lef, and pag, can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2. In atxA+ strains, toxin gene expression is increased 5- to 20-fold in cells grown in 5% CO2 relative to cells grown in air. CO2-enhanced toxin gene transcription is not observed in atx4-null mutants. Here, we used two independent techniques to obtain evidence for additional CO2-induced atxA-regulated genes. First, total protein preparations from atxA4+ and atxA isolates grown in 5% CO2 and in air were examined by two-dimensional electrophoresis. Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA. Second, we generated random transcriptional lacZ fusions in B. anthracis with transposon Tn917-LTV3. Transposon-insertion libraries were screened for mutants expressing CO2-enhanced atxA-dependent beta-galactosidase activity. DNA sequence analysis of transposon insertion sites in 17 mutants carrying CO2- and atxA-regulated fusions revealed 10 mutants carrying independent insertions on the 185-kb toxin plasmid pXO1 which did not map to the toxin genes. The tcr-lacZ fusion mutants (tcr for toxin coregulated) were Tox+, indicating that these genes may not be involved in anthrax toxin gene activation. Our data indicate a clear association of atxA with CO2-enhanced gene expression in B. anthracis and provide evidence that atxA regulates genes other than the structural genes for the anthrax toxin proteins.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "a206db12420442b69f2caeaf30ae590b", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[150, 150], [118, 118], [202, 202], [46, 46], [66, 66]], "char_spans": [[797, 799], [604, 606], [1138, 1141], [214, 216], [307, 309]]}]}], "context_tokens": [["The", 0], ["Bacillus", 4], ["anthracis", 13], ["toxin", 23], ["genes", 29], [",", 34], ["cya", 36], [",", 39], ["lef", 41], [",", 44], ["and", 46], ["pag", 50], [",", 53], ["can", 55], ["be", 59], ["viewed", 62], ["as", 69], ["a", 72], ["regulon", 74], [",", 81], ["in", 83], ["which", 86], ["transcription", 92], ["of", 106], ["all", 109], ["three", 113], ["genes", 119], ["is", 125], ["activated", 128], ["in", 138], ["trans", 141], ["by", 147], ["the", 150], ["same", 154], ["regulatory", 159], ["gene", 170], [",", 174], ["atxA", 176], [",", 180], ["in", 182], ["response", 185], ["to", 194], ["the", 197], ["same", 201], ["signal", 206], [",", 212], ["CO2", 214], [".", 217], ["In", 219], ["atxA+", 222], ["strains", 228], [",", 235], ["toxin", 237], ["gene", 243], ["expression", 248], ["is", 259], ["increased", 262], ["5-", 272], ["to", 275], ["20-fold", 278], ["in", 286], ["cells", 289], ["grown", 295], ["in", 301], ["5", 304], ["%", 305], ["CO2", 307], ["relative", 311], ["to", 320], ["cells", 323], ["grown", 329], ["in", 335], ["air", 338], [".", 341], ["CO2-enhanced", 343], ["toxin", 356], ["gene", 362], ["transcription", 367], ["is", 381], ["not", 384], ["observed", 388], ["in", 397], ["atx4-null", 400], ["mutants", 410], [".", 417], ["Here", 419], [",", 423], ["we", 425], ["used", 428], ["two", 433], ["independent", 437], ["techniques", 449], ["to", 460], ["obtain", 463], ["evidence", 470], ["for", 479], ["additional", 483], ["CO2-induced", 494], ["atxA", 506], ["-", 510], ["regulated", 511], ["genes", 521], [".", 526], ["First", 528], [",", 533], ["total", 535], ["protein", 541], ["preparations", 549], ["from", 562], ["atxA4", 567], ["+", 572], ["and", 574], ["atxA", 578], ["isolates", 583], ["grown", 592], ["in", 598], ["5", 601], ["%", 602], ["CO2", 604], ["and", 608], ["in", 612], ["air", 615], ["were", 619], ["examined", 624], ["by", 633], ["two", 636], ["-", 639], ["dimensional", 640], ["electrophoresis", 652], [".", 667], ["Comparison", 669], ["of", 680], ["the", 683], ["resulting", 687], ["protein", 697], ["patterns", 705], ["indicated", 714], ["that", 724], ["synthesis", 729], ["of", 739], ["non", 742], ["-", 745], ["toxin", 746], ["proteins", 752], ["is", 761], ["influenced", 764], ["by", 775], ["growth", 778], ["in", 785], ["elevated", 788], ["CO2", 797], ["and", 801], ["the", 805], ["toxin", 809], ["gene", 815], ["regulator", 820], [",", 829], ["atxA.", 831], ["Second", 837], [",", 843], ["we", 845], ["generated", 848], ["random", 858], ["transcriptional", 865], ["lacZ", 881], ["fusions", 886], ["in", 894], ["B.", 897], ["anthracis", 900], ["with", 910], ["transposon", 915], ["Tn917-LTV3", 926], [".", 936], ["Transposon", 938], ["-", 948], ["insertion", 949], ["libraries", 959], ["were", 969], ["screened", 974], ["for", 983], ["mutants", 987], ["expressing", 995], ["CO2-enhanced", 1006], ["atxA", 1019], ["-", 1023], ["dependent", 1024], ["beta", 1034], ["-", 1038], ["galactosidase", 1039], ["activity", 1053], [".", 1061], ["DNA", 1063], ["sequence", 1067], ["analysis", 1076], ["of", 1085], ["transposon", 1088], ["insertion", 1099], ["sites", 1109], ["in", 1115], ["17", 1118], ["mutants", 1121], ["carrying", 1129], ["CO2-", 1138], ["and", 1143], ["atxA", 1147], ["-", 1151], ["regulated", 1152], ["fusions", 1162], ["revealed", 1170], ["10", 1179], ["mutants", 1182], ["carrying", 1190], ["independent", 1199], ["insertions", 1211], ["on", 1222], ["the", 1225], ["185-kb", 1229], ["toxin", 1236], ["plasmid", 1242], ["pXO1", 1250], ["which", 1255], ["did", 1261], ["not", 1265], ["map", 1269], ["to", 1273], ["the", 1276], ["toxin", 1280], ["genes", 1286], [".", 1291], ["The", 1293], ["tcr", 1297], ["-", 1300], ["lacZ", 1301], ["fusion", 1306], ["mutants", 1313], ["(", 1321], ["tcr", 1322], ["for", 1326], ["toxin", 1330], ["coregulated", 1336], [")", 1347], ["were", 1349], ["Tox+", 1354], [",", 1358], ["indicating", 1360], ["that", 1371], ["these", 1376], ["genes", 1382], ["may", 1388], ["not", 1392], ["be", 1396], ["involved", 1399], ["in", 1408], ["anthrax", 1411], ["toxin", 1419], ["gene", 1425], ["activation", 1430], [".", 1440], ["Our", 1442], ["data", 1446], ["indicate", 1451], ["a", 1460], ["clear", 1462], ["association", 1468], ["of", 1480], ["atxA", 1483], ["with", 1488], ["CO2-enhanced", 1493], ["gene", 1506], ["expression", 1511], ["in", 1522], ["B.", 1525], ["anthracis", 1528], ["and", 1538], ["provide", 1542], ["evidence", 1550], ["that", 1559], ["atxA", 1564], ["regulates", 1569], ["genes", 1579], ["other", 1585], ["than", 1591], ["the", 1596], ["structural", 1600], ["genes", 1611], ["for", 1617], ["the", 1621], ["anthrax", 1625], ["toxin", 1633], ["proteins", 1639], [".", 1647]]}
{"context": "Normal B lymphocytes receive signals from B-cell antigen receptor (BCR) that are triggered by binding of the BCR to an external antigen. Tonic signaling through the BCR provides growth and signals to chronic lymphocytic leukemia (CLL) cells, and plays an important role in the pathogenesis and progression of the disease. Antigen engagement of BCR is followed by intracellular recruitment and activation of BCR-associated kinases including spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk) and phosphatidylinositol 3-kinases (PI3K). Inhibition of signaling pathways downstream of the BCR induces disruption of chemokine-mediated CLL cell migration and cell killing. BCR signal transduction inhibitors represent a promising new strategy for targeted CLL treatment. A number of therapeutic agents have recently been developed with significant activity in CLL. The compounds that are currently investigated in patients with CLL include ibrutinib -inhibitor of Btk, fostamatinib-inhibitor of Syk and idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. The clinical activity of ibrutinib, GS-1101 and fostamatinib in patients with CLL is associated with marked lymphocytosis due to release of tumor cells from the lymph nodes into the peripheral blood. Further studies are ongoing with single agents and their combinations with other targeted and conventional therapies. This article will review the preclinical rationale of BCR signaling inhibitors in the treatment of CLL, and the clinical evidence supporting the use of these agents in CLL patients.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "a223c16cf85f41ee87a3f1714a34aad3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[191, 191], [159, 159]], "char_spans": [[1103, 1111], [944, 952]]}]}], "context_tokens": [["Normal", 0], ["B", 7], ["lymphocytes", 9], ["receive", 21], ["signals", 29], ["from", 37], ["B", 42], ["-", 43], ["cell", 44], ["antigen", 49], ["receptor", 57], ["(", 66], ["BCR", 67], [")", 70], ["that", 72], ["are", 77], ["triggered", 81], ["by", 91], ["binding", 94], ["of", 102], ["the", 105], ["BCR", 109], ["to", 113], ["an", 116], ["external", 119], ["antigen", 128], [".", 135], ["Tonic", 137], ["signaling", 143], ["through", 153], ["the", 161], ["BCR", 165], ["provides", 169], ["growth", 178], ["and", 185], ["signals", 189], ["to", 197], ["chronic", 200], ["lymphocytic", 208], ["leukemia", 220], ["(", 229], ["CLL", 230], [")", 233], ["cells", 235], [",", 240], ["and", 242], ["plays", 246], ["an", 252], ["important", 255], ["role", 265], ["in", 270], ["the", 273], ["pathogenesis", 277], ["and", 290], ["progression", 294], ["of", 306], ["the", 309], ["disease", 313], [".", 320], ["Antigen", 322], ["engagement", 330], ["of", 341], ["BCR", 344], ["is", 348], ["followed", 351], ["by", 360], ["intracellular", 363], ["recruitment", 377], ["and", 389], ["activation", 393], ["of", 404], ["BCR", 407], ["-", 410], ["associated", 411], ["kinases", 422], ["including", 430], ["spleen", 440], ["tyrosine", 447], ["kinase", 456], ["(", 463], ["Syk", 464], [")", 467], [",", 468], ["Bruton", 470], ["'s", 476], ["tyrosine", 479], ["kinase", 488], ["(", 495], ["Btk", 496], [")", 499], ["and", 501], ["phosphatidylinositol", 505], ["3-kinases", 526], ["(", 536], ["PI3", 537], ["K", 540], [")", 541], [".", 542], ["Inhibition", 544], ["of", 555], ["signaling", 558], ["pathways", 568], ["downstream", 577], ["of", 588], ["the", 591], ["BCR", 595], ["induces", 599], ["disruption", 607], ["of", 618], ["chemokine", 621], ["-", 630], ["mediated", 631], ["CLL", 640], ["cell", 644], ["migration", 649], ["and", 659], ["cell", 663], ["killing", 668], [".", 675], ["BCR", 677], ["signal", 681], ["transduction", 688], ["inhibitors", 701], ["represent", 712], ["a", 722], ["promising", 724], ["new", 734], ["strategy", 738], ["for", 747], ["targeted", 751], ["CLL", 760], ["treatment", 764], [".", 773], ["A", 775], ["number", 777], ["of", 784], ["therapeutic", 787], ["agents", 799], ["have", 806], ["recently", 811], ["been", 820], ["developed", 825], ["with", 835], ["significant", 840], ["activity", 852], ["in", 861], ["CLL", 864], [".", 867], ["The", 869], ["compounds", 873], ["that", 883], ["are", 888], ["currently", 892], ["investigated", 902], ["in", 915], ["patients", 918], ["with", 927], ["CLL", 932], ["include", 936], ["ibrutinib", 944], ["-inhibitor", 954], ["of", 965], ["Btk", 968], [",", 971], ["fostamatinib", 973], ["-", 985], ["inhibitor", 986], ["of", 996], ["Syk", 999], ["and", 1003], ["idelalisib", 1007], ["(", 1018], ["GS-1101", 1019], [")", 1026], ["-a", 1028], ["specific", 1031], ["isoform", 1040], ["of", 1048], ["the", 1051], ["PI3", 1055], ["K", 1058], ["(", 1060], ["PI3", 1061], ["K", 1064], [")", 1065], ["inhibitor", 1067], [".", 1076], ["The", 1078], ["clinical", 1082], ["activity", 1091], ["of", 1100], ["ibrutinib", 1103], [",", 1112], ["GS-1101", 1114], ["and", 1122], ["fostamatinib", 1126], ["in", 1139], ["patients", 1142], ["with", 1151], ["CLL", 1156], ["is", 1160], ["associated", 1163], ["with", 1174], ["marked", 1179], ["lymphocytosis", 1186], ["due", 1200], ["to", 1204], ["release", 1207], ["of", 1215], ["tumor", 1218], ["cells", 1224], ["from", 1230], ["the", 1235], ["lymph", 1239], ["nodes", 1245], ["into", 1251], ["the", 1256], ["peripheral", 1260], ["blood", 1271], [".", 1276], ["Further", 1278], ["studies", 1286], ["are", 1294], ["ongoing", 1298], ["with", 1306], ["single", 1311], ["agents", 1318], ["and", 1325], ["their", 1329], ["combinations", 1335], ["with", 1348], ["other", 1353], ["targeted", 1359], ["and", 1368], ["conventional", 1372], ["therapies", 1385], [".", 1394], ["This", 1396], ["article", 1401], ["will", 1409], ["review", 1414], ["the", 1421], ["preclinical", 1425], ["rationale", 1437], ["of", 1447], ["BCR", 1450], ["signaling", 1454], ["inhibitors", 1464], ["in", 1475], ["the", 1478], ["treatment", 1482], ["of", 1492], ["CLL", 1495], [",", 1498], ["and", 1500], ["the", 1504], ["clinical", 1508], ["evidence", 1517], ["supporting", 1526], ["the", 1537], ["use", 1541], ["of", 1545], ["these", 1548], ["agents", 1554], ["in", 1561], ["CLL", 1564], ["patients", 1568], [".", 1576]]}
{"context": "Bilirubin, a breakdown product of heme, is normally glucuronidated and excreted by the liver into bile. Failure of this system can lead to a buildup of conjugated bilirubin in the blood, resulting in jaundice. The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3. These important detoxification-limiting proteins mediate uptake and clearance of countless drugs and drug conjugates across the sinusoidal hepatocyte membrane. OATP1B1 polymorphisms have previously been linked to drug hypersensitivities. Using mice deficient in Oatp1a/1b and in the multispecific sinusoidal export pump Abcc3, we found that Abcc3 secretes bilirubin conjugates into the blood, while Oatp1a/1b transporters mediate their hepatic reuptake. Transgenic expression of human OATP1B1 or OATP1B3 restored the function of this detoxification-enhancing liver-blood shuttle in Oatp1a/1b-deficient mice. Within liver lobules, this shuttle may allow flexible transfer of bilirubin conjugates (and probably also drug conjugates) formed in upstream hepatocytes to downstream hepatocytes, thereby preventing local saturation of further detoxification processes and hepatocyte toxic injury. Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "qas": [{"question": "Which syndrome is associated with OATP1B1 and OATP1B3 deficiency?", "answers": ["Rotor-syndrome", "Rotor syndrome"], "qid": "46eb9766357f48e88dcbee645ba193cf", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["OATP1B1", 34], ["and", 42], ["OATP1B3", 46], ["deficiency", 54], ["?", 64]], "detected_answers": [{"text": "Rotor syndrome", "token_spans": [[55, 56], [88, 90], [95, 96]], "char_spans": [[323, 336], [538, 551], [577, 590]]}]}], "context_tokens": [["Bilirubin", 0], [",", 9], ["a", 11], ["breakdown", 13], ["product", 23], ["of", 31], ["heme", 34], [",", 38], ["is", 40], ["normally", 43], ["glucuronidated", 52], ["and", 67], ["excreted", 71], ["by", 80], ["the", 83], ["liver", 87], ["into", 93], ["bile", 98], [".", 102], ["Failure", 104], ["of", 112], ["this", 115], ["system", 120], ["can", 127], ["lead", 131], ["to", 136], ["a", 139], ["buildup", 141], ["of", 149], ["conjugated", 152], ["bilirubin", 163], ["in", 173], ["the", 176], ["blood", 180], [",", 185], ["resulting", 187], ["in", 197], ["jaundice", 200], [".", 208], ["The", 210], ["mechanistic", 214], ["basis", 226], ["of", 232], ["bilirubin", 235], ["excretion", 245], ["and", 255], ["hyperbilirubinemia", 259], ["syndromes", 278], ["is", 288], ["largely", 291], ["understood", 299], [",", 309], ["but", 311], ["that", 315], ["of", 320], ["Rotor", 323], ["syndrome", 329], [",", 337], ["an", 339], ["autosomal", 342], ["recessive", 352], ["disorder", 362], ["characterized", 371], ["by", 385], ["conjugated", 388], ["hyperbilirubinemia", 399], [",", 417], ["coproporphyrinuria", 419], [",", 437], ["and", 439], ["near", 443], ["-", 447], ["absent", 448], ["hepatic", 455], ["uptake", 463], ["of", 470], ["anionic", 473], ["diagnostics", 481], [",", 492], ["has", 494], ["remained", 498], ["enigmatic", 507], [".", 516], ["Here", 518], [",", 522], ["we", 524], ["analyzed", 527], ["8", 536], ["Rotor", 538], ["-", 543], ["syndrome", 544], ["families", 553], ["and", 562], ["found", 566], ["that", 572], ["Rotor", 577], ["syndrome", 583], ["was", 592], ["linked", 596], ["to", 603], ["mutations", 606], ["predicted", 616], ["to", 626], ["cause", 629], ["complete", 635], ["and", 644], ["simultaneous", 648], ["deficiencies", 661], ["of", 674], ["the", 677], ["organic", 681], ["anion", 689], ["transporting", 695], ["polypeptides", 708], ["OATP1B1", 721], ["and", 729], ["OATP1B3", 733], [".", 740], ["These", 742], ["important", 748], ["detoxification", 758], ["-", 772], ["limiting", 773], ["proteins", 782], ["mediate", 791], ["uptake", 799], ["and", 806], ["clearance", 810], ["of", 820], ["countless", 823], ["drugs", 833], ["and", 839], ["drug", 843], ["conjugates", 848], ["across", 859], ["the", 866], ["sinusoidal", 870], ["hepatocyte", 881], ["membrane", 892], [".", 900], ["OATP1B1", 902], ["polymorphisms", 910], ["have", 924], ["previously", 929], ["been", 940], ["linked", 945], ["to", 952], ["drug", 955], ["hypersensitivities", 960], [".", 978], ["Using", 980], ["mice", 986], ["deficient", 991], ["in", 1001], ["Oatp1a/1b", 1004], ["and", 1014], ["in", 1018], ["the", 1021], ["multispecific", 1025], ["sinusoidal", 1039], ["export", 1050], ["pump", 1057], ["Abcc3", 1062], [",", 1067], ["we", 1069], ["found", 1072], ["that", 1078], ["Abcc3", 1083], ["secretes", 1089], ["bilirubin", 1098], ["conjugates", 1108], ["into", 1119], ["the", 1124], ["blood", 1128], [",", 1133], ["while", 1135], ["Oatp1a/1b", 1141], ["transporters", 1151], ["mediate", 1164], ["their", 1172], ["hepatic", 1178], ["reuptake", 1186], [".", 1194], ["Transgenic", 1196], ["expression", 1207], ["of", 1218], ["human", 1221], ["OATP1B1", 1227], ["or", 1235], ["OATP1B3", 1238], ["restored", 1246], ["the", 1255], ["function", 1259], ["of", 1268], ["this", 1271], ["detoxification", 1276], ["-", 1290], ["enhancing", 1291], ["liver", 1301], ["-", 1306], ["blood", 1307], ["shuttle", 1313], ["in", 1321], ["Oatp1a/1b", 1324], ["-", 1333], ["deficient", 1334], ["mice", 1344], [".", 1348], ["Within", 1350], ["liver", 1357], ["lobules", 1363], [",", 1370], ["this", 1372], ["shuttle", 1377], ["may", 1385], ["allow", 1389], ["flexible", 1395], ["transfer", 1404], ["of", 1413], ["bilirubin", 1416], ["conjugates", 1426], ["(", 1437], ["and", 1438], ["probably", 1442], ["also", 1451], ["drug", 1456], ["conjugates", 1461], [")", 1471], ["formed", 1473], ["in", 1480], ["upstream", 1483], ["hepatocytes", 1492], ["to", 1504], ["downstream", 1507], ["hepatocytes", 1518], [",", 1529], ["thereby", 1531], ["preventing", 1539], ["local", 1550], ["saturation", 1556], ["of", 1567], ["further", 1570], ["detoxification", 1578], ["processes", 1593], ["and", 1603], ["hepatocyte", 1607], ["toxic", 1618], ["injury", 1624], [".", 1630], ["Thus", 1632], [",", 1636], ["disruption", 1638], ["of", 1649], ["hepatic", 1652], ["reuptake", 1660], ["of", 1669], ["bilirubin", 1672], ["glucuronide", 1682], ["due", 1694], ["to", 1698], ["coexisting", 1701], ["OATP1B1", 1712], ["and", 1720], ["OATP1B3", 1724], ["deficiencies", 1732], ["explains", 1745], ["Rotor", 1754], ["-", 1759], ["type", 1760], ["hyperbilirubinemia", 1765], [".", 1783], ["Moreover", 1785], [",", 1793], ["OATP1B1", 1795], ["and", 1803], ["OATP1B3", 1807], ["null", 1815], ["mutations", 1820], ["may", 1830], ["confer", 1834], ["substantial", 1841], ["drug", 1853], ["toxicity", 1858], ["risks", 1867], [".", 1872]]}
{"context": "The protein alpha-synuclein (AS) is the primary fibrillar component of Lewy bodies, the pathological hallmark of Parkinson's disease. Wild-type human AS and the three mutant forms linked to Parkinson's disease (A53T, A30P, and E46K) all form fibrils through a nucleation-dependent pathway; however, the biophysical details of these fibrillation events are not yet well understood. Atomic-level structural insight is required in order to elucidate the potential role of AS fibrils in Parkinson's disease. Here we show that low temperature acquisition of magic-angle spinning NMR spectra of wild type AS fibrils-greatly enhances spectral sensitivity, enabling the detection of a substantially larger number of spin systems. At 0 +/- 3 degrees C sample temperature, cross polarization (CP) experiments yield weak signals. Lower temperature spectra (-40 +/- 3 degrees C) demonstrated several times greater signal intensity, an effect further amplified in 3D 15N-13C-13C experiments, which are required to perform backbone assignments on this sample. Thus 3D experiments enabled assignments of most amino acids in the rigid part of the fibril (approximately residues 64 to 94), as well as tentative site-specific assignments for T22, V26, A27, Y39, G41, S42, H50, V52, A53, T54, V55, V63, A107, I112, and S129. Most of these signals were not observed in 2D or 3D spectra at 0 +/- 3 degrees C. Spectra acquired at low temperatures therefore permitted more complete chemical shift assignments. Observation of the majority of residues in AS fibrils represents an important step towards solving the 3D structure.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d74834afd23a4192b6b88ed137c2ea87", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[2, 4]], "char_spans": [[12, 26]]}]}], "context_tokens": [["The", 0], ["protein", 4], ["alpha", 12], ["-", 17], ["synuclein", 18], ["(", 28], ["AS", 29], [")", 31], ["is", 33], ["the", 36], ["primary", 40], ["fibrillar", 48], ["component", 58], ["of", 68], ["Lewy", 71], ["bodies", 76], [",", 82], ["the", 84], ["pathological", 88], ["hallmark", 101], ["of", 110], ["Parkinson", 113], ["'s", 122], ["disease", 125], [".", 132], ["Wild", 134], ["-", 138], ["type", 139], ["human", 144], ["AS", 150], ["and", 153], ["the", 157], ["three", 161], ["mutant", 167], ["forms", 174], ["linked", 180], ["to", 187], ["Parkinson", 190], ["'s", 199], ["disease", 202], ["(", 210], ["A53", 211], ["T", 214], [",", 215], ["A30P", 217], [",", 221], ["and", 223], ["E46", 227], ["K", 230], [")", 231], ["all", 233], ["form", 237], ["fibrils", 242], ["through", 250], ["a", 258], ["nucleation", 260], ["-", 270], ["dependent", 271], ["pathway", 281], [";", 288], ["however", 290], [",", 297], ["the", 299], ["biophysical", 303], ["details", 315], ["of", 323], ["these", 326], ["fibrillation", 332], ["events", 345], ["are", 352], ["not", 356], ["yet", 360], ["well", 364], ["understood", 369], [".", 379], ["Atomic", 381], ["-", 387], ["level", 388], ["structural", 394], ["insight", 405], ["is", 413], ["required", 416], ["in", 425], ["order", 428], ["to", 434], ["elucidate", 437], ["the", 447], ["potential", 451], ["role", 461], ["of", 466], ["AS", 469], ["fibrils", 472], ["in", 480], ["Parkinson", 483], ["'s", 492], ["disease", 495], [".", 502], ["Here", 504], ["we", 509], ["show", 512], ["that", 517], ["low", 522], ["temperature", 526], ["acquisition", 538], ["of", 550], ["magic", 553], ["-", 558], ["angle", 559], ["spinning", 565], ["NMR", 574], ["spectra", 578], ["of", 586], ["wild", 589], ["type", 594], ["AS", 599], ["fibrils", 602], ["-", 609], ["greatly", 610], ["enhances", 618], ["spectral", 627], ["sensitivity", 636], [",", 647], ["enabling", 649], ["the", 658], ["detection", 662], ["of", 672], ["a", 675], ["substantially", 677], ["larger", 691], ["number", 698], ["of", 705], ["spin", 708], ["systems", 713], [".", 720], ["At", 722], ["0", 725], ["+", 727], ["/-", 728], ["3", 731], ["degrees", 733], ["C", 741], ["sample", 743], ["temperature", 750], [",", 761], ["cross", 763], ["polarization", 769], ["(", 782], ["CP", 783], [")", 785], ["experiments", 787], ["yield", 799], ["weak", 805], ["signals", 810], [".", 817], ["Lower", 819], ["temperature", 825], ["spectra", 837], ["(", 845], ["-40", 846], ["+", 850], ["/-", 851], ["3", 854], ["degrees", 856], ["C", 864], [")", 865], ["demonstrated", 867], ["several", 880], ["times", 888], ["greater", 894], ["signal", 902], ["intensity", 909], [",", 918], ["an", 920], ["effect", 923], ["further", 930], ["amplified", 938], ["in", 948], ["3D", 951], ["15N-13C-13C", 954], ["experiments", 966], [",", 977], ["which", 979], ["are", 985], ["required", 989], ["to", 998], ["perform", 1001], ["backbone", 1009], ["assignments", 1018], ["on", 1030], ["this", 1033], ["sample", 1038], [".", 1044], ["Thus", 1046], ["3D", 1051], ["experiments", 1054], ["enabled", 1066], ["assignments", 1074], ["of", 1086], ["most", 1089], ["amino", 1094], ["acids", 1100], ["in", 1106], ["the", 1109], ["rigid", 1113], ["part", 1119], ["of", 1124], ["the", 1127], ["fibril", 1131], ["(", 1138], ["approximately", 1139], ["residues", 1153], ["64", 1162], ["to", 1165], ["94", 1168], [")", 1170], [",", 1171], ["as", 1173], ["well", 1176], ["as", 1181], ["tentative", 1184], ["site", 1194], ["-", 1198], ["specific", 1199], ["assignments", 1208], ["for", 1220], ["T22", 1224], [",", 1227], ["V26", 1229], [",", 1232], ["A27", 1234], [",", 1237], ["Y39", 1239], [",", 1242], ["G41", 1244], [",", 1247], ["S42", 1249], [",", 1252], ["H50", 1254], [",", 1257], ["V52", 1259], [",", 1262], ["A53", 1264], [",", 1267], ["T54", 1269], [",", 1272], ["V55", 1274], [",", 1277], ["V63", 1279], [",", 1282], ["A107", 1284], [",", 1288], ["I112", 1290], [",", 1294], ["and", 1296], ["S129", 1300], [".", 1304], ["Most", 1306], ["of", 1311], ["these", 1314], ["signals", 1320], ["were", 1328], ["not", 1333], ["observed", 1337], ["in", 1346], ["2D", 1349], ["or", 1352], ["3D", 1355], ["spectra", 1358], ["at", 1366], ["0", 1369], ["+", 1371], ["/-", 1372], ["3", 1375], ["degrees", 1377], ["C.", 1385], ["Spectra", 1388], ["acquired", 1396], ["at", 1405], ["low", 1408], ["temperatures", 1412], ["therefore", 1425], ["permitted", 1435], ["more", 1445], ["complete", 1450], ["chemical", 1459], ["shift", 1468], ["assignments", 1474], [".", 1485], ["Observation", 1487], ["of", 1499], ["the", 1502], ["majority", 1506], ["of", 1515], ["residues", 1518], ["in", 1527], ["AS", 1530], ["fibrils", 1533], ["represents", 1541], ["an", 1552], ["important", 1555], ["step", 1565], ["towards", 1570], ["solving", 1578], ["the", 1586], ["3D", 1590], ["structure", 1593], [".", 1602]]}
{"context": "LYST is a large cytosolic protein that influences the biogenesis of lysosome-related organelles, and mutation of the encoding gene, LYST, can cause Chediak-Higashi syndrome. Recently, Lyst-mutant mice were recognized to also exhibit an iris disease resembling exfoliation syndrome, a common cause of glaucoma in humans. Here, Lyst-mutant iris phenotypes were used in a search for genes that influence Lyst pathways. In a candidate gene-driven approach, albino Lyst-mutant mice homozygous for a mutation in Tyr, whose product is key to melanin synthesis within melanosomes, exhibited complete rescue of Lyst-mutant iris phenotypes. In a genetic background-driven approach using a DBA/2J strain of congenic mice, an interval containing Tyrp1 enhanced Lyst-dependent iris phenotypes. Thus, both experimental approaches implicated the melanosome, an organelle that is a potential source of oxidative stress, as contributing to the disease phenotype. Confirming an association with oxidative damage, Lyst mutation resulted in genetic context-sensitive changes in iris lipid hydroperoxide levels, being lowest in albino and highest in DBA/2J mice. Surprisingly, the DBA/2J genetic background also exposed a late-onset neurodegenerative phenotype involving cerebellar Purkinje-cell degeneration. These results identify an association between oxidative damage to lipid membranes and the severity of Lyst-mutant phenotypes, revealing a new mechanism that contributes to pathophysiology involving LYST.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "951b2519bc4f461191fcb2cfbdb346b4", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[27, 30]], "char_spans": [[148, 171]]}]}], "context_tokens": [["LYST", 0], ["is", 5], ["a", 8], ["large", 10], ["cytosolic", 16], ["protein", 26], ["that", 34], ["influences", 39], ["the", 50], ["biogenesis", 54], ["of", 65], ["lysosome", 68], ["-", 76], ["related", 77], ["organelles", 85], [",", 95], ["and", 97], ["mutation", 101], ["of", 110], ["the", 113], ["encoding", 117], ["gene", 126], [",", 130], ["LYST", 132], [",", 136], ["can", 138], ["cause", 142], ["Chediak", 148], ["-", 155], ["Higashi", 156], ["syndrome", 164], [".", 172], ["Recently", 174], [",", 182], ["Lyst", 184], ["-", 188], ["mutant", 189], ["mice", 196], ["were", 201], ["recognized", 206], ["to", 217], ["also", 220], ["exhibit", 225], ["an", 233], ["iris", 236], ["disease", 241], ["resembling", 249], ["exfoliation", 260], ["syndrome", 272], [",", 280], ["a", 282], ["common", 284], ["cause", 291], ["of", 297], ["glaucoma", 300], ["in", 309], ["humans", 312], [".", 318], ["Here", 320], [",", 324], ["Lyst", 326], ["-", 330], ["mutant", 331], ["iris", 338], ["phenotypes", 343], ["were", 354], ["used", 359], ["in", 364], ["a", 367], ["search", 369], ["for", 376], ["genes", 380], ["that", 386], ["influence", 391], ["Lyst", 401], ["pathways", 406], [".", 414], ["In", 416], ["a", 419], ["candidate", 421], ["gene", 431], ["-", 435], ["driven", 436], ["approach", 443], [",", 451], ["albino", 453], ["Lyst", 460], ["-", 464], ["mutant", 465], ["mice", 472], ["homozygous", 477], ["for", 488], ["a", 492], ["mutation", 494], ["in", 503], ["Tyr", 506], [",", 509], ["whose", 511], ["product", 517], ["is", 525], ["key", 528], ["to", 532], ["melanin", 535], ["synthesis", 543], ["within", 553], ["melanosomes", 560], [",", 571], ["exhibited", 573], ["complete", 583], ["rescue", 592], ["of", 599], ["Lyst", 602], ["-", 606], ["mutant", 607], ["iris", 614], ["phenotypes", 619], [".", 629], ["In", 631], ["a", 634], ["genetic", 636], ["background", 644], ["-", 654], ["driven", 655], ["approach", 662], ["using", 671], ["a", 677], ["DBA/2J", 679], ["strain", 686], ["of", 693], ["congenic", 696], ["mice", 705], [",", 709], ["an", 711], ["interval", 714], ["containing", 723], ["Tyrp1", 734], ["enhanced", 740], ["Lyst", 749], ["-", 753], ["dependent", 754], ["iris", 764], ["phenotypes", 769], [".", 779], ["Thus", 781], [",", 785], ["both", 787], ["experimental", 792], ["approaches", 805], ["implicated", 816], ["the", 827], ["melanosome", 831], [",", 841], ["an", 843], ["organelle", 846], ["that", 856], ["is", 861], ["a", 864], ["potential", 866], ["source", 876], ["of", 883], ["oxidative", 886], ["stress", 896], [",", 902], ["as", 904], ["contributing", 907], ["to", 920], ["the", 923], ["disease", 927], ["phenotype", 935], [".", 944], ["Confirming", 946], ["an", 957], ["association", 960], ["with", 972], ["oxidative", 977], ["damage", 987], [",", 993], ["Lyst", 995], ["mutation", 1000], ["resulted", 1009], ["in", 1018], ["genetic", 1021], ["context", 1029], ["-", 1036], ["sensitive", 1037], ["changes", 1047], ["in", 1055], ["iris", 1058], ["lipid", 1063], ["hydroperoxide", 1069], ["levels", 1083], [",", 1089], ["being", 1091], ["lowest", 1097], ["in", 1104], ["albino", 1107], ["and", 1114], ["highest", 1118], ["in", 1126], ["DBA/2J", 1129], ["mice", 1136], [".", 1140], ["Surprisingly", 1142], [",", 1154], ["the", 1156], ["DBA/2J", 1160], ["genetic", 1167], ["background", 1175], ["also", 1186], ["exposed", 1191], ["a", 1199], ["late", 1201], ["-", 1205], ["onset", 1206], ["neurodegenerative", 1212], ["phenotype", 1230], ["involving", 1240], ["cerebellar", 1250], ["Purkinje", 1261], ["-", 1269], ["cell", 1270], ["degeneration", 1275], [".", 1287], ["These", 1289], ["results", 1295], ["identify", 1303], ["an", 1312], ["association", 1315], ["between", 1327], ["oxidative", 1335], ["damage", 1345], ["to", 1352], ["lipid", 1355], ["membranes", 1361], ["and", 1371], ["the", 1375], ["severity", 1379], ["of", 1388], ["Lyst", 1391], ["-", 1395], ["mutant", 1396], ["phenotypes", 1403], [",", 1413], ["revealing", 1415], ["a", 1425], ["new", 1427], ["mechanism", 1431], ["that", 1441], ["contributes", 1446], ["to", 1458], ["pathophysiology", 1461], ["involving", 1477], ["LYST", 1487], [".", 1491]]}
{"context": "Vascular endothelial growth factor (VEGF) is supposed to contribute to the pathogenesis of allergic airway disease. VEGF expression is regulated by a variety of stimuli such as nitric oxide, growth factors, and hypoxia-inducible factor-1 alpha (HIF-1\u03b1). Recently, inhibition of the mammalian target of rapamycin (mTOR) has been shown to alleviate cardinal asthmatic features, including airway hyperresponsiveness, eosinophilic inflammation, and increased vascular permeability in asthma models. Based on these observations, we have investigated whether mTOR is associated with HIF-1\u03b1-mediated VEGF expression in allergic asthma. In studies with the mTOR inhibitor rapamycin, we have elucidated the stimulatory role of a mTOR-HIF-1\u03b1-VEGF axis in allergic response. Next, the mechanisms by which mTOR is activated to modulate this response have been evaluated. mTOR is known to be regulated by phosphoinositide 3-kinase (PI3K)/Akt or protein kinase C-delta (PKC \u03b4) in various cell types. Consistent with these, our results have revealed that suppression of PKC \u03b4 by rottlerin leads to the inhibition of PI3K/Akt activity and the subsequent blockade of a mTOR-HIF-1\u03b1-VEGF module, thereby attenuating typical asthmatic attack in a murine model. Thus, the present data indicate that PKC \u03b4 is necessary for the modulation of the PI3K/Akt/mTOR signaling cascade, resulting in a tight regulation of HIF-1\u03b1 activity and VEGF expression. In conclusion, PKC \u03b4 may represent a valuable target for innovative therapeutic treatment of allergic airway disease.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "5fa3ac51559646bc97a2d2bda7967890", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[51, 54]], "char_spans": [[282, 310]]}]}], "context_tokens": [["Vascular", 0], ["endothelial", 9], ["growth", 21], ["factor", 28], ["(", 35], ["VEGF", 36], [")", 40], ["is", 42], ["supposed", 45], ["to", 54], ["contribute", 57], ["to", 68], ["the", 71], ["pathogenesis", 75], ["of", 88], ["allergic", 91], ["airway", 100], ["disease", 107], [".", 114], ["VEGF", 116], ["expression", 121], ["is", 132], ["regulated", 135], ["by", 145], ["a", 148], ["variety", 150], ["of", 158], ["stimuli", 161], ["such", 169], ["as", 174], ["nitric", 177], ["oxide", 184], [",", 189], ["growth", 191], ["factors", 198], [",", 205], ["and", 207], ["hypoxia", 211], ["-", 218], ["inducible", 219], ["factor-1", 229], ["alpha", 238], ["(", 244], ["HIF-1\u03b1", 245], [")", 251], [".", 252], ["Recently", 254], [",", 262], ["inhibition", 264], ["of", 275], ["the", 278], ["mammalian", 282], ["target", 292], ["of", 299], ["rapamycin", 302], ["(", 312], ["mTOR", 313], [")", 317], ["has", 319], ["been", 323], ["shown", 328], ["to", 334], ["alleviate", 337], ["cardinal", 347], ["asthmatic", 356], ["features", 366], [",", 374], ["including", 376], ["airway", 386], ["hyperresponsiveness", 393], [",", 412], ["eosinophilic", 414], ["inflammation", 427], [",", 439], ["and", 441], ["increased", 445], ["vascular", 455], ["permeability", 464], ["in", 477], ["asthma", 480], ["models", 487], [".", 493], ["Based", 495], ["on", 501], ["these", 504], ["observations", 510], [",", 522], ["we", 524], ["have", 527], ["investigated", 532], ["whether", 545], ["mTOR", 553], ["is", 558], ["associated", 561], ["with", 572], ["HIF-1\u03b1", 577], ["-", 583], ["mediated", 584], ["VEGF", 593], ["expression", 598], ["in", 609], ["allergic", 612], ["asthma", 621], [".", 627], ["In", 629], ["studies", 632], ["with", 640], ["the", 645], ["mTOR", 649], ["inhibitor", 654], ["rapamycin", 664], [",", 673], ["we", 675], ["have", 678], ["elucidated", 683], ["the", 694], ["stimulatory", 698], ["role", 710], ["of", 715], ["a", 718], ["mTOR", 720], ["-", 724], ["HIF-1\u03b1", 725], ["-", 731], ["VEGF", 732], ["axis", 737], ["in", 742], ["allergic", 745], ["response", 754], [".", 762], ["Next", 764], [",", 768], ["the", 770], ["mechanisms", 774], ["by", 785], ["which", 788], ["mTOR", 794], ["is", 799], ["activated", 802], ["to", 812], ["modulate", 815], ["this", 824], ["response", 829], ["have", 838], ["been", 843], ["evaluated", 848], [".", 857], ["mTOR", 859], ["is", 864], ["known", 867], ["to", 873], ["be", 876], ["regulated", 879], ["by", 889], ["phosphoinositide", 892], ["3-kinase", 909], ["(", 918], ["PI3K)/Akt", 919], ["or", 929], ["protein", 932], ["kinase", 940], ["C", 947], ["-", 948], ["delta", 949], ["(", 955], ["PKC", 956], ["\u03b4", 960], [")", 961], ["in", 963], ["various", 966], ["cell", 974], ["types", 979], [".", 984], ["Consistent", 986], ["with", 997], ["these", 1002], [",", 1007], ["our", 1009], ["results", 1013], ["have", 1021], ["revealed", 1026], ["that", 1035], ["suppression", 1040], ["of", 1052], ["PKC", 1055], ["\u03b4", 1059], ["by", 1061], ["rottlerin", 1064], ["leads", 1074], ["to", 1080], ["the", 1083], ["inhibition", 1087], ["of", 1098], ["PI3K", 1101], ["/", 1105], ["Akt", 1106], ["activity", 1110], ["and", 1119], ["the", 1123], ["subsequent", 1127], ["blockade", 1138], ["of", 1147], ["a", 1150], ["mTOR", 1152], ["-", 1156], ["HIF-1\u03b1", 1157], ["-", 1163], ["VEGF", 1164], ["module", 1169], [",", 1175], ["thereby", 1177], ["attenuating", 1185], ["typical", 1197], ["asthmatic", 1205], ["attack", 1215], ["in", 1222], ["a", 1225], ["murine", 1227], ["model", 1234], [".", 1239], ["Thus", 1241], [",", 1245], ["the", 1247], ["present", 1251], ["data", 1259], ["indicate", 1264], ["that", 1273], ["PKC", 1278], ["\u03b4", 1282], ["is", 1284], ["necessary", 1287], ["for", 1297], ["the", 1301], ["modulation", 1305], ["of", 1316], ["the", 1319], ["PI3K", 1323], ["/", 1327], ["Akt", 1328], ["/", 1331], ["mTOR", 1332], ["signaling", 1337], ["cascade", 1347], [",", 1354], ["resulting", 1356], ["in", 1366], ["a", 1369], ["tight", 1371], ["regulation", 1377], ["of", 1388], ["HIF-1\u03b1", 1391], ["activity", 1398], ["and", 1407], ["VEGF", 1411], ["expression", 1416], [".", 1426], ["In", 1428], ["conclusion", 1431], [",", 1441], ["PKC", 1443], ["\u03b4", 1447], ["may", 1449], ["represent", 1453], ["a", 1463], ["valuable", 1465], ["target", 1474], ["for", 1481], ["innovative", 1485], ["therapeutic", 1496], ["treatment", 1508], ["of", 1518], ["allergic", 1521], ["airway", 1530], ["disease", 1537], [".", 1544]]}
{"context": "Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome. Turner syndrome effects 1 in every 2000 live births. Short stature is a cardinal feature of Turner Syndrome and the standard treatment is recombinant human growth hormone. When growth hormone is started at an early age a normal adult height can be achieved. With delayed diagnosis young women with Turner Syndrome may not reach a normal height. Adjuvant therapy with oxandrolone is used but there is no consensus on the optimal timing of treatment, the duration of treatment and the long term adverse effects of treatment. The objective of this review and meta-analysis is to examine the effect of oxandrolone on adult height in growth hormone treated Turner syndrome patients. Eligible trials were identified by a literature search using the terms: Turner syndrome, oxandrolone. The search was limited to English language randomized-controlled trials after 1980. Twenty-six articles were reviewed and four were included in the meta-analysis. A random effects model was used to calculate an effect size and confidence interval. The pooled effect size of 2.0759 (95\u00a0% CI 0.0988 to 4.0529) indicates that oxandrolone has a positive effect on adult height in Turner syndrome when combined with growth hormone therapy. In conclusion, the addition of oxandrolone to growth hormone therapy for treatment of short stature in Turner syndrome improves adult height. Further studies are warranted to investigate if there is a subset of Turner syndrome patients that would benefit most from growth hormone plus oxandrolone therapy, and to determine the optimal timing and duration of such therapy.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "1a3826a79f32433bb7acdf6f53049b19", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[16, 16]], "char_spans": [[98, 98]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["chromosomal", 21], ["abnormality", 33], ["in", 45], ["which", 48], ["there", 54], ["is", 60], ["complete", 63], ["or", 72], ["partial", 75], ["absence", 83], ["of", 91], ["the", 94], ["X", 98], ["chromosome", 100], [".", 110], ["Turner", 112], ["syndrome", 119], ["effects", 128], ["1", 136], ["in", 138], ["every", 141], ["2000", 147], ["live", 152], ["births", 157], [".", 163], ["Short", 165], ["stature", 171], ["is", 179], ["a", 182], ["cardinal", 184], ["feature", 193], ["of", 201], ["Turner", 204], ["Syndrome", 211], ["and", 220], ["the", 224], ["standard", 228], ["treatment", 237], ["is", 247], ["recombinant", 250], ["human", 262], ["growth", 268], ["hormone", 275], [".", 282], ["When", 284], ["growth", 289], ["hormone", 296], ["is", 304], ["started", 307], ["at", 315], ["an", 318], ["early", 321], ["age", 327], ["a", 331], ["normal", 333], ["adult", 340], ["height", 346], ["can", 353], ["be", 357], ["achieved", 360], [".", 368], ["With", 370], ["delayed", 375], ["diagnosis", 383], ["young", 393], ["women", 399], ["with", 405], ["Turner", 410], ["Syndrome", 417], ["may", 426], ["not", 430], ["reach", 434], ["a", 440], ["normal", 442], ["height", 449], [".", 455], ["Adjuvant", 457], ["therapy", 466], ["with", 474], ["oxandrolone", 479], ["is", 491], ["used", 494], ["but", 499], ["there", 503], ["is", 509], ["no", 512], ["consensus", 515], ["on", 525], ["the", 528], ["optimal", 532], ["timing", 540], ["of", 547], ["treatment", 550], [",", 559], ["the", 561], ["duration", 565], ["of", 574], ["treatment", 577], ["and", 587], ["the", 591], ["long", 595], ["term", 600], ["adverse", 605], ["effects", 613], ["of", 621], ["treatment", 624], [".", 633], ["The", 635], ["objective", 639], ["of", 649], ["this", 652], ["review", 657], ["and", 664], ["meta", 668], ["-", 672], ["analysis", 673], ["is", 682], ["to", 685], ["examine", 688], ["the", 696], ["effect", 700], ["of", 707], ["oxandrolone", 710], ["on", 722], ["adult", 725], ["height", 731], ["in", 738], ["growth", 741], ["hormone", 748], ["treated", 756], ["Turner", 764], ["syndrome", 771], ["patients", 780], [".", 788], ["Eligible", 790], ["trials", 799], ["were", 806], ["identified", 811], ["by", 822], ["a", 825], ["literature", 827], ["search", 838], ["using", 845], ["the", 851], ["terms", 855], [":", 860], ["Turner", 862], ["syndrome", 869], [",", 877], ["oxandrolone", 879], [".", 890], ["The", 892], ["search", 896], ["was", 903], ["limited", 907], ["to", 915], ["English", 918], ["language", 926], ["randomized", 935], ["-", 945], ["controlled", 946], ["trials", 957], ["after", 964], ["1980", 970], [".", 974], ["Twenty", 976], ["-", 982], ["six", 983], ["articles", 987], ["were", 996], ["reviewed", 1001], ["and", 1010], ["four", 1014], ["were", 1019], ["included", 1024], ["in", 1033], ["the", 1036], ["meta", 1040], ["-", 1044], ["analysis", 1045], [".", 1053], ["A", 1055], ["random", 1057], ["effects", 1064], ["model", 1072], ["was", 1078], ["used", 1082], ["to", 1087], ["calculate", 1090], ["an", 1100], ["effect", 1103], ["size", 1110], ["and", 1115], ["confidence", 1119], ["interval", 1130], [".", 1138], ["The", 1140], ["pooled", 1144], ["effect", 1151], ["size", 1158], ["of", 1163], ["2.0759", 1166], ["(", 1173], ["95", 1174], ["%", 1177], ["CI", 1179], ["0.0988", 1182], ["to", 1189], ["4.0529", 1192], [")", 1198], ["indicates", 1200], ["that", 1210], ["oxandrolone", 1215], ["has", 1227], ["a", 1231], ["positive", 1233], ["effect", 1242], ["on", 1249], ["adult", 1252], ["height", 1258], ["in", 1265], ["Turner", 1268], ["syndrome", 1275], ["when", 1284], ["combined", 1289], ["with", 1298], ["growth", 1303], ["hormone", 1310], ["therapy", 1318], [".", 1325], ["In", 1327], ["conclusion", 1330], [",", 1340], ["the", 1342], ["addition", 1346], ["of", 1355], ["oxandrolone", 1358], ["to", 1370], ["growth", 1373], ["hormone", 1380], ["therapy", 1388], ["for", 1396], ["treatment", 1400], ["of", 1410], ["short", 1413], ["stature", 1419], ["in", 1427], ["Turner", 1430], ["syndrome", 1437], ["improves", 1446], ["adult", 1455], ["height", 1461], [".", 1467], ["Further", 1469], ["studies", 1477], ["are", 1485], ["warranted", 1489], ["to", 1499], ["investigate", 1502], ["if", 1514], ["there", 1517], ["is", 1523], ["a", 1526], ["subset", 1528], ["of", 1535], ["Turner", 1538], ["syndrome", 1545], ["patients", 1554], ["that", 1563], ["would", 1568], ["benefit", 1574], ["most", 1582], ["from", 1587], ["growth", 1592], ["hormone", 1599], ["plus", 1607], ["oxandrolone", 1612], ["therapy", 1624], [",", 1631], ["and", 1633], ["to", 1637], ["determine", 1640], ["the", 1650], ["optimal", 1654], ["timing", 1662], ["and", 1669], ["duration", 1673], ["of", 1682], ["such", 1685], ["therapy", 1690], [".", 1697]]}
{"context": "One major hallmark of Alzheimer's disease (AD) is the massive loss of synapses that occurs at an early clinical stage of the disease. In this study, we characterize alterations in spine density and the expression of synapse-associated immediate early gene Arc (activity-regulated cytoskeleton-associated protein) in the hippocampal CA1 regions of two different amyloid precursor protein (APP) transgenic mouse lines before plaque development and their connection to performance in hippocampus-dependent memory tests. The density of mushroom-type spines was reduced by 34% in the basal dendrites proximal to the soma of CA1 pyramidal neurons in 5.5-month-old Tg2576 mice, carrying the Swedish mutation, compared with wild-type littermates. A similar reduction of 42% was confirmed in the same region of 8-month-old APP/Lo mice, carrying the London mutation. In this strain, the reduction extended to the distal dendritic spines (28%), although no differences were found in apical dendrites in either transgenic mouse line. Both transgenic mice lines presented a significant increase in Arc protein expression in CA1 compared with controls, suggesting rather an overactivity and increased spine turnover that was supported by a significant decrease in number of somatostatin-immunopositive inhibitory interneurons in the stratum oriens of CA1. Behaviorally, the transgenic mice showed decrease freezing in the fear contextual conditioning test and impairment in spatial memory assessed by Morris water maze test. These data indicate that cognitive impairment in APP transgenic mice is correlated with impairment of synaptic connectivity in hippocampal CA1, probably attributable to loss of inhibitory interneurons and subsequent hyperactivity.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "a55e414441024908948b22932972e090", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[4, 6]], "char_spans": [[22, 40]]}, {"text": "AD", "token_spans": [[8, 8]], "char_spans": [[43, 44]]}]}], "context_tokens": [["One", 0], ["major", 4], ["hallmark", 10], ["of", 19], ["Alzheimer", 22], ["'s", 31], ["disease", 34], ["(", 42], ["AD", 43], [")", 45], ["is", 47], ["the", 50], ["massive", 54], ["loss", 62], ["of", 67], ["synapses", 70], ["that", 79], ["occurs", 84], ["at", 91], ["an", 94], ["early", 97], ["clinical", 103], ["stage", 112], ["of", 118], ["the", 121], ["disease", 125], [".", 132], ["In", 134], ["this", 137], ["study", 142], [",", 147], ["we", 149], ["characterize", 152], ["alterations", 165], ["in", 177], ["spine", 180], ["density", 186], ["and", 194], ["the", 198], ["expression", 202], ["of", 213], ["synapse", 216], ["-", 223], ["associated", 224], ["immediate", 235], ["early", 245], ["gene", 251], ["Arc", 256], ["(", 260], ["activity", 261], ["-", 269], ["regulated", 270], ["cytoskeleton", 280], ["-", 292], ["associated", 293], ["protein", 304], [")", 311], ["in", 313], ["the", 316], ["hippocampal", 320], ["CA1", 332], ["regions", 336], ["of", 344], ["two", 347], ["different", 351], ["amyloid", 361], ["precursor", 369], ["protein", 379], ["(", 387], ["APP", 388], [")", 391], ["transgenic", 393], ["mouse", 404], ["lines", 410], ["before", 416], ["plaque", 423], ["development", 430], ["and", 442], ["their", 446], ["connection", 452], ["to", 463], ["performance", 466], ["in", 478], ["hippocampus", 481], ["-", 492], ["dependent", 493], ["memory", 503], ["tests", 510], [".", 515], ["The", 517], ["density", 521], ["of", 529], ["mushroom", 532], ["-", 540], ["type", 541], ["spines", 546], ["was", 553], ["reduced", 557], ["by", 565], ["34", 568], ["%", 570], ["in", 572], ["the", 575], ["basal", 579], ["dendrites", 585], ["proximal", 595], ["to", 604], ["the", 607], ["soma", 611], ["of", 616], ["CA1", 619], ["pyramidal", 623], ["neurons", 633], ["in", 641], ["5.5-month", 644], ["-", 653], ["old", 654], ["Tg2576", 658], ["mice", 665], [",", 669], ["carrying", 671], ["the", 680], ["Swedish", 684], ["mutation", 692], [",", 700], ["compared", 702], ["with", 711], ["wild", 716], ["-", 720], ["type", 721], ["littermates", 726], [".", 737], ["A", 739], ["similar", 741], ["reduction", 749], ["of", 759], ["42", 762], ["%", 764], ["was", 766], ["confirmed", 770], ["in", 780], ["the", 783], ["same", 787], ["region", 792], ["of", 799], ["8-month", 802], ["-", 809], ["old", 810], ["APP", 814], ["/", 817], ["Lo", 818], ["mice", 821], [",", 825], ["carrying", 827], ["the", 836], ["London", 840], ["mutation", 847], [".", 855], ["In", 857], ["this", 860], ["strain", 865], [",", 871], ["the", 873], ["reduction", 877], ["extended", 887], ["to", 896], ["the", 899], ["distal", 903], ["dendritic", 910], ["spines", 920], ["(", 927], ["28", 928], ["%", 930], [")", 931], [",", 932], ["although", 934], ["no", 943], ["differences", 946], ["were", 958], ["found", 963], ["in", 969], ["apical", 972], ["dendrites", 979], ["in", 989], ["either", 992], ["transgenic", 999], ["mouse", 1010], ["line", 1016], [".", 1020], ["Both", 1022], ["transgenic", 1027], ["mice", 1038], ["lines", 1043], ["presented", 1049], ["a", 1059], ["significant", 1061], ["increase", 1073], ["in", 1082], ["Arc", 1085], ["protein", 1089], ["expression", 1097], ["in", 1108], ["CA1", 1111], ["compared", 1115], ["with", 1124], ["controls", 1129], [",", 1137], ["suggesting", 1139], ["rather", 1150], ["an", 1157], ["overactivity", 1160], ["and", 1173], ["increased", 1177], ["spine", 1187], ["turnover", 1193], ["that", 1202], ["was", 1207], ["supported", 1211], ["by", 1221], ["a", 1224], ["significant", 1226], ["decrease", 1238], ["in", 1247], ["number", 1250], ["of", 1257], ["somatostatin", 1260], ["-", 1272], ["immunopositive", 1273], ["inhibitory", 1288], ["interneurons", 1299], ["in", 1312], ["the", 1315], ["stratum", 1319], ["oriens", 1327], ["of", 1334], ["CA1", 1337], [".", 1340], ["Behaviorally", 1342], [",", 1354], ["the", 1356], ["transgenic", 1360], ["mice", 1371], ["showed", 1376], ["decrease", 1383], ["freezing", 1392], ["in", 1401], ["the", 1404], ["fear", 1408], ["contextual", 1413], ["conditioning", 1424], ["test", 1437], ["and", 1442], ["impairment", 1446], ["in", 1457], ["spatial", 1460], ["memory", 1468], ["assessed", 1475], ["by", 1484], ["Morris", 1487], ["water", 1494], ["maze", 1500], ["test", 1505], [".", 1509], ["These", 1511], ["data", 1517], ["indicate", 1522], ["that", 1531], ["cognitive", 1536], ["impairment", 1546], ["in", 1557], ["APP", 1560], ["transgenic", 1564], ["mice", 1575], ["is", 1580], ["correlated", 1583], ["with", 1594], ["impairment", 1599], ["of", 1610], ["synaptic", 1613], ["connectivity", 1622], ["in", 1635], ["hippocampal", 1638], ["CA1", 1650], [",", 1653], ["probably", 1655], ["attributable", 1664], ["to", 1677], ["loss", 1680], ["of", 1685], ["inhibitory", 1688], ["interneurons", 1699], ["and", 1712], ["subsequent", 1716], ["hyperactivity", 1727], [".", 1740]]}
{"context": "The antiparallel side-to-side association of spectrin alpha and beta monomers is a two-step process which occurs in seconds even at 0 degrees C and at low concentrations. Assembly involves initial contact of complementary nucleation sites on each subunit, which are located near the actin binding end of the long, flexible heterodimer rod. The minimum nucleation sites are comprised of approximately four contiguous 106-residue homologous segments or repeats. Three repeats in the nucleation site contain an 8-residue insertion and have the highest homology to the four spectrin-like repeats in alpha-actinin. The adjacent actin binding domain on the beta subunit and the adjacent EF hand motifs on the alpha subunit are not required for heterodimer assembly. The nucleation sites probably have a specific lock and key structure which defines the unique side-to-side pairing of the many homologous segments in both subunits. Assembly of spectrin heterodimers is probably most analogous to a zipper. After initial nucleation site binding, the remainder of the subunits quickly associate along their full lengths to reconstitute a normal dimer by supercoiling around each other to form a rope-like, flexible rod. Assembly is terminated if either polypeptide is interrupted by a protease cleavage. Heterozygotic mutations involving either nucleation site are predicted to affect allele incorporation into the mature membrane skeleton.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "6f535f0663104aabbe0325e73769505f", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[1, 1]], "char_spans": [[4, 15]]}]}], "context_tokens": [["The", 0], ["antiparallel", 4], ["side", 17], ["-", 21], ["to", 22], ["-", 24], ["side", 25], ["association", 30], ["of", 42], ["spectrin", 45], ["alpha", 54], ["and", 60], ["beta", 64], ["monomers", 69], ["is", 78], ["a", 81], ["two", 83], ["-", 86], ["step", 87], ["process", 92], ["which", 100], ["occurs", 106], ["in", 113], ["seconds", 116], ["even", 124], ["at", 129], ["0", 132], ["degrees", 134], ["C", 142], ["and", 144], ["at", 148], ["low", 151], ["concentrations", 155], [".", 169], ["Assembly", 171], ["involves", 180], ["initial", 189], ["contact", 197], ["of", 205], ["complementary", 208], ["nucleation", 222], ["sites", 233], ["on", 239], ["each", 242], ["subunit", 247], [",", 254], ["which", 256], ["are", 262], ["located", 266], ["near", 274], ["the", 279], ["actin", 283], ["binding", 289], ["end", 297], ["of", 301], ["the", 304], ["long", 308], [",", 312], ["flexible", 314], ["heterodimer", 323], ["rod", 335], [".", 338], ["The", 340], ["minimum", 344], ["nucleation", 352], ["sites", 363], ["are", 369], ["comprised", 373], ["of", 383], ["approximately", 386], ["four", 400], ["contiguous", 405], ["106-residue", 416], ["homologous", 428], ["segments", 439], ["or", 448], ["repeats", 451], [".", 458], ["Three", 460], ["repeats", 466], ["in", 474], ["the", 477], ["nucleation", 481], ["site", 492], ["contain", 497], ["an", 505], ["8-residue", 508], ["insertion", 518], ["and", 528], ["have", 532], ["the", 537], ["highest", 541], ["homology", 549], ["to", 558], ["the", 561], ["four", 565], ["spectrin", 570], ["-", 578], ["like", 579], ["repeats", 584], ["in", 592], ["alpha", 595], ["-", 600], ["actinin", 601], [".", 608], ["The", 610], ["adjacent", 614], ["actin", 623], ["binding", 629], ["domain", 637], ["on", 644], ["the", 647], ["beta", 651], ["subunit", 656], ["and", 664], ["the", 668], ["adjacent", 672], ["EF", 681], ["hand", 684], ["motifs", 689], ["on", 696], ["the", 699], ["alpha", 703], ["subunit", 709], ["are", 717], ["not", 721], ["required", 725], ["for", 734], ["heterodimer", 738], ["assembly", 750], [".", 758], ["The", 760], ["nucleation", 764], ["sites", 775], ["probably", 781], ["have", 790], ["a", 795], ["specific", 797], ["lock", 806], ["and", 811], ["key", 815], ["structure", 819], ["which", 829], ["defines", 835], ["the", 843], ["unique", 847], ["side", 854], ["-", 858], ["to", 859], ["-", 861], ["side", 862], ["pairing", 867], ["of", 875], ["the", 878], ["many", 882], ["homologous", 887], ["segments", 898], ["in", 907], ["both", 910], ["subunits", 915], [".", 923], ["Assembly", 925], ["of", 934], ["spectrin", 937], ["heterodimers", 946], ["is", 959], ["probably", 962], ["most", 971], ["analogous", 976], ["to", 986], ["a", 989], ["zipper", 991], [".", 997], ["After", 999], ["initial", 1005], ["nucleation", 1013], ["site", 1024], ["binding", 1029], [",", 1036], ["the", 1038], ["remainder", 1042], ["of", 1052], ["the", 1055], ["subunits", 1059], ["quickly", 1068], ["associate", 1076], ["along", 1086], ["their", 1092], ["full", 1098], ["lengths", 1103], ["to", 1111], ["reconstitute", 1114], ["a", 1127], ["normal", 1129], ["dimer", 1136], ["by", 1142], ["supercoiling", 1145], ["around", 1158], ["each", 1165], ["other", 1170], ["to", 1176], ["form", 1179], ["a", 1184], ["rope", 1186], ["-", 1190], ["like", 1191], [",", 1195], ["flexible", 1197], ["rod", 1206], [".", 1209], ["Assembly", 1211], ["is", 1220], ["terminated", 1223], ["if", 1234], ["either", 1237], ["polypeptide", 1244], ["is", 1256], ["interrupted", 1259], ["by", 1271], ["a", 1274], ["protease", 1276], ["cleavage", 1285], [".", 1293], ["Heterozygotic", 1295], ["mutations", 1309], ["involving", 1319], ["either", 1329], ["nucleation", 1336], ["site", 1347], ["are", 1352], ["predicted", 1356], ["to", 1366], ["affect", 1369], ["allele", 1376], ["incorporation", 1383], ["into", 1397], ["the", 1402], ["mature", 1406], ["membrane", 1413], ["skeleton", 1422], [".", 1430]]}
{"context": "Lewy bodies and Lewy neurites are the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. They are made of abnormal filamentous assemblies of unknown composition. We show here that Lewy bodies and Lewy neurites from Parkinson's disease and dementia with Lewy bodies are stained strongly by antibodies directed against amino-terminal and carboxyl-terminal sequences of alpha-synuclein, showing the presence of full-length or close to full-length alpha-synuclein. The number of alpha-synuclein-stained structures exceeded that immunoreactive for ubiquitin, which is currently the most sensitive marker of Lewy bodies and Lewy neurites. Staining for alpha-synuclein thus will replace staining for ubiquitin as the preferred method for detecting Lewy bodies and Lewy neurites. We have isolated Lewy body filaments by a method used for the extraction of paired helical filaments from Alzheimer's disease brain. By immunoelectron microscopy, extracted filaments were labeled strongly by anti-alpha-synuclein antibodies. The morphologies of the 5- to 10-nm filaments and their staining characteristics suggest that extended alpha-synuclein molecules run parallel to the filament axis and that the filaments are polar structures. These findings indicate that alpha-synuclein forms the major filamentous component of Lewy bodies and Lewy neurites.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "74f41b3184c1456789908466697ca25d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[65, 67], [193, 195], [173, 175], [117, 119], [89, 91], [82, 84], [215, 217]], "char_spans": [[413, 427], [1162, 1176], [1031, 1045], [692, 706], [521, 535], [490, 504], [1296, 1310]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], ["and", 12], ["Lewy", 16], ["neurites", 21], ["are", 30], ["the", 34], ["defining", 38], ["neuropathological", 47], ["characteristics", 65], ["of", 81], ["Parkinson", 84], ["'s", 93], ["disease", 96], ["and", 104], ["dementia", 108], ["with", 117], ["Lewy", 122], ["bodies", 127], [".", 133], ["They", 135], ["are", 140], ["made", 144], ["of", 149], ["abnormal", 152], ["filamentous", 161], ["assemblies", 173], ["of", 184], ["unknown", 187], ["composition", 195], [".", 206], ["We", 208], ["show", 211], ["here", 216], ["that", 221], ["Lewy", 226], ["bodies", 231], ["and", 238], ["Lewy", 242], ["neurites", 247], ["from", 256], ["Parkinson", 261], ["'s", 270], ["disease", 273], ["and", 281], ["dementia", 285], ["with", 294], ["Lewy", 299], ["bodies", 304], ["are", 311], ["stained", 315], ["strongly", 323], ["by", 332], ["antibodies", 335], ["directed", 346], ["against", 355], ["amino", 363], ["-", 368], ["terminal", 369], ["and", 378], ["carboxyl", 382], ["-", 390], ["terminal", 391], ["sequences", 400], ["of", 410], ["alpha", 413], ["-", 418], ["synuclein", 419], [",", 428], ["showing", 430], ["the", 438], ["presence", 442], ["of", 451], ["full", 454], ["-", 458], ["length", 459], ["or", 466], ["close", 469], ["to", 475], ["full", 478], ["-", 482], ["length", 483], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["The", 507], ["number", 511], ["of", 518], ["alpha", 521], ["-", 526], ["synuclein", 527], ["-", 536], ["stained", 537], ["structures", 545], ["exceeded", 556], ["that", 565], ["immunoreactive", 570], ["for", 585], ["ubiquitin", 589], [",", 598], ["which", 600], ["is", 606], ["currently", 609], ["the", 619], ["most", 623], ["sensitive", 628], ["marker", 638], ["of", 645], ["Lewy", 648], ["bodies", 653], ["and", 660], ["Lewy", 664], ["neurites", 669], [".", 677], ["Staining", 679], ["for", 688], ["alpha", 692], ["-", 697], ["synuclein", 698], ["thus", 708], ["will", 713], ["replace", 718], ["staining", 726], ["for", 735], ["ubiquitin", 739], ["as", 749], ["the", 752], ["preferred", 756], ["method", 766], ["for", 773], ["detecting", 777], ["Lewy", 787], ["bodies", 792], ["and", 799], ["Lewy", 803], ["neurites", 808], [".", 816], ["We", 818], ["have", 821], ["isolated", 826], ["Lewy", 835], ["body", 840], ["filaments", 845], ["by", 855], ["a", 858], ["method", 860], ["used", 867], ["for", 872], ["the", 876], ["extraction", 880], ["of", 891], ["paired", 894], ["helical", 901], ["filaments", 909], ["from", 919], ["Alzheimer", 924], ["'s", 933], ["disease", 936], ["brain", 944], [".", 949], ["By", 951], ["immunoelectron", 954], ["microscopy", 969], [",", 979], ["extracted", 981], ["filaments", 991], ["were", 1001], ["labeled", 1006], ["strongly", 1014], ["by", 1023], ["anti", 1026], ["-", 1030], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["antibodies", 1047], [".", 1057], ["The", 1059], ["morphologies", 1063], ["of", 1076], ["the", 1079], ["5-", 1083], ["to", 1086], ["10-nm", 1089], ["filaments", 1095], ["and", 1105], ["their", 1109], ["staining", 1115], ["characteristics", 1124], ["suggest", 1140], ["that", 1148], ["extended", 1153], ["alpha", 1162], ["-", 1167], ["synuclein", 1168], ["molecules", 1178], ["run", 1188], ["parallel", 1192], ["to", 1201], ["the", 1204], ["filament", 1208], ["axis", 1217], ["and", 1222], ["that", 1226], ["the", 1231], ["filaments", 1235], ["are", 1245], ["polar", 1249], ["structures", 1255], [".", 1265], ["These", 1267], ["findings", 1273], ["indicate", 1282], ["that", 1291], ["alpha", 1296], ["-", 1301], ["synuclein", 1302], ["forms", 1312], ["the", 1318], ["major", 1322], ["filamentous", 1328], ["component", 1340], ["of", 1350], ["Lewy", 1353], ["bodies", 1358], ["and", 1365], ["Lewy", 1369], ["neurites", 1374], [".", 1382]]}
{"context": "Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known molecular basis of CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate. However, the success of tyrosine kinase inhibitors, as rationally designed first-line therapies, has been tempered by problems of disease persistence and resistance. Residual disease has been shown to be enriched within the stem cell compartment and to persist at stable levels for up to 5 years of complete cytogenetic response. This finding has led to further searches for novel strategies aimed at eliminating these cells; such strategies may be essential in achieving cure. The most significant recent findings are discussed in this review.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "064cad30ab174490b41457be0ef1e8e3", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[21, 23]], "char_spans": [[133, 139]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["arises", 31], ["as", 38], ["a", 41], ["consequence", 43], ["of", 55], ["a", 58], ["chromosomal", 60], ["translocation", 72], ["giving", 86], ["rise", 93], ["to", 98], ["the", 101], ["Philadelphia", 105], ["chromosome", 118], ["and", 129], ["Bcr", 133], ["-", 136], ["Abl", 137], ["oncogene", 141], [".", 149], ["CML", 151], ["is", 155], ["a", 158], ["clonal", 160], ["disease", 167], ["of", 175], ["stem", 178], ["cell", 183], ["origin", 188], ["and", 195], ["an", 199], ["excellent", 202], ["example", 212], ["of", 220], ["a", 223], ["malignancy", 225], ["in", 236], ["which", 239], ["tumor", 245], ["-", 250], ["initiating", 251], ["cells", 262], ["may", 268], ["hold", 272], ["the", 277], ["key", 281], ["to", 285], ["disease", 288], ["eradication", 296], [".", 307], ["The", 309], ["known", 313], ["molecular", 319], ["basis", 329], ["of", 335], ["CML", 338], ["has", 342], ["enabled", 346], ["the", 354], ["development", 358], ["of", 370], ["Abl", 373], ["-", 376], ["specific", 377], ["tyrosine", 386], ["kinase", 395], ["inhibitors", 402], [",", 412], ["such", 414], ["as", 419], ["imatinib", 422], ["mesylate", 431], [".", 439], ["However", 441], [",", 448], ["the", 450], ["success", 454], ["of", 462], ["tyrosine", 465], ["kinase", 474], ["inhibitors", 481], [",", 491], ["as", 493], ["rationally", 496], ["designed", 507], ["first", 516], ["-", 521], ["line", 522], ["therapies", 527], [",", 536], ["has", 538], ["been", 542], ["tempered", 547], ["by", 556], ["problems", 559], ["of", 568], ["disease", 571], ["persistence", 579], ["and", 591], ["resistance", 595], [".", 605], ["Residual", 607], ["disease", 616], ["has", 624], ["been", 628], ["shown", 633], ["to", 639], ["be", 642], ["enriched", 645], ["within", 654], ["the", 661], ["stem", 665], ["cell", 670], ["compartment", 675], ["and", 687], ["to", 691], ["persist", 694], ["at", 702], ["stable", 705], ["levels", 712], ["for", 719], ["up", 723], ["to", 726], ["5", 729], ["years", 731], ["of", 737], ["complete", 740], ["cytogenetic", 749], ["response", 761], [".", 769], ["This", 771], ["finding", 776], ["has", 784], ["led", 788], ["to", 792], ["further", 795], ["searches", 803], ["for", 812], ["novel", 816], ["strategies", 822], ["aimed", 833], ["at", 839], ["eliminating", 842], ["these", 854], ["cells", 860], [";", 865], ["such", 867], ["strategies", 872], ["may", 883], ["be", 887], ["essential", 890], ["in", 900], ["achieving", 903], ["cure", 913], [".", 917], ["The", 919], ["most", 923], ["significant", 928], ["recent", 940], ["findings", 947], ["are", 956], ["discussed", 960], ["in", 970], ["this", 973], ["review", 978], [".", 984]]}
{"context": "Using targeted next generation sequencing, we have identified a splicing mutation (c.526-9_526-5del) in the SLC9A6 gene in a 9-year-old boy with mild intellectual disability (ID), microcephaly, and social interaction disabilities. This intronic microdeletion leads to the skipping of exon 3 and to an in-frame deletion of 26 amino acids in the TM4 domain. It segregates with cognitive impairment or learning difficulties in other members of the family. Mutations in SLC9A6 have been reported in X-linked Christianson syndrome associating severe to profound intellectual deficiency and an Angelman-like phenotype with microcephaly, absent speech, ataxia with progressive cerebellar atrophy, ophthalmoplegia, epilepsy, and neurological regression. The proband and his maternal uncle both have an attenuated phenotype with mild ID, attention deficit disorder, speech difficulties, and mild asymptomatic cerebellar atrophy. The proband also have microcephaly. The mutation cosegregated with learning disabilities and speech difficulties in the female carriers (mother and three sisters of the proband). Detailed neuropsychological, speech, and occupational therapy investigations in the female carriers revealed impaired oral and written language acquisition, with dissociation between verbal and performance IQ. An abnormal phenotype, ranging from learning disability with predominant speech difficulties to mild intellectual deficiency, has been described previously in a large proportion of female carriers. Besides broadening the clinical spectrum of SLC9A6 gene mutations, we present an example of a monogenic origin of mild learning disability. \u00a9 2016 Wiley Periodicals, Inc.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "c2555b0ac9b54ee5827e62554a179317", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[87, 87], [21, 21], [250, 250]], "char_spans": [[466, 471], [108, 113], [1551, 1556]]}]}], "context_tokens": [["Using", 0], ["targeted", 6], ["next", 15], ["generation", 20], ["sequencing", 31], [",", 41], ["we", 43], ["have", 46], ["identified", 51], ["a", 62], ["splicing", 64], ["mutation", 73], ["(", 82], ["c.526", 83], ["-", 88], ["9_526", 89], ["-", 94], ["5del", 95], [")", 99], ["in", 101], ["the", 104], ["SLC9A6", 108], ["gene", 115], ["in", 120], ["a", 123], ["9-year", 125], ["-", 131], ["old", 132], ["boy", 136], ["with", 140], ["mild", 145], ["intellectual", 150], ["disability", 163], ["(", 174], ["ID", 175], [")", 177], [",", 178], ["microcephaly", 180], [",", 192], ["and", 194], ["social", 198], ["interaction", 205], ["disabilities", 217], [".", 229], ["This", 231], ["intronic", 236], ["microdeletion", 245], ["leads", 259], ["to", 265], ["the", 268], ["skipping", 272], ["of", 281], ["exon", 284], ["3", 289], ["and", 291], ["to", 295], ["an", 298], ["in", 301], ["-", 303], ["frame", 304], ["deletion", 310], ["of", 319], ["26", 322], ["amino", 325], ["acids", 331], ["in", 337], ["the", 340], ["TM4", 344], ["domain", 348], [".", 354], ["It", 356], ["segregates", 359], ["with", 370], ["cognitive", 375], ["impairment", 385], ["or", 396], ["learning", 399], ["difficulties", 408], ["in", 421], ["other", 424], ["members", 430], ["of", 438], ["the", 441], ["family", 445], [".", 451], ["Mutations", 453], ["in", 463], ["SLC9A6", 466], ["have", 473], ["been", 478], ["reported", 483], ["in", 492], ["X", 495], ["-", 496], ["linked", 497], ["Christianson", 504], ["syndrome", 517], ["associating", 526], ["severe", 538], ["to", 545], ["profound", 548], ["intellectual", 557], ["deficiency", 570], ["and", 581], ["an", 585], ["Angelman", 588], ["-", 596], ["like", 597], ["phenotype", 602], ["with", 612], ["microcephaly", 617], [",", 629], ["absent", 631], ["speech", 638], [",", 644], ["ataxia", 646], ["with", 653], ["progressive", 658], ["cerebellar", 670], ["atrophy", 681], [",", 688], ["ophthalmoplegia", 690], [",", 705], ["epilepsy", 707], [",", 715], ["and", 717], ["neurological", 721], ["regression", 734], [".", 744], ["The", 746], ["proband", 750], ["and", 758], ["his", 762], ["maternal", 766], ["uncle", 775], ["both", 781], ["have", 786], ["an", 791], ["attenuated", 794], ["phenotype", 805], ["with", 815], ["mild", 820], ["ID", 825], [",", 827], ["attention", 829], ["deficit", 839], ["disorder", 847], [",", 855], ["speech", 857], ["difficulties", 864], [",", 876], ["and", 878], ["mild", 882], ["asymptomatic", 887], ["cerebellar", 900], ["atrophy", 911], [".", 918], ["The", 920], ["proband", 924], ["also", 932], ["have", 937], ["microcephaly", 942], [".", 954], ["The", 956], ["mutation", 960], ["cosegregated", 969], ["with", 982], ["learning", 987], ["disabilities", 996], ["and", 1009], ["speech", 1013], ["difficulties", 1020], ["in", 1033], ["the", 1036], ["female", 1040], ["carriers", 1047], ["(", 1056], ["mother", 1057], ["and", 1064], ["three", 1068], ["sisters", 1074], ["of", 1082], ["the", 1085], ["proband", 1089], [")", 1096], [".", 1097], ["Detailed", 1099], ["neuropsychological", 1108], [",", 1126], ["speech", 1128], [",", 1134], ["and", 1136], ["occupational", 1140], ["therapy", 1153], ["investigations", 1161], ["in", 1176], ["the", 1179], ["female", 1183], ["carriers", 1190], ["revealed", 1199], ["impaired", 1208], ["oral", 1217], ["and", 1222], ["written", 1226], ["language", 1234], ["acquisition", 1243], [",", 1254], ["with", 1256], ["dissociation", 1261], ["between", 1274], ["verbal", 1282], ["and", 1289], ["performance", 1293], ["IQ", 1305], [".", 1307], ["An", 1309], ["abnormal", 1312], ["phenotype", 1321], [",", 1330], ["ranging", 1332], ["from", 1340], ["learning", 1345], ["disability", 1354], ["with", 1365], ["predominant", 1370], ["speech", 1382], ["difficulties", 1389], ["to", 1402], ["mild", 1405], ["intellectual", 1410], ["deficiency", 1423], [",", 1433], ["has", 1435], ["been", 1439], ["described", 1444], ["previously", 1454], ["in", 1465], ["a", 1468], ["large", 1470], ["proportion", 1476], ["of", 1487], ["female", 1490], ["carriers", 1497], [".", 1505], ["Besides", 1507], ["broadening", 1515], ["the", 1526], ["clinical", 1530], ["spectrum", 1539], ["of", 1548], ["SLC9A6", 1551], ["gene", 1558], ["mutations", 1563], [",", 1572], ["we", 1574], ["present", 1577], ["an", 1585], ["example", 1588], ["of", 1596], ["a", 1599], ["monogenic", 1601], ["origin", 1611], ["of", 1618], ["mild", 1621], ["learning", 1626], ["disability", 1635], [".", 1645], ["\u00a9", 1647], ["2016", 1649], ["Wiley", 1654], ["Periodicals", 1660], [",", 1671], ["Inc.", 1673]]}
{"context": "Mowat-Wilson syndrome (MWS) is a genetic disease caused by heterozygous mutations or deletions of the ZEB2 gene rarely diagnosed prenatally and with little fetal description reported. It is mainly characterized by moderate-to-severe intellectual disability, epilepsy, facial dysmorphism and various malformations including Hirschsprung disease and corpus callosum anomalies. Here we report a fetal case of MWS well described, suspected at standard autopsy. The association of a corpus callosum hypoplasia with a histological Hirschsprung disease and a typical facial gestalt allowed the guiding of genetic testing. Classical fetopathological examination still keeps indications in cases of syndromic association in the era of virtual autopsy.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "111434d707cf40b1b4d6056ddfc2f280", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[19, 19]], "char_spans": [[102, 105]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["genetic", 33], ["disease", 41], ["caused", 49], ["by", 56], ["heterozygous", 59], ["mutations", 72], ["or", 82], ["deletions", 85], ["of", 95], ["the", 98], ["ZEB2", 102], ["gene", 107], ["rarely", 112], ["diagnosed", 119], ["prenatally", 129], ["and", 140], ["with", 144], ["little", 149], ["fetal", 156], ["description", 162], ["reported", 174], [".", 182], ["It", 184], ["is", 187], ["mainly", 190], ["characterized", 197], ["by", 211], ["moderate", 214], ["-", 222], ["to", 223], ["-", 225], ["severe", 226], ["intellectual", 233], ["disability", 246], [",", 256], ["epilepsy", 258], [",", 266], ["facial", 268], ["dysmorphism", 275], ["and", 287], ["various", 291], ["malformations", 299], ["including", 313], ["Hirschsprung", 323], ["disease", 336], ["and", 344], ["corpus", 348], ["callosum", 355], ["anomalies", 364], [".", 373], ["Here", 375], ["we", 380], ["report", 383], ["a", 390], ["fetal", 392], ["case", 398], ["of", 403], ["MWS", 406], ["well", 410], ["described", 415], [",", 424], ["suspected", 426], ["at", 436], ["standard", 439], ["autopsy", 448], [".", 455], ["The", 457], ["association", 461], ["of", 473], ["a", 476], ["corpus", 478], ["callosum", 485], ["hypoplasia", 494], ["with", 505], ["a", 510], ["histological", 512], ["Hirschsprung", 525], ["disease", 538], ["and", 546], ["a", 550], ["typical", 552], ["facial", 560], ["gestalt", 567], ["allowed", 575], ["the", 583], ["guiding", 587], ["of", 595], ["genetic", 598], ["testing", 606], [".", 613], ["Classical", 615], ["fetopathological", 625], ["examination", 642], ["still", 654], ["keeps", 660], ["indications", 666], ["in", 678], ["cases", 681], ["of", 687], ["syndromic", 690], ["association", 700], ["in", 712], ["the", 715], ["era", 719], ["of", 723], ["virtual", 726], ["autopsy", 734], [".", 741]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder (incidence around 1 in 106 births), characterised by a complex immunologic defects, reduced pigmentation, and presence of giant granules in many different cell types. It most likely results from defective organellar trafficking or protein sorting. The causative gene (LYST) has recently been identified and shown to be homologous to the beige locus in the mouse. CHS has always been reported associated with premature-termination-codon mutations in both alleles of LYST. We report a unique patient with CHS, who was homozygous for a stop codon in the LYST gene on chromosome 1 and who had a normal 46,XY karyotype. The mother was found to be a carrier of the mutation, whereas the father had two normal LYST alleles. Non-paternity was excluded by the analysis of microsatellite markers from different chromosomes. The results of 13 informative microsatellite markers spanning the entire chromosome 1 revealed that the proband had a maternal isodisomy of chromosome 1 encompassing the LYST mutation. The proband's clinical presentation also confirms the absence of imprinted genes on chromosome 1.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "ba84f91cf9b6461d9ee02be446bcdffc", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disorder", 61], ["(", 70], ["incidence", 71], ["around", 81], ["1", 88], ["in", 90], ["106", 93], ["births", 97], [")", 103], [",", 104], ["characterised", 106], ["by", 120], ["a", 123], ["complex", 125], ["immunologic", 133], ["defects", 145], [",", 152], ["reduced", 154], ["pigmentation", 162], [",", 174], ["and", 176], ["presence", 180], ["of", 189], ["giant", 192], ["granules", 198], ["in", 207], ["many", 210], ["different", 215], ["cell", 225], ["types", 230], [".", 235], ["It", 237], ["most", 240], ["likely", 245], ["results", 252], ["from", 260], ["defective", 265], ["organellar", 275], ["trafficking", 286], ["or", 298], ["protein", 301], ["sorting", 309], [".", 316], ["The", 318], ["causative", 322], ["gene", 332], ["(", 337], ["LYST", 338], [")", 342], ["has", 344], ["recently", 348], ["been", 357], ["identified", 362], ["and", 373], ["shown", 377], ["to", 383], ["be", 386], ["homologous", 389], ["to", 400], ["the", 403], ["beige", 407], ["locus", 413], ["in", 419], ["the", 422], ["mouse", 426], [".", 431], ["CHS", 433], ["has", 437], ["always", 441], ["been", 448], ["reported", 453], ["associated", 462], ["with", 473], ["premature", 478], ["-", 487], ["termination", 488], ["-", 499], ["codon", 500], ["mutations", 506], ["in", 516], ["both", 519], ["alleles", 524], ["of", 532], ["LYST", 535], [".", 539], ["We", 541], ["report", 544], ["a", 551], ["unique", 553], ["patient", 560], ["with", 568], ["CHS", 573], [",", 576], ["who", 578], ["was", 582], ["homozygous", 586], ["for", 597], ["a", 601], ["stop", 603], ["codon", 608], ["in", 614], ["the", 617], ["LYST", 621], ["gene", 626], ["on", 631], ["chromosome", 634], ["1", 645], ["and", 647], ["who", 651], ["had", 655], ["a", 659], ["normal", 661], ["46,XY", 668], ["karyotype", 674], [".", 683], ["The", 685], ["mother", 689], ["was", 696], ["found", 700], ["to", 706], ["be", 709], ["a", 712], ["carrier", 714], ["of", 722], ["the", 725], ["mutation", 729], [",", 737], ["whereas", 739], ["the", 747], ["father", 751], ["had", 758], ["two", 762], ["normal", 766], ["LYST", 773], ["alleles", 778], [".", 785], ["Non", 787], ["-", 790], ["paternity", 791], ["was", 801], ["excluded", 805], ["by", 814], ["the", 817], ["analysis", 821], ["of", 830], ["microsatellite", 833], ["markers", 848], ["from", 856], ["different", 861], ["chromosomes", 871], [".", 882], ["The", 884], ["results", 888], ["of", 896], ["13", 899], ["informative", 902], ["microsatellite", 914], ["markers", 929], ["spanning", 937], ["the", 946], ["entire", 950], ["chromosome", 957], ["1", 968], ["revealed", 970], ["that", 979], ["the", 984], ["proband", 988], ["had", 996], ["a", 1000], ["maternal", 1002], ["isodisomy", 1011], ["of", 1021], ["chromosome", 1024], ["1", 1035], ["encompassing", 1037], ["the", 1050], ["LYST", 1054], ["mutation", 1059], [".", 1067], ["The", 1069], ["proband", 1073], ["'s", 1080], ["clinical", 1083], ["presentation", 1092], ["also", 1105], ["confirms", 1110], ["the", 1119], ["absence", 1123], ["of", 1131], ["imprinted", 1134], ["genes", 1144], ["on", 1150], ["chromosome", 1153], ["1", 1164], [".", 1165]]}
{"context": "We describe the use of four complementary biosensors (Biacore 3000, Octet QK, ProteOn XPR36, and KinExA 3000) in characterizing the kinetics of human nerve growth factor (NGF) binding to a humanized NGF-neutralizing monoclonal antibody (tanezumab, formerly known as RN624). Tanezumab is a clinical candidate as a therapy for chronic pain. Our measurements were consistent with the NGF/tanezumab binding affinity being tighter than 10 pM due to the formation of an extremely stable complex that had an estimated half-life exceeding 100 h, which was beyond the resolution of any of our methods. The system was particularly challenging to study because NGF is an obligate homodimer, and we describe various assay orientations and immobilization methods that were used to minimize avidity in our experiments while keeping NGF in as native a state as possible. We also explored the interactions of NGF with its natural receptors, TrkA and P75, and how tanezumab blocks them. The Biacore blocking assay that we designed was used to quantify the potency of tanezumab and is more precise and reproducible than the currently available cell-based functional assays.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "220f2fda6f7b4ca1a8b1ce1ca1c93bb3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[28, 30]], "char_spans": [[150, 168]]}, {"text": "NGF", "token_spans": [[32, 32], [160, 160], [70, 70], [38, 38], [119, 119], [145, 145]], "char_spans": [[171, 173], [893, 895], [381, 383], [199, 201], [650, 652], [818, 820]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["use", 16], ["of", 20], ["four", 23], ["complementary", 28], ["biosensors", 42], ["(", 53], ["Biacore", 54], ["3000", 62], [",", 66], ["Octet", 68], ["QK", 74], [",", 76], ["ProteOn", 78], ["XPR36", 86], [",", 91], ["and", 93], ["KinExA", 97], ["3000", 104], [")", 108], ["in", 110], ["characterizing", 113], ["the", 128], ["kinetics", 132], ["of", 141], ["human", 144], ["nerve", 150], ["growth", 156], ["factor", 163], ["(", 170], ["NGF", 171], [")", 174], ["binding", 176], ["to", 184], ["a", 187], ["humanized", 189], ["NGF", 199], ["-", 202], ["neutralizing", 203], ["monoclonal", 216], ["antibody", 227], ["(", 236], ["tanezumab", 237], [",", 246], ["formerly", 248], ["known", 257], ["as", 263], ["RN624", 266], [")", 271], [".", 272], ["Tanezumab", 274], ["is", 284], ["a", 287], ["clinical", 289], ["candidate", 298], ["as", 308], ["a", 311], ["therapy", 313], ["for", 321], ["chronic", 325], ["pain", 333], [".", 337], ["Our", 339], ["measurements", 343], ["were", 356], ["consistent", 361], ["with", 372], ["the", 377], ["NGF", 381], ["/", 384], ["tanezumab", 385], ["binding", 395], ["affinity", 403], ["being", 412], ["tighter", 418], ["than", 426], ["10", 431], ["pM", 434], ["due", 437], ["to", 441], ["the", 444], ["formation", 448], ["of", 458], ["an", 461], ["extremely", 464], ["stable", 474], ["complex", 481], ["that", 489], ["had", 494], ["an", 498], ["estimated", 501], ["half", 511], ["-", 515], ["life", 516], ["exceeding", 521], ["100", 531], ["h", 535], [",", 536], ["which", 538], ["was", 544], ["beyond", 548], ["the", 555], ["resolution", 559], ["of", 570], ["any", 573], ["of", 577], ["our", 580], ["methods", 584], [".", 591], ["The", 593], ["system", 597], ["was", 604], ["particularly", 608], ["challenging", 621], ["to", 633], ["study", 636], ["because", 642], ["NGF", 650], ["is", 654], ["an", 657], ["obligate", 660], ["homodimer", 669], [",", 678], ["and", 680], ["we", 684], ["describe", 687], ["various", 696], ["assay", 704], ["orientations", 710], ["and", 723], ["immobilization", 727], ["methods", 742], ["that", 750], ["were", 755], ["used", 760], ["to", 765], ["minimize", 768], ["avidity", 777], ["in", 785], ["our", 788], ["experiments", 792], ["while", 804], ["keeping", 810], ["NGF", 818], ["in", 822], ["as", 825], ["native", 828], ["a", 835], ["state", 837], ["as", 843], ["possible", 846], [".", 854], ["We", 856], ["also", 859], ["explored", 864], ["the", 873], ["interactions", 877], ["of", 890], ["NGF", 893], ["with", 897], ["its", 902], ["natural", 906], ["receptors", 914], [",", 923], ["TrkA", 925], ["and", 930], ["P75", 934], [",", 937], ["and", 939], ["how", 943], ["tanezumab", 947], ["blocks", 957], ["them", 964], [".", 968], ["The", 970], ["Biacore", 974], ["blocking", 982], ["assay", 991], ["that", 997], ["we", 1002], ["designed", 1005], ["was", 1014], ["used", 1018], ["to", 1023], ["quantify", 1026], ["the", 1035], ["potency", 1039], ["of", 1047], ["tanezumab", 1050], ["and", 1060], ["is", 1064], ["more", 1067], ["precise", 1072], ["and", 1080], ["reproducible", 1084], ["than", 1097], ["the", 1102], ["currently", 1106], ["available", 1116], ["cell", 1126], ["-", 1130], ["based", 1131], ["functional", 1137], ["assays", 1148], [".", 1154]]}
{"context": "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, also known as CD152) has been shown to play a major role in the regulation of T cell activation. Its membrane expression is highly regulated by endocytosis and trafficking through the secretory lysosome pathway. Chediak-Higashi syndrome (CHS) is an inherited disorder caused by mutations in the lysosomal trafficking regulator gene, LYST. It results in defective membrane targeting of the proteins present in secretory lysosomes, and it is associated with a variety of features, including a lymphoproliferative syndrome with hemophagocytosis. The murine equivalent of CHS, beige mice, present similar characteristics but do not develop the lymphoproliferative syndrome. We show herein that CTLA-4 is present in enlarged, abnormal vesicles in CHS T cells and is not properly expressed at the cell surface after T cell activation, whereas its surface expression is not impaired. It is therefore proposed that the defective surface expression of CTLA-4 by CHS T cells is involved in the generation of lymphoproliferative disease. This observation may provide insight into the role of CTLA-4 in humans.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "48de9af03ef14e918760efaeb35e7f7b", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[47, 50]], "char_spans": [[265, 288]]}]}], "context_tokens": [["Cytotoxic", 0], ["T", 10], ["lymphocyte", 12], ["-", 22], ["associated", 23], ["antigen", 34], ["4", 42], ["(", 44], ["CTLA-4", 45], [",", 51], ["also", 53], ["known", 58], ["as", 64], ["CD152", 67], [")", 72], ["has", 74], ["been", 78], ["shown", 83], ["to", 89], ["play", 92], ["a", 97], ["major", 99], ["role", 105], ["in", 110], ["the", 113], ["regulation", 117], ["of", 128], ["T", 131], ["cell", 133], ["activation", 138], [".", 148], ["Its", 150], ["membrane", 154], ["expression", 163], ["is", 174], ["highly", 177], ["regulated", 184], ["by", 194], ["endocytosis", 197], ["and", 209], ["trafficking", 213], ["through", 225], ["the", 233], ["secretory", 237], ["lysosome", 247], ["pathway", 256], [".", 263], ["Chediak", 265], ["-", 272], ["Higashi", 273], ["syndrome", 281], ["(", 290], ["CHS", 291], [")", 294], ["is", 296], ["an", 299], ["inherited", 302], ["disorder", 312], ["caused", 321], ["by", 328], ["mutations", 331], ["in", 341], ["the", 344], ["lysosomal", 348], ["trafficking", 358], ["regulator", 370], ["gene", 380], [",", 384], ["LYST", 386], [".", 390], ["It", 392], ["results", 395], ["in", 403], ["defective", 406], ["membrane", 416], ["targeting", 425], ["of", 435], ["the", 438], ["proteins", 442], ["present", 451], ["in", 459], ["secretory", 462], ["lysosomes", 472], [",", 481], ["and", 483], ["it", 487], ["is", 490], ["associated", 493], ["with", 504], ["a", 509], ["variety", 511], ["of", 519], ["features", 522], [",", 530], ["including", 532], ["a", 542], ["lymphoproliferative", 544], ["syndrome", 564], ["with", 573], ["hemophagocytosis", 578], [".", 594], ["The", 596], ["murine", 600], ["equivalent", 607], ["of", 618], ["CHS", 621], [",", 624], ["beige", 626], ["mice", 632], [",", 636], ["present", 638], ["similar", 646], ["characteristics", 654], ["but", 670], ["do", 674], ["not", 677], ["develop", 681], ["the", 689], ["lymphoproliferative", 693], ["syndrome", 713], [".", 721], ["We", 723], ["show", 726], ["herein", 731], ["that", 738], ["CTLA-4", 743], ["is", 750], ["present", 753], ["in", 761], ["enlarged", 764], [",", 772], ["abnormal", 774], ["vesicles", 783], ["in", 792], ["CHS", 795], ["T", 799], ["cells", 801], ["and", 807], ["is", 811], ["not", 814], ["properly", 818], ["expressed", 827], ["at", 837], ["the", 840], ["cell", 844], ["surface", 849], ["after", 857], ["T", 863], ["cell", 865], ["activation", 870], [",", 880], ["whereas", 882], ["its", 890], ["surface", 894], ["expression", 902], ["is", 913], ["not", 916], ["impaired", 920], [".", 928], ["It", 930], ["is", 933], ["therefore", 936], ["proposed", 946], ["that", 955], ["the", 960], ["defective", 964], ["surface", 974], ["expression", 982], ["of", 993], ["CTLA-4", 996], ["by", 1003], ["CHS", 1006], ["T", 1010], ["cells", 1012], ["is", 1018], ["involved", 1021], ["in", 1030], ["the", 1033], ["generation", 1037], ["of", 1048], ["lymphoproliferative", 1051], ["disease", 1071], [".", 1078], ["This", 1080], ["observation", 1085], ["may", 1097], ["provide", 1101], ["insight", 1109], ["into", 1117], ["the", 1122], ["role", 1126], ["of", 1131], ["CTLA-4", 1134], ["in", 1141], ["humans", 1144], [".", 1150]]}
{"context": "Dapivirine, a nonnucleoside reverse transcriptase inhibitor, is in development as a microbicide for the protection of women against HIV infection. A randomized, double-blind, phase 1 trial was conducted in 36 healthy HIV-negative women to compare the pharmacokinetics of 2 dapivirine vaginal gel formulations (0.05% each) and their safety with the hydroxyethyl cellulose-based universal placebo gel. Gel was self-administered once daily for a total of 11 days. Blood and vaginal fluid samples were collected sequentially over 24 days for pharmacokinetic analysis. Safety was evaluated by pelvic examination, colposcopy, adverse events, and clinical laboratory assessments. Adverse event profiles were similar for the 3 gels. Most events were mild and not related to study gel. Headache and vaginal hemorrhage (any vaginal bleeding) were most common. Plasma concentrations of dapivirine did not exceed 1.1 ng/mL. Steady-state conditions were reached within approximately 10 days. Dapivirine concentrations in vaginal fluids were slightly higher for Gel 4789, but Cmax values on days 1 and 14 were not significantly different. Terminal half-life was 72-73 hours in plasma and 15-17 hours in vaginal fluids. Both formulations of dapivirine gel were safe and well tolerated. Dapivirine was delivered to the lower genital tract at concentrations at least 5 logs greater than in vitro inhibitory concentrations.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "052d139dea73498a90e500c870e0b52c", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[20, 20], [38, 38]], "char_spans": [[132, 134], [217, 219]]}]}], "context_tokens": [["Dapivirine", 0], [",", 10], ["a", 12], ["nonnucleoside", 14], ["reverse", 28], ["transcriptase", 36], ["inhibitor", 50], [",", 59], ["is", 61], ["in", 64], ["development", 67], ["as", 79], ["a", 82], ["microbicide", 84], ["for", 96], ["the", 100], ["protection", 104], ["of", 115], ["women", 118], ["against", 124], ["HIV", 132], ["infection", 136], [".", 145], ["A", 147], ["randomized", 149], [",", 159], ["double", 161], ["-", 167], ["blind", 168], [",", 173], ["phase", 175], ["1", 181], ["trial", 183], ["was", 189], ["conducted", 193], ["in", 203], ["36", 206], ["healthy", 209], ["HIV", 217], ["-", 220], ["negative", 221], ["women", 230], ["to", 236], ["compare", 239], ["the", 247], ["pharmacokinetics", 251], ["of", 268], ["2", 271], ["dapivirine", 273], ["vaginal", 284], ["gel", 292], ["formulations", 296], ["(", 309], ["0.05", 310], ["%", 314], ["each", 316], [")", 320], ["and", 322], ["their", 326], ["safety", 332], ["with", 339], ["the", 344], ["hydroxyethyl", 348], ["cellulose", 361], ["-", 370], ["based", 371], ["universal", 377], ["placebo", 387], ["gel", 395], [".", 398], ["Gel", 400], ["was", 404], ["self", 408], ["-", 412], ["administered", 413], ["once", 426], ["daily", 431], ["for", 437], ["a", 441], ["total", 443], ["of", 449], ["11", 452], ["days", 455], [".", 459], ["Blood", 461], ["and", 467], ["vaginal", 471], ["fluid", 479], ["samples", 485], ["were", 493], ["collected", 498], ["sequentially", 508], ["over", 521], ["24", 526], ["days", 529], ["for", 534], ["pharmacokinetic", 538], ["analysis", 554], [".", 562], ["Safety", 564], ["was", 571], ["evaluated", 575], ["by", 585], ["pelvic", 588], ["examination", 595], [",", 606], ["colposcopy", 608], [",", 618], ["adverse", 620], ["events", 628], [",", 634], ["and", 636], ["clinical", 640], ["laboratory", 649], ["assessments", 660], [".", 671], ["Adverse", 673], ["event", 681], ["profiles", 687], ["were", 696], ["similar", 701], ["for", 709], ["the", 713], ["3", 717], ["gels", 719], [".", 723], ["Most", 725], ["events", 730], ["were", 737], ["mild", 742], ["and", 747], ["not", 751], ["related", 755], ["to", 763], ["study", 766], ["gel", 772], [".", 775], ["Headache", 777], ["and", 786], ["vaginal", 790], ["hemorrhage", 798], ["(", 809], ["any", 810], ["vaginal", 814], ["bleeding", 822], [")", 830], ["were", 832], ["most", 837], ["common", 842], [".", 848], ["Plasma", 850], ["concentrations", 857], ["of", 872], ["dapivirine", 875], ["did", 886], ["not", 890], ["exceed", 894], ["1.1", 901], ["ng", 905], ["/", 907], ["mL.", 908], ["Steady", 912], ["-", 918], ["state", 919], ["conditions", 925], ["were", 936], ["reached", 941], ["within", 949], ["approximately", 956], ["10", 970], ["days", 973], [".", 977], ["Dapivirine", 979], ["concentrations", 990], ["in", 1005], ["vaginal", 1008], ["fluids", 1016], ["were", 1023], ["slightly", 1028], ["higher", 1037], ["for", 1044], ["Gel", 1048], ["4789", 1052], [",", 1056], ["but", 1058], ["Cmax", 1062], ["values", 1067], ["on", 1074], ["days", 1077], ["1", 1082], ["and", 1084], ["14", 1088], ["were", 1091], ["not", 1096], ["significantly", 1100], ["different", 1114], [".", 1123], ["Terminal", 1125], ["half", 1134], ["-", 1138], ["life", 1139], ["was", 1144], ["72", 1148], ["-", 1150], ["73", 1151], ["hours", 1154], ["in", 1160], ["plasma", 1163], ["and", 1170], ["15", 1174], ["-", 1176], ["17", 1177], ["hours", 1180], ["in", 1186], ["vaginal", 1189], ["fluids", 1197], [".", 1203], ["Both", 1205], ["formulations", 1210], ["of", 1223], ["dapivirine", 1226], ["gel", 1237], ["were", 1241], ["safe", 1246], ["and", 1251], ["well", 1255], ["tolerated", 1260], [".", 1269], ["Dapivirine", 1271], ["was", 1282], ["delivered", 1286], ["to", 1296], ["the", 1299], ["lower", 1303], ["genital", 1309], ["tract", 1317], ["at", 1323], ["concentrations", 1326], ["at", 1341], ["least", 1344], ["5", 1350], ["logs", 1352], ["greater", 1357], ["than", 1365], ["in", 1370], ["vitro", 1373], ["inhibitory", 1379], ["concentrations", 1390], [".", 1404]]}
{"context": "LHCII is the most abundant membrane protein on earth. It participates in the first steps of photosynthesis by harvesting sunlight and transferring excitation energy to the core complex. Here we have analyzed the LHCII complex of the green alga Chlamydomonas reinhardtii and its association with the core of Photosystem II (PSII) to form multiprotein complexes. Several PSII supercomplexes with different antenna sizes have been purified, the largest of which contains three LHCII trimers (named S, M and N) per monomeric core. A projection map at a 13\u00c5 resolution was obtained allowing the reconstruction of the 3D structure of the supercomplex. The position and orientation of the S trimer are the same as in plants; trimer M is rotated by 45\u00b0 and the additional trimer (named here as LHCII-N), which is taking the position occupied in plants by CP24, is directly associated with the core. The analysis of supercomplexes with different antenna sizes suggests that LhcbM1, LhcbM2/7 and LhcbM3 are the major components of the trimers in the PSII supercomplex, while LhcbM5 is part of the \"extra\" LHCII pool not directly associated with the supercomplex. It is also shown that Chlamydomonas LHCII has a slightly lower Chlorophyll a/b ratio than the complex from plants and a blue shifted absorption spectrum. Finally the data indicate that there are at least six LHCII trimers per dimeric core in the thylakoid membranes, meaning that the antenna size of PSII of C. reinhardtii is larger than that of plants.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "6b0148faa55441ee8fdde13fe55edb87", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [35, 35], [77, 77], [141, 141], [215, 215], [247, 247], [200, 200]], "char_spans": [[0, 4], [212, 216], [474, 478], [786, 790], [1189, 1193], [1361, 1365], [1095, 1099]]}]}], "context_tokens": [["LHCII", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["earth", 47], [".", 52], ["It", 54], ["participates", 57], ["in", 70], ["the", 73], ["first", 77], ["steps", 83], ["of", 89], ["photosynthesis", 92], ["by", 107], ["harvesting", 110], ["sunlight", 121], ["and", 130], ["transferring", 134], ["excitation", 147], ["energy", 158], ["to", 165], ["the", 168], ["core", 172], ["complex", 177], [".", 184], ["Here", 186], ["we", 191], ["have", 194], ["analyzed", 199], ["the", 208], ["LHCII", 212], ["complex", 218], ["of", 226], ["the", 229], ["green", 233], ["alga", 239], ["Chlamydomonas", 244], ["reinhardtii", 258], ["and", 270], ["its", 274], ["association", 278], ["with", 290], ["the", 295], ["core", 299], ["of", 304], ["Photosystem", 307], ["II", 319], ["(", 322], ["PSII", 323], [")", 327], ["to", 329], ["form", 332], ["multiprotein", 337], ["complexes", 350], [".", 359], ["Several", 361], ["PSII", 369], ["supercomplexes", 374], ["with", 389], ["different", 394], ["antenna", 404], ["sizes", 412], ["have", 418], ["been", 423], ["purified", 428], [",", 436], ["the", 438], ["largest", 442], ["of", 450], ["which", 453], ["contains", 459], ["three", 468], ["LHCII", 474], ["trimers", 480], ["(", 488], ["named", 489], ["S", 495], [",", 496], ["M", 498], ["and", 500], ["N", 504], [")", 505], ["per", 507], ["monomeric", 511], ["core", 521], [".", 525], ["A", 527], ["projection", 529], ["map", 540], ["at", 544], ["a", 547], ["13\u00c5", 549], ["resolution", 553], ["was", 564], ["obtained", 568], ["allowing", 577], ["the", 586], ["reconstruction", 590], ["of", 605], ["the", 608], ["3D", 612], ["structure", 615], ["of", 625], ["the", 628], ["supercomplex", 632], [".", 644], ["The", 646], ["position", 650], ["and", 659], ["orientation", 663], ["of", 675], ["the", 678], ["S", 682], ["trimer", 684], ["are", 691], ["the", 695], ["same", 699], ["as", 704], ["in", 707], ["plants", 710], [";", 716], ["trimer", 718], ["M", 725], ["is", 727], ["rotated", 730], ["by", 738], ["45", 741], ["\u00b0", 743], ["and", 745], ["the", 749], ["additional", 753], ["trimer", 764], ["(", 771], ["named", 772], ["here", 778], ["as", 783], ["LHCII", 786], ["-", 791], ["N", 792], [")", 793], [",", 794], ["which", 796], ["is", 802], ["taking", 805], ["the", 812], ["position", 816], ["occupied", 825], ["in", 834], ["plants", 837], ["by", 844], ["CP24", 847], [",", 851], ["is", 853], ["directly", 856], ["associated", 865], ["with", 876], ["the", 881], ["core", 885], [".", 889], ["The", 891], ["analysis", 895], ["of", 904], ["supercomplexes", 907], ["with", 922], ["different", 927], ["antenna", 937], ["sizes", 945], ["suggests", 951], ["that", 960], ["LhcbM1", 965], [",", 971], ["LhcbM2/7", 973], ["and", 982], ["LhcbM3", 986], ["are", 993], ["the", 997], ["major", 1001], ["components", 1007], ["of", 1018], ["the", 1021], ["trimers", 1025], ["in", 1033], ["the", 1036], ["PSII", 1040], ["supercomplex", 1045], [",", 1057], ["while", 1059], ["LhcbM5", 1065], ["is", 1072], ["part", 1075], ["of", 1080], ["the", 1083], ["\"", 1087], ["extra", 1088], ["\"", 1093], ["LHCII", 1095], ["pool", 1101], ["not", 1106], ["directly", 1110], ["associated", 1119], ["with", 1130], ["the", 1135], ["supercomplex", 1139], [".", 1151], ["It", 1153], ["is", 1156], ["also", 1159], ["shown", 1164], ["that", 1170], ["Chlamydomonas", 1175], ["LHCII", 1189], ["has", 1195], ["a", 1199], ["slightly", 1201], ["lower", 1210], ["Chlorophyll", 1216], ["a", 1228], ["/", 1229], ["b", 1230], ["ratio", 1232], ["than", 1238], ["the", 1243], ["complex", 1247], ["from", 1255], ["plants", 1260], ["and", 1267], ["a", 1271], ["blue", 1273], ["shifted", 1278], ["absorption", 1286], ["spectrum", 1297], [".", 1305], ["Finally", 1307], ["the", 1315], ["data", 1319], ["indicate", 1324], ["that", 1333], ["there", 1338], ["are", 1344], ["at", 1348], ["least", 1351], ["six", 1357], ["LHCII", 1361], ["trimers", 1367], ["per", 1375], ["dimeric", 1379], ["core", 1387], ["in", 1392], ["the", 1395], ["thylakoid", 1399], ["membranes", 1409], [",", 1418], ["meaning", 1420], ["that", 1428], ["the", 1433], ["antenna", 1437], ["size", 1445], ["of", 1450], ["PSII", 1453], ["of", 1458], ["C.", 1461], ["reinhardtii", 1464], ["is", 1476], ["larger", 1479], ["than", 1486], ["that", 1491], ["of", 1496], ["plants", 1499], [".", 1505]]}
{"context": "Determining clinical probability of pulmonary embolism (PE) with Wells scoring system is the first step towards diagnosis of PE. Definitive diagnosis of PE is confirmed by computed tomography pulmonary angiography (CTPA). This was a prospective study on 80 patients referred to the Institute for Pulmonary Diseases of Vojvodina with suspected PE between April 2010 and August 2012. Clinical probability of PE was determined according to the Wells and modified Wells scoring system. CTPA was performed in 60 patients. The degree of pulmonary vascular obstruction was quantified by the Qanadli index. Low clinical probability of PE was present in one patient (1.6%), moderate in 43 (71.6%) and high in 16 (26.6%) patients. PE was confirmed in 50 (83.3%) patients. There were 21 patients (42%) whose Quanadli index was <25%, 18 (36%) between 25%-50%, while Quanadli index was \u226550 in 11 patients (22%). When compared to CTPA findings, modified Wells scoring system showed 90% sensitivity [95% confidence interval (CI) 78.2%-96.6%], and 20% specificity (95% CI 3.11%-55.6%), positive predictive value (PPV) 84.9% (95% CI 72.4%-93.2%) and negative predictive value (NPV) 28.6% (95% CI 4.5%-70.7%). There was weak positive correlation between Wells score and Quanadli index (r\u2009=\u20090.14; P\u2009=\u20090.29), without statistical significance. Wells score was significantly higher in haemodynamically unstable than in haemodynamically stable patients (6.8 vs 5.6, P\u2009=\u20090.014). There was no statistically significant difference between the values of Quanadli index in these two groups (31.33% vs 26.64%, P\u2009=\u20090.062). Modified Wells criteria have high sensitivity but low specificity in PE diagnostics. The Wells score does not correlate well with the Quanadli index.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "862da8740a8c404c925e5d6116db47e5", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[4, 5]], "char_spans": [[36, 53]]}]}], "context_tokens": [["Determining", 0], ["clinical", 12], ["probability", 21], ["of", 33], ["pulmonary", 36], ["embolism", 46], ["(", 55], ["PE", 56], [")", 58], ["with", 60], ["Wells", 65], ["scoring", 71], ["system", 79], ["is", 86], ["the", 89], ["first", 93], ["step", 99], ["towards", 104], ["diagnosis", 112], ["of", 122], ["PE", 125], [".", 127], ["Definitive", 129], ["diagnosis", 140], ["of", 150], ["PE", 153], ["is", 156], ["confirmed", 159], ["by", 169], ["computed", 172], ["tomography", 181], ["pulmonary", 192], ["angiography", 202], ["(", 214], ["CTPA", 215], [")", 219], [".", 220], ["This", 222], ["was", 227], ["a", 231], ["prospective", 233], ["study", 245], ["on", 251], ["80", 254], ["patients", 257], ["referred", 266], ["to", 275], ["the", 278], ["Institute", 282], ["for", 292], ["Pulmonary", 296], ["Diseases", 306], ["of", 315], ["Vojvodina", 318], ["with", 328], ["suspected", 333], ["PE", 343], ["between", 346], ["April", 354], ["2010", 360], ["and", 365], ["August", 369], ["2012", 376], [".", 380], ["Clinical", 382], ["probability", 391], ["of", 403], ["PE", 406], ["was", 409], ["determined", 413], ["according", 424], ["to", 434], ["the", 437], ["Wells", 441], ["and", 447], ["modified", 451], ["Wells", 460], ["scoring", 466], ["system", 474], [".", 480], ["CTPA", 482], ["was", 487], ["performed", 491], ["in", 501], ["60", 504], ["patients", 507], [".", 515], ["The", 517], ["degree", 521], ["of", 528], ["pulmonary", 531], ["vascular", 541], ["obstruction", 550], ["was", 562], ["quantified", 566], ["by", 577], ["the", 580], ["Qanadli", 584], ["index", 592], [".", 597], ["Low", 599], ["clinical", 603], ["probability", 612], ["of", 624], ["PE", 627], ["was", 630], ["present", 634], ["in", 642], ["one", 645], ["patient", 649], ["(", 657], ["1.6", 658], ["%", 661], [")", 662], [",", 663], ["moderate", 665], ["in", 674], ["43", 677], ["(", 680], ["71.6", 681], ["%", 685], [")", 686], ["and", 688], ["high", 692], ["in", 697], ["16", 700], ["(", 703], ["26.6", 704], ["%", 708], [")", 709], ["patients", 711], [".", 719], ["PE", 721], ["was", 724], ["confirmed", 728], ["in", 738], ["50", 741], ["(", 744], ["83.3", 745], ["%", 749], [")", 750], ["patients", 752], [".", 760], ["There", 762], ["were", 768], ["21", 773], ["patients", 776], ["(", 785], ["42", 786], ["%", 788], [")", 789], ["whose", 791], ["Quanadli", 797], ["index", 806], ["was", 812], ["<", 816], ["25", 817], ["%", 819], [",", 820], ["18", 822], ["(", 825], ["36", 826], ["%", 828], [")", 829], ["between", 831], ["25%-50", 839], ["%", 845], [",", 846], ["while", 848], ["Quanadli", 854], ["index", 863], ["was", 869], ["\u226550", 873], ["in", 877], ["11", 880], ["patients", 883], ["(", 892], ["22", 893], ["%", 895], [")", 896], [".", 897], ["When", 899], ["compared", 904], ["to", 913], ["CTPA", 916], ["findings", 921], [",", 929], ["modified", 931], ["Wells", 940], ["scoring", 946], ["system", 954], ["showed", 961], ["90", 968], ["%", 970], ["sensitivity", 972], ["[", 984], ["95", 985], ["%", 987], ["confidence", 989], ["interval", 1000], ["(", 1009], ["CI", 1010], [")", 1012], ["78.2%-96.6", 1014], ["%", 1024], ["]", 1025], [",", 1026], ["and", 1028], ["20", 1032], ["%", 1034], ["specificity", 1036], ["(", 1048], ["95", 1049], ["%", 1051], ["CI", 1053], ["3.11%-55.6", 1056], ["%", 1066], [")", 1067], [",", 1068], ["positive", 1070], ["predictive", 1079], ["value", 1090], ["(", 1096], ["PPV", 1097], [")", 1100], ["84.9", 1102], ["%", 1106], ["(", 1108], ["95", 1109], ["%", 1111], ["CI", 1113], ["72.4%-93.2", 1116], ["%", 1126], [")", 1127], ["and", 1129], ["negative", 1133], ["predictive", 1142], ["value", 1153], ["(", 1159], ["NPV", 1160], [")", 1163], ["28.6", 1165], ["%", 1169], ["(", 1171], ["95", 1172], ["%", 1174], ["CI", 1176], ["4.5%-70.7", 1179], ["%", 1188], [")", 1189], [".", 1190], ["There", 1192], ["was", 1198], ["weak", 1202], ["positive", 1207], ["correlation", 1216], ["between", 1228], ["Wells", 1236], ["score", 1242], ["and", 1248], ["Quanadli", 1252], ["index", 1261], ["(", 1267], ["r", 1268], ["=", 1270], ["0.14", 1272], [";", 1276], ["P", 1278], ["=", 1280], ["0.29", 1282], [")", 1286], [",", 1287], ["without", 1289], ["statistical", 1297], ["significance", 1309], [".", 1321], ["Wells", 1323], ["score", 1329], ["was", 1335], ["significantly", 1339], ["higher", 1353], ["in", 1360], ["haemodynamically", 1363], ["unstable", 1380], ["than", 1389], ["in", 1394], ["haemodynamically", 1397], ["stable", 1414], ["patients", 1421], ["(", 1430], ["6.8", 1431], ["vs", 1435], ["5.6", 1438], [",", 1441], ["P", 1443], ["=", 1445], ["0.014", 1447], [")", 1452], [".", 1453], ["There", 1455], ["was", 1461], ["no", 1465], ["statistically", 1468], ["significant", 1482], ["difference", 1494], ["between", 1505], ["the", 1513], ["values", 1517], ["of", 1524], ["Quanadli", 1527], ["index", 1536], ["in", 1542], ["these", 1545], ["two", 1551], ["groups", 1555], ["(", 1562], ["31.33", 1563], ["%", 1568], ["vs", 1570], ["26.64", 1573], ["%", 1578], [",", 1579], ["P", 1581], ["=", 1583], ["0.062", 1585], [")", 1590], [".", 1591], ["Modified", 1593], ["Wells", 1602], ["criteria", 1608], ["have", 1617], ["high", 1622], ["sensitivity", 1627], ["but", 1639], ["low", 1643], ["specificity", 1647], ["in", 1659], ["PE", 1662], ["diagnostics", 1665], [".", 1676], ["The", 1678], ["Wells", 1682], ["score", 1688], ["does", 1694], ["not", 1699], ["correlate", 1703], ["well", 1713], ["with", 1718], ["the", 1723], ["Quanadli", 1727], ["index", 1736], [".", 1741]]}
{"context": "To assess the efficacy and safety of tanezumab, a humanized monoclonal antibody directed against the pain-mediating neurotrophin, nerve growth factor, to treat pain and other symptoms of chronic prostatitis/chronic pelvic pain syndrome in a Phase IIa, proof-of-concept clinical trial powered to provide 2-sided 90% confidence interval around the primary endpoint. Patients received a single intravenous dose of tanezumab (20 mg) or placebo. The primary efficacy endpoint was the change from baseline to week 6 in average daily numerical rating scale pain score. The secondary endpoints included the change from baseline to week 6 in the National Institutes of Health Chronic Prostatitis Symptom Index and urinary symptoms. Safety was also assessed. Overall, 62 patients were randomized (30 to tanezumab and 32 to placebo). At week 6, tanezumab marginally improved the average daily pain (least-squares mean difference from placebo -0.47, 90% confidence interval -1.150-0.209) and urgency episode frequency (least-squares mean difference from placebo -1.37, 90% confidence interval -3.146-0.401). No difference was seen in the National Institutes of Health chronic prostatitis symptom index total score or micturition frequency at week 6. The most common adverse events were paresthesia and arthralgia. The odds of having a \u2265 30% reduction in pain were 1.75-fold greater (90% confidence interval 0.65-4.69) for patients receiving tanezumab versus placebo. Tanezumab might improve symptoms for some patients with chronic prostatitis/chronic pelvic pain syndrome. Although proof of concept was not demonstrated in the present study, additional studies with larger populations and stricter inclusion criteria according to patient phenotype might identify populations in which antinerve growth factor treatment will provide clinical benefit.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "53453018272b4cbaa4e322487a25246c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[21, 23]], "char_spans": [[130, 148]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["tanezumab", 37], [",", 46], ["a", 48], ["humanized", 50], ["monoclonal", 60], ["antibody", 71], ["directed", 80], ["against", 89], ["the", 97], ["pain", 101], ["-", 105], ["mediating", 106], ["neurotrophin", 116], [",", 128], ["nerve", 130], ["growth", 136], ["factor", 143], [",", 149], ["to", 151], ["treat", 154], ["pain", 160], ["and", 165], ["other", 169], ["symptoms", 175], ["of", 184], ["chronic", 187], ["prostatitis", 195], ["/", 206], ["chronic", 207], ["pelvic", 215], ["pain", 222], ["syndrome", 227], ["in", 236], ["a", 239], ["Phase", 241], ["IIa", 247], [",", 250], ["proof", 252], ["-", 257], ["of", 258], ["-", 260], ["concept", 261], ["clinical", 269], ["trial", 278], ["powered", 284], ["to", 292], ["provide", 295], ["2-sided", 303], ["90", 311], ["%", 313], ["confidence", 315], ["interval", 326], ["around", 335], ["the", 342], ["primary", 346], ["endpoint", 354], [".", 362], ["Patients", 364], ["received", 373], ["a", 382], ["single", 384], ["intravenous", 391], ["dose", 403], ["of", 408], ["tanezumab", 411], ["(", 421], ["20", 422], ["mg", 425], [")", 427], ["or", 429], ["placebo", 432], [".", 439], ["The", 441], ["primary", 445], ["efficacy", 453], ["endpoint", 462], ["was", 471], ["the", 475], ["change", 479], ["from", 486], ["baseline", 491], ["to", 500], ["week", 503], ["6", 508], ["in", 510], ["average", 513], ["daily", 521], ["numerical", 527], ["rating", 537], ["scale", 544], ["pain", 550], ["score", 555], [".", 560], ["The", 562], ["secondary", 566], ["endpoints", 576], ["included", 586], ["the", 595], ["change", 599], ["from", 606], ["baseline", 611], ["to", 620], ["week", 623], ["6", 628], ["in", 630], ["the", 633], ["National", 637], ["Institutes", 646], ["of", 657], ["Health", 660], ["Chronic", 667], ["Prostatitis", 675], ["Symptom", 687], ["Index", 695], ["and", 701], ["urinary", 705], ["symptoms", 713], [".", 721], ["Safety", 723], ["was", 730], ["also", 734], ["assessed", 739], [".", 747], ["Overall", 749], [",", 756], ["62", 758], ["patients", 761], ["were", 770], ["randomized", 775], ["(", 786], ["30", 787], ["to", 790], ["tanezumab", 793], ["and", 803], ["32", 807], ["to", 810], ["placebo", 813], [")", 820], [".", 821], ["At", 823], ["week", 826], ["6", 831], [",", 832], ["tanezumab", 834], ["marginally", 844], ["improved", 855], ["the", 864], ["average", 868], ["daily", 876], ["pain", 882], ["(", 887], ["least", 888], ["-", 893], ["squares", 894], ["mean", 902], ["difference", 907], ["from", 918], ["placebo", 923], ["-0.47", 931], [",", 936], ["90", 938], ["%", 940], ["confidence", 942], ["interval", 953], ["-1.150", 962], ["-", 968], ["0.209", 969], [")", 974], ["and", 976], ["urgency", 980], ["episode", 988], ["frequency", 996], ["(", 1006], ["least", 1007], ["-", 1012], ["squares", 1013], ["mean", 1021], ["difference", 1026], ["from", 1037], ["placebo", 1042], ["-1.37", 1050], [",", 1055], ["90", 1057], ["%", 1059], ["confidence", 1061], ["interval", 1072], ["-3.146", 1081], ["-", 1087], ["0.401", 1088], [")", 1093], [".", 1094], ["No", 1096], ["difference", 1099], ["was", 1110], ["seen", 1114], ["in", 1119], ["the", 1122], ["National", 1126], ["Institutes", 1135], ["of", 1146], ["Health", 1149], ["chronic", 1156], ["prostatitis", 1164], ["symptom", 1176], ["index", 1184], ["total", 1190], ["score", 1196], ["or", 1202], ["micturition", 1205], ["frequency", 1217], ["at", 1227], ["week", 1230], ["6", 1235], [".", 1236], ["The", 1238], ["most", 1242], ["common", 1247], ["adverse", 1254], ["events", 1262], ["were", 1269], ["paresthesia", 1274], ["and", 1286], ["arthralgia", 1290], [".", 1300], ["The", 1302], ["odds", 1306], ["of", 1311], ["having", 1314], ["a", 1321], ["\u2265", 1323], ["30", 1325], ["%", 1327], ["reduction", 1329], ["in", 1339], ["pain", 1342], ["were", 1347], ["1.75-fold", 1352], ["greater", 1362], ["(", 1370], ["90", 1371], ["%", 1373], ["confidence", 1375], ["interval", 1386], ["0.65", 1395], ["-", 1399], ["4.69", 1400], [")", 1404], ["for", 1406], ["patients", 1410], ["receiving", 1419], ["tanezumab", 1429], ["versus", 1439], ["placebo", 1446], [".", 1453], ["Tanezumab", 1455], ["might", 1465], ["improve", 1471], ["symptoms", 1479], ["for", 1488], ["some", 1492], ["patients", 1497], ["with", 1506], ["chronic", 1511], ["prostatitis", 1519], ["/", 1530], ["chronic", 1531], ["pelvic", 1539], ["pain", 1546], ["syndrome", 1551], [".", 1559], ["Although", 1561], ["proof", 1570], ["of", 1576], ["concept", 1579], ["was", 1587], ["not", 1591], ["demonstrated", 1595], ["in", 1608], ["the", 1611], ["present", 1615], ["study", 1623], [",", 1628], ["additional", 1630], ["studies", 1641], ["with", 1649], ["larger", 1654], ["populations", 1661], ["and", 1673], ["stricter", 1677], ["inclusion", 1686], ["criteria", 1696], ["according", 1705], ["to", 1715], ["patient", 1718], ["phenotype", 1726], ["might", 1736], ["identify", 1742], ["populations", 1751], ["in", 1763], ["which", 1766], ["antinerve", 1772], ["growth", 1782], ["factor", 1789], ["treatment", 1796], ["will", 1806], ["provide", 1811], ["clinical", 1819], ["benefit", 1828], [".", 1835]]}
{"context": "To assess the effectiveness of inside-out TVT-ABBREVO in the surgical treatment of female stress urinary incontinence (SUI) with mean two-year follow-up. Fifty-six women underwent surgery for moderate-severe SUI. The technology used was the TVT-ABBREVO inside-out. Each woman at 12 and 24 months underwent postoperative evaluation by means of urodynamics, Q-tip test, CST, transperineal ultrasonography, and administration of \"King's Health Questionnaire\" (KHQ). The mean age of the women was 57.03 +/- 11.1 years (range 42-75). Postoperative urodynamics (12 months follow-up) resulted to be normal in 43/56 patients (76.79%), in 10/56 (17.86%) cases resulted in a considerable improvement of the symptomatology, and only 1/56 (1.78%) case had de novo overactive bladder (OAB), in 2/56 (3.57%) symptomatology unchanged. After administration of the KHQ 43/56 cases (76.79%) had resolution of the symptomatology, 10/56 cases (17.86%) improvement of the symptomatology, and no change in 3/56 cases (5.36%). In the authors' experience, the TVT-ABBREVO resulted technically simple. The TVT-ABBREVO procedure provides high objective and subjective long-term efficacy, a clinically meaningful improvement in patient quality of life, and an excellent safety profile.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "73a1a36fb91449d6a4ac7d06dcdee186", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[17, 19]], "char_spans": [[90, 116]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["effectiveness", 14], ["of", 28], ["inside", 31], ["-", 37], ["out", 38], ["TVT", 42], ["-", 45], ["ABBREVO", 46], ["in", 54], ["the", 57], ["surgical", 61], ["treatment", 70], ["of", 80], ["female", 83], ["stress", 90], ["urinary", 97], ["incontinence", 105], ["(", 118], ["SUI", 119], [")", 122], ["with", 124], ["mean", 129], ["two", 134], ["-", 137], ["year", 138], ["follow", 143], ["-", 149], ["up", 150], [".", 152], ["Fifty", 154], ["-", 159], ["six", 160], ["women", 164], ["underwent", 170], ["surgery", 180], ["for", 188], ["moderate", 192], ["-", 200], ["severe", 201], ["SUI", 208], [".", 211], ["The", 213], ["technology", 217], ["used", 228], ["was", 233], ["the", 237], ["TVT", 241], ["-", 244], ["ABBREVO", 245], ["inside", 253], ["-", 259], ["out", 260], [".", 263], ["Each", 265], ["woman", 270], ["at", 276], ["12", 279], ["and", 282], ["24", 286], ["months", 289], ["underwent", 296], ["postoperative", 306], ["evaluation", 320], ["by", 331], ["means", 334], ["of", 340], ["urodynamics", 343], [",", 354], ["Q", 356], ["-", 357], ["tip", 358], ["test", 362], [",", 366], ["CST", 368], [",", 371], ["transperineal", 373], ["ultrasonography", 387], [",", 402], ["and", 404], ["administration", 408], ["of", 423], ["\"", 426], ["King", 427], ["'s", 431], ["Health", 434], ["Questionnaire", 441], ["\"", 454], ["(", 456], ["KHQ", 457], [")", 460], [".", 461], ["The", 463], ["mean", 467], ["age", 472], ["of", 476], ["the", 479], ["women", 483], ["was", 489], ["57.03", 493], ["+", 499], ["/-", 500], ["11.1", 503], ["years", 508], ["(", 514], ["range", 515], ["42", 521], ["-", 523], ["75", 524], [")", 526], [".", 527], ["Postoperative", 529], ["urodynamics", 543], ["(", 555], ["12", 556], ["months", 559], ["follow", 566], ["-", 572], ["up", 573], [")", 575], ["resulted", 577], ["to", 586], ["be", 589], ["normal", 592], ["in", 599], ["43/56", 602], ["patients", 608], ["(", 617], ["76.79", 618], ["%", 623], [")", 624], [",", 625], ["in", 627], ["10/56", 630], ["(", 636], ["17.86", 637], ["%", 642], [")", 643], ["cases", 645], ["resulted", 651], ["in", 660], ["a", 663], ["considerable", 665], ["improvement", 678], ["of", 690], ["the", 693], ["symptomatology", 697], [",", 711], ["and", 713], ["only", 717], ["1/56", 722], ["(", 727], ["1.78", 728], ["%", 732], [")", 733], ["case", 735], ["had", 740], ["de", 744], ["novo", 747], ["overactive", 752], ["bladder", 763], ["(", 771], ["OAB", 772], [")", 775], [",", 776], ["in", 778], ["2/56", 781], ["(", 786], ["3.57", 787], ["%", 791], [")", 792], ["symptomatology", 794], ["unchanged", 809], [".", 818], ["After", 820], ["administration", 826], ["of", 841], ["the", 844], ["KHQ", 848], ["43/56", 852], ["cases", 858], ["(", 864], ["76.79", 865], ["%", 870], [")", 871], ["had", 873], ["resolution", 877], ["of", 888], ["the", 891], ["symptomatology", 895], [",", 909], ["10/56", 911], ["cases", 917], ["(", 923], ["17.86", 924], ["%", 929], [")", 930], ["improvement", 932], ["of", 944], ["the", 947], ["symptomatology", 951], [",", 965], ["and", 967], ["no", 971], ["change", 974], ["in", 981], ["3/56", 984], ["cases", 989], ["(", 995], ["5.36", 996], ["%", 1000], [")", 1001], [".", 1002], ["In", 1004], ["the", 1007], ["authors", 1011], ["'", 1018], ["experience", 1020], [",", 1030], ["the", 1032], ["TVT", 1036], ["-", 1039], ["ABBREVO", 1040], ["resulted", 1048], ["technically", 1057], ["simple", 1069], [".", 1075], ["The", 1077], ["TVT", 1081], ["-", 1084], ["ABBREVO", 1085], ["procedure", 1093], ["provides", 1103], ["high", 1112], ["objective", 1117], ["and", 1127], ["subjective", 1131], ["long", 1142], ["-", 1146], ["term", 1147], ["efficacy", 1152], [",", 1160], ["a", 1162], ["clinically", 1164], ["meaningful", 1175], ["improvement", 1186], ["in", 1198], ["patient", 1201], ["quality", 1209], ["of", 1217], ["life", 1220], [",", 1224], ["and", 1226], ["an", 1230], ["excellent", 1233], ["safety", 1243], ["profile", 1250], [".", 1257]]}
{"context": "Tissue injury following ischemia-reperfusion (I/R) occurs as a consequence of actions of soluble factors and immune cells. Growing evidence supports a role for platelets in the manifestation of tissue damage following I/R. Spleen tyrosine kinase has been well documented to be important in lymphocyte activation and more recently in platelet activation. We performed experiments to evaluate whether inhibition of platelet activation through inhibition of spleen tyrosine kinase prevents tissue damage after mesenteric I/R injury. Platelets isolated from C57BL/6J mice fed with R788 for 10 days were transfused into C57BL/6J mice depleted of platelets 2 days before mesenteric I/R injury. Platelet-depleted mice transfused with platelets from R788-treated mice before mesenteric I/R displayed a significant reduction in the degree of remote lung damage, but with little change in the degree of local intestinal damage compared with control I/R mice. Transfusion of R788-treated platelets also decreased platelet sequestration, C3 deposition, and immunoglobulin deposition in lung, but not in the intestine, compared with control groups. These findings demonstrate that platelet activation is a requisite for sequestration in the pulmonary vasculature to mediate remote tissue injury after mesenteric I/R. The use of small-molecule inhibitors may be valuable to prevent tissue damage in remote organs following I/R injury.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7deff88ee57a42abac5151b2659908da", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[41, 43], [74, 76]], "char_spans": [[223, 244], [455, 476]]}]}], "context_tokens": [["Tissue", 0], ["injury", 7], ["following", 14], ["ischemia", 24], ["-", 32], ["reperfusion", 33], ["(", 45], ["I", 46], ["/", 47], ["R", 48], [")", 49], ["occurs", 51], ["as", 58], ["a", 61], ["consequence", 63], ["of", 75], ["actions", 78], ["of", 86], ["soluble", 89], ["factors", 97], ["and", 105], ["immune", 109], ["cells", 116], [".", 121], ["Growing", 123], ["evidence", 131], ["supports", 140], ["a", 149], ["role", 151], ["for", 156], ["platelets", 160], ["in", 170], ["the", 173], ["manifestation", 177], ["of", 191], ["tissue", 194], ["damage", 201], ["following", 208], ["I", 218], ["/", 219], ["R.", 220], ["Spleen", 223], ["tyrosine", 230], ["kinase", 239], ["has", 246], ["been", 250], ["well", 255], ["documented", 260], ["to", 271], ["be", 274], ["important", 277], ["in", 287], ["lymphocyte", 290], ["activation", 301], ["and", 312], ["more", 316], ["recently", 321], ["in", 330], ["platelet", 333], ["activation", 342], [".", 352], ["We", 354], ["performed", 357], ["experiments", 367], ["to", 379], ["evaluate", 382], ["whether", 391], ["inhibition", 399], ["of", 410], ["platelet", 413], ["activation", 422], ["through", 433], ["inhibition", 441], ["of", 452], ["spleen", 455], ["tyrosine", 462], ["kinase", 471], ["prevents", 478], ["tissue", 487], ["damage", 494], ["after", 501], ["mesenteric", 507], ["I", 518], ["/", 519], ["R", 520], ["injury", 522], [".", 528], ["Platelets", 530], ["isolated", 540], ["from", 549], ["C57BL/6J", 554], ["mice", 563], ["fed", 568], ["with", 572], ["R788", 577], ["for", 582], ["10", 586], ["days", 589], ["were", 594], ["transfused", 599], ["into", 610], ["C57BL/6J", 615], ["mice", 624], ["depleted", 629], ["of", 638], ["platelets", 641], ["2", 651], ["days", 653], ["before", 658], ["mesenteric", 665], ["I", 676], ["/", 677], ["R", 678], ["injury", 680], [".", 686], ["Platelet", 688], ["-", 696], ["depleted", 697], ["mice", 706], ["transfused", 711], ["with", 722], ["platelets", 727], ["from", 737], ["R788-treated", 742], ["mice", 755], ["before", 760], ["mesenteric", 767], ["I", 778], ["/", 779], ["R", 780], ["displayed", 782], ["a", 792], ["significant", 794], ["reduction", 806], ["in", 816], ["the", 819], ["degree", 823], ["of", 830], ["remote", 833], ["lung", 840], ["damage", 845], [",", 851], ["but", 853], ["with", 857], ["little", 862], ["change", 869], ["in", 876], ["the", 879], ["degree", 883], ["of", 890], ["local", 893], ["intestinal", 899], ["damage", 910], ["compared", 917], ["with", 926], ["control", 931], ["I", 939], ["/", 940], ["R", 941], ["mice", 943], [".", 947], ["Transfusion", 949], ["of", 961], ["R788-treated", 964], ["platelets", 977], ["also", 987], ["decreased", 992], ["platelet", 1002], ["sequestration", 1011], [",", 1024], ["C3", 1026], ["deposition", 1029], [",", 1039], ["and", 1041], ["immunoglobulin", 1045], ["deposition", 1060], ["in", 1071], ["lung", 1074], [",", 1078], ["but", 1080], ["not", 1084], ["in", 1088], ["the", 1091], ["intestine", 1095], [",", 1104], ["compared", 1106], ["with", 1115], ["control", 1120], ["groups", 1128], [".", 1134], ["These", 1136], ["findings", 1142], ["demonstrate", 1151], ["that", 1163], ["platelet", 1168], ["activation", 1177], ["is", 1188], ["a", 1191], ["requisite", 1193], ["for", 1203], ["sequestration", 1207], ["in", 1221], ["the", 1224], ["pulmonary", 1228], ["vasculature", 1238], ["to", 1250], ["mediate", 1253], ["remote", 1261], ["tissue", 1268], ["injury", 1275], ["after", 1282], ["mesenteric", 1288], ["I", 1299], ["/", 1300], ["R.", 1301], ["The", 1304], ["use", 1308], ["of", 1312], ["small", 1315], ["-", 1320], ["molecule", 1321], ["inhibitors", 1330], ["may", 1341], ["be", 1345], ["valuable", 1348], ["to", 1357], ["prevent", 1360], ["tissue", 1368], ["damage", 1375], ["in", 1382], ["remote", 1385], ["organs", 1392], ["following", 1399], ["I", 1409], ["/", 1410], ["R", 1411], ["injury", 1413], [".", 1419]]}
{"context": "Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental factors for proliferation and survival. In particular, the B-cell receptor (BCR) and nuclear factor- \u03baB (NF-\u03baB) pathways are activated in the lymph node (LN) microenvironment. Thus, model systems mimicking tumor-host interactions are important tools to study CLL biology and pathogenesis. We investigated whether the recently established NOD/scid/\u03b3c(null) (NSG) mouse xenograft model can recapitulate the effects of the human microenvironment. We assessed, therefore, tumor characteristics previously defined in LN-resident CLL cells, including proliferation, and activation of the BCR and NF-\u03baB pathways. We found that the murine spleen (SP) microenvironment supported CLL cell proliferation and activation to a similar degree than the human LN, including induction of BCR and NF-\u03baB signaling in the xenografted cells. Next, we used this model to study ibrutinib, a Bruton's tyrosine kinase inhibitor in clinical development. Ibrutinib inhibited BCR and NF-\u03baB signaling induced by the microenvironment, decreased proliferation, induced apoptosis and reduced the tumor burden in vivo. Thus, our data demonstrate that the SP of xenografted NSG mice can, in part, recapitulate the role of the human LN for CLL cells. In addition, we show that ibrutinib effectively disrupts tumor-host interactions essential for CLL cell proliferation and survival in vivo.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "bd86734b94164817a2682dd869cc2412", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[183, 183], [171, 171], [243, 243]], "char_spans": [[997, 1005], [924, 932], [1311, 1319]]}]}], "context_tokens": [["Chronic", 0], ["lymphocytic", 8], ["leukemia", 20], ["(", 29], ["CLL", 30], [")", 33], ["cells", 35], ["depend", 41], ["on", 48], ["microenvironmental", 51], ["factors", 70], ["for", 78], ["proliferation", 82], ["and", 96], ["survival", 100], [".", 108], ["In", 110], ["particular", 113], [",", 123], ["the", 125], ["B", 129], ["-", 130], ["cell", 131], ["receptor", 136], ["(", 145], ["BCR", 146], [")", 149], ["and", 151], ["nuclear", 155], ["factor-", 163], ["\u03baB", 171], ["(", 174], ["NF", 175], ["-", 177], ["\u03baB", 178], [")", 180], ["pathways", 182], ["are", 191], ["activated", 195], ["in", 205], ["the", 208], ["lymph", 212], ["node", 218], ["(", 223], ["LN", 224], [")", 226], ["microenvironment", 228], [".", 244], ["Thus", 246], [",", 250], ["model", 252], ["systems", 258], ["mimicking", 266], ["tumor", 276], ["-", 281], ["host", 282], ["interactions", 287], ["are", 300], ["important", 304], ["tools", 314], ["to", 320], ["study", 323], ["CLL", 329], ["biology", 333], ["and", 341], ["pathogenesis", 345], [".", 357], ["We", 359], ["investigated", 362], ["whether", 375], ["the", 383], ["recently", 387], ["established", 396], ["NOD", 408], ["/", 411], ["scid", 412], ["/", 416], ["\u03b3c(null", 417], [")", 424], ["(", 426], ["NSG", 427], [")", 430], ["mouse", 432], ["xenograft", 438], ["model", 448], ["can", 454], ["recapitulate", 458], ["the", 471], ["effects", 475], ["of", 483], ["the", 486], ["human", 490], ["microenvironment", 496], [".", 512], ["We", 514], ["assessed", 517], [",", 525], ["therefore", 527], [",", 536], ["tumor", 538], ["characteristics", 544], ["previously", 560], ["defined", 571], ["in", 579], ["LN", 582], ["-", 584], ["resident", 585], ["CLL", 594], ["cells", 598], [",", 603], ["including", 605], ["proliferation", 615], [",", 628], ["and", 630], ["activation", 634], ["of", 645], ["the", 648], ["BCR", 652], ["and", 656], ["NF", 660], ["-", 662], ["\u03baB", 663], ["pathways", 666], [".", 674], ["We", 676], ["found", 679], ["that", 685], ["the", 690], ["murine", 694], ["spleen", 701], ["(", 708], ["SP", 709], [")", 711], ["microenvironment", 713], ["supported", 730], ["CLL", 740], ["cell", 744], ["proliferation", 749], ["and", 763], ["activation", 767], ["to", 778], ["a", 781], ["similar", 783], ["degree", 791], ["than", 798], ["the", 803], ["human", 807], ["LN", 813], [",", 815], ["including", 817], ["induction", 827], ["of", 837], ["BCR", 840], ["and", 844], ["NF", 848], ["-", 850], ["\u03baB", 851], ["signaling", 854], ["in", 864], ["the", 867], ["xenografted", 871], ["cells", 883], [".", 888], ["Next", 890], [",", 894], ["we", 896], ["used", 899], ["this", 904], ["model", 909], ["to", 915], ["study", 918], ["ibrutinib", 924], [",", 933], ["a", 935], ["Bruton", 937], ["'s", 943], ["tyrosine", 946], ["kinase", 955], ["inhibitor", 962], ["in", 972], ["clinical", 975], ["development", 984], [".", 995], ["Ibrutinib", 997], ["inhibited", 1007], ["BCR", 1017], ["and", 1021], ["NF", 1025], ["-", 1027], ["\u03baB", 1028], ["signaling", 1031], ["induced", 1041], ["by", 1049], ["the", 1052], ["microenvironment", 1056], [",", 1072], ["decreased", 1074], ["proliferation", 1084], [",", 1097], ["induced", 1099], ["apoptosis", 1107], ["and", 1117], ["reduced", 1121], ["the", 1129], ["tumor", 1133], ["burden", 1139], ["in", 1146], ["vivo", 1149], [".", 1153], ["Thus", 1155], [",", 1159], ["our", 1161], ["data", 1165], ["demonstrate", 1170], ["that", 1182], ["the", 1187], ["SP", 1191], ["of", 1194], ["xenografted", 1197], ["NSG", 1209], ["mice", 1213], ["can", 1218], [",", 1221], ["in", 1223], ["part", 1226], [",", 1230], ["recapitulate", 1232], ["the", 1245], ["role", 1249], ["of", 1254], ["the", 1257], ["human", 1261], ["LN", 1267], ["for", 1270], ["CLL", 1274], ["cells", 1278], [".", 1283], ["In", 1285], ["addition", 1288], [",", 1296], ["we", 1298], ["show", 1301], ["that", 1306], ["ibrutinib", 1311], ["effectively", 1321], ["disrupts", 1333], ["tumor", 1342], ["-", 1347], ["host", 1348], ["interactions", 1353], ["essential", 1366], ["for", 1376], ["CLL", 1380], ["cell", 1384], ["proliferation", 1389], ["and", 1403], ["survival", 1407], ["in", 1416], ["vivo", 1419], [".", 1423]]}
{"context": "ESSENTIALS: When high probability of pulmonary embolism (PE), sensitivity of computed tomography (CT) is unclear. We investigated the sensitivity of multidetector CT among 134 patients with a high probability of PE. A normal CT alone may not safely exclude PE in patients with a high clinical pretest probability. In patients with no clear alternative diagnosis after CTPA, further testing should be strongly considered. Whether patients with a negative multidetector computed tomographic pulmonary angiography (CTPA) result and a high clinical pretest probability of pulmonary embolism (PE) should be further investigated is controversial. This was a prospective investigation of the sensitivity of multidetector CTPA among patients with a priori clinical assessment of a high probability of PE according to the Wells criteria. Among patients with a negative CTPA result, the diagnosis of PE required at least one of the following conditions: ventilation/perfusion lung scan showing a high probability of PE in a patient with no history of PE, abnormal findings on venous ultrasonography in a patient without previous deep vein thrombosis at that site, or the occurrence of venous thromboembolism (VTE) in a 3-month follow-up period after anticoagulation was withheld because of a negative multidetector CTPA result. We identified 498 patients with a priori clinical assessment of a high probability of PE and a completed CTPA study. CTPA excluded PE in 134 patients; in these patients, the pooled incidence of VTE was 5.2% (seven of 134 patients; 95% confidence interval [CI] 1.5-9.0). Five patients had VTEs that were confirmed by an additional imaging test despite a negative CTPA result (five of 48 patients; 10.4%; 95% CI 1.8-19.1), and two patients had objectively confirmed VTEs that occurred during clinical follow-up of at least 3 months (two of 86 patients; 2.3%; 95% CI 0-5.5). None of the patients had a fatal PE during follow-up. A normal multidetector CTPA result alone may not safely exclude PE in patients with a high clinical pretest probability.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "c80dfd34b9334ad1b4191ebe7f406ed0", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[6, 7], [95, 96]], "char_spans": [[37, 54], [568, 585]]}]}], "context_tokens": [["ESSENTIALS", 0], [":", 10], ["When", 12], ["high", 17], ["probability", 22], ["of", 34], ["pulmonary", 37], ["embolism", 47], ["(", 56], ["PE", 57], [")", 59], [",", 60], ["sensitivity", 62], ["of", 74], ["computed", 77], ["tomography", 86], ["(", 97], ["CT", 98], [")", 100], ["is", 102], ["unclear", 105], [".", 112], ["We", 114], ["investigated", 117], ["the", 130], ["sensitivity", 134], ["of", 146], ["multidetector", 149], ["CT", 163], ["among", 166], ["134", 172], ["patients", 176], ["with", 185], ["a", 190], ["high", 192], ["probability", 197], ["of", 209], ["PE", 212], [".", 214], ["A", 216], ["normal", 218], ["CT", 225], ["alone", 228], ["may", 234], ["not", 238], ["safely", 242], ["exclude", 249], ["PE", 257], ["in", 260], ["patients", 263], ["with", 272], ["a", 277], ["high", 279], ["clinical", 284], ["pretest", 293], ["probability", 301], [".", 312], ["In", 314], ["patients", 317], ["with", 326], ["no", 331], ["clear", 334], ["alternative", 340], ["diagnosis", 352], ["after", 362], ["CTPA", 368], [",", 372], ["further", 374], ["testing", 382], ["should", 390], ["be", 397], ["strongly", 400], ["considered", 409], [".", 419], ["Whether", 421], ["patients", 429], ["with", 438], ["a", 443], ["negative", 445], ["multidetector", 454], ["computed", 468], ["tomographic", 477], ["pulmonary", 489], ["angiography", 499], ["(", 511], ["CTPA", 512], [")", 516], ["result", 518], ["and", 525], ["a", 529], ["high", 531], ["clinical", 536], ["pretest", 545], ["probability", 553], ["of", 565], ["pulmonary", 568], ["embolism", 578], ["(", 587], ["PE", 588], [")", 590], ["should", 592], ["be", 599], ["further", 602], ["investigated", 610], ["is", 623], ["controversial", 626], [".", 639], ["This", 641], ["was", 646], ["a", 650], ["prospective", 652], ["investigation", 664], ["of", 678], ["the", 681], ["sensitivity", 685], ["of", 697], ["multidetector", 700], ["CTPA", 714], ["among", 719], ["patients", 725], ["with", 734], ["a", 739], ["priori", 741], ["clinical", 748], ["assessment", 757], ["of", 768], ["a", 771], ["high", 773], ["probability", 778], ["of", 790], ["PE", 793], ["according", 796], ["to", 806], ["the", 809], ["Wells", 813], ["criteria", 819], [".", 827], ["Among", 829], ["patients", 835], ["with", 844], ["a", 849], ["negative", 851], ["CTPA", 860], ["result", 865], [",", 871], ["the", 873], ["diagnosis", 877], ["of", 887], ["PE", 890], ["required", 893], ["at", 902], ["least", 905], ["one", 911], ["of", 915], ["the", 918], ["following", 922], ["conditions", 932], [":", 942], ["ventilation", 944], ["/", 955], ["perfusion", 956], ["lung", 966], ["scan", 971], ["showing", 976], ["a", 984], ["high", 986], ["probability", 991], ["of", 1003], ["PE", 1006], ["in", 1009], ["a", 1012], ["patient", 1014], ["with", 1022], ["no", 1027], ["history", 1030], ["of", 1038], ["PE", 1041], [",", 1043], ["abnormal", 1045], ["findings", 1054], ["on", 1063], ["venous", 1066], ["ultrasonography", 1073], ["in", 1089], ["a", 1092], ["patient", 1094], ["without", 1102], ["previous", 1110], ["deep", 1119], ["vein", 1124], ["thrombosis", 1129], ["at", 1140], ["that", 1143], ["site", 1148], [",", 1152], ["or", 1154], ["the", 1157], ["occurrence", 1161], ["of", 1172], ["venous", 1175], ["thromboembolism", 1182], ["(", 1198], ["VTE", 1199], [")", 1202], ["in", 1204], ["a", 1207], ["3-month", 1209], ["follow", 1217], ["-", 1223], ["up", 1224], ["period", 1227], ["after", 1234], ["anticoagulation", 1240], ["was", 1256], ["withheld", 1260], ["because", 1269], ["of", 1277], ["a", 1280], ["negative", 1282], ["multidetector", 1291], ["CTPA", 1305], ["result", 1310], [".", 1316], ["We", 1318], ["identified", 1321], ["498", 1332], ["patients", 1336], ["with", 1345], ["a", 1350], ["priori", 1352], ["clinical", 1359], ["assessment", 1368], ["of", 1379], ["a", 1382], ["high", 1384], ["probability", 1389], ["of", 1401], ["PE", 1404], ["and", 1407], ["a", 1411], ["completed", 1413], ["CTPA", 1423], ["study", 1428], [".", 1433], ["CTPA", 1435], ["excluded", 1440], ["PE", 1449], ["in", 1452], ["134", 1455], ["patients", 1459], [";", 1467], ["in", 1469], ["these", 1472], ["patients", 1478], [",", 1486], ["the", 1488], ["pooled", 1492], ["incidence", 1499], ["of", 1509], ["VTE", 1512], ["was", 1516], ["5.2", 1520], ["%", 1523], ["(", 1525], ["seven", 1526], ["of", 1532], ["134", 1535], ["patients", 1539], [";", 1547], ["95", 1549], ["%", 1551], ["confidence", 1553], ["interval", 1564], ["[", 1573], ["CI", 1574], ["]", 1576], ["1.5", 1578], ["-", 1581], ["9.0", 1582], [")", 1585], [".", 1586], ["Five", 1588], ["patients", 1593], ["had", 1602], ["VTEs", 1606], ["that", 1611], ["were", 1616], ["confirmed", 1621], ["by", 1631], ["an", 1634], ["additional", 1637], ["imaging", 1648], ["test", 1656], ["despite", 1661], ["a", 1669], ["negative", 1671], ["CTPA", 1680], ["result", 1685], ["(", 1692], ["five", 1693], ["of", 1698], ["48", 1701], ["patients", 1704], [";", 1712], ["10.4", 1714], ["%", 1718], [";", 1719], ["95", 1721], ["%", 1723], ["CI", 1725], ["1.8", 1728], ["-", 1731], ["19.1", 1732], [")", 1736], [",", 1737], ["and", 1739], ["two", 1743], ["patients", 1747], ["had", 1756], ["objectively", 1760], ["confirmed", 1772], ["VTEs", 1782], ["that", 1787], ["occurred", 1792], ["during", 1801], ["clinical", 1808], ["follow", 1817], ["-", 1823], ["up", 1824], ["of", 1827], ["at", 1830], ["least", 1833], ["3", 1839], ["months", 1841], ["(", 1848], ["two", 1849], ["of", 1853], ["86", 1856], ["patients", 1859], [";", 1867], ["2.3", 1869], ["%", 1872], [";", 1873], ["95", 1875], ["%", 1877], ["CI", 1879], ["0", 1882], ["-", 1883], ["5.5", 1884], [")", 1887], [".", 1888], ["None", 1890], ["of", 1895], ["the", 1898], ["patients", 1902], ["had", 1911], ["a", 1915], ["fatal", 1917], ["PE", 1923], ["during", 1926], ["follow", 1933], ["-", 1939], ["up", 1940], [".", 1942], ["A", 1944], ["normal", 1946], ["multidetector", 1953], ["CTPA", 1967], ["result", 1972], ["alone", 1979], ["may", 1985], ["not", 1989], ["safely", 1993], ["exclude", 2000], ["PE", 2008], ["in", 2011], ["patients", 2014], ["with", 2023], ["a", 2028], ["high", 2030], ["clinical", 2035], ["pretest", 2044], ["probability", 2052], [".", 2063]]}
{"context": "Secukinumab is a fully human anti-interleukin-17A monoclonal antibody. Determine the efficacy, safety and usability of secukinumab administered via autoinjector/pen. This phase III trial randomized subjects with moderate to severe plaque psoriasis to secukinumab 300 mg, 150 mg or placebo self-injection once weekly to Week 4, then every 4 weeks. Co-primary end points at Week 12 were \u226575% improvement in Psoriasis Area and Severity Index (PASI 75) and clear/almost clear skin by investigator's global assessment 2011 modified version (IGA mod 2011 0/1). Secondary end points included autoinjector usability, assessed by successful, hazard-free self-injection and subject-reported acceptability on Self-Injection Assessment Questionnaire. Week 12 PASI 75 and IGA mod 2011 0/1 responses were superior with secukinumab 300 mg (86.7% and 73.3%, respectively) and 150 mg (71.7% and 53.3%, respectively) vs. placebo (3.3% and 0%, respectively) (P < 0.0001 for all). All subjects successfully self-administered treatment at Week 1, without critical use-related hazards. Subject acceptability of autoinjector was high throughout 12 weeks. Adverse events were higher with secukinumab (300 mg, 70.0%; 150 mg, 63.9%) vs. placebo (54.1%), with differences largely driven by mild/moderate nasopharyngitis. Secukinumab delivered by autoinjector/pen is efficacious, well-tolerated and associated with high usability in moderate to severe plaque psoriasis.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "48fd74acae1f432cb35a1eea0ee94e16", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[7, 7]], "char_spans": [[34, 48]]}]}], "context_tokens": [["Secukinumab", 0], ["is", 12], ["a", 15], ["fully", 17], ["human", 23], ["anti", 29], ["-", 33], ["interleukin-17A", 34], ["monoclonal", 50], ["antibody", 61], [".", 69], ["Determine", 71], ["the", 81], ["efficacy", 85], [",", 93], ["safety", 95], ["and", 102], ["usability", 106], ["of", 116], ["secukinumab", 119], ["administered", 131], ["via", 144], ["autoinjector", 148], ["/", 160], ["pen", 161], [".", 164], ["This", 166], ["phase", 171], ["III", 177], ["trial", 181], ["randomized", 187], ["subjects", 198], ["with", 207], ["moderate", 212], ["to", 221], ["severe", 224], ["plaque", 231], ["psoriasis", 238], ["to", 248], ["secukinumab", 251], ["300", 263], ["mg", 267], [",", 269], ["150", 271], ["mg", 275], ["or", 278], ["placebo", 281], ["self", 289], ["-", 293], ["injection", 294], ["once", 304], ["weekly", 309], ["to", 316], ["Week", 319], ["4", 324], [",", 325], ["then", 327], ["every", 332], ["4", 338], ["weeks", 340], [".", 345], ["Co", 347], ["-", 349], ["primary", 350], ["end", 358], ["points", 362], ["at", 369], ["Week", 372], ["12", 377], ["were", 380], ["\u226575", 385], ["%", 388], ["improvement", 390], ["in", 402], ["Psoriasis", 405], ["Area", 415], ["and", 420], ["Severity", 424], ["Index", 433], ["(", 439], ["PASI", 440], ["75", 445], [")", 447], ["and", 449], ["clear", 453], ["/", 458], ["almost", 459], ["clear", 466], ["skin", 472], ["by", 477], ["investigator", 480], ["'s", 492], ["global", 495], ["assessment", 502], ["2011", 513], ["modified", 518], ["version", 527], ["(", 535], ["IGA", 536], ["mod", 540], ["2011", 544], ["0/1", 549], [")", 552], [".", 553], ["Secondary", 555], ["end", 565], ["points", 569], ["included", 576], ["autoinjector", 585], ["usability", 598], [",", 607], ["assessed", 609], ["by", 618], ["successful", 621], [",", 631], ["hazard", 633], ["-", 639], ["free", 640], ["self", 645], ["-", 649], ["injection", 650], ["and", 660], ["subject", 664], ["-", 671], ["reported", 672], ["acceptability", 681], ["on", 695], ["Self", 698], ["-", 702], ["Injection", 703], ["Assessment", 713], ["Questionnaire", 724], [".", 737], ["Week", 739], ["12", 744], ["PASI", 747], ["75", 752], ["and", 755], ["IGA", 759], ["mod", 763], ["2011", 767], ["0/1", 772], ["responses", 776], ["were", 786], ["superior", 791], ["with", 800], ["secukinumab", 805], ["300", 817], ["mg", 821], ["(", 824], ["86.7", 825], ["%", 829], ["and", 831], ["73.3", 835], ["%", 839], [",", 840], ["respectively", 842], [")", 854], ["and", 856], ["150", 860], ["mg", 864], ["(", 867], ["71.7", 868], ["%", 872], ["and", 874], ["53.3", 878], ["%", 882], [",", 883], ["respectively", 885], [")", 897], ["vs.", 899], ["placebo", 903], ["(", 911], ["3.3", 912], ["%", 915], ["and", 917], ["0", 921], ["%", 922], [",", 923], ["respectively", 925], [")", 937], ["(", 939], ["P", 940], ["<", 942], ["0.0001", 944], ["for", 951], ["all", 955], [")", 958], [".", 959], ["All", 961], ["subjects", 965], ["successfully", 974], ["self", 987], ["-", 991], ["administered", 992], ["treatment", 1005], ["at", 1015], ["Week", 1018], ["1", 1023], [",", 1024], ["without", 1026], ["critical", 1034], ["use", 1043], ["-", 1046], ["related", 1047], ["hazards", 1055], [".", 1062], ["Subject", 1064], ["acceptability", 1072], ["of", 1086], ["autoinjector", 1089], ["was", 1102], ["high", 1106], ["throughout", 1111], ["12", 1122], ["weeks", 1125], [".", 1130], ["Adverse", 1132], ["events", 1140], ["were", 1147], ["higher", 1152], ["with", 1159], ["secukinumab", 1164], ["(", 1176], ["300", 1177], ["mg", 1181], [",", 1183], ["70.0", 1185], ["%", 1189], [";", 1190], ["150", 1192], ["mg", 1196], [",", 1198], ["63.9", 1200], ["%", 1204], [")", 1205], ["vs.", 1207], ["placebo", 1211], ["(", 1219], ["54.1", 1220], ["%", 1224], [")", 1225], [",", 1226], ["with", 1228], ["differences", 1233], ["largely", 1245], ["driven", 1253], ["by", 1260], ["mild", 1263], ["/", 1267], ["moderate", 1268], ["nasopharyngitis", 1277], [".", 1292], ["Secukinumab", 1294], ["delivered", 1306], ["by", 1316], ["autoinjector", 1319], ["/", 1331], ["pen", 1332], ["is", 1336], ["efficacious", 1339], [",", 1350], ["well", 1352], ["-", 1356], ["tolerated", 1357], ["and", 1367], ["associated", 1371], ["with", 1382], ["high", 1387], ["usability", 1392], ["in", 1402], ["moderate", 1405], ["to", 1414], ["severe", 1417], ["plaque", 1424], ["psoriasis", 1431], [".", 1440]]}
{"context": "Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection. Self-administration by pre-filled syringe (PFS) can offer patients clinical benefits of a drug, with increased convenience. To assess efficacy, safety and usability of secukinumab administration via PFS in subjects with moderate-to-severe plaque psoriasis. Subjects in this phase 3 trial were randomized 1\u00a0:\u00a01\u00a0:\u00a01 to secukinumab 300 or 150\u00a0mg or matching placebo. Results to week 12 are presented here. Each treatment was delivered using a PFS once weekly to week 4, and again at week 8. Co-primary endpoints were secukinumab superiority over placebo for week 12 PASI 75 (\u2265\u00a075% reduction in Psoriasis Area and Severity Index) and IGA mod 2011 (2011 modified Investigator's Global Assessment) 0/1 response rates. Secondary endpoints included PFS usability, determined by observer rating of successful, hazard-free self-injection and subject rating of acceptability by the Self-Injection Assessment Questionnaire (SIAQ). Co-primary endpoints were met, with demonstration of superiority for each secukinumab dose vs. placebo at week 12 (PASI 75: 75\u00b79%, 69\u00b75% and 0% for secukinumab 300\u00a0mg, 150\u00a0mg and placebo; IGA mod 2011 0/1: 69\u00b70%, 52\u00b75% and 0%, respectively; P\u00a0<\u00a00\u00b70001 for all comparisons vs. placebo). PFS usability was high: 100% of subjects successfully self-administered treatment at week 1, and subjects reported high SIAQ-assessed acceptability of the PFS throughout the trial. No new/unexpected safety signals were observed. Secukinumab administration by PFS was effective, with an acceptable safety profile and high usability. The PFS provides a reliable, convenient form of secukinumab administration in subjects with moderate-to-severe plaque psoriasis.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "c282e77d67224f2583173daa54836108", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[7, 7]], "char_spans": [[32, 46]]}]}], "context_tokens": [["Secukinumab", 0], [",", 11], ["a", 13], ["fully", 15], ["human", 21], ["anti", 27], ["-", 31], ["interleukin-17A", 32], ["monoclonal", 48], ["antibody", 59], [",", 67], ["demonstrated", 69], ["efficacy", 82], ["and", 91], ["safety", 95], ["in", 102], ["moderate", 105], ["-", 113], ["to", 114], ["-", 116], ["severe", 117], ["plaque", 124], ["psoriasis", 131], ["when", 141], ["administered", 146], ["via", 159], ["subcutaneous", 163], ["injection", 176], [".", 185], ["Self", 187], ["-", 191], ["administration", 192], ["by", 207], ["pre", 210], ["-", 213], ["filled", 214], ["syringe", 221], ["(", 229], ["PFS", 230], [")", 233], ["can", 235], ["offer", 239], ["patients", 245], ["clinical", 254], ["benefits", 263], ["of", 272], ["a", 275], ["drug", 277], [",", 281], ["with", 283], ["increased", 288], ["convenience", 298], [".", 309], ["To", 311], ["assess", 314], ["efficacy", 321], [",", 329], ["safety", 331], ["and", 338], ["usability", 342], ["of", 352], ["secukinumab", 355], ["administration", 367], ["via", 382], ["PFS", 386], ["in", 390], ["subjects", 393], ["with", 402], ["moderate", 407], ["-", 415], ["to", 416], ["-", 418], ["severe", 419], ["plaque", 426], ["psoriasis", 433], [".", 442], ["Subjects", 444], ["in", 453], ["this", 456], ["phase", 461], ["3", 467], ["trial", 469], ["were", 475], ["randomized", 480], ["1", 491], [":", 493], ["1", 495], [":", 497], ["1", 499], ["to", 501], ["secukinumab", 504], ["300", 516], ["or", 520], ["150", 523], ["mg", 527], ["or", 530], ["matching", 533], ["placebo", 542], [".", 549], ["Results", 551], ["to", 559], ["week", 562], ["12", 567], ["are", 570], ["presented", 574], ["here", 584], [".", 588], ["Each", 590], ["treatment", 595], ["was", 605], ["delivered", 609], ["using", 619], ["a", 625], ["PFS", 627], ["once", 631], ["weekly", 636], ["to", 643], ["week", 646], ["4", 651], [",", 652], ["and", 654], ["again", 658], ["at", 664], ["week", 667], ["8", 672], [".", 673], ["Co", 675], ["-", 677], ["primary", 678], ["endpoints", 686], ["were", 696], ["secukinumab", 701], ["superiority", 713], ["over", 725], ["placebo", 730], ["for", 738], ["week", 742], ["12", 747], ["PASI", 750], ["75", 755], ["(", 758], ["\u2265", 759], ["75", 761], ["%", 763], ["reduction", 765], ["in", 775], ["Psoriasis", 778], ["Area", 788], ["and", 793], ["Severity", 797], ["Index", 806], [")", 811], ["and", 813], ["IGA", 817], ["mod", 821], ["2011", 825], ["(", 830], ["2011", 831], ["modified", 836], ["Investigator", 845], ["'s", 857], ["Global", 860], ["Assessment", 867], [")", 877], ["0/1", 879], ["response", 883], ["rates", 892], [".", 897], ["Secondary", 899], ["endpoints", 909], ["included", 919], ["PFS", 928], ["usability", 932], [",", 941], ["determined", 943], ["by", 954], ["observer", 957], ["rating", 966], ["of", 973], ["successful", 976], [",", 986], ["hazard", 988], ["-", 994], ["free", 995], ["self", 1000], ["-", 1004], ["injection", 1005], ["and", 1015], ["subject", 1019], ["rating", 1027], ["of", 1034], ["acceptability", 1037], ["by", 1051], ["the", 1054], ["Self", 1058], ["-", 1062], ["Injection", 1063], ["Assessment", 1073], ["Questionnaire", 1084], ["(", 1098], ["SIAQ", 1099], [")", 1103], [".", 1104], ["Co", 1106], ["-", 1108], ["primary", 1109], ["endpoints", 1117], ["were", 1127], ["met", 1132], [",", 1135], ["with", 1137], ["demonstration", 1142], ["of", 1156], ["superiority", 1159], ["for", 1171], ["each", 1175], ["secukinumab", 1180], ["dose", 1192], ["vs.", 1197], ["placebo", 1201], ["at", 1209], ["week", 1212], ["12", 1217], ["(", 1220], ["PASI", 1221], ["75", 1226], [":", 1228], ["75\u00b79", 1230], ["%", 1234], [",", 1235], ["69\u00b75", 1237], ["%", 1241], ["and", 1243], ["0", 1247], ["%", 1248], ["for", 1250], ["secukinumab", 1254], ["300", 1266], ["mg", 1270], [",", 1272], ["150", 1274], ["mg", 1278], ["and", 1281], ["placebo", 1285], [";", 1292], ["IGA", 1294], ["mod", 1298], ["2011", 1302], ["0/1", 1307], [":", 1310], ["69\u00b70", 1312], ["%", 1316], [",", 1317], ["52\u00b75", 1319], ["%", 1323], ["and", 1325], ["0", 1329], ["%", 1330], [",", 1331], ["respectively", 1333], [";", 1345], ["P", 1347], ["<", 1349], ["0\u00b70001", 1351], ["for", 1358], ["all", 1362], ["comparisons", 1366], ["vs.", 1378], ["placebo", 1382], [")", 1389], [".", 1390], ["PFS", 1392], ["usability", 1396], ["was", 1406], ["high", 1410], [":", 1414], ["100", 1416], ["%", 1419], ["of", 1421], ["subjects", 1424], ["successfully", 1433], ["self", 1446], ["-", 1450], ["administered", 1451], ["treatment", 1464], ["at", 1474], ["week", 1477], ["1", 1482], [",", 1483], ["and", 1485], ["subjects", 1489], ["reported", 1498], ["high", 1507], ["SIAQ", 1512], ["-", 1516], ["assessed", 1517], ["acceptability", 1526], ["of", 1540], ["the", 1543], ["PFS", 1547], ["throughout", 1551], ["the", 1562], ["trial", 1566], [".", 1571], ["No", 1573], ["new", 1576], ["/", 1579], ["unexpected", 1580], ["safety", 1591], ["signals", 1598], ["were", 1606], ["observed", 1611], [".", 1619], ["Secukinumab", 1621], ["administration", 1633], ["by", 1648], ["PFS", 1651], ["was", 1655], ["effective", 1659], [",", 1668], ["with", 1670], ["an", 1675], ["acceptable", 1678], ["safety", 1689], ["profile", 1696], ["and", 1704], ["high", 1708], ["usability", 1713], [".", 1722], ["The", 1724], ["PFS", 1728], ["provides", 1732], ["a", 1741], ["reliable", 1743], [",", 1751], ["convenient", 1753], ["form", 1764], ["of", 1769], ["secukinumab", 1772], ["administration", 1784], ["in", 1799], ["subjects", 1802], ["with", 1811], ["moderate", 1816], ["-", 1824], ["to", 1825], ["-", 1827], ["severe", 1828], ["plaque", 1835], ["psoriasis", 1842], [".", 1851]]}
{"context": "The loss of chromosome 1p and chromosome 3 is associated with metastatic disease and decreased survival of uveal melanoma (UM) patients. The p53 homologues, p73 and p63, are located on chromosomes 1p and 3q, respectively. Both are able to activate p53 target genes, resulting in growth arrest, apoptosis and differentiation. N-terminally truncated isoforms of these genes may act as dominant negative inhibitors of wild-type p53 and transactivating activity. Although, p53 is frequently involved in several malignancies it does not play a major role in UM. Altered expression has been reported for both p63 and p73 in various malignancies. In this study, fluorescent in-situ hybridization was performed to identify gains or losses of p63 and p73 loci in UM. The expression of the different p63 and p73 isoforms was evaluated by reverse transcriptase PCR followed by Southern blot analysis. Furthermore, the expression pattern of the various DeltaTAp73 transcripts was analysed in seven primary UMs and 11 UM-derived cell lines using isoform-specific real-time PCR. Our results indicated that the isoform p73Deltaex2/3 was abundantly expressed and a relative loss of the p73 locus was associated with the upregulation of p73Deltaex2 and TAp73 transcripts. N-terminal transactivation forms of both p73 and p63 were observed in primary and metastasis-derived cell lines, as well as in primary melanomas, but in only one of the cell lines a DeltaNp63 mRNA transcript was observed. Our data suggest a potential function of p73 deletion transcripts in UM progression.", "qas": [{"question": "How many TAp73 isoforms have been identified in humans?", "answers": ["seven", "7"], "qid": "b9c0d2a6dfcf4b40ba4c7b65373f1159", "question_tokens": [["How", 0], ["many", 4], ["TAp73", 9], ["isoforms", 15], ["have", 24], ["been", 29], ["identified", 34], ["in", 45], ["humans", 48], ["?", 54]], "detected_answers": [{"text": "seven", "token_spans": [[174, 174]], "char_spans": [[980, 984]]}]}], "context_tokens": [["The", 0], ["loss", 4], ["of", 9], ["chromosome", 12], ["1p", 23], ["and", 26], ["chromosome", 30], ["3", 41], ["is", 43], ["associated", 46], ["with", 57], ["metastatic", 62], ["disease", 73], ["and", 81], ["decreased", 85], ["survival", 95], ["of", 104], ["uveal", 107], ["melanoma", 113], ["(", 122], ["UM", 123], [")", 125], ["patients", 127], [".", 135], ["The", 137], ["p53", 141], ["homologues", 145], [",", 155], ["p73", 157], ["and", 161], ["p63", 165], [",", 168], ["are", 170], ["located", 174], ["on", 182], ["chromosomes", 185], ["1p", 197], ["and", 200], ["3q", 204], [",", 206], ["respectively", 208], [".", 220], ["Both", 222], ["are", 227], ["able", 231], ["to", 236], ["activate", 239], ["p53", 248], ["target", 252], ["genes", 259], [",", 264], ["resulting", 266], ["in", 276], ["growth", 279], ["arrest", 286], [",", 292], ["apoptosis", 294], ["and", 304], ["differentiation", 308], [".", 323], ["N", 325], ["-", 326], ["terminally", 327], ["truncated", 338], ["isoforms", 348], ["of", 357], ["these", 360], ["genes", 366], ["may", 372], ["act", 376], ["as", 380], ["dominant", 383], ["negative", 392], ["inhibitors", 401], ["of", 412], ["wild", 415], ["-", 419], ["type", 420], ["p53", 425], ["and", 429], ["transactivating", 433], ["activity", 449], [".", 457], ["Although", 459], [",", 467], ["p53", 469], ["is", 473], ["frequently", 476], ["involved", 487], ["in", 496], ["several", 499], ["malignancies", 507], ["it", 520], ["does", 523], ["not", 528], ["play", 532], ["a", 537], ["major", 539], ["role", 545], ["in", 550], ["UM", 553], [".", 555], ["Altered", 557], ["expression", 565], ["has", 576], ["been", 580], ["reported", 585], ["for", 594], ["both", 598], ["p63", 603], ["and", 607], ["p73", 611], ["in", 615], ["various", 618], ["malignancies", 626], [".", 638], ["In", 640], ["this", 643], ["study", 648], [",", 653], ["fluorescent", 655], ["in", 667], ["-", 669], ["situ", 670], ["hybridization", 675], ["was", 689], ["performed", 693], ["to", 703], ["identify", 706], ["gains", 715], ["or", 721], ["losses", 724], ["of", 731], ["p63", 734], ["and", 738], ["p73", 742], ["loci", 746], ["in", 751], ["UM", 754], [".", 756], ["The", 758], ["expression", 762], ["of", 773], ["the", 776], ["different", 780], ["p63", 790], ["and", 794], ["p73", 798], ["isoforms", 802], ["was", 811], ["evaluated", 815], ["by", 825], ["reverse", 828], ["transcriptase", 836], ["PCR", 850], ["followed", 854], ["by", 863], ["Southern", 866], ["blot", 875], ["analysis", 880], [".", 888], ["Furthermore", 890], [",", 901], ["the", 903], ["expression", 907], ["pattern", 918], ["of", 926], ["the", 929], ["various", 933], ["DeltaTAp73", 941], ["transcripts", 952], ["was", 964], ["analysed", 968], ["in", 977], ["seven", 980], ["primary", 986], ["UMs", 994], ["and", 998], ["11", 1002], ["UM", 1005], ["-", 1007], ["derived", 1008], ["cell", 1016], ["lines", 1021], ["using", 1027], ["isoform", 1033], ["-", 1040], ["specific", 1041], ["real", 1050], ["-", 1054], ["time", 1055], ["PCR", 1060], [".", 1063], ["Our", 1065], ["results", 1069], ["indicated", 1077], ["that", 1087], ["the", 1092], ["isoform", 1096], ["p73Deltaex2/3", 1104], ["was", 1118], ["abundantly", 1122], ["expressed", 1133], ["and", 1143], ["a", 1147], ["relative", 1149], ["loss", 1158], ["of", 1163], ["the", 1166], ["p73", 1170], ["locus", 1174], ["was", 1180], ["associated", 1184], ["with", 1195], ["the", 1200], ["upregulation", 1204], ["of", 1217], ["p73Deltaex2", 1220], ["and", 1232], ["TAp73", 1236], ["transcripts", 1242], [".", 1253], ["N", 1255], ["-", 1256], ["terminal", 1257], ["transactivation", 1266], ["forms", 1282], ["of", 1288], ["both", 1291], ["p73", 1296], ["and", 1300], ["p63", 1304], ["were", 1308], ["observed", 1313], ["in", 1322], ["primary", 1325], ["and", 1333], ["metastasis", 1337], ["-", 1347], ["derived", 1348], ["cell", 1356], ["lines", 1361], [",", 1366], ["as", 1368], ["well", 1371], ["as", 1376], ["in", 1379], ["primary", 1382], ["melanomas", 1390], [",", 1399], ["but", 1401], ["in", 1405], ["only", 1408], ["one", 1413], ["of", 1417], ["the", 1420], ["cell", 1424], ["lines", 1429], ["a", 1435], ["DeltaNp63", 1437], ["mRNA", 1447], ["transcript", 1452], ["was", 1463], ["observed", 1467], [".", 1475], ["Our", 1477], ["data", 1481], ["suggest", 1486], ["a", 1494], ["potential", 1496], ["function", 1506], ["of", 1515], ["p73", 1518], ["deletion", 1522], ["transcripts", 1531], ["in", 1543], ["UM", 1546], ["progression", 1549], [".", 1560]]}
{"context": "The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia in patients with diabetes. SGLT1 enables the small intestine to absorb glucose and contributes to the reabsorption of glucose filtered by the kidney. SGLT2 is responsible for reabsorption of most of the glucose filtered by the kidney. Inhibitors with varying specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose absorption and increase the renal elimination of glucose into the urine. Results of randomised clinical trials have shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as monotherapy or in addition to other glucose-lowering therapies including insulin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and might increase risk of urinary tract and genital infection, and excessive inhibition of SGLT1 can cause gastro-intestinal symptoms. However, the insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering efficacy with low risk of clinically significant hypoglycaemia at any stage in the natural history of type 2 diabetes. SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "b276b8fe9b6948f191fb1b8d4d86167a", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[151, 151], [47, 47], [13, 13]], "char_spans": [[927, 931], [276, 280], [62, 66]]}]}], "context_tokens": [["The", 0], ["two", 4], ["main", 8], ["sodium", 13], ["-", 19], ["glucose", 20], ["cotransporters", 28], ["(", 43], ["SGLTs", 44], [")", 49], [",", 50], ["SGLT1", 52], ["and", 58], ["SGLT2", 62], [",", 67], ["provide", 69], ["new", 77], ["therapeutic", 81], ["targets", 93], ["to", 101], ["reduce", 104], ["hyperglycaemia", 111], ["in", 126], ["patients", 129], ["with", 138], ["diabetes", 143], [".", 151], ["SGLT1", 153], ["enables", 159], ["the", 167], ["small", 171], ["intestine", 177], ["to", 187], ["absorb", 190], ["glucose", 197], ["and", 205], ["contributes", 209], ["to", 221], ["the", 224], ["reabsorption", 228], ["of", 241], ["glucose", 244], ["filtered", 252], ["by", 261], ["the", 264], ["kidney", 268], [".", 274], ["SGLT2", 276], ["is", 282], ["responsible", 285], ["for", 297], ["reabsorption", 301], ["of", 314], ["most", 317], ["of", 322], ["the", 325], ["glucose", 329], ["filtered", 337], ["by", 346], ["the", 349], ["kidney", 353], [".", 359], ["Inhibitors", 361], ["with", 372], ["varying", 377], ["specificities", 385], ["for", 399], ["these", 403], ["transporters", 409], ["(", 422], ["eg", 423], [",", 425], ["dapagliflozin", 427], [",", 440], ["canagliflozin", 442], [",", 455], ["and", 457], ["empagliflozin", 461], [")", 474], ["can", 476], ["slow", 480], ["the", 485], ["rate", 489], ["of", 494], ["intestinal", 497], ["glucose", 508], ["absorption", 516], ["and", 527], ["increase", 531], ["the", 540], ["renal", 544], ["elimination", 550], ["of", 562], ["glucose", 565], ["into", 573], ["the", 578], ["urine", 582], [".", 587], ["Results", 589], ["of", 597], ["randomised", 600], ["clinical", 611], ["trials", 620], ["have", 627], ["shown", 632], ["the", 638], ["blood", 642], ["glucose", 648], ["-", 655], ["lowering", 656], ["efficacy", 665], ["of", 674], ["SGLT", 677], ["inhibitors", 682], ["in", 693], ["type", 696], ["2", 701], ["diabetes", 703], ["when", 712], ["administered", 717], ["as", 730], ["monotherapy", 733], ["or", 745], ["in", 748], ["addition", 751], ["to", 760], ["other", 763], ["glucose", 769], ["-", 776], ["lowering", 777], ["therapies", 786], ["including", 796], ["insulin", 806], [".", 813], ["Increased", 815], ["renal", 825], ["glucose", 831], ["elimination", 839], ["also", 851], ["assists", 856], ["weight", 864], ["loss", 871], ["and", 876], ["could", 880], ["help", 886], ["to", 891], ["reduce", 894], ["blood", 901], ["pressure", 907], [".", 915], ["Effective", 917], ["SGLT2", 927], ["inhibition", 933], ["needs", 944], ["adequate", 950], ["glomerular", 959], ["filtration", 970], ["and", 981], ["might", 985], ["increase", 991], ["risk", 1000], ["of", 1005], ["urinary", 1008], ["tract", 1016], ["and", 1022], ["genital", 1026], ["infection", 1034], [",", 1043], ["and", 1045], ["excessive", 1049], ["inhibition", 1059], ["of", 1070], ["SGLT1", 1073], ["can", 1079], ["cause", 1083], ["gastro", 1089], ["-", 1095], ["intestinal", 1096], ["symptoms", 1107], [".", 1115], ["However", 1117], [",", 1124], ["the", 1126], ["insulin", 1130], ["-", 1137], ["independent", 1138], ["mechanism", 1150], ["of", 1160], ["action", 1163], ["of", 1170], ["SGLT", 1173], ["inhibitors", 1178], ["seems", 1189], ["to", 1195], ["offer", 1198], ["durable", 1204], ["glucose", 1212], ["-", 1219], ["lowering", 1220], ["efficacy", 1229], ["with", 1238], ["low", 1243], ["risk", 1247], ["of", 1252], ["clinically", 1255], ["significant", 1266], ["hypoglycaemia", 1278], ["at", 1292], ["any", 1295], ["stage", 1299], ["in", 1305], ["the", 1308], ["natural", 1312], ["history", 1320], ["of", 1328], ["type", 1331], ["2", 1336], ["diabetes", 1338], [".", 1346], ["SGLT", 1348], ["inhibition", 1353], ["might", 1364], ["also", 1370], ["be", 1375], ["considered", 1378], ["in", 1389], ["conjunction", 1392], ["with", 1404], ["insulin", 1409], ["therapy", 1417], ["in", 1425], ["type", 1428], ["1", 1433], ["diabetes", 1435], [".", 1443]]}
{"context": "Rubinstein-Taybi syndrome (RSTS) is a rare autosomal dominant disorder characterised by facial dysmorphisms, growth and psychomotor development delay, and skeletal defects. The known genetic causes are point mutations or deletions of the CREBBP (50-60%) and EP300 (5%) genes. To detect chromosomal rearrangements indicating novel positional candidate RSTS genes, we used a-CGH to study 26 patients fulfilling the diagnostic criteria for RSTS who were negative at fluorescence in situ hybridisation analyses of the CREBBP and EP300 regions, and direct sequencing analyses of the CREBBP gene. We found seven imbalances (27%): four de novo and three inherited rearrangements not reported among the copy number variants. A de novo 7p21.1 deletion of 500 kb included the TWIST1 gene, a suggested candidate for RSTS that is responsible for the Saethre-Chotzen syndrome, an entity that enters in differential diagnosis with RSTS. A similar issue of differential diagnosis was raised by a large 4.3 Mb 2q22.3q23.1 deletion encompassing ZEB2, the gene responsible for the Mowat-Wilson syndrome, whose signs may overlap with RSTS. Positional candidate genes could not be sought in the remaining pathogenetic imbalances, because of the size of the involved region (a 9 Mb 2q24.3q31.1 deletion) and/or the relative paucity of suitable genes (a 5 Mb 3p13p12.3 duplication). One of the inherited rearrangements, the 17q11.2 379Kb duplication, represents the reciprocal event of the deletion underlying an overgrowth syndrome, both being mediated by the NF1-REP-P1 and REP-P2 sub-duplicons. The contribution of this and the other detected CNVs to the clinical RSTS phenotype is difficult to assess.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "319083e67cd448328850b8010c134c4d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[183, 183]], "char_spans": [[1028, 1031]]}]}], "context_tokens": [["Rubinstein", 0], ["-", 10], ["Taybi", 11], ["syndrome", 17], ["(", 26], ["RSTS", 27], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["autosomal", 43], ["dominant", 53], ["disorder", 62], ["characterised", 71], ["by", 85], ["facial", 88], ["dysmorphisms", 95], [",", 107], ["growth", 109], ["and", 116], ["psychomotor", 120], ["development", 132], ["delay", 144], [",", 149], ["and", 151], ["skeletal", 155], ["defects", 164], [".", 171], ["The", 173], ["known", 177], ["genetic", 183], ["causes", 191], ["are", 198], ["point", 202], ["mutations", 208], ["or", 218], ["deletions", 221], ["of", 231], ["the", 234], ["CREBBP", 238], ["(", 245], ["50", 246], ["-", 248], ["60", 249], ["%", 251], [")", 252], ["and", 254], ["EP300", 258], ["(", 264], ["5", 265], ["%", 266], [")", 267], ["genes", 269], [".", 274], ["To", 276], ["detect", 279], ["chromosomal", 286], ["rearrangements", 298], ["indicating", 313], ["novel", 324], ["positional", 330], ["candidate", 341], ["RSTS", 351], ["genes", 356], [",", 361], ["we", 363], ["used", 366], ["a", 371], ["-", 372], ["CGH", 373], ["to", 377], ["study", 380], ["26", 386], ["patients", 389], ["fulfilling", 398], ["the", 409], ["diagnostic", 413], ["criteria", 424], ["for", 433], ["RSTS", 437], ["who", 442], ["were", 446], ["negative", 451], ["at", 460], ["fluorescence", 463], ["in", 476], ["situ", 479], ["hybridisation", 484], ["analyses", 498], ["of", 507], ["the", 510], ["CREBBP", 514], ["and", 521], ["EP300", 525], ["regions", 531], [",", 538], ["and", 540], ["direct", 544], ["sequencing", 551], ["analyses", 562], ["of", 571], ["the", 574], ["CREBBP", 578], ["gene", 585], [".", 589], ["We", 591], ["found", 594], ["seven", 600], ["imbalances", 606], ["(", 617], ["27", 618], ["%", 620], [")", 621], [":", 622], ["four", 624], ["de", 629], ["novo", 632], ["and", 637], ["three", 641], ["inherited", 647], ["rearrangements", 657], ["not", 672], ["reported", 676], ["among", 685], ["the", 691], ["copy", 695], ["number", 700], ["variants", 707], [".", 715], ["A", 717], ["de", 719], ["novo", 722], ["7p21.1", 727], ["deletion", 734], ["of", 743], ["500", 746], ["kb", 750], ["included", 753], ["the", 762], ["TWIST1", 766], ["gene", 773], [",", 777], ["a", 779], ["suggested", 781], ["candidate", 791], ["for", 801], ["RSTS", 805], ["that", 810], ["is", 815], ["responsible", 818], ["for", 830], ["the", 834], ["Saethre", 838], ["-", 845], ["Chotzen", 846], ["syndrome", 854], [",", 862], ["an", 864], ["entity", 867], ["that", 874], ["enters", 879], ["in", 886], ["differential", 889], ["diagnosis", 902], ["with", 912], ["RSTS", 917], [".", 921], ["A", 923], ["similar", 925], ["issue", 933], ["of", 939], ["differential", 942], ["diagnosis", 955], ["was", 965], ["raised", 969], ["by", 976], ["a", 979], ["large", 981], ["4.3", 987], ["Mb", 991], ["2q22.3q23.1", 994], ["deletion", 1006], ["encompassing", 1015], ["ZEB2", 1028], [",", 1032], ["the", 1034], ["gene", 1038], ["responsible", 1043], ["for", 1055], ["the", 1059], ["Mowat", 1063], ["-", 1068], ["Wilson", 1069], ["syndrome", 1076], [",", 1084], ["whose", 1086], ["signs", 1092], ["may", 1098], ["overlap", 1102], ["with", 1110], ["RSTS", 1115], [".", 1119], ["Positional", 1121], ["candidate", 1132], ["genes", 1142], ["could", 1148], ["not", 1154], ["be", 1158], ["sought", 1161], ["in", 1168], ["the", 1171], ["remaining", 1175], ["pathogenetic", 1185], ["imbalances", 1198], [",", 1208], ["because", 1210], ["of", 1218], ["the", 1221], ["size", 1225], ["of", 1230], ["the", 1233], ["involved", 1237], ["region", 1246], ["(", 1253], ["a", 1254], ["9", 1256], ["Mb", 1258], ["2q24.3q31.1", 1261], ["deletion", 1273], [")", 1281], ["and/or", 1283], ["the", 1290], ["relative", 1294], ["paucity", 1303], ["of", 1311], ["suitable", 1314], ["genes", 1323], ["(", 1329], ["a", 1330], ["5", 1332], ["Mb", 1334], ["3p13p12.3", 1337], ["duplication", 1347], [")", 1358], [".", 1359], ["One", 1361], ["of", 1365], ["the", 1368], ["inherited", 1372], ["rearrangements", 1382], [",", 1396], ["the", 1398], ["17q11.2", 1402], ["379Kb", 1410], ["duplication", 1416], [",", 1427], ["represents", 1429], ["the", 1440], ["reciprocal", 1444], ["event", 1455], ["of", 1461], ["the", 1464], ["deletion", 1468], ["underlying", 1477], ["an", 1488], ["overgrowth", 1491], ["syndrome", 1502], [",", 1510], ["both", 1512], ["being", 1517], ["mediated", 1523], ["by", 1532], ["the", 1535], ["NF1-REP", 1539], ["-", 1546], ["P1", 1547], ["and", 1550], ["REP", 1554], ["-", 1557], ["P2", 1558], ["sub", 1561], ["-", 1564], ["duplicons", 1565], [".", 1574], ["The", 1576], ["contribution", 1580], ["of", 1593], ["this", 1596], ["and", 1601], ["the", 1605], ["other", 1609], ["detected", 1615], ["CNVs", 1624], ["to", 1629], ["the", 1632], ["clinical", 1636], ["RSTS", 1645], ["phenotype", 1650], ["is", 1660], ["difficult", 1663], ["to", 1673], ["assess", 1676], [".", 1682]]}
{"context": "The heart responds to injury and chronic pressure overload by pathologic growth and remodeling, which frequently result in heart failure and sudden death. Calcium-dependent signaling pathways promote cardiac growth and associated changes in gene expression in response to stress. The calcium/calmodulin-dependent phosphatase calcineurin, which signals to nuclear factor of activated T cells (NFAT) transcription factors, serves as a transducer of calcium signals and is sufficient and necessary for pathologic cardiac hypertrophy and remodeling. Transient receptor potential (TRP) proteins regulate cation entry into cells in response to a variety of signals, and in skeletal muscle, expression of TRP cation channel, subfamily C, member 3 (TRPC3) is increased in response to neurostimulation and calcineurin signaling. Here we show that TRPC6 was upregulated in mouse hearts in response to activated calcineurin and pressure overload, as well as in failing human hearts. Two conserved NFAT consensus sites in the promoter of the TRPC6 gene conferred responsiveness to cardiac stress. Cardiac-specific overexpression of TRPC6 in transgenic mice resulted in heightened sensitivity to stress, a propensity for lethal cardiac growth and heart failure, and an increase in NFAT-dependent expression of beta-myosin heavy chain, a sensitive marker for pathologic hypertrophy. These findings implicate TRPC6 as a positive regulator of calcineurin-NFAT signaling and a key component of a calcium-dependent regulatory loop that drives pathologic cardiac remodeling.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "0109efd350d2412484e85a1d74f44015", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[238, 238], [133, 133], [51, 51], [150, 150]], "char_spans": [[1427, 1437], [797, 807], [325, 335], [901, 911]]}]}], "context_tokens": [["The", 0], ["heart", 4], ["responds", 10], ["to", 19], ["injury", 22], ["and", 29], ["chronic", 33], ["pressure", 41], ["overload", 50], ["by", 59], ["pathologic", 62], ["growth", 73], ["and", 80], ["remodeling", 84], [",", 94], ["which", 96], ["frequently", 102], ["result", 113], ["in", 120], ["heart", 123], ["failure", 129], ["and", 137], ["sudden", 141], ["death", 148], [".", 153], ["Calcium", 155], ["-", 162], ["dependent", 163], ["signaling", 173], ["pathways", 183], ["promote", 192], ["cardiac", 200], ["growth", 208], ["and", 215], ["associated", 219], ["changes", 230], ["in", 238], ["gene", 241], ["expression", 246], ["in", 257], ["response", 260], ["to", 269], ["stress", 272], [".", 278], ["The", 280], ["calcium", 284], ["/", 291], ["calmodulin", 292], ["-", 302], ["dependent", 303], ["phosphatase", 313], ["calcineurin", 325], [",", 336], ["which", 338], ["signals", 344], ["to", 352], ["nuclear", 355], ["factor", 363], ["of", 370], ["activated", 373], ["T", 383], ["cells", 385], ["(", 391], ["NFAT", 392], [")", 396], ["transcription", 398], ["factors", 412], [",", 419], ["serves", 421], ["as", 428], ["a", 431], ["transducer", 433], ["of", 444], ["calcium", 447], ["signals", 455], ["and", 463], ["is", 467], ["sufficient", 470], ["and", 481], ["necessary", 485], ["for", 495], ["pathologic", 499], ["cardiac", 510], ["hypertrophy", 518], ["and", 530], ["remodeling", 534], [".", 544], ["Transient", 546], ["receptor", 556], ["potential", 565], ["(", 575], ["TRP", 576], [")", 579], ["proteins", 581], ["regulate", 590], ["cation", 599], ["entry", 606], ["into", 612], ["cells", 617], ["in", 623], ["response", 626], ["to", 635], ["a", 638], ["variety", 640], ["of", 648], ["signals", 651], [",", 658], ["and", 660], ["in", 664], ["skeletal", 667], ["muscle", 676], [",", 682], ["expression", 684], ["of", 695], ["TRP", 698], ["cation", 702], ["channel", 709], [",", 716], ["subfamily", 718], ["C", 728], [",", 729], ["member", 731], ["3", 738], ["(", 740], ["TRPC3", 741], [")", 746], ["is", 748], ["increased", 751], ["in", 761], ["response", 764], ["to", 773], ["neurostimulation", 776], ["and", 793], ["calcineurin", 797], ["signaling", 809], [".", 818], ["Here", 820], ["we", 825], ["show", 828], ["that", 833], ["TRPC6", 838], ["was", 844], ["upregulated", 848], ["in", 860], ["mouse", 863], ["hearts", 869], ["in", 876], ["response", 879], ["to", 888], ["activated", 891], ["calcineurin", 901], ["and", 913], ["pressure", 917], ["overload", 926], [",", 934], ["as", 936], ["well", 939], ["as", 944], ["in", 947], ["failing", 950], ["human", 958], ["hearts", 964], [".", 970], ["Two", 972], ["conserved", 976], ["NFAT", 986], ["consensus", 991], ["sites", 1001], ["in", 1007], ["the", 1010], ["promoter", 1014], ["of", 1023], ["the", 1026], ["TRPC6", 1030], ["gene", 1036], ["conferred", 1041], ["responsiveness", 1051], ["to", 1066], ["cardiac", 1069], ["stress", 1077], [".", 1083], ["Cardiac", 1085], ["-", 1092], ["specific", 1093], ["overexpression", 1102], ["of", 1117], ["TRPC6", 1120], ["in", 1126], ["transgenic", 1129], ["mice", 1140], ["resulted", 1145], ["in", 1154], ["heightened", 1157], ["sensitivity", 1168], ["to", 1180], ["stress", 1183], [",", 1189], ["a", 1191], ["propensity", 1193], ["for", 1204], ["lethal", 1208], ["cardiac", 1215], ["growth", 1223], ["and", 1230], ["heart", 1234], ["failure", 1240], [",", 1247], ["and", 1249], ["an", 1253], ["increase", 1256], ["in", 1265], ["NFAT", 1268], ["-", 1272], ["dependent", 1273], ["expression", 1283], ["of", 1294], ["beta", 1297], ["-", 1301], ["myosin", 1302], ["heavy", 1309], ["chain", 1315], [",", 1320], ["a", 1322], ["sensitive", 1324], ["marker", 1334], ["for", 1341], ["pathologic", 1345], ["hypertrophy", 1356], [".", 1367], ["These", 1369], ["findings", 1375], ["implicate", 1384], ["TRPC6", 1394], ["as", 1400], ["a", 1403], ["positive", 1405], ["regulator", 1414], ["of", 1424], ["calcineurin", 1427], ["-", 1438], ["NFAT", 1439], ["signaling", 1444], ["and", 1454], ["a", 1458], ["key", 1460], ["component", 1464], ["of", 1474], ["a", 1477], ["calcium", 1479], ["-", 1486], ["dependent", 1487], ["regulatory", 1497], ["loop", 1508], ["that", 1513], ["drives", 1518], ["pathologic", 1525], ["cardiac", 1536], ["remodeling", 1544], [".", 1554]]}
{"context": "In anaesthesia and in the intensive care unit, benzodiazepines have proven safe and effective agents for the induction and maintenance of sedation for a variety of therapeutic goals. However, in these contexts, or in benzodiazepine overdose, it is often desirable to be able to terminate or interrupt sedation without waiting for the effect of the benzodiazepine to become dissipated by normal metabolism and excretion. Flumazenil, a 1,4-imidazobenzodiazepine, is a highly effective, specific benzodiazepine antagonist which is indicated for use when the effect of a benzodiazepine must be attenuated or terminated at short notice. It acts by displacing other benzodiazepines from the receptor site by competitive inhibition. The onset of effect after intravenous administration occurs within 1 to 3 minutes. The optimal dosage is determined for each patient by a dose titration procedure and lies in the range 0.2 to 1.0mg in anaesthesiology, and 0.1 to 2.0mg in intensive care use. Despite its short elimination half-life of around 1 hour, after general anaesthesia or conscious to moderate sedation for short procedures, a single dose of flumazenil is usually sufficient to attain and maintain the desired level of consciousness. After intoxication with high benzodiazepine doses, the duration of effect of a single dose of flumazenil is not expected to exceed 1 hour. In such cases, the period of wakefulness can be prolonged as necessary by repeated low intravenous doses of flumazenil or by infusion (0.1 mg/hour). Flumazenil is well tolerated both systemically and locally. The only adverse events seen with greater frequency after flumazenil compared with placebo were nausea and/or vomiting after general anaesthesia, although the incidence of actual vomiting was not significantly different between the 2 groups. Since these effects were virtually absent in studies of intensive care patients and after sedation for short procedures, and were not seen in tolerability studies in healthy volunteers receiving intravenous bolus doses of up to 100mg, there may be a link between these symptoms and the other agents used in general anaesthesia, some of which have well-known emetic properties. Thus, flumazenil provides a safe and effective means of attenuating or reversing the CNS-depressant effects of benzodiazepines whenever indicated, e.g. following benzodiazepine-induced general anaesthesia, conscious sedation, or after benzodiazepine overdose, either alone or in combination with other agents.(ABSTRACT TRUNCATED AT 400 WORDS)", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "1b2cd22acd744de49a797383cab4fcb4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[224, 224], [70, 70], [252, 252], [263, 263], [281, 281], [376, 376], [194, 194]], "char_spans": [[1327, 1336], [420, 429], [1480, 1489], [1521, 1530], [1639, 1648], [2206, 2215], [1141, 1150]]}]}], "context_tokens": [["In", 0], ["anaesthesia", 3], ["and", 15], ["in", 19], ["the", 22], ["intensive", 26], ["care", 36], ["unit", 41], [",", 45], ["benzodiazepines", 47], ["have", 63], ["proven", 68], ["safe", 75], ["and", 80], ["effective", 84], ["agents", 94], ["for", 101], ["the", 105], ["induction", 109], ["and", 119], ["maintenance", 123], ["of", 135], ["sedation", 138], ["for", 147], ["a", 151], ["variety", 153], ["of", 161], ["therapeutic", 164], ["goals", 176], [".", 181], ["However", 183], [",", 190], ["in", 192], ["these", 195], ["contexts", 201], [",", 209], ["or", 211], ["in", 214], ["benzodiazepine", 217], ["overdose", 232], [",", 240], ["it", 242], ["is", 245], ["often", 248], ["desirable", 254], ["to", 264], ["be", 267], ["able", 270], ["to", 275], ["terminate", 278], ["or", 288], ["interrupt", 291], ["sedation", 301], ["without", 310], ["waiting", 318], ["for", 326], ["the", 330], ["effect", 334], ["of", 341], ["the", 344], ["benzodiazepine", 348], ["to", 363], ["become", 366], ["dissipated", 373], ["by", 384], ["normal", 387], ["metabolism", 394], ["and", 405], ["excretion", 409], [".", 418], ["Flumazenil", 420], [",", 430], ["a", 432], ["1,4-imidazobenzodiazepine", 434], [",", 459], ["is", 461], ["a", 464], ["highly", 466], ["effective", 473], [",", 482], ["specific", 484], ["benzodiazepine", 493], ["antagonist", 508], ["which", 519], ["is", 525], ["indicated", 528], ["for", 538], ["use", 542], ["when", 546], ["the", 551], ["effect", 555], ["of", 562], ["a", 565], ["benzodiazepine", 567], ["must", 582], ["be", 587], ["attenuated", 590], ["or", 601], ["terminated", 604], ["at", 615], ["short", 618], ["notice", 624], [".", 630], ["It", 632], ["acts", 635], ["by", 640], ["displacing", 643], ["other", 654], ["benzodiazepines", 660], ["from", 676], ["the", 681], ["receptor", 685], ["site", 694], ["by", 699], ["competitive", 702], ["inhibition", 714], [".", 724], ["The", 726], ["onset", 730], ["of", 736], ["effect", 739], ["after", 746], ["intravenous", 752], ["administration", 764], ["occurs", 779], ["within", 786], ["1", 793], ["to", 795], ["3", 798], ["minutes", 800], [".", 807], ["The", 809], ["optimal", 813], ["dosage", 821], ["is", 828], ["determined", 831], ["for", 842], ["each", 846], ["patient", 851], ["by", 859], ["a", 862], ["dose", 864], ["titration", 869], ["procedure", 879], ["and", 889], ["lies", 893], ["in", 898], ["the", 901], ["range", 905], ["0.2", 911], ["to", 915], ["1.0", 918], ["mg", 921], ["in", 924], ["anaesthesiology", 927], [",", 942], ["and", 944], ["0.1", 948], ["to", 952], ["2.0", 955], ["mg", 958], ["in", 961], ["intensive", 964], ["care", 974], ["use", 979], [".", 982], ["Despite", 984], ["its", 992], ["short", 996], ["elimination", 1002], ["half", 1014], ["-", 1018], ["life", 1019], ["of", 1024], ["around", 1027], ["1", 1034], ["hour", 1036], [",", 1040], ["after", 1042], ["general", 1048], ["anaesthesia", 1056], ["or", 1068], ["conscious", 1071], ["to", 1081], ["moderate", 1084], ["sedation", 1093], ["for", 1102], ["short", 1106], ["procedures", 1112], [",", 1122], ["a", 1124], ["single", 1126], ["dose", 1133], ["of", 1138], ["flumazenil", 1141], ["is", 1152], ["usually", 1155], ["sufficient", 1163], ["to", 1174], ["attain", 1177], ["and", 1184], ["maintain", 1188], ["the", 1197], ["desired", 1201], ["level", 1209], ["of", 1215], ["consciousness", 1218], [".", 1231], ["After", 1233], ["intoxication", 1239], ["with", 1252], ["high", 1257], ["benzodiazepine", 1262], ["doses", 1277], [",", 1282], ["the", 1284], ["duration", 1288], ["of", 1297], ["effect", 1300], ["of", 1307], ["a", 1310], ["single", 1312], ["dose", 1319], ["of", 1324], ["flumazenil", 1327], ["is", 1338], ["not", 1341], ["expected", 1345], ["to", 1354], ["exceed", 1357], ["1", 1364], ["hour", 1366], [".", 1370], ["In", 1372], ["such", 1375], ["cases", 1380], [",", 1385], ["the", 1387], ["period", 1391], ["of", 1398], ["wakefulness", 1401], ["can", 1413], ["be", 1417], ["prolonged", 1420], ["as", 1430], ["necessary", 1433], ["by", 1443], ["repeated", 1446], ["low", 1455], ["intravenous", 1459], ["doses", 1471], ["of", 1477], ["flumazenil", 1480], ["or", 1491], ["by", 1494], ["infusion", 1497], ["(", 1506], ["0.1", 1507], ["mg", 1511], ["/", 1513], ["hour", 1514], [")", 1518], [".", 1519], ["Flumazenil", 1521], ["is", 1532], ["well", 1535], ["tolerated", 1540], ["both", 1550], ["systemically", 1555], ["and", 1568], ["locally", 1572], [".", 1579], ["The", 1581], ["only", 1585], ["adverse", 1590], ["events", 1598], ["seen", 1605], ["with", 1610], ["greater", 1615], ["frequency", 1623], ["after", 1633], ["flumazenil", 1639], ["compared", 1650], ["with", 1659], ["placebo", 1664], ["were", 1672], ["nausea", 1677], ["and/or", 1684], ["vomiting", 1691], ["after", 1700], ["general", 1706], ["anaesthesia", 1714], [",", 1725], ["although", 1727], ["the", 1736], ["incidence", 1740], ["of", 1750], ["actual", 1753], ["vomiting", 1760], ["was", 1769], ["not", 1773], ["significantly", 1777], ["different", 1791], ["between", 1801], ["the", 1809], ["2", 1813], ["groups", 1815], [".", 1821], ["Since", 1823], ["these", 1829], ["effects", 1835], ["were", 1843], ["virtually", 1848], ["absent", 1858], ["in", 1865], ["studies", 1868], ["of", 1876], ["intensive", 1879], ["care", 1889], ["patients", 1894], ["and", 1903], ["after", 1907], ["sedation", 1913], ["for", 1922], ["short", 1926], ["procedures", 1932], [",", 1942], ["and", 1944], ["were", 1948], ["not", 1953], ["seen", 1957], ["in", 1962], ["tolerability", 1965], ["studies", 1978], ["in", 1986], ["healthy", 1989], ["volunteers", 1997], ["receiving", 2008], ["intravenous", 2018], ["bolus", 2030], ["doses", 2036], ["of", 2042], ["up", 2045], ["to", 2048], ["100", 2051], ["mg", 2054], [",", 2056], ["there", 2058], ["may", 2064], ["be", 2068], ["a", 2071], ["link", 2073], ["between", 2078], ["these", 2086], ["symptoms", 2092], ["and", 2101], ["the", 2105], ["other", 2109], ["agents", 2115], ["used", 2122], ["in", 2127], ["general", 2130], ["anaesthesia", 2138], [",", 2149], ["some", 2151], ["of", 2156], ["which", 2159], ["have", 2165], ["well", 2170], ["-", 2174], ["known", 2175], ["emetic", 2181], ["properties", 2188], [".", 2198], ["Thus", 2200], [",", 2204], ["flumazenil", 2206], ["provides", 2217], ["a", 2226], ["safe", 2228], ["and", 2233], ["effective", 2237], ["means", 2247], ["of", 2253], ["attenuating", 2256], ["or", 2268], ["reversing", 2271], ["the", 2281], ["CNS", 2285], ["-", 2288], ["depressant", 2289], ["effects", 2300], ["of", 2308], ["benzodiazepines", 2311], ["whenever", 2327], ["indicated", 2336], [",", 2345], ["e.g.", 2347], ["following", 2352], ["benzodiazepine", 2362], ["-", 2376], ["induced", 2377], ["general", 2385], ["anaesthesia", 2393], [",", 2404], ["conscious", 2406], ["sedation", 2416], [",", 2424], ["or", 2426], ["after", 2429], ["benzodiazepine", 2435], ["overdose", 2450], [",", 2458], ["either", 2460], ["alone", 2467], ["or", 2473], ["in", 2476], ["combination", 2479], ["with", 2491], ["other", 2496], ["agents.(ABSTRACT", 2502], ["TRUNCATED", 2519], ["AT", 2529], ["400", 2532], ["WORDS", 2536], [")", 2541]]}
{"context": "The mechanism of action, pharmacokinetics, and use of flumazenil in benzodiazepine overdose, as well as in the management of other disease states, are reviewed. Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists. Flumazenil has been studied for a variety of indications, including as an antidote to benzodiazepine overdose and for awakening of comatose patients, reversal of sedation after surgery and in critically ill patients, and management of hepatic encephalopathy. It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy. It appears to be effective in reversing sedation induced by midazolam or diazepam, and case reports suggest that it is useful in awakening comatose patients, although its clinical utility is questionable. Flumazenil has proved useful in reversing conscious sedation in critically ill patients, although response may be dose dependent. Animal models indicate that flumazenil is of some benefit in hepatic encephalopathy, but until well-designed clinical trials are conducted, hepatic encephalopathy must be considered an investigational indication for flumazenil. Adverse reactions include CNS manifestations, resedation, cardiovascular effects, seizures, and alterations in intracranial pressure and cerebral perfusion pressure. Hepatic dysfunction results in a substantial change in the pharmacokinetic profile of flumazenil; therefore, dosage adjustment may be necessary in patients with hepatic dysfunction or in those receiving medications that alter flumazenil metabolism. Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected. It may be beneficial after surgery when benzodiazepines have been used as part of anesthesia and after a diagnostic or surgical procedure when assessment of CNS function is necessary.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "3a3a4d37044d45888cb523f558ccae65", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[29, 29], [259, 259], [170, 170], [10, 10], [283, 283], [55, 55], [222, 222], [280, 280], [194, 194]], "char_spans": [[161, 170], [1678, 1687], [1068, 1077], [54, 63], [1841, 1850], [354, 363], [1414, 1423], [1818, 1827], [1226, 1235]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["action", 17], [",", 23], ["pharmacokinetics", 25], [",", 41], ["and", 43], ["use", 47], ["of", 51], ["flumazenil", 54], ["in", 65], ["benzodiazepine", 68], ["overdose", 83], [",", 91], ["as", 93], ["well", 96], ["as", 101], ["in", 104], ["the", 107], ["management", 111], ["of", 122], ["other", 125], ["disease", 131], ["states", 139], [",", 145], ["are", 147], ["reviewed", 151], [".", 159], ["Flumazenil", 161], ["interacts", 172], ["at", 182], ["the", 185], ["central", 189], ["benzodiazepine", 197], ["receptor", 212], ["to", 221], ["antagonize", 224], ["or", 235], ["reverse", 238], ["the", 246], ["behavioral", 250], [",", 260], ["neurologic", 262], [",", 272], ["and", 274], ["electrophysiologic", 278], ["effects", 297], ["of", 305], ["benzodiazepine", 308], ["agonists", 323], ["and", 332], ["inverse", 336], ["agonists", 344], [".", 352], ["Flumazenil", 354], ["has", 365], ["been", 369], ["studied", 374], ["for", 382], ["a", 386], ["variety", 388], ["of", 396], ["indications", 399], [",", 410], ["including", 412], ["as", 422], ["an", 425], ["antidote", 428], ["to", 437], ["benzodiazepine", 440], ["overdose", 455], ["and", 464], ["for", 468], ["awakening", 472], ["of", 482], ["comatose", 485], ["patients", 494], [",", 502], ["reversal", 504], ["of", 513], ["sedation", 516], ["after", 525], ["surgery", 531], ["and", 539], ["in", 543], ["critically", 546], ["ill", 557], ["patients", 561], [",", 569], ["and", 571], ["management", 575], ["of", 586], ["hepatic", 589], ["encephalopathy", 597], [".", 611], ["It", 613], ["improves", 616], ["the", 625], ["level", 629], ["of", 635], ["consciousness", 638], ["in", 652], ["patients", 655], ["with", 664], ["benzodiazepine", 669], ["overdose", 684], [";", 692], ["however", 694], [",", 701], ["resedation", 703], ["may", 714], ["occur", 718], ["within", 724], ["one", 731], ["to", 735], ["two", 738], ["hours", 742], ["after", 748], ["administration", 754], [",", 768], ["so", 770], ["repeated", 773], ["doses", 782], ["or", 788], ["a", 791], ["continuous", 793], ["infusion", 804], ["may", 813], ["be", 817], ["required", 820], ["to", 829], ["maintain", 832], ["therapeutic", 841], ["efficacy", 853], [".", 861], ["It", 863], ["appears", 866], ["to", 874], ["be", 877], ["effective", 880], ["in", 890], ["reversing", 893], ["sedation", 903], ["induced", 912], ["by", 920], ["midazolam", 923], ["or", 933], ["diazepam", 936], [",", 944], ["and", 946], ["case", 950], ["reports", 955], ["suggest", 963], ["that", 971], ["it", 976], ["is", 979], ["useful", 982], ["in", 989], ["awakening", 992], ["comatose", 1002], ["patients", 1011], [",", 1019], ["although", 1021], ["its", 1030], ["clinical", 1034], ["utility", 1043], ["is", 1051], ["questionable", 1054], [".", 1066], ["Flumazenil", 1068], ["has", 1079], ["proved", 1083], ["useful", 1090], ["in", 1097], ["reversing", 1100], ["conscious", 1110], ["sedation", 1120], ["in", 1129], ["critically", 1132], ["ill", 1143], ["patients", 1147], [",", 1155], ["although", 1157], ["response", 1166], ["may", 1175], ["be", 1179], ["dose", 1182], ["dependent", 1187], [".", 1196], ["Animal", 1198], ["models", 1205], ["indicate", 1212], ["that", 1221], ["flumazenil", 1226], ["is", 1237], ["of", 1240], ["some", 1243], ["benefit", 1248], ["in", 1256], ["hepatic", 1259], ["encephalopathy", 1267], [",", 1281], ["but", 1283], ["until", 1287], ["well", 1293], ["-", 1297], ["designed", 1298], ["clinical", 1307], ["trials", 1316], ["are", 1323], ["conducted", 1327], [",", 1336], ["hepatic", 1338], ["encephalopathy", 1346], ["must", 1361], ["be", 1366], ["considered", 1369], ["an", 1380], ["investigational", 1383], ["indication", 1399], ["for", 1410], ["flumazenil", 1414], [".", 1424], ["Adverse", 1426], ["reactions", 1434], ["include", 1444], ["CNS", 1452], ["manifestations", 1456], [",", 1470], ["resedation", 1472], [",", 1482], ["cardiovascular", 1484], ["effects", 1499], [",", 1506], ["seizures", 1508], [",", 1516], ["and", 1518], ["alterations", 1522], ["in", 1534], ["intracranial", 1537], ["pressure", 1550], ["and", 1559], ["cerebral", 1563], ["perfusion", 1572], ["pressure", 1582], [".", 1590], ["Hepatic", 1592], ["dysfunction", 1600], ["results", 1612], ["in", 1620], ["a", 1623], ["substantial", 1625], ["change", 1637], ["in", 1644], ["the", 1647], ["pharmacokinetic", 1651], ["profile", 1667], ["of", 1675], ["flumazenil", 1678], [";", 1688], ["therefore", 1690], [",", 1699], ["dosage", 1701], ["adjustment", 1708], ["may", 1719], ["be", 1723], ["necessary", 1726], ["in", 1736], ["patients", 1739], ["with", 1748], ["hepatic", 1753], ["dysfunction", 1761], ["or", 1773], ["in", 1776], ["those", 1779], ["receiving", 1785], ["medications", 1795], ["that", 1807], ["alter", 1812], ["flumazenil", 1818], ["metabolism", 1829], [".", 1839], ["Flumazenil", 1841], ["has", 1852], ["been", 1856], ["shown", 1861], ["to", 1867], ["reverse", 1870], ["sedation", 1878], ["caused", 1887], ["by", 1894], ["intoxication", 1897], ["with", 1910], ["benzodiazepines", 1915], ["alone", 1931], ["or", 1937], ["benzodiazepines", 1940], ["in", 1956], ["combination", 1959], ["with", 1971], ["other", 1976], ["agents", 1982], [",", 1988], ["but", 1990], ["it", 1994], ["should", 1997], ["not", 2004], ["be", 2008], ["used", 2011], ["when", 2016], ["cyclic", 2021], ["antidepressant", 2028], ["intoxication", 2043], ["is", 2056], ["suspected", 2059], [".", 2068], ["It", 2070], ["may", 2073], ["be", 2077], ["beneficial", 2080], ["after", 2091], ["surgery", 2097], ["when", 2105], ["benzodiazepines", 2110], ["have", 2126], ["been", 2131], ["used", 2136], ["as", 2141], ["part", 2144], ["of", 2149], ["anesthesia", 2152], ["and", 2163], ["after", 2167], ["a", 2173], ["diagnostic", 2175], ["or", 2186], ["surgical", 2189], ["procedure", 2198], ["when", 2208], ["assessment", 2213], ["of", 2224], ["CNS", 2227], ["function", 2231], ["is", 2240], ["necessary", 2243], [".", 2252]]}
{"context": "Riociguat (Adempas(\u00ae)), an oral first-in-class soluble guanylate cyclase (sGC) stimulator, is under global development by Bayer Healthcare Pharmaceuticals Inc. for the treatment of adult patients with inoperable or chronic/persistent chronic thromboembolic pulmonary hypertension (CTEPH) and for the treatment of adult patients with pulmonary arterial hypertension (PAH). The drug directly stimulates sGC in a nitric oxide independent manner, thereby increasing the sensitivity of sGC to nitric oxide, leading to increased cyclic guanosine monophosphate generation (a key signalling molecule involved in regulating vascular tone, proliferation, fibrosis and inflammation). Riociguat is the world's first approved pharmacotherapy for CTEPH, with its first global approval in this indication occurring in Canada. It has subsequently been approved in the USA for the treatment of patients with CTEPH and also received its first global approval in patients with PAH in the USA. It is undergoing regulatory review for these indications in Europe and for use in patients with CTEPH in Japan. This article summarizes the milestones in the development of riociguat, leading to its first global approvals in patients with CTEPH and PAH.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "80fce1b132884d6693c43fd6e45e6cf0", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[0, 0], [113, 113], [195, 195]], "char_spans": [[0, 8], [673, 681], [1147, 1155]]}]}], "context_tokens": [["Riociguat", 0], ["(", 10], ["Adempas", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["an", 24], ["oral", 27], ["first", 32], ["-", 37], ["in", 38], ["-", 40], ["class", 41], ["soluble", 47], ["guanylate", 55], ["cyclase", 65], ["(", 73], ["sGC", 74], [")", 77], ["stimulator", 79], [",", 89], ["is", 91], ["under", 94], ["global", 100], ["development", 107], ["by", 119], ["Bayer", 122], ["Healthcare", 128], ["Pharmaceuticals", 139], ["Inc.", 155], ["for", 160], ["the", 164], ["treatment", 168], ["of", 178], ["adult", 181], ["patients", 187], ["with", 196], ["inoperable", 201], ["or", 212], ["chronic", 215], ["/", 222], ["persistent", 223], ["chronic", 234], ["thromboembolic", 242], ["pulmonary", 257], ["hypertension", 267], ["(", 280], ["CTEPH", 281], [")", 286], ["and", 288], ["for", 292], ["the", 296], ["treatment", 300], ["of", 310], ["adult", 313], ["patients", 319], ["with", 328], ["pulmonary", 333], ["arterial", 343], ["hypertension", 352], ["(", 365], ["PAH", 366], [")", 369], [".", 370], ["The", 372], ["drug", 376], ["directly", 381], ["stimulates", 390], ["sGC", 401], ["in", 405], ["a", 408], ["nitric", 410], ["oxide", 417], ["independent", 423], ["manner", 435], [",", 441], ["thereby", 443], ["increasing", 451], ["the", 462], ["sensitivity", 466], ["of", 478], ["sGC", 481], ["to", 485], ["nitric", 488], ["oxide", 495], [",", 500], ["leading", 502], ["to", 510], ["increased", 513], ["cyclic", 523], ["guanosine", 530], ["monophosphate", 540], ["generation", 554], ["(", 565], ["a", 566], ["key", 568], ["signalling", 572], ["molecule", 583], ["involved", 592], ["in", 601], ["regulating", 604], ["vascular", 615], ["tone", 624], [",", 628], ["proliferation", 630], [",", 643], ["fibrosis", 645], ["and", 654], ["inflammation", 658], [")", 670], [".", 671], ["Riociguat", 673], ["is", 683], ["the", 686], ["world", 690], ["'s", 695], ["first", 698], ["approved", 704], ["pharmacotherapy", 713], ["for", 729], ["CTEPH", 733], [",", 738], ["with", 740], ["its", 745], ["first", 749], ["global", 755], ["approval", 762], ["in", 771], ["this", 774], ["indication", 779], ["occurring", 790], ["in", 800], ["Canada", 803], [".", 809], ["It", 811], ["has", 814], ["subsequently", 818], ["been", 831], ["approved", 836], ["in", 845], ["the", 848], ["USA", 852], ["for", 856], ["the", 860], ["treatment", 864], ["of", 874], ["patients", 877], ["with", 886], ["CTEPH", 891], ["and", 897], ["also", 901], ["received", 906], ["its", 915], ["first", 919], ["global", 925], ["approval", 932], ["in", 941], ["patients", 944], ["with", 953], ["PAH", 958], ["in", 962], ["the", 965], ["USA", 969], [".", 972], ["It", 974], ["is", 977], ["undergoing", 980], ["regulatory", 991], ["review", 1002], ["for", 1009], ["these", 1013], ["indications", 1019], ["in", 1031], ["Europe", 1034], ["and", 1041], ["for", 1045], ["use", 1049], ["in", 1053], ["patients", 1056], ["with", 1065], ["CTEPH", 1070], ["in", 1076], ["Japan", 1079], [".", 1084], ["This", 1086], ["article", 1091], ["summarizes", 1099], ["the", 1110], ["milestones", 1114], ["in", 1125], ["the", 1128], ["development", 1132], ["of", 1144], ["riociguat", 1147], [",", 1156], ["leading", 1158], ["to", 1166], ["its", 1169], ["first", 1173], ["global", 1179], ["approvals", 1186], ["in", 1196], ["patients", 1199], ["with", 1208], ["CTEPH", 1213], ["and", 1219], ["PAH", 1223], [".", 1226]]}
{"context": "In the present study, we used a new training paradigm in the intelliCage automatic behavioral assessment system to investigate cognitive functions of the transgenic mice harboring London mutation of the human amyloid precursor protein (APP.V717I). Three groups of animals: 5-, 12- and 18-24-month old were subjected to both Water Maze training and the IntelliCage-based appetitive conditioning. The spatial memory deficit was observed in all three groups of transgenic mice in both behavioral paradigms. However, the APP mice were capable to learn normally when co-housed with the wild-type (WT) littermates, in contrast to clearly impaired learning observed when the transgenic mice were housed alone. Furthermore, in the transgenic mice kept in the Intellicage alone, the cognitive deficit of the young animals was modulated by the circadian rhythm, namely was prominent only during the active phase of the day. The novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease mouse model.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "4bf55f1486ae40eeb5ec072729959f4a", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[184, 186]], "char_spans": [[1060, 1078]]}]}], "context_tokens": [["In", 0], ["the", 3], ["present", 7], ["study", 15], [",", 20], ["we", 22], ["used", 25], ["a", 30], ["new", 32], ["training", 36], ["paradigm", 45], ["in", 54], ["the", 57], ["intelliCage", 61], ["automatic", 73], ["behavioral", 83], ["assessment", 94], ["system", 105], ["to", 112], ["investigate", 115], ["cognitive", 127], ["functions", 137], ["of", 147], ["the", 150], ["transgenic", 154], ["mice", 165], ["harboring", 170], ["London", 180], ["mutation", 187], ["of", 196], ["the", 199], ["human", 203], ["amyloid", 209], ["precursor", 217], ["protein", 227], ["(", 235], ["APP.V717I", 236], [")", 245], [".", 246], ["Three", 248], ["groups", 254], ["of", 261], ["animals", 264], [":", 271], ["5-", 273], [",", 275], ["12-", 277], ["and", 281], ["18", 285], ["-", 287], ["24-month", 288], ["old", 297], ["were", 301], ["subjected", 306], ["to", 316], ["both", 319], ["Water", 324], ["Maze", 330], ["training", 335], ["and", 344], ["the", 348], ["IntelliCage", 352], ["-", 363], ["based", 364], ["appetitive", 370], ["conditioning", 381], [".", 393], ["The", 395], ["spatial", 399], ["memory", 407], ["deficit", 414], ["was", 422], ["observed", 426], ["in", 435], ["all", 438], ["three", 442], ["groups", 448], ["of", 455], ["transgenic", 458], ["mice", 469], ["in", 474], ["both", 477], ["behavioral", 482], ["paradigms", 493], [".", 502], ["However", 504], [",", 511], ["the", 513], ["APP", 517], ["mice", 521], ["were", 526], ["capable", 531], ["to", 539], ["learn", 542], ["normally", 548], ["when", 557], ["co", 562], ["-", 564], ["housed", 565], ["with", 572], ["the", 577], ["wild", 581], ["-", 585], ["type", 586], ["(", 591], ["WT", 592], [")", 594], ["littermates", 596], [",", 607], ["in", 609], ["contrast", 612], ["to", 621], ["clearly", 624], ["impaired", 632], ["learning", 641], ["observed", 650], ["when", 659], ["the", 664], ["transgenic", 668], ["mice", 679], ["were", 684], ["housed", 689], ["alone", 696], [".", 701], ["Furthermore", 703], [",", 714], ["in", 716], ["the", 719], ["transgenic", 723], ["mice", 734], ["kept", 739], ["in", 744], ["the", 747], ["Intellicage", 751], ["alone", 763], [",", 768], ["the", 770], ["cognitive", 774], ["deficit", 784], ["of", 792], ["the", 795], ["young", 799], ["animals", 805], ["was", 813], ["modulated", 817], ["by", 827], ["the", 830], ["circadian", 834], ["rhythm", 844], [",", 850], ["namely", 852], ["was", 859], ["prominent", 863], ["only", 873], ["during", 878], ["the", 885], ["active", 889], ["phase", 896], ["of", 902], ["the", 905], ["day", 909], [".", 912], ["The", 914], ["novel", 918], ["approach", 924], ["to", 933], ["study", 936], ["the", 942], ["transgenic", 946], ["mice", 957], ["cognitive", 962], ["abilities", 972], ["presented", 982], ["in", 992], ["this", 995], ["paper", 1000], ["offers", 1006], ["new", 1013], ["insight", 1017], ["into", 1025], ["cognitive", 1030], ["dysfunctions", 1040], ["of", 1053], ["the", 1056], ["Alzheimer", 1060], ["'s", 1069], ["disease", 1072], ["mouse", 1080], ["model", 1086], [".", 1091]]}
{"context": "This review paper describes the development of the RTS,S/AS vaccine, from concept to phase III testing. The rationale for selection of the circumsporozoite protein (CSP) as the target antigen and the preclinical development history of the vaccine are described. The RTS,S/AS candidate vaccine has been evaluated in multiple phase I/II studies and was shown to have a favorable safety profile and to be well tolerated in both adults and children. Consistent and significant efficacy has been observed in the target population of infants and children against Plasmodium falciparum infection and disease in different transmission settings, in different age groups, with or without Expanded Program of Immunization (EPI) vaccine co-administration. The RTS,S/AS01(E) malaria vaccine candidate has recently entered phase III testing. Reaching this important milestone is the culmination of more than 20 years of research and development by GlaxoSmithKline, their partners and collaborators. If the phase III results confirm the observations made during phase II testing, the RTS,S/AS01(E) vaccine, when broadly implemented and judiciously integrated with other malaria-prevention measures, would have a major public-health impact in sub-Saharan Africa.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "bab439e02a014e6f9961ed16f6252e78", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[204, 204], [139, 139]], "char_spans": [[1155, 1161], [762, 768]]}]}], "context_tokens": [["This", 0], ["review", 5], ["paper", 12], ["describes", 18], ["the", 28], ["development", 32], ["of", 44], ["the", 47], ["RTS", 51], [",", 54], ["S", 55], ["/", 56], ["AS", 57], ["vaccine", 60], [",", 67], ["from", 69], ["concept", 74], ["to", 82], ["phase", 85], ["III", 91], ["testing", 95], [".", 102], ["The", 104], ["rationale", 108], ["for", 118], ["selection", 122], ["of", 132], ["the", 135], ["circumsporozoite", 139], ["protein", 156], ["(", 164], ["CSP", 165], [")", 168], ["as", 170], ["the", 173], ["target", 177], ["antigen", 184], ["and", 192], ["the", 196], ["preclinical", 200], ["development", 212], ["history", 224], ["of", 232], ["the", 235], ["vaccine", 239], ["are", 247], ["described", 251], [".", 260], ["The", 262], ["RTS", 266], [",", 269], ["S", 270], ["/", 271], ["AS", 272], ["candidate", 275], ["vaccine", 285], ["has", 293], ["been", 297], ["evaluated", 302], ["in", 312], ["multiple", 315], ["phase", 324], ["I", 330], ["/", 331], ["II", 332], ["studies", 335], ["and", 343], ["was", 347], ["shown", 351], ["to", 357], ["have", 360], ["a", 365], ["favorable", 367], ["safety", 377], ["profile", 384], ["and", 392], ["to", 396], ["be", 399], ["well", 402], ["tolerated", 407], ["in", 417], ["both", 420], ["adults", 425], ["and", 432], ["children", 436], [".", 444], ["Consistent", 446], ["and", 457], ["significant", 461], ["efficacy", 473], ["has", 482], ["been", 486], ["observed", 491], ["in", 500], ["the", 503], ["target", 507], ["population", 514], ["of", 525], ["infants", 528], ["and", 536], ["children", 540], ["against", 549], ["Plasmodium", 557], ["falciparum", 568], ["infection", 579], ["and", 589], ["disease", 593], ["in", 601], ["different", 604], ["transmission", 614], ["settings", 627], [",", 635], ["in", 637], ["different", 640], ["age", 650], ["groups", 654], [",", 660], ["with", 662], ["or", 667], ["without", 670], ["Expanded", 678], ["Program", 687], ["of", 695], ["Immunization", 698], ["(", 711], ["EPI", 712], [")", 715], ["vaccine", 717], ["co", 725], ["-", 727], ["administration", 728], [".", 742], ["The", 744], ["RTS", 748], [",", 751], ["S", 752], ["/", 753], ["AS01(E", 754], [")", 760], ["malaria", 762], ["vaccine", 770], ["candidate", 778], ["has", 788], ["recently", 792], ["entered", 801], ["phase", 809], ["III", 815], ["testing", 819], [".", 826], ["Reaching", 828], ["this", 837], ["important", 842], ["milestone", 852], ["is", 862], ["the", 865], ["culmination", 869], ["of", 881], ["more", 884], ["than", 889], ["20", 894], ["years", 897], ["of", 903], ["research", 906], ["and", 915], ["development", 919], ["by", 931], ["GlaxoSmithKline", 934], [",", 949], ["their", 951], ["partners", 957], ["and", 966], ["collaborators", 970], [".", 983], ["If", 985], ["the", 988], ["phase", 992], ["III", 998], ["results", 1002], ["confirm", 1010], ["the", 1018], ["observations", 1022], ["made", 1035], ["during", 1040], ["phase", 1047], ["II", 1053], ["testing", 1056], [",", 1063], ["the", 1065], ["RTS", 1069], [",", 1072], ["S", 1073], ["/", 1074], ["AS01(E", 1075], [")", 1081], ["vaccine", 1083], [",", 1090], ["when", 1092], ["broadly", 1097], ["implemented", 1105], ["and", 1117], ["judiciously", 1121], ["integrated", 1133], ["with", 1144], ["other", 1149], ["malaria", 1155], ["-", 1162], ["prevention", 1163], ["measures", 1174], [",", 1182], ["would", 1184], ["have", 1190], ["a", 1195], ["major", 1197], ["public", 1203], ["-", 1209], ["health", 1210], ["impact", 1217], ["in", 1224], ["sub", 1227], ["-", 1230], ["Saharan", 1231], ["Africa", 1239], [".", 1245]]}
{"context": "The aim of this study was to investigate the methicillin-resistant Staphylococcus aureus (MRSA) clones isolated in a Dutch university hospital, situated near the borders of Belgium and Germany, between 2002 and 2006. MRSA strains (n = 175) were characterized using spa and SCCmec typing. The presence of Panton Valentine leukocidin (PVL) was determined. Between 2002 and 2005, ST5-MRSA-IV was predominant, and the spa type of ST5-MRSA-IV changed from t002 to t447. ST5-MRSA-I, ST5-MRSA-II, ST228-MRSA-I, and ST247-MRSA-I were also observed in this period. From 2004, the MRSA genetic background became more diverse, and in 2006, ST5-MRSA-IV was only sporadically observed. From 2005, ST5-MRSA-II, ST8-MRSA-IV, ST22-MRSA-IV, and ST45-MRSA-IV were increasingly observed. Several other MRSA clones, such as ST239-MRSA-III, were found sporadically. Four PVL-positive MRSA isolates were observed, associated with ST80-MRSA-IV and ST8-MRSA-IV. ST5-MRSA-I, ST5-MRSA-II, ST5-MRSA-IV, and ST228-MRSA-I have not been described previously in The Netherlands.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "533d5719b67846d886c279b70c0eb6d5", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[179, 179], [118, 118], [39, 39], [162, 162], [15, 15]], "char_spans": [[863, 866], [571, 574], [217, 220], [783, 786], [90, 93]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["investigate", 29], ["the", 41], ["methicillin", 45], ["-", 56], ["resistant", 57], ["Staphylococcus", 67], ["aureus", 82], ["(", 89], ["MRSA", 90], [")", 94], ["clones", 96], ["isolated", 103], ["in", 112], ["a", 115], ["Dutch", 117], ["university", 123], ["hospital", 134], [",", 142], ["situated", 144], ["near", 153], ["the", 158], ["borders", 162], ["of", 170], ["Belgium", 173], ["and", 181], ["Germany", 185], [",", 192], ["between", 194], ["2002", 202], ["and", 207], ["2006", 211], [".", 215], ["MRSA", 217], ["strains", 222], ["(", 230], ["n", 231], ["=", 233], ["175", 235], [")", 238], ["were", 240], ["characterized", 245], ["using", 259], ["spa", 265], ["and", 269], ["SCCmec", 273], ["typing", 280], [".", 286], ["The", 288], ["presence", 292], ["of", 301], ["Panton", 304], ["Valentine", 311], ["leukocidin", 321], ["(", 332], ["PVL", 333], [")", 336], ["was", 338], ["determined", 342], [".", 352], ["Between", 354], ["2002", 362], ["and", 367], ["2005", 371], [",", 375], ["ST5-MRSA", 377], ["-", 385], ["IV", 386], ["was", 389], ["predominant", 393], [",", 404], ["and", 406], ["the", 410], ["spa", 414], ["type", 418], ["of", 423], ["ST5-MRSA", 426], ["-", 434], ["IV", 435], ["changed", 438], ["from", 446], ["t002", 451], ["to", 456], ["t447", 459], [".", 463], ["ST5-MRSA", 465], ["-", 473], ["I", 474], [",", 475], ["ST5-MRSA", 477], ["-", 485], ["II", 486], [",", 488], ["ST228-MRSA", 490], ["-", 500], ["I", 501], [",", 502], ["and", 504], ["ST247-MRSA", 508], ["-", 518], ["I", 519], ["were", 521], ["also", 526], ["observed", 531], ["in", 540], ["this", 543], ["period", 548], [".", 554], ["From", 556], ["2004", 561], [",", 565], ["the", 567], ["MRSA", 571], ["genetic", 576], ["background", 584], ["became", 595], ["more", 602], ["diverse", 607], [",", 614], ["and", 616], ["in", 620], ["2006", 623], [",", 627], ["ST5-MRSA", 629], ["-", 637], ["IV", 638], ["was", 641], ["only", 645], ["sporadically", 650], ["observed", 663], [".", 671], ["From", 673], ["2005", 678], [",", 682], ["ST5-MRSA", 684], ["-", 692], ["II", 693], [",", 695], ["ST8-MRSA", 697], ["-", 705], ["IV", 706], [",", 708], ["ST22-MRSA", 710], ["-", 719], ["IV", 720], [",", 722], ["and", 724], ["ST45-MRSA", 728], ["-", 737], ["IV", 738], ["were", 741], ["increasingly", 746], ["observed", 759], [".", 767], ["Several", 769], ["other", 777], ["MRSA", 783], ["clones", 788], [",", 794], ["such", 796], ["as", 801], ["ST239-MRSA", 804], ["-", 814], ["III", 815], [",", 818], ["were", 820], ["found", 825], ["sporadically", 831], [".", 843], ["Four", 845], ["PVL", 850], ["-", 853], ["positive", 854], ["MRSA", 863], ["isolates", 868], ["were", 877], ["observed", 882], [",", 890], ["associated", 892], ["with", 903], ["ST80-MRSA", 908], ["-", 917], ["IV", 918], ["and", 921], ["ST8-MRSA", 925], ["-", 933], ["IV", 934], [".", 936], ["ST5-MRSA", 938], ["-", 946], ["I", 947], [",", 948], ["ST5-MRSA", 950], ["-", 958], ["II", 959], [",", 961], ["ST5-MRSA", 963], ["-", 971], ["IV", 972], [",", 974], ["and", 976], ["ST228-MRSA", 980], ["-", 990], ["I", 991], ["have", 993], ["not", 998], ["been", 1002], ["described", 1007], ["previously", 1017], ["in", 1028], ["The", 1031], ["Netherlands", 1035], [".", 1046]]}
{"context": "Polycystic kidney disease (PKD) includes a group of disorders that are characterized by the presence of cysts in the kidney and other organs, including the pancreas. Here we show that in orpk mice, a model system for PKD that harbors a mutation in the gene that encodes the polaris protein, pancreatic defects start to occur at the end of gestation, with an initial expansion of the developing pancreatic ducts. Ductal dilation continues rapidly after birth and results in the formation of large, interconnected cysts. Expansion of pancreatic ducts is accompanied by apoptosis of neighboring acinar cells, whereas endocrine cell differentiation and islet formation appears to be unaffected. Polaris has been shown to co-localize with primary cilia, and these structures have been implicated in the formation of renal cysts. In the orpk pancreas, cilia numbers are reduced and cilia length is decreased. Expression of polycystin-2, a protein involved in PKD, is mislocalized in orpk mice. Furthermore, the cellular localization of beta-catenin, a protein involved in cell adhesion and Wnt signaling, is altered. Thus, polaris and primary cilia function are required for the maturation and maintenance of proper tissue organization in the pancreas.", "qas": [{"question": "Which is the most common disease attributed to malfunction or absence of primary cilia?", "answers": ["Polycystic kidney disease (PKD)"], "qid": "88255af0d4234ad09cdee7305967cf18", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["disease", 25], ["attributed", 33], ["to", 44], ["malfunction", 47], ["or", 59], ["absence", 62], ["of", 70], ["primary", 73], ["cilia", 81], ["?", 86]], "detected_answers": [{"text": "Polycystic kidney disease (PKD)", "token_spans": [[0, 4]], "char_spans": [[0, 29]]}]}], "context_tokens": [["Polycystic", 0], ["kidney", 11], ["disease", 18], ["(", 26], ["PKD", 27], [")", 30], ["includes", 32], ["a", 41], ["group", 43], ["of", 49], ["disorders", 52], ["that", 62], ["are", 67], ["characterized", 71], ["by", 85], ["the", 88], ["presence", 92], ["of", 101], ["cysts", 104], ["in", 110], ["the", 113], ["kidney", 117], ["and", 124], ["other", 128], ["organs", 134], [",", 140], ["including", 142], ["the", 152], ["pancreas", 156], [".", 164], ["Here", 166], ["we", 171], ["show", 174], ["that", 179], ["in", 184], ["orpk", 187], ["mice", 192], [",", 196], ["a", 198], ["model", 200], ["system", 206], ["for", 213], ["PKD", 217], ["that", 221], ["harbors", 226], ["a", 234], ["mutation", 236], ["in", 245], ["the", 248], ["gene", 252], ["that", 257], ["encodes", 262], ["the", 270], ["polaris", 274], ["protein", 282], [",", 289], ["pancreatic", 291], ["defects", 302], ["start", 310], ["to", 316], ["occur", 319], ["at", 325], ["the", 328], ["end", 332], ["of", 336], ["gestation", 339], [",", 348], ["with", 350], ["an", 355], ["initial", 358], ["expansion", 366], ["of", 376], ["the", 379], ["developing", 383], ["pancreatic", 394], ["ducts", 405], [".", 410], ["Ductal", 412], ["dilation", 419], ["continues", 428], ["rapidly", 438], ["after", 446], ["birth", 452], ["and", 458], ["results", 462], ["in", 470], ["the", 473], ["formation", 477], ["of", 487], ["large", 490], [",", 495], ["interconnected", 497], ["cysts", 512], [".", 517], ["Expansion", 519], ["of", 529], ["pancreatic", 532], ["ducts", 543], ["is", 549], ["accompanied", 552], ["by", 564], ["apoptosis", 567], ["of", 577], ["neighboring", 580], ["acinar", 592], ["cells", 599], [",", 604], ["whereas", 606], ["endocrine", 614], ["cell", 624], ["differentiation", 629], ["and", 645], ["islet", 649], ["formation", 655], ["appears", 665], ["to", 673], ["be", 676], ["unaffected", 679], [".", 689], ["Polaris", 691], ["has", 699], ["been", 703], ["shown", 708], ["to", 714], ["co", 717], ["-", 719], ["localize", 720], ["with", 729], ["primary", 734], ["cilia", 742], [",", 747], ["and", 749], ["these", 753], ["structures", 759], ["have", 770], ["been", 775], ["implicated", 780], ["in", 791], ["the", 794], ["formation", 798], ["of", 808], ["renal", 811], ["cysts", 817], [".", 822], ["In", 824], ["the", 827], ["orpk", 831], ["pancreas", 836], [",", 844], ["cilia", 846], ["numbers", 852], ["are", 860], ["reduced", 864], ["and", 872], ["cilia", 876], ["length", 882], ["is", 889], ["decreased", 892], [".", 901], ["Expression", 903], ["of", 914], ["polycystin-2", 917], [",", 929], ["a", 931], ["protein", 933], ["involved", 941], ["in", 950], ["PKD", 953], [",", 956], ["is", 958], ["mislocalized", 961], ["in", 974], ["orpk", 977], ["mice", 982], [".", 986], ["Furthermore", 988], [",", 999], ["the", 1001], ["cellular", 1005], ["localization", 1014], ["of", 1027], ["beta", 1030], ["-", 1034], ["catenin", 1035], [",", 1042], ["a", 1044], ["protein", 1046], ["involved", 1054], ["in", 1063], ["cell", 1066], ["adhesion", 1071], ["and", 1080], ["Wnt", 1084], ["signaling", 1088], [",", 1097], ["is", 1099], ["altered", 1102], [".", 1109], ["Thus", 1111], [",", 1115], ["polaris", 1117], ["and", 1125], ["primary", 1129], ["cilia", 1137], ["function", 1143], ["are", 1152], ["required", 1156], ["for", 1165], ["the", 1169], ["maturation", 1173], ["and", 1184], ["maintenance", 1188], ["of", 1200], ["proper", 1203], ["tissue", 1210], ["organization", 1217], ["in", 1230], ["the", 1233], ["pancreas", 1237], [".", 1245]]}
{"context": "Mowat-Wilson syndrome (MWS) is a recently delineated mental retardation (MR)-multiple congenital anomaly syndrome, characterized by typical facies, severe MR, epilepsy, and variable congenital malformations, including Hirschsprung disease (HSCR), genital anomalies, congenital heart disease (CHD), and agenesis of the corpus callosum (ACC). It is caused by de novo heterozygous mutations or deletions of the ZFHX1B gene located at 2q22. ZFHX1B encodes Smad-interacting protein-1 (SMADIP1 or SIP1), a transcriptional corepressor involved in the transforming growth factor-beta signaling pathway. It is a highly evolutionarily conserved gene, widely expressed in embryological development. Over 100 mutations have been described in patients with clinically typical MWS, who almost always have whole gene deletions or truncating mutations (nonsense or frameshift) of ZFHX1B, suggesting that haploinsufficiency is the basis of MWS pathology. No obvious genotype-phenotype correlation could be identified so far, but atypical phenotypes have been reported with missense or splice mutations in the ZFHX1B gene. In this work we describe 40 novel mutations and we summarize the various mutational reports published since the identification of the causative gene.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ec16938dc3e040ca96362ca7d7677913", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[148, 148], [73, 73], [185, 185], [79, 79]], "char_spans": [[864, 869], [408, 413], [1092, 1097], [437, 442]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["recently", 33], ["delineated", 42], ["mental", 53], ["retardation", 60], ["(", 72], ["MR)-multiple", 73], ["congenital", 86], ["anomaly", 97], ["syndrome", 105], [",", 113], ["characterized", 115], ["by", 129], ["typical", 132], ["facies", 140], [",", 146], ["severe", 148], ["MR", 155], [",", 157], ["epilepsy", 159], [",", 167], ["and", 169], ["variable", 173], ["congenital", 182], ["malformations", 193], [",", 206], ["including", 208], ["Hirschsprung", 218], ["disease", 231], ["(", 239], ["HSCR", 240], [")", 244], [",", 245], ["genital", 247], ["anomalies", 255], [",", 264], ["congenital", 266], ["heart", 277], ["disease", 283], ["(", 291], ["CHD", 292], [")", 295], [",", 296], ["and", 298], ["agenesis", 302], ["of", 311], ["the", 314], ["corpus", 318], ["callosum", 325], ["(", 334], ["ACC", 335], [")", 338], [".", 339], ["It", 341], ["is", 344], ["caused", 347], ["by", 354], ["de", 357], ["novo", 360], ["heterozygous", 365], ["mutations", 378], ["or", 388], ["deletions", 391], ["of", 401], ["the", 404], ["ZFHX1B", 408], ["gene", 415], ["located", 420], ["at", 428], ["2q22", 431], [".", 435], ["ZFHX1B", 437], ["encodes", 444], ["Smad", 452], ["-", 456], ["interacting", 457], ["protein-1", 469], ["(", 479], ["SMADIP1", 480], ["or", 488], ["SIP1", 491], [")", 495], [",", 496], ["a", 498], ["transcriptional", 500], ["corepressor", 516], ["involved", 528], ["in", 537], ["the", 540], ["transforming", 544], ["growth", 557], ["factor", 564], ["-", 570], ["beta", 571], ["signaling", 576], ["pathway", 586], [".", 593], ["It", 595], ["is", 598], ["a", 601], ["highly", 603], ["evolutionarily", 610], ["conserved", 625], ["gene", 635], [",", 639], ["widely", 641], ["expressed", 648], ["in", 658], ["embryological", 661], ["development", 675], [".", 686], ["Over", 688], ["100", 693], ["mutations", 697], ["have", 707], ["been", 712], ["described", 717], ["in", 727], ["patients", 730], ["with", 739], ["clinically", 744], ["typical", 755], ["MWS", 763], [",", 766], ["who", 768], ["almost", 772], ["always", 779], ["have", 786], ["whole", 791], ["gene", 797], ["deletions", 802], ["or", 812], ["truncating", 815], ["mutations", 826], ["(", 836], ["nonsense", 837], ["or", 846], ["frameshift", 849], [")", 859], ["of", 861], ["ZFHX1B", 864], [",", 870], ["suggesting", 872], ["that", 883], ["haploinsufficiency", 888], ["is", 907], ["the", 910], ["basis", 914], ["of", 920], ["MWS", 923], ["pathology", 927], [".", 936], ["No", 938], ["obvious", 941], ["genotype", 949], ["-", 957], ["phenotype", 958], ["correlation", 968], ["could", 980], ["be", 986], ["identified", 989], ["so", 1000], ["far", 1003], [",", 1006], ["but", 1008], ["atypical", 1012], ["phenotypes", 1021], ["have", 1032], ["been", 1037], ["reported", 1042], ["with", 1051], ["missense", 1056], ["or", 1065], ["splice", 1068], ["mutations", 1075], ["in", 1085], ["the", 1088], ["ZFHX1B", 1092], ["gene", 1099], [".", 1103], ["In", 1105], ["this", 1108], ["work", 1113], ["we", 1118], ["describe", 1121], ["40", 1130], ["novel", 1133], ["mutations", 1139], ["and", 1149], ["we", 1153], ["summarize", 1156], ["the", 1166], ["various", 1170], ["mutational", 1178], ["reports", 1189], ["published", 1197], ["since", 1207], ["the", 1213], ["identification", 1217], ["of", 1232], ["the", 1235], ["causative", 1239], ["gene", 1249], [".", 1253]]}
{"context": "Juvenile neuronal ceroid-lipofuscinosis (JNCL) or Batten/Spielmeyer-Vogt-Sjogren disease (OMIM #204200) is one of a group of nine clinically related inherited neurodegenerative disorders (CLN1-9). JNCL results from mutations in CLN3 on chromosome 16p12.1. The neuronal loss in Batten disease has been shown to be due to a combination of apoptosis and autophagy suggesting that CLN3P, the defective protein, may have an anti-neuronal death function. PANDER (PANcreatic-DERived factor) is a novel cytokine that was recently cloned from pancreatic islet cells. PANDER is specifically expressed in the pancreatic islets, small intestine, testis, prostate, and neurons of the central nervous system, and has been demonstrated to induce apoptosis. In this study, we over-expressed CLN3P in SH-SY5Y neuroblastoma cells and monitored the effects on PANDER-induced apoptosis. CLN3P significantly increased the survival rate of the SH-SY5Y cells in this system. This study provides additional evidence that the function of CLN3P is related to preventing neuronal apoptosis.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "8a6acd5fd68e49d2b775304d9aef5eb9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[54, 55]], "char_spans": [[277, 290]]}, {"text": "JNCL", "token_spans": [[40, 40], [6, 6]], "char_spans": [[197, 200], [41, 44]]}]}], "context_tokens": [["Juvenile", 0], ["neuronal", 9], ["ceroid", 18], ["-", 24], ["lipofuscinosis", 25], ["(", 40], ["JNCL", 41], [")", 45], ["or", 47], ["Batten", 50], ["/", 56], ["Spielmeyer", 57], ["-", 67], ["Vogt", 68], ["-", 72], ["Sjogren", 73], ["disease", 81], ["(", 89], ["OMIM", 90], ["#", 95], ["204200", 96], [")", 102], ["is", 104], ["one", 107], ["of", 111], ["a", 114], ["group", 116], ["of", 122], ["nine", 125], ["clinically", 130], ["related", 141], ["inherited", 149], ["neurodegenerative", 159], ["disorders", 177], ["(", 187], ["CLN1", 188], ["-", 192], ["9", 193], [")", 194], [".", 195], ["JNCL", 197], ["results", 202], ["from", 210], ["mutations", 215], ["in", 225], ["CLN3", 228], ["on", 233], ["chromosome", 236], ["16p12.1", 247], [".", 254], ["The", 256], ["neuronal", 260], ["loss", 269], ["in", 274], ["Batten", 277], ["disease", 284], ["has", 292], ["been", 296], ["shown", 301], ["to", 307], ["be", 310], ["due", 313], ["to", 317], ["a", 320], ["combination", 322], ["of", 334], ["apoptosis", 337], ["and", 347], ["autophagy", 351], ["suggesting", 361], ["that", 372], ["CLN3P", 377], [",", 382], ["the", 384], ["defective", 388], ["protein", 398], [",", 405], ["may", 407], ["have", 411], ["an", 416], ["anti", 419], ["-", 423], ["neuronal", 424], ["death", 433], ["function", 439], [".", 447], ["PANDER", 449], ["(", 456], ["PANcreatic", 457], ["-", 467], ["DERived", 468], ["factor", 476], [")", 482], ["is", 484], ["a", 487], ["novel", 489], ["cytokine", 495], ["that", 504], ["was", 509], ["recently", 513], ["cloned", 522], ["from", 529], ["pancreatic", 534], ["islet", 545], ["cells", 551], [".", 556], ["PANDER", 558], ["is", 565], ["specifically", 568], ["expressed", 581], ["in", 591], ["the", 594], ["pancreatic", 598], ["islets", 609], [",", 615], ["small", 617], ["intestine", 623], [",", 632], ["testis", 634], [",", 640], ["prostate", 642], [",", 650], ["and", 652], ["neurons", 656], ["of", 664], ["the", 667], ["central", 671], ["nervous", 679], ["system", 687], [",", 693], ["and", 695], ["has", 699], ["been", 703], ["demonstrated", 708], ["to", 721], ["induce", 724], ["apoptosis", 731], [".", 740], ["In", 742], ["this", 745], ["study", 750], [",", 755], ["we", 757], ["over", 760], ["-", 764], ["expressed", 765], ["CLN3P", 775], ["in", 781], ["SH", 784], ["-", 786], ["SY5Y", 787], ["neuroblastoma", 792], ["cells", 806], ["and", 812], ["monitored", 816], ["the", 826], ["effects", 830], ["on", 838], ["PANDER", 841], ["-", 847], ["induced", 848], ["apoptosis", 856], [".", 865], ["CLN3P", 867], ["significantly", 873], ["increased", 887], ["the", 897], ["survival", 901], ["rate", 910], ["of", 915], ["the", 918], ["SH", 922], ["-", 924], ["SY5Y", 925], ["cells", 930], ["in", 936], ["this", 939], ["system", 944], [".", 950], ["This", 952], ["study", 957], ["provides", 963], ["additional", 972], ["evidence", 983], ["that", 992], ["the", 997], ["function", 1001], ["of", 1010], ["CLN3P", 1013], ["is", 1019], ["related", 1022], ["to", 1030], ["preventing", 1033], ["neuronal", 1044], ["apoptosis", 1053], [".", 1062]]}
{"context": "Current research in lymphoma is focused on two areas of lymphoma biology-the signal transduction pathways used to maintain the growth of malignant lymphocytes and the role of the tumor microenvironment in lymphoma growth and survival. This review focuses on three signaling pathways: the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway, the B-cell receptor/spleen tyrosine kinase (BCR/Syk) pathway, and the protein kinase C-beta (PKC-\u03b2) pathway, known to be important to lymphoma cells. The mTOR inhibitors temsirolimus and everolimus have demonstrated antitumor activity in all types of lymphoma, the Syk inhibitor fostamatinib has activity in diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and the PKC-\u03b2 inhibitor enzastaurin is being used as consolidation therapy after remission in diffuse large B-cell lymphoma. This review discusses the biology behind the development of each new agent and the results of initial clinical trials. The goal is to provide the hematologist/oncologist background information on these new agents and understand their current and potential role in the management of patients.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "9e08a0761bde49399ae1e7eae4dfde2c", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[67, 69]], "char_spans": [[389, 410]]}]}], "context_tokens": [["Current", 0], ["research", 8], ["in", 17], ["lymphoma", 20], ["is", 29], ["focused", 32], ["on", 40], ["two", 43], ["areas", 47], ["of", 53], ["lymphoma", 56], ["biology", 65], ["-", 72], ["the", 73], ["signal", 77], ["transduction", 84], ["pathways", 97], ["used", 106], ["to", 111], ["maintain", 114], ["the", 123], ["growth", 127], ["of", 134], ["malignant", 137], ["lymphocytes", 147], ["and", 159], ["the", 163], ["role", 167], ["of", 172], ["the", 175], ["tumor", 179], ["microenvironment", 185], ["in", 202], ["lymphoma", 205], ["growth", 214], ["and", 221], ["survival", 225], [".", 233], ["This", 235], ["review", 240], ["focuses", 247], ["on", 255], ["three", 258], ["signaling", 264], ["pathways", 274], [":", 282], ["the", 284], ["phosphatidylinositol", 288], ["3-kinase", 309], ["/", 317], ["mammalian", 318], ["target", 328], ["of", 335], ["rapamycin", 338], ["(", 348], ["PI3K", 349], ["/", 353], ["mTOR", 354], [")", 358], ["pathway", 360], [",", 367], ["the", 369], ["B", 373], ["-", 374], ["cell", 375], ["receptor", 380], ["/", 388], ["spleen", 389], ["tyrosine", 396], ["kinase", 405], ["(", 412], ["BCR", 413], ["/", 416], ["Syk", 417], [")", 420], ["pathway", 422], [",", 429], ["and", 431], ["the", 435], ["protein", 439], ["kinase", 447], ["C", 454], ["-", 455], ["beta", 456], ["(", 461], ["PKC", 462], ["-", 465], ["\u03b2", 466], [")", 467], ["pathway", 469], [",", 476], ["known", 478], ["to", 484], ["be", 487], ["important", 490], ["to", 500], ["lymphoma", 503], ["cells", 512], [".", 517], ["The", 519], ["mTOR", 523], ["inhibitors", 528], ["temsirolimus", 539], ["and", 552], ["everolimus", 556], ["have", 567], ["demonstrated", 572], ["antitumor", 585], ["activity", 595], ["in", 604], ["all", 607], ["types", 611], ["of", 617], ["lymphoma", 620], [",", 628], ["the", 630], ["Syk", 634], ["inhibitor", 638], ["fostamatinib", 648], ["has", 661], ["activity", 665], ["in", 674], ["diffuse", 677], ["large", 685], ["B", 691], ["-", 692], ["cell", 693], ["lymphoma", 698], ["and", 707], ["chronic", 711], ["lymphocytic", 719], ["leukemia", 731], [",", 739], ["and", 741], ["the", 745], ["PKC", 749], ["-", 752], ["\u03b2", 753], ["inhibitor", 755], ["enzastaurin", 765], ["is", 777], ["being", 780], ["used", 786], ["as", 791], ["consolidation", 794], ["therapy", 808], ["after", 816], ["remission", 822], ["in", 832], ["diffuse", 835], ["large", 843], ["B", 849], ["-", 850], ["cell", 851], ["lymphoma", 856], [".", 864], ["This", 866], ["review", 871], ["discusses", 878], ["the", 888], ["biology", 892], ["behind", 900], ["the", 907], ["development", 911], ["of", 923], ["each", 926], ["new", 931], ["agent", 935], ["and", 941], ["the", 945], ["results", 949], ["of", 957], ["initial", 960], ["clinical", 968], ["trials", 977], [".", 983], ["The", 985], ["goal", 989], ["is", 994], ["to", 997], ["provide", 1000], ["the", 1008], ["hematologist", 1012], ["/", 1024], ["oncologist", 1025], ["background", 1036], ["information", 1047], ["on", 1059], ["these", 1062], ["new", 1068], ["agents", 1072], ["and", 1079], ["understand", 1083], ["their", 1094], ["current", 1100], ["and", 1108], ["potential", 1112], ["role", 1122], ["in", 1127], ["the", 1130], ["management", 1134], ["of", 1145], ["patients", 1148], [".", 1156]]}
{"context": "During the past 25 years an increase in the prevalence of methicillin-resistant Staphylococcus aureus (HA-MRSA) was recorded worldwide. Additionally, MRSA infections may occur outside and independent of hospitals, caused by community associated MRSA (CA-MRSA). In Germany, we found that at least 10% of these sporadic infections are due to livestock-associated MRSA (LA-MRSA), which is initially associated with livestock. The majority of these MRSA cases are attributed to clonal complex CC398. LA-MRSA CC398 colonizes the animals asymptomatically in about half of conventional pig farms. For about 77%-86% of humans with occupational exposure to pigs, nasal carriage has been reported; it can be lost when exposure is interrupted. Among family members living at the same farms, only 4%-5% are colonized. Spread beyond this group of people is less frequent. The prevalence of LA-MRSA in livestock seems to be influenced by farm size, farming systems, usage of disinfectants, and in-feed zinc. LA-MRSA CC398 is able to cause the same kind of infections in humans as S. aureus and MRSA in general. It can be introduced to hospitals and cause nosocomial infections such as postoperative surgical site infections, ventilator associated pneumonia, septicemia, and infections after joint replacement. For this reason, screening for MRSA colonization at hospital admittance is recommended for farmers and veterinarians with livestock contacts. Intrahospital dissemination, typical for HA-MRSA in the absence of sufficient hygiene, has only rarely been observed for LA-MRSA to date. The proportion of LA-MRSA among all MRSA from nosocomial infections is about 3% across Germany. In geographical areas with a comparatively high density of conventional farms, LA-MRSA accounts for up to 10% of MRSA from septicemia and 15% of MRSA from wound infections. As known from comparative genome analysis, LA-MRSA has evolved from human-adapted methicillin-susceptible S. aureus, and the jump to livestock was obviously associated with several genetic changes. Reversion of the genetic changes and readaptation to humans bears a potential health risk and requires tight surveillance. Although most LA-MRSA (>80%) is resistant to several antibiotics, there are still sufficient treatment options.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "acb2a63cd4e648af8aa61159baa8dc25", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[272, 272], [288, 288], [45, 45], [19, 19], [211, 211], [250, 250], [333, 333], [403, 403], [300, 300], [340, 340], [325, 325], [68, 68], [194, 194], [27, 27], [86, 86], [41, 41], [297, 297], [72, 72], [168, 168], [354, 354], [97, 97]], "char_spans": [[1482, 1485], [1562, 1565], [254, 257], [106, 109], [1080, 1083], [1327, 1330], [1785, 1788], [2183, 2186], [1612, 1615], [1817, 1820], [1754, 1757], [361, 364], [997, 1000], [150, 153], [445, 448], [245, 248], [1597, 1600], [370, 373], [880, 883], [1891, 1894], [499, 502]]}]}], "context_tokens": [["During", 0], ["the", 7], ["past", 11], ["25", 16], ["years", 19], ["an", 25], ["increase", 28], ["in", 37], ["the", 40], ["prevalence", 44], ["of", 55], ["methicillin", 58], ["-", 69], ["resistant", 70], ["Staphylococcus", 80], ["aureus", 95], ["(", 102], ["HA", 103], ["-", 105], ["MRSA", 106], [")", 110], ["was", 112], ["recorded", 116], ["worldwide", 125], [".", 134], ["Additionally", 136], [",", 148], ["MRSA", 150], ["infections", 155], ["may", 166], ["occur", 170], ["outside", 176], ["and", 184], ["independent", 188], ["of", 200], ["hospitals", 203], [",", 212], ["caused", 214], ["by", 221], ["community", 224], ["associated", 234], ["MRSA", 245], ["(", 250], ["CA", 251], ["-", 253], ["MRSA", 254], [")", 258], [".", 259], ["In", 261], ["Germany", 264], [",", 271], ["we", 273], ["found", 276], ["that", 282], ["at", 287], ["least", 290], ["10", 296], ["%", 298], ["of", 300], ["these", 303], ["sporadic", 309], ["infections", 318], ["are", 329], ["due", 333], ["to", 337], ["livestock", 340], ["-", 349], ["associated", 350], ["MRSA", 361], ["(", 366], ["LA", 367], ["-", 369], ["MRSA", 370], [")", 374], [",", 375], ["which", 377], ["is", 383], ["initially", 386], ["associated", 396], ["with", 407], ["livestock", 412], [".", 421], ["The", 423], ["majority", 427], ["of", 436], ["these", 439], ["MRSA", 445], ["cases", 450], ["are", 456], ["attributed", 460], ["to", 471], ["clonal", 474], ["complex", 481], ["CC398", 489], [".", 494], ["LA", 496], ["-", 498], ["MRSA", 499], ["CC398", 504], ["colonizes", 510], ["the", 520], ["animals", 524], ["asymptomatically", 532], ["in", 549], ["about", 552], ["half", 558], ["of", 563], ["conventional", 566], ["pig", 579], ["farms", 583], [".", 588], ["For", 590], ["about", 594], ["77%-86", 600], ["%", 606], ["of", 608], ["humans", 611], ["with", 618], ["occupational", 623], ["exposure", 636], ["to", 645], ["pigs", 648], [",", 652], ["nasal", 654], ["carriage", 660], ["has", 669], ["been", 673], ["reported", 678], [";", 686], ["it", 688], ["can", 691], ["be", 695], ["lost", 698], ["when", 703], ["exposure", 708], ["is", 717], ["interrupted", 720], [".", 731], ["Among", 733], ["family", 739], ["members", 746], ["living", 754], ["at", 761], ["the", 764], ["same", 768], ["farms", 773], [",", 778], ["only", 780], ["4%-5", 785], ["%", 789], ["are", 791], ["colonized", 795], [".", 804], ["Spread", 806], ["beyond", 813], ["this", 820], ["group", 825], ["of", 831], ["people", 834], ["is", 841], ["less", 844], ["frequent", 849], [".", 857], ["The", 859], ["prevalence", 863], ["of", 874], ["LA", 877], ["-", 879], ["MRSA", 880], ["in", 885], ["livestock", 888], ["seems", 898], ["to", 904], ["be", 907], ["influenced", 910], ["by", 921], ["farm", 924], ["size", 929], [",", 933], ["farming", 935], ["systems", 943], [",", 950], ["usage", 952], ["of", 958], ["disinfectants", 961], [",", 974], ["and", 976], ["in", 980], ["-", 982], ["feed", 983], ["zinc", 988], [".", 992], ["LA", 994], ["-", 996], ["MRSA", 997], ["CC398", 1002], ["is", 1008], ["able", 1011], ["to", 1016], ["cause", 1019], ["the", 1025], ["same", 1029], ["kind", 1034], ["of", 1039], ["infections", 1042], ["in", 1053], ["humans", 1056], ["as", 1063], ["S.", 1066], ["aureus", 1069], ["and", 1076], ["MRSA", 1080], ["in", 1085], ["general", 1088], [".", 1095], ["It", 1097], ["can", 1100], ["be", 1104], ["introduced", 1107], ["to", 1118], ["hospitals", 1121], ["and", 1131], ["cause", 1135], ["nosocomial", 1141], ["infections", 1152], ["such", 1163], ["as", 1168], ["postoperative", 1171], ["surgical", 1185], ["site", 1194], ["infections", 1199], [",", 1209], ["ventilator", 1211], ["associated", 1222], ["pneumonia", 1233], [",", 1242], ["septicemia", 1244], [",", 1254], ["and", 1256], ["infections", 1260], ["after", 1271], ["joint", 1277], ["replacement", 1283], [".", 1294], ["For", 1296], ["this", 1300], ["reason", 1305], [",", 1311], ["screening", 1313], ["for", 1323], ["MRSA", 1327], ["colonization", 1332], ["at", 1345], ["hospital", 1348], ["admittance", 1357], ["is", 1368], ["recommended", 1371], ["for", 1383], ["farmers", 1387], ["and", 1395], ["veterinarians", 1399], ["with", 1413], ["livestock", 1418], ["contacts", 1428], [".", 1436], ["Intrahospital", 1438], ["dissemination", 1452], [",", 1465], ["typical", 1467], ["for", 1475], ["HA", 1479], ["-", 1481], ["MRSA", 1482], ["in", 1487], ["the", 1490], ["absence", 1494], ["of", 1502], ["sufficient", 1505], ["hygiene", 1516], [",", 1523], ["has", 1525], ["only", 1529], ["rarely", 1534], ["been", 1541], ["observed", 1546], ["for", 1555], ["LA", 1559], ["-", 1561], ["MRSA", 1562], ["to", 1567], ["date", 1570], [".", 1574], ["The", 1576], ["proportion", 1580], ["of", 1591], ["LA", 1594], ["-", 1596], ["MRSA", 1597], ["among", 1602], ["all", 1608], ["MRSA", 1612], ["from", 1617], ["nosocomial", 1622], ["infections", 1633], ["is", 1644], ["about", 1647], ["3", 1653], ["%", 1654], ["across", 1656], ["Germany", 1663], [".", 1670], ["In", 1672], ["geographical", 1675], ["areas", 1688], ["with", 1694], ["a", 1699], ["comparatively", 1701], ["high", 1715], ["density", 1720], ["of", 1728], ["conventional", 1731], ["farms", 1744], [",", 1749], ["LA", 1751], ["-", 1753], ["MRSA", 1754], ["accounts", 1759], ["for", 1768], ["up", 1772], ["to", 1775], ["10", 1778], ["%", 1780], ["of", 1782], ["MRSA", 1785], ["from", 1790], ["septicemia", 1795], ["and", 1806], ["15", 1810], ["%", 1812], ["of", 1814], ["MRSA", 1817], ["from", 1822], ["wound", 1827], ["infections", 1833], [".", 1843], ["As", 1845], ["known", 1848], ["from", 1854], ["comparative", 1859], ["genome", 1871], ["analysis", 1878], [",", 1886], ["LA", 1888], ["-", 1890], ["MRSA", 1891], ["has", 1896], ["evolved", 1900], ["from", 1908], ["human", 1913], ["-", 1918], ["adapted", 1919], ["methicillin", 1927], ["-", 1938], ["susceptible", 1939], ["S.", 1951], ["aureus", 1954], [",", 1960], ["and", 1962], ["the", 1966], ["jump", 1970], ["to", 1975], ["livestock", 1978], ["was", 1988], ["obviously", 1992], ["associated", 2002], ["with", 2013], ["several", 2018], ["genetic", 2026], ["changes", 2034], [".", 2041], ["Reversion", 2043], ["of", 2053], ["the", 2056], ["genetic", 2060], ["changes", 2068], ["and", 2076], ["readaptation", 2080], ["to", 2093], ["humans", 2096], ["bears", 2103], ["a", 2109], ["potential", 2111], ["health", 2121], ["risk", 2128], ["and", 2133], ["requires", 2137], ["tight", 2146], ["surveillance", 2152], [".", 2164], ["Although", 2166], ["most", 2175], ["LA", 2180], ["-", 2182], ["MRSA", 2183], ["(", 2188], [">", 2189], ["80", 2190], ["%", 2192], [")", 2193], ["is", 2195], ["resistant", 2198], ["to", 2208], ["several", 2211], ["antibiotics", 2219], [",", 2230], ["there", 2232], ["are", 2238], ["still", 2242], ["sufficient", 2248], ["treatment", 2259], ["options", 2269], [".", 2276]]}
{"context": "The apolipoprotein E type 4 allele is a susceptibility gene for late-onset Alzheimer's disease. Apolipoprotein E is found in neurons, some of which contain paired helical filaments made of the microtubule-associated protein tau. Previous studies have demonstrated that the apoE3 isoform, but not the apoE4 isoform, binds tau with high avidity. Because the microtubule-associated protein MAP2c also effects microtubule assembly and stability, we examined interactions between apoE isoforms and MAP2c. Similar to the tau-binding results, apoE3, but not apoE4, bound MAP2c. Binding was detectable down to 10(-9) M MAP2c and 10(-8) M apoE3. Isoform-specific interactions of apoE with the microtubule-associated proteins MAP2c and tau might affect intracellular maintenance of microtubules and could contribute to a time-dependent pathogenesis of Alzheimer's disease.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2a8c06afe76f42f9ab06708b3adc27fc", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[53, 54]], "char_spans": [[300, 312]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["type", 21], ["4", 26], ["allele", 28], ["is", 35], ["a", 38], ["susceptibility", 40], ["gene", 55], ["for", 60], ["late", 64], ["-", 68], ["onset", 69], ["Alzheimer", 75], ["'s", 84], ["disease", 87], [".", 94], ["Apolipoprotein", 96], ["E", 111], ["is", 113], ["found", 116], ["in", 122], ["neurons", 125], [",", 132], ["some", 134], ["of", 139], ["which", 142], ["contain", 148], ["paired", 156], ["helical", 163], ["filaments", 171], ["made", 181], ["of", 186], ["the", 189], ["microtubule", 193], ["-", 204], ["associated", 205], ["protein", 216], ["tau", 224], [".", 227], ["Previous", 229], ["studies", 238], ["have", 246], ["demonstrated", 251], ["that", 264], ["the", 269], ["apoE3", 273], ["isoform", 279], [",", 286], ["but", 288], ["not", 292], ["the", 296], ["apoE4", 300], ["isoform", 306], [",", 313], ["binds", 315], ["tau", 321], ["with", 325], ["high", 330], ["avidity", 335], [".", 342], ["Because", 344], ["the", 352], ["microtubule", 356], ["-", 367], ["associated", 368], ["protein", 379], ["MAP2c", 387], ["also", 393], ["effects", 398], ["microtubule", 406], ["assembly", 418], ["and", 427], ["stability", 431], [",", 440], ["we", 442], ["examined", 445], ["interactions", 454], ["between", 467], ["apoE", 475], ["isoforms", 480], ["and", 489], ["MAP2c", 493], [".", 498], ["Similar", 500], ["to", 508], ["the", 511], ["tau", 515], ["-", 518], ["binding", 519], ["results", 527], [",", 534], ["apoE3", 536], [",", 541], ["but", 543], ["not", 547], ["apoE4", 551], [",", 556], ["bound", 558], ["MAP2c", 564], [".", 569], ["Binding", 571], ["was", 579], ["detectable", 583], ["down", 594], ["to", 599], ["10(-9", 602], [")", 607], ["M", 609], ["MAP2c", 611], ["and", 617], ["10(-8", 621], [")", 626], ["M", 628], ["apoE3", 630], [".", 635], ["Isoform", 637], ["-", 644], ["specific", 645], ["interactions", 654], ["of", 667], ["apoE", 670], ["with", 675], ["the", 680], ["microtubule", 684], ["-", 695], ["associated", 696], ["proteins", 707], ["MAP2c", 716], ["and", 722], ["tau", 726], ["might", 730], ["affect", 736], ["intracellular", 743], ["maintenance", 757], ["of", 769], ["microtubules", 772], ["and", 785], ["could", 789], ["contribute", 795], ["to", 806], ["a", 809], ["time", 811], ["-", 815], ["dependent", 816], ["pathogenesis", 826], ["of", 839], ["Alzheimer", 842], ["'s", 851], ["disease", 854], [".", 861]]}
{"context": "Urgent surgery or life-threatening bleeding requires prompt reversal of the anticoagulant effects of dabigatran. This study assessed the ability of three- and four-factor prothrombin complex concentrate (PCC) and idarucizumab (specific antidote for dabigatran) to reverse the anticoagulant effects of dabigatran in a porcine model of trauma. Twelve animals were given dabigatran etexilate (DE) orally and dabigatran intravenously, before infliction of trauma. Six animals received tranexamic acid plus fibrinogen concentrate 12 minutes post-injury. Six PCCs (each 30 and 60 U/kg) and idarucizumab (30 and 60 mg/kg) were added to blood samples ex vivo. Coagulation was assessed by several coagulation assays. All coagulation parameters were altered after dabigatran infusion (plasma level: 442 \u00b1 138 ng/ml). Both three- and four-factor PCCs mostly or completely reversed the effects of dabigatran on thromboelastometry variables and PT but not on aPTT. Idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables. Thrombin generation showed dose-dependent over-correction following the addition of PCC, implying that elevated levels of thrombin are required to overcome dabigatran-induced coagulopathy. In contrast, treatment with idarucizumab returned thrombin generation to baseline levels. Following trauma, therapy with tranexamic acid plus fibrinogen improved correction of coagulation parameters by PCC, and thromboelastometry parameters by idarucizumab. All investigated PCCs improved dabigatran- and trauma-induced coagulopathy to a similar degree. In conclusion, this study shows that three- and four-factor PCCs are similarly effective for dabigatran reversal. Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "6c15c6c5007f4bac9ec1454df2719dfa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[48, 48], [160, 160], [67, 67], [176, 176], [214, 214], [259, 259], [60, 60], [132, 132], [40, 40], [296, 296], [287, 287], [15, 15]], "char_spans": [[301, 310], [885, 894], [405, 414], [1002, 1011], [1233, 1242], [1555, 1565], [368, 377], [754, 763], [249, 258], [1776, 1785], [1713, 1722], [101, 110]]}]}], "context_tokens": [["Urgent", 0], ["surgery", 7], ["or", 15], ["life", 18], ["-", 22], ["threatening", 23], ["bleeding", 35], ["requires", 44], ["prompt", 53], ["reversal", 60], ["of", 69], ["the", 72], ["anticoagulant", 76], ["effects", 90], ["of", 98], ["dabigatran", 101], [".", 111], ["This", 113], ["study", 118], ["assessed", 124], ["the", 133], ["ability", 137], ["of", 145], ["three-", 148], ["and", 155], ["four", 159], ["-", 163], ["factor", 164], ["prothrombin", 171], ["complex", 183], ["concentrate", 191], ["(", 203], ["PCC", 204], [")", 207], ["and", 209], ["idarucizumab", 213], ["(", 226], ["specific", 227], ["antidote", 236], ["for", 245], ["dabigatran", 249], [")", 259], ["to", 261], ["reverse", 264], ["the", 272], ["anticoagulant", 276], ["effects", 290], ["of", 298], ["dabigatran", 301], ["in", 312], ["a", 315], ["porcine", 317], ["model", 325], ["of", 331], ["trauma", 334], [".", 340], ["Twelve", 342], ["animals", 349], ["were", 357], ["given", 362], ["dabigatran", 368], ["etexilate", 379], ["(", 389], ["DE", 390], [")", 392], ["orally", 394], ["and", 401], ["dabigatran", 405], ["intravenously", 416], [",", 429], ["before", 431], ["infliction", 438], ["of", 449], ["trauma", 452], [".", 458], ["Six", 460], ["animals", 464], ["received", 472], ["tranexamic", 481], ["acid", 492], ["plus", 497], ["fibrinogen", 502], ["concentrate", 513], ["12", 525], ["minutes", 528], ["post", 536], ["-", 540], ["injury", 541], [".", 547], ["Six", 549], ["PCCs", 553], ["(", 558], ["each", 559], ["30", 564], ["and", 567], ["60", 571], ["U", 574], ["/", 575], ["kg", 576], [")", 578], ["and", 580], ["idarucizumab", 584], ["(", 597], ["30", 598], ["and", 601], ["60", 605], ["mg", 608], ["/", 610], ["kg", 611], [")", 613], ["were", 615], ["added", 620], ["to", 626], ["blood", 629], ["samples", 635], ["ex", 643], ["vivo", 646], [".", 650], ["Coagulation", 652], ["was", 664], ["assessed", 668], ["by", 677], ["several", 680], ["coagulation", 688], ["assays", 700], [".", 706], ["All", 708], ["coagulation", 712], ["parameters", 724], ["were", 735], ["altered", 740], ["after", 748], ["dabigatran", 754], ["infusion", 765], ["(", 774], ["plasma", 775], ["level", 782], [":", 787], ["442", 789], ["\u00b1", 793], ["138", 795], ["ng", 799], ["/", 801], ["ml", 802], [")", 804], [".", 805], ["Both", 807], ["three-", 812], ["and", 819], ["four", 823], ["-", 827], ["factor", 828], ["PCCs", 835], ["mostly", 840], ["or", 847], ["completely", 850], ["reversed", 861], ["the", 870], ["effects", 874], ["of", 882], ["dabigatran", 885], ["on", 896], ["thromboelastometry", 899], ["variables", 918], ["and", 928], ["PT", 932], ["but", 935], ["not", 939], ["on", 943], ["aPTT", 946], [".", 950], ["Idarucizumab", 952], ["neutralised", 965], ["plasma", 977], ["concentrations", 984], ["of", 999], ["dabigatran", 1002], [",", 1012], ["and", 1014], ["reversed", 1018], ["the", 1027], ["effects", 1031], ["of", 1039], ["the", 1042], ["drug", 1046], ["on", 1051], ["coagulation", 1054], ["variables", 1066], [".", 1075], ["Thrombin", 1077], ["generation", 1086], ["showed", 1097], ["dose", 1104], ["-", 1108], ["dependent", 1109], ["over", 1119], ["-", 1123], ["correction", 1124], ["following", 1135], ["the", 1145], ["addition", 1149], ["of", 1158], ["PCC", 1161], [",", 1164], ["implying", 1166], ["that", 1175], ["elevated", 1180], ["levels", 1189], ["of", 1196], ["thrombin", 1199], ["are", 1208], ["required", 1212], ["to", 1221], ["overcome", 1224], ["dabigatran", 1233], ["-", 1243], ["induced", 1244], ["coagulopathy", 1252], [".", 1264], ["In", 1266], ["contrast", 1269], [",", 1277], ["treatment", 1279], ["with", 1289], ["idarucizumab", 1294], ["returned", 1307], ["thrombin", 1316], ["generation", 1325], ["to", 1336], ["baseline", 1339], ["levels", 1348], [".", 1354], ["Following", 1356], ["trauma", 1366], [",", 1372], ["therapy", 1374], ["with", 1382], ["tranexamic", 1387], ["acid", 1398], ["plus", 1403], ["fibrinogen", 1408], ["improved", 1419], ["correction", 1428], ["of", 1439], ["coagulation", 1442], ["parameters", 1454], ["by", 1465], ["PCC", 1468], [",", 1471], ["and", 1473], ["thromboelastometry", 1477], ["parameters", 1496], ["by", 1507], ["idarucizumab", 1510], [".", 1522], ["All", 1524], ["investigated", 1528], ["PCCs", 1541], ["improved", 1546], ["dabigatran-", 1555], ["and", 1567], ["trauma", 1571], ["-", 1577], ["induced", 1578], ["coagulopathy", 1586], ["to", 1599], ["a", 1602], ["similar", 1604], ["degree", 1612], [".", 1618], ["In", 1620], ["conclusion", 1623], [",", 1633], ["this", 1635], ["study", 1640], ["shows", 1646], ["that", 1652], ["three-", 1657], ["and", 1664], ["four", 1668], ["-", 1672], ["factor", 1673], ["PCCs", 1680], ["are", 1685], ["similarly", 1689], ["effective", 1699], ["for", 1709], ["dabigatran", 1713], ["reversal", 1724], [".", 1732], ["Idarucizumab", 1734], ["also", 1747], ["reversed", 1752], ["the", 1761], ["effects", 1765], ["of", 1773], ["dabigatran", 1776], ["and", 1787], [",", 1790], ["unlike", 1792], ["PCCs", 1799], [",", 1803], ["was", 1805], ["not", 1809], ["associated", 1813], ["with", 1824], ["over", 1829], ["-", 1833], ["correction", 1834], ["of", 1845], ["thrombin", 1848], ["generation", 1857], [".", 1867]]}
{"context": "Mitochondrial (mt) genomes from diverse phylogenetic groups vary considerably in size, structure and organization. The genus Plasmodium, the causative agent of malaria, has the smallest mt genome in the form of a tandemly repeated, linear element of 6 kb. The Plasmodium mt genome encodes only three protein genes (cox1, cox3 and cob) and large- and small-subunit ribosomal RNA (rRNA) genes, which are highly fragmented with 19 identified rRNA pieces. The complete mt genome sequences of 21 Plasmodium species have been published but a thorough investigation of the arrangement of rRNA gene fragments has been undertaken for only Plasmodium falciparum, the human malaria parasite. In this study, we determined the arrangement of mt rRNA gene fragments in 23 Plasmodium species, including two newly determined mt genome sequences from P. gallinaceum and P. vinckei vinckei, as well as Leucocytozoon caulleryi, an outgroup of Plasmodium. Comparative analysis reveals complete conservation of the arrangement of rRNA gene fragments in the mt genomes of all the 23 Plasmodium species and L. caulleryi. Surveys for a new rRNA gene fragment using hidden Markov models enriched with recent mt genome sequences led us to suggest the mtR-26 sequence as a novel candidate LSU rRNA fragment in the mt genomes of the 24 species. Additionally, we found 22-25 bp-inverted repeat sequences, which may be involved in the generation of lineage-specific mt genome arrangements after divergence from a common ancestor of the genera Eimeria and Plasmodium/Leucocytozoon.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "edb937b647764c0aa11b371e373061ad", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[93, 94], [186, 187], [137, 138]], "char_spans": [[491, 508], [1061, 1078], [758, 775]]}]}], "context_tokens": [["Mitochondrial", 0], ["(", 14], ["mt", 15], [")", 17], ["genomes", 19], ["from", 27], ["diverse", 32], ["phylogenetic", 40], ["groups", 53], ["vary", 60], ["considerably", 65], ["in", 78], ["size", 81], [",", 85], ["structure", 87], ["and", 97], ["organization", 101], [".", 113], ["The", 115], ["genus", 119], ["Plasmodium", 125], [",", 135], ["the", 137], ["causative", 141], ["agent", 151], ["of", 157], ["malaria", 160], [",", 167], ["has", 169], ["the", 173], ["smallest", 177], ["mt", 186], ["genome", 189], ["in", 196], ["the", 199], ["form", 203], ["of", 208], ["a", 211], ["tandemly", 213], ["repeated", 222], [",", 230], ["linear", 232], ["element", 239], ["of", 247], ["6", 250], ["kb", 252], [".", 254], ["The", 256], ["Plasmodium", 260], ["mt", 271], ["genome", 274], ["encodes", 281], ["only", 289], ["three", 294], ["protein", 300], ["genes", 308], ["(", 314], ["cox1", 315], [",", 319], ["cox3", 321], ["and", 326], ["cob", 330], [")", 333], ["and", 335], ["large-", 339], ["and", 346], ["small", 350], ["-", 355], ["subunit", 356], ["ribosomal", 364], ["RNA", 374], ["(", 378], ["rRNA", 379], [")", 383], ["genes", 385], [",", 390], ["which", 392], ["are", 398], ["highly", 402], ["fragmented", 409], ["with", 420], ["19", 425], ["identified", 428], ["rRNA", 439], ["pieces", 444], [".", 450], ["The", 452], ["complete", 456], ["mt", 465], ["genome", 468], ["sequences", 475], ["of", 485], ["21", 488], ["Plasmodium", 491], ["species", 502], ["have", 510], ["been", 515], ["published", 520], ["but", 530], ["a", 534], ["thorough", 536], ["investigation", 545], ["of", 559], ["the", 562], ["arrangement", 566], ["of", 578], ["rRNA", 581], ["gene", 586], ["fragments", 591], ["has", 601], ["been", 605], ["undertaken", 610], ["for", 621], ["only", 625], ["Plasmodium", 630], ["falciparum", 641], [",", 651], ["the", 653], ["human", 657], ["malaria", 663], ["parasite", 671], [".", 679], ["In", 681], ["this", 684], ["study", 689], [",", 694], ["we", 696], ["determined", 699], ["the", 710], ["arrangement", 714], ["of", 726], ["mt", 729], ["rRNA", 732], ["gene", 737], ["fragments", 742], ["in", 752], ["23", 755], ["Plasmodium", 758], ["species", 769], [",", 776], ["including", 778], ["two", 788], ["newly", 792], ["determined", 798], ["mt", 809], ["genome", 812], ["sequences", 819], ["from", 829], ["P.", 834], ["gallinaceum", 837], ["and", 849], ["P.", 853], ["vinckei", 856], ["vinckei", 864], [",", 871], ["as", 873], ["well", 876], ["as", 881], ["Leucocytozoon", 884], ["caulleryi", 898], [",", 907], ["an", 909], ["outgroup", 912], ["of", 921], ["Plasmodium", 924], [".", 934], ["Comparative", 936], ["analysis", 948], ["reveals", 957], ["complete", 965], ["conservation", 974], ["of", 987], ["the", 990], ["arrangement", 994], ["of", 1006], ["rRNA", 1009], ["gene", 1014], ["fragments", 1019], ["in", 1029], ["the", 1032], ["mt", 1036], ["genomes", 1039], ["of", 1047], ["all", 1050], ["the", 1054], ["23", 1058], ["Plasmodium", 1061], ["species", 1072], ["and", 1080], ["L.", 1084], ["caulleryi", 1087], [".", 1096], ["Surveys", 1098], ["for", 1106], ["a", 1110], ["new", 1112], ["rRNA", 1116], ["gene", 1121], ["fragment", 1126], ["using", 1135], ["hidden", 1141], ["Markov", 1148], ["models", 1155], ["enriched", 1162], ["with", 1171], ["recent", 1176], ["mt", 1183], ["genome", 1186], ["sequences", 1193], ["led", 1203], ["us", 1207], ["to", 1210], ["suggest", 1213], ["the", 1221], ["mtR-26", 1225], ["sequence", 1232], ["as", 1241], ["a", 1244], ["novel", 1246], ["candidate", 1252], ["LSU", 1262], ["rRNA", 1266], ["fragment", 1271], ["in", 1280], ["the", 1283], ["mt", 1287], ["genomes", 1290], ["of", 1298], ["the", 1301], ["24", 1305], ["species", 1308], [".", 1315], ["Additionally", 1317], [",", 1329], ["we", 1331], ["found", 1334], ["22", 1340], ["-", 1342], ["25", 1343], ["bp", 1346], ["-", 1348], ["inverted", 1349], ["repeat", 1358], ["sequences", 1365], [",", 1374], ["which", 1376], ["may", 1382], ["be", 1386], ["involved", 1389], ["in", 1398], ["the", 1401], ["generation", 1405], ["of", 1416], ["lineage", 1419], ["-", 1426], ["specific", 1427], ["mt", 1436], ["genome", 1439], ["arrangements", 1446], ["after", 1459], ["divergence", 1465], ["from", 1476], ["a", 1481], ["common", 1483], ["ancestor", 1490], ["of", 1499], ["the", 1502], ["genera", 1506], ["Eimeria", 1513], ["and", 1521], ["Plasmodium", 1525], ["/", 1535], ["Leucocytozoon", 1536], [".", 1549]]}
{"context": "The glycoprotein sclerostin (Scl; 22 kDa), which is involved in bone metabolism, may play a role in vascular calcification in haemodialysis (HD) patients. In the present study, we investigated the relation between serum Scl (sScl) and mortality. The effects of dialysis modality and the magnitude of the convection volume in haemodiafiltration (HDF) on sScl were also investigated. In a subset of patients from the CONTRAST study, a randomized controlled trial comparing HDF with HD, sScl was measured at baseline and at intervals of 6, 12, 24 and 36 months. Patients were divided into quartiles, according to their baseline sScl. The relation between time-varying sScl and mortality with a 4-year follow-up period was investigated using crude and adjusted Cox regression models. Linear mixed models were used for longitudinal measurements of sScl. The mean (\u00b1standard deviation) age of 396 test subjects was 63.6 (\u00b113.9 years), 61.6% were male and the median follow-up was 2.9 years. Subjects with the highest sScl had a lower mortality risk than those with the lowest concentrations [adjusted hazard ratio 0.51 (95% confidence interval, CI, 0.31-0.86, P = 0.01)]. Stratified models showed a stable sScl in patients treated with HD (\u0394 +2.9 pmol/L/year, 95% CI -0.5 to +6.3, P = 0.09) and a decreasing concentration in those treated with HDF (\u0394 -4.5 pmol/L/year, 95% CI -8.0 to -0.9, P = 0.02). The relative change in the latter group was related to the magnitude of the convection volume. (i) A high sScl is associated with a lower mortality risk in patients with end-stage kidney disease; (ii) treatment with HDF causes sScl to fall; and (iii) the relative decline in patients treated with HDF is dependent on the magnitude of the convection volume.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "0029838703954d16a57a5cc158fd86d5", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[14, 15]], "char_spans": [[64, 78]]}]}], "context_tokens": [["The", 0], ["glycoprotein", 4], ["sclerostin", 17], ["(", 28], ["Scl", 29], [";", 32], ["22", 34], ["kDa", 37], [")", 40], [",", 41], ["which", 43], ["is", 49], ["involved", 52], ["in", 61], ["bone", 64], ["metabolism", 69], [",", 79], ["may", 81], ["play", 85], ["a", 90], ["role", 92], ["in", 97], ["vascular", 100], ["calcification", 109], ["in", 123], ["haemodialysis", 126], ["(", 140], ["HD", 141], [")", 143], ["patients", 145], [".", 153], ["In", 155], ["the", 158], ["present", 162], ["study", 170], [",", 175], ["we", 177], ["investigated", 180], ["the", 193], ["relation", 197], ["between", 206], ["serum", 214], ["Scl", 220], ["(", 224], ["sScl", 225], [")", 229], ["and", 231], ["mortality", 235], [".", 244], ["The", 246], ["effects", 250], ["of", 258], ["dialysis", 261], ["modality", 270], ["and", 279], ["the", 283], ["magnitude", 287], ["of", 297], ["the", 300], ["convection", 304], ["volume", 315], ["in", 322], ["haemodiafiltration", 325], ["(", 344], ["HDF", 345], [")", 348], ["on", 350], ["sScl", 353], ["were", 358], ["also", 363], ["investigated", 368], [".", 380], ["In", 382], ["a", 385], ["subset", 387], ["of", 394], ["patients", 397], ["from", 406], ["the", 411], ["CONTRAST", 415], ["study", 424], [",", 429], ["a", 431], ["randomized", 433], ["controlled", 444], ["trial", 455], ["comparing", 461], ["HDF", 471], ["with", 475], ["HD", 480], [",", 482], ["sScl", 484], ["was", 489], ["measured", 493], ["at", 502], ["baseline", 505], ["and", 514], ["at", 518], ["intervals", 521], ["of", 531], ["6", 534], [",", 535], ["12", 537], [",", 539], ["24", 541], ["and", 544], ["36", 548], ["months", 551], [".", 557], ["Patients", 559], ["were", 568], ["divided", 573], ["into", 581], ["quartiles", 586], [",", 595], ["according", 597], ["to", 607], ["their", 610], ["baseline", 616], ["sScl", 625], [".", 629], ["The", 631], ["relation", 635], ["between", 644], ["time", 652], ["-", 656], ["varying", 657], ["sScl", 665], ["and", 670], ["mortality", 674], ["with", 684], ["a", 689], ["4-year", 691], ["follow", 698], ["-", 704], ["up", 705], ["period", 708], ["was", 715], ["investigated", 719], ["using", 732], ["crude", 738], ["and", 744], ["adjusted", 748], ["Cox", 757], ["regression", 761], ["models", 772], [".", 778], ["Linear", 780], ["mixed", 787], ["models", 793], ["were", 800], ["used", 805], ["for", 810], ["longitudinal", 814], ["measurements", 827], ["of", 840], ["sScl", 843], [".", 847], ["The", 849], ["mean", 853], ["(", 858], ["\u00b1standard", 859], ["deviation", 869], [")", 878], ["age", 880], ["of", 884], ["396", 887], ["test", 891], ["subjects", 896], ["was", 905], ["63.6", 909], ["(", 914], ["\u00b113.9", 915], ["years", 921], [")", 926], [",", 927], ["61.6", 929], ["%", 933], ["were", 935], ["male", 940], ["and", 945], ["the", 949], ["median", 953], ["follow", 960], ["-", 966], ["up", 967], ["was", 970], ["2.9", 974], ["years", 978], [".", 983], ["Subjects", 985], ["with", 994], ["the", 999], ["highest", 1003], ["sScl", 1011], ["had", 1016], ["a", 1020], ["lower", 1022], ["mortality", 1028], ["risk", 1038], ["than", 1043], ["those", 1048], ["with", 1054], ["the", 1059], ["lowest", 1063], ["concentrations", 1070], ["[", 1085], ["adjusted", 1086], ["hazard", 1095], ["ratio", 1102], ["0.51", 1108], ["(", 1113], ["95", 1114], ["%", 1116], ["confidence", 1118], ["interval", 1129], [",", 1137], ["CI", 1139], [",", 1141], ["0.31", 1143], ["-", 1147], ["0.86", 1148], [",", 1152], ["P", 1154], ["=", 1156], ["0.01)].", 1158], ["Stratified", 1166], ["models", 1177], ["showed", 1184], ["a", 1191], ["stable", 1193], ["sScl", 1200], ["in", 1205], ["patients", 1208], ["treated", 1217], ["with", 1225], ["HD", 1230], ["(", 1233], ["\u0394", 1234], ["+2.9", 1236], ["pmol", 1241], ["/", 1245], ["L", 1246], ["/", 1247], ["year", 1248], [",", 1252], ["95", 1254], ["%", 1256], ["CI", 1258], ["-0.5", 1261], ["to", 1266], ["+6.3", 1269], [",", 1273], ["P", 1275], ["=", 1277], ["0.09", 1279], [")", 1283], ["and", 1285], ["a", 1289], ["decreasing", 1291], ["concentration", 1302], ["in", 1316], ["those", 1319], ["treated", 1325], ["with", 1333], ["HDF", 1338], ["(", 1342], ["\u0394", 1343], ["-4.5", 1345], ["pmol", 1350], ["/", 1354], ["L", 1355], ["/", 1356], ["year", 1357], [",", 1361], ["95", 1363], ["%", 1365], ["CI", 1367], ["-8.0", 1370], ["to", 1375], ["-0.9", 1378], [",", 1382], ["P", 1384], ["=", 1386], ["0.02", 1388], [")", 1392], [".", 1393], ["The", 1395], ["relative", 1399], ["change", 1408], ["in", 1415], ["the", 1418], ["latter", 1422], ["group", 1429], ["was", 1435], ["related", 1439], ["to", 1447], ["the", 1450], ["magnitude", 1454], ["of", 1464], ["the", 1467], ["convection", 1471], ["volume", 1482], [".", 1488], ["(", 1490], ["i", 1491], [")", 1492], ["A", 1494], ["high", 1496], ["sScl", 1501], ["is", 1506], ["associated", 1509], ["with", 1520], ["a", 1525], ["lower", 1527], ["mortality", 1533], ["risk", 1543], ["in", 1548], ["patients", 1551], ["with", 1560], ["end", 1565], ["-", 1568], ["stage", 1569], ["kidney", 1575], ["disease", 1582], [";", 1589], ["(", 1591], ["ii", 1592], [")", 1594], ["treatment", 1596], ["with", 1606], ["HDF", 1611], ["causes", 1615], ["sScl", 1622], ["to", 1627], ["fall", 1630], [";", 1634], ["and", 1636], ["(", 1640], ["iii", 1641], [")", 1644], ["the", 1646], ["relative", 1650], ["decline", 1659], ["in", 1667], ["patients", 1670], ["treated", 1679], ["with", 1687], ["HDF", 1692], ["is", 1696], ["dependent", 1699], ["on", 1709], ["the", 1712], ["magnitude", 1716], ["of", 1726], ["the", 1729], ["convection", 1733], ["volume", 1744], [".", 1750]]}
{"context": "Mutations in LYST, a gene encoding a putative lysosomal trafficking protein, cause Ch\u00e9diak-Higashi syndrome (CHS), an autosomal recessive disorder typically characterized by infantile-onset hemophagocytic syndrome and immunodeficiency, and oculocutaneous albinism. A small number of reports of rare, attenuated forms of CHS exist, with affected individuals exhibiting progressive neurodegenerative disease beginning in early adulthood with cognitive decline, parkinsonism, features of spinocerebellar degeneration, and peripheral neuropathy, as well as subtle pigmentary abnormalities and subclinical or absent immune dysfunction. In a consanguineous Pakistani kindred with clinical phenotypes consistent with attenuated CHS, we performed SNP array-based homozygosity mapping and whole gene sequencing of LYST. We identified three individuals homozygous for a novel six base pair in-frame deletion in LYST (c.9827_9832ATACAA), predicting the loss of asparagine and threonine residues from the LYST transcript (p.Asn3276_Thr3277del), and segregating with the phenotype in this family. We further characterize the neurologic features of the attenuated form of CHS, and discuss pathophysiologic mechanisms underlying the neurodegenerative components of CHS. Attenuated CHS is phenotypically heterogenous and should be considered when young adults develop neurodegenerative disease and have pigmentary abnormalities. We briefly discuss surveillance and management of patients with CHS-related neurodegeneration.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "49a8636768594ec69306fe7ad061cffc", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[2, 5]], "char_spans": [[13, 24]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["LYST", 13], [",", 17], ["a", 19], ["gene", 21], ["encoding", 26], ["a", 35], ["putative", 37], ["lysosomal", 46], ["trafficking", 56], ["protein", 68], [",", 75], ["cause", 77], ["Ch\u00e9diak", 83], ["-", 90], ["Higashi", 91], ["syndrome", 99], ["(", 108], ["CHS", 109], [")", 112], [",", 113], ["an", 115], ["autosomal", 118], ["recessive", 128], ["disorder", 138], ["typically", 147], ["characterized", 157], ["by", 171], ["infantile", 174], ["-", 183], ["onset", 184], ["hemophagocytic", 190], ["syndrome", 205], ["and", 214], ["immunodeficiency", 218], [",", 234], ["and", 236], ["oculocutaneous", 240], ["albinism", 255], [".", 263], ["A", 265], ["small", 267], ["number", 273], ["of", 280], ["reports", 283], ["of", 291], ["rare", 294], [",", 298], ["attenuated", 300], ["forms", 311], ["of", 317], ["CHS", 320], ["exist", 324], [",", 329], ["with", 331], ["affected", 336], ["individuals", 345], ["exhibiting", 357], ["progressive", 368], ["neurodegenerative", 380], ["disease", 398], ["beginning", 406], ["in", 416], ["early", 419], ["adulthood", 425], ["with", 435], ["cognitive", 440], ["decline", 450], [",", 457], ["parkinsonism", 459], [",", 471], ["features", 473], ["of", 482], ["spinocerebellar", 485], ["degeneration", 501], [",", 513], ["and", 515], ["peripheral", 519], ["neuropathy", 530], [",", 540], ["as", 542], ["well", 545], ["as", 550], ["subtle", 553], ["pigmentary", 560], ["abnormalities", 571], ["and", 585], ["subclinical", 589], ["or", 601], ["absent", 604], ["immune", 611], ["dysfunction", 618], [".", 629], ["In", 631], ["a", 634], ["consanguineous", 636], ["Pakistani", 651], ["kindred", 661], ["with", 669], ["clinical", 674], ["phenotypes", 683], ["consistent", 694], ["with", 705], ["attenuated", 710], ["CHS", 721], [",", 724], ["we", 726], ["performed", 729], ["SNP", 739], ["array", 743], ["-", 748], ["based", 749], ["homozygosity", 755], ["mapping", 768], ["and", 776], ["whole", 780], ["gene", 786], ["sequencing", 791], ["of", 802], ["LYST", 805], [".", 809], ["We", 811], ["identified", 814], ["three", 825], ["individuals", 831], ["homozygous", 843], ["for", 854], ["a", 858], ["novel", 860], ["six", 866], ["base", 870], ["pair", 875], ["in", 880], ["-", 882], ["frame", 883], ["deletion", 889], ["in", 898], ["LYST", 901], ["(", 906], ["c.9827_9832ATACAA", 907], [")", 924], [",", 925], ["predicting", 927], ["the", 938], ["loss", 942], ["of", 947], ["asparagine", 950], ["and", 961], ["threonine", 965], ["residues", 975], ["from", 984], ["the", 989], ["LYST", 993], ["transcript", 998], ["(", 1009], ["p", 1010], [".", 1011], ["Asn3276_Thr3277del", 1012], [")", 1030], [",", 1031], ["and", 1033], ["segregating", 1037], ["with", 1049], ["the", 1054], ["phenotype", 1058], ["in", 1068], ["this", 1071], ["family", 1076], [".", 1082], ["We", 1084], ["further", 1087], ["characterize", 1095], ["the", 1108], ["neurologic", 1112], ["features", 1123], ["of", 1132], ["the", 1135], ["attenuated", 1139], ["form", 1150], ["of", 1155], ["CHS", 1158], [",", 1161], ["and", 1163], ["discuss", 1167], ["pathophysiologic", 1175], ["mechanisms", 1192], ["underlying", 1203], ["the", 1214], ["neurodegenerative", 1218], ["components", 1236], ["of", 1247], ["CHS", 1250], [".", 1253], ["Attenuated", 1255], ["CHS", 1266], ["is", 1270], ["phenotypically", 1273], ["heterogenous", 1288], ["and", 1301], ["should", 1305], ["be", 1312], ["considered", 1315], ["when", 1326], ["young", 1331], ["adults", 1337], ["develop", 1344], ["neurodegenerative", 1352], ["disease", 1370], ["and", 1378], ["have", 1382], ["pigmentary", 1387], ["abnormalities", 1398], [".", 1411], ["We", 1413], ["briefly", 1416], ["discuss", 1424], ["surveillance", 1432], ["and", 1445], ["management", 1449], ["of", 1460], ["patients", 1463], ["with", 1472], ["CHS", 1477], ["-", 1480], ["related", 1481], ["neurodegeneration", 1489], [".", 1506]]}
{"context": "The Wnt/\u03b2-catenin signaling pathway plays an essential role in osteoblast biology. Sclerostin is a soluble antagonist of Wnt/\u03b2-catenin signaling secreted primarily by osteocytes. Current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone. Nonetheless, circulating sclerostin levels in humans often reflect changes in the bone microenvironment, although there may be exceptions to this observation. Using existing assays, circulating sclerostin levels have been shown to be altered in response to both hormonal stimuli and across a variety of normal physiological and pathophysiological conditions. In both rodents and humans, parathyroid hormone provided either intermittently or continuously suppresses sclerostin levels. Likewise, most evidence from both human and animal studies supports a suppressive effect of estrogen on sclerostin levels. Efforts to examine non-hormonal/systemic regulation of sclerostin have in general shown less consistent findings or have provided associations rather than direct interventional information, with the exception of mechanosensory studies which have consistently demonstrated increased sclerostin levels with skeletal unloading, and conversely decreases in sclerostin with enhanced skeletal loading. Herein, we will review the existent literature on both hormonal and non-hormonal/systemic factors which have been studied for their impact on sclerostin regulation.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "f8aa034423ce4cffb22a4a551f8ad7f6", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[47, 48]], "char_spans": [[273, 287]]}]}], "context_tokens": [["The", 0], ["Wnt", 4], ["/", 7], ["\u03b2", 8], ["-", 9], ["catenin", 10], ["signaling", 18], ["pathway", 28], ["plays", 36], ["an", 42], ["essential", 45], ["role", 55], ["in", 60], ["osteoblast", 63], ["biology", 74], [".", 81], ["Sclerostin", 83], ["is", 94], ["a", 97], ["soluble", 99], ["antagonist", 107], ["of", 118], ["Wnt", 121], ["/", 124], ["\u03b2", 125], ["-", 126], ["catenin", 127], ["signaling", 135], ["secreted", 145], ["primarily", 154], ["by", 164], ["osteocytes", 167], [".", 177], ["Current", 179], ["evidence", 187], ["indicates", 196], ["that", 206], ["sclerostin", 211], ["likely", 222], ["functions", 229], ["as", 239], ["a", 242], ["local", 244], ["/", 249], ["paracrine", 250], ["regulator", 260], ["of", 270], ["bone", 273], ["metabolism", 278], ["rather", 289], ["than", 296], ["as", 301], ["an", 304], ["endocrine", 307], ["hormone", 317], [".", 324], ["Nonetheless", 326], [",", 337], ["circulating", 339], ["sclerostin", 351], ["levels", 362], ["in", 369], ["humans", 372], ["often", 379], ["reflect", 385], ["changes", 393], ["in", 401], ["the", 404], ["bone", 408], ["microenvironment", 413], [",", 429], ["although", 431], ["there", 440], ["may", 446], ["be", 450], ["exceptions", 453], ["to", 464], ["this", 467], ["observation", 472], [".", 483], ["Using", 485], ["existing", 491], ["assays", 500], [",", 506], ["circulating", 508], ["sclerostin", 520], ["levels", 531], ["have", 538], ["been", 543], ["shown", 548], ["to", 554], ["be", 557], ["altered", 560], ["in", 568], ["response", 571], ["to", 580], ["both", 583], ["hormonal", 588], ["stimuli", 597], ["and", 605], ["across", 609], ["a", 616], ["variety", 618], ["of", 626], ["normal", 629], ["physiological", 636], ["and", 650], ["pathophysiological", 654], ["conditions", 673], [".", 683], ["In", 685], ["both", 688], ["rodents", 693], ["and", 701], ["humans", 705], [",", 711], ["parathyroid", 713], ["hormone", 725], ["provided", 733], ["either", 742], ["intermittently", 749], ["or", 764], ["continuously", 767], ["suppresses", 780], ["sclerostin", 791], ["levels", 802], [".", 808], ["Likewise", 810], [",", 818], ["most", 820], ["evidence", 825], ["from", 834], ["both", 839], ["human", 844], ["and", 850], ["animal", 854], ["studies", 861], ["supports", 869], ["a", 878], ["suppressive", 880], ["effect", 892], ["of", 899], ["estrogen", 902], ["on", 911], ["sclerostin", 914], ["levels", 925], [".", 931], ["Efforts", 933], ["to", 941], ["examine", 944], ["non", 952], ["-", 955], ["hormonal", 956], ["/", 964], ["systemic", 965], ["regulation", 974], ["of", 985], ["sclerostin", 988], ["have", 999], ["in", 1004], ["general", 1007], ["shown", 1015], ["less", 1021], ["consistent", 1026], ["findings", 1037], ["or", 1046], ["have", 1049], ["provided", 1054], ["associations", 1063], ["rather", 1076], ["than", 1083], ["direct", 1088], ["interventional", 1095], ["information", 1110], [",", 1121], ["with", 1123], ["the", 1128], ["exception", 1132], ["of", 1142], ["mechanosensory", 1145], ["studies", 1160], ["which", 1168], ["have", 1174], ["consistently", 1179], ["demonstrated", 1192], ["increased", 1205], ["sclerostin", 1215], ["levels", 1226], ["with", 1233], ["skeletal", 1238], ["unloading", 1247], [",", 1256], ["and", 1258], ["conversely", 1262], ["decreases", 1273], ["in", 1283], ["sclerostin", 1286], ["with", 1297], ["enhanced", 1302], ["skeletal", 1311], ["loading", 1320], [".", 1327], ["Herein", 1329], [",", 1335], ["we", 1337], ["will", 1340], ["review", 1345], ["the", 1352], ["existent", 1356], ["literature", 1365], ["on", 1376], ["both", 1379], ["hormonal", 1384], ["and", 1393], ["non", 1397], ["-", 1400], ["hormonal", 1401], ["/", 1409], ["systemic", 1410], ["factors", 1419], ["which", 1427], ["have", 1433], ["been", 1438], ["studied", 1443], ["for", 1451], ["their", 1455], ["impact", 1461], ["on", 1468], ["sclerostin", 1471], ["regulation", 1482], [".", 1492]]}
{"context": "Clostridium difficile infection (CDI) is the main cause of nosocomial diarrhea in industrialized countries and the source of a growing number of cases of diarrhea in the community. The outbreak of the hypervirulent strain belonging to ribotype 027 has increased the incidence and severity of CDI in some countries. Although CDI usually courses as a mild diarrhea it can lead to severe forms such as toxic megacolon or septic shock. One of every 2 episodes of CDI is not diagnosed in Spanish hospitals due to a lack of clinical suspicion or the use of insensitive diagnostic methods. The diagnostic techniques of choice are algorithms based on the detection of glutamate dehydrogenase and molecular detection of the genes of the toxins with or without the direct detection of the toxins. The recommended treatment for CDI depends on the type of infection and the characteristics of the patient.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "08f0df88d96347d39f79a425ef636d4b", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[39, 40]], "char_spans": [[235, 246]]}]}], "context_tokens": [["Clostridium", 0], ["difficile", 12], ["infection", 22], ["(", 32], ["CDI", 33], [")", 36], ["is", 38], ["the", 41], ["main", 45], ["cause", 50], ["of", 56], ["nosocomial", 59], ["diarrhea", 70], ["in", 79], ["industrialized", 82], ["countries", 97], ["and", 107], ["the", 111], ["source", 115], ["of", 122], ["a", 125], ["growing", 127], ["number", 135], ["of", 142], ["cases", 145], ["of", 151], ["diarrhea", 154], ["in", 163], ["the", 166], ["community", 170], [".", 179], ["The", 181], ["outbreak", 185], ["of", 194], ["the", 197], ["hypervirulent", 201], ["strain", 215], ["belonging", 222], ["to", 232], ["ribotype", 235], ["027", 244], ["has", 248], ["increased", 252], ["the", 262], ["incidence", 266], ["and", 276], ["severity", 280], ["of", 289], ["CDI", 292], ["in", 296], ["some", 299], ["countries", 304], [".", 313], ["Although", 315], ["CDI", 324], ["usually", 328], ["courses", 336], ["as", 344], ["a", 347], ["mild", 349], ["diarrhea", 354], ["it", 363], ["can", 366], ["lead", 370], ["to", 375], ["severe", 378], ["forms", 385], ["such", 391], ["as", 396], ["toxic", 399], ["megacolon", 405], ["or", 415], ["septic", 418], ["shock", 425], [".", 430], ["One", 432], ["of", 436], ["every", 439], ["2", 445], ["episodes", 447], ["of", 456], ["CDI", 459], ["is", 463], ["not", 466], ["diagnosed", 470], ["in", 480], ["Spanish", 483], ["hospitals", 491], ["due", 501], ["to", 505], ["a", 508], ["lack", 510], ["of", 515], ["clinical", 518], ["suspicion", 527], ["or", 537], ["the", 540], ["use", 544], ["of", 548], ["insensitive", 551], ["diagnostic", 563], ["methods", 574], [".", 581], ["The", 583], ["diagnostic", 587], ["techniques", 598], ["of", 609], ["choice", 612], ["are", 619], ["algorithms", 623], ["based", 634], ["on", 640], ["the", 643], ["detection", 647], ["of", 657], ["glutamate", 660], ["dehydrogenase", 670], ["and", 684], ["molecular", 688], ["detection", 698], ["of", 708], ["the", 711], ["genes", 715], ["of", 721], ["the", 724], ["toxins", 728], ["with", 735], ["or", 740], ["without", 743], ["the", 751], ["direct", 755], ["detection", 762], ["of", 772], ["the", 775], ["toxins", 779], [".", 785], ["The", 787], ["recommended", 791], ["treatment", 803], ["for", 813], ["CDI", 817], ["depends", 821], ["on", 829], ["the", 832], ["type", 836], ["of", 841], ["infection", 844], ["and", 854], ["the", 858], ["characteristics", 862], ["of", 878], ["the", 881], ["patient", 885], [".", 892]]}
{"context": "PDS5B is a sister chromatid cohesion protein that is crucial for faithful segregation of duplicated chromosomes in lower organisms. Mutations in cohesion proteins are associated with the developmental disorder Cornelia de Lange syndrome (CdLS) in humans. To delineate the physiological roles of PDS5B in mammals, we generated mice lacking PDS5B (APRIN). Pds5B-deficient mice died shortly after birth. They exhibited multiple congenital anomalies, including heart defects, cleft palate, fusion of the ribs, short limbs, distal colon aganglionosis, abnormal migration and axonal projections of sympathetic neurons, and germ cell depletion, many of which are similar to abnormalities found in humans with CdLS. Unexpectedly, we found no cohesion defects in Pds5B(-/-) cells and detected high PDS5B expression in post-mitotic neurons in the brain. These results, along with the developmental anomalies of Pds5B(-/-) mice, the presence of a DNA-binding domain in PDS5B in vertebrates and its nucleolar localization, suggest that PDS5B and the cohesin complex have important functions beyond their role in chromosomal dynamics.", "qas": [{"question": "Which syndrome is caused by deletion of Pds5b in mice?", "answers": ["Cornelia de Lange syndrome."], "qid": "3edca0aa7f0d4e7fba97191c13e28d28", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["caused", 18], ["by", 25], ["deletion", 28], ["of", 37], ["Pds5b", 40], ["in", 46], ["mice", 49], ["?", 53]], "detected_answers": [{"text": "Cornelia de Lange syndrome.", "token_spans": [[30, 33]], "char_spans": [[210, 235]]}]}], "context_tokens": [["PDS5B", 0], ["is", 6], ["a", 9], ["sister", 11], ["chromatid", 18], ["cohesion", 28], ["protein", 37], ["that", 45], ["is", 50], ["crucial", 53], ["for", 61], ["faithful", 65], ["segregation", 74], ["of", 86], ["duplicated", 89], ["chromosomes", 100], ["in", 112], ["lower", 115], ["organisms", 121], [".", 130], ["Mutations", 132], ["in", 142], ["cohesion", 145], ["proteins", 154], ["are", 163], ["associated", 167], ["with", 178], ["the", 183], ["developmental", 187], ["disorder", 201], ["Cornelia", 210], ["de", 219], ["Lange", 222], ["syndrome", 228], ["(", 237], ["CdLS", 238], [")", 242], ["in", 244], ["humans", 247], [".", 253], ["To", 255], ["delineate", 258], ["the", 268], ["physiological", 272], ["roles", 286], ["of", 292], ["PDS5B", 295], ["in", 301], ["mammals", 304], [",", 311], ["we", 313], ["generated", 316], ["mice", 326], ["lacking", 331], ["PDS5B", 339], ["(", 345], ["APRIN", 346], [")", 351], [".", 352], ["Pds5B", 354], ["-", 359], ["deficient", 360], ["mice", 370], ["died", 375], ["shortly", 380], ["after", 388], ["birth", 394], [".", 399], ["They", 401], ["exhibited", 406], ["multiple", 416], ["congenital", 425], ["anomalies", 436], [",", 445], ["including", 447], ["heart", 457], ["defects", 463], [",", 470], ["cleft", 472], ["palate", 478], [",", 484], ["fusion", 486], ["of", 493], ["the", 496], ["ribs", 500], [",", 504], ["short", 506], ["limbs", 512], [",", 517], ["distal", 519], ["colon", 526], ["aganglionosis", 532], [",", 545], ["abnormal", 547], ["migration", 556], ["and", 566], ["axonal", 570], ["projections", 577], ["of", 589], ["sympathetic", 592], ["neurons", 604], [",", 611], ["and", 613], ["germ", 617], ["cell", 622], ["depletion", 627], [",", 636], ["many", 638], ["of", 643], ["which", 646], ["are", 652], ["similar", 656], ["to", 664], ["abnormalities", 667], ["found", 681], ["in", 687], ["humans", 690], ["with", 697], ["CdLS", 702], [".", 706], ["Unexpectedly", 708], [",", 720], ["we", 722], ["found", 725], ["no", 731], ["cohesion", 734], ["defects", 743], ["in", 751], ["Pds5B(-/-", 754], [")", 763], ["cells", 765], ["and", 771], ["detected", 775], ["high", 784], ["PDS5B", 789], ["expression", 795], ["in", 806], ["post", 809], ["-", 813], ["mitotic", 814], ["neurons", 822], ["in", 830], ["the", 833], ["brain", 837], [".", 842], ["These", 844], ["results", 850], [",", 857], ["along", 859], ["with", 865], ["the", 870], ["developmental", 874], ["anomalies", 888], ["of", 898], ["Pds5B(-/-", 901], [")", 910], ["mice", 912], [",", 916], ["the", 918], ["presence", 922], ["of", 931], ["a", 934], ["DNA", 936], ["-", 939], ["binding", 940], ["domain", 948], ["in", 955], ["PDS5B", 958], ["in", 964], ["vertebrates", 967], ["and", 979], ["its", 983], ["nucleolar", 987], ["localization", 997], [",", 1009], ["suggest", 1011], ["that", 1019], ["PDS5B", 1024], ["and", 1030], ["the", 1034], ["cohesin", 1038], ["complex", 1046], ["have", 1054], ["important", 1059], ["functions", 1069], ["beyond", 1079], ["their", 1086], ["role", 1092], ["in", 1097], ["chromosomal", 1100], ["dynamics", 1112], [".", 1120]]}
{"context": "Although ultrasound measurements have been used in previous studies on carpal tunnel syndrome to visualize injury to the median nerve, whether such ultrasound data can indicate the severity of carpal tunnel syndrome remains controversial. The cross-sectional areas of the median nerve at the tunnel inlet and outlet can show swelling and compression of the nerve at the carpal. We hypothesized that the ratio of the cross-sectional areas of the median nerve at the carpal tunnel inlet to outlet accurately reflects the severity of carpal tunnel syndrome. To test this, high-resolution ultrasound with a linear array transducer at 5-17 MHz was used to assess 77 patients with carpal tunnel syndrome. The results showed that the cut-off point for the inlet-to-outlet ratio was 1.14. Significant differences in the inlet-to-outlet ratio were found among patients with mild, moderate, and severe carpal tunnel syndrome. The cut-off point in the ratio of cross-sectional areas of the median nerve was 1.29 between mild and more severe (moderate and severe) carpal tunnel syndrome patients with 64.7% sensitivity and 72.7% specificity. The cut-off point in the ratio of cross-sectional areas of the median nerve was 1.52 between the moderate and severe carpal tunnel syndrome patients with 80.0% sensitivity and 64.7% specificity. These results suggest that the inlet-to-outlet ratio reflected the severity of carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "e7a2970328e24da5a36fb43bd514f72a", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[43, 43], [76, 76], [183, 183], [18, 18], [225, 225]], "char_spans": [[272, 277], [445, 450], [979, 984], [121, 126], [1193, 1198]]}]}], "context_tokens": [["Although", 0], ["ultrasound", 9], ["measurements", 20], ["have", 33], ["been", 38], ["used", 43], ["in", 48], ["previous", 51], ["studies", 60], ["on", 68], ["carpal", 71], ["tunnel", 78], ["syndrome", 85], ["to", 94], ["visualize", 97], ["injury", 107], ["to", 114], ["the", 117], ["median", 121], ["nerve", 128], [",", 133], ["whether", 135], ["such", 143], ["ultrasound", 148], ["data", 159], ["can", 164], ["indicate", 168], ["the", 177], ["severity", 181], ["of", 190], ["carpal", 193], ["tunnel", 200], ["syndrome", 207], ["remains", 216], ["controversial", 224], [".", 237], ["The", 239], ["cross", 243], ["-", 248], ["sectional", 249], ["areas", 259], ["of", 265], ["the", 268], ["median", 272], ["nerve", 279], ["at", 285], ["the", 288], ["tunnel", 292], ["inlet", 299], ["and", 305], ["outlet", 309], ["can", 316], ["show", 320], ["swelling", 325], ["and", 334], ["compression", 338], ["of", 350], ["the", 353], ["nerve", 357], ["at", 363], ["the", 366], ["carpal", 370], [".", 376], ["We", 378], ["hypothesized", 381], ["that", 394], ["the", 399], ["ratio", 403], ["of", 409], ["the", 412], ["cross", 416], ["-", 421], ["sectional", 422], ["areas", 432], ["of", 438], ["the", 441], ["median", 445], ["nerve", 452], ["at", 458], ["the", 461], ["carpal", 465], ["tunnel", 472], ["inlet", 479], ["to", 485], ["outlet", 488], ["accurately", 495], ["reflects", 506], ["the", 515], ["severity", 519], ["of", 528], ["carpal", 531], ["tunnel", 538], ["syndrome", 545], [".", 553], ["To", 555], ["test", 558], ["this", 563], [",", 567], ["high", 569], ["-", 573], ["resolution", 574], ["ultrasound", 585], ["with", 596], ["a", 601], ["linear", 603], ["array", 610], ["transducer", 616], ["at", 627], ["5", 630], ["-", 631], ["17", 632], ["MHz", 635], ["was", 639], ["used", 643], ["to", 648], ["assess", 651], ["77", 658], ["patients", 661], ["with", 670], ["carpal", 675], ["tunnel", 682], ["syndrome", 689], [".", 697], ["The", 699], ["results", 703], ["showed", 711], ["that", 718], ["the", 723], ["cut", 727], ["-", 730], ["off", 731], ["point", 735], ["for", 741], ["the", 745], ["inlet", 749], ["-", 754], ["to", 755], ["-", 757], ["outlet", 758], ["ratio", 765], ["was", 771], ["1.14", 775], [".", 779], ["Significant", 781], ["differences", 793], ["in", 805], ["the", 808], ["inlet", 812], ["-", 817], ["to", 818], ["-", 820], ["outlet", 821], ["ratio", 828], ["were", 834], ["found", 839], ["among", 845], ["patients", 851], ["with", 860], ["mild", 865], [",", 869], ["moderate", 871], [",", 879], ["and", 881], ["severe", 885], ["carpal", 892], ["tunnel", 899], ["syndrome", 906], [".", 914], ["The", 916], ["cut", 920], ["-", 923], ["off", 924], ["point", 928], ["in", 934], ["the", 937], ["ratio", 941], ["of", 947], ["cross", 950], ["-", 955], ["sectional", 956], ["areas", 966], ["of", 972], ["the", 975], ["median", 979], ["nerve", 986], ["was", 992], ["1.29", 996], ["between", 1001], ["mild", 1009], ["and", 1014], ["more", 1018], ["severe", 1023], ["(", 1030], ["moderate", 1031], ["and", 1040], ["severe", 1044], [")", 1050], ["carpal", 1052], ["tunnel", 1059], ["syndrome", 1066], ["patients", 1075], ["with", 1084], ["64.7", 1089], ["%", 1093], ["sensitivity", 1095], ["and", 1107], ["72.7", 1111], ["%", 1115], ["specificity", 1117], [".", 1128], ["The", 1130], ["cut", 1134], ["-", 1137], ["off", 1138], ["point", 1142], ["in", 1148], ["the", 1151], ["ratio", 1155], ["of", 1161], ["cross", 1164], ["-", 1169], ["sectional", 1170], ["areas", 1180], ["of", 1186], ["the", 1189], ["median", 1193], ["nerve", 1200], ["was", 1206], ["1.52", 1210], ["between", 1215], ["the", 1223], ["moderate", 1227], ["and", 1236], ["severe", 1240], ["carpal", 1247], ["tunnel", 1254], ["syndrome", 1261], ["patients", 1270], ["with", 1279], ["80.0", 1284], ["%", 1288], ["sensitivity", 1290], ["and", 1302], ["64.7", 1306], ["%", 1310], ["specificity", 1312], [".", 1323], ["These", 1325], ["results", 1331], ["suggest", 1339], ["that", 1347], ["the", 1352], ["inlet", 1356], ["-", 1361], ["to", 1362], ["-", 1364], ["outlet", 1365], ["ratio", 1372], ["reflected", 1378], ["the", 1388], ["severity", 1392], ["of", 1401], ["carpal", 1404], ["tunnel", 1411], ["syndrome", 1418], [".", 1426]]}
{"context": "Nucleotide excision repair (NER) in eukaryotes is a pathway conserved from yeast to humans that removes many bulky chemical adducts and UV-induced photoproducts from DNA in a relatively error-free manner. In addition to the recognition and excision of DNA damage throughout the genome (GGR), there exists a mechanism, transcription-coupled nucleotide excision repair (TCR), for recognizing some types of DNA damage in the transcribed strand of genes in Escherichia coli, yeast and mammalian cells. An obstacle in the repair of the transcribed strand of active genes is the RNA polymerase complex stalled at sites of DNA damage. The stalled RNA polymerase complex may then mediate recruitment of repair proteins to damage in the transcribed strand. Proteins enabling TCR are the Cockayne syndrome B (CSB) protein in humans and its yeast homologue Rad26. Both CSB and Rad26 belong to the Swi2/Snf2 family of DNA-dependent ATPases, which change DNA accessibility to proteins by altering chromatin structure. To address how Rad26 functions in yeast repair, we used the genetic approach of overexpressing Rad26 and examined phenotypic changes, i.e. changes in NER. We found that repair of both the transcribed and the non-transcribed strands is increased. In addition, overexpression of Rad26 partially bypasses the requirement for Rad7 in GGR, specifically in the repair of non-transcribed sequences. As TCR takes place in very localized regions of DNA (i.e. within genes) in wild-type cells, we propose that overexpression of recombinant Rad26 increases accessibility of the damaged DNA in chromatin for interaction with repair proteins.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "4b717cdd7b514fb5922ab011286b4110", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[131, 132], [78, 79], [98, 99]], "char_spans": [[728, 745], [422, 439], [531, 548]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["in", 33], ["eukaryotes", 36], ["is", 47], ["a", 50], ["pathway", 52], ["conserved", 60], ["from", 70], ["yeast", 75], ["to", 81], ["humans", 84], ["that", 91], ["removes", 96], ["many", 104], ["bulky", 109], ["chemical", 115], ["adducts", 124], ["and", 132], ["UV", 136], ["-", 138], ["induced", 139], ["photoproducts", 147], ["from", 161], ["DNA", 166], ["in", 170], ["a", 173], ["relatively", 175], ["error", 186], ["-", 191], ["free", 192], ["manner", 197], [".", 203], ["In", 205], ["addition", 208], ["to", 217], ["the", 220], ["recognition", 224], ["and", 236], ["excision", 240], ["of", 249], ["DNA", 252], ["damage", 256], ["throughout", 263], ["the", 274], ["genome", 278], ["(", 285], ["GGR", 286], [")", 289], [",", 290], ["there", 292], ["exists", 298], ["a", 305], ["mechanism", 307], [",", 316], ["transcription", 318], ["-", 331], ["coupled", 332], ["nucleotide", 340], ["excision", 351], ["repair", 360], ["(", 367], ["TCR", 368], [")", 371], [",", 372], ["for", 374], ["recognizing", 378], ["some", 390], ["types", 395], ["of", 401], ["DNA", 404], ["damage", 408], ["in", 415], ["the", 418], ["transcribed", 422], ["strand", 434], ["of", 441], ["genes", 444], ["in", 450], ["Escherichia", 453], ["coli", 465], [",", 469], ["yeast", 471], ["and", 477], ["mammalian", 481], ["cells", 491], [".", 496], ["An", 498], ["obstacle", 501], ["in", 510], ["the", 513], ["repair", 517], ["of", 524], ["the", 527], ["transcribed", 531], ["strand", 543], ["of", 550], ["active", 553], ["genes", 560], ["is", 566], ["the", 569], ["RNA", 573], ["polymerase", 577], ["complex", 588], ["stalled", 596], ["at", 604], ["sites", 607], ["of", 613], ["DNA", 616], ["damage", 620], [".", 626], ["The", 628], ["stalled", 632], ["RNA", 640], ["polymerase", 644], ["complex", 655], ["may", 663], ["then", 667], ["mediate", 672], ["recruitment", 680], ["of", 692], ["repair", 695], ["proteins", 702], ["to", 711], ["damage", 714], ["in", 721], ["the", 724], ["transcribed", 728], ["strand", 740], [".", 746], ["Proteins", 748], ["enabling", 757], ["TCR", 766], ["are", 770], ["the", 774], ["Cockayne", 778], ["syndrome", 787], ["B", 796], ["(", 798], ["CSB", 799], [")", 802], ["protein", 804], ["in", 812], ["humans", 815], ["and", 822], ["its", 826], ["yeast", 830], ["homologue", 836], ["Rad26", 846], [".", 851], ["Both", 853], ["CSB", 858], ["and", 862], ["Rad26", 866], ["belong", 872], ["to", 879], ["the", 882], ["Swi2/Snf2", 886], ["family", 896], ["of", 903], ["DNA", 906], ["-", 909], ["dependent", 910], ["ATPases", 920], [",", 927], ["which", 929], ["change", 935], ["DNA", 942], ["accessibility", 946], ["to", 960], ["proteins", 963], ["by", 972], ["altering", 975], ["chromatin", 984], ["structure", 994], [".", 1003], ["To", 1005], ["address", 1008], ["how", 1016], ["Rad26", 1020], ["functions", 1026], ["in", 1036], ["yeast", 1039], ["repair", 1045], [",", 1051], ["we", 1053], ["used", 1056], ["the", 1061], ["genetic", 1065], ["approach", 1073], ["of", 1082], ["overexpressing", 1085], ["Rad26", 1100], ["and", 1106], ["examined", 1110], ["phenotypic", 1119], ["changes", 1130], [",", 1137], ["i.e.", 1139], ["changes", 1144], ["in", 1152], ["NER", 1155], [".", 1158], ["We", 1160], ["found", 1163], ["that", 1169], ["repair", 1174], ["of", 1181], ["both", 1184], ["the", 1189], ["transcribed", 1193], ["and", 1205], ["the", 1209], ["non", 1213], ["-", 1216], ["transcribed", 1217], ["strands", 1229], ["is", 1237], ["increased", 1240], [".", 1249], ["In", 1251], ["addition", 1254], [",", 1262], ["overexpression", 1264], ["of", 1279], ["Rad26", 1282], ["partially", 1288], ["bypasses", 1298], ["the", 1307], ["requirement", 1311], ["for", 1323], ["Rad7", 1327], ["in", 1332], ["GGR", 1335], [",", 1338], ["specifically", 1340], ["in", 1353], ["the", 1356], ["repair", 1360], ["of", 1367], ["non", 1370], ["-", 1373], ["transcribed", 1374], ["sequences", 1386], [".", 1395], ["As", 1397], ["TCR", 1400], ["takes", 1404], ["place", 1410], ["in", 1416], ["very", 1419], ["localized", 1424], ["regions", 1434], ["of", 1442], ["DNA", 1445], ["(", 1449], ["i.e.", 1450], ["within", 1455], ["genes", 1462], [")", 1467], ["in", 1469], ["wild", 1472], ["-", 1476], ["type", 1477], ["cells", 1482], [",", 1487], ["we", 1489], ["propose", 1492], ["that", 1500], ["overexpression", 1505], ["of", 1520], ["recombinant", 1523], ["Rad26", 1535], ["increases", 1541], ["accessibility", 1551], ["of", 1565], ["the", 1568], ["damaged", 1572], ["DNA", 1580], ["in", 1584], ["chromatin", 1587], ["for", 1597], ["interaction", 1601], ["with", 1613], ["repair", 1618], ["proteins", 1625], [".", 1633]]}
{"context": "The centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains, a property conserved among centromeres in fungi and some higher eukaryotes. Surprisingly, little is known about the biological significance or the mechanism of early centromere replication; however, the extensive conservation suggests that it is important for chromosome maintenance. Do centromeres ensure their early replication by promoting early activation of nearby origins, or have they migrated over evolutionary time to reside in early replicating regions? In Candida albicans, a neocentromere contains an early firing origin, supporting the first hypothesis but not addressing whether the new origin is intrinsically early firing or whether the centromere influences replication time. Because the activation time of individual origins is not an intrinsic property of S. cerevisiae origins, but is influenced by surrounding sequences, we sought to test the hypothesis that centromeres influence replication time by moving a centromere to a late replication domain. We used a modified Meselson-Stahl density transfer assay to measure the kinetics of replication for regions of chromosome XIV in which either the functional centromere or a point-mutated version had been moved near origins that reside in a late replication region. We show that a functional centromere acts in cis over a distance as great as 19 kb to advance the initiation time of origins. Our results constitute a direct link between establishment of the kinetochore and the replication initiation machinery, and suggest that the proposed higher-order structure of the pericentric chromatin influences replication initiation.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "55f7e26b1a6a41c08f110ecb1c372358", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[11, 11], [62, 62], [40, 40], [66, 66], [82, 82], [111, 111], [94, 94]], "char_spans": [[81, 85], [420, 424], [268, 272], [451, 455], [545, 549], [733, 737], [621, 625]]}]}], "context_tokens": [["The", 0], ["centromeric", 4], ["regions", 16], ["of", 24], ["all", 27], ["Saccharomyces", 31], ["cerevisiae", 45], ["chromosomes", 56], ["are", 68], ["found", 72], ["in", 78], ["early", 81], ["replicating", 87], ["domains", 99], [",", 106], ["a", 108], ["property", 110], ["conserved", 119], ["among", 129], ["centromeres", 135], ["in", 147], ["fungi", 150], ["and", 156], ["some", 160], ["higher", 165], ["eukaryotes", 172], [".", 182], ["Surprisingly", 184], [",", 196], ["little", 198], ["is", 205], ["known", 208], ["about", 214], ["the", 220], ["biological", 224], ["significance", 235], ["or", 248], ["the", 251], ["mechanism", 255], ["of", 265], ["early", 268], ["centromere", 274], ["replication", 285], [";", 296], ["however", 298], [",", 305], ["the", 307], ["extensive", 311], ["conservation", 321], ["suggests", 334], ["that", 343], ["it", 348], ["is", 351], ["important", 354], ["for", 364], ["chromosome", 368], ["maintenance", 379], [".", 390], ["Do", 392], ["centromeres", 395], ["ensure", 407], ["their", 414], ["early", 420], ["replication", 426], ["by", 438], ["promoting", 441], ["early", 451], ["activation", 457], ["of", 468], ["nearby", 471], ["origins", 478], [",", 485], ["or", 487], ["have", 490], ["they", 495], ["migrated", 500], ["over", 509], ["evolutionary", 514], ["time", 527], ["to", 532], ["reside", 535], ["in", 542], ["early", 545], ["replicating", 551], ["regions", 563], ["?", 570], ["In", 572], ["Candida", 575], ["albicans", 583], [",", 591], ["a", 593], ["neocentromere", 595], ["contains", 609], ["an", 618], ["early", 621], ["firing", 627], ["origin", 634], [",", 640], ["supporting", 642], ["the", 653], ["first", 657], ["hypothesis", 663], ["but", 674], ["not", 678], ["addressing", 682], ["whether", 693], ["the", 701], ["new", 705], ["origin", 709], ["is", 716], ["intrinsically", 719], ["early", 733], ["firing", 739], ["or", 746], ["whether", 749], ["the", 757], ["centromere", 761], ["influences", 772], ["replication", 783], ["time", 795], [".", 799], ["Because", 801], ["the", 809], ["activation", 813], ["time", 824], ["of", 829], ["individual", 832], ["origins", 843], ["is", 851], ["not", 854], ["an", 858], ["intrinsic", 861], ["property", 871], ["of", 880], ["S.", 883], ["cerevisiae", 886], ["origins", 897], [",", 904], ["but", 906], ["is", 910], ["influenced", 913], ["by", 924], ["surrounding", 927], ["sequences", 939], [",", 948], ["we", 950], ["sought", 953], ["to", 960], ["test", 963], ["the", 968], ["hypothesis", 972], ["that", 983], ["centromeres", 988], ["influence", 1000], ["replication", 1010], ["time", 1022], ["by", 1027], ["moving", 1030], ["a", 1037], ["centromere", 1039], ["to", 1050], ["a", 1053], ["late", 1055], ["replication", 1060], ["domain", 1072], [".", 1078], ["We", 1080], ["used", 1083], ["a", 1088], ["modified", 1090], ["Meselson", 1099], ["-", 1107], ["Stahl", 1108], ["density", 1114], ["transfer", 1122], ["assay", 1131], ["to", 1137], ["measure", 1140], ["the", 1148], ["kinetics", 1152], ["of", 1161], ["replication", 1164], ["for", 1176], ["regions", 1180], ["of", 1188], ["chromosome", 1191], ["XIV", 1202], ["in", 1206], ["which", 1209], ["either", 1215], ["the", 1222], ["functional", 1226], ["centromere", 1237], ["or", 1248], ["a", 1251], ["point", 1253], ["-", 1258], ["mutated", 1259], ["version", 1267], ["had", 1275], ["been", 1279], ["moved", 1284], ["near", 1290], ["origins", 1295], ["that", 1303], ["reside", 1308], ["in", 1315], ["a", 1318], ["late", 1320], ["replication", 1325], ["region", 1337], [".", 1343], ["We", 1345], ["show", 1348], ["that", 1353], ["a", 1358], ["functional", 1360], ["centromere", 1371], ["acts", 1382], ["in", 1387], ["cis", 1390], ["over", 1394], ["a", 1399], ["distance", 1401], ["as", 1410], ["great", 1413], ["as", 1419], ["19", 1422], ["kb", 1425], ["to", 1428], ["advance", 1431], ["the", 1439], ["initiation", 1443], ["time", 1454], ["of", 1459], ["origins", 1462], [".", 1469], ["Our", 1471], ["results", 1475], ["constitute", 1483], ["a", 1494], ["direct", 1496], ["link", 1503], ["between", 1508], ["establishment", 1516], ["of", 1530], ["the", 1533], ["kinetochore", 1537], ["and", 1549], ["the", 1553], ["replication", 1557], ["initiation", 1569], ["machinery", 1580], [",", 1589], ["and", 1591], ["suggest", 1595], ["that", 1603], ["the", 1608], ["proposed", 1612], ["higher", 1621], ["-", 1627], ["order", 1628], ["structure", 1634], ["of", 1644], ["the", 1647], ["pericentric", 1651], ["chromatin", 1663], ["influences", 1673], ["replication", 1684], ["initiation", 1696], [".", 1706]]}
{"context": "CpG dinucleotides provide hotspots for transitional mutations in a variety of genes, some leading to genetic diseases in humans. Although this phenomenon is attributed to cytosine methylation at such sites, direct and specific observations of CpG methylation at the sites of recurrent mutations are lacking. We have used a bisulfite genomic sequencing method to analyze DNA methylation within three representative exons from the neurofibromatosis type 1 (NF1) gene, well recognized for its high frequency of spontaneous mutations. We observed that the cytosine methylation within NF1 exons 28, 29, and 31 is restricted to CpG dinucleotides, including the CpG dinucleotide present at the site of the recurrent NF1 mutation (C5839T; also referred to as R1947X). At several sites, clone-specific methylation differences were also observed. Our results provide experimental evidence for the hypothesis that methylatable CpGs in the NF1 gene contribute to spontaneous germline mutations associated with this gene, by showing that DNA methylation does occur at all CpGs contained within these representative NF1 exons. As well, the DNA methylation seen at the common mutation site in exon 31 may explain why this site is frequently mutated. Methylation-dependent mutagenesis may also provide a basis for some somatic (second hit) mutations which disable the normal allele and result in the development of NF1 associated symptoms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "6246c07c53fc4659a83f4955f195a4be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[117, 117], [237, 237], [182, 182], [92, 92], [156, 156], [71, 71]], "char_spans": [[709, 711], [1399, 1401], [1102, 1104], [580, 582], [928, 930], [455, 457]]}]}], "context_tokens": [["CpG", 0], ["dinucleotides", 4], ["provide", 18], ["hotspots", 26], ["for", 35], ["transitional", 39], ["mutations", 52], ["in", 62], ["a", 65], ["variety", 67], ["of", 75], ["genes", 78], [",", 83], ["some", 85], ["leading", 90], ["to", 98], ["genetic", 101], ["diseases", 109], ["in", 118], ["humans", 121], [".", 127], ["Although", 129], ["this", 138], ["phenomenon", 143], ["is", 154], ["attributed", 157], ["to", 168], ["cytosine", 171], ["methylation", 180], ["at", 192], ["such", 195], ["sites", 200], [",", 205], ["direct", 207], ["and", 214], ["specific", 218], ["observations", 227], ["of", 240], ["CpG", 243], ["methylation", 247], ["at", 259], ["the", 262], ["sites", 266], ["of", 272], ["recurrent", 275], ["mutations", 285], ["are", 295], ["lacking", 299], [".", 306], ["We", 308], ["have", 311], ["used", 316], ["a", 321], ["bisulfite", 323], ["genomic", 333], ["sequencing", 341], ["method", 352], ["to", 359], ["analyze", 362], ["DNA", 370], ["methylation", 374], ["within", 386], ["three", 393], ["representative", 399], ["exons", 414], ["from", 420], ["the", 425], ["neurofibromatosis", 429], ["type", 447], ["1", 452], ["(", 454], ["NF1", 455], [")", 458], ["gene", 460], [",", 464], ["well", 466], ["recognized", 471], ["for", 482], ["its", 486], ["high", 490], ["frequency", 495], ["of", 505], ["spontaneous", 508], ["mutations", 520], [".", 529], ["We", 531], ["observed", 534], ["that", 543], ["the", 548], ["cytosine", 552], ["methylation", 561], ["within", 573], ["NF1", 580], ["exons", 584], ["28", 590], [",", 592], ["29", 594], [",", 596], ["and", 598], ["31", 602], ["is", 605], ["restricted", 608], ["to", 619], ["CpG", 622], ["dinucleotides", 626], [",", 639], ["including", 641], ["the", 651], ["CpG", 655], ["dinucleotide", 659], ["present", 672], ["at", 680], ["the", 683], ["site", 687], ["of", 692], ["the", 695], ["recurrent", 699], ["NF1", 709], ["mutation", 713], ["(", 722], ["C5839", 723], ["T", 728], [";", 729], ["also", 731], ["referred", 736], ["to", 745], ["as", 748], ["R1947X", 751], [")", 757], [".", 758], ["At", 760], ["several", 763], ["sites", 771], [",", 776], ["clone", 778], ["-", 783], ["specific", 784], ["methylation", 793], ["differences", 805], ["were", 817], ["also", 822], ["observed", 827], [".", 835], ["Our", 837], ["results", 841], ["provide", 849], ["experimental", 857], ["evidence", 870], ["for", 879], ["the", 883], ["hypothesis", 887], ["that", 898], ["methylatable", 903], ["CpGs", 916], ["in", 921], ["the", 924], ["NF1", 928], ["gene", 932], ["contribute", 937], ["to", 948], ["spontaneous", 951], ["germline", 963], ["mutations", 972], ["associated", 982], ["with", 993], ["this", 998], ["gene", 1003], [",", 1007], ["by", 1009], ["showing", 1012], ["that", 1020], ["DNA", 1025], ["methylation", 1029], ["does", 1041], ["occur", 1046], ["at", 1052], ["all", 1055], ["CpGs", 1059], ["contained", 1064], ["within", 1074], ["these", 1081], ["representative", 1087], ["NF1", 1102], ["exons", 1106], [".", 1111], ["As", 1113], ["well", 1116], [",", 1120], ["the", 1122], ["DNA", 1126], ["methylation", 1130], ["seen", 1142], ["at", 1147], ["the", 1150], ["common", 1154], ["mutation", 1161], ["site", 1170], ["in", 1175], ["exon", 1178], ["31", 1183], ["may", 1186], ["explain", 1190], ["why", 1198], ["this", 1202], ["site", 1207], ["is", 1212], ["frequently", 1215], ["mutated", 1226], [".", 1233], ["Methylation", 1235], ["-", 1246], ["dependent", 1247], ["mutagenesis", 1257], ["may", 1269], ["also", 1273], ["provide", 1278], ["a", 1286], ["basis", 1288], ["for", 1294], ["some", 1298], ["somatic", 1303], ["(", 1311], ["second", 1312], ["hit", 1319], [")", 1322], ["mutations", 1324], ["which", 1334], ["disable", 1340], ["the", 1348], ["normal", 1352], ["allele", 1359], ["and", 1366], ["result", 1370], ["in", 1377], ["the", 1380], ["development", 1384], ["of", 1396], ["NF1", 1399], ["associated", 1403], ["symptoms", 1414], [".", 1422]]}
{"context": "A pivotal phase III study of the RTS,S/AS01 malaria candidate vaccine is ongoing in several research centres across Africa. The development and establishment of quality systems was a requirement for trial conduct to meet international regulatory standards, as well as providing an important capacity strengthening opportunity for study centres. Standardized laboratory methods and quality assurance processes were implemented at each of the study centres, facilitated by funding partners. A robust protocol for determination of parasite density based on actual blood cell counts was set up in accordance with World Health Organization recommendations. Automated equipment including haematology and biochemistry analyzers were put in place with standard methods for bedside testing of glycaemia, base excess and lactacidaemia. Facilities for X-rays and basic microbiology testing were also provided or upgraded alongside health care infrastructure in some centres. External quality assurance assessment of all major laboratory methods was established and method qualification by each laboratory demonstrated. The resulting capacity strengthening has ensured laboratory evaluations are conducted locally to the high standards required in clinical trials. Major efforts by study centres, together with support from collaborating parties, have allowed standardized methods and robust quality assurance processes to be put in place for the phase III evaluation of the RTS, S/AS01 malaria candidate vaccine. Extensive training programmes, coupled with continuous commitment from research centre staff, have been the key elements behind the successful implementation of quality processes. It is expected these activities will culminate in healthcare benefits for the subjects and communities participating in these trials. Clinicaltrials.gov NCT00866619.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "042108de04cf40ea8e1cd8cb48ae295a", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[12, 12], [227, 227]], "char_spans": [[44, 50], [1475, 1481]]}]}], "context_tokens": [["A", 0], ["pivotal", 2], ["phase", 10], ["III", 16], ["study", 20], ["of", 26], ["the", 29], ["RTS", 33], [",", 36], ["S", 37], ["/", 38], ["AS01", 39], ["malaria", 44], ["candidate", 52], ["vaccine", 62], ["is", 70], ["ongoing", 73], ["in", 81], ["several", 84], ["research", 92], ["centres", 101], ["across", 109], ["Africa", 116], [".", 122], ["The", 124], ["development", 128], ["and", 140], ["establishment", 144], ["of", 158], ["quality", 161], ["systems", 169], ["was", 177], ["a", 181], ["requirement", 183], ["for", 195], ["trial", 199], ["conduct", 205], ["to", 213], ["meet", 216], ["international", 221], ["regulatory", 235], ["standards", 246], [",", 255], ["as", 257], ["well", 260], ["as", 265], ["providing", 268], ["an", 278], ["important", 281], ["capacity", 291], ["strengthening", 300], ["opportunity", 314], ["for", 326], ["study", 330], ["centres", 336], [".", 343], ["Standardized", 345], ["laboratory", 358], ["methods", 369], ["and", 377], ["quality", 381], ["assurance", 389], ["processes", 399], ["were", 409], ["implemented", 414], ["at", 426], ["each", 429], ["of", 434], ["the", 437], ["study", 441], ["centres", 447], [",", 454], ["facilitated", 456], ["by", 468], ["funding", 471], ["partners", 479], [".", 487], ["A", 489], ["robust", 491], ["protocol", 498], ["for", 507], ["determination", 511], ["of", 525], ["parasite", 528], ["density", 537], ["based", 545], ["on", 551], ["actual", 554], ["blood", 561], ["cell", 567], ["counts", 572], ["was", 579], ["set", 583], ["up", 587], ["in", 590], ["accordance", 593], ["with", 604], ["World", 609], ["Health", 615], ["Organization", 622], ["recommendations", 635], [".", 650], ["Automated", 652], ["equipment", 662], ["including", 672], ["haematology", 682], ["and", 694], ["biochemistry", 698], ["analyzers", 711], ["were", 721], ["put", 726], ["in", 730], ["place", 733], ["with", 739], ["standard", 744], ["methods", 753], ["for", 761], ["bedside", 765], ["testing", 773], ["of", 781], ["glycaemia", 784], [",", 793], ["base", 795], ["excess", 800], ["and", 807], ["lactacidaemia", 811], [".", 824], ["Facilities", 826], ["for", 837], ["X", 841], ["-", 842], ["rays", 843], ["and", 848], ["basic", 852], ["microbiology", 858], ["testing", 871], ["were", 879], ["also", 884], ["provided", 889], ["or", 898], ["upgraded", 901], ["alongside", 910], ["health", 920], ["care", 927], ["infrastructure", 932], ["in", 947], ["some", 950], ["centres", 955], [".", 962], ["External", 964], ["quality", 973], ["assurance", 981], ["assessment", 991], ["of", 1002], ["all", 1005], ["major", 1009], ["laboratory", 1015], ["methods", 1026], ["was", 1034], ["established", 1038], ["and", 1050], ["method", 1054], ["qualification", 1061], ["by", 1075], ["each", 1078], ["laboratory", 1083], ["demonstrated", 1094], [".", 1106], ["The", 1108], ["resulting", 1112], ["capacity", 1122], ["strengthening", 1131], ["has", 1145], ["ensured", 1149], ["laboratory", 1157], ["evaluations", 1168], ["are", 1180], ["conducted", 1184], ["locally", 1194], ["to", 1202], ["the", 1205], ["high", 1209], ["standards", 1214], ["required", 1224], ["in", 1233], ["clinical", 1236], ["trials", 1245], [".", 1251], ["Major", 1253], ["efforts", 1259], ["by", 1267], ["study", 1270], ["centres", 1276], [",", 1283], ["together", 1285], ["with", 1294], ["support", 1299], ["from", 1307], ["collaborating", 1312], ["parties", 1326], [",", 1333], ["have", 1335], ["allowed", 1340], ["standardized", 1348], ["methods", 1361], ["and", 1369], ["robust", 1373], ["quality", 1380], ["assurance", 1388], ["processes", 1398], ["to", 1408], ["be", 1411], ["put", 1414], ["in", 1418], ["place", 1421], ["for", 1427], ["the", 1431], ["phase", 1435], ["III", 1441], ["evaluation", 1445], ["of", 1456], ["the", 1459], ["RTS", 1463], [",", 1466], ["S", 1468], ["/", 1469], ["AS01", 1470], ["malaria", 1475], ["candidate", 1483], ["vaccine", 1493], [".", 1500], ["Extensive", 1502], ["training", 1512], ["programmes", 1521], [",", 1531], ["coupled", 1533], ["with", 1541], ["continuous", 1546], ["commitment", 1557], ["from", 1568], ["research", 1573], ["centre", 1582], ["staff", 1589], [",", 1594], ["have", 1596], ["been", 1601], ["the", 1606], ["key", 1610], ["elements", 1614], ["behind", 1623], ["the", 1630], ["successful", 1634], ["implementation", 1645], ["of", 1660], ["quality", 1663], ["processes", 1671], [".", 1680], ["It", 1682], ["is", 1685], ["expected", 1688], ["these", 1697], ["activities", 1703], ["will", 1714], ["culminate", 1719], ["in", 1729], ["healthcare", 1732], ["benefits", 1743], ["for", 1752], ["the", 1756], ["subjects", 1760], ["and", 1769], ["communities", 1773], ["participating", 1785], ["in", 1799], ["these", 1802], ["trials", 1808], [".", 1814], ["Clinicaltrials.gov", 1816], ["NCT00866619", 1835], [".", 1846]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder in which an immune deficiency occurs in association with pigmentation abnormalities. Most patients who do not undergo bone marrow transplantation die of a lymphoproliferative syndrome, though some patients with CHS have a relatively milder clinical course of the disease. The large size of the LYST gene, defective in CHS, has made it difficult to screen for mutations in a large number of patients. Only 8 mutations have been identified so far, and all lead to a truncated LYST protein. We conducted protein truncation tests on this gene in 8 patients with CHS. Different LYST mutations were identified in all subjects through this approach, strengthening the observation of a high frequency of truncated LYST proteins as the genetic cause of CHS.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "7b387c3302ca4a718ed588d6618acea4", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disorder", 61], ["in", 70], ["which", 73], ["an", 79], ["immune", 82], ["deficiency", 89], ["occurs", 100], ["in", 107], ["association", 110], ["with", 122], ["pigmentation", 127], ["abnormalities", 140], [".", 153], ["Most", 155], ["patients", 160], ["who", 169], ["do", 173], ["not", 176], ["undergo", 180], ["bone", 188], ["marrow", 193], ["transplantation", 200], ["die", 216], ["of", 220], ["a", 223], ["lymphoproliferative", 225], ["syndrome", 245], [",", 253], ["though", 255], ["some", 262], ["patients", 267], ["with", 276], ["CHS", 281], ["have", 285], ["a", 290], ["relatively", 292], ["milder", 303], ["clinical", 310], ["course", 319], ["of", 326], ["the", 329], ["disease", 333], [".", 340], ["The", 342], ["large", 346], ["size", 352], ["of", 357], ["the", 360], ["LYST", 364], ["gene", 369], [",", 373], ["defective", 375], ["in", 385], ["CHS", 388], [",", 391], ["has", 393], ["made", 397], ["it", 402], ["difficult", 405], ["to", 415], ["screen", 418], ["for", 425], ["mutations", 429], ["in", 439], ["a", 442], ["large", 444], ["number", 450], ["of", 457], ["patients", 460], [".", 468], ["Only", 470], ["8", 475], ["mutations", 477], ["have", 487], ["been", 492], ["identified", 497], ["so", 508], ["far", 511], [",", 514], ["and", 516], ["all", 520], ["lead", 524], ["to", 529], ["a", 532], ["truncated", 534], ["LYST", 544], ["protein", 549], [".", 556], ["We", 558], ["conducted", 561], ["protein", 571], ["truncation", 579], ["tests", 590], ["on", 596], ["this", 599], ["gene", 604], ["in", 609], ["8", 612], ["patients", 614], ["with", 623], ["CHS", 628], [".", 631], ["Different", 633], ["LYST", 643], ["mutations", 648], ["were", 658], ["identified", 663], ["in", 674], ["all", 677], ["subjects", 681], ["through", 690], ["this", 698], ["approach", 703], [",", 711], ["strengthening", 713], ["the", 727], ["observation", 731], ["of", 743], ["a", 746], ["high", 748], ["frequency", 753], ["of", 763], ["truncated", 766], ["LYST", 776], ["proteins", 781], ["as", 790], ["the", 793], ["genetic", 797], ["cause", 805], ["of", 811], ["CHS", 814], [".", 817]]}
{"context": "The Na(+)/Ca(2+)exchanger (NCX) principal function is taking 1 Ca(2+) out of the cytoplasm and introducing 3 Na(+). The increase of cytoplasmic Na(+) concentration induces the NCX reverse mode (NCX(REV)), favoring Ca(2+) influx. NCX(REV) can be inhibited by: KB-R7943 a non-specific compound that blocks voltage-dependent and store-operated Ca(2+) channels; SEA0400 that appears to be selective for NCX(REV), but difficult to obtain and SN-6, which efficacy has been shown only in cardiomyocytes. We found that PPADS, a P2X receptor antagonist, acts as a NCX(REV) inhibitor in guinea pig tracheal myocytes. In these cells, we characterized the NCX(REV) by substituting NaCl and NaHCO(3) with LiCl, resulting in the increase of the intracellular Ca(2+) concentration ([Ca(2+)]i) using fura 2-AM. We analyzed 5 consecutive responses of the NCX(REV) every 10 min, finding no differences among them. To evaluate the effect of different NCX(REV) blockers, concentration response curves to KB-R7943 (1, 3.2 and 10 \u03bcM), and SN-6 (3.2, 10 and 30 \u03bcM) were constructed, whereas PPADS effect was characterized as time- and concentration-dependent (1, 3.2, 10 and 30 \u03bcM). PPADS had similar potency and efficacy as KB-R7943, whereas SN-6 was the least effective. Furthermore, KCl-induced contraction, sensitive to D600 and nifedipine, was blocked by KB-R7943, but not by PPADS. KCl-induced [Ca(2+)]i increment in myocytes was also significantly decreased by KBR-7943 (10 \u03bcM). Our results demonstrate that PPADS can be used as a reliable pharmacological tool to inhibit NCX(REV), with the advantage that it is more specific than KB-R7943 because it does not affect L-type Ca(2+) channels.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "62713f6aedae4fbdb697a36a382a3421", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[32, 32], [3, 3]], "char_spans": [[176, 178], [27, 29]]}]}], "context_tokens": [["The", 0], ["Na(+)/Ca(2+)exchanger", 4], ["(", 26], ["NCX", 27], [")", 30], ["principal", 32], ["function", 42], ["is", 51], ["taking", 54], ["1", 61], ["Ca(2", 63], ["+", 67], [")", 68], ["out", 70], ["of", 74], ["the", 77], ["cytoplasm", 81], ["and", 91], ["introducing", 95], ["3", 107], ["Na(+", 109], [")", 113], [".", 114], ["The", 116], ["increase", 120], ["of", 129], ["cytoplasmic", 132], ["Na(+", 144], [")", 148], ["concentration", 150], ["induces", 164], ["the", 172], ["NCX", 176], ["reverse", 180], ["mode", 188], ["(", 193], ["NCX(REV", 194], [")", 201], [")", 202], [",", 203], ["favoring", 205], ["Ca(2", 214], ["+", 218], [")", 219], ["influx", 221], [".", 227], ["NCX(REV", 229], [")", 236], ["can", 238], ["be", 242], ["inhibited", 245], ["by", 255], [":", 257], ["KB", 259], ["-", 261], ["R7943", 262], ["a", 268], ["non", 270], ["-", 273], ["specific", 274], ["compound", 283], ["that", 292], ["blocks", 297], ["voltage", 304], ["-", 311], ["dependent", 312], ["and", 322], ["store", 326], ["-", 331], ["operated", 332], ["Ca(2", 341], ["+", 345], [")", 346], ["channels", 348], [";", 356], ["SEA0400", 358], ["that", 366], ["appears", 371], ["to", 379], ["be", 382], ["selective", 385], ["for", 395], ["NCX(REV", 399], [")", 406], [",", 407], ["but", 409], ["difficult", 413], ["to", 423], ["obtain", 426], ["and", 433], ["SN-6", 437], [",", 441], ["which", 443], ["efficacy", 449], ["has", 458], ["been", 462], ["shown", 467], ["only", 473], ["in", 478], ["cardiomyocytes", 481], [".", 495], ["We", 497], ["found", 500], ["that", 506], ["PPADS", 511], [",", 516], ["a", 518], ["P2X", 520], ["receptor", 524], ["antagonist", 533], [",", 543], ["acts", 545], ["as", 550], ["a", 553], ["NCX(REV", 555], [")", 562], ["inhibitor", 564], ["in", 574], ["guinea", 577], ["pig", 584], ["tracheal", 588], ["myocytes", 597], [".", 605], ["In", 607], ["these", 610], ["cells", 616], [",", 621], ["we", 623], ["characterized", 626], ["the", 640], ["NCX(REV", 644], [")", 651], ["by", 653], ["substituting", 656], ["NaCl", 669], ["and", 674], ["NaHCO(3", 678], [")", 685], ["with", 687], ["LiCl", 692], [",", 696], ["resulting", 698], ["in", 708], ["the", 711], ["increase", 715], ["of", 724], ["the", 727], ["intracellular", 731], ["Ca(2", 745], ["+", 749], [")", 750], ["concentration", 752], ["(", 766], ["[", 767], ["Ca(2+)]i", 768], [")", 776], ["using", 778], ["fura", 784], ["2-AM", 789], [".", 793], ["We", 795], ["analyzed", 798], ["5", 807], ["consecutive", 809], ["responses", 821], ["of", 831], ["the", 834], ["NCX(REV", 838], [")", 845], ["every", 847], ["10", 853], ["min", 856], [",", 859], ["finding", 861], ["no", 869], ["differences", 872], ["among", 884], ["them", 890], [".", 894], ["To", 896], ["evaluate", 899], ["the", 908], ["effect", 912], ["of", 919], ["different", 922], ["NCX(REV", 932], [")", 939], ["blockers", 941], [",", 949], ["concentration", 951], ["response", 965], ["curves", 974], ["to", 981], ["KB", 984], ["-", 986], ["R7943", 987], ["(", 993], ["1", 994], [",", 995], ["3.2", 997], ["and", 1001], ["10", 1005], ["\u03bcM", 1008], [")", 1010], [",", 1011], ["and", 1013], ["SN-6", 1017], ["(", 1022], ["3.2", 1023], [",", 1026], ["10", 1028], ["and", 1031], ["30", 1035], ["\u03bcM", 1038], [")", 1040], ["were", 1042], ["constructed", 1047], [",", 1058], ["whereas", 1060], ["PPADS", 1068], ["effect", 1074], ["was", 1081], ["characterized", 1085], ["as", 1099], ["time-", 1102], ["and", 1108], ["concentration", 1112], ["-", 1125], ["dependent", 1126], ["(", 1136], ["1", 1137], [",", 1138], ["3.2", 1140], [",", 1143], ["10", 1145], ["and", 1148], ["30", 1152], ["\u03bcM", 1155], [")", 1157], [".", 1158], ["PPADS", 1160], ["had", 1166], ["similar", 1170], ["potency", 1178], ["and", 1186], ["efficacy", 1190], ["as", 1199], ["KB", 1202], ["-", 1204], ["R7943", 1205], [",", 1210], ["whereas", 1212], ["SN-6", 1220], ["was", 1225], ["the", 1229], ["least", 1233], ["effective", 1239], [".", 1248], ["Furthermore", 1250], [",", 1261], ["KCl", 1263], ["-", 1266], ["induced", 1267], ["contraction", 1275], [",", 1286], ["sensitive", 1288], ["to", 1298], ["D600", 1301], ["and", 1306], ["nifedipine", 1310], [",", 1320], ["was", 1322], ["blocked", 1326], ["by", 1334], ["KB", 1337], ["-", 1339], ["R7943", 1340], [",", 1345], ["but", 1347], ["not", 1351], ["by", 1355], ["PPADS", 1358], [".", 1363], ["KCl", 1365], ["-", 1368], ["induced", 1369], ["[", 1377], ["Ca(2+)]i", 1378], ["increment", 1387], ["in", 1397], ["myocytes", 1400], ["was", 1409], ["also", 1413], ["significantly", 1418], ["decreased", 1432], ["by", 1442], ["KBR-7943", 1445], ["(", 1454], ["10", 1455], ["\u03bcM", 1458], [")", 1460], [".", 1461], ["Our", 1463], ["results", 1467], ["demonstrate", 1475], ["that", 1487], ["PPADS", 1492], ["can", 1498], ["be", 1502], ["used", 1505], ["as", 1510], ["a", 1513], ["reliable", 1515], ["pharmacological", 1524], ["tool", 1540], ["to", 1545], ["inhibit", 1548], ["NCX(REV", 1556], [")", 1563], [",", 1564], ["with", 1566], ["the", 1571], ["advantage", 1575], ["that", 1585], ["it", 1590], ["is", 1593], ["more", 1596], ["specific", 1601], ["than", 1610], ["KB", 1615], ["-", 1617], ["R7943", 1618], ["because", 1624], ["it", 1632], ["does", 1635], ["not", 1640], ["affect", 1644], ["L", 1651], ["-", 1652], ["type", 1653], ["Ca(2", 1658], ["+", 1662], [")", 1663], ["channels", 1665], [".", 1673]]}
{"context": "Bone and lung metastases are responsible for the majority of deaths in patients with breast cancer. Following treatment of the primary cancer, emotional and psychosocial factors within this population precipitate time to recurrence and death, however the underlying mechanism(s) remain unclear. Using a mouse model of bone metastasis, we provide experimental evidence that activation of the sympathetic nervous system, which is one of many pathophysiological consequences of severe stress and depression, promotes MDA-231 breast cancer cell colonization of bone via a neurohormonal effect on the host bone marrow stroma. We demonstrate that induction of RANKL expression in bone marrow osteoblasts, following \u03b22AR stimulation, increases the migration of metastatic MDA-231 cells in vitro, independently of SDF1-CXCR4 signaling. We also show that the stimulatory effect of endogenous (chronic stress) or pharmacologic sympathetic activation on breast cancer bone metastasis in vivo can be blocked with the \u03b2-blocker propranolol, and by knockdown of RANK expression in MDA-231 cells. These findings indicate that RANKL promotes breast cancer cell metastasis to bone via its pro-migratory effect on breast cancer cells, independently of its effect on bone turnover. The emerging clinical implication, supported by recent epidemiological studies, is that \u03b2AR-blockers and drugs interfering with RANKL signaling, such as Denosumab, could increase patient survival if used as adjuvant therapy to inhibit both the early colonization of bone by metastatic breast cancer cells and the initiation of the \"vicious cycle\" of bone destruction induced by these cells.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "f239df20b0204fb08398b5c4a58d6f5d", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[224, 224], [103, 103], [177, 177]], "char_spans": [[1391, 1395], [654, 658], [1111, 1115]]}]}], "context_tokens": [["Bone", 0], ["and", 5], ["lung", 9], ["metastases", 14], ["are", 25], ["responsible", 29], ["for", 41], ["the", 45], ["majority", 49], ["of", 58], ["deaths", 61], ["in", 68], ["patients", 71], ["with", 80], ["breast", 85], ["cancer", 92], [".", 98], ["Following", 100], ["treatment", 110], ["of", 120], ["the", 123], ["primary", 127], ["cancer", 135], [",", 141], ["emotional", 143], ["and", 153], ["psychosocial", 157], ["factors", 170], ["within", 178], ["this", 185], ["population", 190], ["precipitate", 201], ["time", 213], ["to", 218], ["recurrence", 221], ["and", 232], ["death", 236], [",", 241], ["however", 243], ["the", 251], ["underlying", 255], ["mechanism(s", 266], [")", 277], ["remain", 279], ["unclear", 286], [".", 293], ["Using", 295], ["a", 301], ["mouse", 303], ["model", 309], ["of", 315], ["bone", 318], ["metastasis", 323], [",", 333], ["we", 335], ["provide", 338], ["experimental", 346], ["evidence", 359], ["that", 368], ["activation", 373], ["of", 384], ["the", 387], ["sympathetic", 391], ["nervous", 403], ["system", 411], [",", 417], ["which", 419], ["is", 425], ["one", 428], ["of", 432], ["many", 435], ["pathophysiological", 440], ["consequences", 459], ["of", 472], ["severe", 475], ["stress", 482], ["and", 489], ["depression", 493], [",", 503], ["promotes", 505], ["MDA-231", 514], ["breast", 522], ["cancer", 529], ["cell", 536], ["colonization", 541], ["of", 554], ["bone", 557], ["via", 562], ["a", 566], ["neurohormonal", 568], ["effect", 582], ["on", 589], ["the", 592], ["host", 596], ["bone", 601], ["marrow", 606], ["stroma", 613], [".", 619], ["We", 621], ["demonstrate", 624], ["that", 636], ["induction", 641], ["of", 651], ["RANKL", 654], ["expression", 660], ["in", 671], ["bone", 674], ["marrow", 679], ["osteoblasts", 686], [",", 697], ["following", 699], ["\u03b22AR", 709], ["stimulation", 714], [",", 725], ["increases", 727], ["the", 737], ["migration", 741], ["of", 751], ["metastatic", 754], ["MDA-231", 765], ["cells", 773], ["in", 779], ["vitro", 782], [",", 787], ["independently", 789], ["of", 803], ["SDF1-CXCR4", 806], ["signaling", 817], [".", 826], ["We", 828], ["also", 831], ["show", 836], ["that", 841], ["the", 846], ["stimulatory", 850], ["effect", 862], ["of", 869], ["endogenous", 872], ["(", 883], ["chronic", 884], ["stress", 892], [")", 898], ["or", 900], ["pharmacologic", 903], ["sympathetic", 917], ["activation", 929], ["on", 940], ["breast", 943], ["cancer", 950], ["bone", 957], ["metastasis", 962], ["in", 973], ["vivo", 976], ["can", 981], ["be", 985], ["blocked", 988], ["with", 996], ["the", 1001], ["\u03b2", 1005], ["-", 1006], ["blocker", 1007], ["propranolol", 1015], [",", 1026], ["and", 1028], ["by", 1032], ["knockdown", 1035], ["of", 1045], ["RANK", 1048], ["expression", 1053], ["in", 1064], ["MDA-231", 1067], ["cells", 1075], [".", 1080], ["These", 1082], ["findings", 1088], ["indicate", 1097], ["that", 1106], ["RANKL", 1111], ["promotes", 1117], ["breast", 1126], ["cancer", 1133], ["cell", 1140], ["metastasis", 1145], ["to", 1156], ["bone", 1159], ["via", 1164], ["its", 1168], ["pro", 1172], ["-", 1175], ["migratory", 1176], ["effect", 1186], ["on", 1193], ["breast", 1196], ["cancer", 1203], ["cells", 1210], [",", 1215], ["independently", 1217], ["of", 1231], ["its", 1234], ["effect", 1238], ["on", 1245], ["bone", 1248], ["turnover", 1253], [".", 1261], ["The", 1263], ["emerging", 1267], ["clinical", 1276], ["implication", 1285], [",", 1296], ["supported", 1298], ["by", 1308], ["recent", 1311], ["epidemiological", 1318], ["studies", 1334], [",", 1341], ["is", 1343], ["that", 1346], ["\u03b2AR", 1351], ["-", 1354], ["blockers", 1355], ["and", 1364], ["drugs", 1368], ["interfering", 1374], ["with", 1386], ["RANKL", 1391], ["signaling", 1397], [",", 1406], ["such", 1408], ["as", 1413], ["Denosumab", 1416], [",", 1425], ["could", 1427], ["increase", 1433], ["patient", 1442], ["survival", 1450], ["if", 1459], ["used", 1462], ["as", 1467], ["adjuvant", 1470], ["therapy", 1479], ["to", 1487], ["inhibit", 1490], ["both", 1498], ["the", 1503], ["early", 1507], ["colonization", 1513], ["of", 1526], ["bone", 1529], ["by", 1534], ["metastatic", 1537], ["breast", 1548], ["cancer", 1555], ["cells", 1562], ["and", 1568], ["the", 1572], ["initiation", 1576], ["of", 1587], ["the", 1590], ["\"", 1594], ["vicious", 1595], ["cycle", 1603], ["\"", 1608], ["of", 1610], ["bone", 1613], ["destruction", 1618], ["induced", 1630], ["by", 1638], ["these", 1641], ["cells", 1647], [".", 1652]]}
{"context": "Flumazenil is a recently discovered pharmacologic antagonist of the CNS effects of benzodiazepines. It acts by binding CNS benzodiazepine receptors and competitively blocking benzodiazepine activation of inhibitory GABAergic synapses. Animal studies and some human studies appear to demonstrate that flumazenil has weak intrinsic agonist activity; on the other hand, studies are inconclusive in demonstrating any inverse agonist effects of this agent. Evidence available suggests that flumazenil is well tolerated in human beings over a broad range of doses when given either orally or parenterally and does not produce serious adverse effects. In the setting of isolated benzodiazepine overdose, flumazenil is capable of completely reversing coma within one to two minutes, with this effect lasting between one and five hours. Repeat doses can be given safely to reverse recurrent effects of longer-acting benzodiazepines. Flumazenil is undergoing further evaluation by the Food and Drug Administration; should this drug receive approval, it is likely to be used in emergency departments as well as in a variety of other clinical settings. First, it could be used to effect rapid reversal of benzodiazepine-induced sedation that has been administered to facilitate medical, orthopedic, and surgical procedures, particularly in the event of inadvertent respiratory depression. Second, flumazenil might have a therapeutic role in the management of patients who have taken benzodiazepine overdoses. Although most of these patients can be managed successfully with supportive therapy alone, it is possible that the use of flumazenil may obviate the need for intubation and respiratory support in such patients and eliminate the possible adverse effects of even short-term endotracheal intubation. Finally, flumazenil could have both diagnostic and therapeutic value in patients with acute alterations of mental status of unknown etiology, particularly when possible drug overdose is a consideration. Because flumazenil appears to be specific in its antagonism of benzodiazepine-induced respiratory and CNS depression, it could be used empirically to confirm or exclude a role of benzodiazepines in the generation of mental status changes in the setting of overdose or coma of unknown origin. This in turn might obviate the need for further expensive (eg, computed tomography) and sometimes invasive (eg, lumbar puncture) diagnostic modalities. This might be particularly useful because there is nothing about benzodiazepine-induced coma that clearly distinguishes it from other causes of coma; thus, there are no signs or symptoms that may reasonably allow benzodiazepine overdose to be confirmed or eliminated on clinical grounds. Further studies will continue to define the ultimate use of this new agent.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "c9a1b2e94527464dbe23ae083f85bd8e", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [144, 144], [70, 70], [260, 260], [105, 105], [41, 41], [222, 222], [319, 319], [289, 289]], "char_spans": [[0, 9], [924, 933], [485, 494], [1619, 1628], [697, 706], [300, 309], [1385, 1394], [2005, 2014], [1803, 1812]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["recently", 16], ["discovered", 25], ["pharmacologic", 36], ["antagonist", 50], ["of", 61], ["the", 64], ["CNS", 68], ["effects", 72], ["of", 80], ["benzodiazepines", 83], [".", 98], ["It", 100], ["acts", 103], ["by", 108], ["binding", 111], ["CNS", 119], ["benzodiazepine", 123], ["receptors", 138], ["and", 148], ["competitively", 152], ["blocking", 166], ["benzodiazepine", 175], ["activation", 190], ["of", 201], ["inhibitory", 204], ["GABAergic", 215], ["synapses", 225], [".", 233], ["Animal", 235], ["studies", 242], ["and", 250], ["some", 254], ["human", 259], ["studies", 265], ["appear", 273], ["to", 280], ["demonstrate", 283], ["that", 295], ["flumazenil", 300], ["has", 311], ["weak", 315], ["intrinsic", 320], ["agonist", 330], ["activity", 338], [";", 346], ["on", 348], ["the", 351], ["other", 355], ["hand", 361], [",", 365], ["studies", 367], ["are", 375], ["inconclusive", 379], ["in", 392], ["demonstrating", 395], ["any", 409], ["inverse", 413], ["agonist", 421], ["effects", 429], ["of", 437], ["this", 440], ["agent", 445], [".", 450], ["Evidence", 452], ["available", 461], ["suggests", 471], ["that", 480], ["flumazenil", 485], ["is", 496], ["well", 499], ["tolerated", 504], ["in", 514], ["human", 517], ["beings", 523], ["over", 530], ["a", 535], ["broad", 537], ["range", 543], ["of", 549], ["doses", 552], ["when", 558], ["given", 563], ["either", 569], ["orally", 576], ["or", 583], ["parenterally", 586], ["and", 599], ["does", 603], ["not", 608], ["produce", 612], ["serious", 620], ["adverse", 628], ["effects", 636], [".", 643], ["In", 645], ["the", 648], ["setting", 652], ["of", 660], ["isolated", 663], ["benzodiazepine", 672], ["overdose", 687], [",", 695], ["flumazenil", 697], ["is", 708], ["capable", 711], ["of", 719], ["completely", 722], ["reversing", 733], ["coma", 743], ["within", 748], ["one", 755], ["to", 759], ["two", 762], ["minutes", 766], [",", 773], ["with", 775], ["this", 780], ["effect", 785], ["lasting", 792], ["between", 800], ["one", 808], ["and", 812], ["five", 816], ["hours", 821], [".", 826], ["Repeat", 828], ["doses", 835], ["can", 841], ["be", 845], ["given", 848], ["safely", 854], ["to", 861], ["reverse", 864], ["recurrent", 872], ["effects", 882], ["of", 890], ["longer", 893], ["-", 899], ["acting", 900], ["benzodiazepines", 907], [".", 922], ["Flumazenil", 924], ["is", 935], ["undergoing", 938], ["further", 949], ["evaluation", 957], ["by", 968], ["the", 971], ["Food", 975], ["and", 980], ["Drug", 984], ["Administration", 989], [";", 1003], ["should", 1005], ["this", 1012], ["drug", 1017], ["receive", 1022], ["approval", 1030], [",", 1038], ["it", 1040], ["is", 1043], ["likely", 1046], ["to", 1053], ["be", 1056], ["used", 1059], ["in", 1064], ["emergency", 1067], ["departments", 1077], ["as", 1089], ["well", 1092], ["as", 1097], ["in", 1100], ["a", 1103], ["variety", 1105], ["of", 1113], ["other", 1116], ["clinical", 1122], ["settings", 1131], [".", 1139], ["First", 1141], [",", 1146], ["it", 1148], ["could", 1151], ["be", 1157], ["used", 1160], ["to", 1165], ["effect", 1168], ["rapid", 1175], ["reversal", 1181], ["of", 1190], ["benzodiazepine", 1193], ["-", 1207], ["induced", 1208], ["sedation", 1216], ["that", 1225], ["has", 1230], ["been", 1234], ["administered", 1239], ["to", 1252], ["facilitate", 1255], ["medical", 1266], [",", 1273], ["orthopedic", 1275], [",", 1285], ["and", 1287], ["surgical", 1291], ["procedures", 1300], [",", 1310], ["particularly", 1312], ["in", 1325], ["the", 1328], ["event", 1332], ["of", 1338], ["inadvertent", 1341], ["respiratory", 1353], ["depression", 1365], [".", 1375], ["Second", 1377], [",", 1383], ["flumazenil", 1385], ["might", 1396], ["have", 1402], ["a", 1407], ["therapeutic", 1409], ["role", 1421], ["in", 1426], ["the", 1429], ["management", 1433], ["of", 1444], ["patients", 1447], ["who", 1456], ["have", 1460], ["taken", 1465], ["benzodiazepine", 1471], ["overdoses", 1486], [".", 1495], ["Although", 1497], ["most", 1506], ["of", 1511], ["these", 1514], ["patients", 1520], ["can", 1529], ["be", 1533], ["managed", 1536], ["successfully", 1544], ["with", 1557], ["supportive", 1562], ["therapy", 1573], ["alone", 1581], [",", 1586], ["it", 1588], ["is", 1591], ["possible", 1594], ["that", 1603], ["the", 1608], ["use", 1612], ["of", 1616], ["flumazenil", 1619], ["may", 1630], ["obviate", 1634], ["the", 1642], ["need", 1646], ["for", 1651], ["intubation", 1655], ["and", 1666], ["respiratory", 1670], ["support", 1682], ["in", 1690], ["such", 1693], ["patients", 1698], ["and", 1707], ["eliminate", 1711], ["the", 1721], ["possible", 1725], ["adverse", 1734], ["effects", 1742], ["of", 1750], ["even", 1753], ["short", 1758], ["-", 1763], ["term", 1764], ["endotracheal", 1769], ["intubation", 1782], [".", 1792], ["Finally", 1794], [",", 1801], ["flumazenil", 1803], ["could", 1814], ["have", 1820], ["both", 1825], ["diagnostic", 1830], ["and", 1841], ["therapeutic", 1845], ["value", 1857], ["in", 1863], ["patients", 1866], ["with", 1875], ["acute", 1880], ["alterations", 1886], ["of", 1898], ["mental", 1901], ["status", 1908], ["of", 1915], ["unknown", 1918], ["etiology", 1926], [",", 1934], ["particularly", 1936], ["when", 1949], ["possible", 1954], ["drug", 1963], ["overdose", 1968], ["is", 1977], ["a", 1980], ["consideration", 1982], [".", 1995], ["Because", 1997], ["flumazenil", 2005], ["appears", 2016], ["to", 2024], ["be", 2027], ["specific", 2030], ["in", 2039], ["its", 2042], ["antagonism", 2046], ["of", 2057], ["benzodiazepine", 2060], ["-", 2074], ["induced", 2075], ["respiratory", 2083], ["and", 2095], ["CNS", 2099], ["depression", 2103], [",", 2113], ["it", 2115], ["could", 2118], ["be", 2124], ["used", 2127], ["empirically", 2132], ["to", 2144], ["confirm", 2147], ["or", 2155], ["exclude", 2158], ["a", 2166], ["role", 2168], ["of", 2173], ["benzodiazepines", 2176], ["in", 2192], ["the", 2195], ["generation", 2199], ["of", 2210], ["mental", 2213], ["status", 2220], ["changes", 2227], ["in", 2235], ["the", 2238], ["setting", 2242], ["of", 2250], ["overdose", 2253], ["or", 2262], ["coma", 2265], ["of", 2270], ["unknown", 2273], ["origin", 2281], [".", 2287], ["This", 2289], ["in", 2294], ["turn", 2297], ["might", 2302], ["obviate", 2308], ["the", 2316], ["need", 2320], ["for", 2325], ["further", 2329], ["expensive", 2337], ["(", 2347], ["eg", 2348], [",", 2350], ["computed", 2352], ["tomography", 2361], [")", 2371], ["and", 2373], ["sometimes", 2377], ["invasive", 2387], ["(", 2396], ["eg", 2397], [",", 2399], ["lumbar", 2401], ["puncture", 2408], [")", 2416], ["diagnostic", 2418], ["modalities", 2429], [".", 2439], ["This", 2441], ["might", 2446], ["be", 2452], ["particularly", 2455], ["useful", 2468], ["because", 2475], ["there", 2483], ["is", 2489], ["nothing", 2492], ["about", 2500], ["benzodiazepine", 2506], ["-", 2520], ["induced", 2521], ["coma", 2529], ["that", 2534], ["clearly", 2539], ["distinguishes", 2547], ["it", 2561], ["from", 2564], ["other", 2569], ["causes", 2575], ["of", 2582], ["coma", 2585], [";", 2589], ["thus", 2591], [",", 2595], ["there", 2597], ["are", 2603], ["no", 2607], ["signs", 2610], ["or", 2616], ["symptoms", 2619], ["that", 2628], ["may", 2633], ["reasonably", 2637], ["allow", 2648], ["benzodiazepine", 2654], ["overdose", 2669], ["to", 2678], ["be", 2681], ["confirmed", 2684], ["or", 2694], ["eliminated", 2697], ["on", 2708], ["clinical", 2711], ["grounds", 2720], [".", 2727], ["Further", 2729], ["studies", 2737], ["will", 2745], ["continue", 2750], ["to", 2759], ["define", 2762], ["the", 2769], ["ultimate", 2773], ["use", 2782], ["of", 2786], ["this", 2789], ["new", 2794], ["agent", 2798], [".", 2803]]}
{"context": "Superoxide production by Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC). The mechanism underlying PMA-induced enhancement of Nox1 activity, however, remains to be elucidated. Here we show that, in response to PMA, Noxo1 undergoes phosphorylation at multiple sites, which is inhibited by the PKC inhibitor GF109203X. Among them, Thr341 in Noxo1 is directly phosphorylated by PKC in\u00a0vitro, and alanine substitution for this residue reduces not only PMA-induced Noxo1 phosphorylation but also PMA-dependent enhancement of Nox1-catalyzed superoxide production. Phosphorylation of Thr341 allows Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox1-catalyzed superoxide production. Furthermore, Ser154 in Noxo1 is phosphorylated in both resting and PMA-stimulated cells, and the phosphorylation probably participates in a PMA-independent constitutive activity of Nox1. Ser154 may also be involved in protein kinase A (PKA) mediated regulation of Nox1; this serine is the major residue that is phosphorylated by PKA in\u00a0vitro. Thus phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1 activity in different manners. Noxo1 binds to p22phox by pull down (1, 2, 3) Noxo1 binds to Noxo1 by pull down (View interaction) Noxa1 binds to Noxo1 by pull down (1, 2, 3, 4, 5).", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9a318d833d4e4621b879888b71809161", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[3, 3], [179, 179], [68, 68], [242, 242], [270, 270], [158, 158], [225, 225]], "char_spans": [[25, 28], [1032, 1035], [370, 373], [1412, 1415], [1565, 1568], [914, 917], [1329, 1332]]}]}], "context_tokens": [["Superoxide", 0], ["production", 11], ["by", 22], ["Nox1", 25], [",", 29], ["a", 31], ["member", 33], ["of", 40], ["the", 43], ["Nox", 47], ["family", 51], ["NAPDH", 58], ["oxidases", 64], [",", 72], ["requires", 74], ["expression", 83], ["of", 94], ["its", 97], ["regulatory", 101], ["soluble", 112], ["proteins", 120], ["Noxo1", 129], ["(", 135], ["Nox", 136], ["organizer", 140], ["1", 150], [")", 151], ["and", 153], ["Noxa1", 157], ["(", 163], ["Nox", 164], ["activator", 168], ["1", 178], [")", 179], ["and", 181], ["is", 185], ["markedly", 188], ["enhanced", 197], ["upon", 206], ["cell", 211], ["stimulation", 216], ["with", 228], ["phorbol", 233], ["12-myristate", 241], ["13-acetate", 254], ["(", 265], ["PMA", 266], [")", 269], [",", 270], ["a", 272], ["potent", 274], ["activator", 281], ["of", 291], ["protein", 294], ["kinase", 302], ["C", 309], ["(", 311], ["PKC", 312], [")", 315], [".", 316], ["The", 318], ["mechanism", 322], ["underlying", 332], ["PMA", 343], ["-", 346], ["induced", 347], ["enhancement", 355], ["of", 367], ["Nox1", 370], ["activity", 375], [",", 383], ["however", 385], [",", 392], ["remains", 394], ["to", 402], ["be", 405], ["elucidated", 408], [".", 418], ["Here", 420], ["we", 425], ["show", 428], ["that", 433], [",", 437], ["in", 439], ["response", 442], ["to", 451], ["PMA", 454], [",", 457], ["Noxo1", 459], ["undergoes", 465], ["phosphorylation", 475], ["at", 491], ["multiple", 494], ["sites", 503], [",", 508], ["which", 510], ["is", 516], ["inhibited", 519], ["by", 529], ["the", 532], ["PKC", 536], ["inhibitor", 540], ["GF109203X.", 550], ["Among", 561], ["them", 567], [",", 571], ["Thr341", 573], ["in", 580], ["Noxo1", 583], ["is", 589], ["directly", 592], ["phosphorylated", 601], ["by", 616], ["PKC", 619], ["in", 623], ["vitro", 626], [",", 631], ["and", 633], ["alanine", 637], ["substitution", 645], ["for", 658], ["this", 662], ["residue", 667], ["reduces", 675], ["not", 683], ["only", 687], ["PMA", 692], ["-", 695], ["induced", 696], ["Noxo1", 704], ["phosphorylation", 710], ["but", 726], ["also", 730], ["PMA", 735], ["-", 738], ["dependent", 739], ["enhancement", 749], ["of", 761], ["Nox1-catalyzed", 764], ["superoxide", 779], ["production", 790], [".", 800], ["Phosphorylation", 802], ["of", 818], ["Thr341", 821], ["allows", 828], ["Noxo1", 835], ["to", 841], ["sufficiently", 844], ["interact", 857], ["with", 866], ["Noxa1", 871], [",", 876], ["an", 878], ["interaction", 881], ["that", 893], ["participates", 898], ["in", 911], ["Nox1", 914], ["activation", 919], [".", 929], ["Thus", 931], ["phosphorylation", 936], ["of", 952], ["Noxo1", 955], ["at", 961], ["Thr341", 964], ["appears", 971], ["to", 979], ["play", 982], ["a", 987], ["crucial", 989], ["role", 997], ["in", 1002], ["PMA", 1005], ["-", 1008], ["elicited", 1009], ["activation", 1018], ["of", 1029], ["Nox1", 1032], [",", 1036], ["providing", 1038], ["a", 1048], ["molecular", 1050], ["link", 1060], ["between", 1065], ["PKC", 1073], ["-", 1076], ["mediated", 1077], ["signal", 1086], ["transduction", 1093], ["and", 1106], ["Nox1-catalyzed", 1110], ["superoxide", 1125], ["production", 1136], [".", 1146], ["Furthermore", 1148], [",", 1159], ["Ser154", 1161], ["in", 1168], ["Noxo1", 1171], ["is", 1177], ["phosphorylated", 1180], ["in", 1195], ["both", 1198], ["resting", 1203], ["and", 1211], ["PMA", 1215], ["-", 1218], ["stimulated", 1219], ["cells", 1230], [",", 1235], ["and", 1237], ["the", 1241], ["phosphorylation", 1245], ["probably", 1261], ["participates", 1270], ["in", 1283], ["a", 1286], ["PMA", 1288], ["-", 1291], ["independent", 1292], ["constitutive", 1304], ["activity", 1317], ["of", 1326], ["Nox1", 1329], [".", 1333], ["Ser154", 1335], ["may", 1342], ["also", 1346], ["be", 1351], ["involved", 1354], ["in", 1363], ["protein", 1366], ["kinase", 1374], ["A", 1381], ["(", 1383], ["PKA", 1384], [")", 1387], ["mediated", 1389], ["regulation", 1398], ["of", 1409], ["Nox1", 1412], [";", 1416], ["this", 1418], ["serine", 1423], ["is", 1430], ["the", 1433], ["major", 1437], ["residue", 1443], ["that", 1451], ["is", 1456], ["phosphorylated", 1459], ["by", 1474], ["PKA", 1477], ["in", 1481], ["vitro", 1484], [".", 1489], ["Thus", 1491], ["phosphorylation", 1496], ["of", 1512], ["Noxo1", 1515], ["at", 1521], ["Thr341", 1524], ["and", 1531], ["at", 1535], ["Ser154", 1538], ["appears", 1545], ["to", 1553], ["regulate", 1556], ["Nox1", 1565], ["activity", 1570], ["in", 1579], ["different", 1582], ["manners", 1592], [".", 1599], ["Noxo1", 1601], ["binds", 1607], ["to", 1613], ["p22phox", 1616], ["by", 1624], ["pull", 1627], ["down", 1632], ["(", 1637], ["1", 1638], [",", 1639], ["2", 1641], [",", 1642], ["3", 1644], [")", 1645], ["Noxo1", 1647], ["binds", 1653], ["to", 1659], ["Noxo1", 1662], ["by", 1668], ["pull", 1671], ["down", 1676], ["(", 1681], ["View", 1682], ["interaction", 1687], [")", 1698], ["Noxa1", 1700], ["binds", 1706], ["to", 1712], ["Noxo1", 1715], ["by", 1721], ["pull", 1724], ["down", 1729], ["(", 1734], ["1", 1735], [",", 1736], ["2", 1738], [",", 1739], ["3", 1741], [",", 1742], ["4", 1744], [",", 1745], ["5", 1747], [")", 1748], [".", 1749]]}
{"context": "The proposition that finger print variability between individuals might be reduced by the absence of an X-chromosome in Turner's syndrome was rejected. In the present study of 58 XO patients, aged 15-50 years, relatives of several cases, unrelated female control samples and three unrelated male samples were investigated. The higher mean value of the TRC among patients supported the hypothesis forwarded by Penrose that an added X- or Y-chromosome reduces the TRC and a missing one increasing it. The figures do not speak against the hypothesis that genes affecting the TRC are located on the X-chromosome. A summary of the major dermatoglyphic investigations in Turner's syndrome is presented.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "2a29c11eb40348279c1e857ce85d292a", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[108, 108], [16, 16], [76, 76]], "char_spans": [[595, 595], [104, 104], [431, 432]]}]}], "context_tokens": [["The", 0], ["proposition", 4], ["that", 16], ["finger", 21], ["print", 28], ["variability", 34], ["between", 46], ["individuals", 54], ["might", 66], ["be", 72], ["reduced", 75], ["by", 83], ["the", 86], ["absence", 90], ["of", 98], ["an", 101], ["X", 104], ["-", 105], ["chromosome", 106], ["in", 117], ["Turner", 120], ["'s", 126], ["syndrome", 129], ["was", 138], ["rejected", 142], [".", 150], ["In", 152], ["the", 155], ["present", 159], ["study", 167], ["of", 173], ["58", 176], ["XO", 179], ["patients", 182], [",", 190], ["aged", 192], ["15", 197], ["-", 199], ["50", 200], ["years", 203], [",", 208], ["relatives", 210], ["of", 220], ["several", 223], ["cases", 231], [",", 236], ["unrelated", 238], ["female", 248], ["control", 255], ["samples", 263], ["and", 271], ["three", 275], ["unrelated", 281], ["male", 291], ["samples", 296], ["were", 304], ["investigated", 309], [".", 321], ["The", 323], ["higher", 327], ["mean", 334], ["value", 339], ["of", 345], ["the", 348], ["TRC", 352], ["among", 356], ["patients", 362], ["supported", 371], ["the", 381], ["hypothesis", 385], ["forwarded", 396], ["by", 406], ["Penrose", 409], ["that", 417], ["an", 422], ["added", 425], ["X-", 431], ["or", 434], ["Y", 437], ["-", 438], ["chromosome", 439], ["reduces", 450], ["the", 458], ["TRC", 462], ["and", 466], ["a", 470], ["missing", 472], ["one", 480], ["increasing", 484], ["it", 495], [".", 497], ["The", 499], ["figures", 503], ["do", 511], ["not", 514], ["speak", 518], ["against", 524], ["the", 532], ["hypothesis", 536], ["that", 547], ["genes", 552], ["affecting", 558], ["the", 568], ["TRC", 572], ["are", 576], ["located", 580], ["on", 588], ["the", 591], ["X", 595], ["-", 596], ["chromosome", 597], [".", 607], ["A", 609], ["summary", 611], ["of", 619], ["the", 622], ["major", 626], ["dermatoglyphic", 632], ["investigations", 647], ["in", 662], ["Turner", 665], ["'s", 671], ["syndrome", 674], ["is", 683], ["presented", 686], [".", 695]]}
{"context": "We report the case of a Japanese boy whose dysmorphic features were consistent with those of Shprintzen-Goldberg syndrome. The radiological features were characterized by late-onset craniosynostosis, arachnodactyly, undermodeling of short tubular bones, mildly undermodeled and slightly bowed long bones, twisted ribs and tall vertebral bodies with elongated neural arches. Apart from the craniosynostosis, these skeletal changes resembled those of frontometaphyseal dysplasia, a well-known craniotubular dysplasia. Shprintzen-Goldberg syndrome also shares many clinical features with frontometaphyseal dysplasia.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "31b5228a9b2e43878afead6abaf040d4", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[62, 62], [30, 30]], "char_spans": [[389, 404], [182, 197]]}]}], "context_tokens": [["We", 0], ["report", 3], ["the", 10], ["case", 14], ["of", 19], ["a", 22], ["Japanese", 24], ["boy", 33], ["whose", 37], ["dysmorphic", 43], ["features", 54], ["were", 63], ["consistent", 68], ["with", 79], ["those", 84], ["of", 90], ["Shprintzen", 93], ["-", 103], ["Goldberg", 104], ["syndrome", 113], [".", 121], ["The", 123], ["radiological", 127], ["features", 140], ["were", 149], ["characterized", 154], ["by", 168], ["late", 171], ["-", 175], ["onset", 176], ["craniosynostosis", 182], [",", 198], ["arachnodactyly", 200], [",", 214], ["undermodeling", 216], ["of", 230], ["short", 233], ["tubular", 239], ["bones", 247], [",", 252], ["mildly", 254], ["undermodeled", 261], ["and", 274], ["slightly", 278], ["bowed", 287], ["long", 293], ["bones", 298], [",", 303], ["twisted", 305], ["ribs", 313], ["and", 318], ["tall", 322], ["vertebral", 327], ["bodies", 337], ["with", 344], ["elongated", 349], ["neural", 359], ["arches", 366], [".", 372], ["Apart", 374], ["from", 380], ["the", 385], ["craniosynostosis", 389], [",", 405], ["these", 407], ["skeletal", 413], ["changes", 422], ["resembled", 430], ["those", 440], ["of", 446], ["frontometaphyseal", 449], ["dysplasia", 467], [",", 476], ["a", 478], ["well", 480], ["-", 484], ["known", 485], ["craniotubular", 491], ["dysplasia", 505], [".", 514], ["Shprintzen", 516], ["-", 526], ["Goldberg", 527], ["syndrome", 536], ["also", 545], ["shares", 550], ["many", 557], ["clinical", 562], ["features", 571], ["with", 580], ["frontometaphyseal", 585], ["dysplasia", 603], [".", 612]]}
{"context": "Genetic alteration of the adaptor protein (AP)-3 complex is responsible for the type 2 Hermansky-Pudlak syndrome, a lysosomal storage disease similar to the Chediak-Higashi syndrome (CHS). AP-3 presumably participates in the biogenesis of late endosomal compartments and may also be critical for the regulated secretion of lysosomes by specialized cells. Here, Dictyostelium discoideum cells defective for the mu3 subunit of the AP-3 complex were used and their phenotype analyzed. In mu3 mutant cells, endosomal maturation and lysosome secretion were markedly slower than that in wild-type cells. This phenotype is similar to that reported previously in lvsB mutant cells where the ortholog of the LYST gene, involved in CHS, is mutated. Detailed analysis revealed however significant differences between these two isogenic mutant cells: in lvsB mutant cells, the primary defect is an inefficient biogenesis of otherwise normal secretory lysosomes, while in mu3 mutant cells, the biogenesis and also the composition and the fusion properties of secretory lysosomes are affected. These results suggest that in D. discoideum, AP-3 controls both the efficiency and the specificity of postlysosome maturation, which represent two critical elements in the control of lysosome secretion.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "c24c1289233c489691969ee391245427", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[119, 120]], "char_spans": [[699, 707]]}]}], "context_tokens": [["Genetic", 0], ["alteration", 8], ["of", 19], ["the", 22], ["adaptor", 26], ["protein", 34], ["(", 42], ["AP)-3", 43], ["complex", 49], ["is", 57], ["responsible", 60], ["for", 72], ["the", 76], ["type", 80], ["2", 85], ["Hermansky", 87], ["-", 96], ["Pudlak", 97], ["syndrome", 104], [",", 112], ["a", 114], ["lysosomal", 116], ["storage", 126], ["disease", 134], ["similar", 142], ["to", 150], ["the", 153], ["Chediak", 157], ["-", 164], ["Higashi", 165], ["syndrome", 173], ["(", 182], ["CHS", 183], [")", 186], [".", 187], ["AP-3", 189], ["presumably", 194], ["participates", 205], ["in", 218], ["the", 221], ["biogenesis", 225], ["of", 236], ["late", 239], ["endosomal", 244], ["compartments", 254], ["and", 267], ["may", 271], ["also", 275], ["be", 280], ["critical", 283], ["for", 292], ["the", 296], ["regulated", 300], ["secretion", 310], ["of", 320], ["lysosomes", 323], ["by", 333], ["specialized", 336], ["cells", 348], [".", 353], ["Here", 355], [",", 359], ["Dictyostelium", 361], ["discoideum", 375], ["cells", 386], ["defective", 392], ["for", 402], ["the", 406], ["mu3", 410], ["subunit", 414], ["of", 422], ["the", 425], ["AP-3", 429], ["complex", 434], ["were", 442], ["used", 447], ["and", 452], ["their", 456], ["phenotype", 462], ["analyzed", 472], [".", 480], ["In", 482], ["mu3", 485], ["mutant", 489], ["cells", 496], [",", 501], ["endosomal", 503], ["maturation", 513], ["and", 524], ["lysosome", 528], ["secretion", 537], ["were", 547], ["markedly", 552], ["slower", 561], ["than", 568], ["that", 573], ["in", 578], ["wild", 581], ["-", 585], ["type", 586], ["cells", 591], [".", 596], ["This", 598], ["phenotype", 603], ["is", 613], ["similar", 616], ["to", 624], ["that", 627], ["reported", 632], ["previously", 641], ["in", 652], ["lvsB", 655], ["mutant", 660], ["cells", 667], ["where", 673], ["the", 679], ["ortholog", 683], ["of", 692], ["the", 695], ["LYST", 699], ["gene", 704], [",", 708], ["involved", 710], ["in", 719], ["CHS", 722], [",", 725], ["is", 727], ["mutated", 730], [".", 737], ["Detailed", 739], ["analysis", 748], ["revealed", 757], ["however", 766], ["significant", 774], ["differences", 786], ["between", 798], ["these", 806], ["two", 812], ["isogenic", 816], ["mutant", 825], ["cells", 832], [":", 837], ["in", 839], ["lvsB", 842], ["mutant", 847], ["cells", 854], [",", 859], ["the", 861], ["primary", 865], ["defect", 873], ["is", 880], ["an", 883], ["inefficient", 886], ["biogenesis", 898], ["of", 909], ["otherwise", 912], ["normal", 922], ["secretory", 929], ["lysosomes", 939], [",", 948], ["while", 950], ["in", 956], ["mu3", 959], ["mutant", 963], ["cells", 970], [",", 975], ["the", 977], ["biogenesis", 981], ["and", 992], ["also", 996], ["the", 1001], ["composition", 1005], ["and", 1017], ["the", 1021], ["fusion", 1025], ["properties", 1032], ["of", 1043], ["secretory", 1046], ["lysosomes", 1056], ["are", 1066], ["affected", 1070], [".", 1078], ["These", 1080], ["results", 1086], ["suggest", 1094], ["that", 1102], ["in", 1107], ["D.", 1110], ["discoideum", 1113], [",", 1123], ["AP-3", 1125], ["controls", 1130], ["both", 1139], ["the", 1144], ["efficiency", 1148], ["and", 1159], ["the", 1163], ["specificity", 1167], ["of", 1179], ["postlysosome", 1182], ["maturation", 1195], [",", 1205], ["which", 1207], ["represent", 1213], ["two", 1223], ["critical", 1227], ["elements", 1236], ["in", 1245], ["the", 1248], ["control", 1252], ["of", 1260], ["lysosome", 1263], ["secretion", 1272], [".", 1281]]}
{"context": "To characterize the patient demographics, clinical features, and antibiotic susceptibility of ocular infections caused by methicillin-resistant Staphylococcus aureus (MRSA), including community-associated (CA) and healthcare-associated (HA) isolates. Retrospective, observational study. Patients (n = 519) with culture-proven S. aureus ocular infections seen between January 1, 1999, and December 31, 2008, in Chang Gung Memorial Hospital. Data collected included patient demographics and clinical information. Antibiotic susceptibility was verified by disc diffusion method. Proportion of MRSA in S. aureus ocular infections and the clinical characteristics, diagnoses, and antibiotic susceptibility patterns of CA-MRSA versus HA-MRSA ocular infections. We identified 274 patients with MRSA ocular infections, which comprised 181 CA-MRSA and 93 HA-MRSA isolates. The average rate of MRSA in S. aureus infections was 52.8% with a stable trend, whereas the annual ratio of CA-MRSA in ocular MRSA infections averaged 66.1% and tended to increase over the 10-year interval. Patients with ocular CA-MRSA were younger. Lid and lacrimal system disorders were more common, but keratitis, endophthalmitis, and wound infection were less common among CA-MRSA cases than HA-MRSA cases. Both CA-MRSA and HA-MRSA isolates were resistant to clindamycin and erythromycin, but CA-MRSA was more susceptible to sulfamethoxazole/trimethoprim. Community-associated MRSA is an important pathogen of ocular infections; CA-MRSA and HA-MRSA ocular infections differ demographically and clinically, but both strains were multi-resistant in Chang Gung Memorial Hospital, one of the biggest referral centers in Taiwan. In a country with a high prevalence of MRSA, ophthalmologists should be aware of such epidemiologic information.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "8a4995f43df745ccad6b73c4c7b343ea", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[147, 147], [277, 277], [262, 262], [250, 250], [120, 120], [223, 223], [133, 133], [315, 315], [124, 124], [196, 196], [142, 142], [177, 177], [154, 154], [234, 234], [100, 100], [228, 228], [23, 23], [174, 174], [238, 238], [273, 273]], "char_spans": [[849, 852], [1512, 1515], [1445, 1448], [1364, 1367], [716, 719], [1244, 1247], [787, 790], [1731, 1734], [731, 734], [1095, 1098], [834, 837], [990, 993], [884, 887], [1283, 1286], [590, 593], [1263, 1266], [167, 170], [975, 978], [1295, 1298], [1500, 1503]]}]}], "context_tokens": [["To", 0], ["characterize", 3], ["the", 16], ["patient", 20], ["demographics", 28], [",", 40], ["clinical", 42], ["features", 51], [",", 59], ["and", 61], ["antibiotic", 65], ["susceptibility", 76], ["of", 91], ["ocular", 94], ["infections", 101], ["caused", 112], ["by", 119], ["methicillin", 122], ["-", 133], ["resistant", 134], ["Staphylococcus", 144], ["aureus", 159], ["(", 166], ["MRSA", 167], [")", 171], [",", 172], ["including", 174], ["community", 184], ["-", 193], ["associated", 194], ["(", 205], ["CA", 206], [")", 208], ["and", 210], ["healthcare", 214], ["-", 224], ["associated", 225], ["(", 236], ["HA", 237], [")", 239], ["isolates", 241], [".", 249], ["Retrospective", 251], [",", 264], ["observational", 266], ["study", 280], [".", 285], ["Patients", 287], ["(", 296], ["n", 297], ["=", 299], ["519", 301], [")", 304], ["with", 306], ["culture", 311], ["-", 318], ["proven", 319], ["S.", 326], ["aureus", 329], ["ocular", 336], ["infections", 343], ["seen", 354], ["between", 359], ["January", 367], ["1", 375], [",", 376], ["1999", 378], [",", 382], ["and", 384], ["December", 388], ["31", 397], [",", 399], ["2008", 401], [",", 405], ["in", 407], ["Chang", 410], ["Gung", 416], ["Memorial", 421], ["Hospital", 430], [".", 438], ["Data", 440], ["collected", 445], ["included", 455], ["patient", 464], ["demographics", 472], ["and", 485], ["clinical", 489], ["information", 498], [".", 509], ["Antibiotic", 511], ["susceptibility", 522], ["was", 537], ["verified", 541], ["by", 550], ["disc", 553], ["diffusion", 558], ["method", 568], [".", 574], ["Proportion", 576], ["of", 587], ["MRSA", 590], ["in", 595], ["S.", 598], ["aureus", 601], ["ocular", 608], ["infections", 615], ["and", 626], ["the", 630], ["clinical", 634], ["characteristics", 643], [",", 658], ["diagnoses", 660], [",", 669], ["and", 671], ["antibiotic", 675], ["susceptibility", 686], ["patterns", 701], ["of", 710], ["CA", 713], ["-", 715], ["MRSA", 716], ["versus", 721], ["HA", 728], ["-", 730], ["MRSA", 731], ["ocular", 736], ["infections", 743], [".", 753], ["We", 755], ["identified", 758], ["274", 769], ["patients", 773], ["with", 782], ["MRSA", 787], ["ocular", 792], ["infections", 799], [",", 809], ["which", 811], ["comprised", 817], ["181", 827], ["CA", 831], ["-", 833], ["MRSA", 834], ["and", 839], ["93", 843], ["HA", 846], ["-", 848], ["MRSA", 849], ["isolates", 854], [".", 862], ["The", 864], ["average", 868], ["rate", 876], ["of", 881], ["MRSA", 884], ["in", 889], ["S.", 892], ["aureus", 895], ["infections", 902], ["was", 913], ["52.8", 917], ["%", 921], ["with", 923], ["a", 928], ["stable", 930], ["trend", 937], [",", 942], ["whereas", 944], ["the", 952], ["annual", 956], ["ratio", 963], ["of", 969], ["CA", 972], ["-", 974], ["MRSA", 975], ["in", 980], ["ocular", 983], ["MRSA", 990], ["infections", 995], ["averaged", 1006], ["66.1", 1015], ["%", 1019], ["and", 1021], ["tended", 1025], ["to", 1032], ["increase", 1035], ["over", 1044], ["the", 1049], ["10-year", 1053], ["interval", 1061], [".", 1069], ["Patients", 1071], ["with", 1080], ["ocular", 1085], ["CA", 1092], ["-", 1094], ["MRSA", 1095], ["were", 1100], ["younger", 1105], [".", 1112], ["Lid", 1114], ["and", 1118], ["lacrimal", 1122], ["system", 1131], ["disorders", 1138], ["were", 1148], ["more", 1153], ["common", 1158], [",", 1164], ["but", 1166], ["keratitis", 1170], [",", 1179], ["endophthalmitis", 1181], [",", 1196], ["and", 1198], ["wound", 1202], ["infection", 1208], ["were", 1218], ["less", 1223], ["common", 1228], ["among", 1235], ["CA", 1241], ["-", 1243], ["MRSA", 1244], ["cases", 1249], ["than", 1255], ["HA", 1260], ["-", 1262], ["MRSA", 1263], ["cases", 1268], [".", 1273], ["Both", 1275], ["CA", 1280], ["-", 1282], ["MRSA", 1283], ["and", 1288], ["HA", 1292], ["-", 1294], ["MRSA", 1295], ["isolates", 1300], ["were", 1309], ["resistant", 1314], ["to", 1324], ["clindamycin", 1327], ["and", 1339], ["erythromycin", 1343], [",", 1355], ["but", 1357], ["CA", 1361], ["-", 1363], ["MRSA", 1364], ["was", 1369], ["more", 1373], ["susceptible", 1378], ["to", 1390], ["sulfamethoxazole", 1393], ["/", 1409], ["trimethoprim", 1410], [".", 1422], ["Community", 1424], ["-", 1433], ["associated", 1434], ["MRSA", 1445], ["is", 1450], ["an", 1453], ["important", 1456], ["pathogen", 1466], ["of", 1475], ["ocular", 1478], ["infections", 1485], [";", 1495], ["CA", 1497], ["-", 1499], ["MRSA", 1500], ["and", 1505], ["HA", 1509], ["-", 1511], ["MRSA", 1512], ["ocular", 1517], ["infections", 1524], ["differ", 1535], ["demographically", 1542], ["and", 1558], ["clinically", 1562], [",", 1572], ["but", 1574], ["both", 1578], ["strains", 1583], ["were", 1591], ["multi", 1596], ["-", 1601], ["resistant", 1602], ["in", 1612], ["Chang", 1615], ["Gung", 1621], ["Memorial", 1626], ["Hospital", 1635], [",", 1643], ["one", 1645], ["of", 1649], ["the", 1652], ["biggest", 1656], ["referral", 1664], ["centers", 1673], ["in", 1681], ["Taiwan", 1684], [".", 1690], ["In", 1692], ["a", 1695], ["country", 1697], ["with", 1705], ["a", 1710], ["high", 1712], ["prevalence", 1717], ["of", 1728], ["MRSA", 1731], [",", 1735], ["ophthalmologists", 1737], ["should", 1754], ["be", 1761], ["aware", 1764], ["of", 1770], ["such", 1773], ["epidemiologic", 1778], ["information", 1792], [".", 1803]]}
{"context": "Iron deficiency is a common cause of anemia in patients with end stage renal disease (ESRD). Intravenous iron administration, especially in those requiring treatment with erythropoiesis stimulating agents (ESA) is an essential component of the management of anemia in ESRD patients. Iron improves hemoglobin, reduces ESA dose requirement and also has nonerythropoietic effects including improvement in physical performance, cognition and amelioration of restless leg syndrome. However, iron can promote oxidative stress, cause endothelial dysfunction, inflammation and tissue injury, and has a potential to cause progression of both CKD and cardiovascular disease. In this review, we discuss the benefits and risks associated with i.v. iron and the practical aspects of iron administration that can minimize the complications related to iron therapy in ESRD.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "b473484f66344d0eab8d7d0180fd88e4", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[48, 48], [0, 0], [77, 77], [20, 20], [135, 135], [120, 120], [126, 126]], "char_spans": [[283, 286], [0, 3], [486, 489], [105, 108], [837, 840], [736, 739], [770, 773]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["is", 16], ["a", 19], ["common", 21], ["cause", 28], ["of", 34], ["anemia", 37], ["in", 44], ["patients", 47], ["with", 56], ["end", 61], ["stage", 65], ["renal", 71], ["disease", 77], ["(", 85], ["ESRD", 86], [")", 90], [".", 91], ["Intravenous", 93], ["iron", 105], ["administration", 110], [",", 124], ["especially", 126], ["in", 137], ["those", 140], ["requiring", 146], ["treatment", 156], ["with", 166], ["erythropoiesis", 171], ["stimulating", 186], ["agents", 198], ["(", 205], ["ESA", 206], [")", 209], ["is", 211], ["an", 214], ["essential", 217], ["component", 227], ["of", 237], ["the", 240], ["management", 244], ["of", 255], ["anemia", 258], ["in", 265], ["ESRD", 268], ["patients", 273], [".", 281], ["Iron", 283], ["improves", 288], ["hemoglobin", 297], [",", 307], ["reduces", 309], ["ESA", 317], ["dose", 321], ["requirement", 326], ["and", 338], ["also", 342], ["has", 347], ["nonerythropoietic", 351], ["effects", 369], ["including", 377], ["improvement", 387], ["in", 399], ["physical", 402], ["performance", 411], [",", 422], ["cognition", 424], ["and", 434], ["amelioration", 438], ["of", 451], ["restless", 454], ["leg", 463], ["syndrome", 467], [".", 475], ["However", 477], [",", 484], ["iron", 486], ["can", 491], ["promote", 495], ["oxidative", 503], ["stress", 513], [",", 519], ["cause", 521], ["endothelial", 527], ["dysfunction", 539], [",", 550], ["inflammation", 552], ["and", 565], ["tissue", 569], ["injury", 576], [",", 582], ["and", 584], ["has", 588], ["a", 592], ["potential", 594], ["to", 604], ["cause", 607], ["progression", 613], ["of", 625], ["both", 628], ["CKD", 633], ["and", 637], ["cardiovascular", 641], ["disease", 656], [".", 663], ["In", 665], ["this", 668], ["review", 673], [",", 679], ["we", 681], ["discuss", 684], ["the", 692], ["benefits", 696], ["and", 705], ["risks", 709], ["associated", 715], ["with", 726], ["i.v", 731], [".", 734], ["iron", 736], ["and", 741], ["the", 745], ["practical", 749], ["aspects", 759], ["of", 767], ["iron", 770], ["administration", 775], ["that", 790], ["can", 795], ["minimize", 799], ["the", 808], ["complications", 812], ["related", 826], ["to", 834], ["iron", 837], ["therapy", 842], ["in", 850], ["ESRD", 853], [".", 857]]}
{"context": "We investigated the distribution of MRSA (methicillin-resistant Staphylococcus aureus) on and around six patients with MRSA infection in our neurosurgical ward. All patients had a disturbance of consciousness and had sputum colonization of MRSA. Samples were obtained from 11 sites (patients' hands, attendances' hands, floors, sidetables, bedclothes, chairs, walls, curtains, door knobs, faucets and disposable gloves) in the patients' rooms by the wiping method. High counts of MRSA were detected on horizontal planes such as floors, sidetables and chairs, but MRSA was not detected on vertical planes such as curtains and walls. The reason why MRSA was detected on the horizontal planes was due to a fall of MRSA spread from sputum in the air. These findings indicate that the disinfection of horizontal planes is important for preventing the spread of MRSA. We also evaluated what disinfectant was useful for floor disinfection and concluded that 0.5% chlorhexidine digluconate (Hibitane) and 0.5% benzalkonium chloride (Osvan) were more effective than the other usually-used disinfectants such as alkyldiaminoethyl glycine (Tego-51).", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ffbd79dfefa548019238ea221228221f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[19, 19], [5, 5], [38, 38], [132, 132], [156, 156], [103, 103], [119, 119], [88, 88]], "char_spans": [[119, 122], [36, 39], [240, 243], [711, 714], [856, 859], [563, 566], [647, 650], [480, 483]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["distribution", 20], ["of", 33], ["MRSA", 36], ["(", 41], ["methicillin", 42], ["-", 53], ["resistant", 54], ["Staphylococcus", 64], ["aureus", 79], [")", 85], ["on", 87], ["and", 90], ["around", 94], ["six", 101], ["patients", 105], ["with", 114], ["MRSA", 119], ["infection", 124], ["in", 134], ["our", 137], ["neurosurgical", 141], ["ward", 155], [".", 159], ["All", 161], ["patients", 165], ["had", 174], ["a", 178], ["disturbance", 180], ["of", 192], ["consciousness", 195], ["and", 209], ["had", 213], ["sputum", 217], ["colonization", 224], ["of", 237], ["MRSA", 240], [".", 244], ["Samples", 246], ["were", 254], ["obtained", 259], ["from", 268], ["11", 273], ["sites", 276], ["(", 282], ["patients", 283], ["'", 291], ["hands", 293], [",", 298], ["attendances", 300], ["'", 311], ["hands", 313], [",", 318], ["floors", 320], [",", 326], ["sidetables", 328], [",", 338], ["bedclothes", 340], [",", 350], ["chairs", 352], [",", 358], ["walls", 360], [",", 365], ["curtains", 367], [",", 375], ["door", 377], ["knobs", 382], [",", 387], ["faucets", 389], ["and", 397], ["disposable", 401], ["gloves", 412], [")", 418], ["in", 420], ["the", 423], ["patients", 427], ["'", 435], ["rooms", 437], ["by", 443], ["the", 446], ["wiping", 450], ["method", 457], [".", 463], ["High", 465], ["counts", 470], ["of", 477], ["MRSA", 480], ["were", 485], ["detected", 490], ["on", 499], ["horizontal", 502], ["planes", 513], ["such", 520], ["as", 525], ["floors", 528], [",", 534], ["sidetables", 536], ["and", 547], ["chairs", 551], [",", 557], ["but", 559], ["MRSA", 563], ["was", 568], ["not", 572], ["detected", 576], ["on", 585], ["vertical", 588], ["planes", 597], ["such", 604], ["as", 609], ["curtains", 612], ["and", 621], ["walls", 625], [".", 630], ["The", 632], ["reason", 636], ["why", 643], ["MRSA", 647], ["was", 652], ["detected", 656], ["on", 665], ["the", 668], ["horizontal", 672], ["planes", 683], ["was", 690], ["due", 694], ["to", 698], ["a", 701], ["fall", 703], ["of", 708], ["MRSA", 711], ["spread", 716], ["from", 723], ["sputum", 728], ["in", 735], ["the", 738], ["air", 742], [".", 745], ["These", 747], ["findings", 753], ["indicate", 762], ["that", 771], ["the", 776], ["disinfection", 780], ["of", 793], ["horizontal", 796], ["planes", 807], ["is", 814], ["important", 817], ["for", 827], ["preventing", 831], ["the", 842], ["spread", 846], ["of", 853], ["MRSA", 856], [".", 860], ["We", 862], ["also", 865], ["evaluated", 870], ["what", 880], ["disinfectant", 885], ["was", 898], ["useful", 902], ["for", 909], ["floor", 913], ["disinfection", 919], ["and", 932], ["concluded", 936], ["that", 946], ["0.5", 951], ["%", 954], ["chlorhexidine", 956], ["digluconate", 970], ["(", 982], ["Hibitane", 983], [")", 991], ["and", 993], ["0.5", 997], ["%", 1000], ["benzalkonium", 1002], ["chloride", 1015], ["(", 1024], ["Osvan", 1025], [")", 1030], ["were", 1032], ["more", 1037], ["effective", 1042], ["than", 1052], ["the", 1057], ["other", 1061], ["usually", 1067], ["-", 1074], ["used", 1075], ["disinfectants", 1080], ["such", 1094], ["as", 1099], ["alkyldiaminoethyl", 1102], ["glycine", 1120], ["(", 1128], ["Tego-51", 1129], [")", 1136], [".", 1137]]}
{"context": "MicroRNAs (miRNAs) are a recently discovered group of small RNA molecules involved in the regulation of gene expression. Analogously to mRNAs, the non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail. Subsequently, the pri-miRNA undergoes a number of processing steps in the nucleus and cytoplasm, and ends up as a mature approximately 22 nt miRNA, which can exert its function by binding to the 3'-untranslated region of a subset of mRNAs. Binding of the miRNA to the mRNA results in a reduced translation rate and/or increased degradation of the mRNA. In this way a large number of cellular pathways, such as cellular proliferation, differentiation, and apoptosis, are regulated by mi-RNAs. As corruption of these pathways is the hallmark of many cancers, dysregulation of miRNA biogenesis or expression levels may lead to tumorigenesis. The mechanisms that alter the expression of miRNAs are similar to those that change the expression levels of mRNAs of tumor suppressor- and oncogenes, i.e. gross genomic aberrations, epigenetic changes, and minor mutations affecting the expression level, processing, or target-interaction potential of the miRNA. Furthermore, expression profiling of miRNAs has been found to be useful for classification of different tumor types. Taken together, miRNAs can be classified as onco-miRs or tumor suppressor-miRs, and may turn out to be potential targets for cancer therapy.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "a71bfab3e52a453389459997d51e71f2", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[37, 39]], "char_spans": [[198, 214]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["a", 23], ["recently", 25], ["discovered", 34], ["group", 45], ["of", 51], ["small", 54], ["RNA", 60], ["molecules", 64], ["involved", 74], ["in", 83], ["the", 86], ["regulation", 90], ["of", 101], ["gene", 104], ["expression", 109], [".", 119], ["Analogously", 121], ["to", 133], ["mRNAs", 136], [",", 141], ["the", 143], ["non", 147], ["-", 150], ["protein", 151], ["-", 158], ["encoding", 159], ["pri", 168], ["-", 171], ["miRNAs", 172], ["are", 179], ["synthesized", 183], ["by", 195], ["RNA", 198], ["polymerase", 202], ["II", 213], ["and", 216], ["post", 220], ["-", 224], ["transcriptionally", 225], ["modified", 243], ["by", 252], ["addition", 255], ["of", 264], ["a", 267], ["5'-cap", 269], ["and", 276], ["a", 280], ["3'-poly", 282], ["(", 290], ["A", 291], [")", 292], ["tail", 294], [".", 298], ["Subsequently", 300], [",", 312], ["the", 314], ["pri", 318], ["-", 321], ["miRNA", 322], ["undergoes", 328], ["a", 338], ["number", 340], ["of", 347], ["processing", 350], ["steps", 361], ["in", 367], ["the", 370], ["nucleus", 374], ["and", 382], ["cytoplasm", 386], [",", 395], ["and", 397], ["ends", 401], ["up", 406], ["as", 409], ["a", 412], ["mature", 414], ["approximately", 421], ["22", 435], ["nt", 438], ["miRNA", 441], [",", 446], ["which", 448], ["can", 454], ["exert", 458], ["its", 464], ["function", 468], ["by", 477], ["binding", 480], ["to", 488], ["the", 491], ["3'-untranslated", 495], ["region", 511], ["of", 518], ["a", 521], ["subset", 523], ["of", 530], ["mRNAs", 533], [".", 538], ["Binding", 540], ["of", 548], ["the", 551], ["miRNA", 555], ["to", 561], ["the", 564], ["mRNA", 568], ["results", 573], ["in", 581], ["a", 584], ["reduced", 586], ["translation", 594], ["rate", 606], ["and/or", 611], ["increased", 618], ["degradation", 628], ["of", 640], ["the", 643], ["mRNA", 647], [".", 651], ["In", 653], ["this", 656], ["way", 661], ["a", 665], ["large", 667], ["number", 673], ["of", 680], ["cellular", 683], ["pathways", 692], [",", 700], ["such", 702], ["as", 707], ["cellular", 710], ["proliferation", 719], [",", 732], ["differentiation", 734], [",", 749], ["and", 751], ["apoptosis", 755], [",", 764], ["are", 766], ["regulated", 770], ["by", 780], ["mi", 783], ["-", 785], ["RNAs", 786], [".", 790], ["As", 792], ["corruption", 795], ["of", 806], ["these", 809], ["pathways", 815], ["is", 824], ["the", 827], ["hallmark", 831], ["of", 840], ["many", 843], ["cancers", 848], [",", 855], ["dysregulation", 857], ["of", 871], ["miRNA", 874], ["biogenesis", 880], ["or", 891], ["expression", 894], ["levels", 905], ["may", 912], ["lead", 916], ["to", 921], ["tumorigenesis", 924], [".", 937], ["The", 939], ["mechanisms", 943], ["that", 954], ["alter", 959], ["the", 965], ["expression", 969], ["of", 980], ["miRNAs", 983], ["are", 990], ["similar", 994], ["to", 1002], ["those", 1005], ["that", 1011], ["change", 1016], ["the", 1023], ["expression", 1027], ["levels", 1038], ["of", 1045], ["mRNAs", 1048], ["of", 1054], ["tumor", 1057], ["suppressor-", 1063], ["and", 1075], ["oncogenes", 1079], [",", 1088], ["i.e.", 1090], ["gross", 1095], ["genomic", 1101], ["aberrations", 1109], [",", 1120], ["epigenetic", 1122], ["changes", 1133], [",", 1140], ["and", 1142], ["minor", 1146], ["mutations", 1152], ["affecting", 1162], ["the", 1172], ["expression", 1176], ["level", 1187], [",", 1192], ["processing", 1194], [",", 1204], ["or", 1206], ["target", 1209], ["-", 1215], ["interaction", 1216], ["potential", 1228], ["of", 1238], ["the", 1241], ["miRNA", 1245], [".", 1250], ["Furthermore", 1252], [",", 1263], ["expression", 1265], ["profiling", 1276], ["of", 1286], ["miRNAs", 1289], ["has", 1296], ["been", 1300], ["found", 1305], ["to", 1311], ["be", 1314], ["useful", 1317], ["for", 1324], ["classification", 1328], ["of", 1343], ["different", 1346], ["tumor", 1356], ["types", 1362], [".", 1367], ["Taken", 1369], ["together", 1375], [",", 1383], ["miRNAs", 1385], ["can", 1392], ["be", 1396], ["classified", 1399], ["as", 1410], ["onco", 1413], ["-", 1417], ["miRs", 1418], ["or", 1423], ["tumor", 1426], ["suppressor", 1432], ["-", 1442], ["miRs", 1443], [",", 1447], ["and", 1449], ["may", 1453], ["turn", 1457], ["out", 1462], ["to", 1466], ["be", 1469], ["potential", 1472], ["targets", 1482], ["for", 1490], ["cancer", 1494], ["therapy", 1501], [".", 1508]]}
{"context": "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene. The aim of this study is to examine the relationship between the neuroimaging and clinical features of children with Sotos syndrome. Six Turkish children with Sotos syndrome were followed up about 3-7 years. The diagnosis was confirmed with molecular genetic analysis. We identified the pathogenic NSD1 mutation including three novel in all patients. All the patients had a characteristic facial gestalt of Sotos syndrome consisting of triangular face with prominent forehead, frontoparietal sparseness of hair and small nose. However, the degree of psychomotor and intellectual development was variable. Severe learning defect and speech delay were remarkable in two patients. The neuroimaging analysis showed abnormalities in four of six patients including bilateral large ventricles, thinning of the corpus callosum and persistent cavum septum pellucidum et vergae. Typical craniofacial appearance is the primary finding for the diagnosis of the disease even in the infantile period. However, the degree of psychomotor and intellectual development is very variable and does not correlate with the neuroimaging findings.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "f970b6e9da0e4f42b3418a51e4e4c545", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[34, 35]], "char_spans": [[225, 233]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["a", 18], ["well", 20], ["-", 24], ["known", 25], ["overgrowth", 31], ["syndrome", 42], ["characterized", 51], ["by", 65], ["excessive", 68], ["growth", 78], ["during", 85], ["childhood", 92], [",", 101], ["macrocephaly", 103], [",", 115], ["distinctive", 117], ["facial", 129], ["appearance", 136], ["and", 147], ["learning", 151], ["disability", 160], [".", 170], ["This", 172], ["disorder", 177], ["is", 186], ["caused", 189], ["by", 196], ["mutations", 199], ["or", 209], ["deletions", 212], ["in", 222], ["NSD1", 225], ["gene", 230], [".", 234], ["The", 236], ["aim", 240], ["of", 244], ["this", 247], ["study", 252], ["is", 258], ["to", 261], ["examine", 264], ["the", 272], ["relationship", 276], ["between", 289], ["the", 297], ["neuroimaging", 301], ["and", 314], ["clinical", 318], ["features", 327], ["of", 336], ["children", 339], ["with", 348], ["Sotos", 353], ["syndrome", 359], [".", 367], ["Six", 369], ["Turkish", 373], ["children", 381], ["with", 390], ["Sotos", 395], ["syndrome", 401], ["were", 410], ["followed", 415], ["up", 424], ["about", 427], ["3", 433], ["-", 434], ["7", 435], ["years", 437], [".", 442], ["The", 444], ["diagnosis", 448], ["was", 458], ["confirmed", 462], ["with", 472], ["molecular", 477], ["genetic", 487], ["analysis", 495], [".", 503], ["We", 505], ["identified", 508], ["the", 519], ["pathogenic", 523], ["NSD1", 534], ["mutation", 539], ["including", 548], ["three", 558], ["novel", 564], ["in", 570], ["all", 573], ["patients", 577], [".", 585], ["All", 587], ["the", 591], ["patients", 595], ["had", 604], ["a", 608], ["characteristic", 610], ["facial", 625], ["gestalt", 632], ["of", 640], ["Sotos", 643], ["syndrome", 649], ["consisting", 658], ["of", 669], ["triangular", 672], ["face", 683], ["with", 688], ["prominent", 693], ["forehead", 703], [",", 711], ["frontoparietal", 713], ["sparseness", 728], ["of", 739], ["hair", 742], ["and", 747], ["small", 751], ["nose", 757], [".", 761], ["However", 763], [",", 770], ["the", 772], ["degree", 776], ["of", 783], ["psychomotor", 786], ["and", 798], ["intellectual", 802], ["development", 815], ["was", 827], ["variable", 831], [".", 839], ["Severe", 841], ["learning", 848], ["defect", 857], ["and", 864], ["speech", 868], ["delay", 875], ["were", 881], ["remarkable", 886], ["in", 897], ["two", 900], ["patients", 904], [".", 912], ["The", 914], ["neuroimaging", 918], ["analysis", 931], ["showed", 940], ["abnormalities", 947], ["in", 961], ["four", 964], ["of", 969], ["six", 972], ["patients", 976], ["including", 985], ["bilateral", 995], ["large", 1005], ["ventricles", 1011], [",", 1021], ["thinning", 1023], ["of", 1032], ["the", 1035], ["corpus", 1039], ["callosum", 1046], ["and", 1055], ["persistent", 1059], ["cavum", 1070], ["septum", 1076], ["pellucidum", 1083], ["et", 1094], ["vergae", 1097], [".", 1103], ["Typical", 1105], ["craniofacial", 1113], ["appearance", 1126], ["is", 1137], ["the", 1140], ["primary", 1144], ["finding", 1152], ["for", 1160], ["the", 1164], ["diagnosis", 1168], ["of", 1178], ["the", 1181], ["disease", 1185], ["even", 1193], ["in", 1198], ["the", 1201], ["infantile", 1205], ["period", 1215], [".", 1221], ["However", 1223], [",", 1230], ["the", 1232], ["degree", 1236], ["of", 1243], ["psychomotor", 1246], ["and", 1258], ["intellectual", 1262], ["development", 1275], ["is", 1287], ["very", 1290], ["variable", 1295], ["and", 1304], ["does", 1308], ["not", 1313], ["correlate", 1317], ["with", 1327], ["the", 1332], ["neuroimaging", 1336], ["findings", 1349], [".", 1357]]}
{"context": "Sotos syndrome (SoS) is a multiple anomaly, congenital disorder characterized by overgrowth, macrocephaly, distinctive facial features and variable degree of intellectual disability. Haploinsufficiency of the NSD1 gene at 5q35.3, arising from 5q35 microdeletions, point mutations, and partial gene deletions, accounts for a majority of patients with SoS. Recently, mutations and possible pathogenetic rare CNVs, both affecting a few candidate genes for overgrowth, have been reported in patients with Sotos-like overgrowth features. To estimate the frequency of NSD1 defects in the Brazilian SoS population and possibly reveal other genes implicated in the etiopathogenesis of this syndrome, we collected a cohort of 21 Brazilian patients, who fulfilled the diagnostic criteria for SoS, and analyzed the NSD1 and PTEN genes by means of multiplex ligation-dependent probe amplification and mutational screening analyses. We identified a classical NSD1 microdeletion, a novel missense mutation (p.C1593W), and 2 previously reported truncating mutations: p.R1984X and p.V1760Gfs*2. In addition, we identified a novel de novo PTEN gene mutation (p.D312Rfs*2) in a patient with a less severe presentation of SoS phenotype, which did not include pre- and postnatal overgrowth. For the first time, our study implies PTEN in the pathogenesis of SoS and further emphasizes the existence of ethno-geographical differences in NSD1 molecular alterations between patients with SoS from Europe/North America (70-93%) and those from South America (10-19%).", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "86eebad997b34e70b99bab30bc82e7b6", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[31, 32]], "char_spans": [[209, 217]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["(", 15], ["SoS", 16], [")", 19], ["is", 21], ["a", 24], ["multiple", 26], ["anomaly", 35], [",", 42], ["congenital", 44], ["disorder", 55], ["characterized", 64], ["by", 78], ["overgrowth", 81], [",", 91], ["macrocephaly", 93], [",", 105], ["distinctive", 107], ["facial", 119], ["features", 126], ["and", 135], ["variable", 139], ["degree", 148], ["of", 155], ["intellectual", 158], ["disability", 171], [".", 181], ["Haploinsufficiency", 183], ["of", 202], ["the", 205], ["NSD1", 209], ["gene", 214], ["at", 219], ["5q35.3", 222], [",", 228], ["arising", 230], ["from", 238], ["5q35", 243], ["microdeletions", 248], [",", 262], ["point", 264], ["mutations", 270], [",", 279], ["and", 281], ["partial", 285], ["gene", 293], ["deletions", 298], [",", 307], ["accounts", 309], ["for", 318], ["a", 322], ["majority", 324], ["of", 333], ["patients", 336], ["with", 345], ["SoS.", 350], ["Recently", 355], [",", 363], ["mutations", 365], ["and", 375], ["possible", 379], ["pathogenetic", 388], ["rare", 401], ["CNVs", 406], [",", 410], ["both", 412], ["affecting", 417], ["a", 427], ["few", 429], ["candidate", 433], ["genes", 443], ["for", 449], ["overgrowth", 453], [",", 463], ["have", 465], ["been", 470], ["reported", 475], ["in", 484], ["patients", 487], ["with", 496], ["Sotos", 501], ["-", 506], ["like", 507], ["overgrowth", 512], ["features", 523], [".", 531], ["To", 533], ["estimate", 536], ["the", 545], ["frequency", 549], ["of", 559], ["NSD1", 562], ["defects", 567], ["in", 575], ["the", 578], ["Brazilian", 582], ["SoS", 592], ["population", 596], ["and", 607], ["possibly", 611], ["reveal", 620], ["other", 627], ["genes", 633], ["implicated", 639], ["in", 650], ["the", 653], ["etiopathogenesis", 657], ["of", 674], ["this", 677], ["syndrome", 682], [",", 690], ["we", 692], ["collected", 695], ["a", 705], ["cohort", 707], ["of", 714], ["21", 717], ["Brazilian", 720], ["patients", 730], [",", 738], ["who", 740], ["fulfilled", 744], ["the", 754], ["diagnostic", 758], ["criteria", 769], ["for", 778], ["SoS", 782], [",", 785], ["and", 787], ["analyzed", 791], ["the", 800], ["NSD1", 804], ["and", 809], ["PTEN", 813], ["genes", 818], ["by", 824], ["means", 827], ["of", 833], ["multiplex", 836], ["ligation", 846], ["-", 854], ["dependent", 855], ["probe", 865], ["amplification", 871], ["and", 885], ["mutational", 889], ["screening", 900], ["analyses", 910], [".", 918], ["We", 920], ["identified", 923], ["a", 934], ["classical", 936], ["NSD1", 946], ["microdeletion", 951], [",", 964], ["a", 966], ["novel", 968], ["missense", 974], ["mutation", 983], ["(", 992], ["p", 993], [".", 994], ["C1593W", 995], [")", 1001], [",", 1002], ["and", 1004], ["2", 1008], ["previously", 1010], ["reported", 1021], ["truncating", 1030], ["mutations", 1041], [":", 1050], ["p", 1052], [".", 1053], ["R1984X", 1054], ["and", 1061], ["p", 1065], [".", 1066], ["V1760Gfs*2", 1067], [".", 1077], ["In", 1079], ["addition", 1082], [",", 1090], ["we", 1092], ["identified", 1095], ["a", 1106], ["novel", 1108], ["de", 1114], ["novo", 1117], ["PTEN", 1122], ["gene", 1127], ["mutation", 1132], ["(", 1141], ["p", 1142], [".", 1143], ["D312Rfs*2", 1144], [")", 1153], ["in", 1155], ["a", 1158], ["patient", 1160], ["with", 1168], ["a", 1173], ["less", 1175], ["severe", 1180], ["presentation", 1187], ["of", 1200], ["SoS", 1203], ["phenotype", 1207], [",", 1216], ["which", 1218], ["did", 1224], ["not", 1228], ["include", 1232], ["pre-", 1240], ["and", 1245], ["postnatal", 1249], ["overgrowth", 1259], [".", 1269], ["For", 1271], ["the", 1275], ["first", 1279], ["time", 1285], [",", 1289], ["our", 1291], ["study", 1295], ["implies", 1301], ["PTEN", 1309], ["in", 1314], ["the", 1317], ["pathogenesis", 1321], ["of", 1334], ["SoS", 1337], ["and", 1341], ["further", 1345], ["emphasizes", 1353], ["the", 1364], ["existence", 1368], ["of", 1378], ["ethno", 1381], ["-", 1386], ["geographical", 1387], ["differences", 1400], ["in", 1412], ["NSD1", 1415], ["molecular", 1420], ["alterations", 1430], ["between", 1442], ["patients", 1450], ["with", 1459], ["SoS", 1464], ["from", 1468], ["Europe", 1473], ["/", 1479], ["North", 1480], ["America", 1486], ["(", 1494], ["70", 1495], ["-", 1497], ["93", 1498], ["%", 1500], [")", 1501], ["and", 1503], ["those", 1507], ["from", 1513], ["South", 1518], ["America", 1524], ["(", 1532], ["10", 1533], ["-", 1535], ["19", 1536], ["%", 1538], [")", 1539], [".", 1540]]}
{"context": "Background. Chediak-Higashi syndrome (CHS) is a rare, autosomal recessive disorder characterized by oculocutaneous albinism, immunodeficiency, coagulopathy and late-onset, progressive neurological dysfunction. It also has an \"accelerated phase\" characterized by hemophagocytic lymphohistiocytosis (HLH). The disease is caused by mutations in the CHS1/LYST gene located on chromosome 1, which affects lysosome morphology and function. We report the case of an African-American child with CHS in Case. This 16-month old African-American girl presented with fever and lethargy. The proband had pale skin compared to her parents, with light brown eyes, silvery hair and massive hepatosplenomegaly. Her laboratory evaluation was remarkable for pancytopenia, high serum ferritin and an elevated LDH. Bone marrow aspirate revealed large inclusions in granulocytes and erythrophagocytosis consistent with HLH. Genetic evaluation revealed two novel nonsense mutations in the CHS1 gene: c.3622C > T (p.Q1208X) and c.11002G > T (p.E3668X). Conclusions. Our patient is one of the few cases of CHS reported in the African American population. We identified 2 nonsense mutations in the CHS1 gene, the first mutation analysis published of an African-American child with Chediak-Higashi Syndrome. These two mutations predict a severe phenotype and thus identification of these mutations has an important clinical significance in CHS.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "5c2891c2c9d1421e9802096802dc5dda", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[2, 5], [222, 225]], "char_spans": [[12, 35], [1255, 1278]]}]}], "context_tokens": [["Background", 0], [".", 10], ["Chediak", 12], ["-", 19], ["Higashi", 20], ["syndrome", 28], ["(", 37], ["CHS", 38], [")", 41], ["is", 43], ["a", 46], ["rare", 48], [",", 52], ["autosomal", 54], ["recessive", 64], ["disorder", 74], ["characterized", 83], ["by", 97], ["oculocutaneous", 100], ["albinism", 115], [",", 123], ["immunodeficiency", 125], [",", 141], ["coagulopathy", 143], ["and", 156], ["late", 160], ["-", 164], ["onset", 165], [",", 170], ["progressive", 172], ["neurological", 184], ["dysfunction", 197], [".", 208], ["It", 210], ["also", 213], ["has", 218], ["an", 222], ["\"", 225], ["accelerated", 226], ["phase", 238], ["\"", 243], ["characterized", 245], ["by", 259], ["hemophagocytic", 262], ["lymphohistiocytosis", 277], ["(", 297], ["HLH", 298], [")", 301], [".", 302], ["The", 304], ["disease", 308], ["is", 316], ["caused", 319], ["by", 326], ["mutations", 329], ["in", 339], ["the", 342], ["CHS1/LYST", 346], ["gene", 356], ["located", 361], ["on", 369], ["chromosome", 372], ["1", 383], [",", 384], ["which", 386], ["affects", 392], ["lysosome", 400], ["morphology", 409], ["and", 420], ["function", 424], [".", 432], ["We", 434], ["report", 437], ["the", 444], ["case", 448], ["of", 453], ["an", 456], ["African", 459], ["-", 466], ["American", 467], ["child", 476], ["with", 482], ["CHS", 487], ["in", 491], ["Case", 494], [".", 498], ["This", 500], ["16-month", 505], ["old", 514], ["African", 518], ["-", 525], ["American", 526], ["girl", 535], ["presented", 540], ["with", 550], ["fever", 555], ["and", 561], ["lethargy", 565], [".", 573], ["The", 575], ["proband", 579], ["had", 587], ["pale", 591], ["skin", 596], ["compared", 601], ["to", 610], ["her", 613], ["parents", 617], [",", 624], ["with", 626], ["light", 631], ["brown", 637], ["eyes", 643], [",", 647], ["silvery", 649], ["hair", 657], ["and", 662], ["massive", 666], ["hepatosplenomegaly", 674], [".", 692], ["Her", 694], ["laboratory", 698], ["evaluation", 709], ["was", 720], ["remarkable", 724], ["for", 735], ["pancytopenia", 739], [",", 751], ["high", 753], ["serum", 758], ["ferritin", 764], ["and", 773], ["an", 777], ["elevated", 780], ["LDH", 789], [".", 792], ["Bone", 794], ["marrow", 799], ["aspirate", 806], ["revealed", 815], ["large", 824], ["inclusions", 830], ["in", 841], ["granulocytes", 844], ["and", 857], ["erythrophagocytosis", 861], ["consistent", 881], ["with", 892], ["HLH", 897], [".", 900], ["Genetic", 902], ["evaluation", 910], ["revealed", 921], ["two", 930], ["novel", 934], ["nonsense", 940], ["mutations", 949], ["in", 959], ["the", 962], ["CHS1", 966], ["gene", 971], [":", 975], ["c.3622C", 977], [">", 985], ["T", 987], ["(", 989], ["p", 990], [".", 991], ["Q1208X", 992], [")", 998], ["and", 1000], ["c.11002", 1004], ["G", 1011], [">", 1013], ["T", 1015], ["(", 1017], ["p", 1018], [".", 1019], ["E3668X", 1020], [")", 1026], [".", 1027], ["Conclusions", 1029], [".", 1040], ["Our", 1042], ["patient", 1046], ["is", 1054], ["one", 1057], ["of", 1061], ["the", 1064], ["few", 1068], ["cases", 1072], ["of", 1078], ["CHS", 1081], ["reported", 1085], ["in", 1094], ["the", 1097], ["African", 1101], ["American", 1109], ["population", 1118], [".", 1128], ["We", 1130], ["identified", 1133], ["2", 1144], ["nonsense", 1146], ["mutations", 1155], ["in", 1165], ["the", 1168], ["CHS1", 1172], ["gene", 1177], [",", 1181], ["the", 1183], ["first", 1187], ["mutation", 1193], ["analysis", 1202], ["published", 1211], ["of", 1221], ["an", 1224], ["African", 1227], ["-", 1234], ["American", 1235], ["child", 1244], ["with", 1250], ["Chediak", 1255], ["-", 1262], ["Higashi", 1263], ["Syndrome", 1271], [".", 1279], ["These", 1281], ["two", 1287], ["mutations", 1291], ["predict", 1301], ["a", 1309], ["severe", 1311], ["phenotype", 1318], ["and", 1328], ["thus", 1332], ["identification", 1337], ["of", 1352], ["these", 1355], ["mutations", 1361], ["has", 1371], ["an", 1375], ["important", 1378], ["clinical", 1388], ["significance", 1397], ["in", 1410], ["CHS", 1413], [".", 1416]]}
{"context": "Acute graft-versus-host disease (GvHD) limits the applicability of allogeneic hematopoietic cell transplantation for the treatment of leukemia. GvHD occurs as a consequence of multiple activating events in antigen-presenting cells (APCs) and T cells (Tcs). Spleen tyrosine kinase (Syk) is an intracellular non-receptor tyrosine kinase involved in multiple signaling events of immune cells. Therefore, we hypothesized that Syk may be a promising target to inhibit GvHD, which involves activation of different immune cell populations. In vivo expansion of luciferase(+) donor Tcs in mice developing GvHD was reduced by treatment with the Syk inhibitor Fostamatinib, which led to increased survival and reduced histologically confirmed GvHD severity. Importantly, in vivo and in vitro cytotoxicity against leukemia target cells and anti-murine cytomegalovirus immune responses were not impacted by Fostamatinib. In APCs Syk inhibition reduced the expression of costimulatory molecules and disrupted cytoskeletal organization with consecutive APC migratory defects in vitro and in vivo while phagocytic activity remained intact. On the basis of these immunomodulatory effects on different cell populations, we conclude that Syk targeting in alloantigen-activated Tcs and APCs with pharmacologic inhibitors, already applied successfully in anti-lymphoma therapy, has clinical potential to reduce GvHD, especially as anti-leukemia and anti-viral immunity were preserved.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "16300354ea174c638aed9b7a90b41019", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[48, 50]], "char_spans": [[257, 278]]}]}], "context_tokens": [["Acute", 0], ["graft", 6], ["-", 11], ["versus", 12], ["-", 18], ["host", 19], ["disease", 24], ["(", 32], ["GvHD", 33], [")", 37], ["limits", 39], ["the", 46], ["applicability", 50], ["of", 64], ["allogeneic", 67], ["hematopoietic", 78], ["cell", 92], ["transplantation", 97], ["for", 113], ["the", 117], ["treatment", 121], ["of", 131], ["leukemia", 134], [".", 142], ["GvHD", 144], ["occurs", 149], ["as", 156], ["a", 159], ["consequence", 161], ["of", 173], ["multiple", 176], ["activating", 185], ["events", 196], ["in", 203], ["antigen", 206], ["-", 213], ["presenting", 214], ["cells", 225], ["(", 231], ["APCs", 232], [")", 236], ["and", 238], ["T", 242], ["cells", 244], ["(", 250], ["Tcs", 251], [")", 254], [".", 255], ["Spleen", 257], ["tyrosine", 264], ["kinase", 273], ["(", 280], ["Syk", 281], [")", 284], ["is", 286], ["an", 289], ["intracellular", 292], ["non", 306], ["-", 309], ["receptor", 310], ["tyrosine", 319], ["kinase", 328], ["involved", 335], ["in", 344], ["multiple", 347], ["signaling", 356], ["events", 366], ["of", 373], ["immune", 376], ["cells", 383], [".", 388], ["Therefore", 390], [",", 399], ["we", 401], ["hypothesized", 404], ["that", 417], ["Syk", 422], ["may", 426], ["be", 430], ["a", 433], ["promising", 435], ["target", 445], ["to", 452], ["inhibit", 455], ["GvHD", 463], [",", 467], ["which", 469], ["involves", 475], ["activation", 484], ["of", 495], ["different", 498], ["immune", 508], ["cell", 515], ["populations", 520], [".", 531], ["In", 533], ["vivo", 536], ["expansion", 541], ["of", 551], ["luciferase(+", 554], [")", 566], ["donor", 568], ["Tcs", 574], ["in", 578], ["mice", 581], ["developing", 586], ["GvHD", 597], ["was", 602], ["reduced", 606], ["by", 614], ["treatment", 617], ["with", 627], ["the", 632], ["Syk", 636], ["inhibitor", 640], ["Fostamatinib", 650], [",", 662], ["which", 664], ["led", 670], ["to", 674], ["increased", 677], ["survival", 687], ["and", 696], ["reduced", 700], ["histologically", 708], ["confirmed", 723], ["GvHD", 733], ["severity", 738], [".", 746], ["Importantly", 748], [",", 759], ["in", 761], ["vivo", 764], ["and", 769], ["in", 773], ["vitro", 776], ["cytotoxicity", 782], ["against", 795], ["leukemia", 803], ["target", 812], ["cells", 819], ["and", 825], ["anti", 829], ["-", 833], ["murine", 834], ["cytomegalovirus", 841], ["immune", 857], ["responses", 864], ["were", 874], ["not", 879], ["impacted", 883], ["by", 892], ["Fostamatinib", 895], [".", 907], ["In", 909], ["APCs", 912], ["Syk", 917], ["inhibition", 921], ["reduced", 932], ["the", 940], ["expression", 944], ["of", 955], ["costimulatory", 958], ["molecules", 972], ["and", 982], ["disrupted", 986], ["cytoskeletal", 996], ["organization", 1009], ["with", 1022], ["consecutive", 1027], ["APC", 1039], ["migratory", 1043], ["defects", 1053], ["in", 1061], ["vitro", 1064], ["and", 1070], ["in", 1074], ["vivo", 1077], ["while", 1082], ["phagocytic", 1088], ["activity", 1099], ["remained", 1108], ["intact", 1117], [".", 1123], ["On", 1125], ["the", 1128], ["basis", 1132], ["of", 1138], ["these", 1141], ["immunomodulatory", 1147], ["effects", 1164], ["on", 1172], ["different", 1175], ["cell", 1185], ["populations", 1190], [",", 1201], ["we", 1203], ["conclude", 1206], ["that", 1215], ["Syk", 1220], ["targeting", 1224], ["in", 1234], ["alloantigen", 1237], ["-", 1248], ["activated", 1249], ["Tcs", 1259], ["and", 1263], ["APCs", 1267], ["with", 1272], ["pharmacologic", 1277], ["inhibitors", 1291], [",", 1301], ["already", 1303], ["applied", 1311], ["successfully", 1319], ["in", 1332], ["anti", 1335], ["-", 1339], ["lymphoma", 1340], ["therapy", 1349], [",", 1356], ["has", 1358], ["clinical", 1362], ["potential", 1371], ["to", 1381], ["reduce", 1384], ["GvHD", 1391], [",", 1395], ["especially", 1397], ["as", 1408], ["anti", 1411], ["-", 1415], ["leukemia", 1416], ["and", 1425], ["anti", 1429], ["-", 1433], ["viral", 1434], ["immunity", 1440], ["were", 1449], ["preserved", 1454], [".", 1463]]}
{"context": "In cells of the immune system that are stimulated by antigen or antigen-antibody complexes, Ca(2+) entry from the extracellular medium is driven by depletion of endoplasmic reticulum Ca(2+) stores and occurs through specialized store-operated Ca(2+) channels known as Ca(2+)-release-activated Ca(2+) (CRAC) channels. The process of store-operated Ca(2+) influx is essential for short-term as well as long-term responses by immune-system cells. Short-term responses include mast cell degranulation and killing of target cells by effector cytolytic T cells, whereas long-term responses typically involve changes in gene transcription and include T and B cell proliferation and differentiation. Transcription downstream of Ca(2+) influx is in large part funneled through the transcription factor nuclear factor of activated T cells (NFAT), a heavily phosphorylated protein that is cytoplasmic in resting cells, but that enters the nucleus when dephosphorylated by the calmodulin-dependent serine/threonine phosphatase calcineurin. The importance of the Ca(2+)/calcineurin/NFAT signalling pathway for lymphocyte activation is underscored by the finding that the underlying defect in a family with a hereditary severe combined immune deficiency (SCID) syndrome is a defect in CRAC channel function, store-operated Ca(2+) entry, NFAT activation and transcription of cytokines, chemokines and many other NFAT target genes whose transcription is essential for productive immune defence. We recently used a two-pronged genetic approach to identify Orai1 as the pore subunit of the CRAC channel. On the one hand, we initiated a positional cloning approach in which we utilised genome-wide single nucleotide polymorphism (SNP) mapping to identify the genomic region linked to the mutant gene in the SCID family described above. In parallel, we used a genome-wide RNAi screen in Drosophila to identify critical regulators of NFAT nuclear translocation and store-operated Ca(2+) entry. These approaches, together with subsequent mutational and electrophysiological analyses, converged to identify human Orai1 as a pore subunit of the CRAC channel and as the gene product mutated in the SCID patients.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "e1cc331e63084604b15264d8724c20de", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[182, 182]], "char_spans": [[1015, 1025]]}]}], "context_tokens": [["In", 0], ["cells", 3], ["of", 9], ["the", 12], ["immune", 16], ["system", 23], ["that", 30], ["are", 35], ["stimulated", 39], ["by", 50], ["antigen", 53], ["or", 61], ["antigen", 64], ["-", 71], ["antibody", 72], ["complexes", 81], [",", 90], ["Ca(2", 92], ["+", 96], [")", 97], ["entry", 99], ["from", 105], ["the", 110], ["extracellular", 114], ["medium", 128], ["is", 135], ["driven", 138], ["by", 145], ["depletion", 148], ["of", 158], ["endoplasmic", 161], ["reticulum", 173], ["Ca(2", 183], ["+", 187], [")", 188], ["stores", 190], ["and", 197], ["occurs", 201], ["through", 208], ["specialized", 216], ["store", 228], ["-", 233], ["operated", 234], ["Ca(2", 243], ["+", 247], [")", 248], ["channels", 250], ["known", 259], ["as", 265], ["Ca(2+)-release", 268], ["-", 282], ["activated", 283], ["Ca(2", 293], ["+", 297], [")", 298], ["(", 300], ["CRAC", 301], [")", 305], ["channels", 307], [".", 315], ["The", 317], ["process", 321], ["of", 329], ["store", 332], ["-", 337], ["operated", 338], ["Ca(2", 347], ["+", 351], [")", 352], ["influx", 354], ["is", 361], ["essential", 364], ["for", 374], ["short", 378], ["-", 383], ["term", 384], ["as", 389], ["well", 392], ["as", 397], ["long", 400], ["-", 404], ["term", 405], ["responses", 410], ["by", 420], ["immune", 423], ["-", 429], ["system", 430], ["cells", 437], [".", 442], ["Short", 444], ["-", 449], ["term", 450], ["responses", 455], ["include", 465], ["mast", 473], ["cell", 478], ["degranulation", 483], ["and", 497], ["killing", 501], ["of", 509], ["target", 512], ["cells", 519], ["by", 525], ["effector", 528], ["cytolytic", 537], ["T", 547], ["cells", 549], [",", 554], ["whereas", 556], ["long", 564], ["-", 568], ["term", 569], ["responses", 574], ["typically", 584], ["involve", 594], ["changes", 602], ["in", 610], ["gene", 613], ["transcription", 618], ["and", 632], ["include", 636], ["T", 644], ["and", 646], ["B", 650], ["cell", 652], ["proliferation", 657], ["and", 671], ["differentiation", 675], [".", 690], ["Transcription", 692], ["downstream", 706], ["of", 717], ["Ca(2", 720], ["+", 724], [")", 725], ["influx", 727], ["is", 734], ["in", 737], ["large", 740], ["part", 746], ["funneled", 751], ["through", 760], ["the", 768], ["transcription", 772], ["factor", 786], ["nuclear", 793], ["factor", 801], ["of", 808], ["activated", 811], ["T", 821], ["cells", 823], ["(", 829], ["NFAT", 830], [")", 834], [",", 835], ["a", 837], ["heavily", 839], ["phosphorylated", 847], ["protein", 862], ["that", 870], ["is", 875], ["cytoplasmic", 878], ["in", 890], ["resting", 893], ["cells", 901], [",", 906], ["but", 908], ["that", 912], ["enters", 917], ["the", 924], ["nucleus", 928], ["when", 936], ["dephosphorylated", 941], ["by", 958], ["the", 961], ["calmodulin", 965], ["-", 975], ["dependent", 976], ["serine", 986], ["/", 992], ["threonine", 993], ["phosphatase", 1003], ["calcineurin", 1015], [".", 1026], ["The", 1028], ["importance", 1032], ["of", 1043], ["the", 1046], ["Ca(2+)/calcineurin", 1050], ["/", 1068], ["NFAT", 1069], ["signalling", 1074], ["pathway", 1085], ["for", 1093], ["lymphocyte", 1097], ["activation", 1108], ["is", 1119], ["underscored", 1122], ["by", 1134], ["the", 1137], ["finding", 1141], ["that", 1149], ["the", 1154], ["underlying", 1158], ["defect", 1169], ["in", 1176], ["a", 1179], ["family", 1181], ["with", 1188], ["a", 1193], ["hereditary", 1195], ["severe", 1206], ["combined", 1213], ["immune", 1222], ["deficiency", 1229], ["(", 1240], ["SCID", 1241], [")", 1245], ["syndrome", 1247], ["is", 1256], ["a", 1259], ["defect", 1261], ["in", 1268], ["CRAC", 1271], ["channel", 1276], ["function", 1284], [",", 1292], ["store", 1294], ["-", 1299], ["operated", 1300], ["Ca(2", 1309], ["+", 1313], [")", 1314], ["entry", 1316], [",", 1321], ["NFAT", 1323], ["activation", 1328], ["and", 1339], ["transcription", 1343], ["of", 1357], ["cytokines", 1360], [",", 1369], ["chemokines", 1371], ["and", 1382], ["many", 1386], ["other", 1391], ["NFAT", 1397], ["target", 1402], ["genes", 1409], ["whose", 1415], ["transcription", 1421], ["is", 1435], ["essential", 1438], ["for", 1448], ["productive", 1452], ["immune", 1463], ["defence", 1470], [".", 1477], ["We", 1479], ["recently", 1482], ["used", 1491], ["a", 1496], ["two", 1498], ["-", 1501], ["pronged", 1502], ["genetic", 1510], ["approach", 1518], ["to", 1527], ["identify", 1530], ["Orai1", 1539], ["as", 1545], ["the", 1548], ["pore", 1552], ["subunit", 1557], ["of", 1565], ["the", 1568], ["CRAC", 1572], ["channel", 1577], [".", 1584], ["On", 1586], ["the", 1589], ["one", 1593], ["hand", 1597], [",", 1601], ["we", 1603], ["initiated", 1606], ["a", 1616], ["positional", 1618], ["cloning", 1629], ["approach", 1637], ["in", 1646], ["which", 1649], ["we", 1655], ["utilised", 1658], ["genome", 1667], ["-", 1673], ["wide", 1674], ["single", 1679], ["nucleotide", 1686], ["polymorphism", 1697], ["(", 1710], ["SNP", 1711], [")", 1714], ["mapping", 1716], ["to", 1724], ["identify", 1727], ["the", 1736], ["genomic", 1740], ["region", 1748], ["linked", 1755], ["to", 1762], ["the", 1765], ["mutant", 1769], ["gene", 1776], ["in", 1781], ["the", 1784], ["SCID", 1788], ["family", 1793], ["described", 1800], ["above", 1810], [".", 1815], ["In", 1817], ["parallel", 1820], [",", 1828], ["we", 1830], ["used", 1833], ["a", 1838], ["genome", 1840], ["-", 1846], ["wide", 1847], ["RNAi", 1852], ["screen", 1857], ["in", 1864], ["Drosophila", 1867], ["to", 1878], ["identify", 1881], ["critical", 1890], ["regulators", 1899], ["of", 1910], ["NFAT", 1913], ["nuclear", 1918], ["translocation", 1926], ["and", 1940], ["store", 1944], ["-", 1949], ["operated", 1950], ["Ca(2", 1959], ["+", 1963], [")", 1964], ["entry", 1966], [".", 1971], ["These", 1973], ["approaches", 1979], [",", 1989], ["together", 1991], ["with", 2000], ["subsequent", 2005], ["mutational", 2016], ["and", 2027], ["electrophysiological", 2031], ["analyses", 2052], [",", 2060], ["converged", 2062], ["to", 2072], ["identify", 2075], ["human", 2084], ["Orai1", 2090], ["as", 2096], ["a", 2099], ["pore", 2101], ["subunit", 2106], ["of", 2114], ["the", 2117], ["CRAC", 2121], ["channel", 2126], ["and", 2134], ["as", 2138], ["the", 2141], ["gene", 2145], ["product", 2150], ["mutated", 2158], ["in", 2166], ["the", 2169], ["SCID", 2173], ["patients", 2178], [".", 2186]]}
{"context": "Opioid overdose has a high mortality, but is often reversible with appropriate overdose management and naloxone (opioid antagonist). Training in these skills has been successfully trialled internationally with opioid users themselves. Healthcare professionals working in substance misuse are in a prime position to deliver overdose prevention training to drug users and may themselves witness opioid overdoses. The best method of training dissemination has not been identified. The study assessed post-training change in clinician knowledge for managing an opioid overdose and administering naloxone, evaluated the 'cascade method' for disseminating training, and identified barriers to implementation. A repeated-measures design evaluated knowledge pre-and-post training. A sub-set of clinicians were interviewed to identify barriers to implementation. Clinicians from addiction services across England received training. Participants self-completed a structured questionnaire recording overdose knowledge, confidence and barriers to implementation. One hundred clinicians were trained initially, who trained a further 119 clinicians (n=219) and thereafter trained 239 drug users. The mean composite score for opioid overdose risk signs and actions to be taken was 18.3/26 (\u00b13.8) which increased to 21.2/26 (\u00b14.1) after training, demonstrating a significant improvement in knowledge (Z=9.2, p<0.001). The proportion of clinicians willing to use naloxone in an opioid overdose rose from 77% to 99% after training. Barriers to implementing training were clinician time and confidence, service resources, client willingness and naloxone formulation. Training clinicians how to manage an opioid overdose and administer naloxone was effective. However the 'cascade method' was only modestly successful for disseminating training to a large clinician workforce, with a range of clinician and service perceived obstacles. Drug policy changes and improvements to educational programmes for drug services would be important to ensure successful implementation of overdose training internationally.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "68e4445ef5d34c65bd2ec1725352e5b2", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[16, 16], [277, 277], [90, 90], [233, 233], [264, 264]], "char_spans": [[103, 110], [1716, 1723], [591, 598], [1446, 1453], [1626, 1633]]}]}], "context_tokens": [["Opioid", 0], ["overdose", 7], ["has", 16], ["a", 20], ["high", 22], ["mortality", 27], [",", 36], ["but", 38], ["is", 42], ["often", 45], ["reversible", 51], ["with", 62], ["appropriate", 67], ["overdose", 79], ["management", 88], ["and", 99], ["naloxone", 103], ["(", 112], ["opioid", 113], ["antagonist", 120], [")", 130], [".", 131], ["Training", 133], ["in", 142], ["these", 145], ["skills", 151], ["has", 158], ["been", 162], ["successfully", 167], ["trialled", 180], ["internationally", 189], ["with", 205], ["opioid", 210], ["users", 217], ["themselves", 223], [".", 233], ["Healthcare", 235], ["professionals", 246], ["working", 260], ["in", 268], ["substance", 271], ["misuse", 281], ["are", 288], ["in", 292], ["a", 295], ["prime", 297], ["position", 303], ["to", 312], ["deliver", 315], ["overdose", 323], ["prevention", 332], ["training", 343], ["to", 352], ["drug", 355], ["users", 360], ["and", 366], ["may", 370], ["themselves", 374], ["witness", 385], ["opioid", 393], ["overdoses", 400], [".", 409], ["The", 411], ["best", 415], ["method", 420], ["of", 427], ["training", 430], ["dissemination", 439], ["has", 453], ["not", 457], ["been", 461], ["identified", 466], [".", 476], ["The", 478], ["study", 482], ["assessed", 488], ["post", 497], ["-", 501], ["training", 502], ["change", 511], ["in", 518], ["clinician", 521], ["knowledge", 531], ["for", 541], ["managing", 545], ["an", 554], ["opioid", 557], ["overdose", 564], ["and", 573], ["administering", 577], ["naloxone", 591], [",", 599], ["evaluated", 601], ["the", 611], ["'", 615], ["cascade", 616], ["method", 624], ["'", 630], ["for", 632], ["disseminating", 636], ["training", 650], [",", 658], ["and", 660], ["identified", 664], ["barriers", 675], ["to", 684], ["implementation", 687], [".", 701], ["A", 703], ["repeated", 705], ["-", 713], ["measures", 714], ["design", 723], ["evaluated", 730], ["knowledge", 740], ["pre", 750], ["-", 753], ["and", 754], ["-", 757], ["post", 758], ["training", 763], [".", 771], ["A", 773], ["sub", 775], ["-", 778], ["set", 779], ["of", 783], ["clinicians", 786], ["were", 797], ["interviewed", 802], ["to", 814], ["identify", 817], ["barriers", 826], ["to", 835], ["implementation", 838], [".", 852], ["Clinicians", 854], ["from", 865], ["addiction", 870], ["services", 880], ["across", 889], ["England", 896], ["received", 904], ["training", 913], [".", 921], ["Participants", 923], ["self", 936], ["-", 940], ["completed", 941], ["a", 951], ["structured", 953], ["questionnaire", 964], ["recording", 978], ["overdose", 988], ["knowledge", 997], [",", 1006], ["confidence", 1008], ["and", 1019], ["barriers", 1023], ["to", 1032], ["implementation", 1035], [".", 1049], ["One", 1051], ["hundred", 1055], ["clinicians", 1063], ["were", 1074], ["trained", 1079], ["initially", 1087], [",", 1096], ["who", 1098], ["trained", 1102], ["a", 1110], ["further", 1112], ["119", 1120], ["clinicians", 1124], ["(", 1135], ["n=219", 1136], [")", 1141], ["and", 1143], ["thereafter", 1147], ["trained", 1158], ["239", 1166], ["drug", 1170], ["users", 1175], [".", 1180], ["The", 1182], ["mean", 1186], ["composite", 1191], ["score", 1201], ["for", 1207], ["opioid", 1211], ["overdose", 1218], ["risk", 1227], ["signs", 1232], ["and", 1238], ["actions", 1242], ["to", 1250], ["be", 1253], ["taken", 1256], ["was", 1262], ["18.3/26", 1266], ["(", 1274], ["\u00b13.8", 1275], [")", 1279], ["which", 1281], ["increased", 1287], ["to", 1297], ["21.2/26", 1300], ["(", 1308], ["\u00b14.1", 1309], [")", 1313], ["after", 1315], ["training", 1321], [",", 1329], ["demonstrating", 1331], ["a", 1345], ["significant", 1347], ["improvement", 1359], ["in", 1371], ["knowledge", 1374], ["(", 1384], ["Z=9.2", 1385], [",", 1390], ["p<0.001", 1392], [")", 1399], [".", 1400], ["The", 1402], ["proportion", 1406], ["of", 1417], ["clinicians", 1420], ["willing", 1431], ["to", 1439], ["use", 1442], ["naloxone", 1446], ["in", 1455], ["an", 1458], ["opioid", 1461], ["overdose", 1468], ["rose", 1477], ["from", 1482], ["77", 1487], ["%", 1489], ["to", 1491], ["99", 1494], ["%", 1496], ["after", 1498], ["training", 1504], [".", 1512], ["Barriers", 1514], ["to", 1523], ["implementing", 1526], ["training", 1539], ["were", 1548], ["clinician", 1553], ["time", 1563], ["and", 1568], ["confidence", 1572], [",", 1582], ["service", 1584], ["resources", 1592], [",", 1601], ["client", 1603], ["willingness", 1610], ["and", 1622], ["naloxone", 1626], ["formulation", 1635], [".", 1646], ["Training", 1648], ["clinicians", 1657], ["how", 1668], ["to", 1672], ["manage", 1675], ["an", 1682], ["opioid", 1685], ["overdose", 1692], ["and", 1701], ["administer", 1705], ["naloxone", 1716], ["was", 1725], ["effective", 1729], [".", 1738], ["However", 1740], ["the", 1748], ["'", 1752], ["cascade", 1753], ["method", 1761], ["'", 1767], ["was", 1769], ["only", 1773], ["modestly", 1778], ["successful", 1787], ["for", 1798], ["disseminating", 1802], ["training", 1816], ["to", 1825], ["a", 1828], ["large", 1830], ["clinician", 1836], ["workforce", 1846], [",", 1855], ["with", 1857], ["a", 1862], ["range", 1864], ["of", 1870], ["clinician", 1873], ["and", 1883], ["service", 1887], ["perceived", 1895], ["obstacles", 1905], [".", 1914], ["Drug", 1916], ["policy", 1921], ["changes", 1928], ["and", 1936], ["improvements", 1940], ["to", 1953], ["educational", 1956], ["programmes", 1968], ["for", 1979], ["drug", 1983], ["services", 1988], ["would", 1997], ["be", 2003], ["important", 2006], ["to", 2016], ["ensure", 2019], ["successful", 2026], ["implementation", 2037], ["of", 2052], ["overdose", 2055], ["training", 2064], ["internationally", 2073], [".", 2088]]}
{"context": "Methylation of certain lysine residues in the N-terminal tails of core histone proteins in nucleosome is of fundamental importance in the regulation of chromatin structure and gene expression. Such histone modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain in almost all of the cases and may transfer one to three methyl groups from S-adenosyl-L-methionine (AdoMet) to the epsilon-amino group of the target lysine residue. Here, quantum mechanical/molecular mechanical molecular dynamics and free-energy simulations are performed on human PKMT SET7/9 and its mutants to understand two outstanding questions for the reaction catalyzed by PKMTs: the mechanism for deprotonation of positively charged methyl lysine (lysine) and origin of product specificity. The results of the simulations suggest that Tyr-335 (an absolute conserved residue in PKMTs) may play the role as the general base for the deprotonation after dissociation of AdoHcy (S-adenosyl-L-homocysteine) and before binding of AdoMet. It is shown that conformational changes could bring Y335 to the target methyl lysine (lysine) for proton abstraction. This mechanism provides an explanation why methyl transfers could be catalyzed by PKMTs processively. The free-energy profiles for methyl transfers are reported and analyzed for wild type and certain mutants (Y305F and Y335F) and the active-site interactions that are of importance for the enzyme's function are discussed. The results of the simulations provide important insights into the catalytic process and lead to a better understanding of experimental observations concerning the origin of product specificity for PKMTs.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f5801149c94f4f65b82ee302b13c0d29", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[48, 49]], "char_spans": [[304, 313]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["certain", 15], ["lysine", 23], ["residues", 30], ["in", 39], ["the", 42], ["N", 46], ["-", 47], ["terminal", 48], ["tails", 57], ["of", 63], ["core", 66], ["histone", 71], ["proteins", 79], ["in", 88], ["nucleosome", 91], ["is", 102], ["of", 105], ["fundamental", 108], ["importance", 120], ["in", 131], ["the", 134], ["regulation", 138], ["of", 149], ["chromatin", 152], ["structure", 162], ["and", 172], ["gene", 176], ["expression", 181], [".", 191], ["Such", 193], ["histone", 198], ["modification", 206], ["is", 219], ["catalyzed", 222], ["by", 232], ["protein", 235], ["lysine", 243], ["methyltransferases", 250], ["(", 269], ["PKMTs", 270], [")", 275], [".", 276], ["PKMTs", 278], ["contain", 284], ["a", 292], ["conserved", 294], ["SET", 304], ["domain", 308], ["in", 315], ["almost", 318], ["all", 325], ["of", 329], ["the", 332], ["cases", 336], ["and", 342], ["may", 346], ["transfer", 350], ["one", 359], ["to", 363], ["three", 366], ["methyl", 372], ["groups", 379], ["from", 386], ["S", 391], ["-", 392], ["adenosyl", 393], ["-", 401], ["L", 402], ["-", 403], ["methionine", 404], ["(", 415], ["AdoMet", 416], [")", 422], ["to", 424], ["the", 427], ["epsilon", 431], ["-", 438], ["amino", 439], ["group", 445], ["of", 451], ["the", 454], ["target", 458], ["lysine", 465], ["residue", 472], [".", 479], ["Here", 481], [",", 485], ["quantum", 487], ["mechanical", 495], ["/", 505], ["molecular", 506], ["mechanical", 516], ["molecular", 527], ["dynamics", 537], ["and", 546], ["free", 550], ["-", 554], ["energy", 555], ["simulations", 562], ["are", 574], ["performed", 578], ["on", 588], ["human", 591], ["PKMT", 597], ["SET7/9", 602], ["and", 609], ["its", 613], ["mutants", 617], ["to", 625], ["understand", 628], ["two", 639], ["outstanding", 643], ["questions", 655], ["for", 665], ["the", 669], ["reaction", 673], ["catalyzed", 682], ["by", 692], ["PKMTs", 695], [":", 700], ["the", 702], ["mechanism", 706], ["for", 716], ["deprotonation", 720], ["of", 734], ["positively", 737], ["charged", 748], ["methyl", 756], ["lysine", 763], ["(", 770], ["lysine", 771], [")", 777], ["and", 779], ["origin", 783], ["of", 790], ["product", 793], ["specificity", 801], [".", 812], ["The", 814], ["results", 818], ["of", 826], ["the", 829], ["simulations", 833], ["suggest", 845], ["that", 853], ["Tyr-335", 858], ["(", 866], ["an", 867], ["absolute", 870], ["conserved", 879], ["residue", 889], ["in", 897], ["PKMTs", 900], [")", 905], ["may", 907], ["play", 911], ["the", 916], ["role", 920], ["as", 925], ["the", 928], ["general", 932], ["base", 940], ["for", 945], ["the", 949], ["deprotonation", 953], ["after", 967], ["dissociation", 973], ["of", 986], ["AdoHcy", 989], ["(", 996], ["S", 997], ["-", 998], ["adenosyl", 999], ["-", 1007], ["L", 1008], ["-", 1009], ["homocysteine", 1010], [")", 1022], ["and", 1024], ["before", 1028], ["binding", 1035], ["of", 1043], ["AdoMet", 1046], [".", 1052], ["It", 1054], ["is", 1057], ["shown", 1060], ["that", 1066], ["conformational", 1071], ["changes", 1086], ["could", 1094], ["bring", 1100], ["Y335", 1106], ["to", 1111], ["the", 1114], ["target", 1118], ["methyl", 1125], ["lysine", 1132], ["(", 1139], ["lysine", 1140], [")", 1146], ["for", 1148], ["proton", 1152], ["abstraction", 1159], [".", 1170], ["This", 1172], ["mechanism", 1177], ["provides", 1187], ["an", 1196], ["explanation", 1199], ["why", 1211], ["methyl", 1215], ["transfers", 1222], ["could", 1232], ["be", 1238], ["catalyzed", 1241], ["by", 1251], ["PKMTs", 1254], ["processively", 1260], [".", 1272], ["The", 1274], ["free", 1278], ["-", 1282], ["energy", 1283], ["profiles", 1290], ["for", 1299], ["methyl", 1303], ["transfers", 1310], ["are", 1320], ["reported", 1324], ["and", 1333], ["analyzed", 1337], ["for", 1346], ["wild", 1350], ["type", 1355], ["and", 1360], ["certain", 1364], ["mutants", 1372], ["(", 1380], ["Y305F", 1381], ["and", 1387], ["Y335F", 1391], [")", 1396], ["and", 1398], ["the", 1402], ["active", 1406], ["-", 1412], ["site", 1413], ["interactions", 1418], ["that", 1431], ["are", 1436], ["of", 1440], ["importance", 1443], ["for", 1454], ["the", 1458], ["enzyme", 1462], ["'s", 1468], ["function", 1471], ["are", 1480], ["discussed", 1484], [".", 1493], ["The", 1495], ["results", 1499], ["of", 1507], ["the", 1510], ["simulations", 1514], ["provide", 1526], ["important", 1534], ["insights", 1544], ["into", 1553], ["the", 1558], ["catalytic", 1562], ["process", 1572], ["and", 1580], ["lead", 1584], ["to", 1589], ["a", 1592], ["better", 1594], ["understanding", 1601], ["of", 1615], ["experimental", 1618], ["observations", 1631], ["concerning", 1644], ["the", 1655], ["origin", 1659], ["of", 1666], ["product", 1669], ["specificity", 1677], ["for", 1689], ["PKMTs", 1693], [".", 1698]]}
{"context": "Ehlers-Danlos syndromes (EDS) and Marfan syndrome (MFS) are multisystemic disorders that primarily affect the soft connective tissues. Both disorders have benefited from recent advances in clinical and molecular characterization, allowing improvements in clinical diagnosis and management. EDS are a heterogeneous group of conditions characterized by skin hyperextensibility, atrophic scarring, joint hypermobility and generalized tissue fragility. The current classification proposes six subtypes based on clinical, biochemical and molecular characteristics. However, examples of unclassified variants and 'overlap phenotypes' are becoming more common. Mutations in genes encoding fibrillar collagens or collagen-modifying enzymes have been identified in most forms of EDS, including the classic and vascular subtypes (collagen type V and III, respectively), and the rare arthrochalasis, kyphoscoliosis and dermatosparaxis variants (type I collagen defects). To date, the genetic background of the hypermobility type of EDS remains unclear, although some new insights have been gained recently. MFS is an autosomal-dominant disorder that affects the cardiovascular, ocular and skeletal system with aortic root dilation/dissection, ectopia lentis and bone overgrowth, respectively. Advances in therapeutic, mainly surgical, techniques have improved median survival significantly, yet severe morbidity and a substantial risk for premature mortality remain associated. The disorder is caused by mutations in the FBN1 gene, encoding the microfibrillar protein fibrillin-1. Recently, new insights in the pathogenesis changed the prevailing concept of this type 1 fibrillinopathy as a structural disorder of the connective tissue into a developmental abnormality manifesting perturbed cytokine signalling. These findings have opened new and unexpected targets for aetiologically directed drug treatments.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "efb13b867d664aa1b52ab77cba850165", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[271, 272]], "char_spans": [[1707, 1723]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["and", 30], ["Marfan", 34], ["syndrome", 41], ["(", 50], ["MFS", 51], [")", 54], ["are", 56], ["multisystemic", 60], ["disorders", 74], ["that", 84], ["primarily", 89], ["affect", 99], ["the", 106], ["soft", 110], ["connective", 115], ["tissues", 126], [".", 133], ["Both", 135], ["disorders", 140], ["have", 150], ["benefited", 155], ["from", 165], ["recent", 170], ["advances", 177], ["in", 186], ["clinical", 189], ["and", 198], ["molecular", 202], ["characterization", 212], [",", 228], ["allowing", 230], ["improvements", 239], ["in", 252], ["clinical", 255], ["diagnosis", 264], ["and", 274], ["management", 278], [".", 288], ["EDS", 290], ["are", 294], ["a", 298], ["heterogeneous", 300], ["group", 314], ["of", 320], ["conditions", 323], ["characterized", 334], ["by", 348], ["skin", 351], ["hyperextensibility", 356], [",", 374], ["atrophic", 376], ["scarring", 385], [",", 393], ["joint", 395], ["hypermobility", 401], ["and", 415], ["generalized", 419], ["tissue", 431], ["fragility", 438], [".", 447], ["The", 449], ["current", 453], ["classification", 461], ["proposes", 476], ["six", 485], ["subtypes", 489], ["based", 498], ["on", 504], ["clinical", 507], [",", 515], ["biochemical", 517], ["and", 529], ["molecular", 533], ["characteristics", 543], [".", 558], ["However", 560], [",", 567], ["examples", 569], ["of", 578], ["unclassified", 581], ["variants", 594], ["and", 603], ["'", 607], ["overlap", 608], ["phenotypes", 616], ["'", 626], ["are", 628], ["becoming", 632], ["more", 641], ["common", 646], [".", 652], ["Mutations", 654], ["in", 664], ["genes", 667], ["encoding", 673], ["fibrillar", 682], ["collagens", 692], ["or", 702], ["collagen", 705], ["-", 713], ["modifying", 714], ["enzymes", 724], ["have", 732], ["been", 737], ["identified", 742], ["in", 753], ["most", 756], ["forms", 761], ["of", 767], ["EDS", 770], [",", 773], ["including", 775], ["the", 785], ["classic", 789], ["and", 797], ["vascular", 801], ["subtypes", 810], ["(", 819], ["collagen", 820], ["type", 829], ["V", 834], ["and", 836], ["III", 840], [",", 843], ["respectively", 845], [")", 857], [",", 858], ["and", 860], ["the", 864], ["rare", 868], ["arthrochalasis", 873], [",", 887], ["kyphoscoliosis", 889], ["and", 904], ["dermatosparaxis", 908], ["variants", 924], ["(", 933], ["type", 934], ["I", 939], ["collagen", 941], ["defects", 950], [")", 957], [".", 958], ["To", 960], ["date", 963], [",", 967], ["the", 969], ["genetic", 973], ["background", 981], ["of", 992], ["the", 995], ["hypermobility", 999], ["type", 1013], ["of", 1018], ["EDS", 1021], ["remains", 1025], ["unclear", 1033], [",", 1040], ["although", 1042], ["some", 1051], ["new", 1056], ["insights", 1060], ["have", 1069], ["been", 1074], ["gained", 1079], ["recently", 1086], [".", 1094], ["MFS", 1096], ["is", 1100], ["an", 1103], ["autosomal", 1106], ["-", 1115], ["dominant", 1116], ["disorder", 1125], ["that", 1134], ["affects", 1139], ["the", 1147], ["cardiovascular", 1151], [",", 1165], ["ocular", 1167], ["and", 1174], ["skeletal", 1178], ["system", 1187], ["with", 1194], ["aortic", 1199], ["root", 1206], ["dilation", 1211], ["/", 1219], ["dissection", 1220], [",", 1230], ["ectopia", 1232], ["lentis", 1240], ["and", 1247], ["bone", 1251], ["overgrowth", 1256], [",", 1266], ["respectively", 1268], [".", 1280], ["Advances", 1282], ["in", 1291], ["therapeutic", 1294], [",", 1305], ["mainly", 1307], ["surgical", 1314], [",", 1322], ["techniques", 1324], ["have", 1335], ["improved", 1340], ["median", 1349], ["survival", 1356], ["significantly", 1365], [",", 1378], ["yet", 1380], ["severe", 1384], ["morbidity", 1391], ["and", 1401], ["a", 1405], ["substantial", 1407], ["risk", 1419], ["for", 1424], ["premature", 1428], ["mortality", 1438], ["remain", 1448], ["associated", 1455], [".", 1465], ["The", 1467], ["disorder", 1471], ["is", 1480], ["caused", 1483], ["by", 1490], ["mutations", 1493], ["in", 1503], ["the", 1506], ["FBN1", 1510], ["gene", 1515], [",", 1519], ["encoding", 1521], ["the", 1530], ["microfibrillar", 1534], ["protein", 1549], ["fibrillin-1", 1557], [".", 1568], ["Recently", 1570], [",", 1578], ["new", 1580], ["insights", 1584], ["in", 1593], ["the", 1596], ["pathogenesis", 1600], ["changed", 1613], ["the", 1621], ["prevailing", 1625], ["concept", 1636], ["of", 1644], ["this", 1647], ["type", 1652], ["1", 1657], ["fibrillinopathy", 1659], ["as", 1675], ["a", 1678], ["structural", 1680], ["disorder", 1691], ["of", 1700], ["the", 1703], ["connective", 1707], ["tissue", 1718], ["into", 1725], ["a", 1730], ["developmental", 1732], ["abnormality", 1746], ["manifesting", 1758], ["perturbed", 1770], ["cytokine", 1780], ["signalling", 1789], [".", 1799], ["These", 1801], ["findings", 1807], ["have", 1816], ["opened", 1821], ["new", 1828], ["and", 1832], ["unexpected", 1836], ["targets", 1847], ["for", 1855], ["aetiologically", 1859], ["directed", 1874], ["drug", 1883], ["treatments", 1888], [".", 1898]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease. The aim of this study was evaluation and analysis of cytogenetic response in different intervals and risk groups as well as finding association between pre-treatment characteristics and later probability of achievement of major cytogenetic response. We analyzed a total of 22 adult patients with newly diagnosed Philadelphia positive early chronic phase chronic myeloid leukemia treated at our institution from June 2006 to December 2009. The median follow-up time for patients during treatment with imatinib was 25.7 months (range, 12-42 months). A complete hematologic response was achieved in all of the analyzed patients within 6 months from the start of the treatment. The major cytogenetic response rate was 81.8%, and the complete cytogenetic response rate was 72.7%. The patients with low or moderate relative risk had the rate of complementary achieving major and complete cytogenetic response of 75-90%. A multivariate analysis identified the following independent prognostic factors for achieving major cytogenetic response: the absence of splenomegaly, white blood cell count less than 10 x 10(9)/L, the platelet count less than 450 x 10(9)/L, the presence of less than 5% of bone marrow blasts and basophils, the absence of blasts in peripheral blood, the presence of less than 7% of basophils in peripheral blood. Patients who early achieve complete and major cytogenetic response as well as those with low and moderate relative risk have a higher rate of achieving and maintaining complete cytogenetic response. There are also characteristics of patients before treatment that may indicate the treatment outcome.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f1bd012a42904b12a152b624439f2533", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7], [17, 19]], "char_spans": [[31, 37], [102, 108]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["revolutionized", 70], ["the", 85], ["treatment", 89], ["of", 99], ["Bcr", 102], ["-", 105], ["Abl", 106], ["positive", 110], ["chronic", 119], ["myeloid", 127], ["leukemia", 135], ["and", 144], ["become", 148], ["the", 155], ["standard", 159], ["of", 168], ["care", 171], ["for", 176], ["this", 180], ["disease", 185], [".", 192], ["The", 194], ["aim", 198], ["of", 202], ["this", 205], ["study", 210], ["was", 216], ["evaluation", 220], ["and", 231], ["analysis", 235], ["of", 244], ["cytogenetic", 247], ["response", 259], ["in", 268], ["different", 271], ["intervals", 281], ["and", 291], ["risk", 295], ["groups", 300], ["as", 307], ["well", 310], ["as", 315], ["finding", 318], ["association", 326], ["between", 338], ["pre", 346], ["-", 349], ["treatment", 350], ["characteristics", 360], ["and", 376], ["later", 380], ["probability", 386], ["of", 398], ["achievement", 401], ["of", 413], ["major", 416], ["cytogenetic", 422], ["response", 434], [".", 442], ["We", 444], ["analyzed", 447], ["a", 456], ["total", 458], ["of", 464], ["22", 467], ["adult", 470], ["patients", 476], ["with", 485], ["newly", 490], ["diagnosed", 496], ["Philadelphia", 506], ["positive", 519], ["early", 528], ["chronic", 534], ["phase", 542], ["chronic", 548], ["myeloid", 556], ["leukemia", 564], ["treated", 573], ["at", 581], ["our", 584], ["institution", 588], ["from", 600], ["June", 605], ["2006", 610], ["to", 615], ["December", 618], ["2009", 627], [".", 631], ["The", 633], ["median", 637], ["follow", 644], ["-", 650], ["up", 651], ["time", 654], ["for", 659], ["patients", 663], ["during", 672], ["treatment", 679], ["with", 689], ["imatinib", 694], ["was", 703], ["25.7", 707], ["months", 712], ["(", 719], ["range", 720], [",", 725], ["12", 727], ["-", 729], ["42", 730], ["months", 733], [")", 739], [".", 740], ["A", 742], ["complete", 744], ["hematologic", 753], ["response", 765], ["was", 774], ["achieved", 778], ["in", 787], ["all", 790], ["of", 794], ["the", 797], ["analyzed", 801], ["patients", 810], ["within", 819], ["6", 826], ["months", 828], ["from", 835], ["the", 840], ["start", 844], ["of", 850], ["the", 853], ["treatment", 857], [".", 866], ["The", 868], ["major", 872], ["cytogenetic", 878], ["response", 890], ["rate", 899], ["was", 904], ["81.8", 908], ["%", 912], [",", 913], ["and", 915], ["the", 919], ["complete", 923], ["cytogenetic", 932], ["response", 944], ["rate", 953], ["was", 958], ["72.7", 962], ["%", 966], [".", 967], ["The", 969], ["patients", 973], ["with", 982], ["low", 987], ["or", 991], ["moderate", 994], ["relative", 1003], ["risk", 1012], ["had", 1017], ["the", 1021], ["rate", 1025], ["of", 1030], ["complementary", 1033], ["achieving", 1047], ["major", 1057], ["and", 1063], ["complete", 1067], ["cytogenetic", 1076], ["response", 1088], ["of", 1097], ["75", 1100], ["-", 1102], ["90", 1103], ["%", 1105], [".", 1106], ["A", 1108], ["multivariate", 1110], ["analysis", 1123], ["identified", 1132], ["the", 1143], ["following", 1147], ["independent", 1157], ["prognostic", 1169], ["factors", 1180], ["for", 1188], ["achieving", 1192], ["major", 1202], ["cytogenetic", 1208], ["response", 1220], [":", 1228], ["the", 1230], ["absence", 1234], ["of", 1242], ["splenomegaly", 1245], [",", 1257], ["white", 1259], ["blood", 1265], ["cell", 1271], ["count", 1276], ["less", 1282], ["than", 1287], ["10", 1292], ["x", 1295], ["10(9)/L", 1297], [",", 1304], ["the", 1306], ["platelet", 1310], ["count", 1319], ["less", 1325], ["than", 1330], ["450", 1335], ["x", 1339], ["10(9)/L", 1341], [",", 1348], ["the", 1350], ["presence", 1354], ["of", 1363], ["less", 1366], ["than", 1371], ["5", 1376], ["%", 1377], ["of", 1379], ["bone", 1382], ["marrow", 1387], ["blasts", 1394], ["and", 1401], ["basophils", 1405], [",", 1414], ["the", 1416], ["absence", 1420], ["of", 1428], ["blasts", 1431], ["in", 1438], ["peripheral", 1441], ["blood", 1452], [",", 1457], ["the", 1459], ["presence", 1463], ["of", 1472], ["less", 1475], ["than", 1480], ["7", 1485], ["%", 1486], ["of", 1488], ["basophils", 1491], ["in", 1501], ["peripheral", 1504], ["blood", 1515], [".", 1520], ["Patients", 1522], ["who", 1531], ["early", 1535], ["achieve", 1541], ["complete", 1549], ["and", 1558], ["major", 1562], ["cytogenetic", 1568], ["response", 1580], ["as", 1589], ["well", 1592], ["as", 1597], ["those", 1600], ["with", 1606], ["low", 1611], ["and", 1615], ["moderate", 1619], ["relative", 1628], ["risk", 1637], ["have", 1642], ["a", 1647], ["higher", 1649], ["rate", 1656], ["of", 1661], ["achieving", 1664], ["and", 1674], ["maintaining", 1678], ["complete", 1690], ["cytogenetic", 1699], ["response", 1711], [".", 1719], ["There", 1721], ["are", 1727], ["also", 1731], ["characteristics", 1736], ["of", 1752], ["patients", 1755], ["before", 1764], ["treatment", 1771], ["that", 1781], ["may", 1786], ["indicate", 1790], ["the", 1799], ["treatment", 1803], ["outcome", 1813], [".", 1820]]}
{"context": "Cornelia de Lange syndrome (CdLS), a disorder caused by mutations in cohesion proteins, is characterized by multisystem developmental abnormalities. PDS5, a cohesion protein, is important for proper chromosome segregation in lower organisms and has two homologues in vertebrates (PDS5A and PDS5B). Pds5B mutant mice have developmental abnormalities resembling CdLS; however the role of Pds5A in mammals and the association of PDS5 proteins with CdLS are unknown. To delineate genetic interactions between Pds5A and Pds5B and explore mechanisms underlying phenotypic variability, we generated Pds5A-deficient mice. Curiously, these mice exhibit multiple abnormalities that were previously observed in Pds5B-deficient mice, including cleft palate, skeletal patterning defects, growth retardation, congenital heart defects and delayed migration of enteric neuron precursors. They also frequently display renal agenesis, an abnormality not observed in Pds5B(-/-) mice. While Pds5A(-/-) and Pds5B(-/-) mice die at birth, embryos harboring 3 mutant Pds5 alleles die between E11.5 and E12.5 most likely of heart failure, indicating that total Pds5 gene dosage is critical for normal development. In addition, characterization of these compound homozygous-heterozygous mice revealed a severe abnormality in lens formation that does not occur in either Pds5A(-/-) or Pds5B(-/-) mice. We further identified a functional missense mutation (R1292Q) in the PDS5B DNA-binding domain in a familial case of CdLS, in which affected individuals also develop megacolon. This study shows that PDS5A and PDS5B functions other than those involving chromosomal dynamics are important for normal development, highlights the sensitivity of key developmental processes on PDS5 signaling, and provides mechanistic insights into how PDS5 mutations may lead to CdLS.", "qas": [{"question": "Which syndrome is caused by deletion of Pds5b in mice?", "answers": ["Cornelia de Lange syndrome."], "qid": "a8c3d79c69324f68819dac844e15f438", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["caused", 18], ["by", 25], ["deletion", 28], ["of", 37], ["Pds5b", 40], ["in", 46], ["mice", 49], ["?", 53]], "detected_answers": [{"text": "Cornelia de Lange syndrome.", "token_spans": [[0, 3]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Cornelia", 0], ["de", 9], ["Lange", 12], ["syndrome", 18], ["(", 27], ["CdLS", 28], [")", 32], [",", 33], ["a", 35], ["disorder", 37], ["caused", 46], ["by", 53], ["mutations", 56], ["in", 66], ["cohesion", 69], ["proteins", 78], [",", 86], ["is", 88], ["characterized", 91], ["by", 105], ["multisystem", 108], ["developmental", 120], ["abnormalities", 134], [".", 147], ["PDS5", 149], [",", 153], ["a", 155], ["cohesion", 157], ["protein", 166], [",", 173], ["is", 175], ["important", 178], ["for", 188], ["proper", 192], ["chromosome", 199], ["segregation", 210], ["in", 222], ["lower", 225], ["organisms", 231], ["and", 241], ["has", 245], ["two", 249], ["homologues", 253], ["in", 264], ["vertebrates", 267], ["(", 279], ["PDS5A", 280], ["and", 286], ["PDS5B", 290], [")", 295], [".", 296], ["Pds5B", 298], ["mutant", 304], ["mice", 311], ["have", 316], ["developmental", 321], ["abnormalities", 335], ["resembling", 349], ["CdLS", 360], [";", 364], ["however", 366], ["the", 374], ["role", 378], ["of", 383], ["Pds5A", 386], ["in", 392], ["mammals", 395], ["and", 403], ["the", 407], ["association", 411], ["of", 423], ["PDS5", 426], ["proteins", 431], ["with", 440], ["CdLS", 445], ["are", 450], ["unknown", 454], [".", 461], ["To", 463], ["delineate", 466], ["genetic", 476], ["interactions", 484], ["between", 497], ["Pds5A", 505], ["and", 511], ["Pds5B", 515], ["and", 521], ["explore", 525], ["mechanisms", 533], ["underlying", 544], ["phenotypic", 555], ["variability", 566], [",", 577], ["we", 579], ["generated", 582], ["Pds5A", 592], ["-", 597], ["deficient", 598], ["mice", 608], [".", 612], ["Curiously", 614], [",", 623], ["these", 625], ["mice", 631], ["exhibit", 636], ["multiple", 644], ["abnormalities", 653], ["that", 667], ["were", 672], ["previously", 677], ["observed", 688], ["in", 697], ["Pds5B", 700], ["-", 705], ["deficient", 706], ["mice", 716], [",", 720], ["including", 722], ["cleft", 732], ["palate", 738], [",", 744], ["skeletal", 746], ["patterning", 755], ["defects", 766], [",", 773], ["growth", 775], ["retardation", 782], [",", 793], ["congenital", 795], ["heart", 806], ["defects", 812], ["and", 820], ["delayed", 824], ["migration", 832], ["of", 842], ["enteric", 845], ["neuron", 853], ["precursors", 860], [".", 870], ["They", 872], ["also", 877], ["frequently", 882], ["display", 893], ["renal", 901], ["agenesis", 907], [",", 915], ["an", 917], ["abnormality", 920], ["not", 932], ["observed", 936], ["in", 945], ["Pds5B(-/-", 948], [")", 957], ["mice", 959], [".", 963], ["While", 965], ["Pds5A(-/-", 971], [")", 980], ["and", 982], ["Pds5B(-/-", 986], [")", 995], ["mice", 997], ["die", 1002], ["at", 1006], ["birth", 1009], [",", 1014], ["embryos", 1016], ["harboring", 1024], ["3", 1034], ["mutant", 1036], ["Pds5", 1043], ["alleles", 1048], ["die", 1056], ["between", 1060], ["E11.5", 1068], ["and", 1074], ["E12.5", 1078], ["most", 1084], ["likely", 1089], ["of", 1096], ["heart", 1099], ["failure", 1105], [",", 1112], ["indicating", 1114], ["that", 1125], ["total", 1130], ["Pds5", 1136], ["gene", 1141], ["dosage", 1146], ["is", 1153], ["critical", 1156], ["for", 1165], ["normal", 1169], ["development", 1176], [".", 1187], ["In", 1189], ["addition", 1192], [",", 1200], ["characterization", 1202], ["of", 1219], ["these", 1222], ["compound", 1228], ["homozygous", 1237], ["-", 1247], ["heterozygous", 1248], ["mice", 1261], ["revealed", 1266], ["a", 1275], ["severe", 1277], ["abnormality", 1284], ["in", 1296], ["lens", 1299], ["formation", 1304], ["that", 1314], ["does", 1319], ["not", 1324], ["occur", 1328], ["in", 1334], ["either", 1337], ["Pds5A(-/-", 1344], [")", 1353], ["or", 1355], ["Pds5B(-/-", 1358], [")", 1367], ["mice", 1369], [".", 1373], ["We", 1375], ["further", 1378], ["identified", 1386], ["a", 1397], ["functional", 1399], ["missense", 1410], ["mutation", 1419], ["(", 1428], ["R1292Q", 1429], [")", 1435], ["in", 1437], ["the", 1440], ["PDS5B", 1444], ["DNA", 1450], ["-", 1453], ["binding", 1454], ["domain", 1462], ["in", 1469], ["a", 1472], ["familial", 1474], ["case", 1483], ["of", 1488], ["CdLS", 1491], [",", 1495], ["in", 1497], ["which", 1500], ["affected", 1506], ["individuals", 1515], ["also", 1527], ["develop", 1532], ["megacolon", 1540], [".", 1549], ["This", 1551], ["study", 1556], ["shows", 1562], ["that", 1568], ["PDS5A", 1573], ["and", 1579], ["PDS5B", 1583], ["functions", 1589], ["other", 1599], ["than", 1605], ["those", 1610], ["involving", 1616], ["chromosomal", 1626], ["dynamics", 1638], ["are", 1647], ["important", 1651], ["for", 1661], ["normal", 1665], ["development", 1672], [",", 1683], ["highlights", 1685], ["the", 1696], ["sensitivity", 1700], ["of", 1712], ["key", 1715], ["developmental", 1719], ["processes", 1733], ["on", 1743], ["PDS5", 1746], ["signaling", 1751], [",", 1760], ["and", 1762], ["provides", 1766], ["mechanistic", 1775], ["insights", 1787], ["into", 1796], ["how", 1801], ["PDS5", 1805], ["mutations", 1810], ["may", 1820], ["lead", 1824], ["to", 1829], ["CdLS", 1832], [".", 1836]]}
{"context": "Selenocysteine (Sec, U) insertion into proteins is directed by translational recoding of specific UGA codons located upstream of a stem-loop structure known as Sec insertion sequence (SECIS) element. Selenoproteins with known functions are oxidoreductases containing a single redox-active Sec in their active sites. In this work, we identified a family of selenoproteins, designated SelL, containing two Sec separated by two other residues to form a UxxU motif. SelL proteins show an unusual occurrence, being present in diverse aquatic organisms, including fish, invertebrates, and marine bacteria. Both eukaryotic and bacterial SelL genes use single SECIS elements for insertion of two Sec. In eukaryotes, the SECIS is located in the 3' UTR, whereas the bacterial SelL SECIS is within a coding region and positioned at a distance that supports the insertion of either of the two Sec or both of these residues. SelL proteins possess a thioredoxin-like fold wherein the UxxU motif corresponds to the catalytic CxxC motif in thioredoxins, suggesting a redox function of SelL proteins. Distantly related SelL-like proteins were also identified in a variety of organisms that had either one or both Sec replaced with Cys. Danio rerio SelL, transiently expressed in mammalian cells, incorporated two Sec and localized to the cytosol. In these cells, it occurred in an oxidized form and was not reducible by DTT. In a bacterial expression system, we directly demonstrated the formation of a diselenide bond between the two Sec, establishing it as the first diselenide bond found in a natural protein.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3624d6c1965c47c49133ffb4a885552b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[138, 138], [32, 32], [113, 113], [125, 125]], "char_spans": [[771, 775], [184, 188], [652, 656], [712, 716]]}]}], "context_tokens": [["Selenocysteine", 0], ["(", 15], ["Sec", 16], [",", 19], ["U", 21], [")", 22], ["insertion", 24], ["into", 34], ["proteins", 39], ["is", 48], ["directed", 51], ["by", 60], ["translational", 63], ["recoding", 77], ["of", 86], ["specific", 89], ["UGA", 98], ["codons", 102], ["located", 109], ["upstream", 117], ["of", 126], ["a", 129], ["stem", 131], ["-", 135], ["loop", 136], ["structure", 141], ["known", 151], ["as", 157], ["Sec", 160], ["insertion", 164], ["sequence", 174], ["(", 183], ["SECIS", 184], [")", 189], ["element", 191], [".", 198], ["Selenoproteins", 200], ["with", 215], ["known", 220], ["functions", 226], ["are", 236], ["oxidoreductases", 240], ["containing", 256], ["a", 267], ["single", 269], ["redox", 276], ["-", 281], ["active", 282], ["Sec", 289], ["in", 293], ["their", 296], ["active", 302], ["sites", 309], [".", 314], ["In", 316], ["this", 319], ["work", 324], [",", 328], ["we", 330], ["identified", 333], ["a", 344], ["family", 346], ["of", 353], ["selenoproteins", 356], [",", 370], ["designated", 372], ["SelL", 383], [",", 387], ["containing", 389], ["two", 400], ["Sec", 404], ["separated", 408], ["by", 418], ["two", 421], ["other", 425], ["residues", 431], ["to", 440], ["form", 443], ["a", 448], ["UxxU", 450], ["motif", 455], [".", 460], ["SelL", 462], ["proteins", 467], ["show", 476], ["an", 481], ["unusual", 484], ["occurrence", 492], [",", 502], ["being", 504], ["present", 510], ["in", 518], ["diverse", 521], ["aquatic", 529], ["organisms", 537], [",", 546], ["including", 548], ["fish", 558], [",", 562], ["invertebrates", 564], [",", 577], ["and", 579], ["marine", 583], ["bacteria", 590], [".", 598], ["Both", 600], ["eukaryotic", 605], ["and", 616], ["bacterial", 620], ["SelL", 630], ["genes", 635], ["use", 641], ["single", 645], ["SECIS", 652], ["elements", 658], ["for", 667], ["insertion", 671], ["of", 681], ["two", 684], ["Sec", 688], [".", 691], ["In", 693], ["eukaryotes", 696], [",", 706], ["the", 708], ["SECIS", 712], ["is", 718], ["located", 721], ["in", 729], ["the", 732], ["3", 736], ["'", 737], ["UTR", 739], [",", 742], ["whereas", 744], ["the", 752], ["bacterial", 756], ["SelL", 766], ["SECIS", 771], ["is", 777], ["within", 780], ["a", 787], ["coding", 789], ["region", 796], ["and", 803], ["positioned", 807], ["at", 818], ["a", 821], ["distance", 823], ["that", 832], ["supports", 837], ["the", 846], ["insertion", 850], ["of", 860], ["either", 863], ["of", 870], ["the", 873], ["two", 877], ["Sec", 881], ["or", 885], ["both", 888], ["of", 893], ["these", 896], ["residues", 902], [".", 910], ["SelL", 912], ["proteins", 917], ["possess", 926], ["a", 934], ["thioredoxin", 936], ["-", 947], ["like", 948], ["fold", 953], ["wherein", 958], ["the", 966], ["UxxU", 970], ["motif", 975], ["corresponds", 981], ["to", 993], ["the", 996], ["catalytic", 1000], ["CxxC", 1010], ["motif", 1015], ["in", 1021], ["thioredoxins", 1024], [",", 1036], ["suggesting", 1038], ["a", 1049], ["redox", 1051], ["function", 1057], ["of", 1066], ["SelL", 1069], ["proteins", 1074], [".", 1082], ["Distantly", 1084], ["related", 1094], ["SelL", 1102], ["-", 1106], ["like", 1107], ["proteins", 1112], ["were", 1121], ["also", 1126], ["identified", 1131], ["in", 1142], ["a", 1145], ["variety", 1147], ["of", 1155], ["organisms", 1158], ["that", 1168], ["had", 1173], ["either", 1177], ["one", 1184], ["or", 1188], ["both", 1191], ["Sec", 1196], ["replaced", 1200], ["with", 1209], ["Cys", 1214], [".", 1217], ["Danio", 1219], ["rerio", 1225], ["SelL", 1231], [",", 1235], ["transiently", 1237], ["expressed", 1249], ["in", 1259], ["mammalian", 1262], ["cells", 1272], [",", 1277], ["incorporated", 1279], ["two", 1292], ["Sec", 1296], ["and", 1300], ["localized", 1304], ["to", 1314], ["the", 1317], ["cytosol", 1321], [".", 1328], ["In", 1330], ["these", 1333], ["cells", 1339], [",", 1344], ["it", 1346], ["occurred", 1349], ["in", 1358], ["an", 1361], ["oxidized", 1364], ["form", 1373], ["and", 1378], ["was", 1382], ["not", 1386], ["reducible", 1390], ["by", 1400], ["DTT", 1403], [".", 1406], ["In", 1408], ["a", 1411], ["bacterial", 1413], ["expression", 1423], ["system", 1434], [",", 1440], ["we", 1442], ["directly", 1445], ["demonstrated", 1454], ["the", 1467], ["formation", 1471], ["of", 1481], ["a", 1484], ["diselenide", 1486], ["bond", 1497], ["between", 1502], ["the", 1510], ["two", 1514], ["Sec", 1518], [",", 1521], ["establishing", 1523], ["it", 1536], ["as", 1539], ["the", 1542], ["first", 1546], ["diselenide", 1552], ["bond", 1563], ["found", 1568], ["in", 1574], ["a", 1577], ["natural", 1579], ["protein", 1587], [".", 1594]]}
{"context": "Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab. We used an open-label, parallel-group, randomized single-center study of 50 healthy subjects. Subjects received a single 150-mg dose of secukinumab or no treatment, followed by vaccination with inactivated trivalent subunit influenza virus and conjugate group C meningococcal vaccine (Agrippal and Menjugate, respectively) 2 weeks later. Primary efficacy variables were responses of \u22654-fold increases in antibody titer (hemagglutination inhibition [HI; for influenza virus] and serum bactericidal assay [SBA; for Neisseria meningitides]) for meningococcus and influenza (at least two out of three serotypes), both at 4 weeks postvaccination. All subjects randomized to secukinumab (n = 25) or the control (n = 25) completed the study. Antibody responses to vaccinations measured at 4 weeks were comparable in both groups, with \u22654-fold increased responses following influenza virus vaccination of 20/25 (80%) for both groups and following meningococcal vaccination of 19/25 (76%) for the secukinumab group and 18/25 (72%) for the control group. Differences between groups were 0% (90% confidence intervals [CI], 19 and 19%) and 4% (90% CI, 16 and 24%) for influenza virus and meningococcal vaccines, respectively. Antibody responses were comparable between the 2 groups at different time points. Headache was the most frequently reported adverse effect. No deaths or serious adverse events were reported. Blockade of IL-17A by secukinumab does not appear to interfere with efficacy of influenza and meningococcal vaccinations, as assessed by the achievement of protective antibody levels. A protective (\u22654-fold) immune response to both vaccinations at 4 weeks was achieved in 80 and 76% of subjects exposed to secukinumab and the control, respectively.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "4db9416efbb340a49f9352809ab90a84", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[20, 20]], "char_spans": [[127, 141]]}]}], "context_tokens": [["Our", 0], ["objective", 4], ["was", 14], ["to", 18], ["evaluate", 21], ["the", 30], ["efficacy", 34], ["of", 43], ["influenza", 46], ["and", 56], ["meningococcal", 60], ["vaccinations", 74], ["in", 87], ["healthy", 90], ["subjects", 98], ["exposed", 107], ["to", 115], ["the", 118], ["anti", 122], ["-", 126], ["interleukin-17A", 127], ["(", 143], ["IL-17A", 144], [")", 150], ["monoclonal", 152], ["antibody", 163], ["(", 172], ["MAb", 173], [")", 176], ["secukinumab", 178], [".", 189], ["We", 191], ["used", 194], ["an", 199], ["open", 202], ["-", 206], ["label", 207], [",", 212], ["parallel", 214], ["-", 222], ["group", 223], [",", 228], ["randomized", 230], ["single", 241], ["-", 247], ["center", 248], ["study", 255], ["of", 261], ["50", 264], ["healthy", 267], ["subjects", 275], [".", 283], ["Subjects", 285], ["received", 294], ["a", 303], ["single", 305], ["150-mg", 312], ["dose", 319], ["of", 324], ["secukinumab", 327], ["or", 339], ["no", 342], ["treatment", 345], [",", 354], ["followed", 356], ["by", 365], ["vaccination", 368], ["with", 380], ["inactivated", 385], ["trivalent", 397], ["subunit", 407], ["influenza", 415], ["virus", 425], ["and", 431], ["conjugate", 435], ["group", 445], ["C", 451], ["meningococcal", 453], ["vaccine", 467], ["(", 475], ["Agrippal", 476], ["and", 485], ["Menjugate", 489], [",", 498], ["respectively", 500], [")", 512], ["2", 514], ["weeks", 516], ["later", 522], [".", 527], ["Primary", 529], ["efficacy", 537], ["variables", 546], ["were", 556], ["responses", 561], ["of", 571], ["\u22654-fold", 574], ["increases", 582], ["in", 592], ["antibody", 595], ["titer", 604], ["(", 610], ["hemagglutination", 611], ["inhibition", 628], ["[", 639], ["HI", 640], [";", 642], ["for", 644], ["influenza", 648], ["virus", 658], ["]", 663], ["and", 665], ["serum", 669], ["bactericidal", 675], ["assay", 688], ["[", 694], ["SBA", 695], [";", 698], ["for", 700], ["Neisseria", 704], ["meningitides", 714], ["]", 726], [")", 727], ["for", 729], ["meningococcus", 733], ["and", 747], ["influenza", 751], ["(", 761], ["at", 762], ["least", 765], ["two", 771], ["out", 775], ["of", 779], ["three", 782], ["serotypes", 788], [")", 797], [",", 798], ["both", 800], ["at", 805], ["4", 808], ["weeks", 810], ["postvaccination", 816], [".", 831], ["All", 833], ["subjects", 837], ["randomized", 846], ["to", 857], ["secukinumab", 860], ["(", 872], ["n", 873], ["=", 875], ["25", 877], [")", 879], ["or", 881], ["the", 884], ["control", 888], ["(", 896], ["n", 897], ["=", 899], ["25", 901], [")", 903], ["completed", 905], ["the", 915], ["study", 919], [".", 924], ["Antibody", 926], ["responses", 935], ["to", 945], ["vaccinations", 948], ["measured", 961], ["at", 970], ["4", 973], ["weeks", 975], ["were", 981], ["comparable", 986], ["in", 997], ["both", 1000], ["groups", 1005], [",", 1011], ["with", 1013], ["\u22654-fold", 1018], ["increased", 1026], ["responses", 1036], ["following", 1046], ["influenza", 1056], ["virus", 1066], ["vaccination", 1072], ["of", 1084], ["20/25", 1087], ["(", 1093], ["80", 1094], ["%", 1096], [")", 1097], ["for", 1099], ["both", 1103], ["groups", 1108], ["and", 1115], ["following", 1119], ["meningococcal", 1129], ["vaccination", 1143], ["of", 1155], ["19/25", 1158], ["(", 1164], ["76", 1165], ["%", 1167], [")", 1168], ["for", 1170], ["the", 1174], ["secukinumab", 1178], ["group", 1190], ["and", 1196], ["18/25", 1200], ["(", 1206], ["72", 1207], ["%", 1209], [")", 1210], ["for", 1212], ["the", 1216], ["control", 1220], ["group", 1228], [".", 1233], ["Differences", 1235], ["between", 1247], ["groups", 1255], ["were", 1262], ["0", 1267], ["%", 1268], ["(", 1270], ["90", 1271], ["%", 1273], ["confidence", 1275], ["intervals", 1286], ["[", 1296], ["CI", 1297], ["]", 1299], [",", 1300], ["19", 1302], ["and", 1305], ["19", 1309], ["%", 1311], [")", 1312], ["and", 1314], ["4", 1318], ["%", 1319], ["(", 1321], ["90", 1322], ["%", 1324], ["CI", 1326], [",", 1328], ["16", 1330], ["and", 1333], ["24", 1337], ["%", 1339], [")", 1340], ["for", 1342], ["influenza", 1346], ["virus", 1356], ["and", 1362], ["meningococcal", 1366], ["vaccines", 1380], [",", 1388], ["respectively", 1390], [".", 1402], ["Antibody", 1404], ["responses", 1413], ["were", 1423], ["comparable", 1428], ["between", 1439], ["the", 1447], ["2", 1451], ["groups", 1453], ["at", 1460], ["different", 1463], ["time", 1473], ["points", 1478], [".", 1484], ["Headache", 1486], ["was", 1495], ["the", 1499], ["most", 1503], ["frequently", 1508], ["reported", 1519], ["adverse", 1528], ["effect", 1536], [".", 1542], ["No", 1544], ["deaths", 1547], ["or", 1554], ["serious", 1557], ["adverse", 1565], ["events", 1573], ["were", 1580], ["reported", 1585], [".", 1593], ["Blockade", 1595], ["of", 1604], ["IL-17A", 1607], ["by", 1614], ["secukinumab", 1617], ["does", 1629], ["not", 1634], ["appear", 1638], ["to", 1645], ["interfere", 1648], ["with", 1658], ["efficacy", 1663], ["of", 1672], ["influenza", 1675], ["and", 1685], ["meningococcal", 1689], ["vaccinations", 1703], [",", 1715], ["as", 1717], ["assessed", 1720], ["by", 1729], ["the", 1732], ["achievement", 1736], ["of", 1748], ["protective", 1751], ["antibody", 1762], ["levels", 1771], [".", 1777], ["A", 1779], ["protective", 1781], ["(", 1792], ["\u22654-fold", 1793], [")", 1800], ["immune", 1802], ["response", 1809], ["to", 1818], ["both", 1821], ["vaccinations", 1826], ["at", 1839], ["4", 1842], ["weeks", 1844], ["was", 1850], ["achieved", 1854], ["in", 1863], ["80", 1866], ["and", 1869], ["76", 1873], ["%", 1875], ["of", 1877], ["subjects", 1880], ["exposed", 1889], ["to", 1897], ["secukinumab", 1900], ["and", 1912], ["the", 1916], ["control", 1920], [",", 1927], ["respectively", 1929], [".", 1941]]}
{"context": "Bacterial species composition in the gut has emerged as an important factor in obesity and its related metabolic diseases such as type 2 diabetes. Out of thousands of bacterial species-level phylotypes inhabiting the human gut, the majority belong to two dominant phyla, the Bacteroidetes and Firmicutes. Members of the Bacteroidetes in particular have been associated with human metabolic diseases. However, their associations with disease are not always consistent between studies. Delving deeper into the diversity within the Bacteroidetes reveals a vast diversity in genomes and capacities, which partly explain how not all members respond equally to similar environmental conditions in their hosts. Here, we discuss the Bacteroidetes phylum, associations of its members with metabolic phenotypes, and efforts to characterize functionally their interactions with their hosts. Harnessing the Bacteroidetes to promote metabolic health will require a nuanced understanding of how specific strains interact with their microbial neighbors and their hosts under various conditions.", "qas": [{"question": "Which are the two main bacterial phyla in human gut?", "answers": ["Bacteroidetes and Firmicutes"], "qid": "9e0895388cc345f698305bfff766a304", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["two", 14], ["main", 18], ["bacterial", 23], ["phyla", 33], ["in", 39], ["human", 42], ["gut", 48], ["?", 51]], "detected_answers": [{"text": "Bacteroidetes and Firmicutes", "token_spans": [[48, 50]], "char_spans": [[275, 302]]}]}], "context_tokens": [["Bacterial", 0], ["species", 10], ["composition", 18], ["in", 30], ["the", 33], ["gut", 37], ["has", 41], ["emerged", 45], ["as", 53], ["an", 56], ["important", 59], ["factor", 69], ["in", 76], ["obesity", 79], ["and", 87], ["its", 91], ["related", 95], ["metabolic", 103], ["diseases", 113], ["such", 122], ["as", 127], ["type", 130], ["2", 135], ["diabetes", 137], [".", 145], ["Out", 147], ["of", 151], ["thousands", 154], ["of", 164], ["bacterial", 167], ["species", 177], ["-", 184], ["level", 185], ["phylotypes", 191], ["inhabiting", 202], ["the", 213], ["human", 217], ["gut", 223], [",", 226], ["the", 228], ["majority", 232], ["belong", 241], ["to", 248], ["two", 251], ["dominant", 255], ["phyla", 264], [",", 269], ["the", 271], ["Bacteroidetes", 275], ["and", 289], ["Firmicutes", 293], [".", 303], ["Members", 305], ["of", 313], ["the", 316], ["Bacteroidetes", 320], ["in", 334], ["particular", 337], ["have", 348], ["been", 353], ["associated", 358], ["with", 369], ["human", 374], ["metabolic", 380], ["diseases", 390], [".", 398], ["However", 400], [",", 407], ["their", 409], ["associations", 415], ["with", 428], ["disease", 433], ["are", 441], ["not", 445], ["always", 449], ["consistent", 456], ["between", 467], ["studies", 475], [".", 482], ["Delving", 484], ["deeper", 492], ["into", 499], ["the", 504], ["diversity", 508], ["within", 518], ["the", 525], ["Bacteroidetes", 529], ["reveals", 543], ["a", 551], ["vast", 553], ["diversity", 558], ["in", 568], ["genomes", 571], ["and", 579], ["capacities", 583], [",", 593], ["which", 595], ["partly", 601], ["explain", 608], ["how", 616], ["not", 620], ["all", 624], ["members", 628], ["respond", 636], ["equally", 644], ["to", 652], ["similar", 655], ["environmental", 663], ["conditions", 677], ["in", 688], ["their", 691], ["hosts", 697], [".", 702], ["Here", 704], [",", 708], ["we", 710], ["discuss", 713], ["the", 721], ["Bacteroidetes", 725], ["phylum", 739], [",", 745], ["associations", 747], ["of", 760], ["its", 763], ["members", 767], ["with", 775], ["metabolic", 780], ["phenotypes", 790], [",", 800], ["and", 802], ["efforts", 806], ["to", 814], ["characterize", 817], ["functionally", 830], ["their", 843], ["interactions", 849], ["with", 862], ["their", 867], ["hosts", 873], [".", 878], ["Harnessing", 880], ["the", 891], ["Bacteroidetes", 895], ["to", 909], ["promote", 912], ["metabolic", 920], ["health", 930], ["will", 937], ["require", 942], ["a", 950], ["nuanced", 952], ["understanding", 960], ["of", 974], ["how", 977], ["specific", 981], ["strains", 990], ["interact", 998], ["with", 1007], ["their", 1012], ["microbial", 1018], ["neighbors", 1028], ["and", 1038], ["their", 1042], ["hosts", 1048], ["under", 1054], ["various", 1060], ["conditions", 1068], [".", 1078]]}
{"context": "Chronic Myeloid Leukemia (CML) has always been an ideal model to understand the molecular pathogenesis of human leukaemias and the way to cure them. This can be ascribed to the fact that CML was the first human cancer demonstrated to be strongly associated to the presence of a recurrent chromosomal translocation (the t(9;22)(q34;q11) that creates the Philadelphia (Ph)-chromosome) and to a specific molecular defect, the formation of a hybrid BCR-ABL gene that generates new fusion proteins endowed with a constitutive tyrosine-kinase (TK) activity, strongly implicated in the pathogenesis of the disease. The introduction into clinical practice of imatinib, (Glivec, Gleevec, Novartis), a potent tyrosine kinase inhibitor of the Bcr-Abl protein as well as of a restricted number of other TKs, has not only produced a substantial improvement in the treatment of CML, but represents a major break-through in the perspective of opening a new era, that of molecularly targeted therapy, in the management of other types of leukemia, lymphoma and cancer in general.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "097ccc6aa9ba4a0fb9739ed812f2180b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[77, 79], [130, 132]], "char_spans": [[445, 451], [732, 738]]}]}], "context_tokens": [["Chronic", 0], ["Myeloid", 8], ["Leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["has", 31], ["always", 35], ["been", 42], ["an", 47], ["ideal", 50], ["model", 56], ["to", 62], ["understand", 65], ["the", 76], ["molecular", 80], ["pathogenesis", 90], ["of", 103], ["human", 106], ["leukaemias", 112], ["and", 123], ["the", 127], ["way", 131], ["to", 135], ["cure", 138], ["them", 143], [".", 147], ["This", 149], ["can", 154], ["be", 158], ["ascribed", 161], ["to", 170], ["the", 173], ["fact", 177], ["that", 182], ["CML", 187], ["was", 191], ["the", 195], ["first", 199], ["human", 205], ["cancer", 211], ["demonstrated", 218], ["to", 231], ["be", 234], ["strongly", 237], ["associated", 246], ["to", 257], ["the", 260], ["presence", 264], ["of", 273], ["a", 276], ["recurrent", 278], ["chromosomal", 288], ["translocation", 300], ["(", 314], ["the", 315], ["t(9;22)(q34;q11", 319], [")", 334], ["that", 336], ["creates", 341], ["the", 349], ["Philadelphia", 353], ["(", 366], ["Ph)-chromosome", 367], [")", 381], ["and", 383], ["to", 387], ["a", 390], ["specific", 392], ["molecular", 401], ["defect", 411], [",", 417], ["the", 419], ["formation", 423], ["of", 433], ["a", 436], ["hybrid", 438], ["BCR", 445], ["-", 448], ["ABL", 449], ["gene", 453], ["that", 458], ["generates", 463], ["new", 473], ["fusion", 477], ["proteins", 484], ["endowed", 493], ["with", 501], ["a", 506], ["constitutive", 508], ["tyrosine", 521], ["-", 529], ["kinase", 530], ["(", 537], ["TK", 538], [")", 540], ["activity", 542], [",", 550], ["strongly", 552], ["implicated", 561], ["in", 572], ["the", 575], ["pathogenesis", 579], ["of", 592], ["the", 595], ["disease", 599], [".", 606], ["The", 608], ["introduction", 612], ["into", 625], ["clinical", 630], ["practice", 639], ["of", 648], ["imatinib", 651], [",", 659], ["(", 661], ["Glivec", 662], [",", 668], ["Gleevec", 670], [",", 677], ["Novartis", 679], [")", 687], [",", 688], ["a", 690], ["potent", 692], ["tyrosine", 699], ["kinase", 708], ["inhibitor", 715], ["of", 725], ["the", 728], ["Bcr", 732], ["-", 735], ["Abl", 736], ["protein", 740], ["as", 748], ["well", 751], ["as", 756], ["of", 759], ["a", 762], ["restricted", 764], ["number", 775], ["of", 782], ["other", 785], ["TKs", 791], [",", 794], ["has", 796], ["not", 800], ["only", 804], ["produced", 809], ["a", 818], ["substantial", 820], ["improvement", 832], ["in", 844], ["the", 847], ["treatment", 851], ["of", 861], ["CML", 864], [",", 867], ["but", 869], ["represents", 873], ["a", 884], ["major", 886], ["break", 892], ["-", 897], ["through", 898], ["in", 906], ["the", 909], ["perspective", 913], ["of", 925], ["opening", 928], ["a", 936], ["new", 938], ["era", 942], [",", 945], ["that", 947], ["of", 952], ["molecularly", 955], ["targeted", 967], ["therapy", 976], [",", 983], ["in", 985], ["the", 988], ["management", 992], ["of", 1003], ["other", 1006], ["types", 1012], ["of", 1018], ["leukemia", 1021], [",", 1029], ["lymphoma", 1031], ["and", 1040], ["cancer", 1044], ["in", 1051], ["general", 1054], [".", 1061]]}
{"context": "The objective of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in development for pulmonary arterial hypertension in healthy subjects. This was a double-blind, placebo-controlled, randomised, multiple-ascending-dose, up-titration study. Male subjects received increasing oral doses of selexipag (400-1,800 \u00b5g; n = 12) or placebo (n = 4) twice daily for 3 days each, using incremental steps of 200 \u00b5g between each dose level. Standard safety and tolerability data were collected. Blood samples were taken to assess the pharmacokinetics of selexipag and its active metabolite ACT-333679 and possible effects on platelet aggregation. Dose levels of selexipag up to 1,600 \u03bcg were well tolerated and this dose was identified as the maximum tolerated dose. Plasma exposure to ACT-333679 was approximately 4 times higher than that to selexipag. Steady-state conditions for both compounds were reached on day 3 of each dose level, and no accumulation of selexipag or ACT-333679 was observed. Based on the area under the curve and the maximum plasma concentration, the pharmacokinetics of selexipag and ACT-333679 were dose proportional. At the highest dose level, the geometric mean terminal half-life of selexipag and ACT-333679 was 1.4 and 8.7 h, respectively. The observed effects on platelet aggregation were variable without obvious drug- or dose-dependent pattern. Oral administration of increasing doses of selexipag was well tolerated. The present results support the conduct of future clinical trials.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "dc412b85fe524e26a165bb4c60c19e0f", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[31, 33]], "char_spans": [[201, 231]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["study", 22], ["was", 28], ["to", 32], ["assess", 35], ["the", 42], ["safety", 46], [",", 52], ["tolerability", 54], [",", 66], ["pharmacokinetics", 68], [",", 84], ["and", 86], ["pharmacodynamics", 90], ["of", 107], ["selexipag", 110], [",", 119], ["an", 121], ["orally", 124], ["available", 131], ["selective", 141], ["prostacyclin", 151], ["receptor", 164], ["agonist", 173], [",", 180], ["in", 182], ["development", 185], ["for", 197], ["pulmonary", 201], ["arterial", 211], ["hypertension", 220], ["in", 233], ["healthy", 236], ["subjects", 244], [".", 252], ["This", 254], ["was", 259], ["a", 263], ["double", 265], ["-", 271], ["blind", 272], [",", 277], ["placebo", 279], ["-", 286], ["controlled", 287], [",", 297], ["randomised", 299], [",", 309], ["multiple", 311], ["-", 319], ["ascending", 320], ["-", 329], ["dose", 330], [",", 334], ["up", 336], ["-", 338], ["titration", 339], ["study", 349], [".", 354], ["Male", 356], ["subjects", 361], ["received", 370], ["increasing", 379], ["oral", 390], ["doses", 395], ["of", 401], ["selexipag", 404], ["(", 414], ["400", 415], ["-", 418], ["1,800", 419], ["\u00b5g", 425], [";", 427], ["n", 429], ["=", 431], ["12", 433], [")", 435], ["or", 437], ["placebo", 440], ["(", 448], ["n", 449], ["=", 451], ["4", 453], [")", 454], ["twice", 456], ["daily", 462], ["for", 468], ["3", 472], ["days", 474], ["each", 479], [",", 483], ["using", 485], ["incremental", 491], ["steps", 503], ["of", 509], ["200", 512], ["\u00b5g", 516], ["between", 519], ["each", 527], ["dose", 532], ["level", 537], [".", 542], ["Standard", 544], ["safety", 553], ["and", 560], ["tolerability", 564], ["data", 577], ["were", 582], ["collected", 587], [".", 596], ["Blood", 598], ["samples", 604], ["were", 612], ["taken", 617], ["to", 623], ["assess", 626], ["the", 633], ["pharmacokinetics", 637], ["of", 654], ["selexipag", 657], ["and", 667], ["its", 671], ["active", 675], ["metabolite", 682], ["ACT-333679", 693], ["and", 704], ["possible", 708], ["effects", 717], ["on", 725], ["platelet", 728], ["aggregation", 737], [".", 748], ["Dose", 750], ["levels", 755], ["of", 762], ["selexipag", 765], ["up", 775], ["to", 778], ["1,600", 781], ["\u03bcg", 787], ["were", 790], ["well", 795], ["tolerated", 800], ["and", 810], ["this", 814], ["dose", 819], ["was", 824], ["identified", 828], ["as", 839], ["the", 842], ["maximum", 846], ["tolerated", 854], ["dose", 864], [".", 868], ["Plasma", 870], ["exposure", 877], ["to", 886], ["ACT-333679", 889], ["was", 900], ["approximately", 904], ["4", 918], ["times", 920], ["higher", 926], ["than", 933], ["that", 938], ["to", 943], ["selexipag", 946], [".", 955], ["Steady", 957], ["-", 963], ["state", 964], ["conditions", 970], ["for", 981], ["both", 985], ["compounds", 990], ["were", 1000], ["reached", 1005], ["on", 1013], ["day", 1016], ["3", 1020], ["of", 1022], ["each", 1025], ["dose", 1030], ["level", 1035], [",", 1040], ["and", 1042], ["no", 1046], ["accumulation", 1049], ["of", 1062], ["selexipag", 1065], ["or", 1075], ["ACT-333679", 1078], ["was", 1089], ["observed", 1093], [".", 1101], ["Based", 1103], ["on", 1109], ["the", 1112], ["area", 1116], ["under", 1121], ["the", 1127], ["curve", 1131], ["and", 1137], ["the", 1141], ["maximum", 1145], ["plasma", 1153], ["concentration", 1160], [",", 1173], ["the", 1175], ["pharmacokinetics", 1179], ["of", 1196], ["selexipag", 1199], ["and", 1209], ["ACT-333679", 1213], ["were", 1224], ["dose", 1229], ["proportional", 1234], [".", 1246], ["At", 1248], ["the", 1251], ["highest", 1255], ["dose", 1263], ["level", 1268], [",", 1273], ["the", 1275], ["geometric", 1279], ["mean", 1289], ["terminal", 1294], ["half", 1303], ["-", 1307], ["life", 1308], ["of", 1313], ["selexipag", 1316], ["and", 1326], ["ACT-333679", 1330], ["was", 1341], ["1.4", 1345], ["and", 1349], ["8.7", 1353], ["h", 1357], [",", 1358], ["respectively", 1360], [".", 1372], ["The", 1374], ["observed", 1378], ["effects", 1387], ["on", 1395], ["platelet", 1398], ["aggregation", 1407], ["were", 1419], ["variable", 1424], ["without", 1433], ["obvious", 1441], ["drug-", 1449], ["or", 1455], ["dose", 1458], ["-", 1462], ["dependent", 1463], ["pattern", 1473], [".", 1480], ["Oral", 1482], ["administration", 1487], ["of", 1502], ["increasing", 1505], ["doses", 1516], ["of", 1522], ["selexipag", 1525], ["was", 1535], ["well", 1539], ["tolerated", 1544], [".", 1553], ["The", 1555], ["present", 1559], ["results", 1567], ["support", 1575], ["the", 1583], ["conduct", 1587], ["of", 1595], ["future", 1598], ["clinical", 1605], ["trials", 1614], [".", 1620]]}
{"context": "To compare the change of urethral mobility after midurethral sling procedures in stress urinary incontinence with hypermobile urethra and assess these findings with surgical outcomes. 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. Preoperatively, urethral mobility was measured by Q tip test. All women were asked to complete Urogenital Distress Inventory Short Form (UDI-6) and Incontinence Impact Questionnaire Short Form (IIQ-7) to assess the quality of life. Six months postoperatively, Q tip test and quality of life assessment were repeated. The primary surgical outcomes were classified as cure, improvement and failure. Transient urinary obstruction, de novo urgency, voiding dysfunction were secondary surgical outcomes. Of 141 women, 50 (35. 5%) women underwent TOT, 91 (64.5%) underwent TVT. In both TOT and TVT groups, postoperative Q tip test values, IIQ-7 and UDI-6 scores were statistically reduced when compared with preoperative values. Postoperative Q tip test value in TVT group was significantly smaller than in TOT group [25\u00b0(15-45\u00b0) and 20\u00b0 (15-45\u00b0), respectively]. When we compared the Q-tip test value, IIQ-7 and UDI-6 scores changes, there were no statistically significant changes between the groups. Postoperative urethral mobility was more frequent in TOT group than in TVT group (40% vs 23.1%, respectively). Postoperative primary and secondary outcomes were similar in both groups. Although midurethral slings decrease the urethtal hypermobility, postoperative mobility status of urethra does not effect surgical outcomes of midurethral slings in women with preoperative urethral hypermobility.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "6ca2123e52db4eabb7129fcdd9ffb251", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[37, 39], [12, 14]], "char_spans": [[252, 278], [81, 107]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["change", 15], ["of", 22], ["urethral", 25], ["mobility", 34], ["after", 43], ["midurethral", 49], ["sling", 61], ["procedures", 67], ["in", 78], ["stress", 81], ["urinary", 88], ["incontinence", 96], ["with", 109], ["hypermobile", 114], ["urethra", 126], ["and", 134], ["assess", 138], ["these", 145], ["findings", 151], ["with", 160], ["surgical", 165], ["outcomes", 174], [".", 182], ["141", 184], ["women", 188], ["who", 194], ["agreed", 198], ["to", 205], ["undergo", 208], ["midurethral", 216], ["sling", 228], ["operations", 234], ["due", 245], ["to", 249], ["stress", 252], ["urinary", 259], ["incontinence", 267], ["with", 280], ["hypermobile", 285], ["urethra", 297], ["were", 305], ["enrolled", 310], ["in", 319], ["this", 322], ["non", 327], ["-", 330], ["randomized", 331], ["prospective", 342], ["observational", 354], ["study", 368], [".", 373], ["Preoperatively", 375], [",", 389], ["urethral", 391], ["mobility", 400], ["was", 409], ["measured", 413], ["by", 422], ["Q", 425], ["tip", 427], ["test", 431], [".", 435], ["All", 437], ["women", 441], ["were", 447], ["asked", 452], ["to", 458], ["complete", 461], ["Urogenital", 470], ["Distress", 481], ["Inventory", 490], ["Short", 500], ["Form", 506], ["(", 511], ["UDI-6", 512], [")", 517], ["and", 519], ["Incontinence", 523], ["Impact", 536], ["Questionnaire", 543], ["Short", 557], ["Form", 563], ["(", 568], ["IIQ-7", 569], [")", 574], ["to", 576], ["assess", 579], ["the", 586], ["quality", 590], ["of", 598], ["life", 601], [".", 605], ["Six", 607], ["months", 611], ["postoperatively", 618], [",", 633], ["Q", 635], ["tip", 637], ["test", 641], ["and", 646], ["quality", 650], ["of", 658], ["life", 661], ["assessment", 666], ["were", 677], ["repeated", 682], [".", 690], ["The", 692], ["primary", 696], ["surgical", 704], ["outcomes", 713], ["were", 722], ["classified", 727], ["as", 738], ["cure", 741], [",", 745], ["improvement", 747], ["and", 759], ["failure", 763], [".", 770], ["Transient", 772], ["urinary", 782], ["obstruction", 790], [",", 801], ["de", 803], ["novo", 806], ["urgency", 811], [",", 818], ["voiding", 820], ["dysfunction", 828], ["were", 840], ["secondary", 845], ["surgical", 855], ["outcomes", 864], [".", 872], ["Of", 874], ["141", 877], ["women", 881], [",", 886], ["50", 888], ["(", 891], ["35", 892], [".", 894], ["5", 896], ["%", 897], [")", 898], ["women", 900], ["underwent", 906], ["TOT", 916], [",", 919], ["91", 921], ["(", 924], ["64.5", 925], ["%", 929], [")", 930], ["underwent", 932], ["TVT", 942], [".", 945], ["In", 947], ["both", 950], ["TOT", 955], ["and", 959], ["TVT", 963], ["groups", 967], [",", 973], ["postoperative", 975], ["Q", 989], ["tip", 991], ["test", 995], ["values", 1000], [",", 1006], ["IIQ-7", 1008], ["and", 1014], ["UDI-6", 1018], ["scores", 1024], ["were", 1031], ["statistically", 1036], ["reduced", 1050], ["when", 1058], ["compared", 1063], ["with", 1072], ["preoperative", 1077], ["values", 1090], [".", 1096], ["Postoperative", 1098], ["Q", 1112], ["tip", 1114], ["test", 1118], ["value", 1123], ["in", 1129], ["TVT", 1132], ["group", 1136], ["was", 1142], ["significantly", 1146], ["smaller", 1160], ["than", 1168], ["in", 1173], ["TOT", 1176], ["group", 1180], ["[", 1186], ["25", 1187], ["\u00b0", 1189], ["(15", 1190], ["-", 1193], ["45", 1194], ["\u00b0", 1196], [")", 1197], ["and", 1199], ["20", 1203], ["\u00b0", 1205], ["(", 1207], ["15", 1208], ["-", 1210], ["45", 1211], ["\u00b0", 1213], [")", 1214], [",", 1215], ["respectively].", 1217], ["When", 1232], ["we", 1237], ["compared", 1240], ["the", 1249], ["Q", 1253], ["-", 1254], ["tip", 1255], ["test", 1259], ["value", 1264], [",", 1269], ["IIQ-7", 1271], ["and", 1277], ["UDI-6", 1281], ["scores", 1287], ["changes", 1294], [",", 1301], ["there", 1303], ["were", 1309], ["no", 1314], ["statistically", 1317], ["significant", 1331], ["changes", 1343], ["between", 1351], ["the", 1359], ["groups", 1363], [".", 1369], ["Postoperative", 1371], ["urethral", 1385], ["mobility", 1394], ["was", 1403], ["more", 1407], ["frequent", 1412], ["in", 1421], ["TOT", 1424], ["group", 1428], ["than", 1434], ["in", 1439], ["TVT", 1442], ["group", 1446], ["(", 1452], ["40", 1453], ["%", 1455], ["vs", 1457], ["23.1", 1460], ["%", 1464], [",", 1465], ["respectively", 1467], [")", 1479], [".", 1480], ["Postoperative", 1482], ["primary", 1496], ["and", 1504], ["secondary", 1508], ["outcomes", 1518], ["were", 1527], ["similar", 1532], ["in", 1540], ["both", 1543], ["groups", 1548], [".", 1554], ["Although", 1556], ["midurethral", 1565], ["slings", 1577], ["decrease", 1584], ["the", 1593], ["urethtal", 1597], ["hypermobility", 1606], [",", 1619], ["postoperative", 1621], ["mobility", 1635], ["status", 1644], ["of", 1651], ["urethra", 1654], ["does", 1662], ["not", 1667], ["effect", 1671], ["surgical", 1678], ["outcomes", 1687], ["of", 1696], ["midurethral", 1699], ["slings", 1711], ["in", 1718], ["women", 1721], ["with", 1727], ["preoperative", 1732], ["urethral", 1745], ["hypermobility", 1754], [".", 1767]]}
{"context": "Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme. Enzyme replacement therapy (ERT) offers a specific treatment for patients with Fabry disease, though monitoring of treatment is hampered by a lack of surrogate markers of response. In this study, the efficacy of long-term ERT in six Fabry hemizygotes and two symptomatic heterozygotes has been evaluated. Patients were administered recombinant alpha-galactosidase A every 2 weeks for up to a year. The efficacy of ERT was assessed by monitoring symptomatology and renal function. Urinary glycolipid concentration was estimated by a novel tandem mass spectrometric method. Urine glycolipid (Gb(3)) was elevated at baseline and fell impressively on ERT where patients were hemizygotes and in the absence of renal transplantation. In heterozygotes and in a recipient of a renal allograft, elevations and changes in urine glycolipids were less pronounced. In one patient, after several months of ERT, there was a transient increase in Gb(3) concentrations to baseline (pre-ERT) levels, associated with the presence of antibodies to the recombinant alpha-galactosidase A. The marked decline in urine Gb(3) on ERT, and its subsequent increase in association with an inhibitory antibody response, suggest that this analyte deserves further investigation as a potential marker of disease severity and response to treatment.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "81c1da5cbe684802901524bab2260719", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[25, 27], [233, 235], [109, 111]], "char_spans": [[132, 150], [1327, 1345], [627, 645]]}]}], "context_tokens": [["Anderson", 0], ["-", 8], ["Fabry", 9], ["disease", 15], ["(", 23], ["referred", 24], ["to", 33], ["as", 36], ["Fabry", 39], ["disease", 45], [")", 52], ["is", 54], ["an", 57], ["X", 60], ["-", 61], ["linked", 62], ["disorder", 69], ["characterized", 78], ["by", 92], ["a", 95], ["deficiency", 97], ["of", 108], ["the", 111], ["lysosomal", 115], ["enzyme", 125], ["alpha", 132], ["-", 137], ["galactosidase", 138], ["A", 152], ["and", 154], ["the", 158], ["subsequent", 162], ["accumulation", 173], ["in", 186], ["various", 189], ["tissues", 197], ["of", 205], ["globotriaosylceramide", 208], ["(", 230], ["Gb(3", 231], [")", 235], [")", 236], [",", 237], ["the", 239], ["main", 243], ["substrate", 248], ["of", 258], ["the", 261], ["defective", 265], ["enzyme", 275], [".", 281], ["Enzyme", 283], ["replacement", 290], ["therapy", 302], ["(", 310], ["ERT", 311], [")", 314], ["offers", 316], ["a", 323], ["specific", 325], ["treatment", 334], ["for", 344], ["patients", 348], ["with", 357], ["Fabry", 362], ["disease", 368], [",", 375], ["though", 377], ["monitoring", 384], ["of", 395], ["treatment", 398], ["is", 408], ["hampered", 411], ["by", 420], ["a", 423], ["lack", 425], ["of", 430], ["surrogate", 433], ["markers", 443], ["of", 451], ["response", 454], [".", 462], ["In", 464], ["this", 467], ["study", 472], [",", 477], ["the", 479], ["efficacy", 483], ["of", 492], ["long", 495], ["-", 499], ["term", 500], ["ERT", 505], ["in", 509], ["six", 512], ["Fabry", 516], ["hemizygotes", 522], ["and", 534], ["two", 538], ["symptomatic", 542], ["heterozygotes", 554], ["has", 568], ["been", 572], ["evaluated", 577], [".", 586], ["Patients", 588], ["were", 597], ["administered", 602], ["recombinant", 615], ["alpha", 627], ["-", 632], ["galactosidase", 633], ["A", 647], ["every", 649], ["2", 655], ["weeks", 657], ["for", 663], ["up", 667], ["to", 670], ["a", 673], ["year", 675], [".", 679], ["The", 681], ["efficacy", 685], ["of", 694], ["ERT", 697], ["was", 701], ["assessed", 705], ["by", 714], ["monitoring", 717], ["symptomatology", 728], ["and", 743], ["renal", 747], ["function", 753], [".", 761], ["Urinary", 763], ["glycolipid", 771], ["concentration", 782], ["was", 796], ["estimated", 800], ["by", 810], ["a", 813], ["novel", 815], ["tandem", 821], ["mass", 828], ["spectrometric", 833], ["method", 847], [".", 853], ["Urine", 855], ["glycolipid", 861], ["(", 872], ["Gb(3", 873], [")", 877], [")", 878], ["was", 880], ["elevated", 884], ["at", 893], ["baseline", 896], ["and", 905], ["fell", 909], ["impressively", 914], ["on", 927], ["ERT", 930], ["where", 934], ["patients", 940], ["were", 949], ["hemizygotes", 954], ["and", 966], ["in", 970], ["the", 973], ["absence", 977], ["of", 985], ["renal", 988], ["transplantation", 994], [".", 1009], ["In", 1011], ["heterozygotes", 1014], ["and", 1028], ["in", 1032], ["a", 1035], ["recipient", 1037], ["of", 1047], ["a", 1050], ["renal", 1052], ["allograft", 1058], [",", 1067], ["elevations", 1069], ["and", 1080], ["changes", 1084], ["in", 1092], ["urine", 1095], ["glycolipids", 1101], ["were", 1113], ["less", 1118], ["pronounced", 1123], [".", 1133], ["In", 1135], ["one", 1138], ["patient", 1142], [",", 1149], ["after", 1151], ["several", 1157], ["months", 1165], ["of", 1172], ["ERT", 1175], [",", 1178], ["there", 1180], ["was", 1186], ["a", 1190], ["transient", 1192], ["increase", 1202], ["in", 1211], ["Gb(3", 1214], [")", 1218], ["concentrations", 1220], ["to", 1235], ["baseline", 1238], ["(", 1247], ["pre", 1248], ["-", 1251], ["ERT", 1252], [")", 1255], ["levels", 1257], [",", 1263], ["associated", 1265], ["with", 1276], ["the", 1281], ["presence", 1285], ["of", 1294], ["antibodies", 1297], ["to", 1308], ["the", 1311], ["recombinant", 1315], ["alpha", 1327], ["-", 1332], ["galactosidase", 1333], ["A.", 1347], ["The", 1350], ["marked", 1354], ["decline", 1361], ["in", 1369], ["urine", 1372], ["Gb(3", 1378], [")", 1382], ["on", 1384], ["ERT", 1387], [",", 1390], ["and", 1392], ["its", 1396], ["subsequent", 1400], ["increase", 1411], ["in", 1420], ["association", 1423], ["with", 1435], ["an", 1440], ["inhibitory", 1443], ["antibody", 1454], ["response", 1463], [",", 1471], ["suggest", 1473], ["that", 1481], ["this", 1486], ["analyte", 1491], ["deserves", 1499], ["further", 1508], ["investigation", 1516], ["as", 1530], ["a", 1533], ["potential", 1535], ["marker", 1545], ["of", 1552], ["disease", 1555], ["severity", 1563], ["and", 1572], ["response", 1576], ["to", 1585], ["treatment", 1588], [".", 1597]]}
{"context": "Fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative Q-tip test (greater than or equal to 30 degrees Q-tip angle change on straining). All 15 had retropubic surgical procedures for stress incontinence in the form of a revised Pereyra procedure (n = 6) or Burch retropubic urethropexy (n = 9). Five of the nine patients undergoing the Burch procedure (55%) and three of the six undergoing the Peyreya procedure (50%) failed the procedure, for an overall failure rate of 53%. This rate was five times higher than that among women with stress urinary incontinence and a positive Q-tip test who underwent the same procedures (P less than .01). We conclude that women with stress urinary incontinence and no anatomic defect in the support of the urethrovesical junction should not undergo retropubic procedures because of their high failure rate. Other occlusive procedures, such as sling operations, should be considered for this group.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "697de39cc87343798ea51f9debbc2c55", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[9, 11], [118, 120], [145, 147]], "char_spans": [[58, 84], [581, 607], [716, 742]]}]}], "context_tokens": [["Fifteen", 0], ["women", 8], ["with", 14], ["a", 19], ["clinical", 21], ["and", 30], ["urodynamic", 34], ["diagnosis", 45], ["of", 55], ["stress", 58], ["urinary", 65], ["incontinence", 73], ["had", 86], ["a", 90], ["negative", 92], ["Q", 101], ["-", 102], ["tip", 103], ["test", 107], ["(", 112], ["greater", 113], ["than", 121], ["or", 126], ["equal", 129], ["to", 135], ["30", 138], ["degrees", 141], ["Q", 149], ["-", 150], ["tip", 151], ["angle", 155], ["change", 161], ["on", 168], ["straining", 171], [")", 180], [".", 181], ["All", 183], ["15", 187], ["had", 190], ["retropubic", 194], ["surgical", 205], ["procedures", 214], ["for", 225], ["stress", 229], ["incontinence", 236], ["in", 249], ["the", 252], ["form", 256], ["of", 261], ["a", 264], ["revised", 266], ["Pereyra", 274], ["procedure", 282], ["(", 292], ["n", 293], ["=", 295], ["6", 297], [")", 298], ["or", 300], ["Burch", 303], ["retropubic", 309], ["urethropexy", 320], ["(", 332], ["n", 333], ["=", 335], ["9", 337], [")", 338], [".", 339], ["Five", 341], ["of", 346], ["the", 349], ["nine", 353], ["patients", 358], ["undergoing", 367], ["the", 378], ["Burch", 382], ["procedure", 388], ["(", 398], ["55", 399], ["%", 401], [")", 402], ["and", 404], ["three", 408], ["of", 414], ["the", 417], ["six", 421], ["undergoing", 425], ["the", 436], ["Peyreya", 440], ["procedure", 448], ["(", 458], ["50", 459], ["%", 461], [")", 462], ["failed", 464], ["the", 471], ["procedure", 475], [",", 484], ["for", 486], ["an", 490], ["overall", 493], ["failure", 501], ["rate", 509], ["of", 514], ["53", 517], ["%", 519], [".", 520], ["This", 522], ["rate", 527], ["was", 532], ["five", 536], ["times", 541], ["higher", 547], ["than", 554], ["that", 559], ["among", 564], ["women", 570], ["with", 576], ["stress", 581], ["urinary", 588], ["incontinence", 596], ["and", 609], ["a", 613], ["positive", 615], ["Q", 624], ["-", 625], ["tip", 626], ["test", 630], ["who", 635], ["underwent", 639], ["the", 649], ["same", 653], ["procedures", 658], ["(", 669], ["P", 670], ["less", 672], ["than", 677], [".01", 682], [")", 685], [".", 686], ["We", 688], ["conclude", 691], ["that", 700], ["women", 705], ["with", 711], ["stress", 716], ["urinary", 723], ["incontinence", 731], ["and", 744], ["no", 748], ["anatomic", 751], ["defect", 760], ["in", 767], ["the", 770], ["support", 774], ["of", 782], ["the", 785], ["urethrovesical", 789], ["junction", 804], ["should", 813], ["not", 820], ["undergo", 824], ["retropubic", 832], ["procedures", 843], ["because", 854], ["of", 862], ["their", 865], ["high", 871], ["failure", 876], ["rate", 884], [".", 888], ["Other", 890], ["occlusive", 896], ["procedures", 906], [",", 916], ["such", 918], ["as", 923], ["sling", 926], ["operations", 932], [",", 942], ["should", 944], ["be", 951], ["considered", 954], ["for", 965], ["this", 969], ["group", 974], [".", 979]]}
{"context": "Incorporation of the 21st amino acid, selenocysteine, into proteins is specified in all three domains of life by dynamic translational redefinition of UGA codons. In eukarya and archaea, selenocysteine insertion requires a cis-acting selenocysteine insertion sequence (SECIS) usually located in the 3'UTR of selenoprotein mRNAs. Here we present comparative sequence analysis and experimental data supporting the presence of a second stop codon redefinition element located adjacent to a selenocysteine-encoding UGA codon in the eukaryal gene, SEPN1. This element is sufficient to stimulate high-level (6%) translational redefinition of the SEPN1 UGA codon in human cells. Readthrough levels further increased to 12% when tested in the presence of the SEPN1 3'UTR SECIS. Directed mutagenesis and phylogeny of the sequence context strongly supports the importance of a stem loop starting six nucleotides 3' of the UGA codon. Sequences capable of forming strong RNA structures were also identified 3' adjacent to, or near, selenocysteine-encoding UGA codons in the Sps2, SelH, SelO, and SelT selenoprotein genes.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "c74fb4970f0c433ca0ed2902b475918f", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[129, 129], [43, 43]], "char_spans": [[763, 767], [269, 273]]}]}], "context_tokens": [["Incorporation", 0], ["of", 14], ["the", 17], ["21st", 21], ["amino", 26], ["acid", 32], [",", 36], ["selenocysteine", 38], [",", 52], ["into", 54], ["proteins", 59], ["is", 68], ["specified", 71], ["in", 81], ["all", 84], ["three", 88], ["domains", 94], ["of", 102], ["life", 105], ["by", 110], ["dynamic", 113], ["translational", 121], ["redefinition", 135], ["of", 148], ["UGA", 151], ["codons", 155], [".", 161], ["In", 163], ["eukarya", 166], ["and", 174], ["archaea", 178], [",", 185], ["selenocysteine", 187], ["insertion", 202], ["requires", 212], ["a", 221], ["cis", 223], ["-", 226], ["acting", 227], ["selenocysteine", 234], ["insertion", 249], ["sequence", 259], ["(", 268], ["SECIS", 269], [")", 274], ["usually", 276], ["located", 284], ["in", 292], ["the", 295], ["3'UTR", 299], ["of", 305], ["selenoprotein", 308], ["mRNAs", 322], [".", 327], ["Here", 329], ["we", 334], ["present", 337], ["comparative", 345], ["sequence", 357], ["analysis", 366], ["and", 375], ["experimental", 379], ["data", 392], ["supporting", 397], ["the", 408], ["presence", 412], ["of", 421], ["a", 424], ["second", 426], ["stop", 433], ["codon", 438], ["redefinition", 444], ["element", 457], ["located", 465], ["adjacent", 473], ["to", 482], ["a", 485], ["selenocysteine", 487], ["-", 501], ["encoding", 502], ["UGA", 511], ["codon", 515], ["in", 521], ["the", 524], ["eukaryal", 528], ["gene", 537], [",", 541], ["SEPN1", 543], [".", 548], ["This", 550], ["element", 555], ["is", 563], ["sufficient", 566], ["to", 577], ["stimulate", 580], ["high", 590], ["-", 594], ["level", 595], ["(", 601], ["6", 602], ["%", 603], [")", 604], ["translational", 606], ["redefinition", 620], ["of", 633], ["the", 636], ["SEPN1", 640], ["UGA", 646], ["codon", 650], ["in", 656], ["human", 659], ["cells", 665], [".", 670], ["Readthrough", 672], ["levels", 684], ["further", 691], ["increased", 699], ["to", 709], ["12", 712], ["%", 714], ["when", 716], ["tested", 721], ["in", 728], ["the", 731], ["presence", 735], ["of", 744], ["the", 747], ["SEPN1", 751], ["3'UTR", 757], ["SECIS", 763], [".", 768], ["Directed", 770], ["mutagenesis", 779], ["and", 791], ["phylogeny", 795], ["of", 805], ["the", 808], ["sequence", 812], ["context", 821], ["strongly", 829], ["supports", 838], ["the", 847], ["importance", 851], ["of", 862], ["a", 865], ["stem", 867], ["loop", 872], ["starting", 877], ["six", 886], ["nucleotides", 890], ["3", 902], ["'", 903], ["of", 905], ["the", 908], ["UGA", 912], ["codon", 916], [".", 921], ["Sequences", 923], ["capable", 933], ["of", 941], ["forming", 944], ["strong", 952], ["RNA", 959], ["structures", 963], ["were", 974], ["also", 979], ["identified", 984], ["3", 995], ["'", 996], ["adjacent", 998], ["to", 1007], [",", 1009], ["or", 1011], ["near", 1014], [",", 1018], ["selenocysteine", 1020], ["-", 1034], ["encoding", 1035], ["UGA", 1044], ["codons", 1048], ["in", 1055], ["the", 1058], ["Sps2", 1062], [",", 1066], ["SelH", 1068], [",", 1072], ["SelO", 1074], [",", 1078], ["and", 1080], ["SelT", 1084], ["selenoprotein", 1089], ["genes", 1103], [".", 1108]]}
{"context": "Corynebacterium minutissimum is the bacteria that leads to cutaneous eruptions of erythrasma and is the most common cause of interdigital foot infections. It is found mostly in occluded intertriginous areas such as the axillae, inframammary areas, interspaces of the toes, intergluteal and crural folds, and is more common in individuals with diabetes mellitus than other clinical patients. This organism can be isolated from a cutaneous site along with a concurrent dermatophyte or Candida albicans infection. The differential diagnosis of erythrasma includes psoriasis, dermatophytosis, candidiasis and intertrigo, and methods for differentiating include Wood's light examination and bacterial and mycological cultures. Erythromycin 250mg four times daily for 14 days is the treatment of choice and other antibacterials include tetracycline and chloramphenicol; however, the use of chloramphenicol is limited by bone marrow suppression potentially leading to neutropenia, agranulocytosis and aplastic anaemia. Further studies are needed but clarithromycin may be an additional drug for use in the future. Where there is therapeutic failure or intertriginous involvement, topical solutions such as clindamycin, Whitfield's ointment, sodium fusidate ointment and antibacterial soaps may be required for both treatment and prophylaxis. Limited studies on the efficacy of these medications exist, however, systemic erythromycin demonstrates cure rates as high as 100%. Compared with tetracyclines, systemic erythromycin has greater efficacy in patients with involvement of the axillae and groin, and similar efficacy for interdigital infections. Whitfield's ointment has equal efficacy to systemic erythromycin in the axillae and groin, but shows greater efficacy in the interdigital areas and is comparable with 2% sodium fusidate ointment for treatment of all areas. Adverse drug effects and potential drug interactions need to be considered. No cost-effectiveness data are available but there are limited data on cost-related treatment issues. A guideline is proposed for the detection, evaluation, treatment and prophylaxis of this cutaneous eruption.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "061225f92c5f46b29866ab54751d547a", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[0, 1]], "char_spans": [[0, 27]]}]}], "context_tokens": [["Corynebacterium", 0], ["minutissimum", 16], ["is", 29], ["the", 32], ["bacteria", 36], ["that", 45], ["leads", 50], ["to", 56], ["cutaneous", 59], ["eruptions", 69], ["of", 79], ["erythrasma", 82], ["and", 93], ["is", 97], ["the", 100], ["most", 104], ["common", 109], ["cause", 116], ["of", 122], ["interdigital", 125], ["foot", 138], ["infections", 143], [".", 153], ["It", 155], ["is", 158], ["found", 161], ["mostly", 167], ["in", 174], ["occluded", 177], ["intertriginous", 186], ["areas", 201], ["such", 207], ["as", 212], ["the", 215], ["axillae", 219], [",", 226], ["inframammary", 228], ["areas", 241], [",", 246], ["interspaces", 248], ["of", 260], ["the", 263], ["toes", 267], [",", 271], ["intergluteal", 273], ["and", 286], ["crural", 290], ["folds", 297], [",", 302], ["and", 304], ["is", 308], ["more", 311], ["common", 316], ["in", 323], ["individuals", 326], ["with", 338], ["diabetes", 343], ["mellitus", 352], ["than", 361], ["other", 366], ["clinical", 372], ["patients", 381], [".", 389], ["This", 391], ["organism", 396], ["can", 405], ["be", 409], ["isolated", 412], ["from", 421], ["a", 426], ["cutaneous", 428], ["site", 438], ["along", 443], ["with", 449], ["a", 454], ["concurrent", 456], ["dermatophyte", 467], ["or", 480], ["Candida", 483], ["albicans", 491], ["infection", 500], [".", 509], ["The", 511], ["differential", 515], ["diagnosis", 528], ["of", 538], ["erythrasma", 541], ["includes", 552], ["psoriasis", 561], [",", 570], ["dermatophytosis", 572], [",", 587], ["candidiasis", 589], ["and", 601], ["intertrigo", 605], [",", 615], ["and", 617], ["methods", 621], ["for", 629], ["differentiating", 633], ["include", 649], ["Wood", 657], ["'s", 661], ["light", 664], ["examination", 670], ["and", 682], ["bacterial", 686], ["and", 696], ["mycological", 700], ["cultures", 712], [".", 720], ["Erythromycin", 722], ["250", 735], ["mg", 738], ["four", 741], ["times", 746], ["daily", 752], ["for", 758], ["14", 762], ["days", 765], ["is", 770], ["the", 773], ["treatment", 777], ["of", 787], ["choice", 790], ["and", 797], ["other", 801], ["antibacterials", 807], ["include", 822], ["tetracycline", 830], ["and", 843], ["chloramphenicol", 847], [";", 862], ["however", 864], [",", 871], ["the", 873], ["use", 877], ["of", 881], ["chloramphenicol", 884], ["is", 900], ["limited", 903], ["by", 911], ["bone", 914], ["marrow", 919], ["suppression", 926], ["potentially", 938], ["leading", 950], ["to", 958], ["neutropenia", 961], [",", 972], ["agranulocytosis", 974], ["and", 990], ["aplastic", 994], ["anaemia", 1003], [".", 1010], ["Further", 1012], ["studies", 1020], ["are", 1028], ["needed", 1032], ["but", 1039], ["clarithromycin", 1043], ["may", 1058], ["be", 1062], ["an", 1065], ["additional", 1068], ["drug", 1079], ["for", 1084], ["use", 1088], ["in", 1092], ["the", 1095], ["future", 1099], [".", 1105], ["Where", 1107], ["there", 1113], ["is", 1119], ["therapeutic", 1122], ["failure", 1134], ["or", 1142], ["intertriginous", 1145], ["involvement", 1160], [",", 1171], ["topical", 1173], ["solutions", 1181], ["such", 1191], ["as", 1196], ["clindamycin", 1199], [",", 1210], ["Whitfield", 1212], ["'s", 1221], ["ointment", 1224], [",", 1232], ["sodium", 1234], ["fusidate", 1241], ["ointment", 1250], ["and", 1259], ["antibacterial", 1263], ["soaps", 1277], ["may", 1283], ["be", 1287], ["required", 1290], ["for", 1299], ["both", 1303], ["treatment", 1308], ["and", 1318], ["prophylaxis", 1322], [".", 1333], ["Limited", 1335], ["studies", 1343], ["on", 1351], ["the", 1354], ["efficacy", 1358], ["of", 1367], ["these", 1370], ["medications", 1376], ["exist", 1388], [",", 1393], ["however", 1395], [",", 1402], ["systemic", 1404], ["erythromycin", 1413], ["demonstrates", 1426], ["cure", 1439], ["rates", 1444], ["as", 1450], ["high", 1453], ["as", 1458], ["100", 1461], ["%", 1464], [".", 1465], ["Compared", 1467], ["with", 1476], ["tetracyclines", 1481], [",", 1494], ["systemic", 1496], ["erythromycin", 1505], ["has", 1518], ["greater", 1522], ["efficacy", 1530], ["in", 1539], ["patients", 1542], ["with", 1551], ["involvement", 1556], ["of", 1568], ["the", 1571], ["axillae", 1575], ["and", 1583], ["groin", 1587], [",", 1592], ["and", 1594], ["similar", 1598], ["efficacy", 1606], ["for", 1615], ["interdigital", 1619], ["infections", 1632], [".", 1642], ["Whitfield", 1644], ["'s", 1653], ["ointment", 1656], ["has", 1665], ["equal", 1669], ["efficacy", 1675], ["to", 1684], ["systemic", 1687], ["erythromycin", 1696], ["in", 1709], ["the", 1712], ["axillae", 1716], ["and", 1724], ["groin", 1728], [",", 1733], ["but", 1735], ["shows", 1739], ["greater", 1745], ["efficacy", 1753], ["in", 1762], ["the", 1765], ["interdigital", 1769], ["areas", 1782], ["and", 1788], ["is", 1792], ["comparable", 1795], ["with", 1806], ["2", 1811], ["%", 1812], ["sodium", 1814], ["fusidate", 1821], ["ointment", 1830], ["for", 1839], ["treatment", 1843], ["of", 1853], ["all", 1856], ["areas", 1860], [".", 1865], ["Adverse", 1867], ["drug", 1875], ["effects", 1880], ["and", 1888], ["potential", 1892], ["drug", 1902], ["interactions", 1907], ["need", 1920], ["to", 1925], ["be", 1928], ["considered", 1931], [".", 1941], ["No", 1943], ["cost", 1946], ["-", 1950], ["effectiveness", 1951], ["data", 1965], ["are", 1970], ["available", 1974], ["but", 1984], ["there", 1988], ["are", 1994], ["limited", 1998], ["data", 2006], ["on", 2011], ["cost", 2014], ["-", 2018], ["related", 2019], ["treatment", 2027], ["issues", 2037], [".", 2043], ["A", 2045], ["guideline", 2047], ["is", 2057], ["proposed", 2060], ["for", 2069], ["the", 2073], ["detection", 2077], [",", 2086], ["evaluation", 2088], [",", 2098], ["treatment", 2100], ["and", 2110], ["prophylaxis", 2114], ["of", 2126], ["this", 2129], ["cutaneous", 2134], ["eruption", 2144], [".", 2152]]}
{"context": "All archaeal and many bacterial genomes contain Clustered Regularly Interspaced Short Palindrome Repeats (CRISPR) and variable arrays of the CRISPR-associated (cas) genes that have been previously implicated in a novel form of DNA repair on the basis of comparative analysis of their protein product sequences. However, the proximity of CRISPR and cas genes strongly suggests that they have related functions which is hard to reconcile with the repair hypothesis. The protein sequences of the numerous cas gene products were classified into approximately 25 distinct protein families; several new functional and structural predictions are described. Comparative-genomic analysis of CRISPR and cas genes leads to the hypothesis that the CRISPR-Cas system (CASS) is a mechanism of defense against invading phages and plasmids that functions analogously to the eukaryotic RNA interference (RNAi) systems. Specific functional analogies are drawn between several components of CASS and proteins involved in eukaryotic RNAi, including the double-stranded RNA-specific helicase-nuclease (dicer), the endonuclease cleaving target mRNAs (slicer), and the RNA-dependent RNA polymerase. However, none of the CASS components is orthologous to its apparent eukaryotic functional counterpart. It is proposed that unique inserts of CRISPR, some of which are homologous to fragments of bacteriophage and plasmid genes, function as prokaryotic siRNAs (psiRNA), by base-pairing with the target mRNAs and promoting their degradation or translation shutdown. Specific hypothetical schemes are developed for the functioning of the predicted prokaryotic siRNA system and for the formation of new CRISPR units with unique inserts encoding psiRNA conferring immunity to the respective newly encountered phages or plasmids. The unique inserts in CRISPR show virtually no similarity even between closely related bacterial strains which suggests their rapid turnover, on evolutionary scale. Corollaries of this finding are that, even among closely related prokaryotes, the most commonly encountered phages and plasmids are different and/or that the dominant phages and plasmids turn over rapidly. We proposed previously that Cas proteins comprise a novel DNA repair system. The association of the cas genes with CRISPR and, especially, the presence, in CRISPR units, of unique inserts homologous to phage and plasmid genes make us abandon this hypothesis. It appears most likely that CASS is a prokaryotic system of defense against phages and plasmids that functions via the RNAi mechanism. The functioning of this system seems to involve integration of fragments of foreign genes into archaeal and bacterial chromosomes yielding heritable immunity to the respective agents. However, it appears that this inheritance is extremely unstable on the evolutionary scale such that the repertoires of unique psiRNAs are completely replaced even in closely related prokaryotes, presumably, in response to rapidly changing repertoires of dominant phages and plasmids.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "ba77ea04dbea4db5b99ee41efc509e2d", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[120, 122]], "char_spans": [[736, 745]]}]}], "context_tokens": [["All", 0], ["archaeal", 4], ["and", 13], ["many", 17], ["bacterial", 22], ["genomes", 32], ["contain", 40], ["Clustered", 48], ["Regularly", 58], ["Interspaced", 68], ["Short", 80], ["Palindrome", 86], ["Repeats", 97], ["(", 105], ["CRISPR", 106], [")", 112], ["and", 114], ["variable", 118], ["arrays", 127], ["of", 134], ["the", 137], ["CRISPR", 141], ["-", 147], ["associated", 148], ["(", 159], ["cas", 160], [")", 163], ["genes", 165], ["that", 171], ["have", 176], ["been", 181], ["previously", 186], ["implicated", 197], ["in", 208], ["a", 211], ["novel", 213], ["form", 219], ["of", 224], ["DNA", 227], ["repair", 231], ["on", 238], ["the", 241], ["basis", 245], ["of", 251], ["comparative", 254], ["analysis", 266], ["of", 275], ["their", 278], ["protein", 284], ["product", 292], ["sequences", 300], [".", 309], ["However", 311], [",", 318], ["the", 320], ["proximity", 324], ["of", 334], ["CRISPR", 337], ["and", 344], ["cas", 348], ["genes", 352], ["strongly", 358], ["suggests", 367], ["that", 376], ["they", 381], ["have", 386], ["related", 391], ["functions", 399], ["which", 409], ["is", 415], ["hard", 418], ["to", 423], ["reconcile", 426], ["with", 436], ["the", 441], ["repair", 445], ["hypothesis", 452], [".", 462], ["The", 464], ["protein", 468], ["sequences", 476], ["of", 486], ["the", 489], ["numerous", 493], ["cas", 502], ["gene", 506], ["products", 511], ["were", 520], ["classified", 525], ["into", 536], ["approximately", 541], ["25", 555], ["distinct", 558], ["protein", 567], ["families", 575], [";", 583], ["several", 585], ["new", 593], ["functional", 597], ["and", 608], ["structural", 612], ["predictions", 623], ["are", 635], ["described", 639], [".", 648], ["Comparative", 650], ["-", 661], ["genomic", 662], ["analysis", 670], ["of", 679], ["CRISPR", 682], ["and", 689], ["cas", 693], ["genes", 697], ["leads", 703], ["to", 709], ["the", 712], ["hypothesis", 716], ["that", 727], ["the", 732], ["CRISPR", 736], ["-", 742], ["Cas", 743], ["system", 747], ["(", 754], ["CASS", 755], [")", 759], ["is", 761], ["a", 764], ["mechanism", 766], ["of", 776], ["defense", 779], ["against", 787], ["invading", 795], ["phages", 804], ["and", 811], ["plasmids", 815], ["that", 824], ["functions", 829], ["analogously", 839], ["to", 851], ["the", 854], ["eukaryotic", 858], ["RNA", 869], ["interference", 873], ["(", 886], ["RNAi", 887], [")", 891], ["systems", 893], [".", 900], ["Specific", 902], ["functional", 911], ["analogies", 922], ["are", 932], ["drawn", 936], ["between", 942], ["several", 950], ["components", 958], ["of", 969], ["CASS", 972], ["and", 977], ["proteins", 981], ["involved", 990], ["in", 999], ["eukaryotic", 1002], ["RNAi", 1013], [",", 1017], ["including", 1019], ["the", 1029], ["double", 1033], ["-", 1039], ["stranded", 1040], ["RNA", 1049], ["-", 1052], ["specific", 1053], ["helicase", 1062], ["-", 1070], ["nuclease", 1071], ["(", 1080], ["dicer", 1081], [")", 1086], [",", 1087], ["the", 1089], ["endonuclease", 1093], ["cleaving", 1106], ["target", 1115], ["mRNAs", 1122], ["(", 1128], ["slicer", 1129], [")", 1135], [",", 1136], ["and", 1138], ["the", 1142], ["RNA", 1146], ["-", 1149], ["dependent", 1150], ["RNA", 1160], ["polymerase", 1164], [".", 1174], ["However", 1176], [",", 1183], ["none", 1185], ["of", 1190], ["the", 1193], ["CASS", 1197], ["components", 1202], ["is", 1213], ["orthologous", 1216], ["to", 1228], ["its", 1231], ["apparent", 1235], ["eukaryotic", 1244], ["functional", 1255], ["counterpart", 1266], [".", 1277], ["It", 1279], ["is", 1282], ["proposed", 1285], ["that", 1294], ["unique", 1299], ["inserts", 1306], ["of", 1314], ["CRISPR", 1317], [",", 1323], ["some", 1325], ["of", 1330], ["which", 1333], ["are", 1339], ["homologous", 1343], ["to", 1354], ["fragments", 1357], ["of", 1367], ["bacteriophage", 1370], ["and", 1384], ["plasmid", 1388], ["genes", 1396], [",", 1401], ["function", 1403], ["as", 1412], ["prokaryotic", 1415], ["siRNAs", 1427], ["(", 1434], ["psiRNA", 1435], [")", 1441], [",", 1442], ["by", 1444], ["base", 1447], ["-", 1451], ["pairing", 1452], ["with", 1460], ["the", 1465], ["target", 1469], ["mRNAs", 1476], ["and", 1482], ["promoting", 1486], ["their", 1496], ["degradation", 1502], ["or", 1514], ["translation", 1517], ["shutdown", 1529], [".", 1537], ["Specific", 1539], ["hypothetical", 1548], ["schemes", 1561], ["are", 1569], ["developed", 1573], ["for", 1583], ["the", 1587], ["functioning", 1591], ["of", 1603], ["the", 1606], ["predicted", 1610], ["prokaryotic", 1620], ["siRNA", 1632], ["system", 1638], ["and", 1645], ["for", 1649], ["the", 1653], ["formation", 1657], ["of", 1667], ["new", 1670], ["CRISPR", 1674], ["units", 1681], ["with", 1687], ["unique", 1692], ["inserts", 1699], ["encoding", 1707], ["psiRNA", 1716], ["conferring", 1723], ["immunity", 1734], ["to", 1743], ["the", 1746], ["respective", 1750], ["newly", 1761], ["encountered", 1767], ["phages", 1779], ["or", 1786], ["plasmids", 1789], [".", 1797], ["The", 1799], ["unique", 1803], ["inserts", 1810], ["in", 1818], ["CRISPR", 1821], ["show", 1828], ["virtually", 1833], ["no", 1843], ["similarity", 1846], ["even", 1857], ["between", 1862], ["closely", 1870], ["related", 1878], ["bacterial", 1886], ["strains", 1896], ["which", 1904], ["suggests", 1910], ["their", 1919], ["rapid", 1925], ["turnover", 1931], [",", 1939], ["on", 1941], ["evolutionary", 1944], ["scale", 1957], [".", 1962], ["Corollaries", 1964], ["of", 1976], ["this", 1979], ["finding", 1984], ["are", 1992], ["that", 1996], [",", 2000], ["even", 2002], ["among", 2007], ["closely", 2013], ["related", 2021], ["prokaryotes", 2029], [",", 2040], ["the", 2042], ["most", 2046], ["commonly", 2051], ["encountered", 2060], ["phages", 2072], ["and", 2079], ["plasmids", 2083], ["are", 2092], ["different", 2096], ["and/or", 2106], ["that", 2113], ["the", 2118], ["dominant", 2122], ["phages", 2131], ["and", 2138], ["plasmids", 2142], ["turn", 2151], ["over", 2156], ["rapidly", 2161], [".", 2168], ["We", 2170], ["proposed", 2173], ["previously", 2182], ["that", 2193], ["Cas", 2198], ["proteins", 2202], ["comprise", 2211], ["a", 2220], ["novel", 2222], ["DNA", 2228], ["repair", 2232], ["system", 2239], [".", 2245], ["The", 2247], ["association", 2251], ["of", 2263], ["the", 2266], ["cas", 2270], ["genes", 2274], ["with", 2280], ["CRISPR", 2285], ["and", 2292], [",", 2295], ["especially", 2297], [",", 2307], ["the", 2309], ["presence", 2313], [",", 2321], ["in", 2323], ["CRISPR", 2326], ["units", 2333], [",", 2338], ["of", 2340], ["unique", 2343], ["inserts", 2350], ["homologous", 2358], ["to", 2369], ["phage", 2372], ["and", 2378], ["plasmid", 2382], ["genes", 2390], ["make", 2396], ["us", 2401], ["abandon", 2404], ["this", 2412], ["hypothesis", 2417], [".", 2427], ["It", 2429], ["appears", 2432], ["most", 2440], ["likely", 2445], ["that", 2452], ["CASS", 2457], ["is", 2462], ["a", 2465], ["prokaryotic", 2467], ["system", 2479], ["of", 2486], ["defense", 2489], ["against", 2497], ["phages", 2505], ["and", 2512], ["plasmids", 2516], ["that", 2525], ["functions", 2530], ["via", 2540], ["the", 2544], ["RNAi", 2548], ["mechanism", 2553], [".", 2562], ["The", 2564], ["functioning", 2568], ["of", 2580], ["this", 2583], ["system", 2588], ["seems", 2595], ["to", 2601], ["involve", 2604], ["integration", 2612], ["of", 2624], ["fragments", 2627], ["of", 2637], ["foreign", 2640], ["genes", 2648], ["into", 2654], ["archaeal", 2659], ["and", 2668], ["bacterial", 2672], ["chromosomes", 2682], ["yielding", 2694], ["heritable", 2703], ["immunity", 2713], ["to", 2722], ["the", 2725], ["respective", 2729], ["agents", 2740], [".", 2746], ["However", 2748], [",", 2755], ["it", 2757], ["appears", 2760], ["that", 2768], ["this", 2773], ["inheritance", 2778], ["is", 2790], ["extremely", 2793], ["unstable", 2803], ["on", 2812], ["the", 2815], ["evolutionary", 2819], ["scale", 2832], ["such", 2838], ["that", 2843], ["the", 2848], ["repertoires", 2852], ["of", 2864], ["unique", 2867], ["psiRNAs", 2874], ["are", 2882], ["completely", 2886], ["replaced", 2897], ["even", 2906], ["in", 2911], ["closely", 2914], ["related", 2922], ["prokaryotes", 2930], [",", 2941], ["presumably", 2943], [",", 2953], ["in", 2955], ["response", 2958], ["to", 2967], ["rapidly", 2970], ["changing", 2978], ["repertoires", 2987], ["of", 2999], ["dominant", 3002], ["phages", 3011], ["and", 3018], ["plasmids", 3022], [".", 3030]]}
{"context": "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. In 2-10% of the cases, this chimeric gene is generated by variant rearrangements, involving 9q34, 22q11, and one or several other genomic regions. All chromosomes have been described as participating in these variants, but there is a marked breakpoint clustering to chromosome bands 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13. Despite their genetically complex nature, available data indicate that variant rearrangements do not confer any specific phenotypic or prognostic impact as compared to CML with a standard Ph chromosome. In most instances, the t(9;22), or a variant thereof, is the sole chromosomal anomaly during the chronic phase (CP) of the disease, whereas additional genetic changes are demonstrable in 60-80% of cases in blast crisis (BC). The secondary chromosomal aberrations are clearly nonrandom, with the most common chromosomal abnormalities being +8 (34% of cases with additional changes), +Ph (30%), i(17q) (20%), +19 (13%), -Y (8% of males), +21 (7%), +17 (5%), and monosomy 7 (5%). We suggest that all these aberrations, occurring in >5% of CML with secondary changes, should be denoted major route abnormalities. Chromosome segments often involved in structural rearrangements include 1q, 3q21, 3q26, 7p, 9p, 11q23, 12p13, 13q11-14, 17p11, 17q10, 21q22, and 22q10. No clear-cut differences as regards type and prevalence of additional aberrations seem to exist between CML with standard t(9;22) and CML with variants, except for slightly lower frequencies of the most common changes in the latter group. The temporal order of the secondary changes varies, but the preferred pathway appears to start with i(17q), followed by +8 and +Ph, and then +19. Molecular genetic abnormalities preceding, or occurring during, BC include overexpression of the BCR/ABL transcript, upregulation of the EVI1 gene, increased telomerase activity, and mutations of the tumor suppressor genes RB1, TP53, and CDKN2A. The cytogenetic evolution patterns vary significantly in relation to treatment given during CP. For example, +8 is more common after busulfan than hydroxyurea therapy, and the secondary changes seen after interferon-alpha treatment or bone marrow transplantation are often unusual, seemingly random, and occasionally transient. Apart from the strong phenotypic impact of addition of acute myeloid leukemia/myelodysplasia-associated translocations and inversions, such as inv(3)(q21q26), t(3;21)(q26;q22), and t(15;17)(q22;q12-21), in CML BC, only a few significant differences between myeloid and lymphoid BC are discerned, with i(17q) and TP53 mutations being more common in myeloid BC and monosomy 7, hypodiploidy, and CDKN2A deletions being more frequent in lymphoid BC. The prognostic significance of the secondary genetic changes is not uniform, although abnormalities involving chromosome 17, e.g., i(17q), have repeatedly been shown to be ominous. However, the clinical impact of additional cytogenetic and molecular genetic aberrations is most likely modified by the treatment modalities used.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "efad110a71da44ecb9d4f661d22b9692", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[22, 26]], "char_spans": [[141, 159]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["genetically", 34], ["characterized", 46], ["by", 60], ["the", 63], ["presence", 67], ["of", 76], ["the", 79], ["reciprocal", 83], ["translocation", 94], ["t(9;22)(q34;q11", 108], [")", 123], [",", 124], ["resulting", 126], ["in", 136], ["a", 139], ["BCR", 141], ["/", 144], ["ABL", 145], ["gene", 149], ["fusion", 154], ["on", 161], ["the", 164], ["derivative", 168], ["chromosome", 179], ["22", 190], ["called", 193], ["the", 200], ["Philadelphia", 204], ["(", 217], ["Ph", 218], [")", 220], ["chromosome", 222], [".", 232], ["In", 234], ["2", 237], ["-", 238], ["10", 239], ["%", 241], ["of", 243], ["the", 246], ["cases", 250], [",", 255], ["this", 257], ["chimeric", 262], ["gene", 271], ["is", 276], ["generated", 279], ["by", 289], ["variant", 292], ["rearrangements", 300], [",", 314], ["involving", 316], ["9q34", 326], [",", 330], ["22q11", 332], [",", 337], ["and", 339], ["one", 343], ["or", 347], ["several", 350], ["other", 358], ["genomic", 364], ["regions", 372], [".", 379], ["All", 381], ["chromosomes", 385], ["have", 397], ["been", 402], ["described", 407], ["as", 417], ["participating", 420], ["in", 434], ["these", 437], ["variants", 443], [",", 451], ["but", 453], ["there", 457], ["is", 463], ["a", 466], ["marked", 468], ["breakpoint", 475], ["clustering", 486], ["to", 497], ["chromosome", 500], ["bands", 511], ["1p36", 517], [",", 521], ["3p21", 523], [",", 527], ["5q13", 529], [",", 533], ["6p21", 535], [",", 539], ["9q22", 541], [",", 545], ["11q13", 547], [",", 552], ["12p13", 554], [",", 559], ["17p13", 561], [",", 566], ["17q21", 568], [",", 573], ["17q25", 575], [",", 580], ["19q13", 582], [",", 587], ["21q22", 589], [",", 594], ["22q12", 596], [",", 601], ["and", 603], ["22q13", 607], [".", 612], ["Despite", 614], ["their", 622], ["genetically", 628], ["complex", 640], ["nature", 648], [",", 654], ["available", 656], ["data", 666], ["indicate", 671], ["that", 680], ["variant", 685], ["rearrangements", 693], ["do", 708], ["not", 711], ["confer", 715], ["any", 722], ["specific", 726], ["phenotypic", 735], ["or", 746], ["prognostic", 749], ["impact", 760], ["as", 767], ["compared", 770], ["to", 779], ["CML", 782], ["with", 786], ["a", 791], ["standard", 793], ["Ph", 802], ["chromosome", 805], [".", 815], ["In", 817], ["most", 820], ["instances", 825], [",", 834], ["the", 836], ["t(9;22", 840], [")", 846], [",", 847], ["or", 849], ["a", 852], ["variant", 854], ["thereof", 862], [",", 869], ["is", 871], ["the", 874], ["sole", 878], ["chromosomal", 883], ["anomaly", 895], ["during", 903], ["the", 910], ["chronic", 914], ["phase", 922], ["(", 928], ["CP", 929], [")", 931], ["of", 933], ["the", 936], ["disease", 940], [",", 947], ["whereas", 949], ["additional", 957], ["genetic", 968], ["changes", 976], ["are", 984], ["demonstrable", 988], ["in", 1001], ["60", 1004], ["-", 1006], ["80", 1007], ["%", 1009], ["of", 1011], ["cases", 1014], ["in", 1020], ["blast", 1023], ["crisis", 1029], ["(", 1036], ["BC", 1037], [")", 1039], [".", 1040], ["The", 1042], ["secondary", 1046], ["chromosomal", 1056], ["aberrations", 1068], ["are", 1080], ["clearly", 1084], ["nonrandom", 1092], [",", 1101], ["with", 1103], ["the", 1108], ["most", 1112], ["common", 1117], ["chromosomal", 1124], ["abnormalities", 1136], ["being", 1150], ["+8", 1156], ["(", 1159], ["34", 1160], ["%", 1162], ["of", 1164], ["cases", 1167], ["with", 1173], ["additional", 1178], ["changes", 1189], [")", 1196], [",", 1197], ["+", 1199], ["Ph", 1200], ["(", 1203], ["30", 1204], ["%", 1206], [")", 1207], [",", 1208], ["i(17q", 1210], [")", 1215], ["(", 1217], ["20", 1218], ["%", 1220], [")", 1221], [",", 1222], ["+19", 1224], ["(", 1228], ["13", 1229], ["%", 1231], [")", 1232], [",", 1233], ["-Y", 1235], ["(", 1238], ["8", 1239], ["%", 1240], ["of", 1242], ["males", 1245], [")", 1250], [",", 1251], ["+21", 1253], ["(", 1257], ["7", 1258], ["%", 1259], [")", 1260], [",", 1261], ["+17", 1263], ["(", 1267], ["5", 1268], ["%", 1269], [")", 1270], [",", 1271], ["and", 1273], ["monosomy", 1277], ["7", 1286], ["(", 1288], ["5", 1289], ["%", 1290], [")", 1291], [".", 1292], ["We", 1294], ["suggest", 1297], ["that", 1305], ["all", 1310], ["these", 1314], ["aberrations", 1320], [",", 1331], ["occurring", 1333], ["in", 1343], [">", 1346], ["5", 1347], ["%", 1348], ["of", 1350], ["CML", 1353], ["with", 1357], ["secondary", 1362], ["changes", 1372], [",", 1379], ["should", 1381], ["be", 1388], ["denoted", 1391], ["major", 1399], ["route", 1405], ["abnormalities", 1411], [".", 1424], ["Chromosome", 1426], ["segments", 1437], ["often", 1446], ["involved", 1452], ["in", 1461], ["structural", 1464], ["rearrangements", 1475], ["include", 1490], ["1q", 1498], [",", 1500], ["3q21", 1502], [",", 1506], ["3q26", 1508], [",", 1512], ["7p", 1514], [",", 1516], ["9p", 1518], [",", 1520], ["11q23", 1522], [",", 1527], ["12p13", 1529], [",", 1534], ["13q11", 1536], ["-", 1541], ["14", 1542], [",", 1544], ["17p11", 1546], [",", 1551], ["17q10", 1553], [",", 1558], ["21q22", 1560], [",", 1565], ["and", 1567], ["22q10", 1571], [".", 1576], ["No", 1578], ["clear", 1581], ["-", 1586], ["cut", 1587], ["differences", 1591], ["as", 1603], ["regards", 1606], ["type", 1614], ["and", 1619], ["prevalence", 1623], ["of", 1634], ["additional", 1637], ["aberrations", 1648], ["seem", 1660], ["to", 1665], ["exist", 1668], ["between", 1674], ["CML", 1682], ["with", 1686], ["standard", 1691], ["t(9;22", 1700], [")", 1706], ["and", 1708], ["CML", 1712], ["with", 1716], ["variants", 1721], [",", 1729], ["except", 1731], ["for", 1738], ["slightly", 1742], ["lower", 1751], ["frequencies", 1757], ["of", 1769], ["the", 1772], ["most", 1776], ["common", 1781], ["changes", 1788], ["in", 1796], ["the", 1799], ["latter", 1803], ["group", 1810], [".", 1815], ["The", 1817], ["temporal", 1821], ["order", 1830], ["of", 1836], ["the", 1839], ["secondary", 1843], ["changes", 1853], ["varies", 1861], [",", 1867], ["but", 1869], ["the", 1873], ["preferred", 1877], ["pathway", 1887], ["appears", 1895], ["to", 1903], ["start", 1906], ["with", 1912], ["i(17q", 1917], [")", 1922], [",", 1923], ["followed", 1925], ["by", 1934], ["+8", 1937], ["and", 1940], ["+", 1944], ["Ph", 1945], [",", 1947], ["and", 1949], ["then", 1953], ["+19", 1958], [".", 1961], ["Molecular", 1963], ["genetic", 1973], ["abnormalities", 1981], ["preceding", 1995], [",", 2004], ["or", 2006], ["occurring", 2009], ["during", 2019], [",", 2025], ["BC", 2027], ["include", 2030], ["overexpression", 2038], ["of", 2053], ["the", 2056], ["BCR", 2060], ["/", 2063], ["ABL", 2064], ["transcript", 2068], [",", 2078], ["upregulation", 2080], ["of", 2093], ["the", 2096], ["EVI1", 2100], ["gene", 2105], [",", 2109], ["increased", 2111], ["telomerase", 2121], ["activity", 2132], [",", 2140], ["and", 2142], ["mutations", 2146], ["of", 2156], ["the", 2159], ["tumor", 2163], ["suppressor", 2169], ["genes", 2180], ["RB1", 2186], [",", 2189], ["TP53", 2191], [",", 2195], ["and", 2197], ["CDKN2A.", 2201], ["The", 2209], ["cytogenetic", 2213], ["evolution", 2225], ["patterns", 2235], ["vary", 2244], ["significantly", 2249], ["in", 2263], ["relation", 2266], ["to", 2275], ["treatment", 2278], ["given", 2288], ["during", 2294], ["CP", 2301], [".", 2303], ["For", 2305], ["example", 2309], [",", 2316], ["+8", 2318], ["is", 2321], ["more", 2324], ["common", 2329], ["after", 2336], ["busulfan", 2342], ["than", 2351], ["hydroxyurea", 2356], ["therapy", 2368], [",", 2375], ["and", 2377], ["the", 2381], ["secondary", 2385], ["changes", 2395], ["seen", 2403], ["after", 2408], ["interferon", 2414], ["-", 2424], ["alpha", 2425], ["treatment", 2431], ["or", 2441], ["bone", 2444], ["marrow", 2449], ["transplantation", 2456], ["are", 2472], ["often", 2476], ["unusual", 2482], [",", 2489], ["seemingly", 2491], ["random", 2501], [",", 2507], ["and", 2509], ["occasionally", 2513], ["transient", 2526], [".", 2535], ["Apart", 2537], ["from", 2543], ["the", 2548], ["strong", 2552], ["phenotypic", 2559], ["impact", 2570], ["of", 2577], ["addition", 2580], ["of", 2589], ["acute", 2592], ["myeloid", 2598], ["leukemia", 2606], ["/", 2614], ["myelodysplasia", 2615], ["-", 2629], ["associated", 2630], ["translocations", 2641], ["and", 2656], ["inversions", 2660], [",", 2670], ["such", 2672], ["as", 2677], ["inv(3)(q21q26", 2680], [")", 2693], [",", 2694], ["t(3;21)(q26;q22", 2696], [")", 2711], [",", 2712], ["and", 2714], ["t(15;17)(q22;q12", 2718], ["-", 2734], ["21", 2735], [")", 2737], [",", 2738], ["in", 2740], ["CML", 2743], ["BC", 2747], [",", 2749], ["only", 2751], ["a", 2756], ["few", 2758], ["significant", 2762], ["differences", 2774], ["between", 2786], ["myeloid", 2794], ["and", 2802], ["lymphoid", 2806], ["BC", 2815], ["are", 2818], ["discerned", 2822], [",", 2831], ["with", 2833], ["i(17q", 2838], [")", 2843], ["and", 2845], ["TP53", 2849], ["mutations", 2854], ["being", 2864], ["more", 2870], ["common", 2875], ["in", 2882], ["myeloid", 2885], ["BC", 2893], ["and", 2896], ["monosomy", 2900], ["7", 2909], [",", 2910], ["hypodiploidy", 2912], [",", 2924], ["and", 2926], ["CDKN2A", 2930], ["deletions", 2937], ["being", 2947], ["more", 2953], ["frequent", 2958], ["in", 2967], ["lymphoid", 2970], ["BC", 2979], [".", 2981], ["The", 2983], ["prognostic", 2987], ["significance", 2998], ["of", 3011], ["the", 3014], ["secondary", 3018], ["genetic", 3028], ["changes", 3036], ["is", 3044], ["not", 3047], ["uniform", 3051], [",", 3058], ["although", 3060], ["abnormalities", 3069], ["involving", 3083], ["chromosome", 3093], ["17", 3104], [",", 3106], ["e.g.", 3108], [",", 3112], ["i(17q", 3114], [")", 3119], [",", 3120], ["have", 3122], ["repeatedly", 3127], ["been", 3138], ["shown", 3143], ["to", 3149], ["be", 3152], ["ominous", 3155], [".", 3162], ["However", 3164], [",", 3171], ["the", 3173], ["clinical", 3177], ["impact", 3186], ["of", 3193], ["additional", 3196], ["cytogenetic", 3207], ["and", 3219], ["molecular", 3223], ["genetic", 3233], ["aberrations", 3241], ["is", 3253], ["most", 3256], ["likely", 3261], ["modified", 3268], ["by", 3277], ["the", 3280], ["treatment", 3284], ["modalities", 3294], ["used", 3305], [".", 3309]]}
{"context": "Meningioangiomatosis is a rare, benign, developmental, or hamartomatous lesion which may involve the leptomeninges and underlying brain parenchyma. Histologically, meningioangiomatosis is marked by a proliferation of blood vessels in the parenchyma, rimmed by collars of spindled meningothelial cells. There are anecdotal reports of an association of meningioangiomatosis with focal cortical dysplasia. We retrospectively analyzed the clinical, histopathologic, and treatment outcomes of 16 patients with a diagnosis of meningioangiomatosis, specifically investigating these cases for evidence of adjacent focal cortical dysplasia. Patients ranged in age from 1 to 34 years (median 18), 12 of whom had medically-intractable epilepsy as their presenting symptom. No patients in this study had a confirmed diagnosis of neurofibromatosis type II. Four patients (25%) were found to have fibrous meningiomas associated with the meningioangiomatosis. Ten of the 12 patients (83%) who had adequate tissue excised adjacent to the meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini type IA, and 4 patients (40%) classified as Palmini type IIA. Seven of the patients (44%) had no post-operative seizures, and were off anti-epileptic drugs, while 2 patients relapsed, and required pharmacologic treatment for seizure control. This study therefore presents evidence to support inclusion of meningioangiomatosis as a focal cortical dysplasia-associated entity, as suggested by the ILAE classification (type IIIc). As focal cortical dysplasia is a developmental malformation, its association with meningioangiomatosis supports a developmental etiology of sporadic meningioangiomatosis.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "60e454922314443b97e1f6b1a486c79a", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[268, 270], [170, 172], [249, 251], [55, 57], [87, 89]], "char_spans": [[1569, 1592], [1068, 1091], [1469, 1492], [377, 400], [606, 629]]}]}], "context_tokens": [["Meningioangiomatosis", 0], ["is", 21], ["a", 24], ["rare", 26], [",", 30], ["benign", 32], [",", 38], ["developmental", 40], [",", 53], ["or", 55], ["hamartomatous", 58], ["lesion", 72], ["which", 79], ["may", 85], ["involve", 89], ["the", 97], ["leptomeninges", 101], ["and", 115], ["underlying", 119], ["brain", 130], ["parenchyma", 136], [".", 146], ["Histologically", 148], [",", 162], ["meningioangiomatosis", 164], ["is", 185], ["marked", 188], ["by", 195], ["a", 198], ["proliferation", 200], ["of", 214], ["blood", 217], ["vessels", 223], ["in", 231], ["the", 234], ["parenchyma", 238], [",", 248], ["rimmed", 250], ["by", 257], ["collars", 260], ["of", 268], ["spindled", 271], ["meningothelial", 280], ["cells", 295], [".", 300], ["There", 302], ["are", 308], ["anecdotal", 312], ["reports", 322], ["of", 330], ["an", 333], ["association", 336], ["of", 348], ["meningioangiomatosis", 351], ["with", 372], ["focal", 377], ["cortical", 383], ["dysplasia", 392], [".", 401], ["We", 403], ["retrospectively", 406], ["analyzed", 422], ["the", 431], ["clinical", 435], [",", 443], ["histopathologic", 445], [",", 460], ["and", 462], ["treatment", 466], ["outcomes", 476], ["of", 485], ["16", 488], ["patients", 491], ["with", 500], ["a", 505], ["diagnosis", 507], ["of", 517], ["meningioangiomatosis", 520], [",", 540], ["specifically", 542], ["investigating", 555], ["these", 569], ["cases", 575], ["for", 581], ["evidence", 585], ["of", 594], ["adjacent", 597], ["focal", 606], ["cortical", 612], ["dysplasia", 621], [".", 630], ["Patients", 632], ["ranged", 641], ["in", 648], ["age", 651], ["from", 655], ["1", 660], ["to", 662], ["34", 665], ["years", 668], ["(", 674], ["median", 675], ["18", 682], [")", 684], [",", 685], ["12", 687], ["of", 690], ["whom", 693], ["had", 698], ["medically", 702], ["-", 711], ["intractable", 712], ["epilepsy", 724], ["as", 733], ["their", 736], ["presenting", 742], ["symptom", 753], [".", 760], ["No", 762], ["patients", 765], ["in", 774], ["this", 777], ["study", 782], ["had", 788], ["a", 792], ["confirmed", 794], ["diagnosis", 804], ["of", 814], ["neurofibromatosis", 817], ["type", 835], ["II", 840], [".", 842], ["Four", 844], ["patients", 849], ["(", 858], ["25", 859], ["%", 861], [")", 862], ["were", 864], ["found", 869], ["to", 875], ["have", 878], ["fibrous", 883], ["meningiomas", 891], ["associated", 903], ["with", 914], ["the", 919], ["meningioangiomatosis", 923], [".", 943], ["Ten", 945], ["of", 949], ["the", 952], ["12", 956], ["patients", 959], ["(", 968], ["83", 969], ["%", 971], [")", 972], ["who", 974], ["had", 978], ["adequate", 982], ["tissue", 991], ["excised", 998], ["adjacent", 1006], ["to", 1015], ["the", 1018], ["meningioangiomatosis", 1022], ["demonstrated", 1043], ["evidence", 1056], ["of", 1065], ["focal", 1068], ["cortical", 1074], ["dysplasia", 1083], [",", 1092], ["with", 1094], ["6", 1099], ["of", 1101], ["those", 1104], ["(", 1110], ["60", 1111], ["%", 1113], [")", 1114], ["classified", 1116], ["as", 1127], ["Palmini", 1130], ["type", 1138], ["IA", 1143], [",", 1145], ["and", 1147], ["4", 1151], ["patients", 1153], ["(", 1162], ["40", 1163], ["%", 1165], [")", 1166], ["classified", 1168], ["as", 1179], ["Palmini", 1182], ["type", 1190], ["IIA", 1195], [".", 1198], ["Seven", 1200], ["of", 1206], ["the", 1209], ["patients", 1213], ["(", 1222], ["44", 1223], ["%", 1225], [")", 1226], ["had", 1228], ["no", 1232], ["post", 1235], ["-", 1239], ["operative", 1240], ["seizures", 1250], [",", 1258], ["and", 1260], ["were", 1264], ["off", 1269], ["anti", 1273], ["-", 1277], ["epileptic", 1278], ["drugs", 1288], [",", 1293], ["while", 1295], ["2", 1301], ["patients", 1303], ["relapsed", 1312], [",", 1320], ["and", 1322], ["required", 1326], ["pharmacologic", 1335], ["treatment", 1349], ["for", 1359], ["seizure", 1363], ["control", 1371], [".", 1378], ["This", 1380], ["study", 1385], ["therefore", 1391], ["presents", 1401], ["evidence", 1410], ["to", 1419], ["support", 1422], ["inclusion", 1430], ["of", 1440], ["meningioangiomatosis", 1443], ["as", 1464], ["a", 1467], ["focal", 1469], ["cortical", 1475], ["dysplasia", 1484], ["-", 1493], ["associated", 1494], ["entity", 1505], [",", 1511], ["as", 1513], ["suggested", 1516], ["by", 1526], ["the", 1529], ["ILAE", 1533], ["classification", 1538], ["(", 1553], ["type", 1554], ["IIIc", 1559], [")", 1563], [".", 1564], ["As", 1566], ["focal", 1569], ["cortical", 1575], ["dysplasia", 1584], ["is", 1594], ["a", 1597], ["developmental", 1599], ["malformation", 1613], [",", 1625], ["its", 1627], ["association", 1631], ["with", 1643], ["meningioangiomatosis", 1648], ["supports", 1669], ["a", 1678], ["developmental", 1680], ["etiology", 1694], ["of", 1703], ["sporadic", 1706], ["meningioangiomatosis", 1715], [".", 1735]]}
{"context": "A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) to develop evidence-based and consensus-based recommendations for the long-term pharmacologic treatment of restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force reviewed the results of all studies of RLS/WED treatments with durations of 6 months or longer presented at meetings over the past 2 years, posted on Web sites of pharmaceutical companies, or published in peer-reviewed journals, asking the questions, \"What is the efficacy of this treatment in patients with RLS/WED?\" and \"What is the safety of this treatment in patients with RLS/WED?\" The Task Force developed guidelines based on their review of 61 papers meeting inclusion criteria, and using a modified evidence-grading scheme. Pregabalin has been established as effective for up to 1 year in treating RLS/WED (Level A evidence). Pramipexole, ropinirole, and rotigotine have been established as effective for up to 6 months in treating RLS/WED (Level A). The following drugs have been established as probably effective (Level B) in treating RLS/WED for durations ranging from 1 to 5 years: gabapentin enacarbil, pramipexole, and ropinirole (1 year); levodopa (2 years); and rotigotine (5 years). Because of associated safety concerns, pergolide and cabergoline should not be used in the treatment of RLS/WED unless the benefits clearly outweigh the risks. Other pharmacologic therapies have insufficient evidence to support their long-term use in treating RLS/WED. The IRLSSG Task Force also developed consensus-based strategies for the prevention and treatment of complications (such as augmentation, loss of efficacy, excessive daytime sleepiness, and impulse control disorders) that may develop with the long-term pharmacologic treatment of RLS/WED. The use of either a dopamine-receptor agonist or \u03b12\u03b4 calcium-channel ligand is recommended as the first-line treatment of RLS/WED for most patients, with the choice of agent dependent on the patient's severity of RLS/WED symptoms, cognitive status, history, and comorbid conditions.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "fa82e7e496c14296a03d4f2993f80ca8", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[34, 36], [8, 10]], "char_spans": [[201, 222], [50, 71]]}]}], "context_tokens": [["A", 0], ["Task", 2], ["Force", 7], ["was", 13], ["established", 17], ["by", 29], ["the", 32], ["International", 36], ["Restless", 50], ["Legs", 59], ["Syndrome", 64], ["Study", 73], ["Group", 79], ["(", 85], ["IRLSSG", 86], [")", 92], ["to", 94], ["develop", 97], ["evidence", 105], ["-", 113], ["based", 114], ["and", 120], ["consensus", 124], ["-", 133], ["based", 134], ["recommendations", 140], ["for", 156], ["the", 160], ["long", 164], ["-", 168], ["term", 169], ["pharmacologic", 174], ["treatment", 188], ["of", 198], ["restless", 201], ["legs", 210], ["syndrome", 215], ["/", 223], ["Willis", 224], ["-", 230], ["Ekbom", 231], ["disease", 237], ["(", 245], ["RLS", 246], ["/", 249], ["WED", 250], [")", 253], [".", 254], ["The", 256], ["Task", 260], ["Force", 265], ["reviewed", 271], ["the", 280], ["results", 284], ["of", 292], ["all", 295], ["studies", 299], ["of", 307], ["RLS", 310], ["/", 313], ["WED", 314], ["treatments", 318], ["with", 329], ["durations", 334], ["of", 344], ["6", 347], ["months", 349], ["or", 356], ["longer", 359], ["presented", 366], ["at", 376], ["meetings", 379], ["over", 388], ["the", 393], ["past", 397], ["2", 402], ["years", 404], [",", 409], ["posted", 411], ["on", 418], ["Web", 421], ["sites", 425], ["of", 431], ["pharmaceutical", 434], ["companies", 449], [",", 458], ["or", 460], ["published", 463], ["in", 473], ["peer", 476], ["-", 480], ["reviewed", 481], ["journals", 490], [",", 498], ["asking", 500], ["the", 507], ["questions", 511], [",", 520], ["\"", 522], ["What", 523], ["is", 528], ["the", 531], ["efficacy", 535], ["of", 544], ["this", 547], ["treatment", 552], ["in", 562], ["patients", 565], ["with", 574], ["RLS", 579], ["/", 582], ["WED", 583], ["?", 586], ["\"", 587], ["and", 589], ["\"", 593], ["What", 594], ["is", 599], ["the", 602], ["safety", 606], ["of", 613], ["this", 616], ["treatment", 621], ["in", 631], ["patients", 634], ["with", 643], ["RLS", 648], ["/", 651], ["WED", 652], ["?", 655], ["\"", 656], ["The", 658], ["Task", 662], ["Force", 667], ["developed", 673], ["guidelines", 683], ["based", 694], ["on", 700], ["their", 703], ["review", 709], ["of", 716], ["61", 719], ["papers", 722], ["meeting", 729], ["inclusion", 737], ["criteria", 747], [",", 755], ["and", 757], ["using", 761], ["a", 767], ["modified", 769], ["evidence", 778], ["-", 786], ["grading", 787], ["scheme", 795], [".", 801], ["Pregabalin", 803], ["has", 814], ["been", 818], ["established", 823], ["as", 835], ["effective", 838], ["for", 848], ["up", 852], ["to", 855], ["1", 858], ["year", 860], ["in", 865], ["treating", 868], ["RLS", 877], ["/", 880], ["WED", 881], ["(", 885], ["Level", 886], ["A", 892], ["evidence", 894], [")", 902], [".", 903], ["Pramipexole", 905], [",", 916], ["ropinirole", 918], [",", 928], ["and", 930], ["rotigotine", 934], ["have", 945], ["been", 950], ["established", 955], ["as", 967], ["effective", 970], ["for", 980], ["up", 984], ["to", 987], ["6", 990], ["months", 992], ["in", 999], ["treating", 1002], ["RLS", 1011], ["/", 1014], ["WED", 1015], ["(", 1019], ["Level", 1020], ["A", 1026], [")", 1027], [".", 1028], ["The", 1030], ["following", 1034], ["drugs", 1044], ["have", 1050], ["been", 1055], ["established", 1060], ["as", 1072], ["probably", 1075], ["effective", 1084], ["(", 1094], ["Level", 1095], ["B", 1101], [")", 1102], ["in", 1104], ["treating", 1107], ["RLS", 1116], ["/", 1119], ["WED", 1120], ["for", 1124], ["durations", 1128], ["ranging", 1138], ["from", 1146], ["1", 1151], ["to", 1153], ["5", 1156], ["years", 1158], [":", 1163], ["gabapentin", 1165], ["enacarbil", 1176], [",", 1185], ["pramipexole", 1187], [",", 1198], ["and", 1200], ["ropinirole", 1204], ["(", 1215], ["1", 1216], ["year", 1218], [")", 1222], [";", 1223], ["levodopa", 1225], ["(", 1234], ["2", 1235], ["years", 1237], [")", 1242], [";", 1243], ["and", 1245], ["rotigotine", 1249], ["(", 1260], ["5", 1261], ["years", 1263], [")", 1268], [".", 1269], ["Because", 1271], ["of", 1279], ["associated", 1282], ["safety", 1293], ["concerns", 1300], [",", 1308], ["pergolide", 1310], ["and", 1320], ["cabergoline", 1324], ["should", 1336], ["not", 1343], ["be", 1347], ["used", 1350], ["in", 1355], ["the", 1358], ["treatment", 1362], ["of", 1372], ["RLS", 1375], ["/", 1378], ["WED", 1379], ["unless", 1383], ["the", 1390], ["benefits", 1394], ["clearly", 1403], ["outweigh", 1411], ["the", 1420], ["risks", 1424], [".", 1429], ["Other", 1431], ["pharmacologic", 1437], ["therapies", 1451], ["have", 1461], ["insufficient", 1466], ["evidence", 1479], ["to", 1488], ["support", 1491], ["their", 1499], ["long", 1505], ["-", 1509], ["term", 1510], ["use", 1515], ["in", 1519], ["treating", 1522], ["RLS", 1531], ["/", 1534], ["WED", 1535], [".", 1538], ["The", 1540], ["IRLSSG", 1544], ["Task", 1551], ["Force", 1556], ["also", 1562], ["developed", 1567], ["consensus", 1577], ["-", 1586], ["based", 1587], ["strategies", 1593], ["for", 1604], ["the", 1608], ["prevention", 1612], ["and", 1623], ["treatment", 1627], ["of", 1637], ["complications", 1640], ["(", 1654], ["such", 1655], ["as", 1660], ["augmentation", 1663], [",", 1675], ["loss", 1677], ["of", 1682], ["efficacy", 1685], [",", 1693], ["excessive", 1695], ["daytime", 1705], ["sleepiness", 1713], [",", 1723], ["and", 1725], ["impulse", 1729], ["control", 1737], ["disorders", 1745], [")", 1754], ["that", 1756], ["may", 1761], ["develop", 1765], ["with", 1773], ["the", 1778], ["long", 1782], ["-", 1786], ["term", 1787], ["pharmacologic", 1792], ["treatment", 1806], ["of", 1816], ["RLS", 1819], ["/", 1822], ["WED", 1823], [".", 1826], ["The", 1828], ["use", 1832], ["of", 1836], ["either", 1839], ["a", 1846], ["dopamine", 1848], ["-", 1856], ["receptor", 1857], ["agonist", 1866], ["or", 1874], ["\u03b12\u03b4", 1877], ["calcium", 1881], ["-", 1888], ["channel", 1889], ["ligand", 1897], ["is", 1904], ["recommended", 1907], ["as", 1919], ["the", 1922], ["first", 1926], ["-", 1931], ["line", 1932], ["treatment", 1937], ["of", 1947], ["RLS", 1950], ["/", 1953], ["WED", 1954], ["for", 1958], ["most", 1962], ["patients", 1967], [",", 1975], ["with", 1977], ["the", 1982], ["choice", 1986], ["of", 1993], ["agent", 1996], ["dependent", 2002], ["on", 2012], ["the", 2015], ["patient", 2019], ["'s", 2026], ["severity", 2029], ["of", 2038], ["RLS", 2041], ["/", 2044], ["WED", 2045], ["symptoms", 2049], [",", 2057], ["cognitive", 2059], ["status", 2069], [",", 2075], ["history", 2077], [",", 2084], ["and", 2086], ["comorbid", 2090], ["conditions", 2099], [".", 2109]]}
{"context": "The gene encoding the small subunit ribosomal protein 19 (RPS19) is mutated in about 25% of cases of the bone marrow failure syndrome Diamond Blackfan Anemia (DBA), a childhood disease characterized by failure of red cell production. In these cases DBA is inherited as an autosomal dominant trait and RPS19 haploinsufficiency is thought to cause the disease. To study the molecular pathogenesis of DBA we used siRNA to decrease the level of RPS19 in two human cell lines, HeLa cells and U-2 OS osteosarcoma cells. Cells with reduced RPS19 levels showed a dramatic reduction in the amounts of small 40S ribosome subunits and mature 80S ribosomes and an excess of large 60S subunits. These cells were defective in 18S rRNA production and accumulated 21S and 20S nuclear pre-rRNA molecules, suggesting that RPS19 is required for specific steps in rRNA processing. RPS19 depletion produced a reduction in steady-state levels of RPS6 and RPS16 via a post-transcriptional mechanism while the levels of RPL7 and RPL26 were unaltered, indicating that levels of ribosomal proteins are determined by subunit assembly. This has interesting implications for the pathogenesis of DBA suggesting that deficiency of any of the RPS proteins might have a similar effect and thus may be responsible for causing DBA. Finally in cell lines from DBA patients with mutations we find increased levels of 21S rRNA precursors but no abnormality in the ribosome profile on sucrose gradients or in the steady-state levels of RPS19 suggesting that some cells can partially compensate for the loss of one allele of RPS19. We conclude that defects in ribosome biogenesis may underlie the pathology of Diamond Blackfan Anemia.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "Diamond Blackfan Anemia", "DBA"], "qid": "3485a7dc574240ef8e15dadfb984bc14", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[293, 295], [26, 28]], "char_spans": [[1670, 1692], [134, 156]]}, {"text": "DBA", "token_spans": [[227, 227], [205, 205], [234, 234], [71, 71], [30, 30], [47, 47]], "char_spans": [[1292, 1294], [1166, 1168], [1324, 1326], [398, 400], [159, 161], [249, 251]]}]}], "context_tokens": [["The", 0], ["gene", 4], ["encoding", 9], ["the", 18], ["small", 22], ["subunit", 28], ["ribosomal", 36], ["protein", 46], ["19", 54], ["(", 57], ["RPS19", 58], [")", 63], ["is", 65], ["mutated", 68], ["in", 76], ["about", 79], ["25", 85], ["%", 87], ["of", 89], ["cases", 92], ["of", 98], ["the", 101], ["bone", 105], ["marrow", 110], ["failure", 117], ["syndrome", 125], ["Diamond", 134], ["Blackfan", 142], ["Anemia", 151], ["(", 158], ["DBA", 159], [")", 162], [",", 163], ["a", 165], ["childhood", 167], ["disease", 177], ["characterized", 185], ["by", 199], ["failure", 202], ["of", 210], ["red", 213], ["cell", 217], ["production", 222], [".", 232], ["In", 234], ["these", 237], ["cases", 243], ["DBA", 249], ["is", 253], ["inherited", 256], ["as", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["trait", 291], ["and", 297], ["RPS19", 301], ["haploinsufficiency", 307], ["is", 326], ["thought", 329], ["to", 337], ["cause", 340], ["the", 346], ["disease", 350], [".", 357], ["To", 359], ["study", 362], ["the", 368], ["molecular", 372], ["pathogenesis", 382], ["of", 395], ["DBA", 398], ["we", 402], ["used", 405], ["siRNA", 410], ["to", 416], ["decrease", 419], ["the", 428], ["level", 432], ["of", 438], ["RPS19", 441], ["in", 447], ["two", 450], ["human", 454], ["cell", 460], ["lines", 465], [",", 470], ["HeLa", 472], ["cells", 477], ["and", 483], ["U-2", 487], ["OS", 491], ["osteosarcoma", 494], ["cells", 507], [".", 512], ["Cells", 514], ["with", 520], ["reduced", 525], ["RPS19", 533], ["levels", 539], ["showed", 546], ["a", 553], ["dramatic", 555], ["reduction", 564], ["in", 574], ["the", 577], ["amounts", 581], ["of", 589], ["small", 592], ["40S", 598], ["ribosome", 602], ["subunits", 611], ["and", 620], ["mature", 624], ["80S", 631], ["ribosomes", 635], ["and", 645], ["an", 649], ["excess", 652], ["of", 659], ["large", 662], ["60S", 668], ["subunits", 672], [".", 680], ["These", 682], ["cells", 688], ["were", 694], ["defective", 699], ["in", 709], ["18S", 712], ["rRNA", 716], ["production", 721], ["and", 732], ["accumulated", 736], ["21S", 748], ["and", 752], ["20S", 756], ["nuclear", 760], ["pre", 768], ["-", 771], ["rRNA", 772], ["molecules", 777], [",", 786], ["suggesting", 788], ["that", 799], ["RPS19", 804], ["is", 810], ["required", 813], ["for", 822], ["specific", 826], ["steps", 835], ["in", 841], ["rRNA", 844], ["processing", 849], [".", 859], ["RPS19", 861], ["depletion", 867], ["produced", 877], ["a", 886], ["reduction", 888], ["in", 898], ["steady", 901], ["-", 907], ["state", 908], ["levels", 914], ["of", 921], ["RPS6", 924], ["and", 929], ["RPS16", 933], ["via", 939], ["a", 943], ["post", 945], ["-", 949], ["transcriptional", 950], ["mechanism", 966], ["while", 976], ["the", 982], ["levels", 986], ["of", 993], ["RPL7", 996], ["and", 1001], ["RPL26", 1005], ["were", 1011], ["unaltered", 1016], [",", 1025], ["indicating", 1027], ["that", 1038], ["levels", 1043], ["of", 1050], ["ribosomal", 1053], ["proteins", 1063], ["are", 1072], ["determined", 1076], ["by", 1087], ["subunit", 1090], ["assembly", 1098], [".", 1106], ["This", 1108], ["has", 1113], ["interesting", 1117], ["implications", 1129], ["for", 1142], ["the", 1146], ["pathogenesis", 1150], ["of", 1163], ["DBA", 1166], ["suggesting", 1170], ["that", 1181], ["deficiency", 1186], ["of", 1197], ["any", 1200], ["of", 1204], ["the", 1207], ["RPS", 1211], ["proteins", 1215], ["might", 1224], ["have", 1230], ["a", 1235], ["similar", 1237], ["effect", 1245], ["and", 1252], ["thus", 1256], ["may", 1261], ["be", 1265], ["responsible", 1268], ["for", 1280], ["causing", 1284], ["DBA", 1292], [".", 1295], ["Finally", 1297], ["in", 1305], ["cell", 1308], ["lines", 1313], ["from", 1319], ["DBA", 1324], ["patients", 1328], ["with", 1337], ["mutations", 1342], ["we", 1352], ["find", 1355], ["increased", 1360], ["levels", 1370], ["of", 1377], ["21S", 1380], ["rRNA", 1384], ["precursors", 1389], ["but", 1400], ["no", 1404], ["abnormality", 1407], ["in", 1419], ["the", 1422], ["ribosome", 1426], ["profile", 1435], ["on", 1443], ["sucrose", 1446], ["gradients", 1454], ["or", 1464], ["in", 1467], ["the", 1470], ["steady", 1474], ["-", 1480], ["state", 1481], ["levels", 1487], ["of", 1494], ["RPS19", 1497], ["suggesting", 1503], ["that", 1514], ["some", 1519], ["cells", 1524], ["can", 1530], ["partially", 1534], ["compensate", 1544], ["for", 1555], ["the", 1559], ["loss", 1563], ["of", 1568], ["one", 1571], ["allele", 1575], ["of", 1582], ["RPS19", 1585], [".", 1590], ["We", 1592], ["conclude", 1595], ["that", 1604], ["defects", 1609], ["in", 1617], ["ribosome", 1620], ["biogenesis", 1629], ["may", 1640], ["underlie", 1644], ["the", 1653], ["pathology", 1657], ["of", 1667], ["Diamond", 1670], ["Blackfan", 1678], ["Anemia", 1687], [".", 1693]]}
{"context": "Nitric oxide (NO) is involved in many pathological conditions including neurodegenerative disorders. We have previously found that sodium nitroprusside (SNP), an NO donor, stimulates mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulating kinase (ERK), c-jun N-terminal protein kinase (JNK) and p38 MAPK, leading to caspase-independent apoptosis in cultured astrocytes. In view of the previous observation that NO stimulates the activity of the Na(+)/Ca(2+) exchanger (NCX), this study examines the involvement of NCX in cytotoxicity. The specific NCX inhibitor SEA0400 blocked SNP-induced phosphorylation of ERK, JNK and p38 MAPK, and decrease in cell viability. SNP-induced phosphorylation of ERK, JNK and p38 MAPK was blocked by removal of external Ca(2+), and SNP treatment caused an increase in (45)Ca(2+) influx. This increase in (45)Ca(2+) influx was blocked by SEA0400, but not the Ca(2+) channel blocker nifedipine. In addition, SNP-induced (45)Ca(2+) influx and cytotoxicity were reduced in NCX1-deficient cells which were transfected with NCX1 siRNA. Inhibitors of intracellular Ca(2+)-dependent proteins such as calpain and calmodulin blocked SNP-induced ERK phosphorylation and decrease in cell viability. Furthermore, the guanylate cyclase inhibitor LY83583 and the cGMP-dependent protein kinase inhibitor KT5823 blocked SNP-induced cytotoxicity. These findings suggest that NCX-mediated Ca(2+) influx triggers SNP-induced apoptosis in astrocytes, which may be mediated by a cGMP-dependent pathway.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "1b48a8555b8b48f79655d8c2e14b0f11", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[88, 91]], "char_spans": [[471, 492]]}, {"text": "NCX", "token_spans": [[108, 108], [93, 93], [260, 260], [102, 102]], "char_spans": [[574, 576], [495, 497], [1415, 1417], [540, 542]]}]}], "context_tokens": [["Nitric", 0], ["oxide", 7], ["(", 13], ["NO", 14], [")", 16], ["is", 18], ["involved", 21], ["in", 30], ["many", 33], ["pathological", 38], ["conditions", 51], ["including", 62], ["neurodegenerative", 72], ["disorders", 90], [".", 99], ["We", 101], ["have", 104], ["previously", 109], ["found", 120], ["that", 126], ["sodium", 131], ["nitroprusside", 138], ["(", 152], ["SNP", 153], [")", 156], [",", 157], ["an", 159], ["NO", 162], ["donor", 165], [",", 170], ["stimulates", 172], ["mitogen", 183], ["-", 190], ["activated", 191], ["protein", 201], ["kinases", 209], ["(", 217], ["MAPKs", 218], [")", 223], ["such", 225], ["as", 230], ["extracellular", 233], ["signal", 247], ["-", 253], ["regulating", 254], ["kinase", 265], ["(", 272], ["ERK", 273], [")", 276], [",", 277], ["c", 279], ["-", 280], ["jun", 281], ["N", 285], ["-", 286], ["terminal", 287], ["protein", 296], ["kinase", 304], ["(", 311], ["JNK", 312], [")", 315], ["and", 317], ["p38", 321], ["MAPK", 325], [",", 329], ["leading", 331], ["to", 339], ["caspase", 342], ["-", 349], ["independent", 350], ["apoptosis", 362], ["in", 372], ["cultured", 375], ["astrocytes", 384], [".", 394], ["In", 396], ["view", 399], ["of", 404], ["the", 407], ["previous", 411], ["observation", 420], ["that", 432], ["NO", 437], ["stimulates", 440], ["the", 451], ["activity", 455], ["of", 464], ["the", 467], ["Na(+)/Ca(2", 471], ["+", 481], [")", 482], ["exchanger", 484], ["(", 494], ["NCX", 495], [")", 498], [",", 499], ["this", 501], ["study", 506], ["examines", 512], ["the", 521], ["involvement", 525], ["of", 537], ["NCX", 540], ["in", 544], ["cytotoxicity", 547], [".", 559], ["The", 561], ["specific", 565], ["NCX", 574], ["inhibitor", 578], ["SEA0400", 588], ["blocked", 596], ["SNP", 604], ["-", 607], ["induced", 608], ["phosphorylation", 616], ["of", 632], ["ERK", 635], [",", 638], ["JNK", 640], ["and", 644], ["p38", 648], ["MAPK", 652], [",", 656], ["and", 658], ["decrease", 662], ["in", 671], ["cell", 674], ["viability", 679], [".", 688], ["SNP", 690], ["-", 693], ["induced", 694], ["phosphorylation", 702], ["of", 718], ["ERK", 721], [",", 724], ["JNK", 726], ["and", 730], ["p38", 734], ["MAPK", 738], ["was", 743], ["blocked", 747], ["by", 755], ["removal", 758], ["of", 766], ["external", 769], ["Ca(2", 778], ["+", 782], [")", 783], [",", 784], ["and", 786], ["SNP", 790], ["treatment", 794], ["caused", 804], ["an", 811], ["increase", 814], ["in", 823], ["(", 826], ["45)Ca(2", 827], ["+", 834], [")", 835], ["influx", 837], [".", 843], ["This", 845], ["increase", 850], ["in", 859], ["(", 862], ["45)Ca(2", 863], ["+", 870], [")", 871], ["influx", 873], ["was", 880], ["blocked", 884], ["by", 892], ["SEA0400", 895], [",", 902], ["but", 904], ["not", 908], ["the", 912], ["Ca(2", 916], ["+", 920], [")", 921], ["channel", 923], ["blocker", 931], ["nifedipine", 939], [".", 949], ["In", 951], ["addition", 954], [",", 962], ["SNP", 964], ["-", 967], ["induced", 968], ["(", 976], ["45)Ca(2", 977], ["+", 984], [")", 985], ["influx", 987], ["and", 994], ["cytotoxicity", 998], ["were", 1011], ["reduced", 1016], ["in", 1024], ["NCX1-deficient", 1027], ["cells", 1042], ["which", 1048], ["were", 1054], ["transfected", 1059], ["with", 1071], ["NCX1", 1076], ["siRNA", 1081], [".", 1086], ["Inhibitors", 1088], ["of", 1099], ["intracellular", 1102], ["Ca(2+)-dependent", 1116], ["proteins", 1133], ["such", 1142], ["as", 1147], ["calpain", 1150], ["and", 1158], ["calmodulin", 1162], ["blocked", 1173], ["SNP", 1181], ["-", 1184], ["induced", 1185], ["ERK", 1193], ["phosphorylation", 1197], ["and", 1213], ["decrease", 1217], ["in", 1226], ["cell", 1229], ["viability", 1234], [".", 1243], ["Furthermore", 1245], [",", 1256], ["the", 1258], ["guanylate", 1262], ["cyclase", 1272], ["inhibitor", 1280], ["LY83583", 1290], ["and", 1298], ["the", 1302], ["cGMP", 1306], ["-", 1310], ["dependent", 1311], ["protein", 1321], ["kinase", 1329], ["inhibitor", 1336], ["KT5823", 1346], ["blocked", 1353], ["SNP", 1361], ["-", 1364], ["induced", 1365], ["cytotoxicity", 1373], [".", 1385], ["These", 1387], ["findings", 1393], ["suggest", 1402], ["that", 1410], ["NCX", 1415], ["-", 1418], ["mediated", 1419], ["Ca(2", 1428], ["+", 1432], [")", 1433], ["influx", 1435], ["triggers", 1442], ["SNP", 1451], ["-", 1454], ["induced", 1455], ["apoptosis", 1463], ["in", 1473], ["astrocytes", 1476], [",", 1486], ["which", 1488], ["may", 1494], ["be", 1498], ["mediated", 1501], ["by", 1510], ["a", 1513], ["cGMP", 1515], ["-", 1519], ["dependent", 1520], ["pathway", 1530], [".", 1537]]}
{"context": "Spleen tyrosine kinase (SYK) is the best known for its involvement in immune receptor signalling, mediated by binding of SYK tandem Src-homology 2 domains to tandem phosphotyrosine in immunoreceptor tyrosine-based activation motifs (ITAMs). ITAM adaptors or ITAM-containing receptor tails mediate signalling from B- and T-cell receptors, Fc receptors and many C-type lectins, including dectin-1. Recent data point to constitutive binding of SYK to the cytoplasmic domain of toll-like receptor-4 (TLR4). This SYK-TLR4 binding increases upon TLR4 dimerization and phosphorylation, and SYK plays a prominent role in TLR4 signalling in response to LPS in neutrophils and monocytes. SYK also plays an important role in TLR4-mediated macrophage responses to minimally oxidized low-density lipoprotein (mmLDL), which is a form of oxidized LDL relevant to development of human atherosclerosis. Interestingly, mmLDL-induced effects in macrophages, which occur via TLR4, are predominantly MyD88 independent. This unmasks the role of the SYK branch of TLR4 signalling, which mediates modest cytokine release via activation of AP-1 transcription and robust reactive oxygen species generation and cytoskeletal rearrangements. The latter results in extensive membrane ruffling and macropinocytosis, leading to lipoprotein uptake and foam cell formation, a hallmark of atherosclerotic lesions. Because inhibitors of SYK activity, such as fostamatinib, are in advanced clinical trials for rheumatoid arthritis and other autoimmune diseases, understanding the role of SYK in signalling via TLR4 is of immediate importance. This signalling pathway seems to be particularly important in TLR4 activation by host-derived, damage-associated molecular pattern ligands, such as mmLDL, relevant to development of atherosclerosis and other chronic inflammatory diseases.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "02fbe83948a24a63a98bde04a8c8943e", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["SYK", 24], [")", 27], ["is", 29], ["the", 32], ["best", 36], ["known", 41], ["for", 47], ["its", 51], ["involvement", 55], ["in", 67], ["immune", 70], ["receptor", 77], ["signalling", 86], [",", 96], ["mediated", 98], ["by", 107], ["binding", 110], ["of", 118], ["SYK", 121], ["tandem", 125], ["Src", 132], ["-", 135], ["homology", 136], ["2", 145], ["domains", 147], ["to", 155], ["tandem", 158], ["phosphotyrosine", 165], ["in", 181], ["immunoreceptor", 184], ["tyrosine", 199], ["-", 207], ["based", 208], ["activation", 214], ["motifs", 225], ["(", 232], ["ITAMs", 233], [")", 238], [".", 239], ["ITAM", 241], ["adaptors", 246], ["or", 255], ["ITAM", 258], ["-", 262], ["containing", 263], ["receptor", 274], ["tails", 283], ["mediate", 289], ["signalling", 297], ["from", 308], ["B-", 313], ["and", 316], ["T", 320], ["-", 321], ["cell", 322], ["receptors", 327], [",", 336], ["Fc", 338], ["receptors", 341], ["and", 351], ["many", 355], ["C", 360], ["-", 361], ["type", 362], ["lectins", 367], [",", 374], ["including", 376], ["dectin-1", 386], [".", 394], ["Recent", 396], ["data", 403], ["point", 408], ["to", 414], ["constitutive", 417], ["binding", 430], ["of", 438], ["SYK", 441], ["to", 445], ["the", 448], ["cytoplasmic", 452], ["domain", 464], ["of", 471], ["toll", 474], ["-", 478], ["like", 479], ["receptor-4", 484], ["(", 495], ["TLR4", 496], [")", 500], [".", 501], ["This", 503], ["SYK", 508], ["-", 511], ["TLR4", 512], ["binding", 517], ["increases", 525], ["upon", 535], ["TLR4", 540], ["dimerization", 545], ["and", 558], ["phosphorylation", 562], [",", 577], ["and", 579], ["SYK", 583], ["plays", 587], ["a", 593], ["prominent", 595], ["role", 605], ["in", 610], ["TLR4", 613], ["signalling", 618], ["in", 629], ["response", 632], ["to", 641], ["LPS", 644], ["in", 648], ["neutrophils", 651], ["and", 663], ["monocytes", 667], [".", 676], ["SYK", 678], ["also", 682], ["plays", 687], ["an", 693], ["important", 696], ["role", 706], ["in", 711], ["TLR4-mediated", 714], ["macrophage", 728], ["responses", 739], ["to", 749], ["minimally", 752], ["oxidized", 762], ["low", 771], ["-", 774], ["density", 775], ["lipoprotein", 783], ["(", 795], ["mmLDL", 796], [")", 801], [",", 802], ["which", 804], ["is", 810], ["a", 813], ["form", 815], ["of", 820], ["oxidized", 823], ["LDL", 832], ["relevant", 836], ["to", 845], ["development", 848], ["of", 860], ["human", 863], ["atherosclerosis", 869], [".", 884], ["Interestingly", 886], [",", 899], ["mmLDL", 901], ["-", 906], ["induced", 907], ["effects", 915], ["in", 923], ["macrophages", 926], [",", 937], ["which", 939], ["occur", 945], ["via", 951], ["TLR4", 955], [",", 959], ["are", 961], ["predominantly", 965], ["MyD88", 979], ["independent", 985], [".", 996], ["This", 998], ["unmasks", 1003], ["the", 1011], ["role", 1015], ["of", 1020], ["the", 1023], ["SYK", 1027], ["branch", 1031], ["of", 1038], ["TLR4", 1041], ["signalling", 1046], [",", 1056], ["which", 1058], ["mediates", 1064], ["modest", 1073], ["cytokine", 1080], ["release", 1089], ["via", 1097], ["activation", 1101], ["of", 1112], ["AP-1", 1115], ["transcription", 1120], ["and", 1134], ["robust", 1138], ["reactive", 1145], ["oxygen", 1154], ["species", 1161], ["generation", 1169], ["and", 1180], ["cytoskeletal", 1184], ["rearrangements", 1197], [".", 1211], ["The", 1213], ["latter", 1217], ["results", 1224], ["in", 1232], ["extensive", 1235], ["membrane", 1245], ["ruffling", 1254], ["and", 1263], ["macropinocytosis", 1267], [",", 1283], ["leading", 1285], ["to", 1293], ["lipoprotein", 1296], ["uptake", 1308], ["and", 1315], ["foam", 1319], ["cell", 1324], ["formation", 1329], [",", 1338], ["a", 1340], ["hallmark", 1342], ["of", 1351], ["atherosclerotic", 1354], ["lesions", 1370], [".", 1377], ["Because", 1379], ["inhibitors", 1387], ["of", 1398], ["SYK", 1401], ["activity", 1405], [",", 1413], ["such", 1415], ["as", 1420], ["fostamatinib", 1423], [",", 1435], ["are", 1437], ["in", 1441], ["advanced", 1444], ["clinical", 1453], ["trials", 1462], ["for", 1469], ["rheumatoid", 1473], ["arthritis", 1484], ["and", 1494], ["other", 1498], ["autoimmune", 1504], ["diseases", 1515], [",", 1523], ["understanding", 1525], ["the", 1539], ["role", 1543], ["of", 1548], ["SYK", 1551], ["in", 1555], ["signalling", 1558], ["via", 1569], ["TLR4", 1573], ["is", 1578], ["of", 1581], ["immediate", 1584], ["importance", 1594], [".", 1604], ["This", 1606], ["signalling", 1611], ["pathway", 1622], ["seems", 1630], ["to", 1636], ["be", 1639], ["particularly", 1642], ["important", 1655], ["in", 1665], ["TLR4", 1668], ["activation", 1673], ["by", 1684], ["host", 1687], ["-", 1691], ["derived", 1692], [",", 1699], ["damage", 1701], ["-", 1707], ["associated", 1708], ["molecular", 1719], ["pattern", 1729], ["ligands", 1737], [",", 1744], ["such", 1746], ["as", 1751], ["mmLDL", 1754], [",", 1759], ["relevant", 1761], ["to", 1770], ["development", 1773], ["of", 1785], ["atherosclerosis", 1788], ["and", 1804], ["other", 1808], ["chronic", 1814], ["inflammatory", 1822], ["diseases", 1835], [".", 1843]]}
{"context": "Malaria is a major human health problem and is responsible for over 2 million deaths per year. It is caused by a number of species of the genus Plasmodium, and Plasmodium falciparum is the causative agent of the most lethal form. Consequently, the development of a vaccine against this parasite is a priority. There are a number of stages of the parasite life cycle that are being targeted for the development of vaccines. Important candidate antigens include proteins on the surface of the asexual merozoite stage, the form that invades the host erythrocyte. The development of methods to manipulate the genome of Plasmodium species has enabled the construction of gain-of-function and loss-of-function mutants and provided new strategies to analyse the role of parasite proteins. This has provided new information on the role of merozoite antigens in erythrocyte invasion and also allows new approaches to address their potential as vaccine candidates.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "b23f331e696e40feb6adbfbacd5c9d94", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[110, 111]], "char_spans": [[615, 632]]}]}], "context_tokens": [["Malaria", 0], ["is", 8], ["a", 11], ["major", 13], ["human", 19], ["health", 25], ["problem", 32], ["and", 40], ["is", 44], ["responsible", 47], ["for", 59], ["over", 63], ["2", 68], ["million", 70], ["deaths", 78], ["per", 85], ["year", 89], [".", 93], ["It", 95], ["is", 98], ["caused", 101], ["by", 108], ["a", 111], ["number", 113], ["of", 120], ["species", 123], ["of", 131], ["the", 134], ["genus", 138], ["Plasmodium", 144], [",", 154], ["and", 156], ["Plasmodium", 160], ["falciparum", 171], ["is", 182], ["the", 185], ["causative", 189], ["agent", 199], ["of", 205], ["the", 208], ["most", 212], ["lethal", 217], ["form", 224], [".", 228], ["Consequently", 230], [",", 242], ["the", 244], ["development", 248], ["of", 260], ["a", 263], ["vaccine", 265], ["against", 273], ["this", 281], ["parasite", 286], ["is", 295], ["a", 298], ["priority", 300], [".", 308], ["There", 310], ["are", 316], ["a", 320], ["number", 322], ["of", 329], ["stages", 332], ["of", 339], ["the", 342], ["parasite", 346], ["life", 355], ["cycle", 360], ["that", 366], ["are", 371], ["being", 375], ["targeted", 381], ["for", 390], ["the", 394], ["development", 398], ["of", 410], ["vaccines", 413], [".", 421], ["Important", 423], ["candidate", 433], ["antigens", 443], ["include", 452], ["proteins", 460], ["on", 469], ["the", 472], ["surface", 476], ["of", 484], ["the", 487], ["asexual", 491], ["merozoite", 499], ["stage", 509], [",", 514], ["the", 516], ["form", 520], ["that", 525], ["invades", 530], ["the", 538], ["host", 542], ["erythrocyte", 547], [".", 558], ["The", 560], ["development", 564], ["of", 576], ["methods", 579], ["to", 587], ["manipulate", 590], ["the", 601], ["genome", 605], ["of", 612], ["Plasmodium", 615], ["species", 626], ["has", 634], ["enabled", 638], ["the", 646], ["construction", 650], ["of", 663], ["gain", 666], ["-", 670], ["of", 671], ["-", 673], ["function", 674], ["and", 683], ["loss", 687], ["-", 691], ["of", 692], ["-", 694], ["function", 695], ["mutants", 704], ["and", 712], ["provided", 716], ["new", 725], ["strategies", 729], ["to", 740], ["analyse", 743], ["the", 751], ["role", 755], ["of", 760], ["parasite", 763], ["proteins", 772], [".", 780], ["This", 782], ["has", 787], ["provided", 791], ["new", 800], ["information", 804], ["on", 816], ["the", 819], ["role", 823], ["of", 828], ["merozoite", 831], ["antigens", 841], ["in", 850], ["erythrocyte", 853], ["invasion", 865], ["and", 874], ["also", 878], ["allows", 883], ["new", 890], ["approaches", 894], ["to", 905], ["address", 908], ["their", 916], ["potential", 922], ["as", 932], ["vaccine", 935], ["candidates", 943], [".", 953]]}
{"context": "Rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis are immune-mediated inflammatory diseases with similarities in pathophysiology, and all can be treated with similar biological agents. Previous studies have shown that there are gender differences with regard to disease characteristics in RA and IBD, with women generally having worse scores on pain and quality of life measurements. The relationship is less clear for psoriasis. Because treatment differences between men and women could explain the dissimilarities, we investigated gender differences in the disease characteristics before treatment initiation and in the biologic treatment prescribed. Data on patients with RA or IBD were collected from two registries in which patients treated with biologic medication were enrolled. Basic demographic data and disease activity parameters were collected from a time point just before the initiation of the biologic treatment. For patients with psoriasis, the data were taken from the 2010 annual report of the Swedish Psoriasis Register for systemic treatment, which included also non-biologic treatment. For all three diseases, the prescribed treatment and disease characteristics were compared between men and women. In total, 4493 adult patients were included in the study (1912 with RA, 131 with IBD, and 2450 with psoriasis). Most of the treated patients with RA were women, whereas most of the patients with IBD or psoriasis were men. There were no significant differences between men and women in the choice of biologics. At treatment start, significant gender differences were seen in the subjective disease measurements for both RA and psoriasis, with women having higher (that is, worse) scores than men. No differences in objective measurements were found for RA, but for psoriasis men had higher (that is, worse) scores for objective disease activity measures. A similar trend to RA was seen in IBD. Women with RA or psoriasis scored significantly higher on subjective, but not on objective, disease activity measures than men, and the same trend was seen in IBD. This indicates that at the same level of treatment, the disease has a greater effect in women. These findings might suggest that in all three diseases, subjective measures are discounted to some extent in the therapeutic decision-making process, which could indicate undertreatment in female patients.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "08cbe847c7dd46e685e5a9239d668120", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[256, 256], [336, 336], [83, 83], [384, 384], [234, 234], [198, 198], [284, 284], [56, 56]], "char_spans": [[1522, 1526], [1939, 1943], [501, 505], [2191, 2195], [1400, 1404], [1239, 1243], [1688, 1692], [331, 335]]}]}], "context_tokens": [["Rheumatoid", 0], ["arthritis", 11], ["(", 21], ["RA", 22], [")", 24], [",", 25], ["inflammatory", 27], ["bowel", 40], ["disease", 46], ["(", 54], ["IBD", 55], [")", 58], [",", 59], ["and", 61], ["psoriasis", 65], ["are", 75], ["immune", 79], ["-", 85], ["mediated", 86], ["inflammatory", 95], ["diseases", 108], ["with", 117], ["similarities", 122], ["in", 135], ["pathophysiology", 138], [",", 153], ["and", 155], ["all", 159], ["can", 163], ["be", 167], ["treated", 170], ["with", 178], ["similar", 183], ["biological", 191], ["agents", 202], [".", 208], ["Previous", 210], ["studies", 219], ["have", 227], ["shown", 232], ["that", 238], ["there", 243], ["are", 249], ["gender", 253], ["differences", 260], ["with", 272], ["regard", 277], ["to", 284], ["disease", 287], ["characteristics", 295], ["in", 311], ["RA", 314], ["and", 317], ["IBD", 321], [",", 324], ["with", 326], ["women", 331], ["generally", 337], ["having", 347], ["worse", 354], ["scores", 360], ["on", 367], ["pain", 370], ["and", 375], ["quality", 379], ["of", 387], ["life", 390], ["measurements", 395], [".", 407], ["The", 409], ["relationship", 413], ["is", 426], ["less", 429], ["clear", 434], ["for", 440], ["psoriasis", 444], [".", 453], ["Because", 455], ["treatment", 463], ["differences", 473], ["between", 485], ["men", 493], ["and", 497], ["women", 501], ["could", 507], ["explain", 513], ["the", 521], ["dissimilarities", 525], [",", 540], ["we", 542], ["investigated", 545], ["gender", 558], ["differences", 565], ["in", 577], ["the", 580], ["disease", 584], ["characteristics", 592], ["before", 608], ["treatment", 615], ["initiation", 625], ["and", 636], ["in", 640], ["the", 643], ["biologic", 647], ["treatment", 656], ["prescribed", 666], [".", 676], ["Data", 678], ["on", 683], ["patients", 686], ["with", 695], ["RA", 700], ["or", 703], ["IBD", 706], ["were", 710], ["collected", 715], ["from", 725], ["two", 730], ["registries", 734], ["in", 745], ["which", 748], ["patients", 754], ["treated", 763], ["with", 771], ["biologic", 776], ["medication", 785], ["were", 796], ["enrolled", 801], [".", 809], ["Basic", 811], ["demographic", 817], ["data", 829], ["and", 834], ["disease", 838], ["activity", 846], ["parameters", 855], ["were", 866], ["collected", 871], ["from", 881], ["a", 886], ["time", 888], ["point", 893], ["just", 899], ["before", 904], ["the", 911], ["initiation", 915], ["of", 926], ["the", 929], ["biologic", 933], ["treatment", 942], [".", 951], ["For", 953], ["patients", 957], ["with", 966], ["psoriasis", 971], [",", 980], ["the", 982], ["data", 986], ["were", 991], ["taken", 996], ["from", 1002], ["the", 1007], ["2010", 1011], ["annual", 1016], ["report", 1023], ["of", 1030], ["the", 1033], ["Swedish", 1037], ["Psoriasis", 1045], ["Register", 1055], ["for", 1064], ["systemic", 1068], ["treatment", 1077], [",", 1086], ["which", 1088], ["included", 1094], ["also", 1103], ["non", 1108], ["-", 1111], ["biologic", 1112], ["treatment", 1121], [".", 1130], ["For", 1132], ["all", 1136], ["three", 1140], ["diseases", 1146], [",", 1154], ["the", 1156], ["prescribed", 1160], ["treatment", 1171], ["and", 1181], ["disease", 1185], ["characteristics", 1193], ["were", 1209], ["compared", 1214], ["between", 1223], ["men", 1231], ["and", 1235], ["women", 1239], [".", 1244], ["In", 1246], ["total", 1249], [",", 1254], ["4493", 1256], ["adult", 1261], ["patients", 1267], ["were", 1276], ["included", 1281], ["in", 1290], ["the", 1293], ["study", 1297], ["(", 1303], ["1912", 1304], ["with", 1309], ["RA", 1314], [",", 1316], ["131", 1318], ["with", 1322], ["IBD", 1327], [",", 1330], ["and", 1332], ["2450", 1336], ["with", 1341], ["psoriasis", 1346], [")", 1355], [".", 1356], ["Most", 1358], ["of", 1363], ["the", 1366], ["treated", 1370], ["patients", 1378], ["with", 1387], ["RA", 1392], ["were", 1395], ["women", 1400], [",", 1405], ["whereas", 1407], ["most", 1415], ["of", 1420], ["the", 1423], ["patients", 1427], ["with", 1436], ["IBD", 1441], ["or", 1445], ["psoriasis", 1448], ["were", 1458], ["men", 1463], [".", 1466], ["There", 1468], ["were", 1474], ["no", 1479], ["significant", 1482], ["differences", 1494], ["between", 1506], ["men", 1514], ["and", 1518], ["women", 1522], ["in", 1528], ["the", 1531], ["choice", 1535], ["of", 1542], ["biologics", 1545], [".", 1554], ["At", 1556], ["treatment", 1559], ["start", 1569], [",", 1574], ["significant", 1576], ["gender", 1588], ["differences", 1595], ["were", 1607], ["seen", 1612], ["in", 1617], ["the", 1620], ["subjective", 1624], ["disease", 1635], ["measurements", 1643], ["for", 1656], ["both", 1660], ["RA", 1665], ["and", 1668], ["psoriasis", 1672], [",", 1681], ["with", 1683], ["women", 1688], ["having", 1694], ["higher", 1701], ["(", 1708], ["that", 1709], ["is", 1714], [",", 1716], ["worse", 1718], [")", 1723], ["scores", 1725], ["than", 1732], ["men", 1737], [".", 1740], ["No", 1742], ["differences", 1745], ["in", 1757], ["objective", 1760], ["measurements", 1770], ["were", 1783], ["found", 1788], ["for", 1794], ["RA", 1798], [",", 1800], ["but", 1802], ["for", 1806], ["psoriasis", 1810], ["men", 1820], ["had", 1824], ["higher", 1828], ["(", 1835], ["that", 1836], ["is", 1841], [",", 1843], ["worse", 1845], [")", 1850], ["scores", 1852], ["for", 1859], ["objective", 1863], ["disease", 1873], ["activity", 1881], ["measures", 1890], [".", 1898], ["A", 1900], ["similar", 1902], ["trend", 1910], ["to", 1916], ["RA", 1919], ["was", 1922], ["seen", 1926], ["in", 1931], ["IBD", 1934], [".", 1937], ["Women", 1939], ["with", 1945], ["RA", 1950], ["or", 1953], ["psoriasis", 1956], ["scored", 1966], ["significantly", 1973], ["higher", 1987], ["on", 1994], ["subjective", 1997], [",", 2007], ["but", 2009], ["not", 2013], ["on", 2017], ["objective", 2020], [",", 2029], ["disease", 2031], ["activity", 2039], ["measures", 2048], ["than", 2057], ["men", 2062], [",", 2065], ["and", 2067], ["the", 2071], ["same", 2075], ["trend", 2080], ["was", 2086], ["seen", 2090], ["in", 2095], ["IBD", 2098], [".", 2101], ["This", 2103], ["indicates", 2108], ["that", 2118], ["at", 2123], ["the", 2126], ["same", 2130], ["level", 2135], ["of", 2141], ["treatment", 2144], [",", 2153], ["the", 2155], ["disease", 2159], ["has", 2167], ["a", 2171], ["greater", 2173], ["effect", 2181], ["in", 2188], ["women", 2191], [".", 2196], ["These", 2198], ["findings", 2204], ["might", 2213], ["suggest", 2219], ["that", 2227], ["in", 2232], ["all", 2235], ["three", 2239], ["diseases", 2245], [",", 2253], ["subjective", 2255], ["measures", 2266], ["are", 2275], ["discounted", 2279], ["to", 2290], ["some", 2293], ["extent", 2298], ["in", 2305], ["the", 2308], ["therapeutic", 2312], ["decision", 2324], ["-", 2332], ["making", 2333], ["process", 2340], [",", 2347], ["which", 2349], ["could", 2355], ["indicate", 2361], ["undertreatment", 2370], ["in", 2385], ["female", 2388], ["patients", 2395], [".", 2403]]}
{"context": "Benzodiazepine (BZD) overdose (OD) continues to cause significant morbidity and mortality in the UK. Flumazenil is an effective antidote but there is a risk of seizures, particularly in those who have co-ingested tricyclic antidepressants. A study was undertaken to examine the frequency of use, safety and efficacy of flumazenil in the management of BZD OD in the UK. A 2-year retrospective cohort study was performed of all enquiries to the UK National Poisons Information Service involving BZD OD. Flumazenil was administered to 80 patients in 4504 BZD-related enquiries, 68 of whom did not have ventilatory failure or had recognised contraindications to flumazenil. Factors associated with flumazenil use were increased age, severe poisoning and ventilatory failure. Co-ingestion of tricyclic antidepressants and chronic obstructive pulmonary disease did not influence flumazenil administration. Seizure frequency in patients not treated with flumazenil was 0.3%. The frequency of prior seizure in flumazenil-treated patients was 30 times higher (8.8%). Seven patients who had seizures prior to flumazenil therapy had no recurrence of their seizures. Ventilation or consciousness improved in 70% of flumazenil-treated patients. Flumazenil administration was followed by one instance each of agitation and brief seizure. Flumazenil is used infrequently in the management of BZD OD in the UK. It was effective and associated with a low incidence of seizure. These results compare favourably with the results of published randomised controlled trials and cohort studies, although previous studies have not reported the use of flumazenil in such a high-risk population. This study should inform the continuing review of national guidance on flumazenil therapy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "4995000228674631b0045fda4996a056", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[224, 224], [19, 19], [147, 147], [90, 90], [58, 58], [157, 157], [205, 205], [116, 116], [188, 188], [121, 121], [275, 275], [295, 295], [168, 168], [210, 210]], "char_spans": [[1324, 1333], [101, 110], [873, 882], [501, 510], [319, 328], [947, 956], [1203, 1212], [658, 667], [1099, 1108], [694, 703], [1627, 1636], [1741, 1750], [1002, 1011], [1232, 1241]]}]}], "context_tokens": [["Benzodiazepine", 0], ["(", 15], ["BZD", 16], [")", 19], ["overdose", 21], ["(", 30], ["OD", 31], [")", 33], ["continues", 35], ["to", 45], ["cause", 48], ["significant", 54], ["morbidity", 66], ["and", 76], ["mortality", 80], ["in", 90], ["the", 93], ["UK", 97], [".", 99], ["Flumazenil", 101], ["is", 112], ["an", 115], ["effective", 118], ["antidote", 128], ["but", 137], ["there", 141], ["is", 147], ["a", 150], ["risk", 152], ["of", 157], ["seizures", 160], [",", 168], ["particularly", 170], ["in", 183], ["those", 186], ["who", 192], ["have", 196], ["co", 201], ["-", 203], ["ingested", 204], ["tricyclic", 213], ["antidepressants", 223], [".", 238], ["A", 240], ["study", 242], ["was", 248], ["undertaken", 252], ["to", 263], ["examine", 266], ["the", 274], ["frequency", 278], ["of", 288], ["use", 291], [",", 294], ["safety", 296], ["and", 303], ["efficacy", 307], ["of", 316], ["flumazenil", 319], ["in", 330], ["the", 333], ["management", 337], ["of", 348], ["BZD", 351], ["OD", 355], ["in", 358], ["the", 361], ["UK", 365], [".", 367], ["A", 369], ["2-year", 371], ["retrospective", 378], ["cohort", 392], ["study", 399], ["was", 405], ["performed", 409], ["of", 419], ["all", 422], ["enquiries", 426], ["to", 436], ["the", 439], ["UK", 443], ["National", 446], ["Poisons", 455], ["Information", 463], ["Service", 475], ["involving", 483], ["BZD", 493], ["OD", 497], [".", 499], ["Flumazenil", 501], ["was", 512], ["administered", 516], ["to", 529], ["80", 532], ["patients", 535], ["in", 544], ["4504", 547], ["BZD", 552], ["-", 555], ["related", 556], ["enquiries", 564], [",", 573], ["68", 575], ["of", 578], ["whom", 581], ["did", 586], ["not", 590], ["have", 594], ["ventilatory", 599], ["failure", 611], ["or", 619], ["had", 622], ["recognised", 626], ["contraindications", 637], ["to", 655], ["flumazenil", 658], [".", 668], ["Factors", 670], ["associated", 678], ["with", 689], ["flumazenil", 694], ["use", 705], ["were", 709], ["increased", 714], ["age", 724], [",", 727], ["severe", 729], ["poisoning", 736], ["and", 746], ["ventilatory", 750], ["failure", 762], [".", 769], ["Co", 771], ["-", 773], ["ingestion", 774], ["of", 784], ["tricyclic", 787], ["antidepressants", 797], ["and", 813], ["chronic", 817], ["obstructive", 825], ["pulmonary", 837], ["disease", 847], ["did", 855], ["not", 859], ["influence", 863], ["flumazenil", 873], ["administration", 884], [".", 898], ["Seizure", 900], ["frequency", 908], ["in", 918], ["patients", 921], ["not", 930], ["treated", 934], ["with", 942], ["flumazenil", 947], ["was", 958], ["0.3", 962], ["%", 965], [".", 966], ["The", 968], ["frequency", 972], ["of", 982], ["prior", 985], ["seizure", 991], ["in", 999], ["flumazenil", 1002], ["-", 1012], ["treated", 1013], ["patients", 1021], ["was", 1030], ["30", 1034], ["times", 1037], ["higher", 1043], ["(", 1050], ["8.8", 1051], ["%", 1054], [")", 1055], [".", 1056], ["Seven", 1058], ["patients", 1064], ["who", 1073], ["had", 1077], ["seizures", 1081], ["prior", 1090], ["to", 1096], ["flumazenil", 1099], ["therapy", 1110], ["had", 1118], ["no", 1122], ["recurrence", 1125], ["of", 1136], ["their", 1139], ["seizures", 1145], [".", 1153], ["Ventilation", 1155], ["or", 1167], ["consciousness", 1170], ["improved", 1184], ["in", 1193], ["70", 1196], ["%", 1198], ["of", 1200], ["flumazenil", 1203], ["-", 1213], ["treated", 1214], ["patients", 1222], [".", 1230], ["Flumazenil", 1232], ["administration", 1243], ["was", 1258], ["followed", 1262], ["by", 1271], ["one", 1274], ["instance", 1278], ["each", 1287], ["of", 1292], ["agitation", 1295], ["and", 1305], ["brief", 1309], ["seizure", 1315], [".", 1322], ["Flumazenil", 1324], ["is", 1335], ["used", 1338], ["infrequently", 1343], ["in", 1356], ["the", 1359], ["management", 1363], ["of", 1374], ["BZD", 1377], ["OD", 1381], ["in", 1384], ["the", 1387], ["UK", 1391], [".", 1393], ["It", 1395], ["was", 1398], ["effective", 1402], ["and", 1412], ["associated", 1416], ["with", 1427], ["a", 1432], ["low", 1434], ["incidence", 1438], ["of", 1448], ["seizure", 1451], [".", 1458], ["These", 1460], ["results", 1466], ["compare", 1474], ["favourably", 1482], ["with", 1493], ["the", 1498], ["results", 1502], ["of", 1510], ["published", 1513], ["randomised", 1523], ["controlled", 1534], ["trials", 1545], ["and", 1552], ["cohort", 1556], ["studies", 1563], [",", 1570], ["although", 1572], ["previous", 1581], ["studies", 1590], ["have", 1598], ["not", 1603], ["reported", 1607], ["the", 1616], ["use", 1620], ["of", 1624], ["flumazenil", 1627], ["in", 1638], ["such", 1641], ["a", 1646], ["high", 1648], ["-", 1652], ["risk", 1653], ["population", 1658], [".", 1668], ["This", 1670], ["study", 1675], ["should", 1681], ["inform", 1688], ["the", 1695], ["continuing", 1699], ["review", 1710], ["of", 1717], ["national", 1720], ["guidance", 1729], ["on", 1738], ["flumazenil", 1741], ["therapy", 1752], [".", 1759]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor of Bcr-Abl, induces major cytogenetic remission (MCR) or complete cytogenetic remission (CCR) in the majority of patients with CML in first chronic phase. However, thorough re-evaluation of cytogenetics in a cohort of patients in MCR or CCR demonstrated clonal karyotypic abnormalities in more than 10% of cases, some of which were clinically associated with a myelodysplastic syndrome (MDS). Further analysis identified previous exposure to cytarabine and idarubicin as significant risk factors for the subsequent occurrence of abnormalities in Philadelphia chromosome-negative (Ph-) cells. To investigate if cytogenetically normal but clonal hematopoiesis might be present in other patients in cytogenetic remission, we studied X-chromosome inactivation as a marker of clonality by polymerase chain reaction analysis of the human androgen receptor (HUMARA). We find that imatinib restores a polyclonal pattern in most patients in CCR and MCR. Nonetheless, our results are consistent with the notion that targeted therapy of CML with imatinib favors the manifestation of Ph- clonal disorders in some patients. They indicate that patients on imatinib should be followed with conventional cytogenetics, even after induction of CCR.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ebd82668eb7c49faaf1bd4cce3dd47cb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[13, 15], [38, 40]], "char_spans": [[73, 79], [231, 237]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["the", 55], ["presence", 59], ["of", 68], ["a", 71], ["Bcr", 73], ["-", 76], ["Abl", 77], ["fusion", 81], ["protein", 88], ["with", 96], ["deregulated", 101], ["tyrosine", 113], ["kinase", 122], ["activity", 129], ["that", 138], ["is", 143], ["required", 146], ["for", 155], ["maintaining", 159], ["the", 171], ["malignant", 175], ["phenotype", 185], [".", 194], ["Imatinib", 196], [",", 204], ["a", 206], ["selective", 208], ["inhibitor", 218], ["of", 228], ["Bcr", 231], ["-", 234], ["Abl", 235], [",", 238], ["induces", 240], ["major", 248], ["cytogenetic", 254], ["remission", 266], ["(", 276], ["MCR", 277], [")", 280], ["or", 282], ["complete", 285], ["cytogenetic", 294], ["remission", 306], ["(", 316], ["CCR", 317], [")", 320], ["in", 322], ["the", 325], ["majority", 329], ["of", 338], ["patients", 341], ["with", 350], ["CML", 355], ["in", 359], ["first", 362], ["chronic", 368], ["phase", 376], [".", 381], ["However", 383], [",", 390], ["thorough", 392], ["re", 401], ["-", 403], ["evaluation", 404], ["of", 415], ["cytogenetics", 418], ["in", 431], ["a", 434], ["cohort", 436], ["of", 443], ["patients", 446], ["in", 455], ["MCR", 458], ["or", 462], ["CCR", 465], ["demonstrated", 469], ["clonal", 482], ["karyotypic", 489], ["abnormalities", 500], ["in", 514], ["more", 517], ["than", 522], ["10", 527], ["%", 529], ["of", 531], ["cases", 534], [",", 539], ["some", 541], ["of", 546], ["which", 549], ["were", 555], ["clinically", 560], ["associated", 571], ["with", 582], ["a", 587], ["myelodysplastic", 589], ["syndrome", 605], ["(", 614], ["MDS", 615], [")", 618], [".", 619], ["Further", 621], ["analysis", 629], ["identified", 638], ["previous", 649], ["exposure", 658], ["to", 667], ["cytarabine", 670], ["and", 681], ["idarubicin", 685], ["as", 696], ["significant", 699], ["risk", 711], ["factors", 716], ["for", 724], ["the", 728], ["subsequent", 732], ["occurrence", 743], ["of", 754], ["abnormalities", 757], ["in", 771], ["Philadelphia", 774], ["chromosome", 787], ["-", 797], ["negative", 798], ["(", 807], ["Ph-", 808], [")", 811], ["cells", 813], [".", 818], ["To", 820], ["investigate", 823], ["if", 835], ["cytogenetically", 838], ["normal", 854], ["but", 861], ["clonal", 865], ["hematopoiesis", 872], ["might", 886], ["be", 892], ["present", 895], ["in", 903], ["other", 906], ["patients", 912], ["in", 921], ["cytogenetic", 924], ["remission", 936], [",", 945], ["we", 947], ["studied", 950], ["X", 958], ["-", 959], ["chromosome", 960], ["inactivation", 971], ["as", 984], ["a", 987], ["marker", 989], ["of", 996], ["clonality", 999], ["by", 1009], ["polymerase", 1012], ["chain", 1023], ["reaction", 1029], ["analysis", 1038], ["of", 1047], ["the", 1050], ["human", 1054], ["androgen", 1060], ["receptor", 1069], ["(", 1078], ["HUMARA", 1079], [")", 1085], [".", 1086], ["We", 1088], ["find", 1091], ["that", 1096], ["imatinib", 1101], ["restores", 1110], ["a", 1119], ["polyclonal", 1121], ["pattern", 1132], ["in", 1140], ["most", 1143], ["patients", 1148], ["in", 1157], ["CCR", 1160], ["and", 1164], ["MCR", 1168], [".", 1171], ["Nonetheless", 1173], [",", 1184], ["our", 1186], ["results", 1190], ["are", 1198], ["consistent", 1202], ["with", 1213], ["the", 1218], ["notion", 1222], ["that", 1229], ["targeted", 1234], ["therapy", 1243], ["of", 1251], ["CML", 1254], ["with", 1258], ["imatinib", 1263], ["favors", 1272], ["the", 1279], ["manifestation", 1283], ["of", 1297], ["Ph-", 1300], ["clonal", 1304], ["disorders", 1311], ["in", 1321], ["some", 1324], ["patients", 1329], [".", 1337], ["They", 1339], ["indicate", 1344], ["that", 1353], ["patients", 1358], ["on", 1367], ["imatinib", 1370], ["should", 1379], ["be", 1386], ["followed", 1389], ["with", 1398], ["conventional", 1403], ["cytogenetics", 1416], [",", 1428], ["even", 1430], ["after", 1435], ["induction", 1441], ["of", 1451], ["CCR", 1454], [".", 1457]]}
{"context": "Selenocysteine (Sec) is co-translationally incorporated into selenoproteins at a reprogrammed UGA codon. In mammals, this requires a dedicated machinery comprising a stem-loop structure in the 3' UTR RNA (the SECIS element) and the specific SECIS Binding Protein 2. In this report, disorder-prediction methods and several biophysical techniques showed that ca. 70% of the SBP2 sequence is disordered, whereas the RNA binding domain appears to be folded and functional. These results are consistent with a recent report on the role of the Hsp90 chaperone for the folding of SBP2 and other functionally unrelated proteins bearing an RNA binding domain homologous to SBP2.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "ebd0c01ec7c04fefaecf5b72360eeaba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[45, 45], [39, 39]], "char_spans": [[241, 245], [209, 213]]}]}], "context_tokens": [["Selenocysteine", 0], ["(", 15], ["Sec", 16], [")", 19], ["is", 21], ["co", 24], ["-", 26], ["translationally", 27], ["incorporated", 43], ["into", 56], ["selenoproteins", 61], ["at", 76], ["a", 79], ["reprogrammed", 81], ["UGA", 94], ["codon", 98], [".", 103], ["In", 105], ["mammals", 108], [",", 115], ["this", 117], ["requires", 122], ["a", 131], ["dedicated", 133], ["machinery", 143], ["comprising", 153], ["a", 164], ["stem", 166], ["-", 170], ["loop", 171], ["structure", 176], ["in", 186], ["the", 189], ["3", 193], ["'", 194], ["UTR", 196], ["RNA", 200], ["(", 204], ["the", 205], ["SECIS", 209], ["element", 215], [")", 222], ["and", 224], ["the", 228], ["specific", 232], ["SECIS", 241], ["Binding", 247], ["Protein", 255], ["2", 263], [".", 264], ["In", 266], ["this", 269], ["report", 274], [",", 280], ["disorder", 282], ["-", 290], ["prediction", 291], ["methods", 302], ["and", 310], ["several", 314], ["biophysical", 322], ["techniques", 334], ["showed", 345], ["that", 352], ["ca", 357], [".", 359], ["70", 361], ["%", 363], ["of", 365], ["the", 368], ["SBP2", 372], ["sequence", 377], ["is", 386], ["disordered", 389], [",", 399], ["whereas", 401], ["the", 409], ["RNA", 413], ["binding", 417], ["domain", 425], ["appears", 432], ["to", 440], ["be", 443], ["folded", 446], ["and", 453], ["functional", 457], [".", 467], ["These", 469], ["results", 475], ["are", 483], ["consistent", 487], ["with", 498], ["a", 503], ["recent", 505], ["report", 512], ["on", 519], ["the", 522], ["role", 526], ["of", 531], ["the", 534], ["Hsp90", 538], ["chaperone", 544], ["for", 554], ["the", 558], ["folding", 562], ["of", 570], ["SBP2", 573], ["and", 578], ["other", 582], ["functionally", 588], ["unrelated", 601], ["proteins", 611], ["bearing", 620], ["an", 628], ["RNA", 631], ["binding", 635], ["domain", 643], ["homologous", 650], ["to", 661], ["SBP2", 664], [".", 668]]}
{"context": "Selenoproteins are a family of proteins that share the common feature of containing selenocysteine, the \"twenty-first\" amino acid. Selenocysteine incorporation occurs during translation of selenoprotein messages by redefinition of UGA codons, which normally specify termination of translation. Studies of the eukaryotic selenocysteine incorporation mechanism suggest that selenocysteine insertion is inefficient compared with termination. Nevertheless, selenoprotein P and several other selenoproteins are known to contain multiple selenocysteines. The production of full-length (FL) protein from these messages would seem to demand highly efficient selenocysteine incorporation due to the compounding effect of termination at each UGA codon. We present data demonstrating that efficient incorporation of multiple selenocysteines can be reconstituted in rabbit reticulocyte lysate translation reactions. Selenocysteine incorporation at the first UGA codon is inefficient but increases by approximately 10-fold at subsequent downstream UGA codons. We found that ribosomes in the \"processive\" phase of selenocysteine incorporation (i.e., after decoding the first UGA codon as selenocysteine) are fully competent to terminate translation at UAG and UAA codons, that ribosomes become less efficient at selenocysteine incorporation as the distance between UGA codons is increased, and that efficient selenocysteine incorporation is not dependent on cis-acting elements unique to selenoprotein P. Furthermore, we found that the percentage of ribosomes decoding a UGA codon as selenocysteine rather than termination can be increased by 3- to 5-fold by placing the murine leukemia virus UAG read-through element upstream of the first UGA codon or by providing a competing messenger RNA in trans. The mechanisms of selenocysteine incorporation and selenoprotein synthesis are discussed in light of these results.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "7a2f5d7d054743f394fabcf4272d4fb5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[64, 65], [219, 220]], "char_spans": [[453, 467], [1474, 1489]]}]}], "context_tokens": [["Selenoproteins", 0], ["are", 15], ["a", 19], ["family", 21], ["of", 28], ["proteins", 31], ["that", 40], ["share", 45], ["the", 51], ["common", 55], ["feature", 62], ["of", 70], ["containing", 73], ["selenocysteine", 84], [",", 98], ["the", 100], ["\"", 104], ["twenty", 105], ["-", 111], ["first", 112], ["\"", 117], ["amino", 119], ["acid", 125], [".", 129], ["Selenocysteine", 131], ["incorporation", 146], ["occurs", 160], ["during", 167], ["translation", 174], ["of", 186], ["selenoprotein", 189], ["messages", 203], ["by", 212], ["redefinition", 215], ["of", 228], ["UGA", 231], ["codons", 235], [",", 241], ["which", 243], ["normally", 249], ["specify", 258], ["termination", 266], ["of", 278], ["translation", 281], [".", 292], ["Studies", 294], ["of", 302], ["the", 305], ["eukaryotic", 309], ["selenocysteine", 320], ["incorporation", 335], ["mechanism", 349], ["suggest", 359], ["that", 367], ["selenocysteine", 372], ["insertion", 387], ["is", 397], ["inefficient", 400], ["compared", 412], ["with", 421], ["termination", 426], [".", 437], ["Nevertheless", 439], [",", 451], ["selenoprotein", 453], ["P", 467], ["and", 469], ["several", 473], ["other", 481], ["selenoproteins", 487], ["are", 502], ["known", 506], ["to", 512], ["contain", 515], ["multiple", 523], ["selenocysteines", 532], [".", 547], ["The", 549], ["production", 553], ["of", 564], ["full", 567], ["-", 571], ["length", 572], ["(", 579], ["FL", 580], [")", 582], ["protein", 584], ["from", 592], ["these", 597], ["messages", 603], ["would", 612], ["seem", 618], ["to", 623], ["demand", 626], ["highly", 633], ["efficient", 640], ["selenocysteine", 650], ["incorporation", 665], ["due", 679], ["to", 683], ["the", 686], ["compounding", 690], ["effect", 702], ["of", 709], ["termination", 712], ["at", 724], ["each", 727], ["UGA", 732], ["codon", 736], [".", 741], ["We", 743], ["present", 746], ["data", 754], ["demonstrating", 759], ["that", 773], ["efficient", 778], ["incorporation", 788], ["of", 802], ["multiple", 805], ["selenocysteines", 814], ["can", 830], ["be", 834], ["reconstituted", 837], ["in", 851], ["rabbit", 854], ["reticulocyte", 861], ["lysate", 874], ["translation", 881], ["reactions", 893], [".", 902], ["Selenocysteine", 904], ["incorporation", 919], ["at", 933], ["the", 936], ["first", 940], ["UGA", 946], ["codon", 950], ["is", 956], ["inefficient", 959], ["but", 971], ["increases", 975], ["by", 985], ["approximately", 988], ["10-fold", 1002], ["at", 1010], ["subsequent", 1013], ["downstream", 1024], ["UGA", 1035], ["codons", 1039], [".", 1045], ["We", 1047], ["found", 1050], ["that", 1056], ["ribosomes", 1061], ["in", 1071], ["the", 1074], ["\"", 1078], ["processive", 1079], ["\"", 1089], ["phase", 1091], ["of", 1097], ["selenocysteine", 1100], ["incorporation", 1115], ["(", 1129], ["i.e.", 1130], [",", 1134], ["after", 1136], ["decoding", 1142], ["the", 1151], ["first", 1155], ["UGA", 1161], ["codon", 1165], ["as", 1171], ["selenocysteine", 1174], [")", 1188], ["are", 1190], ["fully", 1194], ["competent", 1200], ["to", 1210], ["terminate", 1213], ["translation", 1223], ["at", 1235], ["UAG", 1238], ["and", 1242], ["UAA", 1246], ["codons", 1250], [",", 1256], ["that", 1258], ["ribosomes", 1263], ["become", 1273], ["less", 1280], ["efficient", 1285], ["at", 1295], ["selenocysteine", 1298], ["incorporation", 1313], ["as", 1327], ["the", 1330], ["distance", 1334], ["between", 1343], ["UGA", 1351], ["codons", 1355], ["is", 1362], ["increased", 1365], [",", 1374], ["and", 1376], ["that", 1380], ["efficient", 1385], ["selenocysteine", 1395], ["incorporation", 1410], ["is", 1424], ["not", 1427], ["dependent", 1431], ["on", 1441], ["cis", 1444], ["-", 1447], ["acting", 1448], ["elements", 1455], ["unique", 1464], ["to", 1471], ["selenoprotein", 1474], ["P.", 1488], ["Furthermore", 1491], [",", 1502], ["we", 1504], ["found", 1507], ["that", 1513], ["the", 1518], ["percentage", 1522], ["of", 1533], ["ribosomes", 1536], ["decoding", 1546], ["a", 1555], ["UGA", 1557], ["codon", 1561], ["as", 1567], ["selenocysteine", 1570], ["rather", 1585], ["than", 1592], ["termination", 1597], ["can", 1609], ["be", 1613], ["increased", 1616], ["by", 1626], ["3-", 1629], ["to", 1632], ["5-fold", 1635], ["by", 1642], ["placing", 1645], ["the", 1653], ["murine", 1657], ["leukemia", 1664], ["virus", 1673], ["UAG", 1679], ["read", 1683], ["-", 1687], ["through", 1688], ["element", 1696], ["upstream", 1704], ["of", 1713], ["the", 1716], ["first", 1720], ["UGA", 1726], ["codon", 1730], ["or", 1736], ["by", 1739], ["providing", 1742], ["a", 1752], ["competing", 1754], ["messenger", 1764], ["RNA", 1774], ["in", 1778], ["trans", 1781], [".", 1786], ["The", 1788], ["mechanisms", 1792], ["of", 1803], ["selenocysteine", 1806], ["incorporation", 1821], ["and", 1835], ["selenoprotein", 1839], ["synthesis", 1853], ["are", 1863], ["discussed", 1867], ["in", 1877], ["light", 1880], ["of", 1886], ["these", 1889], ["results", 1895], [".", 1902]]}
{"context": "In this study, the epidemiological characteristics of malaria cases in Edirne province were investigated. Between the years of 1994-2002, a total of 317,087 blood samples were collected from soldiers in the province with selective active surveillance and from the resident population with active or passive surveillance methods, by the medical staff of Malaria Control Department and Health Centers, to search the presence of Plasmodium. In 281 of them Plasmodium spp. were detected, and the characteristics of malaria cases were investigated. Of the cases, 238 (84.7%) were detected in the first three years and mostly in September. While the indigenous cases were detected in the districts where rice planted intensely, the imported cases were detected in the districts heavily populated by military staff. Of the imported cases, 62% originated from Diyarbakir, Batman and Sanliurfa provinces (Southeast part of Turkey). P. vivax was detected as the causative agent in all blood samples except one P. ovale. This latter case has been the only one in Turkey so far and he was a student from Afghanistan. Attaching importance to fight off mosquitoes in intensely rice planted districts and strictly surveying the military staff, particularly from the region of Southern-East Anatolia, have led to successful control of the malaria cases in Edirne region.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "62dfb0f0049641648b339a94e27b7262", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium spp.", "token_spans": [[76, 77]], "char_spans": [[453, 466]]}]}], "context_tokens": [["In", 0], ["this", 3], ["study", 8], [",", 13], ["the", 15], ["epidemiological", 19], ["characteristics", 35], ["of", 51], ["malaria", 54], ["cases", 62], ["in", 68], ["Edirne", 71], ["province", 78], ["were", 87], ["investigated", 92], [".", 104], ["Between", 106], ["the", 114], ["years", 118], ["of", 124], ["1994", 127], ["-", 131], ["2002", 132], [",", 136], ["a", 138], ["total", 140], ["of", 146], ["317,087", 149], ["blood", 157], ["samples", 163], ["were", 171], ["collected", 176], ["from", 186], ["soldiers", 191], ["in", 200], ["the", 203], ["province", 207], ["with", 216], ["selective", 221], ["active", 231], ["surveillance", 238], ["and", 251], ["from", 255], ["the", 260], ["resident", 264], ["population", 273], ["with", 284], ["active", 289], ["or", 296], ["passive", 299], ["surveillance", 307], ["methods", 320], [",", 327], ["by", 329], ["the", 332], ["medical", 336], ["staff", 344], ["of", 350], ["Malaria", 353], ["Control", 361], ["Department", 369], ["and", 380], ["Health", 384], ["Centers", 391], [",", 398], ["to", 400], ["search", 403], ["the", 410], ["presence", 414], ["of", 423], ["Plasmodium", 426], [".", 436], ["In", 438], ["281", 441], ["of", 445], ["them", 448], ["Plasmodium", 453], ["spp", 464], [".", 467], ["were", 469], ["detected", 474], [",", 482], ["and", 484], ["the", 488], ["characteristics", 492], ["of", 508], ["malaria", 511], ["cases", 519], ["were", 525], ["investigated", 530], [".", 542], ["Of", 544], ["the", 547], ["cases", 551], [",", 556], ["238", 558], ["(", 562], ["84.7", 563], ["%", 567], [")", 568], ["were", 570], ["detected", 575], ["in", 584], ["the", 587], ["first", 591], ["three", 597], ["years", 603], ["and", 609], ["mostly", 613], ["in", 620], ["September", 623], [".", 632], ["While", 634], ["the", 640], ["indigenous", 644], ["cases", 655], ["were", 661], ["detected", 666], ["in", 675], ["the", 678], ["districts", 682], ["where", 692], ["rice", 698], ["planted", 703], ["intensely", 711], [",", 720], ["the", 722], ["imported", 726], ["cases", 735], ["were", 741], ["detected", 746], ["in", 755], ["the", 758], ["districts", 762], ["heavily", 772], ["populated", 780], ["by", 790], ["military", 793], ["staff", 802], [".", 807], ["Of", 809], ["the", 812], ["imported", 816], ["cases", 825], [",", 830], ["62", 832], ["%", 834], ["originated", 836], ["from", 847], ["Diyarbakir", 852], [",", 862], ["Batman", 864], ["and", 871], ["Sanliurfa", 875], ["provinces", 885], ["(", 895], ["Southeast", 896], ["part", 906], ["of", 911], ["Turkey", 914], [")", 920], [".", 921], ["P.", 923], ["vivax", 926], ["was", 932], ["detected", 936], ["as", 945], ["the", 948], ["causative", 952], ["agent", 962], ["in", 968], ["all", 971], ["blood", 975], ["samples", 981], ["except", 989], ["one", 996], ["P.", 1000], ["ovale", 1003], [".", 1008], ["This", 1010], ["latter", 1015], ["case", 1022], ["has", 1027], ["been", 1031], ["the", 1036], ["only", 1040], ["one", 1045], ["in", 1049], ["Turkey", 1052], ["so", 1059], ["far", 1062], ["and", 1066], ["he", 1070], ["was", 1073], ["a", 1077], ["student", 1079], ["from", 1087], ["Afghanistan", 1092], [".", 1103], ["Attaching", 1105], ["importance", 1115], ["to", 1126], ["fight", 1129], ["off", 1135], ["mosquitoes", 1139], ["in", 1150], ["intensely", 1153], ["rice", 1163], ["planted", 1168], ["districts", 1176], ["and", 1186], ["strictly", 1190], ["surveying", 1199], ["the", 1209], ["military", 1213], ["staff", 1222], [",", 1227], ["particularly", 1229], ["from", 1242], ["the", 1247], ["region", 1251], ["of", 1258], ["Southern", 1261], ["-", 1269], ["East", 1270], ["Anatolia", 1275], [",", 1283], ["have", 1285], ["led", 1290], ["to", 1294], ["successful", 1297], ["control", 1308], ["of", 1316], ["the", 1319], ["malaria", 1323], ["cases", 1331], ["in", 1337], ["Edirne", 1340], ["region", 1347], [".", 1353]]}
{"context": "Puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment. Arm and forearm edema are voluminous and cause functional and aesthetic disturbances. We report two cases successfully treated by low-stretch bandages. A 40-year-old man and a 34-year-old woman, both intravenous drug users, with puffy hand syndrome were hospitalized for 11 days. Treatment included daily multilayer bandaging. Lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16% on the left side and 12% on the right side for the first patient and 31 and 17% for the second. Hand circumference decreased 4.3 cm on the left side and 3.2 cm on the right side in case 1, and 2.5 cm and 1.9 cm respectively for case 2. The patients were taught self-bandaging techniques during their hospital stays. Elastic gloves were fitted at the end of treatment. Reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance. The pathogenesis of this edema is probably multifactorial: venous, lymphatic insufficiency and the direct toxicity of injected drugs. Lymphedema treatment currently consists of low-stretch bandaging and wearing elastic garments, which is effective in decreasing the volume of puffy hand syndrome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "a13f894d41114c86a5a62c07c2b4ee03", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[7, 9]], "char_spans": [[41, 62]]}]}], "context_tokens": [["Puffy", 0], ["hand", 6], ["syndrome", 11], ["is", 20], ["a", 23], ["complication", 25], ["of", 38], ["intravenous", 41], ["drug", 53], ["abuse", 58], [",", 63], ["which", 65], ["has", 71], ["no", 75], ["current", 78], ["available", 86], ["treatment", 96], [".", 105], ["Arm", 107], ["and", 111], ["forearm", 115], ["edema", 123], ["are", 129], ["voluminous", 133], ["and", 144], ["cause", 148], ["functional", 154], ["and", 165], ["aesthetic", 169], ["disturbances", 179], [".", 191], ["We", 193], ["report", 196], ["two", 203], ["cases", 207], ["successfully", 213], ["treated", 226], ["by", 234], ["low", 237], ["-", 240], ["stretch", 241], ["bandages", 249], [".", 257], ["A", 259], ["40-year", 261], ["-", 268], ["old", 269], ["man", 273], ["and", 277], ["a", 281], ["34-year", 283], ["-", 290], ["old", 291], ["woman", 295], [",", 300], ["both", 302], ["intravenous", 307], ["drug", 319], ["users", 324], [",", 329], ["with", 331], ["puffy", 336], ["hand", 342], ["syndrome", 347], ["were", 356], ["hospitalized", 361], ["for", 374], ["11", 378], ["days", 381], [".", 385], ["Treatment", 387], ["included", 397], ["daily", 406], ["multilayer", 412], ["bandaging", 423], [".", 432], ["Lymphedema", 434], ["volumes", 445], ["calculated", 453], ["by", 464], ["utilizing", 467], ["the", 477], ["formula", 481], ["for", 489], ["a", 493], ["truncated", 495], ["cone", 505], ["decreased", 510], ["by", 520], ["16", 523], ["%", 525], ["on", 527], ["the", 530], ["left", 534], ["side", 539], ["and", 544], ["12", 548], ["%", 550], ["on", 552], ["the", 555], ["right", 559], ["side", 565], ["for", 570], ["the", 574], ["first", 578], ["patient", 584], ["and", 592], ["31", 596], ["and", 599], ["17", 603], ["%", 605], ["for", 607], ["the", 611], ["second", 615], [".", 621], ["Hand", 623], ["circumference", 628], ["decreased", 642], ["4.3", 652], ["cm", 656], ["on", 659], ["the", 662], ["left", 666], ["side", 671], ["and", 676], ["3.2", 680], ["cm", 684], ["on", 687], ["the", 690], ["right", 694], ["side", 700], ["in", 705], ["case", 708], ["1", 713], [",", 714], ["and", 716], ["2.5", 720], ["cm", 724], ["and", 727], ["1.9", 731], ["cm", 735], ["respectively", 738], ["for", 751], ["case", 755], ["2", 760], [".", 761], ["The", 763], ["patients", 767], ["were", 776], ["taught", 781], ["self", 788], ["-", 792], ["bandaging", 793], ["techniques", 803], ["during", 814], ["their", 821], ["hospital", 827], ["stays", 836], [".", 841], ["Elastic", 843], ["gloves", 851], ["were", 858], ["fitted", 863], ["at", 870], ["the", 873], ["end", 877], ["of", 881], ["treatment", 884], [".", 893], ["Reduction", 895], ["of", 905], ["lymphedema", 908], ["volume", 919], ["remained", 926], ["stable", 935], ["after", 942], ["18", 948], ["months", 951], ["in", 958], ["one", 961], ["patient", 965], ["while", 973], ["for", 979], ["the", 983], ["second", 987], ["patient", 994], ["further", 1002], ["treatment", 1010], ["and", 1020], ["hospitalization", 1024], ["were", 1040], ["required", 1045], ["due", 1054], ["to", 1058], ["poor", 1061], ["compliance", 1066], [".", 1076], ["The", 1078], ["pathogenesis", 1082], ["of", 1095], ["this", 1098], ["edema", 1103], ["is", 1109], ["probably", 1112], ["multifactorial", 1121], [":", 1135], ["venous", 1137], [",", 1143], ["lymphatic", 1145], ["insufficiency", 1155], ["and", 1169], ["the", 1173], ["direct", 1177], ["toxicity", 1184], ["of", 1193], ["injected", 1196], ["drugs", 1205], [".", 1210], ["Lymphedema", 1212], ["treatment", 1223], ["currently", 1233], ["consists", 1243], ["of", 1252], ["low", 1255], ["-", 1258], ["stretch", 1259], ["bandaging", 1267], ["and", 1277], ["wearing", 1281], ["elastic", 1289], ["garments", 1297], [",", 1305], ["which", 1307], ["is", 1313], ["effective", 1316], ["in", 1326], ["decreasing", 1329], ["the", 1340], ["volume", 1344], ["of", 1351], ["puffy", 1354], ["hand", 1360], ["syndrome", 1365], [".", 1373]]}
{"context": "Restless legs syndrome (RLS) is a common condition that is frequently unrecognized, misdiagnosed and poorly managed. It is characterized by uncomfortable sensations deep in the legs developing at rest that compel the person to move; symptoms are worst at night and sleep disturbance is common. RLS occurs in 7%-11% of the population in Western countries, and many such people experience troublesome symptoms. Primary RLS is familial in up to two thirds of patients. RLS may also be secondary to a number of conditions including iron deficiency, pregnancy and end-stage renal failure and, perhaps, neuropathy. Secondary RLS is most common in those presenting for the first time in later life. The pathogenesis of RLS probably involves the interplay of systemic or brain iron deficiency and impaired dopaminergic neurotransmission in the subcortex of the brain. RLS is very responsive to dopaminergic therapies. Rebound of RLS symptoms during the early morning and development of severe symptoms earlier in the day (augmentation) are problematic in those treated for a prolonged period with levodopa. Consequently, dopamine agonists have become first line treatment. Anti-convulsant medications and opioids are helpful in some patients. Correction of underlying problem wherever possible is important in the management of secondary RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "2d73138d00bc4dfc99e39ba6f78babb8", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[138, 138], [94, 94]], "char_spans": [[769, 772], [528, 531]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["common", 34], ["condition", 41], ["that", 51], ["is", 56], ["frequently", 59], ["unrecognized", 70], [",", 82], ["misdiagnosed", 84], ["and", 97], ["poorly", 101], ["managed", 108], [".", 115], ["It", 117], ["is", 120], ["characterized", 123], ["by", 137], ["uncomfortable", 140], ["sensations", 154], ["deep", 165], ["in", 170], ["the", 173], ["legs", 177], ["developing", 182], ["at", 193], ["rest", 196], ["that", 201], ["compel", 206], ["the", 213], ["person", 217], ["to", 224], ["move", 227], [";", 231], ["symptoms", 233], ["are", 242], ["worst", 246], ["at", 252], ["night", 255], ["and", 261], ["sleep", 265], ["disturbance", 271], ["is", 283], ["common", 286], [".", 292], ["RLS", 294], ["occurs", 298], ["in", 305], ["7%-11", 308], ["%", 313], ["of", 315], ["the", 318], ["population", 322], ["in", 333], ["Western", 336], ["countries", 344], [",", 353], ["and", 355], ["many", 359], ["such", 364], ["people", 369], ["experience", 376], ["troublesome", 387], ["symptoms", 399], [".", 407], ["Primary", 409], ["RLS", 417], ["is", 421], ["familial", 424], ["in", 433], ["up", 436], ["to", 439], ["two", 442], ["thirds", 446], ["of", 453], ["patients", 456], [".", 464], ["RLS", 466], ["may", 470], ["also", 474], ["be", 479], ["secondary", 482], ["to", 492], ["a", 495], ["number", 497], ["of", 504], ["conditions", 507], ["including", 518], ["iron", 528], ["deficiency", 533], [",", 543], ["pregnancy", 545], ["and", 555], ["end", 559], ["-", 562], ["stage", 563], ["renal", 569], ["failure", 575], ["and", 583], [",", 586], ["perhaps", 588], [",", 595], ["neuropathy", 597], [".", 607], ["Secondary", 609], ["RLS", 619], ["is", 623], ["most", 626], ["common", 631], ["in", 638], ["those", 641], ["presenting", 647], ["for", 658], ["the", 662], ["first", 666], ["time", 672], ["in", 677], ["later", 680], ["life", 686], [".", 690], ["The", 692], ["pathogenesis", 696], ["of", 709], ["RLS", 712], ["probably", 716], ["involves", 725], ["the", 734], ["interplay", 738], ["of", 748], ["systemic", 751], ["or", 760], ["brain", 763], ["iron", 769], ["deficiency", 774], ["and", 785], ["impaired", 789], ["dopaminergic", 798], ["neurotransmission", 811], ["in", 829], ["the", 832], ["subcortex", 836], ["of", 846], ["the", 849], ["brain", 853], [".", 858], ["RLS", 860], ["is", 864], ["very", 867], ["responsive", 872], ["to", 883], ["dopaminergic", 886], ["therapies", 899], [".", 908], ["Rebound", 910], ["of", 918], ["RLS", 921], ["symptoms", 925], ["during", 934], ["the", 941], ["early", 945], ["morning", 951], ["and", 959], ["development", 963], ["of", 975], ["severe", 978], ["symptoms", 985], ["earlier", 994], ["in", 1002], ["the", 1005], ["day", 1009], ["(", 1013], ["augmentation", 1014], [")", 1026], ["are", 1028], ["problematic", 1032], ["in", 1044], ["those", 1047], ["treated", 1053], ["for", 1061], ["a", 1065], ["prolonged", 1067], ["period", 1077], ["with", 1084], ["levodopa", 1089], [".", 1097], ["Consequently", 1099], [",", 1111], ["dopamine", 1113], ["agonists", 1122], ["have", 1131], ["become", 1136], ["first", 1143], ["line", 1149], ["treatment", 1154], [".", 1163], ["Anti", 1165], ["-", 1169], ["convulsant", 1170], ["medications", 1181], ["and", 1193], ["opioids", 1197], ["are", 1205], ["helpful", 1209], ["in", 1217], ["some", 1220], ["patients", 1225], [".", 1233], ["Correction", 1235], ["of", 1246], ["underlying", 1249], ["problem", 1260], ["wherever", 1268], ["possible", 1277], ["is", 1286], ["important", 1289], ["in", 1299], ["the", 1302], ["management", 1306], ["of", 1317], ["secondary", 1320], ["RLS", 1330], [".", 1333]]}
{"context": "Accurate cell division requires the proper assembly of high-order septin structures. In fission yeast (Schizosaccharomyces pombe), Spn1-Spn4 are assembled into a primary septin ring at the division site, and the subsequent recruitment of Mid2 to the structure results in a stable septin ring. However, not much is known about the regulation of this key process. Here, we found that deletion of Spt20, a structural subunit of the Spt-Ada-Gcn5-acetyltransferase (SAGA) transcriptional activation complex, caused a severe cell separation defect. The defect was mainly due to impaired septin ring assembly, as 80% of spt20\u0394 cells lost septin rings at the division sites. Spt20 regulates septin ring assembly partially through the transcriptional activation of mid2(+). Spt20 also interacted with Spn2 and Mid2 in vitro and was associated with other components of the ring in vivo. Spt20 colocalized with the septin ring, but did not separate when the septin ring split. Importantly, Spt20 regulated the stability of the septin ring and was required for the recruitment of Mid2. The transcription-dependent and -independent roles of Spt20 in septin ring assembly highlight a multifaceted regulation of one process by a SAGA subunit.", "qas": [{"question": "What does the SAGA complex acronym stands for?", "answers": ["Spt-Ada-Gcn5-acetyltransferase"], "qid": "8879689c14314feb9629e3d724500547", "question_tokens": [["What", 0], ["does", 5], ["the", 10], ["SAGA", 14], ["complex", 19], ["acronym", 27], ["stands", 35], ["for", 42], ["?", 45]], "detected_answers": [{"text": "Spt-Ada-Gcn5-acetyltransferase", "token_spans": [[79, 83]], "char_spans": [[429, 458]]}]}], "context_tokens": [["Accurate", 0], ["cell", 9], ["division", 14], ["requires", 23], ["the", 32], ["proper", 36], ["assembly", 43], ["of", 52], ["high", 55], ["-", 59], ["order", 60], ["septin", 66], ["structures", 73], [".", 83], ["In", 85], ["fission", 88], ["yeast", 96], ["(", 102], ["Schizosaccharomyces", 103], ["pombe", 123], [")", 128], [",", 129], ["Spn1-Spn4", 131], ["are", 141], ["assembled", 145], ["into", 155], ["a", 160], ["primary", 162], ["septin", 170], ["ring", 177], ["at", 182], ["the", 185], ["division", 189], ["site", 198], [",", 202], ["and", 204], ["the", 208], ["subsequent", 212], ["recruitment", 223], ["of", 235], ["Mid2", 238], ["to", 243], ["the", 246], ["structure", 250], ["results", 260], ["in", 268], ["a", 271], ["stable", 273], ["septin", 280], ["ring", 287], [".", 291], ["However", 293], [",", 300], ["not", 302], ["much", 306], ["is", 311], ["known", 314], ["about", 320], ["the", 326], ["regulation", 330], ["of", 341], ["this", 344], ["key", 349], ["process", 353], [".", 360], ["Here", 362], [",", 366], ["we", 368], ["found", 371], ["that", 377], ["deletion", 382], ["of", 391], ["Spt20", 394], [",", 399], ["a", 401], ["structural", 403], ["subunit", 414], ["of", 422], ["the", 425], ["Spt", 429], ["-", 432], ["Ada", 433], ["-", 436], ["Gcn5-acetyltransferase", 437], ["(", 460], ["SAGA", 461], [")", 465], ["transcriptional", 467], ["activation", 483], ["complex", 494], [",", 501], ["caused", 503], ["a", 510], ["severe", 512], ["cell", 519], ["separation", 524], ["defect", 535], [".", 541], ["The", 543], ["defect", 547], ["was", 554], ["mainly", 558], ["due", 565], ["to", 569], ["impaired", 572], ["septin", 581], ["ring", 588], ["assembly", 593], [",", 601], ["as", 603], ["80", 606], ["%", 608], ["of", 610], ["spt20\u0394", 613], ["cells", 620], ["lost", 626], ["septin", 631], ["rings", 638], ["at", 644], ["the", 647], ["division", 651], ["sites", 660], [".", 665], ["Spt20", 667], ["regulates", 673], ["septin", 683], ["ring", 690], ["assembly", 695], ["partially", 704], ["through", 714], ["the", 722], ["transcriptional", 726], ["activation", 742], ["of", 753], ["mid2(+", 756], [")", 762], [".", 763], ["Spt20", 765], ["also", 771], ["interacted", 776], ["with", 787], ["Spn2", 792], ["and", 797], ["Mid2", 801], ["in", 806], ["vitro", 809], ["and", 815], ["was", 819], ["associated", 823], ["with", 834], ["other", 839], ["components", 845], ["of", 856], ["the", 859], ["ring", 863], ["in", 868], ["vivo", 871], [".", 875], ["Spt20", 877], ["colocalized", 883], ["with", 895], ["the", 900], ["septin", 904], ["ring", 911], [",", 915], ["but", 917], ["did", 921], ["not", 925], ["separate", 929], ["when", 938], ["the", 943], ["septin", 947], ["ring", 954], ["split", 959], [".", 964], ["Importantly", 966], [",", 977], ["Spt20", 979], ["regulated", 985], ["the", 995], ["stability", 999], ["of", 1009], ["the", 1012], ["septin", 1016], ["ring", 1023], ["and", 1028], ["was", 1032], ["required", 1036], ["for", 1045], ["the", 1049], ["recruitment", 1053], ["of", 1065], ["Mid2", 1068], [".", 1072], ["The", 1074], ["transcription", 1078], ["-", 1091], ["dependent", 1092], ["and", 1102], ["-independent", 1106], ["roles", 1119], ["of", 1125], ["Spt20", 1128], ["in", 1134], ["septin", 1137], ["ring", 1144], ["assembly", 1149], ["highlight", 1158], ["a", 1168], ["multifaceted", 1170], ["regulation", 1183], ["of", 1194], ["one", 1197], ["process", 1201], ["by", 1209], ["a", 1212], ["SAGA", 1214], ["subunit", 1219], [".", 1226]]}
{"context": "Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combination with dexamethasone, for patients with relapsed or refractory multiple myeloma who had \u2265 2 prior lines of therapy, one of which had to be bortezomib-based. Fourteen initial patients received siltuximab alone, 10 of whom had dexamethasone added for suboptimal response; 39 subsequent patients were treated with concurrent siltuximab and dexamethasone. Patients received a median of four prior lines of therapy, 83% were relapsed and refractory, and 70% refractory to their last dexamethasone-containing regimen. Suppression of serum C-reactive protein levels, a surrogate marker of IL6 inhibition, was demonstrated. There were no responses to siltuximab but combination therapy yielded a partial (17%) + minimal (6%) response rate of 23%, with responses seen in dexamethasone-refractory disease. The median time to progression, progression-free survival and overall survival for combination therapy was 4.4, 3.7 and 20.4 months respectively. Haematological toxicity was common but manageable. Infections occurred in 57% of combination-treated patients, including \u2265 grade 3 infections in 18%. Further study of siltuximab in modern corticosteroid-containing myeloma regimens is warranted, with special attention to infection-related toxicity.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "1e1ef110e6154949bc822e542fff38e2", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL6", 15], [")", 18], ["plays", 20], ["a", 26], ["central", 28], ["role", 36], ["in", 41], ["multiple", 44], ["myeloma", 53], ["pathogenesis", 61], ["and", 74], ["confers", 78], ["resistance", 86], ["to", 97], ["corticosteroid", 100], ["-", 114], ["induced", 115], ["apoptosis", 123], [".", 132], ["We", 134], ["therefore", 137], ["evaluated", 147], ["the", 157], ["efficacy", 161], ["and", 170], ["safety", 174], ["of", 181], ["siltuximab", 184], [",", 194], ["an", 196], ["anti", 199], ["-", 203], ["IL6", 204], ["monoclonal", 208], ["antibody", 219], [",", 227], ["alone", 229], ["and", 235], ["in", 239], ["combination", 242], ["with", 254], ["dexamethasone", 259], [",", 272], ["for", 274], ["patients", 278], ["with", 287], ["relapsed", 292], ["or", 301], ["refractory", 304], ["multiple", 315], ["myeloma", 324], ["who", 332], ["had", 336], ["\u2265", 340], ["2", 342], ["prior", 344], ["lines", 350], ["of", 356], ["therapy", 359], [",", 366], ["one", 368], ["of", 372], ["which", 375], ["had", 381], ["to", 385], ["be", 388], ["bortezomib", 391], ["-", 401], ["based", 402], [".", 407], ["Fourteen", 409], ["initial", 418], ["patients", 426], ["received", 435], ["siltuximab", 444], ["alone", 455], [",", 460], ["10", 462], ["of", 465], ["whom", 468], ["had", 473], ["dexamethasone", 477], ["added", 491], ["for", 497], ["suboptimal", 501], ["response", 512], [";", 520], ["39", 522], ["subsequent", 525], ["patients", 536], ["were", 545], ["treated", 550], ["with", 558], ["concurrent", 563], ["siltuximab", 574], ["and", 585], ["dexamethasone", 589], [".", 602], ["Patients", 604], ["received", 613], ["a", 622], ["median", 624], ["of", 631], ["four", 634], ["prior", 639], ["lines", 645], ["of", 651], ["therapy", 654], [",", 661], ["83", 663], ["%", 665], ["were", 667], ["relapsed", 672], ["and", 681], ["refractory", 685], [",", 695], ["and", 697], ["70", 701], ["%", 703], ["refractory", 705], ["to", 716], ["their", 719], ["last", 725], ["dexamethasone", 730], ["-", 743], ["containing", 744], ["regimen", 755], [".", 762], ["Suppression", 764], ["of", 776], ["serum", 779], ["C", 785], ["-", 786], ["reactive", 787], ["protein", 796], ["levels", 804], [",", 810], ["a", 812], ["surrogate", 814], ["marker", 824], ["of", 831], ["IL6", 834], ["inhibition", 838], [",", 848], ["was", 850], ["demonstrated", 854], [".", 866], ["There", 868], ["were", 874], ["no", 879], ["responses", 882], ["to", 892], ["siltuximab", 895], ["but", 906], ["combination", 910], ["therapy", 922], ["yielded", 930], ["a", 938], ["partial", 940], ["(", 948], ["17", 949], ["%", 951], [")", 952], ["+", 954], ["minimal", 956], ["(", 964], ["6", 965], ["%", 966], [")", 967], ["response", 969], ["rate", 978], ["of", 983], ["23", 986], ["%", 988], [",", 989], ["with", 991], ["responses", 996], ["seen", 1006], ["in", 1011], ["dexamethasone", 1014], ["-", 1027], ["refractory", 1028], ["disease", 1039], [".", 1046], ["The", 1048], ["median", 1052], ["time", 1059], ["to", 1064], ["progression", 1067], [",", 1078], ["progression", 1080], ["-", 1091], ["free", 1092], ["survival", 1097], ["and", 1106], ["overall", 1110], ["survival", 1118], ["for", 1127], ["combination", 1131], ["therapy", 1143], ["was", 1151], ["4.4", 1155], [",", 1158], ["3.7", 1160], ["and", 1164], ["20.4", 1168], ["months", 1173], ["respectively", 1180], [".", 1192], ["Haematological", 1194], ["toxicity", 1209], ["was", 1218], ["common", 1222], ["but", 1229], ["manageable", 1233], [".", 1243], ["Infections", 1245], ["occurred", 1256], ["in", 1265], ["57", 1268], ["%", 1270], ["of", 1272], ["combination", 1275], ["-", 1286], ["treated", 1287], ["patients", 1295], [",", 1303], ["including", 1305], ["\u2265", 1315], ["grade", 1317], ["3", 1323], ["infections", 1325], ["in", 1336], ["18", 1339], ["%", 1341], [".", 1342], ["Further", 1344], ["study", 1352], ["of", 1358], ["siltuximab", 1361], ["in", 1372], ["modern", 1375], ["corticosteroid", 1382], ["-", 1396], ["containing", 1397], ["myeloma", 1408], ["regimens", 1416], ["is", 1425], ["warranted", 1428], [",", 1437], ["with", 1439], ["special", 1444], ["attention", 1452], ["to", 1462], ["infection", 1465], ["-", 1474], ["related", 1475], ["toxicity", 1483], [".", 1491]]}
{"context": "It is generally accepted that the mitochondria play central roles in energy production of most eukaryotes. In contrast, it has been thought that Plasmodium spp., the causative agent of malaria, rely mainly on cytosolic glycolysis but not mitochondrial oxidative phosphorylation for energy production during blood stages. However, Plasmodium spp. possesses all genes necessary for the tricarboxylic acid (TCA) cycle and most of the genes for electron transport chain (ETC) enzymes. Therefore, it remains elusive whether oxidative phosphorylation is essential for the parasite survival. To elucidate the role of TCA metabolism and ETC in malaria parasites, we deleted the gene for flavoprotein (Fp) subunit, Pbsdha, one of four components of complex II, a catalytic subunit for succinate dehydrogenase activity. The Pbsdha(-) parasite grew normally at blood stages in mouse. In contrast, ookinete formation of Pbsdha(-) parasites in the mosquito stage was severely impaired. Finally, Pbsdha(-) ookinetes failed in oocyst formation, leading to complete malaria transmission blockade. These results suggest that malaria parasite may switch the energy metabolism from glycolysis to oxidative phosphorylation to adapt to the insect vector where glucose is not readily available for ATP production.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "88fbc5d11e354ff5b7380c243776c918", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium spp.", "token_spans": [[25, 26], [54, 55]], "char_spans": [[145, 158], [330, 343]]}]}], "context_tokens": [["It", 0], ["is", 3], ["generally", 6], ["accepted", 16], ["that", 25], ["the", 30], ["mitochondria", 34], ["play", 47], ["central", 52], ["roles", 60], ["in", 66], ["energy", 69], ["production", 76], ["of", 87], ["most", 90], ["eukaryotes", 95], [".", 105], ["In", 107], ["contrast", 110], [",", 118], ["it", 120], ["has", 123], ["been", 127], ["thought", 132], ["that", 140], ["Plasmodium", 145], ["spp", 156], [".", 159], [",", 160], ["the", 162], ["causative", 166], ["agent", 176], ["of", 182], ["malaria", 185], [",", 192], ["rely", 194], ["mainly", 199], ["on", 206], ["cytosolic", 209], ["glycolysis", 219], ["but", 230], ["not", 234], ["mitochondrial", 238], ["oxidative", 252], ["phosphorylation", 262], ["for", 278], ["energy", 282], ["production", 289], ["during", 300], ["blood", 307], ["stages", 313], [".", 319], ["However", 321], [",", 328], ["Plasmodium", 330], ["spp", 341], [".", 344], ["possesses", 346], ["all", 356], ["genes", 360], ["necessary", 366], ["for", 376], ["the", 380], ["tricarboxylic", 384], ["acid", 398], ["(", 403], ["TCA", 404], [")", 407], ["cycle", 409], ["and", 415], ["most", 419], ["of", 424], ["the", 427], ["genes", 431], ["for", 437], ["electron", 441], ["transport", 450], ["chain", 460], ["(", 466], ["ETC", 467], [")", 470], ["enzymes", 472], [".", 479], ["Therefore", 481], [",", 490], ["it", 492], ["remains", 495], ["elusive", 503], ["whether", 511], ["oxidative", 519], ["phosphorylation", 529], ["is", 545], ["essential", 548], ["for", 558], ["the", 562], ["parasite", 566], ["survival", 575], [".", 583], ["To", 585], ["elucidate", 588], ["the", 598], ["role", 602], ["of", 607], ["TCA", 610], ["metabolism", 614], ["and", 625], ["ETC", 629], ["in", 633], ["malaria", 636], ["parasites", 644], [",", 653], ["we", 655], ["deleted", 658], ["the", 666], ["gene", 670], ["for", 675], ["flavoprotein", 679], ["(", 692], ["Fp", 693], [")", 695], ["subunit", 697], [",", 704], ["Pbsdha", 706], [",", 712], ["one", 714], ["of", 718], ["four", 721], ["components", 726], ["of", 737], ["complex", 740], ["II", 748], [",", 750], ["a", 752], ["catalytic", 754], ["subunit", 764], ["for", 772], ["succinate", 776], ["dehydrogenase", 786], ["activity", 800], [".", 808], ["The", 810], ["Pbsdha(-", 814], [")", 822], ["parasite", 824], ["grew", 833], ["normally", 838], ["at", 847], ["blood", 850], ["stages", 856], ["in", 863], ["mouse", 866], [".", 871], ["In", 873], ["contrast", 876], [",", 884], ["ookinete", 886], ["formation", 895], ["of", 905], ["Pbsdha(-", 908], [")", 916], ["parasites", 918], ["in", 928], ["the", 931], ["mosquito", 935], ["stage", 944], ["was", 950], ["severely", 954], ["impaired", 963], [".", 971], ["Finally", 973], [",", 980], ["Pbsdha(-", 982], [")", 990], ["ookinetes", 992], ["failed", 1002], ["in", 1009], ["oocyst", 1012], ["formation", 1019], [",", 1028], ["leading", 1030], ["to", 1038], ["complete", 1041], ["malaria", 1050], ["transmission", 1058], ["blockade", 1071], [".", 1079], ["These", 1081], ["results", 1087], ["suggest", 1095], ["that", 1103], ["malaria", 1108], ["parasite", 1116], ["may", 1125], ["switch", 1129], ["the", 1136], ["energy", 1140], ["metabolism", 1147], ["from", 1158], ["glycolysis", 1163], ["to", 1174], ["oxidative", 1177], ["phosphorylation", 1187], ["to", 1203], ["adapt", 1206], ["to", 1212], ["the", 1215], ["insect", 1219], ["vector", 1226], ["where", 1233], ["glucose", 1239], ["is", 1247], ["not", 1250], ["readily", 1254], ["available", 1262], ["for", 1272], ["ATP", 1276], ["production", 1280], [".", 1290]]}
{"context": "The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor, in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm. Despite these discouraging results, therapies that target inflammation to modify pathways in atherogenesis remain an area of active investigation.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "aa3bd2754c49481280548e95e33f1438", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[7, 9]], "char_spans": [[37, 62]]}]}], "context_tokens": [["The", 0], ["VISTA-16", 4], ["trial", 13], ["of", 19], ["varespladib", 22], [",", 33], ["a", 35], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2", 65], [")", 70], ["inhibitor", 72], [",", 81], ["in", 83], ["patients", 86], ["with", 95], ["an", 100], ["acute", 103], ["coronary", 109], ["syndrome", 118], ["was", 127], ["terminated", 131], ["prematurely", 142], ["owing", 154], ["to", 160], ["futility", 163], ["and", 172], ["a", 176], ["signal", 178], ["towards", 185], ["harm", 193], [".", 197], ["Despite", 199], ["these", 207], ["discouraging", 213], ["results", 226], [",", 233], ["therapies", 235], ["that", 245], ["target", 250], ["inflammation", 257], ["to", 270], ["modify", 273], ["pathways", 280], ["in", 289], ["atherogenesis", 292], ["remain", 306], ["an", 313], ["area", 316], ["of", 321], ["active", 324], ["investigation", 331], [".", 344]]}
{"context": "Acrokeratosis paraneoplastica of Bazex is a rare cutaneous syndrome associated with malignant neoplasms of the pulmonary and upper gastrointestinal tract, or cervical metastatic adenopathy, usually seen in middle-aged white men. We present a unique case of Bazex syndrome in that the patient was young, black, and a woman.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "cb6b2fd507404102b664bfb2cb1ad97e", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[41, 42]], "char_spans": [[257, 270]]}]}], "context_tokens": [["Acrokeratosis", 0], ["paraneoplastica", 14], ["of", 30], ["Bazex", 33], ["is", 39], ["a", 42], ["rare", 44], ["cutaneous", 49], ["syndrome", 59], ["associated", 68], ["with", 79], ["malignant", 84], ["neoplasms", 94], ["of", 104], ["the", 107], ["pulmonary", 111], ["and", 121], ["upper", 125], ["gastrointestinal", 131], ["tract", 148], [",", 153], ["or", 155], ["cervical", 158], ["metastatic", 167], ["adenopathy", 178], [",", 188], ["usually", 190], ["seen", 198], ["in", 203], ["middle", 206], ["-", 212], ["aged", 213], ["white", 218], ["men", 224], [".", 227], ["We", 229], ["present", 232], ["a", 240], ["unique", 242], ["case", 249], ["of", 254], ["Bazex", 257], ["syndrome", 263], ["in", 272], ["that", 275], ["the", 280], ["patient", 284], ["was", 292], ["young", 296], [",", 301], ["black", 303], [",", 308], ["and", 310], ["a", 314], ["woman", 316], [".", 321]]}
{"context": "Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative disorder. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph) that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase (TK). The introduction of imatinib, a TK inhibitor (TKI) specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience a loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). In patients for whom standard-dose imatinib therapy (400 mg/day) fails, imatinib dose escalation (600-800 mg/day) is a second-line option. However, high-dose imatinib is not an appropriate approach for patients experiencing drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the newer TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historical response, adverse event tolerance level, and risk factors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "11921800c0c14b66b0d48b80283ca54c", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[235, 237], [67, 69], [209, 211], [39, 41]], "char_spans": [[1287, 1293], [367, 373], [1116, 1122], [233, 239]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["progressive", 36], ["and", 48], ["often", 52], ["fatal", 58], ["myeloproliferative", 64], ["disorder", 83], [".", 91], ["The", 93], ["hallmark", 97], ["of", 106], ["CML", 109], ["is", 113], ["an", 116], ["acquired", 119], ["chromosomal", 128], ["translocation", 140], ["known", 154], ["as", 160], ["the", 163], ["Philadelphia", 167], ["chromosome", 180], ["(", 191], ["Ph", 192], [")", 194], ["that", 196], ["results", 201], ["in", 209], ["the", 212], ["synthesis", 216], ["of", 226], ["the", 229], ["BCR", 233], ["-", 236], ["ABL", 237], ["fusion", 241], ["protein", 248], [",", 255], ["a", 257], ["constitutively", 259], ["active", 274], ["tyrosine", 281], ["kinase", 290], ["(", 297], ["TK", 298], [")", 300], [".", 301], ["The", 303], ["introduction", 307], ["of", 320], ["imatinib", 323], [",", 331], ["a", 333], ["TK", 335], ["inhibitor", 338], ["(", 348], ["TKI", 349], [")", 352], ["specific", 354], ["for", 363], ["BCR", 367], ["-", 370], ["ABL", 371], [",", 374], ["was", 376], ["a", 380], ["major", 382], ["breakthrough", 388], ["in", 401], ["CML", 404], ["therapy", 408], [".", 415], ["Although", 417], ["most", 426], ["patients", 431], ["respond", 440], ["to", 448], ["first", 451], ["-", 456], ["line", 457], ["imatinib", 462], ["therapy", 471], [",", 478], ["some", 480], ["experience", 485], ["a", 496], ["loss", 498], ["of", 503], ["response", 506], ["(", 515], ["resistance", 516], [")", 526], ["or", 528], ["require", 531], ["treatment", 539], ["discontinuation", 549], ["because", 565], ["of", 573], ["toxicity", 576], ["(", 585], ["intolerance", 586], [")", 597], [".", 598], ["In", 600], ["patients", 603], ["for", 612], ["whom", 616], ["standard", 621], ["-", 629], ["dose", 630], ["imatinib", 635], ["therapy", 644], ["(", 652], ["400", 653], ["mg", 657], ["/", 659], ["day", 660], [")", 663], ["fails", 665], [",", 670], ["imatinib", 672], ["dose", 681], ["escalation", 686], ["(", 697], ["600", 698], ["-", 701], ["800", 702], ["mg", 706], ["/", 708], ["day", 709], [")", 712], ["is", 714], ["a", 717], ["second", 719], ["-", 725], ["line", 726], ["option", 731], [".", 737], ["However", 739], [",", 746], ["high", 748], ["-", 752], ["dose", 753], ["imatinib", 758], ["is", 767], ["not", 770], ["an", 774], ["appropriate", 777], ["approach", 789], ["for", 798], ["patients", 802], ["experiencing", 811], ["drug", 824], ["toxicity", 829], [",", 837], ["and", 839], ["there", 843], ["remain", 849], ["questions", 856], ["over", 866], ["the", 871], ["durability", 875], ["of", 886], ["responses", 889], ["achieved", 899], ["with", 908], ["this", 913], ["strategy", 918], [".", 926], ["Alternative", 928], ["second", 940], ["-", 946], ["line", 947], ["options", 952], ["include", 960], ["the", 968], ["newer", 972], ["TKIs", 978], ["dasatinib", 983], ["and", 993], ["nilotinib", 997], [".", 1006], ["A", 1008], ["substantial", 1010], ["amount", 1022], ["of", 1029], ["long", 1032], ["-", 1036], ["term", 1037], ["data", 1042], ["for", 1047], ["these", 1051], ["agents", 1057], ["is", 1064], ["available", 1067], [".", 1076], ["Although", 1078], ["both", 1087], ["are", 1092], ["potent", 1096], ["and", 1103], ["specific", 1107], ["BCR", 1116], ["-", 1119], ["ABL", 1120], ["TKIs", 1124], [",", 1128], ["dasatinib", 1130], ["and", 1140], ["nilotinib", 1144], ["exhibit", 1154], ["unique", 1162], ["pharmacologic", 1169], ["profiles", 1183], ["and", 1192], ["response", 1196], ["patterns", 1205], ["relative", 1214], ["to", 1223], ["different", 1226], ["patient", 1236], ["characteristics", 1244], [",", 1259], ["such", 1261], ["as", 1266], ["disease", 1269], ["stage", 1277], ["and", 1283], ["BCR", 1287], ["-", 1290], ["ABL", 1291], ["mutational", 1295], ["status", 1306], [".", 1312], ["To", 1314], ["optimize", 1317], ["therapeutic", 1326], ["benefit", 1338], [",", 1345], ["clinicians", 1347], ["should", 1358], ["select", 1365], ["treatment", 1372], ["based", 1382], ["on", 1388], ["each", 1391], ["patient", 1396], ["'s", 1403], ["historical", 1406], ["response", 1417], [",", 1425], ["adverse", 1427], ["event", 1435], ["tolerance", 1441], ["level", 1451], [",", 1456], ["and", 1458], ["risk", 1462], ["factors", 1467], [".", 1474]]}
{"context": "Chediak Higashi syndrome (CHS) is an autosomal-recessive disorder characterized by oculocutaneous albinism, recurrent infections and a progressive primary neurological disease. Here, we describe two siblings with CHS due to a novel homozygous R1836X mutation in the LYST gene associated with loss of NK cell degranulation and cytotoxicity. While one sibling was born with fair skin and hair and died of hemophagocytic lymphohistiocytosis (HLH) at 5 months of age, the other sibling had dark black hair and skin and developed HLH at the age of 4 years.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome", "Chediak Higashi syndrome"], "qid": "f0c6e9007d0640d4afd5fdb4f2199ae1", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["autosomal", 37], ["-", 46], ["recessive", 47], ["disorder", 57], ["characterized", 66], ["by", 80], ["oculocutaneous", 83], ["albinism", 98], [",", 106], ["recurrent", 108], ["infections", 118], ["and", 129], ["a", 133], ["progressive", 135], ["primary", 147], ["neurological", 155], ["disease", 168], [".", 175], ["Here", 177], [",", 181], ["we", 183], ["describe", 186], ["two", 195], ["siblings", 199], ["with", 208], ["CHS", 213], ["due", 217], ["to", 221], ["a", 224], ["novel", 226], ["homozygous", 232], ["R1836X", 243], ["mutation", 250], ["in", 259], ["the", 262], ["LYST", 266], ["gene", 271], ["associated", 276], ["with", 287], ["loss", 292], ["of", 297], ["NK", 300], ["cell", 303], ["degranulation", 308], ["and", 322], ["cytotoxicity", 326], [".", 338], ["While", 340], ["one", 346], ["sibling", 350], ["was", 358], ["born", 362], ["with", 367], ["fair", 372], ["skin", 377], ["and", 382], ["hair", 386], ["and", 391], ["died", 395], ["of", 400], ["hemophagocytic", 403], ["lymphohistiocytosis", 418], ["(", 438], ["HLH", 439], [")", 442], ["at", 444], ["5", 447], ["months", 449], ["of", 456], ["age", 459], [",", 462], ["the", 464], ["other", 468], ["sibling", 474], ["had", 482], ["dark", 486], ["black", 491], ["hair", 497], ["and", 502], ["skin", 506], ["and", 511], ["developed", 515], ["HLH", 525], ["at", 529], ["the", 532], ["age", 536], ["of", 540], ["4", 543], ["years", 545], [".", 550]]}
{"context": "Restless leg syndrome (RLS) is a sensorimotor disorder. Clinical studies have implicated the dopaminergic system in RLS, while others have suggested that it is associated with insufficient levels of brain iron. To date, alterations in brain iron status have been demonstrated but, despite suggestions from the clinical literature, there have been no consistent findings documenting a dopaminergic abnormality in RLS brain tissue. In this study, the substantia nigra and putamen were obtained at autopsy from individuals with primary RLS and a neurologically normal control group. A quantitative profile of the dopaminergic system was obtained. Additional assays were performed on a catecholaminergic cell line and animal models of iron deficiency. RLS tissue, compared with controls, showed a significant decrease in D2R in the putamen that correlated with severity of the RLS. RLS also showed significant increases in tyrosine hydroxylase (TH) in the substantia nigra, compared with the controls, but not in the putamen. Both TH and phosphorylated (active) TH were significantly increased in both the substantia nigra and putamen. There were no significant differences in either the putamen or nigra for dopamine receptor 1, dopamine transporters or for VMAT. Significant increases in TH and phosphorylated TH were also seen in both the animal and cell models of iron insufficiency similar to that from the RLS autopsy data. For the first time, a clear indication of dopamine pathology in RLS is revealed in this autopsy study. The results suggest cellular regulation of dopamine production that closely matches the data from cellular and animal iron insufficiency models. The results are consistent with the hypothesis that a primary iron insufficiency produces a dopaminergic abnormality characterized as an overly activated dopaminergic system as part of the RLS pathology.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "cabbfba13115484cb3e878c1ef67ab6b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[42, 42], [294, 294], [119, 119], [280, 280], [232, 232], [34, 34]], "char_spans": [[241, 244], [1736, 1739], [731, 734], [1647, 1650], [1364, 1367], [205, 208]]}]}], "context_tokens": [["Restless", 0], ["leg", 9], ["syndrome", 13], ["(", 22], ["RLS", 23], [")", 26], ["is", 28], ["a", 31], ["sensorimotor", 33], ["disorder", 46], [".", 54], ["Clinical", 56], ["studies", 65], ["have", 73], ["implicated", 78], ["the", 89], ["dopaminergic", 93], ["system", 106], ["in", 113], ["RLS", 116], [",", 119], ["while", 121], ["others", 127], ["have", 134], ["suggested", 139], ["that", 149], ["it", 154], ["is", 157], ["associated", 160], ["with", 171], ["insufficient", 176], ["levels", 189], ["of", 196], ["brain", 199], ["iron", 205], [".", 209], ["To", 211], ["date", 214], [",", 218], ["alterations", 220], ["in", 232], ["brain", 235], ["iron", 241], ["status", 246], ["have", 253], ["been", 258], ["demonstrated", 263], ["but", 276], [",", 279], ["despite", 281], ["suggestions", 289], ["from", 301], ["the", 306], ["clinical", 310], ["literature", 319], [",", 329], ["there", 331], ["have", 337], ["been", 342], ["no", 347], ["consistent", 350], ["findings", 361], ["documenting", 370], ["a", 382], ["dopaminergic", 384], ["abnormality", 397], ["in", 409], ["RLS", 412], ["brain", 416], ["tissue", 422], [".", 428], ["In", 430], ["this", 433], ["study", 438], [",", 443], ["the", 445], ["substantia", 449], ["nigra", 460], ["and", 466], ["putamen", 470], ["were", 478], ["obtained", 483], ["at", 492], ["autopsy", 495], ["from", 503], ["individuals", 508], ["with", 520], ["primary", 525], ["RLS", 533], ["and", 537], ["a", 541], ["neurologically", 543], ["normal", 558], ["control", 565], ["group", 573], [".", 578], ["A", 580], ["quantitative", 582], ["profile", 595], ["of", 603], ["the", 606], ["dopaminergic", 610], ["system", 623], ["was", 630], ["obtained", 634], [".", 642], ["Additional", 644], ["assays", 655], ["were", 662], ["performed", 667], ["on", 677], ["a", 680], ["catecholaminergic", 682], ["cell", 700], ["line", 705], ["and", 710], ["animal", 714], ["models", 721], ["of", 728], ["iron", 731], ["deficiency", 736], [".", 746], ["RLS", 748], ["tissue", 752], [",", 758], ["compared", 760], ["with", 769], ["controls", 774], [",", 782], ["showed", 784], ["a", 791], ["significant", 793], ["decrease", 805], ["in", 814], ["D2R", 817], ["in", 821], ["the", 824], ["putamen", 828], ["that", 836], ["correlated", 841], ["with", 852], ["severity", 857], ["of", 866], ["the", 869], ["RLS", 873], [".", 876], ["RLS", 878], ["also", 882], ["showed", 887], ["significant", 894], ["increases", 906], ["in", 916], ["tyrosine", 919], ["hydroxylase", 928], ["(", 940], ["TH", 941], [")", 943], ["in", 945], ["the", 948], ["substantia", 952], ["nigra", 963], [",", 968], ["compared", 970], ["with", 979], ["the", 984], ["controls", 988], [",", 996], ["but", 998], ["not", 1002], ["in", 1006], ["the", 1009], ["putamen", 1013], [".", 1020], ["Both", 1022], ["TH", 1027], ["and", 1030], ["phosphorylated", 1034], ["(", 1049], ["active", 1050], [")", 1056], ["TH", 1058], ["were", 1061], ["significantly", 1066], ["increased", 1080], ["in", 1090], ["both", 1093], ["the", 1098], ["substantia", 1102], ["nigra", 1113], ["and", 1119], ["putamen", 1123], [".", 1130], ["There", 1132], ["were", 1138], ["no", 1143], ["significant", 1146], ["differences", 1158], ["in", 1170], ["either", 1173], ["the", 1180], ["putamen", 1184], ["or", 1192], ["nigra", 1195], ["for", 1201], ["dopamine", 1205], ["receptor", 1214], ["1", 1223], [",", 1224], ["dopamine", 1226], ["transporters", 1235], ["or", 1248], ["for", 1251], ["VMAT", 1255], [".", 1259], ["Significant", 1261], ["increases", 1273], ["in", 1283], ["TH", 1286], ["and", 1289], ["phosphorylated", 1293], ["TH", 1308], ["were", 1311], ["also", 1316], ["seen", 1321], ["in", 1326], ["both", 1329], ["the", 1334], ["animal", 1338], ["and", 1345], ["cell", 1349], ["models", 1354], ["of", 1361], ["iron", 1364], ["insufficiency", 1369], ["similar", 1383], ["to", 1391], ["that", 1394], ["from", 1399], ["the", 1404], ["RLS", 1408], ["autopsy", 1412], ["data", 1420], [".", 1424], ["For", 1426], ["the", 1430], ["first", 1434], ["time", 1440], [",", 1444], ["a", 1446], ["clear", 1448], ["indication", 1454], ["of", 1465], ["dopamine", 1468], ["pathology", 1477], ["in", 1487], ["RLS", 1490], ["is", 1494], ["revealed", 1497], ["in", 1506], ["this", 1509], ["autopsy", 1514], ["study", 1522], [".", 1527], ["The", 1529], ["results", 1533], ["suggest", 1541], ["cellular", 1549], ["regulation", 1558], ["of", 1569], ["dopamine", 1572], ["production", 1581], ["that", 1592], ["closely", 1597], ["matches", 1605], ["the", 1613], ["data", 1617], ["from", 1622], ["cellular", 1627], ["and", 1636], ["animal", 1640], ["iron", 1647], ["insufficiency", 1652], ["models", 1666], [".", 1672], ["The", 1674], ["results", 1678], ["are", 1686], ["consistent", 1690], ["with", 1701], ["the", 1706], ["hypothesis", 1710], ["that", 1721], ["a", 1726], ["primary", 1728], ["iron", 1736], ["insufficiency", 1741], ["produces", 1755], ["a", 1764], ["dopaminergic", 1766], ["abnormality", 1779], ["characterized", 1791], ["as", 1805], ["an", 1808], ["overly", 1811], ["activated", 1818], ["dopaminergic", 1828], ["system", 1841], ["as", 1848], ["part", 1851], ["of", 1856], ["the", 1859], ["RLS", 1863], ["pathology", 1867], [".", 1876]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial dysmorphism, variable severity of learning disabilities and macrocephaly with overgrowth. Haploinsufficiency of the nuclear receptor SET domain-containing protein 1 (NSD1) gene located on 5q35 has been implicated as the cause of Sotos syndrome. This study was performed to investigate the mutation spectrum of NSD1 abnormalities and meaningful genotype-phenotype correlations in Korean patients with Sotos syndrome. Eighteen unrelated Korean patients with Sotos syndrome were enrolled for clinical and molecular analyses. Cytogenetic studies were performed to confirm 5q35 microdeletion, and NSD1 sequencing analysis was performed to identify intragenic mutations. NSD1 abnormalities were identified in 15 (83%) patients. Among them, eight patients (53%) had 5q35 microdeletions and the other seven patients (47%) had seven different NSD1 intragenic mutations including four novel mutations. The mutation spectrum of Korean patients with Sotos syndrome was similar to that of previous studies for Japanese patients. Height was significantly shorter and age of walking alone was significantly older in the microdeletion group compared with those in the intragenic mutation group. No significant differences were observed for other clinical characteristics between the microdeletion and intragenic mutation groups. Further studies with a larger number of patients will be necessary to draw conclusive genotype-phenotype correlations.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "21b8aedf45d248998d7f1fe63ff3f685", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[33, 35]], "char_spans": [[234, 243]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["dysmorphism", 68], [",", 79], ["variable", 81], ["severity", 90], ["of", 99], ["learning", 102], ["disabilities", 111], ["and", 124], ["macrocephaly", 128], ["with", 141], ["overgrowth", 146], [".", 156], ["Haploinsufficiency", 158], ["of", 177], ["the", 180], ["nuclear", 184], ["receptor", 192], ["SET", 201], ["domain", 205], ["-", 211], ["containing", 212], ["protein", 223], ["1", 231], ["(", 233], ["NSD1", 234], [")", 238], ["gene", 240], ["located", 245], ["on", 253], ["5q35", 256], ["has", 261], ["been", 265], ["implicated", 270], ["as", 281], ["the", 284], ["cause", 288], ["of", 294], ["Sotos", 297], ["syndrome", 303], [".", 311], ["This", 313], ["study", 318], ["was", 324], ["performed", 328], ["to", 338], ["investigate", 341], ["the", 353], ["mutation", 357], ["spectrum", 366], ["of", 375], ["NSD1", 378], ["abnormalities", 383], ["and", 397], ["meaningful", 401], ["genotype", 412], ["-", 420], ["phenotype", 421], ["correlations", 431], ["in", 444], ["Korean", 447], ["patients", 454], ["with", 463], ["Sotos", 468], ["syndrome", 474], [".", 482], ["Eighteen", 484], ["unrelated", 493], ["Korean", 503], ["patients", 510], ["with", 519], ["Sotos", 524], ["syndrome", 530], ["were", 539], ["enrolled", 544], ["for", 553], ["clinical", 557], ["and", 566], ["molecular", 570], ["analyses", 580], [".", 588], ["Cytogenetic", 590], ["studies", 602], ["were", 610], ["performed", 615], ["to", 625], ["confirm", 628], ["5q35", 636], ["microdeletion", 641], [",", 654], ["and", 656], ["NSD1", 660], ["sequencing", 665], ["analysis", 676], ["was", 685], ["performed", 689], ["to", 699], ["identify", 702], ["intragenic", 711], ["mutations", 722], [".", 731], ["NSD1", 733], ["abnormalities", 738], ["were", 752], ["identified", 757], ["in", 768], ["15", 771], ["(", 774], ["83", 775], ["%", 777], [")", 778], ["patients", 780], [".", 788], ["Among", 790], ["them", 796], [",", 800], ["eight", 802], ["patients", 808], ["(", 817], ["53", 818], ["%", 820], [")", 821], ["had", 823], ["5q35", 827], ["microdeletions", 832], ["and", 847], ["the", 851], ["other", 855], ["seven", 861], ["patients", 867], ["(", 876], ["47", 877], ["%", 879], [")", 880], ["had", 882], ["seven", 886], ["different", 892], ["NSD1", 902], ["intragenic", 907], ["mutations", 918], ["including", 928], ["four", 938], ["novel", 943], ["mutations", 949], [".", 958], ["The", 960], ["mutation", 964], ["spectrum", 973], ["of", 982], ["Korean", 985], ["patients", 992], ["with", 1001], ["Sotos", 1006], ["syndrome", 1012], ["was", 1021], ["similar", 1025], ["to", 1033], ["that", 1036], ["of", 1041], ["previous", 1044], ["studies", 1053], ["for", 1061], ["Japanese", 1065], ["patients", 1074], [".", 1082], ["Height", 1084], ["was", 1091], ["significantly", 1095], ["shorter", 1109], ["and", 1117], ["age", 1121], ["of", 1125], ["walking", 1128], ["alone", 1136], ["was", 1142], ["significantly", 1146], ["older", 1160], ["in", 1166], ["the", 1169], ["microdeletion", 1173], ["group", 1187], ["compared", 1193], ["with", 1202], ["those", 1207], ["in", 1213], ["the", 1216], ["intragenic", 1220], ["mutation", 1231], ["group", 1240], [".", 1245], ["No", 1247], ["significant", 1250], ["differences", 1262], ["were", 1274], ["observed", 1279], ["for", 1288], ["other", 1292], ["clinical", 1298], ["characteristics", 1307], ["between", 1323], ["the", 1331], ["microdeletion", 1335], ["and", 1349], ["intragenic", 1353], ["mutation", 1364], ["groups", 1373], [".", 1379], ["Further", 1381], ["studies", 1389], ["with", 1397], ["a", 1402], ["larger", 1404], ["number", 1411], ["of", 1418], ["patients", 1421], ["will", 1430], ["be", 1435], ["necessary", 1438], ["to", 1448], ["draw", 1451], ["conclusive", 1456], ["genotype", 1467], ["-", 1475], ["phenotype", 1476], ["correlations", 1486], [".", 1498]]}
{"context": "To identify and compare the operating characteristics of existing prehospital stroke scales to predict true strokes in the hospital. We searched MEDLINE, EMBASE, and CINAHL databases for articles that evaluated the performance of prehospital stroke scales. Quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. We abstracted the operating characteristics of published prehospital stroke scales and compared them statistically and graphically. We retrieved 254 articles from MEDLINE, 66 articles from EMBASE, and 32 articles from CINAHL Plus database. Of these, 8 studies met all our inclusion criteria, and they studied Cincinnati Pre-Hospital Stroke Scale (CPSS), Los Angeles Pre-Hospital Stroke Screen (LAPSS), Melbourne Ambulance Stroke Screen (MASS), Medic Prehospital Assessment for Code Stroke (Med PACS), Ontario Prehospital Stroke Screening Tool (OPSS), Recognition of Stroke in the Emergency Room (ROSIER), and Face Arm Speech Test (FAST). Although the point estimates for LAPSS accuracy were better than CPSS, they had overlapping confidence intervals on the symmetric summary receiver operating characteristic curve. OPSS performed similar to LAPSS whereas MASS, Med PACS, ROSIER, and FAST had less favorable overall operating characteristics. Prehospital stroke scales varied in their accuracy and missed up to 30% of acute strokes in the field. Inconsistencies in performance may be due to sample size disparity, variability in stroke scale training, and divergent provider educational standards. Although LAPSS performed more consistently, visual comparison of graphical analysis revealed that LAPSS and CPSS had similar diagnostic capabilities.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "4499cb8591df4db39618e8fc1992e197", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[112, 112], [226, 226], [123, 123], [37, 37], [10, 10], [131, 131], [150, 150], [258, 258], [159, 159], [142, 142], [65, 65]], "char_spans": [[703, 708], [1326, 1331], [749, 754], [242, 247], [78, 83], [792, 797], [891, 896], [1500, 1505], [936, 941], [852, 857], [439, 444]]}]}], "context_tokens": [["To", 0], ["identify", 3], ["and", 12], ["compare", 16], ["the", 24], ["operating", 28], ["characteristics", 38], ["of", 54], ["existing", 57], ["prehospital", 66], ["stroke", 78], ["scales", 85], ["to", 92], ["predict", 95], ["true", 103], ["strokes", 108], ["in", 116], ["the", 119], ["hospital", 123], [".", 131], ["We", 133], ["searched", 136], ["MEDLINE", 145], [",", 152], ["EMBASE", 154], [",", 160], ["and", 162], ["CINAHL", 166], ["databases", 173], ["for", 183], ["articles", 187], ["that", 196], ["evaluated", 201], ["the", 211], ["performance", 215], ["of", 227], ["prehospital", 230], ["stroke", 242], ["scales", 249], [".", 255], ["Quality", 257], ["of", 265], ["the", 268], ["included", 272], ["studies", 281], ["was", 289], ["assessed", 293], ["using", 302], ["the", 308], ["Quality", 312], ["Assessment", 320], ["of", 331], ["Diagnostic", 334], ["Accuracy", 345], ["Studies-2", 354], ["tool", 364], [".", 368], ["We", 370], ["abstracted", 373], ["the", 384], ["operating", 388], ["characteristics", 398], ["of", 414], ["published", 417], ["prehospital", 427], ["stroke", 439], ["scales", 446], ["and", 453], ["compared", 457], ["them", 466], ["statistically", 471], ["and", 485], ["graphically", 489], [".", 500], ["We", 502], ["retrieved", 505], ["254", 515], ["articles", 519], ["from", 528], ["MEDLINE", 533], [",", 540], ["66", 542], ["articles", 545], ["from", 554], ["EMBASE", 559], [",", 565], ["and", 567], ["32", 571], ["articles", 574], ["from", 583], ["CINAHL", 588], ["Plus", 595], ["database", 600], [".", 608], ["Of", 610], ["these", 613], [",", 618], ["8", 620], ["studies", 622], ["met", 630], ["all", 634], ["our", 638], ["inclusion", 642], ["criteria", 652], [",", 660], ["and", 662], ["they", 666], ["studied", 671], ["Cincinnati", 679], ["Pre", 690], ["-", 693], ["Hospital", 694], ["Stroke", 703], ["Scale", 710], ["(", 716], ["CPSS", 717], [")", 721], [",", 722], ["Los", 724], ["Angeles", 728], ["Pre", 736], ["-", 739], ["Hospital", 740], ["Stroke", 749], ["Screen", 756], ["(", 763], ["LAPSS", 764], [")", 769], [",", 770], ["Melbourne", 772], ["Ambulance", 782], ["Stroke", 792], ["Screen", 799], ["(", 806], ["MASS", 807], [")", 811], [",", 812], ["Medic", 814], ["Prehospital", 820], ["Assessment", 832], ["for", 843], ["Code", 847], ["Stroke", 852], ["(", 859], ["Med", 860], ["PACS", 864], [")", 868], [",", 869], ["Ontario", 871], ["Prehospital", 879], ["Stroke", 891], ["Screening", 898], ["Tool", 908], ["(", 913], ["OPSS", 914], [")", 918], [",", 919], ["Recognition", 921], ["of", 933], ["Stroke", 936], ["in", 943], ["the", 946], ["Emergency", 950], ["Room", 960], ["(", 965], ["ROSIER", 966], [")", 972], [",", 973], ["and", 975], ["Face", 979], ["Arm", 984], ["Speech", 988], ["Test", 995], ["(", 1000], ["FAST", 1001], [")", 1005], [".", 1006], ["Although", 1008], ["the", 1017], ["point", 1021], ["estimates", 1027], ["for", 1037], ["LAPSS", 1041], ["accuracy", 1047], ["were", 1056], ["better", 1061], ["than", 1068], ["CPSS", 1073], [",", 1077], ["they", 1079], ["had", 1084], ["overlapping", 1088], ["confidence", 1100], ["intervals", 1111], ["on", 1121], ["the", 1124], ["symmetric", 1128], ["summary", 1138], ["receiver", 1146], ["operating", 1155], ["characteristic", 1165], ["curve", 1180], [".", 1185], ["OPSS", 1187], ["performed", 1192], ["similar", 1202], ["to", 1210], ["LAPSS", 1213], ["whereas", 1219], ["MASS", 1227], [",", 1231], ["Med", 1233], ["PACS", 1237], [",", 1241], ["ROSIER", 1243], [",", 1249], ["and", 1251], ["FAST", 1255], ["had", 1260], ["less", 1264], ["favorable", 1269], ["overall", 1279], ["operating", 1287], ["characteristics", 1297], [".", 1312], ["Prehospital", 1314], ["stroke", 1326], ["scales", 1333], ["varied", 1340], ["in", 1347], ["their", 1350], ["accuracy", 1356], ["and", 1365], ["missed", 1369], ["up", 1376], ["to", 1379], ["30", 1382], ["%", 1384], ["of", 1386], ["acute", 1389], ["strokes", 1395], ["in", 1403], ["the", 1406], ["field", 1410], [".", 1415], ["Inconsistencies", 1417], ["in", 1433], ["performance", 1436], ["may", 1448], ["be", 1452], ["due", 1455], ["to", 1459], ["sample", 1462], ["size", 1469], ["disparity", 1474], [",", 1483], ["variability", 1485], ["in", 1497], ["stroke", 1500], ["scale", 1507], ["training", 1513], [",", 1521], ["and", 1523], ["divergent", 1527], ["provider", 1537], ["educational", 1546], ["standards", 1558], [".", 1567], ["Although", 1569], ["LAPSS", 1578], ["performed", 1584], ["more", 1594], ["consistently", 1599], [",", 1611], ["visual", 1613], ["comparison", 1620], ["of", 1631], ["graphical", 1634], ["analysis", 1644], ["revealed", 1653], ["that", 1662], ["LAPSS", 1667], ["and", 1673], ["CPSS", 1677], ["had", 1682], ["similar", 1686], ["diagnostic", 1694], ["capabilities", 1705], [".", 1717]]}
{"context": "A diverse collection of 261 Staphylococcus aureus strains from human, animal, food, and environmental sources were tested for the presence and type of SCCmec elements, antibiotic susceptibility to various antibiotics, and non-\u00df-lactam antibiotic resistance genes. About 18.39% (48/261) of strains were methicillin-resistant S. aureus (MRSA) including 29.75% (36/121) human strains of which 29 strains were hospital-acquired MRSA (HA-MRSA) and 7 strains were community-associated MRSA (CA-MRSA) and 19.67% (12/61) animal strains that all were CA-MRSA strains. The percentage of CA-MRSA strains from animals was significantly higher than that from human (p<0.01). Most of MRSA strains and a part of methicillin-susceptible S. aureus (MSSA) strains harbored unique combinations of non-\u00df-lactamase genes aac(6')/aph(2\u2033), aph(3')-III, ant (4',4\u2033), ermA, ermC, mrsA, tetM, and tetK. Antibiotic resistance genes were detected more frequently in HA-MRSA strains than in CA-MRSA strains (p<0.01). MRSA strains and MSSA strains had 22 and 39 antibiotic profiles to 15 tested antibiotics, respectively. The resistant proportion was higher in HA-MRSA strains than in CA-MSSA strains for various antibiotics, as well as higher in MRSA strains than in MSSA strains. Animal MRSA reservoirs (particularly pigs and cows) might represent an important source of human CA-MRSA. CA-MRSA strains might acquire more different resistance genes gradually, depending on the selective pressure of antibiotics in different regions or environments. CA-MRSA is not yet endemic in China, but could be prevalent in future, contributing to its acquiring more resistance genes and huge animal sources. Infection with multidrug-resistant MSSA strains acquired from food, animal, and human sources might also become a significant problem for human medicine, which warrants further study.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "bd18e4066acc45d0970dbce4a776702f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "methicillin-resistant S. aureus", "token_spans": [[54, 58]], "char_spans": [[302, 332]]}, {"text": "MRSA", "token_spans": [[91, 91], [245, 245], [118, 118], [202, 202], [253, 253], [299, 299], [60, 60], [196, 196], [78, 78], [135, 135], [228, 228], [174, 174], [270, 270], [274, 274], [190, 190], [82, 82], [95, 95], [110, 110]], "char_spans": [[479, 482], [1217, 1220], [580, 583], [988, 991], [1259, 1262], [1523, 1526], [335, 338], [965, 968], [424, 427], [670, 673], [1134, 1137], [855, 858], [1352, 1355], [1361, 1364], [941, 944], [433, 436], [488, 491], [545, 548]]}]}], "context_tokens": [["A", 0], ["diverse", 2], ["collection", 10], ["of", 21], ["261", 24], ["Staphylococcus", 28], ["aureus", 43], ["strains", 50], ["from", 58], ["human", 63], [",", 68], ["animal", 70], [",", 76], ["food", 78], [",", 82], ["and", 84], ["environmental", 88], ["sources", 102], ["were", 110], ["tested", 115], ["for", 122], ["the", 126], ["presence", 130], ["and", 139], ["type", 143], ["of", 148], ["SCCmec", 151], ["elements", 158], [",", 166], ["antibiotic", 168], ["susceptibility", 179], ["to", 194], ["various", 197], ["antibiotics", 205], [",", 216], ["and", 218], ["non", 222], ["-", 225], ["\u00df", 226], ["-", 227], ["lactam", 228], ["antibiotic", 235], ["resistance", 246], ["genes", 257], [".", 262], ["About", 264], ["18.39", 270], ["%", 275], ["(", 277], ["48/261", 278], [")", 284], ["of", 286], ["strains", 289], ["were", 297], ["methicillin", 302], ["-", 313], ["resistant", 314], ["S.", 324], ["aureus", 327], ["(", 334], ["MRSA", 335], [")", 339], ["including", 341], ["29.75", 351], ["%", 356], ["(", 358], ["36/121", 359], [")", 365], ["human", 367], ["strains", 373], ["of", 381], ["which", 384], ["29", 390], ["strains", 393], ["were", 401], ["hospital", 406], ["-", 414], ["acquired", 415], ["MRSA", 424], ["(", 429], ["HA", 430], ["-", 432], ["MRSA", 433], [")", 437], ["and", 439], ["7", 443], ["strains", 445], ["were", 453], ["community", 458], ["-", 467], ["associated", 468], ["MRSA", 479], ["(", 484], ["CA", 485], ["-", 487], ["MRSA", 488], [")", 492], ["and", 494], ["19.67", 498], ["%", 503], ["(", 505], ["12/61", 506], [")", 511], ["animal", 513], ["strains", 520], ["that", 528], ["all", 533], ["were", 537], ["CA", 542], ["-", 544], ["MRSA", 545], ["strains", 550], [".", 557], ["The", 559], ["percentage", 563], ["of", 574], ["CA", 577], ["-", 579], ["MRSA", 580], ["strains", 585], ["from", 593], ["animals", 598], ["was", 606], ["significantly", 610], ["higher", 624], ["than", 631], ["that", 636], ["from", 641], ["human", 646], ["(", 652], ["p<0.01", 653], [")", 659], [".", 660], ["Most", 662], ["of", 667], ["MRSA", 670], ["strains", 675], ["and", 683], ["a", 687], ["part", 689], ["of", 694], ["methicillin", 697], ["-", 708], ["susceptible", 709], ["S.", 721], ["aureus", 724], ["(", 731], ["MSSA", 732], [")", 736], ["strains", 738], ["harbored", 746], ["unique", 755], ["combinations", 762], ["of", 775], ["non", 778], ["-", 781], ["\u00df", 782], ["-", 783], ["lactamase", 784], ["genes", 794], ["aac(6')/aph(2\u2033", 800], [")", 814], [",", 815], ["aph(3')-III", 817], [",", 828], ["ant", 830], ["(", 834], ["4',4\u2033", 835], [")", 840], [",", 841], ["ermA", 843], [",", 847], ["ermC", 849], [",", 853], ["mrsA", 855], [",", 859], ["tetM", 861], [",", 865], ["and", 867], ["tetK.", 871], ["Antibiotic", 877], ["resistance", 888], ["genes", 899], ["were", 905], ["detected", 910], ["more", 919], ["frequently", 924], ["in", 935], ["HA", 938], ["-", 940], ["MRSA", 941], ["strains", 946], ["than", 954], ["in", 959], ["CA", 962], ["-", 964], ["MRSA", 965], ["strains", 970], ["(", 978], ["p<0.01", 979], [")", 985], [".", 986], ["MRSA", 988], ["strains", 993], ["and", 1001], ["MSSA", 1005], ["strains", 1010], ["had", 1018], ["22", 1022], ["and", 1025], ["39", 1029], ["antibiotic", 1032], ["profiles", 1043], ["to", 1052], ["15", 1055], ["tested", 1058], ["antibiotics", 1065], [",", 1076], ["respectively", 1078], [".", 1090], ["The", 1092], ["resistant", 1096], ["proportion", 1106], ["was", 1117], ["higher", 1121], ["in", 1128], ["HA", 1131], ["-", 1133], ["MRSA", 1134], ["strains", 1139], ["than", 1147], ["in", 1152], ["CA", 1155], ["-", 1157], ["MSSA", 1158], ["strains", 1163], ["for", 1171], ["various", 1175], ["antibiotics", 1183], [",", 1194], ["as", 1196], ["well", 1199], ["as", 1204], ["higher", 1207], ["in", 1214], ["MRSA", 1217], ["strains", 1222], ["than", 1230], ["in", 1235], ["MSSA", 1238], ["strains", 1243], [".", 1250], ["Animal", 1252], ["MRSA", 1259], ["reservoirs", 1264], ["(", 1275], ["particularly", 1276], ["pigs", 1289], ["and", 1294], ["cows", 1298], [")", 1302], ["might", 1304], ["represent", 1310], ["an", 1320], ["important", 1323], ["source", 1333], ["of", 1340], ["human", 1343], ["CA", 1349], ["-", 1351], ["MRSA", 1352], [".", 1356], ["CA", 1358], ["-", 1360], ["MRSA", 1361], ["strains", 1366], ["might", 1374], ["acquire", 1380], ["more", 1388], ["different", 1393], ["resistance", 1403], ["genes", 1414], ["gradually", 1420], [",", 1429], ["depending", 1431], ["on", 1441], ["the", 1444], ["selective", 1448], ["pressure", 1458], ["of", 1467], ["antibiotics", 1470], ["in", 1482], ["different", 1485], ["regions", 1495], ["or", 1503], ["environments", 1506], [".", 1518], ["CA", 1520], ["-", 1522], ["MRSA", 1523], ["is", 1528], ["not", 1531], ["yet", 1535], ["endemic", 1539], ["in", 1547], ["China", 1550], [",", 1555], ["but", 1557], ["could", 1561], ["be", 1567], ["prevalent", 1570], ["in", 1580], ["future", 1583], [",", 1589], ["contributing", 1591], ["to", 1604], ["its", 1607], ["acquiring", 1611], ["more", 1621], ["resistance", 1626], ["genes", 1637], ["and", 1643], ["huge", 1647], ["animal", 1652], ["sources", 1659], [".", 1666], ["Infection", 1668], ["with", 1678], ["multidrug", 1683], ["-", 1692], ["resistant", 1693], ["MSSA", 1703], ["strains", 1708], ["acquired", 1716], ["from", 1725], ["food", 1730], [",", 1734], ["animal", 1736], [",", 1742], ["and", 1744], ["human", 1748], ["sources", 1754], ["might", 1762], ["also", 1768], ["become", 1773], ["a", 1780], ["significant", 1782], ["problem", 1794], ["for", 1802], ["human", 1806], ["medicine", 1812], [",", 1820], ["which", 1822], ["warrants", 1828], ["further", 1837], ["study", 1845], [".", 1850]]}
{"context": "Chronic liver injury can result in fibrosis that may progress over years to end-stage liver disease. The most effective anti-fibrotic therapy is treatment of the underlying disease, however when not possible, interventions to reverse or slow fibrosis progression are needed. The aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, in subjects with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or HCV-HIV co-infection and advanced liver disease. Eighteen subjects with advanced liver fibrosis received simtuzumab 700 mg intravenously every 2 weeks for 22 weeks. Transjugular liver biopsies were performed during screening and at the end of treatment to measure hepatic venous pressure gradient (HVPG) and to stage fibrosis. Treatment was well-tolerated with no discontinuations due to adverse events. No significant changes were seen in HVPG or liver biopsy fibrosis score after treatment. Exploratory transcriptional and protein profiling using paired pre- and post-treatment liver biopsy and serum samples suggested up-regulation of TGF-\u03b23 and IL-10 pathways with treatment. In this open-label, pilot clinical trial, simtuzumab treatment was well-tolerated in HCV- and HIV-infected subjects with advanced liver disease. Putative modulation of TGF-\u03b23 and IL-10 pathways during simtuzumab treatment merits investigation in future trials.", "qas": [{"question": "What is the drug target for Simtuzumab?", "answers": ["LOXL2"], "qid": "e7bc7aac09da4b57a6c64fa1b67bf938", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["drug", 12], ["target", 17], ["for", 24], ["Simtuzumab", 28], ["?", 38]], "detected_answers": [{"text": "LOXL2", "token_spans": [[74, 74]], "char_spans": [[414, 418]]}]}], "context_tokens": [["Chronic", 0], ["liver", 8], ["injury", 14], ["can", 21], ["result", 25], ["in", 32], ["fibrosis", 35], ["that", 44], ["may", 49], ["progress", 53], ["over", 62], ["years", 67], ["to", 73], ["end", 76], ["-", 79], ["stage", 80], ["liver", 86], ["disease", 92], [".", 99], ["The", 101], ["most", 105], ["effective", 110], ["anti", 120], ["-", 124], ["fibrotic", 125], ["therapy", 134], ["is", 142], ["treatment", 145], ["of", 155], ["the", 158], ["underlying", 162], ["disease", 173], [",", 180], ["however", 182], ["when", 190], ["not", 195], ["possible", 199], [",", 207], ["interventions", 209], ["to", 223], ["reverse", 226], ["or", 234], ["slow", 237], ["fibrosis", 242], ["progression", 251], ["are", 263], ["needed", 267], [".", 273], ["The", 275], ["aim", 279], ["of", 283], ["this", 286], ["study", 291], ["was", 297], ["to", 301], ["study", 304], ["the", 310], ["safety", 314], ["and", 321], ["tolerability", 325], ["of", 338], ["simtuzumab", 341], [",", 351], ["a", 353], ["monoclonal", 355], ["antibody", 366], ["directed", 375], ["against", 384], ["lysyl", 392], ["oxidase", 398], ["-", 405], ["like", 406], ["2", 411], ["(", 413], ["LOXL2", 414], [")", 419], ["enzyme", 421], [",", 427], ["in", 429], ["subjects", 432], ["with", 441], ["hepatitis", 446], ["C", 456], ["virus", 458], ["(", 464], ["HCV", 465], [")", 468], [",", 469], ["human", 471], ["immunodeficiency", 477], ["virus", 494], ["(", 500], ["HIV", 501], [")", 504], [",", 505], ["or", 507], ["HCV", 510], ["-", 513], ["HIV", 514], ["co", 518], ["-", 520], ["infection", 521], ["and", 531], ["advanced", 535], ["liver", 544], ["disease", 550], [".", 557], ["Eighteen", 559], ["subjects", 568], ["with", 577], ["advanced", 582], ["liver", 591], ["fibrosis", 597], ["received", 606], ["simtuzumab", 615], ["700", 626], ["mg", 630], ["intravenously", 633], ["every", 647], ["2", 653], ["weeks", 655], ["for", 661], ["22", 665], ["weeks", 668], [".", 673], ["Transjugular", 675], ["liver", 688], ["biopsies", 694], ["were", 703], ["performed", 708], ["during", 718], ["screening", 725], ["and", 735], ["at", 739], ["the", 742], ["end", 746], ["of", 750], ["treatment", 753], ["to", 763], ["measure", 766], ["hepatic", 774], ["venous", 782], ["pressure", 789], ["gradient", 798], ["(", 807], ["HVPG", 808], [")", 812], ["and", 814], ["to", 818], ["stage", 821], ["fibrosis", 827], [".", 835], ["Treatment", 837], ["was", 847], ["well", 851], ["-", 855], ["tolerated", 856], ["with", 866], ["no", 871], ["discontinuations", 874], ["due", 891], ["to", 895], ["adverse", 898], ["events", 906], [".", 912], ["No", 914], ["significant", 917], ["changes", 929], ["were", 937], ["seen", 942], ["in", 947], ["HVPG", 950], ["or", 955], ["liver", 958], ["biopsy", 964], ["fibrosis", 971], ["score", 980], ["after", 986], ["treatment", 992], [".", 1001], ["Exploratory", 1003], ["transcriptional", 1015], ["and", 1031], ["protein", 1035], ["profiling", 1043], ["using", 1053], ["paired", 1059], ["pre-", 1066], ["and", 1071], ["post", 1075], ["-", 1079], ["treatment", 1080], ["liver", 1090], ["biopsy", 1096], ["and", 1103], ["serum", 1107], ["samples", 1113], ["suggested", 1121], ["up", 1131], ["-", 1133], ["regulation", 1134], ["of", 1145], ["TGF", 1148], ["-", 1151], ["\u03b23", 1152], ["and", 1155], ["IL-10", 1159], ["pathways", 1165], ["with", 1174], ["treatment", 1179], [".", 1188], ["In", 1190], ["this", 1193], ["open", 1198], ["-", 1202], ["label", 1203], [",", 1208], ["pilot", 1210], ["clinical", 1216], ["trial", 1225], [",", 1230], ["simtuzumab", 1232], ["treatment", 1243], ["was", 1253], ["well", 1257], ["-", 1261], ["tolerated", 1262], ["in", 1272], ["HCV-", 1275], ["and", 1280], ["HIV", 1284], ["-", 1287], ["infected", 1288], ["subjects", 1297], ["with", 1306], ["advanced", 1311], ["liver", 1320], ["disease", 1326], [".", 1333], ["Putative", 1335], ["modulation", 1344], ["of", 1355], ["TGF", 1358], ["-", 1361], ["\u03b23", 1362], ["and", 1365], ["IL-10", 1369], ["pathways", 1375], ["during", 1384], ["simtuzumab", 1391], ["treatment", 1402], ["merits", 1412], ["investigation", 1419], ["in", 1433], ["future", 1436], ["trials", 1443], [".", 1449]]}
{"context": "Pakistan's 2005 earthquake claimed almost 87,000 lives and displaced millions. The present study sought to assess PTSD prevalence among earthquake survivors, to evaluate its determinants, and to identify protective factors that suggest future interventions in the aftermath of disasters. In a cross-sectional survey, three districts were selected based on their proximity to the epicenter and the presence, accessibility, and security of refugees, 300 earthquake survivors were enrolled. Analysis revealed that after 30months, PTSD prevalence was high. Being female, older, unmarried, head of the family, and currently unemployed and having low income and living in temporary housing confer higher risks of PTSD. Having a high social capital and religious inclination seem to have protective, buffer effect and increase resilience against PTSD. This is the first post-quake study in Pakistan that has utilized, adapted and validated Davidson Trauma Scale in the local context. Results imply the significance of continued psychological support, of drawing on resilience factors in PTSD management. Implications and directions for future research are discussed.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "fda25d478d054f8bb5e7cf002113e5e8", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[139, 139], [85, 85], [118, 118], [181, 181], [18, 18]], "char_spans": [[839, 842], [527, 530], [707, 710], [1080, 1083], [114, 117]]}]}], "context_tokens": [["Pakistan", 0], ["'s", 8], ["2005", 11], ["earthquake", 16], ["claimed", 27], ["almost", 35], ["87,000", 42], ["lives", 49], ["and", 55], ["displaced", 59], ["millions", 69], [".", 77], ["The", 79], ["present", 83], ["study", 91], ["sought", 97], ["to", 104], ["assess", 107], ["PTSD", 114], ["prevalence", 119], ["among", 130], ["earthquake", 136], ["survivors", 147], [",", 156], ["to", 158], ["evaluate", 161], ["its", 170], ["determinants", 174], [",", 186], ["and", 188], ["to", 192], ["identify", 195], ["protective", 204], ["factors", 215], ["that", 223], ["suggest", 228], ["future", 236], ["interventions", 243], ["in", 257], ["the", 260], ["aftermath", 264], ["of", 274], ["disasters", 277], [".", 286], ["In", 288], ["a", 291], ["cross", 293], ["-", 298], ["sectional", 299], ["survey", 309], [",", 315], ["three", 317], ["districts", 323], ["were", 333], ["selected", 338], ["based", 347], ["on", 353], ["their", 356], ["proximity", 362], ["to", 372], ["the", 375], ["epicenter", 379], ["and", 389], ["the", 393], ["presence", 397], [",", 405], ["accessibility", 407], [",", 420], ["and", 422], ["security", 426], ["of", 435], ["refugees", 438], [",", 446], ["300", 448], ["earthquake", 452], ["survivors", 463], ["were", 473], ["enrolled", 478], [".", 486], ["Analysis", 488], ["revealed", 497], ["that", 506], ["after", 511], ["30months", 517], [",", 525], ["PTSD", 527], ["prevalence", 532], ["was", 543], ["high", 547], [".", 551], ["Being", 553], ["female", 559], [",", 565], ["older", 567], [",", 572], ["unmarried", 574], [",", 583], ["head", 585], ["of", 590], ["the", 593], ["family", 597], [",", 603], ["and", 605], ["currently", 609], ["unemployed", 619], ["and", 630], ["having", 634], ["low", 641], ["income", 645], ["and", 652], ["living", 656], ["in", 663], ["temporary", 666], ["housing", 676], ["confer", 684], ["higher", 691], ["risks", 698], ["of", 704], ["PTSD", 707], [".", 711], ["Having", 713], ["a", 720], ["high", 722], ["social", 727], ["capital", 734], ["and", 742], ["religious", 746], ["inclination", 756], ["seem", 768], ["to", 773], ["have", 776], ["protective", 781], [",", 791], ["buffer", 793], ["effect", 800], ["and", 807], ["increase", 811], ["resilience", 820], ["against", 831], ["PTSD", 839], [".", 843], ["This", 845], ["is", 850], ["the", 853], ["first", 857], ["post", 863], ["-", 867], ["quake", 868], ["study", 874], ["in", 880], ["Pakistan", 883], ["that", 892], ["has", 897], ["utilized", 901], [",", 909], ["adapted", 911], ["and", 919], ["validated", 923], ["Davidson", 933], ["Trauma", 942], ["Scale", 949], ["in", 955], ["the", 958], ["local", 962], ["context", 968], [".", 975], ["Results", 977], ["imply", 985], ["the", 991], ["significance", 995], ["of", 1008], ["continued", 1011], ["psychological", 1021], ["support", 1035], [",", 1042], ["of", 1044], ["drawing", 1047], ["on", 1055], ["resilience", 1058], ["factors", 1069], ["in", 1077], ["PTSD", 1080], ["management", 1085], [".", 1095], ["Implications", 1097], ["and", 1110], ["directions", 1114], ["for", 1125], ["future", 1129], ["research", 1136], ["are", 1145], ["discussed", 1149], [".", 1158]]}
{"context": "Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options. Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events. Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against \u03b2-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones. Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue. However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA. This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "3839284ce858430f8f66e799ad122c16", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[119, 121]], "char_spans": [[727, 745]]}]}], "context_tokens": [["Osteoarthritis", 0], ["(", 15], ["OA", 16], [")", 18], ["is", 20], ["a", 23], ["degenerative", 25], ["joint", 38], ["disorder", 44], ["commonly", 53], ["encountered", 62], ["in", 74], ["clinical", 77], ["practice", 86], [",", 94], ["and", 96], ["is", 100], ["the", 103], ["leading", 107], ["cause", 115], ["of", 121], ["disability", 124], ["in", 135], ["elderly", 138], ["people", 146], [".", 152], ["Due", 154], ["to", 158], ["the", 161], ["poor", 165], ["self", 170], ["-", 174], ["healing", 175], ["capacity", 183], ["of", 192], ["articular", 195], ["cartilage", 205], ["and", 215], ["lack", 219], ["of", 224], ["specific", 227], ["diagnostic", 236], ["biomarkers", 247], [",", 257], ["OA", 259], ["is", 262], ["a", 265], ["challenging", 267], ["disease", 279], ["with", 287], ["limited", 292], ["treatment", 300], ["options", 310], [".", 317], ["Traditional", 319], ["pharmacologic", 331], ["therapies", 345], ["such", 355], ["as", 360], ["acetaminophen", 363], [",", 376], ["non", 378], ["-", 381], ["steroidal", 382], ["anti", 392], ["-", 396], ["inflammatory", 397], ["drugs", 410], [",", 415], ["and", 417], ["opioids", 421], ["are", 429], ["effective", 433], ["in", 443], ["relieving", 446], ["pain", 456], ["but", 461], ["are", 465], ["incapable", 469], ["of", 479], ["reversing", 482], ["cartilage", 492], ["damage", 502], ["and", 509], ["are", 513], ["frequently", 517], ["associated", 528], ["with", 539], ["adverse", 544], ["events", 552], [".", 558], ["Current", 560], ["research", 568], ["focuses", 577], ["on", 585], ["the", 588], ["development", 592], ["of", 604], ["new", 607], ["OA", 611], ["drugs", 614], ["(", 620], ["such", 621], ["as", 626], ["sprifermin", 629], ["/", 639], ["recombinant", 640], ["human", 652], ["fibroblast", 658], ["growth", 669], ["factor-18", 676], [",", 685], ["tanezumab", 687], ["/", 696], ["monoclonal", 697], ["antibody", 708], ["against", 717], ["\u03b2", 725], ["-", 726], ["nerve", 727], ["growth", 733], ["factor", 740], [")", 746], [",", 747], ["which", 749], ["aims", 755], ["for", 760], ["more", 764], ["effectiveness", 769], ["and", 783], ["less", 787], ["incidence", 792], ["of", 802], ["adverse", 805], ["effects", 813], ["than", 821], ["the", 826], ["traditional", 830], ["ones", 842], [".", 846], ["Furthermore", 848], [",", 859], ["regenerative", 861], ["therapies", 874], ["(", 884], ["such", 885], ["as", 890], ["autologous", 893], ["chondrocyte", 904], ["implantation", 916], ["(", 929], ["ACI", 930], [")", 933], [",", 934], ["new", 936], ["generation", 940], ["of", 951], ["matrix", 954], ["-", 960], ["induced", 961], ["ACI", 969], [",", 972], ["cell", 974], ["-", 978], ["free", 979], ["scaffolds", 984], [",", 993], ["induced", 995], ["pluripotent", 1003], ["stem", 1015], ["cells", 1020], ["(", 1026], ["iPS", 1027], ["cells", 1031], ["or", 1037], ["iPSCs", 1040], [")", 1045], [",", 1046], ["and", 1048], ["endogenous", 1052], ["cell", 1063], ["homing", 1068], [")", 1074], ["are", 1076], ["also", 1080], ["emerging", 1085], ["as", 1094], ["promising", 1097], ["alternatives", 1107], ["as", 1120], ["they", 1123], ["have", 1128], ["potential", 1133], ["to", 1143], ["enhance", 1146], ["cartilage", 1154], ["repair", 1164], [",", 1170], ["and", 1172], ["ultimately", 1176], ["restore", 1187], ["healthy", 1195], ["tissue", 1203], [".", 1209], ["However", 1211], [",", 1218], ["despite", 1220], ["currently", 1228], ["available", 1238], ["therapies", 1248], ["and", 1258], ["research", 1262], ["advances", 1271], [",", 1279], ["there", 1281], ["remain", 1287], ["unmet", 1294], ["medical", 1300], ["needs", 1308], ["in", 1314], ["the", 1317], ["treatment", 1321], ["of", 1331], ["OA", 1334], [".", 1336], ["This", 1338], ["review", 1343], ["highlights", 1350], ["current", 1361], ["research", 1369], ["progress", 1378], ["on", 1387], ["pharmacologic", 1390], ["and", 1404], ["regenerative", 1408], ["therapies", 1421], ["for", 1431], ["OA", 1435], ["including", 1438], ["key", 1448], ["advances", 1452], ["and", 1461], ["potential", 1465], ["limitations", 1475], [".", 1486]]}
{"context": "Very few human genes can be used to identify spontaneous inactivating somatic mutations. We hypothesized that because the XK gene is X-linked, it would be easy to identify spontaneously arising red cells with a phenotype resembling the McLeod syndrome, which results from inherited XK mutations. Here, by flow cytometry, we detect such phenotypic variants at a median frequency of 9 x 10(-6) in neonatal cord blood samples and 39 x 10(-6) in healthy adults (p=0.004). It may be possible to further investigate the relationship between aging, mutations, and cancer using this approach.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "5fd7a2dfb5344090b95d6ffff8d1456c", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[48, 48], [19, 19]], "char_spans": [[282, 283], [122, 123]]}]}], "context_tokens": [["Very", 0], ["few", 5], ["human", 9], ["genes", 15], ["can", 21], ["be", 25], ["used", 28], ["to", 33], ["identify", 36], ["spontaneous", 45], ["inactivating", 57], ["somatic", 70], ["mutations", 78], [".", 87], ["We", 89], ["hypothesized", 92], ["that", 105], ["because", 110], ["the", 118], ["XK", 122], ["gene", 125], ["is", 130], ["X", 133], ["-", 134], ["linked", 135], [",", 141], ["it", 143], ["would", 146], ["be", 152], ["easy", 155], ["to", 160], ["identify", 163], ["spontaneously", 172], ["arising", 186], ["red", 194], ["cells", 198], ["with", 204], ["a", 209], ["phenotype", 211], ["resembling", 221], ["the", 232], ["McLeod", 236], ["syndrome", 243], [",", 251], ["which", 253], ["results", 259], ["from", 267], ["inherited", 272], ["XK", 282], ["mutations", 285], [".", 294], ["Here", 296], [",", 300], ["by", 302], ["flow", 305], ["cytometry", 310], [",", 319], ["we", 321], ["detect", 324], ["such", 331], ["phenotypic", 336], ["variants", 347], ["at", 356], ["a", 359], ["median", 361], ["frequency", 368], ["of", 378], ["9", 381], ["x", 383], ["10(-6", 385], [")", 390], ["in", 392], ["neonatal", 395], ["cord", 404], ["blood", 409], ["samples", 415], ["and", 423], ["39", 427], ["x", 430], ["10(-6", 432], [")", 437], ["in", 439], ["healthy", 442], ["adults", 450], ["(", 457], ["p=0.004", 458], [")", 465], [".", 466], ["It", 468], ["may", 471], ["be", 475], ["possible", 478], ["to", 487], ["further", 490], ["investigate", 498], ["the", 510], ["relationship", 514], ["between", 527], ["aging", 535], [",", 540], ["mutations", 542], [",", 551], ["and", 553], ["cancer", 557], ["using", 564], ["this", 570], ["approach", 575], [".", 583]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease resulting from mutations in the LYST/CHS1 gene, which encodes for a 429\u00a0kDa protein, CHS1/LYST, that regulates vesicle trafficking and determines the size of lysosomes and other organelles. To date, 60 different mutations have been characterized, and a reasonably straightforward phenotype-genotype correlation has been suggested. We describe two patients on opposite ends of the CHS clinical spectrum with novel missense mutations. We characterized these patients in terms of their mutations, protein localization and expression, mRNA stability, and electrostatic potential. Patient 1 is the first report of a severe early-onset CHS with a homozygous missense mutation (c.11362 G>A, p.G3725R) in the LYST/CHS1 gene. This molecular change results in a reduction at the CHS1 protein level, not due to an mRNA effect, but maybe a consequence of both, a change in the structure of the protein and most likely attributable to the remarkable serious perturbation in the electrostatic potential. Patient 2, who exhibited the adolescence form of the disease, was found to be homozygous for a novel missense mutation c.961 T>C, p.C258R, which seemed to have minor effect on the structure of the CHS1/LYST protein. Reexamining accepted premises of missense mutant alleles being reported among patients with clinically mild forms of the disorder should be carried out, and attempts to link genotype and clinical phenotype require identifying the actual molecular effect of the mutation. Early and accurate diagnosis of the severity of the disease is extremely important to early differentiate patients who would benefit from premature enrollment into a transplantation protocol.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "45ce4033bb5f467ea111a26e625b6379", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disease", 61], ["resulting", 69], ["from", 79], ["mutations", 84], ["in", 94], ["the", 97], ["LYST", 101], ["/", 105], ["CHS1", 106], ["gene", 111], [",", 115], ["which", 117], ["encodes", 123], ["for", 131], ["a", 135], ["429", 137], ["kDa", 141], ["protein", 145], [",", 152], ["CHS1/LYST", 154], [",", 163], ["that", 165], ["regulates", 170], ["vesicle", 180], ["trafficking", 188], ["and", 200], ["determines", 204], ["the", 215], ["size", 219], ["of", 224], ["lysosomes", 227], ["and", 237], ["other", 241], ["organelles", 247], [".", 257], ["To", 259], ["date", 262], [",", 266], ["60", 268], ["different", 271], ["mutations", 281], ["have", 291], ["been", 296], ["characterized", 301], [",", 314], ["and", 316], ["a", 320], ["reasonably", 322], ["straightforward", 333], ["phenotype", 349], ["-", 358], ["genotype", 359], ["correlation", 368], ["has", 380], ["been", 384], ["suggested", 389], [".", 398], ["We", 400], ["describe", 403], ["two", 412], ["patients", 416], ["on", 425], ["opposite", 428], ["ends", 437], ["of", 442], ["the", 445], ["CHS", 449], ["clinical", 453], ["spectrum", 462], ["with", 471], ["novel", 476], ["missense", 482], ["mutations", 491], [".", 500], ["We", 502], ["characterized", 505], ["these", 519], ["patients", 525], ["in", 534], ["terms", 537], ["of", 543], ["their", 546], ["mutations", 552], [",", 561], ["protein", 563], ["localization", 571], ["and", 584], ["expression", 588], [",", 598], ["mRNA", 600], ["stability", 605], [",", 614], ["and", 616], ["electrostatic", 620], ["potential", 634], [".", 643], ["Patient", 645], ["1", 653], ["is", 655], ["the", 658], ["first", 662], ["report", 668], ["of", 675], ["a", 678], ["severe", 680], ["early", 687], ["-", 692], ["onset", 693], ["CHS", 699], ["with", 703], ["a", 708], ["homozygous", 710], ["missense", 721], ["mutation", 730], ["(", 739], ["c.11362", 740], ["G", 748], [">", 749], ["A", 750], [",", 751], ["p", 753], [".", 754], ["G3725R", 755], [")", 761], ["in", 763], ["the", 766], ["LYST", 770], ["/", 774], ["CHS1", 775], ["gene", 780], [".", 784], ["This", 786], ["molecular", 791], ["change", 801], ["results", 808], ["in", 816], ["a", 819], ["reduction", 821], ["at", 831], ["the", 834], ["CHS1", 838], ["protein", 843], ["level", 851], [",", 856], ["not", 858], ["due", 862], ["to", 866], ["an", 869], ["mRNA", 872], ["effect", 877], [",", 883], ["but", 885], ["maybe", 889], ["a", 895], ["consequence", 897], ["of", 909], ["both", 912], [",", 916], ["a", 918], ["change", 920], ["in", 927], ["the", 930], ["structure", 934], ["of", 944], ["the", 947], ["protein", 951], ["and", 959], ["most", 963], ["likely", 968], ["attributable", 975], ["to", 988], ["the", 991], ["remarkable", 995], ["serious", 1006], ["perturbation", 1014], ["in", 1027], ["the", 1030], ["electrostatic", 1034], ["potential", 1048], [".", 1057], ["Patient", 1059], ["2", 1067], [",", 1068], ["who", 1070], ["exhibited", 1074], ["the", 1084], ["adolescence", 1088], ["form", 1100], ["of", 1105], ["the", 1108], ["disease", 1112], [",", 1119], ["was", 1121], ["found", 1125], ["to", 1131], ["be", 1134], ["homozygous", 1137], ["for", 1148], ["a", 1152], ["novel", 1154], ["missense", 1160], ["mutation", 1169], ["c.961", 1178], ["T", 1184], [">", 1185], ["C", 1186], [",", 1187], ["p", 1189], [".", 1190], ["C258R", 1191], [",", 1196], ["which", 1198], ["seemed", 1204], ["to", 1211], ["have", 1214], ["minor", 1219], ["effect", 1225], ["on", 1232], ["the", 1235], ["structure", 1239], ["of", 1249], ["the", 1252], ["CHS1/LYST", 1256], ["protein", 1266], [".", 1273], ["Reexamining", 1275], ["accepted", 1287], ["premises", 1296], ["of", 1305], ["missense", 1308], ["mutant", 1317], ["alleles", 1324], ["being", 1332], ["reported", 1338], ["among", 1347], ["patients", 1353], ["with", 1362], ["clinically", 1367], ["mild", 1378], ["forms", 1383], ["of", 1389], ["the", 1392], ["disorder", 1396], ["should", 1405], ["be", 1412], ["carried", 1415], ["out", 1423], [",", 1426], ["and", 1428], ["attempts", 1432], ["to", 1441], ["link", 1444], ["genotype", 1449], ["and", 1458], ["clinical", 1462], ["phenotype", 1471], ["require", 1481], ["identifying", 1489], ["the", 1501], ["actual", 1505], ["molecular", 1512], ["effect", 1522], ["of", 1529], ["the", 1532], ["mutation", 1536], [".", 1544], ["Early", 1546], ["and", 1552], ["accurate", 1556], ["diagnosis", 1565], ["of", 1575], ["the", 1578], ["severity", 1582], ["of", 1591], ["the", 1594], ["disease", 1598], ["is", 1606], ["extremely", 1609], ["important", 1619], ["to", 1629], ["early", 1632], ["differentiate", 1638], ["patients", 1652], ["who", 1661], ["would", 1665], ["benefit", 1671], ["from", 1679], ["premature", 1684], ["enrollment", 1694], ["into", 1705], ["a", 1710], ["transplantation", 1712], ["protocol", 1728], [".", 1736]]}
{"context": "Nerve growth factor (NGF) is an important mediator of pain and hyperalgesia and has become a target of novel analgesic therapeutics. Tanezumab is a humanized IgG(2) antibody that binds NGF with high affinity and specificity. In a study to assess the toxicity and pharmacokinetic properties of tanezumab in adult, male and female, cynomolgus monkeys following weekly intravenous administration of 1, 10, or 30 mg/kg for up to 26 weeks (followed by an 8-week recovery period), tanezumab was well tolerated with no macroscopic or microscopic effects on those brain, spinal cord, nerve, or ganglia sections evaluated. One fifth of tanezumab-treated monkeys developed an antibody response to tanezumab that prevented maintenance of tanezumab exposure between dosing. In the antibody-negative animals, accumulation of tanezumab was observed; steady state was achieved approximately 8 weeks after the first dose of study drug, and exposure to tanezumab was approximately dose proportional with no observed difference between male and female animals. One monkey died during the study; this monkey had findings suggestive of hypersensitivity reaction. The favorable toxicity and pharmacokinetic profile of tanezumab seen in this study supports its further evaluation for the treatment of pain in clinical practice.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "fca52edd5cb744269b2e262e1328a554", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[4, 4], [33, 33]], "char_spans": [[21, 23], [185, 187]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["is", 26], ["an", 29], ["important", 32], ["mediator", 42], ["of", 51], ["pain", 54], ["and", 59], ["hyperalgesia", 63], ["and", 76], ["has", 80], ["become", 84], ["a", 91], ["target", 93], ["of", 100], ["novel", 103], ["analgesic", 109], ["therapeutics", 119], [".", 131], ["Tanezumab", 133], ["is", 143], ["a", 146], ["humanized", 148], ["IgG(2", 158], [")", 163], ["antibody", 165], ["that", 174], ["binds", 179], ["NGF", 185], ["with", 189], ["high", 194], ["affinity", 199], ["and", 208], ["specificity", 212], [".", 223], ["In", 225], ["a", 228], ["study", 230], ["to", 236], ["assess", 239], ["the", 246], ["toxicity", 250], ["and", 259], ["pharmacokinetic", 263], ["properties", 279], ["of", 290], ["tanezumab", 293], ["in", 303], ["adult", 306], [",", 311], ["male", 313], ["and", 318], ["female", 322], [",", 328], ["cynomolgus", 330], ["monkeys", 341], ["following", 349], ["weekly", 359], ["intravenous", 366], ["administration", 378], ["of", 393], ["1", 396], [",", 397], ["10", 399], [",", 401], ["or", 403], ["30", 406], ["mg", 409], ["/", 411], ["kg", 412], ["for", 415], ["up", 419], ["to", 422], ["26", 425], ["weeks", 428], ["(", 434], ["followed", 435], ["by", 444], ["an", 447], ["8-week", 450], ["recovery", 457], ["period", 466], [")", 472], [",", 473], ["tanezumab", 475], ["was", 485], ["well", 489], ["tolerated", 494], ["with", 504], ["no", 509], ["macroscopic", 512], ["or", 524], ["microscopic", 527], ["effects", 539], ["on", 547], ["those", 550], ["brain", 556], [",", 561], ["spinal", 563], ["cord", 570], [",", 574], ["nerve", 576], [",", 581], ["or", 583], ["ganglia", 586], ["sections", 594], ["evaluated", 603], [".", 612], ["One", 614], ["fifth", 618], ["of", 624], ["tanezumab", 627], ["-", 636], ["treated", 637], ["monkeys", 645], ["developed", 653], ["an", 663], ["antibody", 666], ["response", 675], ["to", 684], ["tanezumab", 687], ["that", 697], ["prevented", 702], ["maintenance", 712], ["of", 724], ["tanezumab", 727], ["exposure", 737], ["between", 746], ["dosing", 754], [".", 760], ["In", 762], ["the", 765], ["antibody", 769], ["-", 777], ["negative", 778], ["animals", 787], [",", 794], ["accumulation", 796], ["of", 809], ["tanezumab", 812], ["was", 822], ["observed", 826], [";", 834], ["steady", 836], ["state", 843], ["was", 849], ["achieved", 853], ["approximately", 862], ["8", 876], ["weeks", 878], ["after", 884], ["the", 890], ["first", 894], ["dose", 900], ["of", 905], ["study", 908], ["drug", 914], [",", 918], ["and", 920], ["exposure", 924], ["to", 933], ["tanezumab", 936], ["was", 946], ["approximately", 950], ["dose", 964], ["proportional", 969], ["with", 982], ["no", 987], ["observed", 990], ["difference", 999], ["between", 1010], ["male", 1018], ["and", 1023], ["female", 1027], ["animals", 1034], [".", 1041], ["One", 1043], ["monkey", 1047], ["died", 1054], ["during", 1059], ["the", 1066], ["study", 1070], [";", 1075], ["this", 1077], ["monkey", 1082], ["had", 1089], ["findings", 1093], ["suggestive", 1102], ["of", 1113], ["hypersensitivity", 1116], ["reaction", 1133], [".", 1141], ["The", 1143], ["favorable", 1147], ["toxicity", 1157], ["and", 1166], ["pharmacokinetic", 1170], ["profile", 1186], ["of", 1194], ["tanezumab", 1197], ["seen", 1207], ["in", 1212], ["this", 1215], ["study", 1220], ["supports", 1226], ["its", 1235], ["further", 1239], ["evaluation", 1247], ["for", 1258], ["the", 1262], ["treatment", 1266], ["of", 1276], ["pain", 1279], ["in", 1284], ["clinical", 1287], ["practice", 1296], [".", 1304]]}
{"context": "In this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome (CTS). The study enrolled 72 patients including 34 patients without epineurectomy (Group A) and 38 patients with epineurectomy (Group B). Surgery was performed in patients with severe electrodiagnostic CTS findings, CTS duration >1 year and flattening along with hypervascularization in median nerve. All patients were assessed by visual analog scale, two-point discrimination test as well as subjective and objective findings at baseline and on the months 1, 3, and 6 after surgery. The mean age was 58.3 years (42-75 years) in 38 patients who underwent an epineurectomy, whereas it was 61.5 years (41-82 years) in 34 patients who did not have an epineurectomy. The groups were similar with regard to age, gender, duration of symptoms, and preoperative physical findings. Mean visual analog scale (VAS) scores were 1.7 in Group A and 1.8 in Group B. Again, these differences were not significant, on physical examination, the average two-point discrimination in the distribution of the median nerve was 4.9 mm (range: 3-11 mm) in Group A and 5.3 mm (range: 3-10 mm) in Group B. In postoperative evaluations, there was a better improvement in visual analog scale scores, two-point discrimination test and subjective symptoms including dysesthesia, pain and nocturnal pain within first 3 months; however, there was no marked difference in objective and subjective findings on the 6th month. No complication or recurrence was observed. We believe that median nerve epineurectomy is unnecessary in the surgical management of primary CTS since it has no influence on the midterm outcomes.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "d280d6107fe547dca76066cc0481218e", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[214, 214], [306, 306], [73, 73], [10, 10]], "char_spans": [[1130, 1135], [1593, 1598], [430, 435], [49, 54]]}]}], "context_tokens": [["In", 0], ["this", 3], ["study", 8], [",", 13], ["it", 15], ["was", 18], ["aimed", 22], ["to", 28], ["determine", 31], ["whether", 41], ["median", 49], ["nerve", 56], ["epineurectomy", 62], ["is", 76], ["beneficial", 79], ["in", 90], ["the", 93], ["surgical", 97], ["management", 106], ["of", 117], ["carpal", 120], ["tunnel", 127], ["syndrome", 134], ["(", 143], ["CTS", 144], [")", 147], [".", 148], ["The", 150], ["study", 154], ["enrolled", 160], ["72", 169], ["patients", 172], ["including", 181], ["34", 191], ["patients", 194], ["without", 203], ["epineurectomy", 211], ["(", 225], ["Group", 226], ["A", 232], [")", 233], ["and", 235], ["38", 239], ["patients", 242], ["with", 251], ["epineurectomy", 256], ["(", 270], ["Group", 271], ["B", 277], [")", 278], [".", 279], ["Surgery", 281], ["was", 289], ["performed", 293], ["in", 303], ["patients", 306], ["with", 315], ["severe", 320], ["electrodiagnostic", 327], ["CTS", 345], ["findings", 349], [",", 357], ["CTS", 359], ["duration", 363], [">", 372], ["1", 373], ["year", 375], ["and", 380], ["flattening", 384], ["along", 395], ["with", 401], ["hypervascularization", 406], ["in", 427], ["median", 430], ["nerve", 437], [".", 442], ["All", 444], ["patients", 448], ["were", 457], ["assessed", 462], ["by", 471], ["visual", 474], ["analog", 481], ["scale", 488], [",", 493], ["two", 495], ["-", 498], ["point", 499], ["discrimination", 505], ["test", 520], ["as", 525], ["well", 528], ["as", 533], ["subjective", 536], ["and", 547], ["objective", 551], ["findings", 561], ["at", 570], ["baseline", 573], ["and", 582], ["on", 586], ["the", 589], ["months", 593], ["1", 600], [",", 601], ["3", 603], [",", 604], ["and", 606], ["6", 610], ["after", 612], ["surgery", 618], [".", 625], ["The", 627], ["mean", 631], ["age", 636], ["was", 640], ["58.3", 644], ["years", 649], ["(", 655], ["42", 656], ["-", 658], ["75", 659], ["years", 662], [")", 667], ["in", 669], ["38", 672], ["patients", 675], ["who", 684], ["underwent", 688], ["an", 698], ["epineurectomy", 701], [",", 714], ["whereas", 716], ["it", 724], ["was", 727], ["61.5", 731], ["years", 736], ["(", 742], ["41", 743], ["-", 745], ["82", 746], ["years", 749], [")", 754], ["in", 756], ["34", 759], ["patients", 762], ["who", 771], ["did", 775], ["not", 779], ["have", 783], ["an", 788], ["epineurectomy", 791], [".", 804], ["The", 806], ["groups", 810], ["were", 817], ["similar", 822], ["with", 830], ["regard", 835], ["to", 842], ["age", 845], [",", 848], ["gender", 850], [",", 856], ["duration", 858], ["of", 867], ["symptoms", 870], [",", 878], ["and", 880], ["preoperative", 884], ["physical", 897], ["findings", 906], [".", 914], ["Mean", 916], ["visual", 921], ["analog", 928], ["scale", 935], ["(", 941], ["VAS", 942], [")", 945], ["scores", 947], ["were", 954], ["1.7", 959], ["in", 963], ["Group", 966], ["A", 972], ["and", 974], ["1.8", 978], ["in", 982], ["Group", 985], ["B.", 991], ["Again", 994], [",", 999], ["these", 1001], ["differences", 1007], ["were", 1019], ["not", 1024], ["significant", 1028], [",", 1039], ["on", 1041], ["physical", 1044], ["examination", 1053], [",", 1064], ["the", 1066], ["average", 1070], ["two", 1078], ["-", 1081], ["point", 1082], ["discrimination", 1088], ["in", 1103], ["the", 1106], ["distribution", 1110], ["of", 1123], ["the", 1126], ["median", 1130], ["nerve", 1137], ["was", 1143], ["4.9", 1147], ["mm", 1151], ["(", 1154], ["range", 1155], [":", 1160], ["3", 1162], ["-", 1163], ["11", 1164], ["mm", 1167], [")", 1169], ["in", 1171], ["Group", 1174], ["A", 1180], ["and", 1182], ["5.3", 1186], ["mm", 1190], ["(", 1193], ["range", 1194], [":", 1199], ["3", 1201], ["-", 1202], ["10", 1203], ["mm", 1206], [")", 1208], ["in", 1210], ["Group", 1213], ["B.", 1219], ["In", 1222], ["postoperative", 1225], ["evaluations", 1239], [",", 1250], ["there", 1252], ["was", 1258], ["a", 1262], ["better", 1264], ["improvement", 1271], ["in", 1283], ["visual", 1286], ["analog", 1293], ["scale", 1300], ["scores", 1306], [",", 1312], ["two", 1314], ["-", 1317], ["point", 1318], ["discrimination", 1324], ["test", 1339], ["and", 1344], ["subjective", 1348], ["symptoms", 1359], ["including", 1368], ["dysesthesia", 1378], [",", 1389], ["pain", 1391], ["and", 1396], ["nocturnal", 1400], ["pain", 1410], ["within", 1415], ["first", 1422], ["3", 1428], ["months", 1430], [";", 1436], ["however", 1438], [",", 1445], ["there", 1447], ["was", 1453], ["no", 1457], ["marked", 1460], ["difference", 1467], ["in", 1478], ["objective", 1481], ["and", 1491], ["subjective", 1495], ["findings", 1506], ["on", 1515], ["the", 1518], ["6th", 1522], ["month", 1526], [".", 1531], ["No", 1533], ["complication", 1536], ["or", 1549], ["recurrence", 1552], ["was", 1563], ["observed", 1567], [".", 1575], ["We", 1577], ["believe", 1580], ["that", 1588], ["median", 1593], ["nerve", 1600], ["epineurectomy", 1606], ["is", 1620], ["unnecessary", 1623], ["in", 1635], ["the", 1638], ["surgical", 1642], ["management", 1651], ["of", 1662], ["primary", 1665], ["CTS", 1673], ["since", 1677], ["it", 1683], ["has", 1686], ["no", 1690], ["influence", 1693], ["on", 1703], ["the", 1706], ["midterm", 1710], ["outcomes", 1718], [".", 1726]]}
{"context": "To compare the BD GeneOhm Methicillin Resistant Staphylococcus aureus (MRSA) Achromopeptidase (ACP) polymerase chain reaction (PCR) assay with the culture method for the detection of MRSA colonization. One hundred and two patients were admitted to the Intensive Care Unit in King Khalid Hospital, Najran, Kingdom of Saudi Arabia from July 2010 to February 2011. Separate swabs from the nose, axilla, and groin of each patient were processed by the culture method (sheep blood agar plate and mannitol salt agar plate) and BD GeneOhm MRSA ACP assay. Of the 287 samples, 62 (21.6%) were MRSA positive by the PCR assay and 26 (9%) were MRSA positive by the culture method. The PCR method showed 88.4% sensitivity and 98.6% negative predictive value. The number of MRSA-PCR positive groin specimens was nearly the same as nasal specimens. The PCR method gave positive results in 22.5% of patients by nasal specimens, 27.5% of patients by nasal and groin specimens, and 30.4% of patients by nasal, groin, and axilla specimens. The PCR method detected 30.4% of patients as MRSA positive while the culture method detected 19.6% of patients as positive for MRSA. The BD GeneOhm MRSA ACP assay has high sensitivity and NPV and hence is a useful screening method to exclude patients who are not colonized with MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "77a8e6ff6d4d4b08b5ddf3e5994651eb", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[112, 112], [125, 125], [31, 31], [10, 10], [149, 149], [211, 211], [230, 230], [253, 253], [225, 225], [97, 97]], "char_spans": [[584, 587], [632, 635], [183, 186], [71, 74], [760, 763], [1066, 1069], [1169, 1172], [1299, 1302], [1148, 1151], [532, 535]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["BD", 15], ["GeneOhm", 18], ["Methicillin", 26], ["Resistant", 38], ["Staphylococcus", 48], ["aureus", 63], ["(", 70], ["MRSA", 71], [")", 75], ["Achromopeptidase", 77], ["(", 94], ["ACP", 95], [")", 98], ["polymerase", 100], ["chain", 111], ["reaction", 117], ["(", 126], ["PCR", 127], [")", 130], ["assay", 132], ["with", 138], ["the", 143], ["culture", 147], ["method", 155], ["for", 162], ["the", 166], ["detection", 170], ["of", 180], ["MRSA", 183], ["colonization", 188], [".", 200], ["One", 202], ["hundred", 206], ["and", 214], ["two", 218], ["patients", 222], ["were", 231], ["admitted", 236], ["to", 245], ["the", 248], ["Intensive", 252], ["Care", 262], ["Unit", 267], ["in", 272], ["King", 275], ["Khalid", 280], ["Hospital", 287], [",", 295], ["Najran", 297], [",", 303], ["Kingdom", 305], ["of", 313], ["Saudi", 316], ["Arabia", 322], ["from", 329], ["July", 334], ["2010", 339], ["to", 344], ["February", 347], ["2011", 356], [".", 360], ["Separate", 362], ["swabs", 371], ["from", 377], ["the", 382], ["nose", 386], [",", 390], ["axilla", 392], [",", 398], ["and", 400], ["groin", 404], ["of", 410], ["each", 413], ["patient", 418], ["were", 426], ["processed", 431], ["by", 441], ["the", 444], ["culture", 448], ["method", 456], ["(", 463], ["sheep", 464], ["blood", 470], ["agar", 476], ["plate", 481], ["and", 487], ["mannitol", 491], ["salt", 500], ["agar", 505], ["plate", 510], [")", 515], ["and", 517], ["BD", 521], ["GeneOhm", 524], ["MRSA", 532], ["ACP", 537], ["assay", 541], [".", 546], ["Of", 548], ["the", 551], ["287", 555], ["samples", 559], [",", 566], ["62", 568], ["(", 571], ["21.6", 572], ["%", 576], [")", 577], ["were", 579], ["MRSA", 584], ["positive", 589], ["by", 598], ["the", 601], ["PCR", 605], ["assay", 609], ["and", 615], ["26", 619], ["(", 622], ["9", 623], ["%", 624], [")", 625], ["were", 627], ["MRSA", 632], ["positive", 637], ["by", 646], ["the", 649], ["culture", 653], ["method", 661], [".", 667], ["The", 669], ["PCR", 673], ["method", 677], ["showed", 684], ["88.4", 691], ["%", 695], ["sensitivity", 697], ["and", 709], ["98.6", 713], ["%", 717], ["negative", 719], ["predictive", 728], ["value", 739], [".", 744], ["The", 746], ["number", 750], ["of", 757], ["MRSA", 760], ["-", 764], ["PCR", 765], ["positive", 769], ["groin", 778], ["specimens", 784], ["was", 794], ["nearly", 798], ["the", 805], ["same", 809], ["as", 814], ["nasal", 817], ["specimens", 823], [".", 832], ["The", 834], ["PCR", 838], ["method", 842], ["gave", 849], ["positive", 854], ["results", 863], ["in", 871], ["22.5", 874], ["%", 878], ["of", 880], ["patients", 883], ["by", 892], ["nasal", 895], ["specimens", 901], [",", 910], ["27.5", 912], ["%", 916], ["of", 918], ["patients", 921], ["by", 930], ["nasal", 933], ["and", 939], ["groin", 943], ["specimens", 949], [",", 958], ["and", 960], ["30.4", 964], ["%", 968], ["of", 970], ["patients", 973], ["by", 982], ["nasal", 985], [",", 990], ["groin", 992], [",", 997], ["and", 999], ["axilla", 1003], ["specimens", 1010], [".", 1019], ["The", 1021], ["PCR", 1025], ["method", 1029], ["detected", 1036], ["30.4", 1045], ["%", 1049], ["of", 1051], ["patients", 1054], ["as", 1063], ["MRSA", 1066], ["positive", 1071], ["while", 1080], ["the", 1086], ["culture", 1090], ["method", 1098], ["detected", 1105], ["19.6", 1114], ["%", 1118], ["of", 1120], ["patients", 1123], ["as", 1132], ["positive", 1135], ["for", 1144], ["MRSA", 1148], [".", 1152], ["The", 1154], ["BD", 1158], ["GeneOhm", 1161], ["MRSA", 1169], ["ACP", 1174], ["assay", 1178], ["has", 1184], ["high", 1188], ["sensitivity", 1193], ["and", 1205], ["NPV", 1209], ["and", 1213], ["hence", 1217], ["is", 1223], ["a", 1226], ["useful", 1228], ["screening", 1235], ["method", 1245], ["to", 1252], ["exclude", 1255], ["patients", 1263], ["who", 1272], ["are", 1276], ["not", 1280], ["colonized", 1284], ["with", 1294], ["MRSA", 1299], [".", 1303]]}
{"context": "The ubiquitin-proteasome pathway has been identified as a potential molecular target for cancer therapy. In this study, we investigated the effect of the proteasome inhibitor bortezomib on anaplastic thyroid carcinoma (ATC) characterized by complete refractoriness to multimodal therapeutic approaches. The ATC cell lines C643 and SW1736 were treated with bortezomib (1 nM to 1 \u03bcM) for 12-72 h. Thereafter, growth inhibition was analyzed by thymidine uptake experiments and determination of the viable cell number. Apoptosis was measured and a cell cycle analysis was done. Using gene chip analysis and the real-time quantitative PCR system, we measured transcriptional changes. The activity of the nuclear factor (NF)-\u03baB and p53 signal transduction pathways was monitored using the reporter constructs pNF-\u03baB-TA-Luc and pp53-TA-Luc in the luciferase activity assay. Uptake measurements using (3)H-FDG, (14)C-aminoisobutyric acid, and Na(125)iodide were performed to investigate metabolic changes and iodide symporter activity in vitro. Moreover, the (18)F-FDG uptake was evaluated in ATC tumor-bearing nude mice 1 or 2 d after treatment with bortezomib. Bortezomib induced growth inhibition, apoptosis, and G(2)-M cell cycle arrest associated with upregulation of p21(CIP1/WAF1) expression in SW1736 and C643 cells. Moreover, the glucose metabolism and aminoisobutyric acid uptake significantly decreased in vitro in both of the ATC cell lines in vivo only in SW1736 tumors at 2 d after the bortezomib treatment. The transcriptional profile in bortezomib-treated SW1736 and C643 cells revealed increased expression of genes involved in stress response, apoptosis, regulation of the cell cycle, and differentiation. Using real-time quantitative PCR for the quantification of gene expression, we additionally noticed upregulation of the tumor necrosis factor-related apoptosis-inducing ligand and the thyroid-specific transcription factors Pax8 and TTF-1, leading to expression of the thyroid-specific target genes thyroglobulin, sodium iodide symporter, thyroperoxidase, and thyroid-stimulating hormone receptor and to a moderate accumulation of iodide in ATC cells. On the basis of our data, bortezomib represents a promising antineoplastic agent for the treatment of ATC. To improve the clinical outcome, further investigation into the potential of bortezomib therapy of thyroid cancer is clearly warranted.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "24304bc9cd534c35b4dd425e73e67aa7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[1, 4]], "char_spans": [[4, 31]]}]}], "context_tokens": [["The", 0], ["ubiquitin", 4], ["-", 13], ["proteasome", 14], ["pathway", 25], ["has", 33], ["been", 37], ["identified", 42], ["as", 53], ["a", 56], ["potential", 58], ["molecular", 68], ["target", 78], ["for", 85], ["cancer", 89], ["therapy", 96], [".", 103], ["In", 105], ["this", 108], ["study", 113], [",", 118], ["we", 120], ["investigated", 123], ["the", 136], ["effect", 140], ["of", 147], ["the", 150], ["proteasome", 154], ["inhibitor", 165], ["bortezomib", 175], ["on", 186], ["anaplastic", 189], ["thyroid", 200], ["carcinoma", 208], ["(", 218], ["ATC", 219], [")", 222], ["characterized", 224], ["by", 238], ["complete", 241], ["refractoriness", 250], ["to", 265], ["multimodal", 268], ["therapeutic", 279], ["approaches", 291], [".", 301], ["The", 303], ["ATC", 307], ["cell", 311], ["lines", 316], ["C643", 322], ["and", 327], ["SW1736", 331], ["were", 338], ["treated", 343], ["with", 351], ["bortezomib", 356], ["(", 367], ["1", 368], ["nM", 370], ["to", 373], ["1", 376], ["\u03bcM", 378], [")", 380], ["for", 382], ["12", 386], ["-", 388], ["72", 389], ["h.", 392], ["Thereafter", 395], [",", 405], ["growth", 407], ["inhibition", 414], ["was", 425], ["analyzed", 429], ["by", 438], ["thymidine", 441], ["uptake", 451], ["experiments", 458], ["and", 470], ["determination", 474], ["of", 488], ["the", 491], ["viable", 495], ["cell", 502], ["number", 507], [".", 513], ["Apoptosis", 515], ["was", 525], ["measured", 529], ["and", 538], ["a", 542], ["cell", 544], ["cycle", 549], ["analysis", 555], ["was", 564], ["done", 568], [".", 572], ["Using", 574], ["gene", 580], ["chip", 585], ["analysis", 590], ["and", 599], ["the", 603], ["real", 607], ["-", 611], ["time", 612], ["quantitative", 617], ["PCR", 630], ["system", 634], [",", 640], ["we", 642], ["measured", 645], ["transcriptional", 654], ["changes", 670], [".", 677], ["The", 679], ["activity", 683], ["of", 692], ["the", 695], ["nuclear", 699], ["factor", 707], ["(", 714], ["NF)-\u03baB", 715], ["and", 722], ["p53", 726], ["signal", 730], ["transduction", 737], ["pathways", 750], ["was", 759], ["monitored", 763], ["using", 773], ["the", 779], ["reporter", 783], ["constructs", 792], ["pNF", 803], ["-", 806], ["\u03baB", 807], ["-", 809], ["TA", 810], ["-", 812], ["Luc", 813], ["and", 817], ["pp53-TA", 821], ["-", 828], ["Luc", 829], ["in", 833], ["the", 836], ["luciferase", 840], ["activity", 851], ["assay", 860], [".", 865], ["Uptake", 867], ["measurements", 874], ["using", 887], ["(", 893], ["3)H", 894], ["-", 897], ["FDG", 898], [",", 901], ["(", 903], ["14)C", 904], ["-", 908], ["aminoisobutyric", 909], ["acid", 925], [",", 929], ["and", 931], ["Na(125)iodide", 935], ["were", 949], ["performed", 954], ["to", 964], ["investigate", 967], ["metabolic", 979], ["changes", 989], ["and", 997], ["iodide", 1001], ["symporter", 1008], ["activity", 1018], ["in", 1027], ["vitro", 1030], [".", 1035], ["Moreover", 1037], [",", 1045], ["the", 1047], ["(", 1051], ["18)F", 1052], ["-", 1056], ["FDG", 1057], ["uptake", 1061], ["was", 1068], ["evaluated", 1072], ["in", 1082], ["ATC", 1085], ["tumor", 1089], ["-", 1094], ["bearing", 1095], ["nude", 1103], ["mice", 1108], ["1", 1113], ["or", 1115], ["2", 1118], ["d", 1120], ["after", 1122], ["treatment", 1128], ["with", 1138], ["bortezomib", 1143], [".", 1153], ["Bortezomib", 1155], ["induced", 1166], ["growth", 1174], ["inhibition", 1181], [",", 1191], ["apoptosis", 1193], [",", 1202], ["and", 1204], ["G(2)-M", 1208], ["cell", 1215], ["cycle", 1220], ["arrest", 1226], ["associated", 1233], ["with", 1244], ["upregulation", 1249], ["of", 1262], ["p21(CIP1/WAF1", 1265], [")", 1278], ["expression", 1280], ["in", 1291], ["SW1736", 1294], ["and", 1301], ["C643", 1305], ["cells", 1310], [".", 1315], ["Moreover", 1317], [",", 1325], ["the", 1327], ["glucose", 1331], ["metabolism", 1339], ["and", 1350], ["aminoisobutyric", 1354], ["acid", 1370], ["uptake", 1375], ["significantly", 1382], ["decreased", 1396], ["in", 1406], ["vitro", 1409], ["in", 1415], ["both", 1418], ["of", 1423], ["the", 1426], ["ATC", 1430], ["cell", 1434], ["lines", 1439], ["in", 1445], ["vivo", 1448], ["only", 1453], ["in", 1458], ["SW1736", 1461], ["tumors", 1468], ["at", 1475], ["2", 1478], ["d", 1480], ["after", 1482], ["the", 1488], ["bortezomib", 1492], ["treatment", 1503], [".", 1512], ["The", 1514], ["transcriptional", 1518], ["profile", 1534], ["in", 1542], ["bortezomib", 1545], ["-", 1555], ["treated", 1556], ["SW1736", 1564], ["and", 1571], ["C643", 1575], ["cells", 1580], ["revealed", 1586], ["increased", 1595], ["expression", 1605], ["of", 1616], ["genes", 1619], ["involved", 1625], ["in", 1634], ["stress", 1637], ["response", 1644], [",", 1652], ["apoptosis", 1654], [",", 1663], ["regulation", 1665], ["of", 1676], ["the", 1679], ["cell", 1683], ["cycle", 1688], [",", 1693], ["and", 1695], ["differentiation", 1699], [".", 1714], ["Using", 1716], ["real", 1722], ["-", 1726], ["time", 1727], ["quantitative", 1732], ["PCR", 1745], ["for", 1749], ["the", 1753], ["quantification", 1757], ["of", 1772], ["gene", 1775], ["expression", 1780], [",", 1790], ["we", 1792], ["additionally", 1795], ["noticed", 1808], ["upregulation", 1816], ["of", 1829], ["the", 1832], ["tumor", 1836], ["necrosis", 1842], ["factor", 1851], ["-", 1857], ["related", 1858], ["apoptosis", 1866], ["-", 1875], ["inducing", 1876], ["ligand", 1885], ["and", 1892], ["the", 1896], ["thyroid", 1900], ["-", 1907], ["specific", 1908], ["transcription", 1917], ["factors", 1931], ["Pax8", 1939], ["and", 1944], ["TTF-1", 1948], [",", 1953], ["leading", 1955], ["to", 1963], ["expression", 1966], ["of", 1977], ["the", 1980], ["thyroid", 1984], ["-", 1991], ["specific", 1992], ["target", 2001], ["genes", 2008], ["thyroglobulin", 2014], [",", 2027], ["sodium", 2029], ["iodide", 2036], ["symporter", 2043], [",", 2052], ["thyroperoxidase", 2054], [",", 2069], ["and", 2071], ["thyroid", 2075], ["-", 2082], ["stimulating", 2083], ["hormone", 2095], ["receptor", 2103], ["and", 2112], ["to", 2116], ["a", 2119], ["moderate", 2121], ["accumulation", 2130], ["of", 2143], ["iodide", 2146], ["in", 2153], ["ATC", 2156], ["cells", 2160], [".", 2165], ["On", 2167], ["the", 2170], ["basis", 2174], ["of", 2180], ["our", 2183], ["data", 2187], [",", 2191], ["bortezomib", 2193], ["represents", 2204], ["a", 2215], ["promising", 2217], ["antineoplastic", 2227], ["agent", 2242], ["for", 2248], ["the", 2252], ["treatment", 2256], ["of", 2266], ["ATC", 2269], [".", 2272], ["To", 2274], ["improve", 2277], ["the", 2285], ["clinical", 2289], ["outcome", 2298], [",", 2305], ["further", 2307], ["investigation", 2315], ["into", 2329], ["the", 2334], ["potential", 2338], ["of", 2348], ["bortezomib", 2351], ["therapy", 2362], ["of", 2370], ["thyroid", 2373], ["cancer", 2381], ["is", 2388], ["clearly", 2391], ["warranted", 2399], [".", 2408]]}
{"context": "Ryanodine receptor (RyR), a homotetrameric Ca2+ release channel, is one of the main actors in the generation of Ca2+ signals that trigger muscle contraction. Three genes encode three isoforms of RyRs, which have tissue-restricted distribution. RyR1 and RyR2 are typical of muscle cells, with RyR1 originally considered the skeletal muscle type and RyR2 the cardiac type. However, RyR1 and RyR2 have recently been found in numerous other cell types, including, for instance, peripheral B and T lymphocytes. In contrast, RyR3 is widely distributed among cells. RyR1 and RyR2 are localized in a specialized portion of the sarcoplasmic reticulum (SR), the terminal cisternae, which is the portion of the SR Ca2+ store that releases Ca2+ to control the process of muscle contraction. A specific role for RyR3 has not yet been established: probably, its co-expression with the other RyR isoforms contributes to qualitatively modulate Ca2+-dependent processes in muscle cells and in neurons. Several mutations in the genes encoding RyR1 and RyR2 have been identified in autosomal dominant diseases of skeletal and cardiac muscle, such as malignant hyperthermia (MH), central core disease (CCD), catecholaminergic polymorphic ventricular tachycardia (CPVT), and arrhythmogenic right ventricular dysplasia type 2 (ARVD2). More recently, CCD cases with recessive inheritance have also been described. MH is a pharmacogenetic disease, but the others manifest as congenital myopathies. Even if their clinical phenotypes are well established, particularly in skeletal muscle, the molecular mechanisms that generate the conditions are not clear. A number of studies on cellular models have attempted to elucidate the molecular defects associated with the different mutations, but the problem of understanding how mutations in the same gene generate such an array of diverse pathological traits and diseases of widely different degrees of severity is still open. This review will consider the molecular and cellular effects of RyR mutations, summarizing recent data in the literature on Ca2+ dysregulation, which may lead to a better understanding of the functioning of RyRs.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "8962f8a532fe4886b70e6d2f835f4445", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[198, 199]], "char_spans": [[1063, 1080]]}]}], "context_tokens": [["Ryanodine", 0], ["receptor", 10], ["(", 19], ["RyR", 20], [")", 23], [",", 24], ["a", 26], ["homotetrameric", 28], ["Ca2", 43], ["+", 46], ["release", 48], ["channel", 56], [",", 63], ["is", 65], ["one", 68], ["of", 72], ["the", 75], ["main", 79], ["actors", 84], ["in", 91], ["the", 94], ["generation", 98], ["of", 109], ["Ca2", 112], ["+", 115], ["signals", 117], ["that", 125], ["trigger", 130], ["muscle", 138], ["contraction", 145], [".", 156], ["Three", 158], ["genes", 164], ["encode", 170], ["three", 177], ["isoforms", 183], ["of", 192], ["RyRs", 195], [",", 199], ["which", 201], ["have", 207], ["tissue", 212], ["-", 218], ["restricted", 219], ["distribution", 230], [".", 242], ["RyR1", 244], ["and", 249], ["RyR2", 253], ["are", 258], ["typical", 262], ["of", 270], ["muscle", 273], ["cells", 280], [",", 285], ["with", 287], ["RyR1", 292], ["originally", 297], ["considered", 308], ["the", 319], ["skeletal", 323], ["muscle", 332], ["type", 339], ["and", 344], ["RyR2", 348], ["the", 353], ["cardiac", 357], ["type", 365], [".", 369], ["However", 371], [",", 378], ["RyR1", 380], ["and", 385], ["RyR2", 389], ["have", 394], ["recently", 399], ["been", 408], ["found", 413], ["in", 419], ["numerous", 422], ["other", 431], ["cell", 437], ["types", 442], [",", 447], ["including", 449], [",", 458], ["for", 460], ["instance", 464], [",", 472], ["peripheral", 474], ["B", 485], ["and", 487], ["T", 491], ["lymphocytes", 493], [".", 504], ["In", 506], ["contrast", 509], [",", 517], ["RyR3", 519], ["is", 524], ["widely", 527], ["distributed", 534], ["among", 546], ["cells", 552], [".", 557], ["RyR1", 559], ["and", 564], ["RyR2", 568], ["are", 573], ["localized", 577], ["in", 587], ["a", 590], ["specialized", 592], ["portion", 604], ["of", 612], ["the", 615], ["sarcoplasmic", 619], ["reticulum", 632], ["(", 642], ["SR", 643], [")", 645], [",", 646], ["the", 648], ["terminal", 652], ["cisternae", 661], [",", 670], ["which", 672], ["is", 678], ["the", 681], ["portion", 685], ["of", 693], ["the", 696], ["SR", 700], ["Ca2", 703], ["+", 706], ["store", 708], ["that", 714], ["releases", 719], ["Ca2", 728], ["+", 731], ["to", 733], ["control", 736], ["the", 744], ["process", 748], ["of", 756], ["muscle", 759], ["contraction", 766], [".", 777], ["A", 779], ["specific", 781], ["role", 790], ["for", 795], ["RyR3", 799], ["has", 804], ["not", 808], ["yet", 812], ["been", 816], ["established", 821], [":", 832], ["probably", 834], [",", 842], ["its", 844], ["co", 848], ["-", 850], ["expression", 851], ["with", 862], ["the", 867], ["other", 871], ["RyR", 877], ["isoforms", 881], ["contributes", 890], ["to", 902], ["qualitatively", 905], ["modulate", 919], ["Ca2", 928], ["+", 931], ["-dependent", 932], ["processes", 943], ["in", 953], ["muscle", 956], ["cells", 963], ["and", 969], ["in", 973], ["neurons", 976], [".", 983], ["Several", 985], ["mutations", 993], ["in", 1003], ["the", 1006], ["genes", 1010], ["encoding", 1016], ["RyR1", 1025], ["and", 1030], ["RyR2", 1034], ["have", 1039], ["been", 1044], ["identified", 1049], ["in", 1060], ["autosomal", 1063], ["dominant", 1073], ["diseases", 1082], ["of", 1091], ["skeletal", 1094], ["and", 1103], ["cardiac", 1107], ["muscle", 1115], [",", 1121], ["such", 1123], ["as", 1128], ["malignant", 1131], ["hyperthermia", 1141], ["(", 1154], ["MH", 1155], [")", 1157], [",", 1158], ["central", 1160], ["core", 1168], ["disease", 1173], ["(", 1181], ["CCD", 1182], [")", 1185], [",", 1186], ["catecholaminergic", 1188], ["polymorphic", 1206], ["ventricular", 1218], ["tachycardia", 1230], ["(", 1242], ["CPVT", 1243], [")", 1247], [",", 1248], ["and", 1250], ["arrhythmogenic", 1254], ["right", 1269], ["ventricular", 1275], ["dysplasia", 1287], ["type", 1297], ["2", 1302], ["(", 1304], ["ARVD2", 1305], [")", 1310], [".", 1311], ["More", 1313], ["recently", 1318], [",", 1326], ["CCD", 1328], ["cases", 1332], ["with", 1338], ["recessive", 1343], ["inheritance", 1353], ["have", 1365], ["also", 1370], ["been", 1375], ["described", 1380], [".", 1389], ["MH", 1391], ["is", 1394], ["a", 1397], ["pharmacogenetic", 1399], ["disease", 1415], [",", 1422], ["but", 1424], ["the", 1428], ["others", 1432], ["manifest", 1439], ["as", 1448], ["congenital", 1451], ["myopathies", 1462], [".", 1472], ["Even", 1474], ["if", 1479], ["their", 1482], ["clinical", 1488], ["phenotypes", 1497], ["are", 1508], ["well", 1512], ["established", 1517], [",", 1528], ["particularly", 1530], ["in", 1543], ["skeletal", 1546], ["muscle", 1555], [",", 1561], ["the", 1563], ["molecular", 1567], ["mechanisms", 1577], ["that", 1588], ["generate", 1593], ["the", 1602], ["conditions", 1606], ["are", 1617], ["not", 1621], ["clear", 1625], [".", 1630], ["A", 1632], ["number", 1634], ["of", 1641], ["studies", 1644], ["on", 1652], ["cellular", 1655], ["models", 1664], ["have", 1671], ["attempted", 1676], ["to", 1686], ["elucidate", 1689], ["the", 1699], ["molecular", 1703], ["defects", 1713], ["associated", 1721], ["with", 1732], ["the", 1737], ["different", 1741], ["mutations", 1751], [",", 1760], ["but", 1762], ["the", 1766], ["problem", 1770], ["of", 1778], ["understanding", 1781], ["how", 1795], ["mutations", 1799], ["in", 1809], ["the", 1812], ["same", 1816], ["gene", 1821], ["generate", 1826], ["such", 1835], ["an", 1840], ["array", 1843], ["of", 1849], ["diverse", 1852], ["pathological", 1860], ["traits", 1873], ["and", 1880], ["diseases", 1884], ["of", 1893], ["widely", 1896], ["different", 1903], ["degrees", 1913], ["of", 1921], ["severity", 1924], ["is", 1933], ["still", 1936], ["open", 1942], [".", 1946], ["This", 1948], ["review", 1953], ["will", 1960], ["consider", 1965], ["the", 1974], ["molecular", 1978], ["and", 1988], ["cellular", 1992], ["effects", 2001], ["of", 2009], ["RyR", 2012], ["mutations", 2016], [",", 2025], ["summarizing", 2027], ["recent", 2039], ["data", 2046], ["in", 2051], ["the", 2054], ["literature", 2058], ["on", 2069], ["Ca2", 2072], ["+", 2075], ["dysregulation", 2077], [",", 2090], ["which", 2092], ["may", 2098], ["lead", 2102], ["to", 2107], ["a", 2110], ["better", 2112], ["understanding", 2119], ["of", 2133], ["the", 2136], ["functioning", 2140], ["of", 2152], ["RyRs", 2155], [".", 2159]]}
{"context": "Sulfonylureas (SUs) are commonly used in the treatment of type 2 diabetes (T2DM), usually as second-line treatment after the failure of metformin. However, SUs are associated with poor durability, hypoglycemia and weight gain. Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor in development for the treatment of T2DM. In Phase II/III trials, empagliflozin reduced hyperglycemia, body weight and blood pressure, with a low incidence of hypoglycemia. The aim of this Phase III study is to compare the effects of empagliflozin and the SU glimepiride as second-line therapy in patients with T2DM inadequately controlled with metformin immediate release (IR) and diet/exercise. After a 2-week placebo run-in, patients were randomized to receive empagliflozin 25 mg once daily (qd) or glimepiride 1-4 mg qd double-blind for 2 years, in addition to metformin IR. Patients who participate in the initial 2-year randomization period will be eligible for a 2-year double-blind extension. The primary endpoint is change from baseline in HbA1c. Secondary endpoints are change from baseline in body weight, the incidence of confirmed hypoglycemia and changes in systolic and diastolic blood pressure. Exploratory endpoints include markers of insulin secretion, body composition and responder analyses. Safety endpoints include the incidence of adverse events (AEs) (including macro- and microvascular adverse events) and changes from baseline in clinical laboratory parameters. Between August 2010 and June 2011, 1549 patients were randomized and 1545 patients were treated. At baseline, mean (SD) age was 55.9 (10.4) years, HbA1c was 7.92 (0.84)%, body mass index was 30.11 (5.59) kg/m\u00b2, systolic blood pressure was 133.5 (15.9) mmHg and diastolic blood pressure was 79.5 (9.4) mmHg. This is the largest study to compare the efficacy and safety of an SGLT2 inhibitor with an SU in patients with T2DM inadequately controlled on metformin to date. In addition to determining the effects of these treatments on glycemic control over the long term, this study will investigate effects on beta-cell function, cardiovascular risk factors and markers of renal function/damage. The results will help to inform the choice of second-line treatment in patients with T2DM who have failed on metformin. Clinicaltrials.gov NCT01167881.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "99350de9f10a4165ad5d74c8d6e96534", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[52, 52], [348, 348]], "char_spans": [[278, 282], [1858, 1862]]}]}], "context_tokens": [["Sulfonylureas", 0], ["(", 14], ["SUs", 15], [")", 18], ["are", 20], ["commonly", 24], ["used", 33], ["in", 38], ["the", 41], ["treatment", 45], ["of", 55], ["type", 58], ["2", 63], ["diabetes", 65], ["(", 74], ["T2DM", 75], [")", 79], [",", 80], ["usually", 82], ["as", 90], ["second", 93], ["-", 99], ["line", 100], ["treatment", 105], ["after", 115], ["the", 121], ["failure", 125], ["of", 133], ["metformin", 136], [".", 145], ["However", 147], [",", 154], ["SUs", 156], ["are", 160], ["associated", 164], ["with", 175], ["poor", 180], ["durability", 185], [",", 195], ["hypoglycemia", 197], ["and", 210], ["weight", 214], ["gain", 221], [".", 225], ["Empagliflozin", 227], ["is", 241], ["a", 244], ["sodium", 246], ["glucose", 253], ["cotransporter", 261], ["2", 275], ["(", 277], ["SGLT2", 278], [")", 283], ["inhibitor", 285], ["in", 295], ["development", 298], ["for", 310], ["the", 314], ["treatment", 318], ["of", 328], ["T2DM", 331], [".", 335], ["In", 337], ["Phase", 340], ["II", 346], ["/", 348], ["III", 349], ["trials", 353], [",", 359], ["empagliflozin", 361], ["reduced", 375], ["hyperglycemia", 383], [",", 396], ["body", 398], ["weight", 403], ["and", 410], ["blood", 414], ["pressure", 420], [",", 428], ["with", 430], ["a", 435], ["low", 437], ["incidence", 441], ["of", 451], ["hypoglycemia", 454], [".", 466], ["The", 468], ["aim", 472], ["of", 476], ["this", 479], ["Phase", 484], ["III", 490], ["study", 494], ["is", 500], ["to", 503], ["compare", 506], ["the", 514], ["effects", 518], ["of", 526], ["empagliflozin", 529], ["and", 543], ["the", 547], ["SU", 551], ["glimepiride", 554], ["as", 566], ["second", 569], ["-", 575], ["line", 576], ["therapy", 581], ["in", 589], ["patients", 592], ["with", 601], ["T2DM", 606], ["inadequately", 611], ["controlled", 624], ["with", 635], ["metformin", 640], ["immediate", 650], ["release", 660], ["(", 668], ["IR", 669], [")", 671], ["and", 673], ["diet", 677], ["/", 681], ["exercise", 682], [".", 690], ["After", 692], ["a", 698], ["2-week", 700], ["placebo", 707], ["run", 715], ["-", 718], ["in", 719], [",", 721], ["patients", 723], ["were", 732], ["randomized", 737], ["to", 748], ["receive", 751], ["empagliflozin", 759], ["25", 773], ["mg", 776], ["once", 779], ["daily", 784], ["(", 790], ["qd", 791], [")", 793], ["or", 795], ["glimepiride", 798], ["1", 810], ["-", 811], ["4", 812], ["mg", 814], ["qd", 817], ["double", 820], ["-", 826], ["blind", 827], ["for", 833], ["2", 837], ["years", 839], [",", 844], ["in", 846], ["addition", 849], ["to", 858], ["metformin", 861], ["IR", 871], [".", 873], ["Patients", 875], ["who", 884], ["participate", 888], ["in", 900], ["the", 903], ["initial", 907], ["2-year", 915], ["randomization", 922], ["period", 936], ["will", 943], ["be", 948], ["eligible", 951], ["for", 960], ["a", 964], ["2-year", 966], ["double", 973], ["-", 979], ["blind", 980], ["extension", 986], [".", 995], ["The", 997], ["primary", 1001], ["endpoint", 1009], ["is", 1018], ["change", 1021], ["from", 1028], ["baseline", 1033], ["in", 1042], ["HbA1c", 1045], [".", 1050], ["Secondary", 1052], ["endpoints", 1062], ["are", 1072], ["change", 1076], ["from", 1083], ["baseline", 1088], ["in", 1097], ["body", 1100], ["weight", 1105], [",", 1111], ["the", 1113], ["incidence", 1117], ["of", 1127], ["confirmed", 1130], ["hypoglycemia", 1140], ["and", 1153], ["changes", 1157], ["in", 1165], ["systolic", 1168], ["and", 1177], ["diastolic", 1181], ["blood", 1191], ["pressure", 1197], [".", 1205], ["Exploratory", 1207], ["endpoints", 1219], ["include", 1229], ["markers", 1237], ["of", 1245], ["insulin", 1248], ["secretion", 1256], [",", 1265], ["body", 1267], ["composition", 1272], ["and", 1284], ["responder", 1288], ["analyses", 1298], [".", 1306], ["Safety", 1308], ["endpoints", 1315], ["include", 1325], ["the", 1333], ["incidence", 1337], ["of", 1347], ["adverse", 1350], ["events", 1358], ["(", 1365], ["AEs", 1366], [")", 1369], ["(", 1371], ["including", 1372], ["macro-", 1382], ["and", 1389], ["microvascular", 1393], ["adverse", 1407], ["events", 1415], [")", 1421], ["and", 1423], ["changes", 1427], ["from", 1435], ["baseline", 1440], ["in", 1449], ["clinical", 1452], ["laboratory", 1461], ["parameters", 1472], [".", 1482], ["Between", 1484], ["August", 1492], ["2010", 1499], ["and", 1504], ["June", 1508], ["2011", 1513], [",", 1517], ["1549", 1519], ["patients", 1524], ["were", 1533], ["randomized", 1538], ["and", 1549], ["1545", 1553], ["patients", 1558], ["were", 1567], ["treated", 1572], [".", 1579], ["At", 1581], ["baseline", 1584], [",", 1592], ["mean", 1594], ["(", 1599], ["SD", 1600], [")", 1602], ["age", 1604], ["was", 1608], ["55.9", 1612], ["(", 1617], ["10.4", 1618], [")", 1622], ["years", 1624], [",", 1629], ["HbA1c", 1631], ["was", 1637], ["7.92", 1641], ["(", 1646], ["0.84)%", 1647], [",", 1653], ["body", 1655], ["mass", 1660], ["index", 1665], ["was", 1671], ["30.11", 1675], ["(", 1681], ["5.59", 1682], [")", 1686], ["kg", 1688], ["/", 1690], ["m\u00b2", 1691], [",", 1693], ["systolic", 1695], ["blood", 1704], ["pressure", 1710], ["was", 1719], ["133.5", 1723], ["(", 1729], ["15.9", 1730], [")", 1734], ["mmHg", 1736], ["and", 1741], ["diastolic", 1745], ["blood", 1755], ["pressure", 1761], ["was", 1770], ["79.5", 1774], ["(", 1779], ["9.4", 1780], [")", 1783], ["mmHg", 1785], [".", 1789], ["This", 1791], ["is", 1796], ["the", 1799], ["largest", 1803], ["study", 1811], ["to", 1817], ["compare", 1820], ["the", 1828], ["efficacy", 1832], ["and", 1841], ["safety", 1845], ["of", 1852], ["an", 1855], ["SGLT2", 1858], ["inhibitor", 1864], ["with", 1874], ["an", 1879], ["SU", 1882], ["in", 1885], ["patients", 1888], ["with", 1897], ["T2DM", 1902], ["inadequately", 1907], ["controlled", 1920], ["on", 1931], ["metformin", 1934], ["to", 1944], ["date", 1947], [".", 1951], ["In", 1953], ["addition", 1956], ["to", 1965], ["determining", 1968], ["the", 1980], ["effects", 1984], ["of", 1992], ["these", 1995], ["treatments", 2001], ["on", 2012], ["glycemic", 2015], ["control", 2024], ["over", 2032], ["the", 2037], ["long", 2041], ["term", 2046], [",", 2050], ["this", 2052], ["study", 2057], ["will", 2063], ["investigate", 2068], ["effects", 2080], ["on", 2088], ["beta", 2091], ["-", 2095], ["cell", 2096], ["function", 2101], [",", 2109], ["cardiovascular", 2111], ["risk", 2126], ["factors", 2131], ["and", 2139], ["markers", 2143], ["of", 2151], ["renal", 2154], ["function", 2160], ["/", 2168], ["damage", 2169], [".", 2175], ["The", 2177], ["results", 2181], ["will", 2189], ["help", 2194], ["to", 2199], ["inform", 2202], ["the", 2209], ["choice", 2213], ["of", 2220], ["second", 2223], ["-", 2229], ["line", 2230], ["treatment", 2235], ["in", 2245], ["patients", 2248], ["with", 2257], ["T2DM", 2262], ["who", 2267], ["have", 2271], ["failed", 2276], ["on", 2283], ["metformin", 2286], [".", 2295], ["Clinicaltrials.gov", 2297], ["NCT01167881", 2316], [".", 2327]]}
{"context": "A 45-year-old man developed chorea, behavioural changes, moderate amyotrophy and polyneuropathy. Hypertrophic cardiomyopathy and increased serum lactate dehydrogenase and creatine kinase (CK) were found. Acanthocytes were not detected. The absence of XK protein and faintly expressed Kell antigens on erythrocytes were found. Genetic test revealed a R133X mutation of the XK gene, confirming the McLeod syndrome. After 7 years he suddenly developed delirium followed by severe hypoglycaemia, hyperthermia, rhabdomyolysis, hepatic and renal failure. Malignant arrhythmia caused death.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "b5b0517d354847768bfb0266b7052a80", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[60, 60], [40, 40]], "char_spans": [[372, 373], [251, 252]]}]}], "context_tokens": [["A", 0], ["45-year", 2], ["-", 9], ["old", 10], ["man", 14], ["developed", 18], ["chorea", 28], [",", 34], ["behavioural", 36], ["changes", 48], [",", 55], ["moderate", 57], ["amyotrophy", 66], ["and", 77], ["polyneuropathy", 81], [".", 95], ["Hypertrophic", 97], ["cardiomyopathy", 110], ["and", 125], ["increased", 129], ["serum", 139], ["lactate", 145], ["dehydrogenase", 153], ["and", 167], ["creatine", 171], ["kinase", 180], ["(", 187], ["CK", 188], [")", 190], ["were", 192], ["found", 197], [".", 202], ["Acanthocytes", 204], ["were", 217], ["not", 222], ["detected", 226], [".", 234], ["The", 236], ["absence", 240], ["of", 248], ["XK", 251], ["protein", 254], ["and", 262], ["faintly", 266], ["expressed", 274], ["Kell", 284], ["antigens", 289], ["on", 298], ["erythrocytes", 301], ["were", 314], ["found", 319], [".", 324], ["Genetic", 326], ["test", 334], ["revealed", 339], ["a", 348], ["R133X", 350], ["mutation", 356], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["confirming", 381], ["the", 392], ["McLeod", 396], ["syndrome", 403], [".", 411], ["After", 413], ["7", 419], ["years", 421], ["he", 427], ["suddenly", 430], ["developed", 439], ["delirium", 449], ["followed", 458], ["by", 467], ["severe", 470], ["hypoglycaemia", 477], [",", 490], ["hyperthermia", 492], [",", 504], ["rhabdomyolysis", 506], [",", 520], ["hepatic", 522], ["and", 530], ["renal", 534], ["failure", 540], [".", 547], ["Malignant", 549], ["arrhythmia", 559], ["caused", 570], ["death", 577], [".", 582]]}
{"context": "Previous studies have suggested a link between heart rate (HR) following trauma and the development of posttraumatic stress disorder (PTSD). This study expands on previous work by evaluating HR in burn patients followed longitudinally for symptoms of acute stress disorder (ASD) and PTSD. Data were collected from consecutive patients admitted to the Johns Hopkins Burn Center, Baltimore, Maryland, between 1997 and 2002. Patients completed the Stanford Acute Stress Reaction Questionnaire (n = 157) to assess symptoms of ASD. The Davidson Trauma Scale was completed at 1 (n = 145), 6 (n = 106), 12 (n = 94), and 24 (n = 66) months postdischarge to assess symptoms of PTSD. Heart rate in the ambulance, emergency room, and burn unit were obtained by retrospective medical chart review. Pearson correlations revealed a significant relationship between HR in the ambulance (r = 0.32, P = .016) and burn unit (r = 0.30, P = .001) and ASD scores at baseline. Heart rate in the ambulance was related to PTSD avoidance cluster scores at 1, 6, 12, and 24 months. In women, HR in the ambulance was correlated with PTSD scores at 6 (r = 0.65, P = .005) and 12 (r = 0.78, P = .005) months. When covariates (gender, \u03b2-blockers, Brief Symptom Inventory Global Severity Index score) were included in multivariate linear regression analyses, ambulance HR was associated with ASD and PTSD scores at baseline and 1 month, and the interaction of ambulance HR and gender was associated with PTSD scores at 6 and 12 months. Multivariate logistic regression results were similar at baseline and 12 months, which included an HR association yet no interaction at 6 months and a marginal interaction at 1 month. While peritraumatic HR is most robustly associated with PTSD symptom severity, HR on admission to burn unit also predicts the development of ASD. Gender and avoidance symptoms appear particularly salient in this relationship, and these factors may aid in the identification of subgroups for which HR serves as a biomarker for PTSD. Future work may identify endophenotypic measures of increased risk for PTSD, targeting subgroups for early intervention.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "2948595cc8ae43138ef1c66a44e17706", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[351, 351], [304, 304], [227, 227], [285, 285], [134, 134], [202, 202], [22, 22], [397, 397], [409, 409], [49, 49]], "char_spans": [[1745, 1748], [1473, 1476], [1106, 1109], [1369, 1372], [668, 671], [998, 1001], [134, 137], [2015, 2018], [2092, 2095], [283, 286]]}]}], "context_tokens": [["Previous", 0], ["studies", 9], ["have", 17], ["suggested", 22], ["a", 32], ["link", 34], ["between", 39], ["heart", 47], ["rate", 53], ["(", 58], ["HR", 59], [")", 61], ["following", 63], ["trauma", 73], ["and", 80], ["the", 84], ["development", 88], ["of", 100], ["posttraumatic", 103], ["stress", 117], ["disorder", 124], ["(", 133], ["PTSD", 134], [")", 138], [".", 139], ["This", 141], ["study", 146], ["expands", 152], ["on", 160], ["previous", 163], ["work", 172], ["by", 177], ["evaluating", 180], ["HR", 191], ["in", 194], ["burn", 197], ["patients", 202], ["followed", 211], ["longitudinally", 220], ["for", 235], ["symptoms", 239], ["of", 248], ["acute", 251], ["stress", 257], ["disorder", 264], ["(", 273], ["ASD", 274], [")", 277], ["and", 279], ["PTSD", 283], [".", 287], ["Data", 289], ["were", 294], ["collected", 299], ["from", 309], ["consecutive", 314], ["patients", 326], ["admitted", 335], ["to", 344], ["the", 347], ["Johns", 351], ["Hopkins", 357], ["Burn", 365], ["Center", 370], [",", 376], ["Baltimore", 378], [",", 387], ["Maryland", 389], [",", 397], ["between", 399], ["1997", 407], ["and", 412], ["2002", 416], [".", 420], ["Patients", 422], ["completed", 431], ["the", 441], ["Stanford", 445], ["Acute", 454], ["Stress", 460], ["Reaction", 467], ["Questionnaire", 476], ["(", 490], ["n", 491], ["=", 493], ["157", 495], [")", 498], ["to", 500], ["assess", 503], ["symptoms", 510], ["of", 519], ["ASD", 522], [".", 525], ["The", 527], ["Davidson", 531], ["Trauma", 540], ["Scale", 547], ["was", 553], ["completed", 557], ["at", 567], ["1", 570], ["(", 572], ["n", 573], ["=", 575], ["145", 577], [")", 580], [",", 581], ["6", 583], ["(", 585], ["n", 586], ["=", 588], ["106", 590], [")", 593], [",", 594], ["12", 596], ["(", 599], ["n", 600], ["=", 602], ["94", 604], [")", 606], [",", 607], ["and", 609], ["24", 613], ["(", 616], ["n", 617], ["=", 619], ["66", 621], [")", 623], ["months", 625], ["postdischarge", 632], ["to", 646], ["assess", 649], ["symptoms", 656], ["of", 665], ["PTSD", 668], [".", 672], ["Heart", 674], ["rate", 680], ["in", 685], ["the", 688], ["ambulance", 692], [",", 701], ["emergency", 703], ["room", 713], [",", 717], ["and", 719], ["burn", 723], ["unit", 728], ["were", 733], ["obtained", 738], ["by", 747], ["retrospective", 750], ["medical", 764], ["chart", 772], ["review", 778], [".", 784], ["Pearson", 786], ["correlations", 794], ["revealed", 807], ["a", 816], ["significant", 818], ["relationship", 830], ["between", 843], ["HR", 851], ["in", 854], ["the", 857], ["ambulance", 861], ["(", 871], ["r", 872], ["=", 874], ["0.32", 876], [",", 880], ["P", 882], ["=", 884], [".016", 886], [")", 890], ["and", 892], ["burn", 896], ["unit", 901], ["(", 906], ["r", 907], ["=", 909], ["0.30", 911], [",", 915], ["P", 917], ["=", 919], [".001", 921], [")", 925], ["and", 927], ["ASD", 931], ["scores", 935], ["at", 942], ["baseline", 945], [".", 953], ["Heart", 955], ["rate", 961], ["in", 966], ["the", 969], ["ambulance", 973], ["was", 983], ["related", 987], ["to", 995], ["PTSD", 998], ["avoidance", 1003], ["cluster", 1013], ["scores", 1021], ["at", 1028], ["1", 1031], [",", 1032], ["6", 1034], [",", 1035], ["12", 1037], [",", 1039], ["and", 1041], ["24", 1045], ["months", 1048], [".", 1054], ["In", 1056], ["women", 1059], [",", 1064], ["HR", 1066], ["in", 1069], ["the", 1072], ["ambulance", 1076], ["was", 1086], ["correlated", 1090], ["with", 1101], ["PTSD", 1106], ["scores", 1111], ["at", 1118], ["6", 1121], ["(", 1123], ["r", 1124], ["=", 1126], ["0.65", 1128], [",", 1132], ["P", 1134], ["=", 1136], [".005", 1138], [")", 1142], ["and", 1144], ["12", 1148], ["(", 1151], ["r", 1152], ["=", 1154], ["0.78", 1156], [",", 1160], ["P", 1162], ["=", 1164], [".005", 1166], [")", 1170], ["months", 1172], [".", 1178], ["When", 1180], ["covariates", 1185], ["(", 1196], ["gender", 1197], [",", 1203], ["\u03b2", 1205], ["-", 1206], ["blockers", 1207], [",", 1215], ["Brief", 1217], ["Symptom", 1223], ["Inventory", 1231], ["Global", 1241], ["Severity", 1248], ["Index", 1257], ["score", 1263], [")", 1268], ["were", 1270], ["included", 1275], ["in", 1284], ["multivariate", 1287], ["linear", 1300], ["regression", 1307], ["analyses", 1318], [",", 1326], ["ambulance", 1328], ["HR", 1338], ["was", 1341], ["associated", 1345], ["with", 1356], ["ASD", 1361], ["and", 1365], ["PTSD", 1369], ["scores", 1374], ["at", 1381], ["baseline", 1384], ["and", 1393], ["1", 1397], ["month", 1399], [",", 1404], ["and", 1406], ["the", 1410], ["interaction", 1414], ["of", 1426], ["ambulance", 1429], ["HR", 1439], ["and", 1442], ["gender", 1446], ["was", 1453], ["associated", 1457], ["with", 1468], ["PTSD", 1473], ["scores", 1478], ["at", 1485], ["6", 1488], ["and", 1490], ["12", 1494], ["months", 1497], [".", 1503], ["Multivariate", 1505], ["logistic", 1518], ["regression", 1527], ["results", 1538], ["were", 1546], ["similar", 1551], ["at", 1559], ["baseline", 1562], ["and", 1571], ["12", 1575], ["months", 1578], [",", 1584], ["which", 1586], ["included", 1592], ["an", 1601], ["HR", 1604], ["association", 1607], ["yet", 1619], ["no", 1623], ["interaction", 1626], ["at", 1638], ["6", 1641], ["months", 1643], ["and", 1650], ["a", 1654], ["marginal", 1656], ["interaction", 1665], ["at", 1677], ["1", 1680], ["month", 1682], [".", 1687], ["While", 1689], ["peritraumatic", 1695], ["HR", 1709], ["is", 1712], ["most", 1715], ["robustly", 1720], ["associated", 1729], ["with", 1740], ["PTSD", 1745], ["symptom", 1750], ["severity", 1758], [",", 1766], ["HR", 1768], ["on", 1771], ["admission", 1774], ["to", 1784], ["burn", 1787], ["unit", 1792], ["also", 1797], ["predicts", 1802], ["the", 1811], ["development", 1815], ["of", 1827], ["ASD", 1830], [".", 1833], ["Gender", 1835], ["and", 1842], ["avoidance", 1846], ["symptoms", 1856], ["appear", 1865], ["particularly", 1872], ["salient", 1885], ["in", 1893], ["this", 1896], ["relationship", 1901], [",", 1913], ["and", 1915], ["these", 1919], ["factors", 1925], ["may", 1933], ["aid", 1937], ["in", 1941], ["the", 1944], ["identification", 1948], ["of", 1963], ["subgroups", 1966], ["for", 1976], ["which", 1980], ["HR", 1986], ["serves", 1989], ["as", 1996], ["a", 1999], ["biomarker", 2001], ["for", 2011], ["PTSD", 2015], [".", 2019], ["Future", 2021], ["work", 2028], ["may", 2033], ["identify", 2037], ["endophenotypic", 2046], ["measures", 2061], ["of", 2070], ["increased", 2073], ["risk", 2083], ["for", 2088], ["PTSD", 2092], [",", 2096], ["targeting", 2098], ["subgroups", 2108], ["for", 2118], ["early", 2122], ["intervention", 2128], [".", 2140]]}
{"context": "To explore potential therapeutic strategies for interrupting the interleukin-6 (IL-6) signaling pathway, we measured IL-6 expression in ovarian cancer tissues, and evaluated the effects of a monoclonal anti-IL-6 antibody; siltuximab (CNTO 328), on levels of IL-6-induced Stat3 phosphorylation, Stat3 nuclear translocation, and Stat3 downstream antiapoptotic genes. We then looked for enhancing paclitaxel sensitivity in multidrug-resistant ovarian cancer cell lines. Expressions of IL-6 in ovarian cancer patient specimens were assessed by immunohistochemistry. Effects of siltuximab on IL-6-induced activation of Stat3 in an ovarian cancer cell line were determined by Western blot and real-time analysis of Stat3 nucleocytoplasmic translocation. Influence of combination of siltuximab and paclitaxel on tumor growth was evaluated in a xenograft mouse mode in vivo. Metastatic and drug-resistant recurrent tumors have significantly higher IL-6 expression when compared with the matched primary tumors. Siltuximab specifically suppressed IL-6-induced Stat3 phosphorylation and Stat3 nuclear translocation. Treatment with siltuximab significantly decreased the levels of Stat3 downstream proteins such as MCL-1, Bcl-X(L), and survivin. Treatment with siltuximab reduced expression of multiple IL-6-induced genes in these cell lines. Furthermore, siltuximab increased the cytotoxic effects of paclitaxel in a paclitaxel resistant ovarian cancer cell line in vitro, but combination therapy with siltuximab did not have a significant effect on paclitaxel resistant tumor growth in vivo. These results show that siltuximab effectively block the IL-6 signaling pathways and IL-6-induced gene expression. Blockage of IL-6 signaling may provide benefits for the treatment of ovarian cancer.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "7a2e176738494125886c80681e52a70e", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[8, 8]], "char_spans": [[65, 77]]}]}], "context_tokens": [["To", 0], ["explore", 3], ["potential", 11], ["therapeutic", 21], ["strategies", 33], ["for", 44], ["interrupting", 48], ["the", 61], ["interleukin-6", 65], ["(", 79], ["IL-6", 80], [")", 84], ["signaling", 86], ["pathway", 96], [",", 103], ["we", 105], ["measured", 108], ["IL-6", 117], ["expression", 122], ["in", 133], ["ovarian", 136], ["cancer", 144], ["tissues", 151], [",", 158], ["and", 160], ["evaluated", 164], ["the", 174], ["effects", 178], ["of", 186], ["a", 189], ["monoclonal", 191], ["anti", 202], ["-", 206], ["IL-6", 207], ["antibody", 212], [";", 220], ["siltuximab", 222], ["(", 233], ["CNTO", 234], ["328", 239], [")", 242], [",", 243], ["on", 245], ["levels", 248], ["of", 255], ["IL-6-induced", 258], ["Stat3", 271], ["phosphorylation", 277], [",", 292], ["Stat3", 294], ["nuclear", 300], ["translocation", 308], [",", 321], ["and", 323], ["Stat3", 327], ["downstream", 333], ["antiapoptotic", 344], ["genes", 358], [".", 363], ["We", 365], ["then", 368], ["looked", 373], ["for", 380], ["enhancing", 384], ["paclitaxel", 394], ["sensitivity", 405], ["in", 417], ["multidrug", 420], ["-", 429], ["resistant", 430], ["ovarian", 440], ["cancer", 448], ["cell", 455], ["lines", 460], [".", 465], ["Expressions", 467], ["of", 479], ["IL-6", 482], ["in", 487], ["ovarian", 490], ["cancer", 498], ["patient", 505], ["specimens", 513], ["were", 523], ["assessed", 528], ["by", 537], ["immunohistochemistry", 540], [".", 560], ["Effects", 562], ["of", 570], ["siltuximab", 573], ["on", 584], ["IL-6-induced", 587], ["activation", 600], ["of", 611], ["Stat3", 614], ["in", 620], ["an", 623], ["ovarian", 626], ["cancer", 634], ["cell", 641], ["line", 646], ["were", 651], ["determined", 656], ["by", 667], ["Western", 670], ["blot", 678], ["and", 683], ["real", 687], ["-", 691], ["time", 692], ["analysis", 697], ["of", 706], ["Stat3", 709], ["nucleocytoplasmic", 715], ["translocation", 733], [".", 746], ["Influence", 748], ["of", 758], ["combination", 761], ["of", 773], ["siltuximab", 776], ["and", 787], ["paclitaxel", 791], ["on", 802], ["tumor", 805], ["growth", 811], ["was", 818], ["evaluated", 822], ["in", 832], ["a", 835], ["xenograft", 837], ["mouse", 847], ["mode", 853], ["in", 858], ["vivo", 861], [".", 865], ["Metastatic", 867], ["and", 878], ["drug", 882], ["-", 886], ["resistant", 887], ["recurrent", 897], ["tumors", 907], ["have", 914], ["significantly", 919], ["higher", 933], ["IL-6", 940], ["expression", 945], ["when", 956], ["compared", 961], ["with", 970], ["the", 975], ["matched", 979], ["primary", 987], ["tumors", 995], [".", 1001], ["Siltuximab", 1003], ["specifically", 1014], ["suppressed", 1027], ["IL-6-induced", 1038], ["Stat3", 1051], ["phosphorylation", 1057], ["and", 1073], ["Stat3", 1077], ["nuclear", 1083], ["translocation", 1091], [".", 1104], ["Treatment", 1106], ["with", 1116], ["siltuximab", 1121], ["significantly", 1132], ["decreased", 1146], ["the", 1156], ["levels", 1160], ["of", 1167], ["Stat3", 1170], ["downstream", 1176], ["proteins", 1187], ["such", 1196], ["as", 1201], ["MCL-1", 1204], [",", 1209], ["Bcl", 1211], ["-", 1214], ["X(L", 1215], [")", 1218], [",", 1219], ["and", 1221], ["survivin", 1225], [".", 1233], ["Treatment", 1235], ["with", 1245], ["siltuximab", 1250], ["reduced", 1261], ["expression", 1269], ["of", 1280], ["multiple", 1283], ["IL-6-induced", 1292], ["genes", 1305], ["in", 1311], ["these", 1314], ["cell", 1320], ["lines", 1325], [".", 1330], ["Furthermore", 1332], [",", 1343], ["siltuximab", 1345], ["increased", 1356], ["the", 1366], ["cytotoxic", 1370], ["effects", 1380], ["of", 1388], ["paclitaxel", 1391], ["in", 1402], ["a", 1405], ["paclitaxel", 1407], ["resistant", 1418], ["ovarian", 1428], ["cancer", 1436], ["cell", 1443], ["line", 1448], ["in", 1453], ["vitro", 1456], [",", 1461], ["but", 1463], ["combination", 1467], ["therapy", 1479], ["with", 1487], ["siltuximab", 1492], ["did", 1503], ["not", 1507], ["have", 1511], ["a", 1516], ["significant", 1518], ["effect", 1530], ["on", 1537], ["paclitaxel", 1540], ["resistant", 1551], ["tumor", 1561], ["growth", 1567], ["in", 1574], ["vivo", 1577], [".", 1581], ["These", 1583], ["results", 1589], ["show", 1597], ["that", 1602], ["siltuximab", 1607], ["effectively", 1618], ["block", 1630], ["the", 1636], ["IL-6", 1640], ["signaling", 1645], ["pathways", 1655], ["and", 1664], ["IL-6-induced", 1668], ["gene", 1681], ["expression", 1686], [".", 1696], ["Blockage", 1698], ["of", 1707], ["IL-6", 1710], ["signaling", 1715], ["may", 1725], ["provide", 1729], ["benefits", 1737], ["for", 1746], ["the", 1750], ["treatment", 1754], ["of", 1764], ["ovarian", 1767], ["cancer", 1775], [".", 1781]]}
{"context": "The histone variant H2A.Z is a universal mark of gene promoters, enhancers, and regulatory elements in eukaryotic chromatin. The chromatin remodeler SWR1 mediates site-specific incorporation of H2A.Z by a multi-step histone replacement reaction, evicting histone H2A-H2B from the canonical nucleosome and depositing the H2A.Z-H2B dimer. Binding of both substrates, the canonical nucleosome and the H2A.Z-H2B dimer, is essential for activation of SWR1. We found that SWR1 primarily recognizes key residues within the \u03b12 helix in the histone-fold of nucleosomal histone H2A, a region not previously known to influence remodeler activity. Moreover, SWR1 interacts preferentially with nucleosomal DNA at superhelix location 2 on the nucleosome face distal to its linker-binding site. Our findings provide new molecular insights on recognition of the canonical nucleosome by a chromatin remodeler and have implications for ATP-driven mechanisms of histone eviction and deposition.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "8ab88165ae80445089f0dcaa4d7d2e0e", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[114, 114], [24, 24], [83, 83], [78, 78]], "char_spans": [[646, 649], [149, 152], [466, 469], [446, 449]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2A.Z", 20], ["is", 26], ["a", 29], ["universal", 31], ["mark", 41], ["of", 46], ["gene", 49], ["promoters", 54], [",", 63], ["enhancers", 65], [",", 74], ["and", 76], ["regulatory", 80], ["elements", 91], ["in", 100], ["eukaryotic", 103], ["chromatin", 114], [".", 123], ["The", 125], ["chromatin", 129], ["remodeler", 139], ["SWR1", 149], ["mediates", 154], ["site", 163], ["-", 167], ["specific", 168], ["incorporation", 177], ["of", 191], ["H2A.Z", 194], ["by", 200], ["a", 203], ["multi", 205], ["-", 210], ["step", 211], ["histone", 216], ["replacement", 224], ["reaction", 236], [",", 244], ["evicting", 246], ["histone", 255], ["H2A", 263], ["-", 266], ["H2B", 267], ["from", 271], ["the", 276], ["canonical", 280], ["nucleosome", 290], ["and", 301], ["depositing", 305], ["the", 316], ["H2A.Z", 320], ["-", 325], ["H2B", 326], ["dimer", 330], [".", 335], ["Binding", 337], ["of", 345], ["both", 348], ["substrates", 353], [",", 363], ["the", 365], ["canonical", 369], ["nucleosome", 379], ["and", 390], ["the", 394], ["H2A.Z", 398], ["-", 403], ["H2B", 404], ["dimer", 408], [",", 413], ["is", 415], ["essential", 418], ["for", 428], ["activation", 432], ["of", 443], ["SWR1", 446], [".", 450], ["We", 452], ["found", 455], ["that", 461], ["SWR1", 466], ["primarily", 471], ["recognizes", 481], ["key", 492], ["residues", 496], ["within", 505], ["the", 512], ["\u03b12", 516], ["helix", 519], ["in", 525], ["the", 528], ["histone", 532], ["-", 539], ["fold", 540], ["of", 545], ["nucleosomal", 548], ["histone", 560], ["H2A", 568], [",", 571], ["a", 573], ["region", 575], ["not", 582], ["previously", 586], ["known", 597], ["to", 603], ["influence", 606], ["remodeler", 616], ["activity", 626], [".", 634], ["Moreover", 636], [",", 644], ["SWR1", 646], ["interacts", 651], ["preferentially", 661], ["with", 676], ["nucleosomal", 681], ["DNA", 693], ["at", 697], ["superhelix", 700], ["location", 711], ["2", 720], ["on", 722], ["the", 725], ["nucleosome", 729], ["face", 740], ["distal", 745], ["to", 752], ["its", 755], ["linker", 759], ["-", 765], ["binding", 766], ["site", 774], [".", 778], ["Our", 780], ["findings", 784], ["provide", 793], ["new", 801], ["molecular", 805], ["insights", 815], ["on", 824], ["recognition", 827], ["of", 839], ["the", 842], ["canonical", 846], ["nucleosome", 856], ["by", 867], ["a", 870], ["chromatin", 872], ["remodeler", 882], ["and", 892], ["have", 896], ["implications", 901], ["for", 914], ["ATP", 918], ["-", 921], ["driven", 922], ["mechanisms", 929], ["of", 940], ["histone", 943], ["eviction", 951], ["and", 960], ["deposition", 964], [".", 974]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common form of familial vascular dementia, is caused by mutations of the NOTCH3 gene. Approximately two hundred pathogenic mutations have been reported within five exons (exons 3, 4, 6, 11 and 19) which accounted for 78% of known mutations in worldwide series. We reported twenty-one NOTCH3 pathogenic mutations (including five novel ones) identified in 53 index Italian patients. Exons 4 (28%), 7 (21%) and 19 (24%) were the most frequently involved. To dissect genetic heterogeneity, we analyzed five haplotyped tagging single nucleotide polymorphisms (rs1044009, rs4809030, rs10426042, rs10423702 and rs3815188) in 95 patients, 39 unaffected pedigree members and 50 healthy controls. SNPs were analyzed using the Illumina VeraCode Universal Capture Beads technology by Allele Specific Primer Extension (ASPE). We identified ten different haplotypes named H1-H10; H1 was the most common haplotype in patients and controls and it was associated with at least twelve out of the twenty-one mutations. Detected mutations were not associated to specific haplotypes while genotyping was compatible with a possible founder effect for the novel p.S396C mutation which clustered in a restricted geographical area of northeast Italy. The results added on to the genetic heterogeneity of CADASIL and emphasized difficulties in designing algorithms for molecular diagnosis.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "33f0175a3dd1410a979d8698198ca39b", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[28, 29]], "char_spans": [[184, 194]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], [",", 100], ["the", 102], ["most", 106], ["common", 111], ["form", 118], ["of", 123], ["familial", 126], ["vascular", 135], ["dementia", 144], [",", 152], ["is", 154], ["caused", 157], ["by", 164], ["mutations", 167], ["of", 177], ["the", 180], ["NOTCH3", 184], ["gene", 191], [".", 195], ["Approximately", 197], ["two", 211], ["hundred", 215], ["pathogenic", 223], ["mutations", 234], ["have", 244], ["been", 249], ["reported", 254], ["within", 263], ["five", 270], ["exons", 275], ["(", 281], ["exons", 282], ["3", 288], [",", 289], ["4", 291], [",", 292], ["6", 294], [",", 295], ["11", 297], ["and", 300], ["19", 304], [")", 306], ["which", 308], ["accounted", 314], ["for", 324], ["78", 328], ["%", 330], ["of", 332], ["known", 335], ["mutations", 341], ["in", 351], ["worldwide", 354], ["series", 364], [".", 370], ["We", 372], ["reported", 375], ["twenty", 384], ["-", 390], ["one", 391], ["NOTCH3", 395], ["pathogenic", 402], ["mutations", 413], ["(", 423], ["including", 424], ["five", 434], ["novel", 439], ["ones", 445], [")", 449], ["identified", 451], ["in", 462], ["53", 465], ["index", 468], ["Italian", 474], ["patients", 482], [".", 490], ["Exons", 492], ["4", 498], ["(", 500], ["28", 501], ["%", 503], [")", 504], [",", 505], ["7", 507], ["(", 509], ["21", 510], ["%", 512], [")", 513], ["and", 515], ["19", 519], ["(", 522], ["24", 523], ["%", 525], [")", 526], ["were", 528], ["the", 533], ["most", 537], ["frequently", 542], ["involved", 553], [".", 561], ["To", 563], ["dissect", 566], ["genetic", 574], ["heterogeneity", 582], [",", 595], ["we", 597], ["analyzed", 600], ["five", 609], ["haplotyped", 614], ["tagging", 625], ["single", 633], ["nucleotide", 640], ["polymorphisms", 651], ["(", 665], ["rs1044009", 666], [",", 675], ["rs4809030", 677], [",", 686], ["rs10426042", 688], [",", 698], ["rs10423702", 700], ["and", 711], ["rs3815188", 715], [")", 724], ["in", 726], ["95", 729], ["patients", 732], [",", 740], ["39", 742], ["unaffected", 745], ["pedigree", 756], ["members", 765], ["and", 773], ["50", 777], ["healthy", 780], ["controls", 788], [".", 796], ["SNPs", 798], ["were", 803], ["analyzed", 808], ["using", 817], ["the", 823], ["Illumina", 827], ["VeraCode", 836], ["Universal", 845], ["Capture", 855], ["Beads", 863], ["technology", 869], ["by", 880], ["Allele", 883], ["Specific", 890], ["Primer", 899], ["Extension", 906], ["(", 916], ["ASPE", 917], [")", 921], [".", 922], ["We", 924], ["identified", 927], ["ten", 938], ["different", 942], ["haplotypes", 952], ["named", 963], ["H1-H10", 969], [";", 975], ["H1", 977], ["was", 980], ["the", 984], ["most", 988], ["common", 993], ["haplotype", 1000], ["in", 1010], ["patients", 1013], ["and", 1022], ["controls", 1026], ["and", 1035], ["it", 1039], ["was", 1042], ["associated", 1046], ["with", 1057], ["at", 1062], ["least", 1065], ["twelve", 1071], ["out", 1078], ["of", 1082], ["the", 1085], ["twenty", 1089], ["-", 1095], ["one", 1096], ["mutations", 1100], [".", 1109], ["Detected", 1111], ["mutations", 1120], ["were", 1130], ["not", 1135], ["associated", 1139], ["to", 1150], ["specific", 1153], ["haplotypes", 1162], ["while", 1173], ["genotyping", 1179], ["was", 1190], ["compatible", 1194], ["with", 1205], ["a", 1210], ["possible", 1212], ["founder", 1221], ["effect", 1229], ["for", 1236], ["the", 1240], ["novel", 1244], ["p", 1250], [".", 1251], ["S396C", 1252], ["mutation", 1258], ["which", 1267], ["clustered", 1273], ["in", 1283], ["a", 1286], ["restricted", 1288], ["geographical", 1299], ["area", 1312], ["of", 1317], ["northeast", 1320], ["Italy", 1330], [".", 1335], ["The", 1337], ["results", 1341], ["added", 1349], ["on", 1355], ["to", 1358], ["the", 1361], ["genetic", 1365], ["heterogeneity", 1373], ["of", 1387], ["CADASIL", 1390], ["and", 1398], ["emphasized", 1402], ["difficulties", 1413], ["in", 1426], ["designing", 1429], ["algorithms", 1439], ["for", 1450], ["molecular", 1454], ["diagnosis", 1464], [".", 1473]]}
{"context": "Interleukin-6 (IL-6) induces tumor growth, invasion, metastasis, and angiogenesis. Siltuximab (CNTO 328) is a chimeric, murine-human monoclonal antibody that specifically binds human IL-6 with high affinity. C-reactive protein (CRP) can be a pharmacodynamic (PD) marker of IL-6 bioactivity. Reductions in CRP may correlate with clinical activity and IL-6 bioactivity. Starting-dose selection for this study was based on a previous siltuximab study in multiple myeloma patients. Pharmacokinetic (PK)/PD modeling explored the relationship between siltuximab PK and CRP suppression following i.v. siltuximab infusion in a three-part phase I/II study in 68 metastatic renal cell carcinoma patients. Modeling results were then used to simulate and determine which siltuximab dosage regimens would maintain CRP suppression below the lower limit of quantification (4 mg/L). Siltuximab was given at 1, 3, 6, or 12 mg/kg at weeks 1 and 4 and then every 2 weeks for 2 cycles in part 1; at 3 or 6 mg/kg every 3 weeks for 4 cycles in part 2; and at 6 mg/kg every 2 weeks for 6 cycles in part 3. A two-compartment PK model adequately described the serum siltuximab concentration-time data. An inhibitory indirect response PD model examined the relationship between siltuximab concentrations and CRP suppression. PD parameter estimates seemed reliable and physiologically relevant. Simulations showed that 6 mg/kg siltuximab every 2 weeks or 9 mg/kg every 3 weeks would reduce serum CRP to below 4 mg/L. Using a stepwise design, PK/PD modeling was used to select the dose levels in this study. Furthermore, PK/PD modeling results were used to help select doses to be used in future siltuximab clinical development.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "d1b0a7f704d04ac5a1e6c189c6c46883", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["induces", 21], ["tumor", 29], ["growth", 35], [",", 41], ["invasion", 43], [",", 51], ["metastasis", 53], [",", 63], ["and", 65], ["angiogenesis", 69], [".", 81], ["Siltuximab", 83], ["(", 94], ["CNTO", 95], ["328", 100], [")", 103], ["is", 105], ["a", 108], ["chimeric", 110], [",", 118], ["murine", 120], ["-", 126], ["human", 127], ["monoclonal", 133], ["antibody", 144], ["that", 153], ["specifically", 158], ["binds", 171], ["human", 177], ["IL-6", 183], ["with", 188], ["high", 193], ["affinity", 198], [".", 206], ["C", 208], ["-", 209], ["reactive", 210], ["protein", 219], ["(", 227], ["CRP", 228], [")", 231], ["can", 233], ["be", 237], ["a", 240], ["pharmacodynamic", 242], ["(", 258], ["PD", 259], [")", 261], ["marker", 263], ["of", 270], ["IL-6", 273], ["bioactivity", 278], [".", 289], ["Reductions", 291], ["in", 302], ["CRP", 305], ["may", 309], ["correlate", 313], ["with", 323], ["clinical", 328], ["activity", 337], ["and", 346], ["IL-6", 350], ["bioactivity", 355], [".", 366], ["Starting", 368], ["-", 376], ["dose", 377], ["selection", 382], ["for", 392], ["this", 396], ["study", 401], ["was", 407], ["based", 411], ["on", 417], ["a", 420], ["previous", 422], ["siltuximab", 431], ["study", 442], ["in", 448], ["multiple", 451], ["myeloma", 460], ["patients", 468], [".", 476], ["Pharmacokinetic", 478], ["(", 494], ["PK)/PD", 495], ["modeling", 502], ["explored", 511], ["the", 520], ["relationship", 524], ["between", 537], ["siltuximab", 545], ["PK", 556], ["and", 559], ["CRP", 563], ["suppression", 567], ["following", 579], ["i.v", 589], [".", 592], ["siltuximab", 594], ["infusion", 605], ["in", 614], ["a", 617], ["three", 619], ["-", 624], ["part", 625], ["phase", 630], ["I", 636], ["/", 637], ["II", 638], ["study", 641], ["in", 647], ["68", 650], ["metastatic", 653], ["renal", 664], ["cell", 670], ["carcinoma", 675], ["patients", 685], [".", 693], ["Modeling", 695], ["results", 704], ["were", 712], ["then", 717], ["used", 722], ["to", 727], ["simulate", 730], ["and", 739], ["determine", 743], ["which", 753], ["siltuximab", 759], ["dosage", 770], ["regimens", 777], ["would", 786], ["maintain", 792], ["CRP", 801], ["suppression", 805], ["below", 817], ["the", 823], ["lower", 827], ["limit", 833], ["of", 839], ["quantification", 842], ["(", 857], ["4", 858], ["mg", 860], ["/", 862], ["L", 863], [")", 864], [".", 865], ["Siltuximab", 867], ["was", 878], ["given", 882], ["at", 888], ["1", 891], [",", 892], ["3", 894], [",", 895], ["6", 897], [",", 898], ["or", 900], ["12", 903], ["mg", 906], ["/", 908], ["kg", 909], ["at", 912], ["weeks", 915], ["1", 921], ["and", 923], ["4", 927], ["and", 929], ["then", 933], ["every", 938], ["2", 944], ["weeks", 946], ["for", 952], ["2", 956], ["cycles", 958], ["in", 965], ["part", 968], ["1", 973], [";", 974], ["at", 976], ["3", 979], ["or", 981], ["6", 984], ["mg", 986], ["/", 988], ["kg", 989], ["every", 992], ["3", 998], ["weeks", 1000], ["for", 1006], ["4", 1010], ["cycles", 1012], ["in", 1019], ["part", 1022], ["2", 1027], [";", 1028], ["and", 1030], ["at", 1034], ["6", 1037], ["mg", 1039], ["/", 1041], ["kg", 1042], ["every", 1045], ["2", 1051], ["weeks", 1053], ["for", 1059], ["6", 1063], ["cycles", 1065], ["in", 1072], ["part", 1075], ["3", 1080], [".", 1081], ["A", 1083], ["two", 1085], ["-", 1088], ["compartment", 1089], ["PK", 1101], ["model", 1104], ["adequately", 1110], ["described", 1121], ["the", 1131], ["serum", 1135], ["siltuximab", 1141], ["concentration", 1152], ["-", 1165], ["time", 1166], ["data", 1171], [".", 1175], ["An", 1177], ["inhibitory", 1180], ["indirect", 1191], ["response", 1200], ["PD", 1209], ["model", 1212], ["examined", 1218], ["the", 1227], ["relationship", 1231], ["between", 1244], ["siltuximab", 1252], ["concentrations", 1263], ["and", 1278], ["CRP", 1282], ["suppression", 1286], [".", 1297], ["PD", 1299], ["parameter", 1302], ["estimates", 1312], ["seemed", 1322], ["reliable", 1329], ["and", 1338], ["physiologically", 1342], ["relevant", 1358], [".", 1366], ["Simulations", 1368], ["showed", 1380], ["that", 1387], ["6", 1392], ["mg", 1394], ["/", 1396], ["kg", 1397], ["siltuximab", 1400], ["every", 1411], ["2", 1417], ["weeks", 1419], ["or", 1425], ["9", 1428], ["mg", 1430], ["/", 1432], ["kg", 1433], ["every", 1436], ["3", 1442], ["weeks", 1444], ["would", 1450], ["reduce", 1456], ["serum", 1463], ["CRP", 1469], ["to", 1473], ["below", 1476], ["4", 1482], ["mg", 1484], ["/", 1486], ["L.", 1487], ["Using", 1490], ["a", 1496], ["stepwise", 1498], ["design", 1507], [",", 1513], ["PK", 1515], ["/", 1517], ["PD", 1518], ["modeling", 1521], ["was", 1530], ["used", 1534], ["to", 1539], ["select", 1542], ["the", 1549], ["dose", 1553], ["levels", 1558], ["in", 1565], ["this", 1568], ["study", 1573], [".", 1578], ["Furthermore", 1580], [",", 1591], ["PK", 1593], ["/", 1595], ["PD", 1596], ["modeling", 1599], ["results", 1608], ["were", 1616], ["used", 1621], ["to", 1626], ["help", 1629], ["select", 1634], ["doses", 1641], ["to", 1647], ["be", 1650], ["used", 1653], ["in", 1658], ["future", 1661], ["siltuximab", 1668], ["clinical", 1679], ["development", 1688], [".", 1699]]}
{"context": "Increasing proteomic diversity via the hydrolytic deamination of adenosine to inosine (A-to-I) in select mRNA templates appears crucial to the correct functioning of the nervous system in several model organisms, including Drosophila, Caenorabditis elegans, and mice. The genome of the fruitfly, Drosophila melanogaster, contains a single gene encoding the enzyme responsible for deamination, termed ADAR (for adenosine deaminase acting on RNA). The mRNAs that form the substrates for ADAR primarily function in neuronal signaling, and, correspondingly, deletion of ADAR leads to severe nervous system defects. While several ADAR enzymes are present in mice, the presence of a single ADAR in Drosophila, combined with the diverse genetic toolkit available to researchers and the wide range of ADAR target mRNAs identified to date, make Drosophila an ideal organism to study the genetic basis of A-to-I RNA editing. This chapter describes a variety of methods for genetically manipulating Drosophila A-to-I editing both in time and space, as well as techniques to study the molecular basis of ADAR-mRNA interactions. A prerequisite for experiments in this field is the ability to quantify the levels of editing in a given mRNA. Therefore, several commonly used methods for the quantification of editing levels will also be described.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "5acd66116f6c494d9f3ec6bd4ba2c4c4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[107, 107], [67, 67], [84, 84], [196, 196], [119, 119], [137, 137], [97, 97]], "char_spans": [[625, 628], [400, 403], [485, 488], [1092, 1095], [684, 687], [793, 796], [566, 569]]}]}], "context_tokens": [["Increasing", 0], ["proteomic", 11], ["diversity", 21], ["via", 31], ["the", 35], ["hydrolytic", 39], ["deamination", 50], ["of", 62], ["adenosine", 65], ["to", 75], ["inosine", 78], ["(", 86], ["A", 87], ["-", 88], ["to", 89], ["-", 91], ["I", 92], [")", 93], ["in", 95], ["select", 98], ["mRNA", 105], ["templates", 110], ["appears", 120], ["crucial", 128], ["to", 136], ["the", 139], ["correct", 143], ["functioning", 151], ["of", 163], ["the", 166], ["nervous", 170], ["system", 178], ["in", 185], ["several", 188], ["model", 196], ["organisms", 202], [",", 211], ["including", 213], ["Drosophila", 223], [",", 233], ["Caenorabditis", 235], ["elegans", 249], [",", 256], ["and", 258], ["mice", 262], [".", 266], ["The", 268], ["genome", 272], ["of", 279], ["the", 282], ["fruitfly", 286], [",", 294], ["Drosophila", 296], ["melanogaster", 307], [",", 319], ["contains", 321], ["a", 330], ["single", 332], ["gene", 339], ["encoding", 344], ["the", 353], ["enzyme", 357], ["responsible", 364], ["for", 376], ["deamination", 380], [",", 391], ["termed", 393], ["ADAR", 400], ["(", 405], ["for", 406], ["adenosine", 410], ["deaminase", 420], ["acting", 430], ["on", 437], ["RNA", 440], [")", 443], [".", 444], ["The", 446], ["mRNAs", 450], ["that", 456], ["form", 461], ["the", 466], ["substrates", 470], ["for", 481], ["ADAR", 485], ["primarily", 490], ["function", 500], ["in", 509], ["neuronal", 512], ["signaling", 521], [",", 530], ["and", 532], [",", 535], ["correspondingly", 537], [",", 552], ["deletion", 554], ["of", 563], ["ADAR", 566], ["leads", 571], ["to", 577], ["severe", 580], ["nervous", 587], ["system", 595], ["defects", 602], [".", 609], ["While", 611], ["several", 617], ["ADAR", 625], ["enzymes", 630], ["are", 638], ["present", 642], ["in", 650], ["mice", 653], [",", 657], ["the", 659], ["presence", 663], ["of", 672], ["a", 675], ["single", 677], ["ADAR", 684], ["in", 689], ["Drosophila", 692], [",", 702], ["combined", 704], ["with", 713], ["the", 718], ["diverse", 722], ["genetic", 730], ["toolkit", 738], ["available", 746], ["to", 756], ["researchers", 759], ["and", 771], ["the", 775], ["wide", 779], ["range", 784], ["of", 790], ["ADAR", 793], ["target", 798], ["mRNAs", 805], ["identified", 811], ["to", 822], ["date", 825], [",", 829], ["make", 831], ["Drosophila", 836], ["an", 847], ["ideal", 850], ["organism", 856], ["to", 865], ["study", 868], ["the", 874], ["genetic", 878], ["basis", 886], ["of", 892], ["A", 895], ["-", 896], ["to", 897], ["-", 899], ["I", 900], ["RNA", 902], ["editing", 906], [".", 913], ["This", 915], ["chapter", 920], ["describes", 928], ["a", 938], ["variety", 940], ["of", 948], ["methods", 951], ["for", 959], ["genetically", 963], ["manipulating", 975], ["Drosophila", 988], ["A", 999], ["-", 1000], ["to", 1001], ["-", 1003], ["I", 1004], ["editing", 1006], ["both", 1014], ["in", 1019], ["time", 1022], ["and", 1027], ["space", 1031], [",", 1036], ["as", 1038], ["well", 1041], ["as", 1046], ["techniques", 1049], ["to", 1060], ["study", 1063], ["the", 1069], ["molecular", 1073], ["basis", 1083], ["of", 1089], ["ADAR", 1092], ["-", 1096], ["mRNA", 1097], ["interactions", 1102], [".", 1114], ["A", 1116], ["prerequisite", 1118], ["for", 1131], ["experiments", 1135], ["in", 1147], ["this", 1150], ["field", 1155], ["is", 1161], ["the", 1164], ["ability", 1168], ["to", 1176], ["quantify", 1179], ["the", 1188], ["levels", 1192], ["of", 1199], ["editing", 1202], ["in", 1210], ["a", 1213], ["given", 1215], ["mRNA", 1221], [".", 1225], ["Therefore", 1227], [",", 1236], ["several", 1238], ["commonly", 1246], ["used", 1255], ["methods", 1260], ["for", 1268], ["the", 1272], ["quantification", 1276], ["of", 1291], ["editing", 1294], ["levels", 1302], ["will", 1309], ["also", 1314], ["be", 1319], ["described", 1322], [".", 1331]]}
{"context": "Tumors of the nervous system most often occur in both children and adults as sporadic events with no family history of the disease, but they are also among the clinical manifestations of a significant number of familial cancer syndromes, including familial retinoblastoma, neurofibromatosis 1 and 2, tuberous sclerosis, and Cowden, Turcot, Li-Fraumeni and nevoid basal cell carcinoma (Gorlin) syndromes. All of these syndromes involve transmissible genetic risk resulting from loss of a functional allele, or inheritance of a structurally defective allele, of a specific gene. These genes include RB1, NF1, NF2, TSC1, TSC2, TP53, PTEN, APC, hMLH1, hPSM2, and PTCH, most of which function as tumor suppressor genes. The same genes are also observed in mutated and inactive forms, or are deleted, in tumor cells in sporadic cases of the same tumors. The nature of the mutational events that give rise to these inactivated alleles suggests a possible role of environmental mutagens in their causation. However, only external ionizing radiation at high doses is clearly established as an environmental cause of brain, nerve and meningeal tumors in humans. Transplacental carcinogenesis studies in rodents and other species emphasize the extraordinary susceptibility of the developing mammalian nervous system to carcinogenesis, but the inverse relationship of latency to dose suggests that low transplacental exposures to genotoxicants are more likely to result in brain tumors late in life, rather than in childhood. While not all neurogenic tumor-related genes in humans have similar effects in experimental rodents, genetically engineered mice (GEM) increasingly provide useful insights into the combined effects of multiple tumor suppressor genes and of gene-environment interactions in the genesis of brain tumors, especially pediatric brain tumors such as medulloblastoma.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "630e79bc6d3e43a69d8e28cfdd721151", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[105, 105]], "char_spans": [[602, 604]]}]}], "context_tokens": [["Tumors", 0], ["of", 7], ["the", 10], ["nervous", 14], ["system", 22], ["most", 29], ["often", 34], ["occur", 40], ["in", 46], ["both", 49], ["children", 54], ["and", 63], ["adults", 67], ["as", 74], ["sporadic", 77], ["events", 86], ["with", 93], ["no", 98], ["family", 101], ["history", 108], ["of", 116], ["the", 119], ["disease", 123], [",", 130], ["but", 132], ["they", 136], ["are", 141], ["also", 145], ["among", 150], ["the", 156], ["clinical", 160], ["manifestations", 169], ["of", 184], ["a", 187], ["significant", 189], ["number", 201], ["of", 208], ["familial", 211], ["cancer", 220], ["syndromes", 227], [",", 236], ["including", 238], ["familial", 248], ["retinoblastoma", 257], [",", 271], ["neurofibromatosis", 273], ["1", 291], ["and", 293], ["2", 297], [",", 298], ["tuberous", 300], ["sclerosis", 309], [",", 318], ["and", 320], ["Cowden", 324], [",", 330], ["Turcot", 332], [",", 338], ["Li", 340], ["-", 342], ["Fraumeni", 343], ["and", 352], ["nevoid", 356], ["basal", 363], ["cell", 369], ["carcinoma", 374], ["(", 384], ["Gorlin", 385], [")", 391], ["syndromes", 393], [".", 402], ["All", 404], ["of", 408], ["these", 411], ["syndromes", 417], ["involve", 427], ["transmissible", 435], ["genetic", 449], ["risk", 457], ["resulting", 462], ["from", 472], ["loss", 477], ["of", 482], ["a", 485], ["functional", 487], ["allele", 498], [",", 504], ["or", 506], ["inheritance", 509], ["of", 521], ["a", 524], ["structurally", 526], ["defective", 539], ["allele", 549], [",", 555], ["of", 557], ["a", 560], ["specific", 562], ["gene", 571], [".", 575], ["These", 577], ["genes", 583], ["include", 589], ["RB1", 597], [",", 600], ["NF1", 602], [",", 605], ["NF2", 607], [",", 610], ["TSC1", 612], [",", 616], ["TSC2", 618], [",", 622], ["TP53", 624], [",", 628], ["PTEN", 630], [",", 634], ["APC", 636], [",", 639], ["hMLH1", 641], [",", 646], ["hPSM2", 648], [",", 653], ["and", 655], ["PTCH", 659], [",", 663], ["most", 665], ["of", 670], ["which", 673], ["function", 679], ["as", 688], ["tumor", 691], ["suppressor", 697], ["genes", 708], [".", 713], ["The", 715], ["same", 719], ["genes", 724], ["are", 730], ["also", 734], ["observed", 739], ["in", 748], ["mutated", 751], ["and", 759], ["inactive", 763], ["forms", 772], [",", 777], ["or", 779], ["are", 782], ["deleted", 786], [",", 793], ["in", 795], ["tumor", 798], ["cells", 804], ["in", 810], ["sporadic", 813], ["cases", 822], ["of", 828], ["the", 831], ["same", 835], ["tumors", 840], [".", 846], ["The", 848], ["nature", 852], ["of", 859], ["the", 862], ["mutational", 866], ["events", 877], ["that", 884], ["give", 889], ["rise", 894], ["to", 899], ["these", 902], ["inactivated", 908], ["alleles", 920], ["suggests", 928], ["a", 937], ["possible", 939], ["role", 948], ["of", 953], ["environmental", 956], ["mutagens", 970], ["in", 979], ["their", 982], ["causation", 988], [".", 997], ["However", 999], [",", 1006], ["only", 1008], ["external", 1013], ["ionizing", 1022], ["radiation", 1031], ["at", 1041], ["high", 1044], ["doses", 1049], ["is", 1055], ["clearly", 1058], ["established", 1066], ["as", 1078], ["an", 1081], ["environmental", 1084], ["cause", 1098], ["of", 1104], ["brain", 1107], [",", 1112], ["nerve", 1114], ["and", 1120], ["meningeal", 1124], ["tumors", 1134], ["in", 1141], ["humans", 1144], [".", 1150], ["Transplacental", 1152], ["carcinogenesis", 1167], ["studies", 1182], ["in", 1190], ["rodents", 1193], ["and", 1201], ["other", 1205], ["species", 1211], ["emphasize", 1219], ["the", 1229], ["extraordinary", 1233], ["susceptibility", 1247], ["of", 1262], ["the", 1265], ["developing", 1269], ["mammalian", 1280], ["nervous", 1290], ["system", 1298], ["to", 1305], ["carcinogenesis", 1308], [",", 1322], ["but", 1324], ["the", 1328], ["inverse", 1332], ["relationship", 1340], ["of", 1353], ["latency", 1356], ["to", 1364], ["dose", 1367], ["suggests", 1372], ["that", 1381], ["low", 1386], ["transplacental", 1390], ["exposures", 1405], ["to", 1415], ["genotoxicants", 1418], ["are", 1432], ["more", 1436], ["likely", 1441], ["to", 1448], ["result", 1451], ["in", 1458], ["brain", 1461], ["tumors", 1467], ["late", 1474], ["in", 1479], ["life", 1482], [",", 1486], ["rather", 1488], ["than", 1495], ["in", 1500], ["childhood", 1503], [".", 1512], ["While", 1514], ["not", 1520], ["all", 1524], ["neurogenic", 1528], ["tumor", 1539], ["-", 1544], ["related", 1545], ["genes", 1553], ["in", 1559], ["humans", 1562], ["have", 1569], ["similar", 1574], ["effects", 1582], ["in", 1590], ["experimental", 1593], ["rodents", 1606], [",", 1613], ["genetically", 1615], ["engineered", 1627], ["mice", 1638], ["(", 1643], ["GEM", 1644], [")", 1647], ["increasingly", 1649], ["provide", 1662], ["useful", 1670], ["insights", 1677], ["into", 1686], ["the", 1691], ["combined", 1695], ["effects", 1704], ["of", 1712], ["multiple", 1715], ["tumor", 1724], ["suppressor", 1730], ["genes", 1741], ["and", 1747], ["of", 1751], ["gene", 1754], ["-", 1758], ["environment", 1759], ["interactions", 1771], ["in", 1784], ["the", 1787], ["genesis", 1791], ["of", 1799], ["brain", 1802], ["tumors", 1808], [",", 1814], ["especially", 1816], ["pediatric", 1827], ["brain", 1837], ["tumors", 1843], ["such", 1850], ["as", 1855], ["medulloblastoma", 1858], [".", 1873]]}
{"context": "Kell antigens are encoded by the KEL gene on the long arm of chromosome 7. Kx antigen is encoded by the XK gene on the short arm of the X chromosome. Kell and Kx proteins in the red cell membrane are covalently linked by a disulphide bond. The McLeod phenotype is characterized by weakened expression of antigens in the Kell blood group system, absence of Km and Kx antigens, and acanthocytosis. It has an X-linked mode of inheritance with transmission through carrier females. Some males with the McLeod syndrome also have chronic granulomatous disease (CGD). It is generally believed that patients with non-CGD McLeod may develop anti-Km but not anti-Kx, but that those with CGD McLeod can develop both anti-Km and anti-Kx. We present serological data, DNA genotyping and gene sequencing, monocyte monolayer assay and neutrophil oxidative burst test from a patient with the McLeod phenotype without clinical evidence of CGD. We report here the second example of a patient with non-CGD McLeod who developed anti-Kx in addition to anti-Km. Sequencing of our patient's XK gene confirmed the presence of a mutation resulting in a premature stop codon and lack of Kx protein in the red cell membrane, which is consistent with the diagnosis of McLeod syndrome. Neutrophil oxidative burst test was normal, indicating that our patient did not have CGD. The challenge of providing 10 compatible blood units for multiple surgeries was met. The second case of a rare entity, a patient with non-CGD McLeod who developed anti-Kx and anti-Km, was managed successfully with a combination of autologous donations and procurement of compatible units from national and international sources.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "7ff12940e9c34f73936d58aa6f5f4f8b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[209, 209], [22, 22]], "char_spans": [[1068, 1069], [104, 105]]}]}], "context_tokens": [["Kell", 0], ["antigens", 5], ["are", 14], ["encoded", 18], ["by", 26], ["the", 29], ["KEL", 33], ["gene", 37], ["on", 42], ["the", 45], ["long", 49], ["arm", 54], ["of", 58], ["chromosome", 61], ["7", 72], [".", 73], ["Kx", 75], ["antigen", 78], ["is", 86], ["encoded", 89], ["by", 97], ["the", 100], ["XK", 104], ["gene", 107], ["on", 112], ["the", 115], ["short", 119], ["arm", 125], ["of", 129], ["the", 132], ["X", 136], ["chromosome", 138], [".", 148], ["Kell", 150], ["and", 155], ["Kx", 159], ["proteins", 162], ["in", 171], ["the", 174], ["red", 178], ["cell", 182], ["membrane", 187], ["are", 196], ["covalently", 200], ["linked", 211], ["by", 218], ["a", 221], ["disulphide", 223], ["bond", 234], [".", 238], ["The", 240], ["McLeod", 244], ["phenotype", 251], ["is", 261], ["characterized", 264], ["by", 278], ["weakened", 281], ["expression", 290], ["of", 301], ["antigens", 304], ["in", 313], ["the", 316], ["Kell", 320], ["blood", 325], ["group", 331], ["system", 337], [",", 343], ["absence", 345], ["of", 353], ["Km", 356], ["and", 359], ["Kx", 363], ["antigens", 366], [",", 374], ["and", 376], ["acanthocytosis", 380], [".", 394], ["It", 396], ["has", 399], ["an", 403], ["X", 406], ["-", 407], ["linked", 408], ["mode", 415], ["of", 420], ["inheritance", 423], ["with", 435], ["transmission", 440], ["through", 453], ["carrier", 461], ["females", 469], [".", 476], ["Some", 478], ["males", 483], ["with", 489], ["the", 494], ["McLeod", 498], ["syndrome", 505], ["also", 514], ["have", 519], ["chronic", 524], ["granulomatous", 532], ["disease", 546], ["(", 554], ["CGD", 555], [")", 558], [".", 559], ["It", 561], ["is", 564], ["generally", 567], ["believed", 577], ["that", 586], ["patients", 591], ["with", 600], ["non", 605], ["-", 608], ["CGD", 609], ["McLeod", 613], ["may", 620], ["develop", 624], ["anti", 632], ["-", 636], ["Km", 637], ["but", 640], ["not", 644], ["anti", 648], ["-", 652], ["Kx", 653], [",", 655], ["but", 657], ["that", 661], ["those", 666], ["with", 672], ["CGD", 677], ["McLeod", 681], ["can", 688], ["develop", 692], ["both", 700], ["anti", 705], ["-", 709], ["Km", 710], ["and", 713], ["anti", 717], ["-", 721], ["Kx", 722], [".", 724], ["We", 726], ["present", 729], ["serological", 737], ["data", 749], [",", 753], ["DNA", 755], ["genotyping", 759], ["and", 770], ["gene", 774], ["sequencing", 779], [",", 789], ["monocyte", 791], ["monolayer", 800], ["assay", 810], ["and", 816], ["neutrophil", 820], ["oxidative", 831], ["burst", 841], ["test", 847], ["from", 852], ["a", 857], ["patient", 859], ["with", 867], ["the", 872], ["McLeod", 876], ["phenotype", 883], ["without", 893], ["clinical", 901], ["evidence", 910], ["of", 919], ["CGD", 922], [".", 925], ["We", 927], ["report", 930], ["here", 937], ["the", 942], ["second", 946], ["example", 953], ["of", 961], ["a", 964], ["patient", 966], ["with", 974], ["non", 979], ["-", 982], ["CGD", 983], ["McLeod", 987], ["who", 994], ["developed", 998], ["anti", 1008], ["-", 1012], ["Kx", 1013], ["in", 1016], ["addition", 1019], ["to", 1028], ["anti", 1031], ["-", 1035], ["Km", 1036], [".", 1038], ["Sequencing", 1040], ["of", 1051], ["our", 1054], ["patient", 1058], ["'s", 1065], ["XK", 1068], ["gene", 1071], ["confirmed", 1076], ["the", 1086], ["presence", 1090], ["of", 1099], ["a", 1102], ["mutation", 1104], ["resulting", 1113], ["in", 1123], ["a", 1126], ["premature", 1128], ["stop", 1138], ["codon", 1143], ["and", 1149], ["lack", 1153], ["of", 1158], ["Kx", 1161], ["protein", 1164], ["in", 1172], ["the", 1175], ["red", 1179], ["cell", 1183], ["membrane", 1188], [",", 1196], ["which", 1198], ["is", 1204], ["consistent", 1207], ["with", 1218], ["the", 1223], ["diagnosis", 1227], ["of", 1237], ["McLeod", 1240], ["syndrome", 1247], [".", 1255], ["Neutrophil", 1257], ["oxidative", 1268], ["burst", 1278], ["test", 1284], ["was", 1289], ["normal", 1293], [",", 1299], ["indicating", 1301], ["that", 1312], ["our", 1317], ["patient", 1321], ["did", 1329], ["not", 1333], ["have", 1337], ["CGD", 1342], [".", 1345], ["The", 1347], ["challenge", 1351], ["of", 1361], ["providing", 1364], ["10", 1374], ["compatible", 1377], ["blood", 1388], ["units", 1394], ["for", 1400], ["multiple", 1404], ["surgeries", 1413], ["was", 1423], ["met", 1427], [".", 1430], ["The", 1432], ["second", 1436], ["case", 1443], ["of", 1448], ["a", 1451], ["rare", 1453], ["entity", 1458], [",", 1464], ["a", 1466], ["patient", 1468], ["with", 1476], ["non", 1481], ["-", 1484], ["CGD", 1485], ["McLeod", 1489], ["who", 1496], ["developed", 1500], ["anti", 1510], ["-", 1514], ["Kx", 1515], ["and", 1518], ["anti", 1522], ["-", 1526], ["Km", 1527], [",", 1529], ["was", 1531], ["managed", 1535], ["successfully", 1543], ["with", 1556], ["a", 1561], ["combination", 1563], ["of", 1575], ["autologous", 1578], ["donations", 1589], ["and", 1599], ["procurement", 1603], ["of", 1615], ["compatible", 1618], ["units", 1629], ["from", 1635], ["national", 1640], ["and", 1649], ["international", 1653], ["sources", 1667], [".", 1674]]}
{"context": "For regulatory approval, consistency in manufacturing of vaccine lots is expected to be demonstrated in confirmatory immunogenicity studies using two-sided equivalence trials. This randomized, double-blind study (NCT01323972) assessed consistency of three RTS,S/AS01 malaria vaccine batches formulated from commercial-scale purified antigen bulk lots in terms of anti-CS-responses induced. Healthy children aged 5-17 months were randomized (1:1:1:1) to receive RTS,S/AS01 at 0-1-2 months from one of three commercial-scale purified antigen bulk lots (1600 litres-fermentation scale; commercial-scale lots), or a comparator vaccine batch made from pilot-scale purified antigen bulk lot (20 litres-fermentation scale; pilot-scale lot). The co-primary objectives were to first demonstrate consistency of antibody responses against circumsporozoite (CS) protein at one month post-dose 3 for the three commercial-scale lots and second demonstrate non-inferiority of anti-CS antibody responses at one month post-dose 3 for the commercial-scale lots compared to the pilot-scale lot. Safety and reactogenicity were evaluated as secondary endpoints. One month post-dose-3, anti-CS antibody geometric mean titres (GMT) for the 3 commercial scale lots were 319.6 EU/ml (95% confidence interval (CI): 268.9-379.8), 241.4 EU/ml (207.6-280.7), and 302.3 EU/ml (259.4-352.3). Consistency for the RTS,S/AS01 commercial-scale lots was demonstrated as the two-sided 95% CI of the anti-CS antibody GMT ratio between each pair of lots was within the range of 0.5-2.0. GMT of the pooled commercial-scale lots (285.8 EU/ml (260.7-313.3)) was non-inferior to the pilot-scale lot (271.7 EU/ml (228.5-323.1)). Each RTS,S/AS01 lot had an acceptable tolerability profile, with infrequent reports of grade 3 solicited symptoms. No safety signals were identified and no serious adverse events were considered related to vaccination. RTS,S/AS01 lots formulated from commercial-scale purified antigen bulk batches induced a consistent anti-CS antibody response, and the anti-CS GMT of pooled commercial-scale lots was non-inferior to that of a lot formulated from a pilot-scale antigen bulk batch.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "0bd08263daf14f48abf0c2d991631289", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[45, 45]], "char_spans": [[267, 273]]}]}], "context_tokens": [["For", 0], ["regulatory", 4], ["approval", 15], [",", 23], ["consistency", 25], ["in", 37], ["manufacturing", 40], ["of", 54], ["vaccine", 57], ["lots", 65], ["is", 70], ["expected", 73], ["to", 82], ["be", 85], ["demonstrated", 88], ["in", 101], ["confirmatory", 104], ["immunogenicity", 117], ["studies", 132], ["using", 140], ["two", 146], ["-", 149], ["sided", 150], ["equivalence", 156], ["trials", 168], [".", 174], ["This", 176], ["randomized", 181], [",", 191], ["double", 193], ["-", 199], ["blind", 200], ["study", 206], ["(", 212], ["NCT01323972", 213], [")", 224], ["assessed", 226], ["consistency", 235], ["of", 247], ["three", 250], ["RTS", 256], [",", 259], ["S", 260], ["/", 261], ["AS01", 262], ["malaria", 267], ["vaccine", 275], ["batches", 283], ["formulated", 291], ["from", 302], ["commercial", 307], ["-", 317], ["scale", 318], ["purified", 324], ["antigen", 333], ["bulk", 341], ["lots", 346], ["in", 351], ["terms", 354], ["of", 360], ["anti", 363], ["-", 367], ["CS", 368], ["-", 370], ["responses", 371], ["induced", 381], [".", 388], ["Healthy", 390], ["children", 398], ["aged", 407], ["5", 412], ["-", 413], ["17", 414], ["months", 417], ["were", 424], ["randomized", 429], ["(", 440], ["1:1:1:1", 441], [")", 448], ["to", 450], ["receive", 453], ["RTS", 461], [",", 464], ["S", 465], ["/", 466], ["AS01", 467], ["at", 472], ["0", 475], ["-", 476], ["1", 477], ["-", 478], ["2", 479], ["months", 481], ["from", 488], ["one", 493], ["of", 497], ["three", 500], ["commercial", 506], ["-", 516], ["scale", 517], ["purified", 523], ["antigen", 532], ["bulk", 540], ["lots", 545], ["(", 550], ["1600", 551], ["litres", 556], ["-", 562], ["fermentation", 563], ["scale", 576], [";", 581], ["commercial", 583], ["-", 593], ["scale", 594], ["lots", 600], [")", 604], [",", 605], ["or", 607], ["a", 610], ["comparator", 612], ["vaccine", 623], ["batch", 631], ["made", 637], ["from", 642], ["pilot", 647], ["-", 652], ["scale", 653], ["purified", 659], ["antigen", 668], ["bulk", 676], ["lot", 681], ["(", 685], ["20", 686], ["litres", 689], ["-", 695], ["fermentation", 696], ["scale", 709], [";", 714], ["pilot", 716], ["-", 721], ["scale", 722], ["lot", 728], [")", 731], [".", 732], ["The", 734], ["co", 738], ["-", 740], ["primary", 741], ["objectives", 749], ["were", 760], ["to", 765], ["first", 768], ["demonstrate", 774], ["consistency", 786], ["of", 798], ["antibody", 801], ["responses", 810], ["against", 820], ["circumsporozoite", 828], ["(", 845], ["CS", 846], [")", 848], ["protein", 850], ["at", 858], ["one", 861], ["month", 865], ["post", 871], ["-", 875], ["dose", 876], ["3", 881], ["for", 883], ["the", 887], ["three", 891], ["commercial", 897], ["-", 907], ["scale", 908], ["lots", 914], ["and", 919], ["second", 923], ["demonstrate", 930], ["non", 942], ["-", 945], ["inferiority", 946], ["of", 958], ["anti", 961], ["-", 965], ["CS", 966], ["antibody", 969], ["responses", 978], ["at", 988], ["one", 991], ["month", 995], ["post", 1001], ["-", 1005], ["dose", 1006], ["3", 1011], ["for", 1013], ["the", 1017], ["commercial", 1021], ["-", 1031], ["scale", 1032], ["lots", 1038], ["compared", 1043], ["to", 1052], ["the", 1055], ["pilot", 1059], ["-", 1064], ["scale", 1065], ["lot", 1071], [".", 1074], ["Safety", 1076], ["and", 1083], ["reactogenicity", 1087], ["were", 1102], ["evaluated", 1107], ["as", 1117], ["secondary", 1120], ["endpoints", 1130], [".", 1139], ["One", 1141], ["month", 1145], ["post", 1151], ["-", 1155], ["dose-3", 1156], [",", 1162], ["anti", 1164], ["-", 1168], ["CS", 1169], ["antibody", 1172], ["geometric", 1181], ["mean", 1191], ["titres", 1196], ["(", 1203], ["GMT", 1204], [")", 1207], ["for", 1209], ["the", 1213], ["3", 1217], ["commercial", 1219], ["scale", 1230], ["lots", 1236], ["were", 1241], ["319.6", 1246], ["EU", 1252], ["/", 1254], ["ml", 1255], ["(", 1258], ["95", 1259], ["%", 1261], ["confidence", 1263], ["interval", 1274], ["(", 1283], ["CI", 1284], [")", 1286], [":", 1287], ["268.9", 1289], ["-", 1294], ["379.8", 1295], [")", 1300], [",", 1301], ["241.4", 1303], ["EU", 1309], ["/", 1311], ["ml", 1312], ["(", 1315], ["207.6", 1316], ["-", 1321], ["280.7", 1322], [")", 1327], [",", 1328], ["and", 1330], ["302.3", 1334], ["EU", 1340], ["/", 1342], ["ml", 1343], ["(", 1346], ["259.4", 1347], ["-", 1352], ["352.3", 1353], [")", 1358], [".", 1359], ["Consistency", 1361], ["for", 1373], ["the", 1377], ["RTS", 1381], [",", 1384], ["S", 1385], ["/", 1386], ["AS01", 1387], ["commercial", 1392], ["-", 1402], ["scale", 1403], ["lots", 1409], ["was", 1414], ["demonstrated", 1418], ["as", 1431], ["the", 1434], ["two", 1438], ["-", 1441], ["sided", 1442], ["95", 1448], ["%", 1450], ["CI", 1452], ["of", 1455], ["the", 1458], ["anti", 1462], ["-", 1466], ["CS", 1467], ["antibody", 1470], ["GMT", 1479], ["ratio", 1483], ["between", 1489], ["each", 1497], ["pair", 1502], ["of", 1507], ["lots", 1510], ["was", 1515], ["within", 1519], ["the", 1526], ["range", 1530], ["of", 1536], ["0.5", 1539], ["-", 1542], ["2.0", 1543], [".", 1546], ["GMT", 1548], ["of", 1552], ["the", 1555], ["pooled", 1559], ["commercial", 1566], ["-", 1576], ["scale", 1577], ["lots", 1583], ["(", 1588], ["285.8", 1589], ["EU", 1595], ["/", 1597], ["ml", 1598], ["(", 1601], ["260.7", 1602], ["-", 1607], ["313.3", 1608], [")", 1613], [")", 1614], ["was", 1616], ["non", 1620], ["-", 1623], ["inferior", 1624], ["to", 1633], ["the", 1636], ["pilot", 1640], ["-", 1645], ["scale", 1646], ["lot", 1652], ["(", 1656], ["271.7", 1657], ["EU", 1663], ["/", 1665], ["ml", 1666], ["(", 1669], ["228.5", 1670], ["-", 1675], ["323.1", 1676], [")", 1681], [")", 1682], [".", 1683], ["Each", 1685], ["RTS", 1690], [",", 1693], ["S", 1694], ["/", 1695], ["AS01", 1696], ["lot", 1701], ["had", 1705], ["an", 1709], ["acceptable", 1712], ["tolerability", 1723], ["profile", 1736], [",", 1743], ["with", 1745], ["infrequent", 1750], ["reports", 1761], ["of", 1769], ["grade", 1772], ["3", 1778], ["solicited", 1780], ["symptoms", 1790], [".", 1798], ["No", 1800], ["safety", 1803], ["signals", 1810], ["were", 1818], ["identified", 1823], ["and", 1834], ["no", 1838], ["serious", 1841], ["adverse", 1849], ["events", 1857], ["were", 1864], ["considered", 1869], ["related", 1880], ["to", 1888], ["vaccination", 1891], [".", 1902], ["RTS", 1904], [",", 1907], ["S", 1908], ["/", 1909], ["AS01", 1910], ["lots", 1915], ["formulated", 1920], ["from", 1931], ["commercial", 1936], ["-", 1946], ["scale", 1947], ["purified", 1953], ["antigen", 1962], ["bulk", 1970], ["batches", 1975], ["induced", 1983], ["a", 1991], ["consistent", 1993], ["anti", 2004], ["-", 2008], ["CS", 2009], ["antibody", 2012], ["response", 2021], [",", 2029], ["and", 2031], ["the", 2035], ["anti", 2039], ["-", 2043], ["CS", 2044], ["GMT", 2047], ["of", 2051], ["pooled", 2054], ["commercial", 2061], ["-", 2071], ["scale", 2072], ["lots", 2078], ["was", 2083], ["non", 2087], ["-", 2090], ["inferior", 2091], ["to", 2100], ["that", 2103], ["of", 2108], ["a", 2111], ["lot", 2113], ["formulated", 2117], ["from", 2128], ["a", 2133], ["pilot", 2135], ["-", 2140], ["scale", 2141], ["antigen", 2147], ["bulk", 2155], ["batch", 2160], [".", 2165]]}
{"context": "Willis-Ekbom disease (WED), also called restless legs syndrome (RLS), is a neurologic sensorimotor disease that may be associated with cardiovascular disease. Given high morbidity and mortality rates of cardiovascular disease worldwide, we assessed the relation between WED/RLS and cardiovascular health risks in a native South American population. We prospectively analyzed data from The Atahualpa Project of Ecuadorian adults aged 40\u00a0years and older. Physicians interviewed consented persons on the health behavior and health factors of the American Heart Association (AHA) for ideal cardiovascular health in adults and underwent fasting laboratory blood collection and blood pressure evaluation. Certified neurologists conducted face-to-face interviews using the International Restless Legs Syndrome Study Group (IRLSSG) field instrument. Persons testing positive for WED/RLS and age-and sex-matched controls underwent confirmatory physical examinations conducted by a neurologist and a sleep specialist to whom IRLSSG designation was blinded. Of 665 persons, 94 (14\u00a0%) tested positive in IRLSSG; 40 (6\u00a0%) had a diagnosis of WED/RLS after neurologic examination and interview. Patients with WED/RLS were younger (53.5 vs 59.9\u00a0years, P\u2009=\u2009.001), without significant differences in sex ratios. Among AHA risk factors, only obesity was significantly more prevalent among patients with WED/RLS (42.5\u00a0% vs 23.5\u00a0%, P\u2009=\u2009.01). However, after adjustment for confounders, body mass index was not significantly associated with WED/RLS. In adult Amerindians, although obesity and body mass index were associated with WED/RLS on univariate analyses, the association was not present after adjustment for confounders. No other significant associations were found between WED/RLS and AHA cardiovascular metrics.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2218c4979008424a9f948a7b71448a42", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[125, 127], [10, 12]], "char_spans": [[780, 801], [40, 61]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["(", 21], ["WED", 22], [")", 25], [",", 26], ["also", 28], ["called", 33], ["restless", 40], ["legs", 49], ["syndrome", 54], ["(", 63], ["RLS", 64], [")", 67], [",", 68], ["is", 70], ["a", 73], ["neurologic", 75], ["sensorimotor", 86], ["disease", 99], ["that", 107], ["may", 112], ["be", 116], ["associated", 119], ["with", 130], ["cardiovascular", 135], ["disease", 150], [".", 157], ["Given", 159], ["high", 165], ["morbidity", 170], ["and", 180], ["mortality", 184], ["rates", 194], ["of", 200], ["cardiovascular", 203], ["disease", 218], ["worldwide", 226], [",", 235], ["we", 237], ["assessed", 240], ["the", 249], ["relation", 253], ["between", 262], ["WED", 270], ["/", 273], ["RLS", 274], ["and", 278], ["cardiovascular", 282], ["health", 297], ["risks", 304], ["in", 310], ["a", 313], ["native", 315], ["South", 322], ["American", 328], ["population", 337], [".", 347], ["We", 349], ["prospectively", 352], ["analyzed", 366], ["data", 375], ["from", 380], ["The", 385], ["Atahualpa", 389], ["Project", 399], ["of", 407], ["Ecuadorian", 410], ["adults", 421], ["aged", 428], ["40", 433], ["years", 436], ["and", 442], ["older", 446], [".", 451], ["Physicians", 453], ["interviewed", 464], ["consented", 476], ["persons", 486], ["on", 494], ["the", 497], ["health", 501], ["behavior", 508], ["and", 517], ["health", 521], ["factors", 528], ["of", 536], ["the", 539], ["American", 543], ["Heart", 552], ["Association", 558], ["(", 570], ["AHA", 571], [")", 574], ["for", 576], ["ideal", 580], ["cardiovascular", 586], ["health", 601], ["in", 608], ["adults", 611], ["and", 618], ["underwent", 622], ["fasting", 632], ["laboratory", 640], ["blood", 651], ["collection", 657], ["and", 668], ["blood", 672], ["pressure", 678], ["evaluation", 687], [".", 697], ["Certified", 699], ["neurologists", 709], ["conducted", 722], ["face", 732], ["-", 736], ["to", 737], ["-", 739], ["face", 740], ["interviews", 745], ["using", 756], ["the", 762], ["International", 766], ["Restless", 780], ["Legs", 789], ["Syndrome", 794], ["Study", 803], ["Group", 809], ["(", 815], ["IRLSSG", 816], [")", 822], ["field", 824], ["instrument", 830], [".", 840], ["Persons", 842], ["testing", 850], ["positive", 858], ["for", 867], ["WED", 871], ["/", 874], ["RLS", 875], ["and", 879], ["age", 883], ["-", 886], ["and", 887], ["sex", 891], ["-", 894], ["matched", 895], ["controls", 903], ["underwent", 912], ["confirmatory", 922], ["physical", 935], ["examinations", 944], ["conducted", 957], ["by", 967], ["a", 970], ["neurologist", 972], ["and", 984], ["a", 988], ["sleep", 990], ["specialist", 996], ["to", 1007], ["whom", 1010], ["IRLSSG", 1015], ["designation", 1022], ["was", 1034], ["blinded", 1038], [".", 1045], ["Of", 1047], ["665", 1050], ["persons", 1054], [",", 1061], ["94", 1063], ["(", 1066], ["14", 1067], ["%", 1070], [")", 1071], ["tested", 1073], ["positive", 1080], ["in", 1089], ["IRLSSG", 1092], [";", 1098], ["40", 1100], ["(", 1103], ["6", 1104], ["%", 1106], [")", 1107], ["had", 1109], ["a", 1113], ["diagnosis", 1115], ["of", 1125], ["WED", 1128], ["/", 1131], ["RLS", 1132], ["after", 1136], ["neurologic", 1142], ["examination", 1153], ["and", 1165], ["interview", 1169], [".", 1178], ["Patients", 1180], ["with", 1189], ["WED", 1194], ["/", 1197], ["RLS", 1198], ["were", 1202], ["younger", 1207], ["(", 1215], ["53.5", 1216], ["vs", 1221], ["59.9", 1224], ["years", 1229], [",", 1234], ["P", 1236], ["=", 1238], [".001", 1240], [")", 1244], [",", 1245], ["without", 1247], ["significant", 1255], ["differences", 1267], ["in", 1279], ["sex", 1282], ["ratios", 1286], [".", 1292], ["Among", 1294], ["AHA", 1300], ["risk", 1304], ["factors", 1309], [",", 1316], ["only", 1318], ["obesity", 1323], ["was", 1331], ["significantly", 1335], ["more", 1349], ["prevalent", 1354], ["among", 1364], ["patients", 1370], ["with", 1379], ["WED", 1384], ["/", 1387], ["RLS", 1388], ["(", 1392], ["42.5", 1393], ["%", 1398], ["vs", 1400], ["23.5", 1403], ["%", 1408], [",", 1409], ["P", 1411], ["=", 1413], [".01", 1415], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["after", 1430], ["adjustment", 1436], ["for", 1447], ["confounders", 1451], [",", 1462], ["body", 1464], ["mass", 1469], ["index", 1474], ["was", 1480], ["not", 1484], ["significantly", 1488], ["associated", 1502], ["with", 1513], ["WED", 1518], ["/", 1521], ["RLS", 1522], [".", 1525], ["In", 1527], ["adult", 1530], ["Amerindians", 1536], [",", 1547], ["although", 1549], ["obesity", 1558], ["and", 1566], ["body", 1570], ["mass", 1575], ["index", 1580], ["were", 1586], ["associated", 1591], ["with", 1602], ["WED", 1607], ["/", 1610], ["RLS", 1611], ["on", 1615], ["univariate", 1618], ["analyses", 1629], [",", 1637], ["the", 1639], ["association", 1643], ["was", 1655], ["not", 1659], ["present", 1663], ["after", 1671], ["adjustment", 1677], ["for", 1688], ["confounders", 1692], [".", 1703], ["No", 1705], ["other", 1708], ["significant", 1714], ["associations", 1726], ["were", 1739], ["found", 1744], ["between", 1750], ["WED", 1758], ["/", 1761], ["RLS", 1762], ["and", 1766], ["AHA", 1770], ["cardiovascular", 1774], ["metrics", 1789], [".", 1796]]}
{"context": "A mutation in the ubiquilin 2 gene (UBQLN2) was recently identified as a cause of X-linked amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD) and a major component of the inclusion bodies commonly found with a wide variety of ALS. ALS-linked mutations in UBQLN2 are clustered in a unique proline-X-X repeat region, reportedly leading to impairment of the ubiquitin proteasome system. However, the molecular properties of mutant UBQLN2 remain unclear. To gain insight into the pathogenesis of UBQLN2-linked ALS/FTD, we examined the biochemical and cellular characteristics of mutant UBQLN2 in vitro. UBQLN2 localized in Rab11-positive endosomal vesicles formed by the ALS-linked molecule optineurin (OPTN). These vesicles were ubiquitin- and p62-immunopositive and also co-localized with an initiator of the autophagic process, ULK1, after amino acid starvation. An ALS-linked mutation (E478G) in OPTN abolished vesicle formation. ALS-linked mutations in UBQLN2 additively enhanced UBQLN2 aggregation and formation of inclusion bodies, resulting in mislocation from OPTN vesicles. UBQLN2 was found to be a potent regulator of the levels of the FTD-linked secretory factor progranulin, possibly via the endosomal system, and ALS-linked mutations disturbed these functional consequences. This study demonstrates that ALS-linked mutations in both OPTN and UBQLN2 interfere with the constitution of specific endosomal vesicles, suggesting that the vesicles are involved in protein homeostasis and that these proteins function in common pathological processes. These data suggest a novel disease spectrum and provide new pathological insights into OPTN and UBQLN2, enhancing our understanding of the molecular basis of ALS/FTD.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "de7ad57d11e84ddf995786a4c2ecdfe5", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[46, 46], [170, 170], [156, 156], [44, 44], [220, 220], [233, 233], [295, 295], [120, 120], [94, 94]], "char_spans": [[246, 248], [945, 947], [880, 882], [241, 243], [1238, 1240], [1329, 1331], [1728, 1730], [682, 684], [521, 523]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[20, 22]], "char_spans": [[91, 119]]}]}], "context_tokens": [["A", 0], ["mutation", 2], ["in", 11], ["the", 14], ["ubiquilin", 18], ["2", 28], ["gene", 30], ["(", 35], ["UBQLN2", 36], [")", 42], ["was", 44], ["recently", 48], ["identified", 57], ["as", 68], ["a", 71], ["cause", 73], ["of", 79], ["X", 82], ["-", 83], ["linked", 84], ["amyotrophic", 91], ["lateral", 103], ["sclerosis", 111], ["(", 121], ["ALS)/frontotemporal", 122], ["dementia", 142], ["(", 151], ["FTD", 152], [")", 155], ["and", 157], ["a", 161], ["major", 163], ["component", 169], ["of", 179], ["the", 182], ["inclusion", 186], ["bodies", 196], ["commonly", 203], ["found", 212], ["with", 218], ["a", 223], ["wide", 225], ["variety", 230], ["of", 238], ["ALS", 241], [".", 244], ["ALS", 246], ["-", 249], ["linked", 250], ["mutations", 257], ["in", 267], ["UBQLN2", 270], ["are", 277], ["clustered", 281], ["in", 291], ["a", 294], ["unique", 296], ["proline", 303], ["-", 310], ["X", 311], ["-", 312], ["X", 313], ["repeat", 315], ["region", 322], [",", 328], ["reportedly", 330], ["leading", 341], ["to", 349], ["impairment", 352], ["of", 363], ["the", 366], ["ubiquitin", 370], ["proteasome", 380], ["system", 391], [".", 397], ["However", 399], [",", 406], ["the", 408], ["molecular", 412], ["properties", 422], ["of", 433], ["mutant", 436], ["UBQLN2", 443], ["remain", 450], ["unclear", 457], [".", 464], ["To", 466], ["gain", 469], ["insight", 474], ["into", 482], ["the", 487], ["pathogenesis", 491], ["of", 504], ["UBQLN2-linked", 507], ["ALS", 521], ["/", 524], ["FTD", 525], [",", 528], ["we", 530], ["examined", 533], ["the", 542], ["biochemical", 546], ["and", 558], ["cellular", 562], ["characteristics", 571], ["of", 587], ["mutant", 590], ["UBQLN2", 597], ["in", 604], ["vitro", 607], [".", 612], ["UBQLN2", 614], ["localized", 621], ["in", 631], ["Rab11-positive", 634], ["endosomal", 649], ["vesicles", 659], ["formed", 668], ["by", 675], ["the", 678], ["ALS", 682], ["-", 685], ["linked", 686], ["molecule", 693], ["optineurin", 702], ["(", 713], ["OPTN", 714], [")", 718], [".", 719], ["These", 721], ["vesicles", 727], ["were", 736], ["ubiquitin-", 741], ["and", 752], ["p62-immunopositive", 756], ["and", 775], ["also", 779], ["co", 784], ["-", 786], ["localized", 787], ["with", 797], ["an", 802], ["initiator", 805], ["of", 815], ["the", 818], ["autophagic", 822], ["process", 833], [",", 840], ["ULK1", 842], [",", 846], ["after", 848], ["amino", 854], ["acid", 860], ["starvation", 865], [".", 875], ["An", 877], ["ALS", 880], ["-", 883], ["linked", 884], ["mutation", 891], ["(", 900], ["E478", 901], ["G", 905], [")", 906], ["in", 908], ["OPTN", 911], ["abolished", 916], ["vesicle", 926], ["formation", 934], [".", 943], ["ALS", 945], ["-", 948], ["linked", 949], ["mutations", 956], ["in", 966], ["UBQLN2", 969], ["additively", 976], ["enhanced", 987], ["UBQLN2", 996], ["aggregation", 1003], ["and", 1015], ["formation", 1019], ["of", 1029], ["inclusion", 1032], ["bodies", 1042], [",", 1048], ["resulting", 1050], ["in", 1060], ["mislocation", 1063], ["from", 1075], ["OPTN", 1080], ["vesicles", 1085], [".", 1093], ["UBQLN2", 1095], ["was", 1102], ["found", 1106], ["to", 1112], ["be", 1115], ["a", 1118], ["potent", 1120], ["regulator", 1127], ["of", 1137], ["the", 1140], ["levels", 1144], ["of", 1151], ["the", 1154], ["FTD", 1158], ["-", 1161], ["linked", 1162], ["secretory", 1169], ["factor", 1179], ["progranulin", 1186], [",", 1197], ["possibly", 1199], ["via", 1208], ["the", 1212], ["endosomal", 1216], ["system", 1226], [",", 1232], ["and", 1234], ["ALS", 1238], ["-", 1241], ["linked", 1242], ["mutations", 1249], ["disturbed", 1259], ["these", 1269], ["functional", 1275], ["consequences", 1286], [".", 1298], ["This", 1300], ["study", 1305], ["demonstrates", 1311], ["that", 1324], ["ALS", 1329], ["-", 1332], ["linked", 1333], ["mutations", 1340], ["in", 1350], ["both", 1353], ["OPTN", 1358], ["and", 1363], ["UBQLN2", 1367], ["interfere", 1374], ["with", 1384], ["the", 1389], ["constitution", 1393], ["of", 1406], ["specific", 1409], ["endosomal", 1418], ["vesicles", 1428], [",", 1436], ["suggesting", 1438], ["that", 1449], ["the", 1454], ["vesicles", 1458], ["are", 1467], ["involved", 1471], ["in", 1480], ["protein", 1483], ["homeostasis", 1491], ["and", 1503], ["that", 1507], ["these", 1512], ["proteins", 1518], ["function", 1527], ["in", 1536], ["common", 1539], ["pathological", 1546], ["processes", 1559], [".", 1568], ["These", 1570], ["data", 1576], ["suggest", 1581], ["a", 1589], ["novel", 1591], ["disease", 1597], ["spectrum", 1605], ["and", 1614], ["provide", 1618], ["new", 1626], ["pathological", 1630], ["insights", 1643], ["into", 1652], ["OPTN", 1657], ["and", 1662], ["UBQLN2", 1666], [",", 1672], ["enhancing", 1674], ["our", 1684], ["understanding", 1688], ["of", 1702], ["the", 1705], ["molecular", 1709], ["basis", 1719], ["of", 1725], ["ALS", 1728], ["/", 1731], ["FTD", 1732], [".", 1735]]}
{"context": "Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) is a common cytogenetic abnormality associated with poor outcome in adults. This preliminary study, in the absence of substantial evidence, reported the prevalence of the BCR-ABL gene fusion in ALL patients by RT-PCR in Pakistan. Moreover, the prognostic significance of BCR-ABL fusion along with other characteristics was also ascertained. One hundred forty six newly diagnosed ALL patients treated at our center between 2005 and 2008 comprised the study group. The patients were treated with a Children and Leukemia Group B induction regimen. Among these patients, BCR-ABL fusion oncogene was present in 43 of 78 patients (55%). A statistically significant difference in BCR-ABL-positivity within three age groups (<20 years, 20-50 years, >50 years) was observed (P= 0.001). The median age was significantly higher in the BCR-ABL+ group (30 vs 19 years; P= 0.001). BCR-ABL+ patients were also characterized by higher median WBC counts (96,000/\u00b5L vs 23,000//\u00b5L, P= 0.002). Complete remission was achieved in 74% BCR-ABL- patients and 35% BCR-ABL+ patients (P= 0.001). Only 10% of BCR-ABL- patients achieved continued complete remission (CR). None of the BCR-ABL+ patients maintained a CR further to induction therapy. With the available therapeutic protocol, the presence of a BCR-ABL fusion predicted a lower survival (P= 0.001). A high prevalence of BCR-ABL gene fusion was observed that appeared as a poor prognostic factor. Identification of this genetic entity at diagnosis is crucial for understanding the nature of adult ALL and for deciding optimal treatment.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "5bccb35d6e25413884c6d89ff4623553", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[288, 292], [40, 44]], "char_spans": [[1426, 1444], [244, 262]]}]}], "context_tokens": [["Philadelphia", 0], ["(", 13], ["Ph", 14], [")", 16], ["chromosome", 18], ["positive", 29], ["acute", 38], ["lymphoblastic", 44], ["leukemia", 58], ["(", 67], ["ALL", 68], [")", 71], ["is", 73], ["a", 76], ["common", 78], ["cytogenetic", 85], ["abnormality", 97], ["associated", 109], ["with", 120], ["poor", 125], ["outcome", 130], ["in", 138], ["adults", 141], [".", 147], ["This", 149], ["preliminary", 154], ["study", 166], [",", 171], ["in", 173], ["the", 176], ["absence", 180], ["of", 188], ["substantial", 191], ["evidence", 203], [",", 211], ["reported", 213], ["the", 222], ["prevalence", 226], ["of", 237], ["the", 240], ["BCR", 244], ["-", 247], ["ABL", 248], ["gene", 252], ["fusion", 257], ["in", 264], ["ALL", 267], ["patients", 271], ["by", 280], ["RT", 283], ["-", 285], ["PCR", 286], ["in", 290], ["Pakistan", 293], [".", 301], ["Moreover", 303], [",", 311], ["the", 313], ["prognostic", 317], ["significance", 328], ["of", 341], ["BCR", 344], ["-", 347], ["ABL", 348], ["fusion", 352], ["along", 359], ["with", 365], ["other", 370], ["characteristics", 376], ["was", 392], ["also", 396], ["ascertained", 401], [".", 412], ["One", 414], ["hundred", 418], ["forty", 426], ["six", 432], ["newly", 436], ["diagnosed", 442], ["ALL", 452], ["patients", 456], ["treated", 465], ["at", 473], ["our", 476], ["center", 480], ["between", 487], ["2005", 495], ["and", 500], ["2008", 504], ["comprised", 509], ["the", 519], ["study", 523], ["group", 529], [".", 534], ["The", 536], ["patients", 540], ["were", 549], ["treated", 554], ["with", 562], ["a", 567], ["Children", 569], ["and", 578], ["Leukemia", 582], ["Group", 591], ["B", 597], ["induction", 599], ["regimen", 609], [".", 616], ["Among", 618], ["these", 624], ["patients", 630], [",", 638], ["BCR", 640], ["-", 643], ["ABL", 644], ["fusion", 648], ["oncogene", 655], ["was", 664], ["present", 668], ["in", 676], ["43", 679], ["of", 682], ["78", 685], ["patients", 688], ["(", 697], ["55", 698], ["%", 700], [")", 701], [".", 702], ["A", 704], ["statistically", 706], ["significant", 720], ["difference", 732], ["in", 743], ["BCR", 746], ["-", 749], ["ABL", 750], ["-", 753], ["positivity", 754], ["within", 765], ["three", 772], ["age", 778], ["groups", 782], ["(", 789], ["<", 790], ["20", 791], ["years", 794], [",", 799], ["20", 801], ["-", 803], ["50", 804], ["years", 807], [",", 812], [">", 814], ["50", 815], ["years", 818], [")", 823], ["was", 825], ["observed", 829], ["(", 838], ["P=", 839], ["0.001", 842], [")", 847], [".", 848], ["The", 850], ["median", 854], ["age", 861], ["was", 865], ["significantly", 869], ["higher", 883], ["in", 890], ["the", 893], ["BCR", 897], ["-", 900], ["ABL+", 901], ["group", 906], ["(", 912], ["30", 913], ["vs", 916], ["19", 919], ["years", 922], [";", 927], ["P=", 929], ["0.001", 932], [")", 937], [".", 938], ["BCR", 940], ["-", 943], ["ABL+", 944], ["patients", 949], ["were", 958], ["also", 963], ["characterized", 968], ["by", 982], ["higher", 985], ["median", 992], ["WBC", 999], ["counts", 1003], ["(", 1010], ["96,000/\u00b5L", 1011], ["vs", 1021], ["23,000//\u00b5L", 1024], [",", 1034], ["P=", 1036], ["0.002", 1039], [")", 1044], [".", 1045], ["Complete", 1047], ["remission", 1056], ["was", 1066], ["achieved", 1070], ["in", 1079], ["74", 1082], ["%", 1084], ["BCR", 1086], ["-", 1089], ["ABL-", 1090], ["patients", 1095], ["and", 1104], ["35", 1108], ["%", 1110], ["BCR", 1112], ["-", 1115], ["ABL+", 1116], ["patients", 1121], ["(", 1130], ["P=", 1131], ["0.001", 1134], [")", 1139], [".", 1140], ["Only", 1142], ["10", 1147], ["%", 1149], ["of", 1151], ["BCR", 1154], ["-", 1157], ["ABL-", 1158], ["patients", 1163], ["achieved", 1172], ["continued", 1181], ["complete", 1191], ["remission", 1200], ["(", 1210], ["CR", 1211], [")", 1213], [".", 1214], ["None", 1216], ["of", 1221], ["the", 1224], ["BCR", 1228], ["-", 1231], ["ABL+", 1232], ["patients", 1237], ["maintained", 1246], ["a", 1257], ["CR", 1259], ["further", 1262], ["to", 1270], ["induction", 1273], ["therapy", 1283], [".", 1290], ["With", 1292], ["the", 1297], ["available", 1301], ["therapeutic", 1311], ["protocol", 1323], [",", 1331], ["the", 1333], ["presence", 1337], ["of", 1346], ["a", 1349], ["BCR", 1351], ["-", 1354], ["ABL", 1355], ["fusion", 1359], ["predicted", 1366], ["a", 1376], ["lower", 1378], ["survival", 1384], ["(", 1393], ["P=", 1394], ["0.001", 1397], [")", 1402], [".", 1403], ["A", 1405], ["high", 1407], ["prevalence", 1412], ["of", 1423], ["BCR", 1426], ["-", 1429], ["ABL", 1430], ["gene", 1434], ["fusion", 1439], ["was", 1446], ["observed", 1450], ["that", 1459], ["appeared", 1464], ["as", 1473], ["a", 1476], ["poor", 1478], ["prognostic", 1483], ["factor", 1494], [".", 1500], ["Identification", 1502], ["of", 1517], ["this", 1520], ["genetic", 1525], ["entity", 1533], ["at", 1540], ["diagnosis", 1543], ["is", 1553], ["crucial", 1556], ["for", 1564], ["understanding", 1568], ["the", 1582], ["nature", 1586], ["of", 1593], ["adult", 1596], ["ALL", 1602], ["and", 1606], ["for", 1610], ["deciding", 1614], ["optimal", 1623], ["treatment", 1631], [".", 1640]]}
{"context": "Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. A total of 532 patients with late--chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated. Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "422c039d26e4410290b304947e55dff4", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[10, 12]], "char_spans": [[52, 58]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["caused", 38], ["by", 45], ["the", 48], ["BCR", 52], ["-", 55], ["ABL", 56], ["tyrosine", 60], ["kinase", 69], [",", 75], ["the", 77], ["product", 81], ["of", 89], ["the", 92], ["Philadelphia", 96], ["chromosome", 109], [".", 119], ["Imatinib", 121], ["mesylate", 130], [",", 138], ["formerly", 140], ["STI571", 149], [",", 155], ["is", 157], ["a", 160], ["selective", 162], ["inhibitor", 172], ["of", 182], ["this", 185], ["kinase", 190], [".", 196], ["A", 198], ["total", 200], ["of", 206], ["532", 209], ["patients", 213], ["with", 222], ["late", 227], ["--", 231], ["chronic", 233], ["-", 240], ["phase", 241], ["CML", 247], ["in", 251], ["whom", 254], ["previous", 259], ["therapy", 268], ["with", 276], ["interferon", 281], ["alfa", 292], ["had", 297], ["failed", 301], ["were", 308], ["treated", 313], ["with", 321], ["400", 326], ["mg", 330], ["of", 333], ["oral", 336], ["imatinib", 341], ["daily", 350], [".", 355], ["Patients", 357], ["were", 366], ["evaluated", 371], ["for", 381], ["cytogenetic", 385], ["and", 397], ["hematologic", 401], ["responses", 413], [".", 422], ["Time", 424], ["to", 429], ["progression", 432], [",", 443], ["survival", 445], [",", 453], ["and", 455], ["toxic", 459], ["effects", 465], ["were", 473], ["also", 478], ["evaluated", 483], [".", 492], ["Imatinib", 494], ["induced", 503], ["major", 511], ["cytogenetic", 517], ["responses", 529], ["in", 539], ["60", 542], ["percent", 545], ["of", 553], ["the", 556], ["454", 560], ["patients", 564], ["with", 573], ["confirmed", 578], ["chronic", 588], ["-", 595], ["phase", 596], ["CML", 602], ["and", 606], ["complete", 610], ["hematologic", 619], ["responses", 631], ["in", 641], ["95", 644], ["percent", 647], [".", 654], ["After", 656], ["a", 662], ["median", 664], ["follow", 671], ["-", 677], ["up", 678], ["of", 681], ["18", 684], ["months", 687], [",", 693], ["CML", 695], ["had", 699], ["not", 703], ["progressed", 707], ["to", 718], ["the", 721], ["accelerated", 725], ["or", 737], ["blast", 740], ["phases", 746], ["in", 753], ["an", 756], ["estimated", 759], ["89", 769], ["percent", 772], ["of", 780], ["patients", 783], [",", 791], ["and", 793], ["95", 797], ["percent", 800], ["of", 808], ["the", 811], ["patients", 815], ["were", 824], ["alive", 829], [".", 834], ["Grade", 836], ["3", 842], ["or", 844], ["4", 847], ["nonhematologic", 849], ["toxic", 864], ["effects", 870], ["were", 878], ["infrequent", 883], [",", 893], ["and", 895], ["hematologic", 899], ["toxic", 911], ["effects", 917], ["were", 925], ["manageable", 930], [".", 940], ["Only", 942], ["2", 947], ["percent", 949], ["of", 957], ["patients", 960], ["discontinued", 969], ["treatment", 982], ["because", 992], ["of", 1000], ["drug", 1003], ["-", 1007], ["related", 1008], ["adverse", 1016], ["events", 1024], [",", 1030], ["and", 1032], ["no", 1036], ["treatment", 1039], ["-", 1048], ["related", 1049], ["deaths", 1057], ["occurred", 1064], [".", 1072], ["Imatinib", 1074], ["induced", 1083], ["high", 1091], ["rates", 1096], ["of", 1102], ["cytogenetic", 1105], ["and", 1117], ["hematologic", 1121], ["responses", 1133], ["in", 1143], ["patients", 1146], ["with", 1155], ["chronic", 1160], ["-", 1167], ["phase", 1168], ["CML", 1174], ["in", 1178], ["whom", 1181], ["previous", 1186], ["interferon", 1195], ["therapy", 1206], ["had", 1214], ["failed", 1218], [".", 1224]]}
{"context": "In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH). 43 adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor therapy) were randomised three to one to receive either selexipag or placebo. Dosage was up-titrated in 200-\u03bcg increments from 200 \u03bcg twice daily on day 1 to the maximum tolerated dose by day 35 (maximum allowed dose of 800 \u03bcg twice daily). Change in pulmonary vascular resistance at week 17 expressed as a percentage of the baseline value was the primary efficacy end-point, and was analysed in the per protocol set first and then in the all-treated set to assess robustness of results. A statistically significant 30.3% reduction in geometric mean pulmonary vascular resistance was observed after 17 weeks' treatment with selexipag compared with placebo (95% confidence limits -44.7- -12.2; p=0.0045, Wilcoxon rank sum test). This was supported by a similar result from the all-treated set. Selexipag was well tolerated with a safety profile in line with the expected pharmacological effect. Our results encourage the further investigation of selexipag for the treatment of PAH.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "8ed62063f0ec40858e6e327239600c08", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[36, 38]], "char_spans": [[184, 214]]}]}], "context_tokens": [["In", 0], ["this", 3], ["phase", 8], ["2", 14], ["proof", 16], ["-", 21], ["of", 22], ["-", 24], ["concept", 25], ["study", 33], ["we", 39], ["examined", 42], ["the", 51], ["safety", 55], ["and", 62], ["efficacy", 66], ["of", 75], ["selexipag", 78], [",", 87], ["an", 89], ["orally", 92], ["available", 99], [",", 108], ["selective", 110], ["prostacyclin", 120], ["receptor", 133], ["(", 142], ["IP", 143], ["receptor", 146], [")", 154], ["agonist", 156], [",", 163], ["as", 165], ["a", 168], ["treatment", 170], ["for", 180], ["pulmonary", 184], ["arterial", 194], ["hypertension", 203], ["(", 216], ["PAH", 217], [")", 220], [".", 221], ["43", 223], ["adult", 226], ["patients", 232], ["with", 241], ["symptomatic", 246], ["PAH", 258], ["(", 262], ["receiving", 263], ["stable", 273], ["endothelin", 280], ["receptor", 291], ["antagonist", 300], ["and/or", 311], ["a", 318], ["phosphodiesterase", 320], ["type-5", 338], ["inhibitor", 345], ["therapy", 355], [")", 362], ["were", 364], ["randomised", 369], ["three", 380], ["to", 386], ["one", 389], ["to", 393], ["receive", 396], ["either", 404], ["selexipag", 411], ["or", 421], ["placebo", 424], [".", 431], ["Dosage", 433], ["was", 440], ["up", 444], ["-", 446], ["titrated", 447], ["in", 456], ["200-\u03bcg", 459], ["increments", 466], ["from", 477], ["200", 482], ["\u03bcg", 486], ["twice", 489], ["daily", 495], ["on", 501], ["day", 504], ["1", 508], ["to", 510], ["the", 513], ["maximum", 517], ["tolerated", 525], ["dose", 535], ["by", 540], ["day", 543], ["35", 547], ["(", 550], ["maximum", 551], ["allowed", 559], ["dose", 567], ["of", 572], ["800", 575], ["\u03bcg", 579], ["twice", 582], ["daily", 588], [")", 593], [".", 594], ["Change", 596], ["in", 603], ["pulmonary", 606], ["vascular", 616], ["resistance", 625], ["at", 636], ["week", 639], ["17", 644], ["expressed", 647], ["as", 657], ["a", 660], ["percentage", 662], ["of", 673], ["the", 676], ["baseline", 680], ["value", 689], ["was", 695], ["the", 699], ["primary", 703], ["efficacy", 711], ["end", 720], ["-", 723], ["point", 724], [",", 729], ["and", 731], ["was", 735], ["analysed", 739], ["in", 748], ["the", 751], ["per", 755], ["protocol", 759], ["set", 768], ["first", 772], ["and", 778], ["then", 782], ["in", 787], ["the", 790], ["all", 794], ["-", 797], ["treated", 798], ["set", 806], ["to", 810], ["assess", 813], ["robustness", 820], ["of", 831], ["results", 834], [".", 841], ["A", 843], ["statistically", 845], ["significant", 859], ["30.3", 871], ["%", 875], ["reduction", 877], ["in", 887], ["geometric", 890], ["mean", 900], ["pulmonary", 905], ["vascular", 915], ["resistance", 924], ["was", 935], ["observed", 939], ["after", 948], ["17", 954], ["weeks", 957], ["'", 962], ["treatment", 964], ["with", 974], ["selexipag", 979], ["compared", 989], ["with", 998], ["placebo", 1003], ["(", 1011], ["95", 1012], ["%", 1014], ["confidence", 1016], ["limits", 1027], ["-44.7-", 1034], ["-12.2", 1041], [";", 1046], ["p=0.0045", 1048], [",", 1056], ["Wilcoxon", 1058], ["rank", 1067], ["sum", 1072], ["test", 1076], [")", 1080], [".", 1081], ["This", 1083], ["was", 1088], ["supported", 1092], ["by", 1102], ["a", 1105], ["similar", 1107], ["result", 1115], ["from", 1122], ["the", 1127], ["all", 1131], ["-", 1134], ["treated", 1135], ["set", 1143], [".", 1146], ["Selexipag", 1148], ["was", 1158], ["well", 1162], ["tolerated", 1167], ["with", 1177], ["a", 1182], ["safety", 1184], ["profile", 1191], ["in", 1199], ["line", 1202], ["with", 1207], ["the", 1212], ["expected", 1216], ["pharmacological", 1225], ["effect", 1241], [".", 1247], ["Our", 1249], ["results", 1253], ["encourage", 1261], ["the", 1271], ["further", 1275], ["investigation", 1283], ["of", 1297], ["selexipag", 1300], ["for", 1310], ["the", 1314], ["treatment", 1318], ["of", 1328], ["PAH", 1331], [".", 1334]]}
{"context": "Infective embolic retinopathy as a sequela of bacterial endocarditis is described in a 31-year-old woman with mitral valve prolapse. The infective organism, Corynebacterium minutissimum, has not been previously found to cause ocular or multisystem diseases. It is a common mucocutaneous inhabitant which causes erythrasma. In our case report both ocular involvement and septicaemia were present. The infection was confirmed by positive serial blood cultures. Mitral valve prolapse was confirmed by echocardiography. On clinical examination the retinopathy consisted of white intraretinal lesions which resolved with antibiotic therapy. By fluorescein angiography focal areas of hypofluorescence corresponding to the white fundus lesions were present. Optic disc oedema was also seen.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "9de1c3ee5251428fb8ddac069c49e9e8", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[26, 27]], "char_spans": [[157, 184]]}]}], "context_tokens": [["Infective", 0], ["embolic", 10], ["retinopathy", 18], ["as", 30], ["a", 33], ["sequela", 35], ["of", 43], ["bacterial", 46], ["endocarditis", 56], ["is", 69], ["described", 72], ["in", 82], ["a", 85], ["31-year", 87], ["-", 94], ["old", 95], ["woman", 99], ["with", 105], ["mitral", 110], ["valve", 117], ["prolapse", 123], [".", 131], ["The", 133], ["infective", 137], ["organism", 147], [",", 155], ["Corynebacterium", 157], ["minutissimum", 173], [",", 185], ["has", 187], ["not", 191], ["been", 195], ["previously", 200], ["found", 211], ["to", 217], ["cause", 220], ["ocular", 226], ["or", 233], ["multisystem", 236], ["diseases", 248], [".", 256], ["It", 258], ["is", 261], ["a", 264], ["common", 266], ["mucocutaneous", 273], ["inhabitant", 287], ["which", 298], ["causes", 304], ["erythrasma", 311], [".", 321], ["In", 323], ["our", 326], ["case", 330], ["report", 335], ["both", 342], ["ocular", 347], ["involvement", 354], ["and", 366], ["septicaemia", 370], ["were", 382], ["present", 387], [".", 394], ["The", 396], ["infection", 400], ["was", 410], ["confirmed", 414], ["by", 424], ["positive", 427], ["serial", 436], ["blood", 443], ["cultures", 449], [".", 457], ["Mitral", 459], ["valve", 466], ["prolapse", 472], ["was", 481], ["confirmed", 485], ["by", 495], ["echocardiography", 498], [".", 514], ["On", 516], ["clinical", 519], ["examination", 528], ["the", 540], ["retinopathy", 544], ["consisted", 556], ["of", 566], ["white", 569], ["intraretinal", 575], ["lesions", 588], ["which", 596], ["resolved", 602], ["with", 611], ["antibiotic", 616], ["therapy", 627], [".", 634], ["By", 636], ["fluorescein", 639], ["angiography", 651], ["focal", 663], ["areas", 669], ["of", 675], ["hypofluorescence", 678], ["corresponding", 695], ["to", 709], ["the", 712], ["white", 716], ["fundus", 722], ["lesions", 729], ["were", 737], ["present", 742], [".", 749], ["Optic", 751], ["disc", 757], ["oedema", 762], ["was", 769], ["also", 773], ["seen", 778], [".", 782]]}
{"context": "Previously we reported on L-DOPA's antinociceptive effect on substance P-induced nociceptive behaviors in mice [Shimizu T, Iwata S, Morioka H, Masuyama T, Fukuda T, Nomoto M. Antinociceptive mechanism of L-DOPA. Pain 2004;110;246-9.]. Since significant hyperalgesia was noted following antinociception, our study was designed to investigate the mechanism of this hyperalgesia. Nociceptive behaviors were enhanced 2 h after L-DOPA administration. L-DOPA induced hyperalgesia occurred after conversion to dopamine because co-administration of benserazide, a DOPA decarboxylase inhibitor, completely abolished the L-DOPA-induced hyperalgesia. The D2 receptor agonist, quinpirole, depressed these behaviors entirely, while the D1 antagonist, SCH23390, inhibited the enhancement of these behaviors by L-DOPA. The D2 receptor antagonist, sulpiride, which induced hyperalgesia of the substance P-induced behaviors in naive mice, did not have any effects on L-DOPA-induced hyperalgesia. Spinal cord dopamine content increased rapidly after L-DOPA administration, exhibiting levels 100 times greater than baseline, and then returned to control after 1 h. These results suggested that the dopaminergic inhibitory system for pain sensation was temporarily impaired by excess amounts of exogenous dopamine that were derived from L-DOPA and both D1 and D2 receptors were involved in L-DOPA-induced hyperalgesia.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "a599caa6467c4126af22518a18e24c41", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[4, 6], [228, 230], [183, 185], [240, 242], [40, 42], [138, 140], [105, 107], [169, 171], [80, 82], [75, 77]], "char_spans": [[26, 31], [1317, 1322], [1032, 1037], [1370, 1375], [204, 209], [796, 801], [611, 616], [950, 955], [446, 451], [423, 428]]}]}], "context_tokens": [["Previously", 0], ["we", 11], ["reported", 14], ["on", 23], ["L", 26], ["-", 27], ["DOPA", 28], ["'s", 32], ["antinociceptive", 35], ["effect", 51], ["on", 58], ["substance", 61], ["P", 71], ["-", 72], ["induced", 73], ["nociceptive", 81], ["behaviors", 93], ["in", 103], ["mice", 106], ["[", 111], ["Shimizu", 112], ["T", 120], [",", 121], ["Iwata", 123], ["S", 129], [",", 130], ["Morioka", 132], ["H", 140], [",", 141], ["Masuyama", 143], ["T", 152], [",", 153], ["Fukuda", 155], ["T", 162], [",", 163], ["Nomoto", 165], ["M.", 172], ["Antinociceptive", 175], ["mechanism", 191], ["of", 201], ["L", 204], ["-", 205], ["DOPA", 206], [".", 210], ["Pain", 212], ["2004;110;246", 217], ["-", 229], ["9.].", 230], ["Since", 235], ["significant", 241], ["hyperalgesia", 253], ["was", 266], ["noted", 270], ["following", 276], ["antinociception", 286], [",", 301], ["our", 303], ["study", 307], ["was", 313], ["designed", 317], ["to", 326], ["investigate", 329], ["the", 341], ["mechanism", 345], ["of", 355], ["this", 358], ["hyperalgesia", 363], [".", 375], ["Nociceptive", 377], ["behaviors", 389], ["were", 399], ["enhanced", 404], ["2", 413], ["h", 415], ["after", 417], ["L", 423], ["-", 424], ["DOPA", 425], ["administration", 430], [".", 444], ["L", 446], ["-", 447], ["DOPA", 448], ["induced", 453], ["hyperalgesia", 461], ["occurred", 474], ["after", 483], ["conversion", 489], ["to", 500], ["dopamine", 503], ["because", 512], ["co", 520], ["-", 522], ["administration", 523], ["of", 538], ["benserazide", 541], [",", 552], ["a", 554], ["DOPA", 556], ["decarboxylase", 561], ["inhibitor", 575], [",", 584], ["completely", 586], ["abolished", 597], ["the", 607], ["L", 611], ["-", 612], ["DOPA", 613], ["-", 617], ["induced", 618], ["hyperalgesia", 626], [".", 638], ["The", 640], ["D2", 644], ["receptor", 647], ["agonist", 656], [",", 663], ["quinpirole", 665], [",", 675], ["depressed", 677], ["these", 687], ["behaviors", 693], ["entirely", 703], [",", 711], ["while", 713], ["the", 719], ["D1", 723], ["antagonist", 726], [",", 736], ["SCH23390", 738], [",", 746], ["inhibited", 748], ["the", 758], ["enhancement", 762], ["of", 774], ["these", 777], ["behaviors", 783], ["by", 793], ["L", 796], ["-", 797], ["DOPA", 798], [".", 802], ["The", 804], ["D2", 808], ["receptor", 811], ["antagonist", 820], [",", 830], ["sulpiride", 832], [",", 841], ["which", 843], ["induced", 849], ["hyperalgesia", 857], ["of", 870], ["the", 873], ["substance", 877], ["P", 887], ["-", 888], ["induced", 889], ["behaviors", 897], ["in", 907], ["naive", 910], ["mice", 916], [",", 920], ["did", 922], ["not", 926], ["have", 930], ["any", 935], ["effects", 939], ["on", 947], ["L", 950], ["-", 951], ["DOPA", 952], ["-", 956], ["induced", 957], ["hyperalgesia", 965], [".", 977], ["Spinal", 979], ["cord", 986], ["dopamine", 991], ["content", 1000], ["increased", 1008], ["rapidly", 1018], ["after", 1026], ["L", 1032], ["-", 1033], ["DOPA", 1034], ["administration", 1039], [",", 1053], ["exhibiting", 1055], ["levels", 1066], ["100", 1073], ["times", 1077], ["greater", 1083], ["than", 1091], ["baseline", 1096], [",", 1104], ["and", 1106], ["then", 1110], ["returned", 1115], ["to", 1124], ["control", 1127], ["after", 1135], ["1", 1141], ["h.", 1143], ["These", 1146], ["results", 1152], ["suggested", 1160], ["that", 1170], ["the", 1175], ["dopaminergic", 1179], ["inhibitory", 1192], ["system", 1203], ["for", 1210], ["pain", 1214], ["sensation", 1219], ["was", 1229], ["temporarily", 1233], ["impaired", 1245], ["by", 1254], ["excess", 1257], ["amounts", 1264], ["of", 1272], ["exogenous", 1275], ["dopamine", 1285], ["that", 1294], ["were", 1299], ["derived", 1304], ["from", 1312], ["L", 1317], ["-", 1318], ["DOPA", 1319], ["and", 1324], ["both", 1328], ["D1", 1333], ["and", 1336], ["D2", 1340], ["receptors", 1343], ["were", 1353], ["involved", 1358], ["in", 1367], ["L", 1370], ["-", 1371], ["DOPA", 1372], ["-", 1376], ["induced", 1377], ["hyperalgesia", 1385], [".", 1397]]}
{"context": "Cerebral palsy (CP) with dystonia-choreoathetosis is a common cause of disability in children and in adults, and responds poorly to medical treatment. Bilateral pallidal deep brain stimulation (BP-DBS) of the globus pallidus internus (GPi) is an effective treatment for primary dystonia, but the effect of this reversible surgical procedure on dystonia-choreoathetosis CP, which is a subtype of secondary dystonia, is unknown. Our aim was to test the effectiveness of BP-DBS in adults with dystonia-choreoathetosis CP. We did a multicentre prospective pilot study of BP-DBS in 13 adults with dystonia-choreoathetosis CP who had no cognitive impairment, little spasticity, and only slight abnormalities of the basal ganglia on MRI. The primary endpoint was change in the severity of dystonia-choreoathetosis after 1 year of neurostimulation, as assessed with the Burke-Fahn-Marsden dystonia rating scale. The accuracy of surgical targeting to the GPi was assessed masked to the results of neurostimulation. Analysis was by intention to treat. The mean Burke-Fahn-Marsden dystonia rating scale movement score improved from 44.2 (SD 21.1) before surgery to 34.7 (21.9) at 1 year post-operatively (p=0.009; mean improvement 24.4 [21.1]%, 95% CI 11.6-37.1). Functional disability, pain, and mental health-related quality of life were significantly improved. There was no worsening of cognition or mood. Adverse events were related to stimulation (arrest of the stimulator in one patient, and an adjustment to the current intensity in four patients). The optimum therapeutic target was the posterolateroventral region of the GPi. Little improvement was seen when the neurostimulation diffused to adjacent structures (mainly to the globus pallidus externus [GPe]). Bilateral pallidal neurostimulation could be an effective treatment option for patients with dystonia-choreoathetosis CP. However, given the heterogeneity of motor outcomes and the small sample size, results should be interpreted with caution. The optimum placement of the leads seemed to be a crucial, but not exclusive, factor that could affect a good outcome. National PHRC; Cerebral Palsy Foundation: Fondation Motrice/APETREIMC; French INSERM Dystonia National Network; Medtronic.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "6459013464a14756bc918aec303e7b5a", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[40, 42]], "char_spans": [[209, 232]]}]}], "context_tokens": [["Cerebral", 0], ["palsy", 9], ["(", 15], ["CP", 16], [")", 18], ["with", 20], ["dystonia", 25], ["-", 33], ["choreoathetosis", 34], ["is", 50], ["a", 53], ["common", 55], ["cause", 62], ["of", 68], ["disability", 71], ["in", 82], ["children", 85], ["and", 94], ["in", 98], ["adults", 101], [",", 107], ["and", 109], ["responds", 113], ["poorly", 122], ["to", 129], ["medical", 132], ["treatment", 140], [".", 149], ["Bilateral", 151], ["pallidal", 161], ["deep", 170], ["brain", 175], ["stimulation", 181], ["(", 193], ["BP", 194], ["-", 196], ["DBS", 197], [")", 200], ["of", 202], ["the", 205], ["globus", 209], ["pallidus", 216], ["internus", 225], ["(", 234], ["GPi", 235], [")", 238], ["is", 240], ["an", 243], ["effective", 246], ["treatment", 256], ["for", 266], ["primary", 270], ["dystonia", 278], [",", 286], ["but", 288], ["the", 292], ["effect", 296], ["of", 303], ["this", 306], ["reversible", 311], ["surgical", 322], ["procedure", 331], ["on", 341], ["dystonia", 344], ["-", 352], ["choreoathetosis", 353], ["CP", 369], [",", 371], ["which", 373], ["is", 379], ["a", 382], ["subtype", 384], ["of", 392], ["secondary", 395], ["dystonia", 405], [",", 413], ["is", 415], ["unknown", 418], [".", 425], ["Our", 427], ["aim", 431], ["was", 435], ["to", 439], ["test", 442], ["the", 447], ["effectiveness", 451], ["of", 465], ["BP", 468], ["-", 470], ["DBS", 471], ["in", 475], ["adults", 478], ["with", 485], ["dystonia", 490], ["-", 498], ["choreoathetosis", 499], ["CP", 515], [".", 517], ["We", 519], ["did", 522], ["a", 526], ["multicentre", 528], ["prospective", 540], ["pilot", 552], ["study", 558], ["of", 564], ["BP", 567], ["-", 569], ["DBS", 570], ["in", 574], ["13", 577], ["adults", 580], ["with", 587], ["dystonia", 592], ["-", 600], ["choreoathetosis", 601], ["CP", 617], ["who", 620], ["had", 624], ["no", 628], ["cognitive", 631], ["impairment", 641], [",", 651], ["little", 653], ["spasticity", 660], [",", 670], ["and", 672], ["only", 676], ["slight", 681], ["abnormalities", 688], ["of", 702], ["the", 705], ["basal", 709], ["ganglia", 715], ["on", 723], ["MRI", 726], [".", 729], ["The", 731], ["primary", 735], ["endpoint", 743], ["was", 752], ["change", 756], ["in", 763], ["the", 766], ["severity", 770], ["of", 779], ["dystonia", 782], ["-", 790], ["choreoathetosis", 791], ["after", 807], ["1", 813], ["year", 815], ["of", 820], ["neurostimulation", 823], [",", 839], ["as", 841], ["assessed", 844], ["with", 853], ["the", 858], ["Burke", 862], ["-", 867], ["Fahn", 868], ["-", 872], ["Marsden", 873], ["dystonia", 881], ["rating", 890], ["scale", 897], [".", 902], ["The", 904], ["accuracy", 908], ["of", 917], ["surgical", 920], ["targeting", 929], ["to", 939], ["the", 942], ["GPi", 946], ["was", 950], ["assessed", 954], ["masked", 963], ["to", 970], ["the", 973], ["results", 977], ["of", 985], ["neurostimulation", 988], [".", 1004], ["Analysis", 1006], ["was", 1015], ["by", 1019], ["intention", 1022], ["to", 1032], ["treat", 1035], [".", 1040], ["The", 1042], ["mean", 1046], ["Burke", 1051], ["-", 1056], ["Fahn", 1057], ["-", 1061], ["Marsden", 1062], ["dystonia", 1070], ["rating", 1079], ["scale", 1086], ["movement", 1092], ["score", 1101], ["improved", 1107], ["from", 1116], ["44.2", 1121], ["(", 1126], ["SD", 1127], ["21.1", 1130], [")", 1134], ["before", 1136], ["surgery", 1143], ["to", 1151], ["34.7", 1154], ["(", 1159], ["21.9", 1160], [")", 1164], ["at", 1166], ["1", 1169], ["year", 1171], ["post", 1176], ["-", 1180], ["operatively", 1181], ["(", 1193], ["p=0.009", 1194], [";", 1201], ["mean", 1203], ["improvement", 1208], ["24.4", 1220], ["[", 1225], ["21.1]%", 1226], [",", 1232], ["95", 1234], ["%", 1236], ["CI", 1238], ["11.6", 1241], ["-", 1245], ["37.1", 1246], [")", 1250], [".", 1251], ["Functional", 1253], ["disability", 1264], [",", 1274], ["pain", 1276], [",", 1280], ["and", 1282], ["mental", 1286], ["health", 1293], ["-", 1299], ["related", 1300], ["quality", 1308], ["of", 1316], ["life", 1319], ["were", 1324], ["significantly", 1329], ["improved", 1343], [".", 1351], ["There", 1353], ["was", 1359], ["no", 1363], ["worsening", 1366], ["of", 1376], ["cognition", 1379], ["or", 1389], ["mood", 1392], [".", 1396], ["Adverse", 1398], ["events", 1406], ["were", 1413], ["related", 1418], ["to", 1426], ["stimulation", 1429], ["(", 1441], ["arrest", 1442], ["of", 1449], ["the", 1452], ["stimulator", 1456], ["in", 1467], ["one", 1470], ["patient", 1474], [",", 1481], ["and", 1483], ["an", 1487], ["adjustment", 1490], ["to", 1501], ["the", 1504], ["current", 1508], ["intensity", 1516], ["in", 1526], ["four", 1529], ["patients", 1534], [")", 1542], [".", 1543], ["The", 1545], ["optimum", 1549], ["therapeutic", 1557], ["target", 1569], ["was", 1576], ["the", 1580], ["posterolateroventral", 1584], ["region", 1605], ["of", 1612], ["the", 1615], ["GPi", 1619], [".", 1622], ["Little", 1624], ["improvement", 1631], ["was", 1643], ["seen", 1647], ["when", 1652], ["the", 1657], ["neurostimulation", 1661], ["diffused", 1678], ["to", 1687], ["adjacent", 1690], ["structures", 1699], ["(", 1710], ["mainly", 1711], ["to", 1718], ["the", 1721], ["globus", 1725], ["pallidus", 1732], ["externus", 1741], ["[", 1750], ["GPe", 1751], ["]", 1754], [")", 1755], [".", 1756], ["Bilateral", 1758], ["pallidal", 1768], ["neurostimulation", 1777], ["could", 1794], ["be", 1800], ["an", 1803], ["effective", 1806], ["treatment", 1816], ["option", 1826], ["for", 1833], ["patients", 1837], ["with", 1846], ["dystonia", 1851], ["-", 1859], ["choreoathetosis", 1860], ["CP", 1876], [".", 1878], ["However", 1880], [",", 1887], ["given", 1889], ["the", 1895], ["heterogeneity", 1899], ["of", 1913], ["motor", 1916], ["outcomes", 1922], ["and", 1931], ["the", 1935], ["small", 1939], ["sample", 1945], ["size", 1952], [",", 1956], ["results", 1958], ["should", 1966], ["be", 1973], ["interpreted", 1976], ["with", 1988], ["caution", 1993], [".", 2000], ["The", 2002], ["optimum", 2006], ["placement", 2014], ["of", 2024], ["the", 2027], ["leads", 2031], ["seemed", 2037], ["to", 2044], ["be", 2047], ["a", 2050], ["crucial", 2052], [",", 2059], ["but", 2061], ["not", 2065], ["exclusive", 2069], [",", 2078], ["factor", 2080], ["that", 2087], ["could", 2092], ["affect", 2098], ["a", 2105], ["good", 2107], ["outcome", 2112], [".", 2119], ["National", 2121], ["PHRC", 2130], [";", 2134], ["Cerebral", 2136], ["Palsy", 2145], ["Foundation", 2151], [":", 2161], ["Fondation", 2163], ["Motrice", 2173], ["/", 2180], ["APETREIMC", 2181], [";", 2190], ["French", 2192], ["INSERM", 2199], ["Dystonia", 2206], ["National", 2215], ["Network", 2224], [";", 2231], ["Medtronic", 2233], [".", 2242]]}
{"context": "Genome-wide association studies have identified strong associations between the risk of developing Parkinson's disease (PD) and polymorphisms in the genes encoding \u03b1-synuclein and the microtubule-associated protein tau. However, the contribution of tau and its phosphorylated form (p-tau) to \u03b1-synuclein-induced pathology and neuronal dysfunction remains controversial. We have assessed the effects of NAP (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (Thy1-aSyn mice), a model that recapitulates aspects of PD. We found that the p-tau/tau level increased in a subcortical tissue block that includes the striatum and brain stem, and in the cerebellum of the Thy1-aSyn mice compared to nontransgenic controls. Intermittent intranasal NAP administration at 2 \u03bcg/mouse per day, 5 days a week, for 24 weeks, starting at 4 weeks of age, significantly decreased the ratio of p-tau/tau levels in the subcortical region while a higher dose of 15 \u03bcg/mouse per day induced a decrease in p-tau/tau levels in the cerebellum. Both NAP doses reduced hyperactivity, improved habituation to a novel environment, and reduced olfactory deficits in the Thy1-aSyn mice, but neither dose improved the severe deficits of motor coordination observed on the challenging beam and pole, contrasting with previous data obtained with continuous daily administration of the drug. The data reveal novel effects of NAP on brain p-tau/tau and behavioral outcomes in this model of synucleinopathy and suggest that sustained exposure to NAP may be necessary for maximal benefits.", "qas": [{"question": "How many amino acids does davunetide consist of?", "answers": ["eight"], "qid": "f901b6519f424119a7fa622c79803825", "question_tokens": [["How", 0], ["many", 4], ["amino", 9], ["acids", 15], ["does", 21], ["davunetide", 26], ["consist", 37], ["of", 45], ["?", 47]], "detected_answers": [{"text": "eight", "token_spans": [[77, 77]], "char_spans": [[423, 427]]}]}], "context_tokens": [["Genome", 0], ["-", 6], ["wide", 7], ["association", 12], ["studies", 24], ["have", 32], ["identified", 37], ["strong", 48], ["associations", 55], ["between", 68], ["the", 76], ["risk", 80], ["of", 85], ["developing", 88], ["Parkinson", 99], ["'s", 108], ["disease", 111], ["(", 119], ["PD", 120], [")", 122], ["and", 124], ["polymorphisms", 128], ["in", 142], ["the", 145], ["genes", 149], ["encoding", 155], ["\u03b1", 164], ["-", 165], ["synuclein", 166], ["and", 176], ["the", 180], ["microtubule", 184], ["-", 195], ["associated", 196], ["protein", 207], ["tau", 215], [".", 218], ["However", 220], [",", 227], ["the", 229], ["contribution", 233], ["of", 246], ["tau", 249], ["and", 253], ["its", 257], ["phosphorylated", 261], ["form", 276], ["(", 281], ["p", 282], ["-", 283], ["tau", 284], [")", 287], ["to", 289], ["\u03b1", 292], ["-", 293], ["synuclein", 294], ["-", 303], ["induced", 304], ["pathology", 312], ["and", 322], ["neuronal", 326], ["dysfunction", 335], ["remains", 347], ["controversial", 355], [".", 368], ["We", 370], ["have", 373], ["assessed", 378], ["the", 387], ["effects", 391], ["of", 399], ["NAP", 402], ["(", 406], ["davunetide", 407], [")", 417], [",", 418], ["an", 420], ["eight", 423], ["-", 428], ["amino", 429], ["acid", 435], ["peptide", 440], ["that", 448], ["decreases", 453], ["tau", 463], ["hyperphosphorylation", 467], [",", 487], ["in", 489], ["mice", 492], ["overexpressing", 497], ["wild", 512], ["-", 516], ["type", 517], ["human", 522], ["\u03b1", 528], ["-", 529], ["synuclein", 530], ["(", 540], ["Thy1-aSyn", 541], ["mice", 551], [")", 555], [",", 556], ["a", 558], ["model", 560], ["that", 566], ["recapitulates", 571], ["aspects", 585], ["of", 593], ["PD", 596], [".", 598], ["We", 600], ["found", 603], ["that", 609], ["the", 614], ["p", 618], ["-", 619], ["tau", 620], ["/", 623], ["tau", 624], ["level", 628], ["increased", 634], ["in", 644], ["a", 647], ["subcortical", 649], ["tissue", 661], ["block", 668], ["that", 674], ["includes", 679], ["the", 688], ["striatum", 692], ["and", 701], ["brain", 705], ["stem", 711], [",", 715], ["and", 717], ["in", 721], ["the", 724], ["cerebellum", 728], ["of", 739], ["the", 742], ["Thy1-aSyn", 746], ["mice", 756], ["compared", 761], ["to", 770], ["nontransgenic", 773], ["controls", 787], [".", 795], ["Intermittent", 797], ["intranasal", 810], ["NAP", 821], ["administration", 825], ["at", 840], ["2", 843], ["\u03bcg", 845], ["/", 847], ["mouse", 848], ["per", 854], ["day", 858], [",", 861], ["5", 863], ["days", 865], ["a", 870], ["week", 872], [",", 876], ["for", 878], ["24", 882], ["weeks", 885], [",", 890], ["starting", 892], ["at", 901], ["4", 904], ["weeks", 906], ["of", 912], ["age", 915], [",", 918], ["significantly", 920], ["decreased", 934], ["the", 944], ["ratio", 948], ["of", 954], ["p", 957], ["-", 958], ["tau", 959], ["/", 962], ["tau", 963], ["levels", 967], ["in", 974], ["the", 977], ["subcortical", 981], ["region", 993], ["while", 1000], ["a", 1006], ["higher", 1008], ["dose", 1015], ["of", 1020], ["15", 1023], ["\u03bcg", 1026], ["/", 1028], ["mouse", 1029], ["per", 1035], ["day", 1039], ["induced", 1043], ["a", 1051], ["decrease", 1053], ["in", 1062], ["p", 1065], ["-", 1066], ["tau", 1067], ["/", 1070], ["tau", 1071], ["levels", 1075], ["in", 1082], ["the", 1085], ["cerebellum", 1089], [".", 1099], ["Both", 1101], ["NAP", 1106], ["doses", 1110], ["reduced", 1116], ["hyperactivity", 1124], [",", 1137], ["improved", 1139], ["habituation", 1148], ["to", 1160], ["a", 1163], ["novel", 1165], ["environment", 1171], [",", 1182], ["and", 1184], ["reduced", 1188], ["olfactory", 1196], ["deficits", 1206], ["in", 1215], ["the", 1218], ["Thy1-aSyn", 1222], ["mice", 1232], [",", 1236], ["but", 1238], ["neither", 1242], ["dose", 1250], ["improved", 1255], ["the", 1264], ["severe", 1268], ["deficits", 1275], ["of", 1284], ["motor", 1287], ["coordination", 1293], ["observed", 1306], ["on", 1315], ["the", 1318], ["challenging", 1322], ["beam", 1334], ["and", 1339], ["pole", 1343], [",", 1347], ["contrasting", 1349], ["with", 1361], ["previous", 1366], ["data", 1375], ["obtained", 1380], ["with", 1389], ["continuous", 1394], ["daily", 1405], ["administration", 1411], ["of", 1426], ["the", 1429], ["drug", 1433], [".", 1437], ["The", 1439], ["data", 1443], ["reveal", 1448], ["novel", 1455], ["effects", 1461], ["of", 1469], ["NAP", 1472], ["on", 1476], ["brain", 1479], ["p", 1485], ["-", 1486], ["tau", 1487], ["/", 1490], ["tau", 1491], ["and", 1495], ["behavioral", 1499], ["outcomes", 1510], ["in", 1519], ["this", 1522], ["model", 1527], ["of", 1533], ["synucleinopathy", 1536], ["and", 1552], ["suggest", 1556], ["that", 1564], ["sustained", 1569], ["exposure", 1579], ["to", 1588], ["NAP", 1591], ["may", 1595], ["be", 1599], ["necessary", 1602], ["for", 1612], ["maximal", 1616], ["benefits", 1624], [".", 1632]]}
{"context": "MicroRNAs (miRNAs) represent a family of small noncoding RNAs that are found in plants and animals (for recent reviews, see ). miRNAs are expressed in a developmentally and tissue-specific manner and regulate the translational efficiency and stability of partial or fully sequence-complementary mRNAs. miRNAs are excised in a stepwise process from double-stranded RNA precursors that are embedded in long RNA polymerase II primary transcripts (pri-miRNA). Drosha RNase III catalyzes the first excision event, the release in the nucleus of a hairpin RNA (pre-miRNA), which is followed by export of the pre-miRNA to the cytoplasm and further processing by Dicer to mature miRNAs. Here, we characterize the human DGCR8, the DiGeorge syndrome critical region gene 8, and its Drosophila melanogaster homolog. We provide biochemical and cell-based readouts to demonstrate the requirement of DGCR8 for the maturation of miRNA primary transcripts. RNAi knockdown experiments of fly and human DGCR8 resulted in accumulation of pri-miRNAs and reduction of pre-miRNAs and mature miRNAs. Our results suggest that DGCR8 and Drosha interact in human cells and reside in a functional pri-miRNA processing complex.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "a58fef1200654b849fbfc54e893e1678", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[71, 73]], "char_spans": [[405, 421]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["represent", 19], ["a", 29], ["family", 31], ["of", 38], ["small", 41], ["noncoding", 47], ["RNAs", 57], ["that", 62], ["are", 67], ["found", 71], ["in", 77], ["plants", 80], ["and", 87], ["animals", 91], ["(", 99], ["for", 100], ["recent", 104], ["reviews", 111], [",", 118], ["see", 120], [")", 124], [".", 125], ["miRNAs", 127], ["are", 134], ["expressed", 138], ["in", 148], ["a", 151], ["developmentally", 153], ["and", 169], ["tissue", 173], ["-", 179], ["specific", 180], ["manner", 189], ["and", 196], ["regulate", 200], ["the", 209], ["translational", 213], ["efficiency", 227], ["and", 238], ["stability", 242], ["of", 252], ["partial", 255], ["or", 263], ["fully", 266], ["sequence", 272], ["-", 280], ["complementary", 281], ["mRNAs", 295], [".", 300], ["miRNAs", 302], ["are", 309], ["excised", 313], ["in", 321], ["a", 324], ["stepwise", 326], ["process", 335], ["from", 343], ["double", 348], ["-", 354], ["stranded", 355], ["RNA", 364], ["precursors", 368], ["that", 379], ["are", 384], ["embedded", 388], ["in", 397], ["long", 400], ["RNA", 405], ["polymerase", 409], ["II", 420], ["primary", 423], ["transcripts", 431], ["(", 443], ["pri", 444], ["-", 447], ["miRNA", 448], [")", 453], [".", 454], ["Drosha", 456], ["RNase", 463], ["III", 469], ["catalyzes", 473], ["the", 483], ["first", 487], ["excision", 493], ["event", 502], [",", 507], ["the", 509], ["release", 513], ["in", 521], ["the", 524], ["nucleus", 528], ["of", 536], ["a", 539], ["hairpin", 541], ["RNA", 549], ["(", 553], ["pre", 554], ["-", 557], ["miRNA", 558], [")", 563], [",", 564], ["which", 566], ["is", 572], ["followed", 575], ["by", 584], ["export", 587], ["of", 594], ["the", 597], ["pre", 601], ["-", 604], ["miRNA", 605], ["to", 611], ["the", 614], ["cytoplasm", 618], ["and", 628], ["further", 632], ["processing", 640], ["by", 651], ["Dicer", 654], ["to", 660], ["mature", 663], ["miRNAs", 670], [".", 676], ["Here", 678], [",", 682], ["we", 684], ["characterize", 687], ["the", 700], ["human", 704], ["DGCR8", 710], [",", 715], ["the", 717], ["DiGeorge", 721], ["syndrome", 730], ["critical", 739], ["region", 748], ["gene", 755], ["8", 760], [",", 761], ["and", 763], ["its", 767], ["Drosophila", 771], ["melanogaster", 782], ["homolog", 795], [".", 802], ["We", 804], ["provide", 807], ["biochemical", 815], ["and", 827], ["cell", 831], ["-", 835], ["based", 836], ["readouts", 842], ["to", 851], ["demonstrate", 854], ["the", 866], ["requirement", 870], ["of", 882], ["DGCR8", 885], ["for", 891], ["the", 895], ["maturation", 899], ["of", 910], ["miRNA", 913], ["primary", 919], ["transcripts", 927], [".", 938], ["RNAi", 940], ["knockdown", 945], ["experiments", 955], ["of", 967], ["fly", 970], ["and", 974], ["human", 978], ["DGCR8", 984], ["resulted", 990], ["in", 999], ["accumulation", 1002], ["of", 1015], ["pri", 1018], ["-", 1021], ["miRNAs", 1022], ["and", 1029], ["reduction", 1033], ["of", 1043], ["pre", 1046], ["-", 1049], ["miRNAs", 1050], ["and", 1057], ["mature", 1061], ["miRNAs", 1068], [".", 1074], ["Our", 1076], ["results", 1080], ["suggest", 1088], ["that", 1096], ["DGCR8", 1101], ["and", 1107], ["Drosha", 1111], ["interact", 1118], ["in", 1127], ["human", 1130], ["cells", 1136], ["and", 1142], ["reside", 1146], ["in", 1153], ["a", 1156], ["functional", 1158], ["pri", 1169], ["-", 1172], ["miRNA", 1173], ["processing", 1179], ["complex", 1190], [".", 1197]]}
{"context": "Exosomes are a subset of extracellular vesicles (EVs) that have important roles in intercellular communication. They contain and carry bioactive molecules within their membranes which are delivered to target cells. Reproducible isolation and enrichment of these exosomes will aid in evaluation of cellular communication. We present an approach that involved the pre-processing of plasma, combined with ultracentrifugation (UC) and size exclusion chromatography (SEC) to isolate EVs and subsequently enrich exosomes. Four variations of this approach (denoted methods I to IV) were compared. Coupling an ultracentrifugation method with size exclusion chromatography (Method II) provided the best yield by nanoparticle tracking analyses (NTA), the presence of the exosomal markers CD63, Flotillin-1 and TSG-101 (immunoblotting) and showed exosome morphology using transmission electron microscopy (TEM). This method provides an efficient way to enrich the exosomes from blood (plasma), which could be potentially employed for clinical diagnostic assessment and therapeutic intervention.", "qas": [{"question": "What is an exosome?", "answers": ["Exosomes are a subset of extracellular vesicles (EVs) that have important roles in intercellular communication. They contain and carry bioactive molecules within their membranes which are delivered to target cells."], "qid": "d00037f6cfab4221bc08a505c4dfabe5", "question_tokens": [["What", 0], ["is", 5], ["an", 8], ["exosome", 11], ["?", 18]], "detected_answers": [{"text": "Exosomes are a subset of extracellular vesicles (EVs) that have important roles in intercellular communication. They contain and carry bioactive molecules within their membranes which are delivered to target cells.", "token_spans": [[0, 32]], "char_spans": [[0, 212]]}]}], "context_tokens": [["Exosomes", 0], ["are", 9], ["a", 13], ["subset", 15], ["of", 22], ["extracellular", 25], ["vesicles", 39], ["(", 48], ["EVs", 49], [")", 52], ["that", 54], ["have", 59], ["important", 64], ["roles", 74], ["in", 80], ["intercellular", 83], ["communication", 97], [".", 110], ["They", 112], ["contain", 117], ["and", 125], ["carry", 129], ["bioactive", 135], ["molecules", 145], ["within", 155], ["their", 162], ["membranes", 168], ["which", 178], ["are", 184], ["delivered", 188], ["to", 198], ["target", 201], ["cells", 208], [".", 213], ["Reproducible", 215], ["isolation", 228], ["and", 238], ["enrichment", 242], ["of", 253], ["these", 256], ["exosomes", 262], ["will", 271], ["aid", 276], ["in", 280], ["evaluation", 283], ["of", 294], ["cellular", 297], ["communication", 306], [".", 319], ["We", 321], ["present", 324], ["an", 332], ["approach", 335], ["that", 344], ["involved", 349], ["the", 358], ["pre", 362], ["-", 365], ["processing", 366], ["of", 377], ["plasma", 380], [",", 386], ["combined", 388], ["with", 397], ["ultracentrifugation", 402], ["(", 422], ["UC", 423], [")", 425], ["and", 427], ["size", 431], ["exclusion", 436], ["chromatography", 446], ["(", 461], ["SEC", 462], [")", 465], ["to", 467], ["isolate", 470], ["EVs", 478], ["and", 482], ["subsequently", 486], ["enrich", 499], ["exosomes", 506], [".", 514], ["Four", 516], ["variations", 521], ["of", 532], ["this", 535], ["approach", 540], ["(", 549], ["denoted", 550], ["methods", 558], ["I", 566], ["to", 568], ["IV", 571], [")", 573], ["were", 575], ["compared", 580], [".", 588], ["Coupling", 590], ["an", 599], ["ultracentrifugation", 602], ["method", 622], ["with", 629], ["size", 634], ["exclusion", 639], ["chromatography", 649], ["(", 664], ["Method", 665], ["II", 672], [")", 674], ["provided", 676], ["the", 685], ["best", 689], ["yield", 694], ["by", 700], ["nanoparticle", 703], ["tracking", 716], ["analyses", 725], ["(", 734], ["NTA", 735], [")", 738], [",", 739], ["the", 741], ["presence", 745], ["of", 754], ["the", 757], ["exosomal", 761], ["markers", 770], ["CD63", 778], [",", 782], ["Flotillin-1", 784], ["and", 796], ["TSG-101", 800], ["(", 808], ["immunoblotting", 809], [")", 823], ["and", 825], ["showed", 829], ["exosome", 836], ["morphology", 844], ["using", 855], ["transmission", 861], ["electron", 874], ["microscopy", 883], ["(", 894], ["TEM", 895], [")", 898], [".", 899], ["This", 901], ["method", 906], ["provides", 913], ["an", 922], ["efficient", 925], ["way", 935], ["to", 939], ["enrich", 942], ["the", 949], ["exosomes", 953], ["from", 962], ["blood", 967], ["(", 973], ["plasma", 974], [")", 980], [",", 981], ["which", 983], ["could", 989], ["be", 995], ["potentially", 998], ["employed", 1010], ["for", 1019], ["clinical", 1023], ["diagnostic", 1032], ["assessment", 1043], ["and", 1054], ["therapeutic", 1058], ["intervention", 1070], [".", 1082]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contractions of the D4Z4 repeat array in 4q35. We have previously identified a double homeobox gene (DUX4) within each D4Z4 unit that encodes a transcription factor expressed in FSHD but not control myoblasts. DUX4 and its target genes contribute to the global dysregulation of gene expression observed in FSHD. We have now characterized the homologous DUX4c gene mapped 42 kb centromeric of the D4Z4 repeat array. It encodes a 47-kDa protein with a double homeodomain identical to DUX4 but divergent in the carboxyl-terminal region. DUX4c was detected in primary myoblast extracts by Western blot with a specific antiserum, and was induced upon differentiation. The protein was increased about 2-fold in FSHD versus control myotubes but reached 2-10-fold induction in FSHD muscle biopsies. We have shown by Western blot and by a DNA-binding assay that DUX4c over-expression induced the MYF5 myogenic regulator and its DNA-binding activity. DUX4c might stabilize the MYF5 protein as we detected their interaction by co-immunoprecipitation. In keeping with the known role of Myf5 in myoblast accumulation during mouse muscle regeneration DUX4c over-expression activated proliferation of human primary myoblasts and inhibited their differentiation. Altogether, these results suggested that DUX4c could be involved in muscle regeneration and that changes in its expression could contribute to the FSHD pathology.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "a6bcac6859cd40d8bd74d2ec396850ff", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[64, 64], [144, 144], [43, 43], [133, 133], [4, 4], [247, 247]], "char_spans": [[384, 387], [847, 850], [256, 259], [783, 786], [40, 43], [1472, 1475]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["dominant", 51], ["disease", 60], ["linked", 68], ["to", 75], ["contractions", 78], ["of", 91], ["the", 94], ["D4Z4", 98], ["repeat", 103], ["array", 110], ["in", 116], ["4q35", 119], [".", 123], ["We", 125], ["have", 128], ["previously", 133], ["identified", 144], ["a", 155], ["double", 157], ["homeobox", 164], ["gene", 173], ["(", 178], ["DUX4", 179], [")", 183], ["within", 185], ["each", 192], ["D4Z4", 197], ["unit", 202], ["that", 207], ["encodes", 212], ["a", 220], ["transcription", 222], ["factor", 236], ["expressed", 243], ["in", 253], ["FSHD", 256], ["but", 261], ["not", 265], ["control", 269], ["myoblasts", 277], [".", 286], ["DUX4", 288], ["and", 293], ["its", 297], ["target", 301], ["genes", 308], ["contribute", 314], ["to", 325], ["the", 328], ["global", 332], ["dysregulation", 339], ["of", 353], ["gene", 356], ["expression", 361], ["observed", 372], ["in", 381], ["FSHD", 384], [".", 388], ["We", 390], ["have", 393], ["now", 398], ["characterized", 402], ["the", 416], ["homologous", 420], ["DUX4c", 431], ["gene", 437], ["mapped", 442], ["42", 449], ["kb", 452], ["centromeric", 455], ["of", 467], ["the", 470], ["D4Z4", 474], ["repeat", 479], ["array", 486], [".", 491], ["It", 493], ["encodes", 496], ["a", 504], ["47-kDa", 506], ["protein", 513], ["with", 521], ["a", 526], ["double", 528], ["homeodomain", 535], ["identical", 547], ["to", 557], ["DUX4", 560], ["but", 565], ["divergent", 569], ["in", 579], ["the", 582], ["carboxyl", 586], ["-", 594], ["terminal", 595], ["region", 604], [".", 610], ["DUX4c", 612], ["was", 618], ["detected", 622], ["in", 631], ["primary", 634], ["myoblast", 642], ["extracts", 651], ["by", 660], ["Western", 663], ["blot", 671], ["with", 676], ["a", 681], ["specific", 683], ["antiserum", 692], [",", 701], ["and", 703], ["was", 707], ["induced", 711], ["upon", 719], ["differentiation", 724], [".", 739], ["The", 741], ["protein", 745], ["was", 753], ["increased", 757], ["about", 767], ["2-fold", 773], ["in", 780], ["FSHD", 783], ["versus", 788], ["control", 795], ["myotubes", 803], ["but", 812], ["reached", 816], ["2", 824], ["-", 825], ["10-fold", 826], ["induction", 834], ["in", 844], ["FSHD", 847], ["muscle", 852], ["biopsies", 859], [".", 867], ["We", 869], ["have", 872], ["shown", 877], ["by", 883], ["Western", 886], ["blot", 894], ["and", 899], ["by", 903], ["a", 906], ["DNA", 908], ["-", 911], ["binding", 912], ["assay", 920], ["that", 926], ["DUX4c", 931], ["over", 937], ["-", 941], ["expression", 942], ["induced", 953], ["the", 961], ["MYF5", 965], ["myogenic", 970], ["regulator", 979], ["and", 989], ["its", 993], ["DNA", 997], ["-", 1000], ["binding", 1001], ["activity", 1009], [".", 1017], ["DUX4c", 1019], ["might", 1025], ["stabilize", 1031], ["the", 1041], ["MYF5", 1045], ["protein", 1050], ["as", 1058], ["we", 1061], ["detected", 1064], ["their", 1073], ["interaction", 1079], ["by", 1091], ["co", 1094], ["-", 1096], ["immunoprecipitation", 1097], [".", 1116], ["In", 1118], ["keeping", 1121], ["with", 1129], ["the", 1134], ["known", 1138], ["role", 1144], ["of", 1149], ["Myf5", 1152], ["in", 1157], ["myoblast", 1160], ["accumulation", 1169], ["during", 1182], ["mouse", 1189], ["muscle", 1195], ["regeneration", 1202], ["DUX4c", 1215], ["over", 1221], ["-", 1225], ["expression", 1226], ["activated", 1237], ["proliferation", 1247], ["of", 1261], ["human", 1264], ["primary", 1270], ["myoblasts", 1278], ["and", 1288], ["inhibited", 1292], ["their", 1302], ["differentiation", 1308], [".", 1323], ["Altogether", 1325], [",", 1335], ["these", 1337], ["results", 1343], ["suggested", 1351], ["that", 1361], ["DUX4c", 1366], ["could", 1372], ["be", 1378], ["involved", 1381], ["in", 1390], ["muscle", 1393], ["regeneration", 1400], ["and", 1413], ["that", 1417], ["changes", 1422], ["in", 1430], ["its", 1433], ["expression", 1437], ["could", 1448], ["contribute", 1454], ["to", 1465], ["the", 1468], ["FSHD", 1472], ["pathology", 1477], [".", 1486]]}
{"context": "Diurnal effects on motor control are evident in the human disease of Restless Leg Syndrome (RLS), which is purported to be linked to brain iron deficiency as well as alterations in dopaminergic systems. Thus, we explored the relationship between daily rhythms, the onset of motor dysregulation and brain iron deficiency in an animal model of iron deficiency. Male and female weanling Sprague-Dawley rats consuming control (CN) or iron-deficient (ID) diets were examined weekly for acoustic startle response (ASR) and prepulse inhibition (PPI) for a 5-week period. Iron deficiency reduced the magnitude, but not timing, of the ASR at specific time points. ASR was elevated 60% at the onset of the dark cycle relative to the median of the light cycle in male CN and ID rats. The respective elevation was 400% and 150% in female CN and ID rats during the first 2 weeks of testing. The diurnal cycle of ASR response was attenuated by 3 weeks of testing in both dietary treatment groups. PPI was not affected by iron deficiency, sex, diurnal cycle or the interaction between these factors. These results thus demonstrate that iron deficiency moderately alters ASR signaling although the inhibitory pathways of ASR do not appear to be affected.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "e001a3c4b9fb42529a630cc6884b137b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[27, 27], [61, 61], [106, 106], [54, 54], [198, 198], [217, 217], [78, 78]], "char_spans": [[139, 142], [342, 345], [564, 567], [304, 307], [1007, 1010], [1121, 1124], [430, 433]]}]}], "context_tokens": [["Diurnal", 0], ["effects", 8], ["on", 16], ["motor", 19], ["control", 25], ["are", 33], ["evident", 37], ["in", 45], ["the", 48], ["human", 52], ["disease", 58], ["of", 66], ["Restless", 69], ["Leg", 78], ["Syndrome", 82], ["(", 91], ["RLS", 92], [")", 95], [",", 96], ["which", 98], ["is", 104], ["purported", 107], ["to", 117], ["be", 120], ["linked", 123], ["to", 130], ["brain", 133], ["iron", 139], ["deficiency", 144], ["as", 155], ["well", 158], ["as", 163], ["alterations", 166], ["in", 178], ["dopaminergic", 181], ["systems", 194], [".", 201], ["Thus", 203], [",", 207], ["we", 209], ["explored", 212], ["the", 221], ["relationship", 225], ["between", 238], ["daily", 246], ["rhythms", 252], [",", 259], ["the", 261], ["onset", 265], ["of", 271], ["motor", 274], ["dysregulation", 280], ["and", 294], ["brain", 298], ["iron", 304], ["deficiency", 309], ["in", 320], ["an", 323], ["animal", 326], ["model", 333], ["of", 339], ["iron", 342], ["deficiency", 347], [".", 357], ["Male", 359], ["and", 364], ["female", 368], ["weanling", 375], ["Sprague", 384], ["-", 391], ["Dawley", 392], ["rats", 399], ["consuming", 404], ["control", 414], ["(", 422], ["CN", 423], [")", 425], ["or", 427], ["iron", 430], ["-", 434], ["deficient", 435], ["(", 445], ["ID", 446], [")", 448], ["diets", 450], ["were", 456], ["examined", 461], ["weekly", 470], ["for", 477], ["acoustic", 481], ["startle", 490], ["response", 498], ["(", 507], ["ASR", 508], [")", 511], ["and", 513], ["prepulse", 517], ["inhibition", 526], ["(", 537], ["PPI", 538], [")", 541], ["for", 543], ["a", 547], ["5-week", 549], ["period", 556], [".", 562], ["Iron", 564], ["deficiency", 569], ["reduced", 580], ["the", 588], ["magnitude", 592], [",", 601], ["but", 603], ["not", 607], ["timing", 611], [",", 617], ["of", 619], ["the", 622], ["ASR", 626], ["at", 630], ["specific", 633], ["time", 642], ["points", 647], [".", 653], ["ASR", 655], ["was", 659], ["elevated", 663], ["60", 672], ["%", 674], ["at", 676], ["the", 679], ["onset", 683], ["of", 689], ["the", 692], ["dark", 696], ["cycle", 701], ["relative", 707], ["to", 716], ["the", 719], ["median", 723], ["of", 730], ["the", 733], ["light", 737], ["cycle", 743], ["in", 749], ["male", 752], ["CN", 757], ["and", 760], ["ID", 764], ["rats", 767], [".", 771], ["The", 773], ["respective", 777], ["elevation", 788], ["was", 798], ["400", 802], ["%", 805], ["and", 807], ["150", 811], ["%", 814], ["in", 816], ["female", 819], ["CN", 826], ["and", 829], ["ID", 833], ["rats", 836], ["during", 841], ["the", 848], ["first", 852], ["2", 858], ["weeks", 860], ["of", 866], ["testing", 869], [".", 876], ["The", 878], ["diurnal", 882], ["cycle", 890], ["of", 896], ["ASR", 899], ["response", 903], ["was", 912], ["attenuated", 916], ["by", 927], ["3", 930], ["weeks", 932], ["of", 938], ["testing", 941], ["in", 949], ["both", 952], ["dietary", 957], ["treatment", 965], ["groups", 975], [".", 981], ["PPI", 983], ["was", 987], ["not", 991], ["affected", 995], ["by", 1004], ["iron", 1007], ["deficiency", 1012], [",", 1022], ["sex", 1024], [",", 1027], ["diurnal", 1029], ["cycle", 1037], ["or", 1043], ["the", 1046], ["interaction", 1050], ["between", 1062], ["these", 1070], ["factors", 1076], [".", 1083], ["These", 1085], ["results", 1091], ["thus", 1099], ["demonstrate", 1104], ["that", 1116], ["iron", 1121], ["deficiency", 1126], ["moderately", 1137], ["alters", 1148], ["ASR", 1155], ["signaling", 1159], ["although", 1169], ["the", 1178], ["inhibitory", 1182], ["pathways", 1193], ["of", 1202], ["ASR", 1205], ["do", 1209], ["not", 1212], ["appear", 1216], ["to", 1223], ["be", 1226], ["affected", 1229], [".", 1237]]}
{"context": "McLeod syndrome is an X-linked multisystem disorder characterized by abnormalities in the neuromuscular and hematopoietic systems. We have assembled a cosmid contig of 360 kb that encompasses the McLeod gene locus. A 50 kb deletion was detected by screening DNA from patients with radiolabeled whole cosmids, and two transcription units were identified within this deletion. The mRNA expression pattern of one of them, designated as XK, correlates closely to the McLeod phenotype. XK encodes a novel protein with structural characteristics of prokaryotic and eukaryotic membrane transport proteins. Nucleotide sequence analysis of XK from two unrelated McLeod patients has identified point mutations at conserved splice donor and acceptor sites. These findings provide direct evidence that XK is responsible for McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "b09a032cfe6b458dad0480594898b130", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[72, 72], [81, 81], [101, 101], [125, 125]], "char_spans": [[433, 434], [481, 482], [631, 632], [790, 791]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["is", 16], ["an", 19], ["X", 22], ["-", 23], ["linked", 24], ["multisystem", 31], ["disorder", 43], ["characterized", 52], ["by", 66], ["abnormalities", 69], ["in", 83], ["the", 86], ["neuromuscular", 90], ["and", 104], ["hematopoietic", 108], ["systems", 122], [".", 129], ["We", 131], ["have", 134], ["assembled", 139], ["a", 149], ["cosmid", 151], ["contig", 158], ["of", 165], ["360", 168], ["kb", 172], ["that", 175], ["encompasses", 180], ["the", 192], ["McLeod", 196], ["gene", 203], ["locus", 208], [".", 213], ["A", 215], ["50", 217], ["kb", 220], ["deletion", 223], ["was", 232], ["detected", 236], ["by", 245], ["screening", 248], ["DNA", 258], ["from", 262], ["patients", 267], ["with", 276], ["radiolabeled", 281], ["whole", 294], ["cosmids", 300], [",", 307], ["and", 309], ["two", 313], ["transcription", 317], ["units", 331], ["were", 337], ["identified", 342], ["within", 353], ["this", 360], ["deletion", 365], [".", 373], ["The", 375], ["mRNA", 379], ["expression", 384], ["pattern", 395], ["of", 403], ["one", 406], ["of", 410], ["them", 413], [",", 417], ["designated", 419], ["as", 430], ["XK", 433], [",", 435], ["correlates", 437], ["closely", 448], ["to", 456], ["the", 459], ["McLeod", 463], ["phenotype", 470], [".", 479], ["XK", 481], ["encodes", 484], ["a", 492], ["novel", 494], ["protein", 500], ["with", 508], ["structural", 513], ["characteristics", 524], ["of", 540], ["prokaryotic", 543], ["and", 555], ["eukaryotic", 559], ["membrane", 570], ["transport", 579], ["proteins", 589], [".", 597], ["Nucleotide", 599], ["sequence", 610], ["analysis", 619], ["of", 628], ["XK", 631], ["from", 634], ["two", 639], ["unrelated", 643], ["McLeod", 653], ["patients", 660], ["has", 669], ["identified", 673], ["point", 684], ["mutations", 690], ["at", 700], ["conserved", 703], ["splice", 713], ["donor", 720], ["and", 726], ["acceptor", 730], ["sites", 739], [".", 744], ["These", 746], ["findings", 752], ["provide", 761], ["direct", 769], ["evidence", 776], ["that", 785], ["XK", 790], ["is", 793], ["responsible", 796], ["for", 808], ["McLeod", 812], ["syndrome", 819], [".", 827]]}
{"context": "Cortical dysplasias comprise a variable spectrum of clinical, neuroradiological and histopathological findings. We report about a cohort of 25 pediatric patients (mean age 8.1+/-4.8 years) with severe drug-resistant early onset focal epilepsies (mean duration 2.1+/-0.4 years), mental/psychomotor retardation, and multilobar epileptogenesis. Compared to age-matched biopsy controls, microscopical inspection of neurosurgically resected specimens revealed dysplastic neurons with/without balloon cells in only 7 patients. According to Palmini's classification system, these lesions were categorized as focal cortical dysplasia (FCD) type II. All other patients presented with rather subtle but statistically significant neuroanatomical abnormalities. We identified increased numbers of ectopic neurons in white matter and cortical gliosis. However, most intriguing was our finding of a microcolumnar arrangement of cortical neurons in layer III. These microcolumns can be statistically defined as vertical lining of more than eight neurons (two times standard deviation of cell countings obtained from controls). In addition, neuronal perikarya were significantly smaller in epilepsy patients. Although histological abnormalities occurring during postnatal maturation of the brain challenge any neuropathological classification in this group of young patients, we propose that these findings are classified according to FCD type I. Our observations support a concept compatible with regional loss of high-order brain organization.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "77a1eb46e1a443b7a081e53c29ae2ce0", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[93, 95]], "char_spans": [[601, 624]]}]}], "context_tokens": [["Cortical", 0], ["dysplasias", 9], ["comprise", 20], ["a", 29], ["variable", 31], ["spectrum", 40], ["of", 49], ["clinical", 52], [",", 60], ["neuroradiological", 62], ["and", 80], ["histopathological", 84], ["findings", 102], [".", 110], ["We", 112], ["report", 115], ["about", 122], ["a", 128], ["cohort", 130], ["of", 137], ["25", 140], ["pediatric", 143], ["patients", 153], ["(", 162], ["mean", 163], ["age", 168], ["8.1+/-4.8", 172], ["years", 182], [")", 187], ["with", 189], ["severe", 194], ["drug", 201], ["-", 205], ["resistant", 206], ["early", 216], ["onset", 222], ["focal", 228], ["epilepsies", 234], ["(", 245], ["mean", 246], ["duration", 251], ["2.1+/-0.4", 260], ["years", 270], [")", 275], [",", 276], ["mental", 278], ["/", 284], ["psychomotor", 285], ["retardation", 297], [",", 308], ["and", 310], ["multilobar", 314], ["epileptogenesis", 325], [".", 340], ["Compared", 342], ["to", 351], ["age", 354], ["-", 357], ["matched", 358], ["biopsy", 366], ["controls", 373], [",", 381], ["microscopical", 383], ["inspection", 397], ["of", 408], ["neurosurgically", 411], ["resected", 427], ["specimens", 436], ["revealed", 446], ["dysplastic", 455], ["neurons", 466], ["with", 474], ["/", 478], ["without", 479], ["balloon", 487], ["cells", 495], ["in", 501], ["only", 504], ["7", 509], ["patients", 511], [".", 519], ["According", 521], ["to", 531], ["Palmini", 534], ["'s", 541], ["classification", 544], ["system", 559], [",", 565], ["these", 567], ["lesions", 573], ["were", 581], ["categorized", 586], ["as", 598], ["focal", 601], ["cortical", 607], ["dysplasia", 616], ["(", 626], ["FCD", 627], [")", 630], ["type", 632], ["II", 637], [".", 639], ["All", 641], ["other", 645], ["patients", 651], ["presented", 660], ["with", 670], ["rather", 675], ["subtle", 682], ["but", 689], ["statistically", 693], ["significant", 707], ["neuroanatomical", 719], ["abnormalities", 735], [".", 748], ["We", 750], ["identified", 753], ["increased", 764], ["numbers", 774], ["of", 782], ["ectopic", 785], ["neurons", 793], ["in", 801], ["white", 804], ["matter", 810], ["and", 817], ["cortical", 821], ["gliosis", 830], [".", 837], ["However", 839], [",", 846], ["most", 848], ["intriguing", 853], ["was", 864], ["our", 868], ["finding", 872], ["of", 880], ["a", 883], ["microcolumnar", 885], ["arrangement", 899], ["of", 911], ["cortical", 914], ["neurons", 923], ["in", 931], ["layer", 934], ["III", 940], [".", 943], ["These", 945], ["microcolumns", 951], ["can", 964], ["be", 968], ["statistically", 971], ["defined", 985], ["as", 993], ["vertical", 996], ["lining", 1005], ["of", 1012], ["more", 1015], ["than", 1020], ["eight", 1025], ["neurons", 1031], ["(", 1039], ["two", 1040], ["times", 1044], ["standard", 1050], ["deviation", 1059], ["of", 1069], ["cell", 1072], ["countings", 1077], ["obtained", 1087], ["from", 1096], ["controls", 1101], [")", 1109], [".", 1110], ["In", 1112], ["addition", 1115], [",", 1123], ["neuronal", 1125], ["perikarya", 1134], ["were", 1144], ["significantly", 1149], ["smaller", 1163], ["in", 1171], ["epilepsy", 1174], ["patients", 1183], [".", 1191], ["Although", 1193], ["histological", 1202], ["abnormalities", 1215], ["occurring", 1229], ["during", 1239], ["postnatal", 1246], ["maturation", 1256], ["of", 1267], ["the", 1270], ["brain", 1274], ["challenge", 1280], ["any", 1290], ["neuropathological", 1294], ["classification", 1312], ["in", 1327], ["this", 1330], ["group", 1335], ["of", 1341], ["young", 1344], ["patients", 1350], [",", 1358], ["we", 1360], ["propose", 1363], ["that", 1371], ["these", 1376], ["findings", 1382], ["are", 1391], ["classified", 1395], ["according", 1406], ["to", 1416], ["FCD", 1419], ["type", 1423], ["I.", 1428], ["Our", 1431], ["observations", 1435], ["support", 1448], ["a", 1456], ["concept", 1458], ["compatible", 1466], ["with", 1477], ["regional", 1482], ["loss", 1491], ["of", 1496], ["high", 1499], ["-", 1503], ["order", 1504], ["brain", 1510], ["organization", 1516], [".", 1528]]}
{"context": "Genome-wide association studies (GWASs) have successfully identified many sequence variants that are significantly associated with common diseases and traits. Tens of thousands of such trait-associated SNPs have already been cataloged, which we believe form a great resource for genomic research. Recent studies have demonstrated that the collection of trait-associated SNPs can be exploited to indicate whether a given genomic interval or intervals are likely to be functionally connected with certain phenotypes or diseases. Despite this importance, currently, there is no ready-to-use computational tool able to connect genomic intervals to phenotypes. Here, we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD. The traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.edu Supplementary data are available at Bioinformatics online.", "qas": [{"question": "Which R / bioconductor package is used for performing SNP enrichment analysis?", "answers": ["traseR"], "qid": "4c0b847bbf21420988f6bc921c0b8906", "question_tokens": [["Which", 0], ["R", 6], ["/", 8], ["bioconductor", 10], ["package", 23], ["is", 31], ["used", 34], ["for", 39], ["performing", 43], ["SNP", 54], ["enrichment", 58], ["analysis", 69], ["?", 77]], "detected_answers": [{"text": "traseR", "token_spans": [[156, 156], [113, 113]], "char_spans": [[910, 915], [673, 678]]}]}], "context_tokens": [["Genome", 0], ["-", 6], ["wide", 7], ["association", 12], ["studies", 24], ["(", 32], ["GWASs", 33], [")", 38], ["have", 40], ["successfully", 45], ["identified", 58], ["many", 69], ["sequence", 74], ["variants", 83], ["that", 92], ["are", 97], ["significantly", 101], ["associated", 115], ["with", 126], ["common", 131], ["diseases", 138], ["and", 147], ["traits", 151], [".", 157], ["Tens", 159], ["of", 164], ["thousands", 167], ["of", 177], ["such", 180], ["trait", 185], ["-", 190], ["associated", 191], ["SNPs", 202], ["have", 207], ["already", 212], ["been", 220], ["cataloged", 225], [",", 234], ["which", 236], ["we", 242], ["believe", 245], ["form", 253], ["a", 258], ["great", 260], ["resource", 266], ["for", 275], ["genomic", 279], ["research", 287], [".", 295], ["Recent", 297], ["studies", 304], ["have", 312], ["demonstrated", 317], ["that", 330], ["the", 335], ["collection", 339], ["of", 350], ["trait", 353], ["-", 358], ["associated", 359], ["SNPs", 370], ["can", 375], ["be", 379], ["exploited", 382], ["to", 392], ["indicate", 395], ["whether", 404], ["a", 412], ["given", 414], ["genomic", 420], ["interval", 428], ["or", 437], ["intervals", 440], ["are", 450], ["likely", 454], ["to", 461], ["be", 464], ["functionally", 467], ["connected", 480], ["with", 490], ["certain", 495], ["phenotypes", 503], ["or", 514], ["diseases", 517], [".", 525], ["Despite", 527], ["this", 535], ["importance", 540], [",", 550], ["currently", 552], [",", 561], ["there", 563], ["is", 569], ["no", 572], ["ready", 575], ["-", 580], ["to", 581], ["-", 583], ["use", 584], ["computational", 588], ["tool", 602], ["able", 607], ["to", 612], ["connect", 615], ["genomic", 623], ["intervals", 631], ["to", 641], ["phenotypes", 644], [".", 654], ["Here", 656], [",", 660], ["we", 662], ["present", 665], ["traseR", 673], [",", 679], ["an", 681], ["easy", 684], ["-", 688], ["to", 689], ["-", 691], ["use", 692], ["R", 696], ["Bioconductor", 698], ["package", 711], ["that", 719], ["performs", 724], ["enrichment", 733], ["analyses", 744], ["of", 753], ["trait", 756], ["-", 761], ["associated", 762], ["SNPs", 773], ["in", 778], ["arbitrary", 781], ["genomic", 791], ["intervals", 799], ["with", 809], ["flexible", 814], ["options", 823], [",", 830], ["including", 832], ["testing", 842], ["method", 850], [",", 856], ["type", 858], ["of", 863], ["background", 866], ["and", 877], ["inclusion", 881], ["of", 891], ["SNPs", 894], ["in", 899], ["LD", 902], [".", 904], ["The", 906], ["traseR", 910], ["R", 917], ["package", 919], ["preloaded", 927], ["with", 937], ["up", 942], ["-", 944], ["to", 945], ["-", 947], ["date", 948], ["collection", 953], ["of", 964], ["trait", 967], ["-", 972], ["associated", 973], ["SNPs", 984], ["are", 989], ["freely", 993], ["available", 1000], ["in", 1010], ["Bioconductor", 1013], ["zhaohui.qin@emory.edu", 1026], ["Supplementary", 1048], ["data", 1062], ["are", 1067], ["available", 1071], ["at", 1081], ["Bioinformatics", 1084], ["online", 1099], [".", 1105]]}
{"context": "ESET (ERG-associated protein with a SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-K9). Here we describe the genomic structure and expression of the mouse ESET gene that gives rise to ESET protein and its alternative splicing product. ESET is a 36-kb single copy gene and full-length ESET transcript consisting of 22 exons. The splicing variant retains only the first 12 exons and thus lacks sequences encoding the methyl CpG-binding domain and the catalytic SET domain. The U2 type conserved GT/AG consensus sequence is present at all of the splicing junctions within the ESET gene. The transcription initiation site of the ESET gene was determined by 5'-RACE experiment and by primer extension. The 5'-flanking sequence of the ESET gene does not contain the consensus TATA box. Instead, this ESET promoter region has features such as SP1-binding sites that are typical of housekeeping genes. The ESET promoter was functionally active when tested in transfection and luciferase assay. Full-length ESET transcript appears to be ubiquitously expressed. While the SET domain-deficient splicing variant is present in immortalized cell lines, it is undetectable by RT-PCR in the majority of normal mouse tissues.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "10848a4c98c7472199863319754dae63", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[8, 9], [97, 98], [201, 202]], "char_spans": [[36, 45], [535, 544], [1138, 1147]]}]}], "context_tokens": [["ESET", 0], ["(", 5], ["ERG", 6], ["-", 9], ["associated", 10], ["protein", 21], ["with", 29], ["a", 34], ["SET", 36], ["domain", 40], [",", 46], ["also", 48], ["called", 53], ["SETDB1", 60], [")", 66], ["is", 68], ["a", 71], ["novel", 73], ["histone", 79], ["methyltransferase", 87], ["that", 105], ["catalyzes", 110], ["methylation", 120], ["of", 132], ["histone", 135], ["H3-lysine", 143], ["9", 153], ["(", 155], ["H3-K9", 156], [")", 161], [".", 162], ["Here", 164], ["we", 169], ["describe", 172], ["the", 181], ["genomic", 185], ["structure", 193], ["and", 203], ["expression", 207], ["of", 218], ["the", 221], ["mouse", 225], ["ESET", 231], ["gene", 236], ["that", 241], ["gives", 246], ["rise", 252], ["to", 257], ["ESET", 260], ["protein", 265], ["and", 273], ["its", 277], ["alternative", 281], ["splicing", 293], ["product", 302], [".", 309], ["ESET", 311], ["is", 316], ["a", 319], ["36-kb", 321], ["single", 327], ["copy", 334], ["gene", 339], ["and", 344], ["full", 348], ["-", 352], ["length", 353], ["ESET", 360], ["transcript", 365], ["consisting", 376], ["of", 387], ["22", 390], ["exons", 393], [".", 398], ["The", 400], ["splicing", 404], ["variant", 413], ["retains", 421], ["only", 429], ["the", 434], ["first", 438], ["12", 444], ["exons", 447], ["and", 453], ["thus", 457], ["lacks", 462], ["sequences", 468], ["encoding", 478], ["the", 487], ["methyl", 491], ["CpG", 498], ["-", 501], ["binding", 502], ["domain", 510], ["and", 517], ["the", 521], ["catalytic", 525], ["SET", 535], ["domain", 539], [".", 545], ["The", 547], ["U2", 551], ["type", 554], ["conserved", 559], ["GT", 569], ["/", 571], ["AG", 572], ["consensus", 575], ["sequence", 585], ["is", 594], ["present", 597], ["at", 605], ["all", 608], ["of", 612], ["the", 615], ["splicing", 619], ["junctions", 628], ["within", 638], ["the", 645], ["ESET", 649], ["gene", 654], [".", 658], ["The", 660], ["transcription", 664], ["initiation", 678], ["site", 689], ["of", 694], ["the", 697], ["ESET", 701], ["gene", 706], ["was", 711], ["determined", 715], ["by", 726], ["5'-RACE", 729], ["experiment", 737], ["and", 748], ["by", 752], ["primer", 755], ["extension", 762], [".", 771], ["The", 773], ["5'-flanking", 777], ["sequence", 789], ["of", 798], ["the", 801], ["ESET", 805], ["gene", 810], ["does", 815], ["not", 820], ["contain", 824], ["the", 832], ["consensus", 836], ["TATA", 846], ["box", 851], [".", 854], ["Instead", 856], [",", 863], ["this", 865], ["ESET", 870], ["promoter", 875], ["region", 884], ["has", 891], ["features", 895], ["such", 904], ["as", 909], ["SP1-binding", 912], ["sites", 924], ["that", 930], ["are", 935], ["typical", 939], ["of", 947], ["housekeeping", 950], ["genes", 963], [".", 968], ["The", 970], ["ESET", 974], ["promoter", 979], ["was", 988], ["functionally", 992], ["active", 1005], ["when", 1012], ["tested", 1017], ["in", 1024], ["transfection", 1027], ["and", 1040], ["luciferase", 1044], ["assay", 1055], [".", 1060], ["Full", 1062], ["-", 1066], ["length", 1067], ["ESET", 1074], ["transcript", 1079], ["appears", 1090], ["to", 1098], ["be", 1101], ["ubiquitously", 1104], ["expressed", 1117], [".", 1126], ["While", 1128], ["the", 1134], ["SET", 1138], ["domain", 1142], ["-", 1148], ["deficient", 1149], ["splicing", 1159], ["variant", 1168], ["is", 1176], ["present", 1179], ["in", 1187], ["immortalized", 1190], ["cell", 1203], ["lines", 1208], [",", 1213], ["it", 1215], ["is", 1218], ["undetectable", 1221], ["by", 1234], ["RT", 1237], ["-", 1239], ["PCR", 1240], ["in", 1244], ["the", 1247], ["majority", 1251], ["of", 1260], ["normal", 1263], ["mouse", 1270], ["tissues", 1276], [".", 1283]]}
{"context": "Many studies have reported that the generation of reactive oxygen species (ROS) increases during the differentiation of muscle-derived C2C12 cells. Peroxiredoxin-2 (Prx-2) is an abundant mammalian enzyme that protects against oxidative stress. However, the role of Prx-2 in muscle differentiation has not been investigated. In this study, we demonstrated that Prx-2 expression increases during muscle differentiation and regeneration in response to exogenous H(2)O(2). This increase occurs only in myoblast cell lines because no increase in Prx-2 expression was observed in the NIH3T3, MEF, Chang, or HEK293 cell lines. The antioxidants, N-acetyl L-cysteine (NAC) and 4,5-dihydroxy-1,3-benzenedisulfonic acid (Tiron), both suppressed myogenesis and Prx-2 expression. Moreover, Prx-2 was upregulated at the transcriptional level by NF-\u03baB during the differentiation of muscle-derived C2C12 cells. We also found that inhibition of phosphatidylinositol 3-kinase (PI3K) blocks NF-\u03baB activation and suppresses Prx-2 expression. Interestingly, Prx-2 knockdown increased the expression levels of other antioxidant enzymes, including all of the other Prx family member, thioredoxin-1 (Trx-1) and catalase, but also enhanced the accumulation of endogenous ROS during muscle differentiation. In this study, we demonstrated for the first time that Prx-2 is unregulated during the muscle differentiation and regeneration. Prx-2 is upregulated via the PI3K/NF-\u03baB pathway and attenuates oxidative stress during muscle differentiation and regeneration.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4f34ebb86bd542e3a0ce6e21de3fe86a", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[186, 186]], "char_spans": [[1094, 1104]]}]}], "context_tokens": [["Many", 0], ["studies", 5], ["have", 13], ["reported", 18], ["that", 27], ["the", 32], ["generation", 36], ["of", 47], ["reactive", 50], ["oxygen", 59], ["species", 66], ["(", 74], ["ROS", 75], [")", 78], ["increases", 80], ["during", 90], ["the", 97], ["differentiation", 101], ["of", 117], ["muscle", 120], ["-", 126], ["derived", 127], ["C2C12", 135], ["cells", 141], [".", 146], ["Peroxiredoxin-2", 148], ["(", 164], ["Prx-2", 165], [")", 170], ["is", 172], ["an", 175], ["abundant", 178], ["mammalian", 187], ["enzyme", 197], ["that", 204], ["protects", 209], ["against", 218], ["oxidative", 226], ["stress", 236], [".", 242], ["However", 244], [",", 251], ["the", 253], ["role", 257], ["of", 262], ["Prx-2", 265], ["in", 271], ["muscle", 274], ["differentiation", 281], ["has", 297], ["not", 301], ["been", 305], ["investigated", 310], [".", 322], ["In", 324], ["this", 327], ["study", 332], [",", 337], ["we", 339], ["demonstrated", 342], ["that", 355], ["Prx-2", 360], ["expression", 366], ["increases", 377], ["during", 387], ["muscle", 394], ["differentiation", 401], ["and", 417], ["regeneration", 421], ["in", 434], ["response", 437], ["to", 446], ["exogenous", 449], ["H(2)O(2", 459], [")", 466], [".", 467], ["This", 469], ["increase", 474], ["occurs", 483], ["only", 490], ["in", 495], ["myoblast", 498], ["cell", 507], ["lines", 512], ["because", 518], ["no", 526], ["increase", 529], ["in", 538], ["Prx-2", 541], ["expression", 547], ["was", 558], ["observed", 562], ["in", 571], ["the", 574], ["NIH3T3", 578], [",", 584], ["MEF", 586], [",", 589], ["Chang", 591], [",", 596], ["or", 598], ["HEK293", 601], ["cell", 608], ["lines", 613], [".", 618], ["The", 620], ["antioxidants", 624], [",", 636], ["N", 638], ["-", 639], ["acetyl", 640], ["L", 647], ["-", 648], ["cysteine", 649], ["(", 658], ["NAC", 659], [")", 662], ["and", 664], ["4,5-dihydroxy-1,3-benzenedisulfonic", 668], ["acid", 704], ["(", 709], ["Tiron", 710], [")", 715], [",", 716], ["both", 718], ["suppressed", 723], ["myogenesis", 734], ["and", 745], ["Prx-2", 749], ["expression", 755], [".", 765], ["Moreover", 767], [",", 775], ["Prx-2", 777], ["was", 783], ["upregulated", 787], ["at", 799], ["the", 802], ["transcriptional", 806], ["level", 822], ["by", 828], ["NF", 831], ["-", 833], ["\u03baB", 834], ["during", 837], ["the", 844], ["differentiation", 848], ["of", 864], ["muscle", 867], ["-", 873], ["derived", 874], ["C2C12", 882], ["cells", 888], [".", 893], ["We", 895], ["also", 898], ["found", 903], ["that", 909], ["inhibition", 914], ["of", 925], ["phosphatidylinositol", 928], ["3-kinase", 949], ["(", 958], ["PI3", 959], ["K", 962], [")", 963], ["blocks", 965], ["NF", 972], ["-", 974], ["\u03baB", 975], ["activation", 978], ["and", 989], ["suppresses", 993], ["Prx-2", 1004], ["expression", 1010], [".", 1020], ["Interestingly", 1022], [",", 1035], ["Prx-2", 1037], ["knockdown", 1043], ["increased", 1053], ["the", 1063], ["expression", 1067], ["levels", 1078], ["of", 1085], ["other", 1088], ["antioxidant", 1094], ["enzymes", 1106], [",", 1113], ["including", 1115], ["all", 1125], ["of", 1129], ["the", 1132], ["other", 1136], ["Prx", 1142], ["family", 1146], ["member", 1153], [",", 1159], ["thioredoxin-1", 1161], ["(", 1175], ["Trx-1", 1176], [")", 1181], ["and", 1183], ["catalase", 1187], [",", 1195], ["but", 1197], ["also", 1201], ["enhanced", 1206], ["the", 1215], ["accumulation", 1219], ["of", 1232], ["endogenous", 1235], ["ROS", 1246], ["during", 1250], ["muscle", 1257], ["differentiation", 1264], [".", 1279], ["In", 1281], ["this", 1284], ["study", 1289], [",", 1294], ["we", 1296], ["demonstrated", 1299], ["for", 1312], ["the", 1316], ["first", 1320], ["time", 1326], ["that", 1331], ["Prx-2", 1336], ["is", 1342], ["unregulated", 1345], ["during", 1357], ["the", 1364], ["muscle", 1368], ["differentiation", 1375], ["and", 1391], ["regeneration", 1395], [".", 1407], ["Prx-2", 1409], ["is", 1415], ["upregulated", 1418], ["via", 1430], ["the", 1434], ["PI3K", 1438], ["/", 1442], ["NF", 1443], ["-", 1445], ["\u03baB", 1446], ["pathway", 1449], ["and", 1457], ["attenuates", 1461], ["oxidative", 1472], ["stress", 1482], ["during", 1489], ["muscle", 1496], ["differentiation", 1503], ["and", 1519], ["regeneration", 1523], [".", 1535]]}
{"context": "Human erythrocyte spectrin is an antiparallel heterodimer comprised of a 280 kDa alpha subunit and a 246 kDa beta subunit which further associates into tetramers in the red cell membrane cytoskeleton. Lateral association of the flexible rodlike monomers involves a multiple-step process that is initiated by a high affinity association near the actin-binding end of the molecule (dimer nucleation site). In this study, recombinant alpha and beta proteins comprising two or four \"spectrin type\" motifs with and without adjacent, terminal nonhomologous domains were evaluated for their relative contributions to dimer initiation, and the thermodynamic properties of these heterodimer complexes were measured. Sedimentation equilibrium studies showed that in the absence of the heterologous subunit, individual recombinant proteins formed weak homodimers (K(d) > 0.3 mM). When 2-motif (alpha20-21 and beta1-2) and 4-motif (alpha18-21 and beta1-4) recombinants lacking the terminal nonhomologous domains were paired with the complementary protein, high affinity heterodimers were formed in sedimentation equilibrium analysis. Both the alpha20-21/beta1-2 complex and the alpha20-21EF/betaABD1-2 complex showed stoichiometric binding with similar binding affinities (K(d) approximately 10 nM) using isothermal titration calorimetry. The alpha20-21/beta1-2 complex showed an enthalpy of -10 kcal/mol, while the alpha20-21EF/betaABD1-2 complex showed an enthalpy of -13 kcal/mol. Pull-down assays using alpha spectrin GST fusion proteins showed strong associations between all heterodimer complexes in physiological buffer, but all heterodimer complexes were destabilized by the presence of Triton X-100 and other detergents. Complexes lacking the nonhomologous domains were destabilized to a greater extent than complexes that included the nonhomologous domains. The detergent effect appears to be responsible for the apparent essential role of the nonhomologous domains in prior reports. Taken together, our results indicate that the terminal nonhomologous domains do not contribute to dimer initiation nor are they required for formation of high affinity spectrin heterodimers in physiological buffers.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "fe7f78eec1aa4f8ebb0a554fd87ebe06", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[5, 5]], "char_spans": [[33, 44]]}]}], "context_tokens": [["Human", 0], ["erythrocyte", 6], ["spectrin", 18], ["is", 27], ["an", 30], ["antiparallel", 33], ["heterodimer", 46], ["comprised", 58], ["of", 68], ["a", 71], ["280", 73], ["kDa", 77], ["alpha", 81], ["subunit", 87], ["and", 95], ["a", 99], ["246", 101], ["kDa", 105], ["beta", 109], ["subunit", 114], ["which", 122], ["further", 128], ["associates", 136], ["into", 147], ["tetramers", 152], ["in", 162], ["the", 165], ["red", 169], ["cell", 173], ["membrane", 178], ["cytoskeleton", 187], [".", 199], ["Lateral", 201], ["association", 209], ["of", 221], ["the", 224], ["flexible", 228], ["rodlike", 237], ["monomers", 245], ["involves", 254], ["a", 263], ["multiple", 265], ["-", 273], ["step", 274], ["process", 279], ["that", 287], ["is", 292], ["initiated", 295], ["by", 305], ["a", 308], ["high", 310], ["affinity", 315], ["association", 324], ["near", 336], ["the", 341], ["actin", 345], ["-", 350], ["binding", 351], ["end", 359], ["of", 363], ["the", 366], ["molecule", 370], ["(", 379], ["dimer", 380], ["nucleation", 386], ["site", 397], [")", 401], [".", 402], ["In", 404], ["this", 407], ["study", 412], [",", 417], ["recombinant", 419], ["alpha", 431], ["and", 437], ["beta", 441], ["proteins", 446], ["comprising", 455], ["two", 466], ["or", 470], ["four", 473], ["\"", 478], ["spectrin", 479], ["type", 488], ["\"", 492], ["motifs", 494], ["with", 501], ["and", 506], ["without", 510], ["adjacent", 518], [",", 526], ["terminal", 528], ["nonhomologous", 537], ["domains", 551], ["were", 559], ["evaluated", 564], ["for", 574], ["their", 578], ["relative", 584], ["contributions", 593], ["to", 607], ["dimer", 610], ["initiation", 616], [",", 626], ["and", 628], ["the", 632], ["thermodynamic", 636], ["properties", 650], ["of", 661], ["these", 664], ["heterodimer", 670], ["complexes", 682], ["were", 692], ["measured", 697], [".", 705], ["Sedimentation", 707], ["equilibrium", 721], ["studies", 733], ["showed", 741], ["that", 748], ["in", 753], ["the", 756], ["absence", 760], ["of", 768], ["the", 771], ["heterologous", 775], ["subunit", 788], [",", 795], ["individual", 797], ["recombinant", 808], ["proteins", 820], ["formed", 829], ["weak", 836], ["homodimers", 841], ["(", 852], ["K(d", 853], [")", 856], [">", 858], ["0.3", 860], ["mM", 864], [")", 866], [".", 867], ["When", 869], ["2-motif", 874], ["(", 882], ["alpha20", 883], ["-", 890], ["21", 891], ["and", 894], ["beta1", 898], ["-", 903], ["2", 904], [")", 905], ["and", 907], ["4-motif", 911], ["(", 919], ["alpha18", 920], ["-", 927], ["21", 928], ["and", 931], ["beta1", 935], ["-", 940], ["4", 941], [")", 942], ["recombinants", 944], ["lacking", 957], ["the", 965], ["terminal", 969], ["nonhomologous", 978], ["domains", 992], ["were", 1000], ["paired", 1005], ["with", 1012], ["the", 1017], ["complementary", 1021], ["protein", 1035], [",", 1042], ["high", 1044], ["affinity", 1049], ["heterodimers", 1058], ["were", 1071], ["formed", 1076], ["in", 1083], ["sedimentation", 1086], ["equilibrium", 1100], ["analysis", 1112], [".", 1120], ["Both", 1122], ["the", 1127], ["alpha20", 1131], ["-", 1138], ["21/beta1", 1139], ["-", 1147], ["2", 1148], ["complex", 1150], ["and", 1158], ["the", 1162], ["alpha20", 1166], ["-", 1173], ["21EF", 1174], ["/", 1178], ["betaABD1", 1179], ["-", 1187], ["2", 1188], ["complex", 1190], ["showed", 1198], ["stoichiometric", 1205], ["binding", 1220], ["with", 1228], ["similar", 1233], ["binding", 1241], ["affinities", 1249], ["(", 1260], ["K(d", 1261], [")", 1264], ["approximately", 1266], ["10", 1280], ["nM", 1283], [")", 1285], ["using", 1287], ["isothermal", 1293], ["titration", 1304], ["calorimetry", 1314], [".", 1325], ["The", 1327], ["alpha20", 1331], ["-", 1338], ["21/beta1", 1339], ["-", 1347], ["2", 1348], ["complex", 1350], ["showed", 1358], ["an", 1365], ["enthalpy", 1368], ["of", 1377], ["-10", 1380], ["kcal", 1384], ["/", 1388], ["mol", 1389], [",", 1392], ["while", 1394], ["the", 1400], ["alpha20", 1404], ["-", 1411], ["21EF", 1412], ["/", 1416], ["betaABD1", 1417], ["-", 1425], ["2", 1426], ["complex", 1428], ["showed", 1436], ["an", 1443], ["enthalpy", 1446], ["of", 1455], ["-13", 1458], ["kcal", 1462], ["/", 1466], ["mol", 1467], [".", 1470], ["Pull", 1472], ["-", 1476], ["down", 1477], ["assays", 1482], ["using", 1489], ["alpha", 1495], ["spectrin", 1501], ["GST", 1510], ["fusion", 1514], ["proteins", 1521], ["showed", 1530], ["strong", 1537], ["associations", 1544], ["between", 1557], ["all", 1565], ["heterodimer", 1569], ["complexes", 1581], ["in", 1591], ["physiological", 1594], ["buffer", 1608], [",", 1614], ["but", 1616], ["all", 1620], ["heterodimer", 1624], ["complexes", 1636], ["were", 1646], ["destabilized", 1651], ["by", 1664], ["the", 1667], ["presence", 1671], ["of", 1680], ["Triton", 1683], ["X-100", 1690], ["and", 1696], ["other", 1700], ["detergents", 1706], [".", 1716], ["Complexes", 1718], ["lacking", 1728], ["the", 1736], ["nonhomologous", 1740], ["domains", 1754], ["were", 1762], ["destabilized", 1767], ["to", 1780], ["a", 1783], ["greater", 1785], ["extent", 1793], ["than", 1800], ["complexes", 1805], ["that", 1815], ["included", 1820], ["the", 1829], ["nonhomologous", 1833], ["domains", 1847], [".", 1854], ["The", 1856], ["detergent", 1860], ["effect", 1870], ["appears", 1877], ["to", 1885], ["be", 1888], ["responsible", 1891], ["for", 1903], ["the", 1907], ["apparent", 1911], ["essential", 1920], ["role", 1930], ["of", 1935], ["the", 1938], ["nonhomologous", 1942], ["domains", 1956], ["in", 1964], ["prior", 1967], ["reports", 1973], [".", 1980], ["Taken", 1982], ["together", 1988], [",", 1996], ["our", 1998], ["results", 2002], ["indicate", 2010], ["that", 2019], ["the", 2024], ["terminal", 2028], ["nonhomologous", 2037], ["domains", 2051], ["do", 2059], ["not", 2062], ["contribute", 2066], ["to", 2077], ["dimer", 2080], ["initiation", 2086], ["nor", 2097], ["are", 2101], ["they", 2105], ["required", 2110], ["for", 2119], ["formation", 2123], ["of", 2133], ["high", 2136], ["affinity", 2141], ["spectrin", 2150], ["heterodimers", 2159], ["in", 2172], ["physiological", 2175], ["buffers", 2189], [".", 2196]]}
{"context": "Genetic imprinting has been implicated in the etiology of two clinically distinct but cytogenetically indistinguishable disorders--Angelman syndrome (AS) and Prader-Willi syndrome (PWS). This hypothesis is derived from two lines of evidence. First, while the molecular extents of de novo cytogenetic deletions of chromosome 15q11q13 in AS and PWS patients are the same, the deletions originate from different parental chromosomes. In AS, the deletion occurs in the maternally inherited chromosome 15, while in PWS the deletion is found in the paternally inherited chromosome 15. The second line of evidence comes from the deletion of an abnormal parental contribution of 15q11q13 in PWS patients without a cytogenetic and molecular deletion. These patients have two maternal copies and no paternal copy of 15q11q13 (maternal uniparental disomy) instead of one copy from each parent. By qualitative hybridization with chromosome 15q11q13 specific DNA markers, we have now examined DNA samples from 10 AS patients (at least seven of which are familial cases) with no cytogenetic or molecular deletion of chromosome 15q11q13. Inheritance of one maternal copy and one paternal copy of 15q11q13 was observed in each family, suggesting that paternal uniparental disomy of 15q11q13 is not responsible for expression of the AS phenotype in these patients.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "4f919178eb6f4d1f95f762a80274308e", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[23, 26]], "char_spans": [[158, 178]]}]}], "context_tokens": [["Genetic", 0], ["imprinting", 8], ["has", 19], ["been", 23], ["implicated", 28], ["in", 39], ["the", 42], ["etiology", 46], ["of", 55], ["two", 58], ["clinically", 62], ["distinct", 73], ["but", 82], ["cytogenetically", 86], ["indistinguishable", 102], ["disorders", 120], ["--", 129], ["Angelman", 131], ["syndrome", 140], ["(", 149], ["AS", 150], [")", 152], ["and", 154], ["Prader", 158], ["-", 164], ["Willi", 165], ["syndrome", 171], ["(", 180], ["PWS", 181], [")", 184], [".", 185], ["This", 187], ["hypothesis", 192], ["is", 203], ["derived", 206], ["from", 214], ["two", 219], ["lines", 223], ["of", 229], ["evidence", 232], [".", 240], ["First", 242], [",", 247], ["while", 249], ["the", 255], ["molecular", 259], ["extents", 269], ["of", 277], ["de", 280], ["novo", 283], ["cytogenetic", 288], ["deletions", 300], ["of", 310], ["chromosome", 313], ["15q11q13", 324], ["in", 333], ["AS", 336], ["and", 339], ["PWS", 343], ["patients", 347], ["are", 356], ["the", 360], ["same", 364], [",", 368], ["the", 370], ["deletions", 374], ["originate", 384], ["from", 394], ["different", 399], ["parental", 409], ["chromosomes", 418], [".", 429], ["In", 431], ["AS", 434], [",", 436], ["the", 438], ["deletion", 442], ["occurs", 451], ["in", 458], ["the", 461], ["maternally", 465], ["inherited", 476], ["chromosome", 486], ["15", 497], [",", 499], ["while", 501], ["in", 507], ["PWS", 510], ["the", 514], ["deletion", 518], ["is", 527], ["found", 530], ["in", 536], ["the", 539], ["paternally", 543], ["inherited", 554], ["chromosome", 564], ["15", 575], [".", 577], ["The", 579], ["second", 583], ["line", 590], ["of", 595], ["evidence", 598], ["comes", 607], ["from", 613], ["the", 618], ["deletion", 622], ["of", 631], ["an", 634], ["abnormal", 637], ["parental", 646], ["contribution", 655], ["of", 668], ["15q11q13", 671], ["in", 680], ["PWS", 683], ["patients", 687], ["without", 696], ["a", 704], ["cytogenetic", 706], ["and", 718], ["molecular", 722], ["deletion", 732], [".", 740], ["These", 742], ["patients", 748], ["have", 757], ["two", 762], ["maternal", 766], ["copies", 775], ["and", 782], ["no", 786], ["paternal", 789], ["copy", 798], ["of", 803], ["15q11q13", 806], ["(", 815], ["maternal", 816], ["uniparental", 825], ["disomy", 837], [")", 843], ["instead", 845], ["of", 853], ["one", 856], ["copy", 860], ["from", 865], ["each", 870], ["parent", 875], [".", 881], ["By", 883], ["qualitative", 886], ["hybridization", 898], ["with", 912], ["chromosome", 917], ["15q11q13", 928], ["specific", 937], ["DNA", 946], ["markers", 950], [",", 957], ["we", 959], ["have", 962], ["now", 967], ["examined", 971], ["DNA", 980], ["samples", 984], ["from", 992], ["10", 997], ["AS", 1000], ["patients", 1003], ["(", 1012], ["at", 1013], ["least", 1016], ["seven", 1022], ["of", 1028], ["which", 1031], ["are", 1037], ["familial", 1041], ["cases", 1050], [")", 1055], ["with", 1057], ["no", 1062], ["cytogenetic", 1065], ["or", 1077], ["molecular", 1080], ["deletion", 1090], ["of", 1099], ["chromosome", 1102], ["15q11q13", 1113], [".", 1121], ["Inheritance", 1123], ["of", 1135], ["one", 1138], ["maternal", 1142], ["copy", 1151], ["and", 1156], ["one", 1160], ["paternal", 1164], ["copy", 1173], ["of", 1178], ["15q11q13", 1181], ["was", 1190], ["observed", 1194], ["in", 1203], ["each", 1206], ["family", 1211], [",", 1217], ["suggesting", 1219], ["that", 1230], ["paternal", 1235], ["uniparental", 1244], ["disomy", 1256], ["of", 1263], ["15q11q13", 1266], ["is", 1275], ["not", 1278], ["responsible", 1282], ["for", 1294], ["expression", 1298], ["of", 1309], ["the", 1312], ["AS", 1316], ["phenotype", 1319], ["in", 1329], ["these", 1332], ["patients", 1338], [".", 1346]]}
{"context": "Phthiriasis palpebrarum is an uncommon cause of blepharoconjunctivitis in which Pthirus pubis infest the eyelashes. We report a case of unilateral phthiriasis palpebrarum with crab louse. A 45-year-old man presented with conjunctival hyperaemia and moderate itching associated with irritation, and crusty excretions of the eyelashes in the left eye. Careful slit-lamp examination revealed many lice and nits in left eye and mild conjunctival hyperaemia. No abnormality was found in the right eye. On dermatologic examination, only one louse was found at the pubic area. The patient was treated effectively with petrolatum jelly (Vaseline) and 1% permethrin shampoo (Kwellada 1% shampoo). At the end of the first week no louse or nit was present on eyelashes and pubic area.", "qas": [{"question": "What is the cause of Phthiriasis Palpebrarum?", "answers": ["Pthirus pubis"], "qid": "15635a9670bf475ab611b9b1921bbb96", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Phthiriasis", 21], ["Palpebrarum", 33], ["?", 44]], "detected_answers": [{"text": "Pthirus pubis", "token_spans": [[10, 11]], "char_spans": [[80, 92]]}]}], "context_tokens": [["Phthiriasis", 0], ["palpebrarum", 12], ["is", 24], ["an", 27], ["uncommon", 30], ["cause", 39], ["of", 45], ["blepharoconjunctivitis", 48], ["in", 71], ["which", 74], ["Pthirus", 80], ["pubis", 88], ["infest", 94], ["the", 101], ["eyelashes", 105], [".", 114], ["We", 116], ["report", 119], ["a", 126], ["case", 128], ["of", 133], ["unilateral", 136], ["phthiriasis", 147], ["palpebrarum", 159], ["with", 171], ["crab", 176], ["louse", 181], [".", 186], ["A", 188], ["45-year", 190], ["-", 197], ["old", 198], ["man", 202], ["presented", 206], ["with", 216], ["conjunctival", 221], ["hyperaemia", 234], ["and", 245], ["moderate", 249], ["itching", 258], ["associated", 266], ["with", 277], ["irritation", 282], [",", 292], ["and", 294], ["crusty", 298], ["excretions", 305], ["of", 316], ["the", 319], ["eyelashes", 323], ["in", 333], ["the", 336], ["left", 340], ["eye", 345], [".", 348], ["Careful", 350], ["slit", 358], ["-", 362], ["lamp", 363], ["examination", 368], ["revealed", 380], ["many", 389], ["lice", 394], ["and", 399], ["nits", 403], ["in", 408], ["left", 411], ["eye", 416], ["and", 420], ["mild", 424], ["conjunctival", 429], ["hyperaemia", 442], [".", 452], ["No", 454], ["abnormality", 457], ["was", 469], ["found", 473], ["in", 479], ["the", 482], ["right", 486], ["eye", 492], [".", 495], ["On", 497], ["dermatologic", 500], ["examination", 513], [",", 524], ["only", 526], ["one", 531], ["louse", 535], ["was", 541], ["found", 545], ["at", 551], ["the", 554], ["pubic", 558], ["area", 564], [".", 568], ["The", 570], ["patient", 574], ["was", 582], ["treated", 586], ["effectively", 594], ["with", 606], ["petrolatum", 611], ["jelly", 622], ["(", 628], ["Vaseline", 629], [")", 637], ["and", 639], ["1", 643], ["%", 644], ["permethrin", 646], ["shampoo", 657], ["(", 665], ["Kwellada", 666], ["1", 675], ["%", 676], ["shampoo", 678], [")", 685], [".", 686], ["At", 688], ["the", 691], ["end", 695], ["of", 699], ["the", 702], ["first", 706], ["week", 712], ["no", 717], ["louse", 720], ["or", 726], ["nit", 729], ["was", 733], ["present", 737], ["on", 745], ["eyelashes", 748], ["and", 758], ["pubic", 762], ["area", 768], [".", 772]]}
{"context": "Watanabe et al (Reports, 12 April 2013, p. 195) study the yeast SWR1/SWR-C complex responsible for depositing the histone variant H2A.Z by replacing nucleosomal H2A with H2A.Z. They report that reversal of H2A.Z replacement is mediated by SWR1 and related INO80 on an H2A.Z nucleosome carrying H3K56Q. Using multiple assays and reaction conditions, we find no evidence of such reversal of H2A.Z exchange.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "c3f9a61ef7aa49b99bb12823db16f5fc", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[43, 43]], "char_spans": [[239, 242]]}]}], "context_tokens": [["Watanabe", 0], ["et", 9], ["al", 12], ["(", 15], ["Reports", 16], [",", 23], ["12", 25], ["April", 28], ["2013", 34], [",", 38], ["p.", 40], ["195", 43], [")", 46], ["study", 48], ["the", 54], ["yeast", 58], ["SWR1/SWR", 64], ["-", 72], ["C", 73], ["complex", 75], ["responsible", 83], ["for", 95], ["depositing", 99], ["the", 110], ["histone", 114], ["variant", 122], ["H2A.Z", 130], ["by", 136], ["replacing", 139], ["nucleosomal", 149], ["H2A", 161], ["with", 165], ["H2A.Z.", 170], ["They", 177], ["report", 182], ["that", 189], ["reversal", 194], ["of", 203], ["H2A.Z", 206], ["replacement", 212], ["is", 224], ["mediated", 227], ["by", 236], ["SWR1", 239], ["and", 244], ["related", 248], ["INO80", 256], ["on", 262], ["an", 265], ["H2A.Z", 268], ["nucleosome", 274], ["carrying", 285], ["H3K56Q.", 294], ["Using", 302], ["multiple", 308], ["assays", 317], ["and", 324], ["reaction", 328], ["conditions", 337], [",", 347], ["we", 349], ["find", 352], ["no", 357], ["evidence", 360], ["of", 369], ["such", 372], ["reversal", 377], ["of", 386], ["H2A.Z", 389], ["exchange", 395], [".", 403]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disorder, defined by the presence of resting tremor, muscular rigidity, bradykinesia, and postural instability. PD is characterized by the progressive loss of dopaminergic neurons within the substantia nigra pars compacta of the midbrain. The neuropathological hallmark of the disease is the presence of intracytoplasmic inclusions, called Lewy bodies (LBs) and Lewy neurites (LNs), containing \u03b1-synuclein, a small protein which is widely expressed in the brain. The \u03b1-synuclein gene, SNCA, is located on chromosome 4q22.1; SNCA-linked PD shows an autosomal dominant inheritance pattern with a relatively early onset age, and it usually progresses rapidly. Three missense mutations, A53T, A30P, and E46K, in addition to gene multiplications of the SNCA have been described so far. Although it is clear that LBs and LNs contain mainly the \u03b1-synuclein protein, the mechanism(s) which leads \u03b1-synuclein to accumulate needs to be elucidated. The primary question in the molecular pathology of PD is how wild-type \u03b1-synuclein aggregates in PD, and which interacting partner(s) plays role(s) in the aggregation process. It is known that dopamine synthesis is a stressfull event, and \u03b1-synuclein expression somehow affects the dopamine synthesis. The aberrant interactions of \u03b1-synuclein with the proteins in the dopamine synthesis pathway may cause disturbances in cellular mechanisms. The normal physiological folding state of \u03b1-synuclein is also important for the understanding of pathological aggregates. Recent studies on the \u03b1-synuclein protein and genome-wide association studies of the \u03b1-synuclein gene show that PD has a strong genetic component, and both familial and idiopathic PD have a common denominator, \u03b1-synuclein, at the molecular level. It is clear that the disease process in Parkinson's disease, as in other neurodegenerative disorders, is very complicated; there can be several different molecular pathways which are responsible for diverse and possibly also unrelated functions inside the neuron, playing roles in PD pathogenesis.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d5f8f2fee1f04e1ca38a7afa3aca1b32", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[289, 291], [78, 80], [94, 96], [301, 303], [325, 327], [202, 204], [168, 170], [234, 236], [248, 250], [272, 274], [178, 180]], "char_spans": [[1593, 1603], [463, 473], [536, 546], [1656, 1666], [1781, 1791], [1078, 1088], [907, 917], [1246, 1256], [1338, 1348], [1491, 1501], [957, 967]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disorder", 69], [",", 77], ["defined", 79], ["by", 87], ["the", 90], ["presence", 94], ["of", 103], ["resting", 106], ["tremor", 114], [",", 120], ["muscular", 122], ["rigidity", 131], [",", 139], ["bradykinesia", 141], [",", 153], ["and", 155], ["postural", 159], ["instability", 168], [".", 179], ["PD", 181], ["is", 184], ["characterized", 187], ["by", 201], ["the", 204], ["progressive", 208], ["loss", 220], ["of", 225], ["dopaminergic", 228], ["neurons", 241], ["within", 249], ["the", 256], ["substantia", 260], ["nigra", 271], ["pars", 277], ["compacta", 282], ["of", 291], ["the", 294], ["midbrain", 298], [".", 306], ["The", 308], ["neuropathological", 312], ["hallmark", 330], ["of", 339], ["the", 342], ["disease", 346], ["is", 354], ["the", 357], ["presence", 361], ["of", 370], ["intracytoplasmic", 373], ["inclusions", 390], [",", 400], ["called", 402], ["Lewy", 409], ["bodies", 414], ["(", 421], ["LBs", 422], [")", 425], ["and", 427], ["Lewy", 431], ["neurites", 436], ["(", 445], ["LNs", 446], [")", 449], [",", 450], ["containing", 452], ["\u03b1", 463], ["-", 464], ["synuclein", 465], [",", 474], ["a", 476], ["small", 478], ["protein", 484], ["which", 492], ["is", 498], ["widely", 501], ["expressed", 508], ["in", 518], ["the", 521], ["brain", 525], [".", 530], ["The", 532], ["\u03b1", 536], ["-", 537], ["synuclein", 538], ["gene", 548], [",", 552], ["SNCA", 554], [",", 558], ["is", 560], ["located", 563], ["on", 571], ["chromosome", 574], ["4q22.1", 585], [";", 591], ["SNCA", 593], ["-", 597], ["linked", 598], ["PD", 605], ["shows", 608], ["an", 614], ["autosomal", 617], ["dominant", 627], ["inheritance", 636], ["pattern", 648], ["with", 656], ["a", 661], ["relatively", 663], ["early", 674], ["onset", 680], ["age", 686], [",", 689], ["and", 691], ["it", 695], ["usually", 698], ["progresses", 706], ["rapidly", 717], [".", 724], ["Three", 726], ["missense", 732], ["mutations", 741], [",", 750], ["A53", 752], ["T", 755], [",", 756], ["A30P", 758], [",", 762], ["and", 764], ["E46", 768], ["K", 771], [",", 772], ["in", 774], ["addition", 777], ["to", 786], ["gene", 789], ["multiplications", 794], ["of", 810], ["the", 813], ["SNCA", 817], ["have", 822], ["been", 827], ["described", 832], ["so", 842], ["far", 845], [".", 848], ["Although", 850], ["it", 859], ["is", 862], ["clear", 865], ["that", 871], ["LBs", 876], ["and", 880], ["LNs", 884], ["contain", 888], ["mainly", 896], ["the", 903], ["\u03b1", 907], ["-", 908], ["synuclein", 909], ["protein", 919], [",", 926], ["the", 928], ["mechanism(s", 932], [")", 943], ["which", 945], ["leads", 951], ["\u03b1", 957], ["-", 958], ["synuclein", 959], ["to", 969], ["accumulate", 972], ["needs", 983], ["to", 989], ["be", 992], ["elucidated", 995], [".", 1005], ["The", 1007], ["primary", 1011], ["question", 1019], ["in", 1028], ["the", 1031], ["molecular", 1035], ["pathology", 1045], ["of", 1055], ["PD", 1058], ["is", 1061], ["how", 1064], ["wild", 1068], ["-", 1072], ["type", 1073], ["\u03b1", 1078], ["-", 1079], ["synuclein", 1080], ["aggregates", 1090], ["in", 1101], ["PD", 1104], [",", 1106], ["and", 1108], ["which", 1112], ["interacting", 1118], ["partner(s", 1130], [")", 1139], ["plays", 1141], ["role(s", 1147], [")", 1153], ["in", 1155], ["the", 1158], ["aggregation", 1162], ["process", 1174], [".", 1181], ["It", 1183], ["is", 1186], ["known", 1189], ["that", 1195], ["dopamine", 1200], ["synthesis", 1209], ["is", 1219], ["a", 1222], ["stressfull", 1224], ["event", 1235], [",", 1240], ["and", 1242], ["\u03b1", 1246], ["-", 1247], ["synuclein", 1248], ["expression", 1258], ["somehow", 1269], ["affects", 1277], ["the", 1285], ["dopamine", 1289], ["synthesis", 1298], [".", 1307], ["The", 1309], ["aberrant", 1313], ["interactions", 1322], ["of", 1335], ["\u03b1", 1338], ["-", 1339], ["synuclein", 1340], ["with", 1350], ["the", 1355], ["proteins", 1359], ["in", 1368], ["the", 1371], ["dopamine", 1375], ["synthesis", 1384], ["pathway", 1394], ["may", 1402], ["cause", 1406], ["disturbances", 1412], ["in", 1425], ["cellular", 1428], ["mechanisms", 1437], [".", 1447], ["The", 1449], ["normal", 1453], ["physiological", 1460], ["folding", 1474], ["state", 1482], ["of", 1488], ["\u03b1", 1491], ["-", 1492], ["synuclein", 1493], ["is", 1503], ["also", 1506], ["important", 1511], ["for", 1521], ["the", 1525], ["understanding", 1529], ["of", 1543], ["pathological", 1546], ["aggregates", 1559], [".", 1569], ["Recent", 1571], ["studies", 1578], ["on", 1586], ["the", 1589], ["\u03b1", 1593], ["-", 1594], ["synuclein", 1595], ["protein", 1605], ["and", 1613], ["genome", 1617], ["-", 1623], ["wide", 1624], ["association", 1629], ["studies", 1641], ["of", 1649], ["the", 1652], ["\u03b1", 1656], ["-", 1657], ["synuclein", 1658], ["gene", 1668], ["show", 1673], ["that", 1678], ["PD", 1683], ["has", 1686], ["a", 1690], ["strong", 1692], ["genetic", 1699], ["component", 1707], [",", 1716], ["and", 1718], ["both", 1722], ["familial", 1727], ["and", 1736], ["idiopathic", 1740], ["PD", 1751], ["have", 1754], ["a", 1759], ["common", 1761], ["denominator", 1768], [",", 1779], ["\u03b1", 1781], ["-", 1782], ["synuclein", 1783], [",", 1792], ["at", 1794], ["the", 1797], ["molecular", 1801], ["level", 1811], [".", 1816], ["It", 1818], ["is", 1821], ["clear", 1824], ["that", 1830], ["the", 1835], ["disease", 1839], ["process", 1847], ["in", 1855], ["Parkinson", 1858], ["'s", 1867], ["disease", 1870], [",", 1877], ["as", 1879], ["in", 1882], ["other", 1885], ["neurodegenerative", 1891], ["disorders", 1909], [",", 1918], ["is", 1920], ["very", 1923], ["complicated", 1928], [";", 1939], ["there", 1941], ["can", 1947], ["be", 1951], ["several", 1954], ["different", 1962], ["molecular", 1972], ["pathways", 1982], ["which", 1991], ["are", 1997], ["responsible", 2001], ["for", 2013], ["diverse", 2017], ["and", 2025], ["possibly", 2029], ["also", 2038], ["unrelated", 2043], ["functions", 2053], ["inside", 2063], ["the", 2070], ["neuron", 2074], [",", 2080], ["playing", 2082], ["roles", 2090], ["in", 2096], ["PD", 2099], ["pathogenesis", 2102], [".", 2114]]}
{"context": "Several genetic disorders are characterized by normal head size at birth, followed by deceleration in head growth resulting in postnatal microcephaly. Among these are classic disorders such as Angelman syndrome and MECP2-related disorder (formerly Rett syndrome), as well as more recently described clinical entities associated with mutations in CASK, CDKL5, CREBBP, and EP300 (Rubinstein-Taybi syndrome), FOXG1, SLC9A6 (Christianson syndrome), and TCF4 (Pitt-Hopkins syndrome). These disorders can be identified clinically by phenotyping across multiple neurodevelopmental and neurobehavioral realms, and enough data are available to recognize these postnatal microcephaly disorders as separate diagnostic entities in their own right. A second diagnostic grouping, comprised of Warburg MICRO syndrome, Cockayne syndrome, and Cerebral-oculo-facial skeletal syndrome, share similar features of somatic growth failure, ophthalmologic, and dysmorphologic features. Many postnatal microcephaly syndromes are caused by mutations in genes important in the regulation of gene expression in the developing forebrain and hindbrain, although important synaptic structural genes also play a role. This is an emerging group of disorders with a fascinating combination of brain malformations, specific epilepsies, movement disorders, and other complex neurobehavioral abnormalities.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "6a1f2f3255d649e7b1cd4683b639e954", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[70, 70]], "char_spans": [[413, 418]]}]}], "context_tokens": [["Several", 0], ["genetic", 8], ["disorders", 16], ["are", 26], ["characterized", 30], ["by", 44], ["normal", 47], ["head", 54], ["size", 59], ["at", 64], ["birth", 67], [",", 72], ["followed", 74], ["by", 83], ["deceleration", 86], ["in", 99], ["head", 102], ["growth", 107], ["resulting", 114], ["in", 124], ["postnatal", 127], ["microcephaly", 137], [".", 149], ["Among", 151], ["these", 157], ["are", 163], ["classic", 167], ["disorders", 175], ["such", 185], ["as", 190], ["Angelman", 193], ["syndrome", 202], ["and", 211], ["MECP2-related", 215], ["disorder", 229], ["(", 238], ["formerly", 239], ["Rett", 248], ["syndrome", 253], [")", 261], [",", 262], ["as", 264], ["well", 267], ["as", 272], ["more", 275], ["recently", 280], ["described", 289], ["clinical", 299], ["entities", 308], ["associated", 317], ["with", 328], ["mutations", 333], ["in", 343], ["CASK", 346], [",", 350], ["CDKL5", 352], [",", 357], ["CREBBP", 359], [",", 365], ["and", 367], ["EP300", 371], ["(", 377], ["Rubinstein", 378], ["-", 388], ["Taybi", 389], ["syndrome", 395], [")", 403], [",", 404], ["FOXG1", 406], [",", 411], ["SLC9A6", 413], ["(", 420], ["Christianson", 421], ["syndrome", 434], [")", 442], [",", 443], ["and", 445], ["TCF4", 449], ["(", 454], ["Pitt", 455], ["-", 459], ["Hopkins", 460], ["syndrome", 468], [")", 476], [".", 477], ["These", 479], ["disorders", 485], ["can", 495], ["be", 499], ["identified", 502], ["clinically", 513], ["by", 524], ["phenotyping", 527], ["across", 539], ["multiple", 546], ["neurodevelopmental", 555], ["and", 574], ["neurobehavioral", 578], ["realms", 594], [",", 600], ["and", 602], ["enough", 606], ["data", 613], ["are", 618], ["available", 622], ["to", 632], ["recognize", 635], ["these", 645], ["postnatal", 651], ["microcephaly", 661], ["disorders", 674], ["as", 684], ["separate", 687], ["diagnostic", 696], ["entities", 707], ["in", 716], ["their", 719], ["own", 725], ["right", 729], [".", 734], ["A", 736], ["second", 738], ["diagnostic", 745], ["grouping", 756], [",", 764], ["comprised", 766], ["of", 776], ["Warburg", 779], ["MICRO", 787], ["syndrome", 793], [",", 801], ["Cockayne", 803], ["syndrome", 812], [",", 820], ["and", 822], ["Cerebral", 826], ["-", 834], ["oculo", 835], ["-", 840], ["facial", 841], ["skeletal", 848], ["syndrome", 857], [",", 865], ["share", 867], ["similar", 873], ["features", 881], ["of", 890], ["somatic", 893], ["growth", 901], ["failure", 908], [",", 915], ["ophthalmologic", 917], [",", 931], ["and", 933], ["dysmorphologic", 937], ["features", 952], [".", 960], ["Many", 962], ["postnatal", 967], ["microcephaly", 977], ["syndromes", 990], ["are", 1000], ["caused", 1004], ["by", 1011], ["mutations", 1014], ["in", 1024], ["genes", 1027], ["important", 1033], ["in", 1043], ["the", 1046], ["regulation", 1050], ["of", 1061], ["gene", 1064], ["expression", 1069], ["in", 1080], ["the", 1083], ["developing", 1087], ["forebrain", 1098], ["and", 1108], ["hindbrain", 1112], [",", 1121], ["although", 1123], ["important", 1132], ["synaptic", 1142], ["structural", 1151], ["genes", 1162], ["also", 1168], ["play", 1173], ["a", 1178], ["role", 1180], [".", 1184], ["This", 1186], ["is", 1191], ["an", 1194], ["emerging", 1197], ["group", 1206], ["of", 1212], ["disorders", 1215], ["with", 1225], ["a", 1230], ["fascinating", 1232], ["combination", 1244], ["of", 1256], ["brain", 1259], ["malformations", 1265], [",", 1278], ["specific", 1280], ["epilepsies", 1289], [",", 1299], ["movement", 1301], ["disorders", 1310], [",", 1319], ["and", 1321], ["other", 1325], ["complex", 1331], ["neurobehavioral", 1339], ["abnormalities", 1355], [".", 1368]]}
{"context": "Intermittent hypoxia (IH) occurs in many pathological conditions. However, very little is known about the molecular mechanisms associated with IH. Hypoxia-inducible factor 1 (HIF-1) mediates transcriptional responses to continuous hypoxia. In the present study, we investigated whether IH activates HIF-1 and, if so, which signaling pathways are involved. PC12 cells were exposed to either to 20% O2 (non-hypoxic control) or to 60 cycles consisting of 30 s at 1.5% O2, followed by 4 min at 20% O2 (IH). Western blot analysis revealed significant increases in HIF-1alpha protein in nuclear extracts of cells subjected to IH. Expression of a HIF-1-dependent reporter gene was increased 3-fold in cells subjected to IH. Although IH induced the activation of ERK1, ERK2, JNK, PKC-alpha, and PKC-gamma, inhibitors of these kinases and of phosphatidylinositol 3-kinase did not block HIF-1-mediated reporter gene expression induced by IH, indicating that signaling via these kinases was not required. In contrast, addition of the intracellular Ca2+ chelator BAPTA-AM or the Ca2+/calmodulin-dependent (CaM) kinase inhibitor KN93 blocked reporter gene activation in response to IH. CaM kinase activity was increased 5-fold in cells subjected to IH. KN 93 prevented IH-induced transactivation mediated by HIF-1alpha, and its coactivator p300, which was phosphorylated by CaM kinase II in vitro. Expression of the HIF-1-regulated gene encoding tyrosine hydroxylase was induced by IH and this effect was blocked by KN93. These observations suggest that IH induces HIF-1 transcriptional activity via a novel signaling pathway involving CaM kinase.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "85429e012dfa4820827bfe31697d7c1d", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[251, 253]], "char_spans": [[1361, 1373]]}]}], "context_tokens": [["Intermittent", 0], ["hypoxia", 13], ["(", 21], ["IH", 22], [")", 24], ["occurs", 26], ["in", 33], ["many", 36], ["pathological", 41], ["conditions", 54], [".", 64], ["However", 66], [",", 73], ["very", 75], ["little", 80], ["is", 87], ["known", 90], ["about", 96], ["the", 102], ["molecular", 106], ["mechanisms", 116], ["associated", 127], ["with", 138], ["IH", 143], [".", 145], ["Hypoxia", 147], ["-", 154], ["inducible", 155], ["factor", 165], ["1", 172], ["(", 174], ["HIF-1", 175], [")", 180], ["mediates", 182], ["transcriptional", 191], ["responses", 207], ["to", 217], ["continuous", 220], ["hypoxia", 231], [".", 238], ["In", 240], ["the", 243], ["present", 247], ["study", 255], [",", 260], ["we", 262], ["investigated", 265], ["whether", 278], ["IH", 286], ["activates", 289], ["HIF-1", 299], ["and", 305], [",", 308], ["if", 310], ["so", 313], [",", 315], ["which", 317], ["signaling", 323], ["pathways", 333], ["are", 342], ["involved", 346], [".", 354], ["PC12", 356], ["cells", 361], ["were", 367], ["exposed", 372], ["to", 380], ["either", 383], ["to", 390], ["20", 393], ["%", 395], ["O2", 397], ["(", 400], ["non", 401], ["-", 404], ["hypoxic", 405], ["control", 413], [")", 420], ["or", 422], ["to", 425], ["60", 428], ["cycles", 431], ["consisting", 438], ["of", 449], ["30", 452], ["s", 455], ["at", 457], ["1.5", 460], ["%", 463], ["O2", 465], [",", 467], ["followed", 469], ["by", 478], ["4", 481], ["min", 483], ["at", 487], ["20", 490], ["%", 492], ["O2", 494], ["(", 497], ["IH", 498], [")", 500], [".", 501], ["Western", 503], ["blot", 511], ["analysis", 516], ["revealed", 525], ["significant", 534], ["increases", 546], ["in", 556], ["HIF-1alpha", 559], ["protein", 570], ["in", 578], ["nuclear", 581], ["extracts", 589], ["of", 598], ["cells", 601], ["subjected", 607], ["to", 617], ["IH", 620], [".", 622], ["Expression", 624], ["of", 635], ["a", 638], ["HIF-1-dependent", 640], ["reporter", 656], ["gene", 665], ["was", 670], ["increased", 674], ["3-fold", 684], ["in", 691], ["cells", 694], ["subjected", 700], ["to", 710], ["IH", 713], [".", 715], ["Although", 717], ["IH", 726], ["induced", 729], ["the", 737], ["activation", 741], ["of", 752], ["ERK1", 755], [",", 759], ["ERK2", 761], [",", 765], ["JNK", 767], [",", 770], ["PKC", 772], ["-", 775], ["alpha", 776], [",", 781], ["and", 783], ["PKC", 787], ["-", 790], ["gamma", 791], [",", 796], ["inhibitors", 798], ["of", 809], ["these", 812], ["kinases", 818], ["and", 826], ["of", 830], ["phosphatidylinositol", 833], ["3-kinase", 854], ["did", 863], ["not", 867], ["block", 871], ["HIF-1-mediated", 877], ["reporter", 892], ["gene", 901], ["expression", 906], ["induced", 917], ["by", 925], ["IH", 928], [",", 930], ["indicating", 932], ["that", 943], ["signaling", 948], ["via", 958], ["these", 962], ["kinases", 968], ["was", 976], ["not", 980], ["required", 984], [".", 992], ["In", 994], ["contrast", 997], [",", 1005], ["addition", 1007], ["of", 1016], ["the", 1019], ["intracellular", 1023], ["Ca2", 1037], ["+", 1040], ["chelator", 1042], ["BAPTA", 1051], ["-", 1056], ["AM", 1057], ["or", 1060], ["the", 1063], ["Ca2+/calmodulin", 1067], ["-", 1082], ["dependent", 1083], ["(", 1093], ["CaM", 1094], [")", 1097], ["kinase", 1099], ["inhibitor", 1106], ["KN93", 1116], ["blocked", 1121], ["reporter", 1129], ["gene", 1138], ["activation", 1143], ["in", 1154], ["response", 1157], ["to", 1166], ["IH", 1169], [".", 1171], ["CaM", 1173], ["kinase", 1177], ["activity", 1184], ["was", 1193], ["increased", 1197], ["5-fold", 1207], ["in", 1214], ["cells", 1217], ["subjected", 1223], ["to", 1233], ["IH", 1236], [".", 1238], ["KN", 1240], ["93", 1243], ["prevented", 1246], ["IH", 1256], ["-", 1258], ["induced", 1259], ["transactivation", 1267], ["mediated", 1283], ["by", 1292], ["HIF-1alpha", 1295], [",", 1305], ["and", 1307], ["its", 1311], ["coactivator", 1315], ["p300", 1327], [",", 1331], ["which", 1333], ["was", 1339], ["phosphorylated", 1343], ["by", 1358], ["CaM", 1361], ["kinase", 1365], ["II", 1372], ["in", 1375], ["vitro", 1378], [".", 1383], ["Expression", 1385], ["of", 1396], ["the", 1399], ["HIF-1-regulated", 1403], ["gene", 1419], ["encoding", 1424], ["tyrosine", 1433], ["hydroxylase", 1442], ["was", 1454], ["induced", 1458], ["by", 1466], ["IH", 1469], ["and", 1472], ["this", 1476], ["effect", 1481], ["was", 1488], ["blocked", 1492], ["by", 1500], ["KN93", 1503], [".", 1507], ["These", 1509], ["observations", 1515], ["suggest", 1528], ["that", 1536], ["IH", 1541], ["induces", 1544], ["HIF-1", 1552], ["transcriptional", 1558], ["activity", 1574], ["via", 1583], ["a", 1587], ["novel", 1589], ["signaling", 1595], ["pathway", 1605], ["involving", 1613], ["CaM", 1623], ["kinase", 1627], [".", 1633]]}
{"context": "Transcription-coupled repair (TCR) is a sub-pathway of nucleotide excision repair that allows for the enhanced repair of the transcribed strand of active genes. A classical method to study DNA repair in vivo consists in the molecular analysis of UV-induced DNA damages at specific loci. Cells are irradiated with a defined dose of UV light leading to the formation of DNA lesions and incubated in the dark to allow repair. About 90% of the photoproducts consist of cyclobutane pyrimidine dimers, which can be cleaved by the DNA nicking activity of the T4 endonuclease V (T4endoV) repair enzyme. Strand-specific repair in a suitable restriction fragment is determined by alkaline gel electrophoresis followed by Southern blot transfer and indirect end-labeling using a single-stranded probe. Recent approaches have assessed the role of transcription factors in TCR by analyzing RNA polymerase II occupancy on a damaged template by chromatin immunoprecipitation (ChIP). Cells are treated with formaldehyde in vivo to cross-link proteins to DNA and enrichment of a protein of interest is done by subsequent immunoprecipitation. Upon reversal of the protein-DNA cross-links, the amount of coprecipitated DNA fragments can be detected by quantitative PCR. To perform ChIP on UV-damaged templates, we included an in vitro photoreactivation step prior to PCR analysis to ensure that all precipitated DNA fragments serve as substrates for the PCR reaction. Here, we provide a detailed protocol for both the DNA repair analysis and the ChIP approaches to study TCR in chromatin.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "9c43fc43f2544ef0aba121cf1f3cd2e9", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[24, 25]], "char_spans": [[125, 142]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["sub", 40], ["-", 43], ["pathway", 44], ["of", 52], ["nucleotide", 55], ["excision", 66], ["repair", 75], ["that", 82], ["allows", 87], ["for", 94], ["the", 98], ["enhanced", 102], ["repair", 111], ["of", 118], ["the", 121], ["transcribed", 125], ["strand", 137], ["of", 144], ["active", 147], ["genes", 154], [".", 159], ["A", 161], ["classical", 163], ["method", 173], ["to", 180], ["study", 183], ["DNA", 189], ["repair", 193], ["in", 200], ["vivo", 203], ["consists", 208], ["in", 217], ["the", 220], ["molecular", 224], ["analysis", 234], ["of", 243], ["UV", 246], ["-", 248], ["induced", 249], ["DNA", 257], ["damages", 261], ["at", 269], ["specific", 272], ["loci", 281], [".", 285], ["Cells", 287], ["are", 293], ["irradiated", 297], ["with", 308], ["a", 313], ["defined", 315], ["dose", 323], ["of", 328], ["UV", 331], ["light", 334], ["leading", 340], ["to", 348], ["the", 351], ["formation", 355], ["of", 365], ["DNA", 368], ["lesions", 372], ["and", 380], ["incubated", 384], ["in", 394], ["the", 397], ["dark", 401], ["to", 406], ["allow", 409], ["repair", 415], [".", 421], ["About", 423], ["90", 429], ["%", 431], ["of", 433], ["the", 436], ["photoproducts", 440], ["consist", 454], ["of", 462], ["cyclobutane", 465], ["pyrimidine", 477], ["dimers", 488], [",", 494], ["which", 496], ["can", 502], ["be", 506], ["cleaved", 509], ["by", 517], ["the", 520], ["DNA", 524], ["nicking", 528], ["activity", 536], ["of", 545], ["the", 548], ["T4", 552], ["endonuclease", 555], ["V", 568], ["(", 570], ["T4endoV", 571], [")", 578], ["repair", 580], ["enzyme", 587], [".", 593], ["Strand", 595], ["-", 601], ["specific", 602], ["repair", 611], ["in", 618], ["a", 621], ["suitable", 623], ["restriction", 632], ["fragment", 644], ["is", 653], ["determined", 656], ["by", 667], ["alkaline", 670], ["gel", 679], ["electrophoresis", 683], ["followed", 699], ["by", 708], ["Southern", 711], ["blot", 720], ["transfer", 725], ["and", 734], ["indirect", 738], ["end", 747], ["-", 750], ["labeling", 751], ["using", 760], ["a", 766], ["single", 768], ["-", 774], ["stranded", 775], ["probe", 784], [".", 789], ["Recent", 791], ["approaches", 798], ["have", 809], ["assessed", 814], ["the", 823], ["role", 827], ["of", 832], ["transcription", 835], ["factors", 849], ["in", 857], ["TCR", 860], ["by", 864], ["analyzing", 867], ["RNA", 877], ["polymerase", 881], ["II", 892], ["occupancy", 895], ["on", 905], ["a", 908], ["damaged", 910], ["template", 918], ["by", 927], ["chromatin", 930], ["immunoprecipitation", 940], ["(", 960], ["ChIP", 961], [")", 965], [".", 966], ["Cells", 968], ["are", 974], ["treated", 978], ["with", 986], ["formaldehyde", 991], ["in", 1004], ["vivo", 1007], ["to", 1012], ["cross", 1015], ["-", 1020], ["link", 1021], ["proteins", 1026], ["to", 1035], ["DNA", 1038], ["and", 1042], ["enrichment", 1046], ["of", 1057], ["a", 1060], ["protein", 1062], ["of", 1070], ["interest", 1073], ["is", 1082], ["done", 1085], ["by", 1090], ["subsequent", 1093], ["immunoprecipitation", 1104], [".", 1123], ["Upon", 1125], ["reversal", 1130], ["of", 1139], ["the", 1142], ["protein", 1146], ["-", 1153], ["DNA", 1154], ["cross", 1158], ["-", 1163], ["links", 1164], [",", 1169], ["the", 1171], ["amount", 1175], ["of", 1182], ["coprecipitated", 1185], ["DNA", 1200], ["fragments", 1204], ["can", 1214], ["be", 1218], ["detected", 1221], ["by", 1230], ["quantitative", 1233], ["PCR", 1246], [".", 1249], ["To", 1251], ["perform", 1254], ["ChIP", 1262], ["on", 1267], ["UV", 1270], ["-", 1272], ["damaged", 1273], ["templates", 1281], [",", 1290], ["we", 1292], ["included", 1295], ["an", 1304], ["in", 1307], ["vitro", 1310], ["photoreactivation", 1316], ["step", 1334], ["prior", 1339], ["to", 1345], ["PCR", 1348], ["analysis", 1352], ["to", 1361], ["ensure", 1364], ["that", 1371], ["all", 1376], ["precipitated", 1380], ["DNA", 1393], ["fragments", 1397], ["serve", 1407], ["as", 1413], ["substrates", 1416], ["for", 1427], ["the", 1431], ["PCR", 1435], ["reaction", 1439], [".", 1447], ["Here", 1449], [",", 1453], ["we", 1455], ["provide", 1458], ["a", 1466], ["detailed", 1468], ["protocol", 1477], ["for", 1486], ["both", 1490], ["the", 1495], ["DNA", 1499], ["repair", 1503], ["analysis", 1510], ["and", 1519], ["the", 1523], ["ChIP", 1527], ["approaches", 1532], ["to", 1543], ["study", 1546], ["TCR", 1552], ["in", 1556], ["chromatin", 1559], [".", 1568]]}
{"context": "The authors describe a family with six patients with muscular dystrophy with a variable course. One is a compound heterozygote for CAPN3 mutations (calpainopathy) and the others have a single CAPN3 mutation. Linkage analysis and sequencing revealed a XK gene mutation (McLeod syndrome). This illustrates the variable phenotype of XK mutations and suggests the possibility that CAPN3 heterozygotes may have their condition caused by nonallelic mutations in other unrelated genes.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "30982bbba290475cadfbcc0116b0d9c4", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[56, 56], [42, 42]], "char_spans": [[330, 331], [251, 252]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["describe", 12], ["a", 21], ["family", 23], ["with", 30], ["six", 35], ["patients", 39], ["with", 48], ["muscular", 53], ["dystrophy", 62], ["with", 72], ["a", 77], ["variable", 79], ["course", 88], [".", 94], ["One", 96], ["is", 100], ["a", 103], ["compound", 105], ["heterozygote", 114], ["for", 127], ["CAPN3", 131], ["mutations", 137], ["(", 147], ["calpainopathy", 148], [")", 161], ["and", 163], ["the", 167], ["others", 171], ["have", 178], ["a", 183], ["single", 185], ["CAPN3", 192], ["mutation", 198], [".", 206], ["Linkage", 208], ["analysis", 216], ["and", 225], ["sequencing", 229], ["revealed", 240], ["a", 249], ["XK", 251], ["gene", 254], ["mutation", 259], ["(", 268], ["McLeod", 269], ["syndrome", 276], [")", 284], [".", 285], ["This", 287], ["illustrates", 292], ["the", 304], ["variable", 308], ["phenotype", 317], ["of", 327], ["XK", 330], ["mutations", 333], ["and", 343], ["suggests", 347], ["the", 356], ["possibility", 360], ["that", 372], ["CAPN3", 377], ["heterozygotes", 383], ["may", 397], ["have", 401], ["their", 406], ["condition", 412], ["caused", 422], ["by", 429], ["nonallelic", 432], ["mutations", 443], ["in", 453], ["other", 456], ["unrelated", 462], ["genes", 472], [".", 477]]}
{"context": "The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders characterised by joint hypermobility, involvement of skin and tissue fragility. The Villefranche criteria have simplified its diagnosis, which, however, remains difficult in children and young adults with vascular and hypermobile EDS as well as in patients without a positive family history. Diagnosis of vascular EDS is important for clinical follow-up, genetic counseling and prenatal diagnosis. We describe the biochemical and molecular-genetic diagnosis of vascular EDS. We describe five families with vascular EDS. Analysis of (pro)collagens obtained from cultured fibroblasts was done using SDS-PAGE. The structure and amounts of (pro)collagen I, III and V were determined by autoradioflourography. This was also done in 362 controls or patients without a diagnosis of vascular EDS. Molecular testing was done in Professor Anne de Paepe's laboratory in Belgium by sequencing of COL3A1. (Pro)collagen from all five patients with vascular EDS was abnormal by SDS-PAGE: intracellular retention, reduced secretion and overmodification of the a1 chains of (pro)collagen III. Molecular analysis revealed an abnormality of COL3A1 in all patients. Abnormalities of (pro)collagen III were not observed in patients without a diagnosis of vascular EDS. Among 90 patients with non-vascular EDS, one patient had an abnormality of collagen I. Biochemical analysis of (pro)collagen obtained from cultured fibroblasts is a good screening procedure for vascular EDS, but it is of limited value in non-vascular EDS. Molecular testing will disclose an abnormality of COL3A1 in many patients with abnormal (pro)collagen III on SDS-PAGE. The findings make precise genetic counselling and prenatal diagnosis possible in families with vascular EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "4dddb3b7e1e446fe922c7789a90fc99f", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[14, 15]], "char_spans": [[73, 89]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["are", 34], ["a", 38], ["heterogeneous", 40], ["group", 54], ["of", 60], ["heritable", 63], ["connective", 73], ["tissue", 84], ["disorders", 91], ["characterised", 101], ["by", 115], ["joint", 118], ["hypermobility", 124], [",", 137], ["involvement", 139], ["of", 151], ["skin", 154], ["and", 159], ["tissue", 163], ["fragility", 170], [".", 179], ["The", 181], ["Villefranche", 185], ["criteria", 198], ["have", 207], ["simplified", 212], ["its", 223], ["diagnosis", 227], [",", 236], ["which", 238], [",", 243], ["however", 245], [",", 252], ["remains", 254], ["difficult", 262], ["in", 272], ["children", 275], ["and", 284], ["young", 288], ["adults", 294], ["with", 301], ["vascular", 306], ["and", 315], ["hypermobile", 319], ["EDS", 331], ["as", 335], ["well", 338], ["as", 343], ["in", 346], ["patients", 349], ["without", 358], ["a", 366], ["positive", 368], ["family", 377], ["history", 384], [".", 391], ["Diagnosis", 393], ["of", 403], ["vascular", 406], ["EDS", 415], ["is", 419], ["important", 422], ["for", 432], ["clinical", 436], ["follow", 445], ["-", 451], ["up", 452], [",", 454], ["genetic", 456], ["counseling", 464], ["and", 475], ["prenatal", 479], ["diagnosis", 488], [".", 497], ["We", 499], ["describe", 502], ["the", 511], ["biochemical", 515], ["and", 527], ["molecular", 531], ["-", 540], ["genetic", 541], ["diagnosis", 549], ["of", 559], ["vascular", 562], ["EDS", 571], [".", 574], ["We", 576], ["describe", 579], ["five", 588], ["families", 593], ["with", 602], ["vascular", 607], ["EDS", 616], [".", 619], ["Analysis", 621], ["of", 630], ["(", 633], ["pro)collagens", 634], ["obtained", 648], ["from", 657], ["cultured", 662], ["fibroblasts", 671], ["was", 683], ["done", 687], ["using", 692], ["SDS", 698], ["-", 701], ["PAGE", 702], [".", 706], ["The", 708], ["structure", 712], ["and", 722], ["amounts", 726], ["of", 734], ["(", 737], ["pro)collagen", 738], ["I", 751], [",", 752], ["III", 754], ["and", 758], ["V", 762], ["were", 764], ["determined", 769], ["by", 780], ["autoradioflourography", 783], [".", 804], ["This", 806], ["was", 811], ["also", 815], ["done", 820], ["in", 825], ["362", 828], ["controls", 832], ["or", 841], ["patients", 844], ["without", 853], ["a", 861], ["diagnosis", 863], ["of", 873], ["vascular", 876], ["EDS", 885], [".", 888], ["Molecular", 890], ["testing", 900], ["was", 908], ["done", 912], ["in", 917], ["Professor", 920], ["Anne", 930], ["de", 935], ["Paepe", 938], ["'s", 943], ["laboratory", 946], ["in", 957], ["Belgium", 960], ["by", 968], ["sequencing", 971], ["of", 982], ["COL3A1", 985], [".", 991], ["(", 993], ["Pro)collagen", 994], ["from", 1007], ["all", 1012], ["five", 1016], ["patients", 1021], ["with", 1030], ["vascular", 1035], ["EDS", 1044], ["was", 1048], ["abnormal", 1052], ["by", 1061], ["SDS", 1064], ["-", 1067], ["PAGE", 1068], [":", 1072], ["intracellular", 1074], ["retention", 1088], [",", 1097], ["reduced", 1099], ["secretion", 1107], ["and", 1117], ["overmodification", 1121], ["of", 1138], ["the", 1141], ["a1", 1145], ["chains", 1148], ["of", 1155], ["(", 1158], ["pro)collagen", 1159], ["III", 1172], [".", 1175], ["Molecular", 1177], ["analysis", 1187], ["revealed", 1196], ["an", 1205], ["abnormality", 1208], ["of", 1220], ["COL3A1", 1223], ["in", 1230], ["all", 1233], ["patients", 1237], [".", 1245], ["Abnormalities", 1247], ["of", 1261], ["(", 1264], ["pro)collagen", 1265], ["III", 1278], ["were", 1282], ["not", 1287], ["observed", 1291], ["in", 1300], ["patients", 1303], ["without", 1312], ["a", 1320], ["diagnosis", 1322], ["of", 1332], ["vascular", 1335], ["EDS", 1344], [".", 1347], ["Among", 1349], ["90", 1355], ["patients", 1358], ["with", 1367], ["non", 1372], ["-", 1375], ["vascular", 1376], ["EDS", 1385], [",", 1388], ["one", 1390], ["patient", 1394], ["had", 1402], ["an", 1406], ["abnormality", 1409], ["of", 1421], ["collagen", 1424], ["I.", 1433], ["Biochemical", 1436], ["analysis", 1448], ["of", 1457], ["(", 1460], ["pro)collagen", 1461], ["obtained", 1474], ["from", 1483], ["cultured", 1488], ["fibroblasts", 1497], ["is", 1509], ["a", 1512], ["good", 1514], ["screening", 1519], ["procedure", 1529], ["for", 1539], ["vascular", 1543], ["EDS", 1552], [",", 1555], ["but", 1557], ["it", 1561], ["is", 1564], ["of", 1567], ["limited", 1570], ["value", 1578], ["in", 1584], ["non", 1587], ["-", 1590], ["vascular", 1591], ["EDS", 1600], [".", 1603], ["Molecular", 1605], ["testing", 1615], ["will", 1623], ["disclose", 1628], ["an", 1637], ["abnormality", 1640], ["of", 1652], ["COL3A1", 1655], ["in", 1662], ["many", 1665], ["patients", 1670], ["with", 1679], ["abnormal", 1684], ["(", 1693], ["pro)collagen", 1694], ["III", 1707], ["on", 1711], ["SDS", 1714], ["-", 1717], ["PAGE", 1718], [".", 1722], ["The", 1724], ["findings", 1728], ["make", 1737], ["precise", 1742], ["genetic", 1750], ["counselling", 1758], ["and", 1770], ["prenatal", 1774], ["diagnosis", 1783], ["possible", 1793], ["in", 1802], ["families", 1805], ["with", 1814], ["vascular", 1819], ["EDS", 1828], [".", 1831]]}
{"context": "Bilirubin, a breakdown product of heme, is normally glucuronidated and excreted by the liver into bile. Failure of this system can lead to a buildup of conjugated bilirubin in the blood, resulting in jaundice. The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3. These important detoxification-limiting proteins mediate uptake and clearance of countless drugs and drug conjugates across the sinusoidal hepatocyte membrane. OATP1B1 polymorphisms have previously been linked to drug hypersensitivities. Using mice deficient in Oatp1a/1b and in the multispecific sinusoidal export pump Abcc3, we found that Abcc3 secretes bilirubin conjugates into the blood, while Oatp1a/1b transporters mediate their hepatic re uptake. Transgenic expression of human OATP1B1 or OATP1B3 restored the function of this detoxification-enhancing liver-blood shuttle in Oatp1a/1b-deficient mice. Within liver lobules, this shuttle may allow flexible transfer of bilirubin conjugates (and probably also drug conjugates) formed in upstream hepatocytes to downstream hepatocytes, thereby preventing local saturation of further detoxification processes and hepatocyte toxic injury. Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "qas": [{"question": "Which syndrome is associated with OATP1B1 and OATP1B3 deficiency?", "answers": ["Rotor-syndrome", "Rotor syndrome"], "qid": "e677cafc422f4756ba3a515a8090cbb6", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["OATP1B1", 34], ["and", 42], ["OATP1B3", 46], ["deficiency", 54], ["?", 64]], "detected_answers": [{"text": "Rotor syndrome", "token_spans": [[55, 56], [88, 90], [95, 96]], "char_spans": [[323, 336], [538, 551], [577, 590]]}]}], "context_tokens": [["Bilirubin", 0], [",", 9], ["a", 11], ["breakdown", 13], ["product", 23], ["of", 31], ["heme", 34], [",", 38], ["is", 40], ["normally", 43], ["glucuronidated", 52], ["and", 67], ["excreted", 71], ["by", 80], ["the", 83], ["liver", 87], ["into", 93], ["bile", 98], [".", 102], ["Failure", 104], ["of", 112], ["this", 115], ["system", 120], ["can", 127], ["lead", 131], ["to", 136], ["a", 139], ["buildup", 141], ["of", 149], ["conjugated", 152], ["bilirubin", 163], ["in", 173], ["the", 176], ["blood", 180], [",", 185], ["resulting", 187], ["in", 197], ["jaundice", 200], [".", 208], ["The", 210], ["mechanistic", 214], ["basis", 226], ["of", 232], ["bilirubin", 235], ["excretion", 245], ["and", 255], ["hyperbilirubinemia", 259], ["syndromes", 278], ["is", 288], ["largely", 291], ["understood", 299], [",", 309], ["but", 311], ["that", 315], ["of", 320], ["Rotor", 323], ["syndrome", 329], [",", 337], ["an", 339], ["autosomal", 342], ["recessive", 352], ["disorder", 362], ["characterized", 371], ["by", 385], ["conjugated", 388], ["hyperbilirubinemia", 399], [",", 417], ["coproporphyrinuria", 419], [",", 437], ["and", 439], ["near", 443], ["-", 447], ["absent", 448], ["hepatic", 455], ["uptake", 463], ["of", 470], ["anionic", 473], ["diagnostics", 481], [",", 492], ["has", 494], ["remained", 498], ["enigmatic", 507], [".", 516], ["Here", 518], [",", 522], ["we", 524], ["analyzed", 527], ["8", 536], ["Rotor", 538], ["-", 543], ["syndrome", 544], ["families", 553], ["and", 562], ["found", 566], ["that", 572], ["Rotor", 577], ["syndrome", 583], ["was", 592], ["linked", 596], ["to", 603], ["mutations", 606], ["predicted", 616], ["to", 626], ["cause", 629], ["complete", 635], ["and", 644], ["simultaneous", 648], ["deficiencies", 661], ["of", 674], ["the", 677], ["organic", 681], ["anion", 689], ["transporting", 695], ["polypeptides", 708], ["OATP1B1", 721], ["and", 729], ["OATP1B3", 733], [".", 740], ["These", 742], ["important", 748], ["detoxification", 758], ["-", 772], ["limiting", 773], ["proteins", 782], ["mediate", 791], ["uptake", 799], ["and", 806], ["clearance", 810], ["of", 820], ["countless", 823], ["drugs", 833], ["and", 839], ["drug", 843], ["conjugates", 848], ["across", 859], ["the", 866], ["sinusoidal", 870], ["hepatocyte", 881], ["membrane", 892], [".", 900], ["OATP1B1", 902], ["polymorphisms", 910], ["have", 924], ["previously", 929], ["been", 940], ["linked", 945], ["to", 952], ["drug", 955], ["hypersensitivities", 960], [".", 978], ["Using", 980], ["mice", 986], ["deficient", 991], ["in", 1001], ["Oatp1a/1b", 1004], ["and", 1014], ["in", 1018], ["the", 1021], ["multispecific", 1025], ["sinusoidal", 1039], ["export", 1050], ["pump", 1057], ["Abcc3", 1062], [",", 1067], ["we", 1069], ["found", 1072], ["that", 1078], ["Abcc3", 1083], ["secretes", 1089], ["bilirubin", 1098], ["conjugates", 1108], ["into", 1119], ["the", 1124], ["blood", 1128], [",", 1133], ["while", 1135], ["Oatp1a/1b", 1141], ["transporters", 1151], ["mediate", 1164], ["their", 1172], ["hepatic", 1178], ["re", 1186], ["uptake", 1189], [".", 1195], ["Transgenic", 1197], ["expression", 1208], ["of", 1219], ["human", 1222], ["OATP1B1", 1228], ["or", 1236], ["OATP1B3", 1239], ["restored", 1247], ["the", 1256], ["function", 1260], ["of", 1269], ["this", 1272], ["detoxification", 1277], ["-", 1291], ["enhancing", 1292], ["liver", 1302], ["-", 1307], ["blood", 1308], ["shuttle", 1314], ["in", 1322], ["Oatp1a/1b", 1325], ["-", 1334], ["deficient", 1335], ["mice", 1345], [".", 1349], ["Within", 1351], ["liver", 1358], ["lobules", 1364], [",", 1371], ["this", 1373], ["shuttle", 1378], ["may", 1386], ["allow", 1390], ["flexible", 1396], ["transfer", 1405], ["of", 1414], ["bilirubin", 1417], ["conjugates", 1427], ["(", 1438], ["and", 1439], ["probably", 1443], ["also", 1452], ["drug", 1457], ["conjugates", 1462], [")", 1472], ["formed", 1474], ["in", 1481], ["upstream", 1484], ["hepatocytes", 1493], ["to", 1505], ["downstream", 1508], ["hepatocytes", 1519], [",", 1530], ["thereby", 1532], ["preventing", 1540], ["local", 1551], ["saturation", 1557], ["of", 1568], ["further", 1571], ["detoxification", 1579], ["processes", 1594], ["and", 1604], ["hepatocyte", 1608], ["toxic", 1619], ["injury", 1625], [".", 1631], ["Thus", 1633], [",", 1637], ["disruption", 1639], ["of", 1650], ["hepatic", 1653], ["reuptake", 1661], ["of", 1670], ["bilirubin", 1673], ["glucuronide", 1683], ["due", 1695], ["to", 1699], ["coexisting", 1702], ["OATP1B1", 1713], ["and", 1721], ["OATP1B3", 1725], ["deficiencies", 1733], ["explains", 1746], ["Rotor", 1755], ["-", 1760], ["type", 1761], ["hyperbilirubinemia", 1766], [".", 1784], ["Moreover", 1785], [",", 1793], ["OATP1B1", 1795], ["and", 1803], ["OATP1B3", 1807], ["null", 1815], ["mutations", 1820], ["may", 1830], ["confer", 1834], ["substantial", 1841], ["drug", 1853], ["toxicity", 1858], ["risks", 1867], [".", 1872]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common sensorimotor disorder that can generally be effectively managed in the primary care clinic. However, some treatment complications may arise. According to the recommendations of the International Restless Legs Syndrome Study Group, non-ergot dopamine-receptor agonists have over the past years been one of the first-line treatments for patients with RLS/WED requiring pharmacological therapy. Augmentation is the main complication of long-term dopaminergic treatment of RLS/WED and is defined as an overall worsening of symptoms beyond pretreatment levels in patients who experienced an initial positive therapeutic response. Once identified on the basis of its characteristic clinical features, augmentation requires careful management. In order to provide clinicians with a comprehensive understanding of this common treatment complication, this review discusses the clinical features of augmentation, and its differentiation from morning rebound, symptom fluctuations and natural disease progression. Reported incidences of augmentation in clinical trials of dopaminergic RLS/WED therapies are summarized. Finally, the hypothetical pathophysiology of augmentation and the current recommendations for management of patients with augmented RLS/WED symptoms are discussed.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "017e0735cbc64bf6a05beef4895ac60f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[50, 52], [0, 2]], "char_spans": [[279, 300], [0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["common", 77], ["sensorimotor", 84], ["disorder", 97], ["that", 106], ["can", 111], ["generally", 115], ["be", 125], ["effectively", 128], ["managed", 140], ["in", 148], ["the", 151], ["primary", 155], ["care", 163], ["clinic", 168], [".", 174], ["However", 176], [",", 183], ["some", 185], ["treatment", 190], ["complications", 200], ["may", 214], ["arise", 218], [".", 223], ["According", 225], ["to", 235], ["the", 238], ["recommendations", 242], ["of", 258], ["the", 261], ["International", 265], ["Restless", 279], ["Legs", 288], ["Syndrome", 293], ["Study", 302], ["Group", 308], [",", 313], ["non", 315], ["-", 318], ["ergot", 319], ["dopamine", 325], ["-", 333], ["receptor", 334], ["agonists", 343], ["have", 352], ["over", 357], ["the", 362], ["past", 366], ["years", 371], ["been", 377], ["one", 382], ["of", 386], ["the", 389], ["first", 393], ["-", 398], ["line", 399], ["treatments", 404], ["for", 415], ["patients", 419], ["with", 428], ["RLS", 433], ["/", 436], ["WED", 437], ["requiring", 441], ["pharmacological", 451], ["therapy", 467], [".", 474], ["Augmentation", 476], ["is", 489], ["the", 492], ["main", 496], ["complication", 501], ["of", 514], ["long", 517], ["-", 521], ["term", 522], ["dopaminergic", 527], ["treatment", 540], ["of", 550], ["RLS", 553], ["/", 556], ["WED", 557], ["and", 561], ["is", 565], ["defined", 568], ["as", 576], ["an", 579], ["overall", 582], ["worsening", 590], ["of", 600], ["symptoms", 603], ["beyond", 612], ["pretreatment", 619], ["levels", 632], ["in", 639], ["patients", 642], ["who", 651], ["experienced", 655], ["an", 667], ["initial", 670], ["positive", 678], ["therapeutic", 687], ["response", 699], [".", 707], ["Once", 709], ["identified", 714], ["on", 725], ["the", 728], ["basis", 732], ["of", 738], ["its", 741], ["characteristic", 745], ["clinical", 760], ["features", 769], [",", 777], ["augmentation", 779], ["requires", 792], ["careful", 801], ["management", 809], [".", 819], ["In", 821], ["order", 824], ["to", 830], ["provide", 833], ["clinicians", 841], ["with", 852], ["a", 857], ["comprehensive", 859], ["understanding", 873], ["of", 887], ["this", 890], ["common", 895], ["treatment", 902], ["complication", 912], [",", 924], ["this", 926], ["review", 931], ["discusses", 938], ["the", 948], ["clinical", 952], ["features", 961], ["of", 970], ["augmentation", 973], [",", 985], ["and", 987], ["its", 991], ["differentiation", 995], ["from", 1011], ["morning", 1016], ["rebound", 1024], [",", 1031], ["symptom", 1033], ["fluctuations", 1041], ["and", 1054], ["natural", 1058], ["disease", 1066], ["progression", 1074], [".", 1085], ["Reported", 1087], ["incidences", 1096], ["of", 1107], ["augmentation", 1110], ["in", 1123], ["clinical", 1126], ["trials", 1135], ["of", 1142], ["dopaminergic", 1145], ["RLS", 1158], ["/", 1161], ["WED", 1162], ["therapies", 1166], ["are", 1176], ["summarized", 1180], [".", 1190], ["Finally", 1192], [",", 1199], ["the", 1201], ["hypothetical", 1205], ["pathophysiology", 1218], ["of", 1234], ["augmentation", 1237], ["and", 1250], ["the", 1254], ["current", 1258], ["recommendations", 1266], ["for", 1282], ["management", 1286], ["of", 1297], ["patients", 1300], ["with", 1309], ["augmented", 1314], ["RLS", 1324], ["/", 1327], ["WED", 1328], ["symptoms", 1332], ["are", 1341], ["discussed", 1345], [".", 1354]]}
{"context": "Carpal tunnel syndrome (CTS) is a focal compressive neuropathy of the median nerve at the level of the wrist. CTS is the most common type of compressive neuropathy that occurs in the upper extremity. Typically, patients with CTS have paresthesia, pain, and numbness in the radial three and one-half digits. Nighttime symptoms are more common earlier in the disease process, with daytime symptoms becoming more frequent as CTS progresses. Electrodiagnostic studies may be performed to confirm a diagnosis of CTS or to obtain a baseline before surgical treatment; however, electrodiagnostic studies may be normal in a subset of patients who have CTS. Patients who have mild CTS should undergo an initial trial of nonsurgical treatment that includes lifestyle modifications, nighttime splinting, and corticosteroid injections. Carpal tunnel release should be performed in patients in whom nonsurgical treatment fails and patients who have acute CTS secondary to infection or trauma or have advanced symptoms. Recalcitrant CTS, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. Patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "93ad2db0fa834732a6d5f571bafee311", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[13, 13], [218, 218]], "char_spans": [[70, 75], [1297, 1302]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["(", 23], ["CTS", 24], [")", 27], ["is", 29], ["a", 32], ["focal", 34], ["compressive", 40], ["neuropathy", 52], ["of", 63], ["the", 66], ["median", 70], ["nerve", 77], ["at", 83], ["the", 86], ["level", 90], ["of", 96], ["the", 99], ["wrist", 103], [".", 108], ["CTS", 110], ["is", 114], ["the", 117], ["most", 121], ["common", 126], ["type", 133], ["of", 138], ["compressive", 141], ["neuropathy", 153], ["that", 164], ["occurs", 169], ["in", 176], ["the", 179], ["upper", 183], ["extremity", 189], [".", 198], ["Typically", 200], [",", 209], ["patients", 211], ["with", 220], ["CTS", 225], ["have", 229], ["paresthesia", 234], [",", 245], ["pain", 247], [",", 251], ["and", 253], ["numbness", 257], ["in", 266], ["the", 269], ["radial", 273], ["three", 280], ["and", 286], ["one", 290], ["-", 293], ["half", 294], ["digits", 299], [".", 305], ["Nighttime", 307], ["symptoms", 317], ["are", 326], ["more", 330], ["common", 335], ["earlier", 342], ["in", 350], ["the", 353], ["disease", 357], ["process", 365], [",", 372], ["with", 374], ["daytime", 379], ["symptoms", 387], ["becoming", 396], ["more", 405], ["frequent", 410], ["as", 419], ["CTS", 422], ["progresses", 426], [".", 436], ["Electrodiagnostic", 438], ["studies", 456], ["may", 464], ["be", 468], ["performed", 471], ["to", 481], ["confirm", 484], ["a", 492], ["diagnosis", 494], ["of", 504], ["CTS", 507], ["or", 511], ["to", 514], ["obtain", 517], ["a", 524], ["baseline", 526], ["before", 535], ["surgical", 542], ["treatment", 551], [";", 560], ["however", 562], [",", 569], ["electrodiagnostic", 571], ["studies", 589], ["may", 597], ["be", 601], ["normal", 604], ["in", 611], ["a", 614], ["subset", 616], ["of", 623], ["patients", 626], ["who", 635], ["have", 639], ["CTS", 644], [".", 647], ["Patients", 649], ["who", 658], ["have", 662], ["mild", 667], ["CTS", 672], ["should", 676], ["undergo", 683], ["an", 691], ["initial", 694], ["trial", 702], ["of", 708], ["nonsurgical", 711], ["treatment", 723], ["that", 733], ["includes", 738], ["lifestyle", 747], ["modifications", 757], [",", 770], ["nighttime", 772], ["splinting", 782], [",", 791], ["and", 793], ["corticosteroid", 797], ["injections", 812], [".", 822], ["Carpal", 824], ["tunnel", 831], ["release", 838], ["should", 846], ["be", 853], ["performed", 856], ["in", 866], ["patients", 869], ["in", 878], ["whom", 881], ["nonsurgical", 886], ["treatment", 898], ["fails", 908], ["and", 914], ["patients", 918], ["who", 927], ["have", 931], ["acute", 936], ["CTS", 942], ["secondary", 946], ["to", 956], ["infection", 959], ["or", 969], ["trauma", 972], ["or", 979], ["have", 982], ["advanced", 987], ["symptoms", 996], [".", 1004], ["Recalcitrant", 1006], ["CTS", 1019], [",", 1022], ["which", 1024], ["may", 1030], ["occur", 1034], ["in", 1040], ["as", 1043], ["many", 1046], ["as", 1051], ["25", 1054], ["%", 1056], ["of", 1058], ["patients", 1061], ["who", 1070], ["undergo", 1074], ["carpal", 1082], ["tunnel", 1089], ["release", 1096], [",", 1103], ["most", 1105], ["commonly", 1110], ["results", 1119], ["from", 1127], ["an", 1132], ["incomplete", 1135], ["transverse", 1146], ["carpal", 1157], ["ligament", 1164], ["release", 1173], ["or", 1181], ["an", 1184], ["incorrect", 1187], ["initial", 1197], ["diagnosis", 1205], [".", 1214], ["Patients", 1216], ["with", 1225], ["recurrent", 1230], ["symptoms", 1240], ["often", 1249], ["have", 1255], ["perineural", 1260], ["fibrosis", 1271], ["that", 1280], ["tethers", 1285], ["the", 1293], ["median", 1297], ["nerve", 1304], [".", 1309]]}
{"context": "Gene expression signatures can provide an unbiased view into the molecular changes underlying biologically and medically interesting phenotypes. We therefore initiated this study to identify signatures that would be of utility in studying rheumatoid arthritis (RA). We used microarray profiling of peripheral blood mononuclear cells (PBMCs) in 30 RA patients to assess the effect of different biologic agent (biologics) treatments and to quantify the degree of a type-I interferon (IFN) signature in these patients. A numeric score was derived for the quantification step and applied to patients with RA. To further characterize the IFN response in our cohort, we employed type-I IFN treatment of PBMCs in vitro and in reporter assays. Profiling identified a subset of RA patients with upregulation of type-I IFN-regulated transcripts, thereby corroborating previous reports showing RA to be heterogeneous for an IFN component. A comparison of individuals currently untreated with a biologic with those treated with infliximab, tocilizumab, or abatacept suggested that each biologic induces a specific gene signature in PBMCs. It is possible to observe signs of type-I IFN pathway activation in a subset of clinically active RA patients without C-reactive protein elevation. Furthermore, biologics-specific gene signatures in patients with RA indicate that looking for a biologic-specific response pattern may be a potential future tool for predicting individual patient response.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "445eaec1f42042ac82afda98668e9da8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[80, 82]], "char_spans": [[482, 495]]}]}], "context_tokens": [["Gene", 0], ["expression", 5], ["signatures", 16], ["can", 27], ["provide", 31], ["an", 39], ["unbiased", 42], ["view", 51], ["into", 56], ["the", 61], ["molecular", 65], ["changes", 75], ["underlying", 83], ["biologically", 94], ["and", 107], ["medically", 111], ["interesting", 121], ["phenotypes", 133], [".", 143], ["We", 145], ["therefore", 148], ["initiated", 158], ["this", 168], ["study", 173], ["to", 179], ["identify", 182], ["signatures", 191], ["that", 202], ["would", 207], ["be", 213], ["of", 216], ["utility", 219], ["in", 227], ["studying", 230], ["rheumatoid", 239], ["arthritis", 250], ["(", 260], ["RA", 261], [")", 263], [".", 264], ["We", 266], ["used", 269], ["microarray", 274], ["profiling", 285], ["of", 295], ["peripheral", 298], ["blood", 309], ["mononuclear", 315], ["cells", 327], ["(", 333], ["PBMCs", 334], [")", 339], ["in", 341], ["30", 344], ["RA", 347], ["patients", 350], ["to", 359], ["assess", 362], ["the", 369], ["effect", 373], ["of", 380], ["different", 383], ["biologic", 393], ["agent", 402], ["(", 408], ["biologics", 409], [")", 418], ["treatments", 420], ["and", 431], ["to", 435], ["quantify", 438], ["the", 447], ["degree", 451], ["of", 458], ["a", 461], ["type", 463], ["-", 467], ["I", 468], ["interferon", 470], ["(", 481], ["IFN", 482], [")", 485], ["signature", 487], ["in", 497], ["these", 500], ["patients", 506], [".", 514], ["A", 516], ["numeric", 518], ["score", 526], ["was", 532], ["derived", 536], ["for", 544], ["the", 548], ["quantification", 552], ["step", 567], ["and", 572], ["applied", 576], ["to", 584], ["patients", 587], ["with", 596], ["RA", 601], [".", 603], ["To", 605], ["further", 608], ["characterize", 616], ["the", 629], ["IFN", 633], ["response", 637], ["in", 646], ["our", 649], ["cohort", 653], [",", 659], ["we", 661], ["employed", 664], ["type", 673], ["-", 677], ["I", 678], ["IFN", 680], ["treatment", 684], ["of", 694], ["PBMCs", 697], ["in", 703], ["vitro", 706], ["and", 712], ["in", 716], ["reporter", 719], ["assays", 728], [".", 734], ["Profiling", 736], ["identified", 746], ["a", 757], ["subset", 759], ["of", 766], ["RA", 769], ["patients", 772], ["with", 781], ["upregulation", 786], ["of", 799], ["type", 802], ["-", 806], ["I", 807], ["IFN", 809], ["-", 812], ["regulated", 813], ["transcripts", 823], [",", 834], ["thereby", 836], ["corroborating", 844], ["previous", 858], ["reports", 867], ["showing", 875], ["RA", 883], ["to", 886], ["be", 889], ["heterogeneous", 892], ["for", 906], ["an", 910], ["IFN", 913], ["component", 917], [".", 926], ["A", 928], ["comparison", 930], ["of", 941], ["individuals", 944], ["currently", 956], ["untreated", 966], ["with", 976], ["a", 981], ["biologic", 983], ["with", 992], ["those", 997], ["treated", 1003], ["with", 1011], ["infliximab", 1016], [",", 1026], ["tocilizumab", 1028], [",", 1039], ["or", 1041], ["abatacept", 1044], ["suggested", 1054], ["that", 1064], ["each", 1069], ["biologic", 1074], ["induces", 1083], ["a", 1091], ["specific", 1093], ["gene", 1102], ["signature", 1107], ["in", 1117], ["PBMCs", 1120], [".", 1125], ["It", 1127], ["is", 1130], ["possible", 1133], ["to", 1142], ["observe", 1145], ["signs", 1153], ["of", 1159], ["type", 1162], ["-", 1166], ["I", 1167], ["IFN", 1169], ["pathway", 1173], ["activation", 1181], ["in", 1192], ["a", 1195], ["subset", 1197], ["of", 1204], ["clinically", 1207], ["active", 1218], ["RA", 1225], ["patients", 1228], ["without", 1237], ["C", 1245], ["-", 1246], ["reactive", 1247], ["protein", 1256], ["elevation", 1264], [".", 1273], ["Furthermore", 1275], [",", 1286], ["biologics", 1288], ["-", 1297], ["specific", 1298], ["gene", 1307], ["signatures", 1312], ["in", 1323], ["patients", 1326], ["with", 1335], ["RA", 1340], ["indicate", 1343], ["that", 1352], ["looking", 1357], ["for", 1365], ["a", 1369], ["biologic", 1371], ["-", 1379], ["specific", 1380], ["response", 1389], ["pattern", 1398], ["may", 1406], ["be", 1410], ["a", 1413], ["potential", 1415], ["future", 1425], ["tool", 1432], ["for", 1437], ["predicting", 1441], ["individual", 1452], ["patient", 1463], ["response", 1471], [".", 1479]]}
{"context": "Paired-like homeodomain transcription factor 1 (PITX1) was proposed to be part of the disease mechanisms of facioscapulohumeral muscular dystrophy (FSHD). We generated a tet-repressible muscle-specific Pitx1 transgenic mouse model which develops phenotypes of muscular dystrophy after the PITX1 expression is induced. In this study, we attempted to block the translation of PITX1 protein using morpholinos. Three groups of the transgenic mice received intravenous injections of phosphorodiamidate morpholino oligomers (PMO) (100\u2009mg/kg), octaguanidinium dendrimer-conjugated morpholino (vivo-morpholino) (10\u2009mg/kg), or phosphate-buffered saline (PBS) after the PITX1 expression was induced. Immunoblotting data showed that PITX1 expression in the triceps and quadriceps was significantly reduced 70% and 63% by the vivo-morpholino treatment, respectively. Muscle pathology of the mice treated with the vivo-morpholino was improved by showing 44% fewer angular-shaped atrophic myofibers. Muscle function determined by grip strength was significantly improved by the vivo-morpholino treatment. The study showed that systemic delivery of the vivo-morpholino reduced the PITX1 expression and improved the muscle phenotypes. Aberrant expression of DUX4 from the last unit of the D4Z4 array has been proposed to be the cause of FSHD. The findings of this study suggest that the same principle may be applied to suppress the aberrantly expressed DUX4 in FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "e6310084df7a436e828bdf5b509a3937", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[24, 24], [233, 233], [255, 255]], "char_spans": [[148, 151], [1321, 1324], [1446, 1449]]}]}], "context_tokens": [["Paired", 0], ["-", 6], ["like", 7], ["homeodomain", 12], ["transcription", 24], ["factor", 38], ["1", 45], ["(", 47], ["PITX1", 48], [")", 53], ["was", 55], ["proposed", 59], ["to", 68], ["be", 71], ["part", 74], ["of", 79], ["the", 82], ["disease", 86], ["mechanisms", 94], ["of", 105], ["facioscapulohumeral", 108], ["muscular", 128], ["dystrophy", 137], ["(", 147], ["FSHD", 148], [")", 152], [".", 153], ["We", 155], ["generated", 158], ["a", 168], ["tet", 170], ["-", 173], ["repressible", 174], ["muscle", 186], ["-", 192], ["specific", 193], ["Pitx1", 202], ["transgenic", 208], ["mouse", 219], ["model", 225], ["which", 231], ["develops", 237], ["phenotypes", 246], ["of", 257], ["muscular", 260], ["dystrophy", 269], ["after", 279], ["the", 285], ["PITX1", 289], ["expression", 295], ["is", 306], ["induced", 309], [".", 316], ["In", 318], ["this", 321], ["study", 326], [",", 331], ["we", 333], ["attempted", 336], ["to", 346], ["block", 349], ["the", 355], ["translation", 359], ["of", 371], ["PITX1", 374], ["protein", 380], ["using", 388], ["morpholinos", 394], [".", 405], ["Three", 407], ["groups", 413], ["of", 420], ["the", 423], ["transgenic", 427], ["mice", 438], ["received", 443], ["intravenous", 452], ["injections", 464], ["of", 475], ["phosphorodiamidate", 478], ["morpholino", 497], ["oligomers", 508], ["(", 518], ["PMO", 519], [")", 522], ["(", 524], ["100", 525], ["mg", 529], ["/", 531], ["kg", 532], [")", 534], [",", 535], ["octaguanidinium", 537], ["dendrimer", 553], ["-", 562], ["conjugated", 563], ["morpholino", 574], ["(", 585], ["vivo", 586], ["-", 590], ["morpholino", 591], [")", 601], ["(", 603], ["10", 604], ["mg", 607], ["/", 609], ["kg", 610], [")", 612], [",", 613], ["or", 615], ["phosphate", 618], ["-", 627], ["buffered", 628], ["saline", 637], ["(", 644], ["PBS", 645], [")", 648], ["after", 650], ["the", 656], ["PITX1", 660], ["expression", 666], ["was", 677], ["induced", 681], [".", 688], ["Immunoblotting", 690], ["data", 705], ["showed", 710], ["that", 717], ["PITX1", 722], ["expression", 728], ["in", 739], ["the", 742], ["triceps", 746], ["and", 754], ["quadriceps", 758], ["was", 769], ["significantly", 773], ["reduced", 787], ["70", 795], ["%", 797], ["and", 799], ["63", 803], ["%", 805], ["by", 807], ["the", 810], ["vivo", 814], ["-", 818], ["morpholino", 819], ["treatment", 830], [",", 839], ["respectively", 841], [".", 853], ["Muscle", 855], ["pathology", 862], ["of", 872], ["the", 875], ["mice", 879], ["treated", 884], ["with", 892], ["the", 897], ["vivo", 901], ["-", 905], ["morpholino", 906], ["was", 917], ["improved", 921], ["by", 930], ["showing", 933], ["44", 941], ["%", 943], ["fewer", 945], ["angular", 951], ["-", 958], ["shaped", 959], ["atrophic", 966], ["myofibers", 975], [".", 984], ["Muscle", 986], ["function", 993], ["determined", 1002], ["by", 1013], ["grip", 1016], ["strength", 1021], ["was", 1030], ["significantly", 1034], ["improved", 1048], ["by", 1057], ["the", 1060], ["vivo", 1064], ["-", 1068], ["morpholino", 1069], ["treatment", 1080], [".", 1089], ["The", 1091], ["study", 1095], ["showed", 1101], ["that", 1108], ["systemic", 1113], ["delivery", 1122], ["of", 1131], ["the", 1134], ["vivo", 1138], ["-", 1142], ["morpholino", 1143], ["reduced", 1154], ["the", 1162], ["PITX1", 1166], ["expression", 1172], ["and", 1183], ["improved", 1187], ["the", 1196], ["muscle", 1200], ["phenotypes", 1207], [".", 1217], ["Aberrant", 1219], ["expression", 1228], ["of", 1239], ["DUX4", 1242], ["from", 1247], ["the", 1252], ["last", 1256], ["unit", 1261], ["of", 1266], ["the", 1269], ["D4Z4", 1273], ["array", 1278], ["has", 1284], ["been", 1288], ["proposed", 1293], ["to", 1302], ["be", 1305], ["the", 1308], ["cause", 1312], ["of", 1318], ["FSHD", 1321], [".", 1325], ["The", 1327], ["findings", 1331], ["of", 1340], ["this", 1343], ["study", 1348], ["suggest", 1354], ["that", 1362], ["the", 1367], ["same", 1371], ["principle", 1376], ["may", 1386], ["be", 1390], ["applied", 1393], ["to", 1401], ["suppress", 1404], ["the", 1413], ["aberrantly", 1417], ["expressed", 1428], ["DUX4", 1438], ["in", 1443], ["FSHD", 1446], [".", 1450]]}
{"context": "In the last few years, several tyrosine kinase inhibitors (TKIs) have been synthesized and become available for preclinical studies and clinical trials. This article summarizes recent achievements in the mechanism of action, pharmacological properties, and clinical activity and toxicity, as well as the emerging role of TKIs in lymphoid malignancies, allergic diseases, and autoimmune disorders. A literature review was conducted of the MEDLINE database PubMed for articles in English. Publications from 2000 through January 2012 were scrutinized. The search terms used were Bruton's tyrosine kinase (Btk) inhibitors, PCI-32765, GDC-0834, LFM-A13, AVL-101, AVL-292, spleen tyrosine kinase (Syk) inhibitors, R343, R406, R112, R788, fostamatinib, BAY-61-3606, C-61, piceatannol, Lyn, imatinib, nilotinib, bafetinib, dasatinib, GDC-0834, PP2, SU6656 in conjunction with lymphoid malignancy, NHL, CLL, autoimmune disease, allergic disease, asthma, and rheumatoid arthritis. Conference proceedings from the previous 5 years of the American Society of Hematology, European Hematology Association, American Society of Clinical Oncology, and ACR/ARHP Annual Scientific Meetings were searched manually. Additional relevant publications were obtained by reviewing the references from the chosen articles. The use of TKIs, especially inhibitors of Btk, Syk, and Lyn, is a promising new strategy for targeted treatment of B-cell lymphoid malignancies, autoimmune disorders and allergic diseases. However, definitive data from ongoing and future clinical trials will aid in better defining the status of TKIs in the treatment of these disorders.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "fab303bb445f49959138cf04ba36638a", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[115, 117]], "char_spans": [[667, 688]]}]}], "context_tokens": [["In", 0], ["the", 3], ["last", 7], ["few", 12], ["years", 16], [",", 21], ["several", 23], ["tyrosine", 31], ["kinase", 40], ["inhibitors", 47], ["(", 58], ["TKIs", 59], [")", 63], ["have", 65], ["been", 70], ["synthesized", 75], ["and", 87], ["become", 91], ["available", 98], ["for", 108], ["preclinical", 112], ["studies", 124], ["and", 132], ["clinical", 136], ["trials", 145], [".", 151], ["This", 153], ["article", 158], ["summarizes", 166], ["recent", 177], ["achievements", 184], ["in", 197], ["the", 200], ["mechanism", 204], ["of", 214], ["action", 217], [",", 223], ["pharmacological", 225], ["properties", 241], [",", 251], ["and", 253], ["clinical", 257], ["activity", 266], ["and", 275], ["toxicity", 279], [",", 287], ["as", 289], ["well", 292], ["as", 297], ["the", 300], ["emerging", 304], ["role", 313], ["of", 318], ["TKIs", 321], ["in", 326], ["lymphoid", 329], ["malignancies", 338], [",", 350], ["allergic", 352], ["diseases", 361], [",", 369], ["and", 371], ["autoimmune", 375], ["disorders", 386], [".", 395], ["A", 397], ["literature", 399], ["review", 410], ["was", 417], ["conducted", 421], ["of", 431], ["the", 434], ["MEDLINE", 438], ["database", 446], ["PubMed", 455], ["for", 462], ["articles", 466], ["in", 475], ["English", 478], [".", 485], ["Publications", 487], ["from", 500], ["2000", 505], ["through", 510], ["January", 518], ["2012", 526], ["were", 531], ["scrutinized", 536], [".", 547], ["The", 549], ["search", 553], ["terms", 560], ["used", 566], ["were", 571], ["Bruton", 576], ["'s", 582], ["tyrosine", 585], ["kinase", 594], ["(", 601], ["Btk", 602], [")", 605], ["inhibitors", 607], [",", 617], ["PCI-32765", 619], [",", 628], ["GDC-0834", 630], [",", 638], ["LFM", 640], ["-", 643], ["A13", 644], [",", 647], ["AVL-101", 649], [",", 656], ["AVL-292", 658], [",", 665], ["spleen", 667], ["tyrosine", 674], ["kinase", 683], ["(", 690], ["Syk", 691], [")", 694], ["inhibitors", 696], [",", 706], ["R343", 708], [",", 712], ["R406", 714], [",", 718], ["R112", 720], [",", 724], ["R788", 726], [",", 730], ["fostamatinib", 732], [",", 744], ["BAY-61", 746], ["-", 752], ["3606", 753], [",", 757], ["C-61", 759], [",", 763], ["piceatannol", 765], [",", 776], ["Lyn", 778], [",", 781], ["imatinib", 783], [",", 791], ["nilotinib", 793], [",", 802], ["bafetinib", 804], [",", 813], ["dasatinib", 815], [",", 824], ["GDC-0834", 826], [",", 834], ["PP2", 836], [",", 839], ["SU6656", 841], ["in", 848], ["conjunction", 851], ["with", 863], ["lymphoid", 868], ["malignancy", 877], [",", 887], ["NHL", 889], [",", 892], ["CLL", 894], [",", 897], ["autoimmune", 899], ["disease", 910], [",", 917], ["allergic", 919], ["disease", 928], [",", 935], ["asthma", 937], [",", 943], ["and", 945], ["rheumatoid", 949], ["arthritis", 960], [".", 969], ["Conference", 971], ["proceedings", 982], ["from", 994], ["the", 999], ["previous", 1003], ["5", 1012], ["years", 1014], ["of", 1020], ["the", 1023], ["American", 1027], ["Society", 1036], ["of", 1044], ["Hematology", 1047], [",", 1057], ["European", 1059], ["Hematology", 1068], ["Association", 1079], [",", 1090], ["American", 1092], ["Society", 1101], ["of", 1109], ["Clinical", 1112], ["Oncology", 1121], [",", 1129], ["and", 1131], ["ACR", 1135], ["/", 1138], ["ARHP", 1139], ["Annual", 1144], ["Scientific", 1151], ["Meetings", 1162], ["were", 1171], ["searched", 1176], ["manually", 1185], [".", 1193], ["Additional", 1195], ["relevant", 1206], ["publications", 1215], ["were", 1228], ["obtained", 1233], ["by", 1242], ["reviewing", 1245], ["the", 1255], ["references", 1259], ["from", 1270], ["the", 1275], ["chosen", 1279], ["articles", 1286], [".", 1294], ["The", 1296], ["use", 1300], ["of", 1304], ["TKIs", 1307], [",", 1311], ["especially", 1313], ["inhibitors", 1324], ["of", 1335], ["Btk", 1338], [",", 1341], ["Syk", 1343], [",", 1346], ["and", 1348], ["Lyn", 1352], [",", 1355], ["is", 1357], ["a", 1360], ["promising", 1362], ["new", 1372], ["strategy", 1376], ["for", 1385], ["targeted", 1389], ["treatment", 1398], ["of", 1408], ["B", 1411], ["-", 1412], ["cell", 1413], ["lymphoid", 1418], ["malignancies", 1427], [",", 1439], ["autoimmune", 1441], ["disorders", 1452], ["and", 1462], ["allergic", 1466], ["diseases", 1475], [".", 1483], ["However", 1485], [",", 1492], ["definitive", 1494], ["data", 1505], ["from", 1510], ["ongoing", 1515], ["and", 1523], ["future", 1527], ["clinical", 1534], ["trials", 1543], ["will", 1550], ["aid", 1555], ["in", 1559], ["better", 1562], ["defining", 1569], ["the", 1578], ["status", 1582], ["of", 1589], ["TKIs", 1592], ["in", 1597], ["the", 1600], ["treatment", 1604], ["of", 1614], ["these", 1617], ["disorders", 1623], [".", 1632]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is caused by mutations in the NOTCH3 gene and is clinically characterized by recurrent stroke, cognitive decline, psychiatric disturbances and migraine. The prevalence of migraine in CADASIL is slightly higher than in the general population, and the proportion of migraine with aura is much higher. The pathophysiological mechanism that leads to increased aura prevalence in CADASIL is unknown. Possible mechanisms of the excess of migraine with aura are an increased susceptibility to cortical spreading depression (CSD) or a different expression of CSD. It is also possible that the brainstem migraine area is involved in CADASIL. Last, it is possible that the NOTCH3 mutation acts as a migraine aura susceptibility gene by itself. In this narrative review we summarize the literature about migraine in CADASIL, with a special focus on what CADASIL might teach us about the pathophysiology of migraine.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "56b8eb3015f747f78f3544b919c22c37", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[18, 19]], "char_spans": [[131, 141]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["caused", 104], ["by", 111], ["mutations", 114], ["in", 124], ["the", 127], ["NOTCH3", 131], ["gene", 138], ["and", 143], ["is", 147], ["clinically", 150], ["characterized", 161], ["by", 175], ["recurrent", 178], ["stroke", 188], [",", 194], ["cognitive", 196], ["decline", 206], [",", 213], ["psychiatric", 215], ["disturbances", 227], ["and", 240], ["migraine", 244], [".", 252], ["The", 254], ["prevalence", 258], ["of", 269], ["migraine", 272], ["in", 281], ["CADASIL", 284], ["is", 292], ["slightly", 295], ["higher", 304], ["than", 311], ["in", 316], ["the", 319], ["general", 323], ["population", 331], [",", 341], ["and", 343], ["the", 347], ["proportion", 351], ["of", 362], ["migraine", 365], ["with", 374], ["aura", 379], ["is", 384], ["much", 387], ["higher", 392], [".", 398], ["The", 400], ["pathophysiological", 404], ["mechanism", 423], ["that", 433], ["leads", 438], ["to", 444], ["increased", 447], ["aura", 457], ["prevalence", 462], ["in", 473], ["CADASIL", 476], ["is", 484], ["unknown", 487], [".", 494], ["Possible", 496], ["mechanisms", 505], ["of", 516], ["the", 519], ["excess", 523], ["of", 530], ["migraine", 533], ["with", 542], ["aura", 547], ["are", 552], ["an", 556], ["increased", 559], ["susceptibility", 569], ["to", 584], ["cortical", 587], ["spreading", 596], ["depression", 606], ["(", 617], ["CSD", 618], [")", 621], ["or", 623], ["a", 626], ["different", 628], ["expression", 638], ["of", 649], ["CSD", 652], [".", 655], ["It", 657], ["is", 660], ["also", 663], ["possible", 668], ["that", 677], ["the", 682], ["brainstem", 686], ["migraine", 696], ["area", 705], ["is", 710], ["involved", 713], ["in", 722], ["CADASIL", 725], [".", 732], ["Last", 734], [",", 738], ["it", 740], ["is", 743], ["possible", 746], ["that", 755], ["the", 760], ["NOTCH3", 764], ["mutation", 771], ["acts", 780], ["as", 785], ["a", 788], ["migraine", 790], ["aura", 799], ["susceptibility", 804], ["gene", 819], ["by", 824], ["itself", 827], [".", 833], ["In", 835], ["this", 838], ["narrative", 843], ["review", 853], ["we", 860], ["summarize", 863], ["the", 873], ["literature", 877], ["about", 888], ["migraine", 894], ["in", 903], ["CADASIL", 906], [",", 913], ["with", 915], ["a", 920], ["special", 922], ["focus", 930], ["on", 936], ["what", 939], ["CADASIL", 944], ["might", 952], ["teach", 958], ["us", 964], ["about", 967], ["the", 973], ["pathophysiology", 977], ["of", 993], ["migraine", 996], [".", 1004]]}
{"context": "Differentiation of cancer stem cells (CSCs) into cancer cells causes increased sensitivity to chemotherapeutic agents. Although inhibition of mammalian target of rapamycin (mTOR) leads to CSC survival, the effect of branched chain amino acids (BCAAs), an mTOR complex 1 (mTORC1) activator remains unknown. In this study, we examined the effects of BCAA on hepatocellular carcinoma (HCC) cells expressing a hepatic CSC marker, EpCAM. We examined the effects of BCAA and/or 5-fluorouracil (FU) on expression of EpCAM and other CSC-related markers, as well as cell proliferation in HCC cells and in a xenograft mouse model. We also characterized CSC-related and mTOR signal-related molecule expression and tumorigenicity in HCC cells with knockdown of Rictor or Raptor, or overexpression of constitutively active rheb (caRheb). mTOR signal-related molecule expression was also examined in BCAA-treated HCC cells. In-vitro BCAA reduced the frequency of EpCAM-positive cells and improved sensitivity to the anti-proliferative effect of 5-FU. Combined 5-FU and BCAA provided better antitumor efficacy than 5-FU alone in the xenograft model. Stimulation with high doses of BCAA activated mTORC1. Knockdown and overexpression experiments revealed that inhibition of mTOR complex 2 (mTORC2) or activation of mTORC1 led to decreased EpCAM expression and little or no tumorigenicity. BCAA may enhance the sensitivity to chemotherapy by reducing the population of cscs via the mTOR pathway. This result suggests the utility of BCAA in liver cancer therapy.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "0720cc54f299433bb58ec7af596a77c9", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[21, 24]], "char_spans": [[142, 170]]}]}], "context_tokens": [["Differentiation", 0], ["of", 16], ["cancer", 19], ["stem", 26], ["cells", 31], ["(", 37], ["CSCs", 38], [")", 42], ["into", 44], ["cancer", 49], ["cells", 56], ["causes", 62], ["increased", 69], ["sensitivity", 79], ["to", 91], ["chemotherapeutic", 94], ["agents", 111], [".", 117], ["Although", 119], ["inhibition", 128], ["of", 139], ["mammalian", 142], ["target", 152], ["of", 159], ["rapamycin", 162], ["(", 172], ["mTOR", 173], [")", 177], ["leads", 179], ["to", 185], ["CSC", 188], ["survival", 192], [",", 200], ["the", 202], ["effect", 206], ["of", 213], ["branched", 216], ["chain", 225], ["amino", 231], ["acids", 237], ["(", 243], ["BCAAs", 244], [")", 249], [",", 250], ["an", 252], ["mTOR", 255], ["complex", 260], ["1", 268], ["(", 270], ["mTORC1", 271], [")", 277], ["activator", 279], ["remains", 289], ["unknown", 297], [".", 304], ["In", 306], ["this", 309], ["study", 314], [",", 319], ["we", 321], ["examined", 324], ["the", 333], ["effects", 337], ["of", 345], ["BCAA", 348], ["on", 353], ["hepatocellular", 356], ["carcinoma", 371], ["(", 381], ["HCC", 382], [")", 385], ["cells", 387], ["expressing", 393], ["a", 404], ["hepatic", 406], ["CSC", 414], ["marker", 418], [",", 424], ["EpCAM", 426], [".", 431], ["We", 433], ["examined", 436], ["the", 445], ["effects", 449], ["of", 457], ["BCAA", 460], ["and/or", 465], ["5-fluorouracil", 472], ["(", 487], ["FU", 488], [")", 490], ["on", 492], ["expression", 495], ["of", 506], ["EpCAM", 509], ["and", 515], ["other", 519], ["CSC", 525], ["-", 528], ["related", 529], ["markers", 537], [",", 544], ["as", 546], ["well", 549], ["as", 554], ["cell", 557], ["proliferation", 562], ["in", 576], ["HCC", 579], ["cells", 583], ["and", 589], ["in", 593], ["a", 596], ["xenograft", 598], ["mouse", 608], ["model", 614], [".", 619], ["We", 621], ["also", 624], ["characterized", 629], ["CSC", 643], ["-", 646], ["related", 647], ["and", 655], ["mTOR", 659], ["signal", 664], ["-", 670], ["related", 671], ["molecule", 679], ["expression", 688], ["and", 699], ["tumorigenicity", 703], ["in", 718], ["HCC", 721], ["cells", 725], ["with", 731], ["knockdown", 736], ["of", 746], ["Rictor", 749], ["or", 756], ["Raptor", 759], [",", 765], ["or", 767], ["overexpression", 770], ["of", 785], ["constitutively", 788], ["active", 803], ["rheb", 810], ["(", 815], ["caRheb", 816], [")", 822], [".", 823], ["mTOR", 825], ["signal", 830], ["-", 836], ["related", 837], ["molecule", 845], ["expression", 854], ["was", 865], ["also", 869], ["examined", 874], ["in", 883], ["BCAA", 886], ["-", 890], ["treated", 891], ["HCC", 899], ["cells", 903], [".", 908], ["In", 910], ["-", 912], ["vitro", 913], ["BCAA", 919], ["reduced", 924], ["the", 932], ["frequency", 936], ["of", 946], ["EpCAM", 949], ["-", 954], ["positive", 955], ["cells", 964], ["and", 970], ["improved", 974], ["sensitivity", 983], ["to", 995], ["the", 998], ["anti", 1002], ["-", 1006], ["proliferative", 1007], ["effect", 1021], ["of", 1028], ["5-FU", 1031], [".", 1035], ["Combined", 1037], ["5-FU", 1046], ["and", 1051], ["BCAA", 1055], ["provided", 1060], ["better", 1069], ["antitumor", 1076], ["efficacy", 1086], ["than", 1095], ["5-FU", 1100], ["alone", 1105], ["in", 1111], ["the", 1114], ["xenograft", 1118], ["model", 1128], [".", 1133], ["Stimulation", 1135], ["with", 1147], ["high", 1152], ["doses", 1157], ["of", 1163], ["BCAA", 1166], ["activated", 1171], ["mTORC1", 1181], [".", 1187], ["Knockdown", 1189], ["and", 1199], ["overexpression", 1203], ["experiments", 1218], ["revealed", 1230], ["that", 1239], ["inhibition", 1244], ["of", 1255], ["mTOR", 1258], ["complex", 1263], ["2", 1271], ["(", 1273], ["mTORC2", 1274], [")", 1280], ["or", 1282], ["activation", 1285], ["of", 1296], ["mTORC1", 1299], ["led", 1306], ["to", 1310], ["decreased", 1313], ["EpCAM", 1323], ["expression", 1329], ["and", 1340], ["little", 1344], ["or", 1351], ["no", 1354], ["tumorigenicity", 1357], [".", 1371], ["BCAA", 1373], ["may", 1378], ["enhance", 1382], ["the", 1390], ["sensitivity", 1394], ["to", 1406], ["chemotherapy", 1409], ["by", 1422], ["reducing", 1425], ["the", 1434], ["population", 1438], ["of", 1449], ["cscs", 1452], ["via", 1457], ["the", 1461], ["mTOR", 1465], ["pathway", 1470], [".", 1477], ["This", 1479], ["result", 1484], ["suggests", 1491], ["the", 1500], ["utility", 1504], ["of", 1512], ["BCAA", 1515], ["in", 1520], ["liver", 1523], ["cancer", 1529], ["therapy", 1536], [".", 1543]]}
{"context": "Acromicric dysplasia is a rare bone dysplasia characterised by short stature, short hands and feet, normal intelligence, mild facial dysmorphism, and characteristic x ray abnormalities of the hands. Only a very small number of children with this condition have been reported so far. Here we report on a series of 22 patients including 10 boys and 12 girls with acromicric dysplasia. Length was normal at birth and height fell progressively off the centiles postnatally. The mean adult height was 130 cm (133 cm in males, 129 cm in females). The hands, feet, and limbs were short and OFC was normal. Intelligence was normal and mild dysmorphic features were noted. Other occasional features included well developed muscles, a hoarse voice, generalised joint limitation in some patients, frequent ear, tracheal, and respiratory complication, and spine abnormalities. Long term follow up showed that facial dysmorphism was less obvious in adults and that carpal tunnel syndrome was frequent in older patients. Apart from short metacarpals and phalanges, internal notch of the second metacarpal, external notch of the fifth metacarpal, and internal notch of the femoral heads, there were no major x ray abnormalities. No major complications, such as cardiac disease or major orthopaedic problems, occurred in the course of the disease. The condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant mode of inheritance.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "d8e2390fcaf54e2d922c90ca3601a0fe", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[261, 262]], "char_spans": [[1468, 1485]]}]}], "context_tokens": [["Acromicric", 0], ["dysplasia", 11], ["is", 21], ["a", 24], ["rare", 26], ["bone", 31], ["dysplasia", 36], ["characterised", 46], ["by", 60], ["short", 63], ["stature", 69], [",", 76], ["short", 78], ["hands", 84], ["and", 90], ["feet", 94], [",", 98], ["normal", 100], ["intelligence", 107], [",", 119], ["mild", 121], ["facial", 126], ["dysmorphism", 133], [",", 144], ["and", 146], ["characteristic", 150], ["x", 165], ["ray", 167], ["abnormalities", 171], ["of", 185], ["the", 188], ["hands", 192], [".", 197], ["Only", 199], ["a", 204], ["very", 206], ["small", 211], ["number", 217], ["of", 224], ["children", 227], ["with", 236], ["this", 241], ["condition", 246], ["have", 256], ["been", 261], ["reported", 266], ["so", 275], ["far", 278], [".", 281], ["Here", 283], ["we", 288], ["report", 291], ["on", 298], ["a", 301], ["series", 303], ["of", 310], ["22", 313], ["patients", 316], ["including", 325], ["10", 335], ["boys", 338], ["and", 343], ["12", 347], ["girls", 350], ["with", 356], ["acromicric", 361], ["dysplasia", 372], [".", 381], ["Length", 383], ["was", 390], ["normal", 394], ["at", 401], ["birth", 404], ["and", 410], ["height", 414], ["fell", 421], ["progressively", 426], ["off", 440], ["the", 444], ["centiles", 448], ["postnatally", 457], [".", 468], ["The", 470], ["mean", 474], ["adult", 479], ["height", 485], ["was", 492], ["130", 496], ["cm", 500], ["(", 503], ["133", 504], ["cm", 508], ["in", 511], ["males", 514], [",", 519], ["129", 521], ["cm", 525], ["in", 528], ["females", 531], [")", 538], [".", 539], ["The", 541], ["hands", 545], [",", 550], ["feet", 552], [",", 556], ["and", 558], ["limbs", 562], ["were", 568], ["short", 573], ["and", 579], ["OFC", 583], ["was", 587], ["normal", 591], [".", 597], ["Intelligence", 599], ["was", 612], ["normal", 616], ["and", 623], ["mild", 627], ["dysmorphic", 632], ["features", 643], ["were", 652], ["noted", 657], [".", 662], ["Other", 664], ["occasional", 670], ["features", 681], ["included", 690], ["well", 699], ["developed", 704], ["muscles", 714], [",", 721], ["a", 723], ["hoarse", 725], ["voice", 732], [",", 737], ["generalised", 739], ["joint", 751], ["limitation", 757], ["in", 768], ["some", 771], ["patients", 776], [",", 784], ["frequent", 786], ["ear", 795], [",", 798], ["tracheal", 800], [",", 808], ["and", 810], ["respiratory", 814], ["complication", 826], [",", 838], ["and", 840], ["spine", 844], ["abnormalities", 850], [".", 863], ["Long", 865], ["term", 870], ["follow", 875], ["up", 882], ["showed", 885], ["that", 892], ["facial", 897], ["dysmorphism", 904], ["was", 916], ["less", 920], ["obvious", 925], ["in", 933], ["adults", 936], ["and", 943], ["that", 947], ["carpal", 952], ["tunnel", 959], ["syndrome", 966], ["was", 975], ["frequent", 979], ["in", 988], ["older", 991], ["patients", 997], [".", 1005], ["Apart", 1007], ["from", 1013], ["short", 1018], ["metacarpals", 1024], ["and", 1036], ["phalanges", 1040], [",", 1049], ["internal", 1051], ["notch", 1060], ["of", 1066], ["the", 1069], ["second", 1073], ["metacarpal", 1080], [",", 1090], ["external", 1092], ["notch", 1101], ["of", 1107], ["the", 1110], ["fifth", 1114], ["metacarpal", 1120], [",", 1130], ["and", 1132], ["internal", 1136], ["notch", 1145], ["of", 1151], ["the", 1154], ["femoral", 1158], ["heads", 1166], [",", 1171], ["there", 1173], ["were", 1179], ["no", 1184], ["major", 1187], ["x", 1193], ["ray", 1195], ["abnormalities", 1199], [".", 1212], ["No", 1214], ["major", 1217], ["complications", 1223], [",", 1236], ["such", 1238], ["as", 1243], ["cardiac", 1246], ["disease", 1254], ["or", 1262], ["major", 1265], ["orthopaedic", 1271], ["problems", 1283], [",", 1291], ["occurred", 1293], ["in", 1302], ["the", 1305], ["course", 1309], ["of", 1316], ["the", 1319], ["disease", 1323], [".", 1330], ["The", 1332], ["condition", 1336], ["appeared", 1346], ["to", 1355], ["be", 1358], ["sporadic", 1361], ["in", 1370], ["16", 1373], ["cases", 1376], ["but", 1382], ["the", 1386], ["observation", 1390], ["of", 1402], ["vertical", 1405], ["transmission", 1414], ["in", 1427], ["three", 1430], ["families", 1436], ["was", 1445], ["consistent", 1449], ["with", 1460], ["an", 1465], ["autosomal", 1468], ["dominant", 1478], ["mode", 1487], ["of", 1492], ["inheritance", 1495], [".", 1506]]}
{"context": "Histone H3 lysine 9 (H3K9) methylation is a major component of gene regulation and chromatin organization. SUV39H1 methylates H3K9 at the pericentric heterochromatin region and participates in the maintenance of genome stability. In this study, a recombinant purified SUV39H1 is used for substrate specificity and steady-state kinetic analysis with peptides representing the un- or dimethylated lysine 9 histone H3 tail or full-length human recombinant H3 (rH3). Recombinant SUV39H1 methylated its substrate via a nonprocessive mechanism. Binding of either peptide or AdoMet first to the enzyme made a catalytically competent binary complex. Product inhibition studies with SUV39H1 showed that S-adenosyl-l-homocysteine is a competitive inhibitor of S-adenosyl-l-methionine and a mixed inhibitor of substrate peptide. Similarly, the methylated peptide was a competitive inhibitor of the unmethylated peptide and a mixed inhibitor of AdoMet, suggesting a random mechanism in a bi-bi reaction for recombinant SUV39H1 in which either substrate can bind to the enzyme first and either product can release first. The turnover numbers (k(cat)) for the H3 tail peptide and rH3 were comparable (12 and 8 h(-)(1), respectively) compared to the value of 1.5 h(-)(1) for an identical dimethylated lysine 9 H3 tail peptide. The Michaelis constant for the methylated peptide (K(m)(pep)) was 13-fold lower compared to that of the unmethylated peptide. The Michaelis constants for AdoMet (K(m)(AdoMet)) were 12 and 6 microM for the unmethylated peptide substrate and rH3, respectively. A reduction in the level of methylation was observed at high concentrations of rH3, implying substrate inhibition. Deletion of the chromodomain or point mutation of the conserved amino acids, W64A or W67A, of SUV39H1 impaired enzyme activity despite the presence of an intact catalytic SET domain. Thus, SUV39H1 utilizes both the chromodomain and the SET domain for catalysis.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "9251d4f613a84dea893231ca779d93d1", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[326, 327], [338, 339]], "char_spans": [[1857, 1866], [1922, 1931]]}]}], "context_tokens": [["Histone", 0], ["H3", 8], ["lysine", 11], ["9", 18], ["(", 20], ["H3K9", 21], [")", 25], ["methylation", 27], ["is", 39], ["a", 42], ["major", 44], ["component", 50], ["of", 60], ["gene", 63], ["regulation", 68], ["and", 79], ["chromatin", 83], ["organization", 93], [".", 105], ["SUV39H1", 107], ["methylates", 115], ["H3K9", 126], ["at", 131], ["the", 134], ["pericentric", 138], ["heterochromatin", 150], ["region", 166], ["and", 173], ["participates", 177], ["in", 190], ["the", 193], ["maintenance", 197], ["of", 209], ["genome", 212], ["stability", 219], [".", 228], ["In", 230], ["this", 233], ["study", 238], [",", 243], ["a", 245], ["recombinant", 247], ["purified", 259], ["SUV39H1", 268], ["is", 276], ["used", 279], ["for", 284], ["substrate", 288], ["specificity", 298], ["and", 310], ["steady", 314], ["-", 320], ["state", 321], ["kinetic", 327], ["analysis", 335], ["with", 344], ["peptides", 349], ["representing", 358], ["the", 371], ["un-", 375], ["or", 379], ["dimethylated", 382], ["lysine", 395], ["9", 402], ["histone", 404], ["H3", 412], ["tail", 415], ["or", 420], ["full", 423], ["-", 427], ["length", 428], ["human", 435], ["recombinant", 441], ["H3", 453], ["(", 456], ["rH3", 457], [")", 460], [".", 461], ["Recombinant", 463], ["SUV39H1", 475], ["methylated", 483], ["its", 494], ["substrate", 498], ["via", 508], ["a", 512], ["nonprocessive", 514], ["mechanism", 528], [".", 537], ["Binding", 539], ["of", 547], ["either", 550], ["peptide", 557], ["or", 565], ["AdoMet", 568], ["first", 575], ["to", 581], ["the", 584], ["enzyme", 588], ["made", 595], ["a", 600], ["catalytically", 602], ["competent", 616], ["binary", 626], ["complex", 633], [".", 640], ["Product", 642], ["inhibition", 650], ["studies", 661], ["with", 669], ["SUV39H1", 674], ["showed", 682], ["that", 689], ["S", 694], ["-", 695], ["adenosyl", 696], ["-", 704], ["l", 705], ["-", 706], ["homocysteine", 707], ["is", 720], ["a", 723], ["competitive", 725], ["inhibitor", 737], ["of", 747], ["S", 750], ["-", 751], ["adenosyl", 752], ["-", 760], ["l", 761], ["-", 762], ["methionine", 763], ["and", 774], ["a", 778], ["mixed", 780], ["inhibitor", 786], ["of", 796], ["substrate", 799], ["peptide", 809], [".", 816], ["Similarly", 818], [",", 827], ["the", 829], ["methylated", 833], ["peptide", 844], ["was", 852], ["a", 856], ["competitive", 858], ["inhibitor", 870], ["of", 880], ["the", 883], ["unmethylated", 887], ["peptide", 900], ["and", 908], ["a", 912], ["mixed", 914], ["inhibitor", 920], ["of", 930], ["AdoMet", 933], [",", 939], ["suggesting", 941], ["a", 952], ["random", 954], ["mechanism", 961], ["in", 971], ["a", 974], ["bi", 976], ["-", 978], ["bi", 979], ["reaction", 982], ["for", 991], ["recombinant", 995], ["SUV39H1", 1007], ["in", 1015], ["which", 1018], ["either", 1024], ["substrate", 1031], ["can", 1041], ["bind", 1045], ["to", 1050], ["the", 1053], ["enzyme", 1057], ["first", 1064], ["and", 1070], ["either", 1074], ["product", 1081], ["can", 1089], ["release", 1093], ["first", 1101], [".", 1106], ["The", 1108], ["turnover", 1112], ["numbers", 1121], ["(", 1129], ["k(cat", 1130], [")", 1135], [")", 1136], ["for", 1138], ["the", 1142], ["H3", 1146], ["tail", 1149], ["peptide", 1154], ["and", 1162], ["rH3", 1166], ["were", 1170], ["comparable", 1175], ["(", 1186], ["12", 1187], ["and", 1190], ["8", 1194], ["h(-)(1", 1196], [")", 1202], [",", 1203], ["respectively", 1205], [")", 1217], ["compared", 1219], ["to", 1228], ["the", 1231], ["value", 1235], ["of", 1241], ["1.5", 1244], ["h(-)(1", 1248], [")", 1254], ["for", 1256], ["an", 1260], ["identical", 1263], ["dimethylated", 1273], ["lysine", 1286], ["9", 1293], ["H3", 1295], ["tail", 1298], ["peptide", 1303], [".", 1310], ["The", 1312], ["Michaelis", 1316], ["constant", 1326], ["for", 1335], ["the", 1339], ["methylated", 1343], ["peptide", 1354], ["(", 1362], ["K(m)(pep", 1363], [")", 1371], [")", 1372], ["was", 1374], ["13-fold", 1378], ["lower", 1386], ["compared", 1392], ["to", 1401], ["that", 1404], ["of", 1409], ["the", 1412], ["unmethylated", 1416], ["peptide", 1429], [".", 1436], ["The", 1438], ["Michaelis", 1442], ["constants", 1452], ["for", 1462], ["AdoMet", 1466], ["(", 1473], ["K(m)(AdoMet", 1474], [")", 1485], [")", 1486], ["were", 1488], ["12", 1493], ["and", 1496], ["6", 1500], ["microM", 1502], ["for", 1509], ["the", 1513], ["unmethylated", 1517], ["peptide", 1530], ["substrate", 1538], ["and", 1548], ["rH3", 1552], [",", 1555], ["respectively", 1557], [".", 1569], ["A", 1571], ["reduction", 1573], ["in", 1583], ["the", 1586], ["level", 1590], ["of", 1596], ["methylation", 1599], ["was", 1611], ["observed", 1615], ["at", 1624], ["high", 1627], ["concentrations", 1632], ["of", 1647], ["rH3", 1650], [",", 1653], ["implying", 1655], ["substrate", 1664], ["inhibition", 1674], [".", 1684], ["Deletion", 1686], ["of", 1695], ["the", 1698], ["chromodomain", 1702], ["or", 1715], ["point", 1718], ["mutation", 1724], ["of", 1733], ["the", 1736], ["conserved", 1740], ["amino", 1750], ["acids", 1756], [",", 1761], ["W64A", 1763], ["or", 1768], ["W67A", 1771], [",", 1775], ["of", 1777], ["SUV39H1", 1780], ["impaired", 1788], ["enzyme", 1797], ["activity", 1804], ["despite", 1813], ["the", 1821], ["presence", 1825], ["of", 1834], ["an", 1837], ["intact", 1840], ["catalytic", 1847], ["SET", 1857], ["domain", 1861], [".", 1867], ["Thus", 1869], [",", 1873], ["SUV39H1", 1875], ["utilizes", 1883], ["both", 1892], ["the", 1897], ["chromodomain", 1901], ["and", 1914], ["the", 1918], ["SET", 1922], ["domain", 1926], ["for", 1933], ["catalysis", 1937], [".", 1946]]}
{"context": "The mechanisms underlying lithium's therapeutic efficacy in the chronic treatment of bipolar disorder are not clearly understood. Useful insights can be obtained by identifying genes that are differentially regulated during chronic lithium treatment. Toward this end, we have used microarray technology to identify mRNAs that are differentially expressed in a human neuronal cell line that has been continuously maintained in therapeutic levels of lithium for 33 days. Significantly, unlike other transcriptomes where predominantly rodent cells were used and a limited number of genes probed, we have used human cells probed with more extensive 44,000 gene microarrays. A total of 671 differentially regulated transcripts, after correcting for false discovery rates, were identified, of which 347 and 324, respectively, were found to be up- and downregulated. Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated, implying a beneficial effect of lithium on neuronal cells. Several of the most highly regulated genes are novel, uncharacterized and encode proteins of unknown function. Differentially expressed genes associated with phosphoinositide metabolism include those encoding phosphatidyl inositol 4-phosphate 5-kinase type II alpha (PIP5K2A), WD repeat domain, phosphoinositide interacting 1 protein (WIPI49), tribbles homolog 3 (TRB3) and sorting nexin 14 (SNX14). A protein interactome using some of the saliently regulated genes identified protein kinase C (PKC) as a major target for lithium action while a global analysis of all 671 differentially expressed genes identified the mitogen-activated protein kinase pathway as the most regulated. The list of highly regulated genes, besides encoding putative targets for antimanic agents, should prove useful in defining novel pathways, or to better understand the mechanisms, underlying the mood stabilization process.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "f1d83c49ddc1460baffb741b5751e1c2", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[145, 145]], "char_spans": [[888, 898]]}]}], "context_tokens": [["The", 0], ["mechanisms", 4], ["underlying", 15], ["lithium", 26], ["'s", 33], ["therapeutic", 36], ["efficacy", 48], ["in", 57], ["the", 60], ["chronic", 64], ["treatment", 72], ["of", 82], ["bipolar", 85], ["disorder", 93], ["are", 102], ["not", 106], ["clearly", 110], ["understood", 118], [".", 128], ["Useful", 130], ["insights", 137], ["can", 146], ["be", 150], ["obtained", 153], ["by", 162], ["identifying", 165], ["genes", 177], ["that", 183], ["are", 188], ["differentially", 192], ["regulated", 207], ["during", 217], ["chronic", 224], ["lithium", 232], ["treatment", 240], [".", 249], ["Toward", 251], ["this", 258], ["end", 263], [",", 266], ["we", 268], ["have", 271], ["used", 276], ["microarray", 281], ["technology", 292], ["to", 303], ["identify", 306], ["mRNAs", 315], ["that", 321], ["are", 326], ["differentially", 330], ["expressed", 345], ["in", 355], ["a", 358], ["human", 360], ["neuronal", 366], ["cell", 375], ["line", 380], ["that", 385], ["has", 390], ["been", 394], ["continuously", 399], ["maintained", 412], ["in", 423], ["therapeutic", 426], ["levels", 438], ["of", 445], ["lithium", 448], ["for", 456], ["33", 460], ["days", 463], [".", 467], ["Significantly", 469], [",", 482], ["unlike", 484], ["other", 491], ["transcriptomes", 497], ["where", 512], ["predominantly", 518], ["rodent", 532], ["cells", 539], ["were", 545], ["used", 550], ["and", 555], ["a", 559], ["limited", 561], ["number", 569], ["of", 576], ["genes", 579], ["probed", 585], [",", 591], ["we", 593], ["have", 596], ["used", 601], ["human", 606], ["cells", 612], ["probed", 618], ["with", 625], ["more", 630], ["extensive", 635], ["44,000", 645], ["gene", 652], ["microarrays", 657], [".", 668], ["A", 670], ["total", 672], ["of", 678], ["671", 681], ["differentially", 685], ["regulated", 700], ["transcripts", 710], [",", 721], ["after", 723], ["correcting", 729], ["for", 740], ["false", 744], ["discovery", 750], ["rates", 760], [",", 765], ["were", 767], ["identified", 772], [",", 782], ["of", 784], ["which", 787], ["347", 793], ["and", 797], ["324", 801], [",", 804], ["respectively", 806], [",", 818], ["were", 820], ["found", 825], ["to", 831], ["be", 834], ["up-", 837], ["and", 841], ["downregulated", 845], [".", 858], ["Peroxiredoxin", 860], ["2", 874], ["(", 876], ["PRDX2", 877], [")", 882], [",", 883], ["an", 885], ["antioxidant", 888], ["enzyme", 900], [",", 906], ["was", 908], ["the", 912], ["most", 916], ["upregulated", 921], ["while", 933], ["tribbles", 939], ["homolog", 948], ["3", 956], ["(", 958], ["TRB3", 959], [")", 963], [",", 964], ["a", 966], ["pro", 968], ["-", 971], ["apoptotic", 972], ["protein", 982], [",", 989], ["was", 991], ["the", 995], ["most", 999], ["downregulated", 1004], [",", 1017], ["implying", 1019], ["a", 1028], ["beneficial", 1030], ["effect", 1041], ["of", 1048], ["lithium", 1051], ["on", 1059], ["neuronal", 1062], ["cells", 1071], [".", 1076], ["Several", 1078], ["of", 1086], ["the", 1089], ["most", 1093], ["highly", 1098], ["regulated", 1105], ["genes", 1115], ["are", 1121], ["novel", 1125], [",", 1130], ["uncharacterized", 1132], ["and", 1148], ["encode", 1152], ["proteins", 1159], ["of", 1168], ["unknown", 1171], ["function", 1179], [".", 1187], ["Differentially", 1189], ["expressed", 1204], ["genes", 1214], ["associated", 1220], ["with", 1231], ["phosphoinositide", 1236], ["metabolism", 1253], ["include", 1264], ["those", 1272], ["encoding", 1278], ["phosphatidyl", 1287], ["inositol", 1300], ["4-phosphate", 1309], ["5-kinase", 1321], ["type", 1330], ["II", 1335], ["alpha", 1338], ["(", 1344], ["PIP5K2A", 1345], [")", 1352], [",", 1353], ["WD", 1355], ["repeat", 1358], ["domain", 1365], [",", 1371], ["phosphoinositide", 1373], ["interacting", 1390], ["1", 1402], ["protein", 1404], ["(", 1412], ["WIPI49", 1413], [")", 1419], [",", 1420], ["tribbles", 1422], ["homolog", 1431], ["3", 1439], ["(", 1441], ["TRB3", 1442], [")", 1446], ["and", 1448], ["sorting", 1452], ["nexin", 1460], ["14", 1466], ["(", 1469], ["SNX14", 1470], [")", 1475], [".", 1476], ["A", 1478], ["protein", 1480], ["interactome", 1488], ["using", 1500], ["some", 1506], ["of", 1511], ["the", 1514], ["saliently", 1518], ["regulated", 1528], ["genes", 1538], ["identified", 1544], ["protein", 1555], ["kinase", 1563], ["C", 1570], ["(", 1572], ["PKC", 1573], [")", 1576], ["as", 1578], ["a", 1581], ["major", 1583], ["target", 1589], ["for", 1596], ["lithium", 1600], ["action", 1608], ["while", 1615], ["a", 1621], ["global", 1623], ["analysis", 1630], ["of", 1639], ["all", 1642], ["671", 1646], ["differentially", 1650], ["expressed", 1665], ["genes", 1675], ["identified", 1681], ["the", 1692], ["mitogen", 1696], ["-", 1703], ["activated", 1704], ["protein", 1714], ["kinase", 1722], ["pathway", 1729], ["as", 1737], ["the", 1740], ["most", 1744], ["regulated", 1749], [".", 1758], ["The", 1760], ["list", 1764], ["of", 1769], ["highly", 1772], ["regulated", 1779], ["genes", 1789], [",", 1794], ["besides", 1796], ["encoding", 1804], ["putative", 1813], ["targets", 1822], ["for", 1830], ["antimanic", 1834], ["agents", 1844], [",", 1850], ["should", 1852], ["prove", 1859], ["useful", 1865], ["in", 1872], ["defining", 1875], ["novel", 1884], ["pathways", 1890], [",", 1898], ["or", 1900], ["to", 1903], ["better", 1906], ["understand", 1913], ["the", 1924], ["mechanisms", 1928], [",", 1938], ["underlying", 1940], ["the", 1951], ["mood", 1955], ["stabilization", 1960], ["process", 1974], [".", 1981]]}
{"context": "Alpha-synuclein accumulates in the brains of sporadic Parkinson's disease patients as a major component of Lewy bodies, and mutations in alpha-synuclein are associated with familial forms of Parkinson's disease. The pathogenic mechanisms that precede and promote the aggregation of alpha-synuclein into Lewy bodies in neurons remain to be determined. Here, we constructed a series of alpha-synuclein-enhanced green fluorescent protein (alpha-synucleinEGFP, SynEGFP) fusion proteins to address whether the Parkinson's disease-associated mutations alter the subcellular distribution of alpha-synuclein, and to use as a tool for experimental manipulations to induce aggregate formation. When transfected into mouse cultured primary neurons, the 49-kDa alpha-synucleinEGFP fusion proteins are partially truncated to a approximately 27-kDa form. This non-fluorescent carboxy-terminally modified fusion protein spontaneously forms inclusions in the neuronal cytoplasm. A marked increase in the accumulation of inclusions is detected following treatment with each of three proteasome inhibitors, n-acetyl-leu-leu-norleucinal, lactacystin and MG132. Interestingly, Ala30Pro alpha-synucleinEGFP does not form the cytoplasmic inclusions that are characteristic of wild-type and Ala53Thr alpha-synucleinEGFP, supporting the idea that the Ala30Pro alpha-synuclein protein conformation differs from wild-type alpha-synuclein. Similar inclusions are formed if alpha-synuclein carboxy-terminus is modified by the addition of a V5/6xHistidine epitope tag. By contrast, overexpression of unmodified alpha-synuclein does not lead to aggregate formation. Furthermore, synphilin-1, an alpha-synuclein interacting protein also found in Lewy bodies, colocalizes with the carboxy-terminally truncated alpha-synuclein fusion protein in discrete cytoplasmic inclusions.Our finding that manipulations of the carboxy-terminus of alpha-synuclein lead to inclusion formation may provide a model for studies of the pathogenic mechanisms of alpha-synuclein aggregation in Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8a982cf38c2d47b0b8b6fa7d85dfa679", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[47, 49], [336, 338], [242, 244], [318, 320], [24, 26], [280, 282], [298, 300], [233, 235], [99, 101], [265, 267], [223, 225], [0, 2], [67, 69]], "char_spans": [[282, 296], [2010, 2024], [1446, 1460], [1902, 1916], [137, 151], [1665, 1679], [1778, 1792], [1396, 1410], [584, 598], [1582, 1596], [1336, 1350], [0, 14], [384, 398]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["accumulates", 16], ["in", 28], ["the", 31], ["brains", 35], ["of", 42], ["sporadic", 45], ["Parkinson", 54], ["'s", 63], ["disease", 66], ["patients", 74], ["as", 83], ["a", 86], ["major", 88], ["component", 94], ["of", 104], ["Lewy", 107], ["bodies", 112], [",", 118], ["and", 120], ["mutations", 124], ["in", 134], ["alpha", 137], ["-", 142], ["synuclein", 143], ["are", 153], ["associated", 157], ["with", 168], ["familial", 173], ["forms", 182], ["of", 188], ["Parkinson", 191], ["'s", 200], ["disease", 203], [".", 210], ["The", 212], ["pathogenic", 216], ["mechanisms", 227], ["that", 238], ["precede", 243], ["and", 251], ["promote", 255], ["the", 263], ["aggregation", 267], ["of", 279], ["alpha", 282], ["-", 287], ["synuclein", 288], ["into", 298], ["Lewy", 303], ["bodies", 308], ["in", 315], ["neurons", 318], ["remain", 326], ["to", 333], ["be", 336], ["determined", 339], [".", 349], ["Here", 351], [",", 355], ["we", 357], ["constructed", 360], ["a", 372], ["series", 374], ["of", 381], ["alpha", 384], ["-", 389], ["synuclein", 390], ["-", 399], ["enhanced", 400], ["green", 409], ["fluorescent", 415], ["protein", 427], ["(", 435], ["alpha", 436], ["-", 441], ["synucleinEGFP", 442], [",", 455], ["SynEGFP", 457], [")", 464], ["fusion", 466], ["proteins", 473], ["to", 482], ["address", 485], ["whether", 493], ["the", 501], ["Parkinson", 505], ["'s", 514], ["disease", 517], ["-", 524], ["associated", 525], ["mutations", 536], ["alter", 546], ["the", 552], ["subcellular", 556], ["distribution", 568], ["of", 581], ["alpha", 584], ["-", 589], ["synuclein", 590], [",", 599], ["and", 601], ["to", 605], ["use", 608], ["as", 612], ["a", 615], ["tool", 617], ["for", 622], ["experimental", 626], ["manipulations", 639], ["to", 653], ["induce", 656], ["aggregate", 663], ["formation", 673], [".", 682], ["When", 684], ["transfected", 689], ["into", 701], ["mouse", 706], ["cultured", 712], ["primary", 721], ["neurons", 729], [",", 736], ["the", 738], ["49-kDa", 742], ["alpha", 749], ["-", 754], ["synucleinEGFP", 755], ["fusion", 769], ["proteins", 776], ["are", 785], ["partially", 789], ["truncated", 799], ["to", 809], ["a", 812], ["approximately", 814], ["27-kDa", 828], ["form", 835], [".", 839], ["This", 841], ["non", 846], ["-", 849], ["fluorescent", 850], ["carboxy", 862], ["-", 869], ["terminally", 870], ["modified", 881], ["fusion", 890], ["protein", 897], ["spontaneously", 905], ["forms", 919], ["inclusions", 925], ["in", 936], ["the", 939], ["neuronal", 943], ["cytoplasm", 952], [".", 961], ["A", 963], ["marked", 965], ["increase", 972], ["in", 981], ["the", 984], ["accumulation", 988], ["of", 1001], ["inclusions", 1004], ["is", 1015], ["detected", 1018], ["following", 1027], ["treatment", 1037], ["with", 1047], ["each", 1052], ["of", 1057], ["three", 1060], ["proteasome", 1066], ["inhibitors", 1077], [",", 1087], ["n", 1089], ["-", 1090], ["acetyl", 1091], ["-", 1097], ["leu", 1098], ["-", 1101], ["leu", 1102], ["-", 1105], ["norleucinal", 1106], [",", 1117], ["lactacystin", 1119], ["and", 1131], ["MG132", 1135], [".", 1140], ["Interestingly", 1142], [",", 1155], ["Ala30Pro", 1157], ["alpha", 1166], ["-", 1171], ["synucleinEGFP", 1172], ["does", 1186], ["not", 1191], ["form", 1195], ["the", 1200], ["cytoplasmic", 1204], ["inclusions", 1216], ["that", 1227], ["are", 1232], ["characteristic", 1236], ["of", 1251], ["wild", 1254], ["-", 1258], ["type", 1259], ["and", 1264], ["Ala53Thr", 1268], ["alpha", 1277], ["-", 1282], ["synucleinEGFP", 1283], [",", 1296], ["supporting", 1298], ["the", 1309], ["idea", 1313], ["that", 1318], ["the", 1323], ["Ala30Pro", 1327], ["alpha", 1336], ["-", 1341], ["synuclein", 1342], ["protein", 1352], ["conformation", 1360], ["differs", 1373], ["from", 1381], ["wild", 1386], ["-", 1390], ["type", 1391], ["alpha", 1396], ["-", 1401], ["synuclein", 1402], [".", 1411], ["Similar", 1413], ["inclusions", 1421], ["are", 1432], ["formed", 1436], ["if", 1443], ["alpha", 1446], ["-", 1451], ["synuclein", 1452], ["carboxy", 1462], ["-", 1469], ["terminus", 1470], ["is", 1479], ["modified", 1482], ["by", 1491], ["the", 1494], ["addition", 1498], ["of", 1507], ["a", 1510], ["V5/6xHistidine", 1512], ["epitope", 1527], ["tag", 1535], [".", 1538], ["By", 1540], ["contrast", 1543], [",", 1551], ["overexpression", 1553], ["of", 1568], ["unmodified", 1571], ["alpha", 1582], ["-", 1587], ["synuclein", 1588], ["does", 1598], ["not", 1603], ["lead", 1607], ["to", 1612], ["aggregate", 1615], ["formation", 1625], [".", 1634], ["Furthermore", 1636], [",", 1647], ["synphilin-1", 1649], [",", 1660], ["an", 1662], ["alpha", 1665], ["-", 1670], ["synuclein", 1671], ["interacting", 1681], ["protein", 1693], ["also", 1701], ["found", 1706], ["in", 1712], ["Lewy", 1715], ["bodies", 1720], [",", 1726], ["colocalizes", 1728], ["with", 1740], ["the", 1745], ["carboxy", 1749], ["-", 1756], ["terminally", 1757], ["truncated", 1768], ["alpha", 1778], ["-", 1783], ["synuclein", 1784], ["fusion", 1794], ["protein", 1801], ["in", 1809], ["discrete", 1812], ["cytoplasmic", 1821], ["inclusions", 1833], [".", 1843], ["Our", 1844], ["finding", 1848], ["that", 1856], ["manipulations", 1861], ["of", 1875], ["the", 1878], ["carboxy", 1882], ["-", 1889], ["terminus", 1890], ["of", 1899], ["alpha", 1902], ["-", 1907], ["synuclein", 1908], ["lead", 1918], ["to", 1923], ["inclusion", 1926], ["formation", 1936], ["may", 1946], ["provide", 1950], ["a", 1958], ["model", 1960], ["for", 1966], ["studies", 1970], ["of", 1978], ["the", 1981], ["pathogenic", 1985], ["mechanisms", 1996], ["of", 2007], ["alpha", 2010], ["-", 2015], ["synuclein", 2016], ["aggregation", 2026], ["in", 2038], ["Lewy", 2041], ["bodies", 2046], [".", 2052]]}
{"context": "Mutations in solute carrier family 9 isoform 6 on chromosome Xq26.3 encoding sodium-hydrogen exchanger 6, a protein mainly expressed in early and recycling endosomes are known to cause a complex and slowly progressive degenerative human neurological disease. Three resulting phenotypes have so far been reported: an X-linked Angelman syndrome-like condition, Christianson syndrome and corticobasal degeneration with tau deposition, with each characterized by severe intellectual disability, epilepsy, autistic behaviour and ataxia. Hypothesizing that a sodium-hydrogen exchanger 6 deficiency would most likely disrupt the endosomal-lysosomal system of neurons, we examined Slc9a6 knockout mice with tissue staining and related techniques commonly used to study lysosomal storage disorders. As a result, we found that sodium-hydrogen exchanger 6 depletion leads to abnormal accumulation of GM2 ganglioside and unesterified cholesterol within late endosomes and lysosomes of neurons in selective brain regions, most notably the basolateral nuclei of the amygdala, the CA3 and CA4 regions and dentate gyrus of the hippocampus and some areas of cerebral cortex. In these select neuronal populations, histochemical staining for \u03b2-hexosaminidase activity, a lysosomal enzyme involved in the degradation of GM2 ganglioside, was undetectable. Neuroaxonal dystrophy similar to that observed in lysosomal disease was observed in the cerebellum and was accompanied by a marked and progressive loss of Purkinje cells, particularly in those lacking the expression of Zebrin II. On behavioural testing, Slc9a6 knockout mice displayed a discrete clinical phenotype attributable to motor hyperactivity and cerebellar dysfunction. Importantly, these findings show that sodium-hydrogen exchanger 6 loss of function in the Slc9a6-targeted mouse model leads to compromise of endosomal-lysosomal function similar to lysosomal disease and to conspicuous neuronal abnormalities in specific brain regions, which in concert could provide a unified explanation for the cellular and clinical phenotypes in humans with SLC9A6 mutations.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "3b4719a2c58345f4acb8bac904ff6d5c", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[329, 329], [255, 255], [107, 107]], "char_spans": [[2091, 2096], [1589, 1594], [673, 678]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["solute", 13], ["carrier", 20], ["family", 28], ["9", 35], ["isoform", 37], ["6", 45], ["on", 47], ["chromosome", 50], ["Xq26.3", 61], ["encoding", 68], ["sodium", 77], ["-", 83], ["hydrogen", 84], ["exchanger", 93], ["6", 103], [",", 104], ["a", 106], ["protein", 108], ["mainly", 116], ["expressed", 123], ["in", 133], ["early", 136], ["and", 142], ["recycling", 146], ["endosomes", 156], ["are", 166], ["known", 170], ["to", 176], ["cause", 179], ["a", 185], ["complex", 187], ["and", 195], ["slowly", 199], ["progressive", 206], ["degenerative", 218], ["human", 231], ["neurological", 237], ["disease", 250], [".", 257], ["Three", 259], ["resulting", 265], ["phenotypes", 275], ["have", 286], ["so", 291], ["far", 294], ["been", 298], ["reported", 303], [":", 311], ["an", 313], ["X", 316], ["-", 317], ["linked", 318], ["Angelman", 325], ["syndrome", 334], ["-", 342], ["like", 343], ["condition", 348], [",", 357], ["Christianson", 359], ["syndrome", 372], ["and", 381], ["corticobasal", 385], ["degeneration", 398], ["with", 411], ["tau", 416], ["deposition", 420], [",", 430], ["with", 432], ["each", 437], ["characterized", 442], ["by", 456], ["severe", 459], ["intellectual", 466], ["disability", 479], [",", 489], ["epilepsy", 491], [",", 499], ["autistic", 501], ["behaviour", 510], ["and", 520], ["ataxia", 524], [".", 530], ["Hypothesizing", 532], ["that", 546], ["a", 551], ["sodium", 553], ["-", 559], ["hydrogen", 560], ["exchanger", 569], ["6", 579], ["deficiency", 581], ["would", 592], ["most", 598], ["likely", 603], ["disrupt", 610], ["the", 618], ["endosomal", 622], ["-", 631], ["lysosomal", 632], ["system", 642], ["of", 649], ["neurons", 652], [",", 659], ["we", 661], ["examined", 664], ["Slc9a6", 673], ["knockout", 680], ["mice", 689], ["with", 694], ["tissue", 699], ["staining", 706], ["and", 715], ["related", 719], ["techniques", 727], ["commonly", 738], ["used", 747], ["to", 752], ["study", 755], ["lysosomal", 761], ["storage", 771], ["disorders", 779], [".", 788], ["As", 790], ["a", 793], ["result", 795], [",", 801], ["we", 803], ["found", 806], ["that", 812], ["sodium", 817], ["-", 823], ["hydrogen", 824], ["exchanger", 833], ["6", 843], ["depletion", 845], ["leads", 855], ["to", 861], ["abnormal", 864], ["accumulation", 873], ["of", 886], ["GM2", 889], ["ganglioside", 893], ["and", 905], ["unesterified", 909], ["cholesterol", 922], ["within", 934], ["late", 941], ["endosomes", 946], ["and", 956], ["lysosomes", 960], ["of", 970], ["neurons", 973], ["in", 981], ["selective", 984], ["brain", 994], ["regions", 1000], [",", 1007], ["most", 1009], ["notably", 1014], ["the", 1022], ["basolateral", 1026], ["nuclei", 1038], ["of", 1045], ["the", 1048], ["amygdala", 1052], [",", 1060], ["the", 1062], ["CA3", 1066], ["and", 1070], ["CA4", 1074], ["regions", 1078], ["and", 1086], ["dentate", 1090], ["gyrus", 1098], ["of", 1104], ["the", 1107], ["hippocampus", 1111], ["and", 1123], ["some", 1127], ["areas", 1132], ["of", 1138], ["cerebral", 1141], ["cortex", 1150], [".", 1156], ["In", 1158], ["these", 1161], ["select", 1167], ["neuronal", 1174], ["populations", 1183], [",", 1194], ["histochemical", 1196], ["staining", 1210], ["for", 1219], ["\u03b2", 1223], ["-", 1224], ["hexosaminidase", 1225], ["activity", 1240], [",", 1248], ["a", 1250], ["lysosomal", 1252], ["enzyme", 1262], ["involved", 1269], ["in", 1278], ["the", 1281], ["degradation", 1285], ["of", 1297], ["GM2", 1300], ["ganglioside", 1304], [",", 1315], ["was", 1317], ["undetectable", 1321], [".", 1333], ["Neuroaxonal", 1335], ["dystrophy", 1347], ["similar", 1357], ["to", 1365], ["that", 1368], ["observed", 1373], ["in", 1382], ["lysosomal", 1385], ["disease", 1395], ["was", 1403], ["observed", 1407], ["in", 1416], ["the", 1419], ["cerebellum", 1423], ["and", 1434], ["was", 1438], ["accompanied", 1442], ["by", 1454], ["a", 1457], ["marked", 1459], ["and", 1466], ["progressive", 1470], ["loss", 1482], ["of", 1487], ["Purkinje", 1490], ["cells", 1499], [",", 1504], ["particularly", 1506], ["in", 1519], ["those", 1522], ["lacking", 1528], ["the", 1536], ["expression", 1540], ["of", 1551], ["Zebrin", 1554], ["II", 1561], [".", 1563], ["On", 1565], ["behavioural", 1568], ["testing", 1580], [",", 1587], ["Slc9a6", 1589], ["knockout", 1596], ["mice", 1605], ["displayed", 1610], ["a", 1620], ["discrete", 1622], ["clinical", 1631], ["phenotype", 1640], ["attributable", 1650], ["to", 1663], ["motor", 1666], ["hyperactivity", 1672], ["and", 1686], ["cerebellar", 1690], ["dysfunction", 1701], [".", 1712], ["Importantly", 1714], [",", 1725], ["these", 1727], ["findings", 1733], ["show", 1742], ["that", 1747], ["sodium", 1752], ["-", 1758], ["hydrogen", 1759], ["exchanger", 1768], ["6", 1778], ["loss", 1780], ["of", 1785], ["function", 1788], ["in", 1797], ["the", 1800], ["Slc9a6-targeted", 1804], ["mouse", 1820], ["model", 1826], ["leads", 1832], ["to", 1838], ["compromise", 1841], ["of", 1852], ["endosomal", 1855], ["-", 1864], ["lysosomal", 1865], ["function", 1875], ["similar", 1884], ["to", 1892], ["lysosomal", 1895], ["disease", 1905], ["and", 1913], ["to", 1917], ["conspicuous", 1920], ["neuronal", 1932], ["abnormalities", 1941], ["in", 1955], ["specific", 1958], ["brain", 1967], ["regions", 1973], [",", 1980], ["which", 1982], ["in", 1988], ["concert", 1991], ["could", 1999], ["provide", 2005], ["a", 2013], ["unified", 2015], ["explanation", 2023], ["for", 2035], ["the", 2039], ["cellular", 2043], ["and", 2052], ["clinical", 2056], ["phenotypes", 2065], ["in", 2076], ["humans", 2079], ["with", 2086], ["SLC9A6", 2091], ["mutations", 2098], [".", 2107]]}
{"context": "Restless legs syndrome (RLS) has gradually been recognized as a cause for insomnia in adults, but there have been few reports about children with RLS in Japan. Here we described seven pediatric RLS patients. All of the parents of our patients had difficult times to make their children sleep due to irritability, restlessness, and demanding bedtime routines. All patients had asked their parents to rub their feet in bed, and it took more than half an hour to soothe them until they fell asleep. Their mothers had been exhausted from this night-time routine. However, they did not consider the routine abnormal, as it had been their habitual behavior since infancy. Some parents were too distressed or embarrassed to describe the symptoms of their child properly. Five patients had clear family history and none had obvious periodic leg movements during sleep. All patients showed low levels of ferritin and iron supplementation was effective in five cases. In the severest two cases, pramipexole, but not iron, was dramatically effective. Both patients started to show RLS symptoms in the early days of infancy, which may suggest more severe hereditary dopaminergic dysfunction. RLS does occur in childhood and pediatricians should bear it in mind as one of the differential diagnoses when seeing children who are irritated and/or having difficulty in initiating their sleep.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "bbcb4c12247c4dfe95445768887501e4", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[184, 184], [166, 166]], "char_spans": [[1006, 1009], [908, 911]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["has", 29], ["gradually", 33], ["been", 43], ["recognized", 48], ["as", 59], ["a", 62], ["cause", 64], ["for", 70], ["insomnia", 74], ["in", 83], ["adults", 86], [",", 92], ["but", 94], ["there", 98], ["have", 104], ["been", 109], ["few", 114], ["reports", 118], ["about", 126], ["children", 132], ["with", 141], ["RLS", 146], ["in", 150], ["Japan", 153], [".", 158], ["Here", 160], ["we", 165], ["described", 168], ["seven", 178], ["pediatric", 184], ["RLS", 194], ["patients", 198], [".", 206], ["All", 208], ["of", 212], ["the", 215], ["parents", 219], ["of", 227], ["our", 230], ["patients", 234], ["had", 243], ["difficult", 247], ["times", 257], ["to", 263], ["make", 266], ["their", 271], ["children", 277], ["sleep", 286], ["due", 292], ["to", 296], ["irritability", 299], [",", 311], ["restlessness", 313], [",", 325], ["and", 327], ["demanding", 331], ["bedtime", 341], ["routines", 349], [".", 357], ["All", 359], ["patients", 363], ["had", 372], ["asked", 376], ["their", 382], ["parents", 388], ["to", 396], ["rub", 399], ["their", 403], ["feet", 409], ["in", 414], ["bed", 417], [",", 420], ["and", 422], ["it", 426], ["took", 429], ["more", 434], ["than", 439], ["half", 444], ["an", 449], ["hour", 452], ["to", 457], ["soothe", 460], ["them", 467], ["until", 472], ["they", 478], ["fell", 483], ["asleep", 488], [".", 494], ["Their", 496], ["mothers", 502], ["had", 510], ["been", 514], ["exhausted", 519], ["from", 529], ["this", 534], ["night", 539], ["-", 544], ["time", 545], ["routine", 550], [".", 557], ["However", 559], [",", 566], ["they", 568], ["did", 573], ["not", 577], ["consider", 581], ["the", 590], ["routine", 594], ["abnormal", 602], [",", 610], ["as", 612], ["it", 615], ["had", 618], ["been", 622], ["their", 627], ["habitual", 633], ["behavior", 642], ["since", 651], ["infancy", 657], [".", 664], ["Some", 666], ["parents", 671], ["were", 679], ["too", 684], ["distressed", 688], ["or", 699], ["embarrassed", 702], ["to", 714], ["describe", 717], ["the", 726], ["symptoms", 730], ["of", 739], ["their", 742], ["child", 748], ["properly", 754], [".", 762], ["Five", 764], ["patients", 769], ["had", 778], ["clear", 782], ["family", 788], ["history", 795], ["and", 803], ["none", 807], ["had", 812], ["obvious", 816], ["periodic", 824], ["leg", 833], ["movements", 837], ["during", 847], ["sleep", 854], [".", 859], ["All", 861], ["patients", 865], ["showed", 874], ["low", 881], ["levels", 885], ["of", 892], ["ferritin", 895], ["and", 904], ["iron", 908], ["supplementation", 913], ["was", 929], ["effective", 933], ["in", 943], ["five", 946], ["cases", 951], [".", 956], ["In", 958], ["the", 961], ["severest", 965], ["two", 974], ["cases", 978], [",", 983], ["pramipexole", 985], [",", 996], ["but", 998], ["not", 1002], ["iron", 1006], [",", 1010], ["was", 1012], ["dramatically", 1016], ["effective", 1029], [".", 1038], ["Both", 1040], ["patients", 1045], ["started", 1054], ["to", 1062], ["show", 1065], ["RLS", 1070], ["symptoms", 1074], ["in", 1083], ["the", 1086], ["early", 1090], ["days", 1096], ["of", 1101], ["infancy", 1104], [",", 1111], ["which", 1113], ["may", 1119], ["suggest", 1123], ["more", 1131], ["severe", 1136], ["hereditary", 1143], ["dopaminergic", 1154], ["dysfunction", 1167], [".", 1178], ["RLS", 1180], ["does", 1184], ["occur", 1189], ["in", 1195], ["childhood", 1198], ["and", 1208], ["pediatricians", 1212], ["should", 1226], ["bear", 1233], ["it", 1238], ["in", 1241], ["mind", 1244], ["as", 1249], ["one", 1252], ["of", 1256], ["the", 1259], ["differential", 1263], ["diagnoses", 1276], ["when", 1286], ["seeing", 1291], ["children", 1298], ["who", 1307], ["are", 1311], ["irritated", 1315], ["and/or", 1325], ["having", 1332], ["difficulty", 1339], ["in", 1350], ["initiating", 1353], ["their", 1364], ["sleep", 1370], [".", 1375]]}
{"context": "When developing novel microbicide products for the prevention of HIV infection, the preclinical safety program must evaluate not only the active pharmaceutical ingredient but also the product itself. To that end, we applied several relatively standard toxicology study methodologies to female sheep, incorporating an assessment of the pharmacokinetics, safety, tolerability, and local toxicity of a dapivirine-containing human vaginal ring formulation (Dapivirine Vaginal Ring-004). We performed a 3-month general toxicology study, a preliminary pharmacokinetic study using drug-loaded vaginal gel, and a detailed assessment of the kinetics of dapivirine delivery to plasma, vaginal, and rectal fluid and rectal, vaginal, and cervical tissue over 28 days of exposure and 3 and 7 days after removal of the ring. The findings of the general toxicology study supported the existing data from both preclinical and clinical studies in that there were no signs of toxicity related to dapivirine. In addition, the presence of the physical dapivirine ring did not alter local or systemic toxicity or the pharmacokinetics of dapivirine. Pharmacokinetic studies indicated that the dapivirine ring produced significant vaginal tissue levels of dapivirine. However, no dapivirine was detected in cervical tissue samples using the methods described here. Plasma and vaginal fluid levels were lower than those in previous clinical studies, while there were detectable dapivirine levels in the rectal tissue and fluid. All tissue and fluid levels tailed off rapidly to undetectable levels following removal of the ring. The sheep represents a very useful model for the assessment of the safety and pharmacokinetics of microbicide drug delivery devices, such as the vaginal ring.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "0d2c4d0d428b4c3ab028752e6ddeb939", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[9, 9]], "char_spans": [[65, 67]]}]}], "context_tokens": [["When", 0], ["developing", 5], ["novel", 16], ["microbicide", 22], ["products", 34], ["for", 43], ["the", 47], ["prevention", 51], ["of", 62], ["HIV", 65], ["infection", 69], [",", 78], ["the", 80], ["preclinical", 84], ["safety", 96], ["program", 103], ["must", 111], ["evaluate", 116], ["not", 125], ["only", 129], ["the", 134], ["active", 138], ["pharmaceutical", 145], ["ingredient", 160], ["but", 171], ["also", 175], ["the", 180], ["product", 184], ["itself", 192], [".", 198], ["To", 200], ["that", 203], ["end", 208], [",", 211], ["we", 213], ["applied", 216], ["several", 224], ["relatively", 232], ["standard", 243], ["toxicology", 252], ["study", 263], ["methodologies", 269], ["to", 283], ["female", 286], ["sheep", 293], [",", 298], ["incorporating", 300], ["an", 314], ["assessment", 317], ["of", 328], ["the", 331], ["pharmacokinetics", 335], [",", 351], ["safety", 353], [",", 359], ["tolerability", 361], [",", 373], ["and", 375], ["local", 379], ["toxicity", 385], ["of", 394], ["a", 397], ["dapivirine", 399], ["-", 409], ["containing", 410], ["human", 421], ["vaginal", 427], ["ring", 435], ["formulation", 440], ["(", 452], ["Dapivirine", 453], ["Vaginal", 464], ["Ring-004", 472], [")", 480], [".", 481], ["We", 483], ["performed", 486], ["a", 496], ["3-month", 498], ["general", 506], ["toxicology", 514], ["study", 525], [",", 530], ["a", 532], ["preliminary", 534], ["pharmacokinetic", 546], ["study", 562], ["using", 568], ["drug", 574], ["-", 578], ["loaded", 579], ["vaginal", 586], ["gel", 594], [",", 597], ["and", 599], ["a", 603], ["detailed", 605], ["assessment", 614], ["of", 625], ["the", 628], ["kinetics", 632], ["of", 641], ["dapivirine", 644], ["delivery", 655], ["to", 664], ["plasma", 667], [",", 673], ["vaginal", 675], [",", 682], ["and", 684], ["rectal", 688], ["fluid", 695], ["and", 701], ["rectal", 705], [",", 711], ["vaginal", 713], [",", 720], ["and", 722], ["cervical", 726], ["tissue", 735], ["over", 742], ["28", 747], ["days", 750], ["of", 755], ["exposure", 758], ["and", 767], ["3", 771], ["and", 773], ["7", 777], ["days", 779], ["after", 784], ["removal", 790], ["of", 798], ["the", 801], ["ring", 805], [".", 809], ["The", 811], ["findings", 815], ["of", 824], ["the", 827], ["general", 831], ["toxicology", 839], ["study", 850], ["supported", 856], ["the", 866], ["existing", 870], ["data", 879], ["from", 884], ["both", 889], ["preclinical", 894], ["and", 906], ["clinical", 910], ["studies", 919], ["in", 927], ["that", 930], ["there", 935], ["were", 941], ["no", 946], ["signs", 949], ["of", 955], ["toxicity", 958], ["related", 967], ["to", 975], ["dapivirine", 978], [".", 988], ["In", 990], ["addition", 993], [",", 1001], ["the", 1003], ["presence", 1007], ["of", 1016], ["the", 1019], ["physical", 1023], ["dapivirine", 1032], ["ring", 1043], ["did", 1048], ["not", 1052], ["alter", 1056], ["local", 1062], ["or", 1068], ["systemic", 1071], ["toxicity", 1080], ["or", 1089], ["the", 1092], ["pharmacokinetics", 1096], ["of", 1113], ["dapivirine", 1116], [".", 1126], ["Pharmacokinetic", 1128], ["studies", 1144], ["indicated", 1152], ["that", 1162], ["the", 1167], ["dapivirine", 1171], ["ring", 1182], ["produced", 1187], ["significant", 1196], ["vaginal", 1208], ["tissue", 1216], ["levels", 1223], ["of", 1230], ["dapivirine", 1233], [".", 1243], ["However", 1245], [",", 1252], ["no", 1254], ["dapivirine", 1257], ["was", 1268], ["detected", 1272], ["in", 1281], ["cervical", 1284], ["tissue", 1293], ["samples", 1300], ["using", 1308], ["the", 1314], ["methods", 1318], ["described", 1326], ["here", 1336], [".", 1340], ["Plasma", 1342], ["and", 1349], ["vaginal", 1353], ["fluid", 1361], ["levels", 1367], ["were", 1374], ["lower", 1379], ["than", 1385], ["those", 1390], ["in", 1396], ["previous", 1399], ["clinical", 1408], ["studies", 1417], [",", 1424], ["while", 1426], ["there", 1432], ["were", 1438], ["detectable", 1443], ["dapivirine", 1454], ["levels", 1465], ["in", 1472], ["the", 1475], ["rectal", 1479], ["tissue", 1486], ["and", 1493], ["fluid", 1497], [".", 1502], ["All", 1504], ["tissue", 1508], ["and", 1515], ["fluid", 1519], ["levels", 1525], ["tailed", 1532], ["off", 1539], ["rapidly", 1543], ["to", 1551], ["undetectable", 1554], ["levels", 1567], ["following", 1574], ["removal", 1584], ["of", 1592], ["the", 1595], ["ring", 1599], [".", 1603], ["The", 1605], ["sheep", 1609], ["represents", 1615], ["a", 1626], ["very", 1628], ["useful", 1633], ["model", 1640], ["for", 1646], ["the", 1650], ["assessment", 1654], ["of", 1665], ["the", 1668], ["safety", 1672], ["and", 1679], ["pharmacokinetics", 1683], ["of", 1700], ["microbicide", 1703], ["drug", 1715], ["delivery", 1720], ["devices", 1729], [",", 1736], ["such", 1738], ["as", 1743], ["the", 1746], ["vaginal", 1750], ["ring", 1758], [".", 1762]]}
{"context": "Chronic myeloid leukemia (CML) is caused by Bcr-Abl, a constitutively active tyrosine kinase that is the result of a reciprocal translocation between chromosomes 9 and 22 and cytogenetically evident as the Philadelphia chromosome. Imatinib (Glivec, Gleevec), a specific small molecule inhibitor of Bcr-Abl, has become the standard drug therapy for CML, and has dramatically diminished the use of allogeneic stem cell transplantation. Despite unprecedented rates of complete cytogenetic response, residual disease remains detectable in the majority of patients, suggesting that imatinib fails to eradicate leukemic stem cells. In this publication, the current perspectives for CML patients treated with imatinib are reviewed, focusing on the results of both standard and high-dose therapy. Monitoring of time-dependent prognostic factors is reviewed. The reasons imatinib may not be able to eradicate the disease are discussed, and potential strategies to achieve disease elimination are presented. Lastly, resistance to imatinib and the potential of second-generation Abl kinase inhibitors in the setting of clinical resistance are considered.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "04cb5e56a4624e849a6e56966d0d643e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[9, 11], [52, 54]], "char_spans": [[44, 50], [298, 304]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["caused", 34], ["by", 41], ["Bcr", 44], ["-", 47], ["Abl", 48], [",", 51], ["a", 53], ["constitutively", 55], ["active", 70], ["tyrosine", 77], ["kinase", 86], ["that", 93], ["is", 98], ["the", 101], ["result", 105], ["of", 112], ["a", 115], ["reciprocal", 117], ["translocation", 128], ["between", 142], ["chromosomes", 150], ["9", 162], ["and", 164], ["22", 168], ["and", 171], ["cytogenetically", 175], ["evident", 191], ["as", 199], ["the", 202], ["Philadelphia", 206], ["chromosome", 219], [".", 229], ["Imatinib", 231], ["(", 240], ["Glivec", 241], [",", 247], ["Gleevec", 249], [")", 256], [",", 257], ["a", 259], ["specific", 261], ["small", 270], ["molecule", 276], ["inhibitor", 285], ["of", 295], ["Bcr", 298], ["-", 301], ["Abl", 302], [",", 305], ["has", 307], ["become", 311], ["the", 318], ["standard", 322], ["drug", 331], ["therapy", 336], ["for", 344], ["CML", 348], [",", 351], ["and", 353], ["has", 357], ["dramatically", 361], ["diminished", 374], ["the", 385], ["use", 389], ["of", 393], ["allogeneic", 396], ["stem", 407], ["cell", 412], ["transplantation", 417], [".", 432], ["Despite", 434], ["unprecedented", 442], ["rates", 456], ["of", 462], ["complete", 465], ["cytogenetic", 474], ["response", 486], [",", 494], ["residual", 496], ["disease", 505], ["remains", 513], ["detectable", 521], ["in", 532], ["the", 535], ["majority", 539], ["of", 548], ["patients", 551], [",", 559], ["suggesting", 561], ["that", 572], ["imatinib", 577], ["fails", 586], ["to", 592], ["eradicate", 595], ["leukemic", 605], ["stem", 614], ["cells", 619], [".", 624], ["In", 626], ["this", 629], ["publication", 634], [",", 645], ["the", 647], ["current", 651], ["perspectives", 659], ["for", 672], ["CML", 676], ["patients", 680], ["treated", 689], ["with", 697], ["imatinib", 702], ["are", 711], ["reviewed", 715], [",", 723], ["focusing", 725], ["on", 734], ["the", 737], ["results", 741], ["of", 749], ["both", 752], ["standard", 757], ["and", 766], ["high", 770], ["-", 774], ["dose", 775], ["therapy", 780], [".", 787], ["Monitoring", 789], ["of", 800], ["time", 803], ["-", 807], ["dependent", 808], ["prognostic", 818], ["factors", 829], ["is", 837], ["reviewed", 840], [".", 848], ["The", 850], ["reasons", 854], ["imatinib", 862], ["may", 871], ["not", 875], ["be", 879], ["able", 882], ["to", 887], ["eradicate", 890], ["the", 900], ["disease", 904], ["are", 912], ["discussed", 916], [",", 925], ["and", 927], ["potential", 931], ["strategies", 941], ["to", 952], ["achieve", 955], ["disease", 963], ["elimination", 971], ["are", 983], ["presented", 987], [".", 996], ["Lastly", 998], [",", 1004], ["resistance", 1006], ["to", 1017], ["imatinib", 1020], ["and", 1029], ["the", 1033], ["potential", 1037], ["of", 1047], ["second", 1050], ["-", 1056], ["generation", 1057], ["Abl", 1068], ["kinase", 1072], ["inhibitors", 1079], ["in", 1090], ["the", 1093], ["setting", 1097], ["of", 1105], ["clinical", 1108], ["resistance", 1117], ["are", 1128], ["considered", 1132], [".", 1142]]}
{"context": "Christianson syndrome (CS) is caused by mutations in SLC9A6 and is characterized by severe intellectual disability, absent speech, microcephaly, ataxia, seizures, and behavioral abnormalities. The clinical phenotypes of CS and Angelman syndrome (AS) are similar. Differentiation between CS and AS is important in terms of genetic counseling. We report on two children with CS and confirmed mutations in SLC9A6 focusing on neuroimaging findings and review the available literature. Cerebellar atrophy (CA) occurs in approximately 60% of the patients with CS and develops after the age of 12 months. Hyperintense signal of the cerebellar cortex (CbC) is less common, and may be diffuse, patchy, or involve only the inferior part of the cerebellum and is best seen on coronal fluid attenuation inversion recovery images. CA and CbC-hyperintensity are not neuroimaging features of AS. In a child with the phenotype of AS, CA and/or CbC-hyperintensity are rather specific for CS and should prioritize sequencing of SLC9A6.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "9bcff955534e462aad930acfdb1fef0c", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[182, 182], [70, 70], [10, 10]], "char_spans": [[1010, 1015], [403, 408], [53, 58]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["caused", 30], ["by", 37], ["mutations", 40], ["in", 50], ["SLC9A6", 53], ["and", 60], ["is", 64], ["characterized", 67], ["by", 81], ["severe", 84], ["intellectual", 91], ["disability", 104], [",", 114], ["absent", 116], ["speech", 123], [",", 129], ["microcephaly", 131], [",", 143], ["ataxia", 145], [",", 151], ["seizures", 153], [",", 161], ["and", 163], ["behavioral", 167], ["abnormalities", 178], [".", 191], ["The", 193], ["clinical", 197], ["phenotypes", 206], ["of", 217], ["CS", 220], ["and", 223], ["Angelman", 227], ["syndrome", 236], ["(", 245], ["AS", 246], [")", 248], ["are", 250], ["similar", 254], [".", 261], ["Differentiation", 263], ["between", 279], ["CS", 287], ["and", 290], ["AS", 294], ["is", 297], ["important", 300], ["in", 310], ["terms", 313], ["of", 319], ["genetic", 322], ["counseling", 330], [".", 340], ["We", 342], ["report", 345], ["on", 352], ["two", 355], ["children", 359], ["with", 368], ["CS", 373], ["and", 376], ["confirmed", 380], ["mutations", 390], ["in", 400], ["SLC9A6", 403], ["focusing", 410], ["on", 419], ["neuroimaging", 422], ["findings", 435], ["and", 444], ["review", 448], ["the", 455], ["available", 459], ["literature", 469], [".", 479], ["Cerebellar", 481], ["atrophy", 492], ["(", 500], ["CA", 501], [")", 503], ["occurs", 505], ["in", 512], ["approximately", 515], ["60", 529], ["%", 531], ["of", 533], ["the", 536], ["patients", 540], ["with", 549], ["CS", 554], ["and", 557], ["develops", 561], ["after", 570], ["the", 576], ["age", 580], ["of", 584], ["12", 587], ["months", 590], [".", 596], ["Hyperintense", 598], ["signal", 611], ["of", 618], ["the", 621], ["cerebellar", 625], ["cortex", 636], ["(", 643], ["CbC", 644], [")", 647], ["is", 649], ["less", 652], ["common", 657], [",", 663], ["and", 665], ["may", 669], ["be", 673], ["diffuse", 676], [",", 683], ["patchy", 685], [",", 691], ["or", 693], ["involve", 696], ["only", 704], ["the", 709], ["inferior", 713], ["part", 722], ["of", 727], ["the", 730], ["cerebellum", 734], ["and", 745], ["is", 749], ["best", 752], ["seen", 757], ["on", 762], ["coronal", 765], ["fluid", 773], ["attenuation", 779], ["inversion", 791], ["recovery", 801], ["images", 810], [".", 816], ["CA", 818], ["and", 821], ["CbC", 825], ["-", 828], ["hyperintensity", 829], ["are", 844], ["not", 848], ["neuroimaging", 852], ["features", 865], ["of", 874], ["AS", 877], [".", 879], ["In", 881], ["a", 884], ["child", 886], ["with", 892], ["the", 897], ["phenotype", 901], ["of", 911], ["AS", 914], [",", 916], ["CA", 918], ["and/or", 921], ["CbC", 928], ["-", 931], ["hyperintensity", 932], ["are", 947], ["rather", 951], ["specific", 958], ["for", 967], ["CS", 971], ["and", 974], ["should", 978], ["prioritize", 985], ["sequencing", 996], ["of", 1007], ["SLC9A6", 1010], [".", 1016]]}
{"context": "Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "9f45a919c4ba49198514e6173ce5710f", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[0, 0]], "char_spans": [[0, 8]]}]}], "context_tokens": [["Riociguat", 0], ["(", 10], ["Adempas", 11], [")", 18], [":", 19], ["a", 21], ["novel", 23], ["agent", 29], ["for", 35], ["the", 39], ["treatment", 43], ["of", 53], ["pulmonary", 56], ["arterial", 66], ["hypertension", 75], ["and", 88], ["chronic", 92], ["thromboembolic", 100], ["pulmonary", 115], ["hypertension", 125], [".", 137]]}
{"context": "Amyotrophic Lateral Sclerosis (ALS) is the most frequent motor neuron disease in adults. Classical ALS is characterized by the death of upper and lower motor neurons leading to progressive paralysis. Approximately 10\u00a0% of ALS patients have familial form of the disease. Numerous different gene mutations have been found in familial cases of ALS, such as mutations in superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), C9ORF72, ubiquilin-2 (UBQLN2), optineurin (OPTN) and others. Multiple animal models were generated to mimic the disease and to test future treatments. However, no animal model fully replicates the spectrum of phenotypes in the human disease and it is difficult to assess how a therapeutic effect in disease models can predict efficacy in humans. Importantly, the genetic and phenotypic heterogeneity of ALS leads to a variety of responses to similar treatment regimens. From this has emerged the concept of personalized medicine (PM), which is a medical scheme that combines study of genetic, environmental and clinical diagnostic testing, including biomarkers, to individualized patient care. In this perspective, we used subgroups of specific ALS-linked gene mutations to go through existing animal models and to provide a comprehensive profile of the differences and similarities between animal models of disease and human disease. Finally, we reviewed application of biomarkers and gene therapies relevant in personalized medicine approach. For instance, this includes viral delivering of antisense oligonucleotide and small interfering RNA in SOD1, TDP-43 and C9orf72 mice models. Promising gene therapies raised possibilities for treating differently the major mutations in familial ALS cases.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "c2ede5c0cfed444bbea4d8c26beb9b7e", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[301, 301], [58, 58], [38, 38], [218, 218], [4, 4], [159, 159], [17, 17]], "char_spans": [[1748, 1750], [341, 343], [222, 224], [1204, 1206], [31, 33], [862, 864], [99, 101]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[0, 2]], "char_spans": [[0, 28]]}]}], "context_tokens": [["Amyotrophic", 0], ["Lateral", 12], ["Sclerosis", 20], ["(", 30], ["ALS", 31], [")", 34], ["is", 36], ["the", 39], ["most", 43], ["frequent", 48], ["motor", 57], ["neuron", 63], ["disease", 70], ["in", 78], ["adults", 81], [".", 87], ["Classical", 89], ["ALS", 99], ["is", 103], ["characterized", 106], ["by", 120], ["the", 123], ["death", 127], ["of", 133], ["upper", 136], ["and", 142], ["lower", 146], ["motor", 152], ["neurons", 158], ["leading", 166], ["to", 174], ["progressive", 177], ["paralysis", 189], [".", 198], ["Approximately", 200], ["10", 214], ["%", 217], ["of", 219], ["ALS", 222], ["patients", 226], ["have", 235], ["familial", 240], ["form", 249], ["of", 254], ["the", 257], ["disease", 261], [".", 268], ["Numerous", 270], ["different", 279], ["gene", 289], ["mutations", 294], ["have", 304], ["been", 309], ["found", 314], ["in", 320], ["familial", 323], ["cases", 332], ["of", 338], ["ALS", 341], [",", 344], ["such", 346], ["as", 351], ["mutations", 354], ["in", 364], ["superoxide", 367], ["dismutase", 378], ["1", 388], ["(", 390], ["SOD1", 391], [")", 395], [",", 396], ["TAR", 398], ["DNA", 402], ["-", 405], ["binding", 406], ["protein", 414], ["43", 422], ["(", 425], ["TDP-43", 426], [")", 432], [",", 433], ["fused", 435], ["in", 441], ["sarcoma", 444], ["(", 452], ["FUS", 453], [")", 456], [",", 457], ["C9ORF72", 459], [",", 466], ["ubiquilin-2", 468], ["(", 480], ["UBQLN2", 481], [")", 487], [",", 488], ["optineurin", 490], ["(", 501], ["OPTN", 502], [")", 506], ["and", 508], ["others", 512], [".", 518], ["Multiple", 520], ["animal", 529], ["models", 536], ["were", 543], ["generated", 548], ["to", 558], ["mimic", 561], ["the", 567], ["disease", 571], ["and", 579], ["to", 583], ["test", 586], ["future", 591], ["treatments", 598], [".", 608], ["However", 610], [",", 617], ["no", 619], ["animal", 622], ["model", 629], ["fully", 635], ["replicates", 641], ["the", 652], ["spectrum", 656], ["of", 665], ["phenotypes", 668], ["in", 679], ["the", 682], ["human", 686], ["disease", 692], ["and", 700], ["it", 704], ["is", 707], ["difficult", 710], ["to", 720], ["assess", 723], ["how", 730], ["a", 734], ["therapeutic", 736], ["effect", 748], ["in", 755], ["disease", 758], ["models", 766], ["can", 773], ["predict", 777], ["efficacy", 785], ["in", 794], ["humans", 797], [".", 803], ["Importantly", 805], [",", 816], ["the", 818], ["genetic", 822], ["and", 830], ["phenotypic", 834], ["heterogeneity", 845], ["of", 859], ["ALS", 862], ["leads", 866], ["to", 872], ["a", 875], ["variety", 877], ["of", 885], ["responses", 888], ["to", 898], ["similar", 901], ["treatment", 909], ["regimens", 919], [".", 927], ["From", 929], ["this", 934], ["has", 939], ["emerged", 943], ["the", 951], ["concept", 955], ["of", 963], ["personalized", 966], ["medicine", 979], ["(", 988], ["PM", 989], [")", 991], [",", 992], ["which", 994], ["is", 1000], ["a", 1003], ["medical", 1005], ["scheme", 1013], ["that", 1020], ["combines", 1025], ["study", 1034], ["of", 1040], ["genetic", 1043], [",", 1050], ["environmental", 1052], ["and", 1066], ["clinical", 1070], ["diagnostic", 1079], ["testing", 1090], [",", 1097], ["including", 1099], ["biomarkers", 1109], [",", 1119], ["to", 1121], ["individualized", 1124], ["patient", 1139], ["care", 1147], [".", 1151], ["In", 1153], ["this", 1156], ["perspective", 1161], [",", 1172], ["we", 1174], ["used", 1177], ["subgroups", 1182], ["of", 1192], ["specific", 1195], ["ALS", 1204], ["-", 1207], ["linked", 1208], ["gene", 1215], ["mutations", 1220], ["to", 1230], ["go", 1233], ["through", 1236], ["existing", 1244], ["animal", 1253], ["models", 1260], ["and", 1267], ["to", 1271], ["provide", 1274], ["a", 1282], ["comprehensive", 1284], ["profile", 1298], ["of", 1306], ["the", 1309], ["differences", 1313], ["and", 1325], ["similarities", 1329], ["between", 1342], ["animal", 1350], ["models", 1357], ["of", 1364], ["disease", 1367], ["and", 1375], ["human", 1379], ["disease", 1385], [".", 1392], ["Finally", 1394], [",", 1401], ["we", 1403], ["reviewed", 1406], ["application", 1415], ["of", 1427], ["biomarkers", 1430], ["and", 1441], ["gene", 1445], ["therapies", 1450], ["relevant", 1460], ["in", 1469], ["personalized", 1472], ["medicine", 1485], ["approach", 1494], [".", 1502], ["For", 1504], ["instance", 1508], [",", 1516], ["this", 1518], ["includes", 1523], ["viral", 1532], ["delivering", 1538], ["of", 1549], ["antisense", 1552], ["oligonucleotide", 1562], ["and", 1578], ["small", 1582], ["interfering", 1588], ["RNA", 1600], ["in", 1604], ["SOD1", 1607], [",", 1611], ["TDP-43", 1613], ["and", 1620], ["C9orf72", 1624], ["mice", 1632], ["models", 1637], [".", 1643], ["Promising", 1645], ["gene", 1655], ["therapies", 1660], ["raised", 1670], ["possibilities", 1677], ["for", 1691], ["treating", 1695], ["differently", 1704], ["the", 1716], ["major", 1720], ["mutations", 1726], ["in", 1736], ["familial", 1739], ["ALS", 1748], ["cases", 1752], [".", 1757]]}
{"context": "Lysine 1423 of neurofibromin (neurofibromatosis type I gene product [NF1]) plays a crucial role in the function of NF1. Mutations of this lysine were detected in samples from a neurofibromatosis patient as well as from cancer patients. To further understand the significance of this residue, we have mutated it to all possible amino acids. Functional assays using yeast ira complementation have revealed that lysine is the only amino acid that produced functional NF1. Quantitative analyses of different mutant proteins have suggested that their GTPase-activating protein (GAP) activity is drastically reduced as a result of a decrease in their Ras affinity. Such a requirement for a specific residue is not observed in the case of other conserved residues within the GAP-related domain. We also report that another residue, phenylalanine 1434, plays an important role in NF1 function. This was first indicated by the finding that defective NF1s due to an alteration of lysine 1423 to other amino acids can be rescued by a second site intragenic mutation at residue 1434. The mutation partially restored GAP activity in the lysine mutant. When the mutation phenylalanine 1434 to serine was introduced into a wild-type NF1 protein, the resulting protein acquired the ability to suppress activated phenotypes of RAS2Val-19 cells. This suppression, however, does not involve Ras interaction, since the phenylalanine mutant does not stimulate the intrinsic GTPase activity of RAS2Val-19 protein and does not have an increased affinity for Ras proteins.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "1edbc77172904d679ba101a437cd5cbc", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[80, 80], [11, 11], [22, 22], [153, 153], [215, 215]], "char_spans": [[464, 466], [69, 71], [115, 117], [872, 874], [1218, 1220]]}]}], "context_tokens": [["Lysine", 0], ["1423", 7], ["of", 12], ["neurofibromin", 15], ["(", 29], ["neurofibromatosis", 30], ["type", 48], ["I", 53], ["gene", 55], ["product", 60], ["[", 68], ["NF1", 69], ["]", 72], [")", 73], ["plays", 75], ["a", 81], ["crucial", 83], ["role", 91], ["in", 96], ["the", 99], ["function", 103], ["of", 112], ["NF1", 115], [".", 118], ["Mutations", 120], ["of", 130], ["this", 133], ["lysine", 138], ["were", 145], ["detected", 150], ["in", 159], ["samples", 162], ["from", 170], ["a", 175], ["neurofibromatosis", 177], ["patient", 195], ["as", 203], ["well", 206], ["as", 211], ["from", 214], ["cancer", 219], ["patients", 226], [".", 234], ["To", 236], ["further", 239], ["understand", 247], ["the", 258], ["significance", 262], ["of", 275], ["this", 278], ["residue", 283], [",", 290], ["we", 292], ["have", 295], ["mutated", 300], ["it", 308], ["to", 311], ["all", 314], ["possible", 318], ["amino", 327], ["acids", 333], [".", 338], ["Functional", 340], ["assays", 351], ["using", 358], ["yeast", 364], ["ira", 370], ["complementation", 374], ["have", 390], ["revealed", 395], ["that", 404], ["lysine", 409], ["is", 416], ["the", 419], ["only", 423], ["amino", 428], ["acid", 434], ["that", 439], ["produced", 444], ["functional", 453], ["NF1", 464], [".", 467], ["Quantitative", 469], ["analyses", 482], ["of", 491], ["different", 494], ["mutant", 504], ["proteins", 511], ["have", 520], ["suggested", 525], ["that", 535], ["their", 540], ["GTPase", 546], ["-", 552], ["activating", 553], ["protein", 564], ["(", 572], ["GAP", 573], [")", 576], ["activity", 578], ["is", 587], ["drastically", 590], ["reduced", 602], ["as", 610], ["a", 613], ["result", 615], ["of", 622], ["a", 625], ["decrease", 627], ["in", 636], ["their", 639], ["Ras", 645], ["affinity", 649], [".", 657], ["Such", 659], ["a", 664], ["requirement", 666], ["for", 678], ["a", 682], ["specific", 684], ["residue", 693], ["is", 701], ["not", 704], ["observed", 708], ["in", 717], ["the", 720], ["case", 724], ["of", 729], ["other", 732], ["conserved", 738], ["residues", 748], ["within", 757], ["the", 764], ["GAP", 768], ["-", 771], ["related", 772], ["domain", 780], [".", 786], ["We", 788], ["also", 791], ["report", 796], ["that", 803], ["another", 808], ["residue", 816], [",", 823], ["phenylalanine", 825], ["1434", 839], [",", 843], ["plays", 845], ["an", 851], ["important", 854], ["role", 864], ["in", 869], ["NF1", 872], ["function", 876], [".", 884], ["This", 886], ["was", 891], ["first", 895], ["indicated", 901], ["by", 911], ["the", 914], ["finding", 918], ["that", 926], ["defective", 931], ["NF1s", 941], ["due", 946], ["to", 950], ["an", 953], ["alteration", 956], ["of", 967], ["lysine", 970], ["1423", 977], ["to", 982], ["other", 985], ["amino", 991], ["acids", 997], ["can", 1003], ["be", 1007], ["rescued", 1010], ["by", 1018], ["a", 1021], ["second", 1023], ["site", 1030], ["intragenic", 1035], ["mutation", 1046], ["at", 1055], ["residue", 1058], ["1434", 1066], [".", 1070], ["The", 1072], ["mutation", 1076], ["partially", 1085], ["restored", 1095], ["GAP", 1104], ["activity", 1108], ["in", 1117], ["the", 1120], ["lysine", 1124], ["mutant", 1131], [".", 1137], ["When", 1139], ["the", 1144], ["mutation", 1148], ["phenylalanine", 1157], ["1434", 1171], ["to", 1176], ["serine", 1179], ["was", 1186], ["introduced", 1190], ["into", 1201], ["a", 1206], ["wild", 1208], ["-", 1212], ["type", 1213], ["NF1", 1218], ["protein", 1222], [",", 1229], ["the", 1231], ["resulting", 1235], ["protein", 1245], ["acquired", 1253], ["the", 1262], ["ability", 1266], ["to", 1274], ["suppress", 1277], ["activated", 1286], ["phenotypes", 1296], ["of", 1307], ["RAS2Val-19", 1310], ["cells", 1321], [".", 1326], ["This", 1328], ["suppression", 1333], [",", 1344], ["however", 1346], [",", 1353], ["does", 1355], ["not", 1360], ["involve", 1364], ["Ras", 1372], ["interaction", 1376], [",", 1387], ["since", 1389], ["the", 1395], ["phenylalanine", 1399], ["mutant", 1413], ["does", 1420], ["not", 1425], ["stimulate", 1429], ["the", 1439], ["intrinsic", 1443], ["GTPase", 1453], ["activity", 1460], ["of", 1469], ["RAS2Val-19", 1472], ["protein", 1483], ["and", 1491], ["does", 1495], ["not", 1500], ["have", 1504], ["an", 1509], ["increased", 1512], ["affinity", 1522], ["for", 1531], ["Ras", 1535], ["proteins", 1539], [".", 1547]]}
{"context": "Limited data exist about the molecular types of methicillin-resistant Staphylococcus aureus (MRSA) strains found in children with cystic fibrosis (CF). We sought to characterize MRSA strains from these patients and compare them with MRSA strains from non-CF pediatric patients. All MRSA isolates were collected prospectively at Children's Medical Center in Dallas, TX, and the University of Chicago Comer Children's Hospital in 2004 to 2005. All CF MRSA isolates underwent susceptibility testing, multilocus sequence typing, Panton-Valentine leukocidin gene detection (pvl+), and staphylococcal chromosome cassette mec (SCCmec) typing. A total of 22 of 34 MRSA isolates (64.7%) from patients with CF belonged to clonal complex (CC) 5 and contained SCCmec II, so-called health-care associated MRSA (HA-MRSA) strains. Nine of 34 MRSA strains (26.5%) were CC 8, and contained SCCmec IV, so-called community-associated MRSA (CA-MRSA) strains. The CA-MRSA strains tended to be isolated from newly colonized CF patients. In contrast, CC8 isolates predominated among the non-CF patients (294 of 331 patients; 88.8%). MRSA isolates from children with CF were more likely to be resistant to clindamycin (65% vs 19%, respectively) and ciprofloxacin (62% vs 17%, respectively) compared with strains from non-CF patients (p < 0.001). There was no difference in the rate of pvl+ isolate recovery from children with CF undergoing a surveillance culture (7 of 23 children) compared with those with pulmonary exacerbation (3 of 11 children; p = 1.0). Both CA-MRSA (CC8) isolates and HA-MRSA (CC5) isolates populate the respiratory tracts of children with CF. HA-MRSA isolates predominated, but CA-MRSA strains predominated among CF patients with newly acquired MRSA strains and among the non-CF patients. The presence of CA-MRSA strains in children with CF was not associated with exacerbation or necrotizing pneumonia.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "0467f41146d14632bf81631eab423b2f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[224, 224], [117, 117], [147, 147], [179, 179], [341, 341], [372, 372], [317, 317], [325, 325], [14, 14], [190, 190], [50, 50], [81, 81], [357, 357], [348, 348], [151, 151], [183, 183], [40, 40], [158, 158], [31, 31]], "char_spans": [[1110, 1113], [656, 659], [792, 795], [915, 918], [1646, 1649], [1808, 1811], [1543, 1546], [1570, 1573], [93, 96], [946, 949], [282, 285], [449, 452], [1745, 1748], [1681, 1684], [801, 804], [924, 927], [233, 236], [827, 830], [178, 181]]}]}], "context_tokens": [["Limited", 0], ["data", 8], ["exist", 13], ["about", 19], ["the", 25], ["molecular", 29], ["types", 39], ["of", 45], ["methicillin", 48], ["-", 59], ["resistant", 60], ["Staphylococcus", 70], ["aureus", 85], ["(", 92], ["MRSA", 93], [")", 97], ["strains", 99], ["found", 107], ["in", 113], ["children", 116], ["with", 125], ["cystic", 130], ["fibrosis", 137], ["(", 146], ["CF", 147], [")", 149], [".", 150], ["We", 152], ["sought", 155], ["to", 162], ["characterize", 165], ["MRSA", 178], ["strains", 183], ["from", 191], ["these", 196], ["patients", 202], ["and", 211], ["compare", 215], ["them", 223], ["with", 228], ["MRSA", 233], ["strains", 238], ["from", 246], ["non", 251], ["-", 254], ["CF", 255], ["pediatric", 258], ["patients", 268], [".", 276], ["All", 278], ["MRSA", 282], ["isolates", 287], ["were", 296], ["collected", 301], ["prospectively", 311], ["at", 325], ["Children", 328], ["'s", 336], ["Medical", 339], ["Center", 347], ["in", 354], ["Dallas", 357], [",", 363], ["TX", 365], [",", 367], ["and", 369], ["the", 373], ["University", 377], ["of", 388], ["Chicago", 391], ["Comer", 399], ["Children", 405], ["'s", 413], ["Hospital", 416], ["in", 425], ["2004", 428], ["to", 433], ["2005", 436], [".", 440], ["All", 442], ["CF", 446], ["MRSA", 449], ["isolates", 454], ["underwent", 463], ["susceptibility", 473], ["testing", 488], [",", 495], ["multilocus", 497], ["sequence", 508], ["typing", 517], [",", 523], ["Panton", 525], ["-", 531], ["Valentine", 532], ["leukocidin", 542], ["gene", 553], ["detection", 558], ["(", 568], ["pvl+", 569], [")", 573], [",", 574], ["and", 576], ["staphylococcal", 580], ["chromosome", 595], ["cassette", 606], ["mec", 615], ["(", 619], ["SCCmec", 620], [")", 626], ["typing", 628], [".", 634], ["A", 636], ["total", 638], ["of", 644], ["22", 647], ["of", 650], ["34", 653], ["MRSA", 656], ["isolates", 661], ["(", 670], ["64.7", 671], ["%", 675], [")", 676], ["from", 678], ["patients", 683], ["with", 692], ["CF", 697], ["belonged", 700], ["to", 709], ["clonal", 712], ["complex", 719], ["(", 727], ["CC", 728], [")", 730], ["5", 732], ["and", 734], ["contained", 738], ["SCCmec", 748], ["II", 755], [",", 757], ["so", 759], ["-", 761], ["called", 762], ["health", 769], ["-", 775], ["care", 776], ["associated", 781], ["MRSA", 792], ["(", 797], ["HA", 798], ["-", 800], ["MRSA", 801], [")", 805], ["strains", 807], [".", 814], ["Nine", 816], ["of", 821], ["34", 824], ["MRSA", 827], ["strains", 832], ["(", 840], ["26.5", 841], ["%", 845], [")", 846], ["were", 848], ["CC", 853], ["8", 856], [",", 857], ["and", 859], ["contained", 863], ["SCCmec", 873], ["IV", 880], [",", 882], ["so", 884], ["-", 886], ["called", 887], ["community", 894], ["-", 903], ["associated", 904], ["MRSA", 915], ["(", 920], ["CA", 921], ["-", 923], ["MRSA", 924], [")", 928], ["strains", 930], [".", 937], ["The", 939], ["CA", 943], ["-", 945], ["MRSA", 946], ["strains", 951], ["tended", 959], ["to", 966], ["be", 969], ["isolated", 972], ["from", 981], ["newly", 986], ["colonized", 992], ["CF", 1002], ["patients", 1005], [".", 1013], ["In", 1015], ["contrast", 1018], [",", 1026], ["CC8", 1028], ["isolates", 1032], ["predominated", 1041], ["among", 1054], ["the", 1060], ["non", 1064], ["-", 1067], ["CF", 1068], ["patients", 1071], ["(", 1080], ["294", 1081], ["of", 1085], ["331", 1088], ["patients", 1092], [";", 1100], ["88.8", 1102], ["%", 1106], [")", 1107], [".", 1108], ["MRSA", 1110], ["isolates", 1115], ["from", 1124], ["children", 1129], ["with", 1138], ["CF", 1143], ["were", 1146], ["more", 1151], ["likely", 1156], ["to", 1163], ["be", 1166], ["resistant", 1169], ["to", 1179], ["clindamycin", 1182], ["(", 1194], ["65", 1195], ["%", 1197], ["vs", 1199], ["19", 1202], ["%", 1204], [",", 1205], ["respectively", 1207], [")", 1219], ["and", 1221], ["ciprofloxacin", 1225], ["(", 1239], ["62", 1240], ["%", 1242], ["vs", 1244], ["17", 1247], ["%", 1249], [",", 1250], ["respectively", 1252], [")", 1264], ["compared", 1266], ["with", 1275], ["strains", 1280], ["from", 1288], ["non", 1293], ["-", 1296], ["CF", 1297], ["patients", 1300], ["(", 1309], ["p", 1310], ["<", 1312], ["0.001", 1314], [")", 1319], [".", 1320], ["There", 1322], ["was", 1328], ["no", 1332], ["difference", 1335], ["in", 1346], ["the", 1349], ["rate", 1353], ["of", 1358], ["pvl+", 1361], ["isolate", 1366], ["recovery", 1374], ["from", 1383], ["children", 1388], ["with", 1397], ["CF", 1402], ["undergoing", 1405], ["a", 1416], ["surveillance", 1418], ["culture", 1431], ["(", 1439], ["7", 1440], ["of", 1442], ["23", 1445], ["children", 1448], [")", 1456], ["compared", 1458], ["with", 1467], ["those", 1472], ["with", 1478], ["pulmonary", 1483], ["exacerbation", 1493], ["(", 1506], ["3", 1507], ["of", 1509], ["11", 1512], ["children", 1515], [";", 1523], ["p", 1525], ["=", 1527], ["1.0", 1529], [")", 1532], [".", 1533], ["Both", 1535], ["CA", 1540], ["-", 1542], ["MRSA", 1543], ["(", 1548], ["CC8", 1549], [")", 1552], ["isolates", 1554], ["and", 1563], ["HA", 1567], ["-", 1569], ["MRSA", 1570], ["(", 1575], ["CC5", 1576], [")", 1579], ["isolates", 1581], ["populate", 1590], ["the", 1599], ["respiratory", 1603], ["tracts", 1615], ["of", 1622], ["children", 1625], ["with", 1634], ["CF", 1639], [".", 1641], ["HA", 1643], ["-", 1645], ["MRSA", 1646], ["isolates", 1651], ["predominated", 1660], [",", 1672], ["but", 1674], ["CA", 1678], ["-", 1680], ["MRSA", 1681], ["strains", 1686], ["predominated", 1694], ["among", 1707], ["CF", 1713], ["patients", 1716], ["with", 1725], ["newly", 1730], ["acquired", 1736], ["MRSA", 1745], ["strains", 1750], ["and", 1758], ["among", 1762], ["the", 1768], ["non", 1772], ["-", 1775], ["CF", 1776], ["patients", 1779], [".", 1787], ["The", 1789], ["presence", 1793], ["of", 1802], ["CA", 1805], ["-", 1807], ["MRSA", 1808], ["strains", 1813], ["in", 1821], ["children", 1824], ["with", 1833], ["CF", 1838], ["was", 1841], ["not", 1845], ["associated", 1849], ["with", 1860], ["exacerbation", 1865], ["or", 1878], ["necrotizing", 1881], ["pneumonia", 1893], [".", 1902]]}
{"context": "Activating point mutations in the K-Ras oncogene are among the most common genetic alterations in pancreatic cancer, occurring early in the progression of the disease. However, the function of mutant K-Ras activity in tumor angiogenesis remains poorly understood. Using human pancreatic duct epithelial (HPDE) and K-Ras4B(G12V)-transformed HPDE (HPDE-KRas) cells, we show that activated K-Ras significantly enhanced the production of angiogenic factors including CXC chemokines and vascular endothelial growth factor (VEGF). Western blot analysis revealed that K-Ras activation promoted the phosphorylation of Raf/mitogen-activated protein kinase kinase-1/2 (MEK1/2) and expression of c-Jun. MEK1/2 inhibitors, U0126 and PD98059, significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH(2)-terminal kinase inhibitor SP600125 abrogated only CXC chemokine production. To further elucidate the biological functions of oncogenic K-Ras in promoting angiogenesis, we did in vitro invasion and tube formation assays using human umbilical vein endothelial cells (HUVEC). HUVEC cocultured with HPDE-KRas showed significantly enhanced invasiveness and tube formation as compared with either control (without coculture) or coculture with HPDE. Moreover, SB225002 (a CXCR2 inhibitor) and 2C3 (an anti-VEGF monoclonal antibody) either alone or in a cooperative manner significantly reduced the degree of both Ras-dependent HUVEC invasiveness and tube formation. Similar results were obtained using another pair of immortalized human pancreatic duct-derived cells, E6/E7/st and its oncogenic K-Ras variant, E6/E7/Ras/st. Taken together, our results suggest that angiogenesis is initiated by paracrine epithelial secretion of CXC chemokines and VEGF downstream of activated oncogenic K-Ras, and that this vascular maturation is in part dependent on MEK1/2 and c-Jun signaling.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "f6778f46650c44d6931d8bb4dfce8ca0", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[1, 2]], "char_spans": [[11, 25]]}]}], "context_tokens": [["Activating", 0], ["point", 11], ["mutations", 17], ["in", 27], ["the", 30], ["K", 34], ["-", 35], ["Ras", 36], ["oncogene", 40], ["are", 49], ["among", 53], ["the", 59], ["most", 63], ["common", 68], ["genetic", 75], ["alterations", 83], ["in", 95], ["pancreatic", 98], ["cancer", 109], [",", 115], ["occurring", 117], ["early", 127], ["in", 133], ["the", 136], ["progression", 140], ["of", 152], ["the", 155], ["disease", 159], [".", 166], ["However", 168], [",", 175], ["the", 177], ["function", 181], ["of", 190], ["mutant", 193], ["K", 200], ["-", 201], ["Ras", 202], ["activity", 206], ["in", 215], ["tumor", 218], ["angiogenesis", 224], ["remains", 237], ["poorly", 245], ["understood", 252], [".", 262], ["Using", 264], ["human", 270], ["pancreatic", 276], ["duct", 287], ["epithelial", 292], ["(", 303], ["HPDE", 304], [")", 308], ["and", 310], ["K", 314], ["-", 315], ["Ras4B(G12V)-transformed", 316], ["HPDE", 340], ["(", 345], ["HPDE", 346], ["-", 350], ["KRas", 351], [")", 355], ["cells", 357], [",", 362], ["we", 364], ["show", 367], ["that", 372], ["activated", 377], ["K", 387], ["-", 388], ["Ras", 389], ["significantly", 393], ["enhanced", 407], ["the", 416], ["production", 420], ["of", 431], ["angiogenic", 434], ["factors", 445], ["including", 453], ["CXC", 463], ["chemokines", 467], ["and", 478], ["vascular", 482], ["endothelial", 491], ["growth", 503], ["factor", 510], ["(", 517], ["VEGF", 518], [")", 522], [".", 523], ["Western", 525], ["blot", 533], ["analysis", 538], ["revealed", 547], ["that", 556], ["K", 561], ["-", 562], ["Ras", 563], ["activation", 567], ["promoted", 578], ["the", 587], ["phosphorylation", 591], ["of", 607], ["Raf", 610], ["/", 613], ["mitogen", 614], ["-", 621], ["activated", 622], ["protein", 632], ["kinase", 640], ["kinase-1/2", 647], ["(", 658], ["MEK1/2", 659], [")", 665], ["and", 667], ["expression", 671], ["of", 682], ["c", 685], ["-", 686], ["Jun", 687], [".", 690], ["MEK1/2", 692], ["inhibitors", 699], [",", 709], ["U0126", 711], ["and", 717], ["PD98059", 721], [",", 728], ["significantly", 730], ["inhibited", 744], ["the", 754], ["secretion", 758], ["of", 768], ["both", 771], ["CXC", 776], ["chemokines", 780], ["and", 791], ["VEGF", 795], [",", 799], ["whereas", 801], ["the", 809], ["c", 813], ["-", 814], ["Jun", 815], ["NH(2)-terminal", 819], ["kinase", 834], ["inhibitor", 841], ["SP600125", 851], ["abrogated", 860], ["only", 870], ["CXC", 875], ["chemokine", 879], ["production", 889], [".", 899], ["To", 901], ["further", 904], ["elucidate", 912], ["the", 922], ["biological", 926], ["functions", 937], ["of", 947], ["oncogenic", 950], ["K", 960], ["-", 961], ["Ras", 962], ["in", 966], ["promoting", 969], ["angiogenesis", 979], [",", 991], ["we", 993], ["did", 996], ["in", 1000], ["vitro", 1003], ["invasion", 1009], ["and", 1018], ["tube", 1022], ["formation", 1027], ["assays", 1037], ["using", 1044], ["human", 1050], ["umbilical", 1056], ["vein", 1066], ["endothelial", 1071], ["cells", 1083], ["(", 1089], ["HUVEC", 1090], [")", 1095], [".", 1096], ["HUVEC", 1098], ["cocultured", 1104], ["with", 1115], ["HPDE", 1120], ["-", 1124], ["KRas", 1125], ["showed", 1130], ["significantly", 1137], ["enhanced", 1151], ["invasiveness", 1160], ["and", 1173], ["tube", 1177], ["formation", 1182], ["as", 1192], ["compared", 1195], ["with", 1204], ["either", 1209], ["control", 1216], ["(", 1224], ["without", 1225], ["coculture", 1233], [")", 1242], ["or", 1244], ["coculture", 1247], ["with", 1257], ["HPDE", 1262], [".", 1266], ["Moreover", 1268], [",", 1276], ["SB225002", 1278], ["(", 1287], ["a", 1288], ["CXCR2", 1290], ["inhibitor", 1296], [")", 1305], ["and", 1307], ["2C3", 1311], ["(", 1315], ["an", 1316], ["anti", 1319], ["-", 1323], ["VEGF", 1324], ["monoclonal", 1329], ["antibody", 1340], [")", 1348], ["either", 1350], ["alone", 1357], ["or", 1363], ["in", 1366], ["a", 1369], ["cooperative", 1371], ["manner", 1383], ["significantly", 1390], ["reduced", 1404], ["the", 1412], ["degree", 1416], ["of", 1423], ["both", 1426], ["Ras", 1431], ["-", 1434], ["dependent", 1435], ["HUVEC", 1445], ["invasiveness", 1451], ["and", 1464], ["tube", 1468], ["formation", 1473], [".", 1482], ["Similar", 1484], ["results", 1492], ["were", 1500], ["obtained", 1505], ["using", 1514], ["another", 1520], ["pair", 1528], ["of", 1533], ["immortalized", 1536], ["human", 1549], ["pancreatic", 1555], ["duct", 1566], ["-", 1570], ["derived", 1571], ["cells", 1579], [",", 1584], ["E6/E7/st", 1586], ["and", 1595], ["its", 1599], ["oncogenic", 1603], ["K", 1613], ["-", 1614], ["Ras", 1615], ["variant", 1619], [",", 1626], ["E6/E7/Ras", 1628], ["/", 1637], ["st", 1638], [".", 1640], ["Taken", 1642], ["together", 1648], [",", 1656], ["our", 1658], ["results", 1662], ["suggest", 1670], ["that", 1678], ["angiogenesis", 1683], ["is", 1696], ["initiated", 1699], ["by", 1709], ["paracrine", 1712], ["epithelial", 1722], ["secretion", 1733], ["of", 1743], ["CXC", 1746], ["chemokines", 1750], ["and", 1761], ["VEGF", 1765], ["downstream", 1770], ["of", 1781], ["activated", 1784], ["oncogenic", 1794], ["K", 1804], ["-", 1805], ["Ras", 1806], [",", 1809], ["and", 1811], ["that", 1815], ["this", 1820], ["vascular", 1825], ["maturation", 1834], ["is", 1845], ["in", 1848], ["part", 1851], ["dependent", 1856], ["on", 1866], ["MEK1/2", 1869], ["and", 1876], ["c", 1880], ["-", 1881], ["Jun", 1882], ["signaling", 1886], [".", 1895]]}
{"context": "Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy. These range from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease. The successful development of imatinib as a therapeutic agent for CML can be attributed directly to decades of scientific discoveries. These discoveries determined that the BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib, with imatinib significantly improving the long-term survival of patients with CML. Continuing in this tradition of scientific discoveries leading to improved therapies, the understanding of resistance to imatinib has rapidly led to strategies to circumvent resistance. Continued studies of hematologic malignancies will allow this paradigm of targeting molecular pathogenetic events to be applied to many additional hematologic cancers.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fd6f4f8657ba4d22a07d09f21a98e576", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[74, 76]], "char_spans": [[465, 471]]}]}], "context_tokens": [["Throughout", 0], ["its", 11], ["history", 15], [",", 22], ["chronic", 24], ["myeloid", 32], ["leukemia", 40], ["(", 49], ["CML", 50], [")", 53], ["has", 55], ["set", 59], ["precedents", 63], ["for", 74], ["cancer", 78], ["research", 85], ["and", 94], ["therapy", 98], [".", 105], ["These", 107], ["range", 113], ["from", 119], ["the", 124], ["identification", 128], ["of", 143], ["the", 146], ["first", 150], ["specific", 156], ["chromosomal", 165], ["abnormality", 177], ["associated", 189], ["with", 200], ["cancer", 205], ["to", 212], ["the", 215], ["development", 219], ["of", 231], ["imatinib", 234], ["as", 243], ["a", 246], ["specific", 248], [",", 256], ["targeted", 258], ["therapy", 267], ["for", 275], ["the", 279], ["disease", 283], [".", 290], ["The", 292], ["successful", 296], ["development", 307], ["of", 319], ["imatinib", 322], ["as", 331], ["a", 334], ["therapeutic", 336], ["agent", 348], ["for", 354], ["CML", 358], ["can", 362], ["be", 366], ["attributed", 369], ["directly", 380], ["to", 389], ["decades", 392], ["of", 400], ["scientific", 403], ["discoveries", 414], [".", 425], ["These", 427], ["discoveries", 433], ["determined", 445], ["that", 456], ["the", 461], ["BCR", 465], ["-", 468], ["ABL", 469], ["tyrosine", 473], ["kinase", 482], ["is", 489], ["the", 492], ["critical", 496], ["pathogenetic", 505], ["event", 518], ["in", 524], ["CML", 527], ["and", 531], ["an", 535], ["ideal", 538], ["target", 544], ["for", 551], ["therapy", 555], [".", 562], ["This", 564], ["was", 569], ["confirmed", 573], ["in", 583], ["clinical", 586], ["trials", 595], ["of", 602], ["imatinib", 605], [",", 613], ["with", 615], ["imatinib", 620], ["significantly", 629], ["improving", 643], ["the", 653], ["long", 657], ["-", 661], ["term", 662], ["survival", 667], ["of", 676], ["patients", 679], ["with", 688], ["CML", 693], [".", 696], ["Continuing", 698], ["in", 709], ["this", 712], ["tradition", 717], ["of", 727], ["scientific", 730], ["discoveries", 741], ["leading", 753], ["to", 761], ["improved", 764], ["therapies", 773], [",", 782], ["the", 784], ["understanding", 788], ["of", 802], ["resistance", 805], ["to", 816], ["imatinib", 819], ["has", 828], ["rapidly", 832], ["led", 840], ["to", 844], ["strategies", 847], ["to", 858], ["circumvent", 861], ["resistance", 872], [".", 882], ["Continued", 884], ["studies", 894], ["of", 902], ["hematologic", 905], ["malignancies", 917], ["will", 930], ["allow", 935], ["this", 941], ["paradigm", 946], ["of", 955], ["targeting", 958], ["molecular", 968], ["pathogenetic", 978], ["events", 991], ["to", 998], ["be", 1001], ["applied", 1004], ["to", 1012], ["many", 1015], ["additional", 1020], ["hematologic", 1031], ["cancers", 1043], [".", 1050]]}
{"context": "The apolipoprotein E (APOE) \u03b54 allele has been implicated in a range of neuropsychiatric conditions. The present research examined if the \u03b54 allele of the APOE gene moderated the effect of combat exposure on posttraumatic stress disorder (PTSD) among Iraq/Afghanistan-era veterans. Participants included 765 non-Hispanic White (NHW) and 859 non-Hispanic Black (NHB) Iraq/Afghanistan-era veterans. A structured interview established psychiatric diagnoses. Combat exposure and PTSD symptom severity were assessed via self-report. The most common lifetime diagnoses were depression (39.2%), PTSD (38.4%), and alcohol dependence (24.38%). After correcting for multiple comparisons, no significant effects were observed on any of the outcomes among the NHW sample; however, within the NHB sample, significant gene \u00d7 environment (G \u00d7 E) interactions were observed for lifetime PTSD (P = .0029) and PTSD symptom severity (P = .0009). In each case, the APOE \u03b54 allele had no effect on the outcomes when combat exposure was low; however, when combat exposure was high, an additive effect was observed such that \u03b54 homozygotes exposed to high levels of combat reported the highest rates of PTSD (92%) and the worst symptom severity scores on the Davidson Trauma Scale (M = 79.5). Although preliminary, these findings suggest that the APOE \u03b54 allele, in conjunction with exposure to high levels of combat exposure, may increase veterans' risk for developing PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "ec0f16c438fd46859bb3a5d270a6176f", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[165, 165], [109, 109], [229, 229], [172, 172], [87, 87], [41, 41], [281, 281]], "char_spans": [[871, 874], [588, 591], [1180, 1183], [892, 895], [475, 478], [239, 242], [1447, 1450]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["(", 21], ["APOE", 22], [")", 26], ["\u03b54", 28], ["allele", 31], ["has", 38], ["been", 42], ["implicated", 47], ["in", 58], ["a", 61], ["range", 63], ["of", 69], ["neuropsychiatric", 72], ["conditions", 89], [".", 99], ["The", 101], ["present", 105], ["research", 113], ["examined", 122], ["if", 131], ["the", 134], ["\u03b54", 138], ["allele", 141], ["of", 148], ["the", 151], ["APOE", 155], ["gene", 160], ["moderated", 165], ["the", 175], ["effect", 179], ["of", 186], ["combat", 189], ["exposure", 196], ["on", 205], ["posttraumatic", 208], ["stress", 222], ["disorder", 229], ["(", 238], ["PTSD", 239], [")", 243], ["among", 245], ["Iraq", 251], ["/", 255], ["Afghanistan", 256], ["-", 267], ["era", 268], ["veterans", 272], [".", 280], ["Participants", 282], ["included", 295], ["765", 304], ["non", 308], ["-", 311], ["Hispanic", 312], ["White", 321], ["(", 327], ["NHW", 328], [")", 331], ["and", 333], ["859", 337], ["non", 341], ["-", 344], ["Hispanic", 345], ["Black", 354], ["(", 360], ["NHB", 361], [")", 364], ["Iraq", 366], ["/", 370], ["Afghanistan", 371], ["-", 382], ["era", 383], ["veterans", 387], [".", 395], ["A", 397], ["structured", 399], ["interview", 410], ["established", 420], ["psychiatric", 432], ["diagnoses", 444], [".", 453], ["Combat", 455], ["exposure", 462], ["and", 471], ["PTSD", 475], ["symptom", 480], ["severity", 488], ["were", 497], ["assessed", 502], ["via", 511], ["self", 515], ["-", 519], ["report", 520], [".", 526], ["The", 528], ["most", 532], ["common", 537], ["lifetime", 544], ["diagnoses", 553], ["were", 563], ["depression", 568], ["(", 579], ["39.2", 580], ["%", 584], [")", 585], [",", 586], ["PTSD", 588], ["(", 593], ["38.4", 594], ["%", 598], [")", 599], [",", 600], ["and", 602], ["alcohol", 606], ["dependence", 614], ["(", 625], ["24.38", 626], ["%", 631], [")", 632], [".", 633], ["After", 635], ["correcting", 641], ["for", 652], ["multiple", 656], ["comparisons", 665], [",", 676], ["no", 678], ["significant", 681], ["effects", 693], ["were", 701], ["observed", 706], ["on", 715], ["any", 718], ["of", 722], ["the", 725], ["outcomes", 729], ["among", 738], ["the", 744], ["NHW", 748], ["sample", 752], [";", 758], ["however", 760], [",", 767], ["within", 769], ["the", 776], ["NHB", 780], ["sample", 784], [",", 790], ["significant", 792], ["gene", 804], ["\u00d7", 809], ["environment", 811], ["(", 823], ["G", 824], ["\u00d7", 826], ["E", 828], [")", 829], ["interactions", 831], ["were", 844], ["observed", 849], ["for", 858], ["lifetime", 862], ["PTSD", 871], ["(", 876], ["P", 877], ["=", 879], [".0029", 881], [")", 886], ["and", 888], ["PTSD", 892], ["symptom", 897], ["severity", 905], ["(", 914], ["P", 915], ["=", 917], [".0009", 919], [")", 924], [".", 925], ["In", 927], ["each", 930], ["case", 935], [",", 939], ["the", 941], ["APOE", 945], ["\u03b54", 950], ["allele", 953], ["had", 960], ["no", 964], ["effect", 967], ["on", 974], ["the", 977], ["outcomes", 981], ["when", 990], ["combat", 995], ["exposure", 1002], ["was", 1011], ["low", 1015], [";", 1018], ["however", 1020], [",", 1027], ["when", 1029], ["combat", 1034], ["exposure", 1041], ["was", 1050], ["high", 1054], [",", 1058], ["an", 1060], ["additive", 1063], ["effect", 1072], ["was", 1079], ["observed", 1083], ["such", 1092], ["that", 1097], ["\u03b54", 1102], ["homozygotes", 1105], ["exposed", 1117], ["to", 1125], ["high", 1128], ["levels", 1133], ["of", 1140], ["combat", 1143], ["reported", 1150], ["the", 1159], ["highest", 1163], ["rates", 1171], ["of", 1177], ["PTSD", 1180], ["(", 1185], ["92", 1186], ["%", 1188], [")", 1189], ["and", 1191], ["the", 1195], ["worst", 1199], ["symptom", 1205], ["severity", 1213], ["scores", 1222], ["on", 1229], ["the", 1232], ["Davidson", 1236], ["Trauma", 1245], ["Scale", 1252], ["(", 1258], ["M", 1259], ["=", 1261], ["79.5", 1263], [")", 1267], [".", 1268], ["Although", 1270], ["preliminary", 1279], [",", 1290], ["these", 1292], ["findings", 1298], ["suggest", 1307], ["that", 1315], ["the", 1320], ["APOE", 1324], ["\u03b54", 1329], ["allele", 1332], [",", 1338], ["in", 1340], ["conjunction", 1343], ["with", 1355], ["exposure", 1360], ["to", 1369], ["high", 1372], ["levels", 1377], ["of", 1384], ["combat", 1387], ["exposure", 1394], [",", 1402], ["may", 1404], ["increase", 1408], ["veterans", 1417], ["'", 1425], ["risk", 1427], ["for", 1432], ["developing", 1436], ["PTSD", 1447], [".", 1451]]}
{"context": "The mechanisms regulating the differential selenium (Se)-dependent stability of selenoprotein mRNAs are partially characterized. To further study the Se-dependent regulation of selenoproteins, we developed a novel chemiluminescent reporter to monitor the steady-state mRNA level of an artificial selenoprotein. Our reporter is a fusion of the Renilla luciferase gene and of the \u03b2-globin gene, but contains features required for incorporation of selenocysteine (SEC), namely, a UGA-SEC codon and a 3' untranslated region RNA stem loop called a SEC incorporation sequence (SECIS). At various levels of Se, the activity of reporters containing GPX1 or GPX4 SECIS elements is proportional to the steady-state mRNA level of the reporter construct and reflects the level of the corresponding endogenous mRNA. In a reporter containing a UGA codon and a functional GPX1 SECIS, Se-dependent nonsense-mediated decay (NMD) occurred in the cytoplasm, as opposed to the more typical nuclear location. To validate the reporter system, we used genetic and pharmacologic approaches to inhibit or promote NMD. Modulation of UPF1 by siRNA, overexpression, or by inhibition of SMG1 altered NMD in this system. Our reporter is derived from a Renilla luciferase reporter gene fused to an intron containing B-globin gene and is subject to degradation by NMD when a stop codon is inserted before the second intron.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "1c6613dd665f492bbe1abcd1251441b6", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[151, 151], [115, 115], [98, 98]], "char_spans": [[862, 866], [654, 658], [571, 575]]}]}], "context_tokens": [["The", 0], ["mechanisms", 4], ["regulating", 15], ["the", 26], ["differential", 30], ["selenium", 43], ["(", 52], ["Se)-dependent", 53], ["stability", 67], ["of", 77], ["selenoprotein", 80], ["mRNAs", 94], ["are", 100], ["partially", 104], ["characterized", 114], [".", 127], ["To", 129], ["further", 132], ["study", 140], ["the", 146], ["Se", 150], ["-", 152], ["dependent", 153], ["regulation", 163], ["of", 174], ["selenoproteins", 177], [",", 191], ["we", 193], ["developed", 196], ["a", 206], ["novel", 208], ["chemiluminescent", 214], ["reporter", 231], ["to", 240], ["monitor", 243], ["the", 251], ["steady", 255], ["-", 261], ["state", 262], ["mRNA", 268], ["level", 273], ["of", 279], ["an", 282], ["artificial", 285], ["selenoprotein", 296], [".", 309], ["Our", 311], ["reporter", 315], ["is", 324], ["a", 327], ["fusion", 329], ["of", 336], ["the", 339], ["Renilla", 343], ["luciferase", 351], ["gene", 362], ["and", 367], ["of", 371], ["the", 374], ["\u03b2", 378], ["-", 379], ["globin", 380], ["gene", 387], [",", 391], ["but", 393], ["contains", 397], ["features", 406], ["required", 415], ["for", 424], ["incorporation", 428], ["of", 442], ["selenocysteine", 445], ["(", 460], ["SEC", 461], [")", 464], [",", 465], ["namely", 467], [",", 473], ["a", 475], ["UGA", 477], ["-", 480], ["SEC", 481], ["codon", 485], ["and", 491], ["a", 495], ["3", 497], ["'", 498], ["untranslated", 500], ["region", 513], ["RNA", 520], ["stem", 524], ["loop", 529], ["called", 534], ["a", 541], ["SEC", 543], ["incorporation", 547], ["sequence", 561], ["(", 570], ["SECIS", 571], [")", 576], [".", 577], ["At", 579], ["various", 582], ["levels", 590], ["of", 597], ["Se", 600], [",", 602], ["the", 604], ["activity", 608], ["of", 617], ["reporters", 620], ["containing", 630], ["GPX1", 641], ["or", 646], ["GPX4", 649], ["SECIS", 654], ["elements", 660], ["is", 669], ["proportional", 672], ["to", 685], ["the", 688], ["steady", 692], ["-", 698], ["state", 699], ["mRNA", 705], ["level", 710], ["of", 716], ["the", 719], ["reporter", 723], ["construct", 732], ["and", 742], ["reflects", 746], ["the", 755], ["level", 759], ["of", 765], ["the", 768], ["corresponding", 772], ["endogenous", 786], ["mRNA", 797], [".", 801], ["In", 803], ["a", 806], ["reporter", 808], ["containing", 817], ["a", 828], ["UGA", 830], ["codon", 834], ["and", 840], ["a", 844], ["functional", 846], ["GPX1", 857], ["SECIS", 862], [",", 867], ["Se", 869], ["-", 871], ["dependent", 872], ["nonsense", 882], ["-", 890], ["mediated", 891], ["decay", 900], ["(", 906], ["NMD", 907], [")", 910], ["occurred", 912], ["in", 921], ["the", 924], ["cytoplasm", 928], [",", 937], ["as", 939], ["opposed", 942], ["to", 950], ["the", 953], ["more", 957], ["typical", 962], ["nuclear", 970], ["location", 978], [".", 986], ["To", 988], ["validate", 991], ["the", 1000], ["reporter", 1004], ["system", 1013], [",", 1019], ["we", 1021], ["used", 1024], ["genetic", 1029], ["and", 1037], ["pharmacologic", 1041], ["approaches", 1055], ["to", 1066], ["inhibit", 1069], ["or", 1077], ["promote", 1080], ["NMD", 1088], [".", 1091], ["Modulation", 1093], ["of", 1104], ["UPF1", 1107], ["by", 1112], ["siRNA", 1115], [",", 1120], ["overexpression", 1122], [",", 1136], ["or", 1138], ["by", 1141], ["inhibition", 1144], ["of", 1155], ["SMG1", 1158], ["altered", 1163], ["NMD", 1171], ["in", 1175], ["this", 1178], ["system", 1183], [".", 1189], ["Our", 1191], ["reporter", 1195], ["is", 1204], ["derived", 1207], ["from", 1215], ["a", 1220], ["Renilla", 1222], ["luciferase", 1230], ["reporter", 1241], ["gene", 1250], ["fused", 1255], ["to", 1261], ["an", 1264], ["intron", 1267], ["containing", 1274], ["B", 1285], ["-", 1286], ["globin", 1287], ["gene", 1294], ["and", 1299], ["is", 1303], ["subject", 1306], ["to", 1314], ["degradation", 1317], ["by", 1329], ["NMD", 1332], ["when", 1336], ["a", 1341], ["stop", 1343], ["codon", 1348], ["is", 1354], ["inserted", 1357], ["before", 1366], ["the", 1373], ["second", 1377], ["intron", 1384], [".", 1390]]}
{"context": "In patients with acute stroke, rapid intervention is crucial to maximise early treatment benefits. Stroke patients commonly have their first contact with medical staff in the emergency room (ER). We designed and validated a stroke recognition tool-the Recognition of Stroke in the Emergency Room (ROSIER) scale-for use by ER physicians. We prospectively collected data for 1 year (development phase) on the clinical characteristics of patients with suspected acute stroke who were admitted to hospital from the ER. We used logistic regression analysis and clinical reasoning to develop a stroke recognition instrument for application in this setting. Patients with suspected transient ischaemic attack (TIA) with no symptoms or signs when assessed in the ER were excluded from the analysis. The instrument was assessed using the baseline 1-year dataset and then prospectively validated in a new cohort of ER patients admitted over a 9-month period. In the development phase, 343 suspected stroke patients were assessed (159 stroke, 167 non-stroke, 32 with TIA [17 with symptoms when seen in ER]). Common stroke mimics were seizures (23%), syncope (23%), and sepsis (10%). A seven-item (total score from -2 to +5) stroke recognition instrument was constructed on the basis of clinical history (loss of consciousness, convulsive fits) and neurological signs (face, arm, or leg weakness, speech disturbance, visual field defect). When internally validated at a cut-off score greater than zero, the instrument showed a diagnostic sensitivity of 92%, specificity of 86%, positive predictive value (PPV) of 88%, and negative predictive value (NPV) of 91%. Prospective validation in 173 consecutive suspected stroke referrals (88 stroke, 59 non-stroke, 26 with TIA [13 with symptoms]) showed sensitivity of 93% (95% CI 89-97), specificity 83% (77-89), PPV 90% (85-95), and NPV 88% (83-93). The ROSIER scale had greater sensitivity than existing stroke recognition instruments in this population. The ROSIER scale was effective in the initial differentiation of acute stroke from stroke mimics in the ER. Introduction of the instrument improved the appropriateness of referrals to the stroke team.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "3cd4480a62364a83bc920400cbbe11a2", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[16, 16], [176, 176], [181, 181], [416, 416], [46, 46], [170, 170], [198, 198], [326, 326], [4, 4], [330, 330], [39, 39], [103, 103], [396, 396], [414, 414], [232, 232], [82, 82], [433, 433], [335, 335]], "char_spans": [[99, 104], [1024, 1029], [1040, 1045], [2072, 2077], [267, 272], [989, 994], [1104, 1109], [1702, 1707], [23, 28], [1723, 1728], [224, 229], [588, 593], [1938, 1943], [2060, 2065], [1213, 1218], [465, 470], [2177, 2182], [1738, 1743]]}]}], "context_tokens": [["In", 0], ["patients", 3], ["with", 12], ["acute", 17], ["stroke", 23], [",", 29], ["rapid", 31], ["intervention", 37], ["is", 50], ["crucial", 53], ["to", 61], ["maximise", 64], ["early", 73], ["treatment", 79], ["benefits", 89], [".", 97], ["Stroke", 99], ["patients", 106], ["commonly", 115], ["have", 124], ["their", 129], ["first", 135], ["contact", 141], ["with", 149], ["medical", 154], ["staff", 162], ["in", 168], ["the", 171], ["emergency", 175], ["room", 185], ["(", 190], ["ER", 191], [")", 193], [".", 194], ["We", 196], ["designed", 199], ["and", 208], ["validated", 212], ["a", 222], ["stroke", 224], ["recognition", 231], ["tool", 243], ["-", 247], ["the", 248], ["Recognition", 252], ["of", 264], ["Stroke", 267], ["in", 274], ["the", 277], ["Emergency", 281], ["Room", 291], ["(", 296], ["ROSIER", 297], [")", 303], ["scale", 305], ["-", 310], ["for", 311], ["use", 315], ["by", 319], ["ER", 322], ["physicians", 325], [".", 335], ["We", 337], ["prospectively", 340], ["collected", 354], ["data", 364], ["for", 369], ["1", 373], ["year", 375], ["(", 380], ["development", 381], ["phase", 393], [")", 398], ["on", 400], ["the", 403], ["clinical", 407], ["characteristics", 416], ["of", 432], ["patients", 435], ["with", 444], ["suspected", 449], ["acute", 459], ["stroke", 465], ["who", 472], ["were", 476], ["admitted", 481], ["to", 490], ["hospital", 493], ["from", 502], ["the", 507], ["ER", 511], [".", 513], ["We", 515], ["used", 518], ["logistic", 523], ["regression", 532], ["analysis", 543], ["and", 552], ["clinical", 556], ["reasoning", 565], ["to", 575], ["develop", 578], ["a", 586], ["stroke", 588], ["recognition", 595], ["instrument", 607], ["for", 618], ["application", 622], ["in", 634], ["this", 637], ["setting", 642], [".", 649], ["Patients", 651], ["with", 660], ["suspected", 665], ["transient", 675], ["ischaemic", 685], ["attack", 695], ["(", 702], ["TIA", 703], [")", 706], ["with", 708], ["no", 713], ["symptoms", 716], ["or", 725], ["signs", 728], ["when", 734], ["assessed", 739], ["in", 748], ["the", 751], ["ER", 755], ["were", 758], ["excluded", 763], ["from", 772], ["the", 777], ["analysis", 781], [".", 789], ["The", 791], ["instrument", 795], ["was", 806], ["assessed", 810], ["using", 819], ["the", 825], ["baseline", 829], ["1-year", 838], ["dataset", 845], ["and", 853], ["then", 857], ["prospectively", 862], ["validated", 876], ["in", 886], ["a", 889], ["new", 891], ["cohort", 895], ["of", 902], ["ER", 905], ["patients", 908], ["admitted", 917], ["over", 926], ["a", 931], ["9-month", 933], ["period", 941], [".", 947], ["In", 949], ["the", 952], ["development", 956], ["phase", 968], [",", 973], ["343", 975], ["suspected", 979], ["stroke", 989], ["patients", 996], ["were", 1005], ["assessed", 1010], ["(", 1019], ["159", 1020], ["stroke", 1024], [",", 1030], ["167", 1032], ["non", 1036], ["-", 1039], ["stroke", 1040], [",", 1046], ["32", 1048], ["with", 1051], ["TIA", 1056], ["[", 1060], ["17", 1061], ["with", 1064], ["symptoms", 1069], ["when", 1078], ["seen", 1083], ["in", 1088], ["ER", 1091], ["]", 1093], [")", 1094], [".", 1095], ["Common", 1097], ["stroke", 1104], ["mimics", 1111], ["were", 1118], ["seizures", 1123], ["(", 1132], ["23", 1133], ["%", 1135], [")", 1136], [",", 1137], ["syncope", 1139], ["(", 1147], ["23", 1148], ["%", 1150], [")", 1151], [",", 1152], ["and", 1154], ["sepsis", 1158], ["(", 1165], ["10", 1166], ["%", 1168], [")", 1169], [".", 1170], ["A", 1172], ["seven", 1174], ["-", 1179], ["item", 1180], ["(", 1185], ["total", 1186], ["score", 1192], ["from", 1198], ["-2", 1203], ["to", 1206], ["+5", 1209], [")", 1211], ["stroke", 1213], ["recognition", 1220], ["instrument", 1232], ["was", 1243], ["constructed", 1247], ["on", 1259], ["the", 1262], ["basis", 1266], ["of", 1272], ["clinical", 1275], ["history", 1284], ["(", 1292], ["loss", 1293], ["of", 1298], ["consciousness", 1301], [",", 1314], ["convulsive", 1316], ["fits", 1327], [")", 1331], ["and", 1333], ["neurological", 1337], ["signs", 1350], ["(", 1356], ["face", 1357], [",", 1361], ["arm", 1363], [",", 1366], ["or", 1368], ["leg", 1371], ["weakness", 1375], [",", 1383], ["speech", 1385], ["disturbance", 1392], [",", 1403], ["visual", 1405], ["field", 1412], ["defect", 1418], [")", 1424], [".", 1425], ["When", 1427], ["internally", 1432], ["validated", 1443], ["at", 1453], ["a", 1456], ["cut", 1458], ["-", 1461], ["off", 1462], ["score", 1466], ["greater", 1472], ["than", 1480], ["zero", 1485], [",", 1489], ["the", 1491], ["instrument", 1495], ["showed", 1506], ["a", 1513], ["diagnostic", 1515], ["sensitivity", 1526], ["of", 1538], ["92", 1541], ["%", 1543], [",", 1544], ["specificity", 1546], ["of", 1558], ["86", 1561], ["%", 1563], [",", 1564], ["positive", 1566], ["predictive", 1575], ["value", 1586], ["(", 1592], ["PPV", 1593], [")", 1596], ["of", 1598], ["88", 1601], ["%", 1603], [",", 1604], ["and", 1606], ["negative", 1610], ["predictive", 1619], ["value", 1630], ["(", 1636], ["NPV", 1637], [")", 1640], ["of", 1642], ["91", 1645], ["%", 1647], [".", 1648], ["Prospective", 1650], ["validation", 1662], ["in", 1673], ["173", 1676], ["consecutive", 1680], ["suspected", 1692], ["stroke", 1702], ["referrals", 1709], ["(", 1719], ["88", 1720], ["stroke", 1723], [",", 1729], ["59", 1731], ["non", 1734], ["-", 1737], ["stroke", 1738], [",", 1744], ["26", 1746], ["with", 1749], ["TIA", 1754], ["[", 1758], ["13", 1759], ["with", 1762], ["symptoms", 1767], ["]", 1775], [")", 1776], ["showed", 1778], ["sensitivity", 1785], ["of", 1797], ["93", 1800], ["%", 1802], ["(", 1804], ["95", 1805], ["%", 1807], ["CI", 1809], ["89", 1812], ["-", 1814], ["97", 1815], [")", 1817], [",", 1818], ["specificity", 1820], ["83", 1832], ["%", 1834], ["(", 1836], ["77", 1837], ["-", 1839], ["89", 1840], [")", 1842], [",", 1843], ["PPV", 1845], ["90", 1849], ["%", 1851], ["(", 1853], ["85", 1854], ["-", 1856], ["95", 1857], [")", 1859], [",", 1860], ["and", 1862], ["NPV", 1866], ["88", 1870], ["%", 1872], ["(", 1874], ["83", 1875], ["-", 1877], ["93", 1878], [")", 1880], [".", 1881], ["The", 1883], ["ROSIER", 1887], ["scale", 1894], ["had", 1900], ["greater", 1904], ["sensitivity", 1912], ["than", 1924], ["existing", 1929], ["stroke", 1938], ["recognition", 1945], ["instruments", 1957], ["in", 1969], ["this", 1972], ["population", 1977], [".", 1987], ["The", 1989], ["ROSIER", 1993], ["scale", 2000], ["was", 2006], ["effective", 2010], ["in", 2020], ["the", 2023], ["initial", 2027], ["differentiation", 2035], ["of", 2051], ["acute", 2054], ["stroke", 2060], ["from", 2067], ["stroke", 2072], ["mimics", 2079], ["in", 2086], ["the", 2089], ["ER", 2093], [".", 2095], ["Introduction", 2097], ["of", 2110], ["the", 2113], ["instrument", 2117], ["improved", 2128], ["the", 2137], ["appropriateness", 2141], ["of", 2157], ["referrals", 2160], ["to", 2170], ["the", 2173], ["stroke", 2177], ["team", 2184], [".", 2188]]}
{"context": "Restless legs syndrome is common in patients with multiple sclerosis but has not been reported as occurring due to an acute, inflammatory, demyelinating attack. Restless legs syndrome is known to be related to low brain iron levels. Multiple sclerosis has been associated with the abnormal accumulation of iron in the chronic, progressive phase of axonal degeneration. Iron deficiency may play a role in demyelination. This suggests that restless legs syndrome may be caused by the inflammatory, demyelinating component of multiple sclerosis rather than axonal degeneration. The author presents a case of self-limited restless legs syndrome occurring as an acute attack of multiple sclerosis, supporting the notion that inflammatory demyelination is the underlying pathophysiology of restless legs syndrome in multiple sclerosis.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "bf8c21d529d04c91a88adc9ab2db2f61", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[62, 62], [51, 51], [38, 38]], "char_spans": [[369, 372], [306, 309], [220, 223]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["is", 23], ["common", 26], ["in", 33], ["patients", 36], ["with", 45], ["multiple", 50], ["sclerosis", 59], ["but", 69], ["has", 73], ["not", 77], ["been", 81], ["reported", 86], ["as", 95], ["occurring", 98], ["due", 108], ["to", 112], ["an", 115], ["acute", 118], [",", 123], ["inflammatory", 125], [",", 137], ["demyelinating", 139], ["attack", 153], [".", 159], ["Restless", 161], ["legs", 170], ["syndrome", 175], ["is", 184], ["known", 187], ["to", 193], ["be", 196], ["related", 199], ["to", 207], ["low", 210], ["brain", 214], ["iron", 220], ["levels", 225], [".", 231], ["Multiple", 233], ["sclerosis", 242], ["has", 252], ["been", 256], ["associated", 261], ["with", 272], ["the", 277], ["abnormal", 281], ["accumulation", 290], ["of", 303], ["iron", 306], ["in", 311], ["the", 314], ["chronic", 318], [",", 325], ["progressive", 327], ["phase", 339], ["of", 345], ["axonal", 348], ["degeneration", 355], [".", 367], ["Iron", 369], ["deficiency", 374], ["may", 385], ["play", 389], ["a", 394], ["role", 396], ["in", 401], ["demyelination", 404], [".", 417], ["This", 419], ["suggests", 424], ["that", 433], ["restless", 438], ["legs", 447], ["syndrome", 452], ["may", 461], ["be", 465], ["caused", 468], ["by", 475], ["the", 478], ["inflammatory", 482], [",", 494], ["demyelinating", 496], ["component", 510], ["of", 520], ["multiple", 523], ["sclerosis", 532], ["rather", 542], ["than", 549], ["axonal", 554], ["degeneration", 561], [".", 573], ["The", 575], ["author", 579], ["presents", 586], ["a", 595], ["case", 597], ["of", 602], ["self", 605], ["-", 609], ["limited", 610], ["restless", 618], ["legs", 627], ["syndrome", 632], ["occurring", 641], ["as", 651], ["an", 654], ["acute", 657], ["attack", 663], ["of", 670], ["multiple", 673], ["sclerosis", 682], [",", 691], ["supporting", 693], ["the", 704], ["notion", 708], ["that", 715], ["inflammatory", 720], ["demyelination", 733], ["is", 747], ["the", 750], ["underlying", 754], ["pathophysiology", 765], ["of", 781], ["restless", 784], ["legs", 793], ["syndrome", 798], ["in", 807], ["multiple", 810], ["sclerosis", 819], [".", 828]]}
{"context": "Chemically synthesized DNA can carry small RNA sequence information but converting that information into small RNA is generally thought to require large double-stranded promoters in the context of plasmids, viruses and genes. We previously found evidence that circularized oligodeoxynucleotides (coligos) containing certain sequences and secondary structures can template the synthesis of small RNA by RNA polymerase III in vitro and in human cells. By using immunoprecipitated RNA polymerase III we now report corroborating evidence that this enzyme is the sole polymerase responsible for coligo transcription. The immobilized polymerase enabled experiments showing that coligo transcripts can be formed through transcription termination without subsequent 3' end trimming. To better define the determinants of productive transcription, a structure-activity relationship study was performed using over 20 new coligos. The results show that unpaired nucleotides in the coligo stem facilitate circumtranscription, but also that internal loops and bulges should be kept small to avoid secondary transcription initiation sites. A polymerase termination sequence embedded in the double-stranded region of a hairpin-encoding coligo stem can antagonize transcription. Using lessons learned from new and old coligos, we demonstrate how to convert poorly transcribed coligos into productive templates. Our findings support the possibility that coligos may prove useful as chemically synthesized vectors for the ectopic expression of small RNA in human cells.", "qas": [{"question": "What is a coligo?", "answers": ["circularized oligodeoxynucleotides"], "qid": "60face353b89434397ee1fbd3aa44915", "question_tokens": [["What", 0], ["is", 5], ["a", 8], ["coligo", 10], ["?", 16]], "detected_answers": [{"text": "circularized oligodeoxynucleotides", "token_spans": [[41, 42]], "char_spans": [[260, 293]]}]}], "context_tokens": [["Chemically", 0], ["synthesized", 11], ["DNA", 23], ["can", 27], ["carry", 31], ["small", 37], ["RNA", 43], ["sequence", 47], ["information", 56], ["but", 68], ["converting", 72], ["that", 83], ["information", 88], ["into", 100], ["small", 105], ["RNA", 111], ["is", 115], ["generally", 118], ["thought", 128], ["to", 136], ["require", 139], ["large", 147], ["double", 153], ["-", 159], ["stranded", 160], ["promoters", 169], ["in", 179], ["the", 182], ["context", 186], ["of", 194], ["plasmids", 197], [",", 205], ["viruses", 207], ["and", 215], ["genes", 219], [".", 224], ["We", 226], ["previously", 229], ["found", 240], ["evidence", 246], ["that", 255], ["circularized", 260], ["oligodeoxynucleotides", 273], ["(", 295], ["coligos", 296], [")", 303], ["containing", 305], ["certain", 316], ["sequences", 324], ["and", 334], ["secondary", 338], ["structures", 348], ["can", 359], ["template", 363], ["the", 372], ["synthesis", 376], ["of", 386], ["small", 389], ["RNA", 395], ["by", 399], ["RNA", 402], ["polymerase", 406], ["III", 417], ["in", 421], ["vitro", 424], ["and", 430], ["in", 434], ["human", 437], ["cells", 443], [".", 448], ["By", 450], ["using", 453], ["immunoprecipitated", 459], ["RNA", 478], ["polymerase", 482], ["III", 493], ["we", 497], ["now", 500], ["report", 504], ["corroborating", 511], ["evidence", 525], ["that", 534], ["this", 539], ["enzyme", 544], ["is", 551], ["the", 554], ["sole", 558], ["polymerase", 563], ["responsible", 574], ["for", 586], ["coligo", 590], ["transcription", 597], [".", 610], ["The", 612], ["immobilized", 616], ["polymerase", 628], ["enabled", 639], ["experiments", 647], ["showing", 659], ["that", 667], ["coligo", 672], ["transcripts", 679], ["can", 691], ["be", 695], ["formed", 698], ["through", 705], ["transcription", 713], ["termination", 727], ["without", 739], ["subsequent", 747], ["3", 758], ["'", 759], ["end", 761], ["trimming", 765], [".", 773], ["To", 775], ["better", 778], ["define", 785], ["the", 792], ["determinants", 796], ["of", 809], ["productive", 812], ["transcription", 823], [",", 836], ["a", 838], ["structure", 840], ["-", 849], ["activity", 850], ["relationship", 859], ["study", 872], ["was", 878], ["performed", 882], ["using", 892], ["over", 898], ["20", 903], ["new", 906], ["coligos", 910], [".", 917], ["The", 919], ["results", 923], ["show", 931], ["that", 936], ["unpaired", 941], ["nucleotides", 950], ["in", 962], ["the", 965], ["coligo", 969], ["stem", 976], ["facilitate", 981], ["circumtranscription", 992], [",", 1011], ["but", 1013], ["also", 1017], ["that", 1022], ["internal", 1027], ["loops", 1036], ["and", 1042], ["bulges", 1046], ["should", 1053], ["be", 1060], ["kept", 1063], ["small", 1068], ["to", 1074], ["avoid", 1077], ["secondary", 1083], ["transcription", 1093], ["initiation", 1107], ["sites", 1118], [".", 1123], ["A", 1125], ["polymerase", 1127], ["termination", 1138], ["sequence", 1150], ["embedded", 1159], ["in", 1168], ["the", 1171], ["double", 1175], ["-", 1181], ["stranded", 1182], ["region", 1191], ["of", 1198], ["a", 1201], ["hairpin", 1203], ["-", 1210], ["encoding", 1211], ["coligo", 1220], ["stem", 1227], ["can", 1232], ["antagonize", 1236], ["transcription", 1247], [".", 1260], ["Using", 1262], ["lessons", 1268], ["learned", 1276], ["from", 1284], ["new", 1289], ["and", 1293], ["old", 1297], ["coligos", 1301], [",", 1308], ["we", 1310], ["demonstrate", 1313], ["how", 1325], ["to", 1329], ["convert", 1332], ["poorly", 1340], ["transcribed", 1347], ["coligos", 1359], ["into", 1367], ["productive", 1372], ["templates", 1383], [".", 1392], ["Our", 1394], ["findings", 1398], ["support", 1407], ["the", 1415], ["possibility", 1419], ["that", 1431], ["coligos", 1436], ["may", 1444], ["prove", 1448], ["useful", 1454], ["as", 1461], ["chemically", 1464], ["synthesized", 1475], ["vectors", 1487], ["for", 1495], ["the", 1499], ["ectopic", 1503], ["expression", 1511], ["of", 1522], ["small", 1525], ["RNA", 1531], ["in", 1535], ["human", 1538], ["cells", 1544], [".", 1549]]}
{"context": "Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4 to a size of 1-10 units. The residual number of D4Z4 units inversely correlates with clinical severity, but significant clinical variability exists. Each unit contains a copy of the DUX4 retrogene. Repeat contractions are associated with changes in D4Z4 chromatin structure that increase the likelihood of DUX4 expression in skeletal muscle, but only when the repeat resides in a genetic background that contains a DUX4 polyadenylation signal. Mutations in the structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) gene, encoding a chromatin modifier of D4Z4, also result in the increased likelihood of DUX4 expression in individuals with a rare form of FSHD (FSHD2). Because SMCHD1 directly binds to D4Z4 and suppresses somatic expression of DUX4, we hypothesized that SMCHD1 may act as a genetic modifier in FSHD1. We describe three unrelated individuals with FSHD1 presenting an unusual high clinical severity based on their upper-sized FSHD1 repeat array of nine units. Each of these individuals also carries a mutation in the SMCHD1 gene. Familial carriers of the FSHD1 allele without the SMCHD1 mutation were only mildly affected, suggesting a modifier effect of the SMCHD1 mutation. Knocking down SMCHD1 in FSHD1 myotubes increased DUX4 expression, lending molecular support to a modifier role for SMCHD1 in FSHD1. We conclude that FSHD1 and FSHD2 share a common pathophysiological pathway in which the FSHD2 gene can act as modifier for disease severity in families affected by FSHD1.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "e2c7168e86b7402987c3b9727658207d", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[135, 135]], "char_spans": [[802, 805]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["type", 39], ["1", 44], ["(", 46], ["FSHD1", 47], [")", 52], ["is", 54], ["caused", 57], ["by", 64], ["contraction", 67], ["of", 79], ["the", 82], ["D4Z4", 86], ["repeat", 91], ["array", 98], ["on", 104], ["chromosome", 107], ["4", 118], ["to", 120], ["a", 123], ["size", 125], ["of", 130], ["1", 133], ["-", 134], ["10", 135], ["units", 138], [".", 143], ["The", 145], ["residual", 149], ["number", 158], ["of", 165], ["D4Z4", 168], ["units", 173], ["inversely", 179], ["correlates", 189], ["with", 200], ["clinical", 205], ["severity", 214], [",", 222], ["but", 224], ["significant", 228], ["clinical", 240], ["variability", 249], ["exists", 261], [".", 267], ["Each", 269], ["unit", 274], ["contains", 279], ["a", 288], ["copy", 290], ["of", 295], ["the", 298], ["DUX4", 302], ["retrogene", 307], [".", 316], ["Repeat", 318], ["contractions", 325], ["are", 338], ["associated", 342], ["with", 353], ["changes", 358], ["in", 366], ["D4Z4", 369], ["chromatin", 374], ["structure", 384], ["that", 394], ["increase", 399], ["the", 408], ["likelihood", 412], ["of", 423], ["DUX4", 426], ["expression", 431], ["in", 442], ["skeletal", 445], ["muscle", 454], [",", 460], ["but", 462], ["only", 466], ["when", 471], ["the", 476], ["repeat", 480], ["resides", 487], ["in", 495], ["a", 498], ["genetic", 500], ["background", 508], ["that", 519], ["contains", 524], ["a", 533], ["DUX4", 535], ["polyadenylation", 540], ["signal", 556], [".", 562], ["Mutations", 564], ["in", 574], ["the", 577], ["structural", 581], ["maintenance", 592], ["of", 604], ["chromosomes", 607], ["flexible", 619], ["hinge", 628], ["domain", 634], ["containing", 641], ["1", 652], ["(", 654], ["SMCHD1", 655], [")", 661], ["gene", 663], [",", 667], ["encoding", 669], ["a", 678], ["chromatin", 680], ["modifier", 690], ["of", 699], ["D4Z4", 702], [",", 706], ["also", 708], ["result", 713], ["in", 720], ["the", 723], ["increased", 727], ["likelihood", 737], ["of", 748], ["DUX4", 751], ["expression", 756], ["in", 767], ["individuals", 770], ["with", 782], ["a", 787], ["rare", 789], ["form", 794], ["of", 799], ["FSHD", 802], ["(", 807], ["FSHD2", 808], [")", 813], [".", 814], ["Because", 816], ["SMCHD1", 824], ["directly", 831], ["binds", 840], ["to", 846], ["D4Z4", 849], ["and", 854], ["suppresses", 858], ["somatic", 869], ["expression", 877], ["of", 888], ["DUX4", 891], [",", 895], ["we", 897], ["hypothesized", 900], ["that", 913], ["SMCHD1", 918], ["may", 925], ["act", 929], ["as", 933], ["a", 936], ["genetic", 938], ["modifier", 946], ["in", 955], ["FSHD1", 958], [".", 963], ["We", 965], ["describe", 968], ["three", 977], ["unrelated", 983], ["individuals", 993], ["with", 1005], ["FSHD1", 1010], ["presenting", 1016], ["an", 1027], ["unusual", 1030], ["high", 1038], ["clinical", 1043], ["severity", 1052], ["based", 1061], ["on", 1067], ["their", 1070], ["upper", 1076], ["-", 1081], ["sized", 1082], ["FSHD1", 1088], ["repeat", 1094], ["array", 1101], ["of", 1107], ["nine", 1110], ["units", 1115], [".", 1120], ["Each", 1122], ["of", 1127], ["these", 1130], ["individuals", 1136], ["also", 1148], ["carries", 1153], ["a", 1161], ["mutation", 1163], ["in", 1172], ["the", 1175], ["SMCHD1", 1179], ["gene", 1186], [".", 1190], ["Familial", 1192], ["carriers", 1201], ["of", 1210], ["the", 1213], ["FSHD1", 1217], ["allele", 1223], ["without", 1230], ["the", 1238], ["SMCHD1", 1242], ["mutation", 1249], ["were", 1258], ["only", 1263], ["mildly", 1268], ["affected", 1275], [",", 1283], ["suggesting", 1285], ["a", 1296], ["modifier", 1298], ["effect", 1307], ["of", 1314], ["the", 1317], ["SMCHD1", 1321], ["mutation", 1328], [".", 1336], ["Knocking", 1338], ["down", 1347], ["SMCHD1", 1352], ["in", 1359], ["FSHD1", 1362], ["myotubes", 1368], ["increased", 1377], ["DUX4", 1387], ["expression", 1392], [",", 1402], ["lending", 1404], ["molecular", 1412], ["support", 1422], ["to", 1430], ["a", 1433], ["modifier", 1435], ["role", 1444], ["for", 1449], ["SMCHD1", 1453], ["in", 1460], ["FSHD1", 1463], [".", 1468], ["We", 1470], ["conclude", 1473], ["that", 1482], ["FSHD1", 1487], ["and", 1493], ["FSHD2", 1497], ["share", 1503], ["a", 1509], ["common", 1511], ["pathophysiological", 1518], ["pathway", 1537], ["in", 1545], ["which", 1548], ["the", 1554], ["FSHD2", 1558], ["gene", 1564], ["can", 1569], ["act", 1573], ["as", 1577], ["modifier", 1580], ["for", 1589], ["disease", 1593], ["severity", 1601], ["in", 1610], ["families", 1613], ["affected", 1622], ["by", 1631], ["FSHD1", 1634], [".", 1639]]}
{"context": "The endosomal/lysosomal transmembrane protein CLN3 is mutated in the Batten disease (juvenile neuronal ceroid lipofuscinosis, JNCL). However, the molecular mechanism of JNCL pathogenesis and the exact function of the CLN3 protein have remained unclear. Previous studies have shown that deletion of BTN1, the yeast orthologue of CLN3, leads to increased expression of BTN2. BTN2 encodes Btn2p, a proposed homologue to a novel microtubule-binding protein Hook1, which regulates endocytosis in Drosophila. We analysed here the putative interconnection between CLN3 and Hook1 in the mammalian cells and discovered that overexpression of human CLN3 induces aggregation of Hook1 protein, potentially by mediating its dissociation from the microtubules. Using in vitro binding assay we were able to demonstrate a weak interaction between Hook1 and the cytoplasmic segments of CLN3. We also found receptor-mediated endocytosis to be defective in CLN3-deficient JNCL fibroblasts, connecting CLN3, Hook1 and endocytosis in the mammalian system. Moreover, co-immunoprecipitation experiments showed that Hook1 physically interacts with endocytic Rab7, Rab9 and Rab11, hence delineating a manifold role for mammalian Hook1 in membrane trafficking events. These novel interactions between the microtubule-binding Hook1 and the large family of Rab GTPases also suggest a link between CLN3 function, microtubule cytoskeleton and endocytic membrane trafficking.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "1c5db62efbc145768b9fd53df6a404d5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[11, 12]], "char_spans": [[69, 82]]}, {"text": "JNCL", "token_spans": [[156, 156], [28, 28], [19, 19]], "char_spans": [[953, 956], [169, 172], [126, 129]]}]}], "context_tokens": [["The", 0], ["endosomal", 4], ["/", 13], ["lysosomal", 14], ["transmembrane", 24], ["protein", 38], ["CLN3", 46], ["is", 51], ["mutated", 54], ["in", 62], ["the", 65], ["Batten", 69], ["disease", 76], ["(", 84], ["juvenile", 85], ["neuronal", 94], ["ceroid", 103], ["lipofuscinosis", 110], [",", 124], ["JNCL", 126], [")", 130], [".", 131], ["However", 133], [",", 140], ["the", 142], ["molecular", 146], ["mechanism", 156], ["of", 166], ["JNCL", 169], ["pathogenesis", 174], ["and", 187], ["the", 191], ["exact", 195], ["function", 201], ["of", 210], ["the", 213], ["CLN3", 217], ["protein", 222], ["have", 230], ["remained", 235], ["unclear", 244], [".", 251], ["Previous", 253], ["studies", 262], ["have", 270], ["shown", 275], ["that", 281], ["deletion", 286], ["of", 295], ["BTN1", 298], [",", 302], ["the", 304], ["yeast", 308], ["orthologue", 314], ["of", 325], ["CLN3", 328], [",", 332], ["leads", 334], ["to", 340], ["increased", 343], ["expression", 353], ["of", 364], ["BTN2", 367], [".", 371], ["BTN2", 373], ["encodes", 378], ["Btn2p", 386], [",", 391], ["a", 393], ["proposed", 395], ["homologue", 404], ["to", 414], ["a", 417], ["novel", 419], ["microtubule", 425], ["-", 436], ["binding", 437], ["protein", 445], ["Hook1", 453], [",", 458], ["which", 460], ["regulates", 466], ["endocytosis", 476], ["in", 488], ["Drosophila", 491], [".", 501], ["We", 503], ["analysed", 506], ["here", 515], ["the", 520], ["putative", 524], ["interconnection", 533], ["between", 549], ["CLN3", 557], ["and", 562], ["Hook1", 566], ["in", 572], ["the", 575], ["mammalian", 579], ["cells", 589], ["and", 595], ["discovered", 599], ["that", 610], ["overexpression", 615], ["of", 630], ["human", 633], ["CLN3", 639], ["induces", 644], ["aggregation", 652], ["of", 664], ["Hook1", 667], ["protein", 673], [",", 680], ["potentially", 682], ["by", 694], ["mediating", 697], ["its", 707], ["dissociation", 711], ["from", 724], ["the", 729], ["microtubules", 733], [".", 745], ["Using", 747], ["in", 753], ["vitro", 756], ["binding", 762], ["assay", 770], ["we", 776], ["were", 779], ["able", 784], ["to", 789], ["demonstrate", 792], ["a", 804], ["weak", 806], ["interaction", 811], ["between", 823], ["Hook1", 831], ["and", 837], ["the", 841], ["cytoplasmic", 845], ["segments", 857], ["of", 866], ["CLN3", 869], [".", 873], ["We", 875], ["also", 878], ["found", 883], ["receptor", 889], ["-", 897], ["mediated", 898], ["endocytosis", 907], ["to", 919], ["be", 922], ["defective", 925], ["in", 935], ["CLN3-deficient", 938], ["JNCL", 953], ["fibroblasts", 958], [",", 969], ["connecting", 971], ["CLN3", 982], [",", 986], ["Hook1", 988], ["and", 994], ["endocytosis", 998], ["in", 1010], ["the", 1013], ["mammalian", 1017], ["system", 1027], [".", 1033], ["Moreover", 1035], [",", 1043], ["co", 1045], ["-", 1047], ["immunoprecipitation", 1048], ["experiments", 1068], ["showed", 1080], ["that", 1087], ["Hook1", 1092], ["physically", 1098], ["interacts", 1109], ["with", 1119], ["endocytic", 1124], ["Rab7", 1134], [",", 1138], ["Rab9", 1140], ["and", 1145], ["Rab11", 1149], [",", 1154], ["hence", 1156], ["delineating", 1162], ["a", 1174], ["manifold", 1176], ["role", 1185], ["for", 1190], ["mammalian", 1194], ["Hook1", 1204], ["in", 1210], ["membrane", 1213], ["trafficking", 1222], ["events", 1234], [".", 1240], ["These", 1242], ["novel", 1248], ["interactions", 1254], ["between", 1267], ["the", 1275], ["microtubule", 1279], ["-", 1290], ["binding", 1291], ["Hook1", 1299], ["and", 1305], ["the", 1309], ["large", 1313], ["family", 1319], ["of", 1326], ["Rab", 1329], ["GTPases", 1333], ["also", 1341], ["suggest", 1346], ["a", 1354], ["link", 1356], ["between", 1361], ["CLN3", 1369], ["function", 1374], [",", 1382], ["microtubule", 1384], ["cytoskeleton", 1396], ["and", 1409], ["endocytic", 1413], ["membrane", 1423], ["trafficking", 1432], [".", 1443]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD), the most prevalent myopathy afflicting both children and adults, is predominantly associated with contractions in the 4q35-localized macrosatellite D4Z4 repeat array. Recent studies have proposed that FSHD pathology is caused by the misexpression of the DUX4 (double homeobox 4) gene resulting in production of a pathogenic protein, DUX4-FL, which has been detected in FSHD, but not in unaffected control myogenic cells and muscle tissue. Here, we report the analysis of DUX4 mRNA and protein expression in a much larger collection of myogenic cells and muscle biopsies derived from biceps and deltoid muscles of FSHD affected subjects and their unaffected first-degree relatives. We confirmed that stable DUX4-fl mRNA and protein were expressed in myogenic cells and muscle tissues derived from FSHD affected subjects, including several genetically diagnosed adult FSHD subjects yet to show clinical manifestations of the disease in the assayed muscles. In addition, we report DUX4-fl mRNA and protein expression in muscle biopsies and myogenic cells from genetically unaffected relatives of the FSHD subjects, although at a significantly lower frequency. These results establish that DUX4-fl expression per se is not sufficient for FSHD muscle pathology and indicate that quantitative modifiers of DUX4-fl expression and/or function and family genetic background are determinants of FSHD muscle disease progression.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "c09b13353ce8449cae19747d33b78dc2", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[226, 226], [109, 109], [35, 35], [138, 138], [147, 147], [4, 4], [184, 184], [206, 206], [66, 66]], "char_spans": [[1432, 1435], [660, 663], [248, 251], [843, 846], [913, 916], [40, 43], [1144, 1147], [1281, 1284], [416, 419]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], [",", 45], ["the", 47], ["most", 51], ["prevalent", 56], ["myopathy", 66], ["afflicting", 75], ["both", 86], ["children", 91], ["and", 100], ["adults", 104], [",", 110], ["is", 112], ["predominantly", 115], ["associated", 129], ["with", 140], ["contractions", 145], ["in", 158], ["the", 161], ["4q35-localized", 165], ["macrosatellite", 180], ["D4Z4", 195], ["repeat", 200], ["array", 207], [".", 212], ["Recent", 214], ["studies", 221], ["have", 229], ["proposed", 234], ["that", 243], ["FSHD", 248], ["pathology", 253], ["is", 263], ["caused", 266], ["by", 273], ["the", 276], ["misexpression", 280], ["of", 294], ["the", 297], ["DUX4", 301], ["(", 306], ["double", 307], ["homeobox", 314], ["4", 323], [")", 324], ["gene", 326], ["resulting", 331], ["in", 341], ["production", 344], ["of", 355], ["a", 358], ["pathogenic", 360], ["protein", 371], [",", 378], ["DUX4-FL", 380], [",", 387], ["which", 389], ["has", 395], ["been", 399], ["detected", 404], ["in", 413], ["FSHD", 416], [",", 420], ["but", 422], ["not", 426], ["in", 430], ["unaffected", 433], ["control", 444], ["myogenic", 452], ["cells", 461], ["and", 467], ["muscle", 471], ["tissue", 478], [".", 484], ["Here", 486], [",", 490], ["we", 492], ["report", 495], ["the", 502], ["analysis", 506], ["of", 515], ["DUX4", 518], ["mRNA", 523], ["and", 528], ["protein", 532], ["expression", 540], ["in", 551], ["a", 554], ["much", 556], ["larger", 561], ["collection", 568], ["of", 579], ["myogenic", 582], ["cells", 591], ["and", 597], ["muscle", 601], ["biopsies", 608], ["derived", 617], ["from", 625], ["biceps", 630], ["and", 637], ["deltoid", 641], ["muscles", 649], ["of", 657], ["FSHD", 660], ["affected", 665], ["subjects", 674], ["and", 683], ["their", 687], ["unaffected", 693], ["first", 704], ["-", 709], ["degree", 710], ["relatives", 717], [".", 726], ["We", 728], ["confirmed", 731], ["that", 741], ["stable", 746], ["DUX4-fl", 753], ["mRNA", 761], ["and", 766], ["protein", 770], ["were", 778], ["expressed", 783], ["in", 793], ["myogenic", 796], ["cells", 805], ["and", 811], ["muscle", 815], ["tissues", 822], ["derived", 830], ["from", 838], ["FSHD", 843], ["affected", 848], ["subjects", 857], [",", 865], ["including", 867], ["several", 877], ["genetically", 885], ["diagnosed", 897], ["adult", 907], ["FSHD", 913], ["subjects", 918], ["yet", 927], ["to", 931], ["show", 934], ["clinical", 939], ["manifestations", 948], ["of", 963], ["the", 966], ["disease", 970], ["in", 978], ["the", 981], ["assayed", 985], ["muscles", 993], [".", 1000], ["In", 1002], ["addition", 1005], [",", 1013], ["we", 1015], ["report", 1018], ["DUX4-fl", 1025], ["mRNA", 1033], ["and", 1038], ["protein", 1042], ["expression", 1050], ["in", 1061], ["muscle", 1064], ["biopsies", 1071], ["and", 1080], ["myogenic", 1084], ["cells", 1093], ["from", 1099], ["genetically", 1104], ["unaffected", 1116], ["relatives", 1127], ["of", 1137], ["the", 1140], ["FSHD", 1144], ["subjects", 1149], [",", 1157], ["although", 1159], ["at", 1168], ["a", 1171], ["significantly", 1173], ["lower", 1187], ["frequency", 1193], [".", 1202], ["These", 1204], ["results", 1210], ["establish", 1218], ["that", 1228], ["DUX4-fl", 1233], ["expression", 1241], ["per", 1252], ["se", 1256], ["is", 1259], ["not", 1262], ["sufficient", 1266], ["for", 1277], ["FSHD", 1281], ["muscle", 1286], ["pathology", 1293], ["and", 1303], ["indicate", 1307], ["that", 1316], ["quantitative", 1321], ["modifiers", 1334], ["of", 1344], ["DUX4-fl", 1347], ["expression", 1355], ["and/or", 1366], ["function", 1373], ["and", 1382], ["family", 1386], ["genetic", 1393], ["background", 1401], ["are", 1412], ["determinants", 1416], ["of", 1429], ["FSHD", 1432], ["muscle", 1437], ["disease", 1444], ["progression", 1452], [".", 1463]]}
{"context": "Erythrasma is an uncommon vulvar infection, best diagnosed by its fluorescence under the Wood lamp. This report shows that despite a negative Wood lamp examination, the diagnosis can be made histologically. A 42-year-old woman was referred to our clinic with a persistent candidal infection. Evaluation included a Wood lamp examination, wet mount, and potassium hydroxide test of the affected skin, all of which were negative. A biopsy of the area demonstrated rods and filamentous organisms in the keratotic layer consistent with a Corynebacterium minutissimum infection. The patient was diagnosed as having erythrasma, and she responded to oral erythromycin. Persistent vulvar diseases may be caused by erythrasma despite a negative Wood lamp examination. The diagnosis can be made by biopsy of the lesion.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5bec275c58b4f4e81b005aac5c0e82f", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[93, 94]], "char_spans": [[533, 560]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["an", 14], ["uncommon", 17], ["vulvar", 26], ["infection", 33], [",", 42], ["best", 44], ["diagnosed", 49], ["by", 59], ["its", 62], ["fluorescence", 66], ["under", 79], ["the", 85], ["Wood", 89], ["lamp", 94], [".", 98], ["This", 100], ["report", 105], ["shows", 112], ["that", 118], ["despite", 123], ["a", 131], ["negative", 133], ["Wood", 142], ["lamp", 147], ["examination", 152], [",", 163], ["the", 165], ["diagnosis", 169], ["can", 179], ["be", 183], ["made", 186], ["histologically", 191], [".", 205], ["A", 207], ["42-year", 209], ["-", 216], ["old", 217], ["woman", 221], ["was", 227], ["referred", 231], ["to", 240], ["our", 243], ["clinic", 247], ["with", 254], ["a", 259], ["persistent", 261], ["candidal", 272], ["infection", 281], [".", 290], ["Evaluation", 292], ["included", 303], ["a", 312], ["Wood", 314], ["lamp", 319], ["examination", 324], [",", 335], ["wet", 337], ["mount", 341], [",", 346], ["and", 348], ["potassium", 352], ["hydroxide", 362], ["test", 372], ["of", 377], ["the", 380], ["affected", 384], ["skin", 393], [",", 397], ["all", 399], ["of", 403], ["which", 406], ["were", 412], ["negative", 417], [".", 425], ["A", 427], ["biopsy", 429], ["of", 436], ["the", 439], ["area", 443], ["demonstrated", 448], ["rods", 461], ["and", 466], ["filamentous", 470], ["organisms", 482], ["in", 492], ["the", 495], ["keratotic", 499], ["layer", 509], ["consistent", 515], ["with", 526], ["a", 531], ["Corynebacterium", 533], ["minutissimum", 549], ["infection", 562], [".", 571], ["The", 573], ["patient", 577], ["was", 585], ["diagnosed", 589], ["as", 599], ["having", 602], ["erythrasma", 609], [",", 619], ["and", 621], ["she", 625], ["responded", 629], ["to", 639], ["oral", 642], ["erythromycin", 647], [".", 659], ["Persistent", 661], ["vulvar", 672], ["diseases", 679], ["may", 688], ["be", 692], ["caused", 695], ["by", 702], ["erythrasma", 705], ["despite", 716], ["a", 724], ["negative", 726], ["Wood", 735], ["lamp", 740], ["examination", 745], [".", 756], ["The", 758], ["diagnosis", 762], ["can", 772], ["be", 776], ["made", 779], ["by", 784], ["biopsy", 787], ["of", 794], ["the", 797], ["lesion", 801], [".", 807]]}
{"context": "The Chinese version of the Davidson Trauma Scale (DTS-C) was developed to respond to the need of Chinese-speaking individuals. The DTS is a validated self-rating scale used in the diagnosis of posttraumatic stress disorder (PTSD). The DTS-C is translated from DTS through a two-stage translation. Subjects were drawn from a sample of 210 survivors of the 21 September 1999, Chi-Chi Earthquake. The scale showed good internal consistency (Cronbach's alpha = 0.97) and test-retest reliability (r = 0.88). Concurrent validity was obtained against the clinical diagnostic interview, with a diagnostic accuracy of 0.85 at DTS-C score of 44. It showed that the sensitivity was 0.9, specificity 0.81, positive likelihood ratio 4.74, and negative likelihood ratio 0.12. The recommended stratum-specific likelihood ratios were 0.10 (95% CI: 0.05-0.20) for the score range 0-39, 4 (2.22-7.23) for the score range of 40-59, and 6.14 (3.42-11.02) for the scores above 60. In PTSD diagnosed subjects, the factor structures closely resembled the DSM-IV grouping of PTSD symptoms. The psychometric strength of DTS-C is reliable for its future use, particularly for screening for subjects with possible diagnosis of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "bba18f5535f945b98b8a82421bcbe956", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[44, 44], [248, 248], [207, 207], [222, 222]], "char_spans": [[224, 227], [1200, 1203], [963, 966], [1051, 1054]]}]}], "context_tokens": [["The", 0], ["Chinese", 4], ["version", 12], ["of", 20], ["the", 23], ["Davidson", 27], ["Trauma", 36], ["Scale", 43], ["(", 49], ["DTS", 50], ["-", 53], ["C", 54], [")", 55], ["was", 57], ["developed", 61], ["to", 71], ["respond", 74], ["to", 82], ["the", 85], ["need", 89], ["of", 94], ["Chinese", 97], ["-", 104], ["speaking", 105], ["individuals", 114], [".", 125], ["The", 127], ["DTS", 131], ["is", 135], ["a", 138], ["validated", 140], ["self", 150], ["-", 154], ["rating", 155], ["scale", 162], ["used", 168], ["in", 173], ["the", 176], ["diagnosis", 180], ["of", 190], ["posttraumatic", 193], ["stress", 207], ["disorder", 214], ["(", 223], ["PTSD", 224], [")", 228], [".", 229], ["The", 231], ["DTS", 235], ["-", 238], ["C", 239], ["is", 241], ["translated", 244], ["from", 255], ["DTS", 260], ["through", 264], ["a", 272], ["two", 274], ["-", 277], ["stage", 278], ["translation", 284], [".", 295], ["Subjects", 297], ["were", 306], ["drawn", 311], ["from", 317], ["a", 322], ["sample", 324], ["of", 331], ["210", 334], ["survivors", 338], ["of", 348], ["the", 351], ["21", 355], ["September", 358], ["1999", 368], [",", 372], ["Chi", 374], ["-", 377], ["Chi", 378], ["Earthquake", 382], [".", 392], ["The", 394], ["scale", 398], ["showed", 404], ["good", 411], ["internal", 416], ["consistency", 425], ["(", 437], ["Cronbach", 438], ["'s", 446], ["alpha", 449], ["=", 455], ["0.97", 457], [")", 461], ["and", 463], ["test", 467], ["-", 471], ["retest", 472], ["reliability", 479], ["(", 491], ["r", 492], ["=", 494], ["0.88", 496], [")", 500], [".", 501], ["Concurrent", 503], ["validity", 514], ["was", 523], ["obtained", 527], ["against", 536], ["the", 544], ["clinical", 548], ["diagnostic", 557], ["interview", 568], [",", 577], ["with", 579], ["a", 584], ["diagnostic", 586], ["accuracy", 597], ["of", 606], ["0.85", 609], ["at", 614], ["DTS", 617], ["-", 620], ["C", 621], ["score", 623], ["of", 629], ["44", 632], [".", 634], ["It", 636], ["showed", 639], ["that", 646], ["the", 651], ["sensitivity", 655], ["was", 667], ["0.9", 671], [",", 674], ["specificity", 676], ["0.81", 688], [",", 692], ["positive", 694], ["likelihood", 703], ["ratio", 714], ["4.74", 720], [",", 724], ["and", 726], ["negative", 730], ["likelihood", 739], ["ratio", 750], ["0.12", 756], [".", 760], ["The", 762], ["recommended", 766], ["stratum", 778], ["-", 785], ["specific", 786], ["likelihood", 795], ["ratios", 806], ["were", 813], ["0.10", 818], ["(", 823], ["95", 824], ["%", 826], ["CI", 828], [":", 830], ["0.05", 832], ["-", 836], ["0.20", 837], [")", 841], ["for", 843], ["the", 847], ["score", 851], ["range", 857], ["0", 863], ["-", 864], ["39", 865], [",", 867], ["4", 869], ["(", 871], ["2.22", 872], ["-", 876], ["7.23", 877], [")", 881], ["for", 883], ["the", 887], ["score", 891], ["range", 897], ["of", 903], ["40", 906], ["-", 908], ["59", 909], [",", 911], ["and", 913], ["6.14", 917], ["(", 922], ["3.42", 923], ["-", 927], ["11.02", 928], [")", 933], ["for", 935], ["the", 939], ["scores", 943], ["above", 950], ["60", 956], [".", 958], ["In", 960], ["PTSD", 963], ["diagnosed", 968], ["subjects", 978], [",", 986], ["the", 988], ["factor", 992], ["structures", 999], ["closely", 1010], ["resembled", 1018], ["the", 1028], ["DSM", 1032], ["-", 1035], ["IV", 1036], ["grouping", 1039], ["of", 1048], ["PTSD", 1051], ["symptoms", 1056], [".", 1064], ["The", 1066], ["psychometric", 1070], ["strength", 1083], ["of", 1092], ["DTS", 1095], ["-", 1098], ["C", 1099], ["is", 1101], ["reliable", 1104], ["for", 1113], ["its", 1117], ["future", 1121], ["use", 1128], [",", 1131], ["particularly", 1133], ["for", 1146], ["screening", 1150], ["for", 1160], ["subjects", 1164], ["with", 1173], ["possible", 1178], ["diagnosis", 1187], ["of", 1197], ["PTSD", 1200], [".", 1204]]}
{"context": "Thirty-two female patients with clinical and urodynamic findings of genuine stress urinary incontinence were evaluated before and 6 months after surgery for stress urinary incontinence. Twenty-nine control patients had identical evaluations before and 6 months after surgery which did not involve the urethrovesical junction. Twenty-four patients with primary bladder instability had similar evaluations and served as a second control group. Anatomical landmarks indicating support to the urethrovesical junction were evaluated by the position of the urethra at the most dependent point in the bladder on straining and the urethral descent on straining to beneath the posterior ramus of the symphysis pubis on bead chain cystography. The urethrovesical junction drop on straining was evaluated by transrectal ultrasonography. Cystographic and ultrasonographic tests for the position of the urethrovesical junction at the most dependent position in the bladder during straining were very sensitive in women with stress urinary incontinence (94 and 87% respectively) but much less specific (45 and 48% respectively). When evaluating anatomical support to the urethrovesical junction and its descent on straining, these tests were both highly sensitive (97 and 94% respectively) and specific (76 and 96% respectively) in women with genuine stress urinary incontinence. Simple clinical tests for support of the urethrovesical junction, such as the Q tip test, are non-specific in patients with stress urinary incontinence. Transrectal ultrasonography is a simple and quick out-patient procedure. The availability of ultrasound equipment in most clinics and the high sensitivity and specificity of the test make it an attractive and cost-effective alternative to X-ray cystography in the pre-operative evaluation of anatomical support to the urethrovesical junction.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "7612f12628274b6dbdc14d2f9a22855f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[244, 246], [12, 14], [216, 218], [154, 156], [24, 26]], "char_spans": [[1490, 1516], [76, 102], [1337, 1363], [1011, 1037], [157, 183]]}]}], "context_tokens": [["Thirty", 0], ["-", 6], ["two", 7], ["female", 11], ["patients", 18], ["with", 27], ["clinical", 32], ["and", 41], ["urodynamic", 45], ["findings", 56], ["of", 65], ["genuine", 68], ["stress", 76], ["urinary", 83], ["incontinence", 91], ["were", 104], ["evaluated", 109], ["before", 119], ["and", 126], ["6", 130], ["months", 132], ["after", 139], ["surgery", 145], ["for", 153], ["stress", 157], ["urinary", 164], ["incontinence", 172], [".", 184], ["Twenty", 186], ["-", 192], ["nine", 193], ["control", 198], ["patients", 206], ["had", 215], ["identical", 219], ["evaluations", 229], ["before", 241], ["and", 248], ["6", 252], ["months", 254], ["after", 261], ["surgery", 267], ["which", 275], ["did", 281], ["not", 285], ["involve", 289], ["the", 297], ["urethrovesical", 301], ["junction", 316], [".", 324], ["Twenty", 326], ["-", 332], ["four", 333], ["patients", 338], ["with", 347], ["primary", 352], ["bladder", 360], ["instability", 368], ["had", 380], ["similar", 384], ["evaluations", 392], ["and", 404], ["served", 408], ["as", 415], ["a", 418], ["second", 420], ["control", 427], ["group", 435], [".", 440], ["Anatomical", 442], ["landmarks", 453], ["indicating", 463], ["support", 474], ["to", 482], ["the", 485], ["urethrovesical", 489], ["junction", 504], ["were", 513], ["evaluated", 518], ["by", 528], ["the", 531], ["position", 535], ["of", 544], ["the", 547], ["urethra", 551], ["at", 559], ["the", 562], ["most", 566], ["dependent", 571], ["point", 581], ["in", 587], ["the", 590], ["bladder", 594], ["on", 602], ["straining", 605], ["and", 615], ["the", 619], ["urethral", 623], ["descent", 632], ["on", 640], ["straining", 643], ["to", 653], ["beneath", 656], ["the", 664], ["posterior", 668], ["ramus", 678], ["of", 684], ["the", 687], ["symphysis", 691], ["pubis", 701], ["on", 707], ["bead", 710], ["chain", 715], ["cystography", 721], [".", 732], ["The", 734], ["urethrovesical", 738], ["junction", 753], ["drop", 762], ["on", 767], ["straining", 770], ["was", 780], ["evaluated", 784], ["by", 794], ["transrectal", 797], ["ultrasonography", 809], [".", 824], ["Cystographic", 826], ["and", 839], ["ultrasonographic", 843], ["tests", 860], ["for", 866], ["the", 870], ["position", 874], ["of", 883], ["the", 886], ["urethrovesical", 890], ["junction", 905], ["at", 914], ["the", 917], ["most", 921], ["dependent", 926], ["position", 936], ["in", 945], ["the", 948], ["bladder", 952], ["during", 960], ["straining", 967], ["were", 977], ["very", 982], ["sensitive", 987], ["in", 997], ["women", 1000], ["with", 1006], ["stress", 1011], ["urinary", 1018], ["incontinence", 1026], ["(", 1039], ["94", 1040], ["and", 1043], ["87", 1047], ["%", 1049], ["respectively", 1051], [")", 1063], ["but", 1065], ["much", 1069], ["less", 1074], ["specific", 1079], ["(", 1088], ["45", 1089], ["and", 1092], ["48", 1096], ["%", 1098], ["respectively", 1100], [")", 1112], [".", 1113], ["When", 1115], ["evaluating", 1120], ["anatomical", 1131], ["support", 1142], ["to", 1150], ["the", 1153], ["urethrovesical", 1157], ["junction", 1172], ["and", 1181], ["its", 1185], ["descent", 1189], ["on", 1197], ["straining", 1200], [",", 1209], ["these", 1211], ["tests", 1217], ["were", 1223], ["both", 1228], ["highly", 1233], ["sensitive", 1240], ["(", 1250], ["97", 1251], ["and", 1254], ["94", 1258], ["%", 1260], ["respectively", 1262], [")", 1274], ["and", 1276], ["specific", 1280], ["(", 1289], ["76", 1290], ["and", 1293], ["96", 1297], ["%", 1299], ["respectively", 1301], [")", 1313], ["in", 1315], ["women", 1318], ["with", 1324], ["genuine", 1329], ["stress", 1337], ["urinary", 1344], ["incontinence", 1352], [".", 1364], ["Simple", 1366], ["clinical", 1373], ["tests", 1382], ["for", 1388], ["support", 1392], ["of", 1400], ["the", 1403], ["urethrovesical", 1407], ["junction", 1422], [",", 1430], ["such", 1432], ["as", 1437], ["the", 1440], ["Q", 1444], ["tip", 1446], ["test", 1450], [",", 1454], ["are", 1456], ["non", 1460], ["-", 1463], ["specific", 1464], ["in", 1473], ["patients", 1476], ["with", 1485], ["stress", 1490], ["urinary", 1497], ["incontinence", 1505], [".", 1517], ["Transrectal", 1519], ["ultrasonography", 1531], ["is", 1547], ["a", 1550], ["simple", 1552], ["and", 1559], ["quick", 1563], ["out", 1569], ["-", 1572], ["patient", 1573], ["procedure", 1581], [".", 1590], ["The", 1592], ["availability", 1596], ["of", 1609], ["ultrasound", 1612], ["equipment", 1623], ["in", 1633], ["most", 1636], ["clinics", 1641], ["and", 1649], ["the", 1653], ["high", 1657], ["sensitivity", 1662], ["and", 1674], ["specificity", 1678], ["of", 1690], ["the", 1693], ["test", 1697], ["make", 1702], ["it", 1707], ["an", 1710], ["attractive", 1713], ["and", 1724], ["cost", 1728], ["-", 1732], ["effective", 1733], ["alternative", 1743], ["to", 1755], ["X", 1758], ["-", 1759], ["ray", 1760], ["cystography", 1764], ["in", 1776], ["the", 1779], ["pre", 1783], ["-", 1786], ["operative", 1787], ["evaluation", 1797], ["of", 1808], ["anatomical", 1811], ["support", 1822], ["to", 1830], ["the", 1833], ["urethrovesical", 1837], ["junction", 1852], [".", 1860]]}
{"context": "In a previous study, we reported that two kaempferol glycosides isolated from Laurus nobilis L., kaempferol-3-O-alpha-L-(2'',4''-di-E-p-coumaroyl)-rhamnoside (C2) and kaempferol-3-O-alpha-L-(2''-E-p-coumaroyl-4''-Z-p-coumaroyl)-rhamnoside (C3), showed strong antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. Thereafter we found that these compounds greatly reduced the minimum inhibitory concentrations (MICs) of some fluoroquinolones in MRSA. In other words, C2 and C3 greatly potentiated anti-MRSA activity of fluoroquinolones. The effect of C2 and C3 with fluoroquinolones was found to be synergistic. The potentiation activity was observed with hydrophilic fluoroquinolones, such as norfloxacin and ciprofloxacin, but not with hydrophobic quinolones. We also found that norfloxacin reduced MICs of C2 and C3. The effect was synergistic. Possible mechanism of the synergistic effect was discussed.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ae333a083631463086544ba27a982cf1", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[100, 100], [60, 60], [87, 87]], "char_spans": [[568, 571], [337, 340], [511, 514]]}]}], "context_tokens": [["In", 0], ["a", 3], ["previous", 5], ["study", 14], [",", 19], ["we", 21], ["reported", 24], ["that", 33], ["two", 38], ["kaempferol", 42], ["glycosides", 53], ["isolated", 64], ["from", 73], ["Laurus", 78], ["nobilis", 85], ["L.", 93], [",", 95], ["kaempferol-3-O", 97], ["-", 111], ["alpha", 112], ["-", 117], ["L-(2'',4''-di", 118], ["-", 131], ["E", 132], ["-", 133], ["p", 134], ["-", 135], ["coumaroyl)-rhamnoside", 136], ["(", 158], ["C2", 159], [")", 161], ["and", 163], ["kaempferol-3-O", 167], ["-", 181], ["alpha", 182], ["-", 187], ["L-(2''-E", 188], ["-", 196], ["p", 197], ["-", 198], ["coumaroyl-4''-Z", 199], ["-", 214], ["p", 215], ["-", 216], ["coumaroyl)-rhamnoside", 217], ["(", 239], ["C3", 240], [")", 242], [",", 243], ["showed", 245], ["strong", 252], ["antibacterial", 259], ["activities", 273], ["against", 284], ["methicillin", 292], ["-", 303], ["resistant", 304], ["Staphylococcus", 314], ["aureus", 329], ["(", 336], ["MRSA", 337], [")", 341], ["and", 343], ["vancomycin", 347], ["-", 357], ["resistant", 358], ["enterococci", 368], [".", 379], ["Thereafter", 381], ["we", 392], ["found", 395], ["that", 401], ["these", 406], ["compounds", 412], ["greatly", 422], ["reduced", 430], ["the", 438], ["minimum", 442], ["inhibitory", 450], ["concentrations", 461], ["(", 476], ["MICs", 477], [")", 481], ["of", 483], ["some", 486], ["fluoroquinolones", 491], ["in", 508], ["MRSA", 511], [".", 515], ["In", 517], ["other", 520], ["words", 526], [",", 531], ["C2", 533], ["and", 536], ["C3", 540], ["greatly", 543], ["potentiated", 551], ["anti", 563], ["-", 567], ["MRSA", 568], ["activity", 573], ["of", 582], ["fluoroquinolones", 585], [".", 601], ["The", 603], ["effect", 607], ["of", 614], ["C2", 617], ["and", 620], ["C3", 624], ["with", 627], ["fluoroquinolones", 632], ["was", 649], ["found", 653], ["to", 659], ["be", 662], ["synergistic", 665], [".", 676], ["The", 678], ["potentiation", 682], ["activity", 695], ["was", 704], ["observed", 708], ["with", 717], ["hydrophilic", 722], ["fluoroquinolones", 734], [",", 750], ["such", 752], ["as", 757], ["norfloxacin", 760], ["and", 772], ["ciprofloxacin", 776], [",", 789], ["but", 791], ["not", 795], ["with", 799], ["hydrophobic", 804], ["quinolones", 816], [".", 826], ["We", 828], ["also", 831], ["found", 836], ["that", 842], ["norfloxacin", 847], ["reduced", 859], ["MICs", 867], ["of", 872], ["C2", 875], ["and", 878], ["C3", 882], [".", 884], ["The", 886], ["effect", 890], ["was", 897], ["synergistic", 901], [".", 912], ["Possible", 914], ["mechanism", 923], ["of", 933], ["the", 936], ["synergistic", 940], ["effect", 952], ["was", 959], ["discussed", 963], [".", 972]]}
{"context": "Forkhead box protein P2 (FOXP2) is a well-studied gene known to play an essential role in normal speech development. Deletions in the gene have been shown to result in developmental speech disorders and regulatory disruption of downstream gene targets associated with common forms of language impairments. Despite similarities in motor planning and execution between speech development and oral feeding competence, there have been no reports to date linking deletions within the FOXP2 gene to oral feeding impairments in the newborn. The patient was a nondysmorphic, appropriately and symmetrically grown male infant born at 35-wk gestational age. He had a prolonged neonatal intensive care unit stay because of persistent oral feeding incoordination requiring gastrostomy tube placement. Cardiac and neurological imagings were within normal limits. A microarray analysis found an \u223c9-kb loss within chromosome band 7q3.1 that contains exon 2 of FOXP2, demonstrating a single copy of this region instead of the normal two copies per diploid gene. This case study expands our current understanding of the role FOXP2 exerts on motor planning and coordination necessary for both oral feeding success and speech-language development. This case report has important consequences for future diagnosis and treatment for infants with FOXP2 deletions, mutations, and varying levels of gene expression.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "ea3a586eb5514b869493f732e5740a1c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[5, 5], [213, 213], [180, 180], [151, 151], [78, 78]], "char_spans": [[25, 29], [1325, 1329], [1108, 1112], [945, 949], [479, 483]]}]}], "context_tokens": [["Forkhead", 0], ["box", 9], ["protein", 13], ["P2", 21], ["(", 24], ["FOXP2", 25], [")", 30], ["is", 32], ["a", 35], ["well", 37], ["-", 41], ["studied", 42], ["gene", 50], ["known", 55], ["to", 61], ["play", 64], ["an", 69], ["essential", 72], ["role", 82], ["in", 87], ["normal", 90], ["speech", 97], ["development", 104], [".", 115], ["Deletions", 117], ["in", 127], ["the", 130], ["gene", 134], ["have", 139], ["been", 144], ["shown", 149], ["to", 155], ["result", 158], ["in", 165], ["developmental", 168], ["speech", 182], ["disorders", 189], ["and", 199], ["regulatory", 203], ["disruption", 214], ["of", 225], ["downstream", 228], ["gene", 239], ["targets", 244], ["associated", 252], ["with", 263], ["common", 268], ["forms", 275], ["of", 281], ["language", 284], ["impairments", 293], [".", 304], ["Despite", 306], ["similarities", 314], ["in", 327], ["motor", 330], ["planning", 336], ["and", 345], ["execution", 349], ["between", 359], ["speech", 367], ["development", 374], ["and", 386], ["oral", 390], ["feeding", 395], ["competence", 403], [",", 413], ["there", 415], ["have", 421], ["been", 426], ["no", 431], ["reports", 434], ["to", 442], ["date", 445], ["linking", 450], ["deletions", 458], ["within", 468], ["the", 475], ["FOXP2", 479], ["gene", 485], ["to", 490], ["oral", 493], ["feeding", 498], ["impairments", 506], ["in", 518], ["the", 521], ["newborn", 525], [".", 532], ["The", 534], ["patient", 538], ["was", 546], ["a", 550], ["nondysmorphic", 552], [",", 565], ["appropriately", 567], ["and", 581], ["symmetrically", 585], ["grown", 599], ["male", 605], ["infant", 610], ["born", 617], ["at", 622], ["35-wk", 625], ["gestational", 631], ["age", 643], [".", 646], ["He", 648], ["had", 651], ["a", 655], ["prolonged", 657], ["neonatal", 667], ["intensive", 676], ["care", 686], ["unit", 691], ["stay", 696], ["because", 701], ["of", 709], ["persistent", 712], ["oral", 723], ["feeding", 728], ["incoordination", 736], ["requiring", 751], ["gastrostomy", 761], ["tube", 773], ["placement", 778], [".", 787], ["Cardiac", 789], ["and", 797], ["neurological", 801], ["imagings", 814], ["were", 823], ["within", 828], ["normal", 835], ["limits", 842], [".", 848], ["A", 850], ["microarray", 852], ["analysis", 863], ["found", 872], ["an", 878], ["\u223c9-kb", 881], ["loss", 887], ["within", 892], ["chromosome", 899], ["band", 910], ["7q3.1", 915], ["that", 921], ["contains", 926], ["exon", 935], ["2", 940], ["of", 942], ["FOXP2", 945], [",", 950], ["demonstrating", 952], ["a", 966], ["single", 968], ["copy", 975], ["of", 980], ["this", 983], ["region", 988], ["instead", 995], ["of", 1003], ["the", 1006], ["normal", 1010], ["two", 1017], ["copies", 1021], ["per", 1028], ["diploid", 1032], ["gene", 1040], [".", 1044], ["This", 1046], ["case", 1051], ["study", 1056], ["expands", 1062], ["our", 1070], ["current", 1074], ["understanding", 1082], ["of", 1096], ["the", 1099], ["role", 1103], ["FOXP2", 1108], ["exerts", 1114], ["on", 1121], ["motor", 1124], ["planning", 1130], ["and", 1139], ["coordination", 1143], ["necessary", 1156], ["for", 1166], ["both", 1170], ["oral", 1175], ["feeding", 1180], ["success", 1188], ["and", 1196], ["speech", 1200], ["-", 1206], ["language", 1207], ["development", 1216], [".", 1227], ["This", 1229], ["case", 1234], ["report", 1239], ["has", 1246], ["important", 1250], ["consequences", 1260], ["for", 1273], ["future", 1277], ["diagnosis", 1284], ["and", 1294], ["treatment", 1298], ["for", 1308], ["infants", 1312], ["with", 1320], ["FOXP2", 1325], ["deletions", 1331], [",", 1340], ["mutations", 1342], [",", 1351], ["and", 1353], ["varying", 1357], ["levels", 1365], ["of", 1372], ["gene", 1375], ["expression", 1380], [".", 1390]]}
{"context": "Bone, as well as the lung and liver, is among the sites of predilection for cancer metastasis. The bone stores large amounts of growth factors such as insulin-like growth factors and transforming growth factor-b, and provides fertile soil for metastatic cancer cells by continuously releasing these bone-stored growth factors, which are a consequence of osteoclastic bone resorption. Metastatic cancer cells in turn produce osteoclast-stimulating cytokines such as parathyroid hormone-related protein( PTH-rP), prostaglandin E2.(PGE2), and various interleukins(ILs). These cancer-produced osteoclast-stimulating cytokines bind to their cognitive receptors and promote the expression of ligands for the receptor activators of nuclear factor kB (RANKL)in osteoblasts. RANKL then binds to its receptor RANK, expressed in pre-osteoclasts, stimulates mature osteoclast formation, and subsequently, osteoclastic bone resorption. This vicious cycle between metastatic cancer cells and osteoclasts is critical to the development and progression of bone metastases. In addition, it is likely that metastatic cancer cells are influenced by bone environments(or niche)and acquire additional capacities such as an epithelial-mesenchymal transition(EMT), allowing them to be resistant to chemotherapy or apoptosis, to survive in a dormant state, or to aggressively spread to distant organs including lung and liver. Thus, the bone can serve as transit port. Disrupting this cycle by inhibiting osteoclastic bone resorption, antagonizing bone-derived growth factors, and neutralizing RANKL or PTH-rP, should be a promising therapeutic intervention for bone metastases. Bisphosphonates(BP)are specific inhibitors of osteoclasts, and have been shown to significantly reduce skeletal-related events(SRE)associated with bone metastasis. Denosumab is a neutralizing monoclonal antibody to RANKL and has recently been found to inhibit SRE more effectively than BP. Further understanding of the crosstalk communication between metastatic cancer cells and bone at the molecular level should lead us to design novel, more effective and specific treatments for cancer patients with bone metastases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "e21623a21a1a48faa65c48b080cfc7fe", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[132, 132], [263, 263], [307, 307]], "char_spans": [[766, 770], [1570, 1574], [1870, 1874]]}]}], "context_tokens": [["Bone", 0], [",", 4], ["as", 6], ["well", 9], ["as", 14], ["the", 17], ["lung", 21], ["and", 26], ["liver", 30], [",", 35], ["is", 37], ["among", 40], ["the", 46], ["sites", 50], ["of", 56], ["predilection", 59], ["for", 72], ["cancer", 76], ["metastasis", 83], [".", 93], ["The", 95], ["bone", 99], ["stores", 104], ["large", 111], ["amounts", 117], ["of", 125], ["growth", 128], ["factors", 135], ["such", 143], ["as", 148], ["insulin", 151], ["-", 158], ["like", 159], ["growth", 164], ["factors", 171], ["and", 179], ["transforming", 183], ["growth", 196], ["factor", 203], ["-", 209], ["b", 210], [",", 211], ["and", 213], ["provides", 217], ["fertile", 226], ["soil", 234], ["for", 239], ["metastatic", 243], ["cancer", 254], ["cells", 261], ["by", 267], ["continuously", 270], ["releasing", 283], ["these", 293], ["bone", 299], ["-", 303], ["stored", 304], ["growth", 311], ["factors", 318], [",", 325], ["which", 327], ["are", 333], ["a", 337], ["consequence", 339], ["of", 351], ["osteoclastic", 354], ["bone", 367], ["resorption", 372], [".", 382], ["Metastatic", 384], ["cancer", 395], ["cells", 402], ["in", 408], ["turn", 411], ["produce", 416], ["osteoclast", 424], ["-", 434], ["stimulating", 435], ["cytokines", 447], ["such", 457], ["as", 462], ["parathyroid", 465], ["hormone", 477], ["-", 484], ["related", 485], ["protein", 493], ["(", 500], ["PTH", 502], ["-", 505], ["rP", 506], [")", 508], [",", 509], ["prostaglandin", 511], ["E2.(PGE2", 525], [")", 533], [",", 534], ["and", 536], ["various", 540], ["interleukins(ILs", 548], [")", 564], [".", 565], ["These", 567], ["cancer", 573], ["-", 579], ["produced", 580], ["osteoclast", 589], ["-", 599], ["stimulating", 600], ["cytokines", 612], ["bind", 622], ["to", 627], ["their", 630], ["cognitive", 636], ["receptors", 646], ["and", 656], ["promote", 660], ["the", 668], ["expression", 672], ["of", 683], ["ligands", 686], ["for", 694], ["the", 698], ["receptor", 702], ["activators", 711], ["of", 722], ["nuclear", 725], ["factor", 733], ["kB", 740], ["(", 743], ["RANKL)in", 744], ["osteoblasts", 753], [".", 764], ["RANKL", 766], ["then", 772], ["binds", 777], ["to", 783], ["its", 786], ["receptor", 790], ["RANK", 799], [",", 803], ["expressed", 805], ["in", 815], ["pre", 818], ["-", 821], ["osteoclasts", 822], [",", 833], ["stimulates", 835], ["mature", 846], ["osteoclast", 853], ["formation", 864], [",", 873], ["and", 875], ["subsequently", 879], [",", 891], ["osteoclastic", 893], ["bone", 906], ["resorption", 911], [".", 921], ["This", 923], ["vicious", 928], ["cycle", 936], ["between", 942], ["metastatic", 950], ["cancer", 961], ["cells", 968], ["and", 974], ["osteoclasts", 978], ["is", 990], ["critical", 993], ["to", 1002], ["the", 1005], ["development", 1009], ["and", 1021], ["progression", 1025], ["of", 1037], ["bone", 1040], ["metastases", 1045], [".", 1055], ["In", 1057], ["addition", 1060], [",", 1068], ["it", 1070], ["is", 1073], ["likely", 1076], ["that", 1083], ["metastatic", 1088], ["cancer", 1099], ["cells", 1106], ["are", 1112], ["influenced", 1116], ["by", 1127], ["bone", 1130], ["environments(or", 1135], ["niche)and", 1151], ["acquire", 1161], ["additional", 1169], ["capacities", 1180], ["such", 1191], ["as", 1196], ["an", 1199], ["epithelial", 1202], ["-", 1212], ["mesenchymal", 1213], ["transition(EMT", 1225], [")", 1239], [",", 1240], ["allowing", 1242], ["them", 1251], ["to", 1256], ["be", 1259], ["resistant", 1262], ["to", 1272], ["chemotherapy", 1275], ["or", 1288], ["apoptosis", 1291], [",", 1300], ["to", 1302], ["survive", 1305], ["in", 1313], ["a", 1316], ["dormant", 1318], ["state", 1326], [",", 1331], ["or", 1333], ["to", 1336], ["aggressively", 1339], ["spread", 1352], ["to", 1359], ["distant", 1362], ["organs", 1370], ["including", 1377], ["lung", 1387], ["and", 1392], ["liver", 1396], [".", 1401], ["Thus", 1403], [",", 1407], ["the", 1409], ["bone", 1413], ["can", 1418], ["serve", 1422], ["as", 1428], ["transit", 1431], ["port", 1439], [".", 1443], ["Disrupting", 1445], ["this", 1456], ["cycle", 1461], ["by", 1467], ["inhibiting", 1470], ["osteoclastic", 1481], ["bone", 1494], ["resorption", 1499], [",", 1509], ["antagonizing", 1511], ["bone", 1524], ["-", 1528], ["derived", 1529], ["growth", 1537], ["factors", 1544], [",", 1551], ["and", 1553], ["neutralizing", 1557], ["RANKL", 1570], ["or", 1576], ["PTH", 1579], ["-", 1582], ["rP", 1583], [",", 1585], ["should", 1587], ["be", 1594], ["a", 1597], ["promising", 1599], ["therapeutic", 1609], ["intervention", 1621], ["for", 1634], ["bone", 1638], ["metastases", 1643], [".", 1653], ["Bisphosphonates(BP)are", 1655], ["specific", 1678], ["inhibitors", 1687], ["of", 1698], ["osteoclasts", 1701], [",", 1712], ["and", 1714], ["have", 1718], ["been", 1723], ["shown", 1728], ["to", 1734], ["significantly", 1737], ["reduce", 1751], ["skeletal", 1758], ["-", 1766], ["related", 1767], ["events(SRE)associated", 1775], ["with", 1797], ["bone", 1802], ["metastasis", 1807], [".", 1817], ["Denosumab", 1819], ["is", 1829], ["a", 1832], ["neutralizing", 1834], ["monoclonal", 1847], ["antibody", 1858], ["to", 1867], ["RANKL", 1870], ["and", 1876], ["has", 1880], ["recently", 1884], ["been", 1893], ["found", 1898], ["to", 1904], ["inhibit", 1907], ["SRE", 1915], ["more", 1919], ["effectively", 1924], ["than", 1936], ["BP", 1941], [".", 1943], ["Further", 1945], ["understanding", 1953], ["of", 1967], ["the", 1970], ["crosstalk", 1974], ["communication", 1984], ["between", 1998], ["metastatic", 2006], ["cancer", 2017], ["cells", 2024], ["and", 2030], ["bone", 2034], ["at", 2039], ["the", 2042], ["molecular", 2046], ["level", 2056], ["should", 2062], ["lead", 2069], ["us", 2074], ["to", 2077], ["design", 2080], ["novel", 2087], [",", 2092], ["more", 2094], ["effective", 2099], ["and", 2109], ["specific", 2113], ["treatments", 2122], ["for", 2133], ["cancer", 2137], ["patients", 2144], ["with", 2153], ["bone", 2158], ["metastases", 2163], [".", 2173]]}
{"context": "Proadrenomedullin (ProADM) confers additional prognostic information to established clinical risk scores in lower respiratory tract infections (LRTI). We aimed to derive a practical algorithm combining the CURB65 score with ProADM-levels in patients with community-acquired pneumonia (CAP) and non-CAP-LRTI. We used data of 1359 patients with LRTI enrolled in a multicenter study. We chose two ProADM cut-off values by assessing the association between ProADM levels and the risk of adverse events and mortality. A composite score (CURB65-A) was created combining CURB65 classes with ProADM cut-offs to further risk-stratify patients. CURB65 and ProADM predicted both adverse events and mortality similarly well in CAP and non-CAP-LRTI. The combined CURB65-A risk score provided better prediction of death and adverse events than the CURB65 score in the entire cohort and in CAP and non-CAP-LRTI patients. Within each CURB65 class, higher ProADM-levels were associated with an increased risk of adverse events and mortality. Overall, risk of adverse events (3.9%) and mortality (0.65%) was low for patients with CURB65 score 0-1 and ProADM \u22640.75 nmol/l (CURB65-A risk class I); intermediate (8.6% and 2.6%, respectively) for patients with CURB65 score of 2 and ProADM \u22641.5 nmol/l or CURB classes 0-1 and ProADM levels between 0.75-1.5 nmol/L (CURB65-A risk class II), and high (21.6% and 9.8%, respectively) for all other patients (CURB65-A risk class III). If outpatient treatment was recommended for CURB65-A risk class I and short hospitalization for CURB65-A risk class II, 17.9% and 40.8% of 1217 hospitalized patients could have received ambulatory treatment or a short hospitalization, respectively. The new CURB65-A risk score combining CURB65 risk classes with ProADM cut-off values accurately predicts adverse events and mortality in patients with CAP and non-CAP-LRTI. Additional prospective cohort or intervention studies need to validate this score and demonstrate its safety and efficacy for the management of patients with LRTI. Procalcitonin-guided antibiotic therapy and hospitalisation in patients with lower respiratory tract infections: the prohosp study; isrctn.org Identifier: ISRCTN: ISRCTN95122877.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "91d802a8576d4cdd95d43becdb1ecd56", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[43, 43]], "char_spans": [[274, 282]]}]}], "context_tokens": [["Proadrenomedullin", 0], ["(", 18], ["ProADM", 19], [")", 25], ["confers", 27], ["additional", 35], ["prognostic", 46], ["information", 57], ["to", 69], ["established", 72], ["clinical", 84], ["risk", 93], ["scores", 98], ["in", 105], ["lower", 108], ["respiratory", 114], ["tract", 126], ["infections", 132], ["(", 143], ["LRTI", 144], [")", 148], [".", 149], ["We", 151], ["aimed", 154], ["to", 160], ["derive", 163], ["a", 170], ["practical", 172], ["algorithm", 182], ["combining", 192], ["the", 202], ["CURB65", 206], ["score", 213], ["with", 219], ["ProADM", 224], ["-", 230], ["levels", 231], ["in", 238], ["patients", 241], ["with", 250], ["community", 255], ["-", 264], ["acquired", 265], ["pneumonia", 274], ["(", 284], ["CAP", 285], [")", 288], ["and", 290], ["non", 294], ["-", 297], ["CAP", 298], ["-", 301], ["LRTI", 302], [".", 306], ["We", 308], ["used", 311], ["data", 316], ["of", 321], ["1359", 324], ["patients", 329], ["with", 338], ["LRTI", 343], ["enrolled", 348], ["in", 357], ["a", 360], ["multicenter", 362], ["study", 374], [".", 379], ["We", 381], ["chose", 384], ["two", 390], ["ProADM", 394], ["cut", 401], ["-", 404], ["off", 405], ["values", 409], ["by", 416], ["assessing", 419], ["the", 429], ["association", 433], ["between", 445], ["ProADM", 453], ["levels", 460], ["and", 467], ["the", 471], ["risk", 475], ["of", 480], ["adverse", 483], ["events", 491], ["and", 498], ["mortality", 502], [".", 511], ["A", 513], ["composite", 515], ["score", 525], ["(", 531], ["CURB65-A", 532], [")", 540], ["was", 542], ["created", 546], ["combining", 554], ["CURB65", 564], ["classes", 571], ["with", 579], ["ProADM", 584], ["cut", 591], ["-", 594], ["offs", 595], ["to", 600], ["further", 603], ["risk", 611], ["-", 615], ["stratify", 616], ["patients", 625], [".", 633], ["CURB65", 635], ["and", 642], ["ProADM", 646], ["predicted", 653], ["both", 663], ["adverse", 668], ["events", 676], ["and", 683], ["mortality", 687], ["similarly", 697], ["well", 707], ["in", 712], ["CAP", 715], ["and", 719], ["non", 723], ["-", 726], ["CAP", 727], ["-", 730], ["LRTI", 731], [".", 735], ["The", 737], ["combined", 741], ["CURB65-A", 750], ["risk", 759], ["score", 764], ["provided", 770], ["better", 779], ["prediction", 786], ["of", 797], ["death", 800], ["and", 806], ["adverse", 810], ["events", 818], ["than", 825], ["the", 830], ["CURB65", 834], ["score", 841], ["in", 847], ["the", 850], ["entire", 854], ["cohort", 861], ["and", 868], ["in", 872], ["CAP", 875], ["and", 879], ["non", 883], ["-", 886], ["CAP", 887], ["-", 890], ["LRTI", 891], ["patients", 896], [".", 904], ["Within", 906], ["each", 913], ["CURB65", 918], ["class", 925], [",", 930], ["higher", 932], ["ProADM", 939], ["-", 945], ["levels", 946], ["were", 953], ["associated", 958], ["with", 969], ["an", 974], ["increased", 977], ["risk", 987], ["of", 992], ["adverse", 995], ["events", 1003], ["and", 1010], ["mortality", 1014], [".", 1023], ["Overall", 1025], [",", 1032], ["risk", 1034], ["of", 1039], ["adverse", 1042], ["events", 1050], ["(", 1057], ["3.9", 1058], ["%", 1061], [")", 1062], ["and", 1064], ["mortality", 1068], ["(", 1078], ["0.65", 1079], ["%", 1083], [")", 1084], ["was", 1086], ["low", 1090], ["for", 1094], ["patients", 1098], ["with", 1107], ["CURB65", 1112], ["score", 1119], ["0", 1125], ["-", 1126], ["1", 1127], ["and", 1129], ["ProADM", 1133], ["\u22640.75", 1140], ["nmol", 1146], ["/", 1150], ["l", 1151], ["(", 1153], ["CURB65-A", 1154], ["risk", 1163], ["class", 1168], ["I", 1174], [")", 1175], [";", 1176], ["intermediate", 1178], ["(", 1191], ["8.6", 1192], ["%", 1195], ["and", 1197], ["2.6", 1201], ["%", 1204], [",", 1205], ["respectively", 1207], [")", 1219], ["for", 1221], ["patients", 1225], ["with", 1234], ["CURB65", 1239], ["score", 1246], ["of", 1252], ["2", 1255], ["and", 1257], ["ProADM", 1261], ["\u22641.5", 1268], ["nmol", 1273], ["/", 1277], ["l", 1278], ["or", 1280], ["CURB", 1283], ["classes", 1288], ["0", 1296], ["-", 1297], ["1", 1298], ["and", 1300], ["ProADM", 1304], ["levels", 1311], ["between", 1318], ["0.75", 1326], ["-", 1330], ["1.5", 1331], ["nmol", 1335], ["/", 1339], ["L", 1340], ["(", 1342], ["CURB65-A", 1343], ["risk", 1352], ["class", 1357], ["II", 1363], [")", 1365], [",", 1366], ["and", 1368], ["high", 1372], ["(", 1377], ["21.6", 1378], ["%", 1382], ["and", 1384], ["9.8", 1388], ["%", 1391], [",", 1392], ["respectively", 1394], [")", 1406], ["for", 1408], ["all", 1412], ["other", 1416], ["patients", 1422], ["(", 1431], ["CURB65-A", 1432], ["risk", 1441], ["class", 1446], ["III", 1452], [")", 1455], [".", 1456], ["If", 1458], ["outpatient", 1461], ["treatment", 1472], ["was", 1482], ["recommended", 1486], ["for", 1498], ["CURB65-A", 1502], ["risk", 1511], ["class", 1516], ["I", 1522], ["and", 1524], ["short", 1528], ["hospitalization", 1534], ["for", 1550], ["CURB65-A", 1554], ["risk", 1563], ["class", 1568], ["II", 1574], [",", 1576], ["17.9", 1578], ["%", 1582], ["and", 1584], ["40.8", 1588], ["%", 1592], ["of", 1594], ["1217", 1597], ["hospitalized", 1602], ["patients", 1615], ["could", 1624], ["have", 1630], ["received", 1635], ["ambulatory", 1644], ["treatment", 1655], ["or", 1665], ["a", 1668], ["short", 1670], ["hospitalization", 1676], [",", 1691], ["respectively", 1693], [".", 1705], ["The", 1707], ["new", 1711], ["CURB65-A", 1715], ["risk", 1724], ["score", 1729], ["combining", 1735], ["CURB65", 1745], ["risk", 1752], ["classes", 1757], ["with", 1765], ["ProADM", 1770], ["cut", 1777], ["-", 1780], ["off", 1781], ["values", 1785], ["accurately", 1792], ["predicts", 1803], ["adverse", 1812], ["events", 1820], ["and", 1827], ["mortality", 1831], ["in", 1841], ["patients", 1844], ["with", 1853], ["CAP", 1858], ["and", 1862], ["non", 1866], ["-", 1869], ["CAP", 1870], ["-", 1873], ["LRTI", 1874], [".", 1878], ["Additional", 1880], ["prospective", 1891], ["cohort", 1903], ["or", 1910], ["intervention", 1913], ["studies", 1926], ["need", 1934], ["to", 1939], ["validate", 1942], ["this", 1951], ["score", 1956], ["and", 1962], ["demonstrate", 1966], ["its", 1978], ["safety", 1982], ["and", 1989], ["efficacy", 1993], ["for", 2002], ["the", 2006], ["management", 2010], ["of", 2021], ["patients", 2024], ["with", 2033], ["LRTI", 2038], [".", 2042], ["Procalcitonin", 2044], ["-", 2057], ["guided", 2058], ["antibiotic", 2065], ["therapy", 2076], ["and", 2084], ["hospitalisation", 2088], ["in", 2104], ["patients", 2107], ["with", 2116], ["lower", 2121], ["respiratory", 2127], ["tract", 2139], ["infections", 2145], [":", 2155], ["the", 2157], ["prohosp", 2161], ["study", 2169], [";", 2174], ["isrctn.org", 2176], ["Identifier", 2187], [":", 2197], ["ISRCTN", 2199], [":", 2205], ["ISRCTN95122877", 2207], [".", 2221]]}
{"context": "Parkinson's disease is the most common neurodegenerative movement disorder. The motor impairments of Parkinson's disease are caused by the loss of dopaminergic neurons in the substantia nigra and associated with the appearance of fibrillar aggregates of \u03b1-synuclein (\u03b1-syn) called Lewy bodies. Approximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain. This suggests that the accumulation of Ser129-phosphorylated \u03b1-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's disease. Our laboratory and others have performed experiments using in vivo models of Parkinson's disease to elucidate the role of increased Ser129 phosphorylation in \u03b1-syn neurotoxicity. However, there has been a lack of consistency among these models. In this review, we summarize the main findings regarding the relationship between Ser129 phosphorylation and \u03b1-syn neurotoxicity, and examine the differences among models. We further discuss the role of Ser129 phosphorylation in \u03b1-syn aggregation and the future directions to test the potential of Ser129 phosphorylation as a therapeutic target for slowing the progression of Parkinson's disease.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "19423394bc5f47e9b3ab1ee3b8cca638", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[65, 66]], "char_spans": [[367, 376]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["is", 20], ["the", 23], ["most", 27], ["common", 32], ["neurodegenerative", 39], ["movement", 57], ["disorder", 66], [".", 74], ["The", 76], ["motor", 80], ["impairments", 86], ["of", 98], ["Parkinson", 101], ["'s", 110], ["disease", 113], ["are", 121], ["caused", 125], ["by", 132], ["the", 135], ["loss", 139], ["of", 144], ["dopaminergic", 147], ["neurons", 160], ["in", 168], ["the", 171], ["substantia", 175], ["nigra", 186], ["and", 192], ["associated", 196], ["with", 207], ["the", 212], ["appearance", 216], ["of", 227], ["fibrillar", 230], ["aggregates", 240], ["of", 251], ["\u03b1", 254], ["-", 255], ["synuclein", 256], ["(", 266], ["\u03b1", 267], ["-", 268], ["syn", 269], [")", 272], ["called", 274], ["Lewy", 281], ["bodies", 286], [".", 292], ["Approximately", 294], ["90", 308], ["%", 310], ["of", 312], ["\u03b1", 315], ["-", 316], ["syn", 317], ["deposited", 321], ["in", 331], ["Lewy", 334], ["bodies", 339], ["is", 346], ["phosphorylated", 349], ["at", 364], ["serine", 367], ["129", 374], ["(", 378], ["Ser129", 379], [")", 385], [".", 386], ["In", 388], ["contrast", 391], [",", 399], ["only", 401], ["4", 406], ["%", 407], ["or", 409], ["less", 412], ["of", 417], ["total", 420], ["\u03b1", 426], ["-", 427], ["syn", 428], ["is", 432], ["phosphorylated", 435], ["at", 450], ["this", 453], ["residue", 458], ["in", 466], ["the", 469], ["normal", 473], ["brain", 480], [".", 485], ["This", 487], ["suggests", 492], ["that", 501], ["the", 506], ["accumulation", 510], ["of", 523], ["Ser129-phosphorylated", 526], ["\u03b1", 548], ["-", 549], ["syn", 550], ["leads", 554], ["to", 560], ["the", 563], ["formation", 567], ["of", 577], ["Lewy", 580], ["bodies", 585], ["and", 592], ["dopaminergic", 596], ["neurodegeneration", 609], ["in", 627], ["Parkinson", 630], ["'s", 639], ["disease", 642], [".", 649], ["Our", 651], ["laboratory", 655], ["and", 666], ["others", 670], ["have", 677], ["performed", 682], ["experiments", 692], ["using", 704], ["in", 710], ["vivo", 713], ["models", 718], ["of", 725], ["Parkinson", 728], ["'s", 737], ["disease", 740], ["to", 748], ["elucidate", 751], ["the", 761], ["role", 765], ["of", 770], ["increased", 773], ["Ser129", 783], ["phosphorylation", 790], ["in", 806], ["\u03b1", 809], ["-", 810], ["syn", 811], ["neurotoxicity", 815], [".", 828], ["However", 830], [",", 837], ["there", 839], ["has", 845], ["been", 849], ["a", 854], ["lack", 856], ["of", 861], ["consistency", 864], ["among", 876], ["these", 882], ["models", 888], [".", 894], ["In", 896], ["this", 899], ["review", 904], [",", 910], ["we", 912], ["summarize", 915], ["the", 925], ["main", 929], ["findings", 934], ["regarding", 943], ["the", 953], ["relationship", 957], ["between", 970], ["Ser129", 978], ["phosphorylation", 985], ["and", 1001], ["\u03b1", 1005], ["-", 1006], ["syn", 1007], ["neurotoxicity", 1011], [",", 1024], ["and", 1026], ["examine", 1030], ["the", 1038], ["differences", 1042], ["among", 1054], ["models", 1060], [".", 1066], ["We", 1068], ["further", 1071], ["discuss", 1079], ["the", 1087], ["role", 1091], ["of", 1096], ["Ser129", 1099], ["phosphorylation", 1106], ["in", 1122], ["\u03b1", 1125], ["-", 1126], ["syn", 1127], ["aggregation", 1131], ["and", 1143], ["the", 1147], ["future", 1151], ["directions", 1158], ["to", 1169], ["test", 1172], ["the", 1177], ["potential", 1181], ["of", 1191], ["Ser129", 1194], ["phosphorylation", 1201], ["as", 1217], ["a", 1220], ["therapeutic", 1222], ["target", 1234], ["for", 1241], ["slowing", 1245], ["the", 1253], ["progression", 1257], ["of", 1269], ["Parkinson", 1272], ["'s", 1281], ["disease", 1284], [".", 1291]]}
{"context": "To determine whether naloxone administered i.v. to out-of-hospital patients with suspected opioid overdose would have a more rapid therapeutic onset than naloxone given subcutaneously (s.q.). A prospective, sequential, observational cohort study of 196 consecutive patients with suspected opioid overdose was conducted in an urban out-of-hospital setting, comparing time intervals from arrival at the patient's side to development of a respiratory rate > or =10 breaths/min, and durations of bag-valve-mask ventilation. Subjects received either naloxone 0.4 mg i.v. (n = 74) or naloxone 0.8 mg s.q. (n = 122), for respiratory depression of <10 breaths/min. Mean interval from crew arrival to respiratory rate > or =10 breaths/min was 9.3 +/- 4.2 min for the i.v. group vs 9.6 +/- 4.58 min for the s.q. group (95% CI of the difference -1.55, 1.00). Mean duration of bag-valve-mask ventilation was 8.1 +/- 6.0 min for the i.v. group vs 9.1 +/- 4.8 min for the s.q. group. Cost of materials for administering naloxone 0.4 mg i.v. was $12.30/patient, compared with $10.70/patient for naloxone 0.8 mg s.q. There was no clinical difference in the time interval to respiratory rate > or =10 breaths/min between naloxone 0.8 mg s.q. and naloxone 0.4 mg i.v. for the out-of-hospital management of patients with suspected opioid overdose. The slower rate of absorption via the s.q. route was offset by the delay in establishing an i.v.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "00d9954d30b64647a55f59618756c1ce", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[256, 256], [99, 99], [3, 3], [26, 26], [262, 262], [217, 217], [231, 231], [110, 110]], "char_spans": [[1204, 1211], [545, 552], [21, 28], [154, 161], [1229, 1236], [1006, 1013], [1080, 1087], [578, 585]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["whether", 13], ["naloxone", 21], ["administered", 30], ["i.v", 43], [".", 46], ["to", 48], ["out", 51], ["-", 54], ["of", 55], ["-", 57], ["hospital", 58], ["patients", 67], ["with", 76], ["suspected", 81], ["opioid", 91], ["overdose", 98], ["would", 107], ["have", 113], ["a", 118], ["more", 120], ["rapid", 125], ["therapeutic", 131], ["onset", 143], ["than", 149], ["naloxone", 154], ["given", 163], ["subcutaneously", 169], ["(", 184], ["s.q", 185], [".", 188], [")", 189], [".", 190], ["A", 192], ["prospective", 194], [",", 205], ["sequential", 207], [",", 217], ["observational", 219], ["cohort", 233], ["study", 240], ["of", 246], ["196", 249], ["consecutive", 253], ["patients", 265], ["with", 274], ["suspected", 279], ["opioid", 289], ["overdose", 296], ["was", 305], ["conducted", 309], ["in", 319], ["an", 322], ["urban", 325], ["out", 331], ["-", 334], ["of", 335], ["-", 337], ["hospital", 338], ["setting", 347], [",", 354], ["comparing", 356], ["time", 366], ["intervals", 371], ["from", 381], ["arrival", 386], ["at", 394], ["the", 397], ["patient", 401], ["'s", 408], ["side", 411], ["to", 416], ["development", 419], ["of", 431], ["a", 434], ["respiratory", 436], ["rate", 448], [">", 453], ["or", 455], ["=", 458], ["10", 459], ["breaths", 462], ["/", 469], ["min", 470], [",", 473], ["and", 475], ["durations", 479], ["of", 489], ["bag", 492], ["-", 495], ["valve", 496], ["-", 501], ["mask", 502], ["ventilation", 507], [".", 518], ["Subjects", 520], ["received", 529], ["either", 538], ["naloxone", 545], ["0.4", 554], ["mg", 558], ["i.v", 561], [".", 564], ["(", 566], ["n", 567], ["=", 569], ["74", 571], [")", 573], ["or", 575], ["naloxone", 578], ["0.8", 587], ["mg", 591], ["s.q", 594], [".", 597], ["(", 599], ["n", 600], ["=", 602], ["122", 604], [")", 607], [",", 608], ["for", 610], ["respiratory", 614], ["depression", 626], ["of", 637], ["<", 640], ["10", 641], ["breaths", 644], ["/", 651], ["min", 652], [".", 655], ["Mean", 657], ["interval", 662], ["from", 671], ["crew", 676], ["arrival", 681], ["to", 689], ["respiratory", 692], ["rate", 704], [">", 709], ["or", 711], ["=", 714], ["10", 715], ["breaths", 718], ["/", 725], ["min", 726], ["was", 730], ["9.3", 734], ["+", 738], ["/-", 739], ["4.2", 742], ["min", 746], ["for", 750], ["the", 754], ["i.v", 758], [".", 761], ["group", 763], ["vs", 769], ["9.6", 772], ["+", 776], ["/-", 777], ["4.58", 780], ["min", 785], ["for", 789], ["the", 793], ["s.q", 797], [".", 800], ["group", 802], ["(", 808], ["95", 809], ["%", 811], ["CI", 813], ["of", 816], ["the", 819], ["difference", 823], ["-1.55", 834], [",", 839], ["1.00", 841], [")", 845], [".", 846], ["Mean", 848], ["duration", 853], ["of", 862], ["bag", 865], ["-", 868], ["valve", 869], ["-", 874], ["mask", 875], ["ventilation", 880], ["was", 892], ["8.1", 896], ["+", 900], ["/-", 901], ["6.0", 904], ["min", 908], ["for", 912], ["the", 916], ["i.v", 920], [".", 923], ["group", 925], ["vs", 931], ["9.1", 934], ["+", 938], ["/-", 939], ["4.8", 942], ["min", 946], ["for", 950], ["the", 954], ["s.q", 958], [".", 961], ["group", 963], [".", 968], ["Cost", 970], ["of", 975], ["materials", 978], ["for", 988], ["administering", 992], ["naloxone", 1006], ["0.4", 1015], ["mg", 1019], ["i.v", 1022], [".", 1025], ["was", 1027], ["$", 1031], ["12.30/patient", 1032], [",", 1045], ["compared", 1047], ["with", 1056], ["$", 1061], ["10.70/patient", 1062], ["for", 1076], ["naloxone", 1080], ["0.8", 1089], ["mg", 1093], ["s.q", 1096], [".", 1099], ["There", 1101], ["was", 1107], ["no", 1111], ["clinical", 1114], ["difference", 1123], ["in", 1134], ["the", 1137], ["time", 1141], ["interval", 1146], ["to", 1155], ["respiratory", 1158], ["rate", 1170], [">", 1175], ["or", 1177], ["=", 1180], ["10", 1181], ["breaths", 1184], ["/", 1191], ["min", 1192], ["between", 1196], ["naloxone", 1204], ["0.8", 1213], ["mg", 1217], ["s.q", 1220], [".", 1223], ["and", 1225], ["naloxone", 1229], ["0.4", 1238], ["mg", 1242], ["i.v", 1245], [".", 1248], ["for", 1250], ["the", 1254], ["out", 1258], ["-", 1261], ["of", 1262], ["-", 1264], ["hospital", 1265], ["management", 1274], ["of", 1285], ["patients", 1288], ["with", 1297], ["suspected", 1302], ["opioid", 1312], ["overdose", 1319], [".", 1327], ["The", 1329], ["slower", 1333], ["rate", 1340], ["of", 1345], ["absorption", 1348], ["via", 1359], ["the", 1363], ["s.q", 1367], [".", 1370], ["route", 1372], ["was", 1378], ["offset", 1382], ["by", 1389], ["the", 1392], ["delay", 1396], ["in", 1402], ["establishing", 1405], ["an", 1418], ["i.v", 1421], [".", 1424]]}
{"context": "Motion of the median nerve was compared on an axial ultrasonographic image in the mid-carpal tunnel in 30 wrists of 15 women with bilateral idiopathic carpal tunnel syndrome and 30 wrists of 15 healthy women. During passive flexion and extension of the index finger, the control wrists had transverse sliding of the nerve beneath the flexor retinaculum (1.75 +/- 0.49 mm), which was regarded as a physiological phenomenon. In contrast, the wrists of patients with carpal tunnel syndrome had significantly less sliding (0.37 +/- 0.34 mm; P = 0.0001), which indicates that physiological motion of the nerve is restricted. This decrease in nerve mobility may be of significance in the pathophysiology of carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "7bd8a7a1bafe47c3abd747f77a580738", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[3, 3]], "char_spans": [[14, 19]]}]}], "context_tokens": [["Motion", 0], ["of", 7], ["the", 10], ["median", 14], ["nerve", 21], ["was", 27], ["compared", 31], ["on", 40], ["an", 43], ["axial", 46], ["ultrasonographic", 52], ["image", 69], ["in", 75], ["the", 78], ["mid", 82], ["-", 85], ["carpal", 86], ["tunnel", 93], ["in", 100], ["30", 103], ["wrists", 106], ["of", 113], ["15", 116], ["women", 119], ["with", 125], ["bilateral", 130], ["idiopathic", 140], ["carpal", 151], ["tunnel", 158], ["syndrome", 165], ["and", 174], ["30", 178], ["wrists", 181], ["of", 188], ["15", 191], ["healthy", 194], ["women", 202], [".", 207], ["During", 209], ["passive", 216], ["flexion", 224], ["and", 232], ["extension", 236], ["of", 246], ["the", 249], ["index", 253], ["finger", 259], [",", 265], ["the", 267], ["control", 271], ["wrists", 279], ["had", 286], ["transverse", 290], ["sliding", 301], ["of", 309], ["the", 312], ["nerve", 316], ["beneath", 322], ["the", 330], ["flexor", 334], ["retinaculum", 341], ["(", 353], ["1.75", 354], ["+", 359], ["/-", 360], ["0.49", 363], ["mm", 368], [")", 370], [",", 371], ["which", 373], ["was", 379], ["regarded", 383], ["as", 392], ["a", 395], ["physiological", 397], ["phenomenon", 411], [".", 421], ["In", 423], ["contrast", 426], [",", 434], ["the", 436], ["wrists", 440], ["of", 447], ["patients", 450], ["with", 459], ["carpal", 464], ["tunnel", 471], ["syndrome", 478], ["had", 487], ["significantly", 491], ["less", 505], ["sliding", 510], ["(", 518], ["0.37", 519], ["+", 524], ["/-", 525], ["0.34", 528], ["mm", 533], [";", 535], ["P", 537], ["=", 539], ["0.0001", 541], [")", 547], [",", 548], ["which", 550], ["indicates", 556], ["that", 566], ["physiological", 571], ["motion", 585], ["of", 592], ["the", 595], ["nerve", 599], ["is", 605], ["restricted", 608], [".", 618], ["This", 620], ["decrease", 625], ["in", 634], ["nerve", 637], ["mobility", 643], ["may", 652], ["be", 656], ["of", 659], ["significance", 662], ["in", 675], ["the", 678], ["pathophysiology", 682], ["of", 698], ["carpal", 701], ["tunnel", 708], ["syndrome", 715], [".", 723]]}
{"context": "Synucleinopathies comprise a diverse group of neurodegenerative proteinopathies that share common pathological lesions composed of aggregates of conformational and posttranslational modifications of alpha-synuclein in selected populations of neurons and glia. Abnormal filamentous aggregates of misfolded alpha-synuclein protein are the major components of Lewy bodies, dystrophic (Lewy) neurites, and the Papp-Lantos filaments in oligodendroglia and neurons in multiple system atrophy linked to degeneration of affected brain regions. The synucleinopathies include (1) Lewy body disorders and dementia with Lewy bodies, (2) multiple system atrophy (MSA), and (3) Hallervorden-Spatz disease. (1) The pathological diagnosis of Lewy body disorders and dementia with Lewy bodies is established by validated consensus criteria based on semiquantitative assessment of subcortical and cortical Lewy bodies as their common hallmarks. They are accompanied by subcortical multisystem degeneration with neuronal loss and gliosis with or without Alzheimer pathologic state. Lewy bodies also occur in numerous other disorders, including pure autonomic failure, neuroaxonal dystrophies, and various amyloidoses and tauopathies. (2) Multiple system atrophy, a sporadic, adult-onset degenerative movement disorder of unknown cause, is characterized by alpha-synuclein-positive glial cytoplasmic and rare neuronal inclusions throughout the central nervous system associated with striatonigral degeneration, olivopontocerebellar atrophy, and involvement of medullar and spinal autonomic nuclei. (3) In neurodegeneration with brain iron accumulation type I, or Hallervorden-Spatz disease, alpha-synuclein is present in axonal spheroids and glial and neuronal inclusions. While the identity of the major components of Lewy bodies suggests that a pathway leading from normal soluble to abnormal misfolded filamentous proteins is central for their pathogenesis, regardless of the primary disorder, there are conformational differences in alpha-synuclein between neuronal and glial aggregates, showing nonuniform mapping for its epitopes. Despite several cellular and transgenic models, it is not clear whether inclusion body formation is an adaptive/neuroprotective or a pathogenic reaction/process generated in response to different, mostly undetermined, functional triggers linked to neurodegeneration.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "85f89f3d85be487db0659a2ec7d6968f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[38, 40], [22, 24], [318, 320], [213, 215], [264, 266]], "char_spans": [[305, 319], [199, 213], [2017, 2031], [1337, 1351], [1671, 1685]]}]}], "context_tokens": [["Synucleinopathies", 0], ["comprise", 18], ["a", 27], ["diverse", 29], ["group", 37], ["of", 43], ["neurodegenerative", 46], ["proteinopathies", 64], ["that", 80], ["share", 85], ["common", 91], ["pathological", 98], ["lesions", 111], ["composed", 119], ["of", 128], ["aggregates", 131], ["of", 142], ["conformational", 145], ["and", 160], ["posttranslational", 164], ["modifications", 182], ["of", 196], ["alpha", 199], ["-", 204], ["synuclein", 205], ["in", 215], ["selected", 218], ["populations", 227], ["of", 239], ["neurons", 242], ["and", 250], ["glia", 254], [".", 258], ["Abnormal", 260], ["filamentous", 269], ["aggregates", 281], ["of", 292], ["misfolded", 295], ["alpha", 305], ["-", 310], ["synuclein", 311], ["protein", 321], ["are", 329], ["the", 333], ["major", 337], ["components", 343], ["of", 354], ["Lewy", 357], ["bodies", 362], [",", 368], ["dystrophic", 370], ["(", 381], ["Lewy", 382], [")", 386], ["neurites", 388], [",", 396], ["and", 398], ["the", 402], ["Papp", 406], ["-", 410], ["Lantos", 411], ["filaments", 418], ["in", 428], ["oligodendroglia", 431], ["and", 447], ["neurons", 451], ["in", 459], ["multiple", 462], ["system", 471], ["atrophy", 478], ["linked", 486], ["to", 493], ["degeneration", 496], ["of", 509], ["affected", 512], ["brain", 521], ["regions", 527], [".", 534], ["The", 536], ["synucleinopathies", 540], ["include", 558], ["(", 566], ["1", 567], [")", 568], ["Lewy", 570], ["body", 575], ["disorders", 580], ["and", 590], ["dementia", 594], ["with", 603], ["Lewy", 608], ["bodies", 613], [",", 619], ["(", 621], ["2", 622], [")", 623], ["multiple", 625], ["system", 634], ["atrophy", 641], ["(", 649], ["MSA", 650], [")", 653], [",", 654], ["and", 656], ["(", 660], ["3", 661], [")", 662], ["Hallervorden", 664], ["-", 676], ["Spatz", 677], ["disease", 683], [".", 690], ["(", 692], ["1", 693], [")", 694], ["The", 696], ["pathological", 700], ["diagnosis", 713], ["of", 723], ["Lewy", 726], ["body", 731], ["disorders", 736], ["and", 746], ["dementia", 750], ["with", 759], ["Lewy", 764], ["bodies", 769], ["is", 776], ["established", 779], ["by", 791], ["validated", 794], ["consensus", 804], ["criteria", 814], ["based", 823], ["on", 829], ["semiquantitative", 832], ["assessment", 849], ["of", 860], ["subcortical", 863], ["and", 875], ["cortical", 879], ["Lewy", 888], ["bodies", 893], ["as", 900], ["their", 903], ["common", 909], ["hallmarks", 916], [".", 925], ["They", 927], ["are", 932], ["accompanied", 936], ["by", 948], ["subcortical", 951], ["multisystem", 963], ["degeneration", 975], ["with", 988], ["neuronal", 993], ["loss", 1002], ["and", 1007], ["gliosis", 1011], ["with", 1019], ["or", 1024], ["without", 1027], ["Alzheimer", 1035], ["pathologic", 1045], ["state", 1056], [".", 1061], ["Lewy", 1063], ["bodies", 1068], ["also", 1075], ["occur", 1080], ["in", 1086], ["numerous", 1089], ["other", 1098], ["disorders", 1104], [",", 1113], ["including", 1115], ["pure", 1125], ["autonomic", 1130], ["failure", 1140], [",", 1147], ["neuroaxonal", 1149], ["dystrophies", 1161], [",", 1172], ["and", 1174], ["various", 1178], ["amyloidoses", 1186], ["and", 1198], ["tauopathies", 1202], [".", 1213], ["(", 1215], ["2", 1216], [")", 1217], ["Multiple", 1219], ["system", 1228], ["atrophy", 1235], [",", 1242], ["a", 1244], ["sporadic", 1246], [",", 1254], ["adult", 1256], ["-", 1261], ["onset", 1262], ["degenerative", 1268], ["movement", 1281], ["disorder", 1290], ["of", 1299], ["unknown", 1302], ["cause", 1310], [",", 1315], ["is", 1317], ["characterized", 1320], ["by", 1334], ["alpha", 1337], ["-", 1342], ["synuclein", 1343], ["-", 1352], ["positive", 1353], ["glial", 1362], ["cytoplasmic", 1368], ["and", 1380], ["rare", 1384], ["neuronal", 1389], ["inclusions", 1398], ["throughout", 1409], ["the", 1420], ["central", 1424], ["nervous", 1432], ["system", 1440], ["associated", 1447], ["with", 1458], ["striatonigral", 1463], ["degeneration", 1477], [",", 1489], ["olivopontocerebellar", 1491], ["atrophy", 1512], [",", 1519], ["and", 1521], ["involvement", 1525], ["of", 1537], ["medullar", 1540], ["and", 1549], ["spinal", 1553], ["autonomic", 1560], ["nuclei", 1570], [".", 1576], ["(", 1578], ["3", 1579], [")", 1580], ["In", 1582], ["neurodegeneration", 1585], ["with", 1603], ["brain", 1608], ["iron", 1614], ["accumulation", 1619], ["type", 1632], ["I", 1637], [",", 1638], ["or", 1640], ["Hallervorden", 1643], ["-", 1655], ["Spatz", 1656], ["disease", 1662], [",", 1669], ["alpha", 1671], ["-", 1676], ["synuclein", 1677], ["is", 1687], ["present", 1690], ["in", 1698], ["axonal", 1701], ["spheroids", 1708], ["and", 1718], ["glial", 1722], ["and", 1728], ["neuronal", 1732], ["inclusions", 1741], [".", 1751], ["While", 1753], ["the", 1759], ["identity", 1763], ["of", 1772], ["the", 1775], ["major", 1779], ["components", 1785], ["of", 1796], ["Lewy", 1799], ["bodies", 1804], ["suggests", 1811], ["that", 1820], ["a", 1825], ["pathway", 1827], ["leading", 1835], ["from", 1843], ["normal", 1848], ["soluble", 1855], ["to", 1863], ["abnormal", 1866], ["misfolded", 1875], ["filamentous", 1885], ["proteins", 1897], ["is", 1906], ["central", 1909], ["for", 1917], ["their", 1921], ["pathogenesis", 1927], [",", 1939], ["regardless", 1941], ["of", 1952], ["the", 1955], ["primary", 1959], ["disorder", 1967], [",", 1975], ["there", 1977], ["are", 1983], ["conformational", 1987], ["differences", 2002], ["in", 2014], ["alpha", 2017], ["-", 2022], ["synuclein", 2023], ["between", 2033], ["neuronal", 2041], ["and", 2050], ["glial", 2054], ["aggregates", 2060], [",", 2070], ["showing", 2072], ["nonuniform", 2080], ["mapping", 2091], ["for", 2099], ["its", 2103], ["epitopes", 2107], [".", 2115], ["Despite", 2117], ["several", 2125], ["cellular", 2133], ["and", 2142], ["transgenic", 2146], ["models", 2157], [",", 2163], ["it", 2165], ["is", 2168], ["not", 2171], ["clear", 2175], ["whether", 2181], ["inclusion", 2189], ["body", 2199], ["formation", 2204], ["is", 2214], ["an", 2217], ["adaptive", 2220], ["/", 2228], ["neuroprotective", 2229], ["or", 2245], ["a", 2248], ["pathogenic", 2250], ["reaction", 2261], ["/", 2269], ["process", 2270], ["generated", 2278], ["in", 2288], ["response", 2291], ["to", 2300], ["different", 2303], [",", 2312], ["mostly", 2314], ["undetermined", 2321], [",", 2333], ["functional", 2335], ["triggers", 2346], ["linked", 2355], ["to", 2362], ["neurodegeneration", 2365], [".", 2382]]}
{"context": "Iron deficiency is a frequent side effect of blood donation. In recent years, several studies have described genetic variants associated with iron concentrations. However, the impact of these variants on iron levels is unknown in blood donors. Knowledge of genetic variants that predispose donors to iron deficiency would allow bleeding frequency and iron supplementation to be tailored to the individual donor. The genotypes of five specific single-nucleotide polymorphisms (SNPs) in three genes that have been previously associated with iron status and/or restless leg syndrome (RLS) were investigated in two groups of female blood donors. The first group had low iron stores (serum ferritin \u2264 12\u2003\u00b5g/L, n\u2003=\u2003657), and the second group had normal to high iron stores (serum ferritin > 30\u2003\u00b5g/L, n\u2003=\u2003645). Genotype distribution for each of the SNPs was compared between the two groups. Homozygosity for the T-allele of BTBD9 rs9296249 was associated with lower serum ferritin. The odds ratio for low serum ferritin was 1.35 (95% confidence interval, 1.02-1.77; p\u2003=\u20030.03) when comparing donors with the TT genotype with donors with the CT genotype. A frequent polymorphism in BTBD9 was significantly associated with serum ferritin. This polymorphism has previously been associated with RLS, but not low iron stores in blood donors.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "e633c81c3daa42ecbd9ffd1b9f3106ab", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [112, 112], [243, 243], [23, 23], [57, 57], [34, 34], [88, 88], [136, 136], [50, 50]], "char_spans": [[0, 3], [666, 669], [1300, 1303], [142, 145], [351, 354], [204, 207], [539, 542], [755, 758], [300, 303]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["is", 16], ["a", 19], ["frequent", 21], ["side", 30], ["effect", 35], ["of", 42], ["blood", 45], ["donation", 51], [".", 59], ["In", 61], ["recent", 64], ["years", 71], [",", 76], ["several", 78], ["studies", 86], ["have", 94], ["described", 99], ["genetic", 109], ["variants", 117], ["associated", 126], ["with", 137], ["iron", 142], ["concentrations", 147], [".", 161], ["However", 163], [",", 170], ["the", 172], ["impact", 176], ["of", 183], ["these", 186], ["variants", 192], ["on", 201], ["iron", 204], ["levels", 209], ["is", 216], ["unknown", 219], ["in", 227], ["blood", 230], ["donors", 236], [".", 242], ["Knowledge", 244], ["of", 254], ["genetic", 257], ["variants", 265], ["that", 274], ["predispose", 279], ["donors", 290], ["to", 297], ["iron", 300], ["deficiency", 305], ["would", 316], ["allow", 322], ["bleeding", 328], ["frequency", 337], ["and", 347], ["iron", 351], ["supplementation", 356], ["to", 372], ["be", 375], ["tailored", 378], ["to", 387], ["the", 390], ["individual", 394], ["donor", 405], [".", 410], ["The", 412], ["genotypes", 416], ["of", 426], ["five", 429], ["specific", 434], ["single", 443], ["-", 449], ["nucleotide", 450], ["polymorphisms", 461], ["(", 475], ["SNPs", 476], [")", 480], ["in", 482], ["three", 485], ["genes", 491], ["that", 497], ["have", 502], ["been", 507], ["previously", 512], ["associated", 523], ["with", 534], ["iron", 539], ["status", 544], ["and/or", 551], ["restless", 558], ["leg", 567], ["syndrome", 571], ["(", 580], ["RLS", 581], [")", 584], ["were", 586], ["investigated", 591], ["in", 604], ["two", 607], ["groups", 611], ["of", 618], ["female", 621], ["blood", 628], ["donors", 634], [".", 640], ["The", 642], ["first", 646], ["group", 652], ["had", 658], ["low", 662], ["iron", 666], ["stores", 671], ["(", 678], ["serum", 679], ["ferritin", 685], ["\u2264", 694], ["12", 696], ["\u00b5g", 699], ["/", 701], ["L", 702], [",", 703], ["n", 705], ["=", 707], ["657", 709], [")", 712], [",", 713], ["and", 715], ["the", 719], ["second", 723], ["group", 730], ["had", 736], ["normal", 740], ["to", 747], ["high", 750], ["iron", 755], ["stores", 760], ["(", 767], ["serum", 768], ["ferritin", 774], [">", 783], ["30", 785], ["\u00b5g", 788], ["/", 790], ["L", 791], [",", 792], ["n", 794], ["=", 796], ["645", 798], [")", 801], [".", 802], ["Genotype", 804], ["distribution", 813], ["for", 826], ["each", 830], ["of", 835], ["the", 838], ["SNPs", 842], ["was", 847], ["compared", 851], ["between", 860], ["the", 868], ["two", 872], ["groups", 876], [".", 882], ["Homozygosity", 884], ["for", 897], ["the", 901], ["T", 905], ["-", 906], ["allele", 907], ["of", 914], ["BTBD9", 917], ["rs9296249", 923], ["was", 933], ["associated", 937], ["with", 948], ["lower", 953], ["serum", 959], ["ferritin", 965], [".", 973], ["The", 975], ["odds", 979], ["ratio", 984], ["for", 990], ["low", 994], ["serum", 998], ["ferritin", 1004], ["was", 1013], ["1.35", 1017], ["(", 1022], ["95", 1023], ["%", 1025], ["confidence", 1027], ["interval", 1038], [",", 1046], ["1.02", 1048], ["-", 1052], ["1.77", 1053], [";", 1057], ["p", 1059], ["=", 1061], ["0.03", 1063], [")", 1067], ["when", 1069], ["comparing", 1074], ["donors", 1084], ["with", 1091], ["the", 1096], ["TT", 1100], ["genotype", 1103], ["with", 1112], ["donors", 1117], ["with", 1124], ["the", 1129], ["CT", 1133], ["genotype", 1136], [".", 1144], ["A", 1146], ["frequent", 1148], ["polymorphism", 1157], ["in", 1170], ["BTBD9", 1173], ["was", 1179], ["significantly", 1183], ["associated", 1197], ["with", 1208], ["serum", 1213], ["ferritin", 1219], [".", 1227], ["This", 1229], ["polymorphism", 1234], ["has", 1247], ["previously", 1251], ["been", 1262], ["associated", 1267], ["with", 1278], ["RLS", 1283], [",", 1286], ["but", 1288], ["not", 1292], ["low", 1296], ["iron", 1300], ["stores", 1305], ["in", 1312], ["blood", 1315], ["donors", 1321], [".", 1327]]}
{"context": "Sotos syndrome is a well-known overgrowth syndrome caused by haploinsufficiency of NSD1 gene located at 5q35. There are two types of mutations that cause NSD1 haploinsufficiency: mutations within the NSD1 gene (mutation type) and a 5q35 submicroscopic deletion encompassing the entire NSD1 gene (deletion type). We investigated detailed craniofacial, dental, and oral findings in five patients with deletion type, and three patients with mutation type Sotos syndrome. All eight patients had a high palate, excessive tooth wear, crowding, and all but one patient had hypodontia and deep bite. Hypodontia was exclusively observed in the second premolars, and there were no differences between the deletion and mutation types in the number of missing teeth. Another feature frequently seen in common with both types was maxillary recession. Findings seen more frequently and more pronounced in deletion-type than in mutation-type included mandibular recession, scissors or posterior cross bite, and small dental arch with labioclination of the maxillary central incisors. It is noteworthy that although either scissors bite or cross bite was present in all of the deletion-type patients, neither of these was observed in mutation-type patients. Other features seen in a few patients include enamel hypoplasia (two deletion patients), and ectopic tooth eruption (one deletion and one mutation patients). Our study suggests that Sotos syndrome patients should be observed closely for possible dental and oral complications especially for malocculusion in the deletion-type patients.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "1a50ca89e68b478197f95616dd07746e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[13, 14], [33, 34], [47, 48]], "char_spans": [[83, 91], [200, 208], [285, 293]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["a", 18], ["well", 20], ["-", 24], ["known", 25], ["overgrowth", 31], ["syndrome", 42], ["caused", 51], ["by", 58], ["haploinsufficiency", 61], ["of", 80], ["NSD1", 83], ["gene", 88], ["located", 93], ["at", 101], ["5q35", 104], [".", 108], ["There", 110], ["are", 116], ["two", 120], ["types", 124], ["of", 130], ["mutations", 133], ["that", 143], ["cause", 148], ["NSD1", 154], ["haploinsufficiency", 159], [":", 177], ["mutations", 179], ["within", 189], ["the", 196], ["NSD1", 200], ["gene", 205], ["(", 210], ["mutation", 211], ["type", 220], [")", 224], ["and", 226], ["a", 230], ["5q35", 232], ["submicroscopic", 237], ["deletion", 252], ["encompassing", 261], ["the", 274], ["entire", 278], ["NSD1", 285], ["gene", 290], ["(", 295], ["deletion", 296], ["type", 305], [")", 309], [".", 310], ["We", 312], ["investigated", 315], ["detailed", 328], ["craniofacial", 337], [",", 349], ["dental", 351], [",", 357], ["and", 359], ["oral", 363], ["findings", 368], ["in", 377], ["five", 380], ["patients", 385], ["with", 394], ["deletion", 399], ["type", 408], [",", 412], ["and", 414], ["three", 418], ["patients", 424], ["with", 433], ["mutation", 438], ["type", 447], ["Sotos", 452], ["syndrome", 458], [".", 466], ["All", 468], ["eight", 472], ["patients", 478], ["had", 487], ["a", 491], ["high", 493], ["palate", 498], [",", 504], ["excessive", 506], ["tooth", 516], ["wear", 522], [",", 526], ["crowding", 528], [",", 536], ["and", 538], ["all", 542], ["but", 546], ["one", 550], ["patient", 554], ["had", 562], ["hypodontia", 566], ["and", 577], ["deep", 581], ["bite", 586], [".", 590], ["Hypodontia", 592], ["was", 603], ["exclusively", 607], ["observed", 619], ["in", 628], ["the", 631], ["second", 635], ["premolars", 642], [",", 651], ["and", 653], ["there", 657], ["were", 663], ["no", 668], ["differences", 671], ["between", 683], ["the", 691], ["deletion", 695], ["and", 704], ["mutation", 708], ["types", 717], ["in", 723], ["the", 726], ["number", 730], ["of", 737], ["missing", 740], ["teeth", 748], [".", 753], ["Another", 755], ["feature", 763], ["frequently", 771], ["seen", 782], ["in", 787], ["common", 790], ["with", 797], ["both", 802], ["types", 807], ["was", 813], ["maxillary", 817], ["recession", 827], [".", 836], ["Findings", 838], ["seen", 847], ["more", 852], ["frequently", 857], ["and", 868], ["more", 872], ["pronounced", 877], ["in", 888], ["deletion", 891], ["-", 899], ["type", 900], ["than", 905], ["in", 910], ["mutation", 913], ["-", 921], ["type", 922], ["included", 927], ["mandibular", 936], ["recession", 947], [",", 956], ["scissors", 958], ["or", 967], ["posterior", 970], ["cross", 980], ["bite", 986], [",", 990], ["and", 992], ["small", 996], ["dental", 1002], ["arch", 1009], ["with", 1014], ["labioclination", 1019], ["of", 1034], ["the", 1037], ["maxillary", 1041], ["central", 1051], ["incisors", 1059], [".", 1067], ["It", 1069], ["is", 1072], ["noteworthy", 1075], ["that", 1086], ["although", 1091], ["either", 1100], ["scissors", 1107], ["bite", 1116], ["or", 1121], ["cross", 1124], ["bite", 1130], ["was", 1135], ["present", 1139], ["in", 1147], ["all", 1150], ["of", 1154], ["the", 1157], ["deletion", 1161], ["-", 1169], ["type", 1170], ["patients", 1175], [",", 1183], ["neither", 1185], ["of", 1193], ["these", 1196], ["was", 1202], ["observed", 1206], ["in", 1215], ["mutation", 1218], ["-", 1226], ["type", 1227], ["patients", 1232], [".", 1240], ["Other", 1242], ["features", 1248], ["seen", 1257], ["in", 1262], ["a", 1265], ["few", 1267], ["patients", 1271], ["include", 1280], ["enamel", 1288], ["hypoplasia", 1295], ["(", 1306], ["two", 1307], ["deletion", 1311], ["patients", 1320], [")", 1328], [",", 1329], ["and", 1331], ["ectopic", 1335], ["tooth", 1343], ["eruption", 1349], ["(", 1358], ["one", 1359], ["deletion", 1363], ["and", 1372], ["one", 1376], ["mutation", 1380], ["patients", 1389], [")", 1397], [".", 1398], ["Our", 1400], ["study", 1404], ["suggests", 1410], ["that", 1419], ["Sotos", 1424], ["syndrome", 1430], ["patients", 1439], ["should", 1448], ["be", 1455], ["observed", 1458], ["closely", 1467], ["for", 1475], ["possible", 1479], ["dental", 1488], ["and", 1495], ["oral", 1499], ["complications", 1504], ["especially", 1518], ["for", 1529], ["malocculusion", 1533], ["in", 1547], ["the", 1550], ["deletion", 1554], ["-", 1562], ["type", 1563], ["patients", 1568], [".", 1576]]}
{"context": "The Romano-Ward long QT syndrome, an autosomal dominant inherited disorder, is an increasingly recognized cause of sudden cardiac death in children and adults. Sudden death may or may not be preceded by a history of \"seizures\" and recurrent syncope; the diagnosis relies on electrocardiographic evidence, including prolongation of the QT interval corrected for heart rate, T wave abnormalities, sinus bradycardia, and polymorphous ventricular tachycardia (torsades de pointes). Recently, a gene responsible for causing long QT syndrome was localized (using molecular genetic methods) to the short arm of chromosome 11 (11p15.5) in the region near the Harvey ras-1 locus. The purpose of this report is to describe the current molecular genetic understanding of long QT syndrome, including information regarding gene mapping, genetic heterogeneity, and prenatal or presymptomatic diagnosis.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "c56e3d34c08a4d009fb83d8ed37c636a", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10]], "char_spans": [[37, 54]]}]}], "context_tokens": [["The", 0], ["Romano", 4], ["-", 10], ["Ward", 11], ["long", 16], ["QT", 21], ["syndrome", 24], [",", 32], ["an", 34], ["autosomal", 37], ["dominant", 47], ["inherited", 56], ["disorder", 66], [",", 74], ["is", 76], ["an", 79], ["increasingly", 82], ["recognized", 95], ["cause", 106], ["of", 112], ["sudden", 115], ["cardiac", 122], ["death", 130], ["in", 136], ["children", 139], ["and", 148], ["adults", 152], [".", 158], ["Sudden", 160], ["death", 167], ["may", 173], ["or", 177], ["may", 180], ["not", 184], ["be", 188], ["preceded", 191], ["by", 200], ["a", 203], ["history", 205], ["of", 213], ["\"", 216], ["seizures", 217], ["\"", 225], ["and", 227], ["recurrent", 231], ["syncope", 241], [";", 248], ["the", 250], ["diagnosis", 254], ["relies", 264], ["on", 271], ["electrocardiographic", 274], ["evidence", 295], [",", 303], ["including", 305], ["prolongation", 315], ["of", 328], ["the", 331], ["QT", 335], ["interval", 338], ["corrected", 347], ["for", 357], ["heart", 361], ["rate", 367], [",", 371], ["T", 373], ["wave", 375], ["abnormalities", 380], [",", 393], ["sinus", 395], ["bradycardia", 401], [",", 412], ["and", 414], ["polymorphous", 418], ["ventricular", 431], ["tachycardia", 443], ["(", 455], ["torsades", 456], ["de", 465], ["pointes", 468], [")", 475], [".", 476], ["Recently", 478], [",", 486], ["a", 488], ["gene", 490], ["responsible", 495], ["for", 507], ["causing", 511], ["long", 519], ["QT", 524], ["syndrome", 527], ["was", 536], ["localized", 540], ["(", 550], ["using", 551], ["molecular", 557], ["genetic", 567], ["methods", 575], [")", 582], ["to", 584], ["the", 587], ["short", 591], ["arm", 597], ["of", 601], ["chromosome", 604], ["11", 615], ["(", 618], ["11p15.5", 619], [")", 626], ["in", 628], ["the", 631], ["region", 635], ["near", 642], ["the", 647], ["Harvey", 651], ["ras-1", 658], ["locus", 664], [".", 669], ["The", 671], ["purpose", 675], ["of", 683], ["this", 686], ["report", 691], ["is", 698], ["to", 701], ["describe", 704], ["the", 713], ["current", 717], ["molecular", 725], ["genetic", 735], ["understanding", 743], ["of", 757], ["long", 760], ["QT", 765], ["syndrome", 768], [",", 776], ["including", 778], ["information", 788], ["regarding", 800], ["gene", 810], ["mapping", 815], [",", 822], ["genetic", 824], ["heterogeneity", 832], [",", 845], ["and", 847], ["prenatal", 851], ["or", 860], ["presymptomatic", 863], ["diagnosis", 878], [".", 887]]}
{"context": "Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This fusion protein constitutively activate ABL tyrosine kinase and causes CML. Imatinib mesylate is a selective tyrosine kinase inhibitor on ABL, c-Kit and PGDF-receptor, and functions through competitive inhibition at the ATP-binding site of the enzyme, which leads to growth arrest or apoptosis in cells that express BCR-ABL. Imatinib has revolutionized the management of patients with CML, and at a dose of 400 mg daily has become the current standard therapy for newly diagnosed patients with CML even when they have HLA-matched family donors. Although imatinib therapy has only a 5-year history, it is hoped that CML will be cured with this drug and with forthcoming second-generation tyrosine kinase inhibitors as well as by allogeneic stem cell transplantation in patients who have become resistant to these drugs.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "387fa7dc1d984dacbbaa4fab370ed6ed", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[24, 26], [30, 32], [91, 93]], "char_spans": [[133, 139], [158, 164], [487, 493]]}]}], "context_tokens": [["Philadelphia", 0], ["(", 13], ["Ph", 14], [")", 16], ["chromosome", 18], ["is", 29], ["the", 32], ["cytogenetic", 36], ["hallmark", 48], ["of", 57], ["chronic", 60], ["myeloid", 68], ["leukemia", 76], ["(", 85], ["CML", 86], [")", 89], [".", 90], ["The", 92], ["translocation", 96], ["forms", 110], ["a", 116], ["chimeric", 118], ["gene", 127], [",", 131], ["bcr", 133], ["-", 136], ["abl", 137], [",", 140], ["which", 142], ["generates", 148], ["BCR", 158], ["-", 161], ["ABL", 162], [".", 165], ["This", 167], ["fusion", 172], ["protein", 179], ["constitutively", 187], ["activate", 202], ["ABL", 211], ["tyrosine", 215], ["kinase", 224], ["and", 231], ["causes", 235], ["CML", 242], [".", 245], ["Imatinib", 247], ["mesylate", 256], ["is", 265], ["a", 268], ["selective", 270], ["tyrosine", 280], ["kinase", 289], ["inhibitor", 296], ["on", 306], ["ABL", 309], [",", 312], ["c", 314], ["-", 315], ["Kit", 316], ["and", 320], ["PGDF", 324], ["-", 328], ["receptor", 329], [",", 337], ["and", 339], ["functions", 343], ["through", 353], ["competitive", 361], ["inhibition", 373], ["at", 384], ["the", 387], ["ATP", 391], ["-", 394], ["binding", 395], ["site", 403], ["of", 408], ["the", 411], ["enzyme", 415], [",", 421], ["which", 423], ["leads", 429], ["to", 435], ["growth", 438], ["arrest", 445], ["or", 452], ["apoptosis", 455], ["in", 465], ["cells", 468], ["that", 474], ["express", 479], ["BCR", 487], ["-", 490], ["ABL", 491], [".", 494], ["Imatinib", 496], ["has", 505], ["revolutionized", 509], ["the", 524], ["management", 528], ["of", 539], ["patients", 542], ["with", 551], ["CML", 556], [",", 559], ["and", 561], ["at", 565], ["a", 568], ["dose", 570], ["of", 575], ["400", 578], ["mg", 582], ["daily", 585], ["has", 591], ["become", 595], ["the", 602], ["current", 606], ["standard", 614], ["therapy", 623], ["for", 631], ["newly", 635], ["diagnosed", 641], ["patients", 651], ["with", 660], ["CML", 665], ["even", 669], ["when", 674], ["they", 679], ["have", 684], ["HLA", 689], ["-", 692], ["matched", 693], ["family", 701], ["donors", 708], [".", 714], ["Although", 716], ["imatinib", 725], ["therapy", 734], ["has", 742], ["only", 746], ["a", 751], ["5-year", 753], ["history", 760], [",", 767], ["it", 769], ["is", 772], ["hoped", 775], ["that", 781], ["CML", 786], ["will", 790], ["be", 795], ["cured", 798], ["with", 804], ["this", 809], ["drug", 814], ["and", 819], ["with", 823], ["forthcoming", 828], ["second", 840], ["-", 846], ["generation", 847], ["tyrosine", 858], ["kinase", 867], ["inhibitors", 874], ["as", 885], ["well", 888], ["as", 893], ["by", 896], ["allogeneic", 899], ["stem", 910], ["cell", 915], ["transplantation", 920], ["in", 936], ["patients", 939], ["who", 948], ["have", 952], ["become", 957], ["resistant", 964], ["to", 974], ["these", 977], ["drugs", 983], [".", 988]]}
{"context": "Co-occurring psychiatric diagnoses have a negative impact on quality of life and change the presentation and prognosis of bipolar disorder (BD). To date, comorbidity research on patients with BD has primarily focused on co-occurring anxiety disorders and trauma history; only recently has there been a specific focus on co-occurring PTSD and BD. Although rates of trauma and PTSD are higher in those with bipolar disorder than in the general population, little is known about differences across bipolar subtypes. Using the NIMH STEP-BD dataset (N=3158), this study evaluated whether there were baseline differences in the prevalence of PTSD between participants with bipolar disorder I (BDI) and bipolar disorder II (BDII), using the MINI and the Davidson Trauma Scale. Differences in PTSD symptom clusters between patients with BDI and BDII were also evaluated. A significantly greater proportion of participants with BDI had co-occurring PTSD at time of study entry (\u03a7(2)(1)=12.6; p<.001). BDI and BDII subgroups did not significantly differ in re-experiencing, avoidance, or arousal symptoms. The analysis may suggest a correlational relationship between PTSD and BD, not a causal one. Further, it is possible this population seeks treatment more often than individuals with PTSD alone. Finally, due to the episodic nature of BD and symptom overlap between the two disorders, misdiagnosis is possible. PTSD may be more prevalent in patients with BDI. However, the symptom presentation of PTSD appears similar across BD subtypes. Individuals should be thoroughly assessed for co-occurring diagnoses in an effort to provide appropriate treatment.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "462db152238a4653847a20f341201b84", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[144, 144], [208, 208], [69, 69], [115, 115], [60, 60], [169, 169], [231, 231], [255, 255], [271, 271]], "char_spans": [[785, 788], [1158, 1161], [375, 378], [636, 639], [333, 336], [940, 943], [1278, 1281], [1405, 1408], [1491, 1494]]}]}], "context_tokens": [["Co", 0], ["-", 2], ["occurring", 3], ["psychiatric", 13], ["diagnoses", 25], ["have", 35], ["a", 40], ["negative", 42], ["impact", 51], ["on", 58], ["quality", 61], ["of", 69], ["life", 72], ["and", 77], ["change", 81], ["the", 88], ["presentation", 92], ["and", 105], ["prognosis", 109], ["of", 119], ["bipolar", 122], ["disorder", 130], ["(", 139], ["BD", 140], [")", 142], [".", 143], ["To", 145], ["date", 148], [",", 152], ["comorbidity", 154], ["research", 166], ["on", 175], ["patients", 178], ["with", 187], ["BD", 192], ["has", 195], ["primarily", 199], ["focused", 209], ["on", 217], ["co", 220], ["-", 222], ["occurring", 223], ["anxiety", 233], ["disorders", 241], ["and", 251], ["trauma", 255], ["history", 262], [";", 269], ["only", 271], ["recently", 276], ["has", 285], ["there", 289], ["been", 295], ["a", 300], ["specific", 302], ["focus", 311], ["on", 317], ["co", 320], ["-", 322], ["occurring", 323], ["PTSD", 333], ["and", 338], ["BD", 342], [".", 344], ["Although", 346], ["rates", 355], ["of", 361], ["trauma", 364], ["and", 371], ["PTSD", 375], ["are", 380], ["higher", 384], ["in", 391], ["those", 394], ["with", 400], ["bipolar", 405], ["disorder", 413], ["than", 422], ["in", 427], ["the", 430], ["general", 434], ["population", 442], [",", 452], ["little", 454], ["is", 461], ["known", 464], ["about", 470], ["differences", 476], ["across", 488], ["bipolar", 495], ["subtypes", 503], [".", 511], ["Using", 513], ["the", 519], ["NIMH", 523], ["STEP", 528], ["-", 532], ["BD", 533], ["dataset", 536], ["(", 544], ["N=3158", 545], [")", 551], [",", 552], ["this", 554], ["study", 559], ["evaluated", 565], ["whether", 575], ["there", 583], ["were", 589], ["baseline", 594], ["differences", 603], ["in", 615], ["the", 618], ["prevalence", 622], ["of", 633], ["PTSD", 636], ["between", 641], ["participants", 649], ["with", 662], ["bipolar", 667], ["disorder", 675], ["I", 684], ["(", 686], ["BDI", 687], [")", 690], ["and", 692], ["bipolar", 696], ["disorder", 704], ["II", 713], ["(", 716], ["BDII", 717], [")", 721], [",", 722], ["using", 724], ["the", 730], ["MINI", 734], ["and", 739], ["the", 743], ["Davidson", 747], ["Trauma", 756], ["Scale", 763], [".", 768], ["Differences", 770], ["in", 782], ["PTSD", 785], ["symptom", 790], ["clusters", 798], ["between", 807], ["patients", 815], ["with", 824], ["BDI", 829], ["and", 833], ["BDII", 837], ["were", 842], ["also", 847], ["evaluated", 852], [".", 861], ["A", 863], ["significantly", 865], ["greater", 879], ["proportion", 887], ["of", 898], ["participants", 901], ["with", 914], ["BDI", 919], ["had", 923], ["co", 927], ["-", 929], ["occurring", 930], ["PTSD", 940], ["at", 945], ["time", 948], ["of", 953], ["study", 956], ["entry", 962], ["(", 968], ["\u03a7(2)(1)=12.6", 969], [";", 981], ["p<.001", 983], [")", 989], [".", 990], ["BDI", 992], ["and", 996], ["BDII", 1000], ["subgroups", 1005], ["did", 1015], ["not", 1019], ["significantly", 1023], ["differ", 1037], ["in", 1044], ["re", 1047], ["-", 1049], ["experiencing", 1050], [",", 1062], ["avoidance", 1064], [",", 1073], ["or", 1075], ["arousal", 1078], ["symptoms", 1086], [".", 1094], ["The", 1096], ["analysis", 1100], ["may", 1109], ["suggest", 1113], ["a", 1121], ["correlational", 1123], ["relationship", 1137], ["between", 1150], ["PTSD", 1158], ["and", 1163], ["BD", 1167], [",", 1169], ["not", 1171], ["a", 1175], ["causal", 1177], ["one", 1184], [".", 1187], ["Further", 1189], [",", 1196], ["it", 1198], ["is", 1201], ["possible", 1204], ["this", 1213], ["population", 1218], ["seeks", 1229], ["treatment", 1235], ["more", 1245], ["often", 1250], ["than", 1256], ["individuals", 1261], ["with", 1273], ["PTSD", 1278], ["alone", 1283], [".", 1288], ["Finally", 1290], [",", 1297], ["due", 1299], ["to", 1303], ["the", 1306], ["episodic", 1310], ["nature", 1319], ["of", 1326], ["BD", 1329], ["and", 1332], ["symptom", 1336], ["overlap", 1344], ["between", 1352], ["the", 1360], ["two", 1364], ["disorders", 1368], [",", 1377], ["misdiagnosis", 1379], ["is", 1392], ["possible", 1395], [".", 1403], ["PTSD", 1405], ["may", 1410], ["be", 1414], ["more", 1417], ["prevalent", 1422], ["in", 1432], ["patients", 1435], ["with", 1444], ["BDI", 1449], [".", 1452], ["However", 1454], [",", 1461], ["the", 1463], ["symptom", 1467], ["presentation", 1475], ["of", 1488], ["PTSD", 1491], ["appears", 1496], ["similar", 1504], ["across", 1512], ["BD", 1519], ["subtypes", 1522], [".", 1530], ["Individuals", 1532], ["should", 1544], ["be", 1551], ["thoroughly", 1554], ["assessed", 1565], ["for", 1574], ["co", 1578], ["-", 1580], ["occurring", 1581], ["diagnoses", 1591], ["in", 1601], ["an", 1604], ["effort", 1607], ["to", 1614], ["provide", 1617], ["appropriate", 1625], ["treatment", 1637], [".", 1646]]}
{"context": "Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for immunoglobulin G. In collagen-induced arthritis, R788/R406, a novel and potent small molecule Syk inhibitor suppressed clinical arthritis, bone erosions, pannus formation, and synovitis. Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406. Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats. Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity. These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addition to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "6058f2f8356844f09683a30ad50f344f", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], [",", 28], ["a", 30], ["key", 32], ["mediator", 36], ["of", 45], ["immunoreceptor", 48], ["signaling", 63], ["in", 73], ["inflammatory", 76], ["cells", 89], [",", 94], ["is", 96], ["essential", 99], ["for", 109], ["immune", 113], ["complex", 120], ["-", 127], ["mediated", 128], ["signal", 137], ["transduction", 144], ["initiated", 157], ["by", 167], ["activated", 170], ["receptors", 180], ["for", 190], ["immunoglobulin", 194], ["G.", 209], ["In", 212], ["collagen", 215], ["-", 223], ["induced", 224], ["arthritis", 232], [",", 241], ["R788/R406", 243], [",", 252], ["a", 254], ["novel", 256], ["and", 262], ["potent", 266], ["small", 273], ["molecule", 279], ["Syk", 288], ["inhibitor", 292], ["suppressed", 302], ["clinical", 313], ["arthritis", 322], [",", 331], ["bone", 333], ["erosions", 338], [",", 346], ["pannus", 348], ["formation", 355], [",", 364], ["and", 366], ["synovitis", 370], [".", 379], ["Serum", 381], ["anti", 387], ["-", 391], ["collagen", 392], ["type", 401], ["II", 406], ["antibody", 409], ["levels", 418], ["were", 425], ["unaltered", 430], [",", 439], ["while", 441], ["the", 447], ["half", 451], ["-", 455], ["life", 456], ["of", 461], ["exogenous", 464], ["antibody", 474], ["was", 483], ["extended", 487], ["when", 496], ["co", 501], ["-", 503], ["administered", 504], ["with", 517], ["R406", 522], [".", 526], ["Expression", 528], ["of", 539], ["the", 542], ["targeted", 546], ["kinase", 555], ["(", 562], ["Syk", 563], [")", 566], ["in", 568], ["synovial", 571], ["tissue", 580], ["correlated", 587], ["with", 598], ["the", 603], ["joint", 607], ["level", 613], ["of", 619], ["inflammatory", 622], ["cell", 635], ["infiltrates", 640], ["and", 652], ["was", 656], ["virtually", 660], ["undetectable", 670], ["in", 683], ["treated", 686], ["rats", 694], [".", 698], ["Syk", 700], ["inhibition", 704], ["suppressed", 715], ["synovial", 726], ["cytokines", 735], ["and", 745], ["cartilage", 749], ["oligomeric", 759], ["matrix", 770], ["protein", 777], ["(", 785], ["COMP", 786], [")", 790], ["in", 792], ["serum", 795], [",", 800], ["suggesting", 802], ["a", 813], ["sensitive", 815], ["and", 825], ["reliable", 829], ["biomarker", 838], ["for", 848], ["R406", 852], ["activity", 857], [".", 865], ["These", 867], ["results", 873], ["highlight", 881], ["the", 891], ["role", 895], ["of", 900], ["activating", 903], ["Fcgamma", 914], ["receptors", 922], ["in", 932], ["inflammatory", 935], ["synovitis", 948], ["and", 958], ["suggest", 962], ["that", 970], ["interruption", 975], ["of", 988], ["the", 991], ["signaling", 995], ["cascade", 1005], ["with", 1013], ["a", 1018], ["novel", 1020], ["Syk", 1026], ["inhibitor", 1030], ["may", 1040], ["be", 1044], ["a", 1047], ["useful", 1049], ["addition", 1056], ["to", 1065], ["immunosuppressive", 1068], ["disease", 1086], ["-", 1093], ["modifying", 1094], ["anti", 1104], ["-", 1108], ["rheumatic", 1109], ["drugs", 1119], ["currently", 1125], ["used", 1135], ["in", 1140], ["the", 1143], ["treatment", 1147], ["of", 1157], ["human", 1160], ["autoimmune", 1166], ["diseases", 1177], ["such", 1186], ["as", 1191], ["rheumatoid", 1194], ["arthritis", 1205], [".", 1214]]}
{"context": "\u03b1-Synuclein is an abundant presynaptic protein and a primary component of Lewy bodies in Parkinson disease. Although its pathogenic role remains unclear, in healthy nerve terminals \u03b1-synuclein undergoes a cycle of membrane binding and dissociation. An \u03b1-synuclein binding assay was used to screen for vesicle proteins involved in \u03b1-synuclein membrane interactions and showed that antibodies directed to the Ras-related GTPase Rab3a and its chaperone RabGDI abrogated \u03b1-synuclein membrane binding. Biochemical analyses, including density gradient sedimentation and co-immunoprecipitation, suggested that \u03b1-synuclein interacts with membrane-associated GTP-bound Rab3a but not to cytosolic GDP-Rab3a. Accumulation of membrane-bound \u03b1-synuclein was induced by the expression of a GTPase-deficient Rab3a mutant, by a dominant-negative GDP dissociation inhibitor mutant unable to recycle Rab3a off membranes, and by Hsp90 inhibitors, radicicol and geldanamycin, which are known to inhibit Rab3a dissociation from membranes. Thus, all treatments that inhibited Rab3a recycling also increased \u03b1-synuclein sequestration on intracellular membranes. Our results suggest that membrane-bound GTP-Rab3a stabilizes \u03b1-synuclein on synaptic vesicles and that the GDP dissociation inhibitor\u00b7Hsp90 complex that controls Rab3a membrane dissociation also regulates \u03b1-synuclein dissociation during synaptic activity.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "e855ce976fe14a41ae526b78066b56f7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[43, 45], [30, 32], [124, 126], [204, 206], [224, 226], [57, 59], [99, 101], [185, 187], [0, 2], [79, 81]], "char_spans": [[252, 262], [181, 191], [729, 739], [1200, 1210], [1344, 1354], [330, 340], [603, 613], [1085, 1095], [0, 10], [467, 477]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["an", 15], ["abundant", 18], ["presynaptic", 27], ["protein", 39], ["and", 47], ["a", 51], ["primary", 53], ["component", 61], ["of", 71], ["Lewy", 74], ["bodies", 79], ["in", 86], ["Parkinson", 89], ["disease", 99], [".", 106], ["Although", 108], ["its", 117], ["pathogenic", 121], ["role", 132], ["remains", 137], ["unclear", 145], [",", 152], ["in", 154], ["healthy", 157], ["nerve", 165], ["terminals", 171], ["\u03b1", 181], ["-", 182], ["synuclein", 183], ["undergoes", 193], ["a", 203], ["cycle", 205], ["of", 211], ["membrane", 214], ["binding", 223], ["and", 231], ["dissociation", 235], [".", 247], ["An", 249], ["\u03b1", 252], ["-", 253], ["synuclein", 254], ["binding", 264], ["assay", 272], ["was", 278], ["used", 282], ["to", 287], ["screen", 290], ["for", 297], ["vesicle", 301], ["proteins", 309], ["involved", 318], ["in", 327], ["\u03b1", 330], ["-", 331], ["synuclein", 332], ["membrane", 342], ["interactions", 351], ["and", 364], ["showed", 368], ["that", 375], ["antibodies", 380], ["directed", 391], ["to", 400], ["the", 403], ["Ras", 407], ["-", 410], ["related", 411], ["GTPase", 419], ["Rab3a", 426], ["and", 432], ["its", 436], ["chaperone", 440], ["RabGDI", 450], ["abrogated", 457], ["\u03b1", 467], ["-", 468], ["synuclein", 469], ["membrane", 479], ["binding", 488], [".", 495], ["Biochemical", 497], ["analyses", 509], [",", 517], ["including", 519], ["density", 529], ["gradient", 537], ["sedimentation", 546], ["and", 560], ["co", 564], ["-", 566], ["immunoprecipitation", 567], [",", 586], ["suggested", 588], ["that", 598], ["\u03b1", 603], ["-", 604], ["synuclein", 605], ["interacts", 615], ["with", 625], ["membrane", 630], ["-", 638], ["associated", 639], ["GTP", 650], ["-", 653], ["bound", 654], ["Rab3a", 660], ["but", 666], ["not", 670], ["to", 674], ["cytosolic", 677], ["GDP", 687], ["-", 690], ["Rab3a", 691], [".", 696], ["Accumulation", 698], ["of", 711], ["membrane", 714], ["-", 722], ["bound", 723], ["\u03b1", 729], ["-", 730], ["synuclein", 731], ["was", 741], ["induced", 745], ["by", 753], ["the", 756], ["expression", 760], ["of", 771], ["a", 774], ["GTPase", 776], ["-", 782], ["deficient", 783], ["Rab3a", 793], ["mutant", 799], [",", 805], ["by", 807], ["a", 810], ["dominant", 812], ["-", 820], ["negative", 821], ["GDP", 830], ["dissociation", 834], ["inhibitor", 847], ["mutant", 857], ["unable", 864], ["to", 871], ["recycle", 874], ["Rab3a", 882], ["off", 888], ["membranes", 892], [",", 901], ["and", 903], ["by", 907], ["Hsp90", 910], ["inhibitors", 916], [",", 926], ["radicicol", 928], ["and", 938], ["geldanamycin", 942], [",", 954], ["which", 956], ["are", 962], ["known", 966], ["to", 972], ["inhibit", 975], ["Rab3a", 983], ["dissociation", 989], ["from", 1002], ["membranes", 1007], [".", 1016], ["Thus", 1018], [",", 1022], ["all", 1024], ["treatments", 1028], ["that", 1039], ["inhibited", 1044], ["Rab3a", 1054], ["recycling", 1060], ["also", 1070], ["increased", 1075], ["\u03b1", 1085], ["-", 1086], ["synuclein", 1087], ["sequestration", 1097], ["on", 1111], ["intracellular", 1114], ["membranes", 1128], [".", 1137], ["Our", 1139], ["results", 1143], ["suggest", 1151], ["that", 1159], ["membrane", 1164], ["-", 1172], ["bound", 1173], ["GTP", 1179], ["-", 1182], ["Rab3a", 1183], ["stabilizes", 1189], ["\u03b1", 1200], ["-", 1201], ["synuclein", 1202], ["on", 1212], ["synaptic", 1215], ["vesicles", 1224], ["and", 1233], ["that", 1237], ["the", 1242], ["GDP", 1246], ["dissociation", 1250], ["inhibitor\u00b7Hsp90", 1263], ["complex", 1279], ["that", 1287], ["controls", 1292], ["Rab3a", 1301], ["membrane", 1307], ["dissociation", 1316], ["also", 1329], ["regulates", 1334], ["\u03b1", 1344], ["-", 1345], ["synuclein", 1346], ["dissociation", 1356], ["during", 1369], ["synaptic", 1376], ["activity", 1385], [".", 1393]]}
{"context": "This study was aimed to explore the mutations of ribosomal protein (RP) genes in patients with Diamond Blackfan anemia (DBA). Twenty-one cases of DBA admitted in our hospital from Dec 2008 to Aug 2012 were screened by PCR for mutations in the nine known genes associated with DBA: RPS19, RPS24, RPS17, RPL5, RPL11, RPS7, RPL35a, RPS10 and RPS26. The results found that 8 patients (38.1%) with DBA had mutations in the genes coding for ribosomal protein, in which RPS19 mutation was identified in 3 patients, RPS24, RPS7, RPL5, RPL11 and RPL35A mutations were identified respectively in 1 of the patient. No mutations were detected in RPS17, RPS10 or RPS26 genes. Thumb anomalies were found in 2 patients with RPL11 or RPL5 mutation, and hypospadias was found in 1 patient with RPS19 mutation. It is concluded that the mutation frequency of the genes coding for ribosomal protein in the patients with DBA here is lower than that in western countries. The hypospadias can be observed in some patients with RPS19 mutation and some dactyl anomalies are associated with RPL11 and RPL5 mutations.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "Diamond Blackfan anemia", "DBA"], "qid": "575a6d0ae33a41199e0f015ee20f982f", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[18, 20]], "char_spans": [[95, 117]]}, {"text": "DBA", "token_spans": [[85, 85], [179, 179], [54, 54], [22, 22], [30, 30]], "char_spans": [[393, 395], [900, 902], [276, 278], [120, 122], [146, 148]]}]}], "context_tokens": [["This", 0], ["study", 5], ["was", 11], ["aimed", 15], ["to", 21], ["explore", 24], ["the", 32], ["mutations", 36], ["of", 46], ["ribosomal", 49], ["protein", 59], ["(", 67], ["RP", 68], [")", 70], ["genes", 72], ["in", 78], ["patients", 81], ["with", 90], ["Diamond", 95], ["Blackfan", 103], ["anemia", 112], ["(", 119], ["DBA", 120], [")", 123], [".", 124], ["Twenty", 126], ["-", 132], ["one", 133], ["cases", 137], ["of", 143], ["DBA", 146], ["admitted", 150], ["in", 159], ["our", 162], ["hospital", 166], ["from", 175], ["Dec", 180], ["2008", 184], ["to", 189], ["Aug", 192], ["2012", 196], ["were", 201], ["screened", 206], ["by", 215], ["PCR", 218], ["for", 222], ["mutations", 226], ["in", 236], ["the", 239], ["nine", 243], ["known", 248], ["genes", 254], ["associated", 260], ["with", 271], ["DBA", 276], [":", 279], ["RPS19", 281], [",", 286], ["RPS24", 288], [",", 293], ["RPS17", 295], [",", 300], ["RPL5", 302], [",", 306], ["RPL11", 308], [",", 313], ["RPS7", 315], [",", 319], ["RPL35a", 321], [",", 327], ["RPS10", 329], ["and", 335], ["RPS26", 339], [".", 344], ["The", 346], ["results", 350], ["found", 358], ["that", 364], ["8", 369], ["patients", 371], ["(", 380], ["38.1", 381], ["%", 385], [")", 386], ["with", 388], ["DBA", 393], ["had", 397], ["mutations", 401], ["in", 411], ["the", 414], ["genes", 418], ["coding", 424], ["for", 431], ["ribosomal", 435], ["protein", 445], [",", 452], ["in", 454], ["which", 457], ["RPS19", 463], ["mutation", 469], ["was", 478], ["identified", 482], ["in", 493], ["3", 496], ["patients", 498], [",", 506], ["RPS24", 508], [",", 513], ["RPS7", 515], [",", 519], ["RPL5", 521], [",", 525], ["RPL11", 527], ["and", 533], ["RPL35A", 537], ["mutations", 544], ["were", 554], ["identified", 559], ["respectively", 570], ["in", 583], ["1", 586], ["of", 588], ["the", 591], ["patient", 595], [".", 602], ["No", 604], ["mutations", 607], ["were", 617], ["detected", 622], ["in", 631], ["RPS17", 634], [",", 639], ["RPS10", 641], ["or", 647], ["RPS26", 650], ["genes", 656], [".", 661], ["Thumb", 663], ["anomalies", 669], ["were", 679], ["found", 684], ["in", 690], ["2", 693], ["patients", 695], ["with", 704], ["RPL11", 709], ["or", 715], ["RPL5", 718], ["mutation", 723], [",", 731], ["and", 733], ["hypospadias", 737], ["was", 749], ["found", 753], ["in", 759], ["1", 762], ["patient", 764], ["with", 772], ["RPS19", 777], ["mutation", 783], [".", 791], ["It", 793], ["is", 796], ["concluded", 799], ["that", 809], ["the", 814], ["mutation", 818], ["frequency", 827], ["of", 837], ["the", 840], ["genes", 844], ["coding", 850], ["for", 857], ["ribosomal", 861], ["protein", 871], ["in", 879], ["the", 882], ["patients", 886], ["with", 895], ["DBA", 900], ["here", 904], ["is", 909], ["lower", 912], ["than", 918], ["that", 923], ["in", 928], ["western", 931], ["countries", 939], [".", 948], ["The", 950], ["hypospadias", 954], ["can", 966], ["be", 970], ["observed", 973], ["in", 982], ["some", 985], ["patients", 990], ["with", 999], ["RPS19", 1004], ["mutation", 1010], ["and", 1019], ["some", 1023], ["dactyl", 1028], ["anomalies", 1035], ["are", 1045], ["associated", 1049], ["with", 1060], ["RPL11", 1065], ["and", 1071], ["RPL5", 1075], ["mutations", 1080], [".", 1089]]}
{"context": "In chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be successfully targeted with the BCRABL- inhibitors imatinib, nilotinib, and dasatinib leading to complete cytogenetic (Philadelphia chromosome not detectable upon cytogenetic testing of bone marrow) and even complete molecular (BCR-ABL not detectable by PCR in peripheral blood) responses. However, CML apparently can not be cured by BCR-ABL inhibitors alone, likely due to treatment-resistance of CML stem/progenitor cells, which provokes a relapse of disease after cessation of therapy. Evidence from patients treated with allogenic stem cell transplantation or IFN-\u03b1 points to an important role of anti-tumor immunity for durable control of CML disease. Data from multiple in vitro and ex vivo studies indicate that BCR-ABL inhibitors may also influence anti-tumor immunity. Varying effects on different immune effector cell subsets and of the different compounds have been reported, the latter being due to their particular and diverse potency and spectrum of target kinases. As multiple approaches presently aim to combine BCR-ABL inhibition with immunotherapeutic strategies to improve disease control in CML, immunomodulatory effects of the available BCR-ABL inhibitors may be of direct clinical relevance. Here we review the available data regarding the effects of imatinib, nilotinib, and dasatinib on dendritic cells, T cells and natural killer cells as important cellular components of anti-tumor immunity.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "bce2c2d0b05543af83e6b5f57e3ce6da", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[143, 145], [214, 216], [8, 10], [72, 74], [50, 52], [195, 197]], "char_spans": [[797, 803], [1236, 1242], [35, 41], [412, 418], [306, 312], [1106, 1112]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["myeloid", 11], ["leukemia", 19], ["(", 28], ["CML", 29], [")", 32], [",", 33], ["BCR", 35], ["-", 38], ["ABL", 39], ["-", 42], ["mediated", 43], ["oncogenic", 52], ["signaling", 62], ["can", 72], ["be", 76], ["successfully", 79], ["targeted", 92], ["with", 101], ["the", 106], ["BCRABL-", 110], ["inhibitors", 118], ["imatinib", 129], [",", 137], ["nilotinib", 139], [",", 148], ["and", 150], ["dasatinib", 154], ["leading", 164], ["to", 172], ["complete", 175], ["cytogenetic", 184], ["(", 196], ["Philadelphia", 197], ["chromosome", 210], ["not", 221], ["detectable", 225], ["upon", 236], ["cytogenetic", 241], ["testing", 253], ["of", 261], ["bone", 264], ["marrow", 269], [")", 275], ["and", 277], ["even", 281], ["complete", 286], ["molecular", 295], ["(", 305], ["BCR", 306], ["-", 309], ["ABL", 310], ["not", 314], ["detectable", 318], ["by", 329], ["PCR", 332], ["in", 336], ["peripheral", 339], ["blood", 350], [")", 355], ["responses", 357], [".", 366], ["However", 368], [",", 375], ["CML", 377], ["apparently", 381], ["can", 392], ["not", 396], ["be", 400], ["cured", 403], ["by", 409], ["BCR", 412], ["-", 415], ["ABL", 416], ["inhibitors", 420], ["alone", 431], [",", 436], ["likely", 438], ["due", 445], ["to", 449], ["treatment", 452], ["-", 461], ["resistance", 462], ["of", 473], ["CML", 476], ["stem", 480], ["/", 484], ["progenitor", 485], ["cells", 496], [",", 501], ["which", 503], ["provokes", 509], ["a", 518], ["relapse", 520], ["of", 528], ["disease", 531], ["after", 539], ["cessation", 545], ["of", 555], ["therapy", 558], [".", 565], ["Evidence", 567], ["from", 576], ["patients", 581], ["treated", 590], ["with", 598], ["allogenic", 603], ["stem", 613], ["cell", 618], ["transplantation", 623], ["or", 639], ["IFN", 642], ["-", 645], ["\u03b1", 646], ["points", 648], ["to", 655], ["an", 658], ["important", 661], ["role", 671], ["of", 676], ["anti", 679], ["-", 683], ["tumor", 684], ["immunity", 690], ["for", 699], ["durable", 703], ["control", 711], ["of", 719], ["CML", 722], ["disease", 726], [".", 733], ["Data", 735], ["from", 740], ["multiple", 745], ["in", 754], ["vitro", 757], ["and", 763], ["ex", 767], ["vivo", 770], ["studies", 775], ["indicate", 783], ["that", 792], ["BCR", 797], ["-", 800], ["ABL", 801], ["inhibitors", 805], ["may", 816], ["also", 820], ["influence", 825], ["anti", 835], ["-", 839], ["tumor", 840], ["immunity", 846], [".", 854], ["Varying", 856], ["effects", 864], ["on", 872], ["different", 875], ["immune", 885], ["effector", 892], ["cell", 901], ["subsets", 906], ["and", 914], ["of", 918], ["the", 921], ["different", 925], ["compounds", 935], ["have", 945], ["been", 950], ["reported", 955], [",", 963], ["the", 965], ["latter", 969], ["being", 976], ["due", 982], ["to", 986], ["their", 989], ["particular", 995], ["and", 1006], ["diverse", 1010], ["potency", 1018], ["and", 1026], ["spectrum", 1030], ["of", 1039], ["target", 1042], ["kinases", 1049], [".", 1056], ["As", 1058], ["multiple", 1061], ["approaches", 1070], ["presently", 1081], ["aim", 1091], ["to", 1095], ["combine", 1098], ["BCR", 1106], ["-", 1109], ["ABL", 1110], ["inhibition", 1114], ["with", 1125], ["immunotherapeutic", 1130], ["strategies", 1148], ["to", 1159], ["improve", 1162], ["disease", 1170], ["control", 1178], ["in", 1186], ["CML", 1189], [",", 1192], ["immunomodulatory", 1194], ["effects", 1211], ["of", 1219], ["the", 1222], ["available", 1226], ["BCR", 1236], ["-", 1239], ["ABL", 1240], ["inhibitors", 1244], ["may", 1255], ["be", 1259], ["of", 1262], ["direct", 1265], ["clinical", 1272], ["relevance", 1281], [".", 1290], ["Here", 1292], ["we", 1297], ["review", 1300], ["the", 1307], ["available", 1311], ["data", 1321], ["regarding", 1326], ["the", 1336], ["effects", 1340], ["of", 1348], ["imatinib", 1351], [",", 1359], ["nilotinib", 1361], [",", 1370], ["and", 1372], ["dasatinib", 1376], ["on", 1386], ["dendritic", 1389], ["cells", 1399], [",", 1404], ["T", 1406], ["cells", 1408], ["and", 1414], ["natural", 1418], ["killer", 1426], ["cells", 1433], ["as", 1439], ["important", 1442], ["cellular", 1452], ["components", 1461], ["of", 1472], ["anti", 1475], ["-", 1479], ["tumor", 1480], ["immunity", 1486], [".", 1494]]}
{"context": "The interpretation of non-coding variants still constitutes a major challenge in the application of whole-genome sequencing in Mendelian disease, especially for single-nucleotide and other small non-coding variants. Here we present Genomiser, an analysis framework that is able not only to score the relevance of variation in the non-coding genome, but also to associate regulatory variants to specific Mendelian diseases. Genomiser scores variants through either existing methods such as CADD or a bespoke machine learning method and combines these with allele frequency, regulatory sequences, chromosomal topological domains, and phenotypic relevance to\u00a0discover variants associated to specific Mendelian disorders. Overall, Genomiser is able to identify causal regulatory variants as the\u00a0top candidate in 77% of simulated whole genomes, allowing effective detection and discovery of regulatory variants in Mendelian disease.", "qas": [{"question": "Which method is available for whole genome identification of pathogenic regulatory variants in mendelian disease?", "answers": ["Genomiser"], "qid": "4a495d88d0714bcc97e38046daa518c9", "question_tokens": [["Which", 0], ["method", 6], ["is", 13], ["available", 16], ["for", 26], ["whole", 30], ["genome", 36], ["identification", 43], ["of", 58], ["pathogenic", 61], ["regulatory", 72], ["variants", 83], ["in", 92], ["mendelian", 95], ["disease", 105], ["?", 112]], "detected_answers": [{"text": "Genomiser", "token_spans": [[40, 40], [118, 118], [74, 74]], "char_spans": [[232, 240], [727, 735], [423, 431]]}]}], "context_tokens": [["The", 0], ["interpretation", 4], ["of", 19], ["non", 22], ["-", 25], ["coding", 26], ["variants", 33], ["still", 42], ["constitutes", 48], ["a", 60], ["major", 62], ["challenge", 68], ["in", 78], ["the", 81], ["application", 85], ["of", 97], ["whole", 100], ["-", 105], ["genome", 106], ["sequencing", 113], ["in", 124], ["Mendelian", 127], ["disease", 137], [",", 144], ["especially", 146], ["for", 157], ["single", 161], ["-", 167], ["nucleotide", 168], ["and", 179], ["other", 183], ["small", 189], ["non", 195], ["-", 198], ["coding", 199], ["variants", 206], [".", 214], ["Here", 216], ["we", 221], ["present", 224], ["Genomiser", 232], [",", 241], ["an", 243], ["analysis", 246], ["framework", 255], ["that", 265], ["is", 270], ["able", 273], ["not", 278], ["only", 282], ["to", 287], ["score", 290], ["the", 296], ["relevance", 300], ["of", 310], ["variation", 313], ["in", 323], ["the", 326], ["non", 330], ["-", 333], ["coding", 334], ["genome", 341], [",", 347], ["but", 349], ["also", 353], ["to", 358], ["associate", 361], ["regulatory", 371], ["variants", 382], ["to", 391], ["specific", 394], ["Mendelian", 403], ["diseases", 413], [".", 421], ["Genomiser", 423], ["scores", 433], ["variants", 440], ["through", 449], ["either", 457], ["existing", 464], ["methods", 473], ["such", 481], ["as", 486], ["CADD", 489], ["or", 494], ["a", 497], ["bespoke", 499], ["machine", 507], ["learning", 515], ["method", 524], ["and", 531], ["combines", 535], ["these", 544], ["with", 550], ["allele", 555], ["frequency", 562], [",", 571], ["regulatory", 573], ["sequences", 584], [",", 593], ["chromosomal", 595], ["topological", 607], ["domains", 619], [",", 626], ["and", 628], ["phenotypic", 632], ["relevance", 643], ["to", 653], ["discover", 656], ["variants", 665], ["associated", 674], ["to", 685], ["specific", 688], ["Mendelian", 697], ["disorders", 707], [".", 716], ["Overall", 718], [",", 725], ["Genomiser", 727], ["is", 737], ["able", 740], ["to", 745], ["identify", 748], ["causal", 757], ["regulatory", 764], ["variants", 775], ["as", 784], ["the", 787], ["top", 791], ["candidate", 795], ["in", 805], ["77", 808], ["%", 810], ["of", 812], ["simulated", 815], ["whole", 825], ["genomes", 831], [",", 838], ["allowing", 840], ["effective", 849], ["detection", 859], ["and", 869], ["discovery", 873], ["of", 883], ["regulatory", 886], ["variants", 897], ["in", 906], ["Mendelian", 909], ["disease", 919], [".", 926]]}
{"context": "Ca(+)/calmodulin-dependent protein kinase II (CaM kinase II) has been implicated in the regulation of smooth muscle contractility. The goals of this study were to determine: 1) to what extent CaM kinase II is activated by contractile stimuli in intact arterial smooth muscle, and 2) the effect of a CaM kinase II inhibitor (KN-93) on CaM kinase II activation, phosphorylation of myosin regulatory light chains (MLC(20)), and force. Both histamine (1 microM) and KCl depolarization activated CaM kinase II with a time course preceding maximal force development, and suprabasal CaM kinase II activation was sustained during tonic contractions. CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM). KN-93 inhibited histamine-induced tonic force maintenance, whereas early force development and MLC(20) phosphorylation responses during the entire time course were unaffected. Both force development and maintenance in response to KCl were inhibited by KN-93. Rapid increases in KCl-induced MLC(20) phosphorylation were also inhibited by KN-93, whereas steady-state MLC(20) phosphorylation responses were unaffected. In contrast, phorbol 12,13-dibutyrate (PDBu) did not activate CaM kinase II and PDBu-stimulated force development was unaffected by KN-93. Thus KN-93 appears to target a step(s) essential for force maintenance in response to physiological stimuli, suggesting a role for CaM kinase II in regulating tonic contractile responses in arterial smooth muscle. Pharmacological activation of protein kinase C bypasses the KN-93 sensitive step.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "09c09f04d62340e7a2d99bac736f71ae", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[65, 67], [36, 38], [94, 96], [108, 110], [118, 120], [212, 214], [248, 250], [57, 59], [7, 9]], "char_spans": [[334, 346], [192, 204], [491, 503], [576, 588], [642, 654], [1214, 1226], [1422, 1434], [299, 311], [46, 58]]}]}], "context_tokens": [["Ca(+)/calmodulin", 0], ["-", 16], ["dependent", 17], ["protein", 27], ["kinase", 35], ["II", 42], ["(", 45], ["CaM", 46], ["kinase", 50], ["II", 57], [")", 59], ["has", 61], ["been", 65], ["implicated", 70], ["in", 81], ["the", 84], ["regulation", 88], ["of", 99], ["smooth", 102], ["muscle", 109], ["contractility", 116], [".", 129], ["The", 131], ["goals", 135], ["of", 141], ["this", 144], ["study", 149], ["were", 155], ["to", 160], ["determine", 163], [":", 172], ["1", 174], [")", 175], ["to", 177], ["what", 180], ["extent", 185], ["CaM", 192], ["kinase", 196], ["II", 203], ["is", 206], ["activated", 209], ["by", 219], ["contractile", 222], ["stimuli", 234], ["in", 242], ["intact", 245], ["arterial", 252], ["smooth", 261], ["muscle", 268], [",", 274], ["and", 276], ["2", 280], [")", 281], ["the", 283], ["effect", 287], ["of", 294], ["a", 297], ["CaM", 299], ["kinase", 303], ["II", 310], ["inhibitor", 313], ["(", 323], ["KN-93", 324], [")", 329], ["on", 331], ["CaM", 334], ["kinase", 338], ["II", 345], ["activation", 348], [",", 358], ["phosphorylation", 360], ["of", 376], ["myosin", 379], ["regulatory", 386], ["light", 397], ["chains", 403], ["(", 410], ["MLC(20", 411], [")", 417], [")", 418], [",", 419], ["and", 421], ["force", 425], [".", 430], ["Both", 432], ["histamine", 437], ["(", 447], ["1", 448], ["microM", 450], [")", 456], ["and", 458], ["KCl", 462], ["depolarization", 466], ["activated", 481], ["CaM", 491], ["kinase", 495], ["II", 502], ["with", 505], ["a", 510], ["time", 512], ["course", 517], ["preceding", 524], ["maximal", 534], ["force", 542], ["development", 548], [",", 559], ["and", 561], ["suprabasal", 565], ["CaM", 576], ["kinase", 580], ["II", 587], ["activation", 590], ["was", 601], ["sustained", 605], ["during", 615], ["tonic", 622], ["contractions", 628], [".", 640], ["CaM", 642], ["kinase", 646], ["II", 653], ["activation", 656], ["was", 667], ["inhibited", 671], ["by", 681], ["KN-93", 684], ["pretreatment", 690], ["(", 703], ["IC(50", 704], [")", 709], ["approximately", 711], ["1", 725], ["microM", 727], [")", 733], [".", 734], ["KN-93", 736], ["inhibited", 742], ["histamine", 752], ["-", 761], ["induced", 762], ["tonic", 770], ["force", 776], ["maintenance", 782], [",", 793], ["whereas", 795], ["early", 803], ["force", 809], ["development", 815], ["and", 827], ["MLC(20", 831], [")", 837], ["phosphorylation", 839], ["responses", 855], ["during", 865], ["the", 872], ["entire", 876], ["time", 883], ["course", 888], ["were", 895], ["unaffected", 900], [".", 910], ["Both", 912], ["force", 917], ["development", 923], ["and", 935], ["maintenance", 939], ["in", 951], ["response", 954], ["to", 963], ["KCl", 966], ["were", 970], ["inhibited", 975], ["by", 985], ["KN-93", 988], [".", 993], ["Rapid", 995], ["increases", 1001], ["in", 1011], ["KCl", 1014], ["-", 1017], ["induced", 1018], ["MLC(20", 1026], [")", 1032], ["phosphorylation", 1034], ["were", 1050], ["also", 1055], ["inhibited", 1060], ["by", 1070], ["KN-93", 1073], [",", 1078], ["whereas", 1080], ["steady", 1088], ["-", 1094], ["state", 1095], ["MLC(20", 1101], [")", 1107], ["phosphorylation", 1109], ["responses", 1125], ["were", 1135], ["unaffected", 1140], [".", 1150], ["In", 1152], ["contrast", 1155], [",", 1163], ["phorbol", 1165], ["12,13-dibutyrate", 1173], ["(", 1190], ["PDBu", 1191], [")", 1195], ["did", 1197], ["not", 1201], ["activate", 1205], ["CaM", 1214], ["kinase", 1218], ["II", 1225], ["and", 1228], ["PDBu", 1232], ["-", 1236], ["stimulated", 1237], ["force", 1248], ["development", 1254], ["was", 1266], ["unaffected", 1270], ["by", 1281], ["KN-93", 1284], [".", 1289], ["Thus", 1291], ["KN-93", 1296], ["appears", 1302], ["to", 1310], ["target", 1313], ["a", 1320], ["step(s", 1322], [")", 1328], ["essential", 1330], ["for", 1340], ["force", 1344], ["maintenance", 1350], ["in", 1362], ["response", 1365], ["to", 1374], ["physiological", 1377], ["stimuli", 1391], [",", 1398], ["suggesting", 1400], ["a", 1411], ["role", 1413], ["for", 1418], ["CaM", 1422], ["kinase", 1426], ["II", 1433], ["in", 1436], ["regulating", 1439], ["tonic", 1450], ["contractile", 1456], ["responses", 1468], ["in", 1478], ["arterial", 1481], ["smooth", 1490], ["muscle", 1497], [".", 1503], ["Pharmacological", 1505], ["activation", 1521], ["of", 1532], ["protein", 1535], ["kinase", 1543], ["C", 1550], ["bypasses", 1552], ["the", 1561], ["KN-93", 1565], ["sensitive", 1571], ["step", 1581], [".", 1585]]}
{"context": "Diffuse Lewy body disease (DLBD) is characterized by the presence of Lewy bodies (LB) in the neurons and neurites of cortical, subcortical, and brain stem structures. Recently, alpha-synuclein (alphaS) has been found to be a central constituent of LB. In DLBD, abnormal accumulation of alphaS has been reported in both neurons and glia, but studies on glial lesions in DLBD have been limited. We examined in detail the constituents and distribution of glial lesions in eight patients with DLBD and report the pathogenesis of the glial lesions. alphaS-positive neuronal cytoplasmic inclusions (NI), neuropil threads (NT), and coiled bodies (CB) showed similar immunostaining profiles. Without pretreatment, NI, NT, and CB were detected by all antibodies against alphaS. The immunostaining profile of star-like astrocytes (SLA) was quite different from those of NI, NT, and CB. A few SLA were stained by an antibody against the non-Abeta component portion of alphaS without pretreatment, but formic acid pretreatment dramatically enhanced SLA immunoreactivity. SLA and CB were found in all eight brains with DLBD. SLA were scarce in the brain stem, but there were hundreds of SLA per visual field at x100 magnification in the temporal cortex of most cases, while CB were found diffusely in both the cerebral cortex and brain stem, similar to NI. This suggests that the pathogenesis of SLA is different from those of NI and CB.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "0d833841a938438ba27b155f675edff5", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[35, 37]], "char_spans": [[177, 191]]}]}], "context_tokens": [["Diffuse", 0], ["Lewy", 8], ["body", 13], ["disease", 18], ["(", 26], ["DLBD", 27], [")", 31], ["is", 33], ["characterized", 36], ["by", 50], ["the", 53], ["presence", 57], ["of", 66], ["Lewy", 69], ["bodies", 74], ["(", 81], ["LB", 82], [")", 84], ["in", 86], ["the", 89], ["neurons", 93], ["and", 101], ["neurites", 105], ["of", 114], ["cortical", 117], [",", 125], ["subcortical", 127], [",", 138], ["and", 140], ["brain", 144], ["stem", 150], ["structures", 155], [".", 165], ["Recently", 167], [",", 175], ["alpha", 177], ["-", 182], ["synuclein", 183], ["(", 193], ["alphaS", 194], [")", 200], ["has", 202], ["been", 206], ["found", 211], ["to", 217], ["be", 220], ["a", 223], ["central", 225], ["constituent", 233], ["of", 245], ["LB", 248], [".", 250], ["In", 252], ["DLBD", 255], [",", 259], ["abnormal", 261], ["accumulation", 270], ["of", 283], ["alphaS", 286], ["has", 293], ["been", 297], ["reported", 302], ["in", 311], ["both", 314], ["neurons", 319], ["and", 327], ["glia", 331], [",", 335], ["but", 337], ["studies", 341], ["on", 349], ["glial", 352], ["lesions", 358], ["in", 366], ["DLBD", 369], ["have", 374], ["been", 379], ["limited", 384], [".", 391], ["We", 393], ["examined", 396], ["in", 405], ["detail", 408], ["the", 415], ["constituents", 419], ["and", 432], ["distribution", 436], ["of", 449], ["glial", 452], ["lesions", 458], ["in", 466], ["eight", 469], ["patients", 475], ["with", 484], ["DLBD", 489], ["and", 494], ["report", 498], ["the", 505], ["pathogenesis", 509], ["of", 522], ["the", 525], ["glial", 529], ["lesions", 535], [".", 542], ["alphaS", 544], ["-", 550], ["positive", 551], ["neuronal", 560], ["cytoplasmic", 569], ["inclusions", 581], ["(", 592], ["NI", 593], [")", 595], [",", 596], ["neuropil", 598], ["threads", 607], ["(", 615], ["NT", 616], [")", 618], [",", 619], ["and", 621], ["coiled", 625], ["bodies", 632], ["(", 639], ["CB", 640], [")", 642], ["showed", 644], ["similar", 651], ["immunostaining", 659], ["profiles", 674], [".", 682], ["Without", 684], ["pretreatment", 692], [",", 704], ["NI", 706], [",", 708], ["NT", 710], [",", 712], ["and", 714], ["CB", 718], ["were", 721], ["detected", 726], ["by", 735], ["all", 738], ["antibodies", 742], ["against", 753], ["alphaS.", 761], ["The", 769], ["immunostaining", 773], ["profile", 788], ["of", 796], ["star", 799], ["-", 803], ["like", 804], ["astrocytes", 809], ["(", 820], ["SLA", 821], [")", 824], ["was", 826], ["quite", 830], ["different", 836], ["from", 846], ["those", 851], ["of", 857], ["NI", 860], [",", 862], ["NT", 864], [",", 866], ["and", 868], ["CB", 872], [".", 874], ["A", 876], ["few", 878], ["SLA", 882], ["were", 886], ["stained", 891], ["by", 899], ["an", 902], ["antibody", 905], ["against", 914], ["the", 922], ["non", 926], ["-", 929], ["Abeta", 930], ["component", 936], ["portion", 946], ["of", 954], ["alphaS", 957], ["without", 964], ["pretreatment", 972], [",", 984], ["but", 986], ["formic", 990], ["acid", 997], ["pretreatment", 1002], ["dramatically", 1015], ["enhanced", 1028], ["SLA", 1037], ["immunoreactivity", 1041], [".", 1057], ["SLA", 1059], ["and", 1063], ["CB", 1067], ["were", 1070], ["found", 1075], ["in", 1081], ["all", 1084], ["eight", 1088], ["brains", 1094], ["with", 1101], ["DLBD", 1106], [".", 1110], ["SLA", 1112], ["were", 1116], ["scarce", 1121], ["in", 1128], ["the", 1131], ["brain", 1135], ["stem", 1141], [",", 1145], ["but", 1147], ["there", 1151], ["were", 1157], ["hundreds", 1162], ["of", 1171], ["SLA", 1174], ["per", 1178], ["visual", 1182], ["field", 1189], ["at", 1195], ["x100", 1198], ["magnification", 1203], ["in", 1217], ["the", 1220], ["temporal", 1224], ["cortex", 1233], ["of", 1240], ["most", 1243], ["cases", 1248], [",", 1253], ["while", 1255], ["CB", 1261], ["were", 1264], ["found", 1269], ["diffusely", 1275], ["in", 1285], ["both", 1288], ["the", 1293], ["cerebral", 1297], ["cortex", 1306], ["and", 1313], ["brain", 1317], ["stem", 1323], [",", 1327], ["similar", 1329], ["to", 1337], ["NI", 1340], [".", 1342], ["This", 1344], ["suggests", 1349], ["that", 1358], ["the", 1363], ["pathogenesis", 1367], ["of", 1380], ["SLA", 1383], ["is", 1387], ["different", 1390], ["from", 1400], ["those", 1405], ["of", 1411], ["NI", 1414], ["and", 1417], ["CB", 1421], [".", 1423]]}
{"context": "The SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and regulate chromatin function. Here we report the structure of the SET7/9 protein in the absence and presence of its cofactor product, S-adenosyl-L-homocysteine (AdoHcy). A knot within the SET domain helps form the methyltransferase active site, where AdoHcy binds and lysine methylation is likely to occur. A structure-guided comparison of sequences within the SET protein family suggests that the knot substructure and active site environment are conserved features of the SET domain.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "cdc42c838604450c83009db175c03137", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[1, 2], [58, 59], [104, 105]], "char_spans": [[4, 13], [310, 319], [596, 605]]}]}], "context_tokens": [["The", 0], ["SET", 4], ["domain", 8], ["contains", 15], ["the", 24], ["catalytic", 28], ["center", 38], ["of", 45], ["lysine", 48], ["methyltransferases", 55], ["that", 74], ["target", 79], ["the", 86], ["N", 90], ["-", 91], ["terminal", 92], ["tails", 101], ["of", 107], ["histones", 110], ["and", 119], ["regulate", 123], ["chromatin", 132], ["function", 142], [".", 150], ["Here", 152], ["we", 157], ["report", 160], ["the", 167], ["structure", 171], ["of", 181], ["the", 184], ["SET7/9", 188], ["protein", 195], ["in", 203], ["the", 206], ["absence", 210], ["and", 218], ["presence", 222], ["of", 231], ["its", 234], ["cofactor", 238], ["product", 247], [",", 254], ["S", 256], ["-", 257], ["adenosyl", 258], ["-", 266], ["L", 267], ["-", 268], ["homocysteine", 269], ["(", 282], ["AdoHcy", 283], [")", 289], [".", 290], ["A", 292], ["knot", 294], ["within", 299], ["the", 306], ["SET", 310], ["domain", 314], ["helps", 321], ["form", 327], ["the", 332], ["methyltransferase", 336], ["active", 354], ["site", 361], [",", 365], ["where", 367], ["AdoHcy", 373], ["binds", 380], ["and", 386], ["lysine", 390], ["methylation", 397], ["is", 409], ["likely", 412], ["to", 419], ["occur", 422], [".", 427], ["A", 429], ["structure", 431], ["-", 440], ["guided", 441], ["comparison", 448], ["of", 459], ["sequences", 462], ["within", 472], ["the", 479], ["SET", 483], ["protein", 487], ["family", 495], ["suggests", 502], ["that", 511], ["the", 516], ["knot", 520], ["substructure", 525], ["and", 538], ["active", 542], ["site", 549], ["environment", 554], ["are", 566], ["conserved", 570], ["features", 580], ["of", 589], ["the", 592], ["SET", 596], ["domain", 600], [".", 606]]}
{"context": "Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood-counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5640bc900f45497f94ba9ba680a9a645", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[42, 44], [159, 161]], "char_spans": [[250, 256], [914, 920]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["was", 31], ["the", 35], ["first", 39], ["human", 45], ["malignancy", 51], ["to", 62], ["be", 65], ["associated", 68], ["with", 79], ["a", 84], ["single", 86], ["genetic", 93], ["abnormality", 101], [",", 112], ["characterized", 114], ["by", 128], ["a", 131], ["reciprocal", 133], ["translocation", 144], ["involving", 158], ["chromosomes", 168], ["9", 180], ["and", 182], ["22", 186], ["(", 189], ["the", 190], ["Philadelphia", 194], ["chromosome", 207], [")", 217], [".", 218], ["The", 220], ["fusion", 224], ["gene", 231], ["that", 236], ["results", 241], ["(", 249], ["BCR", 250], ["-", 253], ["ABL", 254], [")", 257], ["produces", 259], ["a", 268], ["constitutively", 270], ["activated", 285], ["tyrosine", 295], ["kinase", 304], ["that", 311], ["exists", 316], ["in", 323], ["different", 326], ["isoforms", 336], ["depending", 345], ["on", 355], ["BCR", 358], ["break", 362], ["-", 367], ["points", 368], [".", 374], ["Imatinib", 376], ["mesylate", 385], ["is", 394], ["a", 397], ["highly", 399], ["selective", 406], ["inhibitor", 416], ["of", 426], ["this", 429], ["kinase", 434], [",", 440], ["producing", 442], ["normal", 452], ["blood", 459], ["-", 464], ["counts", 465], ["in", 472], ["98", 475], ["%", 477], ["of", 479], ["patients", 482], ["in", 491], ["chronic", 494], ["phase", 502], ["CML", 508], ["and", 512], ["disappearance", 516], ["of", 530], ["the", 533], ["Philadelphia", 537], ["chromosome", 550], ["in", 561], ["86", 564], ["%", 566], [".", 567], ["However", 569], [",", 576], ["17", 578], ["%", 580], ["of", 582], ["patients", 585], ["in", 594], ["the", 597], ["chronic", 601], ["phase", 609], ["will", 615], ["either", 620], ["relapse", 627], ["or", 635], ["develop", 638], ["resistance", 646], ["resulting", 657], ["mainly", 667], ["from", 674], ["one", 679], ["or", 683], ["more", 686], ["point", 691], ["mutations", 697], ["affecting", 707], ["at", 717], ["least", 720], ["30", 726], ["amino", 729], ["acids", 735], ["within", 741], ["the", 748], ["Abl", 752], ["kinase", 756], ["protein", 763], [".", 770], ["This", 772], ["review", 777], ["focuses", 784], ["on", 792], ["the", 795], ["relevant", 799], ["biology", 808], ["of", 816], ["CML", 819], [",", 822], ["imatinib", 824], ["mesylate", 833], ["resistance", 842], ["mechanisms", 853], [",", 863], ["and", 865], ["the", 869], ["current", 873], ["status", 881], ["of", 888], ["the", 891], ["next", 895], ["generation", 900], ["of", 911], ["Bcr", 914], ["-", 917], ["Abl", 918], ["inhibitors", 922], [".", 932]]}
{"context": "Parkinson's disease is the most common neurodegenerative movement disorder. \u03b1-Synuclein is a small synaptic protein that has been linked to familial Parkinson's disease (PD) and is also the primary component of Lewy bodies, the hallmark neuropathology found in the brain of sporadic and familial PD patients. The function of \u03b1-synuclein is currently unknown, although it has been implicated in the regulation of synaptic vesicle localization or fusion. Recently, overexpression of \u03b1-synuclein was shown to cause cytoplasmic vesicle accumulation in a yeast model of \u03b1-synuclein toxicity, but the exact role \u03b1-synuclein played in mediating this vesicle aggregation is unclear. Here, we show that \u03b1-synuclein induces aggregation of many yeast Rab GTPase proteins, that \u03b1-synuclein aggregation is enhanced in yeast mutants that produce high levels of acidic phospholipids, and that \u03b1-synuclein colocalizes with yeast membranes that are enriched for phosphatidic acid. Significantly, we demonstrate that \u03b1-synuclein expression induces vulnerability to perturbations of Ypt6 and other proteins involved in retrograde endosome-Golgi transport, linking a specific trafficking defect to \u03b1-synuclein phospholipid binding. These data suggest new pathogenic mechanisms for \u03b1-synuclein neurotoxicity.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "dcbeada03bcb4f4d8ba89ab6cff60b0d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[84, 86], [108, 110], [125, 127], [157, 159], [58, 60], [138, 140], [216, 218], [11, 13], [203, 205], [176, 178], [99, 101]], "char_spans": [[481, 491], [606, 616], [694, 704], [878, 888], [325, 335], [766, 776], [1261, 1271], [76, 86], [1178, 1188], [999, 1009], [565, 575]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["is", 20], ["the", 23], ["most", 27], ["common", 32], ["neurodegenerative", 39], ["movement", 57], ["disorder", 66], [".", 74], ["\u03b1", 76], ["-", 77], ["Synuclein", 78], ["is", 88], ["a", 91], ["small", 93], ["synaptic", 99], ["protein", 108], ["that", 116], ["has", 121], ["been", 125], ["linked", 130], ["to", 137], ["familial", 140], ["Parkinson", 149], ["'s", 158], ["disease", 161], ["(", 169], ["PD", 170], [")", 172], ["and", 174], ["is", 178], ["also", 181], ["the", 186], ["primary", 190], ["component", 198], ["of", 208], ["Lewy", 211], ["bodies", 216], [",", 222], ["the", 224], ["hallmark", 228], ["neuropathology", 237], ["found", 252], ["in", 258], ["the", 261], ["brain", 265], ["of", 271], ["sporadic", 274], ["and", 283], ["familial", 287], ["PD", 296], ["patients", 299], [".", 307], ["The", 309], ["function", 313], ["of", 322], ["\u03b1", 325], ["-", 326], ["synuclein", 327], ["is", 337], ["currently", 340], ["unknown", 350], [",", 357], ["although", 359], ["it", 368], ["has", 371], ["been", 375], ["implicated", 380], ["in", 391], ["the", 394], ["regulation", 398], ["of", 409], ["synaptic", 412], ["vesicle", 421], ["localization", 429], ["or", 442], ["fusion", 445], [".", 451], ["Recently", 453], [",", 461], ["overexpression", 463], ["of", 478], ["\u03b1", 481], ["-", 482], ["synuclein", 483], ["was", 493], ["shown", 497], ["to", 503], ["cause", 506], ["cytoplasmic", 512], ["vesicle", 524], ["accumulation", 532], ["in", 545], ["a", 548], ["yeast", 550], ["model", 556], ["of", 562], ["\u03b1", 565], ["-", 566], ["synuclein", 567], ["toxicity", 577], [",", 585], ["but", 587], ["the", 591], ["exact", 595], ["role", 601], ["\u03b1", 606], ["-", 607], ["synuclein", 608], ["played", 618], ["in", 625], ["mediating", 628], ["this", 638], ["vesicle", 643], ["aggregation", 651], ["is", 663], ["unclear", 666], [".", 673], ["Here", 675], [",", 679], ["we", 681], ["show", 684], ["that", 689], ["\u03b1", 694], ["-", 695], ["synuclein", 696], ["induces", 706], ["aggregation", 714], ["of", 726], ["many", 729], ["yeast", 734], ["Rab", 740], ["GTPase", 744], ["proteins", 751], [",", 759], ["that", 761], ["\u03b1", 766], ["-", 767], ["synuclein", 768], ["aggregation", 778], ["is", 790], ["enhanced", 793], ["in", 802], ["yeast", 805], ["mutants", 811], ["that", 819], ["produce", 824], ["high", 832], ["levels", 837], ["of", 844], ["acidic", 847], ["phospholipids", 854], [",", 867], ["and", 869], ["that", 873], ["\u03b1", 878], ["-", 879], ["synuclein", 880], ["colocalizes", 890], ["with", 902], ["yeast", 907], ["membranes", 913], ["that", 923], ["are", 928], ["enriched", 932], ["for", 941], ["phosphatidic", 945], ["acid", 958], [".", 962], ["Significantly", 964], [",", 977], ["we", 979], ["demonstrate", 982], ["that", 994], ["\u03b1", 999], ["-", 1000], ["synuclein", 1001], ["expression", 1011], ["induces", 1022], ["vulnerability", 1030], ["to", 1044], ["perturbations", 1047], ["of", 1061], ["Ypt6", 1064], ["and", 1069], ["other", 1073], ["proteins", 1079], ["involved", 1088], ["in", 1097], ["retrograde", 1100], ["endosome", 1111], ["-", 1119], ["Golgi", 1120], ["transport", 1126], [",", 1135], ["linking", 1137], ["a", 1145], ["specific", 1147], ["trafficking", 1156], ["defect", 1168], ["to", 1175], ["\u03b1", 1178], ["-", 1179], ["synuclein", 1180], ["phospholipid", 1190], ["binding", 1203], [".", 1210], ["These", 1212], ["data", 1218], ["suggest", 1223], ["new", 1231], ["pathogenic", 1235], ["mechanisms", 1246], ["for", 1257], ["\u03b1", 1261], ["-", 1262], ["synuclein", 1263], ["neurotoxicity", 1273], [".", 1286]]}
{"context": "Alpha-synuclein\u00a0(\u03b1-syn) is the main protein component of Lewy bodies (LBs), that together with nigrostriatal dopamine neuron loss constitute typical pathological hallmarks of Parkinson's disease (PD). Glutamate N-methyl-d-aspartate receptor (NMDAR) abnormalities, peculiarly involving NR2B-containing NMDAR, have been observed in the brain of PD patients and in several experimental models of the disease. Recent findings, indicating that \u03b1-syn can modulate NMDAR trafficking and function, suggest that this protein may be a pivotal regulator of NMDAR activity. Prompted by these evidences, we used fluorescence immunocytochemistry, western blotting and ratiometric Ca(2+) measurements to investigate whether wild type (wt) or C-terminally truncated \u03b1-syn can specifically modulate NR2B-containing NMDAR levels, subcellular trafficking and function. In addition, we evaluated whether the exposure of primary cortical neurons to increasing concentrations of rotenone could differentially regulate NR2B levels and cell viability in the presence or in the absence of \u03b1-syn. Our results indicate that both wt and C-terminally truncated \u03b1-syn negatively modulate NR2B-containing NMDAR levels, membrane translocation and function. Moreover, we found that absence of \u03b1-syn abolishes the rotenone-dependent decrease of NR2B levels and reduces neuronal vulnerability in primary cortical neurons. These findings suggest that \u03b1-syn can modulate neuronal resilience by regulating NR2B-containing NMDAR, whose specific alterations could connect \u03b1-syn pathology to neuronal degeneration in PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8d63de36b0444dddb8a5c62a74c27315", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["syn", 19], [")", 22], ["is", 24], ["the", 27], ["main", 31], ["protein", 36], ["component", 44], ["of", 54], ["Lewy", 57], ["bodies", 62], ["(", 69], ["LBs", 70], [")", 73], [",", 74], ["that", 76], ["together", 81], ["with", 90], ["nigrostriatal", 95], ["dopamine", 109], ["neuron", 118], ["loss", 125], ["constitute", 130], ["typical", 141], ["pathological", 149], ["hallmarks", 162], ["of", 172], ["Parkinson", 175], ["'s", 184], ["disease", 187], ["(", 195], ["PD", 196], [")", 198], [".", 199], ["Glutamate", 201], ["N", 211], ["-", 212], ["methyl", 213], ["-", 219], ["d", 220], ["-", 221], ["aspartate", 222], ["receptor", 232], ["(", 241], ["NMDAR", 242], [")", 247], ["abnormalities", 249], [",", 262], ["peculiarly", 264], ["involving", 275], ["NR2B", 285], ["-", 289], ["containing", 290], ["NMDAR", 301], [",", 306], ["have", 308], ["been", 313], ["observed", 318], ["in", 327], ["the", 330], ["brain", 334], ["of", 340], ["PD", 343], ["patients", 346], ["and", 355], ["in", 359], ["several", 362], ["experimental", 370], ["models", 383], ["of", 390], ["the", 393], ["disease", 397], [".", 404], ["Recent", 406], ["findings", 413], [",", 421], ["indicating", 423], ["that", 434], ["\u03b1", 439], ["-", 440], ["syn", 441], ["can", 445], ["modulate", 449], ["NMDAR", 458], ["trafficking", 464], ["and", 476], ["function", 480], [",", 488], ["suggest", 490], ["that", 498], ["this", 503], ["protein", 508], ["may", 516], ["be", 520], ["a", 523], ["pivotal", 525], ["regulator", 533], ["of", 543], ["NMDAR", 546], ["activity", 552], [".", 560], ["Prompted", 562], ["by", 571], ["these", 574], ["evidences", 580], [",", 589], ["we", 591], ["used", 594], ["fluorescence", 599], ["immunocytochemistry", 612], [",", 631], ["western", 633], ["blotting", 641], ["and", 650], ["ratiometric", 654], ["Ca(2", 666], ["+", 670], [")", 671], ["measurements", 673], ["to", 686], ["investigate", 689], ["whether", 701], ["wild", 709], ["type", 714], ["(", 719], ["wt", 720], [")", 722], ["or", 724], ["C", 727], ["-", 728], ["terminally", 729], ["truncated", 740], ["\u03b1", 750], ["-", 751], ["syn", 752], ["can", 756], ["specifically", 760], ["modulate", 773], ["NR2B", 782], ["-", 786], ["containing", 787], ["NMDAR", 798], ["levels", 804], [",", 810], ["subcellular", 812], ["trafficking", 824], ["and", 836], ["function", 840], [".", 848], ["In", 850], ["addition", 853], [",", 861], ["we", 863], ["evaluated", 866], ["whether", 876], ["the", 884], ["exposure", 888], ["of", 897], ["primary", 900], ["cortical", 908], ["neurons", 917], ["to", 925], ["increasing", 928], ["concentrations", 939], ["of", 954], ["rotenone", 957], ["could", 966], ["differentially", 972], ["regulate", 987], ["NR2B", 996], ["levels", 1001], ["and", 1008], ["cell", 1012], ["viability", 1017], ["in", 1027], ["the", 1030], ["presence", 1034], ["or", 1043], ["in", 1046], ["the", 1049], ["absence", 1053], ["of", 1061], ["\u03b1", 1064], ["-", 1065], ["syn", 1066], [".", 1069], ["Our", 1071], ["results", 1075], ["indicate", 1083], ["that", 1092], ["both", 1097], ["wt", 1102], ["and", 1105], ["C", 1109], ["-", 1110], ["terminally", 1111], ["truncated", 1122], ["\u03b1", 1132], ["-", 1133], ["syn", 1134], ["negatively", 1138], ["modulate", 1149], ["NR2B", 1158], ["-", 1162], ["containing", 1163], ["NMDAR", 1174], ["levels", 1180], [",", 1186], ["membrane", 1188], ["translocation", 1197], ["and", 1211], ["function", 1215], [".", 1223], ["Moreover", 1225], [",", 1233], ["we", 1235], ["found", 1238], ["that", 1244], ["absence", 1249], ["of", 1257], ["\u03b1", 1260], ["-", 1261], ["syn", 1262], ["abolishes", 1266], ["the", 1276], ["rotenone", 1280], ["-", 1288], ["dependent", 1289], ["decrease", 1299], ["of", 1308], ["NR2B", 1311], ["levels", 1316], ["and", 1323], ["reduces", 1327], ["neuronal", 1335], ["vulnerability", 1344], ["in", 1358], ["primary", 1361], ["cortical", 1369], ["neurons", 1378], [".", 1385], ["These", 1387], ["findings", 1393], ["suggest", 1402], ["that", 1410], ["\u03b1", 1415], ["-", 1416], ["syn", 1417], ["can", 1421], ["modulate", 1425], ["neuronal", 1434], ["resilience", 1443], ["by", 1454], ["regulating", 1457], ["NR2B", 1468], ["-", 1472], ["containing", 1473], ["NMDAR", 1484], [",", 1489], ["whose", 1491], ["specific", 1497], ["alterations", 1506], ["could", 1518], ["connect", 1524], ["\u03b1", 1532], ["-", 1533], ["syn", 1534], ["pathology", 1538], ["to", 1548], ["neuronal", 1551], ["degeneration", 1560], ["in", 1573], ["PD", 1576], [".", 1578]]}
{"context": "Parkinson's disease (PD) is one of the most common degenerative disorders of the central nervous system that produces motor and non-motor symptoms. The majority of cases are idiopathic and characterized by the presence of Lewy bodies containing fibrillar \u03b1-synuclein. Small ubiquitin-related modifier (SUMO) immunoreactivity was observed among others in cases with PD. Key disease-associated proteins are SUMO-modified, linking this posttranslational modification to neurodegeneration. SUMOylation and SUMO-mediated mechanisms have been intensively studied in recent years, revealing nuclear and extranuclear functions for SUMO in a variety of cellular processes, including the regulation of transcriptional activity, modulation of signal transduction pathways, and response to cellular stress. This points to a role for SUMO more than just an antagonist to ubiquitin and proteasomal degradation. The identification of risk and age-at-onset gene loci was a breakthrough in PD and promoted the understanding of molecular mechanisms in the pathology. PD has been increasingly linked with mitochondrial dysfunction and impaired mitochondrial quality control. Interestingly, SUMO is involved in many of these processes and up-regulated in response to cellular stress, further emphasizing the importance of SUMOylation in physiology and disease.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "5116ed1e5bce44f9a571d769db4825bf", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["one", 28], ["of", 32], ["the", 35], ["most", 39], ["common", 44], ["degenerative", 51], ["disorders", 64], ["of", 74], ["the", 77], ["central", 81], ["nervous", 89], ["system", 97], ["that", 104], ["produces", 109], ["motor", 118], ["and", 124], ["non", 128], ["-", 131], ["motor", 132], ["symptoms", 138], [".", 146], ["The", 148], ["majority", 152], ["of", 161], ["cases", 164], ["are", 170], ["idiopathic", 174], ["and", 185], ["characterized", 189], ["by", 203], ["the", 206], ["presence", 210], ["of", 219], ["Lewy", 222], ["bodies", 227], ["containing", 234], ["fibrillar", 245], ["\u03b1", 255], ["-", 256], ["synuclein", 257], [".", 266], ["Small", 268], ["ubiquitin", 274], ["-", 283], ["related", 284], ["modifier", 292], ["(", 301], ["SUMO", 302], [")", 306], ["immunoreactivity", 308], ["was", 325], ["observed", 329], ["among", 338], ["others", 344], ["in", 351], ["cases", 354], ["with", 360], ["PD", 365], [".", 367], ["Key", 369], ["disease", 373], ["-", 380], ["associated", 381], ["proteins", 392], ["are", 401], ["SUMO", 405], ["-", 409], ["modified", 410], [",", 418], ["linking", 420], ["this", 428], ["posttranslational", 433], ["modification", 451], ["to", 464], ["neurodegeneration", 467], [".", 484], ["SUMOylation", 486], ["and", 498], ["SUMO", 502], ["-", 506], ["mediated", 507], ["mechanisms", 516], ["have", 527], ["been", 532], ["intensively", 537], ["studied", 549], ["in", 557], ["recent", 560], ["years", 567], [",", 572], ["revealing", 574], ["nuclear", 584], ["and", 592], ["extranuclear", 596], ["functions", 609], ["for", 619], ["SUMO", 623], ["in", 628], ["a", 631], ["variety", 633], ["of", 641], ["cellular", 644], ["processes", 653], [",", 662], ["including", 664], ["the", 674], ["regulation", 678], ["of", 689], ["transcriptional", 692], ["activity", 708], [",", 716], ["modulation", 718], ["of", 729], ["signal", 732], ["transduction", 739], ["pathways", 752], [",", 760], ["and", 762], ["response", 766], ["to", 775], ["cellular", 778], ["stress", 787], [".", 793], ["This", 795], ["points", 800], ["to", 807], ["a", 810], ["role", 812], ["for", 817], ["SUMO", 821], ["more", 826], ["than", 831], ["just", 836], ["an", 841], ["antagonist", 844], ["to", 855], ["ubiquitin", 858], ["and", 868], ["proteasomal", 872], ["degradation", 884], [".", 895], ["The", 897], ["identification", 901], ["of", 916], ["risk", 919], ["and", 924], ["age", 928], ["-", 931], ["at", 932], ["-", 934], ["onset", 935], ["gene", 941], ["loci", 946], ["was", 951], ["a", 955], ["breakthrough", 957], ["in", 970], ["PD", 973], ["and", 976], ["promoted", 980], ["the", 989], ["understanding", 993], ["of", 1007], ["molecular", 1010], ["mechanisms", 1020], ["in", 1031], ["the", 1034], ["pathology", 1038], [".", 1047], ["PD", 1049], ["has", 1052], ["been", 1056], ["increasingly", 1061], ["linked", 1074], ["with", 1081], ["mitochondrial", 1086], ["dysfunction", 1100], ["and", 1112], ["impaired", 1116], ["mitochondrial", 1125], ["quality", 1139], ["control", 1147], [".", 1154], ["Interestingly", 1156], [",", 1169], ["SUMO", 1171], ["is", 1176], ["involved", 1179], ["in", 1188], ["many", 1191], ["of", 1196], ["these", 1199], ["processes", 1205], ["and", 1215], ["up", 1219], ["-", 1221], ["regulated", 1222], ["in", 1232], ["response", 1235], ["to", 1244], ["cellular", 1247], ["stress", 1256], [",", 1262], ["further", 1264], ["emphasizing", 1272], ["the", 1284], ["importance", 1288], ["of", 1299], ["SUMOylation", 1302], ["in", 1314], ["physiology", 1317], ["and", 1328], ["disease", 1332], [".", 1339]]}
{"context": "This study evaluated the effectiveness of quetiapine for subjects with post-traumatic stress disorder (PTSD) who were already on a stable dose of a selective serotonin reuptake inhibitor (SSRI) but had significant PTSD symptoms. Fifteen subjects were enrolled in an 8-week open-label trial for PTSD in which quetiapine was added to an SSRI. Subjects were on a stable dose of the SSRI for at least 6 weeks before study entry and had a Clincian-Administered PTSD Scale (CAPS) score of greater than or equal to 50 at study baseline. The mean age of subjects was 49 years (eight men and seven women). The average duration of PTSD was 29 years, one-third of subjects had combat-related PTSD, and two-thirds had noncombat PTSD. The mean dose prescribed in the study was 216 mg per day. The initial median CAPS score was 80, indicating severe PTSD. The addition of a modest dose of quetiapine provided significant relief from PTSD symptoms with a 42% overall improvement in PTSD symptoms based on the CAPS and significant improvement along each dimension of symptoms: re-experiencing (Z=-3.24, P=0.0012), hyperarousal (Z=-3.30, P=0.001) and avoidance (Z=-2.13, P=0.03). Subjects rated themselves as 45% improved on average on the Davidson Trauma Scale and reported a 44% decrease in their level of disability and impairment as reflected by the Sheehan Disability Scale. Subjects with PTSD who had significant PTSD symptoms when on an SSRI benefited from the addition of quetiapine. Patients improved significantly on all three clusters of PTSD symptoms: re-experiencing, hyperarousal and avoidance.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "de9aff425efc4c5493a66c2ba35ef6cf", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[10, 14]], "char_spans": [[71, 100]]}, {"text": "PTSD", "token_spans": [[16, 16], [144, 144], [37, 37], [85, 85], [122, 122], [192, 192], [267, 267], [52, 52], [292, 292], [169, 169], [183, 183], [136, 136], [271, 271]], "char_spans": [[103, 106], [716, 719], [214, 217], [456, 459], [621, 624], [967, 970], [1377, 1380], [294, 297], [1532, 1535], [836, 839], [919, 922], [681, 684], [1402, 1405]]}]}], "context_tokens": [["This", 0], ["study", 5], ["evaluated", 11], ["the", 21], ["effectiveness", 25], ["of", 39], ["quetiapine", 42], ["for", 53], ["subjects", 57], ["with", 66], ["post", 71], ["-", 75], ["traumatic", 76], ["stress", 86], ["disorder", 93], ["(", 102], ["PTSD", 103], [")", 107], ["who", 109], ["were", 113], ["already", 118], ["on", 126], ["a", 129], ["stable", 131], ["dose", 138], ["of", 143], ["a", 146], ["selective", 148], ["serotonin", 158], ["reuptake", 168], ["inhibitor", 177], ["(", 187], ["SSRI", 188], [")", 192], ["but", 194], ["had", 198], ["significant", 202], ["PTSD", 214], ["symptoms", 219], [".", 227], ["Fifteen", 229], ["subjects", 237], ["were", 246], ["enrolled", 251], ["in", 260], ["an", 263], ["8-week", 266], ["open", 273], ["-", 277], ["label", 278], ["trial", 284], ["for", 290], ["PTSD", 294], ["in", 299], ["which", 302], ["quetiapine", 308], ["was", 319], ["added", 323], ["to", 329], ["an", 332], ["SSRI", 335], [".", 339], ["Subjects", 341], ["were", 350], ["on", 355], ["a", 358], ["stable", 360], ["dose", 367], ["of", 372], ["the", 375], ["SSRI", 379], ["for", 384], ["at", 388], ["least", 391], ["6", 397], ["weeks", 399], ["before", 405], ["study", 412], ["entry", 418], ["and", 424], ["had", 428], ["a", 432], ["Clincian", 434], ["-", 442], ["Administered", 443], ["PTSD", 456], ["Scale", 461], ["(", 467], ["CAPS", 468], [")", 472], ["score", 474], ["of", 480], ["greater", 483], ["than", 491], ["or", 496], ["equal", 499], ["to", 505], ["50", 508], ["at", 511], ["study", 514], ["baseline", 520], [".", 528], ["The", 530], ["mean", 534], ["age", 539], ["of", 543], ["subjects", 546], ["was", 555], ["49", 559], ["years", 562], ["(", 568], ["eight", 569], ["men", 575], ["and", 579], ["seven", 583], ["women", 589], [")", 594], [".", 595], ["The", 597], ["average", 601], ["duration", 609], ["of", 618], ["PTSD", 621], ["was", 626], ["29", 630], ["years", 633], [",", 638], ["one", 640], ["-", 643], ["third", 644], ["of", 650], ["subjects", 653], ["had", 662], ["combat", 666], ["-", 672], ["related", 673], ["PTSD", 681], [",", 685], ["and", 687], ["two", 691], ["-", 694], ["thirds", 695], ["had", 702], ["noncombat", 706], ["PTSD", 716], [".", 720], ["The", 722], ["mean", 726], ["dose", 731], ["prescribed", 736], ["in", 747], ["the", 750], ["study", 754], ["was", 760], ["216", 764], ["mg", 768], ["per", 771], ["day", 775], [".", 778], ["The", 780], ["initial", 784], ["median", 792], ["CAPS", 799], ["score", 804], ["was", 810], ["80", 814], [",", 816], ["indicating", 818], ["severe", 829], ["PTSD", 836], [".", 840], ["The", 842], ["addition", 846], ["of", 855], ["a", 858], ["modest", 860], ["dose", 867], ["of", 872], ["quetiapine", 875], ["provided", 886], ["significant", 895], ["relief", 907], ["from", 914], ["PTSD", 919], ["symptoms", 924], ["with", 933], ["a", 938], ["42", 940], ["%", 942], ["overall", 944], ["improvement", 952], ["in", 964], ["PTSD", 967], ["symptoms", 972], ["based", 981], ["on", 987], ["the", 990], ["CAPS", 994], ["and", 999], ["significant", 1003], ["improvement", 1015], ["along", 1027], ["each", 1033], ["dimension", 1038], ["of", 1048], ["symptoms", 1051], [":", 1059], ["re", 1061], ["-", 1063], ["experiencing", 1064], ["(", 1077], ["Z=-3.24", 1078], [",", 1085], ["P=0.0012", 1087], [")", 1095], [",", 1096], ["hyperarousal", 1098], ["(", 1111], ["Z=-3.30", 1112], [",", 1119], ["P=0.001", 1121], [")", 1128], ["and", 1130], ["avoidance", 1134], ["(", 1144], ["Z=-2.13", 1145], [",", 1152], ["P=0.03", 1154], [")", 1160], [".", 1161], ["Subjects", 1163], ["rated", 1172], ["themselves", 1178], ["as", 1189], ["45", 1192], ["%", 1194], ["improved", 1196], ["on", 1205], ["average", 1208], ["on", 1216], ["the", 1219], ["Davidson", 1223], ["Trauma", 1232], ["Scale", 1239], ["and", 1245], ["reported", 1249], ["a", 1258], ["44", 1260], ["%", 1262], ["decrease", 1264], ["in", 1273], ["their", 1276], ["level", 1282], ["of", 1288], ["disability", 1291], ["and", 1302], ["impairment", 1306], ["as", 1317], ["reflected", 1320], ["by", 1330], ["the", 1333], ["Sheehan", 1337], ["Disability", 1345], ["Scale", 1356], [".", 1361], ["Subjects", 1363], ["with", 1372], ["PTSD", 1377], ["who", 1382], ["had", 1386], ["significant", 1390], ["PTSD", 1402], ["symptoms", 1407], ["when", 1416], ["on", 1421], ["an", 1424], ["SSRI", 1427], ["benefited", 1432], ["from", 1442], ["the", 1447], ["addition", 1451], ["of", 1460], ["quetiapine", 1463], [".", 1473], ["Patients", 1475], ["improved", 1484], ["significantly", 1493], ["on", 1507], ["all", 1510], ["three", 1514], ["clusters", 1520], ["of", 1529], ["PTSD", 1532], ["symptoms", 1537], [":", 1545], ["re", 1547], ["-", 1549], ["experiencing", 1550], [",", 1562], ["hyperarousal", 1564], ["and", 1577], ["avoidance", 1581], [".", 1590]]}
{"context": "To analyze the relationship between the type I interferon (IFN) signature and clinical response to rituximab in rheumatoid arthritis (RA) patients. Twenty RA patients were treated with rituximab (cohort 1). Clinical response was defined as a decrease in the Disease Activity Score evaluated in 28 joints (DAS28) and as a response according to the European League Against Rheumatism (EULAR) criteria at week 12 and week 24. The presence of an IFN signature was analyzed in peripheral blood mononuclear cells by measuring the expression levels of 3 IFN response genes by quantitative polymerase chain reaction analysis. After comparison with the findings in healthy controls, patients were classified as having an IFN high or an IFN low signature. The data were confirmed in a second independent cohort (n = 31). Serum IFN\u03b1 bioactivity was analyzed using a reporter assay. In cohort 1, there was a better clinical response to rituximab in the IFN low signature group. Consistent with these findings, patients with an IFN low signature had a significantly greater reduction in the DAS28 and more often achieved a EULAR response at weeks 12 and 24 as compared with the patients with an IFN high signature in cohort 2 versus cohort 1. The pooled data showed a significantly stronger decrease in the DAS28 in IFN low signature patients at weeks 12 and 24 as compared with the IFN high signature group and a more frequent EULAR response at week 12. Accordingly, serum IFN\u03b1 bioactivity at baseline was inversely associated with the clinical response, although this result did not reach statistical significance. The type I IFN signature negatively predicts the clinical response to rituximab treatment in patients with RA. This finding supports the notion that IFN signaling plays a role in the immunopathology of RA.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "0c569438ed394a3b9e7d3c5ed7abd507", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[290, 291], [83, 84], [10, 12]], "char_spans": [[1615, 1627], [442, 454], [59, 72]]}]}], "context_tokens": [["To", 0], ["analyze", 3], ["the", 11], ["relationship", 15], ["between", 28], ["the", 36], ["type", 40], ["I", 45], ["interferon", 47], ["(", 58], ["IFN", 59], [")", 62], ["signature", 64], ["and", 74], ["clinical", 78], ["response", 87], ["to", 96], ["rituximab", 99], ["in", 109], ["rheumatoid", 112], ["arthritis", 123], ["(", 133], ["RA", 134], [")", 136], ["patients", 138], [".", 146], ["Twenty", 148], ["RA", 155], ["patients", 158], ["were", 167], ["treated", 172], ["with", 180], ["rituximab", 185], ["(", 195], ["cohort", 196], ["1", 203], [")", 204], [".", 205], ["Clinical", 207], ["response", 216], ["was", 225], ["defined", 229], ["as", 237], ["a", 240], ["decrease", 242], ["in", 251], ["the", 254], ["Disease", 258], ["Activity", 266], ["Score", 275], ["evaluated", 281], ["in", 291], ["28", 294], ["joints", 297], ["(", 304], ["DAS28", 305], [")", 310], ["and", 312], ["as", 316], ["a", 319], ["response", 321], ["according", 330], ["to", 340], ["the", 343], ["European", 347], ["League", 356], ["Against", 363], ["Rheumatism", 371], ["(", 382], ["EULAR", 383], [")", 388], ["criteria", 390], ["at", 399], ["week", 402], ["12", 407], ["and", 410], ["week", 414], ["24", 419], [".", 421], ["The", 423], ["presence", 427], ["of", 436], ["an", 439], ["IFN", 442], ["signature", 446], ["was", 456], ["analyzed", 460], ["in", 469], ["peripheral", 472], ["blood", 483], ["mononuclear", 489], ["cells", 501], ["by", 507], ["measuring", 510], ["the", 520], ["expression", 524], ["levels", 535], ["of", 542], ["3", 545], ["IFN", 547], ["response", 551], ["genes", 560], ["by", 566], ["quantitative", 569], ["polymerase", 582], ["chain", 593], ["reaction", 599], ["analysis", 608], [".", 616], ["After", 618], ["comparison", 624], ["with", 635], ["the", 640], ["findings", 644], ["in", 653], ["healthy", 656], ["controls", 664], [",", 672], ["patients", 674], ["were", 683], ["classified", 688], ["as", 699], ["having", 702], ["an", 709], ["IFN", 712], ["high", 716], ["or", 721], ["an", 724], ["IFN", 727], ["low", 731], ["signature", 735], [".", 744], ["The", 746], ["data", 750], ["were", 755], ["confirmed", 760], ["in", 770], ["a", 773], ["second", 775], ["independent", 782], ["cohort", 794], ["(", 801], ["n", 802], ["=", 804], ["31", 806], [")", 808], [".", 809], ["Serum", 811], ["IFN\u03b1", 817], ["bioactivity", 822], ["was", 834], ["analyzed", 838], ["using", 847], ["a", 853], ["reporter", 855], ["assay", 864], [".", 869], ["In", 871], ["cohort", 874], ["1", 881], [",", 882], ["there", 884], ["was", 890], ["a", 894], ["better", 896], ["clinical", 903], ["response", 912], ["to", 921], ["rituximab", 924], ["in", 934], ["the", 937], ["IFN", 941], ["low", 945], ["signature", 949], ["group", 959], [".", 964], ["Consistent", 966], ["with", 977], ["these", 982], ["findings", 988], [",", 996], ["patients", 998], ["with", 1007], ["an", 1012], ["IFN", 1015], ["low", 1019], ["signature", 1023], ["had", 1033], ["a", 1037], ["significantly", 1039], ["greater", 1053], ["reduction", 1061], ["in", 1071], ["the", 1074], ["DAS28", 1078], ["and", 1084], ["more", 1088], ["often", 1093], ["achieved", 1099], ["a", 1108], ["EULAR", 1110], ["response", 1116], ["at", 1125], ["weeks", 1128], ["12", 1134], ["and", 1137], ["24", 1141], ["as", 1144], ["compared", 1147], ["with", 1156], ["the", 1161], ["patients", 1165], ["with", 1174], ["an", 1179], ["IFN", 1182], ["high", 1186], ["signature", 1191], ["in", 1201], ["cohort", 1204], ["2", 1211], ["versus", 1213], ["cohort", 1220], ["1", 1227], [".", 1228], ["The", 1230], ["pooled", 1234], ["data", 1241], ["showed", 1246], ["a", 1253], ["significantly", 1255], ["stronger", 1269], ["decrease", 1278], ["in", 1287], ["the", 1290], ["DAS28", 1294], ["in", 1300], ["IFN", 1303], ["low", 1307], ["signature", 1311], ["patients", 1321], ["at", 1330], ["weeks", 1333], ["12", 1339], ["and", 1342], ["24", 1346], ["as", 1349], ["compared", 1352], ["with", 1361], ["the", 1366], ["IFN", 1370], ["high", 1374], ["signature", 1379], ["group", 1389], ["and", 1395], ["a", 1399], ["more", 1401], ["frequent", 1406], ["EULAR", 1415], ["response", 1421], ["at", 1430], ["week", 1433], ["12", 1438], [".", 1440], ["Accordingly", 1442], [",", 1453], ["serum", 1455], ["IFN\u03b1", 1461], ["bioactivity", 1466], ["at", 1478], ["baseline", 1481], ["was", 1490], ["inversely", 1494], ["associated", 1504], ["with", 1515], ["the", 1520], ["clinical", 1524], ["response", 1533], [",", 1541], ["although", 1543], ["this", 1552], ["result", 1557], ["did", 1564], ["not", 1568], ["reach", 1572], ["statistical", 1578], ["significance", 1590], [".", 1602], ["The", 1604], ["type", 1608], ["I", 1613], ["IFN", 1615], ["signature", 1619], ["negatively", 1629], ["predicts", 1640], ["the", 1649], ["clinical", 1653], ["response", 1662], ["to", 1671], ["rituximab", 1674], ["treatment", 1684], ["in", 1694], ["patients", 1697], ["with", 1706], ["RA", 1711], [".", 1713], ["This", 1715], ["finding", 1720], ["supports", 1728], ["the", 1737], ["notion", 1741], ["that", 1748], ["IFN", 1753], ["signaling", 1757], ["plays", 1767], ["a", 1773], ["role", 1775], ["in", 1780], ["the", 1783], ["immunopathology", 1787], ["of", 1803], ["RA", 1806], [".", 1808]]}
{"context": "Some missense mutations and small deletions in the NOTCH3 gene, not involving cysteine residues, have been described in patients considered to be affected by paucisymptomatic CADASIL. However, the significance of such molecular variants is still unclear. We describe a 49-year-old woman with a CADASIL-like phenotype, carrying a novel cysteine-sparing mutation in exon 29 of the NOTCH3 gene, and discuss the possible pathogenetic role of this molecular variant. Even though atypical clinical and MRI findings make a diagnosis of CADASIL unlikely in this patient, our report nevertheless underlines the intriguing genotype-phenotype relationship in NOTCH3 mutations and the importance of functional investigation to ascertain the role of new NOTCH3 mutations in CADASIL pathogenesis.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "a13b2f0d01ac4624a36ad19165836bef", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[13, 13], [58, 58]], "char_spans": [[78, 85], [335, 342]]}]}], "context_tokens": [["Some", 0], ["missense", 5], ["mutations", 14], ["and", 24], ["small", 28], ["deletions", 34], ["in", 44], ["the", 47], ["NOTCH3", 51], ["gene", 58], [",", 62], ["not", 64], ["involving", 68], ["cysteine", 78], ["residues", 87], [",", 95], ["have", 97], ["been", 102], ["described", 107], ["in", 117], ["patients", 120], ["considered", 129], ["to", 140], ["be", 143], ["affected", 146], ["by", 155], ["paucisymptomatic", 158], ["CADASIL", 175], [".", 182], ["However", 184], [",", 191], ["the", 193], ["significance", 197], ["of", 210], ["such", 213], ["molecular", 218], ["variants", 228], ["is", 237], ["still", 240], ["unclear", 246], [".", 253], ["We", 255], ["describe", 258], ["a", 267], ["49-year", 269], ["-", 276], ["old", 277], ["woman", 281], ["with", 287], ["a", 292], ["CADASIL", 294], ["-", 301], ["like", 302], ["phenotype", 307], [",", 316], ["carrying", 318], ["a", 327], ["novel", 329], ["cysteine", 335], ["-", 343], ["sparing", 344], ["mutation", 352], ["in", 361], ["exon", 364], ["29", 369], ["of", 372], ["the", 375], ["NOTCH3", 379], ["gene", 386], [",", 390], ["and", 392], ["discuss", 396], ["the", 404], ["possible", 408], ["pathogenetic", 417], ["role", 430], ["of", 435], ["this", 438], ["molecular", 443], ["variant", 453], [".", 460], ["Even", 462], ["though", 467], ["atypical", 474], ["clinical", 483], ["and", 492], ["MRI", 496], ["findings", 500], ["make", 509], ["a", 514], ["diagnosis", 516], ["of", 526], ["CADASIL", 529], ["unlikely", 537], ["in", 546], ["this", 549], ["patient", 554], [",", 561], ["our", 563], ["report", 567], ["nevertheless", 574], ["underlines", 587], ["the", 598], ["intriguing", 602], ["genotype", 613], ["-", 621], ["phenotype", 622], ["relationship", 632], ["in", 645], ["NOTCH3", 648], ["mutations", 655], ["and", 665], ["the", 669], ["importance", 673], ["of", 684], ["functional", 687], ["investigation", 698], ["to", 712], ["ascertain", 715], ["the", 725], ["role", 729], ["of", 734], ["new", 737], ["NOTCH3", 741], ["mutations", 748], ["in", 758], ["CADASIL", 761], ["pathogenesis", 769], [".", 781]]}
{"context": "Vesicular transport to and from the lysosome and late endosome is defective in patients with Chediak-Higashi syndrome (CHS) and in mutant beige (bg) mice. CHS and bg cells have giant, perinuclear vesicles with characteristics of late endosomes and lysosomes that arise from dysregulated homotypic fusion. CHS and bg lysosomes also exhibit compartmental missorting of proteins, such as elastase, glucuronidase and cathepsin G. Lyst, a candidate gene for bg, was identified by direct complementary DNA selection from a yeast artificial chromosome (YAC) clone containing a 650-kilobase segment of the bg-critical region on mouse chromosome 13. Lyst is disrupted by a 5-kilobase deletion in bg mice, and Lyst messenger RNA is markedly reduced in bg homozygotes. The homologous human gene, LYST, is highly conserved with mouse Lyst, and contains a frame-shift mutation at nucleotides 117-118 of the coding domain in a CHS patient. Thus bg mice and human CHS patients have homologous disorders associated with Lyst mutations. Lyst encodes a protein with a carboxy-terminal prenylation motif and multiple potential phosphorylation sites. Lyst protein is predicted to form extended helical domains, and has a region of sequence similar to stathmin, a coiled-coil phosphoprotein thought to act as a relay integrating cellular signal response coupling.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "29efec5e73924fffae1401b29f98e261", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[15, 18]], "char_spans": [[93, 116]]}]}], "context_tokens": [["Vesicular", 0], ["transport", 10], ["to", 20], ["and", 23], ["from", 27], ["the", 32], ["lysosome", 36], ["and", 45], ["late", 49], ["endosome", 54], ["is", 63], ["defective", 66], ["in", 76], ["patients", 79], ["with", 88], ["Chediak", 93], ["-", 100], ["Higashi", 101], ["syndrome", 109], ["(", 118], ["CHS", 119], [")", 122], ["and", 124], ["in", 128], ["mutant", 131], ["beige", 138], ["(", 144], ["bg", 145], [")", 147], ["mice", 149], [".", 153], ["CHS", 155], ["and", 159], ["bg", 163], ["cells", 166], ["have", 172], ["giant", 177], [",", 182], ["perinuclear", 184], ["vesicles", 196], ["with", 205], ["characteristics", 210], ["of", 226], ["late", 229], ["endosomes", 234], ["and", 244], ["lysosomes", 248], ["that", 258], ["arise", 263], ["from", 269], ["dysregulated", 274], ["homotypic", 287], ["fusion", 297], [".", 303], ["CHS", 305], ["and", 309], ["bg", 313], ["lysosomes", 316], ["also", 326], ["exhibit", 331], ["compartmental", 339], ["missorting", 353], ["of", 364], ["proteins", 367], [",", 375], ["such", 377], ["as", 382], ["elastase", 385], [",", 393], ["glucuronidase", 395], ["and", 409], ["cathepsin", 413], ["G.", 423], ["Lyst", 426], [",", 430], ["a", 432], ["candidate", 434], ["gene", 444], ["for", 449], ["bg", 453], [",", 455], ["was", 457], ["identified", 461], ["by", 472], ["direct", 475], ["complementary", 482], ["DNA", 496], ["selection", 500], ["from", 510], ["a", 515], ["yeast", 517], ["artificial", 523], ["chromosome", 534], ["(", 545], ["YAC", 546], [")", 549], ["clone", 551], ["containing", 557], ["a", 568], ["650-kilobase", 570], ["segment", 583], ["of", 591], ["the", 594], ["bg", 598], ["-", 600], ["critical", 601], ["region", 610], ["on", 617], ["mouse", 620], ["chromosome", 626], ["13", 637], [".", 639], ["Lyst", 641], ["is", 646], ["disrupted", 649], ["by", 659], ["a", 662], ["5-kilobase", 664], ["deletion", 675], ["in", 684], ["bg", 687], ["mice", 690], [",", 694], ["and", 696], ["Lyst", 700], ["messenger", 705], ["RNA", 715], ["is", 719], ["markedly", 722], ["reduced", 731], ["in", 739], ["bg", 742], ["homozygotes", 745], [".", 756], ["The", 758], ["homologous", 762], ["human", 773], ["gene", 779], [",", 783], ["LYST", 785], [",", 789], ["is", 791], ["highly", 794], ["conserved", 801], ["with", 811], ["mouse", 816], ["Lyst", 822], [",", 826], ["and", 828], ["contains", 832], ["a", 841], ["frame", 843], ["-", 848], ["shift", 849], ["mutation", 855], ["at", 864], ["nucleotides", 867], ["117", 879], ["-", 882], ["118", 883], ["of", 887], ["the", 890], ["coding", 894], ["domain", 901], ["in", 908], ["a", 911], ["CHS", 913], ["patient", 917], [".", 924], ["Thus", 926], ["bg", 931], ["mice", 934], ["and", 939], ["human", 943], ["CHS", 949], ["patients", 953], ["have", 962], ["homologous", 967], ["disorders", 978], ["associated", 988], ["with", 999], ["Lyst", 1004], ["mutations", 1009], [".", 1018], ["Lyst", 1020], ["encodes", 1025], ["a", 1033], ["protein", 1035], ["with", 1043], ["a", 1048], ["carboxy", 1050], ["-", 1057], ["terminal", 1058], ["prenylation", 1067], ["motif", 1079], ["and", 1085], ["multiple", 1089], ["potential", 1098], ["phosphorylation", 1108], ["sites", 1124], [".", 1129], ["Lyst", 1131], ["protein", 1136], ["is", 1144], ["predicted", 1147], ["to", 1157], ["form", 1160], ["extended", 1165], ["helical", 1174], ["domains", 1182], [",", 1189], ["and", 1191], ["has", 1195], ["a", 1199], ["region", 1201], ["of", 1208], ["sequence", 1211], ["similar", 1220], ["to", 1228], ["stathmin", 1231], [",", 1239], ["a", 1241], ["coiled", 1243], ["-", 1249], ["coil", 1250], ["phosphoprotein", 1255], ["thought", 1270], ["to", 1278], ["act", 1281], ["as", 1285], ["a", 1288], ["relay", 1290], ["integrating", 1296], ["cellular", 1308], ["signal", 1317], ["response", 1324], ["coupling", 1333], [".", 1341]]}
{"context": "Most selenoproteins contain a single selenocysteine residue per polypeptide chain, encoded by an in-frame UGA codon. Selenoprotein P is unique in that its mRNA encodes 10-12 selenocysteine residues, depending on species. In addition to the high number of selenocysteines, the protein is cysteine- and histidine-rich. The function of selenoprotein P has remained elusive, in part due to the inability to express the recombinant protein. This has been attributed to presumed inefficient translation through the selenocysteine/stop codons. Herein, we report for the first time the expression of recombinant rat selenoprotein P in a transiently transfected human epithelial kidney cell line, as well as the endogenously expressed protein from HepG2 and Chinese hamster ovary cells. The majority of the expressed protein migrates with the predicted 57-kDa size of full-length glycosylated selenoprotein P. Based on the histidine-rich nature of selenoprotein P, we have purified the recombinant and endogenously expressed proteins using nickel-agarose affinity chromatography. We show that the recombinant rat and endogenous human proteins react in Western blotting and immunoprecipitation assays with commercial anti-histidine antibodies. The ability to express, purify, and immunochemically detect the recombinant protein provides a foundation for investigating the functions and efficiency of expression of this intriguing protein.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "5eea1742ec204acbbbefefd542130ee9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[160, 161], [150, 151], [106, 107], [20, 21], [60, 61]], "char_spans": [[939, 953], [884, 899], [608, 622], [117, 131], [333, 347]]}]}], "context_tokens": [["Most", 0], ["selenoproteins", 5], ["contain", 20], ["a", 28], ["single", 30], ["selenocysteine", 37], ["residue", 52], ["per", 60], ["polypeptide", 64], ["chain", 76], [",", 81], ["encoded", 83], ["by", 91], ["an", 94], ["in", 97], ["-", 99], ["frame", 100], ["UGA", 106], ["codon", 110], [".", 115], ["Selenoprotein", 117], ["P", 131], ["is", 133], ["unique", 136], ["in", 143], ["that", 146], ["its", 151], ["mRNA", 155], ["encodes", 160], ["10", 168], ["-", 170], ["12", 171], ["selenocysteine", 174], ["residues", 189], [",", 197], ["depending", 199], ["on", 209], ["species", 212], [".", 219], ["In", 221], ["addition", 224], ["to", 233], ["the", 236], ["high", 240], ["number", 245], ["of", 252], ["selenocysteines", 255], [",", 270], ["the", 272], ["protein", 276], ["is", 284], ["cysteine-", 287], ["and", 297], ["histidine", 301], ["-", 310], ["rich", 311], [".", 315], ["The", 317], ["function", 321], ["of", 330], ["selenoprotein", 333], ["P", 347], ["has", 349], ["remained", 353], ["elusive", 362], [",", 369], ["in", 371], ["part", 374], ["due", 379], ["to", 383], ["the", 386], ["inability", 390], ["to", 400], ["express", 403], ["the", 411], ["recombinant", 415], ["protein", 427], [".", 434], ["This", 436], ["has", 441], ["been", 445], ["attributed", 450], ["to", 461], ["presumed", 464], ["inefficient", 473], ["translation", 485], ["through", 497], ["the", 505], ["selenocysteine", 509], ["/", 523], ["stop", 524], ["codons", 529], [".", 535], ["Herein", 537], [",", 543], ["we", 545], ["report", 548], ["for", 555], ["the", 559], ["first", 563], ["time", 569], ["the", 574], ["expression", 578], ["of", 589], ["recombinant", 592], ["rat", 604], ["selenoprotein", 608], ["P", 622], ["in", 624], ["a", 627], ["transiently", 629], ["transfected", 641], ["human", 653], ["epithelial", 659], ["kidney", 670], ["cell", 677], ["line", 682], [",", 686], ["as", 688], ["well", 691], ["as", 696], ["the", 699], ["endogenously", 703], ["expressed", 716], ["protein", 726], ["from", 734], ["HepG2", 739], ["and", 745], ["Chinese", 749], ["hamster", 757], ["ovary", 765], ["cells", 771], [".", 776], ["The", 778], ["majority", 782], ["of", 791], ["the", 794], ["expressed", 798], ["protein", 808], ["migrates", 816], ["with", 825], ["the", 830], ["predicted", 834], ["57-kDa", 844], ["size", 851], ["of", 856], ["full", 859], ["-", 863], ["length", 864], ["glycosylated", 871], ["selenoprotein", 884], ["P.", 898], ["Based", 901], ["on", 907], ["the", 910], ["histidine", 914], ["-", 923], ["rich", 924], ["nature", 929], ["of", 936], ["selenoprotein", 939], ["P", 953], [",", 954], ["we", 956], ["have", 959], ["purified", 964], ["the", 973], ["recombinant", 977], ["and", 989], ["endogenously", 993], ["expressed", 1006], ["proteins", 1016], ["using", 1025], ["nickel", 1031], ["-", 1037], ["agarose", 1038], ["affinity", 1046], ["chromatography", 1055], [".", 1069], ["We", 1071], ["show", 1074], ["that", 1079], ["the", 1084], ["recombinant", 1088], ["rat", 1100], ["and", 1104], ["endogenous", 1108], ["human", 1119], ["proteins", 1125], ["react", 1134], ["in", 1140], ["Western", 1143], ["blotting", 1151], ["and", 1160], ["immunoprecipitation", 1164], ["assays", 1184], ["with", 1191], ["commercial", 1196], ["anti", 1207], ["-", 1211], ["histidine", 1212], ["antibodies", 1222], [".", 1232], ["The", 1234], ["ability", 1238], ["to", 1246], ["express", 1249], [",", 1256], ["purify", 1258], [",", 1264], ["and", 1266], ["immunochemically", 1270], ["detect", 1287], ["the", 1294], ["recombinant", 1298], ["protein", 1310], ["provides", 1318], ["a", 1327], ["foundation", 1329], ["for", 1340], ["investigating", 1344], ["the", 1358], ["functions", 1362], ["and", 1372], ["efficiency", 1376], ["of", 1387], ["expression", 1390], ["of", 1401], ["this", 1404], ["intriguing", 1409], ["protein", 1420], [".", 1427]]}
{"context": "Erythrasma is a superficial skin infection caused by Corynebacterium minutissimum . Interdigital erythrasma is the most common form and is easily confused with tinea pedis. The aim of this study was to determine the prevalence of interdigital erythrasma in patients with clinically suspected tinea pedis. This study was performed between January 1, 2011, and January 31, 2012. It included 182 patients who presented with concerns about interdigital lesions. All of the patients were examined with a Wood's lamp, and smears were stained with Gram's method. Direct examination with 20% potassium hydroxide was performed. Of 182 patients with interdigital lesions, 73 (40.1%) were diagnosed as having erythrasma. The mean \u00b1 SD age of the patients with erythrasma was 45.52 \u00b1 10.83 years (range, 22-70 years). Most of the patients with erythrasma were women (56.2%). The most often clinical finding was desquamation. Using only Wood's lamp examination or Gram's staining resulted in 31 (42.5%) or 14 (19.2%) positive patients, respectively. Using Wood's lamp examination and Gram's staining concurrently resulted in 28 positive patients (38.4%). Interdigital erythrasma is a common condition and can be difficult to differentiate from tinea pedis. Simple and rapid diagnosis can be made with Wood's lamp examination, but Gram's staining is also a useful method, especially in patients with negative Wood's lamp examination findings.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "621a8b1e22974c4191648d5fc91e9ce2", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[53, 80]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["skin", 28], ["infection", 33], ["caused", 43], ["by", 50], ["Corynebacterium", 53], ["minutissimum", 69], [".", 82], ["Interdigital", 84], ["erythrasma", 97], ["is", 108], ["the", 111], ["most", 115], ["common", 120], ["form", 127], ["and", 132], ["is", 136], ["easily", 139], ["confused", 146], ["with", 155], ["tinea", 160], ["pedis", 166], [".", 171], ["The", 173], ["aim", 177], ["of", 181], ["this", 184], ["study", 189], ["was", 195], ["to", 199], ["determine", 202], ["the", 212], ["prevalence", 216], ["of", 227], ["interdigital", 230], ["erythrasma", 243], ["in", 254], ["patients", 257], ["with", 266], ["clinically", 271], ["suspected", 282], ["tinea", 292], ["pedis", 298], [".", 303], ["This", 305], ["study", 310], ["was", 316], ["performed", 320], ["between", 330], ["January", 338], ["1", 346], [",", 347], ["2011", 349], [",", 353], ["and", 355], ["January", 359], ["31", 367], [",", 369], ["2012", 371], [".", 375], ["It", 377], ["included", 380], ["182", 389], ["patients", 393], ["who", 402], ["presented", 406], ["with", 416], ["concerns", 421], ["about", 430], ["interdigital", 436], ["lesions", 449], [".", 456], ["All", 458], ["of", 462], ["the", 465], ["patients", 469], ["were", 478], ["examined", 483], ["with", 492], ["a", 497], ["Wood", 499], ["'s", 503], ["lamp", 506], [",", 510], ["and", 512], ["smears", 516], ["were", 523], ["stained", 528], ["with", 536], ["Gram", 541], ["'s", 545], ["method", 548], [".", 554], ["Direct", 556], ["examination", 563], ["with", 575], ["20", 580], ["%", 582], ["potassium", 584], ["hydroxide", 594], ["was", 604], ["performed", 608], [".", 617], ["Of", 619], ["182", 622], ["patients", 626], ["with", 635], ["interdigital", 640], ["lesions", 653], [",", 660], ["73", 662], ["(", 665], ["40.1", 666], ["%", 670], [")", 671], ["were", 673], ["diagnosed", 678], ["as", 688], ["having", 691], ["erythrasma", 698], [".", 708], ["The", 710], ["mean", 714], ["\u00b1", 719], ["SD", 721], ["age", 724], ["of", 728], ["the", 731], ["patients", 735], ["with", 744], ["erythrasma", 749], ["was", 760], ["45.52", 764], ["\u00b1", 770], ["10.83", 772], ["years", 778], ["(", 784], ["range", 785], [",", 790], ["22", 792], ["-", 794], ["70", 795], ["years", 798], [")", 803], [".", 804], ["Most", 806], ["of", 811], ["the", 814], ["patients", 818], ["with", 827], ["erythrasma", 832], ["were", 843], ["women", 848], ["(", 854], ["56.2", 855], ["%", 859], [")", 860], [".", 861], ["The", 863], ["most", 867], ["often", 872], ["clinical", 878], ["finding", 887], ["was", 895], ["desquamation", 899], [".", 911], ["Using", 913], ["only", 919], ["Wood", 924], ["'s", 928], ["lamp", 931], ["examination", 936], ["or", 948], ["Gram", 951], ["'s", 955], ["staining", 958], ["resulted", 967], ["in", 976], ["31", 979], ["(", 982], ["42.5", 983], ["%", 987], [")", 988], ["or", 990], ["14", 993], ["(", 996], ["19.2", 997], ["%", 1001], [")", 1002], ["positive", 1004], ["patients", 1013], [",", 1021], ["respectively", 1023], [".", 1035], ["Using", 1037], ["Wood", 1043], ["'s", 1047], ["lamp", 1050], ["examination", 1055], ["and", 1067], ["Gram", 1071], ["'s", 1075], ["staining", 1078], ["concurrently", 1087], ["resulted", 1100], ["in", 1109], ["28", 1112], ["positive", 1115], ["patients", 1124], ["(", 1133], ["38.4", 1134], ["%", 1138], [")", 1139], [".", 1140], ["Interdigital", 1142], ["erythrasma", 1155], ["is", 1166], ["a", 1169], ["common", 1171], ["condition", 1178], ["and", 1188], ["can", 1192], ["be", 1196], ["difficult", 1199], ["to", 1209], ["differentiate", 1212], ["from", 1226], ["tinea", 1231], ["pedis", 1237], [".", 1242], ["Simple", 1244], ["and", 1251], ["rapid", 1255], ["diagnosis", 1261], ["can", 1271], ["be", 1275], ["made", 1278], ["with", 1283], ["Wood", 1288], ["'s", 1292], ["lamp", 1295], ["examination", 1300], [",", 1311], ["but", 1313], ["Gram", 1317], ["'s", 1321], ["staining", 1324], ["is", 1333], ["also", 1336], ["a", 1341], ["useful", 1343], ["method", 1350], [",", 1356], ["especially", 1358], ["in", 1369], ["patients", 1372], ["with", 1381], ["negative", 1386], ["Wood", 1395], ["'s", 1399], ["lamp", 1402], ["examination", 1407], ["findings", 1419], [".", 1427]]}
{"context": "Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality in adults worldwide, but its epidemiology varies markedly by region. Whilst in high-income countries, the predominant burden of CAP is in the elderly and those with chronic cardiovascular and pulmonary co-morbidity, CAP patients in low-income settings are often of working age and, in sub-Saharan Africa, frequently HIV-positive. Although region-specific aetiological data are limited, they are sufficient to highlight major trends: in high-burden settings, tuberculosis (TB) is a common cause of acute CAP; Gram-negative pathogens such as Klebsiella pneumoniae are regionally important; and HIV-associated opportunistic infections are common but difficult to diagnose. These differences in epidemiology and aetiological profile suggest that modified approaches to diagnosis, severity assessment and empirical antimicrobial therapy of CAP are necessary, but tailored individualized management approaches are constrained by limitations in the availability of radiological and laboratory diagnostic services, as well as medical expertise. The widespread introduction of the Xpert MTB/RIF platform represents a major advance for TB diagnosis, but innovations in rapid diagnostics for other opportunistic pathogens are urgently needed. Severity assessment tools (e.g. CURB65) that are used to guide early management decisions in CAP have not been widely validated in low-income settings and locally adapted tools are required. The optimal approach to initial antimicrobial therapy choices such as the need to provide early empirical cover for atypical bacteria and TB remain poorly defined. Improvements in supportive care such as correcting hypoxaemia and intravenous fluid management represent opportunities for substantial reductions in mortality.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "2b4d642eb6aa447ea6ee20683b83444a", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[3, 3]], "char_spans": [[19, 27]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["pneumonia", 19], ["(", 29], ["CAP", 30], [")", 33], ["is", 35], ["a", 38], ["common", 40], ["cause", 47], ["of", 53], ["morbidity", 56], ["and", 66], ["mortality", 70], ["in", 80], ["adults", 83], ["worldwide", 90], [",", 99], ["but", 101], ["its", 105], ["epidemiology", 109], ["varies", 122], ["markedly", 129], ["by", 138], ["region", 141], [".", 147], ["Whilst", 149], ["in", 156], ["high", 159], ["-", 163], ["income", 164], ["countries", 171], [",", 180], ["the", 182], ["predominant", 186], ["burden", 198], ["of", 205], ["CAP", 208], ["is", 212], ["in", 215], ["the", 218], ["elderly", 222], ["and", 230], ["those", 234], ["with", 240], ["chronic", 245], ["cardiovascular", 253], ["and", 268], ["pulmonary", 272], ["co", 282], ["-", 284], ["morbidity", 285], [",", 294], ["CAP", 296], ["patients", 300], ["in", 309], ["low", 312], ["-", 315], ["income", 316], ["settings", 323], ["are", 332], ["often", 336], ["of", 342], ["working", 345], ["age", 353], ["and", 357], [",", 360], ["in", 362], ["sub", 365], ["-", 368], ["Saharan", 369], ["Africa", 377], [",", 383], ["frequently", 385], ["HIV", 396], ["-", 399], ["positive", 400], [".", 408], ["Although", 410], ["region", 419], ["-", 425], ["specific", 426], ["aetiological", 435], ["data", 448], ["are", 453], ["limited", 457], [",", 464], ["they", 466], ["are", 471], ["sufficient", 475], ["to", 486], ["highlight", 489], ["major", 499], ["trends", 505], [":", 511], ["in", 513], ["high", 516], ["-", 520], ["burden", 521], ["settings", 528], [",", 536], ["tuberculosis", 538], ["(", 551], ["TB", 552], [")", 554], ["is", 556], ["a", 559], ["common", 561], ["cause", 568], ["of", 574], ["acute", 577], ["CAP", 583], [";", 586], ["Gram", 588], ["-", 592], ["negative", 593], ["pathogens", 602], ["such", 612], ["as", 617], ["Klebsiella", 620], ["pneumoniae", 631], ["are", 642], ["regionally", 646], ["important", 657], [";", 666], ["and", 668], ["HIV", 672], ["-", 675], ["associated", 676], ["opportunistic", 687], ["infections", 701], ["are", 712], ["common", 716], ["but", 723], ["difficult", 727], ["to", 737], ["diagnose", 740], [".", 748], ["These", 750], ["differences", 756], ["in", 768], ["epidemiology", 771], ["and", 784], ["aetiological", 788], ["profile", 801], ["suggest", 809], ["that", 817], ["modified", 822], ["approaches", 831], ["to", 842], ["diagnosis", 845], [",", 854], ["severity", 856], ["assessment", 865], ["and", 876], ["empirical", 880], ["antimicrobial", 890], ["therapy", 904], ["of", 912], ["CAP", 915], ["are", 919], ["necessary", 923], [",", 932], ["but", 934], ["tailored", 938], ["individualized", 947], ["management", 962], ["approaches", 973], ["are", 984], ["constrained", 988], ["by", 1000], ["limitations", 1003], ["in", 1015], ["the", 1018], ["availability", 1022], ["of", 1035], ["radiological", 1038], ["and", 1051], ["laboratory", 1055], ["diagnostic", 1066], ["services", 1077], [",", 1085], ["as", 1087], ["well", 1090], ["as", 1095], ["medical", 1098], ["expertise", 1106], [".", 1115], ["The", 1117], ["widespread", 1121], ["introduction", 1132], ["of", 1145], ["the", 1148], ["Xpert", 1152], ["MTB", 1158], ["/", 1161], ["RIF", 1162], ["platform", 1166], ["represents", 1175], ["a", 1186], ["major", 1188], ["advance", 1194], ["for", 1202], ["TB", 1206], ["diagnosis", 1209], [",", 1218], ["but", 1220], ["innovations", 1224], ["in", 1236], ["rapid", 1239], ["diagnostics", 1245], ["for", 1257], ["other", 1261], ["opportunistic", 1267], ["pathogens", 1281], ["are", 1291], ["urgently", 1295], ["needed", 1304], [".", 1310], ["Severity", 1312], ["assessment", 1321], ["tools", 1332], ["(", 1338], ["e.g.", 1339], ["CURB65", 1344], [")", 1350], ["that", 1352], ["are", 1357], ["used", 1361], ["to", 1366], ["guide", 1369], ["early", 1375], ["management", 1381], ["decisions", 1392], ["in", 1402], ["CAP", 1405], ["have", 1409], ["not", 1414], ["been", 1418], ["widely", 1423], ["validated", 1430], ["in", 1440], ["low", 1443], ["-", 1446], ["income", 1447], ["settings", 1454], ["and", 1463], ["locally", 1467], ["adapted", 1475], ["tools", 1483], ["are", 1489], ["required", 1493], [".", 1501], ["The", 1503], ["optimal", 1507], ["approach", 1515], ["to", 1524], ["initial", 1527], ["antimicrobial", 1535], ["therapy", 1549], ["choices", 1557], ["such", 1565], ["as", 1570], ["the", 1573], ["need", 1577], ["to", 1582], ["provide", 1585], ["early", 1593], ["empirical", 1599], ["cover", 1609], ["for", 1615], ["atypical", 1619], ["bacteria", 1628], ["and", 1637], ["TB", 1641], ["remain", 1644], ["poorly", 1651], ["defined", 1658], [".", 1665], ["Improvements", 1667], ["in", 1680], ["supportive", 1683], ["care", 1694], ["such", 1699], ["as", 1704], ["correcting", 1707], ["hypoxaemia", 1718], ["and", 1729], ["intravenous", 1733], ["fluid", 1745], ["management", 1751], ["represent", 1762], ["opportunities", 1772], ["for", 1786], ["substantial", 1790], ["reductions", 1802], ["in", 1813], ["mortality", 1816], [".", 1825]]}
{"context": "Microbicides are being developed in order to prevent sexual transmission of HIV. Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is one of the leading drug candidates in the field, currently being tested in various dosage forms, namely vaginal rings, gels, and films. In particular, a ring allowing sustained drug release for 1month is in an advanced stage of clinical testing. Two parallel phase III clinical trials are underway in sub-Saharan Africa and results are expected to be released in early 2016. This article overviews the development of dapivirine and its multiple products as potential microbicides, with particular emphasis being placed on clinical evaluation. Also, critical aspects regarding regulatory approval, manufacturing, distribution, and access are discussed.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "a9c0c53d05f1474083e2f1ad8ea28756", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[11, 11]], "char_spans": [[76, 78]]}]}], "context_tokens": [["Microbicides", 0], ["are", 13], ["being", 17], ["developed", 23], ["in", 33], ["order", 36], ["to", 42], ["prevent", 45], ["sexual", 53], ["transmission", 60], ["of", 73], ["HIV", 76], [".", 79], ["Dapivirine", 81], [",", 91], ["a", 93], ["non", 95], ["-", 98], ["nucleoside", 99], ["reverse", 110], ["transcriptase", 118], ["inhibitor", 132], [",", 141], ["is", 143], ["one", 146], ["of", 150], ["the", 153], ["leading", 157], ["drug", 165], ["candidates", 170], ["in", 181], ["the", 184], ["field", 188], [",", 193], ["currently", 195], ["being", 205], ["tested", 211], ["in", 218], ["various", 221], ["dosage", 229], ["forms", 236], [",", 241], ["namely", 243], ["vaginal", 250], ["rings", 258], [",", 263], ["gels", 265], [",", 269], ["and", 271], ["films", 275], [".", 280], ["In", 282], ["particular", 285], [",", 295], ["a", 297], ["ring", 299], ["allowing", 304], ["sustained", 313], ["drug", 323], ["release", 328], ["for", 336], ["1month", 340], ["is", 347], ["in", 350], ["an", 353], ["advanced", 356], ["stage", 365], ["of", 371], ["clinical", 374], ["testing", 383], [".", 390], ["Two", 392], ["parallel", 396], ["phase", 405], ["III", 411], ["clinical", 415], ["trials", 424], ["are", 431], ["underway", 435], ["in", 444], ["sub", 447], ["-", 450], ["Saharan", 451], ["Africa", 459], ["and", 466], ["results", 470], ["are", 478], ["expected", 482], ["to", 491], ["be", 494], ["released", 497], ["in", 506], ["early", 509], ["2016", 515], [".", 519], ["This", 521], ["article", 526], ["overviews", 534], ["the", 544], ["development", 548], ["of", 560], ["dapivirine", 563], ["and", 574], ["its", 578], ["multiple", 582], ["products", 591], ["as", 600], ["potential", 603], ["microbicides", 613], [",", 625], ["with", 627], ["particular", 632], ["emphasis", 643], ["being", 652], ["placed", 658], ["on", 665], ["clinical", 668], ["evaluation", 677], [".", 687], ["Also", 689], [",", 693], ["critical", 695], ["aspects", 704], ["regarding", 712], ["regulatory", 722], ["approval", 733], [",", 741], ["manufacturing", 743], [",", 756], ["distribution", 758], [",", 770], ["and", 772], ["access", 776], ["are", 783], ["discussed", 787], [".", 796]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary cerebrovascular disease leading to accumulating neurologic deficits and dementia. CADASIL has been linked to nucleotide substitutions and deletions in the Notch3 gene. All the mutations described until now lead to unpaired cysteine residue in the epidermal growth factor-like repeats. The authors report a family with CADASIL carrying a deletion in the Notch3 gene that did not involve a cysteine residue.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "9027c3fd24a14863929469111bec18ae", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[48, 48], [78, 78]], "char_spans": [[340, 347], [505, 512]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["hereditary", 106], ["cerebrovascular", 117], ["disease", 133], ["leading", 141], ["to", 149], ["accumulating", 152], ["neurologic", 165], ["deficits", 176], ["and", 185], ["dementia", 189], [".", 197], ["CADASIL", 199], ["has", 207], ["been", 211], ["linked", 216], ["to", 223], ["nucleotide", 226], ["substitutions", 237], ["and", 251], ["deletions", 255], ["in", 265], ["the", 268], ["Notch3", 272], ["gene", 279], [".", 283], ["All", 285], ["the", 289], ["mutations", 293], ["described", 303], ["until", 313], ["now", 319], ["lead", 323], ["to", 328], ["unpaired", 331], ["cysteine", 340], ["residue", 349], ["in", 357], ["the", 360], ["epidermal", 364], ["growth", 374], ["factor", 381], ["-", 387], ["like", 388], ["repeats", 393], [".", 400], ["The", 402], ["authors", 406], ["report", 414], ["a", 421], ["family", 423], ["with", 430], ["CADASIL", 435], ["carrying", 443], ["a", 452], ["deletion", 454], ["in", 463], ["the", 466], ["Notch3", 470], ["gene", 477], ["that", 482], ["did", 487], ["not", 491], ["involve", 495], ["a", 503], ["cysteine", 505], ["residue", 514], [".", 521]]}
{"context": "Mowat-Wilson syndrome (MWS) is characterized by severe mental retardation with seizures, specific facial dysmorphism, Hirschsprung disease, anomalies of the corpus callosum, and genitourinary and cardiac malformations. The cause of MWS is a de novo mutation in the ZEB2 gene. This report describes a Turkish boy who was clinically diagnosed with MWS and had his diagnosis confirmed by molecular analysis of the ZEB2 gene. The investigation identified a heterozygous complex rearrangement in exon 8 of ZEB2, specifically a 48-nucleotide deletion and a 44-nucleotide insertion that caused a frameshift. MWS is a relatively newly identified disorder, and even MWS patients without Hirschsprung disease can be diagnosed easily based on clinical findings alone.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "d84bc6e39f2f44b6973107b386e250ba", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[71, 71], [85, 85], [46, 46]], "char_spans": [[411, 414], [501, 504], [265, 268]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["characterized", 31], ["by", 45], ["severe", 48], ["mental", 55], ["retardation", 62], ["with", 74], ["seizures", 79], [",", 87], ["specific", 89], ["facial", 98], ["dysmorphism", 105], [",", 116], ["Hirschsprung", 118], ["disease", 131], [",", 138], ["anomalies", 140], ["of", 150], ["the", 153], ["corpus", 157], ["callosum", 164], [",", 172], ["and", 174], ["genitourinary", 178], ["and", 192], ["cardiac", 196], ["malformations", 204], [".", 217], ["The", 219], ["cause", 223], ["of", 229], ["MWS", 232], ["is", 236], ["a", 239], ["de", 241], ["novo", 244], ["mutation", 249], ["in", 258], ["the", 261], ["ZEB2", 265], ["gene", 270], [".", 274], ["This", 276], ["report", 281], ["describes", 288], ["a", 298], ["Turkish", 300], ["boy", 308], ["who", 312], ["was", 316], ["clinically", 320], ["diagnosed", 331], ["with", 341], ["MWS", 346], ["and", 350], ["had", 354], ["his", 358], ["diagnosis", 362], ["confirmed", 372], ["by", 382], ["molecular", 385], ["analysis", 395], ["of", 404], ["the", 407], ["ZEB2", 411], ["gene", 416], [".", 420], ["The", 422], ["investigation", 426], ["identified", 440], ["a", 451], ["heterozygous", 453], ["complex", 466], ["rearrangement", 474], ["in", 488], ["exon", 491], ["8", 496], ["of", 498], ["ZEB2", 501], [",", 505], ["specifically", 507], ["a", 520], ["48-nucleotide", 522], ["deletion", 536], ["and", 545], ["a", 549], ["44-nucleotide", 551], ["insertion", 565], ["that", 575], ["caused", 580], ["a", 587], ["frameshift", 589], [".", 599], ["MWS", 601], ["is", 605], ["a", 608], ["relatively", 610], ["newly", 621], ["identified", 627], ["disorder", 638], [",", 646], ["and", 648], ["even", 652], ["MWS", 657], ["patients", 661], ["without", 670], ["Hirschsprung", 678], ["disease", 691], ["can", 699], ["be", 703], ["diagnosed", 706], ["easily", 716], ["based", 723], ["on", 729], ["clinical", 732], ["findings", 741], ["alone", 750], [".", 755]]}
{"context": "The acromelic dysplasia group includes three rare disorders: Weill-Marchesani syndrome (WMS), Geleophysic dysplasia (GD) and Acromicric dysplasia (AD) all characterized by short stature, short hands and stiff joints. The clinical overlap between the three disorders is striking. Indeed, in addition to the diagnostic criteria, they all share common features including delayed bone age, cone shaped epiphyses, thick skin and heart disease. In contrast, a microspherophakic lens seems to be a characteristic feature of WMS whereas hepatomegaly and a severe outcome are encountered only in the most severe forms of GD. Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. Using genetic approaches, we have identified the molecular basis of WMS and GD which both involved the same superfamily of proteins, the ADAMTS [A Disintegrin-like And Metalloproteinase domain (reprolysin type) with ThromboSpondin type 1 repeats (TSR)]. We have found ADAMTS10 mutations in the recessive form of WMS and Fibrillin 1 mutations in the dominant form of WMS. More recently, we have identified ADAMTSL2 mutations in GD. The function of ADAMTS1 0 and AD AMTSL 2 are unknown. But the findings of FBN1 and ADAMTS10 mutations in WMS suggest a direct link between the two proteins. Using a yeast double hybrid screen, we have identified LTBP1 (Latent TGFbeta Binding protein 1) as a partner of ADAMTSL2. The combination of these findings suggests that ADAMTS10 and ADAMTSL2 are both involved in the microfibrillar network.", "qas": [{"question": "What is the mode of inheritance of Marchesani syndrome?", "answers": ["autosomal dominant or autosomal recessive"], "qid": "ec124190a5da4d4fa7754892711da6f6", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Marchesani", 35], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "autosomal dominant or autosomal recessive", "token_spans": [[118, 123]], "char_spans": [[657, 700]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["includes", 30], ["three", 39], ["rare", 45], ["disorders", 50], [":", 59], ["Weill", 61], ["-", 66], ["Marchesani", 67], ["syndrome", 78], ["(", 87], ["WMS", 88], [")", 91], [",", 92], ["Geleophysic", 94], ["dysplasia", 106], ["(", 116], ["GD", 117], [")", 119], ["and", 121], ["Acromicric", 125], ["dysplasia", 136], ["(", 146], ["AD", 147], [")", 149], ["all", 151], ["characterized", 155], ["by", 169], ["short", 172], ["stature", 178], [",", 185], ["short", 187], ["hands", 193], ["and", 199], ["stiff", 203], ["joints", 209], [".", 215], ["The", 217], ["clinical", 221], ["overlap", 230], ["between", 238], ["the", 246], ["three", 250], ["disorders", 256], ["is", 266], ["striking", 269], [".", 277], ["Indeed", 279], [",", 285], ["in", 287], ["addition", 290], ["to", 299], ["the", 302], ["diagnostic", 306], ["criteria", 317], [",", 325], ["they", 327], ["all", 332], ["share", 336], ["common", 342], ["features", 349], ["including", 358], ["delayed", 368], ["bone", 376], ["age", 381], [",", 384], ["cone", 386], ["shaped", 391], ["epiphyses", 398], [",", 407], ["thick", 409], ["skin", 415], ["and", 420], ["heart", 424], ["disease", 430], [".", 437], ["In", 439], ["contrast", 442], [",", 450], ["a", 452], ["microspherophakic", 454], ["lens", 472], ["seems", 477], ["to", 483], ["be", 486], ["a", 489], ["characteristic", 491], ["feature", 506], ["of", 514], ["WMS", 517], ["whereas", 521], ["hepatomegaly", 529], ["and", 542], ["a", 546], ["severe", 548], ["outcome", 555], ["are", 563], ["encountered", 567], ["only", 579], ["in", 584], ["the", 587], ["most", 591], ["severe", 596], ["forms", 603], ["of", 609], ["GD", 612], [".", 614], ["Finally", 616], [",", 623], ["WMS", 625], ["is", 629], ["transmitted", 632], ["either", 644], ["by", 651], ["an", 654], ["autosomal", 657], ["dominant", 667], ["or", 676], ["an", 679], ["autosomal", 682], ["recessive", 692], ["(", 702], ["AR", 703], [")", 705], ["mode", 707], ["of", 712], ["inheritance", 715], [",", 726], ["GD", 728], ["by", 731], ["an", 734], ["autosomal", 737], ["recessive", 747], ["mode", 757], ["of", 762], ["inheritance", 765], ["and", 777], ["AD", 781], ["by", 784], ["an", 787], ["autosomal", 790], ["dominant", 800], ["mode", 809], ["of", 814], ["inheritance", 817], [".", 828], ["Using", 830], ["genetic", 836], ["approaches", 844], [",", 854], ["we", 856], ["have", 859], ["identified", 864], ["the", 875], ["molecular", 879], ["basis", 889], ["of", 895], ["WMS", 898], ["and", 902], ["GD", 906], ["which", 909], ["both", 915], ["involved", 920], ["the", 929], ["same", 933], ["superfamily", 938], ["of", 950], ["proteins", 953], [",", 961], ["the", 963], ["ADAMTS", 967], ["[", 974], ["A", 975], ["Disintegrin", 977], ["-", 988], ["like", 989], ["And", 994], ["Metalloproteinase", 998], ["domain", 1016], ["(", 1023], ["reprolysin", 1024], ["type", 1035], [")", 1039], ["with", 1041], ["ThromboSpondin", 1046], ["type", 1061], ["1", 1066], ["repeats", 1068], ["(", 1076], ["TSR)].", 1077], ["We", 1084], ["have", 1087], ["found", 1092], ["ADAMTS10", 1098], ["mutations", 1107], ["in", 1117], ["the", 1120], ["recessive", 1124], ["form", 1134], ["of", 1139], ["WMS", 1142], ["and", 1146], ["Fibrillin", 1150], ["1", 1160], ["mutations", 1162], ["in", 1172], ["the", 1175], ["dominant", 1179], ["form", 1188], ["of", 1193], ["WMS", 1196], [".", 1199], ["More", 1201], ["recently", 1206], [",", 1214], ["we", 1216], ["have", 1219], ["identified", 1224], ["ADAMTSL2", 1235], ["mutations", 1244], ["in", 1254], ["GD", 1257], [".", 1259], ["The", 1261], ["function", 1265], ["of", 1274], ["ADAMTS1", 1277], ["0", 1285], ["and", 1287], ["AD", 1291], ["AMTSL", 1294], ["2", 1300], ["are", 1302], ["unknown", 1306], [".", 1313], ["But", 1315], ["the", 1319], ["findings", 1323], ["of", 1332], ["FBN1", 1335], ["and", 1340], ["ADAMTS10", 1344], ["mutations", 1353], ["in", 1363], ["WMS", 1366], ["suggest", 1370], ["a", 1378], ["direct", 1380], ["link", 1387], ["between", 1392], ["the", 1400], ["two", 1404], ["proteins", 1408], [".", 1416], ["Using", 1418], ["a", 1424], ["yeast", 1426], ["double", 1432], ["hybrid", 1439], ["screen", 1446], [",", 1452], ["we", 1454], ["have", 1457], ["identified", 1462], ["LTBP1", 1473], ["(", 1479], ["Latent", 1480], ["TGFbeta", 1487], ["Binding", 1495], ["protein", 1503], ["1", 1511], [")", 1512], ["as", 1514], ["a", 1517], ["partner", 1519], ["of", 1527], ["ADAMTSL2", 1530], [".", 1538], ["The", 1540], ["combination", 1544], ["of", 1556], ["these", 1559], ["findings", 1565], ["suggests", 1574], ["that", 1583], ["ADAMTS10", 1588], ["and", 1597], ["ADAMTSL2", 1601], ["are", 1610], ["both", 1614], ["involved", 1619], ["in", 1628], ["the", 1631], ["microfibrillar", 1635], ["network", 1650], [".", 1657]]}
{"context": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein, but other proteins, in particular the microtubule-associated protein tau, have been implicated in the pathogenesis of LBs. Tau is the major structural component of neurofibrillary tangles (NFTs). Both direct immunochemical studies of partially purified LBs and indirect immunohistochemical studies have suggested that LBs may contain tau, but most of these studies were based upon a single tau antibody, and immunologic cross-reactivity was not completely excluded. To gain insight into the relation between tau and alpha-synuclein in LBs, double immunostaining was performed in Lewy body cases with a rabbit polyclonal antibody to alpha-synuclein and a panel of monoclonal antibodies to phospho- and nonphospho-tau epitopes (Alz50, CP9, CP13, PG5, TG3, PHFI) that spanned the length of the tau molecule. Tau-immunoreactive LBs were present in the medulla in 80% of the cases, irrespective of Braak stage. All tau antibodies recognized at least some LBs, arguing against nonspecific antibody cross-reactivity. In most lesions the tau immunostaining was present at the periphery of the LB. The phospho-tau antibody, TG3, detected more LBs than any of the other tau antibodies. The proportion of LBs with tau immunoreactivity was greatest in neurons vulnerable to NETs, such as those in the locus ceruleus and basal nucleus of Meynert, and least in neurons resistant to NFTs, such as the dorsal motor nucleus of the vagus in the medulla. The present results suggest that tau may coaggregate with alpha-synuclein in LBs, especially in neuronal populations vulnerable to both NFTs and LBs.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "85b37fa6f6cb4803bcf4aa988b62bbac", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[306, 308], [138, 140], [118, 120], [27, 29]], "char_spans": [[1661, 1675], [799, 813], [683, 697], [150, 164]]}]}], "context_tokens": [["The", 0], ["major", 4], ["protein", 10], ["constituent", 18], ["of", 30], ["Lewy", 33], ["bodies", 38], ["(", 45], ["LBs", 46], [")", 49], [",", 50], ["the", 52], ["pathological", 56], ["hallmark", 69], ["of", 78], ["Parkinson", 81], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [",", 128], ["is", 130], ["considered", 133], ["to", 144], ["be", 147], ["alpha", 150], ["-", 155], ["synuclein", 156], [",", 165], ["but", 167], ["other", 171], ["proteins", 177], [",", 185], ["in", 187], ["particular", 190], ["the", 201], ["microtubule", 205], ["-", 216], ["associated", 217], ["protein", 228], ["tau", 236], [",", 239], ["have", 241], ["been", 246], ["implicated", 251], ["in", 262], ["the", 265], ["pathogenesis", 269], ["of", 282], ["LBs", 285], [".", 288], ["Tau", 290], ["is", 294], ["the", 297], ["major", 301], ["structural", 307], ["component", 318], ["of", 328], ["neurofibrillary", 331], ["tangles", 347], ["(", 355], ["NFTs", 356], [")", 360], [".", 361], ["Both", 363], ["direct", 368], ["immunochemical", 375], ["studies", 390], ["of", 398], ["partially", 401], ["purified", 411], ["LBs", 420], ["and", 424], ["indirect", 428], ["immunohistochemical", 437], ["studies", 457], ["have", 465], ["suggested", 470], ["that", 480], ["LBs", 485], ["may", 489], ["contain", 493], ["tau", 501], [",", 504], ["but", 506], ["most", 510], ["of", 515], ["these", 518], ["studies", 524], ["were", 532], ["based", 537], ["upon", 543], ["a", 548], ["single", 550], ["tau", 557], ["antibody", 561], [",", 569], ["and", 571], ["immunologic", 575], ["cross", 587], ["-", 592], ["reactivity", 593], ["was", 604], ["not", 608], ["completely", 612], ["excluded", 623], [".", 631], ["To", 633], ["gain", 636], ["insight", 641], ["into", 649], ["the", 654], ["relation", 658], ["between", 667], ["tau", 675], ["and", 679], ["alpha", 683], ["-", 688], ["synuclein", 689], ["in", 699], ["LBs", 702], [",", 705], ["double", 707], ["immunostaining", 714], ["was", 729], ["performed", 733], ["in", 743], ["Lewy", 746], ["body", 751], ["cases", 756], ["with", 762], ["a", 767], ["rabbit", 769], ["polyclonal", 776], ["antibody", 787], ["to", 796], ["alpha", 799], ["-", 804], ["synuclein", 805], ["and", 815], ["a", 819], ["panel", 821], ["of", 827], ["monoclonal", 830], ["antibodies", 841], ["to", 852], ["phospho-", 855], ["and", 864], ["nonphospho", 868], ["-", 878], ["tau", 879], ["epitopes", 883], ["(", 892], ["Alz50", 893], [",", 898], ["CP9", 900], [",", 903], ["CP13", 905], [",", 909], ["PG5", 911], [",", 914], ["TG3", 916], [",", 919], ["PHFI", 921], [")", 925], ["that", 927], ["spanned", 932], ["the", 940], ["length", 944], ["of", 951], ["the", 954], ["tau", 958], ["molecule", 962], [".", 970], ["Tau", 972], ["-", 975], ["immunoreactive", 976], ["LBs", 991], ["were", 995], ["present", 1000], ["in", 1008], ["the", 1011], ["medulla", 1015], ["in", 1023], ["80", 1026], ["%", 1028], ["of", 1030], ["the", 1033], ["cases", 1037], [",", 1042], ["irrespective", 1044], ["of", 1057], ["Braak", 1060], ["stage", 1066], [".", 1071], ["All", 1073], ["tau", 1077], ["antibodies", 1081], ["recognized", 1092], ["at", 1103], ["least", 1106], ["some", 1112], ["LBs", 1117], [",", 1120], ["arguing", 1122], ["against", 1130], ["nonspecific", 1138], ["antibody", 1150], ["cross", 1159], ["-", 1164], ["reactivity", 1165], [".", 1175], ["In", 1177], ["most", 1180], ["lesions", 1185], ["the", 1193], ["tau", 1197], ["immunostaining", 1201], ["was", 1216], ["present", 1220], ["at", 1228], ["the", 1231], ["periphery", 1235], ["of", 1245], ["the", 1248], ["LB", 1252], [".", 1254], ["The", 1256], ["phospho", 1260], ["-", 1267], ["tau", 1268], ["antibody", 1272], [",", 1280], ["TG3", 1282], [",", 1285], ["detected", 1287], ["more", 1296], ["LBs", 1301], ["than", 1305], ["any", 1310], ["of", 1314], ["the", 1317], ["other", 1321], ["tau", 1327], ["antibodies", 1331], [".", 1341], ["The", 1343], ["proportion", 1347], ["of", 1358], ["LBs", 1361], ["with", 1365], ["tau", 1370], ["immunoreactivity", 1374], ["was", 1391], ["greatest", 1395], ["in", 1404], ["neurons", 1407], ["vulnerable", 1415], ["to", 1426], ["NETs", 1429], [",", 1433], ["such", 1435], ["as", 1440], ["those", 1443], ["in", 1449], ["the", 1452], ["locus", 1456], ["ceruleus", 1462], ["and", 1471], ["basal", 1475], ["nucleus", 1481], ["of", 1489], ["Meynert", 1492], [",", 1499], ["and", 1501], ["least", 1505], ["in", 1511], ["neurons", 1514], ["resistant", 1522], ["to", 1532], ["NFTs", 1535], [",", 1539], ["such", 1541], ["as", 1546], ["the", 1549], ["dorsal", 1553], ["motor", 1560], ["nucleus", 1566], ["of", 1574], ["the", 1577], ["vagus", 1581], ["in", 1587], ["the", 1590], ["medulla", 1594], [".", 1601], ["The", 1603], ["present", 1607], ["results", 1615], ["suggest", 1623], ["that", 1631], ["tau", 1636], ["may", 1640], ["coaggregate", 1644], ["with", 1656], ["alpha", 1661], ["-", 1666], ["synuclein", 1667], ["in", 1677], ["LBs", 1680], [",", 1683], ["especially", 1685], ["in", 1696], ["neuronal", 1699], ["populations", 1708], ["vulnerable", 1720], ["to", 1731], ["both", 1734], ["NFTs", 1739], ["and", 1744], ["LBs", 1748], [".", 1751]]}
{"context": "The Ehlers-Danlos syndrome is characterized by abnormal connective tissue but bone involvement is debated. We found a reduced BMD and bone quality and increased prevalence of asymptomatic vertebral fractures in eugonadal patients with Ehlers-Danlos syndrome. These findings suggest the need of a bone health evaluation in these patients. The Ehlers-Danlos (EDS) syndrome is characterized by abnormalities of the connective tissue leading to ligamentous laxity and skin and tissue fragility. We evaluated the bone metabolism, bone mineral density (BMD) and bone quality (measured by trabecular bone score, TBS), and the prevalence of vertebral fractures (VFx) in a group of eugonadal adult EDS patients. Fifty consecutive Caucasian patients, aged 30-50\u00a0years (36 females, 14 males) with classical or hypermobility EDS and 50 age-, gender-, and body mass index (BMI)-matched control subjects were enrolled. In all subjects' calcium-phosphorous metabolism, bone turnover, BMD at the lumbar spine (LS) and femur (femoral neck, FN and total femur, FT) and TBS by dual-energy X-ray absorptiometry, and the VFx presence by spine radiograph were assessed. Patients showed reduced BMD (Z-scores LS -0.45\u2009\u00b1\u20091.00, FN -0.56\u2009\u00b1\u20091.01, FT -0.58\u2009\u00b1\u20090.92) and TBS (1.299\u2009\u00b1\u20090.111) and increased prevalence of morphometric VFx (32\u00a0%) than controls (Z-scores LS 0.09\u2009\u00b1\u20091.22, FN 0.01\u2009\u00b1\u20090.97, FT 0.08\u2009\u00b1\u20090.89; TBS 1.382\u2009\u00b1\u20090.176; VFx 8\u00a0%, p <0.05 for all comparisons), while vitamin D levels, calcium-phosphorous metabolism, and bone turnover were comparable. Fractured EDS patients showed lower TBS values than non-fractured ones (1.245\u2009\u00b1\u20090.138 vs 1.325\u2009\u00b1\u20090.086, p\u2009<\u20090.05), despite comparable BMD. In EDS patients, the VFx presence was significantly associated with TBS even after adjusting for sex, age, BMD, EDS type, and falls frequency. EDS patients have reduced BMD and bone quality (as measured by TBS) and increased prevalence of VFx.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "04374cd790ae4b8a9eae1bd08859a21e", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10], [69, 70]], "char_spans": [[56, 72], [412, 428]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["characterized", 30], ["by", 44], ["abnormal", 47], ["connective", 56], ["tissue", 67], ["but", 74], ["bone", 78], ["involvement", 83], ["is", 95], ["debated", 98], [".", 105], ["We", 107], ["found", 110], ["a", 116], ["reduced", 118], ["BMD", 126], ["and", 130], ["bone", 134], ["quality", 139], ["and", 147], ["increased", 151], ["prevalence", 161], ["of", 172], ["asymptomatic", 175], ["vertebral", 188], ["fractures", 198], ["in", 208], ["eugonadal", 211], ["patients", 221], ["with", 230], ["Ehlers", 235], ["-", 241], ["Danlos", 242], ["syndrome", 249], [".", 257], ["These", 259], ["findings", 265], ["suggest", 274], ["the", 282], ["need", 286], ["of", 291], ["a", 294], ["bone", 296], ["health", 301], ["evaluation", 308], ["in", 319], ["these", 322], ["patients", 328], [".", 336], ["The", 338], ["Ehlers", 342], ["-", 348], ["Danlos", 349], ["(", 356], ["EDS", 357], [")", 360], ["syndrome", 362], ["is", 371], ["characterized", 374], ["by", 388], ["abnormalities", 391], ["of", 405], ["the", 408], ["connective", 412], ["tissue", 423], ["leading", 430], ["to", 438], ["ligamentous", 441], ["laxity", 453], ["and", 460], ["skin", 464], ["and", 469], ["tissue", 473], ["fragility", 480], [".", 489], ["We", 491], ["evaluated", 494], ["the", 504], ["bone", 508], ["metabolism", 513], [",", 523], ["bone", 525], ["mineral", 530], ["density", 538], ["(", 546], ["BMD", 547], [")", 550], ["and", 552], ["bone", 556], ["quality", 561], ["(", 569], ["measured", 570], ["by", 579], ["trabecular", 582], ["bone", 593], ["score", 598], [",", 603], ["TBS", 605], [")", 608], [",", 609], ["and", 611], ["the", 615], ["prevalence", 619], ["of", 630], ["vertebral", 633], ["fractures", 643], ["(", 653], ["VFx", 654], [")", 657], ["in", 659], ["a", 662], ["group", 664], ["of", 670], ["eugonadal", 673], ["adult", 683], ["EDS", 689], ["patients", 693], [".", 701], ["Fifty", 703], ["consecutive", 709], ["Caucasian", 721], ["patients", 731], [",", 739], ["aged", 741], ["30", 746], ["-", 748], ["50", 749], ["years", 752], ["(", 758], ["36", 759], ["females", 762], [",", 769], ["14", 771], ["males", 774], [")", 779], ["with", 781], ["classical", 786], ["or", 796], ["hypermobility", 799], ["EDS", 813], ["and", 817], ["50", 821], ["age-", 824], [",", 828], ["gender-", 830], [",", 837], ["and", 839], ["body", 843], ["mass", 848], ["index", 853], ["(", 859], ["BMI)-matched", 860], ["control", 873], ["subjects", 881], ["were", 890], ["enrolled", 895], [".", 903], ["In", 905], ["all", 908], ["subjects", 912], ["'", 920], ["calcium", 922], ["-", 929], ["phosphorous", 930], ["metabolism", 942], [",", 952], ["bone", 954], ["turnover", 959], [",", 967], ["BMD", 969], ["at", 973], ["the", 976], ["lumbar", 980], ["spine", 987], ["(", 993], ["LS", 994], [")", 996], ["and", 998], ["femur", 1002], ["(", 1008], ["femoral", 1009], ["neck", 1017], [",", 1021], ["FN", 1023], ["and", 1026], ["total", 1030], ["femur", 1036], [",", 1041], ["FT", 1043], [")", 1045], ["and", 1047], ["TBS", 1051], ["by", 1055], ["dual", 1058], ["-", 1062], ["energy", 1063], ["X", 1070], ["-", 1071], ["ray", 1072], ["absorptiometry", 1076], [",", 1090], ["and", 1092], ["the", 1096], ["VFx", 1100], ["presence", 1104], ["by", 1113], ["spine", 1116], ["radiograph", 1122], ["were", 1133], ["assessed", 1138], [".", 1146], ["Patients", 1148], ["showed", 1157], ["reduced", 1164], ["BMD", 1172], ["(", 1176], ["Z", 1177], ["-", 1178], ["scores", 1179], ["LS", 1186], ["-0.45", 1189], ["\u00b1", 1195], ["1.00", 1197], [",", 1201], ["FN", 1203], ["-0.56", 1206], ["\u00b1", 1212], ["1.01", 1214], [",", 1218], ["FT", 1220], ["-0.58", 1223], ["\u00b1", 1229], ["0.92", 1231], [")", 1235], ["and", 1237], ["TBS", 1241], ["(", 1245], ["1.299", 1246], ["\u00b1", 1252], ["0.111", 1254], [")", 1259], ["and", 1261], ["increased", 1265], ["prevalence", 1275], ["of", 1286], ["morphometric", 1289], ["VFx", 1302], ["(", 1306], ["32", 1307], ["%", 1310], [")", 1311], ["than", 1313], ["controls", 1318], ["(", 1327], ["Z", 1328], ["-", 1329], ["scores", 1330], ["LS", 1337], ["0.09", 1340], ["\u00b1", 1345], ["1.22", 1347], [",", 1351], ["FN", 1353], ["0.01", 1356], ["\u00b1", 1361], ["0.97", 1363], [",", 1367], ["FT", 1369], ["0.08", 1372], ["\u00b1", 1377], ["0.89", 1379], [";", 1383], ["TBS", 1385], ["1.382", 1389], ["\u00b1", 1395], ["0.176", 1397], [";", 1402], ["VFx", 1404], ["8", 1408], ["%", 1410], [",", 1411], ["p", 1413], ["<", 1415], ["0.05", 1416], ["for", 1421], ["all", 1425], ["comparisons", 1429], [")", 1440], [",", 1441], ["while", 1443], ["vitamin", 1449], ["D", 1457], ["levels", 1459], [",", 1465], ["calcium", 1467], ["-", 1474], ["phosphorous", 1475], ["metabolism", 1487], [",", 1497], ["and", 1499], ["bone", 1503], ["turnover", 1508], ["were", 1517], ["comparable", 1522], [".", 1532], ["Fractured", 1534], ["EDS", 1544], ["patients", 1548], ["showed", 1557], ["lower", 1564], ["TBS", 1570], ["values", 1574], ["than", 1581], ["non", 1586], ["-", 1589], ["fractured", 1590], ["ones", 1600], ["(", 1605], ["1.245", 1606], ["\u00b1", 1612], ["0.138", 1614], ["vs", 1620], ["1.325", 1623], ["\u00b1", 1629], ["0.086", 1631], [",", 1636], ["p", 1638], ["<", 1640], ["0.05", 1642], [")", 1646], [",", 1647], ["despite", 1649], ["comparable", 1657], ["BMD", 1668], [".", 1671], ["In", 1673], ["EDS", 1676], ["patients", 1680], [",", 1688], ["the", 1690], ["VFx", 1694], ["presence", 1698], ["was", 1707], ["significantly", 1711], ["associated", 1725], ["with", 1736], ["TBS", 1741], ["even", 1745], ["after", 1750], ["adjusting", 1756], ["for", 1766], ["sex", 1770], [",", 1773], ["age", 1775], [",", 1778], ["BMD", 1780], [",", 1783], ["EDS", 1785], ["type", 1789], [",", 1793], ["and", 1795], ["falls", 1799], ["frequency", 1805], [".", 1814], ["EDS", 1816], ["patients", 1820], ["have", 1829], ["reduced", 1834], ["BMD", 1842], ["and", 1846], ["bone", 1850], ["quality", 1855], ["(", 1863], ["as", 1864], ["measured", 1867], ["by", 1876], ["TBS", 1879], [")", 1882], ["and", 1884], ["increased", 1888], ["prevalence", 1898], ["of", 1909], ["VFx", 1912], [".", 1915]]}
{"context": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran. This drug can be used for patients who need emergency surgery or invasive procedures, as well as those with life-threatening or uncontrolled bleeding.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "f73ca3611d5841e2923535d013cca075", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[14, 14]], "char_spans": [[102, 111]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["humanized", 18], ["monoclonal", 28], ["antibody", 39], ["fragment", 48], ["for", 57], ["reversal", 61], ["of", 70], ["the", 73], ["anticoagulant", 77], ["effects", 91], ["of", 99], ["dabigatran", 102], [".", 112], ["This", 114], ["drug", 119], ["can", 124], ["be", 128], ["used", 131], ["for", 136], ["patients", 140], ["who", 149], ["need", 153], ["emergency", 158], ["surgery", 168], ["or", 176], ["invasive", 179], ["procedures", 188], [",", 198], ["as", 200], ["well", 203], ["as", 208], ["those", 211], ["with", 217], ["life", 222], ["-", 226], ["threatening", 227], ["or", 239], ["uncontrolled", 242], ["bleeding", 255], [".", 263]]}
{"context": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell cancer driven by the BCR-ABL fusion protein that arises from the translocation of chromosomes 9 and 22. The disease begins with an indolent chronic phase (CP) that can last for 3 to 5 years. If untreated, it progresses into accelerated phase (AP) and within a year, blast phase (BP). Survival at this point is less than 1 year. during disease progression, mutations and the Philadelphia chromosome (Ph) appear (a process called clonal evolution). The only known curative therapy for CML is allogeneic bone marrow transplant (BMT). However, toxicity is formidable, with treatment- related mortality reported in the 30% range. Thus, effective therapy that maintains the patient with CML in CP with minimal toxicity is the goal for treatment of modern therapies. Because the preeminent mutation driving CML is BCr-ABL, therapies targeting BCR-ABL are the logical choice for disease-specific therapy. BCR-ABL inhibitors, such as imatinib, are proof that targeting specific genetic mutations associated with cancer yields a high degree of efficacy with minimal toxicity. This review will outline the evolution of therapy in CML. Preimatinib and imatinib-based treatment strategies, clinical efficacy, and the mechanism of imatinib resistance will be discussed. The discovery of the Ph and, subsequently, the identification of BCr-ABL revolutionized the treatment of CML. Cytoreductive chemotherapy, such as busulfan and hydroxyurea, was a mainstay of therapy to control white blood cell (WBC) counts; however, it did not modify the progression of the disease to AP and BP. The overall survival with CML ranges from 45 to 58 months in patients treated with cytoreductive therapy only. Treatment was advanced with the introduction of interferon (IFn ) immunotherapy in the 1980s. In some studies, IFn produced a complete hematologic response (CHR) in more than 50% of patients; however, its nonspecific immunostimulatory mechanism also produced severe flulike symptoms that limited tolerability. despite the significant toxicity, cost, and inconvenience of injecting IFN thrice weekly, median survival ranged from 60 to 89 months. Allogeneic BMT is the only known curative therapy for CML; however, treatment-related mortality from infection, bleeding, and graft versus host disease, age, and the availability of suitable donors limits its widespread use. Imatinib functions by competing with adenosine triphosphate (ATP) for binding to the BCr-ABL tyrosine kinase. In the absence of ATP, BCR-ABL is not able to activate downstream effector tyrosine kinase molecules that drive wBC proliferation. The International randomized Interferon versus STI571 clinical trial was the first to document the efficacy of imatinib as a first-line therapy for patients in CP. More than 90% of these patients had a CHr. Toxicities associated with this therapy are low. response in patients with advanced CML is less pronounced than in CP and is shorter lived, with less than 30% of patients achieving a CHR. For patients with CML in BP, the only viable therapy is to attempt a temporary reduction in disease burden with a salvage chemotherapy regimen, such as VAC (etoposide, cytarabine, and carboplatin). The goal of this induction chemotherapy is to induce a second remission; then the patient may be considered for allogeneic BMT. The main toxicities seen with imatinib therapy are myelosuppression, edema, and myalgia/arthralgia. In many cases, imatinib dosage can be briefly halted or lowered while the toxicity is managed. Imatinib resistance may develop at any time and inevitably leads to disease progression. resistance is usually caused by mutations within BCr-ABL, decreasing the affinity of imatinib binding. next-generation kinase inhibitors are focused on the ability to inhibit these mutated forms of BCR-ABL. For the majority of patients with CML in CP, the standard of care is to maintain the patient in CP with imatinib therapy. Clinical trials have been extraordinarily successful, with 5-year survival rates greater than 90%. Allogeneic BMT continues to be an option for those who cannot tolerate imatinib or when CML progresses on imatinib therapy.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fa4fd4baa0d847a58726d0c012409795", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[260, 262], [174, 176], [459, 461], [708, 710], [168, 170], [471, 473], [681, 683], [15, 17], [187, 189]], "char_spans": [[1381, 1387], [896, 902], [2494, 2500], [3853, 3859], [867, 873], [2542, 2548], [3704, 3710], [81, 87], [957, 963]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["hematopoietic", 36], ["stem", 50], ["cell", 55], ["cancer", 60], ["driven", 67], ["by", 74], ["the", 77], ["BCR", 81], ["-", 84], ["ABL", 85], ["fusion", 89], ["protein", 96], ["that", 104], ["arises", 109], ["from", 116], ["the", 121], ["translocation", 125], ["of", 139], ["chromosomes", 142], ["9", 154], ["and", 156], ["22", 160], [".", 162], ["The", 164], ["disease", 168], ["begins", 176], ["with", 183], ["an", 188], ["indolent", 191], ["chronic", 200], ["phase", 208], ["(", 214], ["CP", 215], [")", 217], ["that", 219], ["can", 224], ["last", 228], ["for", 233], ["3", 237], ["to", 239], ["5", 242], ["years", 244], [".", 249], ["If", 251], ["untreated", 254], [",", 263], ["it", 265], ["progresses", 268], ["into", 279], ["accelerated", 284], ["phase", 296], ["(", 302], ["AP", 303], [")", 305], ["and", 307], ["within", 311], ["a", 318], ["year", 320], [",", 324], ["blast", 326], ["phase", 332], ["(", 338], ["BP", 339], [")", 341], [".", 342], ["Survival", 344], ["at", 353], ["this", 356], ["point", 361], ["is", 367], ["less", 370], ["than", 375], ["1", 380], ["year", 382], [".", 386], ["during", 388], ["disease", 395], ["progression", 403], [",", 414], ["mutations", 416], ["and", 426], ["the", 430], ["Philadelphia", 434], ["chromosome", 447], ["(", 458], ["Ph", 459], [")", 461], ["appear", 463], ["(", 470], ["a", 471], ["process", 473], ["called", 481], ["clonal", 488], ["evolution", 495], [")", 504], [".", 505], ["The", 507], ["only", 511], ["known", 516], ["curative", 522], ["therapy", 531], ["for", 539], ["CML", 543], ["is", 547], ["allogeneic", 550], ["bone", 561], ["marrow", 566], ["transplant", 573], ["(", 584], ["BMT", 585], [")", 588], [".", 589], ["However", 591], [",", 598], ["toxicity", 600], ["is", 609], ["formidable", 612], [",", 622], ["with", 624], ["treatment-", 629], ["related", 640], ["mortality", 648], ["reported", 658], ["in", 667], ["the", 670], ["30", 674], ["%", 676], ["range", 678], [".", 683], ["Thus", 685], [",", 689], ["effective", 691], ["therapy", 701], ["that", 709], ["maintains", 714], ["the", 724], ["patient", 728], ["with", 736], ["CML", 741], ["in", 745], ["CP", 748], ["with", 751], ["minimal", 756], ["toxicity", 764], ["is", 773], ["the", 776], ["goal", 780], ["for", 785], ["treatment", 789], ["of", 799], ["modern", 802], ["therapies", 809], [".", 818], ["Because", 820], ["the", 828], ["preeminent", 832], ["mutation", 843], ["driving", 852], ["CML", 860], ["is", 864], ["BCr", 867], ["-", 870], ["ABL", 871], [",", 874], ["therapies", 876], ["targeting", 886], ["BCR", 896], ["-", 899], ["ABL", 900], ["are", 904], ["the", 908], ["logical", 912], ["choice", 920], ["for", 927], ["disease", 931], ["-", 938], ["specific", 939], ["therapy", 948], [".", 955], ["BCR", 957], ["-", 960], ["ABL", 961], ["inhibitors", 965], [",", 975], ["such", 977], ["as", 982], ["imatinib", 985], [",", 993], ["are", 995], ["proof", 999], ["that", 1005], ["targeting", 1010], ["specific", 1020], ["genetic", 1029], ["mutations", 1037], ["associated", 1047], ["with", 1058], ["cancer", 1063], ["yields", 1070], ["a", 1077], ["high", 1079], ["degree", 1084], ["of", 1091], ["efficacy", 1094], ["with", 1103], ["minimal", 1108], ["toxicity", 1116], [".", 1124], ["This", 1126], ["review", 1131], ["will", 1138], ["outline", 1143], ["the", 1151], ["evolution", 1155], ["of", 1165], ["therapy", 1168], ["in", 1176], ["CML", 1179], [".", 1182], ["Preimatinib", 1184], ["and", 1196], ["imatinib", 1200], ["-", 1208], ["based", 1209], ["treatment", 1215], ["strategies", 1225], [",", 1235], ["clinical", 1237], ["efficacy", 1246], [",", 1254], ["and", 1256], ["the", 1260], ["mechanism", 1264], ["of", 1274], ["imatinib", 1277], ["resistance", 1286], ["will", 1297], ["be", 1302], ["discussed", 1305], [".", 1314], ["The", 1316], ["discovery", 1320], ["of", 1330], ["the", 1333], ["Ph", 1337], ["and", 1340], [",", 1343], ["subsequently", 1345], [",", 1357], ["the", 1359], ["identification", 1363], ["of", 1378], ["BCr", 1381], ["-", 1384], ["ABL", 1385], ["revolutionized", 1389], ["the", 1404], ["treatment", 1408], ["of", 1418], ["CML", 1421], [".", 1424], ["Cytoreductive", 1426], ["chemotherapy", 1440], [",", 1452], ["such", 1454], ["as", 1459], ["busulfan", 1462], ["and", 1471], ["hydroxyurea", 1475], [",", 1486], ["was", 1488], ["a", 1492], ["mainstay", 1494], ["of", 1503], ["therapy", 1506], ["to", 1514], ["control", 1517], ["white", 1525], ["blood", 1531], ["cell", 1537], ["(", 1542], ["WBC", 1543], [")", 1546], ["counts", 1548], [";", 1554], ["however", 1556], [",", 1563], ["it", 1565], ["did", 1568], ["not", 1572], ["modify", 1576], ["the", 1583], ["progression", 1587], ["of", 1599], ["the", 1602], ["disease", 1606], ["to", 1614], ["AP", 1617], ["and", 1620], ["BP", 1624], [".", 1626], ["The", 1628], ["overall", 1632], ["survival", 1640], ["with", 1649], ["CML", 1654], ["ranges", 1658], ["from", 1665], ["45", 1670], ["to", 1673], ["58", 1676], ["months", 1679], ["in", 1686], ["patients", 1689], ["treated", 1698], ["with", 1706], ["cytoreductive", 1711], ["therapy", 1725], ["only", 1733], [".", 1737], ["Treatment", 1739], ["was", 1749], ["advanced", 1753], ["with", 1762], ["the", 1767], ["introduction", 1771], ["of", 1784], ["interferon", 1787], ["(", 1798], ["IFn", 1799], [")", 1803], ["immunotherapy", 1805], ["in", 1819], ["the", 1822], ["1980s", 1826], [".", 1831], ["In", 1833], ["some", 1836], ["studies", 1841], [",", 1848], ["IFn", 1850], ["produced", 1854], ["a", 1863], ["complete", 1865], ["hematologic", 1874], ["response", 1886], ["(", 1895], ["CHR", 1896], [")", 1899], ["in", 1901], ["more", 1904], ["than", 1909], ["50", 1914], ["%", 1916], ["of", 1918], ["patients", 1921], [";", 1929], ["however", 1931], [",", 1938], ["its", 1940], ["nonspecific", 1944], ["immunostimulatory", 1956], ["mechanism", 1974], ["also", 1984], ["produced", 1989], ["severe", 1998], ["flulike", 2005], ["symptoms", 2013], ["that", 2022], ["limited", 2027], ["tolerability", 2035], [".", 2047], ["despite", 2049], ["the", 2057], ["significant", 2061], ["toxicity", 2073], [",", 2081], ["cost", 2083], [",", 2087], ["and", 2089], ["inconvenience", 2093], ["of", 2107], ["injecting", 2110], ["IFN", 2120], ["thrice", 2124], ["weekly", 2131], [",", 2137], ["median", 2139], ["survival", 2146], ["ranged", 2155], ["from", 2162], ["60", 2167], ["to", 2170], ["89", 2173], ["months", 2176], [".", 2182], ["Allogeneic", 2184], ["BMT", 2195], ["is", 2199], ["the", 2202], ["only", 2206], ["known", 2211], ["curative", 2217], ["therapy", 2226], ["for", 2234], ["CML", 2238], [";", 2241], ["however", 2243], [",", 2250], ["treatment", 2252], ["-", 2261], ["related", 2262], ["mortality", 2270], ["from", 2280], ["infection", 2285], [",", 2294], ["bleeding", 2296], [",", 2304], ["and", 2306], ["graft", 2310], ["versus", 2316], ["host", 2323], ["disease", 2328], [",", 2335], ["age", 2337], [",", 2340], ["and", 2342], ["the", 2346], ["availability", 2350], ["of", 2363], ["suitable", 2366], ["donors", 2375], ["limits", 2382], ["its", 2389], ["widespread", 2393], ["use", 2404], [".", 2407], ["Imatinib", 2409], ["functions", 2418], ["by", 2428], ["competing", 2431], ["with", 2441], ["adenosine", 2446], ["triphosphate", 2456], ["(", 2469], ["ATP", 2470], [")", 2473], ["for", 2475], ["binding", 2479], ["to", 2487], ["the", 2490], ["BCr", 2494], ["-", 2497], ["ABL", 2498], ["tyrosine", 2502], ["kinase", 2511], [".", 2517], ["In", 2519], ["the", 2522], ["absence", 2526], ["of", 2534], ["ATP", 2537], [",", 2540], ["BCR", 2542], ["-", 2545], ["ABL", 2546], ["is", 2550], ["not", 2553], ["able", 2557], ["to", 2562], ["activate", 2565], ["downstream", 2574], ["effector", 2585], ["tyrosine", 2594], ["kinase", 2603], ["molecules", 2610], ["that", 2620], ["drive", 2625], ["wBC", 2631], ["proliferation", 2635], [".", 2648], ["The", 2650], ["International", 2654], ["randomized", 2668], ["Interferon", 2679], ["versus", 2690], ["STI571", 2697], ["clinical", 2704], ["trial", 2713], ["was", 2719], ["the", 2723], ["first", 2727], ["to", 2733], ["document", 2736], ["the", 2745], ["efficacy", 2749], ["of", 2758], ["imatinib", 2761], ["as", 2770], ["a", 2773], ["first", 2775], ["-", 2780], ["line", 2781], ["therapy", 2786], ["for", 2794], ["patients", 2798], ["in", 2807], ["CP", 2810], [".", 2812], ["More", 2814], ["than", 2819], ["90", 2824], ["%", 2826], ["of", 2828], ["these", 2831], ["patients", 2837], ["had", 2846], ["a", 2850], ["CHr", 2852], [".", 2855], ["Toxicities", 2857], ["associated", 2868], ["with", 2879], ["this", 2884], ["therapy", 2889], ["are", 2897], ["low", 2901], [".", 2904], ["response", 2906], ["in", 2915], ["patients", 2918], ["with", 2927], ["advanced", 2932], ["CML", 2941], ["is", 2945], ["less", 2948], ["pronounced", 2953], ["than", 2964], ["in", 2969], ["CP", 2972], ["and", 2975], ["is", 2979], ["shorter", 2982], ["lived", 2990], [",", 2995], ["with", 2997], ["less", 3002], ["than", 3007], ["30", 3012], ["%", 3014], ["of", 3016], ["patients", 3019], ["achieving", 3028], ["a", 3038], ["CHR", 3040], [".", 3043], ["For", 3045], ["patients", 3049], ["with", 3058], ["CML", 3063], ["in", 3067], ["BP", 3070], [",", 3072], ["the", 3074], ["only", 3078], ["viable", 3083], ["therapy", 3090], ["is", 3098], ["to", 3101], ["attempt", 3104], ["a", 3112], ["temporary", 3114], ["reduction", 3124], ["in", 3134], ["disease", 3137], ["burden", 3145], ["with", 3152], ["a", 3157], ["salvage", 3159], ["chemotherapy", 3167], ["regimen", 3180], [",", 3187], ["such", 3189], ["as", 3194], ["VAC", 3197], ["(", 3201], ["etoposide", 3202], [",", 3211], ["cytarabine", 3213], [",", 3223], ["and", 3225], ["carboplatin", 3229], [")", 3240], [".", 3241], ["The", 3243], ["goal", 3247], ["of", 3252], ["this", 3255], ["induction", 3260], ["chemotherapy", 3270], ["is", 3283], ["to", 3286], ["induce", 3289], ["a", 3296], ["second", 3298], ["remission", 3305], [";", 3314], ["then", 3316], ["the", 3321], ["patient", 3325], ["may", 3333], ["be", 3337], ["considered", 3340], ["for", 3351], ["allogeneic", 3355], ["BMT", 3366], [".", 3369], ["The", 3371], ["main", 3375], ["toxicities", 3380], ["seen", 3391], ["with", 3396], ["imatinib", 3401], ["therapy", 3410], ["are", 3418], ["myelosuppression", 3422], [",", 3438], ["edema", 3440], [",", 3445], ["and", 3447], ["myalgia", 3451], ["/", 3458], ["arthralgia", 3459], [".", 3469], ["In", 3471], ["many", 3474], ["cases", 3479], [",", 3484], ["imatinib", 3486], ["dosage", 3495], ["can", 3502], ["be", 3506], ["briefly", 3509], ["halted", 3517], ["or", 3524], ["lowered", 3527], ["while", 3535], ["the", 3541], ["toxicity", 3545], ["is", 3554], ["managed", 3557], [".", 3564], ["Imatinib", 3566], ["resistance", 3575], ["may", 3586], ["develop", 3590], ["at", 3598], ["any", 3601], ["time", 3605], ["and", 3610], ["inevitably", 3614], ["leads", 3625], ["to", 3631], ["disease", 3634], ["progression", 3642], [".", 3653], ["resistance", 3655], ["is", 3666], ["usually", 3669], ["caused", 3677], ["by", 3684], ["mutations", 3687], ["within", 3697], ["BCr", 3704], ["-", 3707], ["ABL", 3708], [",", 3711], ["decreasing", 3713], ["the", 3724], ["affinity", 3728], ["of", 3737], ["imatinib", 3740], ["binding", 3749], [".", 3756], ["next", 3758], ["-", 3762], ["generation", 3763], ["kinase", 3774], ["inhibitors", 3781], ["are", 3792], ["focused", 3796], ["on", 3804], ["the", 3807], ["ability", 3811], ["to", 3819], ["inhibit", 3822], ["these", 3830], ["mutated", 3836], ["forms", 3844], ["of", 3850], ["BCR", 3853], ["-", 3856], ["ABL", 3857], [".", 3860], ["For", 3862], ["the", 3866], ["majority", 3870], ["of", 3879], ["patients", 3882], ["with", 3891], ["CML", 3896], ["in", 3900], ["CP", 3903], [",", 3905], ["the", 3907], ["standard", 3911], ["of", 3920], ["care", 3923], ["is", 3928], ["to", 3931], ["maintain", 3934], ["the", 3943], ["patient", 3947], ["in", 3955], ["CP", 3958], ["with", 3961], ["imatinib", 3966], ["therapy", 3975], [".", 3982], ["Clinical", 3984], ["trials", 3993], ["have", 4000], ["been", 4005], ["extraordinarily", 4010], ["successful", 4026], [",", 4036], ["with", 4038], ["5-year", 4043], ["survival", 4050], ["rates", 4059], ["greater", 4065], ["than", 4073], ["90", 4078], ["%", 4080], [".", 4081], ["Allogeneic", 4083], ["BMT", 4094], ["continues", 4098], ["to", 4108], ["be", 4111], ["an", 4114], ["option", 4117], ["for", 4124], ["those", 4128], ["who", 4134], ["can", 4138], ["not", 4141], ["tolerate", 4145], ["imatinib", 4154], ["or", 4163], ["when", 4166], ["CML", 4171], ["progresses", 4175], ["on", 4186], ["imatinib", 4189], ["therapy", 4198], [".", 4205]]}
{"context": "Mutations in the ribosomal protein S19 gene (RPS19) have been found in 25% of patients with Diamond-Blackfan anemia, a rare syndrome of congenital bone marrow failure characterized by erythroblastopenia and various malformations. Mechanistic understanding of the role of RPS19 in normal erythropoiesis and in the Diamond-Blackfan anemia defect is still poor. However, defective ribosome biogenesis and, in particular, impaired 18S ribosomal RNA maturation have been documented in association with various identified RPS19 mutations. Recently, new genes, all encoding ribosomal proteins, have been found to be mutated in Diamond-Blackfan anemia, adding further support to the concept that ribosome biogenesis plays an important role in regulating erythropoiesis. We previously showed variability in the levels of expression and subcellular localization of a subset of RPS19 mutant proteins. To define the mechanistic basis for this variability better, we studied a large number of mutant proteins and characterized both RPS19 expression level using a specific antibody against RPS19 and RPS19 subcellular localization after transfection of Cos-7 cells with various green fluorescent protein-RPS19 mutants. To investigate the role of the proteasome in RPS19 degradation, we examined the effect of various proteasome inhibitors, namely lactacystin, MG132, and bortezomib on RPS19 expression and subcellular localization We found two distinct classes of RPS19 protein defects in Diamond-Blackfan anemia based on the stability of the mutant proteins: (i) slightly decreased to normal levels of expression and normal nucleolar localization and (ii) markedly deficient expression and failure to localize to the nucleolus. All the proteasome inhibitors tested were able to restore the expression levels and normal subcellular localization of several unstable mutant proteins. Our findings demonstrate an important role for the proteasomal degradation pathway in regulating the expression levels and nucleolar localization of certain mutant RPS19 proteins in Diamond-Blackfan anemia.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "2f5baf79244c4758a2924c9c539783e3", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[52, 55], [326, 329], [104, 107], [237, 240], [19, 22]], "char_spans": [[313, 335], [2050, 2072], [620, 642], [1475, 1497], [92, 114]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["ribosomal", 17], ["protein", 27], ["S19", 35], ["gene", 39], ["(", 44], ["RPS19", 45], [")", 50], ["have", 52], ["been", 57], ["found", 62], ["in", 68], ["25", 71], ["%", 73], ["of", 75], ["patients", 78], ["with", 87], ["Diamond", 92], ["-", 99], ["Blackfan", 100], ["anemia", 109], [",", 115], ["a", 117], ["rare", 119], ["syndrome", 124], ["of", 133], ["congenital", 136], ["bone", 147], ["marrow", 152], ["failure", 159], ["characterized", 167], ["by", 181], ["erythroblastopenia", 184], ["and", 203], ["various", 207], ["malformations", 215], [".", 228], ["Mechanistic", 230], ["understanding", 242], ["of", 256], ["the", 259], ["role", 263], ["of", 268], ["RPS19", 271], ["in", 277], ["normal", 280], ["erythropoiesis", 287], ["and", 302], ["in", 306], ["the", 309], ["Diamond", 313], ["-", 320], ["Blackfan", 321], ["anemia", 330], ["defect", 337], ["is", 344], ["still", 347], ["poor", 353], [".", 357], ["However", 359], [",", 366], ["defective", 368], ["ribosome", 378], ["biogenesis", 387], ["and", 398], [",", 401], ["in", 403], ["particular", 406], [",", 416], ["impaired", 418], ["18S", 427], ["ribosomal", 431], ["RNA", 441], ["maturation", 445], ["have", 456], ["been", 461], ["documented", 466], ["in", 477], ["association", 480], ["with", 492], ["various", 497], ["identified", 505], ["RPS19", 516], ["mutations", 522], [".", 531], ["Recently", 533], [",", 541], ["new", 543], ["genes", 547], [",", 552], ["all", 554], ["encoding", 558], ["ribosomal", 567], ["proteins", 577], [",", 585], ["have", 587], ["been", 592], ["found", 597], ["to", 603], ["be", 606], ["mutated", 609], ["in", 617], ["Diamond", 620], ["-", 627], ["Blackfan", 628], ["anemia", 637], [",", 643], ["adding", 645], ["further", 652], ["support", 660], ["to", 668], ["the", 671], ["concept", 675], ["that", 683], ["ribosome", 688], ["biogenesis", 697], ["plays", 708], ["an", 714], ["important", 717], ["role", 727], ["in", 732], ["regulating", 735], ["erythropoiesis", 746], [".", 760], ["We", 762], ["previously", 765], ["showed", 776], ["variability", 783], ["in", 795], ["the", 798], ["levels", 802], ["of", 809], ["expression", 812], ["and", 823], ["subcellular", 827], ["localization", 839], ["of", 852], ["a", 855], ["subset", 857], ["of", 864], ["RPS19", 867], ["mutant", 873], ["proteins", 880], [".", 888], ["To", 890], ["define", 893], ["the", 900], ["mechanistic", 904], ["basis", 916], ["for", 922], ["this", 926], ["variability", 931], ["better", 943], [",", 949], ["we", 951], ["studied", 954], ["a", 962], ["large", 964], ["number", 970], ["of", 977], ["mutant", 980], ["proteins", 987], ["and", 996], ["characterized", 1000], ["both", 1014], ["RPS19", 1019], ["expression", 1025], ["level", 1036], ["using", 1042], ["a", 1048], ["specific", 1050], ["antibody", 1059], ["against", 1068], ["RPS19", 1076], ["and", 1082], ["RPS19", 1086], ["subcellular", 1092], ["localization", 1104], ["after", 1117], ["transfection", 1123], ["of", 1136], ["Cos-7", 1139], ["cells", 1145], ["with", 1151], ["various", 1156], ["green", 1164], ["fluorescent", 1170], ["protein", 1182], ["-", 1189], ["RPS19", 1190], ["mutants", 1196], [".", 1203], ["To", 1205], ["investigate", 1208], ["the", 1220], ["role", 1224], ["of", 1229], ["the", 1232], ["proteasome", 1236], ["in", 1247], ["RPS19", 1250], ["degradation", 1256], [",", 1267], ["we", 1269], ["examined", 1272], ["the", 1281], ["effect", 1285], ["of", 1292], ["various", 1295], ["proteasome", 1303], ["inhibitors", 1314], [",", 1324], ["namely", 1326], ["lactacystin", 1333], [",", 1344], ["MG132", 1346], [",", 1351], ["and", 1353], ["bortezomib", 1357], ["on", 1368], ["RPS19", 1371], ["expression", 1377], ["and", 1388], ["subcellular", 1392], ["localization", 1404], ["We", 1417], ["found", 1420], ["two", 1426], ["distinct", 1430], ["classes", 1439], ["of", 1447], ["RPS19", 1450], ["protein", 1456], ["defects", 1464], ["in", 1472], ["Diamond", 1475], ["-", 1482], ["Blackfan", 1483], ["anemia", 1492], ["based", 1499], ["on", 1505], ["the", 1508], ["stability", 1512], ["of", 1522], ["the", 1525], ["mutant", 1529], ["proteins", 1536], [":", 1544], ["(", 1546], ["i", 1547], [")", 1548], ["slightly", 1550], ["decreased", 1559], ["to", 1569], ["normal", 1572], ["levels", 1579], ["of", 1586], ["expression", 1589], ["and", 1600], ["normal", 1604], ["nucleolar", 1611], ["localization", 1621], ["and", 1634], ["(", 1638], ["ii", 1639], [")", 1641], ["markedly", 1643], ["deficient", 1652], ["expression", 1662], ["and", 1673], ["failure", 1677], ["to", 1685], ["localize", 1688], ["to", 1697], ["the", 1700], ["nucleolus", 1704], [".", 1713], ["All", 1715], ["the", 1719], ["proteasome", 1723], ["inhibitors", 1734], ["tested", 1745], ["were", 1752], ["able", 1757], ["to", 1762], ["restore", 1765], ["the", 1773], ["expression", 1777], ["levels", 1788], ["and", 1795], ["normal", 1799], ["subcellular", 1806], ["localization", 1818], ["of", 1831], ["several", 1834], ["unstable", 1842], ["mutant", 1851], ["proteins", 1858], [".", 1866], ["Our", 1868], ["findings", 1872], ["demonstrate", 1881], ["an", 1893], ["important", 1896], ["role", 1906], ["for", 1911], ["the", 1915], ["proteasomal", 1919], ["degradation", 1931], ["pathway", 1943], ["in", 1951], ["regulating", 1954], ["the", 1965], ["expression", 1969], ["levels", 1980], ["and", 1987], ["nucleolar", 1991], ["localization", 2001], ["of", 2014], ["certain", 2017], ["mutant", 2025], ["RPS19", 2032], ["proteins", 2038], ["in", 2047], ["Diamond", 2050], ["-", 2057], ["Blackfan", 2058], ["anemia", 2067], [".", 2073]]}
{"context": "Myotonic dystrophy type 1 is a neuromuscular, degenerative and progressive disease, with an autosomal dominant pattern of inheritance, variable expressivity and incomplete penetrance. The genetic defect is an unstable mutation due to the expansion of the triplet CTG in the 3 unstranslated region at the DMPK gene on chromosome 19q13.3. The main objective was to study the intergenerational behavior of the DM1 mutation in order to evaluate the importance of this disease as a neurological problem that could be manageable by genetic counseling. The study involved 84 patients with clinical diagnosis of DM1 and their relatives, which were confirmed through molecular diagnosis using Southern blot and PCR. Data analysis reveals the size of the mutation presents a positive correlation with the severity of the symptoms and a negative correlation with the age of onset. Transmission of the DM1 mutation is sex and size dependent among the Costa Rican patients. There is an important increment in the size of the mutation between generations and there are no differences in mutation size respect to the transmitting sex. The worldwide intergenerational behavior of the DM1 mutation is similar in Costa Rica", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "e6f62469f2c6413a8f4161544dcb6f44", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[15, 16]], "char_spans": [[92, 109]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["type", 19], ["1", 24], ["is", 26], ["a", 29], ["neuromuscular", 31], [",", 44], ["degenerative", 46], ["and", 59], ["progressive", 63], ["disease", 75], [",", 82], ["with", 84], ["an", 89], ["autosomal", 92], ["dominant", 102], ["pattern", 111], ["of", 119], ["inheritance", 122], [",", 133], ["variable", 135], ["expressivity", 144], ["and", 157], ["incomplete", 161], ["penetrance", 172], [".", 182], ["The", 184], ["genetic", 188], ["defect", 196], ["is", 203], ["an", 206], ["unstable", 209], ["mutation", 218], ["due", 227], ["to", 231], ["the", 234], ["expansion", 238], ["of", 248], ["the", 251], ["triplet", 255], ["CTG", 263], ["in", 267], ["the", 270], ["3", 274], ["unstranslated", 276], ["region", 290], ["at", 297], ["the", 300], ["DMPK", 304], ["gene", 309], ["on", 314], ["chromosome", 317], ["19q13.3", 328], [".", 335], ["The", 337], ["main", 341], ["objective", 346], ["was", 356], ["to", 360], ["study", 363], ["the", 369], ["intergenerational", 373], ["behavior", 391], ["of", 400], ["the", 403], ["DM1", 407], ["mutation", 411], ["in", 420], ["order", 423], ["to", 429], ["evaluate", 432], ["the", 441], ["importance", 445], ["of", 456], ["this", 459], ["disease", 464], ["as", 472], ["a", 475], ["neurological", 477], ["problem", 490], ["that", 498], ["could", 503], ["be", 509], ["manageable", 512], ["by", 523], ["genetic", 526], ["counseling", 534], [".", 544], ["The", 546], ["study", 550], ["involved", 556], ["84", 565], ["patients", 568], ["with", 577], ["clinical", 582], ["diagnosis", 591], ["of", 601], ["DM1", 604], ["and", 608], ["their", 612], ["relatives", 618], [",", 627], ["which", 629], ["were", 635], ["confirmed", 640], ["through", 650], ["molecular", 658], ["diagnosis", 668], ["using", 678], ["Southern", 684], ["blot", 693], ["and", 698], ["PCR", 702], [".", 705], ["Data", 707], ["analysis", 712], ["reveals", 721], ["the", 729], ["size", 733], ["of", 738], ["the", 741], ["mutation", 745], ["presents", 754], ["a", 763], ["positive", 765], ["correlation", 774], ["with", 786], ["the", 791], ["severity", 795], ["of", 804], ["the", 807], ["symptoms", 811], ["and", 820], ["a", 824], ["negative", 826], ["correlation", 835], ["with", 847], ["the", 852], ["age", 856], ["of", 860], ["onset", 863], [".", 868], ["Transmission", 870], ["of", 883], ["the", 886], ["DM1", 890], ["mutation", 894], ["is", 903], ["sex", 906], ["and", 910], ["size", 914], ["dependent", 919], ["among", 929], ["the", 935], ["Costa", 939], ["Rican", 945], ["patients", 951], [".", 959], ["There", 961], ["is", 967], ["an", 970], ["important", 973], ["increment", 983], ["in", 993], ["the", 996], ["size", 1000], ["of", 1005], ["the", 1008], ["mutation", 1012], ["between", 1021], ["generations", 1029], ["and", 1041], ["there", 1045], ["are", 1051], ["no", 1055], ["differences", 1058], ["in", 1070], ["mutation", 1073], ["size", 1082], ["respect", 1087], ["to", 1095], ["the", 1098], ["transmitting", 1102], ["sex", 1115], [".", 1118], ["The", 1120], ["worldwide", 1124], ["intergenerational", 1134], ["behavior", 1152], ["of", 1161], ["the", 1164], ["DM1", 1168], ["mutation", 1172], ["is", 1181], ["similar", 1184], ["in", 1192], ["Costa", 1195], ["Rica", 1201]]}
{"context": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons. INCA is available for the Win32 platform and is free of charge for academic use. For details, visit the web page http://www.bioinfo-hr.org/inca or contact the author directly. Software is accompanied with a user manual and a short tutorial.", "qas": [{"question": "Which tool employs self organizing maps for analyzing synonymous codon usage?", "answers": ["INCA"], "qid": "9bd63fef68a04a01ba5834b3974db52c", "question_tokens": [["Which", 0], ["tool", 6], ["employs", 11], ["self", 19], ["organizing", 24], ["maps", 35], ["for", 40], ["analyzing", 44], ["synonymous", 54], ["codon", 65], ["usage", 71], ["?", 76]], "detected_answers": [{"text": "INCA", "token_spans": [[103, 103], [76, 76], [5, 5], [50, 50]], "char_spans": [[595, 598], [431, 434], [34, 37], [271, 274]]}]}], "context_tokens": [["INteractive", 0], ["Codon", 12], ["usage", 18], ["Analysis", 24], ["(", 33], ["INCA", 34], [")", 38], ["provides", 40], ["an", 49], ["array", 52], ["of", 58], ["features", 61], ["useful", 70], ["in", 77], ["analysis", 80], ["of", 89], ["synonymous", 92], ["codon", 103], ["usage", 109], ["in", 115], ["whole", 118], ["genomes", 124], [".", 131], ["In", 133], ["addition", 136], ["to", 145], ["computing", 148], ["codon", 158], ["frequencies", 164], ["and", 176], ["several", 180], ["usage", 188], ["indices", 194], [",", 201], ["such", 203], ["as", 208], ["'", 211], ["codon", 212], ["bias", 218], ["'", 222], [",", 223], ["effective", 225], ["Nc", 235], ["and", 238], ["CAI", 242], [",", 245], ["the", 247], ["primary", 251], ["strength", 259], ["of", 268], ["INCA", 271], ["has", 276], ["numerous", 280], ["options", 289], ["for", 297], ["the", 301], ["interactive", 305], ["graphical", 317], ["display", 327], ["of", 335], ["calculated", 338], ["values", 349], [",", 355], ["thus", 357], ["allowing", 362], ["visual", 371], ["detection", 378], ["of", 388], ["various", 391], ["trends", 399], ["in", 406], ["codon", 409], ["usage", 415], [".", 420], ["Finally", 422], [",", 429], ["INCA", 431], ["includes", 436], ["a", 445], ["specific", 447], ["unsupervised", 456], ["neural", 469], ["network", 476], ["algorithm", 484], [",", 493], ["the", 495], ["self", 499], ["-", 503], ["organizing", 504], ["map", 515], [",", 518], ["used", 520], ["for", 525], ["gene", 529], ["clustering", 534], ["according", 545], ["to", 555], ["the", 558], ["preferred", 562], ["utilization", 572], ["of", 584], ["codons", 587], [".", 593], ["INCA", 595], ["is", 600], ["available", 603], ["for", 613], ["the", 617], ["Win32", 621], ["platform", 627], ["and", 636], ["is", 640], ["free", 643], ["of", 648], ["charge", 651], ["for", 658], ["academic", 662], ["use", 671], [".", 674], ["For", 676], ["details", 680], [",", 687], ["visit", 689], ["the", 695], ["web", 699], ["page", 703], ["http://www.bioinfo-hr.org/inca", 708], ["or", 739], ["contact", 742], ["the", 750], ["author", 754], ["directly", 761], [".", 769], ["Software", 771], ["is", 780], ["accompanied", 783], ["with", 795], ["a", 800], ["user", 802], ["manual", 807], ["and", 814], ["a", 818], ["short", 820], ["tutorial", 826], [".", 834]]}
{"context": "We examined the involvement of the Na(+)/Ca(2+) exchanger in the automaticity of the pulmonary vein myocardium with a specific inhibitor, SEA0400. Action potentials were recorded from the myocardial layer of isolated guinea-pig pulmonary vein preparations, and Ca(2+) transients were recorded from the cardiomyocytes. Spontaneous electrical activity was observed in 17.7% of the preparations, which was inhibited by either SEA0400 or ryanodine. In quiescent preparations, ouabain induced electrical activity and spontaneous Ca(2+) transients, which were inhibited by SEA0400, as well as ryanodine. These results provide pharmacological evidence that the Na(+)/Ca(2+) exchanger underlies the automaticity of the pulmonary vein myocardium.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "34ac789f67124c93ba8b76414c533807", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[6, 9], [107, 110]], "char_spans": [[35, 56], [654, 675]]}]}], "context_tokens": [["We", 0], ["examined", 3], ["the", 12], ["involvement", 16], ["of", 28], ["the", 31], ["Na(+)/Ca(2", 35], ["+", 45], [")", 46], ["exchanger", 48], ["in", 58], ["the", 61], ["automaticity", 65], ["of", 78], ["the", 81], ["pulmonary", 85], ["vein", 95], ["myocardium", 100], ["with", 111], ["a", 116], ["specific", 118], ["inhibitor", 127], [",", 136], ["SEA0400", 138], [".", 145], ["Action", 147], ["potentials", 154], ["were", 165], ["recorded", 170], ["from", 179], ["the", 184], ["myocardial", 188], ["layer", 199], ["of", 205], ["isolated", 208], ["guinea", 217], ["-", 223], ["pig", 224], ["pulmonary", 228], ["vein", 238], ["preparations", 243], [",", 255], ["and", 257], ["Ca(2", 261], ["+", 265], [")", 266], ["transients", 268], ["were", 279], ["recorded", 284], ["from", 293], ["the", 298], ["cardiomyocytes", 302], [".", 316], ["Spontaneous", 318], ["electrical", 330], ["activity", 341], ["was", 350], ["observed", 354], ["in", 363], ["17.7", 366], ["%", 370], ["of", 372], ["the", 375], ["preparations", 379], [",", 391], ["which", 393], ["was", 399], ["inhibited", 403], ["by", 413], ["either", 416], ["SEA0400", 423], ["or", 431], ["ryanodine", 434], [".", 443], ["In", 445], ["quiescent", 448], ["preparations", 458], [",", 470], ["ouabain", 472], ["induced", 480], ["electrical", 488], ["activity", 499], ["and", 508], ["spontaneous", 512], ["Ca(2", 524], ["+", 528], [")", 529], ["transients", 531], [",", 541], ["which", 543], ["were", 549], ["inhibited", 554], ["by", 564], ["SEA0400", 567], [",", 574], ["as", 576], ["well", 579], ["as", 584], ["ryanodine", 587], [".", 596], ["These", 598], ["results", 604], ["provide", 612], ["pharmacological", 620], ["evidence", 636], ["that", 645], ["the", 650], ["Na(+)/Ca(2", 654], ["+", 664], [")", 665], ["exchanger", 667], ["underlies", 677], ["the", 687], ["automaticity", 691], ["of", 704], ["the", 707], ["pulmonary", 711], ["vein", 721], ["myocardium", 726], [".", 736]]}
{"context": "Restriction endonucleases play a very important role in genetic engineering and DNA mapping. Among hundreds of restriction endonucleases, the Eco R1 enzyme is the most useful and widely investigated enzyme. After sonication and ultracentrifugation, crude extracts of E. coli RY 13 were purified by employing the polyethyleneimine precipitate, ammonium sulfate precipitate and heparin Sepharose-4B affinity column chromatography. The Eco R1 enzyme were purified at about 42 folds and the specific activity was about 100,000 U/mg of protein. The whole purification procedure was finished within two days. The recovery was about 42%. The enzyme was sufficiently concentrated for direct specific DNA hydrolysis.", "qas": [{"question": "Which bacteria was EcoRI, restriction endonuclease isolated from?", "answers": ["E coli"], "qid": "f4212bc102cf47dea8b1a2b10b5fe090", "question_tokens": [["Which", 0], ["bacteria", 6], ["was", 15], ["EcoRI", 19], [",", 24], ["restriction", 26], ["endonuclease", 38], ["isolated", 51], ["from", 60], ["?", 64]], "detected_answers": [{"text": "E coli", "token_spans": [[41, 42]], "char_spans": [[267, 273]]}]}], "context_tokens": [["Restriction", 0], ["endonucleases", 12], ["play", 26], ["a", 31], ["very", 33], ["important", 38], ["role", 48], ["in", 53], ["genetic", 56], ["engineering", 64], ["and", 76], ["DNA", 80], ["mapping", 84], [".", 91], ["Among", 93], ["hundreds", 99], ["of", 108], ["restriction", 111], ["endonucleases", 123], [",", 136], ["the", 138], ["Eco", 142], ["R1", 146], ["enzyme", 149], ["is", 156], ["the", 159], ["most", 163], ["useful", 168], ["and", 175], ["widely", 179], ["investigated", 186], ["enzyme", 199], [".", 205], ["After", 207], ["sonication", 213], ["and", 224], ["ultracentrifugation", 228], [",", 247], ["crude", 249], ["extracts", 255], ["of", 264], ["E.", 267], ["coli", 270], ["RY", 275], ["13", 278], ["were", 281], ["purified", 286], ["by", 295], ["employing", 298], ["the", 308], ["polyethyleneimine", 312], ["precipitate", 330], [",", 341], ["ammonium", 343], ["sulfate", 352], ["precipitate", 360], ["and", 372], ["heparin", 376], ["Sepharose-4B", 384], ["affinity", 397], ["column", 406], ["chromatography", 413], [".", 427], ["The", 429], ["Eco", 433], ["R1", 437], ["enzyme", 440], ["were", 447], ["purified", 452], ["at", 461], ["about", 464], ["42", 470], ["folds", 473], ["and", 479], ["the", 483], ["specific", 487], ["activity", 496], ["was", 505], ["about", 509], ["100,000", 515], ["U", 523], ["/", 524], ["mg", 525], ["of", 528], ["protein", 531], [".", 538], ["The", 540], ["whole", 544], ["purification", 550], ["procedure", 563], ["was", 573], ["finished", 577], ["within", 586], ["two", 593], ["days", 597], [".", 601], ["The", 603], ["recovery", 607], ["was", 616], ["about", 620], ["42", 626], ["%", 628], [".", 629], ["The", 631], ["enzyme", 635], ["was", 642], ["sufficiently", 646], ["concentrated", 659], ["for", 672], ["direct", 676], ["specific", 683], ["DNA", 692], ["hydrolysis", 696], [".", 706]]}
{"context": "Constitutive nuclear factor (NF)-kappaB activation in haematological malignancies is caused in several cases by loss of function mutations within the coding sequence of NF-kappaB inhibitory molecules such as IkappaBalpha or p100. Hut-78, a truncated form of p100, constitutively generates p52 and contributes to the development of T-cell lymphomas but the molecular mechanism underlying this oncogenic potential remains unclear. We show here that MMP9 gene expression is induced through the alternative NF-kappaB-activating pathway in fibroblasts and also on Hut-78 or p52 overexpression in fibroblasts as well as in lymphoma cells. p52 is critical for Hut-78-mediated MMP9 gene induction as a Hut-78 mutant as well as other truncated NF-kappaB2 proteins that are not processed into p52 failed to induce the expression of this metalloproteinase. Conversely, MMP9 gene expression is impaired in p52-depleted HUT-78 cells. Interestingly, MLL1 and MLL2 H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyltransferase activity recruited on the MMP9 promoter is impaired in p52-depleted HUT-78 cells. Moreover, MLL1 and MLL2 are associated with Hut-78 in a native chromatin-enriched extract. Thus, we identified a molecular mechanism by which the recruitment of a H3K4 histone methyltransferase complex on the promoter of a NF-kappaB-dependent gene induces its expression and potentially the invasive potential of lymphoma cells harbouring constitutive activity of the alternative NF-kappaB-activating pathway.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "df4391d3d5f2494faee51e0fa0eb024c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[156, 156], [175, 175], [220, 220]], "char_spans": [[950, 953], [1061, 1064], [1332, 1335]]}]}], "context_tokens": [["Constitutive", 0], ["nuclear", 13], ["factor", 21], ["(", 28], ["NF)-kappaB", 29], ["activation", 40], ["in", 51], ["haematological", 54], ["malignancies", 69], ["is", 82], ["caused", 85], ["in", 92], ["several", 95], ["cases", 103], ["by", 109], ["loss", 112], ["of", 117], ["function", 120], ["mutations", 129], ["within", 139], ["the", 146], ["coding", 150], ["sequence", 157], ["of", 166], ["NF", 169], ["-", 171], ["kappaB", 172], ["inhibitory", 179], ["molecules", 190], ["such", 200], ["as", 205], ["IkappaBalpha", 208], ["or", 221], ["p100", 224], [".", 228], ["Hut-78", 230], [",", 236], ["a", 238], ["truncated", 240], ["form", 250], ["of", 255], ["p100", 258], [",", 262], ["constitutively", 264], ["generates", 279], ["p52", 289], ["and", 293], ["contributes", 297], ["to", 309], ["the", 312], ["development", 316], ["of", 328], ["T", 331], ["-", 332], ["cell", 333], ["lymphomas", 338], ["but", 348], ["the", 352], ["molecular", 356], ["mechanism", 366], ["underlying", 376], ["this", 387], ["oncogenic", 392], ["potential", 402], ["remains", 412], ["unclear", 420], [".", 427], ["We", 429], ["show", 432], ["here", 437], ["that", 442], ["MMP9", 447], ["gene", 452], ["expression", 457], ["is", 468], ["induced", 471], ["through", 479], ["the", 487], ["alternative", 491], ["NF", 503], ["-", 505], ["kappaB", 506], ["-", 512], ["activating", 513], ["pathway", 524], ["in", 532], ["fibroblasts", 535], ["and", 547], ["also", 551], ["on", 556], ["Hut-78", 559], ["or", 566], ["p52", 569], ["overexpression", 573], ["in", 588], ["fibroblasts", 591], ["as", 603], ["well", 606], ["as", 611], ["in", 614], ["lymphoma", 617], ["cells", 626], [".", 631], ["p52", 633], ["is", 637], ["critical", 640], ["for", 649], ["Hut-78-mediated", 653], ["MMP9", 669], ["gene", 674], ["induction", 679], ["as", 689], ["a", 692], ["Hut-78", 694], ["mutant", 701], ["as", 708], ["well", 711], ["as", 716], ["other", 719], ["truncated", 725], ["NF", 735], ["-", 737], ["kappaB2", 738], ["proteins", 746], ["that", 755], ["are", 760], ["not", 764], ["processed", 768], ["into", 778], ["p52", 783], ["failed", 787], ["to", 794], ["induce", 797], ["the", 804], ["expression", 808], ["of", 819], ["this", 822], ["metalloproteinase", 827], [".", 844], ["Conversely", 846], [",", 856], ["MMP9", 858], ["gene", 863], ["expression", 868], ["is", 879], ["impaired", 882], ["in", 891], ["p52-depleted", 894], ["HUT-78", 907], ["cells", 914], [".", 919], ["Interestingly", 921], [",", 934], ["MLL1", 936], ["and", 941], ["MLL2", 945], ["H3K4", 950], ["methyltransferase", 955], ["complexes", 973], ["are", 983], ["tethered", 987], ["by", 996], ["p52", 999], ["on", 1003], ["the", 1006], ["MMP9", 1010], ["but", 1015], ["not", 1019], ["on", 1023], ["the", 1026], ["IkappaBalpha", 1030], ["promoter", 1043], [",", 1051], ["and", 1053], ["the", 1057], ["H3K4", 1061], ["trimethyltransferase", 1066], ["activity", 1087], ["recruited", 1096], ["on", 1106], ["the", 1109], ["MMP9", 1113], ["promoter", 1118], ["is", 1127], ["impaired", 1130], ["in", 1139], ["p52-depleted", 1142], ["HUT-78", 1155], ["cells", 1162], [".", 1167], ["Moreover", 1169], [",", 1177], ["MLL1", 1179], ["and", 1184], ["MLL2", 1188], ["are", 1193], ["associated", 1197], ["with", 1208], ["Hut-78", 1213], ["in", 1220], ["a", 1223], ["native", 1225], ["chromatin", 1232], ["-", 1241], ["enriched", 1242], ["extract", 1251], [".", 1258], ["Thus", 1260], [",", 1264], ["we", 1266], ["identified", 1269], ["a", 1280], ["molecular", 1282], ["mechanism", 1292], ["by", 1302], ["which", 1305], ["the", 1311], ["recruitment", 1315], ["of", 1327], ["a", 1330], ["H3K4", 1332], ["histone", 1337], ["methyltransferase", 1345], ["complex", 1363], ["on", 1371], ["the", 1374], ["promoter", 1378], ["of", 1387], ["a", 1390], ["NF", 1392], ["-", 1394], ["kappaB", 1395], ["-", 1401], ["dependent", 1402], ["gene", 1412], ["induces", 1417], ["its", 1425], ["expression", 1429], ["and", 1440], ["potentially", 1444], ["the", 1456], ["invasive", 1460], ["potential", 1469], ["of", 1479], ["lymphoma", 1482], ["cells", 1491], ["harbouring", 1497], ["constitutive", 1508], ["activity", 1521], ["of", 1530], ["the", 1533], ["alternative", 1537], ["NF", 1549], ["-", 1551], ["kappaB", 1552], ["-", 1558], ["activating", 1559], ["pathway", 1570], [".", 1577]]}
{"context": "This was the first microbicide trial conducted in Africa to evaluate an antiretroviral-containing vaginal ring as an HIV prevention technology for women. The trial assessed and compared the safety, acceptability and adherence to product use of a 4-weekly administered vaginal ring containing the antiretroviral microbicide, dapivirine, with a matching placebo ring among women from four countries in sub-Saharan Africa. 280 Healthy, sexually active, HIV-negative women, aged 18 to 40 years were enrolled with 140 women randomised to a dapivirine vaginal ring (25 mg) and 140 women to a matching placebo ring, inserted 4-weekly and used over a 12-week period. Safety was evaluated by pelvic examination, colposcopy, clinical laboratory assessments, and adverse events. Blood samples for determination of plasma concentrations of dapivirine were collected at Weeks 0, 4 and 12. Residual dapivirine levels in returned rings from dapivirine ring users were determined post-trial. Participant acceptability and adherence to ring use were assessed by self-reports. No safety concerns or clinically relevant differences were observed between the dapivirine and placebo ring groups. Plasma dapivirine concentrations immediately prior to ring removal were similar after removal of the first and third ring, suggesting consistent ring use over the 12-week period. No clear relationship was observed between the residual amount of dapivirine in used rings and corresponding plasma concentrations. Self-reported adherence to daily use of the vaginal rings over the 12-week trial period was very high. At the end of the trial, 96% of participants reported that the ring was usually comfortable to wear, and 97% reported that they would be willing to use it in the future if proven effective. The dapivirine vaginal ring has a favourable safety and acceptability profile. If proven safe and effective in large-scale trials, it will be an important component of combination HIV prevention approaches for women. ClinicalTrials.gov NCT01071174.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c83c84f9c33345268a80de699a70104f", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[338, 338], [19, 19], [74, 74]], "char_spans": [[1959, 1961], [117, 119], [450, 452]]}]}], "context_tokens": [["This", 0], ["was", 5], ["the", 9], ["first", 13], ["microbicide", 19], ["trial", 31], ["conducted", 37], ["in", 47], ["Africa", 50], ["to", 57], ["evaluate", 60], ["an", 69], ["antiretroviral", 72], ["-", 86], ["containing", 87], ["vaginal", 98], ["ring", 106], ["as", 111], ["an", 114], ["HIV", 117], ["prevention", 121], ["technology", 132], ["for", 143], ["women", 147], [".", 152], ["The", 154], ["trial", 158], ["assessed", 164], ["and", 173], ["compared", 177], ["the", 186], ["safety", 190], [",", 196], ["acceptability", 198], ["and", 212], ["adherence", 216], ["to", 226], ["product", 229], ["use", 237], ["of", 241], ["a", 244], ["4-weekly", 246], ["administered", 255], ["vaginal", 268], ["ring", 276], ["containing", 281], ["the", 292], ["antiretroviral", 296], ["microbicide", 311], [",", 322], ["dapivirine", 324], [",", 334], ["with", 336], ["a", 341], ["matching", 343], ["placebo", 352], ["ring", 360], ["among", 365], ["women", 371], ["from", 377], ["four", 382], ["countries", 387], ["in", 397], ["sub", 400], ["-", 403], ["Saharan", 404], ["Africa", 412], [".", 418], ["280", 420], ["Healthy", 424], [",", 431], ["sexually", 433], ["active", 442], [",", 448], ["HIV", 450], ["-", 453], ["negative", 454], ["women", 463], [",", 468], ["aged", 470], ["18", 475], ["to", 478], ["40", 481], ["years", 484], ["were", 490], ["enrolled", 495], ["with", 504], ["140", 509], ["women", 513], ["randomised", 519], ["to", 530], ["a", 533], ["dapivirine", 535], ["vaginal", 546], ["ring", 554], ["(", 559], ["25", 560], ["mg", 563], [")", 565], ["and", 567], ["140", 571], ["women", 575], ["to", 581], ["a", 584], ["matching", 586], ["placebo", 595], ["ring", 603], [",", 607], ["inserted", 609], ["4-weekly", 618], ["and", 627], ["used", 631], ["over", 636], ["a", 641], ["12-week", 643], ["period", 651], [".", 657], ["Safety", 659], ["was", 666], ["evaluated", 670], ["by", 680], ["pelvic", 683], ["examination", 690], [",", 701], ["colposcopy", 703], [",", 713], ["clinical", 715], ["laboratory", 724], ["assessments", 735], [",", 746], ["and", 748], ["adverse", 752], ["events", 760], [".", 766], ["Blood", 768], ["samples", 774], ["for", 782], ["determination", 786], ["of", 800], ["plasma", 803], ["concentrations", 810], ["of", 825], ["dapivirine", 828], ["were", 839], ["collected", 844], ["at", 854], ["Weeks", 857], ["0", 863], [",", 864], ["4", 866], ["and", 868], ["12", 872], [".", 874], ["Residual", 876], ["dapivirine", 885], ["levels", 896], ["in", 903], ["returned", 906], ["rings", 915], ["from", 921], ["dapivirine", 926], ["ring", 937], ["users", 942], ["were", 948], ["determined", 953], ["post", 964], ["-", 968], ["trial", 969], [".", 974], ["Participant", 976], ["acceptability", 988], ["and", 1002], ["adherence", 1006], ["to", 1016], ["ring", 1019], ["use", 1024], ["were", 1028], ["assessed", 1033], ["by", 1042], ["self", 1045], ["-", 1049], ["reports", 1050], [".", 1057], ["No", 1059], ["safety", 1062], ["concerns", 1069], ["or", 1078], ["clinically", 1081], ["relevant", 1092], ["differences", 1101], ["were", 1113], ["observed", 1118], ["between", 1127], ["the", 1135], ["dapivirine", 1139], ["and", 1150], ["placebo", 1154], ["ring", 1162], ["groups", 1167], [".", 1173], ["Plasma", 1175], ["dapivirine", 1182], ["concentrations", 1193], ["immediately", 1208], ["prior", 1220], ["to", 1226], ["ring", 1229], ["removal", 1234], ["were", 1242], ["similar", 1247], ["after", 1255], ["removal", 1261], ["of", 1269], ["the", 1272], ["first", 1276], ["and", 1282], ["third", 1286], ["ring", 1292], [",", 1296], ["suggesting", 1298], ["consistent", 1309], ["ring", 1320], ["use", 1325], ["over", 1329], ["the", 1334], ["12-week", 1338], ["period", 1346], [".", 1352], ["No", 1354], ["clear", 1357], ["relationship", 1363], ["was", 1376], ["observed", 1380], ["between", 1389], ["the", 1397], ["residual", 1401], ["amount", 1410], ["of", 1417], ["dapivirine", 1420], ["in", 1431], ["used", 1434], ["rings", 1439], ["and", 1445], ["corresponding", 1449], ["plasma", 1463], ["concentrations", 1470], [".", 1484], ["Self", 1486], ["-", 1490], ["reported", 1491], ["adherence", 1500], ["to", 1510], ["daily", 1513], ["use", 1519], ["of", 1523], ["the", 1526], ["vaginal", 1530], ["rings", 1538], ["over", 1544], ["the", 1549], ["12-week", 1553], ["trial", 1561], ["period", 1567], ["was", 1574], ["very", 1578], ["high", 1583], [".", 1587], ["At", 1589], ["the", 1592], ["end", 1596], ["of", 1600], ["the", 1603], ["trial", 1607], [",", 1612], ["96", 1614], ["%", 1616], ["of", 1618], ["participants", 1621], ["reported", 1634], ["that", 1643], ["the", 1648], ["ring", 1652], ["was", 1657], ["usually", 1661], ["comfortable", 1669], ["to", 1681], ["wear", 1684], [",", 1688], ["and", 1690], ["97", 1694], ["%", 1696], ["reported", 1698], ["that", 1707], ["they", 1712], ["would", 1717], ["be", 1723], ["willing", 1726], ["to", 1734], ["use", 1737], ["it", 1741], ["in", 1744], ["the", 1747], ["future", 1751], ["if", 1758], ["proven", 1761], ["effective", 1768], [".", 1777], ["The", 1779], ["dapivirine", 1783], ["vaginal", 1794], ["ring", 1802], ["has", 1807], ["a", 1811], ["favourable", 1813], ["safety", 1824], ["and", 1831], ["acceptability", 1835], ["profile", 1849], [".", 1856], ["If", 1858], ["proven", 1861], ["safe", 1868], ["and", 1873], ["effective", 1877], ["in", 1887], ["large", 1890], ["-", 1895], ["scale", 1896], ["trials", 1902], [",", 1908], ["it", 1910], ["will", 1913], ["be", 1918], ["an", 1921], ["important", 1924], ["component", 1934], ["of", 1944], ["combination", 1947], ["HIV", 1959], ["prevention", 1963], ["approaches", 1974], ["for", 1985], ["women", 1989], [".", 1994], ["ClinicalTrials.gov", 1996], ["NCT01071174", 2015], [".", 2026]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature. The purpose of our study was to assess the rate of strength deterioration, functional condition and performance of activity of daily living of patients with FSHD in Taiwan. Twenty patients diagnosed with FSHD were included in this study. Manual muscle testing (MMT) was used to evaluate muscle strength. The Brooke and Vignos scales were used to assess upper and lower extremity function respectively, and the capability of the activity of daily living was measured by Barthel index. The result of the strength testing was characterized by the presence of a progressive asymmetrical muscular weakness in patients with FSHD. The mean muscular strength of the right extremity was weaker than its left counterparts (p < 0.05) and the shoulder muscle group was the weakest. According to the Brooke functional scale, 20% of our patients were graded as 1, 30% as grade 2, and 50% as grade 3. On the Vignos functional scale, 50% of patients fell into grade 1, 10% in grade 2, and 40% in grades 3-5. Vignos scale was significantly correlated with mean muscle strength (p < 0.05). The average value of Barthel index was 97.8 +/- 4.7. The muscle strength decline in this Taiwanese of FSHD population was more severe in shoulder girdle area. The mean muscle strength of the right extremity was weaker than the left. Most of our patients suffered from mild or moderate physical disability. Finding of these Taiwanese FSHD population is similar to those reported elsewhere in the world.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "5ae5529a5ae241daa090d3d9f369eb09", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[12, 13]], "char_spans": [[84, 101]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["slowly", 51], ["progressive", 58], ["myopathy", 70], ["with", 79], ["autosomal", 84], ["dominant", 94], ["inheritance", 103], ["remarkable", 115], ["for", 126], ["its", 130], ["early", 134], ["involvement", 140], ["of", 152], ["facial", 155], ["musculature", 162], [".", 173], ["The", 175], ["purpose", 179], ["of", 187], ["our", 190], ["study", 194], ["was", 200], ["to", 204], ["assess", 207], ["the", 214], ["rate", 218], ["of", 223], ["strength", 226], ["deterioration", 235], [",", 248], ["functional", 250], ["condition", 261], ["and", 271], ["performance", 275], ["of", 287], ["activity", 290], ["of", 299], ["daily", 302], ["living", 308], ["of", 315], ["patients", 318], ["with", 327], ["FSHD", 332], ["in", 337], ["Taiwan", 340], [".", 346], ["Twenty", 348], ["patients", 355], ["diagnosed", 364], ["with", 374], ["FSHD", 379], ["were", 384], ["included", 389], ["in", 398], ["this", 401], ["study", 406], [".", 411], ["Manual", 413], ["muscle", 420], ["testing", 427], ["(", 435], ["MMT", 436], [")", 439], ["was", 441], ["used", 445], ["to", 450], ["evaluate", 453], ["muscle", 462], ["strength", 469], [".", 477], ["The", 479], ["Brooke", 483], ["and", 490], ["Vignos", 494], ["scales", 501], ["were", 508], ["used", 513], ["to", 518], ["assess", 521], ["upper", 528], ["and", 534], ["lower", 538], ["extremity", 544], ["function", 554], ["respectively", 563], [",", 575], ["and", 577], ["the", 581], ["capability", 585], ["of", 596], ["the", 599], ["activity", 603], ["of", 612], ["daily", 615], ["living", 621], ["was", 628], ["measured", 632], ["by", 641], ["Barthel", 644], ["index", 652], [".", 657], ["The", 659], ["result", 663], ["of", 670], ["the", 673], ["strength", 677], ["testing", 686], ["was", 694], ["characterized", 698], ["by", 712], ["the", 715], ["presence", 719], ["of", 728], ["a", 731], ["progressive", 733], ["asymmetrical", 745], ["muscular", 758], ["weakness", 767], ["in", 776], ["patients", 779], ["with", 788], ["FSHD", 793], [".", 797], ["The", 799], ["mean", 803], ["muscular", 808], ["strength", 817], ["of", 826], ["the", 829], ["right", 833], ["extremity", 839], ["was", 849], ["weaker", 853], ["than", 860], ["its", 865], ["left", 869], ["counterparts", 874], ["(", 887], ["p", 888], ["<", 890], ["0.05", 892], [")", 896], ["and", 898], ["the", 902], ["shoulder", 906], ["muscle", 915], ["group", 922], ["was", 928], ["the", 932], ["weakest", 936], [".", 943], ["According", 945], ["to", 955], ["the", 958], ["Brooke", 962], ["functional", 969], ["scale", 980], [",", 985], ["20", 987], ["%", 989], ["of", 991], ["our", 994], ["patients", 998], ["were", 1007], ["graded", 1012], ["as", 1019], ["1", 1022], [",", 1023], ["30", 1025], ["%", 1027], ["as", 1029], ["grade", 1032], ["2", 1038], [",", 1039], ["and", 1041], ["50", 1045], ["%", 1047], ["as", 1049], ["grade", 1052], ["3", 1058], [".", 1059], ["On", 1061], ["the", 1064], ["Vignos", 1068], ["functional", 1075], ["scale", 1086], [",", 1091], ["50", 1093], ["%", 1095], ["of", 1097], ["patients", 1100], ["fell", 1109], ["into", 1114], ["grade", 1119], ["1", 1125], [",", 1126], ["10", 1128], ["%", 1130], ["in", 1132], ["grade", 1135], ["2", 1141], [",", 1142], ["and", 1144], ["40", 1148], ["%", 1150], ["in", 1152], ["grades", 1155], ["3", 1162], ["-", 1163], ["5", 1164], [".", 1165], ["Vignos", 1167], ["scale", 1174], ["was", 1180], ["significantly", 1184], ["correlated", 1198], ["with", 1209], ["mean", 1214], ["muscle", 1219], ["strength", 1226], ["(", 1235], ["p", 1236], ["<", 1238], ["0.05", 1240], [")", 1244], [".", 1245], ["The", 1247], ["average", 1251], ["value", 1259], ["of", 1265], ["Barthel", 1268], ["index", 1276], ["was", 1282], ["97.8", 1286], ["+", 1291], ["/-", 1292], ["4.7", 1295], [".", 1298], ["The", 1300], ["muscle", 1304], ["strength", 1311], ["decline", 1320], ["in", 1328], ["this", 1331], ["Taiwanese", 1336], ["of", 1346], ["FSHD", 1349], ["population", 1354], ["was", 1365], ["more", 1369], ["severe", 1374], ["in", 1381], ["shoulder", 1384], ["girdle", 1393], ["area", 1400], [".", 1404], ["The", 1406], ["mean", 1410], ["muscle", 1415], ["strength", 1422], ["of", 1431], ["the", 1434], ["right", 1438], ["extremity", 1444], ["was", 1454], ["weaker", 1458], ["than", 1465], ["the", 1470], ["left", 1474], [".", 1478], ["Most", 1480], ["of", 1485], ["our", 1488], ["patients", 1492], ["suffered", 1501], ["from", 1510], ["mild", 1515], ["or", 1520], ["moderate", 1523], ["physical", 1532], ["disability", 1541], [".", 1551], ["Finding", 1553], ["of", 1561], ["these", 1564], ["Taiwanese", 1570], ["FSHD", 1580], ["population", 1585], ["is", 1596], ["similar", 1599], ["to", 1607], ["those", 1610], ["reported", 1616], ["elsewhere", 1625], ["in", 1635], ["the", 1638], ["world", 1642], [".", 1647]]}
{"context": "Light-harvesting pigment-protein complex of Photosystem II (LHCII) is the largest photosynthetic antenna complex of plants and the most abundant membrane protein in the biosphere. Plant fitness and productivity depend directly on a balance between excitations in the photosynthetic apparatus, generated by captured light quanta, and the rate of photochemical processes. Excess excitation energy leads to oxidative damage of the photosynthetic apparatus and entire organism and therefore the balance between the excitation density and photosynthesis requires precise and efficient regulation, operating also at the level of antenna complexes. We show that illumination of the isolated LHCII leads to isomerization of the protein-bound neoxanthin from conformation 9'-cis to 9',13- and 9',13'-dicis forms. At the same time light-driven excitation quenching is observed, manifested by a decrease in chlorophyll a fluorescence intensity and shortened fluorescence lifetimes. Both processes, the neoxanthin isomerization and the chlorophyll excitation quenching, are reversible in dim light. The results of the 77K florescence measurements of LHCII show that illumination is associated with appearance of the low-energy states, which can serve as energy traps in the pigment-protein complex subjected to excess excitation. Possible sequence of the molecular events is proposed, leading to a protective excess excitation energy quenching: neoxanthin photo-isomerization\u2192formation of LHCII supramolecular structures which potentiate creation of energy traps\u2192excitation quenching.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "d30650e611f64f46abbf5b525ce53a92", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "Light-harvesting pigment-protein complex of Photosystem II", "token_spans": [[0, 9]], "char_spans": [[0, 57]]}, {"text": "LHCII", "token_spans": [[233, 233], [11, 11], [178, 178], [106, 106]], "char_spans": [[1477, 1481], [60, 64], [1138, 1142], [684, 688]]}]}], "context_tokens": [["Light", 0], ["-", 5], ["harvesting", 6], ["pigment", 17], ["-", 24], ["protein", 25], ["complex", 33], ["of", 41], ["Photosystem", 44], ["II", 56], ["(", 59], ["LHCII", 60], [")", 65], ["is", 67], ["the", 70], ["largest", 74], ["photosynthetic", 82], ["antenna", 97], ["complex", 105], ["of", 113], ["plants", 116], ["and", 123], ["the", 127], ["most", 131], ["abundant", 136], ["membrane", 145], ["protein", 154], ["in", 162], ["the", 165], ["biosphere", 169], [".", 178], ["Plant", 180], ["fitness", 186], ["and", 194], ["productivity", 198], ["depend", 211], ["directly", 218], ["on", 227], ["a", 230], ["balance", 232], ["between", 240], ["excitations", 248], ["in", 260], ["the", 263], ["photosynthetic", 267], ["apparatus", 282], [",", 291], ["generated", 293], ["by", 303], ["captured", 306], ["light", 315], ["quanta", 321], [",", 327], ["and", 329], ["the", 333], ["rate", 337], ["of", 342], ["photochemical", 345], ["processes", 359], [".", 368], ["Excess", 370], ["excitation", 377], ["energy", 388], ["leads", 395], ["to", 401], ["oxidative", 404], ["damage", 414], ["of", 421], ["the", 424], ["photosynthetic", 428], ["apparatus", 443], ["and", 453], ["entire", 457], ["organism", 464], ["and", 473], ["therefore", 477], ["the", 487], ["balance", 491], ["between", 499], ["the", 507], ["excitation", 511], ["density", 522], ["and", 530], ["photosynthesis", 534], ["requires", 549], ["precise", 558], ["and", 566], ["efficient", 570], ["regulation", 580], [",", 590], ["operating", 592], ["also", 602], ["at", 607], ["the", 610], ["level", 614], ["of", 620], ["antenna", 623], ["complexes", 631], [".", 640], ["We", 642], ["show", 645], ["that", 650], ["illumination", 655], ["of", 668], ["the", 671], ["isolated", 675], ["LHCII", 684], ["leads", 690], ["to", 696], ["isomerization", 699], ["of", 713], ["the", 716], ["protein", 720], ["-", 727], ["bound", 728], ["neoxanthin", 734], ["from", 745], ["conformation", 750], ["9'-cis", 763], ["to", 770], ["9',13-", 773], ["and", 780], ["9',13'-dicis", 784], ["forms", 797], [".", 802], ["At", 804], ["the", 807], ["same", 811], ["time", 816], ["light", 821], ["-", 826], ["driven", 827], ["excitation", 834], ["quenching", 845], ["is", 855], ["observed", 858], [",", 866], ["manifested", 868], ["by", 879], ["a", 882], ["decrease", 884], ["in", 893], ["chlorophyll", 896], ["a", 908], ["fluorescence", 910], ["intensity", 923], ["and", 933], ["shortened", 937], ["fluorescence", 947], ["lifetimes", 960], [".", 969], ["Both", 971], ["processes", 976], [",", 985], ["the", 987], ["neoxanthin", 991], ["isomerization", 1002], ["and", 1016], ["the", 1020], ["chlorophyll", 1024], ["excitation", 1036], ["quenching", 1047], [",", 1056], ["are", 1058], ["reversible", 1062], ["in", 1073], ["dim", 1076], ["light", 1080], [".", 1085], ["The", 1087], ["results", 1091], ["of", 1099], ["the", 1102], ["77", 1106], ["K", 1108], ["florescence", 1110], ["measurements", 1122], ["of", 1135], ["LHCII", 1138], ["show", 1144], ["that", 1149], ["illumination", 1154], ["is", 1167], ["associated", 1170], ["with", 1181], ["appearance", 1186], ["of", 1197], ["the", 1200], ["low", 1204], ["-", 1207], ["energy", 1208], ["states", 1215], [",", 1221], ["which", 1223], ["can", 1229], ["serve", 1233], ["as", 1239], ["energy", 1242], ["traps", 1249], ["in", 1255], ["the", 1258], ["pigment", 1262], ["-", 1269], ["protein", 1270], ["complex", 1278], ["subjected", 1286], ["to", 1296], ["excess", 1299], ["excitation", 1306], [".", 1316], ["Possible", 1318], ["sequence", 1327], ["of", 1336], ["the", 1339], ["molecular", 1343], ["events", 1353], ["is", 1360], ["proposed", 1363], [",", 1371], ["leading", 1373], ["to", 1381], ["a", 1384], ["protective", 1386], ["excess", 1397], ["excitation", 1404], ["energy", 1415], ["quenching", 1422], [":", 1431], ["neoxanthin", 1433], ["photo", 1444], ["-", 1449], ["isomerization\u2192formation", 1450], ["of", 1474], ["LHCII", 1477], ["supramolecular", 1483], ["structures", 1498], ["which", 1509], ["potentiate", 1515], ["creation", 1526], ["of", 1535], ["energy", 1538], ["traps\u2192excitation", 1545], ["quenching", 1562], [".", 1571]]}
{"context": "There is considerable interest in developing new multipurpose prevention technologies to address women's reproductive health needs. This study describes an innovative barrier contraceptive device--based on the SILCS diaphragm--that also provides long-term controlled release of the lead candidate anti-HIV microbicide dapivirine. Diaphragm devices comprising various dapivirine-loaded polymer spring cores overmolded with a nonmedicated silicone elastomer sheath were fabricated by injection molding processes. In vitro release testing, thermal analysis and mechanical characterization were performed on the devices. A diaphragm device containing a polyoxymethylene spring core loaded with 10% w/w dapivirine provided continuous and controlled release of dapivirine over a 6-month period, with a mean in vitro daily release rate of 174 mcg/day. The mechanical properties of the new diaphragm were closely matched to the SILCS diaphragm. The study demonstrates proof of concept for a dapivirine-releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission. In discontinuous clinical use, release of dapivirine may be readily extended over 1 or more years.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "47ab244b4b6d4e7191c1323df4d61251", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[168, 168], [47, 47]], "char_spans": [[1078, 1080], [302, 304]]}]}], "context_tokens": [["There", 0], ["is", 6], ["considerable", 9], ["interest", 22], ["in", 31], ["developing", 34], ["new", 45], ["multipurpose", 49], ["prevention", 62], ["technologies", 73], ["to", 86], ["address", 89], ["women", 97], ["'s", 102], ["reproductive", 105], ["health", 118], ["needs", 125], [".", 130], ["This", 132], ["study", 137], ["describes", 143], ["an", 153], ["innovative", 156], ["barrier", 167], ["contraceptive", 175], ["device", 189], ["--", 195], ["based", 197], ["on", 203], ["the", 206], ["SILCS", 210], ["diaphragm", 216], ["--", 225], ["that", 227], ["also", 232], ["provides", 237], ["long", 246], ["-", 250], ["term", 251], ["controlled", 256], ["release", 267], ["of", 275], ["the", 278], ["lead", 282], ["candidate", 287], ["anti", 297], ["-", 301], ["HIV", 302], ["microbicide", 306], ["dapivirine", 318], [".", 328], ["Diaphragm", 330], ["devices", 340], ["comprising", 348], ["various", 359], ["dapivirine", 367], ["-", 377], ["loaded", 378], ["polymer", 385], ["spring", 393], ["cores", 400], ["overmolded", 406], ["with", 417], ["a", 422], ["nonmedicated", 424], ["silicone", 437], ["elastomer", 446], ["sheath", 456], ["were", 463], ["fabricated", 468], ["by", 479], ["injection", 482], ["molding", 492], ["processes", 500], [".", 509], ["In", 511], ["vitro", 514], ["release", 520], ["testing", 528], [",", 535], ["thermal", 537], ["analysis", 545], ["and", 554], ["mechanical", 558], ["characterization", 569], ["were", 586], ["performed", 591], ["on", 601], ["the", 604], ["devices", 608], [".", 615], ["A", 617], ["diaphragm", 619], ["device", 629], ["containing", 636], ["a", 647], ["polyoxymethylene", 649], ["spring", 666], ["core", 673], ["loaded", 678], ["with", 685], ["10", 690], ["%", 692], ["w", 694], ["/", 695], ["w", 696], ["dapivirine", 698], ["provided", 709], ["continuous", 718], ["and", 729], ["controlled", 733], ["release", 744], ["of", 752], ["dapivirine", 755], ["over", 766], ["a", 771], ["6-month", 773], ["period", 781], [",", 787], ["with", 789], ["a", 794], ["mean", 796], ["in", 801], ["vitro", 804], ["daily", 810], ["release", 816], ["rate", 824], ["of", 829], ["174", 832], ["mcg", 836], ["/", 839], ["day", 840], [".", 843], ["The", 845], ["mechanical", 849], ["properties", 860], ["of", 871], ["the", 874], ["new", 878], ["diaphragm", 882], ["were", 892], ["closely", 897], ["matched", 905], ["to", 913], ["the", 916], ["SILCS", 920], ["diaphragm", 926], [".", 935], ["The", 937], ["study", 941], ["demonstrates", 947], ["proof", 960], ["of", 966], ["concept", 969], ["for", 977], ["a", 981], ["dapivirine", 983], ["-", 993], ["releasing", 994], ["diaphragm", 1004], ["with", 1014], ["daily", 1019], ["release", 1025], ["quantities", 1033], ["potentially", 1044], ["capable", 1056], ["of", 1064], ["preventing", 1067], ["HIV", 1078], ["transmission", 1082], [".", 1094], ["In", 1096], ["discontinuous", 1099], ["clinical", 1113], ["use", 1122], [",", 1125], ["release", 1127], ["of", 1135], ["dapivirine", 1138], ["may", 1149], ["be", 1153], ["readily", 1156], ["extended", 1164], ["over", 1173], ["1", 1178], ["or", 1180], ["more", 1183], ["years", 1188], [".", 1193]]}
{"context": "New treatment options are urgently needed for patients with relapsed chronic lymphocytic leukemia (CLL) who fail to respond to currently available therapies or cannot achieve a sustained response. Moreover, targeted agents with less myelotoxicity are necessary to treat patients with multiple comorbidities who would otherwise be unable to tolerate standard regimens. Ibrutinib, a Bruton's tyrosine kinase inhibitor, has shown highly encouraging results in phase I/II trials in patients with treatment-naive, relapsed and refractory CLL even in the presence of high risk disease or poor prognostic markers. In phase I/II trials, ibrutinib 420 mg or 840 mg - given continuously as single agent or at a dose of 420 mg daily in combination with a monoclonal antibody or chemoimmunotherapy - has been associated with high response rates and durable clinical remissions. Phase II and III trials are currently under way for treatment-naive patients, relapsed/refractory patients, and for those patients harboring a 17p deletion.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "1deabfc2b8134cc6addbbe34af4c2d6b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[108, 108], [57, 57]], "char_spans": [[629, 637], [368, 376]]}]}], "context_tokens": [["New", 0], ["treatment", 4], ["options", 14], ["are", 22], ["urgently", 26], ["needed", 35], ["for", 42], ["patients", 46], ["with", 55], ["relapsed", 60], ["chronic", 69], ["lymphocytic", 77], ["leukemia", 89], ["(", 98], ["CLL", 99], [")", 102], ["who", 104], ["fail", 108], ["to", 113], ["respond", 116], ["to", 124], ["currently", 127], ["available", 137], ["therapies", 147], ["or", 157], ["can", 160], ["not", 163], ["achieve", 167], ["a", 175], ["sustained", 177], ["response", 187], [".", 195], ["Moreover", 197], [",", 205], ["targeted", 207], ["agents", 216], ["with", 223], ["less", 228], ["myelotoxicity", 233], ["are", 247], ["necessary", 251], ["to", 261], ["treat", 264], ["patients", 270], ["with", 279], ["multiple", 284], ["comorbidities", 293], ["who", 307], ["would", 311], ["otherwise", 317], ["be", 327], ["unable", 330], ["to", 337], ["tolerate", 340], ["standard", 349], ["regimens", 358], [".", 366], ["Ibrutinib", 368], [",", 377], ["a", 379], ["Bruton", 381], ["'s", 387], ["tyrosine", 390], ["kinase", 399], ["inhibitor", 406], [",", 415], ["has", 417], ["shown", 421], ["highly", 427], ["encouraging", 434], ["results", 446], ["in", 454], ["phase", 457], ["I", 463], ["/", 464], ["II", 465], ["trials", 468], ["in", 475], ["patients", 478], ["with", 487], ["treatment", 492], ["-", 501], ["naive", 502], [",", 507], ["relapsed", 509], ["and", 518], ["refractory", 522], ["CLL", 533], ["even", 537], ["in", 542], ["the", 545], ["presence", 549], ["of", 558], ["high", 561], ["risk", 566], ["disease", 571], ["or", 579], ["poor", 582], ["prognostic", 587], ["markers", 598], [".", 605], ["In", 607], ["phase", 610], ["I", 616], ["/", 617], ["II", 618], ["trials", 621], [",", 627], ["ibrutinib", 629], ["420", 639], ["mg", 643], ["or", 646], ["840", 649], ["mg", 653], ["-", 656], ["given", 658], ["continuously", 664], ["as", 677], ["single", 680], ["agent", 687], ["or", 693], ["at", 696], ["a", 699], ["dose", 701], ["of", 706], ["420", 709], ["mg", 713], ["daily", 716], ["in", 722], ["combination", 725], ["with", 737], ["a", 742], ["monoclonal", 744], ["antibody", 755], ["or", 764], ["chemoimmunotherapy", 767], ["-", 786], ["has", 788], ["been", 792], ["associated", 797], ["with", 808], ["high", 813], ["response", 818], ["rates", 827], ["and", 833], ["durable", 837], ["clinical", 845], ["remissions", 854], [".", 864], ["Phase", 866], ["II", 872], ["and", 875], ["III", 879], ["trials", 883], ["are", 890], ["currently", 894], ["under", 904], ["way", 910], ["for", 914], ["treatment", 918], ["-", 927], ["naive", 928], ["patients", 934], [",", 942], ["relapsed", 944], ["/", 952], ["refractory", 953], ["patients", 964], [",", 972], ["and", 974], ["for", 978], ["those", 982], ["patients", 988], ["harboring", 997], ["a", 1007], ["17p", 1009], ["deletion", 1013], [".", 1021]]}
{"context": "An effective malaria vaccine, deployed in conjunction with other malaria interventions, is likely to substantially reduce the malaria burden. Efficacy against severe malaria will be a key driver for decisions on implementation. An initial study of an RTS, S vaccine candidate showed promising efficacy against severe malaria in children in Mozambique. Further evidence of its protective efficacy will be gained in a pivotal, multi-centre, phase III study. This paper describes the case definitions of severe malaria used in this study and the programme for standardized assessment of severe malaria according to the case definition. Case definitions of severe malaria were developed from a literature review and a consensus meeting of expert consultants and the RTS, S Clinical Trial Partnership Committee, in collaboration with the World Health Organization and the Malaria Clinical Trials Alliance. The same groups, with input from an Independent Data Monitoring Committee, developed and implemented a programme for standardized data collection.The case definitions developed reflect the typical presentations of severe malaria in African hospitals. Markers of disease severity were chosen on the basis of their association with poor outcome, occurrence in a significant proportion of cases and on an ability to standardize their measurement across research centres. For the primary case definition, one or more clinical and/or laboratory markers of disease severity have to be present, four major co-morbidities (pneumonia, meningitis, bacteraemia or gastroenteritis with severe dehydration) are excluded, and a Plasmodium falciparum parasite density threshold is introduced, in order to maximize the specificity of the case definition. Secondary case definitions allow inclusion of co-morbidities and/or allow for the presence of parasitaemia at any density. The programmatic implementation of standardized case assessment included a clinical algorithm for evaluating seriously sick children, improvements to care delivery and a robust training and evaluation programme for clinicians. The case definition developed for the pivotal phase III RTS, S vaccine study is consistent with WHO recommendations, is locally applicable and appropriately balances sensitivity and specificity in the diagnosis of severe malaria. Processes set up to standardize severe malaria data collection will allow robust assessment of the efficacy of the RTS, S vaccine against severe malaria, strengthen local capacity and benefit patient care for subjects in the trial. Clinicaltrials.gov NCT00866619.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "94fef0193ac04cd1bd0618898b7f9efd", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[368, 368], [19, 19], [51, 51], [10, 10], [86, 86], [99, 99], [181, 181], [394, 394], [25, 25], [376, 376], [2, 2], [143, 143], [110, 110]], "char_spans": [[2311, 2317], [126, 132], [317, 323], [65, 71], [508, 514], [591, 597], [1122, 1128], [2465, 2471], [166, 172], [2359, 2365], [13, 19], [867, 873], [660, 666]]}]}], "context_tokens": [["An", 0], ["effective", 3], ["malaria", 13], ["vaccine", 21], [",", 28], ["deployed", 30], ["in", 39], ["conjunction", 42], ["with", 54], ["other", 59], ["malaria", 65], ["interventions", 73], [",", 86], ["is", 88], ["likely", 91], ["to", 98], ["substantially", 101], ["reduce", 115], ["the", 122], ["malaria", 126], ["burden", 134], [".", 140], ["Efficacy", 142], ["against", 151], ["severe", 159], ["malaria", 166], ["will", 174], ["be", 179], ["a", 182], ["key", 184], ["driver", 188], ["for", 195], ["decisions", 199], ["on", 209], ["implementation", 212], [".", 226], ["An", 228], ["initial", 231], ["study", 239], ["of", 245], ["an", 248], ["RTS", 251], [",", 254], ["S", 256], ["vaccine", 258], ["candidate", 266], ["showed", 276], ["promising", 283], ["efficacy", 293], ["against", 302], ["severe", 310], ["malaria", 317], ["in", 325], ["children", 328], ["in", 337], ["Mozambique", 340], [".", 350], ["Further", 352], ["evidence", 360], ["of", 369], ["its", 372], ["protective", 376], ["efficacy", 387], ["will", 396], ["be", 401], ["gained", 404], ["in", 411], ["a", 414], ["pivotal", 416], [",", 423], ["multi", 425], ["-", 430], ["centre", 431], [",", 437], ["phase", 439], ["III", 445], ["study", 449], [".", 454], ["This", 456], ["paper", 461], ["describes", 467], ["the", 477], ["case", 481], ["definitions", 486], ["of", 498], ["severe", 501], ["malaria", 508], ["used", 516], ["in", 521], ["this", 524], ["study", 529], ["and", 535], ["the", 539], ["programme", 543], ["for", 553], ["standardized", 557], ["assessment", 570], ["of", 581], ["severe", 584], ["malaria", 591], ["according", 599], ["to", 609], ["the", 612], ["case", 616], ["definition", 621], [".", 631], ["Case", 633], ["definitions", 638], ["of", 650], ["severe", 653], ["malaria", 660], ["were", 668], ["developed", 673], ["from", 683], ["a", 688], ["literature", 690], ["review", 701], ["and", 708], ["a", 712], ["consensus", 714], ["meeting", 724], ["of", 732], ["expert", 735], ["consultants", 742], ["and", 754], ["the", 758], ["RTS", 762], [",", 765], ["S", 767], ["Clinical", 769], ["Trial", 778], ["Partnership", 784], ["Committee", 796], [",", 805], ["in", 807], ["collaboration", 810], ["with", 824], ["the", 829], ["World", 833], ["Health", 839], ["Organization", 846], ["and", 859], ["the", 863], ["Malaria", 867], ["Clinical", 875], ["Trials", 884], ["Alliance", 891], [".", 899], ["The", 901], ["same", 905], ["groups", 910], [",", 916], ["with", 918], ["input", 923], ["from", 929], ["an", 934], ["Independent", 937], ["Data", 949], ["Monitoring", 954], ["Committee", 965], [",", 974], ["developed", 976], ["and", 986], ["implemented", 990], ["a", 1002], ["programme", 1004], ["for", 1014], ["standardized", 1018], ["data", 1031], ["collection", 1036], [".", 1046], ["The", 1047], ["case", 1051], ["definitions", 1056], ["developed", 1068], ["reflect", 1078], ["the", 1086], ["typical", 1090], ["presentations", 1098], ["of", 1112], ["severe", 1115], ["malaria", 1122], ["in", 1130], ["African", 1133], ["hospitals", 1141], [".", 1150], ["Markers", 1152], ["of", 1160], ["disease", 1163], ["severity", 1171], ["were", 1180], ["chosen", 1185], ["on", 1192], ["the", 1195], ["basis", 1199], ["of", 1205], ["their", 1208], ["association", 1214], ["with", 1226], ["poor", 1231], ["outcome", 1236], [",", 1243], ["occurrence", 1245], ["in", 1256], ["a", 1259], ["significant", 1261], ["proportion", 1273], ["of", 1284], ["cases", 1287], ["and", 1293], ["on", 1297], ["an", 1300], ["ability", 1303], ["to", 1311], ["standardize", 1314], ["their", 1326], ["measurement", 1332], ["across", 1344], ["research", 1351], ["centres", 1360], [".", 1367], ["For", 1369], ["the", 1373], ["primary", 1377], ["case", 1385], ["definition", 1390], [",", 1400], ["one", 1402], ["or", 1406], ["more", 1409], ["clinical", 1414], ["and/or", 1423], ["laboratory", 1430], ["markers", 1441], ["of", 1449], ["disease", 1452], ["severity", 1460], ["have", 1469], ["to", 1474], ["be", 1477], ["present", 1480], [",", 1487], ["four", 1489], ["major", 1494], ["co", 1500], ["-", 1502], ["morbidities", 1503], ["(", 1515], ["pneumonia", 1516], [",", 1525], ["meningitis", 1527], [",", 1537], ["bacteraemia", 1539], ["or", 1551], ["gastroenteritis", 1554], ["with", 1570], ["severe", 1575], ["dehydration", 1582], [")", 1593], ["are", 1595], ["excluded", 1599], [",", 1607], ["and", 1609], ["a", 1613], ["Plasmodium", 1615], ["falciparum", 1626], ["parasite", 1637], ["density", 1646], ["threshold", 1654], ["is", 1664], ["introduced", 1667], [",", 1677], ["in", 1679], ["order", 1682], ["to", 1688], ["maximize", 1691], ["the", 1700], ["specificity", 1704], ["of", 1716], ["the", 1719], ["case", 1723], ["definition", 1728], [".", 1738], ["Secondary", 1740], ["case", 1750], ["definitions", 1755], ["allow", 1767], ["inclusion", 1773], ["of", 1783], ["co", 1786], ["-", 1788], ["morbidities", 1789], ["and/or", 1801], ["allow", 1808], ["for", 1814], ["the", 1818], ["presence", 1822], ["of", 1831], ["parasitaemia", 1834], ["at", 1847], ["any", 1850], ["density", 1854], [".", 1861], ["The", 1863], ["programmatic", 1867], ["implementation", 1880], ["of", 1895], ["standardized", 1898], ["case", 1911], ["assessment", 1916], ["included", 1927], ["a", 1936], ["clinical", 1938], ["algorithm", 1947], ["for", 1957], ["evaluating", 1961], ["seriously", 1972], ["sick", 1982], ["children", 1987], [",", 1995], ["improvements", 1997], ["to", 2010], ["care", 2013], ["delivery", 2018], ["and", 2027], ["a", 2031], ["robust", 2033], ["training", 2040], ["and", 2049], ["evaluation", 2053], ["programme", 2064], ["for", 2074], ["clinicians", 2078], [".", 2088], ["The", 2090], ["case", 2094], ["definition", 2099], ["developed", 2110], ["for", 2120], ["the", 2124], ["pivotal", 2128], ["phase", 2136], ["III", 2142], ["RTS", 2146], [",", 2149], ["S", 2151], ["vaccine", 2153], ["study", 2161], ["is", 2167], ["consistent", 2170], ["with", 2181], ["WHO", 2186], ["recommendations", 2190], [",", 2205], ["is", 2207], ["locally", 2210], ["applicable", 2218], ["and", 2229], ["appropriately", 2233], ["balances", 2247], ["sensitivity", 2256], ["and", 2268], ["specificity", 2272], ["in", 2284], ["the", 2287], ["diagnosis", 2291], ["of", 2301], ["severe", 2304], ["malaria", 2311], [".", 2318], ["Processes", 2320], ["set", 2330], ["up", 2334], ["to", 2337], ["standardize", 2340], ["severe", 2352], ["malaria", 2359], ["data", 2367], ["collection", 2372], ["will", 2383], ["allow", 2388], ["robust", 2394], ["assessment", 2401], ["of", 2412], ["the", 2415], ["efficacy", 2419], ["of", 2428], ["the", 2431], ["RTS", 2435], [",", 2438], ["S", 2440], ["vaccine", 2442], ["against", 2450], ["severe", 2458], ["malaria", 2465], [",", 2472], ["strengthen", 2474], ["local", 2485], ["capacity", 2491], ["and", 2500], ["benefit", 2504], ["patient", 2512], ["care", 2520], ["for", 2525], ["subjects", 2529], ["in", 2538], ["the", 2541], ["trial", 2545], [".", 2550], ["Clinicaltrials.gov", 2552], ["NCT00866619", 2571], [".", 2582]]}
{"context": "Mutations of the epidermal growth factor receptor (EGFR) gene have been reported in non-small-cell lung cancer (NSCLC), especially in patients with adenocarcinoma and never smokers. Some common somatic mutations in EGFR, including deletion mutations in exon 19 and leucine-to-arginine substitution at amino acid position 858 (L858R) in exon 21, have been examined for their ability to predict sensitivity to gefitinib or erlotinib, which are selective EGFR tyrosine kinase inhibitors (EGFR-TKIs). On the other hand, reports have shown that the threonine-to-methionine substitution at amino acid position 790 (T790M) in exon 20 is related to gefitinib resistance. Some studies have indicated that high copy numbers of the EGFR gene may be a more effective molecular predictor to responsiveness and prolonged survival in patients treated with EGFR-TKIs. Here, we describe two NSCLC patients with the L858R mutation who did not respond to gefitinib. Case 1 harbored both the T790M and L858R mutations, and fluorescence in situ hybridization showed EGFR gene amplification. Case 2 harbored both the L858R and aspartic acid-to-tyrosine substitution at amino acid position 761 in exon 19 of EGFR mutations and had a high polysomy status for EGFR. In these two cases, tumors showed resistance to gefitinib treatment despite the presence of EGFR L858R mutation and increased copy number. Our findings encourage further molecular analysis to elucidate the relationship between the EGFR status, including mutations and amplifications, and the responsiveness of NSCLC to gefitinib.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "7082bcfbfa9a4128987d569a4296cbb7", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[3, 10]], "char_spans": [[17, 60]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["the", 13], ["epidermal", 17], ["growth", 27], ["factor", 34], ["receptor", 41], ["(", 50], ["EGFR", 51], [")", 55], ["gene", 57], ["have", 62], ["been", 67], ["reported", 72], ["in", 81], ["non", 84], ["-", 87], ["small", 88], ["-", 93], ["cell", 94], ["lung", 99], ["cancer", 104], ["(", 111], ["NSCLC", 112], [")", 117], [",", 118], ["especially", 120], ["in", 131], ["patients", 134], ["with", 143], ["adenocarcinoma", 148], ["and", 163], ["never", 167], ["smokers", 173], [".", 180], ["Some", 182], ["common", 187], ["somatic", 194], ["mutations", 202], ["in", 212], ["EGFR", 215], [",", 219], ["including", 221], ["deletion", 231], ["mutations", 240], ["in", 250], ["exon", 253], ["19", 258], ["and", 261], ["leucine", 265], ["-", 272], ["to", 273], ["-", 275], ["arginine", 276], ["substitution", 285], ["at", 298], ["amino", 301], ["acid", 307], ["position", 312], ["858", 321], ["(", 325], ["L858R", 326], [")", 331], ["in", 333], ["exon", 336], ["21", 341], [",", 343], ["have", 345], ["been", 350], ["examined", 355], ["for", 364], ["their", 368], ["ability", 374], ["to", 382], ["predict", 385], ["sensitivity", 393], ["to", 405], ["gefitinib", 408], ["or", 418], ["erlotinib", 421], [",", 430], ["which", 432], ["are", 438], ["selective", 442], ["EGFR", 452], ["tyrosine", 457], ["kinase", 466], ["inhibitors", 473], ["(", 484], ["EGFR", 485], ["-", 489], ["TKIs", 490], [")", 494], [".", 495], ["On", 497], ["the", 500], ["other", 504], ["hand", 510], [",", 514], ["reports", 516], ["have", 524], ["shown", 529], ["that", 535], ["the", 540], ["threonine", 544], ["-", 553], ["to", 554], ["-", 556], ["methionine", 557], ["substitution", 568], ["at", 581], ["amino", 584], ["acid", 590], ["position", 595], ["790", 604], ["(", 608], ["T790", 609], ["M", 613], [")", 614], ["in", 616], ["exon", 619], ["20", 624], ["is", 627], ["related", 630], ["to", 638], ["gefitinib", 641], ["resistance", 651], [".", 661], ["Some", 663], ["studies", 668], ["have", 676], ["indicated", 681], ["that", 691], ["high", 696], ["copy", 701], ["numbers", 706], ["of", 714], ["the", 717], ["EGFR", 721], ["gene", 726], ["may", 731], ["be", 735], ["a", 738], ["more", 740], ["effective", 745], ["molecular", 755], ["predictor", 765], ["to", 775], ["responsiveness", 778], ["and", 793], ["prolonged", 797], ["survival", 807], ["in", 816], ["patients", 819], ["treated", 828], ["with", 836], ["EGFR", 841], ["-", 845], ["TKIs", 846], [".", 850], ["Here", 852], [",", 856], ["we", 858], ["describe", 861], ["two", 870], ["NSCLC", 874], ["patients", 880], ["with", 889], ["the", 894], ["L858R", 898], ["mutation", 904], ["who", 913], ["did", 917], ["not", 921], ["respond", 925], ["to", 933], ["gefitinib", 936], [".", 945], ["Case", 947], ["1", 952], ["harbored", 954], ["both", 963], ["the", 968], ["T790", 972], ["M", 976], ["and", 978], ["L858R", 982], ["mutations", 988], [",", 997], ["and", 999], ["fluorescence", 1003], ["in", 1016], ["situ", 1019], ["hybridization", 1024], ["showed", 1038], ["EGFR", 1045], ["gene", 1050], ["amplification", 1055], [".", 1068], ["Case", 1070], ["2", 1075], ["harbored", 1077], ["both", 1086], ["the", 1091], ["L858R", 1095], ["and", 1101], ["aspartic", 1105], ["acid", 1114], ["-", 1118], ["to", 1119], ["-", 1121], ["tyrosine", 1122], ["substitution", 1131], ["at", 1144], ["amino", 1147], ["acid", 1153], ["position", 1158], ["761", 1167], ["in", 1171], ["exon", 1174], ["19", 1179], ["of", 1182], ["EGFR", 1185], ["mutations", 1190], ["and", 1200], ["had", 1204], ["a", 1208], ["high", 1210], ["polysomy", 1215], ["status", 1224], ["for", 1231], ["EGFR", 1235], [".", 1239], ["In", 1241], ["these", 1244], ["two", 1250], ["cases", 1254], [",", 1259], ["tumors", 1261], ["showed", 1268], ["resistance", 1275], ["to", 1286], ["gefitinib", 1289], ["treatment", 1299], ["despite", 1309], ["the", 1317], ["presence", 1321], ["of", 1330], ["EGFR", 1333], ["L858R", 1338], ["mutation", 1344], ["and", 1353], ["increased", 1357], ["copy", 1367], ["number", 1372], [".", 1378], ["Our", 1380], ["findings", 1384], ["encourage", 1393], ["further", 1403], ["molecular", 1411], ["analysis", 1421], ["to", 1430], ["elucidate", 1433], ["the", 1443], ["relationship", 1447], ["between", 1460], ["the", 1468], ["EGFR", 1472], ["status", 1477], [",", 1483], ["including", 1485], ["mutations", 1495], ["and", 1505], ["amplifications", 1509], [",", 1523], ["and", 1525], ["the", 1529], ["responsiveness", 1533], ["of", 1548], ["NSCLC", 1551], ["to", 1557], ["gefitinib", 1560], [".", 1569]]}
{"context": "The study analyzes the occurrence of high frequency oscillations in different types of focal cortical dysplasia in 22 patients with refractory epilepsy. High frequency oscillations are biomarkers for epileptic tissue, but it is unknown whether they can reflect increasingly dysplastic tissue changes as well as epileptic disease activity. High frequency oscillations (80-450 Hz) were visually marked by two independent reviewers in all channels of intracranial implanted grid, strips, and depth electrodes in patients with focal cortical dysplasia and refractory epilepsy. Rates of high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia of Palmini type 1a and b were compared with those in type 2a and b. Patients with focal cortical dysplasia type 2 had significantly more seizures than those with type 1 (p < 0.001). Rates of high frequency oscillations were significantly higher in patients with focal cortical dysplasia type 2 versus type 1 (p < 0.001). In addition, it could be confirmed that rates of high frequency oscillations were significantly higher in presumed epileptogenic areas than outside (p < 0.001). Activity of high frequency oscillations mirrors the higher epileptogenicity of focal cortical dysplasia type 2 lesions compared to type 1 lesions. Therefore, rates of high frequency oscillations can reflect disease activity of a lesion. This has implications for the use of high frequency oscillations as biomarkers for epileptogenic areas, because a detailed analysis of their rates may be necessary to use high frequency oscillations as a predictive tool in epilepsy surgery.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "72198761654a45ae94b82109ef387fe0", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[100, 102], [13, 15], [120, 122], [203, 205], [83, 85], [151, 153]], "char_spans": [[652, 675], [87, 110], [759, 782], [1238, 1261], [523, 546], [939, 962]]}]}], "context_tokens": [["The", 0], ["study", 4], ["analyzes", 10], ["the", 19], ["occurrence", 23], ["of", 34], ["high", 37], ["frequency", 42], ["oscillations", 52], ["in", 65], ["different", 68], ["types", 78], ["of", 84], ["focal", 87], ["cortical", 93], ["dysplasia", 102], ["in", 112], ["22", 115], ["patients", 118], ["with", 127], ["refractory", 132], ["epilepsy", 143], [".", 151], ["High", 153], ["frequency", 158], ["oscillations", 168], ["are", 181], ["biomarkers", 185], ["for", 196], ["epileptic", 200], ["tissue", 210], [",", 216], ["but", 218], ["it", 222], ["is", 225], ["unknown", 228], ["whether", 236], ["they", 244], ["can", 249], ["reflect", 253], ["increasingly", 261], ["dysplastic", 274], ["tissue", 285], ["changes", 292], ["as", 300], ["well", 303], ["as", 308], ["epileptic", 311], ["disease", 321], ["activity", 329], [".", 337], ["High", 339], ["frequency", 344], ["oscillations", 354], ["(", 367], ["80", 368], ["-", 370], ["450", 371], ["Hz", 375], [")", 377], ["were", 379], ["visually", 384], ["marked", 393], ["by", 400], ["two", 403], ["independent", 407], ["reviewers", 419], ["in", 429], ["all", 432], ["channels", 436], ["of", 445], ["intracranial", 448], ["implanted", 461], ["grid", 471], [",", 475], ["strips", 477], [",", 483], ["and", 485], ["depth", 489], ["electrodes", 495], ["in", 506], ["patients", 509], ["with", 518], ["focal", 523], ["cortical", 529], ["dysplasia", 538], ["and", 548], ["refractory", 552], ["epilepsy", 563], [".", 571], ["Rates", 573], ["of", 579], ["high", 582], ["frequency", 587], ["oscillations", 597], ["in", 610], ["patients", 613], ["with", 622], ["pathologically", 627], ["confirmed", 642], ["focal", 652], ["cortical", 658], ["dysplasia", 667], ["of", 677], ["Palmini", 680], ["type", 688], ["1a", 693], ["and", 696], ["b", 700], ["were", 702], ["compared", 707], ["with", 716], ["those", 721], ["in", 727], ["type", 730], ["2a", 735], ["and", 738], ["b.", 742], ["Patients", 745], ["with", 754], ["focal", 759], ["cortical", 765], ["dysplasia", 774], ["type", 784], ["2", 789], ["had", 791], ["significantly", 795], ["more", 809], ["seizures", 814], ["than", 823], ["those", 828], ["with", 834], ["type", 839], ["1", 844], ["(", 846], ["p", 847], ["<", 849], ["0.001", 851], [")", 856], [".", 857], ["Rates", 859], ["of", 865], ["high", 868], ["frequency", 873], ["oscillations", 883], ["were", 896], ["significantly", 901], ["higher", 915], ["in", 922], ["patients", 925], ["with", 934], ["focal", 939], ["cortical", 945], ["dysplasia", 954], ["type", 964], ["2", 969], ["versus", 971], ["type", 978], ["1", 983], ["(", 985], ["p", 986], ["<", 988], ["0.001", 990], [")", 995], [".", 996], ["In", 998], ["addition", 1001], [",", 1009], ["it", 1011], ["could", 1014], ["be", 1020], ["confirmed", 1023], ["that", 1033], ["rates", 1038], ["of", 1044], ["high", 1047], ["frequency", 1052], ["oscillations", 1062], ["were", 1075], ["significantly", 1080], ["higher", 1094], ["in", 1101], ["presumed", 1104], ["epileptogenic", 1113], ["areas", 1127], ["than", 1133], ["outside", 1138], ["(", 1146], ["p", 1147], ["<", 1149], ["0.001", 1151], [")", 1156], [".", 1157], ["Activity", 1159], ["of", 1168], ["high", 1171], ["frequency", 1176], ["oscillations", 1186], ["mirrors", 1199], ["the", 1207], ["higher", 1211], ["epileptogenicity", 1218], ["of", 1235], ["focal", 1238], ["cortical", 1244], ["dysplasia", 1253], ["type", 1263], ["2", 1268], ["lesions", 1270], ["compared", 1278], ["to", 1287], ["type", 1290], ["1", 1295], ["lesions", 1297], [".", 1304], ["Therefore", 1306], [",", 1315], ["rates", 1317], ["of", 1323], ["high", 1326], ["frequency", 1331], ["oscillations", 1341], ["can", 1354], ["reflect", 1358], ["disease", 1366], ["activity", 1374], ["of", 1383], ["a", 1386], ["lesion", 1388], [".", 1394], ["This", 1396], ["has", 1401], ["implications", 1405], ["for", 1418], ["the", 1422], ["use", 1426], ["of", 1430], ["high", 1433], ["frequency", 1438], ["oscillations", 1448], ["as", 1461], ["biomarkers", 1464], ["for", 1475], ["epileptogenic", 1479], ["areas", 1493], [",", 1498], ["because", 1500], ["a", 1508], ["detailed", 1510], ["analysis", 1519], ["of", 1528], ["their", 1531], ["rates", 1537], ["may", 1543], ["be", 1547], ["necessary", 1550], ["to", 1560], ["use", 1563], ["high", 1567], ["frequency", 1572], ["oscillations", 1582], ["as", 1595], ["a", 1598], ["predictive", 1600], ["tool", 1611], ["in", 1616], ["epilepsy", 1619], ["surgery", 1628], [".", 1635]]}
{"context": "Selenocysteine is incorporated into proteins via \"recoding\" of UGA from a stop codon to a sense codon, a process that requires specific secondary structures in the 3' untranslated region, termed selenocysteine incorporation sequence (SECIS) elements, and the protein factors that they recruit. Whereas most selenoprotein mRNAs contain a single UGA codon and a single SECIS element, selenoprotein P genes encode multiple UGAs and two SECIS elements. We have identified evolutionary adaptations in selenoprotein P genes that contribute to the efficiency of incorporating multiple selenocysteine residues in this protein. The first is a conserved, inefficiently decoded UGA codon in the N-terminal region, which appears to serve both as a checkpoint for the presence of factors required for selenocysteine incorporation and as a \"bottleneck,\" slowing down the progress of elongating ribosomes. The second adaptation involves the presence of introns downstream of this inefficiently decoded UGA which confer the potential for nonsense-mediated decay when factors required for selenocysteine incorporation are limiting. Third, the two SECIS elements in selenoprotein P mRNA function with differing efficiencies, affecting both the rate and the efficiency of decoding different UGAs. The implications for how these factors contribute to the decoding of multiple selenocysteine residues are discussed.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "47da715dad124f3690dc1764042458cc", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[188, 189], [83, 84], [66, 67]], "char_spans": [[1148, 1162], [496, 510], [382, 396]]}]}], "context_tokens": [["Selenocysteine", 0], ["is", 15], ["incorporated", 18], ["into", 31], ["proteins", 36], ["via", 45], ["\"", 49], ["recoding", 50], ["\"", 58], ["of", 60], ["UGA", 63], ["from", 67], ["a", 72], ["stop", 74], ["codon", 79], ["to", 85], ["a", 88], ["sense", 90], ["codon", 96], [",", 101], ["a", 103], ["process", 105], ["that", 113], ["requires", 118], ["specific", 127], ["secondary", 136], ["structures", 146], ["in", 157], ["the", 160], ["3", 164], ["'", 165], ["untranslated", 167], ["region", 180], [",", 186], ["termed", 188], ["selenocysteine", 195], ["incorporation", 210], ["sequence", 224], ["(", 233], ["SECIS", 234], [")", 239], ["elements", 241], [",", 249], ["and", 251], ["the", 255], ["protein", 259], ["factors", 267], ["that", 275], ["they", 280], ["recruit", 285], [".", 292], ["Whereas", 294], ["most", 302], ["selenoprotein", 307], ["mRNAs", 321], ["contain", 327], ["a", 335], ["single", 337], ["UGA", 344], ["codon", 348], ["and", 354], ["a", 358], ["single", 360], ["SECIS", 367], ["element", 373], [",", 380], ["selenoprotein", 382], ["P", 396], ["genes", 398], ["encode", 404], ["multiple", 411], ["UGAs", 420], ["and", 425], ["two", 429], ["SECIS", 433], ["elements", 439], [".", 447], ["We", 449], ["have", 452], ["identified", 457], ["evolutionary", 468], ["adaptations", 481], ["in", 493], ["selenoprotein", 496], ["P", 510], ["genes", 512], ["that", 518], ["contribute", 523], ["to", 534], ["the", 537], ["efficiency", 541], ["of", 552], ["incorporating", 555], ["multiple", 569], ["selenocysteine", 578], ["residues", 593], ["in", 602], ["this", 605], ["protein", 610], [".", 617], ["The", 619], ["first", 623], ["is", 629], ["a", 632], ["conserved", 634], [",", 643], ["inefficiently", 645], ["decoded", 659], ["UGA", 667], ["codon", 671], ["in", 677], ["the", 680], ["N", 684], ["-", 685], ["terminal", 686], ["region", 695], [",", 701], ["which", 703], ["appears", 709], ["to", 717], ["serve", 720], ["both", 726], ["as", 731], ["a", 734], ["checkpoint", 736], ["for", 747], ["the", 751], ["presence", 755], ["of", 764], ["factors", 767], ["required", 775], ["for", 784], ["selenocysteine", 788], ["incorporation", 803], ["and", 817], ["as", 821], ["a", 824], ["\"", 826], ["bottleneck", 827], [",", 837], ["\"", 838], ["slowing", 840], ["down", 848], ["the", 853], ["progress", 857], ["of", 866], ["elongating", 869], ["ribosomes", 880], [".", 889], ["The", 891], ["second", 895], ["adaptation", 902], ["involves", 913], ["the", 922], ["presence", 926], ["of", 935], ["introns", 938], ["downstream", 946], ["of", 957], ["this", 960], ["inefficiently", 965], ["decoded", 979], ["UGA", 987], ["which", 991], ["confer", 997], ["the", 1004], ["potential", 1008], ["for", 1018], ["nonsense", 1022], ["-", 1030], ["mediated", 1031], ["decay", 1040], ["when", 1046], ["factors", 1051], ["required", 1059], ["for", 1068], ["selenocysteine", 1072], ["incorporation", 1087], ["are", 1101], ["limiting", 1105], [".", 1113], ["Third", 1115], [",", 1120], ["the", 1122], ["two", 1126], ["SECIS", 1130], ["elements", 1136], ["in", 1145], ["selenoprotein", 1148], ["P", 1162], ["mRNA", 1164], ["function", 1169], ["with", 1178], ["differing", 1183], ["efficiencies", 1193], [",", 1205], ["affecting", 1207], ["both", 1217], ["the", 1222], ["rate", 1226], ["and", 1231], ["the", 1235], ["efficiency", 1239], ["of", 1250], ["decoding", 1253], ["different", 1262], ["UGAs", 1272], [".", 1276], ["The", 1278], ["implications", 1282], ["for", 1295], ["how", 1299], ["these", 1303], ["factors", 1309], ["contribute", 1317], ["to", 1328], ["the", 1331], ["decoding", 1335], ["of", 1344], ["multiple", 1347], ["selenocysteine", 1356], ["residues", 1371], ["are", 1380], ["discussed", 1384], [".", 1393]]}
{"context": "Activation of the superoxide-producing NADPH oxidase Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1. Here we describe an alternative splicing form of Noxo1, Noxo1gamma, which is expressed in the testis and fetal brain. The Noxo1gamma protein contains an additional five amino acids in the N-terminal PX domain, a phosphoinositide-binding module; the domain plays an essential role in supporting superoxide production by NADPH oxidase (Nox) family oxidases including Nox1, gp91(phox)/Nox2, and Nox3, as shown in this study. The PX domain isolated from Noxo1gamma shows a lower affinity for phosphoinositides than that from the classical splicing form Noxo1beta. Consistent with this, in resting cells, Noxo1gamma is poorly localized to the membrane, and thus less effective in activating Nox1 than Noxo1beta, which is constitutively present at the membrane. On the other hand, cell stimulation with phorbol 12-myristate 13-acetate (PMA), an activator of Nox1-3, facilitates membrane translocation of Noxo1gamma; as a result, Noxo1gamma is equivalent to Noxo1beta in Nox1 activation in PMA-stimulated cells. The effect of the five-amino-acid insertion in the Noxo1 PX domain appears to depend on the type of Nox; in activation of gp91(phox)/Nox2, Noxo1gamma is less active than Noxo1beta even in the presence of PMA, whereas Noxo1gamma and Noxo1beta support the superoxide-producing activity of Nox3 to the same extent in a manner independent of cell stimulation.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "a4ff84e6a2b74095928e6c42a934aca5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[85, 85], [141, 141], [171, 171], [8, 8], [191, 191]], "char_spans": [[498, 501], [819, 822], [985, 988], [53, 56], [1097, 1100]]}]}], "context_tokens": [["Activation", 0], ["of", 11], ["the", 14], ["superoxide", 18], ["-", 28], ["producing", 29], ["NADPH", 39], ["oxidase", 45], ["Nox1", 53], ["requires", 58], ["both", 67], ["the", 72], ["organizer", 76], ["protein", 86], ["Noxo1", 94], ["and", 100], ["the", 104], ["activator", 108], ["protein", 118], ["Noxa1", 126], [".", 131], ["Here", 133], ["we", 138], ["describe", 141], ["an", 150], ["alternative", 153], ["splicing", 165], ["form", 174], ["of", 179], ["Noxo1", 182], [",", 187], ["Noxo1gamma", 189], [",", 199], ["which", 201], ["is", 207], ["expressed", 210], ["in", 220], ["the", 223], ["testis", 227], ["and", 234], ["fetal", 238], ["brain", 244], [".", 249], ["The", 251], ["Noxo1gamma", 255], ["protein", 266], ["contains", 274], ["an", 283], ["additional", 286], ["five", 297], ["amino", 302], ["acids", 308], ["in", 314], ["the", 317], ["N", 321], ["-", 322], ["terminal", 323], ["PX", 332], ["domain", 335], [",", 341], ["a", 343], ["phosphoinositide", 345], ["-", 361], ["binding", 362], ["module", 370], [";", 376], ["the", 378], ["domain", 382], ["plays", 389], ["an", 395], ["essential", 398], ["role", 408], ["in", 413], ["supporting", 416], ["superoxide", 427], ["production", 438], ["by", 449], ["NADPH", 452], ["oxidase", 458], ["(", 466], ["Nox", 467], [")", 470], ["family", 472], ["oxidases", 479], ["including", 488], ["Nox1", 498], [",", 502], ["gp91(phox)/Nox2", 504], [",", 519], ["and", 521], ["Nox3", 525], [",", 529], ["as", 531], ["shown", 534], ["in", 540], ["this", 543], ["study", 548], [".", 553], ["The", 555], ["PX", 559], ["domain", 562], ["isolated", 569], ["from", 578], ["Noxo1gamma", 583], ["shows", 594], ["a", 600], ["lower", 602], ["affinity", 608], ["for", 617], ["phosphoinositides", 621], ["than", 639], ["that", 644], ["from", 649], ["the", 654], ["classical", 658], ["splicing", 668], ["form", 677], ["Noxo1beta", 682], [".", 691], ["Consistent", 693], ["with", 704], ["this", 709], [",", 713], ["in", 715], ["resting", 718], ["cells", 726], [",", 731], ["Noxo1gamma", 733], ["is", 744], ["poorly", 747], ["localized", 754], ["to", 764], ["the", 767], ["membrane", 771], [",", 779], ["and", 781], ["thus", 785], ["less", 790], ["effective", 795], ["in", 805], ["activating", 808], ["Nox1", 819], ["than", 824], ["Noxo1beta", 829], [",", 838], ["which", 840], ["is", 846], ["constitutively", 849], ["present", 864], ["at", 872], ["the", 875], ["membrane", 879], [".", 887], ["On", 889], ["the", 892], ["other", 896], ["hand", 902], [",", 906], ["cell", 908], ["stimulation", 913], ["with", 925], ["phorbol", 930], ["12-myristate", 938], ["13-acetate", 951], ["(", 962], ["PMA", 963], [")", 966], [",", 967], ["an", 969], ["activator", 972], ["of", 982], ["Nox1", 985], ["-", 989], ["3", 990], [",", 991], ["facilitates", 993], ["membrane", 1005], ["translocation", 1014], ["of", 1028], ["Noxo1gamma", 1031], [";", 1041], ["as", 1043], ["a", 1046], ["result", 1048], [",", 1054], ["Noxo1gamma", 1056], ["is", 1067], ["equivalent", 1070], ["to", 1081], ["Noxo1beta", 1084], ["in", 1094], ["Nox1", 1097], ["activation", 1102], ["in", 1113], ["PMA", 1116], ["-", 1119], ["stimulated", 1120], ["cells", 1131], [".", 1136], ["The", 1138], ["effect", 1142], ["of", 1149], ["the", 1152], ["five", 1156], ["-", 1160], ["amino", 1161], ["-", 1166], ["acid", 1167], ["insertion", 1172], ["in", 1182], ["the", 1185], ["Noxo1", 1189], ["PX", 1195], ["domain", 1198], ["appears", 1205], ["to", 1213], ["depend", 1216], ["on", 1223], ["the", 1226], ["type", 1230], ["of", 1235], ["Nox", 1238], [";", 1241], ["in", 1243], ["activation", 1246], ["of", 1257], ["gp91(phox)/Nox2", 1260], [",", 1275], ["Noxo1gamma", 1277], ["is", 1288], ["less", 1291], ["active", 1296], ["than", 1303], ["Noxo1beta", 1308], ["even", 1318], ["in", 1323], ["the", 1326], ["presence", 1330], ["of", 1339], ["PMA", 1342], [",", 1345], ["whereas", 1347], ["Noxo1gamma", 1355], ["and", 1366], ["Noxo1beta", 1370], ["support", 1380], ["the", 1388], ["superoxide", 1392], ["-", 1402], ["producing", 1403], ["activity", 1413], ["of", 1422], ["Nox3", 1425], ["to", 1430], ["the", 1433], ["same", 1437], ["extent", 1442], ["in", 1449], ["a", 1452], ["manner", 1454], ["independent", 1461], ["of", 1473], ["cell", 1476], ["stimulation", 1481], [".", 1492]]}
{"context": "Peripheral neuropathy (PN) has been reported in idiopathic and hereditary forms of parkinsonism, but the pathogenic mechanisms are unclear and likely heterogeneous. Levodopa-induced vitamin B12 deficiency has been discussed as a causal factor of PN in idiopathic Parkinson's disease, but peripheral nervous system involvement might also be a consequence of the underlying neurodegenerative process. Occurrence of PN with parkinsonism has been associated with a panel of mitochondrial cytopathies, more frequently related to a nuclear gene defect and mainly polymerase gamma (POLG1) gene. Parkin (PARK2) gene mutations are responsible for juvenile parkinsonism, and possible peripheral nervous system involvement has been reported. Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations. This article reviews conditions in which PN may coexist with parkinsonism.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "2d94618b5f9d418e967e8d0aff6598aa", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[210, 213]], "char_spans": [[1253, 1276]]}]}], "context_tokens": [["Peripheral", 0], ["neuropathy", 11], ["(", 22], ["PN", 23], [")", 25], ["has", 27], ["been", 31], ["reported", 36], ["in", 45], ["idiopathic", 48], ["and", 59], ["hereditary", 63], ["forms", 74], ["of", 80], ["parkinsonism", 83], [",", 95], ["but", 97], ["the", 101], ["pathogenic", 105], ["mechanisms", 116], ["are", 127], ["unclear", 131], ["and", 139], ["likely", 143], ["heterogeneous", 150], [".", 163], ["Levodopa", 165], ["-", 173], ["induced", 174], ["vitamin", 182], ["B12", 190], ["deficiency", 194], ["has", 205], ["been", 209], ["discussed", 214], ["as", 224], ["a", 227], ["causal", 229], ["factor", 236], ["of", 243], ["PN", 246], ["in", 249], ["idiopathic", 252], ["Parkinson", 263], ["'s", 272], ["disease", 275], [",", 282], ["but", 284], ["peripheral", 288], ["nervous", 299], ["system", 307], ["involvement", 314], ["might", 326], ["also", 332], ["be", 337], ["a", 340], ["consequence", 342], ["of", 354], ["the", 357], ["underlying", 361], ["neurodegenerative", 372], ["process", 390], [".", 397], ["Occurrence", 399], ["of", 410], ["PN", 413], ["with", 416], ["parkinsonism", 421], ["has", 434], ["been", 438], ["associated", 443], ["with", 454], ["a", 459], ["panel", 461], ["of", 467], ["mitochondrial", 470], ["cytopathies", 484], [",", 495], ["more", 497], ["frequently", 502], ["related", 513], ["to", 521], ["a", 524], ["nuclear", 526], ["gene", 534], ["defect", 539], ["and", 546], ["mainly", 550], ["polymerase", 557], ["gamma", 568], ["(", 574], ["POLG1", 575], [")", 580], ["gene", 582], [".", 586], ["Parkin", 588], ["(", 595], ["PARK2", 596], [")", 601], ["gene", 603], ["mutations", 608], ["are", 618], ["responsible", 622], ["for", 634], ["juvenile", 638], ["parkinsonism", 647], [",", 659], ["and", 661], ["possible", 665], ["peripheral", 674], ["nervous", 685], ["system", 693], ["involvement", 700], ["has", 712], ["been", 716], ["reported", 721], [".", 729], ["Rarely", 731], [",", 737], ["an", 739], ["association", 742], ["of", 754], ["parkinsonism", 757], ["with", 770], ["PN", 775], ["may", 778], ["be", 782], ["encountered", 785], ["in", 797], ["other", 800], ["neurodegenerative", 806], ["diseases", 824], ["such", 833], ["as", 838], ["fragile", 841], ["X", 849], ["-", 850], ["associated", 851], ["tremor", 862], ["and", 869], ["ataxia", 873], ["syndrome", 880], ["related", 889], ["to", 897], ["premutation", 900], ["CGG", 912], ["repeat", 916], ["expansion", 923], ["in", 933], ["the", 936], ["fragile", 940], ["X", 948], ["mental", 950], ["retardation", 957], ["(", 969], ["FMR1", 970], [")", 974], ["gene", 976], [",", 980], ["Machado", 982], ["-", 989], ["Joseph", 990], ["disease", 997], ["related", 1005], ["to", 1013], ["an", 1016], ["abnormal", 1019], ["CAG", 1028], ["repeat", 1032], ["expansion", 1039], ["in", 1049], ["ataxin-3", 1052], ["(", 1061], ["ATXN3", 1062], [")", 1067], ["gene", 1069], [",", 1073], ["Kufor", 1075], ["-", 1080], ["Rakeb", 1081], ["syndrome", 1087], ["caused", 1096], ["by", 1103], ["mutations", 1106], ["in", 1116], ["ATP13A2", 1119], ["gene", 1127], [",", 1131], ["or", 1133], ["in", 1136], ["hereditary", 1139], ["systemic", 1150], ["disorders", 1159], ["such", 1169], ["as", 1174], ["Gaucher", 1177], ["disease", 1185], ["due", 1193], ["to", 1197], ["mutations", 1200], ["in", 1210], ["the", 1213], ["\u03b2", 1217], ["-", 1218], ["glucocerebrosidase", 1219], ["(", 1238], ["GBA", 1239], [")", 1242], ["gene", 1244], ["and", 1249], ["Chediak", 1253], ["-", 1260], ["Higashi", 1261], ["syndrome", 1269], ["due", 1278], ["to", 1282], ["LYST", 1285], ["gene", 1290], ["mutations", 1295], [".", 1304], ["This", 1306], ["article", 1311], ["reviews", 1319], ["conditions", 1327], ["in", 1338], ["which", 1341], ["PN", 1347], ["may", 1350], ["coexist", 1354], ["with", 1362], ["parkinsonism", 1367], [".", 1379]]}
{"context": "To develop clinical rules for the safe and effective use of flumazenil in suspected benzodiazepine overdose. We assembled a retrospective series of 35 consecutive comatose patients admitted between October 1992 and July 1993 to a toxicologic ICU with the presumptive diagnosis of drug overdose. These patients were divided into two groups. Group A (low-risk) patients had a clinical picture compatible with uncomplicated benzodiazepine intoxication (calm, without abnormalities in pulse or blood pressure, lateralizing signs, hypertonia, hyperreflexia, or myoclonus) in the absence of predefined electrocardiographic or clinical signs of tricyclic antidepressant or other proconvulsant overdose, and absence of an available history of long-term benzodiazepine treatment or an underlying seizure disorder. Group B (\"non-low risk\") comprised all other patients. Efficacy of flumazenil was categorized as complete awakening (with normal level of alertness), partial awakening, or no change in alertness level. The safety of flumazenil was defined on the basis of the absence of seizures or death. In group A (n=4), flumazenil was associated with complete awakening in three patients and partial awakening in one. No seizures were observed. In group B (n=31), flumazenil was associated with complete awakening in 4 patients, partial awakening in 5, and no response in 22. In group B, five seizures occurred. Comatose patients with clinical or ECG criteria thought to contraindicate the use of flumazenil have a reasonably high risk of seizures after administration of this drug. Low-risk patients may be able to receive flumazenil safely, but they may be only a small portion of comatose patients with suspected overdose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "0852624d3eb84ea89be6dce27c79703c", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[192, 192], [144, 144], [219, 219], [11, 11], [171, 171], [261, 261], [284, 284]], "char_spans": [[1112, 1121], [872, 881], [1256, 1265], [60, 69], [1021, 1030], [1489, 1498], [1616, 1625]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["clinical", 11], ["rules", 20], ["for", 26], ["the", 30], ["safe", 34], ["and", 39], ["effective", 43], ["use", 53], ["of", 57], ["flumazenil", 60], ["in", 71], ["suspected", 74], ["benzodiazepine", 84], ["overdose", 99], [".", 107], ["We", 109], ["assembled", 112], ["a", 122], ["retrospective", 124], ["series", 138], ["of", 145], ["35", 148], ["consecutive", 151], ["comatose", 163], ["patients", 172], ["admitted", 181], ["between", 190], ["October", 198], ["1992", 206], ["and", 211], ["July", 215], ["1993", 220], ["to", 225], ["a", 228], ["toxicologic", 230], ["ICU", 242], ["with", 246], ["the", 251], ["presumptive", 255], ["diagnosis", 267], ["of", 277], ["drug", 280], ["overdose", 285], [".", 293], ["These", 295], ["patients", 301], ["were", 310], ["divided", 315], ["into", 323], ["two", 328], ["groups", 332], [".", 338], ["Group", 340], ["A", 346], ["(", 348], ["low", 349], ["-", 352], ["risk", 353], [")", 357], ["patients", 359], ["had", 368], ["a", 372], ["clinical", 374], ["picture", 383], ["compatible", 391], ["with", 402], ["uncomplicated", 407], ["benzodiazepine", 421], ["intoxication", 436], ["(", 449], ["calm", 450], [",", 454], ["without", 456], ["abnormalities", 464], ["in", 478], ["pulse", 481], ["or", 487], ["blood", 490], ["pressure", 496], [",", 504], ["lateralizing", 506], ["signs", 519], [",", 524], ["hypertonia", 526], [",", 536], ["hyperreflexia", 538], [",", 551], ["or", 553], ["myoclonus", 556], [")", 565], ["in", 567], ["the", 570], ["absence", 574], ["of", 582], ["predefined", 585], ["electrocardiographic", 596], ["or", 617], ["clinical", 620], ["signs", 629], ["of", 635], ["tricyclic", 638], ["antidepressant", 648], ["or", 663], ["other", 666], ["proconvulsant", 672], ["overdose", 686], [",", 694], ["and", 696], ["absence", 700], ["of", 708], ["an", 711], ["available", 714], ["history", 724], ["of", 732], ["long", 735], ["-", 739], ["term", 740], ["benzodiazepine", 745], ["treatment", 760], ["or", 770], ["an", 773], ["underlying", 776], ["seizure", 787], ["disorder", 795], [".", 803], ["Group", 805], ["B", 811], ["(", 813], ["\"", 814], ["non", 815], ["-", 818], ["low", 819], ["risk", 823], ["\"", 827], [")", 828], ["comprised", 830], ["all", 840], ["other", 844], ["patients", 850], [".", 858], ["Efficacy", 860], ["of", 869], ["flumazenil", 872], ["was", 883], ["categorized", 887], ["as", 899], ["complete", 902], ["awakening", 911], ["(", 921], ["with", 922], ["normal", 927], ["level", 934], ["of", 940], ["alertness", 943], [")", 952], [",", 953], ["partial", 955], ["awakening", 963], [",", 972], ["or", 974], ["no", 977], ["change", 980], ["in", 987], ["alertness", 990], ["level", 1000], [".", 1005], ["The", 1007], ["safety", 1011], ["of", 1018], ["flumazenil", 1021], ["was", 1032], ["defined", 1036], ["on", 1044], ["the", 1047], ["basis", 1051], ["of", 1057], ["the", 1060], ["absence", 1064], ["of", 1072], ["seizures", 1075], ["or", 1084], ["death", 1087], [".", 1092], ["In", 1094], ["group", 1097], ["A", 1103], ["(", 1105], ["n=4", 1106], [")", 1109], [",", 1110], ["flumazenil", 1112], ["was", 1123], ["associated", 1127], ["with", 1138], ["complete", 1143], ["awakening", 1152], ["in", 1162], ["three", 1165], ["patients", 1171], ["and", 1180], ["partial", 1184], ["awakening", 1192], ["in", 1202], ["one", 1205], [".", 1208], ["No", 1210], ["seizures", 1213], ["were", 1222], ["observed", 1227], [".", 1235], ["In", 1237], ["group", 1240], ["B", 1246], ["(", 1248], ["n=31", 1249], [")", 1253], [",", 1254], ["flumazenil", 1256], ["was", 1267], ["associated", 1271], ["with", 1282], ["complete", 1287], ["awakening", 1296], ["in", 1306], ["4", 1309], ["patients", 1311], [",", 1319], ["partial", 1321], ["awakening", 1329], ["in", 1339], ["5", 1342], [",", 1343], ["and", 1345], ["no", 1349], ["response", 1352], ["in", 1361], ["22", 1364], [".", 1366], ["In", 1368], ["group", 1371], ["B", 1377], [",", 1378], ["five", 1380], ["seizures", 1385], ["occurred", 1394], [".", 1402], ["Comatose", 1404], ["patients", 1413], ["with", 1422], ["clinical", 1427], ["or", 1436], ["ECG", 1439], ["criteria", 1443], ["thought", 1452], ["to", 1460], ["contraindicate", 1463], ["the", 1478], ["use", 1482], ["of", 1486], ["flumazenil", 1489], ["have", 1500], ["a", 1505], ["reasonably", 1507], ["high", 1518], ["risk", 1523], ["of", 1528], ["seizures", 1531], ["after", 1540], ["administration", 1546], ["of", 1561], ["this", 1564], ["drug", 1569], [".", 1573], ["Low", 1575], ["-", 1578], ["risk", 1579], ["patients", 1584], ["may", 1593], ["be", 1597], ["able", 1600], ["to", 1605], ["receive", 1608], ["flumazenil", 1616], ["safely", 1627], [",", 1633], ["but", 1635], ["they", 1639], ["may", 1644], ["be", 1648], ["only", 1651], ["a", 1656], ["small", 1658], ["portion", 1664], ["of", 1672], ["comatose", 1675], ["patients", 1684], ["with", 1693], ["suspected", 1698], ["overdose", 1708], [".", 1716]]}
{"context": "We present RADAR--a rigorously annotated database of A-to-I RNA editing (available at http://RNAedit.com). The identification of A-to-I RNA editing sites has been dramatically accelerated in the past few years by high-throughput RNA sequencing studies. RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site. RADAR also includes an expandable listing of tissue-specific editing levels for each editing site, which will facilitate the assignment of biological functions to specific editing sites.", "qas": [{"question": "Which annotated database of A-to-I RNA editing is available?", "answers": ["RADAR"], "qid": "9ed4f4385bc94c1f8e4317bb859818ae", "question_tokens": [["Which", 0], ["annotated", 6], ["database", 16], ["of", 25], ["A", 28], ["-", 29], ["to", 30], ["-", 32], ["I", 33], ["RNA", 35], ["editing", 39], ["is", 47], ["available", 50], ["?", 59]], "detected_answers": [{"text": "RADAR", "token_spans": [[95, 95], [50, 50], [2, 2]], "char_spans": [[493, 497], [253, 257], [11, 15]]}]}], "context_tokens": [["We", 0], ["present", 3], ["RADAR", 11], ["--", 16], ["a", 18], ["rigorously", 20], ["annotated", 31], ["database", 41], ["of", 50], ["A", 53], ["-", 54], ["to", 55], ["-", 57], ["I", 58], ["RNA", 60], ["editing", 64], ["(", 72], ["available", 73], ["at", 83], ["http://RNAedit.com", 86], [")", 104], [".", 105], ["The", 107], ["identification", 111], ["of", 126], ["A", 129], ["-", 130], ["to", 131], ["-", 133], ["I", 134], ["RNA", 136], ["editing", 140], ["sites", 148], ["has", 154], ["been", 158], ["dramatically", 163], ["accelerated", 176], ["in", 188], ["the", 191], ["past", 195], ["few", 200], ["years", 204], ["by", 210], ["high", 213], ["-", 217], ["throughput", 218], ["RNA", 229], ["sequencing", 233], ["studies", 244], [".", 251], ["RADAR", 253], ["includes", 259], ["a", 268], ["comprehensive", 270], ["collection", 284], ["of", 295], ["A", 298], ["-", 299], ["to", 300], ["-", 302], ["I", 303], ["RNA", 305], ["editing", 309], ["sites", 317], ["identified", 323], ["in", 334], ["humans", 337], ["(", 344], ["Homo", 345], ["sapiens", 350], [")", 357], [",", 358], ["mice", 360], ["(", 365], ["Mus", 366], ["musculus", 370], [")", 378], ["and", 380], ["flies", 384], ["(", 390], ["Drosophila", 391], ["melanogaster", 402], [")", 414], [",", 415], ["together", 417], ["with", 426], ["extensive", 431], ["manually", 441], ["curated", 450], ["annotations", 458], ["for", 470], ["each", 474], ["editing", 479], ["site", 487], [".", 491], ["RADAR", 493], ["also", 499], ["includes", 504], ["an", 513], ["expandable", 516], ["listing", 527], ["of", 535], ["tissue", 538], ["-", 544], ["specific", 545], ["editing", 554], ["levels", 562], ["for", 569], ["each", 573], ["editing", 578], ["site", 586], [",", 590], ["which", 592], ["will", 598], ["facilitate", 603], ["the", 614], ["assignment", 618], ["of", 629], ["biological", 632], ["functions", 643], ["to", 653], ["specific", 656], ["editing", 665], ["sites", 673], [".", 678]]}
{"context": "Alveolar macrophages (AMs) play a major role in host defense against microbial infections in the lung. To perform this function, these cells must ingest and destroy pathogens, generally in phagosomes, as well as secrete a number of products that signal other immune cells to respond. Recently, we demonstrated that murine alveolar macrophages employ the cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channel as a determinant in lysosomal acidification (Di, A., Brown, M. E., Deriy, L. V., Li, C., Szeto, F. L., Chen, Y., Huang, P., Tong, J., Naren, A. P., Bindokas, V., Palfrey, H. C., and Nelson, D. J. (2006) Nat. Cell Biol. 8, 933-944). Lysosomes and phagosomes in murine cftr(-/-) AMs failed to acidify, and the cells were deficient in bacterial killing compared with wild type controls. Cystic fibrosis is caused by mutations in CFTR and is characterized by chronic lung infections. The information about relationships between the CFTR genotype and the disease phenotype is scarce both on the organismal and cellular level. The most common disease-causing mutation, DeltaF508, is found in 70% of patients with cystic fibrosis. The mutant protein fails to fold properly and is targeted for proteosomal degradation. G551D, the second most common mutation, causes loss of function of the protein at the plasma membrane. In this study, we have investigated the impact of CFTR DeltaF508 and G551D on a set of core intracellular functions, including organellar acidification, granule secretion, and microbicidal activity in the AM. Utilizing primary AMs from wild type, cftr(-/-), as well as mutant mice, we show a tight correlation between CFTR genotype and levels of lysosomal acidification, bacterial killing, and agonist-induced secretory responses, all of which would be expected to contribute to a significant impact on microbial clearance in the lung.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "64d835315a7e48858f130cb33645cd8c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[279, 279], [221, 221]], "char_spans": [[1396, 1404], [1090, 1098]]}]}], "context_tokens": [["Alveolar", 0], ["macrophages", 9], ["(", 21], ["AMs", 22], [")", 25], ["play", 27], ["a", 32], ["major", 34], ["role", 40], ["in", 45], ["host", 48], ["defense", 53], ["against", 61], ["microbial", 69], ["infections", 79], ["in", 90], ["the", 93], ["lung", 97], [".", 101], ["To", 103], ["perform", 106], ["this", 114], ["function", 119], [",", 127], ["these", 129], ["cells", 135], ["must", 141], ["ingest", 146], ["and", 153], ["destroy", 157], ["pathogens", 165], [",", 174], ["generally", 176], ["in", 186], ["phagosomes", 189], [",", 199], ["as", 201], ["well", 204], ["as", 209], ["secrete", 212], ["a", 220], ["number", 222], ["of", 229], ["products", 232], ["that", 241], ["signal", 246], ["other", 253], ["immune", 259], ["cells", 266], ["to", 272], ["respond", 275], [".", 282], ["Recently", 284], [",", 292], ["we", 294], ["demonstrated", 297], ["that", 310], ["murine", 315], ["alveolar", 322], ["macrophages", 331], ["employ", 343], ["the", 350], ["cystic", 354], ["fibrosis", 361], ["transmembrane", 370], ["conductance", 384], ["regulator", 396], ["(", 406], ["CFTR", 407], [")", 411], ["Cl(-", 413], [")", 417], ["channel", 419], ["as", 427], ["a", 430], ["determinant", 432], ["in", 444], ["lysosomal", 447], ["acidification", 457], ["(", 471], ["Di", 472], [",", 474], ["A.", 476], [",", 478], ["Brown", 480], [",", 485], ["M.", 487], ["E.", 490], [",", 492], ["Deriy", 494], [",", 499], ["L.", 501], ["V.", 504], [",", 506], ["Li", 508], [",", 510], ["C.", 512], [",", 514], ["Szeto", 516], [",", 521], ["F.", 523], ["L.", 526], [",", 528], ["Chen", 530], [",", 534], ["Y.", 536], [",", 538], ["Huang", 540], [",", 545], ["P.", 547], [",", 549], ["Tong", 551], [",", 555], ["J.", 557], [",", 559], ["Naren", 561], [",", 566], ["A.", 568], ["P.", 571], [",", 573], ["Bindokas", 575], [",", 583], ["V.", 585], [",", 587], ["Palfrey", 589], [",", 596], ["H.", 598], ["C.", 601], [",", 603], ["and", 605], ["Nelson", 609], [",", 615], ["D.", 617], ["J.", 620], ["(", 623], ["2006", 624], [")", 628], ["Nat", 630], [".", 633], ["Cell", 635], ["Biol", 640], [".", 644], ["8", 646], [",", 647], ["933", 649], ["-", 652], ["944", 653], [")", 656], [".", 657], ["Lysosomes", 659], ["and", 669], ["phagosomes", 673], ["in", 684], ["murine", 687], ["cftr(-/-", 694], [")", 702], ["AMs", 704], ["failed", 708], ["to", 715], ["acidify", 718], [",", 725], ["and", 727], ["the", 731], ["cells", 735], ["were", 741], ["deficient", 746], ["in", 756], ["bacterial", 759], ["killing", 769], ["compared", 777], ["with", 786], ["wild", 791], ["type", 796], ["controls", 801], [".", 809], ["Cystic", 811], ["fibrosis", 818], ["is", 827], ["caused", 830], ["by", 837], ["mutations", 840], ["in", 850], ["CFTR", 853], ["and", 858], ["is", 862], ["characterized", 865], ["by", 879], ["chronic", 882], ["lung", 890], ["infections", 895], [".", 905], ["The", 907], ["information", 911], ["about", 923], ["relationships", 929], ["between", 943], ["the", 951], ["CFTR", 955], ["genotype", 960], ["and", 969], ["the", 973], ["disease", 977], ["phenotype", 985], ["is", 995], ["scarce", 998], ["both", 1005], ["on", 1010], ["the", 1013], ["organismal", 1017], ["and", 1028], ["cellular", 1032], ["level", 1041], [".", 1046], ["The", 1048], ["most", 1052], ["common", 1057], ["disease", 1064], ["-", 1071], ["causing", 1072], ["mutation", 1080], [",", 1088], ["DeltaF508", 1090], [",", 1099], ["is", 1101], ["found", 1104], ["in", 1110], ["70", 1113], ["%", 1115], ["of", 1117], ["patients", 1120], ["with", 1129], ["cystic", 1134], ["fibrosis", 1141], [".", 1149], ["The", 1151], ["mutant", 1155], ["protein", 1162], ["fails", 1170], ["to", 1176], ["fold", 1179], ["properly", 1184], ["and", 1193], ["is", 1197], ["targeted", 1200], ["for", 1209], ["proteosomal", 1213], ["degradation", 1225], [".", 1236], ["G551D", 1238], [",", 1243], ["the", 1245], ["second", 1249], ["most", 1256], ["common", 1261], ["mutation", 1268], [",", 1276], ["causes", 1278], ["loss", 1285], ["of", 1290], ["function", 1293], ["of", 1302], ["the", 1305], ["protein", 1309], ["at", 1317], ["the", 1320], ["plasma", 1324], ["membrane", 1331], [".", 1339], ["In", 1341], ["this", 1344], ["study", 1349], [",", 1354], ["we", 1356], ["have", 1359], ["investigated", 1364], ["the", 1377], ["impact", 1381], ["of", 1388], ["CFTR", 1391], ["DeltaF508", 1396], ["and", 1406], ["G551D", 1410], ["on", 1416], ["a", 1419], ["set", 1421], ["of", 1425], ["core", 1428], ["intracellular", 1433], ["functions", 1447], [",", 1456], ["including", 1458], ["organellar", 1468], ["acidification", 1479], [",", 1492], ["granule", 1494], ["secretion", 1502], [",", 1511], ["and", 1513], ["microbicidal", 1517], ["activity", 1530], ["in", 1539], ["the", 1542], ["AM", 1546], [".", 1548], ["Utilizing", 1550], ["primary", 1560], ["AMs", 1568], ["from", 1572], ["wild", 1577], ["type", 1582], [",", 1586], ["cftr(-/-", 1588], [")", 1596], [",", 1597], ["as", 1599], ["well", 1602], ["as", 1607], ["mutant", 1610], ["mice", 1617], [",", 1621], ["we", 1623], ["show", 1626], ["a", 1631], ["tight", 1633], ["correlation", 1639], ["between", 1651], ["CFTR", 1659], ["genotype", 1664], ["and", 1673], ["levels", 1677], ["of", 1684], ["lysosomal", 1687], ["acidification", 1697], [",", 1710], ["bacterial", 1712], ["killing", 1722], [",", 1729], ["and", 1731], ["agonist", 1735], ["-", 1742], ["induced", 1743], ["secretory", 1751], ["responses", 1761], [",", 1770], ["all", 1772], ["of", 1776], ["which", 1779], ["would", 1785], ["be", 1791], ["expected", 1794], ["to", 1803], ["contribute", 1806], ["to", 1817], ["a", 1820], ["significant", 1822], ["impact", 1834], ["on", 1841], ["microbial", 1844], ["clearance", 1854], ["in", 1864], ["the", 1867], ["lung", 1871], [".", 1875]]}
{"context": "Flumazenil (Ro 15-1788) proved to be a very efficacious competitive antagonist of benzodiazepines that reliably counteracts their pharmacological actions within 1-2 min as could be demonstrated in clinical and EEG studies. In general, a total dose of 0.3-0.8 mg will be sufficient in clinical practice, avoiding side effects like nausea, tremor, sweating, or transient anxiety that could be observed when higher dosages were administered. Its therapeutic range is very high as could be demonstrated in experimental animal in which up to 8.000-fold the clinical dose was administered. The total volume of distribution (Vdes) amounts to nearly 1.000 ml/kg BW and the total clearance exceeds 1.200 ml/min, resulting in a biological half-life of less than 60 min. According to the benzodiazepine dosage and the rapid plasma concentration decline of flumazenil, in some cases a resedation could be observed. Hence, a careful observation of the antagonised patient on the ward is mandatory for 1.5-2 h, even if at first sight the antagonization seemed successful and the patient fully awake and cooperative. In anaesthesia, indications to administer flumazenil are adverse drug reactions and prolonged recovery after adequate benzodiazepine dosage. In intensive care medicine, the antagonist may be used in the treatment of benzodiazepine overdose as well as in the differential diagnosis of a coma of unknown origin. Additionally, the antagonist may be administered to interrupt benzodiazepine sedation e.g. for neurological examination.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "767ca74416ef41738a08d2aef5208410", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [208, 208], [154, 154]], "char_spans": [[0, 9], [1144, 1153], [845, 854]]}]}], "context_tokens": [["Flumazenil", 0], ["(", 11], ["Ro", 12], ["15", 15], ["-", 17], ["1788", 18], [")", 22], ["proved", 24], ["to", 31], ["be", 34], ["a", 37], ["very", 39], ["efficacious", 44], ["competitive", 56], ["antagonist", 68], ["of", 79], ["benzodiazepines", 82], ["that", 98], ["reliably", 103], ["counteracts", 112], ["their", 124], ["pharmacological", 130], ["actions", 146], ["within", 154], ["1", 161], ["-", 162], ["2", 163], ["min", 165], ["as", 169], ["could", 172], ["be", 178], ["demonstrated", 181], ["in", 194], ["clinical", 197], ["and", 206], ["EEG", 210], ["studies", 214], [".", 221], ["In", 223], ["general", 226], [",", 233], ["a", 235], ["total", 237], ["dose", 243], ["of", 248], ["0.3", 251], ["-", 254], ["0.8", 255], ["mg", 259], ["will", 262], ["be", 267], ["sufficient", 270], ["in", 281], ["clinical", 284], ["practice", 293], [",", 301], ["avoiding", 303], ["side", 312], ["effects", 317], ["like", 325], ["nausea", 330], [",", 336], ["tremor", 338], [",", 344], ["sweating", 346], [",", 354], ["or", 356], ["transient", 359], ["anxiety", 369], ["that", 377], ["could", 382], ["be", 388], ["observed", 391], ["when", 400], ["higher", 405], ["dosages", 412], ["were", 420], ["administered", 425], [".", 437], ["Its", 439], ["therapeutic", 443], ["range", 455], ["is", 461], ["very", 464], ["high", 469], ["as", 474], ["could", 477], ["be", 483], ["demonstrated", 486], ["in", 499], ["experimental", 502], ["animal", 515], ["in", 522], ["which", 525], ["up", 531], ["to", 534], ["8.000-fold", 537], ["the", 548], ["clinical", 552], ["dose", 561], ["was", 566], ["administered", 570], [".", 582], ["The", 584], ["total", 588], ["volume", 594], ["of", 601], ["distribution", 604], ["(", 617], ["Vdes", 618], [")", 622], ["amounts", 624], ["to", 632], ["nearly", 635], ["1.000", 642], ["ml", 648], ["/", 650], ["kg", 651], ["BW", 654], ["and", 657], ["the", 661], ["total", 665], ["clearance", 671], ["exceeds", 681], ["1.200", 689], ["ml", 695], ["/", 697], ["min", 698], [",", 701], ["resulting", 703], ["in", 713], ["a", 716], ["biological", 718], ["half", 729], ["-", 733], ["life", 734], ["of", 739], ["less", 742], ["than", 747], ["60", 752], ["min", 755], [".", 758], ["According", 760], ["to", 770], ["the", 773], ["benzodiazepine", 777], ["dosage", 792], ["and", 799], ["the", 803], ["rapid", 807], ["plasma", 813], ["concentration", 820], ["decline", 834], ["of", 842], ["flumazenil", 845], [",", 855], ["in", 857], ["some", 860], ["cases", 865], ["a", 871], ["resedation", 873], ["could", 884], ["be", 890], ["observed", 893], [".", 901], ["Hence", 903], [",", 908], ["a", 910], ["careful", 912], ["observation", 920], ["of", 932], ["the", 935], ["antagonised", 939], ["patient", 951], ["on", 959], ["the", 962], ["ward", 966], ["is", 971], ["mandatory", 974], ["for", 984], ["1.5", 988], ["-", 991], ["2", 992], ["h", 994], [",", 995], ["even", 997], ["if", 1002], ["at", 1005], ["first", 1008], ["sight", 1014], ["the", 1020], ["antagonization", 1024], ["seemed", 1039], ["successful", 1046], ["and", 1057], ["the", 1061], ["patient", 1065], ["fully", 1073], ["awake", 1079], ["and", 1085], ["cooperative", 1089], [".", 1100], ["In", 1102], ["anaesthesia", 1105], [",", 1116], ["indications", 1118], ["to", 1130], ["administer", 1133], ["flumazenil", 1144], ["are", 1155], ["adverse", 1159], ["drug", 1167], ["reactions", 1172], ["and", 1182], ["prolonged", 1186], ["recovery", 1196], ["after", 1205], ["adequate", 1211], ["benzodiazepine", 1220], ["dosage", 1235], [".", 1241], ["In", 1243], ["intensive", 1246], ["care", 1256], ["medicine", 1261], [",", 1269], ["the", 1271], ["antagonist", 1275], ["may", 1286], ["be", 1290], ["used", 1293], ["in", 1298], ["the", 1301], ["treatment", 1305], ["of", 1315], ["benzodiazepine", 1318], ["overdose", 1333], ["as", 1342], ["well", 1345], ["as", 1350], ["in", 1353], ["the", 1356], ["differential", 1360], ["diagnosis", 1373], ["of", 1383], ["a", 1386], ["coma", 1388], ["of", 1393], ["unknown", 1396], ["origin", 1404], [".", 1410], ["Additionally", 1412], [",", 1424], ["the", 1426], ["antagonist", 1430], ["may", 1441], ["be", 1445], ["administered", 1448], ["to", 1461], ["interrupt", 1464], ["benzodiazepine", 1474], ["sedation", 1489], ["e.g.", 1498], ["for", 1503], ["neurological", 1507], ["examination", 1520], [".", 1531]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by a specific deficiency in erythroid progenitors. Since some patients with DBA develop a reduction in thrombocytes and granulocytes with age, we asked whether multipotent hematopoietic progenitors from DBA patients had normal proliferative capacity in liquid expansion cultures. CD34(+) cells derived from DBA patients showed deficient proliferation in liquid culture containing IL-3, IL-6, and SCF. Single CD34(+) CD38(-) cells from DBA patients exhibited deficient proliferation recruitment in a limiting dilution assay containing IL-3, IL-6, SCF, Tpo, FL, and G-CSF or containing IL-3, IL-6, and SCF. Our findings suggest that the underlying hematopoietic defect in DBA may not be limited to the erythroid lineage. Since a fraction of DBA patients have a deficiency in ribosomal protein S19 (RPS19), we constructed lentiviral vectors containing the RPS19 gene for overexpression in hematopoietic progenitors from RPS19-deficient DBA patients. Enforced expression of the RPS19 transgene improved the proliferation of CD34(+) cells from DBA patients with RPS19 mutation. Similarly, enforced expression of RPS19 improved erythroid development of RPS19-deficient hematopoietic progenitors as determined by colony assays and erythroid differentiation cultures. These findings suggest that gene therapy for RPS19-deficient DBA is feasible.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "0f4f89a6d7184d93bab72240637a0ccf", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[128, 128], [224, 224], [45, 45], [5, 5], [61, 61], [27, 27], [170, 170], [187, 187], [84, 84], [142, 142]], "char_spans": [[759, 761], [1410, 1412], [292, 294], [25, 27], [396, 398], [165, 167], [1022, 1024], [1128, 1130], [524, 526], [828, 830]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["a", 92], ["specific", 94], ["deficiency", 103], ["in", 114], ["erythroid", 117], ["progenitors", 127], [".", 138], ["Since", 140], ["some", 146], ["patients", 151], ["with", 160], ["DBA", 165], ["develop", 169], ["a", 177], ["reduction", 179], ["in", 189], ["thrombocytes", 192], ["and", 205], ["granulocytes", 209], ["with", 222], ["age", 227], [",", 230], ["we", 232], ["asked", 235], ["whether", 241], ["multipotent", 249], ["hematopoietic", 261], ["progenitors", 275], ["from", 287], ["DBA", 292], ["patients", 296], ["had", 305], ["normal", 309], ["proliferative", 316], ["capacity", 330], ["in", 339], ["liquid", 342], ["expansion", 349], ["cultures", 359], [".", 367], ["CD34(+", 369], [")", 375], ["cells", 377], ["derived", 383], ["from", 391], ["DBA", 396], ["patients", 400], ["showed", 409], ["deficient", 416], ["proliferation", 426], ["in", 440], ["liquid", 443], ["culture", 450], ["containing", 458], ["IL-3", 469], [",", 473], ["IL-6", 475], [",", 479], ["and", 481], ["SCF", 485], [".", 488], ["Single", 490], ["CD34(+", 497], [")", 503], ["CD38(-", 505], [")", 511], ["cells", 513], ["from", 519], ["DBA", 524], ["patients", 528], ["exhibited", 537], ["deficient", 547], ["proliferation", 557], ["recruitment", 571], ["in", 583], ["a", 586], ["limiting", 588], ["dilution", 597], ["assay", 606], ["containing", 612], ["IL-3", 623], [",", 627], ["IL-6", 629], [",", 633], ["SCF", 635], [",", 638], ["Tpo", 640], [",", 643], ["FL", 645], [",", 647], ["and", 649], ["G", 653], ["-", 654], ["CSF", 655], ["or", 659], ["containing", 662], ["IL-3", 673], [",", 677], ["IL-6", 679], [",", 683], ["and", 685], ["SCF", 689], [".", 692], ["Our", 694], ["findings", 698], ["suggest", 707], ["that", 715], ["the", 720], ["underlying", 724], ["hematopoietic", 735], ["defect", 749], ["in", 756], ["DBA", 759], ["may", 763], ["not", 767], ["be", 771], ["limited", 774], ["to", 782], ["the", 785], ["erythroid", 789], ["lineage", 799], [".", 806], ["Since", 808], ["a", 814], ["fraction", 816], ["of", 825], ["DBA", 828], ["patients", 832], ["have", 841], ["a", 846], ["deficiency", 848], ["in", 859], ["ribosomal", 862], ["protein", 872], ["S19", 880], ["(", 884], ["RPS19", 885], [")", 890], [",", 891], ["we", 893], ["constructed", 896], ["lentiviral", 908], ["vectors", 919], ["containing", 927], ["the", 938], ["RPS19", 942], ["gene", 948], ["for", 953], ["overexpression", 957], ["in", 972], ["hematopoietic", 975], ["progenitors", 989], ["from", 1001], ["RPS19-deficient", 1006], ["DBA", 1022], ["patients", 1026], [".", 1034], ["Enforced", 1036], ["expression", 1045], ["of", 1056], ["the", 1059], ["RPS19", 1063], ["transgene", 1069], ["improved", 1079], ["the", 1088], ["proliferation", 1092], ["of", 1106], ["CD34(+", 1109], [")", 1115], ["cells", 1117], ["from", 1123], ["DBA", 1128], ["patients", 1132], ["with", 1141], ["RPS19", 1146], ["mutation", 1152], [".", 1160], ["Similarly", 1162], [",", 1171], ["enforced", 1173], ["expression", 1182], ["of", 1193], ["RPS19", 1196], ["improved", 1202], ["erythroid", 1211], ["development", 1221], ["of", 1233], ["RPS19-deficient", 1236], ["hematopoietic", 1252], ["progenitors", 1266], ["as", 1278], ["determined", 1281], ["by", 1292], ["colony", 1295], ["assays", 1302], ["and", 1309], ["erythroid", 1313], ["differentiation", 1323], ["cultures", 1339], [".", 1347], ["These", 1349], ["findings", 1355], ["suggest", 1364], ["that", 1372], ["gene", 1377], ["therapy", 1382], ["for", 1390], ["RPS19-deficient", 1394], ["DBA", 1410], ["is", 1414], ["feasible", 1417], [".", 1425]]}
{"context": "Phthiriasis palpebrarum is an infestation of the eyelashes caused by the louse Pthirus pubis (Linnaeus, 1758). We report a case of phthiriasis palpebrarum in a 6-year-old girl, which was initially misdiagnosed as allergic blepharoconjunctivitis. Parasites and their nits were found adhering to the eyelashes and eyelids of her right eye as well as scalp hairs. No abnormality was found in the left eye. The histopathology exam revealed the presence of adults and eggs of Pthirus pubis. We mechanically removed all the eyelashes of the right eye at their base, with lice and nits. The scalp was shaved and washed with phenothrin shampoo. No recurrence was found during 3 months of follow-up. Removal of the eyelashes, cutting of scalp hairs, and phenothrin shampoo may be effective in treating phthiriasis palpebrarum. In cases of blepharoconjunctivitis, eyelids and eyelashes should be carefully examined by slit lamp to avoid misdiagnosis.", "qas": [{"question": "What is the cause of Phthiriasis Palpebrarum?", "answers": ["Pthirus pubis"], "qid": "43b0abaf398b499e989d529cdb03c301", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Phthiriasis", 21], ["Palpebrarum", 33], ["?", 44]], "detected_answers": [{"text": "Pthirus pubis", "token_spans": [[12, 13], [84, 85]], "char_spans": [[79, 91], [471, 483]]}]}], "context_tokens": [["Phthiriasis", 0], ["palpebrarum", 12], ["is", 24], ["an", 27], ["infestation", 30], ["of", 42], ["the", 45], ["eyelashes", 49], ["caused", 59], ["by", 66], ["the", 69], ["louse", 73], ["Pthirus", 79], ["pubis", 87], ["(", 93], ["Linnaeus", 94], [",", 102], ["1758", 104], [")", 108], [".", 109], ["We", 111], ["report", 114], ["a", 121], ["case", 123], ["of", 128], ["phthiriasis", 131], ["palpebrarum", 143], ["in", 155], ["a", 158], ["6-year", 160], ["-", 166], ["old", 167], ["girl", 171], [",", 175], ["which", 177], ["was", 183], ["initially", 187], ["misdiagnosed", 197], ["as", 210], ["allergic", 213], ["blepharoconjunctivitis", 222], [".", 244], ["Parasites", 246], ["and", 256], ["their", 260], ["nits", 266], ["were", 271], ["found", 276], ["adhering", 282], ["to", 291], ["the", 294], ["eyelashes", 298], ["and", 308], ["eyelids", 312], ["of", 320], ["her", 323], ["right", 327], ["eye", 333], ["as", 337], ["well", 340], ["as", 345], ["scalp", 348], ["hairs", 354], [".", 359], ["No", 361], ["abnormality", 364], ["was", 376], ["found", 380], ["in", 386], ["the", 389], ["left", 393], ["eye", 398], [".", 401], ["The", 403], ["histopathology", 407], ["exam", 422], ["revealed", 427], ["the", 436], ["presence", 440], ["of", 449], ["adults", 452], ["and", 459], ["eggs", 463], ["of", 468], ["Pthirus", 471], ["pubis", 479], [".", 484], ["We", 486], ["mechanically", 489], ["removed", 502], ["all", 510], ["the", 514], ["eyelashes", 518], ["of", 528], ["the", 531], ["right", 535], ["eye", 541], ["at", 545], ["their", 548], ["base", 554], [",", 558], ["with", 560], ["lice", 565], ["and", 570], ["nits", 574], [".", 578], ["The", 580], ["scalp", 584], ["was", 590], ["shaved", 594], ["and", 601], ["washed", 605], ["with", 612], ["phenothrin", 617], ["shampoo", 628], [".", 635], ["No", 637], ["recurrence", 640], ["was", 651], ["found", 655], ["during", 661], ["3", 668], ["months", 670], ["of", 677], ["follow", 680], ["-", 686], ["up", 687], [".", 689], ["Removal", 691], ["of", 699], ["the", 702], ["eyelashes", 706], [",", 715], ["cutting", 717], ["of", 725], ["scalp", 728], ["hairs", 734], [",", 739], ["and", 741], ["phenothrin", 745], ["shampoo", 756], ["may", 764], ["be", 768], ["effective", 771], ["in", 781], ["treating", 784], ["phthiriasis", 793], ["palpebrarum", 805], [".", 816], ["In", 818], ["cases", 821], ["of", 827], ["blepharoconjunctivitis", 830], [",", 852], ["eyelids", 854], ["and", 862], ["eyelashes", 866], ["should", 876], ["be", 883], ["carefully", 886], ["examined", 896], ["by", 905], ["slit", 908], ["lamp", 913], ["to", 918], ["avoid", 921], ["misdiagnosis", 927], [".", 939]]}
{"context": "Infectious Mononucleosis (IM), a benign lymphoproliferative disease, is the best known clinical syndrome caused by Epstein-Barr Virus (EBV). It usually resolves over a period of weeks or months without sequelae but may occasionally be complicated by a wide variety of neurologic, hematologic, hepatic, respiratory, and psychological complications. In this report we describe a patient with acute hepatitis following EBV-IM in a previously healthy woman. A 26-year-old woman who presented with fever, generalized weakness, nausea, sore throat, yellowing of skin, and a generalized skin rash was admitted to our clinic. Tonsillar enlargement, pharyngeal erythema, palatal petechiae, lymphadenopathy, and jaundice were noted. Significant atypical lymphocytes ( > 10%) were seen on the peripheral blood smear. Liver function tests such as ALT: 303 U/L, AST: 172 U/L, ALP: 193 U/L and total bilirubin: 7.3 mg/dl were elevated. Serological tests for EBV infection were consistent with acute infection (EBV virus capsid antigen was reactive with IgM and IgG antibodies). The Monospot test was also positive. On the seventh day, liver function tests and bilirubin had risen to peak level and platelets were decreased. The patient was managed supportively and her critical condition improved and was finally stabilized. Although the prognosis for IM is very favorable, a variety of acute complications may occur.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "ce748f9834504d5097c7be8b5b4ac49e", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[19, 22]], "char_spans": [[115, 132]]}]}], "context_tokens": [["Infectious", 0], ["Mononucleosis", 11], ["(", 25], ["IM", 26], [")", 28], [",", 29], ["a", 31], ["benign", 33], ["lymphoproliferative", 40], ["disease", 60], [",", 67], ["is", 69], ["the", 72], ["best", 76], ["known", 81], ["clinical", 87], ["syndrome", 96], ["caused", 105], ["by", 112], ["Epstein", 115], ["-", 122], ["Barr", 123], ["Virus", 128], ["(", 134], ["EBV", 135], [")", 138], [".", 139], ["It", 141], ["usually", 144], ["resolves", 152], ["over", 161], ["a", 166], ["period", 168], ["of", 175], ["weeks", 178], ["or", 184], ["months", 187], ["without", 194], ["sequelae", 202], ["but", 211], ["may", 215], ["occasionally", 219], ["be", 232], ["complicated", 235], ["by", 247], ["a", 250], ["wide", 252], ["variety", 257], ["of", 265], ["neurologic", 268], [",", 278], ["hematologic", 280], [",", 291], ["hepatic", 293], [",", 300], ["respiratory", 302], [",", 313], ["and", 315], ["psychological", 319], ["complications", 333], [".", 346], ["In", 348], ["this", 351], ["report", 356], ["we", 363], ["describe", 366], ["a", 375], ["patient", 377], ["with", 385], ["acute", 390], ["hepatitis", 396], ["following", 406], ["EBV", 416], ["-", 419], ["IM", 420], ["in", 423], ["a", 426], ["previously", 428], ["healthy", 439], ["woman", 447], [".", 452], ["A", 454], ["26-year", 456], ["-", 463], ["old", 464], ["woman", 468], ["who", 474], ["presented", 478], ["with", 488], ["fever", 493], [",", 498], ["generalized", 500], ["weakness", 512], [",", 520], ["nausea", 522], [",", 528], ["sore", 530], ["throat", 535], [",", 541], ["yellowing", 543], ["of", 553], ["skin", 556], [",", 560], ["and", 562], ["a", 566], ["generalized", 568], ["skin", 580], ["rash", 585], ["was", 590], ["admitted", 594], ["to", 603], ["our", 606], ["clinic", 610], [".", 616], ["Tonsillar", 618], ["enlargement", 628], [",", 639], ["pharyngeal", 641], ["erythema", 652], [",", 660], ["palatal", 662], ["petechiae", 670], [",", 679], ["lymphadenopathy", 681], [",", 696], ["and", 698], ["jaundice", 702], ["were", 711], ["noted", 716], [".", 721], ["Significant", 723], ["atypical", 735], ["lymphocytes", 744], ["(", 756], [">", 758], ["10", 760], ["%", 762], [")", 763], ["were", 765], ["seen", 770], ["on", 775], ["the", 778], ["peripheral", 782], ["blood", 793], ["smear", 799], [".", 804], ["Liver", 806], ["function", 812], ["tests", 821], ["such", 827], ["as", 832], ["ALT", 835], [":", 838], ["303", 840], ["U", 844], ["/", 845], ["L", 846], [",", 847], ["AST", 849], [":", 852], ["172", 854], ["U", 858], ["/", 859], ["L", 860], [",", 861], ["ALP", 863], [":", 866], ["193", 868], ["U", 872], ["/", 873], ["L", 874], ["and", 876], ["total", 880], ["bilirubin", 886], [":", 895], ["7.3", 897], ["mg", 901], ["/", 903], ["dl", 904], ["were", 907], ["elevated", 912], [".", 920], ["Serological", 922], ["tests", 934], ["for", 940], ["EBV", 944], ["infection", 948], ["were", 958], ["consistent", 963], ["with", 974], ["acute", 979], ["infection", 985], ["(", 995], ["EBV", 996], ["virus", 1000], ["capsid", 1006], ["antigen", 1013], ["was", 1021], ["reactive", 1025], ["with", 1034], ["IgM", 1039], ["and", 1043], ["IgG", 1047], ["antibodies", 1051], [")", 1061], [".", 1062], ["The", 1064], ["Monospot", 1068], ["test", 1077], ["was", 1082], ["also", 1086], ["positive", 1091], [".", 1099], ["On", 1101], ["the", 1104], ["seventh", 1108], ["day", 1116], [",", 1119], ["liver", 1121], ["function", 1127], ["tests", 1136], ["and", 1142], ["bilirubin", 1146], ["had", 1156], ["risen", 1160], ["to", 1166], ["peak", 1169], ["level", 1174], ["and", 1180], ["platelets", 1184], ["were", 1194], ["decreased", 1199], [".", 1208], ["The", 1210], ["patient", 1214], ["was", 1222], ["managed", 1226], ["supportively", 1234], ["and", 1247], ["her", 1251], ["critical", 1255], ["condition", 1264], ["improved", 1274], ["and", 1283], ["was", 1287], ["finally", 1291], ["stabilized", 1299], [".", 1309], ["Although", 1311], ["the", 1320], ["prognosis", 1324], ["for", 1334], ["IM", 1338], ["is", 1341], ["very", 1344], ["favorable", 1349], [",", 1358], ["a", 1360], ["variety", 1362], ["of", 1370], ["acute", 1373], ["complications", 1379], ["may", 1393], ["occur", 1397], [".", 1402]]}
{"context": "Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the responses to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with non-small-cell lung cancer (NSCLC). Although various methods for detecting EGFR gene mutations have been developed, they have several disadvantages. We attempted to establish a new method for the detection of EGFR gene mutations with the use of paraffin-embedded samples. The detections of T790M mutations in exon 20 and L858R mutations in exon 21 are based on the principle of allele-specific oligonucleotide polymerase chain reaction (PCR). We also designed PCR primers that enable to detect all types of deletions in exon 19. We assessed the basic performance efficiency of this method, and to confirm its clinical applicability, we performed PCR using DNA extracted from 66 tissue sections that were obtained from patients with NSCLC and embedded in paraffin. The sensitivity of this method for the detection of deletions or mutations was as low as 0.5%. In the 66 subjects whose samples were analyzed, we detected the following deletions and mutations in the EGFR gene: 11 deletions in exon 19, 8 L858R mutations, and 1 double mutation of L858R and T790M. The present method is sensitive and specific for the detection of deletions and mutations in the EGFR gene and is thus suitable for use in laboratory tests.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "8748822cf025490fa5c05702c435c394", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[4, 11]], "char_spans": [[25, 68]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["epidermal", 25], ["growth", 35], ["factor", 42], ["receptor", 49], ["(", 58], ["EGFR", 59], [")", 63], ["gene", 65], ["are", 70], ["associated", 74], ["with", 85], ["the", 90], ["responses", 94], ["to", 104], ["the", 107], ["tyrosine", 111], ["kinase", 120], ["inhibitors", 127], ["gefitinib", 138], ["and", 148], ["erlotinib", 152], ["in", 162], ["patients", 165], ["with", 174], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], ["(", 206], ["NSCLC", 207], [")", 212], [".", 213], ["Although", 215], ["various", 224], ["methods", 232], ["for", 240], ["detecting", 244], ["EGFR", 254], ["gene", 259], ["mutations", 264], ["have", 274], ["been", 279], ["developed", 284], [",", 293], ["they", 295], ["have", 300], ["several", 305], ["disadvantages", 313], [".", 326], ["We", 328], ["attempted", 331], ["to", 341], ["establish", 344], ["a", 354], ["new", 356], ["method", 360], ["for", 367], ["the", 371], ["detection", 375], ["of", 385], ["EGFR", 388], ["gene", 393], ["mutations", 398], ["with", 408], ["the", 413], ["use", 417], ["of", 421], ["paraffin", 424], ["-", 432], ["embedded", 433], ["samples", 442], [".", 449], ["The", 451], ["detections", 455], ["of", 466], ["T790", 469], ["M", 473], ["mutations", 475], ["in", 485], ["exon", 488], ["20", 493], ["and", 496], ["L858R", 500], ["mutations", 506], ["in", 516], ["exon", 519], ["21", 524], ["are", 527], ["based", 531], ["on", 537], ["the", 540], ["principle", 544], ["of", 554], ["allele", 557], ["-", 563], ["specific", 564], ["oligonucleotide", 573], ["polymerase", 589], ["chain", 600], ["reaction", 606], ["(", 615], ["PCR", 616], [")", 619], [".", 620], ["We", 622], ["also", 625], ["designed", 630], ["PCR", 639], ["primers", 643], ["that", 651], ["enable", 656], ["to", 663], ["detect", 666], ["all", 673], ["types", 677], ["of", 683], ["deletions", 686], ["in", 696], ["exon", 699], ["19", 704], [".", 706], ["We", 708], ["assessed", 711], ["the", 720], ["basic", 724], ["performance", 730], ["efficiency", 742], ["of", 753], ["this", 756], ["method", 761], [",", 767], ["and", 769], ["to", 773], ["confirm", 776], ["its", 784], ["clinical", 788], ["applicability", 797], [",", 810], ["we", 812], ["performed", 815], ["PCR", 825], ["using", 829], ["DNA", 835], ["extracted", 839], ["from", 849], ["66", 854], ["tissue", 857], ["sections", 864], ["that", 873], ["were", 878], ["obtained", 883], ["from", 892], ["patients", 897], ["with", 906], ["NSCLC", 911], ["and", 917], ["embedded", 921], ["in", 930], ["paraffin", 933], [".", 941], ["The", 943], ["sensitivity", 947], ["of", 959], ["this", 962], ["method", 967], ["for", 974], ["the", 978], ["detection", 982], ["of", 992], ["deletions", 995], ["or", 1005], ["mutations", 1008], ["was", 1018], ["as", 1022], ["low", 1025], ["as", 1029], ["0.5", 1032], ["%", 1035], [".", 1036], ["In", 1038], ["the", 1041], ["66", 1045], ["subjects", 1048], ["whose", 1057], ["samples", 1063], ["were", 1071], ["analyzed", 1076], [",", 1084], ["we", 1086], ["detected", 1089], ["the", 1098], ["following", 1102], ["deletions", 1112], ["and", 1122], ["mutations", 1126], ["in", 1136], ["the", 1139], ["EGFR", 1143], ["gene", 1148], [":", 1152], ["11", 1154], ["deletions", 1157], ["in", 1167], ["exon", 1170], ["19", 1175], [",", 1177], ["8", 1179], ["L858R", 1181], ["mutations", 1187], [",", 1196], ["and", 1198], ["1", 1202], ["double", 1204], ["mutation", 1211], ["of", 1220], ["L858R", 1223], ["and", 1229], ["T790M.", 1233], ["The", 1240], ["present", 1244], ["method", 1252], ["is", 1259], ["sensitive", 1262], ["and", 1272], ["specific", 1276], ["for", 1285], ["the", 1289], ["detection", 1293], ["of", 1303], ["deletions", 1306], ["and", 1316], ["mutations", 1320], ["in", 1330], ["the", 1333], ["EGFR", 1337], ["gene", 1342], ["and", 1347], ["is", 1351], ["thus", 1354], ["suitable", 1359], ["for", 1368], ["use", 1372], ["in", 1376], ["laboratory", 1379], ["tests", 1390], [".", 1395]]}
{"context": "The human endoplasmic reticulum aminopeptidase (ERAP) 1 and 2 proteins were initially identified as homologues of human placental leucine aminopeptidase/insulin-regulated aminopeptidase. They are categorized as a unique class of proteases based on their subcellular localization on the luminal side of the endoplasmic reticulum. ERAPs play an important role in the N-terminal processing of the antigenic precursors that are presented on the major histocompatibility complex (MHC) class I molecules. ERAPs are also implicated in the regulation of a wide variety of physiological phenomena and pathogenic conditions. In this review, the current knowledge on ERAPs is summarized.", "qas": [{"question": "Which is the  subcellular localization of ERAP2?", "answers": ["luminal side of the endoplasmic reticulum"], "qid": "80d65d38d32c49f49b86b800be1f276d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], [" ", 13], ["subcellular", 14], ["localization", 26], ["of", 39], ["ERAP2", 42], ["?", 47]], "detected_answers": [{"text": "luminal side of the endoplasmic reticulum", "token_spans": [[44, 49]], "char_spans": [[286, 326]]}]}], "context_tokens": [["The", 0], ["human", 4], ["endoplasmic", 10], ["reticulum", 22], ["aminopeptidase", 32], ["(", 47], ["ERAP", 48], [")", 52], ["1", 54], ["and", 56], ["2", 60], ["proteins", 62], ["were", 71], ["initially", 76], ["identified", 86], ["as", 97], ["homologues", 100], ["of", 111], ["human", 114], ["placental", 120], ["leucine", 130], ["aminopeptidase", 138], ["/", 152], ["insulin", 153], ["-", 160], ["regulated", 161], ["aminopeptidase", 171], [".", 185], ["They", 187], ["are", 192], ["categorized", 196], ["as", 208], ["a", 211], ["unique", 213], ["class", 220], ["of", 226], ["proteases", 229], ["based", 239], ["on", 245], ["their", 248], ["subcellular", 254], ["localization", 266], ["on", 279], ["the", 282], ["luminal", 286], ["side", 294], ["of", 299], ["the", 302], ["endoplasmic", 306], ["reticulum", 318], [".", 327], ["ERAPs", 329], ["play", 335], ["an", 340], ["important", 343], ["role", 353], ["in", 358], ["the", 361], ["N", 365], ["-", 366], ["terminal", 367], ["processing", 376], ["of", 387], ["the", 390], ["antigenic", 394], ["precursors", 404], ["that", 415], ["are", 420], ["presented", 424], ["on", 434], ["the", 437], ["major", 441], ["histocompatibility", 447], ["complex", 466], ["(", 474], ["MHC", 475], [")", 478], ["class", 480], ["I", 486], ["molecules", 488], [".", 497], ["ERAPs", 499], ["are", 505], ["also", 509], ["implicated", 514], ["in", 525], ["the", 528], ["regulation", 532], ["of", 543], ["a", 546], ["wide", 548], ["variety", 553], ["of", 561], ["physiological", 564], ["phenomena", 578], ["and", 588], ["pathogenic", 592], ["conditions", 603], [".", 613], ["In", 615], ["this", 618], ["review", 623], [",", 629], ["the", 631], ["current", 635], ["knowledge", 643], ["on", 653], ["ERAPs", 656], ["is", 662], ["summarized", 665], [".", 675]]}
{"context": "Transcription factors of the NFAT (nuclear factor of activated T cells) family are expressed in most immune system cells and in a range of other cell types. Signaling through NFAT is implicated in the regulation of transcription for the immune response and other processes, including differentiation and apoptosis. NFAT normally resides in the cytoplasm, and a key aspect of the NFAT activation pathway is the regulation of its nuclear import by the Ca(2+)/calmodulin-dependent phosphatase calcineurin. In a cell line stably expressing green fluorescent protein (GFP)-NFAT, this import can be triggered by elevation of intracellular calcium and visualized in live cells. Here we show that the inducible nuclear import of GFP-NFAT is efficiently blocked at early stages of herpes simplex virus (HSV) infection. This is a specific effect, since we observed abundant nuclear accumulation of a test viral protein and no impediment to general nuclear localization signal-dependent nuclear import and retention in infected cells. We show that virus binding at the cell surface is not itself sufficient to inhibit the signaling that induces NFAT nuclear translocation. Since the block occurs following infection in the presence of phosphonoacetic acid but not cycloheximide, we infer that the entry of the virion and early gene transcription are required but the effect is independent of DNA replication or late virus gene expression. A consequence of the block to GFP-NFAT import is a reduction in NFAT-dependent transcriptional activation from the interleukin-2 promoter in infected cells. This HSV-mediated repression of the NFAT pathway may constitute an immune evasion strategy or subversion of other NFAT-dependent cellular processes to promote viral replication.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "a04105f6bf4b4673810a0bf54d8c8206", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[82, 82]], "char_spans": [[490, 500]]}, {"text": "CaN", "token_spans": [[98, 98]], "char_spans": [[586, 588]]}]}], "context_tokens": [["Transcription", 0], ["factors", 14], ["of", 22], ["the", 25], ["NFAT", 29], ["(", 34], ["nuclear", 35], ["factor", 43], ["of", 50], ["activated", 53], ["T", 63], ["cells", 65], [")", 70], ["family", 72], ["are", 79], ["expressed", 83], ["in", 93], ["most", 96], ["immune", 101], ["system", 108], ["cells", 115], ["and", 121], ["in", 125], ["a", 128], ["range", 130], ["of", 136], ["other", 139], ["cell", 145], ["types", 150], [".", 155], ["Signaling", 157], ["through", 167], ["NFAT", 175], ["is", 180], ["implicated", 183], ["in", 194], ["the", 197], ["regulation", 201], ["of", 212], ["transcription", 215], ["for", 229], ["the", 233], ["immune", 237], ["response", 244], ["and", 253], ["other", 257], ["processes", 263], [",", 272], ["including", 274], ["differentiation", 284], ["and", 300], ["apoptosis", 304], [".", 313], ["NFAT", 315], ["normally", 320], ["resides", 329], ["in", 337], ["the", 340], ["cytoplasm", 344], [",", 353], ["and", 355], ["a", 359], ["key", 361], ["aspect", 365], ["of", 372], ["the", 375], ["NFAT", 379], ["activation", 384], ["pathway", 395], ["is", 403], ["the", 406], ["regulation", 410], ["of", 421], ["its", 424], ["nuclear", 428], ["import", 436], ["by", 443], ["the", 446], ["Ca(2+)/calmodulin", 450], ["-", 467], ["dependent", 468], ["phosphatase", 478], ["calcineurin", 490], [".", 501], ["In", 503], ["a", 506], ["cell", 508], ["line", 513], ["stably", 518], ["expressing", 525], ["green", 536], ["fluorescent", 542], ["protein", 554], ["(", 562], ["GFP)-NFAT", 563], [",", 572], ["this", 574], ["import", 579], ["can", 586], ["be", 590], ["triggered", 593], ["by", 603], ["elevation", 606], ["of", 616], ["intracellular", 619], ["calcium", 633], ["and", 641], ["visualized", 645], ["in", 656], ["live", 659], ["cells", 664], [".", 669], ["Here", 671], ["we", 676], ["show", 679], ["that", 684], ["the", 689], ["inducible", 693], ["nuclear", 703], ["import", 711], ["of", 718], ["GFP", 721], ["-", 724], ["NFAT", 725], ["is", 730], ["efficiently", 733], ["blocked", 745], ["at", 753], ["early", 756], ["stages", 762], ["of", 769], ["herpes", 772], ["simplex", 779], ["virus", 787], ["(", 793], ["HSV", 794], [")", 797], ["infection", 799], [".", 808], ["This", 810], ["is", 815], ["a", 818], ["specific", 820], ["effect", 829], [",", 835], ["since", 837], ["we", 843], ["observed", 846], ["abundant", 855], ["nuclear", 864], ["accumulation", 872], ["of", 885], ["a", 888], ["test", 890], ["viral", 895], ["protein", 901], ["and", 909], ["no", 913], ["impediment", 916], ["to", 927], ["general", 930], ["nuclear", 938], ["localization", 946], ["signal", 959], ["-", 965], ["dependent", 966], ["nuclear", 976], ["import", 984], ["and", 991], ["retention", 995], ["in", 1005], ["infected", 1008], ["cells", 1017], [".", 1022], ["We", 1024], ["show", 1027], ["that", 1032], ["virus", 1037], ["binding", 1043], ["at", 1051], ["the", 1054], ["cell", 1058], ["surface", 1063], ["is", 1071], ["not", 1074], ["itself", 1078], ["sufficient", 1085], ["to", 1096], ["inhibit", 1099], ["the", 1107], ["signaling", 1111], ["that", 1121], ["induces", 1126], ["NFAT", 1134], ["nuclear", 1139], ["translocation", 1147], [".", 1160], ["Since", 1162], ["the", 1168], ["block", 1172], ["occurs", 1178], ["following", 1185], ["infection", 1195], ["in", 1205], ["the", 1208], ["presence", 1212], ["of", 1221], ["phosphonoacetic", 1224], ["acid", 1240], ["but", 1245], ["not", 1249], ["cycloheximide", 1253], [",", 1266], ["we", 1268], ["infer", 1271], ["that", 1277], ["the", 1282], ["entry", 1286], ["of", 1292], ["the", 1295], ["virion", 1299], ["and", 1306], ["early", 1310], ["gene", 1316], ["transcription", 1321], ["are", 1335], ["required", 1339], ["but", 1348], ["the", 1352], ["effect", 1356], ["is", 1363], ["independent", 1366], ["of", 1378], ["DNA", 1381], ["replication", 1385], ["or", 1397], ["late", 1400], ["virus", 1405], ["gene", 1411], ["expression", 1416], [".", 1426], ["A", 1428], ["consequence", 1430], ["of", 1442], ["the", 1445], ["block", 1449], ["to", 1455], ["GFP", 1458], ["-", 1461], ["NFAT", 1462], ["import", 1467], ["is", 1474], ["a", 1477], ["reduction", 1479], ["in", 1489], ["NFAT", 1492], ["-", 1496], ["dependent", 1497], ["transcriptional", 1507], ["activation", 1523], ["from", 1534], ["the", 1539], ["interleukin-2", 1543], ["promoter", 1557], ["in", 1566], ["infected", 1569], ["cells", 1578], [".", 1583], ["This", 1585], ["HSV", 1590], ["-", 1593], ["mediated", 1594], ["repression", 1603], ["of", 1614], ["the", 1617], ["NFAT", 1621], ["pathway", 1626], ["may", 1634], ["constitute", 1638], ["an", 1649], ["immune", 1652], ["evasion", 1659], ["strategy", 1667], ["or", 1676], ["subversion", 1679], ["of", 1690], ["other", 1693], ["NFAT", 1699], ["-", 1703], ["dependent", 1704], ["cellular", 1714], ["processes", 1723], ["to", 1733], ["promote", 1736], ["viral", 1744], ["replication", 1750], [".", 1761]]}
{"context": "Women with Turner's syndrome (TS), who lack a complete X-chromosome, show an impairment in remembering faces and in classifying \"fear\" in face images. Could their difficulties extend to the processing of gaze? Three tasks, all of which rely on the ability to make use of the eye-region of a pictured face, are reported. Women with TS were impaired at judging mental state from images of the upper face (\"reading the mind in the eyes\"). They were also specifically impaired at interpreting \"fear\" from displays of the eye-region of the face. However, they showed normal susceptibility to direction of gaze as an attentional cue (social cueing), since they were as sensitive as controls to the validity of the cue, under conditions where it should be ignored. In this task, unlike those of reading the upper face for intention or expression, PIQ accounted for a significant amount of individual variance in task performance. The processing of displays of the eye region affording social and affective information is specifically affected in TS. We speculate that amygdala dysfunction is likely to be implicated in this anomalous behaviour. The presence in the female karyotype of two complete X-chromosomes is protective for some socio-cognitive abilities related to the modulation of behaviour by the interpretation of gaze.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "24a7496511044cb081a2b7f0953bc895", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[229, 229], [13, 13]], "char_spans": [[1191, 1191], [55, 55]]}]}], "context_tokens": [["Women", 0], ["with", 6], ["Turner", 11], ["'s", 17], ["syndrome", 20], ["(", 29], ["TS", 30], [")", 32], [",", 33], ["who", 35], ["lack", 39], ["a", 44], ["complete", 46], ["X", 55], ["-", 56], ["chromosome", 57], [",", 67], ["show", 69], ["an", 74], ["impairment", 77], ["in", 88], ["remembering", 91], ["faces", 103], ["and", 109], ["in", 113], ["classifying", 116], ["\"", 128], ["fear", 129], ["\"", 133], ["in", 135], ["face", 138], ["images", 143], [".", 149], ["Could", 151], ["their", 157], ["difficulties", 163], ["extend", 176], ["to", 183], ["the", 186], ["processing", 190], ["of", 201], ["gaze", 204], ["?", 208], ["Three", 210], ["tasks", 216], [",", 221], ["all", 223], ["of", 227], ["which", 230], ["rely", 236], ["on", 241], ["the", 244], ["ability", 248], ["to", 256], ["make", 259], ["use", 264], ["of", 268], ["the", 271], ["eye", 275], ["-", 278], ["region", 279], ["of", 286], ["a", 289], ["pictured", 291], ["face", 300], [",", 304], ["are", 306], ["reported", 310], [".", 318], ["Women", 320], ["with", 326], ["TS", 331], ["were", 334], ["impaired", 339], ["at", 348], ["judging", 351], ["mental", 359], ["state", 366], ["from", 372], ["images", 377], ["of", 384], ["the", 387], ["upper", 391], ["face", 397], ["(", 402], ["\"", 403], ["reading", 404], ["the", 412], ["mind", 416], ["in", 421], ["the", 424], ["eyes", 428], ["\"", 432], [")", 433], [".", 434], ["They", 436], ["were", 441], ["also", 446], ["specifically", 451], ["impaired", 464], ["at", 473], ["interpreting", 476], ["\"", 489], ["fear", 490], ["\"", 494], ["from", 496], ["displays", 501], ["of", 510], ["the", 513], ["eye", 517], ["-", 520], ["region", 521], ["of", 528], ["the", 531], ["face", 535], [".", 539], ["However", 541], [",", 548], ["they", 550], ["showed", 555], ["normal", 562], ["susceptibility", 569], ["to", 584], ["direction", 587], ["of", 597], ["gaze", 600], ["as", 605], ["an", 608], ["attentional", 611], ["cue", 623], ["(", 627], ["social", 628], ["cueing", 635], [")", 641], [",", 642], ["since", 644], ["they", 650], ["were", 655], ["as", 660], ["sensitive", 663], ["as", 673], ["controls", 676], ["to", 685], ["the", 688], ["validity", 692], ["of", 701], ["the", 704], ["cue", 708], [",", 711], ["under", 713], ["conditions", 719], ["where", 730], ["it", 736], ["should", 739], ["be", 746], ["ignored", 749], [".", 756], ["In", 758], ["this", 761], ["task", 766], [",", 770], ["unlike", 772], ["those", 779], ["of", 785], ["reading", 788], ["the", 796], ["upper", 800], ["face", 806], ["for", 811], ["intention", 815], ["or", 825], ["expression", 828], [",", 838], ["PIQ", 840], ["accounted", 844], ["for", 854], ["a", 858], ["significant", 860], ["amount", 872], ["of", 879], ["individual", 882], ["variance", 893], ["in", 902], ["task", 905], ["performance", 910], [".", 921], ["The", 923], ["processing", 927], ["of", 938], ["displays", 941], ["of", 950], ["the", 953], ["eye", 957], ["region", 961], ["affording", 968], ["social", 978], ["and", 985], ["affective", 989], ["information", 999], ["is", 1011], ["specifically", 1014], ["affected", 1027], ["in", 1036], ["TS", 1039], [".", 1041], ["We", 1043], ["speculate", 1046], ["that", 1056], ["amygdala", 1061], ["dysfunction", 1070], ["is", 1082], ["likely", 1085], ["to", 1092], ["be", 1095], ["implicated", 1098], ["in", 1109], ["this", 1112], ["anomalous", 1117], ["behaviour", 1127], [".", 1136], ["The", 1138], ["presence", 1142], ["in", 1151], ["the", 1154], ["female", 1158], ["karyotype", 1165], ["of", 1175], ["two", 1178], ["complete", 1182], ["X", 1191], ["-", 1192], ["chromosomes", 1193], ["is", 1205], ["protective", 1208], ["for", 1219], ["some", 1223], ["socio", 1228], ["-", 1233], ["cognitive", 1234], ["abilities", 1244], ["related", 1254], ["to", 1262], ["the", 1265], ["modulation", 1269], ["of", 1280], ["behaviour", 1283], ["by", 1293], ["the", 1296], ["interpretation", 1300], ["of", 1315], ["gaze", 1318], [".", 1322]]}
{"context": "Focal cortical dysplasias are a well-recognized cause of medically intractable seizures. The clinical relevance of certain subgroups of the International League Against Epilepsy (ILAE) classification scheme remains to be determined. The aim of the present work is to assess the effect of the focal cortical dysplasia type Ib and Ic histologic subtypes on surgical outcome with respect to seizure frequency. This study also provides an opportunity to compare the predictive value of the ILAE and Palmini et al classification schemes with regard to the type I focal cortical dysplasias. We retrospectively reviewed 91 focal cortical dysplasia patients (55% female; median age: 19 years (interquartile range 8-34); median seizure duration: 108 months (interquartile range 36-204)) with chronic epilepsy who underwent surgery. We compared the pathological subtypes, evaluating the patients' post-surgical outcome with respect to seizure frequency according to the Engel's classification and the ILAE outcome classification. Both the ILAE classification scheme and Palmini et al classification scheme were utilized to classify the histologic subtype. Using \u03c7(2) and Fisher's exact tests, we compared the post-surgical outcomes among these groups. Of the 91 patients, there were 50 patients with ILAE focal cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA, and 28 with Palmini et al focal cortical dysplasia type IB. After surgery, 44 patients (48%) were seizure-free. Crude analysis revealed no significant difference between patients with subtypes of ILAE focal cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according to the Engel and ILAE scoring systems on seizure frequency. Our findings revealed no significant difference concerning surgical outcome with respect to seizure frequency for the histologic subtypes of ILAE focal cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I (IA vs IB). In isolation, the histologic subtype of focal cortical dysplasia type I does not appear predictive of postoperative outcome.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "e1524573cdd7436d8cd3549b8bac2c1c", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[225, 227], [49, 51], [257, 259], [289, 291], [370, 372], [101, 103], [245, 247], [234, 236], [298, 300], [352, 354], [338, 340]], "char_spans": [[1295, 1318], [292, 315], [1458, 1481], [1633, 1656], [2107, 2130], [616, 639], [1398, 1421], [1342, 1365], [1682, 1705], [2023, 2046], [1963, 1986]]}]}], "context_tokens": [["Focal", 0], ["cortical", 6], ["dysplasias", 15], ["are", 26], ["a", 30], ["well", 32], ["-", 36], ["recognized", 37], ["cause", 48], ["of", 54], ["medically", 57], ["intractable", 67], ["seizures", 79], [".", 87], ["The", 89], ["clinical", 93], ["relevance", 102], ["of", 112], ["certain", 115], ["subgroups", 123], ["of", 133], ["the", 136], ["International", 140], ["League", 154], ["Against", 161], ["Epilepsy", 169], ["(", 178], ["ILAE", 179], [")", 183], ["classification", 185], ["scheme", 200], ["remains", 207], ["to", 215], ["be", 218], ["determined", 221], [".", 231], ["The", 233], ["aim", 237], ["of", 241], ["the", 244], ["present", 248], ["work", 256], ["is", 261], ["to", 264], ["assess", 267], ["the", 274], ["effect", 278], ["of", 285], ["the", 288], ["focal", 292], ["cortical", 298], ["dysplasia", 307], ["type", 317], ["Ib", 322], ["and", 325], ["Ic", 329], ["histologic", 332], ["subtypes", 343], ["on", 352], ["surgical", 355], ["outcome", 364], ["with", 372], ["respect", 377], ["to", 385], ["seizure", 388], ["frequency", 396], [".", 405], ["This", 407], ["study", 412], ["also", 418], ["provides", 423], ["an", 432], ["opportunity", 435], ["to", 447], ["compare", 450], ["the", 458], ["predictive", 462], ["value", 473], ["of", 479], ["the", 482], ["ILAE", 486], ["and", 491], ["Palmini", 495], ["et", 503], ["al", 506], ["classification", 509], ["schemes", 524], ["with", 532], ["regard", 537], ["to", 544], ["the", 547], ["type", 551], ["I", 556], ["focal", 558], ["cortical", 564], ["dysplasias", 573], [".", 583], ["We", 585], ["retrospectively", 588], ["reviewed", 604], ["91", 613], ["focal", 616], ["cortical", 622], ["dysplasia", 631], ["patients", 641], ["(", 650], ["55", 651], ["%", 653], ["female", 655], [";", 661], ["median", 663], ["age", 670], [":", 673], ["19", 675], ["years", 678], ["(", 684], ["interquartile", 685], ["range", 699], ["8", 705], ["-", 706], ["34", 707], [")", 709], [";", 710], ["median", 712], ["seizure", 719], ["duration", 727], [":", 735], ["108", 737], ["months", 741], ["(", 748], ["interquartile", 749], ["range", 763], ["36", 769], ["-", 771], ["204", 772], [")", 775], [")", 776], ["with", 778], ["chronic", 783], ["epilepsy", 791], ["who", 800], ["underwent", 804], ["surgery", 814], [".", 821], ["We", 823], ["compared", 826], ["the", 835], ["pathological", 839], ["subtypes", 852], [",", 860], ["evaluating", 862], ["the", 873], ["patients", 877], ["'", 885], ["post", 887], ["-", 891], ["surgical", 892], ["outcome", 901], ["with", 909], ["respect", 914], ["to", 922], ["seizure", 925], ["frequency", 933], ["according", 943], ["to", 953], ["the", 956], ["Engel", 960], ["'s", 965], ["classification", 968], ["and", 983], ["the", 987], ["ILAE", 991], ["outcome", 996], ["classification", 1004], [".", 1018], ["Both", 1020], ["the", 1025], ["ILAE", 1029], ["classification", 1034], ["scheme", 1049], ["and", 1056], ["Palmini", 1060], ["et", 1068], ["al", 1071], ["classification", 1074], ["scheme", 1089], ["were", 1096], ["utilized", 1101], ["to", 1110], ["classify", 1113], ["the", 1122], ["histologic", 1126], ["subtype", 1137], [".", 1144], ["Using", 1146], ["\u03c7(2", 1152], [")", 1155], ["and", 1157], ["Fisher", 1161], ["'s", 1167], ["exact", 1170], ["tests", 1176], [",", 1181], ["we", 1183], ["compared", 1186], ["the", 1195], ["post", 1199], ["-", 1203], ["surgical", 1204], ["outcomes", 1213], ["among", 1222], ["these", 1228], ["groups", 1234], [".", 1240], ["Of", 1242], ["the", 1245], ["91", 1249], ["patients", 1252], [",", 1260], ["there", 1262], ["were", 1268], ["50", 1273], ["patients", 1276], ["with", 1285], ["ILAE", 1290], ["focal", 1295], ["cortical", 1301], ["dysplasia", 1310], ["type", 1320], ["Ib", 1325], [",", 1327], ["41", 1329], ["with", 1332], ["ILAE", 1337], ["focal", 1342], ["cortical", 1348], ["dysplasia", 1357], ["type", 1367], ["Ic", 1372], [",", 1374], ["63", 1376], ["with", 1379], ["Palmini", 1384], ["et", 1392], ["al", 1395], ["focal", 1398], ["cortical", 1404], ["dysplasia", 1413], ["type", 1423], ["IA", 1428], [",", 1430], ["and", 1432], ["28", 1436], ["with", 1439], ["Palmini", 1444], ["et", 1452], ["al", 1455], ["focal", 1458], ["cortical", 1464], ["dysplasia", 1473], ["type", 1483], ["IB", 1488], [".", 1490], ["After", 1492], ["surgery", 1498], [",", 1505], ["44", 1507], ["patients", 1510], ["(", 1519], ["48", 1520], ["%", 1522], [")", 1523], ["were", 1525], ["seizure", 1530], ["-", 1537], ["free", 1538], [".", 1542], ["Crude", 1544], ["analysis", 1550], ["revealed", 1559], ["no", 1568], ["significant", 1571], ["difference", 1583], ["between", 1594], ["patients", 1602], ["with", 1611], ["subtypes", 1616], ["of", 1625], ["ILAE", 1628], ["focal", 1633], ["cortical", 1639], ["dysplasia", 1648], ["type", 1658], ["I", 1663], ["or", 1665], ["Palmini", 1668], ["et", 1676], ["al", 1679], ["focal", 1682], ["cortical", 1688], ["dysplasia", 1697], ["type", 1707], ["I", 1712], ["concerning", 1714], ["postoperative", 1725], ["outcome", 1739], ["according", 1747], ["to", 1757], ["the", 1760], ["Engel", 1764], ["and", 1770], ["ILAE", 1774], ["scoring", 1779], ["systems", 1787], ["on", 1795], ["seizure", 1798], ["frequency", 1806], [".", 1815], ["Our", 1817], ["findings", 1821], ["revealed", 1830], ["no", 1839], ["significant", 1842], ["difference", 1854], ["concerning", 1865], ["surgical", 1876], ["outcome", 1885], ["with", 1893], ["respect", 1898], ["to", 1906], ["seizure", 1909], ["frequency", 1917], ["for", 1927], ["the", 1931], ["histologic", 1935], ["subtypes", 1946], ["of", 1955], ["ILAE", 1958], ["focal", 1963], ["cortical", 1969], ["dysplasia", 1978], ["type", 1988], ["I", 1993], ["(", 1995], ["Ib", 1996], ["vs", 1999], ["Ic", 2002], [")", 2004], ["or", 2006], ["Palmini", 2009], ["et", 2017], ["al", 2020], ["focal", 2023], ["cortical", 2029], ["dysplasia", 2038], ["type", 2048], ["I", 2053], ["(", 2055], ["IA", 2056], ["vs", 2059], ["IB", 2062], [")", 2064], [".", 2065], ["In", 2067], ["isolation", 2070], [",", 2079], ["the", 2081], ["histologic", 2085], ["subtype", 2096], ["of", 2104], ["focal", 2107], ["cortical", 2113], ["dysplasia", 2122], ["type", 2132], ["I", 2137], ["does", 2139], ["not", 2144], ["appear", 2148], ["predictive", 2155], ["of", 2166], ["postoperative", 2169], ["outcome", 2183], [".", 2190]]}
{"context": "Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition induces apoptosis. These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL). Dose-limiting toxicity in the phase 1 portion was neutropenia, diarrhea, and thrombocytopenia, and 200 mg twice daily was chosen for phase 2 testing. Sixty-eight patients with recurrent B-NHL were then enrolled in 3 cohorts: (1) diffuse large B-cell lymphoma (DLBCL), (2) follicular lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphomas, and small lymphocytic leukemia/chronic lymphocytic leukemia (SLL/CLL). Common toxicities included diarrhea, fatigue, cytopenias, hypertension, and nausea. Objective response rates were 22% (5 of 23) for DLBCL, 10% (2 of 21) for FL, 55% (6 of 11) for SLL/CLL, and 11% (1/9) for MCL. Median progression-free survival was 4.2 months. Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL. This trial was registered at www.clinicaltrials.gov as #NCT00446095.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "09ebf96c823548e9a0908cc35606cc13", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[15, 17]], "char_spans": [[83, 104]]}]}], "context_tokens": [["Certain", 0], ["malignant", 8], ["B", 18], ["cells", 20], ["rely", 26], ["on", 31], ["B", 34], ["-", 35], ["cell", 36], ["receptor", 41], ["(", 50], ["BCR)-mediated", 51], ["survival", 65], ["signals", 74], [".", 81], ["Spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], ["initiates", 112], ["and", 122], ["amplifies", 126], ["the", 136], ["BCR", 140], ["signal", 144], [".", 150], ["In", 152], ["in", 155], ["vivo", 158], ["analyses", 163], ["of", 172], ["B", 175], ["-", 176], ["cell", 177], ["lymphoma", 182], ["cell", 191], ["lines", 196], ["and", 202], ["primary", 206], ["tumors", 214], [",", 220], ["Syk", 222], ["inhibition", 226], ["induces", 237], ["apoptosis", 245], [".", 254], ["These", 256], ["data", 262], ["prompted", 267], ["a", 276], ["phase", 278], ["1/2", 284], ["clinical", 288], ["trial", 297], ["of", 303], ["fostamatinib", 306], ["disodium", 319], [",", 327], ["the", 329], ["first", 333], ["clinically", 339], ["available", 350], ["oral", 360], ["Syk", 365], ["inhibitor", 369], [",", 378], ["in", 380], ["patients", 383], ["with", 392], ["recurrent", 397], ["B", 407], ["-", 408], ["cell", 409], ["non", 414], ["-", 417], ["Hodgkin", 418], ["lymphoma", 426], ["(", 435], ["B", 436], ["-", 437], ["NHL", 438], [")", 441], [".", 442], ["Dose", 444], ["-", 448], ["limiting", 449], ["toxicity", 458], ["in", 467], ["the", 470], ["phase", 474], ["1", 480], ["portion", 482], ["was", 490], ["neutropenia", 494], [",", 505], ["diarrhea", 507], [",", 515], ["and", 517], ["thrombocytopenia", 521], [",", 537], ["and", 539], ["200", 543], ["mg", 547], ["twice", 550], ["daily", 556], ["was", 562], ["chosen", 566], ["for", 573], ["phase", 577], ["2", 583], ["testing", 585], [".", 592], ["Sixty", 594], ["-", 599], ["eight", 600], ["patients", 606], ["with", 615], ["recurrent", 620], ["B", 630], ["-", 631], ["NHL", 632], ["were", 636], ["then", 641], ["enrolled", 646], ["in", 655], ["3", 658], ["cohorts", 660], [":", 667], ["(", 669], ["1", 670], [")", 671], ["diffuse", 673], ["large", 681], ["B", 687], ["-", 688], ["cell", 689], ["lymphoma", 694], ["(", 703], ["DLBCL", 704], [")", 709], [",", 710], ["(", 712], ["2", 713], [")", 714], ["follicular", 716], ["lymphoma", 727], ["(", 736], ["FL", 737], [")", 739], [",", 740], ["and", 742], ["(", 746], ["3", 747], [")", 748], ["other", 750], ["NHL", 756], [",", 759], ["including", 761], ["mantle", 771], ["cell", 778], ["lymphoma", 783], ["(", 792], ["MCL", 793], [")", 796], [",", 797], ["marginal", 799], ["zone", 808], ["lymphoma", 813], ["(", 822], ["MZL", 823], [")", 826], [",", 827], ["mucosa", 829], ["-", 835], ["associated", 836], ["lymphoid", 847], ["tissue", 856], ["lymphoma", 863], [",", 871], ["lymphoplasmacytic", 873], ["lymphomas", 891], [",", 900], ["and", 902], ["small", 906], ["lymphocytic", 912], ["leukemia", 924], ["/", 932], ["chronic", 933], ["lymphocytic", 941], ["leukemia", 953], ["(", 962], ["SLL", 963], ["/", 966], ["CLL", 967], [")", 970], [".", 971], ["Common", 973], ["toxicities", 980], ["included", 991], ["diarrhea", 1000], [",", 1008], ["fatigue", 1010], [",", 1017], ["cytopenias", 1019], [",", 1029], ["hypertension", 1031], [",", 1043], ["and", 1045], ["nausea", 1049], [".", 1055], ["Objective", 1057], ["response", 1067], ["rates", 1076], ["were", 1082], ["22", 1087], ["%", 1089], ["(", 1091], ["5", 1092], ["of", 1094], ["23", 1097], [")", 1099], ["for", 1101], ["DLBCL", 1105], [",", 1110], ["10", 1112], ["%", 1114], ["(", 1116], ["2", 1117], ["of", 1119], ["21", 1122], [")", 1124], ["for", 1126], ["FL", 1130], [",", 1132], ["55", 1134], ["%", 1136], ["(", 1138], ["6", 1139], ["of", 1141], ["11", 1144], [")", 1146], ["for", 1148], ["SLL", 1152], ["/", 1155], ["CLL", 1156], [",", 1159], ["and", 1161], ["11", 1165], ["%", 1167], ["(", 1169], ["1/9", 1170], [")", 1173], ["for", 1175], ["MCL", 1179], [".", 1182], ["Median", 1184], ["progression", 1191], ["-", 1202], ["free", 1203], ["survival", 1208], ["was", 1217], ["4.2", 1221], ["months", 1225], [".", 1231], ["Disrupting", 1233], ["BCR", 1244], ["-", 1247], ["induced", 1248], ["signaling", 1256], ["by", 1266], ["inhibiting", 1269], ["Syk", 1280], ["represents", 1284], ["a", 1295], ["novel", 1297], ["and", 1303], ["active", 1307], ["therapeutic", 1314], ["approach", 1326], ["for", 1335], ["NHL", 1339], ["and", 1343], ["SLL", 1347], ["/", 1350], ["CLL", 1351], [".", 1354], ["This", 1356], ["trial", 1361], ["was", 1367], ["registered", 1371], ["at", 1382], ["www.clinicaltrials.gov", 1385], ["as", 1408], ["#", 1411], ["NCT00446095", 1412], [".", 1423]]}
{"context": "Children with chromosome 22q11.2 deletion syndrome (22q11.2DS), Fragile X syndrome (FXS), or Turner syndrome (TS) are considered to belong to distinct genetic groups, as each disorder is caused by separate genetic alterations. Even so, they have similar cognitive and behavioral dysfunctions, particularly in visuospatial and numerical abilities. To assess evidence for common underlying neural microstructural alterations, we set out to determine whether these groups have partially overlapping white matter abnormalities, relative to typically developing controls. We scanned 101 female children between 7 and 14years old: 25 with 22q11.2DS, 18 with FXS, 17 with TS, and 41 aged-matched controls using diffusion tensor imaging (DTI). Anisotropy and diffusivity measures were calculated and all brain scans were nonlinearly aligned to population and site-specific templates. We performed voxel-based statistical comparisons of the DTI-derived metrics between each disease group and the controls, while adjusting for age. Girls with 22q11.2DS showed lower fractional anisotropy (FA) than controls in the association fibers of the superior and inferior longitudinal fasciculi, the splenium of the corpus callosum, and the corticospinal tract. FA was abnormally lower in girls with FXS in the posterior limbs of the internal capsule, posterior thalami, and precentral gyrus. Girls with TS had lower FA in the inferior longitudinal fasciculus, right internal capsule and left cerebellar peduncle. Partially overlapping neurodevelopmental anomalies were detected in all three neurogenetic disorders. Altered white matter integrity in the superior and inferior longitudinal fasciculi and thalamic to frontal tracts may contribute to the behavioral characteristics of all of these disorders.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "6874df2a5c5d43888cd33a65d4def0f4", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[11, 11]], "char_spans": [[72, 72]]}]}], "context_tokens": [["Children", 0], ["with", 9], ["chromosome", 14], ["22q11.2", 25], ["deletion", 33], ["syndrome", 42], ["(", 51], ["22q11.2DS", 52], [")", 61], [",", 62], ["Fragile", 64], ["X", 72], ["syndrome", 74], ["(", 83], ["FXS", 84], [")", 87], [",", 88], ["or", 90], ["Turner", 93], ["syndrome", 100], ["(", 109], ["TS", 110], [")", 112], ["are", 114], ["considered", 118], ["to", 129], ["belong", 132], ["to", 139], ["distinct", 142], ["genetic", 151], ["groups", 159], [",", 165], ["as", 167], ["each", 170], ["disorder", 175], ["is", 184], ["caused", 187], ["by", 194], ["separate", 197], ["genetic", 206], ["alterations", 214], [".", 225], ["Even", 227], ["so", 232], [",", 234], ["they", 236], ["have", 241], ["similar", 246], ["cognitive", 254], ["and", 264], ["behavioral", 268], ["dysfunctions", 279], [",", 291], ["particularly", 293], ["in", 306], ["visuospatial", 309], ["and", 322], ["numerical", 326], ["abilities", 336], [".", 345], ["To", 347], ["assess", 350], ["evidence", 357], ["for", 366], ["common", 370], ["underlying", 377], ["neural", 388], ["microstructural", 395], ["alterations", 411], [",", 422], ["we", 424], ["set", 427], ["out", 431], ["to", 435], ["determine", 438], ["whether", 448], ["these", 456], ["groups", 462], ["have", 469], ["partially", 474], ["overlapping", 484], ["white", 496], ["matter", 502], ["abnormalities", 509], [",", 522], ["relative", 524], ["to", 533], ["typically", 536], ["developing", 546], ["controls", 557], [".", 565], ["We", 567], ["scanned", 570], ["101", 578], ["female", 582], ["children", 589], ["between", 598], ["7", 606], ["and", 608], ["14years", 612], ["old", 620], [":", 623], ["25", 625], ["with", 628], ["22q11.2DS", 633], [",", 642], ["18", 644], ["with", 647], ["FXS", 652], [",", 655], ["17", 657], ["with", 660], ["TS", 665], [",", 667], ["and", 669], ["41", 673], ["aged", 676], ["-", 680], ["matched", 681], ["controls", 689], ["using", 698], ["diffusion", 704], ["tensor", 714], ["imaging", 721], ["(", 729], ["DTI", 730], [")", 733], [".", 734], ["Anisotropy", 736], ["and", 747], ["diffusivity", 751], ["measures", 763], ["were", 772], ["calculated", 777], ["and", 788], ["all", 792], ["brain", 796], ["scans", 802], ["were", 808], ["nonlinearly", 813], ["aligned", 825], ["to", 833], ["population", 836], ["and", 847], ["site", 851], ["-", 855], ["specific", 856], ["templates", 865], [".", 874], ["We", 876], ["performed", 879], ["voxel", 889], ["-", 894], ["based", 895], ["statistical", 901], ["comparisons", 913], ["of", 925], ["the", 928], ["DTI", 932], ["-", 935], ["derived", 936], ["metrics", 944], ["between", 952], ["each", 960], ["disease", 965], ["group", 973], ["and", 979], ["the", 983], ["controls", 987], [",", 995], ["while", 997], ["adjusting", 1003], ["for", 1013], ["age", 1017], [".", 1020], ["Girls", 1022], ["with", 1028], ["22q11.2DS", 1033], ["showed", 1043], ["lower", 1050], ["fractional", 1056], ["anisotropy", 1067], ["(", 1078], ["FA", 1079], [")", 1081], ["than", 1083], ["controls", 1088], ["in", 1097], ["the", 1100], ["association", 1104], ["fibers", 1116], ["of", 1123], ["the", 1126], ["superior", 1130], ["and", 1139], ["inferior", 1143], ["longitudinal", 1152], ["fasciculi", 1165], [",", 1174], ["the", 1176], ["splenium", 1180], ["of", 1189], ["the", 1192], ["corpus", 1196], ["callosum", 1203], [",", 1211], ["and", 1213], ["the", 1217], ["corticospinal", 1221], ["tract", 1235], [".", 1240], ["FA", 1242], ["was", 1245], ["abnormally", 1249], ["lower", 1260], ["in", 1266], ["girls", 1269], ["with", 1275], ["FXS", 1280], ["in", 1284], ["the", 1287], ["posterior", 1291], ["limbs", 1301], ["of", 1307], ["the", 1310], ["internal", 1314], ["capsule", 1323], [",", 1330], ["posterior", 1332], ["thalami", 1342], [",", 1349], ["and", 1351], ["precentral", 1355], ["gyrus", 1366], [".", 1371], ["Girls", 1373], ["with", 1379], ["TS", 1384], ["had", 1387], ["lower", 1391], ["FA", 1397], ["in", 1400], ["the", 1403], ["inferior", 1407], ["longitudinal", 1416], ["fasciculus", 1429], [",", 1439], ["right", 1441], ["internal", 1447], ["capsule", 1456], ["and", 1464], ["left", 1468], ["cerebellar", 1473], ["peduncle", 1484], [".", 1492], ["Partially", 1494], ["overlapping", 1504], ["neurodevelopmental", 1516], ["anomalies", 1535], ["were", 1545], ["detected", 1550], ["in", 1559], ["all", 1562], ["three", 1566], ["neurogenetic", 1572], ["disorders", 1585], [".", 1594], ["Altered", 1596], ["white", 1604], ["matter", 1610], ["integrity", 1617], ["in", 1627], ["the", 1630], ["superior", 1634], ["and", 1643], ["inferior", 1647], ["longitudinal", 1656], ["fasciculi", 1669], ["and", 1679], ["thalamic", 1683], ["to", 1692], ["frontal", 1695], ["tracts", 1703], ["may", 1710], ["contribute", 1714], ["to", 1725], ["the", 1728], ["behavioral", 1732], ["characteristics", 1743], ["of", 1759], ["all", 1762], ["of", 1766], ["these", 1769], ["disorders", 1775], [".", 1784]]}
{"context": "Selenocysteine (Sec), the 21st amino acid in protein, is encoded by UGA. The Sec insertion sequence (SECIS) element, which is the stem-loop structure present in 3' untranslated regions (UTRs) of eukaryotic selenoprotein-encoding genes, is essential for recognition of UGA as a codon for Sec rather than as a stop signal. We now report the identification of a new eukaryotic selenoprotein, designated selenoprotein M (SelM). The 3-kb human SelM-encoding gene has five exons and is located on chromosome 22 but has not been correctly identified by either Celera or the public Human Genome Project. We characterized human and mouse SelM cDNA sequences and expressed the selenoprotein in various mammalian cell lines. The 3\" UTR of the human, mouse, and rat SelM-encoding genes lacks a canonical SECIS element. Instead, Sec is incorporated in response to a conserved mRNA structure, in which cytidines are present in place of the adenosines previously considered invariant. Substitution of adenosines for cytidines did not alter Sec incorporation; however, other mutant structures did not support selenoprotein synthesis, demonstrating that this new form of SECIS element is functional. SelM is expressed in a variety of tissues, with increased levels in the brain. It is localized to the perinuclear structures, and its N-terminal signal peptide is necessary for protein translocation.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "414be8e3552c4a35af6a2803ffbea6d7", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[212, 212], [154, 154], [22, 22]], "char_spans": [[1154, 1158], [792, 796], [101, 105]]}]}], "context_tokens": [["Selenocysteine", 0], ["(", 15], ["Sec", 16], [")", 19], [",", 20], ["the", 22], ["21st", 26], ["amino", 31], ["acid", 37], ["in", 42], ["protein", 45], [",", 52], ["is", 54], ["encoded", 57], ["by", 65], ["UGA", 68], [".", 71], ["The", 73], ["Sec", 77], ["insertion", 81], ["sequence", 91], ["(", 100], ["SECIS", 101], [")", 106], ["element", 108], [",", 115], ["which", 117], ["is", 123], ["the", 126], ["stem", 130], ["-", 134], ["loop", 135], ["structure", 140], ["present", 150], ["in", 158], ["3", 161], ["'", 162], ["untranslated", 164], ["regions", 177], ["(", 185], ["UTRs", 186], [")", 190], ["of", 192], ["eukaryotic", 195], ["selenoprotein", 206], ["-", 219], ["encoding", 220], ["genes", 229], [",", 234], ["is", 236], ["essential", 239], ["for", 249], ["recognition", 253], ["of", 265], ["UGA", 268], ["as", 272], ["a", 275], ["codon", 277], ["for", 283], ["Sec", 287], ["rather", 291], ["than", 298], ["as", 303], ["a", 306], ["stop", 308], ["signal", 313], [".", 319], ["We", 321], ["now", 324], ["report", 328], ["the", 335], ["identification", 339], ["of", 354], ["a", 357], ["new", 359], ["eukaryotic", 363], ["selenoprotein", 374], [",", 387], ["designated", 389], ["selenoprotein", 400], ["M", 414], ["(", 416], ["SelM", 417], [")", 421], [".", 422], ["The", 424], ["3-kb", 428], ["human", 433], ["SelM", 439], ["-", 443], ["encoding", 444], ["gene", 453], ["has", 458], ["five", 462], ["exons", 467], ["and", 473], ["is", 477], ["located", 480], ["on", 488], ["chromosome", 491], ["22", 502], ["but", 505], ["has", 509], ["not", 513], ["been", 517], ["correctly", 522], ["identified", 532], ["by", 543], ["either", 546], ["Celera", 553], ["or", 560], ["the", 563], ["public", 567], ["Human", 574], ["Genome", 580], ["Project", 587], [".", 594], ["We", 596], ["characterized", 599], ["human", 613], ["and", 619], ["mouse", 623], ["SelM", 629], ["cDNA", 634], ["sequences", 639], ["and", 649], ["expressed", 653], ["the", 663], ["selenoprotein", 667], ["in", 681], ["various", 684], ["mammalian", 692], ["cell", 702], ["lines", 707], [".", 712], ["The", 714], ["3", 718], ["\"", 719], ["UTR", 721], ["of", 725], ["the", 728], ["human", 732], [",", 737], ["mouse", 739], [",", 744], ["and", 746], ["rat", 750], ["SelM", 754], ["-", 758], ["encoding", 759], ["genes", 768], ["lacks", 774], ["a", 780], ["canonical", 782], ["SECIS", 792], ["element", 798], [".", 805], ["Instead", 807], [",", 814], ["Sec", 816], ["is", 820], ["incorporated", 823], ["in", 836], ["response", 839], ["to", 848], ["a", 851], ["conserved", 853], ["mRNA", 863], ["structure", 868], [",", 877], ["in", 879], ["which", 882], ["cytidines", 888], ["are", 898], ["present", 902], ["in", 910], ["place", 913], ["of", 919], ["the", 922], ["adenosines", 926], ["previously", 937], ["considered", 948], ["invariant", 959], [".", 968], ["Substitution", 970], ["of", 983], ["adenosines", 986], ["for", 997], ["cytidines", 1001], ["did", 1011], ["not", 1015], ["alter", 1019], ["Sec", 1025], ["incorporation", 1029], [";", 1042], ["however", 1044], [",", 1051], ["other", 1053], ["mutant", 1059], ["structures", 1066], ["did", 1077], ["not", 1081], ["support", 1085], ["selenoprotein", 1093], ["synthesis", 1107], [",", 1116], ["demonstrating", 1118], ["that", 1132], ["this", 1137], ["new", 1142], ["form", 1146], ["of", 1151], ["SECIS", 1154], ["element", 1160], ["is", 1168], ["functional", 1171], [".", 1181], ["SelM", 1183], ["is", 1188], ["expressed", 1191], ["in", 1201], ["a", 1204], ["variety", 1206], ["of", 1214], ["tissues", 1217], [",", 1224], ["with", 1226], ["increased", 1231], ["levels", 1241], ["in", 1248], ["the", 1251], ["brain", 1255], [".", 1260], ["It", 1262], ["is", 1265], ["localized", 1268], ["to", 1278], ["the", 1281], ["perinuclear", 1285], ["structures", 1297], [",", 1307], ["and", 1309], ["its", 1313], ["N", 1317], ["-", 1318], ["terminal", 1319], ["signal", 1328], ["peptide", 1335], ["is", 1343], ["necessary", 1346], ["for", 1356], ["protein", 1360], ["translocation", 1368], [".", 1381]]}
{"context": "Treatment and prevention of bone metastases is a major problem in patients with cancer. New treatment of bone metastases are needed to maintain the quality of life of our patients with metastastic bone disease. In addition, promising preliminary results suggest that bone-directed therapies may be able to prevent both skeletal and extraskeletal metastases For the past decade intravenous bisphosphonates have been the mainstay of treatment of patients with bone metastases. New therapies such as the antibody to RANKL (denosumab) are undergoing phase III clinical testing. In addition, confirmatory studies suggesting that bisphosphonates can prevent metastatic disease are underway. Understanding the biology of bone metastases has uncovered many new potential therapies for the treatment and prevention of bone metastases. Many of these potential new approaches are discussed in the enclosed article.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "6e6d84a65f4e4894b3e184eec8aec0ff", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[83, 83]], "char_spans": [[513, 517]]}]}], "context_tokens": [["Treatment", 0], ["and", 10], ["prevention", 14], ["of", 25], ["bone", 28], ["metastases", 33], ["is", 44], ["a", 47], ["major", 49], ["problem", 55], ["in", 63], ["patients", 66], ["with", 75], ["cancer", 80], [".", 86], ["New", 88], ["treatment", 92], ["of", 102], ["bone", 105], ["metastases", 110], ["are", 121], ["needed", 125], ["to", 132], ["maintain", 135], ["the", 144], ["quality", 148], ["of", 156], ["life", 159], ["of", 164], ["our", 167], ["patients", 171], ["with", 180], ["metastastic", 185], ["bone", 197], ["disease", 202], [".", 209], ["In", 211], ["addition", 214], [",", 222], ["promising", 224], ["preliminary", 234], ["results", 246], ["suggest", 254], ["that", 262], ["bone", 267], ["-", 271], ["directed", 272], ["therapies", 281], ["may", 291], ["be", 295], ["able", 298], ["to", 303], ["prevent", 306], ["both", 314], ["skeletal", 319], ["and", 328], ["extraskeletal", 332], ["metastases", 346], ["For", 357], ["the", 361], ["past", 365], ["decade", 370], ["intravenous", 377], ["bisphosphonates", 389], ["have", 405], ["been", 410], ["the", 415], ["mainstay", 419], ["of", 428], ["treatment", 431], ["of", 441], ["patients", 444], ["with", 453], ["bone", 458], ["metastases", 463], [".", 473], ["New", 475], ["therapies", 479], ["such", 489], ["as", 494], ["the", 497], ["antibody", 501], ["to", 510], ["RANKL", 513], ["(", 519], ["denosumab", 520], [")", 529], ["are", 531], ["undergoing", 535], ["phase", 546], ["III", 552], ["clinical", 556], ["testing", 565], [".", 572], ["In", 574], ["addition", 577], [",", 585], ["confirmatory", 587], ["studies", 600], ["suggesting", 608], ["that", 619], ["bisphosphonates", 624], ["can", 640], ["prevent", 644], ["metastatic", 652], ["disease", 663], ["are", 671], ["underway", 675], [".", 683], ["Understanding", 685], ["the", 699], ["biology", 703], ["of", 711], ["bone", 714], ["metastases", 719], ["has", 730], ["uncovered", 734], ["many", 744], ["new", 749], ["potential", 753], ["therapies", 763], ["for", 773], ["the", 777], ["treatment", 781], ["and", 791], ["prevention", 795], ["of", 806], ["bone", 809], ["metastases", 814], [".", 824], ["Many", 826], ["of", 831], ["these", 834], ["potential", 840], ["new", 850], ["approaches", 854], ["are", 865], ["discussed", 869], ["in", 879], ["the", 882], ["enclosed", 886], ["article", 895], [".", 902]]}
{"context": "Variant histone H2AZ-containing nucleosomes are involved in the regulation of gene expression. In Saccharomyces cerevisiae, chromatin deposition of histone H2AZ is mediated by the fourteen-subunit SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Previous work defined the role of seven SWR1 subunits (Swr1 ATPase, Swc2, Swc3, Arp6, Swc5, Yaf9, and Swc6) in maintaining complex integrity and H2AZ histone replacement activity. Here we examined the function of three additional SWR1 subunits, bromodomain containing Bdf1, actin-related protein Arp4 and Swc7, by analyzing affinity-purified mutant SWR1 complexes. We observed that depletion of Arp4 (arp4-td) substantially impaired the association of Bdf1, Yaf9, and Swc4. In contrast, loss of either Bdf1 or Swc7 had minimal effects on overall complex integrity. Furthermore, the basic H2AZ histone replacement activity of SWR1 in vitro required Arp4, but not Bdf1 or Swc7. Thus, three out of fourteen SWR1 subunits, Bdf1, Swc7, and previously noted Swc3, appear to have roles auxiliary to the basic histone replacement activity. The N-terminal region of the Swr1 ATPase subunit is necessary and sufficient to direct association of Bdf1 and Swc7, as well as Arp4, Act1, Yaf9 and Swc4. This same region contains an additional H2AZ-H2B specific binding site, distinct from the previously identified Swc2 subunit. These findings suggest that one SWR1 enzyme might be capable of binding two H2AZ-H2B dimers, and provide further insight on the hierarchy and interdependency of molecular interactions within the SWR1 complex.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "76475db3f85f4bccba0b5febb2054087", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[112, 112], [91, 91], [211, 211], [54, 54], [180, 180], [57, 57], [263, 263], [290, 290], [162, 162], [31, 31]], "char_spans": [[636, 639], [517, 520], [1148, 1151], [327, 330], [991, 994], [342, 345], [1432, 1435], [1595, 1598], [912, 915], [197, 200]]}]}], "context_tokens": [["Variant", 0], ["histone", 8], ["H2AZ", 16], ["-", 20], ["containing", 21], ["nucleosomes", 32], ["are", 44], ["involved", 48], ["in", 57], ["the", 60], ["regulation", 64], ["of", 75], ["gene", 78], ["expression", 83], [".", 93], ["In", 95], ["Saccharomyces", 98], ["cerevisiae", 112], [",", 122], ["chromatin", 124], ["deposition", 134], ["of", 145], ["histone", 148], ["H2AZ", 156], ["is", 161], ["mediated", 164], ["by", 173], ["the", 176], ["fourteen", 180], ["-", 188], ["subunit", 189], ["SWR1", 197], ["complex", 202], [",", 209], ["which", 211], ["catalyzes", 217], ["ATP", 227], ["-", 230], ["dependent", 231], ["exchange", 241], ["of", 250], ["nucleosomal", 253], ["histone", 265], ["H2A", 273], ["for", 277], ["H2AZ", 281], [".", 285], ["Previous", 287], ["work", 296], ["defined", 301], ["the", 309], ["role", 313], ["of", 318], ["seven", 321], ["SWR1", 327], ["subunits", 332], ["(", 341], ["Swr1", 342], ["ATPase", 347], [",", 353], ["Swc2", 355], [",", 359], ["Swc3", 361], [",", 365], ["Arp6", 367], [",", 371], ["Swc5", 373], [",", 377], ["Yaf9", 379], [",", 383], ["and", 385], ["Swc6", 389], [")", 393], ["in", 395], ["maintaining", 398], ["complex", 410], ["integrity", 418], ["and", 428], ["H2AZ", 432], ["histone", 437], ["replacement", 445], ["activity", 457], [".", 465], ["Here", 467], ["we", 472], ["examined", 475], ["the", 484], ["function", 488], ["of", 497], ["three", 500], ["additional", 506], ["SWR1", 517], ["subunits", 522], [",", 530], ["bromodomain", 532], ["containing", 544], ["Bdf1", 555], [",", 559], ["actin", 561], ["-", 566], ["related", 567], ["protein", 575], ["Arp4", 583], ["and", 588], ["Swc7", 592], [",", 596], ["by", 598], ["analyzing", 601], ["affinity", 611], ["-", 619], ["purified", 620], ["mutant", 629], ["SWR1", 636], ["complexes", 641], [".", 650], ["We", 652], ["observed", 655], ["that", 664], ["depletion", 669], ["of", 679], ["Arp4", 682], ["(", 687], ["arp4-td", 688], [")", 695], ["substantially", 697], ["impaired", 711], ["the", 720], ["association", 724], ["of", 736], ["Bdf1", 739], [",", 743], ["Yaf9", 745], [",", 749], ["and", 751], ["Swc4", 755], [".", 759], ["In", 761], ["contrast", 764], [",", 772], ["loss", 774], ["of", 779], ["either", 782], ["Bdf1", 789], ["or", 794], ["Swc7", 797], ["had", 802], ["minimal", 806], ["effects", 814], ["on", 822], ["overall", 825], ["complex", 833], ["integrity", 841], [".", 850], ["Furthermore", 852], [",", 863], ["the", 865], ["basic", 869], ["H2AZ", 875], ["histone", 880], ["replacement", 888], ["activity", 900], ["of", 909], ["SWR1", 912], ["in", 917], ["vitro", 920], ["required", 926], ["Arp4", 935], [",", 939], ["but", 941], ["not", 945], ["Bdf1", 949], ["or", 954], ["Swc7", 957], [".", 961], ["Thus", 963], [",", 967], ["three", 969], ["out", 975], ["of", 979], ["fourteen", 982], ["SWR1", 991], ["subunits", 996], [",", 1004], ["Bdf1", 1006], [",", 1010], ["Swc7", 1012], [",", 1016], ["and", 1018], ["previously", 1022], ["noted", 1033], ["Swc3", 1039], [",", 1043], ["appear", 1045], ["to", 1052], ["have", 1055], ["roles", 1060], ["auxiliary", 1066], ["to", 1076], ["the", 1079], ["basic", 1083], ["histone", 1089], ["replacement", 1097], ["activity", 1109], [".", 1117], ["The", 1119], ["N", 1123], ["-", 1124], ["terminal", 1125], ["region", 1134], ["of", 1141], ["the", 1144], ["Swr1", 1148], ["ATPase", 1153], ["subunit", 1160], ["is", 1168], ["necessary", 1171], ["and", 1181], ["sufficient", 1185], ["to", 1196], ["direct", 1199], ["association", 1206], ["of", 1218], ["Bdf1", 1221], ["and", 1226], ["Swc7", 1230], [",", 1234], ["as", 1236], ["well", 1239], ["as", 1244], ["Arp4", 1247], [",", 1251], ["Act1", 1253], [",", 1257], ["Yaf9", 1259], ["and", 1264], ["Swc4", 1268], [".", 1272], ["This", 1274], ["same", 1279], ["region", 1284], ["contains", 1291], ["an", 1300], ["additional", 1303], ["H2AZ", 1314], ["-", 1318], ["H2B", 1319], ["specific", 1323], ["binding", 1332], ["site", 1340], [",", 1344], ["distinct", 1346], ["from", 1355], ["the", 1360], ["previously", 1364], ["identified", 1375], ["Swc2", 1386], ["subunit", 1391], [".", 1398], ["These", 1400], ["findings", 1406], ["suggest", 1415], ["that", 1423], ["one", 1428], ["SWR1", 1432], ["enzyme", 1437], ["might", 1444], ["be", 1450], ["capable", 1453], ["of", 1461], ["binding", 1464], ["two", 1472], ["H2AZ", 1476], ["-", 1480], ["H2B", 1481], ["dimers", 1485], [",", 1491], ["and", 1493], ["provide", 1497], ["further", 1505], ["insight", 1513], ["on", 1521], ["the", 1524], ["hierarchy", 1528], ["and", 1538], ["interdependency", 1542], ["of", 1558], ["molecular", 1561], ["interactions", 1571], ["within", 1584], ["the", 1591], ["SWR1", 1595], ["complex", 1600], [".", 1607]]}
{"context": "The mammalian target of rapamycin (mTOR) has been suggested as a target for radiosensitization. Given that radiotherapy is a primary treatment modality for glioblastoma (GBM) and that mTOR is often dysregulated in GBM, the goal of this study was to determine the effects of AZD2014, a dual mTORC1/2 inhibitor, on the radiosensitivity of GBM stem-like cells (GSCs). mTORC1 and mTORC2 activities were defined by immunoblot analysis. The effects of this mTOR inhibitor on the in vitro radiosensitivity of GSCs were determined using a clonogenic assay. DNA double strand breaks were evaluated according to \u03b3H2AX foci. Orthotopic xenografts initiated from GSCs were used to define the in vivo response to AZD2014 and radiation. Exposure of GSCs to AZD2014 resulted in the inhibition of mTORC1 and 2 activities. Based on clonogenic survival analysis, addition of AZD2014 to culture media 1 hour before irradiation enhanced the radiosensitivity of CD133+ and CD15+ GSC cell lines. Whereas AZD2014 treatment had no effect on the initial level of \u03b3H2AX foci, the dispersal of radiation-induced \u03b3H2AX foci was significantly delayed. Finally, the combination of AZD2014 and radiation delivered to mice bearing GSC-initiated orthotopic xenografts significantly prolonged survival as compared with the individual treatments. These data indicate that AZD2014 enhances the radiosensitivity of GSCs both in vitro and under orthotopic in vivo conditions and suggest that this effect involves an inhibition of DNA repair. Moreover, these results suggest that this dual mTORC1/2 inhibitor may be a radiosensitizer applicable to GBM therapy.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "2b5a9a60a149451fa5beab92cdc9a704", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[1, 4]], "char_spans": [[4, 32]]}]}], "context_tokens": [["The", 0], ["mammalian", 4], ["target", 14], ["of", 21], ["rapamycin", 24], ["(", 34], ["mTOR", 35], [")", 39], ["has", 41], ["been", 45], ["suggested", 50], ["as", 60], ["a", 63], ["target", 65], ["for", 72], ["radiosensitization", 76], [".", 94], ["Given", 96], ["that", 102], ["radiotherapy", 107], ["is", 120], ["a", 123], ["primary", 125], ["treatment", 133], ["modality", 143], ["for", 152], ["glioblastoma", 156], ["(", 169], ["GBM", 170], [")", 173], ["and", 175], ["that", 179], ["mTOR", 184], ["is", 189], ["often", 192], ["dysregulated", 198], ["in", 211], ["GBM", 214], [",", 217], ["the", 219], ["goal", 223], ["of", 228], ["this", 231], ["study", 236], ["was", 242], ["to", 246], ["determine", 249], ["the", 259], ["effects", 263], ["of", 271], ["AZD2014", 274], [",", 281], ["a", 283], ["dual", 285], ["mTORC1/2", 290], ["inhibitor", 299], [",", 308], ["on", 310], ["the", 313], ["radiosensitivity", 317], ["of", 334], ["GBM", 337], ["stem", 341], ["-", 345], ["like", 346], ["cells", 351], ["(", 357], ["GSCs", 358], [")", 362], [".", 363], ["mTORC1", 365], ["and", 372], ["mTORC2", 376], ["activities", 383], ["were", 394], ["defined", 399], ["by", 407], ["immunoblot", 410], ["analysis", 421], [".", 429], ["The", 431], ["effects", 435], ["of", 443], ["this", 446], ["mTOR", 451], ["inhibitor", 456], ["on", 466], ["the", 469], ["in", 473], ["vitro", 476], ["radiosensitivity", 482], ["of", 499], ["GSCs", 502], ["were", 507], ["determined", 512], ["using", 523], ["a", 529], ["clonogenic", 531], ["assay", 542], [".", 547], ["DNA", 549], ["double", 553], ["strand", 560], ["breaks", 567], ["were", 574], ["evaluated", 579], ["according", 589], ["to", 599], ["\u03b3H2AX", 602], ["foci", 608], [".", 612], ["Orthotopic", 614], ["xenografts", 625], ["initiated", 636], ["from", 646], ["GSCs", 651], ["were", 656], ["used", 661], ["to", 666], ["define", 669], ["the", 676], ["in", 680], ["vivo", 683], ["response", 688], ["to", 697], ["AZD2014", 700], ["and", 708], ["radiation", 712], [".", 721], ["Exposure", 723], ["of", 732], ["GSCs", 735], ["to", 740], ["AZD2014", 743], ["resulted", 751], ["in", 760], ["the", 763], ["inhibition", 767], ["of", 778], ["mTORC1", 781], ["and", 788], ["2", 792], ["activities", 794], [".", 804], ["Based", 806], ["on", 812], ["clonogenic", 815], ["survival", 826], ["analysis", 835], [",", 843], ["addition", 845], ["of", 854], ["AZD2014", 857], ["to", 865], ["culture", 868], ["media", 876], ["1", 882], ["hour", 884], ["before", 889], ["irradiation", 896], ["enhanced", 908], ["the", 917], ["radiosensitivity", 921], ["of", 938], ["CD133", 941], ["+", 946], ["and", 948], ["CD15", 952], ["+", 956], ["GSC", 958], ["cell", 962], ["lines", 967], [".", 972], ["Whereas", 974], ["AZD2014", 982], ["treatment", 990], ["had", 1000], ["no", 1004], ["effect", 1007], ["on", 1014], ["the", 1017], ["initial", 1021], ["level", 1029], ["of", 1035], ["\u03b3H2AX", 1038], ["foci", 1044], [",", 1048], ["the", 1050], ["dispersal", 1054], ["of", 1064], ["radiation", 1067], ["-", 1076], ["induced", 1077], ["\u03b3H2AX", 1085], ["foci", 1091], ["was", 1096], ["significantly", 1100], ["delayed", 1114], [".", 1121], ["Finally", 1123], [",", 1130], ["the", 1132], ["combination", 1136], ["of", 1148], ["AZD2014", 1151], ["and", 1159], ["radiation", 1163], ["delivered", 1173], ["to", 1183], ["mice", 1186], ["bearing", 1191], ["GSC", 1199], ["-", 1202], ["initiated", 1203], ["orthotopic", 1213], ["xenografts", 1224], ["significantly", 1235], ["prolonged", 1249], ["survival", 1259], ["as", 1268], ["compared", 1271], ["with", 1280], ["the", 1285], ["individual", 1289], ["treatments", 1300], [".", 1310], ["These", 1312], ["data", 1318], ["indicate", 1323], ["that", 1332], ["AZD2014", 1337], ["enhances", 1345], ["the", 1354], ["radiosensitivity", 1358], ["of", 1375], ["GSCs", 1378], ["both", 1383], ["in", 1388], ["vitro", 1391], ["and", 1397], ["under", 1401], ["orthotopic", 1407], ["in", 1418], ["vivo", 1421], ["conditions", 1426], ["and", 1437], ["suggest", 1441], ["that", 1449], ["this", 1454], ["effect", 1459], ["involves", 1466], ["an", 1475], ["inhibition", 1478], ["of", 1489], ["DNA", 1492], ["repair", 1496], [".", 1502], ["Moreover", 1504], [",", 1512], ["these", 1514], ["results", 1520], ["suggest", 1528], ["that", 1536], ["this", 1541], ["dual", 1546], ["mTORC1/2", 1551], ["inhibitor", 1560], ["may", 1570], ["be", 1574], ["a", 1577], ["radiosensitizer", 1579], ["applicable", 1595], ["to", 1606], ["GBM", 1609], ["therapy", 1613], [".", 1620]]}
{"context": "The first U.S. multicenter clinical trial to assess the performance of the Cepheid Xpert MRSA assay (Xpert MRSA) was conducted. The assay is a qualitative test designed for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) directly from nares swabs. This novel test combines integrated nucleic acid extraction and automated real-time PCR for the detection of a MRSA-specific signature sequence. A total of 1,077 nares specimens were collected from seven geographically distinct health care sites across the United States with prevalence rates ranging from 5.2% to 44%. Nares specimens were tested by (i) the Xpert MRSA assay, (ii) direct culture on CHROMagar MRSA medium (direct CM culture), and (iii) broth-enriched culture (Trypticase soy broth with 6.5% sodium chloride) followed by plating onto CHROMagar MRSA medium (broth-enriched CM culture). When direct CM culture was designated the reference method, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the Xpert MRSA assay were 94.3%, 93.2%, 73.0%, and 98.8%, respectively. When broth-enriched CM culture was used as the reference method, the clinical sensitivity, specificity, PPV, and NPV of the Xpert MRSA assay were 86.3%, 94.9%, 80.5%, and 96.6%, respectively. The BD GeneOhm MRSA (BDGO) assay was performed as a comparative molecular method. No statistical performance differences were observed between the Xpert MRSA and BDGO assays when they were compared to culture methods. From this large-scale, multicenter clinical comparison, we conclude that the Xpert MRSA assay is a simple, rapid, and accurate method for performing active surveillance for MRSA in a variety of health care populations.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "1f0c6f94bfa249aeaddae73d9c7c9abe", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [240, 240], [67, 67], [123, 123], [154, 154], [261, 261], [283, 283], [310, 310], [196, 196], [326, 326], [41, 41], [18, 18], [113, 113]], "char_spans": [[89, 92], [1238, 1241], [385, 388], [683, 686], [833, 836], [1315, 1318], [1453, 1456], [1601, 1604], [1046, 1049], [1691, 1694], [241, 244], [107, 110], [638, 641]]}]}], "context_tokens": [["The", 0], ["first", 4], ["U.S.", 10], ["multicenter", 15], ["clinical", 27], ["trial", 36], ["to", 42], ["assess", 45], ["the", 52], ["performance", 56], ["of", 68], ["the", 71], ["Cepheid", 75], ["Xpert", 83], ["MRSA", 89], ["assay", 94], ["(", 100], ["Xpert", 101], ["MRSA", 107], [")", 111], ["was", 113], ["conducted", 117], [".", 126], ["The", 128], ["assay", 132], ["is", 138], ["a", 141], ["qualitative", 143], ["test", 155], ["designed", 160], ["for", 169], ["the", 173], ["rapid", 177], ["detection", 183], ["of", 193], ["methicillin", 196], ["-", 207], ["resistant", 208], ["Staphylococcus", 218], ["aureus", 233], ["(", 240], ["MRSA", 241], [")", 245], ["directly", 247], ["from", 256], ["nares", 261], ["swabs", 267], [".", 272], ["This", 274], ["novel", 279], ["test", 285], ["combines", 290], ["integrated", 299], ["nucleic", 310], ["acid", 318], ["extraction", 323], ["and", 334], ["automated", 338], ["real", 348], ["-", 352], ["time", 353], ["PCR", 358], ["for", 362], ["the", 366], ["detection", 370], ["of", 380], ["a", 383], ["MRSA", 385], ["-", 389], ["specific", 390], ["signature", 399], ["sequence", 409], [".", 417], ["A", 419], ["total", 421], ["of", 427], ["1,077", 430], ["nares", 436], ["specimens", 442], ["were", 452], ["collected", 457], ["from", 467], ["seven", 472], ["geographically", 478], ["distinct", 493], ["health", 502], ["care", 509], ["sites", 514], ["across", 520], ["the", 527], ["United", 531], ["States", 538], ["with", 545], ["prevalence", 550], ["rates", 561], ["ranging", 567], ["from", 575], ["5.2", 580], ["%", 583], ["to", 585], ["44", 588], ["%", 590], [".", 591], ["Nares", 593], ["specimens", 599], ["were", 609], ["tested", 614], ["by", 621], ["(", 624], ["i", 625], [")", 626], ["the", 628], ["Xpert", 632], ["MRSA", 638], ["assay", 643], [",", 648], ["(", 650], ["ii", 651], [")", 653], ["direct", 655], ["culture", 662], ["on", 670], ["CHROMagar", 673], ["MRSA", 683], ["medium", 688], ["(", 695], ["direct", 696], ["CM", 703], ["culture", 706], [")", 713], [",", 714], ["and", 716], ["(", 720], ["iii", 721], [")", 724], ["broth", 726], ["-", 731], ["enriched", 732], ["culture", 741], ["(", 749], ["Trypticase", 750], ["soy", 761], ["broth", 765], ["with", 771], ["6.5", 776], ["%", 779], ["sodium", 781], ["chloride", 788], [")", 796], ["followed", 798], ["by", 807], ["plating", 810], ["onto", 818], ["CHROMagar", 823], ["MRSA", 833], ["medium", 838], ["(", 845], ["broth", 846], ["-", 851], ["enriched", 852], ["CM", 861], ["culture", 864], [")", 871], [".", 872], ["When", 874], ["direct", 879], ["CM", 886], ["culture", 889], ["was", 897], ["designated", 901], ["the", 912], ["reference", 916], ["method", 926], [",", 932], ["the", 934], ["sensitivity", 938], [",", 949], ["specificity", 951], [",", 962], ["positive", 964], ["predictive", 973], ["value", 984], ["(", 990], ["PPV", 991], [")", 994], [",", 995], ["and", 997], ["negative", 1001], ["predictive", 1010], ["value", 1021], ["(", 1027], ["NPV", 1028], [")", 1031], ["of", 1033], ["the", 1036], ["Xpert", 1040], ["MRSA", 1046], ["assay", 1051], ["were", 1057], ["94.3", 1062], ["%", 1066], [",", 1067], ["93.2", 1069], ["%", 1073], [",", 1074], ["73.0", 1076], ["%", 1080], [",", 1081], ["and", 1083], ["98.8", 1087], ["%", 1091], [",", 1092], ["respectively", 1094], [".", 1106], ["When", 1108], ["broth", 1113], ["-", 1118], ["enriched", 1119], ["CM", 1128], ["culture", 1131], ["was", 1139], ["used", 1143], ["as", 1148], ["the", 1151], ["reference", 1155], ["method", 1165], [",", 1171], ["the", 1173], ["clinical", 1177], ["sensitivity", 1186], [",", 1197], ["specificity", 1199], [",", 1210], ["PPV", 1212], [",", 1215], ["and", 1217], ["NPV", 1221], ["of", 1225], ["the", 1228], ["Xpert", 1232], ["MRSA", 1238], ["assay", 1243], ["were", 1249], ["86.3", 1254], ["%", 1258], [",", 1259], ["94.9", 1261], ["%", 1265], [",", 1266], ["80.5", 1268], ["%", 1272], [",", 1273], ["and", 1275], ["96.6", 1279], ["%", 1283], [",", 1284], ["respectively", 1286], [".", 1298], ["The", 1300], ["BD", 1304], ["GeneOhm", 1307], ["MRSA", 1315], ["(", 1320], ["BDGO", 1321], [")", 1325], ["assay", 1327], ["was", 1333], ["performed", 1337], ["as", 1347], ["a", 1350], ["comparative", 1352], ["molecular", 1364], ["method", 1374], [".", 1380], ["No", 1382], ["statistical", 1385], ["performance", 1397], ["differences", 1409], ["were", 1421], ["observed", 1426], ["between", 1435], ["the", 1443], ["Xpert", 1447], ["MRSA", 1453], ["and", 1458], ["BDGO", 1462], ["assays", 1467], ["when", 1474], ["they", 1479], ["were", 1484], ["compared", 1489], ["to", 1498], ["culture", 1501], ["methods", 1509], [".", 1516], ["From", 1518], ["this", 1523], ["large", 1528], ["-", 1533], ["scale", 1534], [",", 1539], ["multicenter", 1541], ["clinical", 1553], ["comparison", 1562], [",", 1572], ["we", 1574], ["conclude", 1577], ["that", 1586], ["the", 1591], ["Xpert", 1595], ["MRSA", 1601], ["assay", 1606], ["is", 1612], ["a", 1615], ["simple", 1617], [",", 1623], ["rapid", 1625], [",", 1630], ["and", 1632], ["accurate", 1636], ["method", 1645], ["for", 1652], ["performing", 1656], ["active", 1667], ["surveillance", 1674], ["for", 1687], ["MRSA", 1691], ["in", 1696], ["a", 1699], ["variety", 1701], ["of", 1709], ["health", 1712], ["care", 1719], ["populations", 1724], [".", 1735]]}
{"context": "Bloodstream infections with Staphylococcus aureus are clinically significant and are often treated with empirical methicillin resistance (MRSA, methicillin-resistant S. aureus) coverage. However, vancomycin has associated harms. We hypothesized that MRSA screening correlated with resistance in S. aureus bacteremia and could help determine the requirement for empirical vancomycin therapy. We reviewed consecutive S. aureus bacteremias over a 5-year period at two tertiary care hospitals. MRSA colonization was evaluated in three ways: as tested within 30 days of bacteremia (30-day criterion), as tested within 30 days but accounting for any prior positive results (ever-positive criterion), or as tested in known-positive patients, with patients with unknown MRSA status being labeled negative (known-positive criterion). There were 409 S. aureus bacteremias: 302 (73.8%) methicillin-susceptible S. aureus (MSSA) and 107 (26.2%) MRSA bacteremias. In the 167 patients with MSSA bacteremias, 7.2% had a positive MRSA test within 30 days. Of 107 patients with MRSA bacteremia, 68 were tested within 30 days (54 positive; 79.8%), and another 21 (19.6%) were previously positive. The 30-day criterion provided negative predictive values (NPV) exceeding 90% and 95% if the prevalence of MRSA in S. aureus bacteremia was less than 33.4% and 19.2%, respectively. The same NPVs were predicted at MRSA proportions below 39.7% and 23.8%, respectively, for the ever-positive criterion and 34.4% and 19.9%, respectively, for the known-positive criterion. In MRSA-colonized patients, positive predictive values exceeded 50% at low prevalence. MRSA screening could help avoid empirical vancomycin therapy and its complications in stable patients and settings with low-to-moderate proportions of MRSA bacteremia.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "9acd37ca200b46afa27f75a9f8b082ed", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "methicillin-resistant S. aureus", "token_spans": [[19, 23]], "char_spans": [[144, 174]]}, {"text": "MRSA", "token_spans": [[37, 37], [163, 163], [125, 125], [179, 179], [189, 189], [237, 237], [259, 259], [293, 293], [73, 73], [308, 308], [332, 332], [17, 17]], "char_spans": [[250, 253], [932, 935], [762, 765], [1013, 1016], [1060, 1063], [1284, 1287], [1390, 1393], [1548, 1551], [490, 493], [1632, 1635], [1783, 1786], [138, 141]]}]}], "context_tokens": [["Bloodstream", 0], ["infections", 12], ["with", 23], ["Staphylococcus", 28], ["aureus", 43], ["are", 50], ["clinically", 54], ["significant", 65], ["and", 77], ["are", 81], ["often", 85], ["treated", 91], ["with", 99], ["empirical", 104], ["methicillin", 114], ["resistance", 126], ["(", 137], ["MRSA", 138], [",", 142], ["methicillin", 144], ["-", 155], ["resistant", 156], ["S.", 166], ["aureus", 169], [")", 175], ["coverage", 177], [".", 185], ["However", 187], [",", 194], ["vancomycin", 196], ["has", 207], ["associated", 211], ["harms", 222], [".", 227], ["We", 229], ["hypothesized", 232], ["that", 245], ["MRSA", 250], ["screening", 255], ["correlated", 265], ["with", 276], ["resistance", 281], ["in", 292], ["S.", 295], ["aureus", 298], ["bacteremia", 305], ["and", 316], ["could", 320], ["help", 326], ["determine", 331], ["the", 341], ["requirement", 345], ["for", 357], ["empirical", 361], ["vancomycin", 371], ["therapy", 382], [".", 389], ["We", 391], ["reviewed", 394], ["consecutive", 403], ["S.", 415], ["aureus", 418], ["bacteremias", 425], ["over", 437], ["a", 442], ["5-year", 444], ["period", 451], ["at", 458], ["two", 461], ["tertiary", 465], ["care", 474], ["hospitals", 479], [".", 488], ["MRSA", 490], ["colonization", 495], ["was", 508], ["evaluated", 512], ["in", 522], ["three", 525], ["ways", 531], [":", 535], ["as", 537], ["tested", 540], ["within", 547], ["30", 554], ["days", 557], ["of", 562], ["bacteremia", 565], ["(", 576], ["30-day", 577], ["criterion", 584], [")", 593], [",", 594], ["as", 596], ["tested", 599], ["within", 606], ["30", 613], ["days", 616], ["but", 621], ["accounting", 625], ["for", 636], ["any", 640], ["prior", 644], ["positive", 650], ["results", 659], ["(", 667], ["ever", 668], ["-", 672], ["positive", 673], ["criterion", 682], [")", 691], [",", 692], ["or", 694], ["as", 697], ["tested", 700], ["in", 707], ["known", 710], ["-", 715], ["positive", 716], ["patients", 725], [",", 733], ["with", 735], ["patients", 740], ["with", 749], ["unknown", 754], ["MRSA", 762], ["status", 767], ["being", 774], ["labeled", 780], ["negative", 788], ["(", 797], ["known", 798], ["-", 803], ["positive", 804], ["criterion", 813], [")", 822], [".", 823], ["There", 825], ["were", 831], ["409", 836], ["S.", 840], ["aureus", 843], ["bacteremias", 850], [":", 861], ["302", 863], ["(", 867], ["73.8", 868], ["%", 872], [")", 873], ["methicillin", 875], ["-", 886], ["susceptible", 887], ["S.", 899], ["aureus", 902], ["(", 909], ["MSSA", 910], [")", 914], ["and", 916], ["107", 920], ["(", 924], ["26.2", 925], ["%", 929], [")", 930], ["MRSA", 932], ["bacteremias", 937], [".", 948], ["In", 950], ["the", 953], ["167", 957], ["patients", 961], ["with", 970], ["MSSA", 975], ["bacteremias", 980], [",", 991], ["7.2", 993], ["%", 996], ["had", 998], ["a", 1002], ["positive", 1004], ["MRSA", 1013], ["test", 1018], ["within", 1023], ["30", 1030], ["days", 1033], [".", 1037], ["Of", 1039], ["107", 1042], ["patients", 1046], ["with", 1055], ["MRSA", 1060], ["bacteremia", 1065], [",", 1075], ["68", 1077], ["were", 1080], ["tested", 1085], ["within", 1092], ["30", 1099], ["days", 1102], ["(", 1107], ["54", 1108], ["positive", 1111], [";", 1119], ["79.8", 1121], ["%", 1125], [")", 1126], [",", 1127], ["and", 1129], ["another", 1133], ["21", 1141], ["(", 1144], ["19.6", 1145], ["%", 1149], [")", 1150], ["were", 1152], ["previously", 1157], ["positive", 1168], [".", 1176], ["The", 1178], ["30-day", 1182], ["criterion", 1189], ["provided", 1199], ["negative", 1208], ["predictive", 1217], ["values", 1228], ["(", 1235], ["NPV", 1236], [")", 1239], ["exceeding", 1241], ["90", 1251], ["%", 1253], ["and", 1255], ["95", 1259], ["%", 1261], ["if", 1263], ["the", 1266], ["prevalence", 1270], ["of", 1281], ["MRSA", 1284], ["in", 1289], ["S.", 1292], ["aureus", 1295], ["bacteremia", 1302], ["was", 1313], ["less", 1317], ["than", 1322], ["33.4", 1327], ["%", 1331], ["and", 1333], ["19.2", 1337], ["%", 1341], [",", 1342], ["respectively", 1344], [".", 1356], ["The", 1358], ["same", 1362], ["NPVs", 1367], ["were", 1372], ["predicted", 1377], ["at", 1387], ["MRSA", 1390], ["proportions", 1395], ["below", 1407], ["39.7", 1413], ["%", 1417], ["and", 1419], ["23.8", 1423], ["%", 1427], [",", 1428], ["respectively", 1430], [",", 1442], ["for", 1444], ["the", 1448], ["ever", 1452], ["-", 1456], ["positive", 1457], ["criterion", 1466], ["and", 1476], ["34.4", 1480], ["%", 1484], ["and", 1486], ["19.9", 1490], ["%", 1494], [",", 1495], ["respectively", 1497], [",", 1509], ["for", 1511], ["the", 1515], ["known", 1519], ["-", 1524], ["positive", 1525], ["criterion", 1534], [".", 1543], ["In", 1545], ["MRSA", 1548], ["-", 1552], ["colonized", 1553], ["patients", 1563], [",", 1571], ["positive", 1573], ["predictive", 1582], ["values", 1593], ["exceeded", 1600], ["50", 1609], ["%", 1611], ["at", 1613], ["low", 1616], ["prevalence", 1620], [".", 1630], ["MRSA", 1632], ["screening", 1637], ["could", 1647], ["help", 1653], ["avoid", 1658], ["empirical", 1664], ["vancomycin", 1674], ["therapy", 1685], ["and", 1693], ["its", 1697], ["complications", 1701], ["in", 1715], ["stable", 1718], ["patients", 1725], ["and", 1734], ["settings", 1738], ["with", 1747], ["low", 1752], ["-", 1755], ["to", 1756], ["-", 1758], ["moderate", 1759], ["proportions", 1768], ["of", 1780], ["MRSA", 1783], ["bacteremia", 1788], [".", 1798]]}
{"context": "Peroxiredoxin 2 (Prx2), a thiol-dependent peroxidase, is the third most abundant protein in the erythrocyte, and its absence in knock-out mice gives rise to hemolytic anemia. We have found that in human erythrocytes, Prx2 was extremely sensitive to oxidation by H(2)O(2), as dimerization was observed after exposure of 5 x 10(6) cells/mL to 0.5 muM H(2)O(2). In contrast to Prx2 in Jurkat T lymphocytes, Prx2 was resistant to overoxidation (oxidation of the cysteine thiol to a sulfinic/sulfonic acid) in erythrocytes. Reduction of dimerized Prx2 in the erythrocyte occurred very slowly, with reversal occurring gradually over a 20-minute period. Very low thioredoxin reductase activity was detected in hemolysates. We postulate that this limits the rate of Prx2 regeneration, and this inefficiency in recycling prevents the overoxidation of Prx2. We also found that Prx2 was oxidized by endogenously generated H(2)O(2), which was mainly derived from hemoglobin autoxidation. Our results demonstrate that in the erythrocyte Prx2 is extremely efficient at scavenging H(2)O(2) noncatalytically. Although it does not act as a classical antioxidant enzyme, its high concentration and substrate sensitivity enable it to handle low H(2)O(2) concentrations efficiently. These unique redox properties may account for its nonredundant role in erythrocyte defense against oxidative stress.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "e02be922827e4845bcfa8b7bbd3e8a3e", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[202, 202]], "char_spans": [[1133, 1143]]}]}], "context_tokens": [["Peroxiredoxin", 0], ["2", 14], ["(", 16], ["Prx2", 17], [")", 21], [",", 22], ["a", 24], ["thiol", 26], ["-", 31], ["dependent", 32], ["peroxidase", 42], [",", 52], ["is", 54], ["the", 57], ["third", 61], ["most", 67], ["abundant", 72], ["protein", 81], ["in", 89], ["the", 92], ["erythrocyte", 96], [",", 107], ["and", 109], ["its", 113], ["absence", 117], ["in", 125], ["knock", 128], ["-", 133], ["out", 134], ["mice", 138], ["gives", 143], ["rise", 149], ["to", 154], ["hemolytic", 157], ["anemia", 167], [".", 173], ["We", 175], ["have", 178], ["found", 183], ["that", 189], ["in", 194], ["human", 197], ["erythrocytes", 203], [",", 215], ["Prx2", 217], ["was", 222], ["extremely", 226], ["sensitive", 236], ["to", 246], ["oxidation", 249], ["by", 259], ["H(2)O(2", 262], [")", 269], [",", 270], ["as", 272], ["dimerization", 275], ["was", 288], ["observed", 292], ["after", 301], ["exposure", 307], ["of", 316], ["5", 319], ["x", 321], ["10(6", 323], [")", 327], ["cells", 329], ["/", 334], ["mL", 335], ["to", 338], ["0.5", 341], ["muM", 345], ["H(2)O(2", 349], [")", 356], [".", 357], ["In", 359], ["contrast", 362], ["to", 371], ["Prx2", 374], ["in", 379], ["Jurkat", 382], ["T", 389], ["lymphocytes", 391], [",", 402], ["Prx2", 404], ["was", 409], ["resistant", 413], ["to", 423], ["overoxidation", 426], ["(", 440], ["oxidation", 441], ["of", 451], ["the", 454], ["cysteine", 458], ["thiol", 467], ["to", 473], ["a", 476], ["sulfinic", 478], ["/", 486], ["sulfonic", 487], ["acid", 496], [")", 500], ["in", 502], ["erythrocytes", 505], [".", 517], ["Reduction", 519], ["of", 529], ["dimerized", 532], ["Prx2", 542], ["in", 547], ["the", 550], ["erythrocyte", 554], ["occurred", 566], ["very", 575], ["slowly", 580], [",", 586], ["with", 588], ["reversal", 593], ["occurring", 602], ["gradually", 612], ["over", 622], ["a", 627], ["20-minute", 629], ["period", 639], [".", 645], ["Very", 647], ["low", 652], ["thioredoxin", 656], ["reductase", 668], ["activity", 678], ["was", 687], ["detected", 691], ["in", 700], ["hemolysates", 703], [".", 714], ["We", 716], ["postulate", 719], ["that", 729], ["this", 734], ["limits", 739], ["the", 746], ["rate", 750], ["of", 755], ["Prx2", 758], ["regeneration", 763], [",", 775], ["and", 777], ["this", 781], ["inefficiency", 786], ["in", 799], ["recycling", 802], ["prevents", 812], ["the", 821], ["overoxidation", 825], ["of", 839], ["Prx2", 842], [".", 846], ["We", 848], ["also", 851], ["found", 856], ["that", 862], ["Prx2", 867], ["was", 872], ["oxidized", 876], ["by", 885], ["endogenously", 888], ["generated", 901], ["H(2)O(2", 911], [")", 918], [",", 919], ["which", 921], ["was", 927], ["mainly", 931], ["derived", 938], ["from", 946], ["hemoglobin", 951], ["autoxidation", 962], [".", 974], ["Our", 976], ["results", 980], ["demonstrate", 988], ["that", 1000], ["in", 1005], ["the", 1008], ["erythrocyte", 1012], ["Prx2", 1024], ["is", 1029], ["extremely", 1032], ["efficient", 1042], ["at", 1052], ["scavenging", 1055], ["H(2)O(2", 1066], [")", 1073], ["noncatalytically", 1075], [".", 1091], ["Although", 1093], ["it", 1102], ["does", 1105], ["not", 1110], ["act", 1114], ["as", 1118], ["a", 1121], ["classical", 1123], ["antioxidant", 1133], ["enzyme", 1145], [",", 1151], ["its", 1153], ["high", 1157], ["concentration", 1162], ["and", 1176], ["substrate", 1180], ["sensitivity", 1190], ["enable", 1202], ["it", 1209], ["to", 1212], ["handle", 1215], ["low", 1222], ["H(2)O(2", 1226], [")", 1233], ["concentrations", 1235], ["efficiently", 1250], [".", 1261], ["These", 1263], ["unique", 1269], ["redox", 1276], ["properties", 1282], ["may", 1293], ["account", 1297], ["for", 1305], ["its", 1309], ["nonredundant", 1313], ["role", 1326], ["in", 1331], ["erythrocyte", 1334], ["defense", 1346], ["against", 1354], ["oxidative", 1362], ["stress", 1372], [".", 1378]]}
{"context": "Data on the effect of gender in rheumatoid arthritis (RA) in non-Caucasian populations is scarce. Latin America and the Caribbean (LAC) is a large population with unique characteristics, including high admixture. Our aim was to examine the effect of gender in patients with RA in LAC. This was a 2-phase study. First we conducted a cross-sectional and analytical study in which 1128 consecutive Colombian patients with RA were assessed. Second, a systematic review of the literature was done to evaluate the effect of gender in LAC patients with RA. Our results show a high prevalence of RA in LAC women with a ratio of 5.2 women per man. Colombian women with RA are more at risk of having an early age at onset and developing polyautoimmunity and abdominal obesity, and they perform more household duties than their male counterparts. However, male gender was associated with the presence of extra-articular manifestations. Of a total of 641 potentially relevant articles, 38 were considered for final analysis, in which several factors and outcomes related to gender were identified. RA in LAC women is not only more common but presents with some clinical characteristics that differ from RA presentation in men. Some of those characteristics could explain the high rates of disability and worse prognosis observed in women with RA in LAC.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "7996bd8205754c248b98cf55204c7a56", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[240, 240], [115, 115], [204, 204], [121, 121], [126, 126]], "char_spans": [[1320, 1324], [598, 602], [1096, 1100], [624, 628], [649, 653]]}]}], "context_tokens": [["Data", 0], ["on", 5], ["the", 8], ["effect", 12], ["of", 19], ["gender", 22], ["in", 29], ["rheumatoid", 32], ["arthritis", 43], ["(", 53], ["RA", 54], [")", 56], ["in", 58], ["non", 61], ["-", 64], ["Caucasian", 65], ["populations", 75], ["is", 87], ["scarce", 90], [".", 96], ["Latin", 98], ["America", 104], ["and", 112], ["the", 116], ["Caribbean", 120], ["(", 130], ["LAC", 131], [")", 134], ["is", 136], ["a", 139], ["large", 141], ["population", 147], ["with", 158], ["unique", 163], ["characteristics", 170], [",", 185], ["including", 187], ["high", 197], ["admixture", 202], [".", 211], ["Our", 213], ["aim", 217], ["was", 221], ["to", 225], ["examine", 228], ["the", 236], ["effect", 240], ["of", 247], ["gender", 250], ["in", 257], ["patients", 260], ["with", 269], ["RA", 274], ["in", 277], ["LAC", 280], [".", 283], ["This", 285], ["was", 290], ["a", 294], ["2-phase", 296], ["study", 304], [".", 309], ["First", 311], ["we", 317], ["conducted", 320], ["a", 330], ["cross", 332], ["-", 337], ["sectional", 338], ["and", 348], ["analytical", 352], ["study", 363], ["in", 369], ["which", 372], ["1128", 378], ["consecutive", 383], ["Colombian", 395], ["patients", 405], ["with", 414], ["RA", 419], ["were", 422], ["assessed", 427], [".", 435], ["Second", 437], [",", 443], ["a", 445], ["systematic", 447], ["review", 458], ["of", 465], ["the", 468], ["literature", 472], ["was", 483], ["done", 487], ["to", 492], ["evaluate", 495], ["the", 504], ["effect", 508], ["of", 515], ["gender", 518], ["in", 525], ["LAC", 528], ["patients", 532], ["with", 541], ["RA", 546], [".", 548], ["Our", 550], ["results", 554], ["show", 562], ["a", 567], ["high", 569], ["prevalence", 574], ["of", 585], ["RA", 588], ["in", 591], ["LAC", 594], ["women", 598], ["with", 604], ["a", 609], ["ratio", 611], ["of", 617], ["5.2", 620], ["women", 624], ["per", 630], ["man", 634], [".", 637], ["Colombian", 639], ["women", 649], ["with", 655], ["RA", 660], ["are", 663], ["more", 667], ["at", 672], ["risk", 675], ["of", 680], ["having", 683], ["an", 690], ["early", 693], ["age", 699], ["at", 703], ["onset", 706], ["and", 712], ["developing", 716], ["polyautoimmunity", 727], ["and", 744], ["abdominal", 748], ["obesity", 758], [",", 765], ["and", 767], ["they", 771], ["perform", 776], ["more", 784], ["household", 789], ["duties", 799], ["than", 806], ["their", 811], ["male", 817], ["counterparts", 822], [".", 834], ["However", 836], [",", 843], ["male", 845], ["gender", 850], ["was", 857], ["associated", 861], ["with", 872], ["the", 877], ["presence", 881], ["of", 890], ["extra", 893], ["-", 898], ["articular", 899], ["manifestations", 909], [".", 923], ["Of", 925], ["a", 928], ["total", 930], ["of", 936], ["641", 939], ["potentially", 943], ["relevant", 955], ["articles", 964], [",", 972], ["38", 974], ["were", 977], ["considered", 982], ["for", 993], ["final", 997], ["analysis", 1003], [",", 1011], ["in", 1013], ["which", 1016], ["several", 1022], ["factors", 1030], ["and", 1038], ["outcomes", 1042], ["related", 1051], ["to", 1059], ["gender", 1062], ["were", 1069], ["identified", 1074], [".", 1084], ["RA", 1086], ["in", 1089], ["LAC", 1092], ["women", 1096], ["is", 1102], ["not", 1105], ["only", 1109], ["more", 1114], ["common", 1119], ["but", 1126], ["presents", 1130], ["with", 1139], ["some", 1144], ["clinical", 1149], ["characteristics", 1158], ["that", 1174], ["differ", 1179], ["from", 1186], ["RA", 1191], ["presentation", 1194], ["in", 1207], ["men", 1210], [".", 1213], ["Some", 1215], ["of", 1220], ["those", 1223], ["characteristics", 1229], ["could", 1245], ["explain", 1251], ["the", 1259], ["high", 1263], ["rates", 1268], ["of", 1274], ["disability", 1277], ["and", 1288], ["worse", 1292], ["prognosis", 1298], ["observed", 1308], ["in", 1317], ["women", 1320], ["with", 1326], ["RA", 1331], ["in", 1334], ["LAC", 1337], [".", 1340]]}
{"context": "In post-traumatic stress disorder (PTSD) there is a need for self-rating scales that are sensitive to treatment effects and have been tested in a broad range of trauma survivors. Separate measures of frequency and severity may also provide an advantage. Three hundred and fifty-three men and women completed the Davidson Trauma Scale (DTS), a 17-item scale measuring each DSM-IV symptom of PTSD on 5-point frequency and severity scales. These subjects comprised war veterans, survivors of rape or hurricane and a mixed trauma group participating in a clinical trial. Other scales were included as validity checks as follows: Global ratings, SCL-90-R, Eysenck Scale, Impact of Event Scale and Structured Clinical Interview for DSM-III-R. The scale demonstrated good test-retest reliability (r = 0.86), internal consistency (r = 0.99). One main factor emerged for severity and a smaller one for intrusion. In PTSD diagnosed subjects, and the factor structure more closely resembled the traditional grouping of symptoms. Concurrent validity was obtained against the SCID, with a diagnostic accuracy of 83% at a DTS score of 40. Good convergent and divergent validity was obtained. The DTS showed predictive validity against response to treatment, as well as being sensitive to treatment effects. The DTS showed good reliability and validity, and offers promised as a scale which is particularly suited to assessing symptom severity, treatment outcome and in screening for the likely diagnosis of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "cc8a41f6a6f0463db5968ac4b582400e", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[1, 5]], "char_spans": [[3, 32]]}, {"text": "PTSD", "token_spans": [[273, 273], [76, 76], [7, 7], [174, 174]], "char_spans": [[1493, 1496], [390, 393], [35, 38], [907, 910]]}]}], "context_tokens": [["In", 0], ["post", 3], ["-", 7], ["traumatic", 8], ["stress", 18], ["disorder", 25], ["(", 34], ["PTSD", 35], [")", 39], ["there", 41], ["is", 47], ["a", 50], ["need", 52], ["for", 57], ["self", 61], ["-", 65], ["rating", 66], ["scales", 73], ["that", 80], ["are", 85], ["sensitive", 89], ["to", 99], ["treatment", 102], ["effects", 112], ["and", 120], ["have", 124], ["been", 129], ["tested", 134], ["in", 141], ["a", 144], ["broad", 146], ["range", 152], ["of", 158], ["trauma", 161], ["survivors", 168], [".", 177], ["Separate", 179], ["measures", 188], ["of", 197], ["frequency", 200], ["and", 210], ["severity", 214], ["may", 223], ["also", 227], ["provide", 232], ["an", 240], ["advantage", 243], [".", 252], ["Three", 254], ["hundred", 260], ["and", 268], ["fifty", 272], ["-", 277], ["three", 278], ["men", 284], ["and", 288], ["women", 292], ["completed", 298], ["the", 308], ["Davidson", 312], ["Trauma", 321], ["Scale", 328], ["(", 334], ["DTS", 335], [")", 338], [",", 339], ["a", 341], ["17-item", 343], ["scale", 351], ["measuring", 357], ["each", 367], ["DSM", 372], ["-", 375], ["IV", 376], ["symptom", 379], ["of", 387], ["PTSD", 390], ["on", 395], ["5-point", 398], ["frequency", 406], ["and", 416], ["severity", 420], ["scales", 429], [".", 435], ["These", 437], ["subjects", 443], ["comprised", 452], ["war", 462], ["veterans", 466], [",", 474], ["survivors", 476], ["of", 486], ["rape", 489], ["or", 494], ["hurricane", 497], ["and", 507], ["a", 511], ["mixed", 513], ["trauma", 519], ["group", 526], ["participating", 532], ["in", 546], ["a", 549], ["clinical", 551], ["trial", 560], [".", 565], ["Other", 567], ["scales", 573], ["were", 580], ["included", 585], ["as", 594], ["validity", 597], ["checks", 606], ["as", 613], ["follows", 616], [":", 623], ["Global", 625], ["ratings", 632], [",", 639], ["SCL-90-R", 641], [",", 649], ["Eysenck", 651], ["Scale", 659], [",", 664], ["Impact", 666], ["of", 673], ["Event", 676], ["Scale", 682], ["and", 688], ["Structured", 692], ["Clinical", 703], ["Interview", 712], ["for", 722], ["DSM", 726], ["-", 729], ["III", 730], ["-", 733], ["R.", 734], ["The", 737], ["scale", 741], ["demonstrated", 747], ["good", 760], ["test", 765], ["-", 769], ["retest", 770], ["reliability", 777], ["(", 789], ["r", 790], ["=", 792], ["0.86", 794], [")", 798], [",", 799], ["internal", 801], ["consistency", 810], ["(", 822], ["r", 823], ["=", 825], ["0.99", 827], [")", 831], [".", 832], ["One", 834], ["main", 838], ["factor", 843], ["emerged", 850], ["for", 858], ["severity", 862], ["and", 871], ["a", 875], ["smaller", 877], ["one", 885], ["for", 889], ["intrusion", 893], [".", 902], ["In", 904], ["PTSD", 907], ["diagnosed", 912], ["subjects", 922], [",", 930], ["and", 932], ["the", 936], ["factor", 940], ["structure", 947], ["more", 957], ["closely", 962], ["resembled", 970], ["the", 980], ["traditional", 984], ["grouping", 996], ["of", 1005], ["symptoms", 1008], [".", 1016], ["Concurrent", 1018], ["validity", 1029], ["was", 1038], ["obtained", 1042], ["against", 1051], ["the", 1059], ["SCID", 1063], [",", 1067], ["with", 1069], ["a", 1074], ["diagnostic", 1076], ["accuracy", 1087], ["of", 1096], ["83", 1099], ["%", 1101], ["at", 1103], ["a", 1106], ["DTS", 1108], ["score", 1112], ["of", 1118], ["40", 1121], [".", 1123], ["Good", 1125], ["convergent", 1130], ["and", 1141], ["divergent", 1145], ["validity", 1155], ["was", 1164], ["obtained", 1168], [".", 1176], ["The", 1178], ["DTS", 1182], ["showed", 1186], ["predictive", 1193], ["validity", 1204], ["against", 1213], ["response", 1221], ["to", 1230], ["treatment", 1233], [",", 1242], ["as", 1244], ["well", 1247], ["as", 1252], ["being", 1255], ["sensitive", 1261], ["to", 1271], ["treatment", 1274], ["effects", 1284], [".", 1291], ["The", 1293], ["DTS", 1297], ["showed", 1301], ["good", 1308], ["reliability", 1313], ["and", 1325], ["validity", 1329], [",", 1337], ["and", 1339], ["offers", 1343], ["promised", 1350], ["as", 1359], ["a", 1362], ["scale", 1364], ["which", 1370], ["is", 1376], ["particularly", 1379], ["suited", 1392], ["to", 1399], ["assessing", 1402], ["symptom", 1412], ["severity", 1420], [",", 1428], ["treatment", 1430], ["outcome", 1440], ["and", 1448], ["in", 1452], ["screening", 1455], ["for", 1465], ["the", 1469], ["likely", 1473], ["diagnosis", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "Alpha-synuclein is believed to play an important role in Parkinson's disease (PD). Mutations in the alpha-synuclein gene are responsible for familial forms of PD and alpha-synuclein protein is a major component of Lewy bodies in patients with sporadic PD. Synphilin-1 is a novel protein that we have previously found to associate in vivo with alpha-synuclein. We now show that synphilin-1 is present in Lewy bodies of patients with PD. Our data suggest that synphilin-1 could play a role in Lewy body formation and the pathogenesis of PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "69c3caa799bb4990932019ccbabd967e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[65, 67], [21, 23], [0, 2], [33, 35]], "char_spans": [[343, 357], [100, 114], [0, 14], [166, 180]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["believed", 19], ["to", 28], ["play", 31], ["an", 36], ["important", 39], ["role", 49], ["in", 54], ["Parkinson", 57], ["'s", 66], ["disease", 69], ["(", 77], ["PD", 78], [")", 80], [".", 81], ["Mutations", 83], ["in", 93], ["the", 96], ["alpha", 100], ["-", 105], ["synuclein", 106], ["gene", 116], ["are", 121], ["responsible", 125], ["for", 137], ["familial", 141], ["forms", 150], ["of", 156], ["PD", 159], ["and", 162], ["alpha", 166], ["-", 171], ["synuclein", 172], ["protein", 182], ["is", 190], ["a", 193], ["major", 195], ["component", 201], ["of", 211], ["Lewy", 214], ["bodies", 219], ["in", 226], ["patients", 229], ["with", 238], ["sporadic", 243], ["PD", 252], [".", 254], ["Synphilin-1", 256], ["is", 268], ["a", 271], ["novel", 273], ["protein", 279], ["that", 287], ["we", 292], ["have", 295], ["previously", 300], ["found", 311], ["to", 317], ["associate", 320], ["in", 330], ["vivo", 333], ["with", 338], ["alpha", 343], ["-", 348], ["synuclein", 349], [".", 358], ["We", 360], ["now", 363], ["show", 367], ["that", 372], ["synphilin-1", 377], ["is", 389], ["present", 392], ["in", 400], ["Lewy", 403], ["bodies", 408], ["of", 415], ["patients", 418], ["with", 427], ["PD", 432], [".", 434], ["Our", 436], ["data", 440], ["suggest", 445], ["that", 453], ["synphilin-1", 458], ["could", 470], ["play", 476], ["a", 481], ["role", 483], ["in", 488], ["Lewy", 491], ["body", 496], ["formation", 501], ["and", 511], ["the", 515], ["pathogenesis", 519], ["of", 532], ["PD", 535], [".", 537]]}
{"context": "Biological products have proven its high efficacy on autoimmune disease such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Meanwhile, small molecular drugs have attracted attention over the years because of its availability of oral administration and cost effectiveness. Spleen tyrosine kinase (Syk) is a 72 kDa protein tyrosine kinase widely expressed on cells that are involved in the immune system and inflammation such as B cells, T cells, macrophages and synovial fibroblast. Syk is involved in intracellular signaling of the multi-chain immune receptors, including B cell receptor (BCR), \u03b6chain of T-cell receptor (TCR), FcR and integrins, which contains the immune-receptor tyrosine-based activation motif (ITAM). Recently, Syk inhibitor fostamatinib has exerted potent therapeutic efficacy against autoimmune and allergic diseases such as rheumatoid arthritis (RA), bronchial asthma and thrombocytopenic purpura (ITP). Moreover, Syk blockade prevented the development of skin and kidney lesions in lupus-prone mice, however the mechanism of action is unclear. We have revealed that Syk-mediated BCR-signaling is prerequisite for optimal induction of toll-like receptor (TLR)-9, thereby allowing efficient propagation of CD40- and TLR9- signaling in human B cells. These results indicate that inhibition of Syk have a potential to regulate B-cell mediated inflammatory diseases such as SLE. We here document the in vitro and in vivo effects of a Syk inhibitor for the treatment of autoimmune diseases, mainly in RA and SLE.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "fc8abf2bd2b748b1b2b83f689571c1fa", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[47, 49]], "char_spans": [[294, 315]]}]}], "context_tokens": [["Biological", 0], ["products", 11], ["have", 20], ["proven", 25], ["its", 32], ["high", 36], ["efficacy", 41], ["on", 50], ["autoimmune", 53], ["disease", 64], ["such", 72], ["as", 77], ["rheumatoid", 80], ["arthritis", 91], ["(", 101], ["RA", 102], [")", 104], ["and", 106], ["systemic", 110], ["lupus", 119], ["erythematosus", 125], ["(", 139], ["SLE", 140], [")", 143], [".", 144], ["Meanwhile", 146], [",", 155], ["small", 157], ["molecular", 163], ["drugs", 173], ["have", 179], ["attracted", 184], ["attention", 194], ["over", 204], ["the", 209], ["years", 213], ["because", 219], ["of", 227], ["its", 230], ["availability", 234], ["of", 247], ["oral", 250], ["administration", 255], ["and", 270], ["cost", 274], ["effectiveness", 279], [".", 292], ["Spleen", 294], ["tyrosine", 301], ["kinase", 310], ["(", 317], ["Syk", 318], [")", 321], ["is", 323], ["a", 326], ["72", 328], ["kDa", 331], ["protein", 335], ["tyrosine", 343], ["kinase", 352], ["widely", 359], ["expressed", 366], ["on", 376], ["cells", 379], ["that", 385], ["are", 390], ["involved", 394], ["in", 403], ["the", 406], ["immune", 410], ["system", 417], ["and", 424], ["inflammation", 428], ["such", 441], ["as", 446], ["B", 449], ["cells", 451], [",", 456], ["T", 458], ["cells", 460], [",", 465], ["macrophages", 467], ["and", 479], ["synovial", 483], ["fibroblast", 492], [".", 502], ["Syk", 504], ["is", 508], ["involved", 511], ["in", 520], ["intracellular", 523], ["signaling", 537], ["of", 547], ["the", 550], ["multi", 554], ["-", 559], ["chain", 560], ["immune", 566], ["receptors", 573], [",", 582], ["including", 584], ["B", 594], ["cell", 596], ["receptor", 601], ["(", 610], ["BCR", 611], [")", 614], [",", 615], ["\u03b6chain", 617], ["of", 624], ["T", 627], ["-", 628], ["cell", 629], ["receptor", 634], ["(", 643], ["TCR", 644], [")", 647], [",", 648], ["FcR", 650], ["and", 654], ["integrins", 658], [",", 667], ["which", 669], ["contains", 675], ["the", 684], ["immune", 688], ["-", 694], ["receptor", 695], ["tyrosine", 704], ["-", 712], ["based", 713], ["activation", 719], ["motif", 730], ["(", 736], ["ITAM", 737], [")", 741], [".", 742], ["Recently", 744], [",", 752], ["Syk", 754], ["inhibitor", 758], ["fostamatinib", 768], ["has", 781], ["exerted", 785], ["potent", 793], ["therapeutic", 800], ["efficacy", 812], ["against", 821], ["autoimmune", 829], ["and", 840], ["allergic", 844], ["diseases", 853], ["such", 862], ["as", 867], ["rheumatoid", 870], ["arthritis", 881], ["(", 891], ["RA", 892], [")", 894], [",", 895], ["bronchial", 897], ["asthma", 907], ["and", 914], ["thrombocytopenic", 918], ["purpura", 935], ["(", 943], ["ITP", 944], [")", 947], [".", 948], ["Moreover", 950], [",", 958], ["Syk", 960], ["blockade", 964], ["prevented", 973], ["the", 983], ["development", 987], ["of", 999], ["skin", 1002], ["and", 1007], ["kidney", 1011], ["lesions", 1018], ["in", 1026], ["lupus", 1029], ["-", 1034], ["prone", 1035], ["mice", 1041], [",", 1045], ["however", 1047], ["the", 1055], ["mechanism", 1059], ["of", 1069], ["action", 1072], ["is", 1079], ["unclear", 1082], [".", 1089], ["We", 1091], ["have", 1094], ["revealed", 1099], ["that", 1108], ["Syk", 1113], ["-", 1116], ["mediated", 1117], ["BCR", 1126], ["-", 1129], ["signaling", 1130], ["is", 1140], ["prerequisite", 1143], ["for", 1156], ["optimal", 1160], ["induction", 1168], ["of", 1178], ["toll", 1181], ["-", 1185], ["like", 1186], ["receptor", 1191], ["(", 1200], ["TLR)-9", 1201], [",", 1207], ["thereby", 1209], ["allowing", 1217], ["efficient", 1226], ["propagation", 1236], ["of", 1248], ["CD40-", 1251], ["and", 1257], ["TLR9-", 1261], ["signaling", 1267], ["in", 1277], ["human", 1280], ["B", 1286], ["cells", 1288], [".", 1293], ["These", 1295], ["results", 1301], ["indicate", 1309], ["that", 1318], ["inhibition", 1323], ["of", 1334], ["Syk", 1337], ["have", 1341], ["a", 1346], ["potential", 1348], ["to", 1358], ["regulate", 1361], ["B", 1370], ["-", 1371], ["cell", 1372], ["mediated", 1377], ["inflammatory", 1386], ["diseases", 1399], ["such", 1408], ["as", 1413], ["SLE", 1416], [".", 1419], ["We", 1421], ["here", 1424], ["document", 1429], ["the", 1438], ["in", 1442], ["vitro", 1445], ["and", 1451], ["in", 1455], ["vivo", 1458], ["effects", 1463], ["of", 1471], ["a", 1474], ["Syk", 1476], ["inhibitor", 1480], ["for", 1490], ["the", 1494], ["treatment", 1498], ["of", 1508], ["autoimmune", 1511], ["diseases", 1522], [",", 1530], ["mainly", 1532], ["in", 1539], ["RA", 1542], ["and", 1545], ["SLE", 1549], [".", 1552]]}
{"context": "There are three major apolipoprotein E (apoE) isoforms. Although APOE-epsilon3 is considered a longevity gene, APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer disease. We have expressed full-length and N- and C-terminal truncated apoE3 and apoE4 tailored to eliminate helix and domain interactions to unveil structural and functional disturbances. The N-terminal truncated apoE4-(72-299) and C-terminal truncated apoE4-(1-231) showed more complicated or aggregated species than those of the corresponding apoE3 counterparts. This isoformic structural variation did not exist in the presence of dihexanoylphosphatidylcholine. The C-terminal truncated apoE-(1-191) and apoE-(1-231) proteins greatly lost lipid binding ability as illustrated by the dimyristoylphosphatidylcholine turbidity clearance. The low density lipoprotein (LDL) receptor binding ability, determined by a competition binding assay of 3H-LDL to the LDL receptor of HepG2 cells, showed that apoE4 proteins with N-terminal (apoE4-(72-299)), C-terminal (apoE4-(1-231)), or complete C-terminal truncation (apoE4-(1-191)) maintained greater receptor binding abilities than their apoE3 counterparts. The cholesterol-lowering abilities of apoE3-(72-299) and apoE3-(1-231) in apoE-deficient mice were decreased significantly. The structural preference of apoE4 to remain functional in solution may explain the enhanced opportunity of apoE4 isoform to display its pathophysiologic functions in atherosclerosis and Alzheimer disease.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "27c2cbb7582d45599f9b7c6674f08fc8", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[254, 255]], "char_spans": [[1415, 1427]]}]}], "context_tokens": [["There", 0], ["are", 6], ["three", 10], ["major", 16], ["apolipoprotein", 22], ["E", 37], ["(", 39], ["apoE", 40], [")", 44], ["isoforms", 46], [".", 54], ["Although", 56], ["APOE", 65], ["-", 69], ["epsilon3", 70], ["is", 79], ["considered", 82], ["a", 93], ["longevity", 95], ["gene", 105], [",", 109], ["APOE", 111], ["-", 115], ["epsilon4", 116], ["is", 125], ["a", 128], ["dual", 130], ["risk", 135], ["factor", 140], ["to", 147], ["atherosclerosis", 150], ["and", 166], ["Alzheimer", 170], ["disease", 180], [".", 187], ["We", 189], ["have", 192], ["expressed", 197], ["full", 207], ["-", 211], ["length", 212], ["and", 219], ["N-", 223], ["and", 226], ["C", 230], ["-", 231], ["terminal", 232], ["truncated", 241], ["apoE3", 251], ["and", 257], ["apoE4", 261], ["tailored", 267], ["to", 276], ["eliminate", 279], ["helix", 289], ["and", 295], ["domain", 299], ["interactions", 306], ["to", 319], ["unveil", 322], ["structural", 329], ["and", 340], ["functional", 344], ["disturbances", 355], [".", 367], ["The", 369], ["N", 373], ["-", 374], ["terminal", 375], ["truncated", 384], ["apoE4-(72", 394], ["-", 403], ["299", 404], [")", 407], ["and", 409], ["C", 413], ["-", 414], ["terminal", 415], ["truncated", 424], ["apoE4-(1", 434], ["-", 442], ["231", 443], [")", 446], ["showed", 448], ["more", 455], ["complicated", 460], ["or", 472], ["aggregated", 475], ["species", 486], ["than", 494], ["those", 499], ["of", 505], ["the", 508], ["corresponding", 512], ["apoE3", 526], ["counterparts", 532], [".", 544], ["This", 546], ["isoformic", 551], ["structural", 561], ["variation", 572], ["did", 582], ["not", 586], ["exist", 590], ["in", 596], ["the", 599], ["presence", 603], ["of", 612], ["dihexanoylphosphatidylcholine", 615], [".", 644], ["The", 646], ["C", 650], ["-", 651], ["terminal", 652], ["truncated", 661], ["apoE-(1", 671], ["-", 678], ["191", 679], [")", 682], ["and", 684], ["apoE-(1", 688], ["-", 695], ["231", 696], [")", 699], ["proteins", 701], ["greatly", 710], ["lost", 718], ["lipid", 723], ["binding", 729], ["ability", 737], ["as", 745], ["illustrated", 748], ["by", 760], ["the", 763], ["dimyristoylphosphatidylcholine", 767], ["turbidity", 798], ["clearance", 808], [".", 817], ["The", 819], ["low", 823], ["density", 827], ["lipoprotein", 835], ["(", 847], ["LDL", 848], [")", 851], ["receptor", 853], ["binding", 862], ["ability", 870], [",", 877], ["determined", 879], ["by", 890], ["a", 893], ["competition", 895], ["binding", 907], ["assay", 915], ["of", 921], ["3H", 924], ["-", 926], ["LDL", 927], ["to", 931], ["the", 934], ["LDL", 938], ["receptor", 942], ["of", 951], ["HepG2", 954], ["cells", 960], [",", 965], ["showed", 967], ["that", 974], ["apoE4", 979], ["proteins", 985], ["with", 994], ["N", 999], ["-", 1000], ["terminal", 1001], ["(", 1010], ["apoE4-(72", 1011], ["-", 1020], ["299", 1021], [")", 1024], [")", 1025], [",", 1026], ["C", 1028], ["-", 1029], ["terminal", 1030], ["(", 1039], ["apoE4-(1", 1040], ["-", 1048], ["231", 1049], [")", 1052], [")", 1053], [",", 1054], ["or", 1056], ["complete", 1059], ["C", 1068], ["-", 1069], ["terminal", 1070], ["truncation", 1079], ["(", 1090], ["apoE4-(1", 1091], ["-", 1099], ["191", 1100], [")", 1103], [")", 1104], ["maintained", 1106], ["greater", 1117], ["receptor", 1125], ["binding", 1134], ["abilities", 1142], ["than", 1152], ["their", 1157], ["apoE3", 1163], ["counterparts", 1169], [".", 1181], ["The", 1183], ["cholesterol", 1187], ["-", 1198], ["lowering", 1199], ["abilities", 1208], ["of", 1218], ["apoE3-(72", 1221], ["-", 1230], ["299", 1231], [")", 1234], ["and", 1236], ["apoE3-(1", 1240], ["-", 1248], ["231", 1249], [")", 1252], ["in", 1254], ["apoE", 1257], ["-", 1261], ["deficient", 1262], ["mice", 1272], ["were", 1277], ["decreased", 1282], ["significantly", 1292], [".", 1305], ["The", 1307], ["structural", 1311], ["preference", 1322], ["of", 1333], ["apoE4", 1336], ["to", 1342], ["remain", 1345], ["functional", 1352], ["in", 1363], ["solution", 1366], ["may", 1375], ["explain", 1379], ["the", 1387], ["enhanced", 1391], ["opportunity", 1400], ["of", 1412], ["apoE4", 1415], ["isoform", 1421], ["to", 1429], ["display", 1432], ["its", 1440], ["pathophysiologic", 1444], ["functions", 1461], ["in", 1471], ["atherosclerosis", 1474], ["and", 1490], ["Alzheimer", 1494], ["disease", 1504], [".", 1511]]}
{"context": "McLeod Syndrome (MLS) is a rare X-linked disorder characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. The McLeod blood group phenotype is typically associated with erythrocyte acanthocytosis, absence of the Kx antigen and reduced expression of Kell system antigens. MLS is caused by hemizygosity for mutations in the XK gene. We describe a patient with MLS who first showed symptoms in 1989 (aged 51 years). As the disease progressed, the patient developed a slight dementia, aggressive behaviour and choreatic movements. A cardiomyopathy was also diagnosed. An electroneuromyography showed neuropathic and myopathic changes. Liver enzymes were elevated and a blood smear showed acanthocytes. MLS was confirmed by serological analysis of the Kell antigens. Analysis of red blood cells by flow cytometry revealed the patient and his grandson to have reduced Kell antigen expression. The patient's daughters had two populations of red cells, consistent with them being heterozygous for an XK0 allele. The molecular basis of MLS in this family is a novel mutation consisting of a 7453-bp deletion that includes exon 2 of the XK gene. This confirms that the patient's 7-year-old grandson, who is currently asymptomatic, also has the XK0 allele and is therefore likely to develop MLS.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "abc48333075f4fbd8c6a3a5ac4b684a2", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[59, 59], [199, 199]], "char_spans": [[359, 360], [1164, 1165]]}]}], "context_tokens": [["McLeod", 0], ["Syndrome", 7], ["(", 16], ["MLS", 17], [")", 20], ["is", 22], ["a", 25], ["rare", 27], ["X", 32], ["-", 33], ["linked", 34], ["disorder", 41], ["characterized", 50], ["by", 64], ["haemopoietic", 67], ["abnormalities", 80], ["and", 94], ["late", 98], ["-", 102], ["onset", 103], ["neurological", 109], ["and", 122], ["muscular", 126], ["defects", 135], [".", 142], ["The", 144], ["McLeod", 148], ["blood", 155], ["group", 161], ["phenotype", 167], ["is", 177], ["typically", 180], ["associated", 190], ["with", 201], ["erythrocyte", 206], ["acanthocytosis", 218], [",", 232], ["absence", 234], ["of", 242], ["the", 245], ["Kx", 249], ["antigen", 252], ["and", 260], ["reduced", 264], ["expression", 272], ["of", 283], ["Kell", 286], ["system", 291], ["antigens", 298], [".", 306], ["MLS", 308], ["is", 312], ["caused", 315], ["by", 322], ["hemizygosity", 325], ["for", 338], ["mutations", 342], ["in", 352], ["the", 355], ["XK", 359], ["gene", 362], [".", 366], ["We", 368], ["describe", 371], ["a", 380], ["patient", 382], ["with", 390], ["MLS", 395], ["who", 399], ["first", 403], ["showed", 409], ["symptoms", 416], ["in", 425], ["1989", 428], ["(", 433], ["aged", 434], ["51", 439], ["years", 442], [")", 447], [".", 448], ["As", 450], ["the", 453], ["disease", 457], ["progressed", 465], [",", 475], ["the", 477], ["patient", 481], ["developed", 489], ["a", 499], ["slight", 501], ["dementia", 508], [",", 516], ["aggressive", 518], ["behaviour", 529], ["and", 539], ["choreatic", 543], ["movements", 553], [".", 562], ["A", 564], ["cardiomyopathy", 566], ["was", 581], ["also", 585], ["diagnosed", 590], [".", 599], ["An", 601], ["electroneuromyography", 604], ["showed", 626], ["neuropathic", 633], ["and", 645], ["myopathic", 649], ["changes", 659], [".", 666], ["Liver", 668], ["enzymes", 674], ["were", 682], ["elevated", 687], ["and", 696], ["a", 700], ["blood", 702], ["smear", 708], ["showed", 714], ["acanthocytes", 721], [".", 733], ["MLS", 735], ["was", 739], ["confirmed", 743], ["by", 753], ["serological", 756], ["analysis", 768], ["of", 777], ["the", 780], ["Kell", 784], ["antigens", 789], [".", 797], ["Analysis", 799], ["of", 808], ["red", 811], ["blood", 815], ["cells", 821], ["by", 827], ["flow", 830], ["cytometry", 835], ["revealed", 845], ["the", 854], ["patient", 858], ["and", 866], ["his", 870], ["grandson", 874], ["to", 883], ["have", 886], ["reduced", 891], ["Kell", 899], ["antigen", 904], ["expression", 912], [".", 922], ["The", 924], ["patient", 928], ["'s", 935], ["daughters", 938], ["had", 948], ["two", 952], ["populations", 956], ["of", 968], ["red", 971], ["cells", 975], [",", 980], ["consistent", 982], ["with", 993], ["them", 998], ["being", 1003], ["heterozygous", 1009], ["for", 1022], ["an", 1026], ["XK0", 1029], ["allele", 1033], [".", 1039], ["The", 1041], ["molecular", 1045], ["basis", 1055], ["of", 1061], ["MLS", 1064], ["in", 1068], ["this", 1071], ["family", 1076], ["is", 1083], ["a", 1086], ["novel", 1088], ["mutation", 1094], ["consisting", 1103], ["of", 1114], ["a", 1117], ["7453-bp", 1119], ["deletion", 1127], ["that", 1136], ["includes", 1141], ["exon", 1150], ["2", 1155], ["of", 1157], ["the", 1160], ["XK", 1164], ["gene", 1167], [".", 1171], ["This", 1173], ["confirms", 1178], ["that", 1187], ["the", 1192], ["patient", 1196], ["'s", 1203], ["7-year", 1206], ["-", 1212], ["old", 1213], ["grandson", 1217], [",", 1225], ["who", 1227], ["is", 1231], ["currently", 1234], ["asymptomatic", 1244], [",", 1256], ["also", 1258], ["has", 1263], ["the", 1267], ["XK0", 1271], ["allele", 1275], ["and", 1282], ["is", 1286], ["therefore", 1289], ["likely", 1299], ["to", 1306], ["develop", 1309], ["MLS", 1317], [".", 1320]]}
{"context": "Lysyl oxidase-like 2 (LOXL2) catalyses collagen cross-linking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF. In this randomised, double-blind, phase 2 trial, we recruited patients aged 45-85 years with definite IPF diagnosed prior to 3 years of screening from 183 hospitals and respiratory clinics in 14 countries. Eligible patients, stratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concentrations, and pirfenidone and nintedanib use, were randomly assigned (1:1) to inject 125 mg/mL simtuzumab or placebo subcutaneously once a week. The primary endpoints were progression-free survival, defined as time to all-cause death or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, in patients with sLOXL2 concentrations in the 50th percentile or higher, and in patients with sLOXL2 concentrations in the 75th percentile or higher. Treatment duration was event-driven, and interim analyses were planned and conducted after approximately 120 and 200 progression-free survival events, respectively, occurred. We compared treatment groups with the stratified log-rank test. This study is registered with ClinicalTrials.gov, number NCT01769196. Patients with IPF were recruited between Jan 31, 2013, and June 1, 2015. The intention-to-treat population included 544 randomly assigned patients (272 patients in both groups), and the safety population included 543 randomly assigned patients who received at least one dose of study medication. The study was terminated when the second interim analysis met the prespecified futility stopping criteria in the intention-to-treat population. We noted no difference in progression-free survival between simtuzumab and placebo in the intention-to-treat population (median progression free survival times of 12\u00b76 months and 15\u00b74 months for simtuzumab and placebo, respectively; stratified HR 1\u00b713, 95% CI 0\u00b788-1\u00b745; p=0\u00b7329) and in patients with baseline sLOXL2 in the 50th percentile or higher (median progression-free survival 11\u00b77 months and 14\u00b73 months for simtuzumab and placebo, respectively; stratified HR 1\u00b703, 95% CI 0\u00b774-1\u00b743; p=0\u00b7851), or in the 75th percentile or higher (median progression-free survival 11\u00b76 months and 16\u00b79 months for simtuzumab and placebo, respectively; stratified HR 1\u00b720, 95% CI 0\u00b772-2\u00b700; p=0\u00b7475). The incidence of adverse events and serious adverse events was similar between treatment groups. The most common adverse events in both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and the most common grade 3 or 4 adverse events were worsening of IPF, dyspnoea, and pneumonia. Simtuzumab did not improve progression-free survival in a well-defined population of patients with IPF. Our data do not support the use of simtuzumab for patients with IPF. Gilead Sciences Inc.", "qas": [{"question": "What is the drug target for Simtuzumab?", "answers": ["LOXL2"], "qid": "b15e8d06f5fd489fabcc01ff6245e692", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["drug", 12], ["target", 17], ["for", 24], ["Simtuzumab", 28], ["?", 38]], "detected_answers": [{"text": "LOXL2", "token_spans": [[107, 107], [46, 46], [6, 6]], "char_spans": [[562, 566], [250, 254], [22, 26]]}]}], "context_tokens": [["Lysyl", 0], ["oxidase", 6], ["-", 13], ["like", 14], ["2", 19], ["(", 21], ["LOXL2", 22], [")", 27], ["catalyses", 29], ["collagen", 39], ["cross", 48], ["-", 53], ["linking", 54], ["and", 62], ["is", 66], ["implicated", 69], ["in", 80], ["the", 83], ["pathogenesis", 87], ["of", 100], ["idiopathic", 103], ["pulmonary", 114], ["fibrosis", 124], ["(", 133], ["IPF", 134], [")", 137], [".", 138], ["The", 140], ["aim", 144], ["of", 148], ["this", 151], ["study", 156], ["was", 162], ["to", 166], ["investigate", 169], ["the", 181], ["efficacy", 185], ["and", 194], ["safety", 198], ["of", 205], ["simtuzumab", 208], [",", 218], ["a", 220], ["monoclonal", 222], ["antibody", 233], ["against", 242], ["LOXL2", 250], [",", 255], ["in", 257], ["patients", 260], ["with", 269], ["IPF", 274], [".", 277], ["In", 279], ["this", 282], ["randomised", 287], [",", 297], ["double", 299], ["-", 305], ["blind", 306], [",", 311], ["phase", 313], ["2", 319], ["trial", 321], [",", 326], ["we", 328], ["recruited", 331], ["patients", 341], ["aged", 350], ["45", 355], ["-", 357], ["85", 358], ["years", 361], ["with", 367], ["definite", 372], ["IPF", 381], ["diagnosed", 385], ["prior", 395], ["to", 401], ["3", 404], ["years", 406], ["of", 412], ["screening", 415], ["from", 425], ["183", 430], ["hospitals", 434], ["and", 444], ["respiratory", 448], ["clinics", 460], ["in", 468], ["14", 471], ["countries", 474], [".", 483], ["Eligible", 485], ["patients", 494], [",", 502], ["stratified", 504], ["by", 515], ["baseline", 518], ["forced", 527], ["vital", 534], ["capacity", 540], ["(", 549], ["FVC", 550], [")", 553], [",", 554], ["serum", 556], ["LOXL2", 562], ["(", 568], ["sLOXL2", 569], [")", 575], ["concentrations", 577], [",", 591], ["and", 593], ["pirfenidone", 597], ["and", 609], ["nintedanib", 613], ["use", 624], [",", 627], ["were", 629], ["randomly", 634], ["assigned", 643], ["(", 652], ["1:1", 653], [")", 656], ["to", 658], ["inject", 661], ["125", 668], ["mg", 672], ["/", 674], ["mL", 675], ["simtuzumab", 678], ["or", 689], ["placebo", 692], ["subcutaneously", 700], ["once", 715], ["a", 720], ["week", 722], [".", 726], ["The", 728], ["primary", 732], ["endpoints", 740], ["were", 750], ["progression", 755], ["-", 766], ["free", 767], ["survival", 772], [",", 780], ["defined", 782], ["as", 790], ["time", 793], ["to", 798], ["all", 801], ["-", 804], ["cause", 805], ["death", 811], ["or", 817], ["a", 820], ["categorical", 822], ["decrease", 834], ["from", 843], ["baseline", 848], ["in", 857], ["FVC", 860], ["%", 864], ["predicted", 866], [",", 875], ["in", 877], ["the", 880], ["intention", 884], ["-", 893], ["to", 894], ["-", 896], ["treat", 897], ["population", 903], [",", 913], ["in", 915], ["patients", 918], ["with", 927], ["sLOXL2", 932], ["concentrations", 939], ["in", 954], ["the", 957], ["50th", 961], ["percentile", 966], ["or", 977], ["higher", 980], [",", 986], ["and", 988], ["in", 992], ["patients", 995], ["with", 1004], ["sLOXL2", 1009], ["concentrations", 1016], ["in", 1031], ["the", 1034], ["75th", 1038], ["percentile", 1043], ["or", 1054], ["higher", 1057], [".", 1063], ["Treatment", 1065], ["duration", 1075], ["was", 1084], ["event", 1088], ["-", 1093], ["driven", 1094], [",", 1100], ["and", 1102], ["interim", 1106], ["analyses", 1114], ["were", 1123], ["planned", 1128], ["and", 1136], ["conducted", 1140], ["after", 1150], ["approximately", 1156], ["120", 1170], ["and", 1174], ["200", 1178], ["progression", 1182], ["-", 1193], ["free", 1194], ["survival", 1199], ["events", 1208], [",", 1214], ["respectively", 1216], [",", 1228], ["occurred", 1230], [".", 1238], ["We", 1240], ["compared", 1243], ["treatment", 1252], ["groups", 1262], ["with", 1269], ["the", 1274], ["stratified", 1278], ["log", 1289], ["-", 1292], ["rank", 1293], ["test", 1298], [".", 1302], ["This", 1304], ["study", 1309], ["is", 1315], ["registered", 1318], ["with", 1329], ["ClinicalTrials.gov", 1334], [",", 1352], ["number", 1354], ["NCT01769196", 1361], [".", 1372], ["Patients", 1374], ["with", 1383], ["IPF", 1388], ["were", 1392], ["recruited", 1397], ["between", 1407], ["Jan", 1415], ["31", 1419], [",", 1421], ["2013", 1423], [",", 1427], ["and", 1429], ["June", 1433], ["1", 1438], [",", 1439], ["2015", 1441], [".", 1445], ["The", 1447], ["intention", 1451], ["-", 1460], ["to", 1461], ["-", 1463], ["treat", 1464], ["population", 1470], ["included", 1481], ["544", 1490], ["randomly", 1494], ["assigned", 1503], ["patients", 1512], ["(", 1521], ["272", 1522], ["patients", 1526], ["in", 1535], ["both", 1538], ["groups", 1543], [")", 1549], [",", 1550], ["and", 1552], ["the", 1556], ["safety", 1560], ["population", 1567], ["included", 1578], ["543", 1587], ["randomly", 1591], ["assigned", 1600], ["patients", 1609], ["who", 1618], ["received", 1622], ["at", 1631], ["least", 1634], ["one", 1640], ["dose", 1644], ["of", 1649], ["study", 1652], ["medication", 1658], [".", 1668], ["The", 1670], ["study", 1674], ["was", 1680], ["terminated", 1684], ["when", 1695], ["the", 1700], ["second", 1704], ["interim", 1711], ["analysis", 1719], ["met", 1728], ["the", 1732], ["prespecified", 1736], ["futility", 1749], ["stopping", 1758], ["criteria", 1767], ["in", 1776], ["the", 1779], ["intention", 1783], ["-", 1792], ["to", 1793], ["-", 1795], ["treat", 1796], ["population", 1802], [".", 1812], ["We", 1814], ["noted", 1817], ["no", 1823], ["difference", 1826], ["in", 1837], ["progression", 1840], ["-", 1851], ["free", 1852], ["survival", 1857], ["between", 1866], ["simtuzumab", 1874], ["and", 1885], ["placebo", 1889], ["in", 1897], ["the", 1900], ["intention", 1904], ["-", 1913], ["to", 1914], ["-", 1916], ["treat", 1917], ["population", 1923], ["(", 1934], ["median", 1935], ["progression", 1942], ["free", 1954], ["survival", 1959], ["times", 1968], ["of", 1974], ["12\u00b76", 1977], ["months", 1982], ["and", 1989], ["15\u00b74", 1993], ["months", 1998], ["for", 2005], ["simtuzumab", 2009], ["and", 2020], ["placebo", 2024], [",", 2031], ["respectively", 2033], [";", 2045], ["stratified", 2047], ["HR", 2058], ["1\u00b713", 2061], [",", 2065], ["95", 2067], ["%", 2069], ["CI", 2071], ["0\u00b788", 2074], ["-", 2078], ["1\u00b745", 2079], [";", 2083], ["p=0\u00b7329", 2085], [")", 2092], ["and", 2094], ["in", 2098], ["patients", 2101], ["with", 2110], ["baseline", 2115], ["sLOXL2", 2124], ["in", 2131], ["the", 2134], ["50th", 2138], ["percentile", 2143], ["or", 2154], ["higher", 2157], ["(", 2164], ["median", 2165], ["progression", 2172], ["-", 2183], ["free", 2184], ["survival", 2189], ["11\u00b77", 2198], ["months", 2203], ["and", 2210], ["14\u00b73", 2214], ["months", 2219], ["for", 2226], ["simtuzumab", 2230], ["and", 2241], ["placebo", 2245], [",", 2252], ["respectively", 2254], [";", 2266], ["stratified", 2268], ["HR", 2279], ["1\u00b703", 2282], [",", 2286], ["95", 2288], ["%", 2290], ["CI", 2292], ["0\u00b774", 2295], ["-", 2299], ["1\u00b743", 2300], [";", 2304], ["p=0\u00b7851", 2306], [")", 2313], [",", 2314], ["or", 2316], ["in", 2319], ["the", 2322], ["75th", 2326], ["percentile", 2331], ["or", 2342], ["higher", 2345], ["(", 2352], ["median", 2353], ["progression", 2360], ["-", 2371], ["free", 2372], ["survival", 2377], ["11\u00b76", 2386], ["months", 2391], ["and", 2398], ["16\u00b79", 2402], ["months", 2407], ["for", 2414], ["simtuzumab", 2418], ["and", 2429], ["placebo", 2433], [",", 2440], ["respectively", 2442], [";", 2454], ["stratified", 2456], ["HR", 2467], ["1\u00b720", 2470], [",", 2474], ["95", 2476], ["%", 2478], ["CI", 2480], ["0\u00b772", 2483], ["-", 2487], ["2\u00b700", 2488], [";", 2492], ["p=0\u00b7475", 2494], [")", 2501], [".", 2502], ["The", 2504], ["incidence", 2508], ["of", 2518], ["adverse", 2521], ["events", 2529], ["and", 2536], ["serious", 2540], ["adverse", 2548], ["events", 2556], ["was", 2563], ["similar", 2567], ["between", 2575], ["treatment", 2583], ["groups", 2593], [".", 2599], ["The", 2601], ["most", 2605], ["common", 2610], ["adverse", 2617], ["events", 2625], ["in", 2632], ["both", 2635], ["the", 2640], ["simtuzumab", 2644], ["and", 2655], ["placebo", 2659], ["groups", 2667], ["were", 2674], ["dyspnoea", 2679], [",", 2687], ["cough", 2689], [",", 2694], ["upper", 2696], ["respiratory", 2702], ["tract", 2714], ["infection", 2720], [",", 2729], ["and", 2731], ["worsening", 2735], ["of", 2745], ["IPF", 2748], [";", 2751], ["and", 2753], ["the", 2757], ["most", 2761], ["common", 2766], ["grade", 2773], ["3", 2779], ["or", 2781], ["4", 2784], ["adverse", 2786], ["events", 2794], ["were", 2801], ["worsening", 2806], ["of", 2816], ["IPF", 2819], [",", 2822], ["dyspnoea", 2824], [",", 2832], ["and", 2834], ["pneumonia", 2838], [".", 2847], ["Simtuzumab", 2849], ["did", 2860], ["not", 2864], ["improve", 2868], ["progression", 2876], ["-", 2887], ["free", 2888], ["survival", 2893], ["in", 2902], ["a", 2905], ["well", 2907], ["-", 2911], ["defined", 2912], ["population", 2920], ["of", 2931], ["patients", 2934], ["with", 2943], ["IPF", 2948], [".", 2951], ["Our", 2953], ["data", 2957], ["do", 2962], ["not", 2965], ["support", 2969], ["the", 2977], ["use", 2981], ["of", 2985], ["simtuzumab", 2988], ["for", 2999], ["patients", 3003], ["with", 3012], ["IPF", 3017], [".", 3020], ["Gilead", 3022], ["Sciences", 3029], ["Inc.", 3038]]}
{"context": "Disturbance of intracellular trafficking plays a major role in several neurodegenerative disorders including Alzheimer or Parkinson's disease. The Chediak-Higashi syndrome (CHS), a life-threatening autosomal recessive disease with frequent mutations in the LYST gene, and its animal model, the beige mouse, are both characterized by lysosomal defects with accumulation of giant lysosomes. Clinically they manifest as hypopigmentation, abnormal bleeding and increased susceptibility to infection with various degrees of involvement of the nervous system. In the course of a recessive N-ethyl-N-nitrosurea (ENU) mutagenesis screen, we identified the first murine missense mutation in the lysosomal trafficking regulator gene (Lyst(Ing3618)) located at a highly conserved position in the WD40 protein domain. Nearly all described human Lyst alleles lead to protein truncation and fatal childhood CHS. Only four different missense mutations have been reported in patients with adolescent or adult forms of CHS involving the nervous system. Interestingly, the Lyst(Ing3618) model presents with a predominant neurodegenerative phenotype with progressive degeneration and loss of Purkinje cells and lacks severe impairment of the immune system. Therefore, the Lyst(Ing3618 )allele could represent a new model for adult CHS with neurological impairment. It could also provide an important tool to elucidate the role of neuronal lysosomal trafficking in the pathophysiology of neurodegeneration.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "d6994d74aee440879b8c68ca849fa9db", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[20, 23]], "char_spans": [[147, 170]]}]}], "context_tokens": [["Disturbance", 0], ["of", 12], ["intracellular", 15], ["trafficking", 29], ["plays", 41], ["a", 47], ["major", 49], ["role", 55], ["in", 60], ["several", 63], ["neurodegenerative", 71], ["disorders", 89], ["including", 99], ["Alzheimer", 109], ["or", 119], ["Parkinson", 122], ["'s", 131], ["disease", 134], [".", 141], ["The", 143], ["Chediak", 147], ["-", 154], ["Higashi", 155], ["syndrome", 163], ["(", 172], ["CHS", 173], [")", 176], [",", 177], ["a", 179], ["life", 181], ["-", 185], ["threatening", 186], ["autosomal", 198], ["recessive", 208], ["disease", 218], ["with", 226], ["frequent", 231], ["mutations", 240], ["in", 250], ["the", 253], ["LYST", 257], ["gene", 262], [",", 266], ["and", 268], ["its", 272], ["animal", 276], ["model", 283], [",", 288], ["the", 290], ["beige", 294], ["mouse", 300], [",", 305], ["are", 307], ["both", 311], ["characterized", 316], ["by", 330], ["lysosomal", 333], ["defects", 343], ["with", 351], ["accumulation", 356], ["of", 369], ["giant", 372], ["lysosomes", 378], [".", 387], ["Clinically", 389], ["they", 400], ["manifest", 405], ["as", 414], ["hypopigmentation", 417], [",", 433], ["abnormal", 435], ["bleeding", 444], ["and", 453], ["increased", 457], ["susceptibility", 467], ["to", 482], ["infection", 485], ["with", 495], ["various", 500], ["degrees", 508], ["of", 516], ["involvement", 519], ["of", 531], ["the", 534], ["nervous", 538], ["system", 546], [".", 552], ["In", 554], ["the", 557], ["course", 561], ["of", 568], ["a", 571], ["recessive", 573], ["N", 583], ["-", 584], ["ethyl", 585], ["-", 590], ["N", 591], ["-", 592], ["nitrosurea", 593], ["(", 604], ["ENU", 605], [")", 608], ["mutagenesis", 610], ["screen", 622], [",", 628], ["we", 630], ["identified", 633], ["the", 644], ["first", 648], ["murine", 654], ["missense", 661], ["mutation", 670], ["in", 679], ["the", 682], ["lysosomal", 686], ["trafficking", 696], ["regulator", 708], ["gene", 718], ["(", 723], ["Lyst(Ing3618", 724], [")", 736], [")", 737], ["located", 739], ["at", 747], ["a", 750], ["highly", 752], ["conserved", 759], ["position", 769], ["in", 778], ["the", 781], ["WD40", 785], ["protein", 790], ["domain", 798], [".", 804], ["Nearly", 806], ["all", 813], ["described", 817], ["human", 827], ["Lyst", 833], ["alleles", 838], ["lead", 846], ["to", 851], ["protein", 854], ["truncation", 862], ["and", 873], ["fatal", 877], ["childhood", 883], ["CHS", 893], [".", 896], ["Only", 898], ["four", 903], ["different", 908], ["missense", 918], ["mutations", 927], ["have", 937], ["been", 942], ["reported", 947], ["in", 956], ["patients", 959], ["with", 968], ["adolescent", 973], ["or", 984], ["adult", 987], ["forms", 993], ["of", 999], ["CHS", 1002], ["involving", 1006], ["the", 1016], ["nervous", 1020], ["system", 1028], [".", 1034], ["Interestingly", 1036], [",", 1049], ["the", 1051], ["Lyst(Ing3618", 1055], [")", 1067], ["model", 1069], ["presents", 1075], ["with", 1084], ["a", 1089], ["predominant", 1091], ["neurodegenerative", 1103], ["phenotype", 1121], ["with", 1131], ["progressive", 1136], ["degeneration", 1148], ["and", 1161], ["loss", 1165], ["of", 1170], ["Purkinje", 1173], ["cells", 1182], ["and", 1188], ["lacks", 1192], ["severe", 1198], ["impairment", 1205], ["of", 1216], ["the", 1219], ["immune", 1223], ["system", 1230], [".", 1236], ["Therefore", 1238], [",", 1247], ["the", 1249], ["Lyst(Ing3618", 1253], [")", 1266], ["allele", 1267], ["could", 1274], ["represent", 1280], ["a", 1290], ["new", 1292], ["model", 1296], ["for", 1302], ["adult", 1306], ["CHS", 1312], ["with", 1316], ["neurological", 1321], ["impairment", 1334], [".", 1344], ["It", 1346], ["could", 1349], ["also", 1355], ["provide", 1360], ["an", 1368], ["important", 1371], ["tool", 1381], ["to", 1386], ["elucidate", 1389], ["the", 1399], ["role", 1403], ["of", 1408], ["neuronal", 1411], ["lysosomal", 1420], ["trafficking", 1430], ["in", 1442], ["the", 1445], ["pathophysiology", 1449], ["of", 1465], ["neurodegeneration", 1468], [".", 1485]]}
{"context": "Despite ongoing efforts to decipher the cancer genome, discoveries of new targetable genetic lesions within cancer cells are rare. Therefore, alternative approaches are needed. Signals from the microenvironment are increasingly recognized as drivers of disease progression in hematologic and solid cancers. Consequently, there is growing interest in targeting the tumor-microenvironment cross-talk. This review highlights recent therapeutic advances in targeting the microenvironment in chronic lymphocytic leukemia (CLL). CLL is the poster child for microenvironment-dependent malignancies, because the clonal CLL B cells are highly dependent on external signals for maintenance and expansion. These pathways recapitulate those responsible for normal B-cell expansion in germinal centers. The most prominent, conserved mechanism is B-cell receptor (BCR) signaling, which promotes CLL cell survival and expansion in lymphatic tissue areas designated proliferation centers. BCR signaling now can be targeted by new targeted kinase inhibitors. Small molecule inhibitors of BCR signaling kinases, Bruton's tyrosine kinase (Btk) inhibitor ibrutinib and the phosphoinositide 3'-kinase delta (PI3K\u03b4) inhibitor GS-1101, are currently transforming the landscape of CLL therapy. This development exemplifies that the microenvironment has become a lively successful area of translational research.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "6999c77ec9e74a558797ede82bccb01b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[182, 182]], "char_spans": [[1135, 1143]]}]}], "context_tokens": [["Despite", 0], ["ongoing", 8], ["efforts", 16], ["to", 24], ["decipher", 27], ["the", 36], ["cancer", 40], ["genome", 47], [",", 53], ["discoveries", 55], ["of", 67], ["new", 70], ["targetable", 74], ["genetic", 85], ["lesions", 93], ["within", 101], ["cancer", 108], ["cells", 115], ["are", 121], ["rare", 125], [".", 129], ["Therefore", 131], [",", 140], ["alternative", 142], ["approaches", 154], ["are", 165], ["needed", 169], [".", 175], ["Signals", 177], ["from", 185], ["the", 190], ["microenvironment", 194], ["are", 211], ["increasingly", 215], ["recognized", 228], ["as", 239], ["drivers", 242], ["of", 250], ["disease", 253], ["progression", 261], ["in", 273], ["hematologic", 276], ["and", 288], ["solid", 292], ["cancers", 298], [".", 305], ["Consequently", 307], [",", 319], ["there", 321], ["is", 327], ["growing", 330], ["interest", 338], ["in", 347], ["targeting", 350], ["the", 360], ["tumor", 364], ["-", 369], ["microenvironment", 370], ["cross", 387], ["-", 392], ["talk", 393], [".", 397], ["This", 399], ["review", 404], ["highlights", 411], ["recent", 422], ["therapeutic", 429], ["advances", 441], ["in", 450], ["targeting", 453], ["the", 463], ["microenvironment", 467], ["in", 484], ["chronic", 487], ["lymphocytic", 495], ["leukemia", 507], ["(", 516], ["CLL", 517], [")", 520], [".", 521], ["CLL", 523], ["is", 527], ["the", 530], ["poster", 534], ["child", 541], ["for", 547], ["microenvironment", 551], ["-", 567], ["dependent", 568], ["malignancies", 578], [",", 590], ["because", 592], ["the", 600], ["clonal", 604], ["CLL", 611], ["B", 615], ["cells", 617], ["are", 623], ["highly", 627], ["dependent", 634], ["on", 644], ["external", 647], ["signals", 656], ["for", 664], ["maintenance", 668], ["and", 680], ["expansion", 684], [".", 693], ["These", 695], ["pathways", 701], ["recapitulate", 710], ["those", 723], ["responsible", 729], ["for", 741], ["normal", 745], ["B", 752], ["-", 753], ["cell", 754], ["expansion", 759], ["in", 769], ["germinal", 772], ["centers", 781], [".", 788], ["The", 790], ["most", 794], ["prominent", 799], [",", 808], ["conserved", 810], ["mechanism", 820], ["is", 830], ["B", 833], ["-", 834], ["cell", 835], ["receptor", 840], ["(", 849], ["BCR", 850], [")", 853], ["signaling", 855], [",", 864], ["which", 866], ["promotes", 872], ["CLL", 881], ["cell", 885], ["survival", 890], ["and", 899], ["expansion", 903], ["in", 913], ["lymphatic", 916], ["tissue", 926], ["areas", 933], ["designated", 939], ["proliferation", 950], ["centers", 964], [".", 971], ["BCR", 973], ["signaling", 977], ["now", 987], ["can", 991], ["be", 995], ["targeted", 998], ["by", 1007], ["new", 1010], ["targeted", 1014], ["kinase", 1023], ["inhibitors", 1030], [".", 1040], ["Small", 1042], ["molecule", 1048], ["inhibitors", 1057], ["of", 1068], ["BCR", 1071], ["signaling", 1075], ["kinases", 1085], [",", 1092], ["Bruton", 1094], ["'s", 1100], ["tyrosine", 1103], ["kinase", 1112], ["(", 1119], ["Btk", 1120], [")", 1123], ["inhibitor", 1125], ["ibrutinib", 1135], ["and", 1145], ["the", 1149], ["phosphoinositide", 1153], ["3'-kinase", 1170], ["delta", 1180], ["(", 1186], ["PI3K\u03b4", 1187], [")", 1192], ["inhibitor", 1194], ["GS-1101", 1204], [",", 1211], ["are", 1213], ["currently", 1217], ["transforming", 1227], ["the", 1240], ["landscape", 1244], ["of", 1254], ["CLL", 1257], ["therapy", 1261], [".", 1268], ["This", 1270], ["development", 1275], ["exemplifies", 1287], ["that", 1299], ["the", 1304], ["microenvironment", 1308], ["has", 1325], ["become", 1329], ["a", 1336], ["lively", 1338], ["successful", 1345], ["area", 1356], ["of", 1361], ["translational", 1364], ["research", 1378], [".", 1386]]}
{"context": "In a phase I study, Gilead Sciences' PI3K-\u03b4 inhibitor idelalisib produced rapid tumor shrinkage-a response that lasted for 17 months on average-in about half of the 54 patients with chronic lymphocytic leukemia who participated.", "qas": [{"question": "What is the target protein of the drug Idelalisib?", "answers": ["PI3K-\u03b4", "phosphoinositol-3 kinase delta isoform"], "qid": "9369385dfdc54cd5b5310b9caa60fb49", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["protein", 19], ["of", 27], ["the", 30], ["drug", 34], ["Idelalisib", 39], ["?", 49]], "detected_answers": [{"text": "PI3K-\u03b4", "token_spans": [[9, 11]], "char_spans": [[37, 42]]}]}], "context_tokens": [["In", 0], ["a", 3], ["phase", 5], ["I", 11], ["study", 13], [",", 18], ["Gilead", 20], ["Sciences", 27], ["'", 35], ["PI3K", 37], ["-", 41], ["\u03b4", 42], ["inhibitor", 44], ["idelalisib", 54], ["produced", 65], ["rapid", 74], ["tumor", 80], ["shrinkage", 86], ["-", 95], ["a", 96], ["response", 98], ["that", 107], ["lasted", 112], ["for", 119], ["17", 123], ["months", 126], ["on", 133], ["average", 136], ["-", 143], ["in", 144], ["about", 147], ["half", 153], ["of", 158], ["the", 161], ["54", 165], ["patients", 168], ["with", 177], ["chronic", 182], ["lymphocytic", 190], ["leukemia", 202], ["who", 211], ["participated", 215], [".", 227]]}
{"context": "The positive regulatory machinery in the microRNA (miRNA) processing pathway is relatively well characterized, but negative regulation of the pathway is largely unknown. Here we show that a complex of nuclear factor 90 (NF90) and NF45 proteins functions as a negative regulator in miRNA biogenesis. Primary miRNA (pri-miRNA) processing into precursor miRNA (pre-miRNA) was inhibited by overexpression of the NF90 and NF45 proteins, and considerable amounts of pri-miRNAs accumulated in cells coexpressing NF90 and NF45. Treatment of cells overexpressing NF90 and NF45 with an RNA polymerase II inhibitor, alpha-amanitin, did not reduce the amounts of pri-miRNAs, suggesting that the accumulation of pri-miRNAs is not due to transcriptional activation. In addition, the NF90 and NF45 complex was not found to interact with the Microprocessor complex, which is a processing factor of pri-miRNAs, but was found to bind endogenous pri-miRNAs. NF90-NF45 exhibited higher binding activity for pri-let-7a than pri-miR-21. Of note, depletion of NF90 caused a reduction of pri-let-7a and an increase of mature let-7a miRNA, which has a potent antiproliferative activity, and caused growth suppression of transformed cells. These findings suggest that the association of the NF90-NF45 complex with pri-miRNAs impairs access of the Microprocessor complex to the pri-miRNAs, resulting in a reduction of mature miRNA production.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "8e8bc2fb6f4f494c94d828de7c279203", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[103, 105]], "char_spans": [[576, 592]]}]}], "context_tokens": [["The", 0], ["positive", 4], ["regulatory", 13], ["machinery", 24], ["in", 34], ["the", 37], ["microRNA", 41], ["(", 50], ["miRNA", 51], [")", 56], ["processing", 58], ["pathway", 69], ["is", 77], ["relatively", 80], ["well", 91], ["characterized", 96], [",", 109], ["but", 111], ["negative", 115], ["regulation", 124], ["of", 135], ["the", 138], ["pathway", 142], ["is", 150], ["largely", 153], ["unknown", 161], [".", 168], ["Here", 170], ["we", 175], ["show", 178], ["that", 183], ["a", 188], ["complex", 190], ["of", 198], ["nuclear", 201], ["factor", 209], ["90", 216], ["(", 219], ["NF90", 220], [")", 224], ["and", 226], ["NF45", 230], ["proteins", 235], ["functions", 244], ["as", 254], ["a", 257], ["negative", 259], ["regulator", 268], ["in", 278], ["miRNA", 281], ["biogenesis", 287], [".", 297], ["Primary", 299], ["miRNA", 307], ["(", 313], ["pri", 314], ["-", 317], ["miRNA", 318], [")", 323], ["processing", 325], ["into", 336], ["precursor", 341], ["miRNA", 351], ["(", 357], ["pre", 358], ["-", 361], ["miRNA", 362], [")", 367], ["was", 369], ["inhibited", 373], ["by", 383], ["overexpression", 386], ["of", 401], ["the", 404], ["NF90", 408], ["and", 413], ["NF45", 417], ["proteins", 422], [",", 430], ["and", 432], ["considerable", 436], ["amounts", 449], ["of", 457], ["pri", 460], ["-", 463], ["miRNAs", 464], ["accumulated", 471], ["in", 483], ["cells", 486], ["coexpressing", 492], ["NF90", 505], ["and", 510], ["NF45", 514], [".", 518], ["Treatment", 520], ["of", 530], ["cells", 533], ["overexpressing", 539], ["NF90", 554], ["and", 559], ["NF45", 563], ["with", 568], ["an", 573], ["RNA", 576], ["polymerase", 580], ["II", 591], ["inhibitor", 594], [",", 603], ["alpha", 605], ["-", 610], ["amanitin", 611], [",", 619], ["did", 621], ["not", 625], ["reduce", 629], ["the", 636], ["amounts", 640], ["of", 648], ["pri", 651], ["-", 654], ["miRNAs", 655], [",", 661], ["suggesting", 663], ["that", 674], ["the", 679], ["accumulation", 683], ["of", 696], ["pri", 699], ["-", 702], ["miRNAs", 703], ["is", 710], ["not", 713], ["due", 717], ["to", 721], ["transcriptional", 724], ["activation", 740], [".", 750], ["In", 752], ["addition", 755], [",", 763], ["the", 765], ["NF90", 769], ["and", 774], ["NF45", 778], ["complex", 783], ["was", 791], ["not", 795], ["found", 799], ["to", 805], ["interact", 808], ["with", 817], ["the", 822], ["Microprocessor", 826], ["complex", 841], [",", 848], ["which", 850], ["is", 856], ["a", 859], ["processing", 861], ["factor", 872], ["of", 879], ["pri", 882], ["-", 885], ["miRNAs", 886], [",", 892], ["but", 894], ["was", 898], ["found", 902], ["to", 908], ["bind", 911], ["endogenous", 916], ["pri", 927], ["-", 930], ["miRNAs", 931], [".", 937], ["NF90-NF45", 939], ["exhibited", 949], ["higher", 959], ["binding", 966], ["activity", 974], ["for", 983], ["pri", 987], ["-", 990], ["let-7a", 991], ["than", 998], ["pri", 1003], ["-", 1006], ["miR-21", 1007], [".", 1013], ["Of", 1015], ["note", 1018], [",", 1022], ["depletion", 1024], ["of", 1034], ["NF90", 1037], ["caused", 1042], ["a", 1049], ["reduction", 1051], ["of", 1061], ["pri", 1064], ["-", 1067], ["let-7a", 1068], ["and", 1075], ["an", 1079], ["increase", 1082], ["of", 1091], ["mature", 1094], ["let-7a", 1101], ["miRNA", 1108], [",", 1113], ["which", 1115], ["has", 1121], ["a", 1125], ["potent", 1127], ["antiproliferative", 1134], ["activity", 1152], [",", 1160], ["and", 1162], ["caused", 1166], ["growth", 1173], ["suppression", 1180], ["of", 1192], ["transformed", 1195], ["cells", 1207], [".", 1212], ["These", 1214], ["findings", 1220], ["suggest", 1229], ["that", 1237], ["the", 1242], ["association", 1246], ["of", 1258], ["the", 1261], ["NF90-NF45", 1265], ["complex", 1275], ["with", 1283], ["pri", 1288], ["-", 1291], ["miRNAs", 1292], ["impairs", 1299], ["access", 1307], ["of", 1314], ["the", 1317], ["Microprocessor", 1321], ["complex", 1336], ["to", 1344], ["the", 1347], ["pri", 1351], ["-", 1354], ["miRNAs", 1355], [",", 1361], ["resulting", 1363], ["in", 1373], ["a", 1376], ["reduction", 1378], ["of", 1388], ["mature", 1391], ["miRNA", 1398], ["production", 1404], [".", 1414]]}
{"context": "The acromelic dysplasia group is characterized by short stature, short hands and feet, stiff joint, and \"muscular\" build. Four disorders can now be ascribed to this group, namely Weill-Marchesani syndrome (WMS), geleophysic dysplasia (GD), acromicric dysplasia (AD), and Myhre syndrome (MS). Although closely similar, they can be distinguished by subtle clinical features and their pattern inheritance. WMS is characterized by the presence of dislocation of microspherophakia and has autosomal dominant or recessive mode of inheritance. GD is the more severe one, with a progressive cardiac valvular thickening, tracheal stenosis, bronchopulmonary insufficiency, often leading to an early death. AD has an autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head). Finally, MS is sporadic, characterized by prognathism, deafness, developmental delay, thickened calvarium, and large vertebrae with short and large pedicles. We first identified mutations in Fibrillin-1 (FBN1) in the dominant form of WMS and then mutations in A Disintegrin-like And Metalloproteinase domain with ThromboSpondin type 1 repeats 10 (ADAMTS10) in the recessive form of WMS. The function of ADAMTS10 is unknown but these findings support a direct interaction between ADAMTS10 and FBN1. We then identified mutations in ADAMTSL2 in the recessive form of GD and a hotspot of mutations in FBN1 in the dominant form of GD and in AD (exon 41-42, encoding TGF\u03b2 binding protein-like domain 5 (TB5) of FBN1). The function of ADAMTSL2 is unknown. Using a yeast double hybrid screen, we identified latent transforming growth factor-\u03b2 (TGF\u03b2) binding protein 1 as a partner of ADAMTSL2. We found an increased level of active TGF\u03b2 in the fibroblast medium from patients with FBN1 or ADAMTSL2 mutations and an enhanced phosphorylated SMAD2 level, allowing us to conclude at an enhanced TGF\u03b2 signaling in GD and AD. Finally, a direct interaction between ADAMTSL2 and FBN1 was demonstrated suggesting a dysregulation of FBN1/ADAMTSL2 interrelationship as the underlying mechanism of the short stature phenotypes. Using exome sequencing in MS probands, we identified de novo SMAD4 missense mutations, all involving isoleucine residue at position 500, in the MH2 domain. In MS fibroblasts, we found decreased ubiquitination level of SMAD4 and increased level of SMAD4 supporting a stabilization of SMAD4 protein. Functional SMAD4 is required for canonical signal transduction through the oligomerization with phosphorylated SMAD2/3 and SMAD1/5/8. We therefore studied the nuclear localization of mutant SMAD complexes and found that the complexes translocate to the nucleus. We finally observed a decreased expression of downstream TGF\u03b2 target genes supporting impaired TGF\u03b2 driven transcriptional control in MS. Our findings support a direct link between the short stature phenotypes and the TGF\u03b2 signaling. However, the finding of enhanced TGF\u03b2 signaling in Marfan phenotypes supports the existence of yet unknown mechanisms regulating TGF\u03b2 action.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "2b1cbc97f08540448a7f9be2e32cd04c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[129, 130], [91, 92]], "char_spans": [[706, 723], [484, 501]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["is", 30], ["characterized", 33], ["by", 47], ["short", 50], ["stature", 56], [",", 63], ["short", 65], ["hands", 71], ["and", 77], ["feet", 81], [",", 85], ["stiff", 87], ["joint", 93], [",", 98], ["and", 100], ["\"", 104], ["muscular", 105], ["\"", 113], ["build", 115], [".", 120], ["Four", 122], ["disorders", 127], ["can", 137], ["now", 141], ["be", 145], ["ascribed", 148], ["to", 157], ["this", 160], ["group", 165], [",", 170], ["namely", 172], ["Weill", 179], ["-", 184], ["Marchesani", 185], ["syndrome", 196], ["(", 205], ["WMS", 206], [")", 209], [",", 210], ["geleophysic", 212], ["dysplasia", 224], ["(", 234], ["GD", 235], [")", 237], [",", 238], ["acromicric", 240], ["dysplasia", 251], ["(", 261], ["AD", 262], [")", 264], [",", 265], ["and", 267], ["Myhre", 271], ["syndrome", 277], ["(", 286], ["MS", 287], [")", 289], [".", 290], ["Although", 292], ["closely", 301], ["similar", 309], [",", 316], ["they", 318], ["can", 323], ["be", 327], ["distinguished", 330], ["by", 344], ["subtle", 347], ["clinical", 354], ["features", 363], ["and", 372], ["their", 376], ["pattern", 382], ["inheritance", 390], [".", 401], ["WMS", 403], ["is", 407], ["characterized", 410], ["by", 424], ["the", 427], ["presence", 431], ["of", 440], ["dislocation", 443], ["of", 455], ["microspherophakia", 458], ["and", 476], ["has", 480], ["autosomal", 484], ["dominant", 494], ["or", 503], ["recessive", 506], ["mode", 516], ["of", 521], ["inheritance", 524], [".", 535], ["GD", 537], ["is", 540], ["the", 543], ["more", 547], ["severe", 552], ["one", 559], [",", 562], ["with", 564], ["a", 569], ["progressive", 571], ["cardiac", 583], ["valvular", 591], ["thickening", 600], [",", 610], ["tracheal", 612], ["stenosis", 621], [",", 629], ["bronchopulmonary", 631], ["insufficiency", 648], [",", 661], ["often", 663], ["leading", 669], ["to", 677], ["an", 680], ["early", 683], ["death", 689], [".", 694], ["AD", 696], ["has", 699], ["an", 703], ["autosomal", 706], ["dominant", 716], ["mode", 725], ["of", 730], ["inheritance", 733], [",", 744], ["distinct", 746], ["facial", 755], ["and", 762], ["skeleton", 766], ["features", 775], ["(", 784], ["a", 785], ["hoarse", 787], ["voice", 794], ["and", 800], ["internal", 804], ["notch", 813], ["of", 819], ["the", 822], ["femoral", 826], ["head", 834], [")", 838], [".", 839], ["Finally", 841], [",", 848], ["MS", 850], ["is", 853], ["sporadic", 856], [",", 864], ["characterized", 866], ["by", 880], ["prognathism", 883], [",", 894], ["deafness", 896], [",", 904], ["developmental", 906], ["delay", 920], [",", 925], ["thickened", 927], ["calvarium", 937], [",", 946], ["and", 948], ["large", 952], ["vertebrae", 958], ["with", 968], ["short", 973], ["and", 979], ["large", 983], ["pedicles", 989], [".", 997], ["We", 999], ["first", 1002], ["identified", 1008], ["mutations", 1019], ["in", 1029], ["Fibrillin-1", 1032], ["(", 1044], ["FBN1", 1045], [")", 1049], ["in", 1051], ["the", 1054], ["dominant", 1058], ["form", 1067], ["of", 1072], ["WMS", 1075], ["and", 1079], ["then", 1083], ["mutations", 1088], ["in", 1098], ["A", 1101], ["Disintegrin", 1103], ["-", 1114], ["like", 1115], ["And", 1120], ["Metalloproteinase", 1124], ["domain", 1142], ["with", 1149], ["ThromboSpondin", 1154], ["type", 1169], ["1", 1174], ["repeats", 1176], ["10", 1184], ["(", 1187], ["ADAMTS10", 1188], [")", 1196], ["in", 1198], ["the", 1201], ["recessive", 1205], ["form", 1215], ["of", 1220], ["WMS", 1223], [".", 1226], ["The", 1228], ["function", 1232], ["of", 1241], ["ADAMTS10", 1244], ["is", 1253], ["unknown", 1256], ["but", 1264], ["these", 1268], ["findings", 1274], ["support", 1283], ["a", 1291], ["direct", 1293], ["interaction", 1300], ["between", 1312], ["ADAMTS10", 1320], ["and", 1329], ["FBN1", 1333], [".", 1337], ["We", 1339], ["then", 1342], ["identified", 1347], ["mutations", 1358], ["in", 1368], ["ADAMTSL2", 1371], ["in", 1380], ["the", 1383], ["recessive", 1387], ["form", 1397], ["of", 1402], ["GD", 1405], ["and", 1408], ["a", 1412], ["hotspot", 1414], ["of", 1422], ["mutations", 1425], ["in", 1435], ["FBN1", 1438], ["in", 1443], ["the", 1446], ["dominant", 1450], ["form", 1459], ["of", 1464], ["GD", 1467], ["and", 1470], ["in", 1474], ["AD", 1477], ["(", 1480], ["exon", 1481], ["41", 1486], ["-", 1488], ["42", 1489], [",", 1491], ["encoding", 1493], ["TGF\u03b2", 1502], ["binding", 1507], ["protein", 1515], ["-", 1522], ["like", 1523], ["domain", 1528], ["5", 1535], ["(", 1537], ["TB5", 1538], [")", 1541], ["of", 1543], ["FBN1", 1546], [")", 1550], [".", 1551], ["The", 1553], ["function", 1557], ["of", 1566], ["ADAMTSL2", 1569], ["is", 1578], ["unknown", 1581], [".", 1588], ["Using", 1590], ["a", 1596], ["yeast", 1598], ["double", 1604], ["hybrid", 1611], ["screen", 1618], [",", 1624], ["we", 1626], ["identified", 1629], ["latent", 1640], ["transforming", 1647], ["growth", 1660], ["factor", 1667], ["-", 1673], ["\u03b2", 1674], ["(", 1676], ["TGF\u03b2", 1677], [")", 1681], ["binding", 1683], ["protein", 1691], ["1", 1699], ["as", 1701], ["a", 1704], ["partner", 1706], ["of", 1714], ["ADAMTSL2", 1717], [".", 1725], ["We", 1727], ["found", 1730], ["an", 1736], ["increased", 1739], ["level", 1749], ["of", 1755], ["active", 1758], ["TGF\u03b2", 1765], ["in", 1770], ["the", 1773], ["fibroblast", 1777], ["medium", 1788], ["from", 1795], ["patients", 1800], ["with", 1809], ["FBN1", 1814], ["or", 1819], ["ADAMTSL2", 1822], ["mutations", 1831], ["and", 1841], ["an", 1845], ["enhanced", 1848], ["phosphorylated", 1857], ["SMAD2", 1872], ["level", 1878], [",", 1883], ["allowing", 1885], ["us", 1894], ["to", 1897], ["conclude", 1900], ["at", 1909], ["an", 1912], ["enhanced", 1915], ["TGF\u03b2", 1924], ["signaling", 1929], ["in", 1939], ["GD", 1942], ["and", 1945], ["AD", 1949], [".", 1951], ["Finally", 1953], [",", 1960], ["a", 1962], ["direct", 1964], ["interaction", 1971], ["between", 1983], ["ADAMTSL2", 1991], ["and", 2000], ["FBN1", 2004], ["was", 2009], ["demonstrated", 2013], ["suggesting", 2026], ["a", 2037], ["dysregulation", 2039], ["of", 2053], ["FBN1/ADAMTSL2", 2056], ["interrelationship", 2070], ["as", 2088], ["the", 2091], ["underlying", 2095], ["mechanism", 2106], ["of", 2116], ["the", 2119], ["short", 2123], ["stature", 2129], ["phenotypes", 2137], [".", 2147], ["Using", 2149], ["exome", 2155], ["sequencing", 2161], ["in", 2172], ["MS", 2175], ["probands", 2178], [",", 2186], ["we", 2188], ["identified", 2191], ["de", 2202], ["novo", 2205], ["SMAD4", 2210], ["missense", 2216], ["mutations", 2225], [",", 2234], ["all", 2236], ["involving", 2240], ["isoleucine", 2250], ["residue", 2261], ["at", 2269], ["position", 2272], ["500", 2281], [",", 2284], ["in", 2286], ["the", 2289], ["MH2", 2293], ["domain", 2297], [".", 2303], ["In", 2305], ["MS", 2308], ["fibroblasts", 2311], [",", 2322], ["we", 2324], ["found", 2327], ["decreased", 2333], ["ubiquitination", 2343], ["level", 2358], ["of", 2364], ["SMAD4", 2367], ["and", 2373], ["increased", 2377], ["level", 2387], ["of", 2393], ["SMAD4", 2396], ["supporting", 2402], ["a", 2413], ["stabilization", 2415], ["of", 2429], ["SMAD4", 2432], ["protein", 2438], [".", 2445], ["Functional", 2447], ["SMAD4", 2458], ["is", 2464], ["required", 2467], ["for", 2476], ["canonical", 2480], ["signal", 2490], ["transduction", 2497], ["through", 2510], ["the", 2518], ["oligomerization", 2522], ["with", 2538], ["phosphorylated", 2543], ["SMAD2/3", 2558], ["and", 2566], ["SMAD1/5/8", 2570], [".", 2579], ["We", 2581], ["therefore", 2584], ["studied", 2594], ["the", 2602], ["nuclear", 2606], ["localization", 2614], ["of", 2627], ["mutant", 2630], ["SMAD", 2637], ["complexes", 2642], ["and", 2652], ["found", 2656], ["that", 2662], ["the", 2667], ["complexes", 2671], ["translocate", 2681], ["to", 2693], ["the", 2696], ["nucleus", 2700], [".", 2707], ["We", 2709], ["finally", 2712], ["observed", 2720], ["a", 2729], ["decreased", 2731], ["expression", 2741], ["of", 2752], ["downstream", 2755], ["TGF\u03b2", 2766], ["target", 2771], ["genes", 2778], ["supporting", 2784], ["impaired", 2795], ["TGF\u03b2", 2804], ["driven", 2809], ["transcriptional", 2816], ["control", 2832], ["in", 2840], ["MS", 2843], [".", 2845], ["Our", 2847], ["findings", 2851], ["support", 2860], ["a", 2868], ["direct", 2870], ["link", 2877], ["between", 2882], ["the", 2890], ["short", 2894], ["stature", 2900], ["phenotypes", 2908], ["and", 2919], ["the", 2923], ["TGF\u03b2", 2927], ["signaling", 2932], [".", 2941], ["However", 2943], [",", 2950], ["the", 2952], ["finding", 2956], ["of", 2964], ["enhanced", 2967], ["TGF\u03b2", 2976], ["signaling", 2981], ["in", 2991], ["Marfan", 2994], ["phenotypes", 3001], ["supports", 3012], ["the", 3021], ["existence", 3025], ["of", 3035], ["yet", 3038], ["unknown", 3042], ["mechanisms", 3050], ["regulating", 3061], ["TGF\u03b2", 3072], ["action", 3077], [".", 3083]]}
{"context": "Several Nox family NADPH oxidases function as multicomponent enzyme systems. We explored determinants of assembly of the multicomponent oxidases Nox1 and Nox3 and examined the involvement of Rac1 in their regulation. Both enzymes are supported by p47phox and p67phox or homologous regulators called Noxo1 and Noxa1, although Nox3 is less dependent on these cofactors for activity. Plasma membrane targeting of Noxa1 depends on Noxo1, through tail-to-tail interactions between these proteins. Noxa1 can support Nox1 without Noxo1, when targeted to the plasma membrane by fusing membrane-binding sequences from Rac1 (amino acids 183 to 192) to the C terminus of Noxa1. However, membrane targeting of Noxa1 is not sufficient for activation of Nox1. Both the Noxo1-independent and -dependent Nox1 systems involve Rac1, since they are affected by Rac1 mutants or Noxa1 mutants defective in Rac binding or short interfering RNA-mediated Rac1 silencing. Nox1 or Nox3 expression promotes p22phox transport to the plasma membrane, and both oxidases are inhibited by mutations in the p22phox binding sites (SH3 domains) of the Nox organizers (p47phox or Noxo1). Regulation of Nox3 by Rac1 was also evident from the effects of mutant Rac1 or mutant Nox3 activators (p67phox or Noxa1) or Rac1 silencing. In the absence of Nox organizers, the Nox activators (p67phox or Noxa1) colocalize with Rac1 within ruffling membranes, independently of their ability to bind Rac1. Thus, Rac1 regulates both oxidases through the Nox activators, although it does not appear to direct the subcellular localization of these activators.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "57eb41d2c868493082e639c7f17fc839", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[83, 83], [134, 134], [20, 20], [162, 162], [127, 127]], "char_spans": [[510, 513], [788, 791], [145, 148], [947, 950], [740, 743]]}]}], "context_tokens": [["Several", 0], ["Nox", 8], ["family", 12], ["NADPH", 19], ["oxidases", 25], ["function", 34], ["as", 43], ["multicomponent", 46], ["enzyme", 61], ["systems", 68], [".", 75], ["We", 77], ["explored", 80], ["determinants", 89], ["of", 102], ["assembly", 105], ["of", 114], ["the", 117], ["multicomponent", 121], ["oxidases", 136], ["Nox1", 145], ["and", 150], ["Nox3", 154], ["and", 159], ["examined", 163], ["the", 172], ["involvement", 176], ["of", 188], ["Rac1", 191], ["in", 196], ["their", 199], ["regulation", 205], [".", 215], ["Both", 217], ["enzymes", 222], ["are", 230], ["supported", 234], ["by", 244], ["p47phox", 247], ["and", 255], ["p67phox", 259], ["or", 267], ["homologous", 270], ["regulators", 281], ["called", 292], ["Noxo1", 299], ["and", 305], ["Noxa1", 309], [",", 314], ["although", 316], ["Nox3", 325], ["is", 330], ["less", 333], ["dependent", 338], ["on", 348], ["these", 351], ["cofactors", 357], ["for", 367], ["activity", 371], [".", 379], ["Plasma", 381], ["membrane", 388], ["targeting", 397], ["of", 407], ["Noxa1", 410], ["depends", 416], ["on", 424], ["Noxo1", 427], [",", 432], ["through", 434], ["tail", 442], ["-", 446], ["to", 447], ["-", 449], ["tail", 450], ["interactions", 455], ["between", 468], ["these", 476], ["proteins", 482], [".", 490], ["Noxa1", 492], ["can", 498], ["support", 502], ["Nox1", 510], ["without", 515], ["Noxo1", 523], [",", 528], ["when", 530], ["targeted", 535], ["to", 544], ["the", 547], ["plasma", 551], ["membrane", 558], ["by", 567], ["fusing", 570], ["membrane", 577], ["-", 585], ["binding", 586], ["sequences", 594], ["from", 604], ["Rac1", 609], ["(", 614], ["amino", 615], ["acids", 621], ["183", 627], ["to", 631], ["192", 634], [")", 637], ["to", 639], ["the", 642], ["C", 646], ["terminus", 648], ["of", 657], ["Noxa1", 660], [".", 665], ["However", 667], [",", 674], ["membrane", 676], ["targeting", 685], ["of", 695], ["Noxa1", 698], ["is", 704], ["not", 707], ["sufficient", 711], ["for", 722], ["activation", 726], ["of", 737], ["Nox1", 740], [".", 744], ["Both", 746], ["the", 751], ["Noxo1-independent", 755], ["and", 773], ["-dependent", 777], ["Nox1", 788], ["systems", 793], ["involve", 801], ["Rac1", 809], [",", 813], ["since", 815], ["they", 821], ["are", 826], ["affected", 830], ["by", 839], ["Rac1", 842], ["mutants", 847], ["or", 855], ["Noxa1", 858], ["mutants", 864], ["defective", 872], ["in", 882], ["Rac", 885], ["binding", 889], ["or", 897], ["short", 900], ["interfering", 906], ["RNA", 918], ["-", 921], ["mediated", 922], ["Rac1", 931], ["silencing", 936], [".", 945], ["Nox1", 947], ["or", 952], ["Nox3", 955], ["expression", 960], ["promotes", 971], ["p22phox", 980], ["transport", 988], ["to", 998], ["the", 1001], ["plasma", 1005], ["membrane", 1012], [",", 1020], ["and", 1022], ["both", 1026], ["oxidases", 1031], ["are", 1040], ["inhibited", 1044], ["by", 1054], ["mutations", 1057], ["in", 1067], ["the", 1070], ["p22phox", 1074], ["binding", 1082], ["sites", 1090], ["(", 1096], ["SH3", 1097], ["domains", 1101], [")", 1108], ["of", 1110], ["the", 1113], ["Nox", 1117], ["organizers", 1121], ["(", 1132], ["p47phox", 1133], ["or", 1141], ["Noxo1", 1144], [")", 1149], [".", 1150], ["Regulation", 1152], ["of", 1163], ["Nox3", 1166], ["by", 1171], ["Rac1", 1174], ["was", 1179], ["also", 1183], ["evident", 1188], ["from", 1196], ["the", 1201], ["effects", 1205], ["of", 1213], ["mutant", 1216], ["Rac1", 1223], ["or", 1228], ["mutant", 1231], ["Nox3", 1238], ["activators", 1243], ["(", 1254], ["p67phox", 1255], ["or", 1263], ["Noxa1", 1266], [")", 1271], ["or", 1273], ["Rac1", 1276], ["silencing", 1281], [".", 1290], ["In", 1292], ["the", 1295], ["absence", 1299], ["of", 1307], ["Nox", 1310], ["organizers", 1314], [",", 1324], ["the", 1326], ["Nox", 1330], ["activators", 1334], ["(", 1345], ["p67phox", 1346], ["or", 1354], ["Noxa1", 1357], [")", 1362], ["colocalize", 1364], ["with", 1375], ["Rac1", 1380], ["within", 1385], ["ruffling", 1392], ["membranes", 1401], [",", 1410], ["independently", 1412], ["of", 1426], ["their", 1429], ["ability", 1435], ["to", 1443], ["bind", 1446], ["Rac1", 1451], [".", 1455], ["Thus", 1457], [",", 1461], ["Rac1", 1463], ["regulates", 1468], ["both", 1478], ["oxidases", 1483], ["through", 1492], ["the", 1500], ["Nox", 1504], ["activators", 1508], [",", 1518], ["although", 1520], ["it", 1529], ["does", 1532], ["not", 1537], ["appear", 1541], ["to", 1548], ["direct", 1551], ["the", 1558], ["subcellular", 1562], ["localization", 1574], ["of", 1587], ["these", 1590], ["activators", 1596], [".", 1606]]}
{"context": "The circumsporozoite protein (CS protein) on the malaria parasites in mosquitoes plays an important role in sporogony in mosquitoes. The RTS,S/AS01 malaria vaccine candidate, which has shown significant efficacy against clinical malaria in a large Phase 3 trial, targets the Plasmodium falciparum CS protein, but the ability of serum from vaccinated individuals to inhibit sporogony in mosquitoes has not been evaluated. Previously a double-blind, randomized trial of RTS,S/AS01 vaccine, as compared with rabies vaccine, in five- to 17-month old children in Tanzania was conducted. In this study, polyclonal human antibodies were purified from the pools of sera taken one month after the third vaccination. IgGs were purified from four pools of sera from 25 RTS,S/AS01 vaccinated children each, and two pools of sera from 25 children vaccinated with rabies vaccine each. The ability of antibodies to inhibit P. falciparum oocyst formation and/or sporogony in the mosquito host was evaluated by a standard membrane-feeding assay. The test antibodies were fed on day 0 (at the same time as the gametocyte feed), or on days 3 or 6 (serial-feed experiments). The oocyst and sporozoite counts were performed on days 8 and 16, respectively. In addition, two human anti-CS monoclonal antibodies (mAb) and a control mAb were also evaluated. Polyclonal anti-CS IgG preparations from RTS,S-vaccinated children tested at concentrations of 149-210 ELISA units (EU)/ml did not show significant inhibition in oocyst and sporozoite formation when the antibodies were fed with gametocytes at the same time, or later (serial-feed experiments). Similarly, anti-CS mAbs tested at 6,421 or 7,122 EU/ml did not show reduction in oocyst and sporozoite formation. This study does not support the concept that anti-CS antibodies induced by the RTS,S/AS01 vaccines in humans noticeably reduce malaria transmission by blocking P. falciparum sporozoite development or salivary gland invasion in mosquitoes when taken up during feeding.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "51baa45baf634976aba834f1b1354eb0", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[28, 28], [39, 39], [9, 9], [358, 358]], "char_spans": [[148, 154], [229, 235], [49, 55], [1868, 1874]]}]}], "context_tokens": [["The", 0], ["circumsporozoite", 4], ["protein", 21], ["(", 29], ["CS", 30], ["protein", 33], [")", 40], ["on", 42], ["the", 45], ["malaria", 49], ["parasites", 57], ["in", 67], ["mosquitoes", 70], ["plays", 81], ["an", 87], ["important", 90], ["role", 100], ["in", 105], ["sporogony", 108], ["in", 118], ["mosquitoes", 121], [".", 131], ["The", 133], ["RTS", 137], [",", 140], ["S", 141], ["/", 142], ["AS01", 143], ["malaria", 148], ["vaccine", 156], ["candidate", 164], [",", 173], ["which", 175], ["has", 181], ["shown", 185], ["significant", 191], ["efficacy", 203], ["against", 212], ["clinical", 220], ["malaria", 229], ["in", 237], ["a", 240], ["large", 242], ["Phase", 248], ["3", 254], ["trial", 256], [",", 261], ["targets", 263], ["the", 271], ["Plasmodium", 275], ["falciparum", 286], ["CS", 297], ["protein", 300], [",", 307], ["but", 309], ["the", 313], ["ability", 317], ["of", 325], ["serum", 328], ["from", 334], ["vaccinated", 339], ["individuals", 350], ["to", 362], ["inhibit", 365], ["sporogony", 373], ["in", 383], ["mosquitoes", 386], ["has", 397], ["not", 401], ["been", 405], ["evaluated", 410], [".", 419], ["Previously", 421], ["a", 432], ["double", 434], ["-", 440], ["blind", 441], [",", 446], ["randomized", 448], ["trial", 459], ["of", 465], ["RTS", 468], [",", 471], ["S", 472], ["/", 473], ["AS01", 474], ["vaccine", 479], [",", 486], ["as", 488], ["compared", 491], ["with", 500], ["rabies", 505], ["vaccine", 512], [",", 519], ["in", 521], ["five-", 524], ["to", 530], ["17-month", 533], ["old", 542], ["children", 546], ["in", 555], ["Tanzania", 558], ["was", 567], ["conducted", 571], [".", 580], ["In", 582], ["this", 585], ["study", 590], [",", 595], ["polyclonal", 597], ["human", 608], ["antibodies", 614], ["were", 625], ["purified", 630], ["from", 639], ["the", 644], ["pools", 648], ["of", 654], ["sera", 657], ["taken", 662], ["one", 668], ["month", 672], ["after", 678], ["the", 684], ["third", 688], ["vaccination", 694], [".", 705], ["IgGs", 707], ["were", 712], ["purified", 717], ["from", 726], ["four", 731], ["pools", 736], ["of", 742], ["sera", 745], ["from", 750], ["25", 755], ["RTS", 758], [",", 761], ["S", 762], ["/", 763], ["AS01", 764], ["vaccinated", 769], ["children", 780], ["each", 789], [",", 793], ["and", 795], ["two", 799], ["pools", 803], ["of", 809], ["sera", 812], ["from", 817], ["25", 822], ["children", 825], ["vaccinated", 834], ["with", 845], ["rabies", 850], ["vaccine", 857], ["each", 865], [".", 869], ["The", 871], ["ability", 875], ["of", 883], ["antibodies", 886], ["to", 897], ["inhibit", 900], ["P.", 908], ["falciparum", 911], ["oocyst", 922], ["formation", 929], ["and/or", 939], ["sporogony", 946], ["in", 956], ["the", 959], ["mosquito", 963], ["host", 972], ["was", 977], ["evaluated", 981], ["by", 991], ["a", 994], ["standard", 996], ["membrane", 1005], ["-", 1013], ["feeding", 1014], ["assay", 1022], [".", 1027], ["The", 1029], ["test", 1033], ["antibodies", 1038], ["were", 1049], ["fed", 1054], ["on", 1058], ["day", 1061], ["0", 1065], ["(", 1067], ["at", 1068], ["the", 1071], ["same", 1075], ["time", 1080], ["as", 1085], ["the", 1088], ["gametocyte", 1092], ["feed", 1103], [")", 1107], [",", 1108], ["or", 1110], ["on", 1113], ["days", 1116], ["3", 1121], ["or", 1123], ["6", 1126], ["(", 1128], ["serial", 1129], ["-", 1135], ["feed", 1136], ["experiments", 1141], [")", 1152], [".", 1153], ["The", 1155], ["oocyst", 1159], ["and", 1166], ["sporozoite", 1170], ["counts", 1181], ["were", 1188], ["performed", 1193], ["on", 1203], ["days", 1206], ["8", 1211], ["and", 1213], ["16", 1217], [",", 1219], ["respectively", 1221], [".", 1233], ["In", 1235], ["addition", 1238], [",", 1246], ["two", 1248], ["human", 1252], ["anti", 1258], ["-", 1262], ["CS", 1263], ["monoclonal", 1266], ["antibodies", 1277], ["(", 1288], ["mAb", 1289], [")", 1292], ["and", 1294], ["a", 1298], ["control", 1300], ["mAb", 1308], ["were", 1312], ["also", 1317], ["evaluated", 1322], [".", 1331], ["Polyclonal", 1333], ["anti", 1344], ["-", 1348], ["CS", 1349], ["IgG", 1352], ["preparations", 1356], ["from", 1369], ["RTS", 1374], [",", 1377], ["S", 1378], ["-", 1379], ["vaccinated", 1380], ["children", 1391], ["tested", 1400], ["at", 1407], ["concentrations", 1410], ["of", 1425], ["149", 1428], ["-", 1431], ["210", 1432], ["ELISA", 1436], ["units", 1442], ["(", 1448], ["EU)/ml", 1449], ["did", 1456], ["not", 1460], ["show", 1464], ["significant", 1469], ["inhibition", 1481], ["in", 1492], ["oocyst", 1495], ["and", 1502], ["sporozoite", 1506], ["formation", 1517], ["when", 1527], ["the", 1532], ["antibodies", 1536], ["were", 1547], ["fed", 1552], ["with", 1556], ["gametocytes", 1561], ["at", 1573], ["the", 1576], ["same", 1580], ["time", 1585], [",", 1589], ["or", 1591], ["later", 1594], ["(", 1600], ["serial", 1601], ["-", 1607], ["feed", 1608], ["experiments", 1613], [")", 1624], [".", 1625], ["Similarly", 1627], [",", 1636], ["anti", 1638], ["-", 1642], ["CS", 1643], ["mAbs", 1646], ["tested", 1651], ["at", 1658], ["6,421", 1661], ["or", 1667], ["7,122", 1670], ["EU", 1676], ["/", 1678], ["ml", 1679], ["did", 1682], ["not", 1686], ["show", 1690], ["reduction", 1695], ["in", 1705], ["oocyst", 1708], ["and", 1715], ["sporozoite", 1719], ["formation", 1730], [".", 1739], ["This", 1741], ["study", 1746], ["does", 1752], ["not", 1757], ["support", 1761], ["the", 1769], ["concept", 1773], ["that", 1781], ["anti", 1786], ["-", 1790], ["CS", 1791], ["antibodies", 1794], ["induced", 1805], ["by", 1813], ["the", 1816], ["RTS", 1820], [",", 1823], ["S", 1824], ["/", 1825], ["AS01", 1826], ["vaccines", 1831], ["in", 1840], ["humans", 1843], ["noticeably", 1850], ["reduce", 1861], ["malaria", 1868], ["transmission", 1876], ["by", 1889], ["blocking", 1892], ["P.", 1901], ["falciparum", 1904], ["sporozoite", 1915], ["development", 1926], ["or", 1938], ["salivary", 1941], ["gland", 1950], ["invasion", 1956], ["in", 1965], ["mosquitoes", 1968], ["when", 1979], ["taken", 1984], ["up", 1990], ["during", 1993], ["feeding", 2000], [".", 2007]]}
{"context": "To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA). Nusinersen was delivered by intrathecal injection to medically stable patients with type 2 and type 3 SMA aged 2-14 years in an open-label phase 1 study and its long-term extension. Four ascending single-dose levels (1, 3, 6, and 9 mg) were examined in cohorts of 6-10 participants. Participants were monitored for safety and tolerability, and CSF and plasma pharmacokinetics were measured. Exploratory efficacy endpoints included the Hammersmith Functional Motor Scale Expanded (HFMSE) and Pediatric Quality of Life Inventory. A total of 28 participants enrolled in the study (n = 6 in first 3 dose cohorts; n = 10 in the 9-mg cohort). Intrathecal nusinersen was well-tolerated with no safety/tolerability concerns identified. Plasma and CSF drug levels were dose-dependent, consistent with preclinical data. Extended pharmacokinetics indicated a prolonged CSF drug half-life of 4-6 months after initial clearance. A significant increase in HFMSE scores was observed at the 9-mg dose at 3 months postdose (3.1 points; p = 0.016), which was further increased 9-14 months postdose (5.8 points; p = 0.008) during the extension study. Results from this study support continued development of nusinersen for treatment of SMA. This study provides Class IV evidence that in children with SMA, intrathecal nusinersen is not associated with safety or tolerability concerns.", "qas": [{"question": "Which disease is treated with Nusinersen?", "answers": ["Spinal Muscular Atrophy", "SMA"], "qid": "929fe34ca98f493f90876a2789451097", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["treated", 17], ["with", 25], ["Nusinersen", 30], ["?", 40]], "detected_answers": [{"text": "Spinal Muscular Atrophy", "token_spans": [[37, 39]], "char_spans": [[233, 255]]}, {"text": "SMA", "token_spans": [[279, 279], [291, 291], [60, 60], [41, 41]], "char_spans": [[1481, 1483], [1546, 1548], [366, 368], [258, 260]]}]}], "context_tokens": [["To", 0], ["examine", 3], ["safety", 11], [",", 17], ["tolerability", 19], [",", 31], ["pharmacokinetics", 33], [",", 49], ["and", 51], ["preliminary", 55], ["clinical", 67], ["efficacy", 76], ["of", 85], ["intrathecal", 88], ["nusinersen", 100], ["(", 111], ["previously", 112], ["ISIS", 123], ["-", 127], ["SMNRx", 128], [")", 133], [",", 134], ["an", 136], ["antisense", 139], ["oligonucleotide", 149], ["designed", 165], ["to", 174], ["alter", 177], ["splicing", 183], ["of", 192], ["SMN2", 195], ["mRNA", 200], [",", 204], ["in", 206], ["patients", 209], ["with", 218], ["childhood", 223], ["spinal", 233], ["muscular", 240], ["atrophy", 249], ["(", 257], ["SMA", 258], [")", 261], [".", 262], ["Nusinersen", 264], ["was", 275], ["delivered", 279], ["by", 289], ["intrathecal", 292], ["injection", 304], ["to", 314], ["medically", 317], ["stable", 327], ["patients", 334], ["with", 343], ["type", 348], ["2", 353], ["and", 355], ["type", 359], ["3", 364], ["SMA", 366], ["aged", 370], ["2", 375], ["-", 376], ["14", 377], ["years", 380], ["in", 386], ["an", 389], ["open", 392], ["-", 396], ["label", 397], ["phase", 403], ["1", 409], ["study", 411], ["and", 417], ["its", 421], ["long", 425], ["-", 429], ["term", 430], ["extension", 435], [".", 444], ["Four", 446], ["ascending", 451], ["single", 461], ["-", 467], ["dose", 468], ["levels", 473], ["(", 480], ["1", 481], [",", 482], ["3", 484], [",", 485], ["6", 487], [",", 488], ["and", 490], ["9", 494], ["mg", 496], [")", 498], ["were", 500], ["examined", 505], ["in", 514], ["cohorts", 517], ["of", 525], ["6", 528], ["-", 529], ["10", 530], ["participants", 533], [".", 545], ["Participants", 547], ["were", 560], ["monitored", 565], ["for", 575], ["safety", 579], ["and", 586], ["tolerability", 590], [",", 602], ["and", 604], ["CSF", 608], ["and", 612], ["plasma", 616], ["pharmacokinetics", 623], ["were", 640], ["measured", 645], [".", 653], ["Exploratory", 655], ["efficacy", 667], ["endpoints", 676], ["included", 686], ["the", 695], ["Hammersmith", 699], ["Functional", 711], ["Motor", 722], ["Scale", 728], ["Expanded", 734], ["(", 743], ["HFMSE", 744], [")", 749], ["and", 751], ["Pediatric", 755], ["Quality", 765], ["of", 773], ["Life", 776], ["Inventory", 781], [".", 790], ["A", 792], ["total", 794], ["of", 800], ["28", 803], ["participants", 806], ["enrolled", 819], ["in", 828], ["the", 831], ["study", 835], ["(", 841], ["n", 842], ["=", 844], ["6", 846], ["in", 848], ["first", 851], ["3", 857], ["dose", 859], ["cohorts", 864], [";", 871], ["n", 873], ["=", 875], ["10", 877], ["in", 880], ["the", 883], ["9-mg", 887], ["cohort", 892], [")", 898], [".", 899], ["Intrathecal", 901], ["nusinersen", 913], ["was", 924], ["well", 928], ["-", 932], ["tolerated", 933], ["with", 943], ["no", 948], ["safety", 951], ["/", 957], ["tolerability", 958], ["concerns", 971], ["identified", 980], [".", 990], ["Plasma", 992], ["and", 999], ["CSF", 1003], ["drug", 1007], ["levels", 1012], ["were", 1019], ["dose", 1024], ["-", 1028], ["dependent", 1029], [",", 1038], ["consistent", 1040], ["with", 1051], ["preclinical", 1056], ["data", 1068], [".", 1072], ["Extended", 1074], ["pharmacokinetics", 1083], ["indicated", 1100], ["a", 1110], ["prolonged", 1112], ["CSF", 1122], ["drug", 1126], ["half", 1131], ["-", 1135], ["life", 1136], ["of", 1141], ["4", 1144], ["-", 1145], ["6", 1146], ["months", 1148], ["after", 1155], ["initial", 1161], ["clearance", 1169], [".", 1178], ["A", 1180], ["significant", 1182], ["increase", 1194], ["in", 1203], ["HFMSE", 1206], ["scores", 1212], ["was", 1219], ["observed", 1223], ["at", 1232], ["the", 1235], ["9-mg", 1239], ["dose", 1244], ["at", 1249], ["3", 1252], ["months", 1254], ["postdose", 1261], ["(", 1270], ["3.1", 1271], ["points", 1275], [";", 1281], ["p", 1283], ["=", 1285], ["0.016", 1287], [")", 1292], [",", 1293], ["which", 1295], ["was", 1301], ["further", 1305], ["increased", 1313], ["9", 1323], ["-", 1324], ["14", 1325], ["months", 1328], ["postdose", 1335], ["(", 1344], ["5.8", 1345], ["points", 1349], [";", 1355], ["p", 1357], ["=", 1359], ["0.008", 1361], [")", 1366], ["during", 1368], ["the", 1375], ["extension", 1379], ["study", 1389], [".", 1394], ["Results", 1396], ["from", 1404], ["this", 1409], ["study", 1414], ["support", 1420], ["continued", 1428], ["development", 1438], ["of", 1450], ["nusinersen", 1453], ["for", 1464], ["treatment", 1468], ["of", 1478], ["SMA", 1481], [".", 1484], ["This", 1486], ["study", 1491], ["provides", 1497], ["Class", 1506], ["IV", 1512], ["evidence", 1515], ["that", 1524], ["in", 1529], ["children", 1532], ["with", 1541], ["SMA", 1546], [",", 1549], ["intrathecal", 1551], ["nusinersen", 1563], ["is", 1574], ["not", 1577], ["associated", 1581], ["with", 1592], ["safety", 1597], ["or", 1604], ["tolerability", 1607], ["concerns", 1620], [".", 1628]]}
{"context": "The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of inherited connective tissue disorders characterized by tissue fragility, hyperelasticity of the skin and joint hypermobility. This phenotype, accompanied by kyphoscoliosis and/or ocular fragility, is present in patients with the autosomal recessive type VI form of EDS. These patients have significantly decreased levels of lysyl hydroxylase (LH) activity, due to mutations in the LH1 gene. LH hydroxylates specific lysine residues in the collagen molecule that are precursors for the formation of cross-links which provide collagen with its tensile strength. No disorder has been directly linked to decreased expression of LH2 and LH3, two other isoforms of LH. This study describes 3 patients with mixed phenotypes of EDS, who have significantly decreased mRNAs for LH2, but normal levels of LH1 and LH3 mRNAs, in their skin fibroblasts. In contrast to the effect of LH1 deficiency in EDS VI patients, the decreased expression of LH2 does not affect LH activity, bifunctional collagen cross-links (measured after reduction as dihydroxylysinonorleucine (DHLNL) and hydroxylysinonorleucine (HLNL)), or helical lysine hydroxylation in these cell lines. Sequence analysis of full length LH2 cDNAs and 1kb of the promoter region of LH2 does not show mutations that could explain the decreased expression of LH2. These results suggest that the deficiency of LH2 in these fibroblasts may be caused by changes in other factors required for the expression of LH2.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "43917eac9f9f4c7095a7adc22a283663", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[14, 15]], "char_spans": [[73, 89]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["are", 34], ["a", 38], ["heterogeneous", 40], ["group", 54], ["of", 60], ["inherited", 63], ["connective", 73], ["tissue", 84], ["disorders", 91], ["characterized", 101], ["by", 115], ["tissue", 118], ["fragility", 125], [",", 134], ["hyperelasticity", 136], ["of", 152], ["the", 155], ["skin", 159], ["and", 164], ["joint", 168], ["hypermobility", 174], [".", 187], ["This", 189], ["phenotype", 194], [",", 203], ["accompanied", 205], ["by", 217], ["kyphoscoliosis", 220], ["and/or", 235], ["ocular", 242], ["fragility", 249], [",", 258], ["is", 260], ["present", 263], ["in", 271], ["patients", 274], ["with", 283], ["the", 288], ["autosomal", 292], ["recessive", 302], ["type", 312], ["VI", 317], ["form", 320], ["of", 325], ["EDS", 328], [".", 331], ["These", 333], ["patients", 339], ["have", 348], ["significantly", 353], ["decreased", 367], ["levels", 377], ["of", 384], ["lysyl", 387], ["hydroxylase", 393], ["(", 405], ["LH", 406], [")", 408], ["activity", 410], [",", 418], ["due", 420], ["to", 424], ["mutations", 427], ["in", 437], ["the", 440], ["LH1", 444], ["gene", 448], [".", 452], ["LH", 454], ["hydroxylates", 457], ["specific", 470], ["lysine", 479], ["residues", 486], ["in", 495], ["the", 498], ["collagen", 502], ["molecule", 511], ["that", 520], ["are", 525], ["precursors", 529], ["for", 540], ["the", 544], ["formation", 548], ["of", 558], ["cross", 561], ["-", 566], ["links", 567], ["which", 573], ["provide", 579], ["collagen", 587], ["with", 596], ["its", 601], ["tensile", 605], ["strength", 613], [".", 621], ["No", 623], ["disorder", 626], ["has", 635], ["been", 639], ["directly", 644], ["linked", 653], ["to", 660], ["decreased", 663], ["expression", 673], ["of", 684], ["LH2", 687], ["and", 691], ["LH3", 695], [",", 698], ["two", 700], ["other", 704], ["isoforms", 710], ["of", 719], ["LH", 722], [".", 724], ["This", 726], ["study", 731], ["describes", 737], ["3", 747], ["patients", 749], ["with", 758], ["mixed", 763], ["phenotypes", 769], ["of", 780], ["EDS", 783], [",", 786], ["who", 788], ["have", 792], ["significantly", 797], ["decreased", 811], ["mRNAs", 821], ["for", 827], ["LH2", 831], [",", 834], ["but", 836], ["normal", 840], ["levels", 847], ["of", 854], ["LH1", 857], ["and", 861], ["LH3", 865], ["mRNAs", 869], [",", 874], ["in", 876], ["their", 879], ["skin", 885], ["fibroblasts", 890], [".", 901], ["In", 903], ["contrast", 906], ["to", 915], ["the", 918], ["effect", 922], ["of", 929], ["LH1", 932], ["deficiency", 936], ["in", 947], ["EDS", 950], ["VI", 954], ["patients", 957], [",", 965], ["the", 967], ["decreased", 971], ["expression", 981], ["of", 992], ["LH2", 995], ["does", 999], ["not", 1004], ["affect", 1008], ["LH", 1015], ["activity", 1018], [",", 1026], ["bifunctional", 1028], ["collagen", 1041], ["cross", 1050], ["-", 1055], ["links", 1056], ["(", 1062], ["measured", 1063], ["after", 1072], ["reduction", 1078], ["as", 1088], ["dihydroxylysinonorleucine", 1091], ["(", 1117], ["DHLNL", 1118], [")", 1123], ["and", 1125], ["hydroxylysinonorleucine", 1129], ["(", 1153], ["HLNL", 1154], [")", 1158], [")", 1159], [",", 1160], ["or", 1162], ["helical", 1165], ["lysine", 1173], ["hydroxylation", 1180], ["in", 1194], ["these", 1197], ["cell", 1203], ["lines", 1208], [".", 1213], ["Sequence", 1215], ["analysis", 1224], ["of", 1233], ["full", 1236], ["length", 1241], ["LH2", 1248], ["cDNAs", 1252], ["and", 1258], ["1", 1262], ["kb", 1263], ["of", 1266], ["the", 1269], ["promoter", 1273], ["region", 1282], ["of", 1289], ["LH2", 1292], ["does", 1296], ["not", 1301], ["show", 1305], ["mutations", 1310], ["that", 1320], ["could", 1325], ["explain", 1331], ["the", 1339], ["decreased", 1343], ["expression", 1353], ["of", 1364], ["LH2", 1367], [".", 1370], ["These", 1372], ["results", 1378], ["suggest", 1386], ["that", 1394], ["the", 1399], ["deficiency", 1403], ["of", 1414], ["LH2", 1417], ["in", 1421], ["these", 1424], ["fibroblasts", 1430], ["may", 1442], ["be", 1446], ["caused", 1449], ["by", 1456], ["changes", 1459], ["in", 1467], ["other", 1470], ["factors", 1476], ["required", 1484], ["for", 1493], ["the", 1497], ["expression", 1501], ["of", 1512], ["LH2", 1515], [".", 1518]]}
{"context": "The analysis of gene expression data shows that many genes display similarity in their expression profiles suggesting some co-regulation. Here, we investigated the co-expression patterns in gene expression data and proposed a correlation-based research method to stratify individuals. Using blood from rheumatoid arthritis (RA) patients, we investigated the gene expression profiles from whole blood using Affymetrix microarray technology. Co-expressed genes were analyzed by a biclustering method, followed by gene ontology analysis of the relevant biclusters. Taking the type I interferon (IFN) pathway as an example, a classification algorithm was developed from the 102 RA patients and extended to 10 systemic lupus erythematosus (SLE) patients and 100 healthy volunteers to further characterize individuals. We developed a correlation-based algorithm referred to as Classification Algorithm Based on a Biological Signature (CABS), an alternative to other approaches focused specifically on the expression levels. This algorithm applied to the expression of 35 IFN-related genes showed that the IFN signature presented a heterogeneous expression between RA, SLE and healthy controls which could reflect the level of global IFN signature activation. Moreover, the monitoring of the IFN-related genes during the anti-TNF treatment identified changes in type I IFN gene activity induced in RA patients. In conclusion, we have proposed an original method to analyze genes sharing an expression pattern and a biological function showing that the activation levels of a biological signature could be characterized by its overall state of correlation.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "f6eab2419905453ca9b5d473fbd2264f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[203, 204], [183, 184]], "char_spans": [[1227, 1239], [1099, 1111]]}]}], "context_tokens": [["The", 0], ["analysis", 4], ["of", 13], ["gene", 16], ["expression", 21], ["data", 32], ["shows", 37], ["that", 43], ["many", 48], ["genes", 53], ["display", 59], ["similarity", 67], ["in", 78], ["their", 81], ["expression", 87], ["profiles", 98], ["suggesting", 107], ["some", 118], ["co", 123], ["-", 125], ["regulation", 126], [".", 136], ["Here", 138], [",", 142], ["we", 144], ["investigated", 147], ["the", 160], ["co", 164], ["-", 166], ["expression", 167], ["patterns", 178], ["in", 187], ["gene", 190], ["expression", 195], ["data", 206], ["and", 211], ["proposed", 215], ["a", 224], ["correlation", 226], ["-", 237], ["based", 238], ["research", 244], ["method", 253], ["to", 260], ["stratify", 263], ["individuals", 272], [".", 283], ["Using", 285], ["blood", 291], ["from", 297], ["rheumatoid", 302], ["arthritis", 313], ["(", 323], ["RA", 324], [")", 326], ["patients", 328], [",", 336], ["we", 338], ["investigated", 341], ["the", 354], ["gene", 358], ["expression", 363], ["profiles", 374], ["from", 383], ["whole", 388], ["blood", 394], ["using", 400], ["Affymetrix", 406], ["microarray", 417], ["technology", 428], [".", 438], ["Co", 440], ["-", 442], ["expressed", 443], ["genes", 453], ["were", 459], ["analyzed", 464], ["by", 473], ["a", 476], ["biclustering", 478], ["method", 491], [",", 497], ["followed", 499], ["by", 508], ["gene", 511], ["ontology", 516], ["analysis", 525], ["of", 534], ["the", 537], ["relevant", 541], ["biclusters", 550], [".", 560], ["Taking", 562], ["the", 569], ["type", 573], ["I", 578], ["interferon", 580], ["(", 591], ["IFN", 592], [")", 595], ["pathway", 597], ["as", 605], ["an", 608], ["example", 611], [",", 618], ["a", 620], ["classification", 622], ["algorithm", 637], ["was", 647], ["developed", 651], ["from", 661], ["the", 666], ["102", 670], ["RA", 674], ["patients", 677], ["and", 686], ["extended", 690], ["to", 699], ["10", 702], ["systemic", 705], ["lupus", 714], ["erythematosus", 720], ["(", 734], ["SLE", 735], [")", 738], ["patients", 740], ["and", 749], ["100", 753], ["healthy", 757], ["volunteers", 765], ["to", 776], ["further", 779], ["characterize", 787], ["individuals", 800], [".", 811], ["We", 813], ["developed", 816], ["a", 826], ["correlation", 828], ["-", 839], ["based", 840], ["algorithm", 846], ["referred", 856], ["to", 865], ["as", 868], ["Classification", 871], ["Algorithm", 886], ["Based", 896], ["on", 902], ["a", 905], ["Biological", 907], ["Signature", 918], ["(", 928], ["CABS", 929], [")", 933], [",", 934], ["an", 936], ["alternative", 939], ["to", 951], ["other", 954], ["approaches", 960], ["focused", 971], ["specifically", 979], ["on", 992], ["the", 995], ["expression", 999], ["levels", 1010], [".", 1016], ["This", 1018], ["algorithm", 1023], ["applied", 1033], ["to", 1041], ["the", 1044], ["expression", 1048], ["of", 1059], ["35", 1062], ["IFN", 1065], ["-", 1068], ["related", 1069], ["genes", 1077], ["showed", 1083], ["that", 1090], ["the", 1095], ["IFN", 1099], ["signature", 1103], ["presented", 1113], ["a", 1123], ["heterogeneous", 1125], ["expression", 1139], ["between", 1150], ["RA", 1158], [",", 1160], ["SLE", 1162], ["and", 1166], ["healthy", 1170], ["controls", 1178], ["which", 1187], ["could", 1193], ["reflect", 1199], ["the", 1207], ["level", 1211], ["of", 1217], ["global", 1220], ["IFN", 1227], ["signature", 1231], ["activation", 1241], [".", 1251], ["Moreover", 1253], [",", 1261], ["the", 1263], ["monitoring", 1267], ["of", 1278], ["the", 1281], ["IFN", 1285], ["-", 1288], ["related", 1289], ["genes", 1297], ["during", 1303], ["the", 1310], ["anti", 1314], ["-", 1318], ["TNF", 1319], ["treatment", 1323], ["identified", 1333], ["changes", 1344], ["in", 1352], ["type", 1355], ["I", 1360], ["IFN", 1362], ["gene", 1366], ["activity", 1371], ["induced", 1380], ["in", 1388], ["RA", 1391], ["patients", 1394], [".", 1402], ["In", 1404], ["conclusion", 1407], [",", 1417], ["we", 1419], ["have", 1422], ["proposed", 1427], ["an", 1436], ["original", 1439], ["method", 1448], ["to", 1455], ["analyze", 1458], ["genes", 1466], ["sharing", 1472], ["an", 1480], ["expression", 1483], ["pattern", 1494], ["and", 1502], ["a", 1506], ["biological", 1508], ["function", 1519], ["showing", 1528], ["that", 1536], ["the", 1541], ["activation", 1545], ["levels", 1556], ["of", 1563], ["a", 1566], ["biological", 1568], ["signature", 1579], ["could", 1589], ["be", 1595], ["characterized", 1598], ["by", 1612], ["its", 1615], ["overall", 1619], ["state", 1627], ["of", 1633], ["correlation", 1636], [".", 1647]]}
{"context": "A 65-year-old white man presented with all the clinical features of acrokeratosis paraneoplastica of Bazex, characterized by violaceous erythema and scaling of the nose, aural helices, fingers, and toes, with keratoderma and severe nail dystrophy. Examination of the patient for possible associated malignancy disclosed an asymptomatic squamous cell carcinoma at the oropharyngeal region. The skin lesions resolved almost completely following radiation therapy of the neoplasm, but the onychodystrophy persisted. This case report illustrates the importance of early recognition of Bazex syndrome.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "fecb8a65f2cf49afa3fcf85558513068", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[90, 91]], "char_spans": [[581, 594]]}]}], "context_tokens": [["A", 0], ["65-year", 2], ["-", 9], ["old", 10], ["white", 14], ["man", 20], ["presented", 24], ["with", 34], ["all", 39], ["the", 43], ["clinical", 47], ["features", 56], ["of", 65], ["acrokeratosis", 68], ["paraneoplastica", 82], ["of", 98], ["Bazex", 101], [",", 106], ["characterized", 108], ["by", 122], ["violaceous", 125], ["erythema", 136], ["and", 145], ["scaling", 149], ["of", 157], ["the", 160], ["nose", 164], [",", 168], ["aural", 170], ["helices", 176], [",", 183], ["fingers", 185], [",", 192], ["and", 194], ["toes", 198], [",", 202], ["with", 204], ["keratoderma", 209], ["and", 221], ["severe", 225], ["nail", 232], ["dystrophy", 237], [".", 246], ["Examination", 248], ["of", 260], ["the", 263], ["patient", 267], ["for", 275], ["possible", 279], ["associated", 288], ["malignancy", 299], ["disclosed", 310], ["an", 320], ["asymptomatic", 323], ["squamous", 336], ["cell", 345], ["carcinoma", 350], ["at", 360], ["the", 363], ["oropharyngeal", 367], ["region", 381], [".", 387], ["The", 389], ["skin", 393], ["lesions", 398], ["resolved", 406], ["almost", 415], ["completely", 422], ["following", 433], ["radiation", 443], ["therapy", 453], ["of", 461], ["the", 464], ["neoplasm", 468], [",", 476], ["but", 478], ["the", 482], ["onychodystrophy", 486], ["persisted", 502], [".", 511], ["This", 513], ["case", 518], ["report", 523], ["illustrates", 530], ["the", 542], ["importance", 546], ["of", 557], ["early", 560], ["recognition", 566], ["of", 578], ["Bazex", 581], ["syndrome", 587], [".", 595]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the presence of a BCR-ABL fusion gene, which is the result of a reciprocal translocation between chromosomes 9 and 22, and is cytogenetically visible as a shortened chromosome 22 (Philadelphia). Research during the past two decades has established that BCR-ABL is probably the pathogenetic pathway leading to CML, and that constitutive tyrosine kinase activity is central to BCR-ABL capacity to transform hematopoietic cells in vitro and in vivo. The tyrosine kinase inhibitor imatinib mesylate was introduced into the treatment regimen for CML in 1998. During the last few years, reports on chromosomal changes during imatinib treatment have been described. In this study, we evaluated the random aneuploidy rate with chromosomes 9 and 18 in bone marrow from treated and untreated patients. We found higher aneuploidy rates in both treated and untreated patients compared to the control group. In three patients who were treated with imatinib mesylate for more than 1.5 years, triploidy also appeared in some nuclei. To our knowledge, this is the first report on new chromosomal changes such as random aneuploidy and triploidy under imatinib treatment, but more studies are needed to investigate the long-term effect of the imatinib treatment on genetic instability.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "217e551aa17c458399dd0adc87a81d3c", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[13, 15], [76, 78], [55, 57]], "char_spans": [[69, 75], [426, 432], [304, 310]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["presence", 55], ["of", 64], ["a", 67], ["BCR", 69], ["-", 72], ["ABL", 73], ["fusion", 77], ["gene", 84], [",", 88], ["which", 90], ["is", 96], ["the", 99], ["result", 103], ["of", 110], ["a", 113], ["reciprocal", 115], ["translocation", 126], ["between", 140], ["chromosomes", 148], ["9", 160], ["and", 162], ["22", 166], [",", 168], ["and", 170], ["is", 174], ["cytogenetically", 177], ["visible", 193], ["as", 201], ["a", 204], ["shortened", 206], ["chromosome", 216], ["22", 227], ["(", 230], ["Philadelphia", 231], [")", 243], [".", 244], ["Research", 246], ["during", 255], ["the", 262], ["past", 266], ["two", 271], ["decades", 275], ["has", 283], ["established", 287], ["that", 299], ["BCR", 304], ["-", 307], ["ABL", 308], ["is", 312], ["probably", 315], ["the", 324], ["pathogenetic", 328], ["pathway", 341], ["leading", 349], ["to", 357], ["CML", 360], [",", 363], ["and", 365], ["that", 369], ["constitutive", 374], ["tyrosine", 387], ["kinase", 396], ["activity", 403], ["is", 412], ["central", 415], ["to", 423], ["BCR", 426], ["-", 429], ["ABL", 430], ["capacity", 434], ["to", 443], ["transform", 446], ["hematopoietic", 456], ["cells", 470], ["in", 476], ["vitro", 479], ["and", 485], ["in", 489], ["vivo", 492], [".", 496], ["The", 498], ["tyrosine", 502], ["kinase", 511], ["inhibitor", 518], ["imatinib", 528], ["mesylate", 537], ["was", 546], ["introduced", 550], ["into", 561], ["the", 566], ["treatment", 570], ["regimen", 580], ["for", 588], ["CML", 592], ["in", 596], ["1998", 599], [".", 603], ["During", 605], ["the", 612], ["last", 616], ["few", 621], ["years", 625], [",", 630], ["reports", 632], ["on", 640], ["chromosomal", 643], ["changes", 655], ["during", 663], ["imatinib", 670], ["treatment", 679], ["have", 689], ["been", 694], ["described", 699], [".", 708], ["In", 710], ["this", 713], ["study", 718], [",", 723], ["we", 725], ["evaluated", 728], ["the", 738], ["random", 742], ["aneuploidy", 749], ["rate", 760], ["with", 765], ["chromosomes", 770], ["9", 782], ["and", 784], ["18", 788], ["in", 791], ["bone", 794], ["marrow", 799], ["from", 806], ["treated", 811], ["and", 819], ["untreated", 823], ["patients", 833], [".", 841], ["We", 843], ["found", 846], ["higher", 852], ["aneuploidy", 859], ["rates", 870], ["in", 876], ["both", 879], ["treated", 884], ["and", 892], ["untreated", 896], ["patients", 906], ["compared", 915], ["to", 924], ["the", 927], ["control", 931], ["group", 939], [".", 944], ["In", 946], ["three", 949], ["patients", 955], ["who", 964], ["were", 968], ["treated", 973], ["with", 981], ["imatinib", 986], ["mesylate", 995], ["for", 1004], ["more", 1008], ["than", 1013], ["1.5", 1018], ["years", 1022], [",", 1027], ["triploidy", 1029], ["also", 1039], ["appeared", 1044], ["in", 1053], ["some", 1056], ["nuclei", 1061], [".", 1067], ["To", 1069], ["our", 1072], ["knowledge", 1076], [",", 1085], ["this", 1087], ["is", 1092], ["the", 1095], ["first", 1099], ["report", 1105], ["on", 1112], ["new", 1115], ["chromosomal", 1119], ["changes", 1131], ["such", 1139], ["as", 1144], ["random", 1147], ["aneuploidy", 1154], ["and", 1165], ["triploidy", 1169], ["under", 1179], ["imatinib", 1185], ["treatment", 1194], [",", 1203], ["but", 1205], ["more", 1209], ["studies", 1214], ["are", 1222], ["needed", 1226], ["to", 1233], ["investigate", 1236], ["the", 1248], ["long", 1252], ["-", 1256], ["term", 1257], ["effect", 1262], ["of", 1269], ["the", 1272], ["imatinib", 1276], ["treatment", 1285], ["on", 1295], ["genetic", 1298], ["instability", 1306], [".", 1317]]}
{"context": "The cellular cytoskeleton is composed of three fibrillar systems, namely actin microfilaments, microtubules and intermediate filaments (IFs). It not only is a structural system, which mediates functional compartmentalization, but also contributes to many cellular processes such as transport, mitosis, secretion, formation of cell extensions, intercellular communication and apoptosis. In this study, we have examined the distribution of four groups of IFs [cytokeratins (CKs), vimentin, desmin and lamins] in the somatic and germinal cells of the bovine ovary using RT-PCR and immunohistochemical techniques. Using RT-PCR, specific transcripts for all intermediate proteins studied (CK8, CK18, desmin, vimentin, lamin A/C and lamin B1) were detected. A characteristic immunohistochemical staining pattern was observed for the different IFs within the ovary. In this study, we used antibodies against type I CK (acidic CKs: CK14, CK18 and CK19) and type II CK (basic CKs: CK5 and CK8). Among these, only antibodies against CK18 gave a characteristic pattern of immunostaining in the ovary, which included the surface epithelium, the follicle cells, the endothelium of blood vessels and rete ovarii. Antibodies against all other CKs resulted in a weak staining of a limited number of cellular structures (CK5 and CK19) or were completely negative (CK8 and CK14, apart from the surface epithelium). Vimentin antibodies resulted occasionally in a weak staining of the granulosa cells of primary and secondary follicles. In late secondary follicles, the basal and the most apical follicle cells contacting the zona pellucida usually showed a marked immunostaining for vimentin. In antral follicles, three different immunostaining patterns for vimentin were observed. Desmin immunostaining was confined to the smooth muscle cells of blood vessels. Although mRNA for lamin A/C and lamin B1 could be demonstrated using RT-PCR, no immunostaining was found for lamins, neither in the follicle cells nor in the oocytes.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "91b011596fe84b0abcbf4608f94d3748", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[16, 17]], "char_spans": [[112, 133]]}]}], "context_tokens": [["The", 0], ["cellular", 4], ["cytoskeleton", 13], ["is", 26], ["composed", 29], ["of", 38], ["three", 41], ["fibrillar", 47], ["systems", 57], [",", 64], ["namely", 66], ["actin", 73], ["microfilaments", 79], [",", 93], ["microtubules", 95], ["and", 108], ["intermediate", 112], ["filaments", 125], ["(", 135], ["IFs", 136], [")", 139], [".", 140], ["It", 142], ["not", 145], ["only", 149], ["is", 154], ["a", 157], ["structural", 159], ["system", 170], [",", 176], ["which", 178], ["mediates", 184], ["functional", 193], ["compartmentalization", 204], [",", 224], ["but", 226], ["also", 230], ["contributes", 235], ["to", 247], ["many", 250], ["cellular", 255], ["processes", 264], ["such", 274], ["as", 279], ["transport", 282], [",", 291], ["mitosis", 293], [",", 300], ["secretion", 302], [",", 311], ["formation", 313], ["of", 323], ["cell", 326], ["extensions", 331], [",", 341], ["intercellular", 343], ["communication", 357], ["and", 371], ["apoptosis", 375], [".", 384], ["In", 386], ["this", 389], ["study", 394], [",", 399], ["we", 401], ["have", 404], ["examined", 409], ["the", 418], ["distribution", 422], ["of", 435], ["four", 438], ["groups", 443], ["of", 450], ["IFs", 453], ["[", 457], ["cytokeratins", 458], ["(", 471], ["CKs", 472], [")", 475], [",", 476], ["vimentin", 478], [",", 486], ["desmin", 488], ["and", 495], ["lamins", 499], ["]", 505], ["in", 507], ["the", 510], ["somatic", 514], ["and", 522], ["germinal", 526], ["cells", 535], ["of", 541], ["the", 544], ["bovine", 548], ["ovary", 555], ["using", 561], ["RT", 567], ["-", 569], ["PCR", 570], ["and", 574], ["immunohistochemical", 578], ["techniques", 598], [".", 608], ["Using", 610], ["RT", 616], ["-", 618], ["PCR", 619], [",", 622], ["specific", 624], ["transcripts", 633], ["for", 645], ["all", 649], ["intermediate", 653], ["proteins", 666], ["studied", 675], ["(", 683], ["CK8", 684], [",", 687], ["CK18", 689], [",", 693], ["desmin", 695], [",", 701], ["vimentin", 703], [",", 711], ["lamin", 713], ["A", 719], ["/", 720], ["C", 721], ["and", 723], ["lamin", 727], ["B1", 733], [")", 735], ["were", 737], ["detected", 742], [".", 750], ["A", 752], ["characteristic", 754], ["immunohistochemical", 769], ["staining", 789], ["pattern", 798], ["was", 806], ["observed", 810], ["for", 819], ["the", 823], ["different", 827], ["IFs", 837], ["within", 841], ["the", 848], ["ovary", 852], [".", 857], ["In", 859], ["this", 862], ["study", 867], [",", 872], ["we", 874], ["used", 877], ["antibodies", 882], ["against", 893], ["type", 901], ["I", 906], ["CK", 908], ["(", 911], ["acidic", 912], ["CKs", 919], [":", 922], ["CK14", 924], [",", 928], ["CK18", 930], ["and", 935], ["CK19", 939], [")", 943], ["and", 945], ["type", 949], ["II", 954], ["CK", 957], ["(", 960], ["basic", 961], ["CKs", 967], [":", 970], ["CK5", 972], ["and", 976], ["CK8", 980], [")", 983], [".", 984], ["Among", 986], ["these", 992], [",", 997], ["only", 999], ["antibodies", 1004], ["against", 1015], ["CK18", 1023], ["gave", 1028], ["a", 1033], ["characteristic", 1035], ["pattern", 1050], ["of", 1058], ["immunostaining", 1061], ["in", 1076], ["the", 1079], ["ovary", 1083], [",", 1088], ["which", 1090], ["included", 1096], ["the", 1105], ["surface", 1109], ["epithelium", 1117], [",", 1127], ["the", 1129], ["follicle", 1133], ["cells", 1142], [",", 1147], ["the", 1149], ["endothelium", 1153], ["of", 1165], ["blood", 1168], ["vessels", 1174], ["and", 1182], ["rete", 1186], ["ovarii", 1191], [".", 1197], ["Antibodies", 1199], ["against", 1210], ["all", 1218], ["other", 1222], ["CKs", 1228], ["resulted", 1232], ["in", 1241], ["a", 1244], ["weak", 1246], ["staining", 1251], ["of", 1260], ["a", 1263], ["limited", 1265], ["number", 1273], ["of", 1280], ["cellular", 1283], ["structures", 1292], ["(", 1303], ["CK5", 1304], ["and", 1308], ["CK19", 1312], [")", 1316], ["or", 1318], ["were", 1321], ["completely", 1326], ["negative", 1337], ["(", 1346], ["CK8", 1347], ["and", 1351], ["CK14", 1355], [",", 1359], ["apart", 1361], ["from", 1367], ["the", 1372], ["surface", 1376], ["epithelium", 1384], [")", 1394], [".", 1395], ["Vimentin", 1397], ["antibodies", 1406], ["resulted", 1417], ["occasionally", 1426], ["in", 1439], ["a", 1442], ["weak", 1444], ["staining", 1449], ["of", 1458], ["the", 1461], ["granulosa", 1465], ["cells", 1475], ["of", 1481], ["primary", 1484], ["and", 1492], ["secondary", 1496], ["follicles", 1506], [".", 1515], ["In", 1517], ["late", 1520], ["secondary", 1525], ["follicles", 1535], [",", 1544], ["the", 1546], ["basal", 1550], ["and", 1556], ["the", 1560], ["most", 1564], ["apical", 1569], ["follicle", 1576], ["cells", 1585], ["contacting", 1591], ["the", 1602], ["zona", 1606], ["pellucida", 1611], ["usually", 1621], ["showed", 1629], ["a", 1636], ["marked", 1638], ["immunostaining", 1645], ["for", 1660], ["vimentin", 1664], [".", 1672], ["In", 1674], ["antral", 1677], ["follicles", 1684], [",", 1693], ["three", 1695], ["different", 1701], ["immunostaining", 1711], ["patterns", 1726], ["for", 1735], ["vimentin", 1739], ["were", 1748], ["observed", 1753], [".", 1761], ["Desmin", 1763], ["immunostaining", 1770], ["was", 1785], ["confined", 1789], ["to", 1798], ["the", 1801], ["smooth", 1805], ["muscle", 1812], ["cells", 1819], ["of", 1825], ["blood", 1828], ["vessels", 1834], [".", 1841], ["Although", 1843], ["mRNA", 1852], ["for", 1857], ["lamin", 1861], ["A", 1867], ["/", 1868], ["C", 1869], ["and", 1871], ["lamin", 1875], ["B1", 1881], ["could", 1884], ["be", 1890], ["demonstrated", 1893], ["using", 1906], ["RT", 1912], ["-", 1914], ["PCR", 1915], [",", 1918], ["no", 1920], ["immunostaining", 1923], ["was", 1938], ["found", 1942], ["for", 1948], ["lamins", 1952], [",", 1958], ["neither", 1960], ["in", 1968], ["the", 1971], ["follicle", 1975], ["cells", 1984], ["nor", 1990], ["in", 1994], ["the", 1997], ["oocytes", 2001], [".", 2008]]}
{"context": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is projected to be completed in 2016. The outcomes achieved with this specific reversal agent are likely to be of continued interest to treating physicians.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "6ce8edfd805842feb2b5ebab77cc5750", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [140, 140], [23, 23], [9, 9], [50, 50], [193, 193], [81, 81]], "char_spans": [[405, 414], [903, 912], [164, 173], [72, 81], [338, 347], [1219, 1228], [550, 559]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["specifically", 47], ["targeted", 60], ["to", 69], ["dabigatran", 72], [".", 82], ["It", 84], ["has", 87], ["demonstrated", 91], ["prompt", 104], ["and", 111], ["durable", 115], ["reversal", 123], ["of", 132], ["the", 135], ["anticoagulant", 139], ["effects", 153], ["of", 161], ["dabigatran", 164], ["in", 175], ["animal", 178], ["studies", 185], ["and", 193], ["phase", 197], ["1", 203], ["studies", 205], ["of", 213], ["young", 216], [",", 221], ["elderly", 223], [",", 230], ["and", 232], ["renally", 236], ["impaired", 244], ["volunteers", 253], [".", 263], ["Although", 265], ["elective", 274], ["invasive", 283], ["procedures", 292], ["and", 303], ["most", 307], ["bleeding", 312], ["complications", 321], ["in", 335], ["dabigatran", 338], ["-", 348], ["treated", 349], ["patients", 357], ["can", 366], ["be", 370], ["managed", 373], ["by", 381], ["temporarily", 384], ["stopping", 396], ["dabigatran", 405], ["therapy", 416], ["and", 424], ["using", 428], ["supportive", 434], ["measures", 445], [",", 453], ["there", 455], ["are", 461], ["rare", 465], ["clinical", 470], ["situations", 479], ["that", 490], ["require", 495], ["urgent", 503], ["reversal", 510], ["of", 519], ["the", 522], ["anticoagulant", 526], ["effect", 540], ["of", 547], ["dabigatran", 550], [".", 560], ["The", 562], ["effectiveness", 566], ["and", 580], ["safety", 584], ["of", 591], ["5", 594], ["g", 596], ["of", 598], ["intravenous", 601], ["idarucizumab", 613], ["is", 626], ["being", 629], ["investigated", 635], ["in", 648], ["a", 651], ["prospective", 653], [",", 664], ["open", 666], ["-", 670], ["label", 671], [",", 676], ["single", 678], ["-", 684], ["cohort", 685], ["study", 692], ["in", 698], ["patients", 701], ["with", 710], ["serious", 715], ["bleeding", 723], ["or", 732], ["in", 735], ["those", 738], ["requiring", 744], ["an", 754], ["urgent", 757], ["procedure", 764], [".", 773], ["In", 775], ["an", 778], ["interim", 781], ["analysis", 789], ["of", 798], ["the", 801], ["first", 805], ["90", 811], ["participants", 814], [",", 826], ["idarucizumab", 828], ["rapidly", 841], ["and", 849], ["completely", 853], ["reversed", 864], ["the", 873], ["anticoagulant", 877], ["activity", 891], ["of", 900], ["dabigatran", 903], ["in", 914], ["88%-98", 917], ["%", 923], ["of", 925], ["participants", 928], [",", 940], ["and", 942], ["there", 946], ["were", 952], ["no", 957], ["safety", 960], ["concerns", 967], [",", 975], ["with", 977], ["no", 982], ["deaths", 985], ["or", 992], ["serious", 995], ["adverse", 1003], ["events", 1011], ["being", 1018], ["attributable", 1024], ["to", 1037], ["idarucizumab", 1040], [".", 1052], ["Supported", 1054], ["by", 1064], ["these", 1067], ["interim", 1073], ["results", 1081], [",", 1088], ["idarucizumab", 1090], ["has", 1103], ["been", 1107], ["approved", 1112], ["in", 1121], ["the", 1124], ["United", 1128], ["States", 1135], ["and", 1142], ["the", 1146], ["European", 1150], ["Union", 1159], ["for", 1165], ["use", 1169], ["when", 1173], ["reversal", 1178], ["of", 1187], ["the", 1190], ["anticoagulant", 1194], ["effects", 1208], ["of", 1216], ["dabigatran", 1219], ["is", 1230], ["needed", 1233], ["for", 1240], ["emergency", 1244], ["surgery", 1254], ["/", 1261], ["urgent", 1262], ["procedures", 1269], ["or", 1280], ["in", 1283], ["patients", 1286], ["with", 1295], ["life", 1300], ["-", 1304], ["threatening", 1305], ["or", 1317], ["uncontrolled", 1320], ["bleeding", 1333], [".", 1341], ["Clinical", 1343], ["use", 1352], ["of", 1356], ["idarucizumab", 1359], ["should", 1372], ["follow", 1379], ["the", 1386], ["same", 1390], ["processes", 1395], ["as", 1405], ["patient", 1408], ["enrollment", 1416], ["in", 1427], ["this", 1430], ["study", 1435], [",", 1440], ["which", 1442], ["is", 1448], ["projected", 1451], ["to", 1461], ["be", 1464], ["completed", 1467], ["in", 1477], ["2016", 1480], [".", 1484], ["The", 1486], ["outcomes", 1490], ["achieved", 1499], ["with", 1508], ["this", 1513], ["specific", 1518], ["reversal", 1527], ["agent", 1536], ["are", 1542], ["likely", 1546], ["to", 1553], ["be", 1556], ["of", 1559], ["continued", 1562], ["interest", 1572], ["to", 1581], ["treating", 1584], ["physicians", 1593], [".", 1603]]}
{"context": "Speech and language disorders are some of the most common referral reasons to child development centers accounting for approximately 40% of cases. Stuttering is a disorder in which involuntary repetition, prolongation, or cessation of the sound precludes the flow of speech. About 5% of individuals in the general population have a stuttering problem, and about 80% of the affected children recover naturally. The causal factors of stuttering remain uncertain in most cases; studies suggest that genetic factors are responsible for 70% of the variance in liability for stuttering, whereas the remaining 30% is due to environmental effects supporting a complex cause of the disorder. The use of high-resolution genome wide array comparative genomic hybridization has proven to be a powerful strategy to narrow down candidate regions for complex disorders. We report on a case with a complex set of speech and language difficulties including stuttering who presented with a 10\u2009Mb deletion of chromosome region 7q33-35 causing the deletion of several genes and the disruption of CNTNAP2 by deleting the first three exons of the gene. CNTNAP2 is known to be involved in the cause of language and speech disorders and autism spectrum disorder and is in the same pathway as FOXP2, another important language gene, which makes it a candidate gene for causal studies speech and language disorders such as stuttering.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "9680c264ad214a85a779948408ae403b", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[221, 221]], "char_spans": [[1268, 1272]]}]}], "context_tokens": [["Speech", 0], ["and", 7], ["language", 11], ["disorders", 20], ["are", 30], ["some", 34], ["of", 39], ["the", 42], ["most", 46], ["common", 51], ["referral", 58], ["reasons", 67], ["to", 75], ["child", 78], ["development", 84], ["centers", 96], ["accounting", 104], ["for", 115], ["approximately", 119], ["40", 133], ["%", 135], ["of", 137], ["cases", 140], [".", 145], ["Stuttering", 147], ["is", 158], ["a", 161], ["disorder", 163], ["in", 172], ["which", 175], ["involuntary", 181], ["repetition", 193], [",", 203], ["prolongation", 205], [",", 217], ["or", 219], ["cessation", 222], ["of", 232], ["the", 235], ["sound", 239], ["precludes", 245], ["the", 255], ["flow", 259], ["of", 264], ["speech", 267], [".", 273], ["About", 275], ["5", 281], ["%", 282], ["of", 284], ["individuals", 287], ["in", 299], ["the", 302], ["general", 306], ["population", 314], ["have", 325], ["a", 330], ["stuttering", 332], ["problem", 343], [",", 350], ["and", 352], ["about", 356], ["80", 362], ["%", 364], ["of", 366], ["the", 369], ["affected", 373], ["children", 382], ["recover", 391], ["naturally", 399], [".", 408], ["The", 410], ["causal", 414], ["factors", 421], ["of", 429], ["stuttering", 432], ["remain", 443], ["uncertain", 450], ["in", 460], ["most", 463], ["cases", 468], [";", 473], ["studies", 475], ["suggest", 483], ["that", 491], ["genetic", 496], ["factors", 504], ["are", 512], ["responsible", 516], ["for", 528], ["70", 532], ["%", 534], ["of", 536], ["the", 539], ["variance", 543], ["in", 552], ["liability", 555], ["for", 565], ["stuttering", 569], [",", 579], ["whereas", 581], ["the", 589], ["remaining", 593], ["30", 603], ["%", 605], ["is", 607], ["due", 610], ["to", 614], ["environmental", 617], ["effects", 631], ["supporting", 639], ["a", 650], ["complex", 652], ["cause", 660], ["of", 666], ["the", 669], ["disorder", 673], [".", 681], ["The", 683], ["use", 687], ["of", 691], ["high", 694], ["-", 698], ["resolution", 699], ["genome", 710], ["wide", 717], ["array", 722], ["comparative", 728], ["genomic", 740], ["hybridization", 748], ["has", 762], ["proven", 766], ["to", 773], ["be", 776], ["a", 779], ["powerful", 781], ["strategy", 790], ["to", 799], ["narrow", 802], ["down", 809], ["candidate", 814], ["regions", 824], ["for", 832], ["complex", 836], ["disorders", 844], [".", 853], ["We", 855], ["report", 858], ["on", 865], ["a", 868], ["case", 870], ["with", 875], ["a", 880], ["complex", 882], ["set", 890], ["of", 894], ["speech", 897], ["and", 904], ["language", 908], ["difficulties", 917], ["including", 930], ["stuttering", 940], ["who", 951], ["presented", 955], ["with", 965], ["a", 970], ["10", 972], ["Mb", 975], ["deletion", 978], ["of", 987], ["chromosome", 990], ["region", 1001], ["7q33", 1008], ["-", 1012], ["35", 1013], ["causing", 1016], ["the", 1024], ["deletion", 1028], ["of", 1037], ["several", 1040], ["genes", 1048], ["and", 1054], ["the", 1058], ["disruption", 1062], ["of", 1073], ["CNTNAP2", 1076], ["by", 1084], ["deleting", 1087], ["the", 1096], ["first", 1100], ["three", 1106], ["exons", 1112], ["of", 1118], ["the", 1121], ["gene", 1125], [".", 1129], ["CNTNAP2", 1131], ["is", 1139], ["known", 1142], ["to", 1148], ["be", 1151], ["involved", 1154], ["in", 1163], ["the", 1166], ["cause", 1170], ["of", 1176], ["language", 1179], ["and", 1188], ["speech", 1192], ["disorders", 1199], ["and", 1209], ["autism", 1213], ["spectrum", 1220], ["disorder", 1229], ["and", 1238], ["is", 1242], ["in", 1245], ["the", 1248], ["same", 1252], ["pathway", 1257], ["as", 1265], ["FOXP2", 1268], [",", 1273], ["another", 1275], ["important", 1283], ["language", 1293], ["gene", 1302], [",", 1306], ["which", 1308], ["makes", 1314], ["it", 1320], ["a", 1323], ["candidate", 1325], ["gene", 1335], ["for", 1340], ["causal", 1344], ["studies", 1351], ["speech", 1359], ["and", 1366], ["language", 1370], ["disorders", 1379], ["such", 1389], ["as", 1394], ["stuttering", 1397], [".", 1407]]}
{"context": "Mowat-Wilson syndrome (MWS) is a rare mental retardation-multiple congenital anomalies syndrome associated with typical facial dysmorphism. Patients can show a variety of other anomalies like short stature, microcephaly, Hirschsprung disease, malformations of the brain, seizures, congenital heart defects and urogenital anomalies. Mutations leading to haploinsufficiency of the ZFHX1B gene have been described as the underlying cause of this condition. We report on the clinical findings in a 2(1/2)-year-old boy with some aspects out of the MWS-spectrum in addition to unusual anomalies and a novel missense mutation in the ZFHX1B gene.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c280b30564a84cffb0c76349584f7d2f", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[60, 60], [106, 106]], "char_spans": [[379, 384], [626, 631]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["rare", 33], ["mental", 38], ["retardation", 45], ["-", 56], ["multiple", 57], ["congenital", 66], ["anomalies", 77], ["syndrome", 87], ["associated", 96], ["with", 107], ["typical", 112], ["facial", 120], ["dysmorphism", 127], [".", 138], ["Patients", 140], ["can", 149], ["show", 153], ["a", 158], ["variety", 160], ["of", 168], ["other", 171], ["anomalies", 177], ["like", 187], ["short", 192], ["stature", 198], [",", 205], ["microcephaly", 207], [",", 219], ["Hirschsprung", 221], ["disease", 234], [",", 241], ["malformations", 243], ["of", 257], ["the", 260], ["brain", 264], [",", 269], ["seizures", 271], [",", 279], ["congenital", 281], ["heart", 292], ["defects", 298], ["and", 306], ["urogenital", 310], ["anomalies", 321], [".", 330], ["Mutations", 332], ["leading", 342], ["to", 350], ["haploinsufficiency", 353], ["of", 372], ["the", 375], ["ZFHX1B", 379], ["gene", 386], ["have", 391], ["been", 396], ["described", 401], ["as", 411], ["the", 414], ["underlying", 418], ["cause", 429], ["of", 435], ["this", 438], ["condition", 443], [".", 452], ["We", 454], ["report", 457], ["on", 464], ["the", 467], ["clinical", 471], ["findings", 480], ["in", 489], ["a", 492], ["2(1/2)-year", 494], ["-", 505], ["old", 506], ["boy", 510], ["with", 514], ["some", 519], ["aspects", 524], ["out", 532], ["of", 536], ["the", 539], ["MWS", 543], ["-", 546], ["spectrum", 547], ["in", 556], ["addition", 559], ["to", 568], ["unusual", 571], ["anomalies", 579], ["and", 589], ["a", 593], ["novel", 595], ["missense", 601], ["mutation", 610], ["in", 619], ["the", 622], ["ZFHX1B", 626], ["gene", 633], [".", 637]]}
{"context": "Gaucher disease is an inborn recessive autosomal disease due to a partial deficiency of the lysosomal enzyme beta glucocerebrosidase. The deficient activity leads to accumulation of the lipid glucocerebroside in the liver, the spleen and bone marrow with concomitant anemia and thrombocytopenia. Patients with Gaucher disease have been classified in three types: type I is the more common, neurological manifestations occur in types II and III. Enzyme replacement therapy (ERT) with modified placental human glucocerebrosidase (ceredase) or recombinant glucocerebrosidase (cerezyme) is effective in most type I Gaucher disease and has become the current standard care administered to thousand of patients worldwide. ERT has obviated the need for bone marrow transplantation and virtually eliminated the need for splenectomy. We report here the French study including adults and children. ERT of 30 to 60 U/K every two weeks as starting dose was administrated to 108 patients with severe type I Gaucher disease. ERT fully reverse many of the manifestations of the disease. ERT regimen alleviated fatigue, and hematological and visceral signs and symptoms in nearly all severely-ill patients. Skeletal responses to treatment develop much more slowly than hematological or visceral responses. Studies in pediatrics show that the disease is more severe in children. These children should be treated early in the course of their disease to avoid irreparable damage. Hematological manifestation in type II cannot be reversed with enzyme replacement. In type III treatment can rarely reverse neurological deficit. Gaucher disease is also an excellent candidate for gene therapy.", "qas": [{"question": "Which enzyme is deficient in Gaucher's disease?", "answers": ["Beta glucocerebrosidase"], "qid": "edb5b97a3a7341bdb6cfc2b80433d4f0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["deficient", 16], ["in", 26], ["Gaucher", 29], ["'s", 36], ["disease", 39], ["?", 46]], "detected_answers": [{"text": "Beta glucocerebrosidase", "token_spans": [[17, 18]], "char_spans": [[109, 131]]}]}], "context_tokens": [["Gaucher", 0], ["disease", 8], ["is", 16], ["an", 19], ["inborn", 22], ["recessive", 29], ["autosomal", 39], ["disease", 49], ["due", 57], ["to", 61], ["a", 64], ["partial", 66], ["deficiency", 74], ["of", 85], ["the", 88], ["lysosomal", 92], ["enzyme", 102], ["beta", 109], ["glucocerebrosidase", 114], [".", 132], ["The", 134], ["deficient", 138], ["activity", 148], ["leads", 157], ["to", 163], ["accumulation", 166], ["of", 179], ["the", 182], ["lipid", 186], ["glucocerebroside", 192], ["in", 209], ["the", 212], ["liver", 216], [",", 221], ["the", 223], ["spleen", 227], ["and", 234], ["bone", 238], ["marrow", 243], ["with", 250], ["concomitant", 255], ["anemia", 267], ["and", 274], ["thrombocytopenia", 278], [".", 294], ["Patients", 296], ["with", 305], ["Gaucher", 310], ["disease", 318], ["have", 326], ["been", 331], ["classified", 336], ["in", 347], ["three", 350], ["types", 356], [":", 361], ["type", 363], ["I", 368], ["is", 370], ["the", 373], ["more", 377], ["common", 382], [",", 388], ["neurological", 390], ["manifestations", 403], ["occur", 418], ["in", 424], ["types", 427], ["II", 433], ["and", 436], ["III", 440], [".", 443], ["Enzyme", 445], ["replacement", 452], ["therapy", 464], ["(", 472], ["ERT", 473], [")", 476], ["with", 478], ["modified", 483], ["placental", 492], ["human", 502], ["glucocerebrosidase", 508], ["(", 527], ["ceredase", 528], [")", 536], ["or", 538], ["recombinant", 541], ["glucocerebrosidase", 553], ["(", 572], ["cerezyme", 573], [")", 581], ["is", 583], ["effective", 586], ["in", 596], ["most", 599], ["type", 604], ["I", 609], ["Gaucher", 611], ["disease", 619], ["and", 627], ["has", 631], ["become", 635], ["the", 642], ["current", 646], ["standard", 654], ["care", 663], ["administered", 668], ["to", 681], ["thousand", 684], ["of", 693], ["patients", 696], ["worldwide", 705], [".", 714], ["ERT", 716], ["has", 720], ["obviated", 724], ["the", 733], ["need", 737], ["for", 742], ["bone", 746], ["marrow", 751], ["transplantation", 758], ["and", 774], ["virtually", 778], ["eliminated", 788], ["the", 799], ["need", 803], ["for", 808], ["splenectomy", 812], [".", 823], ["We", 825], ["report", 828], ["here", 835], ["the", 840], ["French", 844], ["study", 851], ["including", 857], ["adults", 867], ["and", 874], ["children", 878], [".", 886], ["ERT", 888], ["of", 892], ["30", 895], ["to", 898], ["60", 901], ["U", 904], ["/", 905], ["K", 906], ["every", 908], ["two", 914], ["weeks", 918], ["as", 924], ["starting", 927], ["dose", 936], ["was", 941], ["administrated", 945], ["to", 959], ["108", 962], ["patients", 966], ["with", 975], ["severe", 980], ["type", 987], ["I", 992], ["Gaucher", 994], ["disease", 1002], [".", 1009], ["ERT", 1011], ["fully", 1015], ["reverse", 1021], ["many", 1029], ["of", 1034], ["the", 1037], ["manifestations", 1041], ["of", 1056], ["the", 1059], ["disease", 1063], [".", 1070], ["ERT", 1072], ["regimen", 1076], ["alleviated", 1084], ["fatigue", 1095], [",", 1102], ["and", 1104], ["hematological", 1108], ["and", 1122], ["visceral", 1126], ["signs", 1135], ["and", 1141], ["symptoms", 1145], ["in", 1154], ["nearly", 1157], ["all", 1164], ["severely", 1168], ["-", 1176], ["ill", 1177], ["patients", 1181], [".", 1189], ["Skeletal", 1191], ["responses", 1200], ["to", 1210], ["treatment", 1213], ["develop", 1223], ["much", 1231], ["more", 1236], ["slowly", 1241], ["than", 1248], ["hematological", 1253], ["or", 1267], ["visceral", 1270], ["responses", 1279], [".", 1288], ["Studies", 1290], ["in", 1298], ["pediatrics", 1301], ["show", 1312], ["that", 1317], ["the", 1322], ["disease", 1326], ["is", 1334], ["more", 1337], ["severe", 1342], ["in", 1349], ["children", 1352], [".", 1360], ["These", 1362], ["children", 1368], ["should", 1377], ["be", 1384], ["treated", 1387], ["early", 1395], ["in", 1401], ["the", 1404], ["course", 1408], ["of", 1415], ["their", 1418], ["disease", 1424], ["to", 1432], ["avoid", 1435], ["irreparable", 1441], ["damage", 1453], [".", 1459], ["Hematological", 1461], ["manifestation", 1475], ["in", 1489], ["type", 1492], ["II", 1497], ["can", 1500], ["not", 1503], ["be", 1507], ["reversed", 1510], ["with", 1519], ["enzyme", 1524], ["replacement", 1531], [".", 1542], ["In", 1544], ["type", 1547], ["III", 1552], ["treatment", 1556], ["can", 1566], ["rarely", 1570], ["reverse", 1577], ["neurological", 1585], ["deficit", 1598], [".", 1605], ["Gaucher", 1607], ["disease", 1615], ["is", 1623], ["also", 1626], ["an", 1631], ["excellent", 1634], ["candidate", 1644], ["for", 1654], ["gene", 1658], ["therapy", 1663], [".", 1670]]}
{"context": "The molecular functions of TMEM132 genes remain poorly understood and under-investigated despite their mutations associated with non-syndromic hearing loss, panic disorder and cancer. Here we show the full domain architecture of human TMEM132 family proteins solved using in-depth sequence and structural analysis. We reveal them to be five previously unappreciated cell adhesion molecules whose domain architecture has an early holozoan origin prior to the emergence of choanoflagellates and metazoa. The extra-cellular portions of TMEM132 proteins contain five conserved domains including three tandem immunoglobulin domains, and a cohesin domain homologue, the first such domain found in animals. These findings strongly predict a cellular adhesion function for TMEM132 family, connecting the extracellular medium with the intracellular actin cytoskeleton. luis.sanchez-pulido@igmm.ed.ac.uk. Supplementary data are available at Bioinformatics online.", "qas": [{"question": "What is the function of the TMEM132 genes?", "answers": ["Cellular adhesion function"], "qid": "966b0a95d1b84227ac890a3daaef2086", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["the", 24], ["TMEM132", 28], ["genes", 36], ["?", 41]], "detected_answers": [{"text": "Cellular adhesion function", "token_spans": [[116, 118]], "char_spans": [[734, 759]]}]}], "context_tokens": [["The", 0], ["molecular", 4], ["functions", 14], ["of", 24], ["TMEM132", 27], ["genes", 35], ["remain", 41], ["poorly", 48], ["understood", 55], ["and", 66], ["under", 70], ["-", 75], ["investigated", 76], ["despite", 89], ["their", 97], ["mutations", 103], ["associated", 113], ["with", 124], ["non", 129], ["-", 132], ["syndromic", 133], ["hearing", 143], ["loss", 151], [",", 155], ["panic", 157], ["disorder", 163], ["and", 172], ["cancer", 176], [".", 182], ["Here", 184], ["we", 189], ["show", 192], ["the", 197], ["full", 201], ["domain", 206], ["architecture", 213], ["of", 226], ["human", 229], ["TMEM132", 235], ["family", 243], ["proteins", 250], ["solved", 259], ["using", 266], ["in", 272], ["-", 274], ["depth", 275], ["sequence", 281], ["and", 290], ["structural", 294], ["analysis", 305], [".", 313], ["We", 315], ["reveal", 318], ["them", 325], ["to", 330], ["be", 333], ["five", 336], ["previously", 341], ["unappreciated", 352], ["cell", 366], ["adhesion", 371], ["molecules", 380], ["whose", 390], ["domain", 396], ["architecture", 403], ["has", 416], ["an", 420], ["early", 423], ["holozoan", 429], ["origin", 438], ["prior", 445], ["to", 451], ["the", 454], ["emergence", 458], ["of", 468], ["choanoflagellates", 471], ["and", 489], ["metazoa", 493], [".", 500], ["The", 502], ["extra", 506], ["-", 511], ["cellular", 512], ["portions", 521], ["of", 530], ["TMEM132", 533], ["proteins", 541], ["contain", 550], ["five", 558], ["conserved", 563], ["domains", 573], ["including", 581], ["three", 591], ["tandem", 597], ["immunoglobulin", 604], ["domains", 619], [",", 626], ["and", 628], ["a", 632], ["cohesin", 634], ["domain", 642], ["homologue", 649], [",", 658], ["the", 660], ["first", 664], ["such", 670], ["domain", 675], ["found", 682], ["in", 688], ["animals", 691], [".", 698], ["These", 700], ["findings", 706], ["strongly", 715], ["predict", 724], ["a", 732], ["cellular", 734], ["adhesion", 743], ["function", 752], ["for", 761], ["TMEM132", 765], ["family", 773], [",", 779], ["connecting", 781], ["the", 792], ["extracellular", 796], ["medium", 810], ["with", 817], ["the", 822], ["intracellular", 826], ["actin", 840], ["cytoskeleton", 846], [".", 858], ["luis.sanchez-pulido@igmm.ed.ac.uk", 860], [".", 893], ["Supplementary", 895], ["data", 909], ["are", 914], ["available", 918], ["at", 928], ["Bioinformatics", 931], ["online", 946], [".", 952]]}
{"context": "DNA damage is preferentially repaired in the transcribed strand of many active genes. Although the concept of DNA repair coupled with transcription has been widely accepted, its mechanisms remain elusive. We recently reported that in Chinese hamster ovary cells while ultraviolet light-induced cyclobutane pyrimidine dimers (CPDs) are preferentially repaired in the transcribed strand of dihydrofolate reductase gene, CPDs are efficiently repaired in both strands of adenine phosphoribosyltransferase (APRT) locus, in either a transcribed or nontranscribed APRT gene (1). These results suggested that the transcription dependence of repair may depend on genomic context. To test this hypothesis, we constructed transfectant cell lines containing a single, actively transcribed APRT gene, integrated at different genomic sites. Mapping of CPD repair in the integrated APRT genes in three transfectant cell lines revealed two distinct repair patterns, either preferential repair of CPDs in the transcribed strand or very poor repair in both strands. Similar kinetics of micrococcal nuclease digestion were seen for all three transfectant APRT gene domains and endogenous APRT locus. Our results suggest that both the efficiency and strand-specificity of repair of an actively transcribed gene are profoundly affected by genomic context but do not reflect changes in first order nucleosomal structure.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d161b97805de4abe9ce8e5aff755c987", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[159, 160], [58, 59], [7, 8]], "char_spans": [[992, 1009], [366, 383], [45, 62]]}]}], "context_tokens": [["DNA", 0], ["damage", 4], ["is", 11], ["preferentially", 14], ["repaired", 29], ["in", 38], ["the", 41], ["transcribed", 45], ["strand", 57], ["of", 64], ["many", 67], ["active", 72], ["genes", 79], [".", 84], ["Although", 86], ["the", 95], ["concept", 99], ["of", 107], ["DNA", 110], ["repair", 114], ["coupled", 121], ["with", 129], ["transcription", 134], ["has", 148], ["been", 152], ["widely", 157], ["accepted", 164], [",", 172], ["its", 174], ["mechanisms", 178], ["remain", 189], ["elusive", 196], [".", 203], ["We", 205], ["recently", 208], ["reported", 217], ["that", 226], ["in", 231], ["Chinese", 234], ["hamster", 242], ["ovary", 250], ["cells", 256], ["while", 262], ["ultraviolet", 268], ["light", 280], ["-", 285], ["induced", 286], ["cyclobutane", 294], ["pyrimidine", 306], ["dimers", 317], ["(", 324], ["CPDs", 325], [")", 329], ["are", 331], ["preferentially", 335], ["repaired", 350], ["in", 359], ["the", 362], ["transcribed", 366], ["strand", 378], ["of", 385], ["dihydrofolate", 388], ["reductase", 402], ["gene", 412], [",", 416], ["CPDs", 418], ["are", 423], ["efficiently", 427], ["repaired", 439], ["in", 448], ["both", 451], ["strands", 456], ["of", 464], ["adenine", 467], ["phosphoribosyltransferase", 475], ["(", 501], ["APRT", 502], [")", 506], ["locus", 508], [",", 513], ["in", 515], ["either", 518], ["a", 525], ["transcribed", 527], ["or", 539], ["nontranscribed", 542], ["APRT", 557], ["gene", 562], ["(", 567], ["1", 568], [")", 569], [".", 570], ["These", 572], ["results", 578], ["suggested", 586], ["that", 596], ["the", 601], ["transcription", 605], ["dependence", 619], ["of", 630], ["repair", 633], ["may", 640], ["depend", 644], ["on", 651], ["genomic", 654], ["context", 662], [".", 669], ["To", 671], ["test", 674], ["this", 679], ["hypothesis", 684], [",", 694], ["we", 696], ["constructed", 699], ["transfectant", 711], ["cell", 724], ["lines", 729], ["containing", 735], ["a", 746], ["single", 748], [",", 754], ["actively", 756], ["transcribed", 765], ["APRT", 777], ["gene", 782], [",", 786], ["integrated", 788], ["at", 799], ["different", 802], ["genomic", 812], ["sites", 820], [".", 825], ["Mapping", 827], ["of", 835], ["CPD", 838], ["repair", 842], ["in", 849], ["the", 852], ["integrated", 856], ["APRT", 867], ["genes", 872], ["in", 878], ["three", 881], ["transfectant", 887], ["cell", 900], ["lines", 905], ["revealed", 911], ["two", 920], ["distinct", 924], ["repair", 933], ["patterns", 940], [",", 948], ["either", 950], ["preferential", 957], ["repair", 970], ["of", 977], ["CPDs", 980], ["in", 985], ["the", 988], ["transcribed", 992], ["strand", 1004], ["or", 1011], ["very", 1014], ["poor", 1019], ["repair", 1024], ["in", 1031], ["both", 1034], ["strands", 1039], [".", 1046], ["Similar", 1048], ["kinetics", 1056], ["of", 1065], ["micrococcal", 1068], ["nuclease", 1080], ["digestion", 1089], ["were", 1099], ["seen", 1104], ["for", 1109], ["all", 1113], ["three", 1117], ["transfectant", 1123], ["APRT", 1136], ["gene", 1141], ["domains", 1146], ["and", 1154], ["endogenous", 1158], ["APRT", 1169], ["locus", 1174], [".", 1179], ["Our", 1181], ["results", 1185], ["suggest", 1193], ["that", 1201], ["both", 1206], ["the", 1211], ["efficiency", 1215], ["and", 1226], ["strand", 1230], ["-", 1236], ["specificity", 1237], ["of", 1249], ["repair", 1252], ["of", 1259], ["an", 1262], ["actively", 1265], ["transcribed", 1274], ["gene", 1286], ["are", 1291], ["profoundly", 1295], ["affected", 1306], ["by", 1315], ["genomic", 1318], ["context", 1326], ["but", 1334], ["do", 1338], ["not", 1341], ["reflect", 1345], ["changes", 1353], ["in", 1361], ["first", 1364], ["order", 1370], ["nucleosomal", 1376], ["structure", 1388], [".", 1397]]}
{"context": "Brown and beige adipocytes are specialized cells that express uncoupling protein 1 (UCP1) and dissipate chemical energy as heat. These cells likely possess alternative UCP1-independent thermogenic mechanisms. Here, we identify a secreted enzyme, peptidase M20 domain containing 1 (PM20D1), that is enriched in UCP1(+) versus UCP1(-) adipocytes. We\u00a0demonstrate that PM20D1 is a bidirectional enzyme in\u00a0vitro, catalyzing both the condensation of fatty acids and amino acids to generate N-acyl amino acids and also the reverse hydrolytic reaction. N-acyl amino acids directly bind mitochondria and function as endogenous uncouplers of UCP1-independent respiration. Mice with increased circulating PM20D1 have augmented respiration and increased N-acyl amino acids in blood. Lastly, administration of N-acyl amino acids to mice improves glucose homeostasis and increases energy expenditure. These data identify an enzymatic node and a family of metabolites that regulate energy homeostasis. This pathway might be useful for treating obesity and associated disorders.", "qas": [{"question": "Where is the enzyme PM20D1 localized?", "answers": ["UCP1+ adipocytes"], "qid": "33398486efbc4a99900b44a64f12568d", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["enzyme", 13], ["PM20D1", 20], ["localized", 27], ["?", 36]], "detected_answers": [{"text": "UCP1+ adipocytes", "token_spans": [[55, 57]], "char_spans": [[325, 342]]}]}], "context_tokens": [["Brown", 0], ["and", 6], ["beige", 10], ["adipocytes", 16], ["are", 27], ["specialized", 31], ["cells", 43], ["that", 49], ["express", 54], ["uncoupling", 62], ["protein", 73], ["1", 81], ["(", 83], ["UCP1", 84], [")", 88], ["and", 90], ["dissipate", 94], ["chemical", 104], ["energy", 113], ["as", 120], ["heat", 123], [".", 127], ["These", 129], ["cells", 135], ["likely", 141], ["possess", 148], ["alternative", 156], ["UCP1-independent", 168], ["thermogenic", 185], ["mechanisms", 197], [".", 207], ["Here", 209], [",", 213], ["we", 215], ["identify", 218], ["a", 227], ["secreted", 229], ["enzyme", 238], [",", 244], ["peptidase", 246], ["M20", 256], ["domain", 260], ["containing", 267], ["1", 278], ["(", 280], ["PM20D1", 281], [")", 287], [",", 288], ["that", 290], ["is", 295], ["enriched", 298], ["in", 307], ["UCP1(+", 310], [")", 316], ["versus", 318], ["UCP1(-", 325], [")", 331], ["adipocytes", 333], [".", 343], ["We", 345], ["demonstrate", 348], ["that", 360], ["PM20D1", 365], ["is", 372], ["a", 375], ["bidirectional", 377], ["enzyme", 391], ["in", 398], ["vitro", 401], [",", 406], ["catalyzing", 408], ["both", 419], ["the", 424], ["condensation", 428], ["of", 441], ["fatty", 444], ["acids", 450], ["and", 456], ["amino", 460], ["acids", 466], ["to", 472], ["generate", 475], ["N", 484], ["-", 485], ["acyl", 486], ["amino", 491], ["acids", 497], ["and", 503], ["also", 507], ["the", 512], ["reverse", 516], ["hydrolytic", 524], ["reaction", 535], [".", 543], ["N", 545], ["-", 546], ["acyl", 547], ["amino", 552], ["acids", 558], ["directly", 564], ["bind", 573], ["mitochondria", 578], ["and", 591], ["function", 595], ["as", 604], ["endogenous", 607], ["uncouplers", 618], ["of", 629], ["UCP1-independent", 632], ["respiration", 649], [".", 660], ["Mice", 662], ["with", 667], ["increased", 672], ["circulating", 682], ["PM20D1", 694], ["have", 701], ["augmented", 706], ["respiration", 716], ["and", 728], ["increased", 732], ["N", 742], ["-", 743], ["acyl", 744], ["amino", 749], ["acids", 755], ["in", 761], ["blood", 764], [".", 769], ["Lastly", 771], [",", 777], ["administration", 779], ["of", 794], ["N", 797], ["-", 798], ["acyl", 799], ["amino", 804], ["acids", 810], ["to", 816], ["mice", 819], ["improves", 824], ["glucose", 833], ["homeostasis", 841], ["and", 853], ["increases", 857], ["energy", 867], ["expenditure", 874], [".", 885], ["These", 887], ["data", 893], ["identify", 898], ["an", 907], ["enzymatic", 910], ["node", 920], ["and", 925], ["a", 929], ["family", 931], ["of", 938], ["metabolites", 941], ["that", 953], ["regulate", 958], ["energy", 967], ["homeostasis", 974], [".", 985], ["This", 987], ["pathway", 992], ["might", 1000], ["be", 1006], ["useful", 1009], ["for", 1016], ["treating", 1020], ["obesity", 1029], ["and", 1037], ["associated", 1041], ["disorders", 1052], [".", 1061]]}
{"context": "Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes. Mutations in the gene encoding ribosomal protein S19 (RPS19) have been identified in approximately 25% of DBA families. Most of these mutations disrupt either the translation or stability of the RPS19 protein and are predicted to cause DBA by haploinsufficiency. However, approximately 30% of RPS19 mutations are missense mutations that do not alter the stability of the RPS19 protein and are hypothesized to act by a dominant negative mechanism. To formally test this hypothesis, we generated a transgenic mouse model expressing an RPS19 mutation in which an arginine residue is replaced with a tryptophan residue at codon 62 (RPS19R62W). Constitutive expression of RPS19R62W in developing mice was lethal. Conditional expression of RPS19R62W resulted in growth retardation, a mild anemia with reduced numbers of erythroid progenitors, and significant inhibition of terminal erythroid maturation, similar to DBA. RNA profiling demonstrated more than 700 dysregulated genes belonging to the same pathways that are disrupted in RNA profiles of DBA patient cells. We conclude that RPS19R62W is a dominant negative DBA mutation.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "Diamond Blackfan anemia", "DBA"], "qid": "796122644c79446f872e37f300157090", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 2]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[4, 4], [172, 172], [41, 41], [206, 206], [194, 194], [63, 63]], "char_spans": [[25, 27], [1049, 1051], [246, 248], [1252, 1254], [1183, 1185], [376, 378]]}]}], "context_tokens": [["Diamond", 0], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["an", 33], ["inherited", 36], ["erythroblastopenia", 46], ["associated", 65], ["with", 76], ["mutations", 81], ["in", 91], ["at", 94], ["least", 97], ["8", 103], ["different", 105], ["ribosomal", 115], ["protein", 125], ["genes", 133], [".", 138], ["Mutations", 140], ["in", 150], ["the", 153], ["gene", 157], ["encoding", 162], ["ribosomal", 171], ["protein", 181], ["S19", 189], ["(", 193], ["RPS19", 194], [")", 199], ["have", 201], ["been", 206], ["identified", 211], ["in", 222], ["approximately", 225], ["25", 239], ["%", 241], ["of", 243], ["DBA", 246], ["families", 250], [".", 258], ["Most", 260], ["of", 265], ["these", 268], ["mutations", 274], ["disrupt", 284], ["either", 292], ["the", 299], ["translation", 303], ["or", 315], ["stability", 318], ["of", 328], ["the", 331], ["RPS19", 335], ["protein", 341], ["and", 349], ["are", 353], ["predicted", 357], ["to", 367], ["cause", 370], ["DBA", 376], ["by", 380], ["haploinsufficiency", 383], [".", 401], ["However", 403], [",", 410], ["approximately", 412], ["30", 426], ["%", 428], ["of", 430], ["RPS19", 433], ["mutations", 439], ["are", 449], ["missense", 453], ["mutations", 462], ["that", 472], ["do", 477], ["not", 480], ["alter", 484], ["the", 490], ["stability", 494], ["of", 504], ["the", 507], ["RPS19", 511], ["protein", 517], ["and", 525], ["are", 529], ["hypothesized", 533], ["to", 546], ["act", 549], ["by", 553], ["a", 556], ["dominant", 558], ["negative", 567], ["mechanism", 576], [".", 585], ["To", 587], ["formally", 590], ["test", 599], ["this", 604], ["hypothesis", 609], [",", 619], ["we", 621], ["generated", 624], ["a", 634], ["transgenic", 636], ["mouse", 647], ["model", 653], ["expressing", 659], ["an", 670], ["RPS19", 673], ["mutation", 679], ["in", 688], ["which", 691], ["an", 697], ["arginine", 700], ["residue", 709], ["is", 717], ["replaced", 720], ["with", 729], ["a", 734], ["tryptophan", 736], ["residue", 747], ["at", 755], ["codon", 758], ["62", 764], ["(", 767], ["RPS19R62W", 768], [")", 777], [".", 778], ["Constitutive", 780], ["expression", 793], ["of", 804], ["RPS19R62W", 807], ["in", 817], ["developing", 820], ["mice", 831], ["was", 836], ["lethal", 840], [".", 846], ["Conditional", 848], ["expression", 860], ["of", 871], ["RPS19R62W", 874], ["resulted", 884], ["in", 893], ["growth", 896], ["retardation", 903], [",", 914], ["a", 916], ["mild", 918], ["anemia", 923], ["with", 930], ["reduced", 935], ["numbers", 943], ["of", 951], ["erythroid", 954], ["progenitors", 964], [",", 975], ["and", 977], ["significant", 981], ["inhibition", 993], ["of", 1004], ["terminal", 1007], ["erythroid", 1016], ["maturation", 1026], [",", 1036], ["similar", 1038], ["to", 1046], ["DBA", 1049], [".", 1052], ["RNA", 1054], ["profiling", 1058], ["demonstrated", 1068], ["more", 1081], ["than", 1086], ["700", 1091], ["dysregulated", 1095], ["genes", 1108], ["belonging", 1114], ["to", 1124], ["the", 1127], ["same", 1131], ["pathways", 1136], ["that", 1145], ["are", 1150], ["disrupted", 1154], ["in", 1164], ["RNA", 1167], ["profiles", 1171], ["of", 1180], ["DBA", 1183], ["patient", 1187], ["cells", 1195], [".", 1200], ["We", 1202], ["conclude", 1205], ["that", 1214], ["RPS19R62W", 1219], ["is", 1229], ["a", 1232], ["dominant", 1234], ["negative", 1243], ["DBA", 1252], ["mutation", 1256], [".", 1264]]}
{"context": "Enhanced proliferation, resistance to apoptosis, and metabolic shift to glycolysis of pulmonary arterial vascular smooth muscle cells (PAVSMCs) are key pathophysiological components of pulmonary vascular remodeling in idiopathic pulmonary arterial hypertension (PAH). The role of the distinct mammalian target of rapamycin (mTOR) complexes mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor) in PAVSMC proliferation and survival in PAH and their therapeutic relevance are unknown. Immunohistochemical and immunoblot analyses revealed that mTORC1 and mTORC2 pathways are markedly upregulated in small remodeled pulmonary arteries and isolated distal PAVSMCs from subjects with idiopathic PAH that have increased ATP levels, proliferation, and survival that depend on glycolytic metabolism. Small interfering RNA- and pharmacology-based analysis showed that although both mTORC1 and mTORC2 contribute to proliferation, only mTORC2 is required for ATP generation and survival of idiopathic PAH PAVSMCs. mTORC2 downregulated the energy sensor AMP-activated protein kinase, which led to activation of mTORC1-S6 and increased proliferation, as well as a deficiency of the proapoptotic protein Bim and idiopathic PAH PAVSMC survival. NADPH oxidase 4 (Nox4) protein levels were increased in idiopathic PAH PAVSMCs, which was necessary for mTORC2 activation, proliferation, and survival. Nox4 levels and mTORC2 signaling were significantly upregulated in small pulmonary arteries from hypoxia-exposed rats at days 2 to 28 of hypoxia. Treatment with the mTOR kinase inhibitor PP242 at days 15 to 28 suppressed mTORC2 but not Nox4, induced smooth muscle-specific apoptosis in small pulmonary arteries, and reversed hypoxia-induced pulmonary vascular remodeling in rats. These data provide a novel mechanistic link of Nox4-dependent activation of mTORC2 via the energy sensor AMP-activated protein kinase to increased proliferation and survival of PAVSMCs in PAH, which suggests a new potential pathway for therapeutic interventions.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "344979f88cea475c9aa74a98325a3ad1", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[44, 47]], "char_spans": [[293, 321]]}]}], "context_tokens": [["Enhanced", 0], ["proliferation", 9], [",", 22], ["resistance", 24], ["to", 35], ["apoptosis", 38], [",", 47], ["and", 49], ["metabolic", 53], ["shift", 63], ["to", 69], ["glycolysis", 72], ["of", 83], ["pulmonary", 86], ["arterial", 96], ["vascular", 105], ["smooth", 114], ["muscle", 121], ["cells", 128], ["(", 134], ["PAVSMCs", 135], [")", 142], ["are", 144], ["key", 148], ["pathophysiological", 152], ["components", 171], ["of", 182], ["pulmonary", 185], ["vascular", 195], ["remodeling", 204], ["in", 215], ["idiopathic", 218], ["pulmonary", 229], ["arterial", 239], ["hypertension", 248], ["(", 261], ["PAH", 262], [")", 265], [".", 266], ["The", 268], ["role", 272], ["of", 277], ["the", 280], ["distinct", 284], ["mammalian", 293], ["target", 303], ["of", 310], ["rapamycin", 313], ["(", 323], ["mTOR", 324], [")", 328], ["complexes", 330], ["mTORC1", 340], ["(", 347], ["mTOR", 348], ["-", 352], ["Raptor", 353], [")", 359], ["and", 361], ["mTORC2", 365], ["(", 372], ["mTOR", 373], ["-", 377], ["Rictor", 378], [")", 384], ["in", 386], ["PAVSMC", 389], ["proliferation", 396], ["and", 410], ["survival", 414], ["in", 423], ["PAH", 426], ["and", 430], ["their", 434], ["therapeutic", 440], ["relevance", 452], ["are", 462], ["unknown", 466], [".", 473], ["Immunohistochemical", 475], ["and", 495], ["immunoblot", 499], ["analyses", 510], ["revealed", 519], ["that", 528], ["mTORC1", 533], ["and", 540], ["mTORC2", 544], ["pathways", 551], ["are", 560], ["markedly", 564], ["upregulated", 573], ["in", 585], ["small", 588], ["remodeled", 594], ["pulmonary", 604], ["arteries", 614], ["and", 623], ["isolated", 627], ["distal", 636], ["PAVSMCs", 643], ["from", 651], ["subjects", 656], ["with", 665], ["idiopathic", 670], ["PAH", 681], ["that", 685], ["have", 690], ["increased", 695], ["ATP", 705], ["levels", 709], [",", 715], ["proliferation", 717], [",", 730], ["and", 732], ["survival", 736], ["that", 745], ["depend", 750], ["on", 757], ["glycolytic", 760], ["metabolism", 771], [".", 781], ["Small", 783], ["interfering", 789], ["RNA-", 801], ["and", 806], ["pharmacology", 810], ["-", 822], ["based", 823], ["analysis", 829], ["showed", 838], ["that", 845], ["although", 850], ["both", 859], ["mTORC1", 864], ["and", 871], ["mTORC2", 875], ["contribute", 882], ["to", 893], ["proliferation", 896], [",", 909], ["only", 911], ["mTORC2", 916], ["is", 923], ["required", 926], ["for", 935], ["ATP", 939], ["generation", 943], ["and", 954], ["survival", 958], ["of", 967], ["idiopathic", 970], ["PAH", 981], ["PAVSMCs", 985], [".", 992], ["mTORC2", 994], ["downregulated", 1001], ["the", 1015], ["energy", 1019], ["sensor", 1026], ["AMP", 1033], ["-", 1036], ["activated", 1037], ["protein", 1047], ["kinase", 1055], [",", 1061], ["which", 1063], ["led", 1069], ["to", 1073], ["activation", 1076], ["of", 1087], ["mTORC1-S6", 1090], ["and", 1100], ["increased", 1104], ["proliferation", 1114], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["a", 1140], ["deficiency", 1142], ["of", 1153], ["the", 1156], ["proapoptotic", 1160], ["protein", 1173], ["Bim", 1181], ["and", 1185], ["idiopathic", 1189], ["PAH", 1200], ["PAVSMC", 1204], ["survival", 1211], [".", 1219], ["NADPH", 1221], ["oxidase", 1227], ["4", 1235], ["(", 1237], ["Nox4", 1238], [")", 1242], ["protein", 1244], ["levels", 1252], ["were", 1259], ["increased", 1264], ["in", 1274], ["idiopathic", 1277], ["PAH", 1288], ["PAVSMCs", 1292], [",", 1299], ["which", 1301], ["was", 1307], ["necessary", 1311], ["for", 1321], ["mTORC2", 1325], ["activation", 1332], [",", 1342], ["proliferation", 1344], [",", 1357], ["and", 1359], ["survival", 1363], [".", 1371], ["Nox4", 1373], ["levels", 1378], ["and", 1385], ["mTORC2", 1389], ["signaling", 1396], ["were", 1406], ["significantly", 1411], ["upregulated", 1425], ["in", 1437], ["small", 1440], ["pulmonary", 1446], ["arteries", 1456], ["from", 1465], ["hypoxia", 1470], ["-", 1477], ["exposed", 1478], ["rats", 1486], ["at", 1491], ["days", 1494], ["2", 1499], ["to", 1501], ["28", 1504], ["of", 1507], ["hypoxia", 1510], [".", 1517], ["Treatment", 1519], ["with", 1529], ["the", 1534], ["mTOR", 1538], ["kinase", 1543], ["inhibitor", 1550], ["PP242", 1560], ["at", 1566], ["days", 1569], ["15", 1574], ["to", 1577], ["28", 1580], ["suppressed", 1583], ["mTORC2", 1594], ["but", 1601], ["not", 1605], ["Nox4", 1609], [",", 1613], ["induced", 1615], ["smooth", 1623], ["muscle", 1630], ["-", 1636], ["specific", 1637], ["apoptosis", 1646], ["in", 1656], ["small", 1659], ["pulmonary", 1665], ["arteries", 1675], [",", 1683], ["and", 1685], ["reversed", 1689], ["hypoxia", 1698], ["-", 1705], ["induced", 1706], ["pulmonary", 1714], ["vascular", 1724], ["remodeling", 1733], ["in", 1744], ["rats", 1747], [".", 1751], ["These", 1753], ["data", 1759], ["provide", 1764], ["a", 1772], ["novel", 1774], ["mechanistic", 1780], ["link", 1792], ["of", 1797], ["Nox4-dependent", 1800], ["activation", 1815], ["of", 1826], ["mTORC2", 1829], ["via", 1836], ["the", 1840], ["energy", 1844], ["sensor", 1851], ["AMP", 1858], ["-", 1861], ["activated", 1862], ["protein", 1872], ["kinase", 1880], ["to", 1887], ["increased", 1890], ["proliferation", 1900], ["and", 1914], ["survival", 1918], ["of", 1927], ["PAVSMCs", 1930], ["in", 1938], ["PAH", 1941], [",", 1944], ["which", 1946], ["suggests", 1952], ["a", 1961], ["new", 1963], ["potential", 1967], ["pathway", 1977], ["for", 1985], ["therapeutic", 1989], ["interventions", 2001], [".", 2014]]}
{"context": "Willis-Ekbom's disease (WED), formerly called restless legs syndrome, is more common in pregnant than in non-pregnant women, implying that the physiological and biochemical changes during pregnancy influence its development. During pregnancy, many hormone levels undergo significant changes, and some hormones significantly increase in activity and can interfere with other hormones. For example, the steroid hormone estradiol interferes with the neuroendocrine hormone dopamine. During pregnancy, the activity of the thyroid axis is enhanced to meet the increased demand for thyroid hormones during this state. Dopamine is a neuroendocrine hormone that diminishes the levels of thyrotropin and consequently of thyroxine, and one of the roles of the dopaminergic system is to counteract the activity of thyroid hormones. When the activity of dopamine is not sufficient to modulate thyroid hormones, WED may occur. Robust evidence in the medical literature suggests that an imbalance between thyroid hormones and the dopaminergic system underpins WED pathophysiology. In this article, we present evidence that this imbalance may also mediate transient WED during pregnancy. It is possible that the main hormonal alteration responsible for transient WED of pregnancy is the excessive modulation of dopamine release in the pituitary stalk by estradiol. The reduced quantities of dopamine then cause decreased modulation of thyrotropin, leading to enhanced thyroid axis activity and subsequent WED symptoms. Iron deficiency may also be a predisposing factor for WED during pregnancy, as it can both diminish dopamine and increase thyroid hormone.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "3216ab3e241a45eea283765e3bee89ef", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[242, 242]], "char_spans": [[1504, 1507]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["'s", 12], ["disease", 15], ["(", 23], ["WED", 24], [")", 27], [",", 28], ["formerly", 30], ["called", 39], ["restless", 46], ["legs", 55], ["syndrome", 60], [",", 68], ["is", 70], ["more", 73], ["common", 78], ["in", 85], ["pregnant", 88], ["than", 97], ["in", 102], ["non", 105], ["-", 108], ["pregnant", 109], ["women", 118], [",", 123], ["implying", 125], ["that", 134], ["the", 139], ["physiological", 143], ["and", 157], ["biochemical", 161], ["changes", 173], ["during", 181], ["pregnancy", 188], ["influence", 198], ["its", 208], ["development", 212], [".", 223], ["During", 225], ["pregnancy", 232], [",", 241], ["many", 243], ["hormone", 248], ["levels", 256], ["undergo", 263], ["significant", 271], ["changes", 283], [",", 290], ["and", 292], ["some", 296], ["hormones", 301], ["significantly", 310], ["increase", 324], ["in", 333], ["activity", 336], ["and", 345], ["can", 349], ["interfere", 353], ["with", 363], ["other", 368], ["hormones", 374], [".", 382], ["For", 384], ["example", 388], [",", 395], ["the", 397], ["steroid", 401], ["hormone", 409], ["estradiol", 417], ["interferes", 427], ["with", 438], ["the", 443], ["neuroendocrine", 447], ["hormone", 462], ["dopamine", 470], [".", 478], ["During", 480], ["pregnancy", 487], [",", 496], ["the", 498], ["activity", 502], ["of", 511], ["the", 514], ["thyroid", 518], ["axis", 526], ["is", 531], ["enhanced", 534], ["to", 543], ["meet", 546], ["the", 551], ["increased", 555], ["demand", 565], ["for", 572], ["thyroid", 576], ["hormones", 584], ["during", 593], ["this", 600], ["state", 605], [".", 610], ["Dopamine", 612], ["is", 621], ["a", 624], ["neuroendocrine", 626], ["hormone", 641], ["that", 649], ["diminishes", 654], ["the", 665], ["levels", 669], ["of", 676], ["thyrotropin", 679], ["and", 691], ["consequently", 695], ["of", 708], ["thyroxine", 711], [",", 720], ["and", 722], ["one", 726], ["of", 730], ["the", 733], ["roles", 737], ["of", 743], ["the", 746], ["dopaminergic", 750], ["system", 763], ["is", 770], ["to", 773], ["counteract", 776], ["the", 787], ["activity", 791], ["of", 800], ["thyroid", 803], ["hormones", 811], [".", 819], ["When", 821], ["the", 826], ["activity", 830], ["of", 839], ["dopamine", 842], ["is", 851], ["not", 854], ["sufficient", 858], ["to", 869], ["modulate", 872], ["thyroid", 881], ["hormones", 889], [",", 897], ["WED", 899], ["may", 903], ["occur", 907], [".", 912], ["Robust", 914], ["evidence", 921], ["in", 930], ["the", 933], ["medical", 937], ["literature", 945], ["suggests", 956], ["that", 965], ["an", 970], ["imbalance", 973], ["between", 983], ["thyroid", 991], ["hormones", 999], ["and", 1008], ["the", 1012], ["dopaminergic", 1016], ["system", 1029], ["underpins", 1036], ["WED", 1046], ["pathophysiology", 1050], [".", 1065], ["In", 1067], ["this", 1070], ["article", 1075], [",", 1082], ["we", 1084], ["present", 1087], ["evidence", 1095], ["that", 1104], ["this", 1109], ["imbalance", 1114], ["may", 1124], ["also", 1128], ["mediate", 1133], ["transient", 1141], ["WED", 1151], ["during", 1155], ["pregnancy", 1162], [".", 1171], ["It", 1173], ["is", 1176], ["possible", 1179], ["that", 1188], ["the", 1193], ["main", 1197], ["hormonal", 1202], ["alteration", 1211], ["responsible", 1222], ["for", 1234], ["transient", 1238], ["WED", 1248], ["of", 1252], ["pregnancy", 1255], ["is", 1265], ["the", 1268], ["excessive", 1272], ["modulation", 1282], ["of", 1293], ["dopamine", 1296], ["release", 1305], ["in", 1313], ["the", 1316], ["pituitary", 1320], ["stalk", 1330], ["by", 1336], ["estradiol", 1339], [".", 1348], ["The", 1350], ["reduced", 1354], ["quantities", 1362], ["of", 1373], ["dopamine", 1376], ["then", 1385], ["cause", 1390], ["decreased", 1396], ["modulation", 1406], ["of", 1417], ["thyrotropin", 1420], [",", 1431], ["leading", 1433], ["to", 1441], ["enhanced", 1444], ["thyroid", 1453], ["axis", 1461], ["activity", 1466], ["and", 1475], ["subsequent", 1479], ["WED", 1490], ["symptoms", 1494], [".", 1502], ["Iron", 1504], ["deficiency", 1509], ["may", 1520], ["also", 1524], ["be", 1529], ["a", 1532], ["predisposing", 1534], ["factor", 1547], ["for", 1554], ["WED", 1558], ["during", 1562], ["pregnancy", 1569], [",", 1578], ["as", 1580], ["it", 1583], ["can", 1586], ["both", 1590], ["diminish", 1595], ["dopamine", 1604], ["and", 1613], ["increase", 1617], ["thyroid", 1626], ["hormone", 1634], [".", 1641]]}
{"context": "Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K\u03b4-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "5b4281bf26774411a2c18e34edadb7e3", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[147, 149]], "char_spans": [[828, 849]]}]}], "context_tokens": [["Protein", 0], ["kinases", 8], ["(", 16], ["PKs", 17], [")", 20], ["and", 22], ["lipid", 26], ["kinases", 32], ["(", 40], ["LKs", 41], [")", 44], ["are", 46], ["good", 50], ["choices", 55], ["for", 63], ["targets", 67], ["of", 75], ["signal", 78], ["transduction", 85], ["therapy", 98], ["as", 106], ["these", 109], ["enzymes", 115], ["are", 123], ["involved", 127], ["in", 136], ["signaling", 139], ["pathways", 149], [",", 157], ["and", 159], ["are", 163], ["often", 167], ["related", 173], ["to", 181], ["the", 184], ["pathogenesis", 188], ["of", 201], ["lymphoid", 204], ["malignancies", 213], [".", 225], ["The", 227], ["attractiveness", 231], ["of", 246], ["PKs", 249], ["and", 253], ["LKs", 257], ["as", 261], ["drug", 264], ["able", 269], ["targets", 274], ["is", 282], ["enhanced", 285], ["by", 294], ["the", 297], ["fact", 301], ["that", 306], ["they", 311], ["are", 316], ["enzymes", 320], ["whose", 328], ["biological", 334], ["activity", 345], ["can", 354], ["be", 358], ["turned", 361], ["off", 368], ["by", 372], ["drugs", 375], ["that", 381], ["block", 386], ["their", 392], ["catalytic", 398], ["site", 408], [".", 412], ["In", 414], ["the", 417], ["last", 421], ["few", 426], ["years", 430], ["small", 436], ["molecular", 442], ["kinase", 452], ["inhibitors", 459], ["(", 470], ["KIs", 471], [")", 474], ["have", 476], ["been", 481], ["synthesized", 486], ["and", 498], ["become", 502], ["available", 509], ["for", 519], ["preclinical", 523], ["studies", 535], ["and", 543], ["clinical", 547], ["trials", 556], [".", 562], ["The", 564], ["first", 568], ["KI", 574], [",", 576], ["introduced", 578], ["into", 589], ["clinical", 594], ["practice", 603], ["in", 612], ["1998", 615], [",", 619], ["was", 621], ["imatinib", 625], ["mesylate", 634], [",", 642], ["which", 644], ["became", 650], ["the", 657], ["first", 661], ["choice", 667], ["drug", 674], ["in", 679], ["chronic", 682], ["myeloid", 690], ["leukemia", 698], [".", 706], ["More", 708], ["recently", 713], [",", 721], ["several", 723], ["KIs", 731], ["have", 735], ["been", 740], ["developed", 745], ["to", 755], ["target", 758], ["the", 765], ["proximal", 769], ["B", 778], ["-", 779], ["cell", 780], ["receptor", 785], ["(", 794], ["BCR", 795], [")", 798], ["signaling", 800], ["pathway", 810], ["including", 818], ["spleen", 828], ["tyrosine", 835], ["kinase", 844], ["inhibitor", 851], ["(", 861], ["Fostamatinib", 862], [")", 874], ["and", 876], ["Bruton", 880], ["'s", 886], ["tyrosine", 889], ["kinase", 898], ["inhibitors", 905], ["(", 916], ["Ibrutinib", 917], [",", 926], ["AVL-263", 928], [")", 935], [".", 936], ["These", 938], ["agents", 944], ["are", 951], ["currently", 955], ["evaluated", 965], ["in", 975], ["early", 978], ["clinical", 984], ["trials", 993], ["in", 1000], ["chronic", 1003], ["lymphocytic", 1011], ["leukemia", 1023], ["(", 1032], ["CLL", 1033], [")", 1036], ["and", 1038], ["other", 1042], ["diseases", 1048], [".", 1056], ["Cyclin", 1058], ["-", 1064], ["dependent", 1065], ["kinase", 1075], ["(", 1082], ["Cdk", 1083], [")", 1086], ["inhibitors", 1088], [",", 1098], ["flavopiridol", 1100], ["(", 1113], ["alvocidib", 1114], [")", 1123], [",", 1124], ["BMS-387032", 1126], ["(", 1137], ["SNS-032", 1138], [")", 1145], [",", 1146], ["sunitinib", 1148], ["and", 1158], ["sorafenib", 1162], ["are", 1172], ["currently", 1176], ["under", 1186], ["evaluation", 1192], ["in", 1203], ["clinical", 1206], ["trials", 1215], ["for", 1222], ["relapsed", 1226], ["/", 1234], ["refractory", 1235], ["CLL", 1246], [".", 1249], ["Multi", 1251], ["-", 1256], ["tyrosine", 1257], ["kinase", 1266], ["inhibitors", 1273], ["including", 1284], ["vandetanib", 1294], ["(", 1305], ["ZD6474", 1306], [")", 1312], ["bosutinib", 1314], ["(", 1324], ["SKI-606", 1325], [")", 1332], [",", 1333], ["TKI258", 1335], ["(", 1342], ["CHIR-258", 1343], [")", 1351], [",", 1352], ["pazopanib", 1354], ["(", 1364], ["GW786034", 1365], [")", 1373], ["and", 1375], ["axitinib", 1379], ["(", 1388], ["AG013736", 1389], [")", 1397], ["have", 1399], ["been", 1404], ["also", 1409], ["developed", 1414], ["for", 1424], ["the", 1428], ["treatment", 1432], ["of", 1442], ["lymphoid", 1445], ["malignancies", 1454], [".", 1466], ["Phosphatidylinositol", 1468], ["3-kinases", 1489], ["(", 1499], ["PI3", 1500], ["K", 1503], [")", 1505], ["are", 1507], ["a", 1511], ["family", 1513], ["of", 1520], ["lipid", 1523], ["kinases", 1529], ["that", 1537], ["mediate", 1542], ["signals", 1550], ["from", 1558], ["cell", 1563], ["surface", 1568], ["receptors", 1576], [".", 1585], ["CAL-101", 1587], ["(", 1595], ["GS-1101", 1596], [")", 1603], ["is", 1605], ["an", 1608], ["oral", 1611], ["PI3K\u03b4", 1616], ["-", 1621], ["specific", 1622], ["inhibitor", 1631], ["which", 1641], ["has", 1647], ["shown", 1651], ["preclinical", 1657], ["and", 1669], ["clinical", 1673], ["activity", 1682], ["against", 1691], ["CLL", 1699], [".", 1702], ["This", 1704], ["article", 1709], ["summarizes", 1717], ["recent", 1728], ["achievements", 1735], ["in", 1748], ["the", 1751], ["mechanism", 1755], ["of", 1765], ["action", 1768], [",", 1774], ["pharmacological", 1776], ["properties", 1792], ["and", 1803], ["clinical", 1807], ["activity", 1816], ["and", 1825], ["toxicity", 1829], ["of", 1838], ["PK", 1841], ["and", 1844], ["LK", 1848], ["inhibitors", 1851], ["in", 1862], ["CLL", 1865], [".", 1868]]}
{"context": "Christianson Syndrome, a recently identified X-linked neurodevelopmental disorder, is caused by mutations in the human gene SLC9A6 encoding the recycling endosomal alkali cation/proton exchanger NHE6. The patients have pronounced limitations in cognitive ability, motor skills and adaptive behaviour. However, the mechanistic basis for this disorder is poorly understood as few of the more than 20 mutations identified thus far have been studied in detail. Here, we examined the molecular and cellular consequences of a 6 base-pair deletion of amino acids Glu(287) and Ser(288) (\u2206ES) in the predicted seventh transmembrane helix of human NHE6 expressed in established cell lines (CHO/AP-1, HeLa and neuroblastoma SH-SY5Y) and primary cultures of mouse hippocampal neurons by measuring levels of protein expression, stability, membrane trafficking, endosomal function and cell viability. In the cell lines, immunoblot analyses showed that the nascent mutant protein was properly synthesized and assembled as a homodimer, but its oligosaccharide maturation and half-life were markedly reduced compared to wild-type (WT) and correlated with enhanced ubiquitination leading to both proteasomal and lysosomal degradation. Despite this instability, a measurable fraction of the transporter was correctly sorted to the plasma membrane. However, the rates of clathrin-mediated endocytosis of the \u2206ES mutant as well as uptake of companion vesicular cargo, such as the ligand-bound transferrin receptor, were significantly reduced and correlated with excessive endosomal acidification. Notably, ectopic expression of \u2206ES but not WT induced apoptosis when examined in AP-1 cells. Similarly, in transfected primary cultures of mouse hippocampal neurons, membrane trafficking of the \u2206ES mutant was impaired and elicited marked reductions in total dendritic length, area and arborization, and triggered apoptotic cell death. These results suggest that loss-of-function mutations in NHE6 disrupt recycling endosomal function and trafficking of cargo which ultimately leads to neuronal degeneration and cell death in Christianson Syndrome.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "c411a46cdf7345d8a5ed11e24dde3a88", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[20, 20]], "char_spans": [[124, 129]]}]}], "context_tokens": [["Christianson", 0], ["Syndrome", 13], [",", 21], ["a", 23], ["recently", 25], ["identified", 34], ["X", 45], ["-", 46], ["linked", 47], ["neurodevelopmental", 54], ["disorder", 73], [",", 81], ["is", 83], ["caused", 86], ["by", 93], ["mutations", 96], ["in", 106], ["the", 109], ["human", 113], ["gene", 119], ["SLC9A6", 124], ["encoding", 131], ["the", 140], ["recycling", 144], ["endosomal", 154], ["alkali", 164], ["cation", 171], ["/", 177], ["proton", 178], ["exchanger", 185], ["NHE6", 195], [".", 199], ["The", 201], ["patients", 205], ["have", 214], ["pronounced", 219], ["limitations", 230], ["in", 242], ["cognitive", 245], ["ability", 255], [",", 262], ["motor", 264], ["skills", 270], ["and", 277], ["adaptive", 281], ["behaviour", 290], [".", 299], ["However", 301], [",", 308], ["the", 310], ["mechanistic", 314], ["basis", 326], ["for", 332], ["this", 336], ["disorder", 341], ["is", 350], ["poorly", 353], ["understood", 360], ["as", 371], ["few", 374], ["of", 378], ["the", 381], ["more", 385], ["than", 390], ["20", 395], ["mutations", 398], ["identified", 408], ["thus", 419], ["far", 424], ["have", 428], ["been", 433], ["studied", 438], ["in", 446], ["detail", 449], [".", 455], ["Here", 457], [",", 461], ["we", 463], ["examined", 466], ["the", 475], ["molecular", 479], ["and", 489], ["cellular", 493], ["consequences", 502], ["of", 515], ["a", 518], ["6", 520], ["base", 522], ["-", 526], ["pair", 527], ["deletion", 532], ["of", 541], ["amino", 544], ["acids", 550], ["Glu(287", 556], [")", 563], ["and", 565], ["Ser(288", 569], [")", 576], ["(", 578], ["\u2206ES", 579], [")", 582], ["in", 584], ["the", 587], ["predicted", 591], ["seventh", 601], ["transmembrane", 609], ["helix", 623], ["of", 629], ["human", 632], ["NHE6", 638], ["expressed", 643], ["in", 653], ["established", 656], ["cell", 668], ["lines", 673], ["(", 679], ["CHO", 680], ["/", 683], ["AP-1", 684], [",", 688], ["HeLa", 690], ["and", 695], ["neuroblastoma", 699], ["SH", 713], ["-", 715], ["SY5Y", 716], [")", 720], ["and", 722], ["primary", 726], ["cultures", 734], ["of", 743], ["mouse", 746], ["hippocampal", 752], ["neurons", 764], ["by", 772], ["measuring", 775], ["levels", 785], ["of", 792], ["protein", 795], ["expression", 803], [",", 813], ["stability", 815], [",", 824], ["membrane", 826], ["trafficking", 835], [",", 846], ["endosomal", 848], ["function", 858], ["and", 867], ["cell", 871], ["viability", 876], [".", 885], ["In", 887], ["the", 890], ["cell", 894], ["lines", 899], [",", 904], ["immunoblot", 906], ["analyses", 917], ["showed", 926], ["that", 933], ["the", 938], ["nascent", 942], ["mutant", 950], ["protein", 957], ["was", 965], ["properly", 969], ["synthesized", 978], ["and", 990], ["assembled", 994], ["as", 1004], ["a", 1007], ["homodimer", 1009], [",", 1018], ["but", 1020], ["its", 1024], ["oligosaccharide", 1028], ["maturation", 1044], ["and", 1055], ["half", 1059], ["-", 1063], ["life", 1064], ["were", 1069], ["markedly", 1074], ["reduced", 1083], ["compared", 1091], ["to", 1100], ["wild", 1103], ["-", 1107], ["type", 1108], ["(", 1113], ["WT", 1114], [")", 1116], ["and", 1118], ["correlated", 1122], ["with", 1133], ["enhanced", 1138], ["ubiquitination", 1147], ["leading", 1162], ["to", 1170], ["both", 1173], ["proteasomal", 1178], ["and", 1190], ["lysosomal", 1194], ["degradation", 1204], [".", 1215], ["Despite", 1217], ["this", 1225], ["instability", 1230], [",", 1241], ["a", 1243], ["measurable", 1245], ["fraction", 1256], ["of", 1265], ["the", 1268], ["transporter", 1272], ["was", 1284], ["correctly", 1288], ["sorted", 1298], ["to", 1305], ["the", 1308], ["plasma", 1312], ["membrane", 1319], [".", 1327], ["However", 1329], [",", 1336], ["the", 1338], ["rates", 1342], ["of", 1348], ["clathrin", 1351], ["-", 1359], ["mediated", 1360], ["endocytosis", 1369], ["of", 1381], ["the", 1384], ["\u2206ES", 1388], ["mutant", 1392], ["as", 1399], ["well", 1402], ["as", 1407], ["uptake", 1410], ["of", 1417], ["companion", 1420], ["vesicular", 1430], ["cargo", 1440], [",", 1445], ["such", 1447], ["as", 1452], ["the", 1455], ["ligand", 1459], ["-", 1465], ["bound", 1466], ["transferrin", 1472], ["receptor", 1484], [",", 1492], ["were", 1494], ["significantly", 1499], ["reduced", 1513], ["and", 1521], ["correlated", 1525], ["with", 1536], ["excessive", 1541], ["endosomal", 1551], ["acidification", 1561], [".", 1574], ["Notably", 1576], [",", 1583], ["ectopic", 1585], ["expression", 1593], ["of", 1604], ["\u2206ES", 1607], ["but", 1611], ["not", 1615], ["WT", 1619], ["induced", 1622], ["apoptosis", 1630], ["when", 1640], ["examined", 1645], ["in", 1654], ["AP-1", 1657], ["cells", 1662], [".", 1667], ["Similarly", 1669], [",", 1678], ["in", 1680], ["transfected", 1683], ["primary", 1695], ["cultures", 1703], ["of", 1712], ["mouse", 1715], ["hippocampal", 1721], ["neurons", 1733], [",", 1740], ["membrane", 1742], ["trafficking", 1751], ["of", 1763], ["the", 1766], ["\u2206ES", 1770], ["mutant", 1774], ["was", 1781], ["impaired", 1785], ["and", 1794], ["elicited", 1798], ["marked", 1807], ["reductions", 1814], ["in", 1825], ["total", 1828], ["dendritic", 1834], ["length", 1844], [",", 1850], ["area", 1852], ["and", 1857], ["arborization", 1861], [",", 1873], ["and", 1875], ["triggered", 1879], ["apoptotic", 1889], ["cell", 1899], ["death", 1904], [".", 1909], ["These", 1911], ["results", 1917], ["suggest", 1925], ["that", 1933], ["loss", 1938], ["-", 1942], ["of", 1943], ["-", 1945], ["function", 1946], ["mutations", 1955], ["in", 1965], ["NHE6", 1968], ["disrupt", 1973], ["recycling", 1981], ["endosomal", 1991], ["function", 2001], ["and", 2010], ["trafficking", 2014], ["of", 2026], ["cargo", 2029], ["which", 2035], ["ultimately", 2041], ["leads", 2052], ["to", 2058], ["neuronal", 2061], ["degeneration", 2070], ["and", 2083], ["cell", 2087], ["death", 2092], ["in", 2098], ["Christianson", 2101], ["Syndrome", 2114], [".", 2122]]}
{"context": "Neurofibroma is a benign tumor that arises from small or large nerves. This neoplastic lesion is a common feature of neurofibromatosis type 1 (NF1), one of the most common autosomal dominant disorders. The NF1 gene codes for a protein called \"neurofibromin.\" It possesses a region that shares a high homology with the family of GTPase-activating proteins, which are negative regulators of RAS function and thereby control cell growth and differentiation. The evidence points to the NF1 gene being a tumor-suppressor gene. NF1 patients also have an increased incidence of certain malignant tumors that are believed to follow the \"two hit\" hypothesis, with one allele constitutionally inactivated and the other somatically mutated. Recently, somatic loss of heterozygosity (LOH) has been described for neurofibromas, and mutations in both copies of the NF1 gene have been reported for a dermal neurofibroma. The aim of our study was the analysis of the NF1 locus in benign neurofibromas in NF1 patients. We performed LOH analysis on 60 neurofibromas belonging to 17 patients, 9 of them with family history of the disease and 8 of them sporadic. We have analyzed five intragenic NF1 markers and six extragenic markers, and we have found LOH in 25% of the neurofibromas (corresponding to 53% of the patients). In addition, we found that in the neurofibromas of patients from familial cases the deletions occurred in the allele that is not transmitted with the disease, indicating that both copies of the NF1 gene were inactivated in these tumors. Therefore, the recent reports mentioned above, together with our findings, strongly support the double inactivation of the NF1 gene in benign neurofibromas.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "0fbe509cc92143e19f8c06a29e4137e7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[96, 96], [213, 213], [275, 275], [38, 38], [172, 172], [87, 87], [25, 25], [152, 152], [178, 178], [303, 303]], "char_spans": [[522, 524], [1176, 1178], [1500, 1502], [206, 208], [951, 953], [482, 484], [143, 145], [851, 853], [988, 990], [1666, 1668]]}]}], "context_tokens": [["Neurofibroma", 0], ["is", 13], ["a", 16], ["benign", 18], ["tumor", 25], ["that", 31], ["arises", 36], ["from", 43], ["small", 48], ["or", 54], ["large", 57], ["nerves", 63], [".", 69], ["This", 71], ["neoplastic", 76], ["lesion", 87], ["is", 94], ["a", 97], ["common", 99], ["feature", 106], ["of", 114], ["neurofibromatosis", 117], ["type", 135], ["1", 140], ["(", 142], ["NF1", 143], [")", 146], [",", 147], ["one", 149], ["of", 153], ["the", 156], ["most", 160], ["common", 165], ["autosomal", 172], ["dominant", 182], ["disorders", 191], [".", 200], ["The", 202], ["NF1", 206], ["gene", 210], ["codes", 215], ["for", 221], ["a", 225], ["protein", 227], ["called", 235], ["\"", 242], ["neurofibromin", 243], [".", 256], ["\"", 257], ["It", 259], ["possesses", 262], ["a", 272], ["region", 274], ["that", 281], ["shares", 286], ["a", 293], ["high", 295], ["homology", 300], ["with", 309], ["the", 314], ["family", 318], ["of", 325], ["GTPase", 328], ["-", 334], ["activating", 335], ["proteins", 346], [",", 354], ["which", 356], ["are", 362], ["negative", 366], ["regulators", 375], ["of", 386], ["RAS", 389], ["function", 393], ["and", 402], ["thereby", 406], ["control", 414], ["cell", 422], ["growth", 427], ["and", 434], ["differentiation", 438], [".", 453], ["The", 455], ["evidence", 459], ["points", 468], ["to", 475], ["the", 478], ["NF1", 482], ["gene", 486], ["being", 491], ["a", 497], ["tumor", 499], ["-", 504], ["suppressor", 505], ["gene", 516], [".", 520], ["NF1", 522], ["patients", 526], ["also", 535], ["have", 540], ["an", 545], ["increased", 548], ["incidence", 558], ["of", 568], ["certain", 571], ["malignant", 579], ["tumors", 589], ["that", 596], ["are", 601], ["believed", 605], ["to", 614], ["follow", 617], ["the", 624], ["\"", 628], ["two", 629], ["hit", 633], ["\"", 636], ["hypothesis", 638], [",", 648], ["with", 650], ["one", 655], ["allele", 659], ["constitutionally", 666], ["inactivated", 683], ["and", 695], ["the", 699], ["other", 703], ["somatically", 709], ["mutated", 721], [".", 728], ["Recently", 730], [",", 738], ["somatic", 740], ["loss", 748], ["of", 753], ["heterozygosity", 756], ["(", 771], ["LOH", 772], [")", 775], ["has", 777], ["been", 781], ["described", 786], ["for", 796], ["neurofibromas", 800], [",", 813], ["and", 815], ["mutations", 819], ["in", 829], ["both", 832], ["copies", 837], ["of", 844], ["the", 847], ["NF1", 851], ["gene", 855], ["have", 860], ["been", 865], ["reported", 870], ["for", 879], ["a", 883], ["dermal", 885], ["neurofibroma", 892], [".", 904], ["The", 906], ["aim", 910], ["of", 914], ["our", 917], ["study", 921], ["was", 927], ["the", 931], ["analysis", 935], ["of", 944], ["the", 947], ["NF1", 951], ["locus", 955], ["in", 961], ["benign", 964], ["neurofibromas", 971], ["in", 985], ["NF1", 988], ["patients", 992], [".", 1000], ["We", 1002], ["performed", 1005], ["LOH", 1015], ["analysis", 1019], ["on", 1028], ["60", 1031], ["neurofibromas", 1034], ["belonging", 1048], ["to", 1058], ["17", 1061], ["patients", 1064], [",", 1072], ["9", 1074], ["of", 1076], ["them", 1079], ["with", 1084], ["family", 1089], ["history", 1096], ["of", 1104], ["the", 1107], ["disease", 1111], ["and", 1119], ["8", 1123], ["of", 1125], ["them", 1128], ["sporadic", 1133], [".", 1141], ["We", 1143], ["have", 1146], ["analyzed", 1151], ["five", 1160], ["intragenic", 1165], ["NF1", 1176], ["markers", 1180], ["and", 1188], ["six", 1192], ["extragenic", 1196], ["markers", 1207], [",", 1214], ["and", 1216], ["we", 1220], ["have", 1223], ["found", 1228], ["LOH", 1234], ["in", 1238], ["25", 1241], ["%", 1243], ["of", 1245], ["the", 1248], ["neurofibromas", 1252], ["(", 1266], ["corresponding", 1267], ["to", 1281], ["53", 1284], ["%", 1286], ["of", 1288], ["the", 1291], ["patients", 1295], [")", 1303], [".", 1304], ["In", 1306], ["addition", 1309], [",", 1317], ["we", 1319], ["found", 1322], ["that", 1328], ["in", 1333], ["the", 1336], ["neurofibromas", 1340], ["of", 1354], ["patients", 1357], ["from", 1366], ["familial", 1371], ["cases", 1380], ["the", 1386], ["deletions", 1390], ["occurred", 1400], ["in", 1409], ["the", 1412], ["allele", 1416], ["that", 1423], ["is", 1428], ["not", 1431], ["transmitted", 1435], ["with", 1447], ["the", 1452], ["disease", 1456], [",", 1463], ["indicating", 1465], ["that", 1476], ["both", 1481], ["copies", 1486], ["of", 1493], ["the", 1496], ["NF1", 1500], ["gene", 1504], ["were", 1509], ["inactivated", 1514], ["in", 1526], ["these", 1529], ["tumors", 1535], [".", 1541], ["Therefore", 1543], [",", 1552], ["the", 1554], ["recent", 1558], ["reports", 1565], ["mentioned", 1573], ["above", 1583], [",", 1588], ["together", 1590], ["with", 1599], ["our", 1604], ["findings", 1608], [",", 1616], ["strongly", 1618], ["support", 1627], ["the", 1635], ["double", 1639], ["inactivation", 1646], ["of", 1659], ["the", 1662], ["NF1", 1666], ["gene", 1670], ["in", 1675], ["benign", 1678], ["neurofibromas", 1685], [".", 1698]]}
{"context": "Some neurological conditions require admission to an intensive care unit (ICU) where deep sedation and mechanical ventilation are administered to improve the patient's condition. Nevertheless, these treatments are not always helpful in disease control. At this stage, deep brain stimulation (DBS) could become a viable alternative in the treatment of critical neurological conditions with long-lasting clinical benefit. The value of deep brain stimulation has been investigated in the treatment of patients who had undergone surgical electrode implants as an emergency procedure to treat acute life-threatening conditions requiring admission to neurological ICU (NICU). A before-and-after perspective study was examined of seven patients who were treated with DBS for status dystonicus (SD) and post-stroke severe hemiballismus. Bilateral globus pallidus internus (GPi) DBS was performed in five SD patients and unilateral ventralis oralis anterior and posterior (Voa/Vop) nucleus of the thalamus DBS in two post-stroke hemiballismus patients. Bilateral GPi-DBS allowed SD resolution in a time lapse varying from 1\u00a0week to 3\u00a0months. No clear improvements compared to the baseline clinical condition were observed. Unilateral Voa/Vop-DBS intervention controlled hemiballismus after 10\u00a0h, and the patient was discharged in 2\u00a0days. The other patient was transferred from the NICU to the neurosurgery ward after 13\u00a0days. No surgical complications were observed in any of the above procedures. Neurostimulation procedures could represent a valuable choice in critical care conditions, when involuntary movements are continuous, life-threatening and refractory to intensive care procedures. DBS is feasible, safe and effective in selected cases.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "2c1bd1c29737403c884ad051c6440ed5", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[141, 143]], "char_spans": [[839, 862]]}]}], "context_tokens": [["Some", 0], ["neurological", 5], ["conditions", 18], ["require", 29], ["admission", 37], ["to", 47], ["an", 50], ["intensive", 53], ["care", 63], ["unit", 68], ["(", 73], ["ICU", 74], [")", 77], ["where", 79], ["deep", 85], ["sedation", 90], ["and", 99], ["mechanical", 103], ["ventilation", 114], ["are", 126], ["administered", 130], ["to", 143], ["improve", 146], ["the", 154], ["patient", 158], ["'s", 165], ["condition", 168], [".", 177], ["Nevertheless", 179], [",", 191], ["these", 193], ["treatments", 199], ["are", 210], ["not", 214], ["always", 218], ["helpful", 225], ["in", 233], ["disease", 236], ["control", 244], [".", 251], ["At", 253], ["this", 256], ["stage", 261], [",", 266], ["deep", 268], ["brain", 273], ["stimulation", 279], ["(", 291], ["DBS", 292], [")", 295], ["could", 297], ["become", 303], ["a", 310], ["viable", 312], ["alternative", 319], ["in", 331], ["the", 334], ["treatment", 338], ["of", 348], ["critical", 351], ["neurological", 360], ["conditions", 373], ["with", 384], ["long", 389], ["-", 393], ["lasting", 394], ["clinical", 402], ["benefit", 411], [".", 418], ["The", 420], ["value", 424], ["of", 430], ["deep", 433], ["brain", 438], ["stimulation", 444], ["has", 456], ["been", 460], ["investigated", 465], ["in", 478], ["the", 481], ["treatment", 485], ["of", 495], ["patients", 498], ["who", 507], ["had", 511], ["undergone", 515], ["surgical", 525], ["electrode", 534], ["implants", 544], ["as", 553], ["an", 556], ["emergency", 559], ["procedure", 569], ["to", 579], ["treat", 582], ["acute", 588], ["life", 594], ["-", 598], ["threatening", 599], ["conditions", 611], ["requiring", 622], ["admission", 632], ["to", 642], ["neurological", 645], ["ICU", 658], ["(", 662], ["NICU", 663], [")", 667], [".", 668], ["A", 670], ["before", 672], ["-", 678], ["and", 679], ["-", 682], ["after", 683], ["perspective", 689], ["study", 701], ["was", 707], ["examined", 711], ["of", 720], ["seven", 723], ["patients", 729], ["who", 738], ["were", 742], ["treated", 747], ["with", 755], ["DBS", 760], ["for", 764], ["status", 768], ["dystonicus", 775], ["(", 786], ["SD", 787], [")", 789], ["and", 791], ["post", 795], ["-", 799], ["stroke", 800], ["severe", 807], ["hemiballismus", 814], [".", 827], ["Bilateral", 829], ["globus", 839], ["pallidus", 846], ["internus", 855], ["(", 864], ["GPi", 865], [")", 868], ["DBS", 870], ["was", 874], ["performed", 878], ["in", 888], ["five", 891], ["SD", 896], ["patients", 899], ["and", 908], ["unilateral", 912], ["ventralis", 923], ["oralis", 933], ["anterior", 940], ["and", 949], ["posterior", 953], ["(", 963], ["Voa", 964], ["/", 967], ["Vop", 968], [")", 971], ["nucleus", 973], ["of", 981], ["the", 984], ["thalamus", 988], ["DBS", 997], ["in", 1001], ["two", 1004], ["post", 1008], ["-", 1012], ["stroke", 1013], ["hemiballismus", 1020], ["patients", 1034], [".", 1042], ["Bilateral", 1044], ["GPi", 1054], ["-", 1057], ["DBS", 1058], ["allowed", 1062], ["SD", 1070], ["resolution", 1073], ["in", 1084], ["a", 1087], ["time", 1089], ["lapse", 1094], ["varying", 1100], ["from", 1108], ["1", 1113], ["week", 1115], ["to", 1120], ["3", 1123], ["months", 1125], [".", 1131], ["No", 1133], ["clear", 1136], ["improvements", 1142], ["compared", 1155], ["to", 1164], ["the", 1167], ["baseline", 1171], ["clinical", 1180], ["condition", 1189], ["were", 1199], ["observed", 1204], [".", 1212], ["Unilateral", 1214], ["Voa", 1225], ["/", 1228], ["Vop", 1229], ["-", 1232], ["DBS", 1233], ["intervention", 1237], ["controlled", 1250], ["hemiballismus", 1261], ["after", 1275], ["10", 1281], ["h", 1284], [",", 1285], ["and", 1287], ["the", 1291], ["patient", 1295], ["was", 1303], ["discharged", 1307], ["in", 1318], ["2", 1321], ["days", 1323], [".", 1327], ["The", 1329], ["other", 1333], ["patient", 1339], ["was", 1347], ["transferred", 1351], ["from", 1363], ["the", 1368], ["NICU", 1372], ["to", 1377], ["the", 1380], ["neurosurgery", 1384], ["ward", 1397], ["after", 1402], ["13", 1408], ["days", 1411], [".", 1415], ["No", 1417], ["surgical", 1420], ["complications", 1429], ["were", 1443], ["observed", 1448], ["in", 1457], ["any", 1460], ["of", 1464], ["the", 1467], ["above", 1471], ["procedures", 1477], [".", 1487], ["Neurostimulation", 1489], ["procedures", 1506], ["could", 1517], ["represent", 1523], ["a", 1533], ["valuable", 1535], ["choice", 1544], ["in", 1551], ["critical", 1554], ["care", 1563], ["conditions", 1568], [",", 1578], ["when", 1580], ["involuntary", 1585], ["movements", 1597], ["are", 1607], ["continuous", 1611], [",", 1621], ["life", 1623], ["-", 1627], ["threatening", 1628], ["and", 1640], ["refractory", 1644], ["to", 1655], ["intensive", 1658], ["care", 1668], ["procedures", 1673], [".", 1683], ["DBS", 1685], ["is", 1689], ["feasible", 1692], [",", 1700], ["safe", 1702], ["and", 1707], ["effective", 1711], ["in", 1721], ["selected", 1724], ["cases", 1733], [".", 1738]]}
{"context": "Astrocytomas are the leading cause of brain cancer in humans. Because these tumours are highly infiltrative, current treatments that rely on targeting the tumour mass are often ineffective. A mouse model for astrocytoma would be a powerful tool for dissecting tumour progression and testing therapeutics. Mouse models of astrocytoma have been designed to express oncogenic proteins in astrocytes, but have had limited success due to low tumour penetrance or limited tumour progression. We present here a mouse model of astrocytomas involving mutation of two tumour-suppressor genes, Nf1 and Trp53. Humans with mutations in NF1 develop neurofibromatosis type I (NF1) and have increased risk of optic gliomas, astrocytomas and glioblastomas. The TP53 tumour suppressor is often mutated in a subset of astrocytomas that develop at a young age and progress slowly to glioblastoma (termed secondary glioblastomas, in contrast to primary glioblastomas that develop rapidly de novo). This mouse model shows a range of astrocytoma stages, from low-grade astrocytoma to glioblastoma multiforme, and may accurately model human secondary glioblastoma involving TP53 loss. This is the first reported mouse model of astrocytoma initiated by loss of tumour suppressors, rather than overexpression of transgenic oncogenes.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "fcb4893a6cb14ad6b24d3eecd91305b9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[103, 103], [109, 109], [95, 95]], "char_spans": [[623, 625], [661, 663], [583, 585]]}]}], "context_tokens": [["Astrocytomas", 0], ["are", 13], ["the", 17], ["leading", 21], ["cause", 29], ["of", 35], ["brain", 38], ["cancer", 44], ["in", 51], ["humans", 54], [".", 60], ["Because", 62], ["these", 70], ["tumours", 76], ["are", 84], ["highly", 88], ["infiltrative", 95], [",", 107], ["current", 109], ["treatments", 117], ["that", 128], ["rely", 133], ["on", 138], ["targeting", 141], ["the", 151], ["tumour", 155], ["mass", 162], ["are", 167], ["often", 171], ["ineffective", 177], [".", 188], ["A", 190], ["mouse", 192], ["model", 198], ["for", 204], ["astrocytoma", 208], ["would", 220], ["be", 226], ["a", 229], ["powerful", 231], ["tool", 240], ["for", 245], ["dissecting", 249], ["tumour", 260], ["progression", 267], ["and", 279], ["testing", 283], ["therapeutics", 291], [".", 303], ["Mouse", 305], ["models", 311], ["of", 318], ["astrocytoma", 321], ["have", 333], ["been", 338], ["designed", 343], ["to", 352], ["express", 355], ["oncogenic", 363], ["proteins", 373], ["in", 382], ["astrocytes", 385], [",", 395], ["but", 397], ["have", 401], ["had", 406], ["limited", 410], ["success", 418], ["due", 426], ["to", 430], ["low", 433], ["tumour", 437], ["penetrance", 444], ["or", 455], ["limited", 458], ["tumour", 466], ["progression", 473], [".", 484], ["We", 486], ["present", 489], ["here", 497], ["a", 502], ["mouse", 504], ["model", 510], ["of", 516], ["astrocytomas", 519], ["involving", 532], ["mutation", 542], ["of", 551], ["two", 554], ["tumour", 558], ["-", 564], ["suppressor", 565], ["genes", 576], [",", 581], ["Nf1", 583], ["and", 587], ["Trp53", 591], [".", 596], ["Humans", 598], ["with", 605], ["mutations", 610], ["in", 620], ["NF1", 623], ["develop", 627], ["neurofibromatosis", 635], ["type", 653], ["I", 658], ["(", 660], ["NF1", 661], [")", 664], ["and", 666], ["have", 670], ["increased", 675], ["risk", 685], ["of", 690], ["optic", 693], ["gliomas", 699], [",", 706], ["astrocytomas", 708], ["and", 721], ["glioblastomas", 725], [".", 738], ["The", 740], ["TP53", 744], ["tumour", 749], ["suppressor", 756], ["is", 767], ["often", 770], ["mutated", 776], ["in", 784], ["a", 787], ["subset", 789], ["of", 796], ["astrocytomas", 799], ["that", 812], ["develop", 817], ["at", 825], ["a", 828], ["young", 830], ["age", 836], ["and", 840], ["progress", 844], ["slowly", 853], ["to", 860], ["glioblastoma", 863], ["(", 876], ["termed", 877], ["secondary", 884], ["glioblastomas", 894], [",", 907], ["in", 909], ["contrast", 912], ["to", 921], ["primary", 924], ["glioblastomas", 932], ["that", 946], ["develop", 951], ["rapidly", 959], ["de", 967], ["novo", 970], [")", 974], [".", 975], ["This", 977], ["mouse", 982], ["model", 988], ["shows", 994], ["a", 1000], ["range", 1002], ["of", 1008], ["astrocytoma", 1011], ["stages", 1023], [",", 1029], ["from", 1031], ["low", 1036], ["-", 1039], ["grade", 1040], ["astrocytoma", 1046], ["to", 1058], ["glioblastoma", 1061], ["multiforme", 1074], [",", 1084], ["and", 1086], ["may", 1090], ["accurately", 1094], ["model", 1105], ["human", 1111], ["secondary", 1117], ["glioblastoma", 1127], ["involving", 1140], ["TP53", 1150], ["loss", 1155], [".", 1159], ["This", 1161], ["is", 1166], ["the", 1169], ["first", 1173], ["reported", 1179], ["mouse", 1188], ["model", 1194], ["of", 1200], ["astrocytoma", 1203], ["initiated", 1215], ["by", 1225], ["loss", 1228], ["of", 1233], ["tumour", 1236], ["suppressors", 1243], [",", 1254], ["rather", 1256], ["than", 1263], ["overexpression", 1268], ["of", 1283], ["transgenic", 1286], ["oncogenes", 1297], [".", 1306]]}
{"context": "Compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome. Carpal tunnel syndrome is usually caused by compression of the median nerve due to synovial swelling, tumor, or anomalous anatomical structure within the carpal tunnel. During a routine carpal tunnel decompression, a large vessel was identified within the carpal tunnel. The large vessel was the radial artery. It ran along the radial aspect of the carpal tunnel just adjacent to the median nerve. The unusual presence of the radial artery within the carpal tunnel could be a contributing factor to the development of carpal tunnel syndrome. In this case, after surgical carpal tunnel release, all symptoms of carpal tunnel syndrome resolved.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "f1a38a0735d74f2580015f818c2fe6de", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[33, 33], [3, 3], [90, 90]], "char_spans": [[195, 200], [19, 24], [516, 521]]}]}], "context_tokens": [["Compression", 0], ["of", 12], ["the", 15], ["median", 19], ["nerve", 26], ["at", 32], ["the", 35], ["wrist", 39], [",", 44], ["or", 46], ["carpal", 49], ["tunnel", 56], ["syndrome", 63], [",", 71], ["is", 73], ["the", 76], ["most", 80], ["commonly", 85], ["recognized", 94], ["nerve", 105], ["entrapment", 111], ["syndrome", 122], [".", 130], ["Carpal", 132], ["tunnel", 139], ["syndrome", 146], ["is", 155], ["usually", 158], ["caused", 166], ["by", 173], ["compression", 176], ["of", 188], ["the", 191], ["median", 195], ["nerve", 202], ["due", 208], ["to", 212], ["synovial", 215], ["swelling", 224], [",", 232], ["tumor", 234], [",", 239], ["or", 241], ["anomalous", 244], ["anatomical", 254], ["structure", 265], ["within", 275], ["the", 282], ["carpal", 286], ["tunnel", 293], [".", 299], ["During", 301], ["a", 308], ["routine", 310], ["carpal", 318], ["tunnel", 325], ["decompression", 332], [",", 345], ["a", 347], ["large", 349], ["vessel", 355], ["was", 362], ["identified", 366], ["within", 377], ["the", 384], ["carpal", 388], ["tunnel", 395], [".", 401], ["The", 403], ["large", 407], ["vessel", 413], ["was", 420], ["the", 424], ["radial", 428], ["artery", 435], [".", 441], ["It", 443], ["ran", 446], ["along", 450], ["the", 456], ["radial", 460], ["aspect", 467], ["of", 474], ["the", 477], ["carpal", 481], ["tunnel", 488], ["just", 495], ["adjacent", 500], ["to", 509], ["the", 512], ["median", 516], ["nerve", 523], [".", 528], ["The", 530], ["unusual", 534], ["presence", 542], ["of", 551], ["the", 554], ["radial", 558], ["artery", 565], ["within", 572], ["the", 579], ["carpal", 583], ["tunnel", 590], ["could", 597], ["be", 603], ["a", 606], ["contributing", 608], ["factor", 621], ["to", 628], ["the", 631], ["development", 635], ["of", 647], ["carpal", 650], ["tunnel", 657], ["syndrome", 664], [".", 672], ["In", 674], ["this", 677], ["case", 682], [",", 686], ["after", 688], ["surgical", 694], ["carpal", 703], ["tunnel", 710], ["release", 717], [",", 724], ["all", 726], ["symptoms", 730], ["of", 739], ["carpal", 742], ["tunnel", 749], ["syndrome", 756], ["resolved", 765], [".", 773]]}
{"context": "Ch\u00e9diak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by immunodeficiency, neurological dysfunction, and oculocutaneous albinism. Recently, several clinical CHS phenotypes have been reported. Here, we report results of a nationwide survey performed to clarify clinical characteristics and outcomes of CHS patients in Japan. Questionnaires were sent to 287 institutions to collect data regarding CHS patients diagnosed between 2000 and 2010, including results of lysosomal trafficking regulator (LYST) gene analysis. Cytotoxicity and degranulation activity of cytotoxic T lymphocytes were analyzed in available patient samples. A total of 15 patients diagnosed with CHS were eligible for enrollment in this study. Of these, 10 (67%) had recurrent bacterial infections, five (33%) developed life-threatening hemophagocytic lymphohistiocytosis (HLH), and one patient had complicated malignant lymphoma. Hematopoietic stem cell transplantation (HSCT) was performed for six patients including three with HLH, and 10 of the enrolled patients have survived at the time of this writing. LYST analysis was performed for 10 patients; seven different mutations were detected in seven patients, whereas no mutation was identified in three patients. Cytotoxicity and degranulation activity were impaired in patients with and without LYST mutation. Results of this survey indicate that one or two patients with CHS were newly diagnosed each year in Japan. The incidence of HLH was not as high as expected. Mutations of genes other than LYST were suspected in some cases. We conclude that determining indication for HSCT for CHS patients should be based on genetic and cytotoxic analysis.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "f1f7239d2a0c4cb885c35010f04d0b4a", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[81, 83]], "char_spans": [[525, 534]]}]}], "context_tokens": [["Ch\u00e9diak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disorder", 61], ["characterized", 70], ["by", 84], ["immunodeficiency", 87], [",", 103], ["neurological", 105], ["dysfunction", 118], [",", 129], ["and", 131], ["oculocutaneous", 135], ["albinism", 150], [".", 158], ["Recently", 160], [",", 168], ["several", 170], ["clinical", 178], ["CHS", 187], ["phenotypes", 191], ["have", 202], ["been", 207], ["reported", 212], [".", 220], ["Here", 222], [",", 226], ["we", 228], ["report", 231], ["results", 238], ["of", 246], ["a", 249], ["nationwide", 251], ["survey", 262], ["performed", 269], ["to", 279], ["clarify", 282], ["clinical", 290], ["characteristics", 299], ["and", 315], ["outcomes", 319], ["of", 328], ["CHS", 331], ["patients", 335], ["in", 344], ["Japan", 347], [".", 352], ["Questionnaires", 354], ["were", 369], ["sent", 374], ["to", 379], ["287", 382], ["institutions", 386], ["to", 399], ["collect", 402], ["data", 410], ["regarding", 415], ["CHS", 425], ["patients", 429], ["diagnosed", 438], ["between", 448], ["2000", 456], ["and", 461], ["2010", 465], [",", 469], ["including", 471], ["results", 481], ["of", 489], ["lysosomal", 492], ["trafficking", 502], ["regulator", 514], ["(", 524], ["LYST", 525], [")", 529], ["gene", 531], ["analysis", 536], [".", 544], ["Cytotoxicity", 546], ["and", 559], ["degranulation", 563], ["activity", 577], ["of", 586], ["cytotoxic", 589], ["T", 599], ["lymphocytes", 601], ["were", 613], ["analyzed", 618], ["in", 627], ["available", 630], ["patient", 640], ["samples", 648], [".", 655], ["A", 657], ["total", 659], ["of", 665], ["15", 668], ["patients", 671], ["diagnosed", 680], ["with", 690], ["CHS", 695], ["were", 699], ["eligible", 704], ["for", 713], ["enrollment", 717], ["in", 728], ["this", 731], ["study", 736], [".", 741], ["Of", 743], ["these", 746], [",", 751], ["10", 753], ["(", 756], ["67", 757], ["%", 759], [")", 760], ["had", 762], ["recurrent", 766], ["bacterial", 776], ["infections", 786], [",", 796], ["five", 798], ["(", 803], ["33", 804], ["%", 806], [")", 807], ["developed", 809], ["life", 819], ["-", 823], ["threatening", 824], ["hemophagocytic", 836], ["lymphohistiocytosis", 851], ["(", 871], ["HLH", 872], [")", 875], [",", 876], ["and", 878], ["one", 882], ["patient", 886], ["had", 894], ["complicated", 898], ["malignant", 910], ["lymphoma", 920], [".", 928], ["Hematopoietic", 930], ["stem", 944], ["cell", 949], ["transplantation", 954], ["(", 970], ["HSCT", 971], [")", 975], ["was", 977], ["performed", 981], ["for", 991], ["six", 995], ["patients", 999], ["including", 1008], ["three", 1018], ["with", 1024], ["HLH", 1029], [",", 1032], ["and", 1034], ["10", 1038], ["of", 1041], ["the", 1044], ["enrolled", 1048], ["patients", 1057], ["have", 1066], ["survived", 1071], ["at", 1080], ["the", 1083], ["time", 1087], ["of", 1092], ["this", 1095], ["writing", 1100], [".", 1107], ["LYST", 1109], ["analysis", 1114], ["was", 1123], ["performed", 1127], ["for", 1137], ["10", 1141], ["patients", 1144], [";", 1152], ["seven", 1154], ["different", 1160], ["mutations", 1170], ["were", 1180], ["detected", 1185], ["in", 1194], ["seven", 1197], ["patients", 1203], [",", 1211], ["whereas", 1213], ["no", 1221], ["mutation", 1224], ["was", 1233], ["identified", 1237], ["in", 1248], ["three", 1251], ["patients", 1257], [".", 1265], ["Cytotoxicity", 1267], ["and", 1280], ["degranulation", 1284], ["activity", 1298], ["were", 1307], ["impaired", 1312], ["in", 1321], ["patients", 1324], ["with", 1333], ["and", 1338], ["without", 1342], ["LYST", 1350], ["mutation", 1355], [".", 1363], ["Results", 1365], ["of", 1373], ["this", 1376], ["survey", 1381], ["indicate", 1388], ["that", 1397], ["one", 1402], ["or", 1406], ["two", 1409], ["patients", 1413], ["with", 1422], ["CHS", 1427], ["were", 1431], ["newly", 1436], ["diagnosed", 1442], ["each", 1452], ["year", 1457], ["in", 1462], ["Japan", 1465], [".", 1470], ["The", 1472], ["incidence", 1476], ["of", 1486], ["HLH", 1489], ["was", 1493], ["not", 1497], ["as", 1501], ["high", 1504], ["as", 1509], ["expected", 1512], [".", 1520], ["Mutations", 1522], ["of", 1532], ["genes", 1535], ["other", 1541], ["than", 1547], ["LYST", 1552], ["were", 1557], ["suspected", 1562], ["in", 1572], ["some", 1575], ["cases", 1580], [".", 1585], ["We", 1587], ["conclude", 1590], ["that", 1599], ["determining", 1604], ["indication", 1616], ["for", 1627], ["HSCT", 1631], ["for", 1636], ["CHS", 1640], ["patients", 1644], ["should", 1653], ["be", 1660], ["based", 1663], ["on", 1669], ["genetic", 1672], ["and", 1680], ["cytotoxic", 1684], ["analysis", 1694], [".", 1702]]}
{"context": "Translation of UGA as selenocysteine requires specific RNA secondary structures in the mRNAs of selenoproteins. These elements differ in sequence, structure, and location in the mRNA, that is, coding versus 3' untranslated region, in prokaryotes, eukaryotes, and archaea. Analyses of eukaryotic selenocysteine insertion sequence (SECIS) elements via computer folding programs, mutagenesis studies, and chemical and enzymatic probing has led to the derivation of a predicted consensus structural model for these elements. This model consists of a stem-loop or hairpin, with conserved nucleotides in the loop and in a non-Watson-Crick motif at the base of the stem. However, the sequences of a number of SECIS elements predict that they would diverge from the consensus structure in the loop region. Using site-directed mutagenesis to introduce mutations predicted to either disrupt or restore structure, or to manipulate loop size or stem length, we show that eukaryotic SECIS elements fall into two distinct classes, termed forms 1 and 2. Form 2 elements have additional secondary structures not present in form 1 elements. By either insertion or deletion of the sequences and structures distinguishing the two classes of elements while maintaining appropriate loop size, conversion of a form 1 element to a functional form 2-like element and of a form 2 to a functional form 1-like element was achieved. These results suggest commonality of function of the two classes. The information obtained regarding the existence of two classes of SECIS elements and the tolerances for manipulations of stem length and loop size should facilitate designing RNA molecules for obtaining high-resolution structural information about these elements.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "b3180bd2a2c74801ad23a33210e43134", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[127, 127], [172, 172], [55, 55], [269, 269]], "char_spans": [[702, 706], [970, 974], [330, 334], [1538, 1542]]}]}], "context_tokens": [["Translation", 0], ["of", 12], ["UGA", 15], ["as", 19], ["selenocysteine", 22], ["requires", 37], ["specific", 46], ["RNA", 55], ["secondary", 59], ["structures", 69], ["in", 80], ["the", 83], ["mRNAs", 87], ["of", 93], ["selenoproteins", 96], [".", 110], ["These", 112], ["elements", 118], ["differ", 127], ["in", 134], ["sequence", 137], [",", 145], ["structure", 147], [",", 156], ["and", 158], ["location", 162], ["in", 171], ["the", 174], ["mRNA", 178], [",", 182], ["that", 184], ["is", 189], [",", 191], ["coding", 193], ["versus", 200], ["3", 207], ["'", 208], ["untranslated", 210], ["region", 223], [",", 229], ["in", 231], ["prokaryotes", 234], [",", 245], ["eukaryotes", 247], [",", 257], ["and", 259], ["archaea", 263], [".", 270], ["Analyses", 272], ["of", 281], ["eukaryotic", 284], ["selenocysteine", 295], ["insertion", 310], ["sequence", 320], ["(", 329], ["SECIS", 330], [")", 335], ["elements", 337], ["via", 346], ["computer", 350], ["folding", 359], ["programs", 367], [",", 375], ["mutagenesis", 377], ["studies", 389], [",", 396], ["and", 398], ["chemical", 402], ["and", 411], ["enzymatic", 415], ["probing", 425], ["has", 433], ["led", 437], ["to", 441], ["the", 444], ["derivation", 448], ["of", 459], ["a", 462], ["predicted", 464], ["consensus", 474], ["structural", 484], ["model", 495], ["for", 501], ["these", 505], ["elements", 511], [".", 519], ["This", 521], ["model", 526], ["consists", 532], ["of", 541], ["a", 544], ["stem", 546], ["-", 550], ["loop", 551], ["or", 556], ["hairpin", 559], [",", 566], ["with", 568], ["conserved", 573], ["nucleotides", 583], ["in", 595], ["the", 598], ["loop", 602], ["and", 607], ["in", 611], ["a", 614], ["non", 616], ["-", 619], ["Watson", 620], ["-", 626], ["Crick", 627], ["motif", 633], ["at", 639], ["the", 642], ["base", 646], ["of", 651], ["the", 654], ["stem", 658], [".", 662], ["However", 664], [",", 671], ["the", 673], ["sequences", 677], ["of", 687], ["a", 690], ["number", 692], ["of", 699], ["SECIS", 702], ["elements", 708], ["predict", 717], ["that", 725], ["they", 730], ["would", 735], ["diverge", 741], ["from", 749], ["the", 754], ["consensus", 758], ["structure", 768], ["in", 778], ["the", 781], ["loop", 785], ["region", 790], [".", 796], ["Using", 798], ["site", 804], ["-", 808], ["directed", 809], ["mutagenesis", 818], ["to", 830], ["introduce", 833], ["mutations", 843], ["predicted", 853], ["to", 863], ["either", 866], ["disrupt", 873], ["or", 881], ["restore", 884], ["structure", 892], [",", 901], ["or", 903], ["to", 906], ["manipulate", 909], ["loop", 920], ["size", 925], ["or", 930], ["stem", 933], ["length", 938], [",", 944], ["we", 946], ["show", 949], ["that", 954], ["eukaryotic", 959], ["SECIS", 970], ["elements", 976], ["fall", 985], ["into", 990], ["two", 995], ["distinct", 999], ["classes", 1008], [",", 1015], ["termed", 1017], ["forms", 1024], ["1", 1030], ["and", 1032], ["2", 1036], [".", 1037], ["Form", 1039], ["2", 1044], ["elements", 1046], ["have", 1055], ["additional", 1060], ["secondary", 1071], ["structures", 1081], ["not", 1092], ["present", 1096], ["in", 1104], ["form", 1107], ["1", 1112], ["elements", 1114], [".", 1122], ["By", 1124], ["either", 1127], ["insertion", 1134], ["or", 1144], ["deletion", 1147], ["of", 1156], ["the", 1159], ["sequences", 1163], ["and", 1173], ["structures", 1177], ["distinguishing", 1188], ["the", 1203], ["two", 1207], ["classes", 1211], ["of", 1219], ["elements", 1222], ["while", 1231], ["maintaining", 1237], ["appropriate", 1249], ["loop", 1261], ["size", 1266], [",", 1270], ["conversion", 1272], ["of", 1283], ["a", 1286], ["form", 1288], ["1", 1293], ["element", 1295], ["to", 1303], ["a", 1306], ["functional", 1308], ["form", 1319], ["2-like", 1324], ["element", 1331], ["and", 1339], ["of", 1343], ["a", 1346], ["form", 1348], ["2", 1353], ["to", 1355], ["a", 1358], ["functional", 1360], ["form", 1371], ["1-like", 1376], ["element", 1383], ["was", 1391], ["achieved", 1395], [".", 1403], ["These", 1405], ["results", 1411], ["suggest", 1419], ["commonality", 1427], ["of", 1439], ["function", 1442], ["of", 1451], ["the", 1454], ["two", 1458], ["classes", 1462], [".", 1469], ["The", 1471], ["information", 1475], ["obtained", 1487], ["regarding", 1496], ["the", 1506], ["existence", 1510], ["of", 1520], ["two", 1523], ["classes", 1527], ["of", 1535], ["SECIS", 1538], ["elements", 1544], ["and", 1553], ["the", 1557], ["tolerances", 1561], ["for", 1572], ["manipulations", 1576], ["of", 1590], ["stem", 1593], ["length", 1598], ["and", 1605], ["loop", 1609], ["size", 1614], ["should", 1619], ["facilitate", 1626], ["designing", 1637], ["RNA", 1647], ["molecules", 1651], ["for", 1661], ["obtaining", 1665], ["high", 1675], ["-", 1679], ["resolution", 1680], ["structural", 1691], ["information", 1702], ["about", 1714], ["these", 1720], ["elements", 1726], [".", 1734]]}
{"context": "The t(9;22)(q34;q11) translocation leading to the Philadelphia (Ph) chromosome resulting in BCR-ABL gene fusion is associated with a poor prognosis in acute lymphoblastic leukemia (ALL). We studied the relation between t(9;22), determined by karyotype, fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR), and in vitro drug resistance, measured by the MTT assay, in precursor B-cell ALL at diagnosis. The findings in twenty-one Ph-positive (Ph+) childhood common/precursorB (c/preB) cases were compared with 254 Ph-negative (Ph-) ALL cases. A large range of LC(50) values was found within the Ph+ patients. Moreover, LC(50) values did not differ significantly between Ph+ and Ph- samples for prednisolone, dexamethasone, L-asparaginase, vincristine, anthracyclines, thiopurines, epipodophyllotoxins, and 4H00-ifosfamide, even after matching for important prognostic features (age, white blood cell count (WBC), and immunophenotype). Adult Ph+ (n = 12) ALL was more resistant to prednisolone (> 270-fold, P = 0.030), and displayed an overall tendency to resistance when compared to matched cases of Ph- (n = 15) adult precursor B-cell ALL. Within Ph+ ALL, in vitro prednisolone resistance increased significantly with age (P = 0.006). The expression of lung resistance protein (LRP), but not P-glycoprotein (P-gp) or multidrug resistance protein (MRP), was significantly higher in all Ph+ patients. Both childhood and adult Ph+ precursor B-cell ALL samples display a heterogeneous in vitro resistance profile, with relatively sensitive and resistant cases. The adult Ph+ samples, however, are generally more resistant compared to matched Ph- controls, reaching significance for prednisolone. The correlation of prednisolone resistance with age within the Ph+ cases might help explain the poorer prognosis of adult Ph+ ALL.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "b60b5fefa0974ab9bf4f02ae03d69a4c", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[14, 18]], "char_spans": [[92, 110]]}]}], "context_tokens": [["The", 0], ["t(9;22)(q34;q11", 4], [")", 19], ["translocation", 21], ["leading", 35], ["to", 43], ["the", 46], ["Philadelphia", 50], ["(", 63], ["Ph", 64], [")", 66], ["chromosome", 68], ["resulting", 79], ["in", 89], ["BCR", 92], ["-", 95], ["ABL", 96], ["gene", 100], ["fusion", 105], ["is", 112], ["associated", 115], ["with", 126], ["a", 131], ["poor", 133], ["prognosis", 138], ["in", 148], ["acute", 151], ["lymphoblastic", 157], ["leukemia", 171], ["(", 180], ["ALL", 181], [")", 184], [".", 185], ["We", 187], ["studied", 190], ["the", 198], ["relation", 202], ["between", 211], ["t(9;22", 219], [")", 225], [",", 226], ["determined", 228], ["by", 239], ["karyotype", 242], [",", 251], ["fluorescence", 253], ["in", 266], ["situ", 269], ["hybridization", 274], ["(", 288], ["FISH", 289], [")", 293], ["or", 295], ["polymerase", 298], ["chain", 309], ["reaction", 315], ["(", 324], ["PCR", 325], [")", 328], [",", 329], ["and", 331], ["in", 335], ["vitro", 338], ["drug", 344], ["resistance", 349], [",", 359], ["measured", 361], ["by", 370], ["the", 373], ["MTT", 377], ["assay", 381], [",", 386], ["in", 388], ["precursor", 391], ["B", 401], ["-", 402], ["cell", 403], ["ALL", 408], ["at", 412], ["diagnosis", 415], [".", 424], ["The", 426], ["findings", 430], ["in", 439], ["twenty", 442], ["-", 448], ["one", 449], ["Ph", 453], ["-", 455], ["positive", 456], ["(", 465], ["Ph+", 466], [")", 469], ["childhood", 471], ["common", 481], ["/", 487], ["precursorB", 488], ["(", 499], ["c", 500], ["/", 501], ["preB", 502], [")", 506], ["cases", 508], ["were", 514], ["compared", 519], ["with", 528], ["254", 533], ["Ph", 537], ["-", 539], ["negative", 540], ["(", 549], ["Ph-", 550], [")", 553], ["ALL", 555], ["cases", 559], [".", 564], ["A", 566], ["large", 568], ["range", 574], ["of", 580], ["LC(50", 583], [")", 588], ["values", 590], ["was", 597], ["found", 601], ["within", 607], ["the", 614], ["Ph+", 618], ["patients", 622], [".", 630], ["Moreover", 632], [",", 640], ["LC(50", 642], [")", 647], ["values", 649], ["did", 656], ["not", 660], ["differ", 664], ["significantly", 671], ["between", 685], ["Ph+", 693], ["and", 697], ["Ph-", 701], ["samples", 705], ["for", 713], ["prednisolone", 717], [",", 729], ["dexamethasone", 731], [",", 744], ["L", 746], ["-", 747], ["asparaginase", 748], [",", 760], ["vincristine", 762], [",", 773], ["anthracyclines", 775], [",", 789], ["thiopurines", 791], [",", 802], ["epipodophyllotoxins", 804], [",", 823], ["and", 825], ["4H00-ifosfamide", 829], [",", 844], ["even", 846], ["after", 851], ["matching", 857], ["for", 866], ["important", 870], ["prognostic", 880], ["features", 891], ["(", 900], ["age", 901], [",", 904], ["white", 906], ["blood", 912], ["cell", 918], ["count", 923], ["(", 929], ["WBC", 930], [")", 933], [",", 934], ["and", 936], ["immunophenotype", 940], [")", 955], [".", 956], ["Adult", 958], ["Ph+", 964], ["(", 968], ["n", 969], ["=", 971], ["12", 973], [")", 975], ["ALL", 977], ["was", 981], ["more", 985], ["resistant", 990], ["to", 1000], ["prednisolone", 1003], ["(", 1016], [">", 1017], ["270-fold", 1019], [",", 1027], ["P", 1029], ["=", 1031], ["0.030", 1033], [")", 1038], [",", 1039], ["and", 1041], ["displayed", 1045], ["an", 1055], ["overall", 1058], ["tendency", 1066], ["to", 1075], ["resistance", 1078], ["when", 1089], ["compared", 1094], ["to", 1103], ["matched", 1106], ["cases", 1114], ["of", 1120], ["Ph-", 1123], ["(", 1127], ["n", 1128], ["=", 1130], ["15", 1132], [")", 1134], ["adult", 1136], ["precursor", 1142], ["B", 1152], ["-", 1153], ["cell", 1154], ["ALL", 1159], [".", 1162], ["Within", 1164], ["Ph+", 1171], ["ALL", 1175], [",", 1178], ["in", 1180], ["vitro", 1183], ["prednisolone", 1189], ["resistance", 1202], ["increased", 1213], ["significantly", 1223], ["with", 1237], ["age", 1242], ["(", 1246], ["P", 1247], ["=", 1249], ["0.006", 1251], [")", 1256], [".", 1257], ["The", 1259], ["expression", 1263], ["of", 1274], ["lung", 1277], ["resistance", 1282], ["protein", 1293], ["(", 1301], ["LRP", 1302], [")", 1305], [",", 1306], ["but", 1308], ["not", 1312], ["P", 1316], ["-", 1317], ["glycoprotein", 1318], ["(", 1331], ["P", 1332], ["-", 1333], ["gp", 1334], [")", 1336], ["or", 1338], ["multidrug", 1341], ["resistance", 1351], ["protein", 1362], ["(", 1370], ["MRP", 1371], [")", 1374], [",", 1375], ["was", 1377], ["significantly", 1381], ["higher", 1395], ["in", 1402], ["all", 1405], ["Ph+", 1409], ["patients", 1413], [".", 1421], ["Both", 1423], ["childhood", 1428], ["and", 1438], ["adult", 1442], ["Ph+", 1448], ["precursor", 1452], ["B", 1462], ["-", 1463], ["cell", 1464], ["ALL", 1469], ["samples", 1473], ["display", 1481], ["a", 1489], ["heterogeneous", 1491], ["in", 1505], ["vitro", 1508], ["resistance", 1514], ["profile", 1525], [",", 1532], ["with", 1534], ["relatively", 1539], ["sensitive", 1550], ["and", 1560], ["resistant", 1564], ["cases", 1574], [".", 1579], ["The", 1581], ["adult", 1585], ["Ph+", 1591], ["samples", 1595], [",", 1602], ["however", 1604], [",", 1611], ["are", 1613], ["generally", 1617], ["more", 1627], ["resistant", 1632], ["compared", 1642], ["to", 1651], ["matched", 1654], ["Ph-", 1662], ["controls", 1666], [",", 1674], ["reaching", 1676], ["significance", 1685], ["for", 1698], ["prednisolone", 1702], [".", 1714], ["The", 1716], ["correlation", 1720], ["of", 1732], ["prednisolone", 1735], ["resistance", 1748], ["with", 1759], ["age", 1764], ["within", 1768], ["the", 1775], ["Ph+", 1779], ["cases", 1783], ["might", 1789], ["help", 1795], ["explain", 1800], ["the", 1808], ["poorer", 1812], ["prognosis", 1819], ["of", 1829], ["adult", 1832], ["Ph+", 1838], ["ALL", 1842], [".", 1845]]}
{"context": "3-Methyladenine DNA glycosylase II (AlkA) is a DNA-repair enzyme that removes alkylated bases in DNA via the base-excision repair (BER) pathway. The enzyme belongs to the helix-hairpin-helix (HhH) superfamily of DNA glycosylases and possesses broad substrate specificity. In the genome of Deinococcus radiodurans, two genes encoding putative AlkA have been identified (Dr_2074 and Dr_2584). Dr_2074 is a homologue of human AlkA (MPG or AAG) and Dr_2584 is a homologue of bacterial AlkAs. Here, the three-dimensional structure of Dr_2584 (DrAlkA2) is presented and compared with the previously determined structure of Escherichia coli AlkA (EcAlkA). The results show that the enzyme consists of two helical-bundle domains separated by a wide DNA-binding cleft and contains an HhH motif. Overall, the protein fold is similar to the two helical-bundle domains of EcAlkA, while the third N-terminal mixed \u03b1/\u03b2 domain observed in EcAlkA is absent. Substrate-specificity analyses show that DrAlkA2, like EcAlkA, is able to remove both 3-methyladenine (3meA) and 7-methylguanine (7meG) from DNA; however, the enzyme possesses no activity towards 1,N(6)-ethenoadenine (\u2107A) and hypoxanthine (Hx). In addition, it shows activity towards the AlkB\u00a0dioxygenase substrates 3-methylcytosine (3meC) and 1-methyladenine (1meA). Thus, the enzyme seems to preferentially repair methylated bases with weakened N-glycosidic bonds; this is an unusual specificity for a bacterial AlkA protein and is probably dictated by a combination of the wide DNA-binding cleft and a highly accessible specificity pocket.", "qas": [{"question": "What type of DNA repair pathways is initiated by AlkA glycosylase?", "answers": ["base-excision repair (BER) pathway", "base excision repair (BER) pathway"], "qid": "250caa665c8448fb98e285306f80e63e", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["DNA", 13], ["repair", 17], ["pathways", 24], ["is", 33], ["initiated", 36], ["by", 46], ["AlkA", 49], ["glycosylase", 54], ["?", 65]], "detected_answers": [{"text": "base excision repair (BER) pathway", "token_spans": [[21, 28]], "char_spans": [[109, 142]]}]}], "context_tokens": [["3-Methyladenine", 0], ["DNA", 16], ["glycosylase", 20], ["II", 32], ["(", 35], ["AlkA", 36], [")", 40], ["is", 42], ["a", 45], ["DNA", 47], ["-", 50], ["repair", 51], ["enzyme", 58], ["that", 65], ["removes", 70], ["alkylated", 78], ["bases", 88], ["in", 94], ["DNA", 97], ["via", 101], ["the", 105], ["base", 109], ["-", 113], ["excision", 114], ["repair", 123], ["(", 130], ["BER", 131], [")", 134], ["pathway", 136], [".", 143], ["The", 145], ["enzyme", 149], ["belongs", 156], ["to", 164], ["the", 167], ["helix", 171], ["-", 176], ["hairpin", 177], ["-", 184], ["helix", 185], ["(", 191], ["HhH", 192], [")", 195], ["superfamily", 197], ["of", 209], ["DNA", 212], ["glycosylases", 216], ["and", 229], ["possesses", 233], ["broad", 243], ["substrate", 249], ["specificity", 259], [".", 270], ["In", 272], ["the", 275], ["genome", 279], ["of", 286], ["Deinococcus", 289], ["radiodurans", 301], [",", 312], ["two", 314], ["genes", 318], ["encoding", 324], ["putative", 333], ["AlkA", 342], ["have", 347], ["been", 352], ["identified", 357], ["(", 368], ["Dr_2074", 369], ["and", 377], ["Dr_2584", 381], [")", 388], [".", 389], ["Dr_2074", 391], ["is", 399], ["a", 402], ["homologue", 404], ["of", 414], ["human", 417], ["AlkA", 423], ["(", 428], ["MPG", 429], ["or", 433], ["AAG", 436], [")", 439], ["and", 441], ["Dr_2584", 445], ["is", 453], ["a", 456], ["homologue", 458], ["of", 468], ["bacterial", 471], ["AlkAs", 481], [".", 486], ["Here", 488], [",", 492], ["the", 494], ["three", 498], ["-", 503], ["dimensional", 504], ["structure", 516], ["of", 526], ["Dr_2584", 529], ["(", 537], ["DrAlkA2", 538], [")", 545], ["is", 547], ["presented", 550], ["and", 560], ["compared", 564], ["with", 573], ["the", 578], ["previously", 582], ["determined", 593], ["structure", 604], ["of", 614], ["Escherichia", 617], ["coli", 629], ["AlkA", 634], ["(", 639], ["EcAlkA", 640], [")", 646], [".", 647], ["The", 649], ["results", 653], ["show", 661], ["that", 666], ["the", 671], ["enzyme", 675], ["consists", 682], ["of", 691], ["two", 694], ["helical", 698], ["-", 705], ["bundle", 706], ["domains", 713], ["separated", 721], ["by", 731], ["a", 734], ["wide", 736], ["DNA", 741], ["-", 744], ["binding", 745], ["cleft", 753], ["and", 759], ["contains", 763], ["an", 772], ["HhH", 775], ["motif", 779], [".", 784], ["Overall", 786], [",", 793], ["the", 795], ["protein", 799], ["fold", 807], ["is", 812], ["similar", 815], ["to", 823], ["the", 826], ["two", 830], ["helical", 834], ["-", 841], ["bundle", 842], ["domains", 849], ["of", 857], ["EcAlkA", 860], [",", 866], ["while", 868], ["the", 874], ["third", 878], ["N", 884], ["-", 885], ["terminal", 886], ["mixed", 895], ["\u03b1", 901], ["/", 902], ["\u03b2", 903], ["domain", 905], ["observed", 912], ["in", 921], ["EcAlkA", 924], ["is", 931], ["absent", 934], [".", 940], ["Substrate", 942], ["-", 951], ["specificity", 952], ["analyses", 964], ["show", 973], ["that", 978], ["DrAlkA2", 983], [",", 990], ["like", 992], ["EcAlkA", 997], [",", 1003], ["is", 1005], ["able", 1008], ["to", 1013], ["remove", 1016], ["both", 1023], ["3-methyladenine", 1028], ["(", 1044], ["3meA", 1045], [")", 1049], ["and", 1051], ["7-methylguanine", 1055], ["(", 1071], ["7meG", 1072], [")", 1076], ["from", 1078], ["DNA", 1083], [";", 1086], ["however", 1088], [",", 1095], ["the", 1097], ["enzyme", 1101], ["possesses", 1108], ["no", 1118], ["activity", 1121], ["towards", 1130], ["1,N(6)-ethenoadenine", 1138], ["(", 1159], ["\u2107A", 1160], [")", 1162], ["and", 1164], ["hypoxanthine", 1168], ["(", 1181], ["Hx", 1182], [")", 1184], [".", 1185], ["In", 1187], ["addition", 1190], [",", 1198], ["it", 1200], ["shows", 1203], ["activity", 1209], ["towards", 1218], ["the", 1226], ["AlkB", 1230], ["dioxygenase", 1235], ["substrates", 1247], ["3-methylcytosine", 1258], ["(", 1275], ["3meC", 1276], [")", 1280], ["and", 1282], ["1-methyladenine", 1286], ["(", 1302], ["1meA", 1303], [")", 1307], [".", 1308], ["Thus", 1310], [",", 1314], ["the", 1316], ["enzyme", 1320], ["seems", 1327], ["to", 1333], ["preferentially", 1336], ["repair", 1351], ["methylated", 1358], ["bases", 1369], ["with", 1375], ["weakened", 1380], ["N", 1389], ["-", 1390], ["glycosidic", 1391], ["bonds", 1402], [";", 1407], ["this", 1409], ["is", 1414], ["an", 1417], ["unusual", 1420], ["specificity", 1428], ["for", 1440], ["a", 1444], ["bacterial", 1446], ["AlkA", 1456], ["protein", 1461], ["and", 1469], ["is", 1473], ["probably", 1476], ["dictated", 1485], ["by", 1494], ["a", 1497], ["combination", 1499], ["of", 1511], ["the", 1514], ["wide", 1518], ["DNA", 1523], ["-", 1526], ["binding", 1527], ["cleft", 1535], ["and", 1541], ["a", 1545], ["highly", 1547], ["accessible", 1554], ["specificity", 1565], ["pocket", 1577], [".", 1583]]}
{"context": "Transcription-coupled repair (TCR) is a universal sub-pathway of the nucleotide excision repair (NER) system that is limited to the transcribed strand of active structural genes. It accomplishes the preferential elimination of transcription-blocking DNA lesions and permits rapid resumption of the vital process of transcription. A defect in TCR is responsible for the rare hereditary disorder Cockayne syndrome (CS). Recently we found that mutations in the ERCC6 repair gene, encoding a putative helicase, underly the repair defect of CS complementation group B. Here we report the cloning and characterization of the Saccharomyces cerevisiae homolog of CSB/ERCC6, which we designate RAD26. A rad26 disruption mutant appears viable and grows normally, indicating that the gene does not have an essential function. In analogy with CS, preferential repair of UV-induced cyclobutane pyrimidine dimers in the transcribed strand of the active RBP2 gene is severely impaired. Surprisingly, in contrast to the human CS mutant, yeast RAD26 disruption does not induce any UV-, cisPt- or X-ray sensitivity, explaining why it was not isolated as a mutant before. Recovery of growth after UV exposure was somewhat delayed in rad26. These findings suggest that TCR in lower eukaryotes is not very important for cell survival and that the global genome repair pathway of NER is the major determinant of cellular resistance to genotoxicity.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "8dc0bd08c09641c4a267b4b2ca0ddb25", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[157, 158], [27, 28]], "char_spans": [[906, 923], [132, 149]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["universal", 40], ["sub", 50], ["-", 53], ["pathway", 54], ["of", 62], ["the", 65], ["nucleotide", 69], ["excision", 80], ["repair", 89], ["(", 96], ["NER", 97], [")", 100], ["system", 102], ["that", 109], ["is", 114], ["limited", 117], ["to", 125], ["the", 128], ["transcribed", 132], ["strand", 144], ["of", 151], ["active", 154], ["structural", 161], ["genes", 172], [".", 177], ["It", 179], ["accomplishes", 182], ["the", 195], ["preferential", 199], ["elimination", 212], ["of", 224], ["transcription", 227], ["-", 240], ["blocking", 241], ["DNA", 250], ["lesions", 254], ["and", 262], ["permits", 266], ["rapid", 274], ["resumption", 280], ["of", 291], ["the", 294], ["vital", 298], ["process", 304], ["of", 312], ["transcription", 315], [".", 328], ["A", 330], ["defect", 332], ["in", 339], ["TCR", 342], ["is", 346], ["responsible", 349], ["for", 361], ["the", 365], ["rare", 369], ["hereditary", 374], ["disorder", 385], ["Cockayne", 394], ["syndrome", 403], ["(", 412], ["CS", 413], [")", 415], [".", 416], ["Recently", 418], ["we", 427], ["found", 430], ["that", 436], ["mutations", 441], ["in", 451], ["the", 454], ["ERCC6", 458], ["repair", 464], ["gene", 471], [",", 475], ["encoding", 477], ["a", 486], ["putative", 488], ["helicase", 497], [",", 505], ["underly", 507], ["the", 515], ["repair", 519], ["defect", 526], ["of", 533], ["CS", 536], ["complementation", 539], ["group", 555], ["B.", 561], ["Here", 564], ["we", 569], ["report", 572], ["the", 579], ["cloning", 583], ["and", 591], ["characterization", 595], ["of", 612], ["the", 615], ["Saccharomyces", 619], ["cerevisiae", 633], ["homolog", 644], ["of", 652], ["CSB", 655], ["/", 658], ["ERCC6", 659], [",", 664], ["which", 666], ["we", 672], ["designate", 675], ["RAD26", 685], [".", 690], ["A", 692], ["rad26", 694], ["disruption", 700], ["mutant", 711], ["appears", 718], ["viable", 726], ["and", 733], ["grows", 737], ["normally", 743], [",", 751], ["indicating", 753], ["that", 764], ["the", 769], ["gene", 773], ["does", 778], ["not", 783], ["have", 787], ["an", 792], ["essential", 795], ["function", 805], [".", 813], ["In", 815], ["analogy", 818], ["with", 826], ["CS", 831], [",", 833], ["preferential", 835], ["repair", 848], ["of", 855], ["UV", 858], ["-", 860], ["induced", 861], ["cyclobutane", 869], ["pyrimidine", 881], ["dimers", 892], ["in", 899], ["the", 902], ["transcribed", 906], ["strand", 918], ["of", 925], ["the", 928], ["active", 932], ["RBP2", 939], ["gene", 944], ["is", 949], ["severely", 952], ["impaired", 961], [".", 969], ["Surprisingly", 971], [",", 983], ["in", 985], ["contrast", 988], ["to", 997], ["the", 1000], ["human", 1004], ["CS", 1010], ["mutant", 1013], [",", 1019], ["yeast", 1021], ["RAD26", 1027], ["disruption", 1033], ["does", 1044], ["not", 1049], ["induce", 1053], ["any", 1060], ["UV-", 1064], [",", 1067], ["cisPt-", 1069], ["or", 1076], ["X", 1079], ["-", 1080], ["ray", 1081], ["sensitivity", 1085], [",", 1096], ["explaining", 1098], ["why", 1109], ["it", 1113], ["was", 1116], ["not", 1120], ["isolated", 1124], ["as", 1133], ["a", 1136], ["mutant", 1138], ["before", 1145], [".", 1151], ["Recovery", 1153], ["of", 1162], ["growth", 1165], ["after", 1172], ["UV", 1178], ["exposure", 1181], ["was", 1190], ["somewhat", 1194], ["delayed", 1203], ["in", 1211], ["rad26", 1214], [".", 1219], ["These", 1221], ["findings", 1227], ["suggest", 1236], ["that", 1244], ["TCR", 1249], ["in", 1253], ["lower", 1256], ["eukaryotes", 1262], ["is", 1273], ["not", 1276], ["very", 1280], ["important", 1285], ["for", 1295], ["cell", 1299], ["survival", 1304], ["and", 1313], ["that", 1317], ["the", 1322], ["global", 1326], ["genome", 1333], ["repair", 1340], ["pathway", 1347], ["of", 1355], ["NER", 1358], ["is", 1362], ["the", 1365], ["major", 1369], ["determinant", 1375], ["of", 1387], ["cellular", 1390], ["resistance", 1399], ["to", 1410], ["genotoxicity", 1413], [".", 1425]]}
{"context": "There is no consensus about mechanisms underlying restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED). Cortical excitability may be abnormal in RLS. Transcranial magnetic stimulation (TMS) can provide insight about cortical excitability. We reviewed studies about measures of excitability to TMS in RLS. Original studies published between January 1999 and January 2015 were searched in PubMed, Scopus, and Web of Science databases. Inclusion criteria were as follows: original studies involving primary RLS in patients from both sexes and ages between 18 and 85 years; TMS protocols clearly described; and they were written in English, in peer-reviewed journals. Fifteen manuscripts were identified. TMS protocols were heterogeneous across studies. Resting motor threshold, active motor threshold, and amplitudes of motor-evoked potentials were typically reported to be normal in RLS. A reduction in short-interval intracortical inhibition (SICI) was the most consistent finding, whereas conflicting results were described in regard to short-interval intracortical facilitation and the contralateral silent period. Decreased SICI can be reversed by treatment with dopaminergic agonists. Plasticity in the motor cortex and sensorimotor integration may be disrupted. TMS may become a useful biomarker of responsiveness to drug treatment in RLS. The field can benefit from increases in homogeneity and sizes of samples, as well as from decrease in methodological variability across studies.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "79c7aa35077b48c2acc944b37cf15dca", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[7, 9]], "char_spans": [[50, 71]]}]}], "context_tokens": [["There", 0], ["is", 6], ["no", 9], ["consensus", 12], ["about", 22], ["mechanisms", 28], ["underlying", 39], ["restless", 50], ["legs", 59], ["syndrome", 64], ["(", 73], ["RLS", 74], [")", 77], [",", 78], ["also", 80], ["known", 85], ["as", 91], ["Willis", 94], ["-", 100], ["Ekbom", 101], ["disease", 107], ["(", 115], ["WED", 116], [")", 119], [".", 120], ["Cortical", 122], ["excitability", 131], ["may", 144], ["be", 148], ["abnormal", 151], ["in", 160], ["RLS", 163], [".", 166], ["Transcranial", 168], ["magnetic", 181], ["stimulation", 190], ["(", 202], ["TMS", 203], [")", 206], ["can", 208], ["provide", 212], ["insight", 220], ["about", 228], ["cortical", 234], ["excitability", 243], [".", 255], ["We", 257], ["reviewed", 260], ["studies", 269], ["about", 277], ["measures", 283], ["of", 292], ["excitability", 295], ["to", 308], ["TMS", 311], ["in", 315], ["RLS", 318], [".", 321], ["Original", 323], ["studies", 332], ["published", 340], ["between", 350], ["January", 358], ["1999", 366], ["and", 371], ["January", 375], ["2015", 383], ["were", 388], ["searched", 393], ["in", 402], ["PubMed", 405], [",", 411], ["Scopus", 413], [",", 419], ["and", 421], ["Web", 425], ["of", 429], ["Science", 432], ["databases", 440], [".", 449], ["Inclusion", 451], ["criteria", 461], ["were", 470], ["as", 475], ["follows", 478], [":", 485], ["original", 487], ["studies", 496], ["involving", 504], ["primary", 514], ["RLS", 522], ["in", 526], ["patients", 529], ["from", 538], ["both", 543], ["sexes", 548], ["and", 554], ["ages", 558], ["between", 563], ["18", 571], ["and", 574], ["85", 578], ["years", 581], [";", 586], ["TMS", 588], ["protocols", 592], ["clearly", 602], ["described", 610], [";", 619], ["and", 621], ["they", 625], ["were", 630], ["written", 635], ["in", 643], ["English", 646], [",", 653], ["in", 655], ["peer", 658], ["-", 662], ["reviewed", 663], ["journals", 672], [".", 680], ["Fifteen", 682], ["manuscripts", 690], ["were", 702], ["identified", 707], [".", 717], ["TMS", 719], ["protocols", 723], ["were", 733], ["heterogeneous", 738], ["across", 752], ["studies", 759], [".", 766], ["Resting", 768], ["motor", 776], ["threshold", 782], [",", 791], ["active", 793], ["motor", 800], ["threshold", 806], [",", 815], ["and", 817], ["amplitudes", 821], ["of", 832], ["motor", 835], ["-", 840], ["evoked", 841], ["potentials", 848], ["were", 859], ["typically", 864], ["reported", 874], ["to", 883], ["be", 886], ["normal", 889], ["in", 896], ["RLS", 899], [".", 902], ["A", 904], ["reduction", 906], ["in", 916], ["short", 919], ["-", 924], ["interval", 925], ["intracortical", 934], ["inhibition", 948], ["(", 959], ["SICI", 960], [")", 964], ["was", 966], ["the", 970], ["most", 974], ["consistent", 979], ["finding", 990], [",", 997], ["whereas", 999], ["conflicting", 1007], ["results", 1019], ["were", 1027], ["described", 1032], ["in", 1042], ["regard", 1045], ["to", 1052], ["short", 1055], ["-", 1060], ["interval", 1061], ["intracortical", 1070], ["facilitation", 1084], ["and", 1097], ["the", 1101], ["contralateral", 1105], ["silent", 1119], ["period", 1126], [".", 1132], ["Decreased", 1134], ["SICI", 1144], ["can", 1149], ["be", 1153], ["reversed", 1156], ["by", 1165], ["treatment", 1168], ["with", 1178], ["dopaminergic", 1183], ["agonists", 1196], [".", 1204], ["Plasticity", 1206], ["in", 1217], ["the", 1220], ["motor", 1224], ["cortex", 1230], ["and", 1237], ["sensorimotor", 1241], ["integration", 1254], ["may", 1266], ["be", 1270], ["disrupted", 1273], [".", 1282], ["TMS", 1284], ["may", 1288], ["become", 1292], ["a", 1299], ["useful", 1301], ["biomarker", 1308], ["of", 1318], ["responsiveness", 1321], ["to", 1336], ["drug", 1339], ["treatment", 1344], ["in", 1354], ["RLS", 1357], [".", 1360], ["The", 1362], ["field", 1366], ["can", 1372], ["benefit", 1376], ["from", 1384], ["increases", 1389], ["in", 1399], ["homogeneity", 1402], ["and", 1414], ["sizes", 1418], ["of", 1424], ["samples", 1427], [",", 1434], ["as", 1436], ["well", 1439], ["as", 1444], ["from", 1447], ["decrease", 1452], ["in", 1461], ["methodological", 1464], ["variability", 1479], ["across", 1491], ["studies", 1498], [".", 1505]]}
{"context": "Cell-mediated immunity plays a crucial role in the control of many infectious diseases, necessitating the need for adjuvants that can augment cellular immune responses elicited by vaccines. It is well established that protection against one such disease, malaria, requires strong CD8(+) T cell responses targeted against the liver stages of the causative agent, Plasmodium spp. In this report we show that the dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1 (DC-CK1), which is produced in humans and acts on naive lymphocytes, can enhance Ag-specific CD8(+) T cell responses when coadministered with either irradiated Plasmodium yoelii sporozoites or a recombinant adenovirus expressing the P. yoelii circumsporozoite protein in mice. We further show that these enhanced T cell responses result in increased protection to malaria in immunized mice challenged with live P. yoelii sporozoites, revealing an adjuvant activity for DC-CK1. DC-CK1 appears to act preferentially on naive mouse lymphocytes, and its adjuvant effect requires IL-12, but not IFN-gamma or CD40. Overall, our results show for the first time an in vivo role for DC-CK1 in the establishment of primary T cell responses and indicate the potential of this chemokine as an adjuvant for vaccines against malaria as well as other diseases in which cellular immune responses are important.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "72c14e2563a94713baea221bbf150180", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium spp.", "token_spans": [[61, 62]], "char_spans": [[362, 375]]}]}], "context_tokens": [["Cell", 0], ["-", 4], ["mediated", 5], ["immunity", 14], ["plays", 23], ["a", 29], ["crucial", 31], ["role", 39], ["in", 44], ["the", 47], ["control", 51], ["of", 59], ["many", 62], ["infectious", 67], ["diseases", 78], [",", 86], ["necessitating", 88], ["the", 102], ["need", 106], ["for", 111], ["adjuvants", 115], ["that", 125], ["can", 130], ["augment", 134], ["cellular", 142], ["immune", 151], ["responses", 158], ["elicited", 168], ["by", 177], ["vaccines", 180], [".", 188], ["It", 190], ["is", 193], ["well", 196], ["established", 201], ["that", 213], ["protection", 218], ["against", 229], ["one", 237], ["such", 241], ["disease", 246], [",", 253], ["malaria", 255], [",", 262], ["requires", 264], ["strong", 273], ["CD8(+", 280], [")", 285], ["T", 287], ["cell", 289], ["responses", 294], ["targeted", 304], ["against", 313], ["the", 321], ["liver", 325], ["stages", 331], ["of", 338], ["the", 341], ["causative", 345], ["agent", 355], [",", 360], ["Plasmodium", 362], ["spp", 373], [".", 376], ["In", 378], ["this", 381], ["report", 386], ["we", 393], ["show", 396], ["that", 401], ["the", 406], ["dendritic", 410], ["cell", 420], ["-", 424], ["specific", 425], ["chemokine", 434], [",", 443], ["dendritic", 445], ["cell", 455], ["-", 459], ["derived", 460], ["CC", 468], ["chemokine", 471], ["1", 481], ["(", 483], ["DC", 484], ["-", 486], ["CK1", 487], [")", 490], [",", 491], ["which", 493], ["is", 499], ["produced", 502], ["in", 511], ["humans", 514], ["and", 521], ["acts", 525], ["on", 530], ["naive", 533], ["lymphocytes", 539], [",", 550], ["can", 552], ["enhance", 556], ["Ag", 564], ["-", 566], ["specific", 567], ["CD8(+", 576], [")", 581], ["T", 583], ["cell", 585], ["responses", 590], ["when", 600], ["coadministered", 605], ["with", 620], ["either", 625], ["irradiated", 632], ["Plasmodium", 643], ["yoelii", 654], ["sporozoites", 661], ["or", 673], ["a", 676], ["recombinant", 678], ["adenovirus", 690], ["expressing", 701], ["the", 712], ["P.", 716], ["yoelii", 719], ["circumsporozoite", 726], ["protein", 743], ["in", 751], ["mice", 754], [".", 758], ["We", 760], ["further", 763], ["show", 771], ["that", 776], ["these", 781], ["enhanced", 787], ["T", 796], ["cell", 798], ["responses", 803], ["result", 813], ["in", 820], ["increased", 823], ["protection", 833], ["to", 844], ["malaria", 847], ["in", 855], ["immunized", 858], ["mice", 868], ["challenged", 873], ["with", 884], ["live", 889], ["P.", 894], ["yoelii", 897], ["sporozoites", 904], [",", 915], ["revealing", 917], ["an", 927], ["adjuvant", 930], ["activity", 939], ["for", 948], ["DC", 952], ["-", 954], ["CK1", 955], [".", 958], ["DC", 960], ["-", 962], ["CK1", 963], ["appears", 967], ["to", 975], ["act", 978], ["preferentially", 982], ["on", 997], ["naive", 1000], ["mouse", 1006], ["lymphocytes", 1012], [",", 1023], ["and", 1025], ["its", 1029], ["adjuvant", 1033], ["effect", 1042], ["requires", 1049], ["IL-12", 1058], [",", 1063], ["but", 1065], ["not", 1069], ["IFN", 1073], ["-", 1076], ["gamma", 1077], ["or", 1083], ["CD40", 1086], [".", 1090], ["Overall", 1092], [",", 1099], ["our", 1101], ["results", 1105], ["show", 1113], ["for", 1118], ["the", 1122], ["first", 1126], ["time", 1132], ["an", 1137], ["in", 1140], ["vivo", 1143], ["role", 1148], ["for", 1153], ["DC", 1157], ["-", 1159], ["CK1", 1160], ["in", 1164], ["the", 1167], ["establishment", 1171], ["of", 1185], ["primary", 1188], ["T", 1196], ["cell", 1198], ["responses", 1203], ["and", 1213], ["indicate", 1217], ["the", 1226], ["potential", 1230], ["of", 1240], ["this", 1243], ["chemokine", 1248], ["as", 1258], ["an", 1261], ["adjuvant", 1264], ["for", 1273], ["vaccines", 1277], ["against", 1286], ["malaria", 1294], ["as", 1302], ["well", 1305], ["as", 1310], ["other", 1313], ["diseases", 1319], ["in", 1328], ["which", 1331], ["cellular", 1337], ["immune", 1346], ["responses", 1353], ["are", 1363], ["important", 1367], [".", 1376]]}
{"context": "Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR/ABL-kinase \"escapes\" the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia. The efficacy of this approach on the leukemogenic potential of BCR/ABL was studied in Ba/F3 cells, primary murine bone marrow cells, and untransformed Rat-1 fibroblasts expressing BCR/ABL or BCR/ABL-T315I as well as in patient-derived long-term cultures (PDLTC) from Ph + ALL-patients. Here, we show that GNF-2 increased the effects of AKIs on unmutated BCR/ABL. Interestingly, the combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic manner. Our observations establish a new approach for the molecular targeting of BCR/ABL and its resistant mutants using a combination of AKIs and allosteric inhibitors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "1af188b73cef4f9eac8c74a2bb6fc768", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[180, 182], [46, 48], [158, 160], [238, 240], [263, 265], [184, 186], [223, 225], [103, 105], [119, 121]], "char_spans": [[944, 950], [248, 254], [827, 833], [1204, 1210], [1335, 1341], [955, 961], [1118, 1124], [524, 530], [609, 615]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["and", 35], ["Philadelphia", 39], ["chromosome", 52], ["-", 62], ["positive", 63], ["(", 72], ["Ph+", 73], [")", 76], ["acute", 78], ["lymphatic", 84], ["leukemia", 94], ["(", 103], ["Ph", 104], ["+", 107], ["ALL", 109], [")", 112], ["are", 114], ["caused", 118], ["by", 125], ["the", 128], ["t(9;22", 132], [")", 138], [",", 139], ["which", 141], ["fuses", 147], ["BCR", 153], ["to", 157], ["ABL", 160], ["resulting", 164], ["in", 174], ["deregulated", 177], ["ABL", 189], ["-", 192], ["tyrosine", 193], ["kinase", 202], ["activity", 209], [".", 217], ["The", 219], ["constitutively", 223], ["activated", 238], ["BCR", 248], ["/", 251], ["ABL", 252], ["-", 255], ["kinase", 256], ["\"", 263], ["escapes", 264], ["\"", 271], ["the", 273], ["auto", 277], ["-", 281], ["inhibition", 282], ["mechanisms", 293], ["of", 304], ["c", 307], ["-", 308], ["ABL", 309], [",", 312], ["such", 314], ["as", 319], ["allosteric", 322], ["inhibition", 333], [".", 343], ["The", 345], ["ABL", 349], ["-", 352], ["kinase", 353], ["inhibitors", 360], ["(", 371], ["AKIs", 372], [")", 376], ["Imatinib", 378], [",", 386], ["Nilotinib", 388], ["or", 398], ["Dasatinib", 401], [",", 410], ["which", 412], ["target", 418], ["the", 425], ["ATP", 429], ["-", 432], ["binding", 433], ["site", 441], [",", 445], ["are", 447], ["effective", 451], ["in", 461], ["Ph", 464], ["+", 467], ["leukemia", 469], [".", 477], ["Another", 479], ["molecular", 487], ["therapy", 497], ["approach", 505], ["targeting", 514], ["BCR", 524], ["/", 527], ["ABL", 528], ["restores", 532], ["allosteric", 541], ["inhibition", 552], [".", 562], ["Given", 564], ["the", 570], ["fact", 574], ["that", 579], ["all", 584], ["AKIs", 588], ["fail", 593], ["to", 598], ["inhibit", 601], ["BCR", 609], ["/", 612], ["ABL", 613], ["harboring", 617], ["the", 627], ["'", 631], ["gatekeeper", 632], ["'", 642], ["mutation", 644], ["T315I", 653], [",", 658], ["we", 660], ["investigated", 663], ["the", 676], ["effects", 680], ["of", 688], ["AKIs", 691], ["in", 696], ["combination", 699], ["with", 711], ["the", 716], ["allosteric", 720], ["inhibitor", 731], ["GNF2", 741], ["in", 746], ["Ph", 749], ["+", 752], ["leukemia", 754], [".", 762], ["The", 764], ["efficacy", 768], ["of", 777], ["this", 780], ["approach", 785], ["on", 794], ["the", 797], ["leukemogenic", 801], ["potential", 814], ["of", 824], ["BCR", 827], ["/", 830], ["ABL", 831], ["was", 835], ["studied", 839], ["in", 847], ["Ba", 850], ["/", 852], ["F3", 853], ["cells", 856], [",", 861], ["primary", 863], ["murine", 871], ["bone", 878], ["marrow", 883], ["cells", 890], [",", 895], ["and", 897], ["untransformed", 901], ["Rat-1", 915], ["fibroblasts", 921], ["expressing", 933], ["BCR", 944], ["/", 947], ["ABL", 948], ["or", 952], ["BCR", 955], ["/", 958], ["ABL", 959], ["-", 962], ["T315I", 963], ["as", 969], ["well", 972], ["as", 977], ["in", 980], ["patient", 983], ["-", 990], ["derived", 991], ["long", 999], ["-", 1003], ["term", 1004], ["cultures", 1009], ["(", 1018], ["PDLTC", 1019], [")", 1024], ["from", 1026], ["Ph", 1031], ["+", 1034], ["ALL", 1036], ["-", 1039], ["patients", 1040], [".", 1048], ["Here", 1050], [",", 1054], ["we", 1056], ["show", 1059], ["that", 1064], ["GNF-2", 1069], ["increased", 1075], ["the", 1085], ["effects", 1089], ["of", 1097], ["AKIs", 1100], ["on", 1105], ["unmutated", 1108], ["BCR", 1118], ["/", 1121], ["ABL", 1122], [".", 1125], ["Interestingly", 1127], [",", 1140], ["the", 1142], ["combination", 1146], ["of", 1158], ["Dasatinib", 1161], ["and", 1171], ["GNF-2", 1175], ["overcame", 1181], ["resistance", 1190], ["of", 1201], ["BCR", 1204], ["/", 1207], ["ABL", 1208], ["-", 1211], ["T315I", 1212], ["in", 1218], ["all", 1221], ["models", 1225], ["used", 1232], ["in", 1237], ["a", 1240], ["synergistic", 1242], ["manner", 1254], [".", 1260], ["Our", 1262], ["observations", 1266], ["establish", 1279], ["a", 1289], ["new", 1291], ["approach", 1295], ["for", 1304], ["the", 1308], ["molecular", 1312], ["targeting", 1322], ["of", 1332], ["BCR", 1335], ["/", 1338], ["ABL", 1339], ["and", 1343], ["its", 1347], ["resistant", 1351], ["mutants", 1361], ["using", 1369], ["a", 1375], ["combination", 1377], ["of", 1389], ["AKIs", 1392], ["and", 1397], ["allosteric", 1401], ["inhibitors", 1412], [".", 1422]]}
{"context": "The stratum corneum (SC) is the outermost region of the epidermis and plays key roles in cutaneous barrier function in mammals. The SC is composed of 'bricks', represented by flattened, protein-enriched corneocytes, and 'mortar', represented by intercellular lipid-enriched layers. As a result of this 'bricks and mortar' structure, the SC can be considered as a 'rampart' that encloses water and solutes essential for physiological homeostasis and that protects mammals from physical, chemical and biological assaults. The corneocyte cytoskeleton contains tight bundles of keratin intermediate filaments aggregated with filaggrin monomers, which are subsequently degraded into natural moisturizing compounds by various proteases, including caspase 14. A cornified cell envelope is formed on the inner surface of the corneocyte plasma membrane by transglutaminase-catalysed cross-linking of involucrin and loricrin. Ceramides form a lipid envelope by covalently binding to the cornified cell envelope, and extracellular lamellar lipids play an important role in permeability barrier function. Corneodesmosomes are the main adhesive structures in the SC and are degraded by certain serine proteases, such as kallikreins, during desquamation. The roles of the different SC components, including the structural proteins in corneocytes, extracellular lipids and some proteins associated with lipid metabolism, have been investigated in genetically engineered mice and in naturally occurring hereditary skin diseases, such as ichthyosis, ichthyosis syndrome and atopic dermatitis in humans, cattle and dogs.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "0396509bd1664b019a93887131c5917a", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[106, 107]], "char_spans": [[582, 603]]}]}], "context_tokens": [["The", 0], ["stratum", 4], ["corneum", 12], ["(", 20], ["SC", 21], [")", 23], ["is", 25], ["the", 28], ["outermost", 32], ["region", 42], ["of", 49], ["the", 52], ["epidermis", 56], ["and", 66], ["plays", 70], ["key", 76], ["roles", 80], ["in", 86], ["cutaneous", 89], ["barrier", 99], ["function", 107], ["in", 116], ["mammals", 119], [".", 126], ["The", 128], ["SC", 132], ["is", 135], ["composed", 138], ["of", 147], ["'", 150], ["bricks", 151], ["'", 157], [",", 158], ["represented", 160], ["by", 172], ["flattened", 175], [",", 184], ["protein", 186], ["-", 193], ["enriched", 194], ["corneocytes", 203], [",", 214], ["and", 216], ["'", 220], ["mortar", 221], ["'", 227], [",", 228], ["represented", 230], ["by", 242], ["intercellular", 245], ["lipid", 259], ["-", 264], ["enriched", 265], ["layers", 274], [".", 280], ["As", 282], ["a", 285], ["result", 287], ["of", 294], ["this", 297], ["'", 302], ["bricks", 303], ["and", 310], ["mortar", 314], ["'", 320], ["structure", 322], [",", 331], ["the", 333], ["SC", 337], ["can", 340], ["be", 344], ["considered", 347], ["as", 358], ["a", 361], ["'", 363], ["rampart", 364], ["'", 371], ["that", 373], ["encloses", 378], ["water", 387], ["and", 393], ["solutes", 397], ["essential", 405], ["for", 415], ["physiological", 419], ["homeostasis", 433], ["and", 445], ["that", 449], ["protects", 454], ["mammals", 463], ["from", 471], ["physical", 476], [",", 484], ["chemical", 486], ["and", 495], ["biological", 499], ["assaults", 510], [".", 518], ["The", 520], ["corneocyte", 524], ["cytoskeleton", 535], ["contains", 548], ["tight", 557], ["bundles", 563], ["of", 571], ["keratin", 574], ["intermediate", 582], ["filaments", 595], ["aggregated", 605], ["with", 616], ["filaggrin", 621], ["monomers", 631], [",", 639], ["which", 641], ["are", 647], ["subsequently", 651], ["degraded", 664], ["into", 673], ["natural", 678], ["moisturizing", 686], ["compounds", 699], ["by", 709], ["various", 712], ["proteases", 720], [",", 729], ["including", 731], ["caspase", 741], ["14", 749], [".", 751], ["A", 753], ["cornified", 755], ["cell", 765], ["envelope", 770], ["is", 779], ["formed", 782], ["on", 789], ["the", 792], ["inner", 796], ["surface", 802], ["of", 810], ["the", 813], ["corneocyte", 817], ["plasma", 828], ["membrane", 835], ["by", 844], ["transglutaminase", 847], ["-", 863], ["catalysed", 864], ["cross", 874], ["-", 879], ["linking", 880], ["of", 888], ["involucrin", 891], ["and", 902], ["loricrin", 906], [".", 914], ["Ceramides", 916], ["form", 926], ["a", 931], ["lipid", 933], ["envelope", 939], ["by", 948], ["covalently", 951], ["binding", 962], ["to", 970], ["the", 973], ["cornified", 977], ["cell", 987], ["envelope", 992], [",", 1000], ["and", 1002], ["extracellular", 1006], ["lamellar", 1020], ["lipids", 1029], ["play", 1036], ["an", 1041], ["important", 1044], ["role", 1054], ["in", 1059], ["permeability", 1062], ["barrier", 1075], ["function", 1083], [".", 1091], ["Corneodesmosomes", 1093], ["are", 1110], ["the", 1114], ["main", 1118], ["adhesive", 1123], ["structures", 1132], ["in", 1143], ["the", 1146], ["SC", 1150], ["and", 1153], ["are", 1157], ["degraded", 1161], ["by", 1170], ["certain", 1173], ["serine", 1181], ["proteases", 1188], [",", 1197], ["such", 1199], ["as", 1204], ["kallikreins", 1207], [",", 1218], ["during", 1220], ["desquamation", 1227], [".", 1239], ["The", 1241], ["roles", 1245], ["of", 1251], ["the", 1254], ["different", 1258], ["SC", 1268], ["components", 1271], [",", 1281], ["including", 1283], ["the", 1293], ["structural", 1297], ["proteins", 1308], ["in", 1317], ["corneocytes", 1320], [",", 1331], ["extracellular", 1333], ["lipids", 1347], ["and", 1354], ["some", 1358], ["proteins", 1363], ["associated", 1372], ["with", 1383], ["lipid", 1388], ["metabolism", 1394], [",", 1404], ["have", 1406], ["been", 1411], ["investigated", 1416], ["in", 1429], ["genetically", 1432], ["engineered", 1444], ["mice", 1455], ["and", 1460], ["in", 1464], ["naturally", 1467], ["occurring", 1477], ["hereditary", 1487], ["skin", 1498], ["diseases", 1503], [",", 1511], ["such", 1513], ["as", 1518], ["ichthyosis", 1521], [",", 1531], ["ichthyosis", 1533], ["syndrome", 1544], ["and", 1553], ["atopic", 1557], ["dermatitis", 1564], ["in", 1575], ["humans", 1578], [",", 1584], ["cattle", 1586], ["and", 1593], ["dogs", 1597], [".", 1601]]}
{"context": "Cerebrolysin (Cere) is a peptidergic nootropic drug with neurotrophic properties which has been used to treat dementia and sequelae of stroke. Use of Cere prevents nuclear structural changes typical of apoptosis and significantly reduces the number of apoptotic cells after several apoptotic stimuli. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary disease caused by mutations of the Notch3 gene encoding the Notch3 protein. Notch3 is involved in the regulation of apoptosis, modulating Fas-Ligand (Fas-L)- induced apoptosis. The aim of this study was to evaluate the in vitro protective effects of Cere against oxidative stress-induced apoptosis in cells from CADASIL patients. We used peripheral blood lymphocytes (PBLs) from 15 CADASIL patients (age range 34-70 years); 2-deoxy-D-ribose (dRib), a highly reducing sugar, was used as paradigm pro-apoptotic stimulus. Apoptosis was analyzed by flow cytometry and fluorescence microscopy. Administration of Cere to PBLs from CADASIL patients cultured under standard conditions had no effect on the percentage of apoptotic cells. Administration of Cere to PBLs cultured with dRib caused a significant decrease in apoptosis after 48 h of culture in only 5 patients, whereas in the other 10 patients, Cere treatment was not associated with any significant difference in the percentage of apoptosis. This result showed a protective effect of Cere against oxidative stress-induced apoptosis only in 30 % of the CADASIL patients, suggesting that the Notch3 gene probably does not influence the anti-apoptotic properties of Cere in vitro.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "af0fd3f5bf9540ba8eb2d1ef50fc1544", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[68, 69], [270, 271]], "char_spans": [[453, 463], [1562, 1572]]}]}], "context_tokens": [["Cerebrolysin", 0], ["(", 13], ["Cere", 14], [")", 18], ["is", 20], ["a", 23], ["peptidergic", 25], ["nootropic", 37], ["drug", 47], ["with", 52], ["neurotrophic", 57], ["properties", 70], ["which", 81], ["has", 87], ["been", 91], ["used", 96], ["to", 101], ["treat", 104], ["dementia", 110], ["and", 119], ["sequelae", 123], ["of", 132], ["stroke", 135], [".", 141], ["Use", 143], ["of", 147], ["Cere", 150], ["prevents", 155], ["nuclear", 164], ["structural", 172], ["changes", 183], ["typical", 191], ["of", 199], ["apoptosis", 202], ["and", 212], ["significantly", 216], ["reduces", 230], ["the", 238], ["number", 242], ["of", 249], ["apoptotic", 252], ["cells", 262], ["after", 268], ["several", 274], ["apoptotic", 282], ["stimuli", 292], [".", 299], ["Cerebral", 301], ["Autosomal", 310], ["Dominant", 320], ["Arteriopathy", 329], ["with", 342], ["Subcortical", 347], ["Infarcts", 359], ["and", 368], ["Leukoencephalopathy", 372], ["(", 392], ["CADASIL", 393], [")", 400], ["is", 402], ["a", 405], ["hereditary", 407], ["disease", 418], ["caused", 426], ["by", 433], ["mutations", 436], ["of", 446], ["the", 449], ["Notch3", 453], ["gene", 460], ["encoding", 465], ["the", 474], ["Notch3", 478], ["protein", 485], [".", 492], ["Notch3", 494], ["is", 501], ["involved", 504], ["in", 513], ["the", 516], ["regulation", 520], ["of", 531], ["apoptosis", 534], [",", 543], ["modulating", 545], ["Fas", 556], ["-", 559], ["Ligand", 560], ["(", 567], ["Fas", 568], ["-", 571], ["L)-", 572], ["induced", 576], ["apoptosis", 584], [".", 593], ["The", 595], ["aim", 599], ["of", 603], ["this", 606], ["study", 611], ["was", 617], ["to", 621], ["evaluate", 624], ["the", 633], ["in", 637], ["vitro", 640], ["protective", 646], ["effects", 657], ["of", 665], ["Cere", 668], ["against", 673], ["oxidative", 681], ["stress", 691], ["-", 697], ["induced", 698], ["apoptosis", 706], ["in", 716], ["cells", 719], ["from", 725], ["CADASIL", 730], ["patients", 738], [".", 746], ["We", 748], ["used", 751], ["peripheral", 756], ["blood", 767], ["lymphocytes", 773], ["(", 785], ["PBLs", 786], [")", 790], ["from", 792], ["15", 797], ["CADASIL", 800], ["patients", 808], ["(", 817], ["age", 818], ["range", 822], ["34", 828], ["-", 830], ["70", 831], ["years", 834], [")", 839], [";", 840], ["2-deoxy", 842], ["-", 849], ["D", 850], ["-", 851], ["ribose", 852], ["(", 859], ["dRib", 860], [")", 864], [",", 865], ["a", 867], ["highly", 869], ["reducing", 876], ["sugar", 885], [",", 890], ["was", 892], ["used", 896], ["as", 901], ["paradigm", 904], ["pro", 913], ["-", 916], ["apoptotic", 917], ["stimulus", 927], [".", 935], ["Apoptosis", 937], ["was", 947], ["analyzed", 951], ["by", 960], ["flow", 963], ["cytometry", 968], ["and", 978], ["fluorescence", 982], ["microscopy", 995], [".", 1005], ["Administration", 1007], ["of", 1022], ["Cere", 1025], ["to", 1030], ["PBLs", 1033], ["from", 1038], ["CADASIL", 1043], ["patients", 1051], ["cultured", 1060], ["under", 1069], ["standard", 1075], ["conditions", 1084], ["had", 1095], ["no", 1099], ["effect", 1102], ["on", 1109], ["the", 1112], ["percentage", 1116], ["of", 1127], ["apoptotic", 1130], ["cells", 1140], [".", 1145], ["Administration", 1147], ["of", 1162], ["Cere", 1165], ["to", 1170], ["PBLs", 1173], ["cultured", 1178], ["with", 1187], ["dRib", 1192], ["caused", 1197], ["a", 1204], ["significant", 1206], ["decrease", 1218], ["in", 1227], ["apoptosis", 1230], ["after", 1240], ["48", 1246], ["h", 1249], ["of", 1251], ["culture", 1254], ["in", 1262], ["only", 1265], ["5", 1270], ["patients", 1272], [",", 1280], ["whereas", 1282], ["in", 1290], ["the", 1293], ["other", 1297], ["10", 1303], ["patients", 1306], [",", 1314], ["Cere", 1316], ["treatment", 1321], ["was", 1331], ["not", 1335], ["associated", 1339], ["with", 1350], ["any", 1355], ["significant", 1359], ["difference", 1371], ["in", 1382], ["the", 1385], ["percentage", 1389], ["of", 1400], ["apoptosis", 1403], [".", 1412], ["This", 1414], ["result", 1419], ["showed", 1426], ["a", 1433], ["protective", 1435], ["effect", 1446], ["of", 1453], ["Cere", 1456], ["against", 1461], ["oxidative", 1469], ["stress", 1479], ["-", 1485], ["induced", 1486], ["apoptosis", 1494], ["only", 1504], ["in", 1509], ["30", 1512], ["%", 1515], ["of", 1517], ["the", 1520], ["CADASIL", 1524], ["patients", 1532], [",", 1540], ["suggesting", 1542], ["that", 1553], ["the", 1558], ["Notch3", 1562], ["gene", 1569], ["probably", 1574], ["does", 1583], ["not", 1588], ["influence", 1592], ["the", 1602], ["anti", 1606], ["-", 1610], ["apoptotic", 1611], ["properties", 1621], ["of", 1632], ["Cere", 1635], ["in", 1640], ["vitro", 1643], [".", 1648]]}
{"context": "NSD3/WHSC1L1 histone methyltransferase gene aberrations are observed in leukemia and in breast and lung carcinomas, suggesting that NSD3 is implicated in carcinogenesis. In this study we examined in human breast cancer cells the NSD3L isoform which contains the catalytic histone methyltransferase SET-domain. siRNA directed depletion of NSD3L followed by genome-wide microarray analysis identified NSD3L regulated genes which could be functionally linked to cellular signaling pathways such as cell growth, cell cycle, cell motility, transcription, and apoptosis. Notably up-regulated genes are the cell cycle regulators E2F2 and Arl2. In accordance with a function of NSD3L in cell cycle regulation NSD3L depletion resulted in an increase in the number of cells in the S and G2/M cell cycle phases. Moreover, NSD3L depletion increased the invasiveness of MDA-MB-231 breast cancer cells indicating that NSD3L normally restrain cellular metastatic potential. Together the presented data indicates that NSD3L is a candidate tumor suppressor.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET-domain", "SET domain"], "qid": "704744227c8048f0b703848334d6ec87", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[43, 45]], "char_spans": [[298, 307]]}]}], "context_tokens": [["NSD3/WHSC1L1", 0], ["histone", 13], ["methyltransferase", 21], ["gene", 39], ["aberrations", 44], ["are", 56], ["observed", 60], ["in", 69], ["leukemia", 72], ["and", 81], ["in", 85], ["breast", 88], ["and", 95], ["lung", 99], ["carcinomas", 104], [",", 114], ["suggesting", 116], ["that", 127], ["NSD3", 132], ["is", 137], ["implicated", 140], ["in", 151], ["carcinogenesis", 154], [".", 168], ["In", 170], ["this", 173], ["study", 178], ["we", 184], ["examined", 187], ["in", 196], ["human", 199], ["breast", 205], ["cancer", 212], ["cells", 219], ["the", 225], ["NSD3L", 229], ["isoform", 235], ["which", 243], ["contains", 249], ["the", 258], ["catalytic", 262], ["histone", 272], ["methyltransferase", 280], ["SET", 298], ["-", 301], ["domain", 302], [".", 308], ["siRNA", 310], ["directed", 316], ["depletion", 325], ["of", 335], ["NSD3L", 338], ["followed", 344], ["by", 353], ["genome", 356], ["-", 362], ["wide", 363], ["microarray", 368], ["analysis", 379], ["identified", 388], ["NSD3L", 399], ["regulated", 405], ["genes", 415], ["which", 421], ["could", 427], ["be", 433], ["functionally", 436], ["linked", 449], ["to", 456], ["cellular", 459], ["signaling", 468], ["pathways", 478], ["such", 487], ["as", 492], ["cell", 495], ["growth", 500], [",", 506], ["cell", 508], ["cycle", 513], [",", 518], ["cell", 520], ["motility", 525], [",", 533], ["transcription", 535], [",", 548], ["and", 550], ["apoptosis", 554], [".", 563], ["Notably", 565], ["up", 573], ["-", 575], ["regulated", 576], ["genes", 586], ["are", 592], ["the", 596], ["cell", 600], ["cycle", 605], ["regulators", 611], ["E2F2", 622], ["and", 627], ["Arl2", 631], [".", 635], ["In", 637], ["accordance", 640], ["with", 651], ["a", 656], ["function", 658], ["of", 667], ["NSD3L", 670], ["in", 676], ["cell", 679], ["cycle", 684], ["regulation", 690], ["NSD3L", 701], ["depletion", 707], ["resulted", 717], ["in", 726], ["an", 729], ["increase", 732], ["in", 741], ["the", 744], ["number", 748], ["of", 755], ["cells", 758], ["in", 764], ["the", 767], ["S", 771], ["and", 773], ["G2/M", 777], ["cell", 782], ["cycle", 787], ["phases", 793], [".", 799], ["Moreover", 801], [",", 809], ["NSD3L", 811], ["depletion", 817], ["increased", 827], ["the", 837], ["invasiveness", 841], ["of", 854], ["MDA", 857], ["-", 860], ["MB-231", 861], ["breast", 868], ["cancer", 875], ["cells", 882], ["indicating", 888], ["that", 899], ["NSD3L", 904], ["normally", 910], ["restrain", 919], ["cellular", 928], ["metastatic", 937], ["potential", 948], [".", 957], ["Together", 959], ["the", 968], ["presented", 972], ["data", 982], ["indicates", 987], ["that", 997], ["NSD3L", 1002], ["is", 1008], ["a", 1011], ["candidate", 1013], ["tumor", 1023], ["suppressor", 1029], [".", 1039]]}
{"context": "McLeod neuroacanthocytosis syndrome is a late-onset X-linked multisystem disorder affecting the peripheral and central nervous systems, red blood cells (RBCs), and internal organs. A variety of mutations have been found in the responsible gene (XK) including single nonsense and missense mutations, nucleotide mutations at or near the splice junctions of introns of XK, and different deletion mutations. To date no clear phenotype-genotype correlation is apparent. The clinical details of one case of McLeod phenotype without apparent neuromuscular abnormalities have been reported. Here the clinical details of two additional cases are presented, of which the genetic details have previously been published. Two asymptomatic or minimally symptomatic cases at ages expected to manifest the McLeod syndrome (MLS) were evaluated. The first case had been authenticated as a genuine McLeod both by serology and by genotyping (R222G missense mutation) and the second case had a mutation in XK (IVS2+5G>A) and by serology exhibited very weak Kx antigen and no detectable Kell antigens, except extremely low k antigen by adsorption-elution technique. The patients were examined for hematologic, neurologic, and other clinical abnormalities. Despite documented McLeod phenotype on RBCs, and identified mutations of XK, neurologic and other clinical findings were minimal at ages expected to manifest MLS. The different XK mutations may have different effects upon the XK gene product and thus may account for the variable phenotype.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "2dd00a7d6c44433e8886712abfe64730", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[64, 64], [246, 246], [170, 170], [44, 44], [228, 228], [254, 254]], "char_spans": [[366, 367], [1411, 1412], [985, 986], [245, 246], [1307, 1308], [1460, 1461]]}]}], "context_tokens": [["McLeod", 0], ["neuroacanthocytosis", 7], ["syndrome", 27], ["is", 36], ["a", 39], ["late", 41], ["-", 45], ["onset", 46], ["X", 52], ["-", 53], ["linked", 54], ["multisystem", 61], ["disorder", 73], ["affecting", 82], ["the", 92], ["peripheral", 96], ["and", 107], ["central", 111], ["nervous", 119], ["systems", 127], [",", 134], ["red", 136], ["blood", 140], ["cells", 146], ["(", 152], ["RBCs", 153], [")", 157], [",", 158], ["and", 160], ["internal", 164], ["organs", 173], [".", 179], ["A", 181], ["variety", 183], ["of", 191], ["mutations", 194], ["have", 204], ["been", 209], ["found", 214], ["in", 220], ["the", 223], ["responsible", 227], ["gene", 239], ["(", 244], ["XK", 245], [")", 247], ["including", 249], ["single", 259], ["nonsense", 266], ["and", 275], ["missense", 279], ["mutations", 288], [",", 297], ["nucleotide", 299], ["mutations", 310], ["at", 320], ["or", 323], ["near", 326], ["the", 331], ["splice", 335], ["junctions", 342], ["of", 352], ["introns", 355], ["of", 363], ["XK", 366], [",", 368], ["and", 370], ["different", 374], ["deletion", 384], ["mutations", 393], [".", 402], ["To", 404], ["date", 407], ["no", 412], ["clear", 415], ["phenotype", 421], ["-", 430], ["genotype", 431], ["correlation", 440], ["is", 452], ["apparent", 455], [".", 463], ["The", 465], ["clinical", 469], ["details", 478], ["of", 486], ["one", 489], ["case", 493], ["of", 498], ["McLeod", 501], ["phenotype", 508], ["without", 518], ["apparent", 526], ["neuromuscular", 535], ["abnormalities", 549], ["have", 563], ["been", 568], ["reported", 573], [".", 581], ["Here", 583], ["the", 588], ["clinical", 592], ["details", 601], ["of", 609], ["two", 612], ["additional", 616], ["cases", 627], ["are", 633], ["presented", 637], [",", 646], ["of", 648], ["which", 651], ["the", 657], ["genetic", 661], ["details", 669], ["have", 677], ["previously", 682], ["been", 693], ["published", 698], [".", 707], ["Two", 709], ["asymptomatic", 713], ["or", 726], ["minimally", 729], ["symptomatic", 739], ["cases", 751], ["at", 757], ["ages", 760], ["expected", 765], ["to", 774], ["manifest", 777], ["the", 786], ["McLeod", 790], ["syndrome", 797], ["(", 806], ["MLS", 807], [")", 810], ["were", 812], ["evaluated", 817], [".", 826], ["The", 828], ["first", 832], ["case", 838], ["had", 843], ["been", 847], ["authenticated", 852], ["as", 866], ["a", 869], ["genuine", 871], ["McLeod", 879], ["both", 886], ["by", 891], ["serology", 894], ["and", 903], ["by", 907], ["genotyping", 910], ["(", 921], ["R222", 922], ["G", 926], ["missense", 928], ["mutation", 937], [")", 945], ["and", 947], ["the", 951], ["second", 955], ["case", 962], ["had", 967], ["a", 971], ["mutation", 973], ["in", 982], ["XK", 985], ["(", 988], ["IVS2", 989], ["+", 993], ["5G", 994], [">", 996], ["A", 997], [")", 998], ["and", 1000], ["by", 1004], ["serology", 1007], ["exhibited", 1016], ["very", 1026], ["weak", 1031], ["Kx", 1036], ["antigen", 1039], ["and", 1047], ["no", 1051], ["detectable", 1054], ["Kell", 1065], ["antigens", 1070], [",", 1078], ["except", 1080], ["extremely", 1087], ["low", 1097], ["k", 1101], ["antigen", 1103], ["by", 1111], ["adsorption", 1114], ["-", 1124], ["elution", 1125], ["technique", 1133], [".", 1142], ["The", 1144], ["patients", 1148], ["were", 1157], ["examined", 1162], ["for", 1171], ["hematologic", 1175], [",", 1186], ["neurologic", 1188], [",", 1198], ["and", 1200], ["other", 1204], ["clinical", 1210], ["abnormalities", 1219], [".", 1232], ["Despite", 1234], ["documented", 1242], ["McLeod", 1253], ["phenotype", 1260], ["on", 1270], ["RBCs", 1273], [",", 1277], ["and", 1279], ["identified", 1283], ["mutations", 1294], ["of", 1304], ["XK", 1307], [",", 1309], ["neurologic", 1311], ["and", 1322], ["other", 1326], ["clinical", 1332], ["findings", 1341], ["were", 1350], ["minimal", 1355], ["at", 1363], ["ages", 1366], ["expected", 1371], ["to", 1380], ["manifest", 1383], ["MLS", 1392], [".", 1395], ["The", 1397], ["different", 1401], ["XK", 1411], ["mutations", 1414], ["may", 1424], ["have", 1428], ["different", 1433], ["effects", 1443], ["upon", 1451], ["the", 1456], ["XK", 1460], ["gene", 1463], ["product", 1468], ["and", 1476], ["thus", 1480], ["may", 1485], ["account", 1489], ["for", 1497], ["the", 1501], ["variable", 1505], ["phenotype", 1514], [".", 1523]]}
{"context": "Two forms of the inherited long QT syndrome have been known for many years: the autosomal recessive Jervell and Lange-Nielsen form and the autosomal dominant Romano-Ward form. A gene marker at the 11p 15.5 locus has been identified for some, but not all, families with the autosomal dominant form, but as yet the gene has not been identified. It is apparent that mutations of at least four genes, and possibly more, can cause the syndrome. The molecular biology of the syndrome is not yet clarified, but abnormalities of ion channel function are likely, particularly the potassium delayed rectifier current. Proposals for the pathophysiology include an abnormality of a G protein which controls ion channel and adrenergic pathway function, as well as a disturbance of the sympathetic nervous system. The identification of the abnormal gene(s) and the gene products will provide precise information on the molecular physiology of the syndrome.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "83d7f282309948759aa19ff5ddcdd45c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[26, 27], [54, 55]], "char_spans": [[139, 156], [273, 290]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["the", 13], ["inherited", 17], ["long", 27], ["QT", 32], ["syndrome", 35], ["have", 44], ["been", 49], ["known", 54], ["for", 60], ["many", 64], ["years", 69], [":", 74], ["the", 76], ["autosomal", 80], ["recessive", 90], ["Jervell", 100], ["and", 108], ["Lange", 112], ["-", 117], ["Nielsen", 118], ["form", 126], ["and", 131], ["the", 135], ["autosomal", 139], ["dominant", 149], ["Romano", 158], ["-", 164], ["Ward", 165], ["form", 170], [".", 174], ["A", 176], ["gene", 178], ["marker", 183], ["at", 190], ["the", 193], ["11p", 197], ["15.5", 201], ["locus", 206], ["has", 212], ["been", 216], ["identified", 221], ["for", 232], ["some", 236], [",", 240], ["but", 242], ["not", 246], ["all", 250], [",", 253], ["families", 255], ["with", 264], ["the", 269], ["autosomal", 273], ["dominant", 283], ["form", 292], [",", 296], ["but", 298], ["as", 302], ["yet", 305], ["the", 309], ["gene", 313], ["has", 318], ["not", 322], ["been", 326], ["identified", 331], [".", 341], ["It", 343], ["is", 346], ["apparent", 349], ["that", 358], ["mutations", 363], ["of", 373], ["at", 376], ["least", 379], ["four", 385], ["genes", 390], [",", 395], ["and", 397], ["possibly", 401], ["more", 410], [",", 414], ["can", 416], ["cause", 420], ["the", 426], ["syndrome", 430], [".", 438], ["The", 440], ["molecular", 444], ["biology", 454], ["of", 462], ["the", 465], ["syndrome", 469], ["is", 478], ["not", 481], ["yet", 485], ["clarified", 489], [",", 498], ["but", 500], ["abnormalities", 504], ["of", 518], ["ion", 521], ["channel", 525], ["function", 533], ["are", 542], ["likely", 546], [",", 552], ["particularly", 554], ["the", 567], ["potassium", 571], ["delayed", 581], ["rectifier", 589], ["current", 599], [".", 606], ["Proposals", 608], ["for", 618], ["the", 622], ["pathophysiology", 626], ["include", 642], ["an", 650], ["abnormality", 653], ["of", 665], ["a", 668], ["G", 670], ["protein", 672], ["which", 680], ["controls", 686], ["ion", 695], ["channel", 699], ["and", 707], ["adrenergic", 711], ["pathway", 722], ["function", 730], [",", 738], ["as", 740], ["well", 743], ["as", 748], ["a", 751], ["disturbance", 753], ["of", 765], ["the", 768], ["sympathetic", 772], ["nervous", 784], ["system", 792], [".", 798], ["The", 800], ["identification", 804], ["of", 819], ["the", 822], ["abnormal", 826], ["gene(s", 835], [")", 841], ["and", 843], ["the", 847], ["gene", 851], ["products", 856], ["will", 865], ["provide", 870], ["precise", 878], ["information", 886], ["on", 898], ["the", 901], ["molecular", 905], ["physiology", 915], ["of", 926], ["the", 929], ["syndrome", 933], [".", 941]]}
{"context": "Rosiglitazone, a synthetic peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) agonist, prevents cell death after cerebral ischemia in animal models, but the underlying mechanism has not been clarified. In this study, we examined how rosiglitazone protects neurons against ischemia. Mice treated with rosiglitazone were subjected to 60 minutes of focal ischemia followed by reperfusion. Rosiglitazone reduced infarct volume after ischemia and reperfusion. We show that this neuroprotective effect was reversed with a PPAR\u03b3 antagonist. Western blot analysis showed a significant increase in expression of phosphorylated stress-activated protein kinases (c-Jun N-terminal kinase (JNK) and p38) in ischemic brain tissue. Rosiglitazone blocked this increase. Furthermore, we observed that rosiglitazone increased expression of the dual-specificity phosphatase 8 (DUSP8) protein and messenger RNA in ischemic brain tissue. Dual-specificity phosphatase 8 is a mitogen-activated protein kinase phosphatase that can dephosphorylate JNK and p38. Another key finding of the present study was that knockdown of DUSP8 in primary cultured cortical neurons that were subjected to oxygen-glucose deprivation diminished rosiglitazone's effect on downregulation of JNK phosphorylation. Thus, rosiglitazone's neuroprotective effect after ischemia is mediated by blocking JNK phosphorylation induced by ischemia via DUSP8 upregulation.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "8bdfb8eb6c274633b133fbadf8eaa257", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[169, 169], [220, 220], [111, 111], [205, 205]], "char_spans": [[1025, 1027], [1354, 1356], [679, 681], [1249, 1251]]}]}], "context_tokens": [["Rosiglitazone", 0], [",", 13], ["a", 15], ["synthetic", 17], ["peroxisome", 27], ["proliferator", 38], ["-", 50], ["activated", 51], ["receptor", 61], ["-", 69], ["\u03b3", 70], ["(", 72], ["PPAR\u03b3", 73], [")", 78], ["agonist", 80], [",", 87], ["prevents", 89], ["cell", 98], ["death", 103], ["after", 109], ["cerebral", 115], ["ischemia", 124], ["in", 133], ["animal", 136], ["models", 143], [",", 149], ["but", 151], ["the", 155], ["underlying", 159], ["mechanism", 170], ["has", 180], ["not", 184], ["been", 188], ["clarified", 193], [".", 202], ["In", 204], ["this", 207], ["study", 212], [",", 217], ["we", 219], ["examined", 222], ["how", 231], ["rosiglitazone", 235], ["protects", 249], ["neurons", 258], ["against", 266], ["ischemia", 274], [".", 282], ["Mice", 284], ["treated", 289], ["with", 297], ["rosiglitazone", 302], ["were", 316], ["subjected", 321], ["to", 331], ["60", 334], ["minutes", 337], ["of", 345], ["focal", 348], ["ischemia", 354], ["followed", 363], ["by", 372], ["reperfusion", 375], [".", 386], ["Rosiglitazone", 388], ["reduced", 402], ["infarct", 410], ["volume", 418], ["after", 425], ["ischemia", 431], ["and", 440], ["reperfusion", 444], [".", 455], ["We", 457], ["show", 460], ["that", 465], ["this", 470], ["neuroprotective", 475], ["effect", 491], ["was", 498], ["reversed", 502], ["with", 511], ["a", 516], ["PPAR\u03b3", 518], ["antagonist", 524], [".", 534], ["Western", 536], ["blot", 544], ["analysis", 549], ["showed", 558], ["a", 565], ["significant", 567], ["increase", 579], ["in", 588], ["expression", 591], ["of", 602], ["phosphorylated", 605], ["stress", 620], ["-", 626], ["activated", 627], ["protein", 637], ["kinases", 645], ["(", 653], ["c", 654], ["-", 655], ["Jun", 656], ["N", 660], ["-", 661], ["terminal", 662], ["kinase", 671], ["(", 678], ["JNK", 679], [")", 682], ["and", 684], ["p38", 688], [")", 691], ["in", 693], ["ischemic", 696], ["brain", 705], ["tissue", 711], [".", 717], ["Rosiglitazone", 719], ["blocked", 733], ["this", 741], ["increase", 746], [".", 754], ["Furthermore", 756], [",", 767], ["we", 769], ["observed", 772], ["that", 781], ["rosiglitazone", 786], ["increased", 800], ["expression", 810], ["of", 821], ["the", 824], ["dual", 828], ["-", 832], ["specificity", 833], ["phosphatase", 845], ["8", 857], ["(", 859], ["DUSP8", 860], [")", 865], ["protein", 867], ["and", 875], ["messenger", 879], ["RNA", 889], ["in", 893], ["ischemic", 896], ["brain", 905], ["tissue", 911], [".", 917], ["Dual", 919], ["-", 923], ["specificity", 924], ["phosphatase", 936], ["8", 948], ["is", 950], ["a", 953], ["mitogen", 955], ["-", 962], ["activated", 963], ["protein", 973], ["kinase", 981], ["phosphatase", 988], ["that", 1000], ["can", 1005], ["dephosphorylate", 1009], ["JNK", 1025], ["and", 1029], ["p38", 1033], [".", 1036], ["Another", 1038], ["key", 1046], ["finding", 1050], ["of", 1058], ["the", 1061], ["present", 1065], ["study", 1073], ["was", 1079], ["that", 1083], ["knockdown", 1088], ["of", 1098], ["DUSP8", 1101], ["in", 1107], ["primary", 1110], ["cultured", 1118], ["cortical", 1127], ["neurons", 1136], ["that", 1144], ["were", 1149], ["subjected", 1154], ["to", 1164], ["oxygen", 1167], ["-", 1173], ["glucose", 1174], ["deprivation", 1182], ["diminished", 1194], ["rosiglitazone", 1205], ["'s", 1218], ["effect", 1221], ["on", 1228], ["downregulation", 1231], ["of", 1246], ["JNK", 1249], ["phosphorylation", 1253], [".", 1268], ["Thus", 1270], [",", 1274], ["rosiglitazone", 1276], ["'s", 1289], ["neuroprotective", 1292], ["effect", 1308], ["after", 1315], ["ischemia", 1321], ["is", 1330], ["mediated", 1333], ["by", 1342], ["blocking", 1345], ["JNK", 1354], ["phosphorylation", 1358], ["induced", 1374], ["by", 1382], ["ischemia", 1385], ["via", 1394], ["DUSP8", 1398], ["upregulation", 1404], [".", 1416]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein (PBP)2a. The relationship of the BORSA phenotype with specific genetic backgrounds was assessed, as well as amino acid sequence variation in the normal PBP2. Among 38 BORSA, 26 had a common PFGE profile of genomic DNA, and were multilocus sequence type (ST)25. The other isolates were genetically diverse. Complete pbp2 sequences were determined for three BORSA, corresponding to ST25, ST1 and ST47, which were selected on the basis of lacking blaZ-encoded beta-lactamase. The essential transpeptidase-domain-encoding segment of pbp2 was also sequenced from seven additional ST25 isolates. Amino acid substitutions occurred in the transpeptidase domain of all BORSA, irrespective of clonal type. A Gln(629)-->Pro substitution was common to all ST25 BORSA, but most could be distinguished from one another by additional unique substitutions in the transpeptidase domain. The ST1 and ST47 isolates also possessed unique substitutions in the transpeptidase domain. Plasmid-mediated expression of pbp2 from an ST25 or ST1 isolate in S. aureus RN6390 increased its oxacillin MIC from 0.25 to 4 microg ml(-1), while pbp2 from a susceptible strain, ATCC 25923, had no effect. Therefore, different amino acid substitutions in PBP2 of diverse BORSA lineages contribute to borderline resistance. The predominant ST25 lineage was not related to any of the five clonal complexes that contain meticillin-resistant S. aureus (MRSA), suggesting that ST25 cannot readily acquire mecA-mediated resistance.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "550dd36b5da9418ba956fba3c25e7423", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["exhibit", 61], ["oxacillin", 69], ["MIC", 79], ["values", 83], ["of", 90], ["1", 93], ["-", 94], ["8", 95], ["microg", 97], ["ml(-1", 104], [")", 109], [",", 110], ["but", 112], ["lack", 116], ["mecA", 121], [",", 125], ["which", 127], ["encodes", 133], ["the", 141], ["low", 145], ["-", 148], ["affinity", 149], ["penicillin", 158], ["-", 168], ["binding", 169], ["protein", 177], ["(", 185], ["PBP)2a", 186], [".", 192], ["The", 194], ["relationship", 198], ["of", 211], ["the", 214], ["BORSA", 218], ["phenotype", 224], ["with", 234], ["specific", 239], ["genetic", 248], ["backgrounds", 256], ["was", 268], ["assessed", 272], [",", 280], ["as", 282], ["well", 285], ["as", 290], ["amino", 293], ["acid", 299], ["sequence", 304], ["variation", 313], ["in", 323], ["the", 326], ["normal", 330], ["PBP2", 337], [".", 341], ["Among", 343], ["38", 349], ["BORSA", 352], [",", 357], ["26", 359], ["had", 362], ["a", 366], ["common", 368], ["PFGE", 375], ["profile", 380], ["of", 388], ["genomic", 391], ["DNA", 399], [",", 402], ["and", 404], ["were", 408], ["multilocus", 413], ["sequence", 424], ["type", 433], ["(", 438], ["ST)25", 439], [".", 444], ["The", 446], ["other", 450], ["isolates", 456], ["were", 465], ["genetically", 470], ["diverse", 482], [".", 489], ["Complete", 491], ["pbp2", 500], ["sequences", 505], ["were", 515], ["determined", 520], ["for", 531], ["three", 535], ["BORSA", 541], [",", 546], ["corresponding", 548], ["to", 562], ["ST25", 565], [",", 569], ["ST1", 571], ["and", 575], ["ST47", 579], [",", 583], ["which", 585], ["were", 591], ["selected", 596], ["on", 605], ["the", 608], ["basis", 612], ["of", 618], ["lacking", 621], ["blaZ", 629], ["-", 633], ["encoded", 634], ["beta", 642], ["-", 646], ["lactamase", 647], [".", 656], ["The", 658], ["essential", 662], ["transpeptidase", 672], ["-", 686], ["domain", 687], ["-", 693], ["encoding", 694], ["segment", 703], ["of", 711], ["pbp2", 714], ["was", 719], ["also", 723], ["sequenced", 728], ["from", 738], ["seven", 743], ["additional", 749], ["ST25", 760], ["isolates", 765], [".", 773], ["Amino", 775], ["acid", 781], ["substitutions", 786], ["occurred", 800], ["in", 809], ["the", 812], ["transpeptidase", 816], ["domain", 831], ["of", 838], ["all", 841], ["BORSA", 845], [",", 850], ["irrespective", 852], ["of", 865], ["clonal", 868], ["type", 875], [".", 879], ["A", 881], ["Gln(629)-->Pro", 883], ["substitution", 898], ["was", 911], ["common", 915], ["to", 922], ["all", 925], ["ST25", 929], ["BORSA", 934], [",", 939], ["but", 941], ["most", 945], ["could", 950], ["be", 956], ["distinguished", 959], ["from", 973], ["one", 978], ["another", 982], ["by", 990], ["additional", 993], ["unique", 1004], ["substitutions", 1011], ["in", 1025], ["the", 1028], ["transpeptidase", 1032], ["domain", 1047], [".", 1053], ["The", 1055], ["ST1", 1059], ["and", 1063], ["ST47", 1067], ["isolates", 1072], ["also", 1081], ["possessed", 1086], ["unique", 1096], ["substitutions", 1103], ["in", 1117], ["the", 1120], ["transpeptidase", 1124], ["domain", 1139], [".", 1145], ["Plasmid", 1147], ["-", 1154], ["mediated", 1155], ["expression", 1164], ["of", 1175], ["pbp2", 1178], ["from", 1183], ["an", 1188], ["ST25", 1191], ["or", 1196], ["ST1", 1199], ["isolate", 1203], ["in", 1211], ["S.", 1214], ["aureus", 1217], ["RN6390", 1224], ["increased", 1231], ["its", 1241], ["oxacillin", 1245], ["MIC", 1255], ["from", 1259], ["0.25", 1264], ["to", 1269], ["4", 1272], ["microg", 1274], ["ml(-1", 1281], [")", 1286], [",", 1287], ["while", 1289], ["pbp2", 1295], ["from", 1300], ["a", 1305], ["susceptible", 1307], ["strain", 1319], [",", 1325], ["ATCC", 1327], ["25923", 1332], [",", 1337], ["had", 1339], ["no", 1343], ["effect", 1346], [".", 1352], ["Therefore", 1354], [",", 1363], ["different", 1365], ["amino", 1375], ["acid", 1381], ["substitutions", 1386], ["in", 1400], ["PBP2", 1403], ["of", 1408], ["diverse", 1411], ["BORSA", 1419], ["lineages", 1425], ["contribute", 1434], ["to", 1445], ["borderline", 1448], ["resistance", 1459], [".", 1469], ["The", 1471], ["predominant", 1475], ["ST25", 1487], ["lineage", 1492], ["was", 1500], ["not", 1504], ["related", 1508], ["to", 1516], ["any", 1519], ["of", 1523], ["the", 1526], ["five", 1530], ["clonal", 1535], ["complexes", 1542], ["that", 1552], ["contain", 1557], ["meticillin", 1565], ["-", 1575], ["resistant", 1576], ["S.", 1586], ["aureus", 1589], ["(", 1596], ["MRSA", 1597], [")", 1601], [",", 1602], ["suggesting", 1604], ["that", 1615], ["ST25", 1620], ["can", 1625], ["not", 1628], ["readily", 1632], ["acquire", 1640], ["mecA", 1648], ["-", 1652], ["mediated", 1653], ["resistance", 1662], [".", 1672]]}
{"context": "Many patients with restless legs syndrome (Willis-Ekbom disease) complain of burning sensations in their feet associated with the desire to move, such that they seek cooler environments. This pilot study aimed to characterise the microvascular skin changes in 12 patients with restless legs syndrome compared with 12 age- and sex-matched controls. Patients with moderate or severe restless legs syndrome and controls underwent detailed thermovascular assessment in a controlled temperature room at three different stages (normothermic phase 23\u00a0\u00b0C, hot phase 30\u00a0\u00b0C, cold phase 18\u00a0\u00b0C). Microvascular activity was recorded during all phases by bilateral great toe laser-Doppler flowmetry and also by whole-body thermography. Patient and control measurements were compared. The study protocol was well tolerated. Parameters extracted from the laser-Doppler flowmetry measurements were used to model a logistic function using binary logistic regression. This demonstrated a statistically significant difference between patients with restless legs syndrome and healthy controls (P\u00a0<\u00a00.001). Visual inspection of the body thermography image sequences showed increased lower limb movement in patients with restless legs syndrome patients compared with controls. Thermography analysis also showed significant differences between foot temperatures in patients with restless legs syndrome compared with controls during the hot phase (P\u00a0=\u00a00.011). Notably, patients with restless legs syndrome had more uniform foot temperatures, whereas controls had a wider variability in surface temperature across the feet. This novel study demonstrates impaired microvascular circulation in patients with restless legs syndrome in comparison to matched controls and a potential mechanism for the sensation of burning feet. The protocol also provides an experimental paradigm to test therapeutic interventions for the future.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "5826e9533ec54fc48c71e5eede6a3e1d", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[3, 5], [65, 67], [198, 200], [238, 240], [270, 272], [170, 172], [218, 220], [47, 49]], "char_spans": [[19, 40], [381, 402], [1198, 1219], [1458, 1479], [1680, 1701], [1028, 1049], [1355, 1376], [277, 298]]}]}], "context_tokens": [["Many", 0], ["patients", 5], ["with", 14], ["restless", 19], ["legs", 28], ["syndrome", 33], ["(", 42], ["Willis", 43], ["-", 49], ["Ekbom", 50], ["disease", 56], [")", 63], ["complain", 65], ["of", 74], ["burning", 77], ["sensations", 85], ["in", 96], ["their", 99], ["feet", 105], ["associated", 110], ["with", 121], ["the", 126], ["desire", 130], ["to", 137], ["move", 140], [",", 144], ["such", 146], ["that", 151], ["they", 156], ["seek", 161], ["cooler", 166], ["environments", 173], [".", 185], ["This", 187], ["pilot", 192], ["study", 198], ["aimed", 204], ["to", 210], ["characterise", 213], ["the", 226], ["microvascular", 230], ["skin", 244], ["changes", 249], ["in", 257], ["12", 260], ["patients", 263], ["with", 272], ["restless", 277], ["legs", 286], ["syndrome", 291], ["compared", 300], ["with", 309], ["12", 314], ["age-", 317], ["and", 322], ["sex", 326], ["-", 329], ["matched", 330], ["controls", 338], [".", 346], ["Patients", 348], ["with", 357], ["moderate", 362], ["or", 371], ["severe", 374], ["restless", 381], ["legs", 390], ["syndrome", 395], ["and", 404], ["controls", 408], ["underwent", 417], ["detailed", 427], ["thermovascular", 436], ["assessment", 451], ["in", 462], ["a", 465], ["controlled", 467], ["temperature", 478], ["room", 490], ["at", 495], ["three", 498], ["different", 504], ["stages", 514], ["(", 521], ["normothermic", 522], ["phase", 535], ["23", 541], ["\u00b0", 544], ["C", 545], [",", 546], ["hot", 548], ["phase", 552], ["30", 558], ["\u00b0", 561], ["C", 562], [",", 563], ["cold", 565], ["phase", 570], ["18", 576], ["\u00b0", 579], ["C", 580], [")", 581], [".", 582], ["Microvascular", 584], ["activity", 598], ["was", 607], ["recorded", 611], ["during", 620], ["all", 627], ["phases", 631], ["by", 638], ["bilateral", 641], ["great", 651], ["toe", 657], ["laser", 661], ["-", 666], ["Doppler", 667], ["flowmetry", 675], ["and", 685], ["also", 689], ["by", 694], ["whole", 697], ["-", 702], ["body", 703], ["thermography", 708], [".", 720], ["Patient", 722], ["and", 730], ["control", 734], ["measurements", 742], ["were", 755], ["compared", 760], [".", 768], ["The", 770], ["study", 774], ["protocol", 780], ["was", 789], ["well", 793], ["tolerated", 798], [".", 807], ["Parameters", 809], ["extracted", 820], ["from", 830], ["the", 835], ["laser", 839], ["-", 844], ["Doppler", 845], ["flowmetry", 853], ["measurements", 863], ["were", 876], ["used", 881], ["to", 886], ["model", 889], ["a", 895], ["logistic", 897], ["function", 906], ["using", 915], ["binary", 921], ["logistic", 928], ["regression", 937], [".", 947], ["This", 949], ["demonstrated", 954], ["a", 967], ["statistically", 969], ["significant", 983], ["difference", 995], ["between", 1006], ["patients", 1014], ["with", 1023], ["restless", 1028], ["legs", 1037], ["syndrome", 1042], ["and", 1051], ["healthy", 1055], ["controls", 1063], ["(", 1072], ["P", 1073], ["<", 1075], ["0.001", 1077], [")", 1082], [".", 1083], ["Visual", 1085], ["inspection", 1092], ["of", 1103], ["the", 1106], ["body", 1110], ["thermography", 1115], ["image", 1128], ["sequences", 1134], ["showed", 1144], ["increased", 1151], ["lower", 1161], ["limb", 1167], ["movement", 1172], ["in", 1181], ["patients", 1184], ["with", 1193], ["restless", 1198], ["legs", 1207], ["syndrome", 1212], ["patients", 1221], ["compared", 1230], ["with", 1239], ["controls", 1244], [".", 1252], ["Thermography", 1254], ["analysis", 1267], ["also", 1276], ["showed", 1281], ["significant", 1288], ["differences", 1300], ["between", 1312], ["foot", 1320], ["temperatures", 1325], ["in", 1338], ["patients", 1341], ["with", 1350], ["restless", 1355], ["legs", 1364], ["syndrome", 1369], ["compared", 1378], ["with", 1387], ["controls", 1392], ["during", 1401], ["the", 1408], ["hot", 1412], ["phase", 1416], ["(", 1422], ["P", 1423], ["=", 1425], ["0.011", 1427], [")", 1432], [".", 1433], ["Notably", 1435], [",", 1442], ["patients", 1444], ["with", 1453], ["restless", 1458], ["legs", 1467], ["syndrome", 1472], ["had", 1481], ["more", 1485], ["uniform", 1490], ["foot", 1498], ["temperatures", 1503], [",", 1515], ["whereas", 1517], ["controls", 1525], ["had", 1534], ["a", 1538], ["wider", 1540], ["variability", 1546], ["in", 1558], ["surface", 1561], ["temperature", 1569], ["across", 1581], ["the", 1588], ["feet", 1592], [".", 1596], ["This", 1598], ["novel", 1603], ["study", 1609], ["demonstrates", 1615], ["impaired", 1628], ["microvascular", 1637], ["circulation", 1651], ["in", 1663], ["patients", 1666], ["with", 1675], ["restless", 1680], ["legs", 1689], ["syndrome", 1694], ["in", 1703], ["comparison", 1706], ["to", 1717], ["matched", 1720], ["controls", 1728], ["and", 1737], ["a", 1741], ["potential", 1743], ["mechanism", 1753], ["for", 1763], ["the", 1767], ["sensation", 1771], ["of", 1781], ["burning", 1784], ["feet", 1792], [".", 1796], ["The", 1798], ["protocol", 1802], ["also", 1811], ["provides", 1816], ["an", 1825], ["experimental", 1828], ["paradigm", 1841], ["to", 1850], ["test", 1853], ["therapeutic", 1858], ["interventions", 1870], ["for", 1884], ["the", 1888], ["future", 1892], [".", 1898]]}
{"context": "On the basis of remarkable antitumor activity, programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma in the second-line setting following progression on either CTLA-4 inhibitor ipilimumab or BRAF/MEK inhibitors (for BRAF mutated melanoma). Given hypothesized risk of triggering exacerbations of autoimmune diseases and/or chronic viral infections, clinical trials (including regulatory studies) evaluating checkpoint blocking antibodies PD-1 and CTLA-4 have excluded patients with autoimmune diseases, chronic hepatitis B/C virus (HBV/HCV), and/or human immunodeficiency virus (HIV) infections. Herein, we describe two patients with advanced melanoma and concomitant HCV/HIV infections treated with PD-1 inhibitor pembrolizumab. Patient 2 with HIV/HCV coinfection progressed after 2 doses of pembrolizumab. Patient 1 who had HCV alone was treated with pembrolizumab with initial partial response. HCV viral load remained stable after 9 cycles of pembrolizumab following which 12-week course of HCV-directed therapy was commenced, resulting in prompt reduction of HCV viral load below detectable levels. Response is ongoing and HCV viral load remains undetectable. In both patients, no significant toxicities were observed when pembrolizumab was initiated. We argue for the further investigation of checkpoint inhibition in cancer patients with underlying chronic viral infections in the context of carefully designed clinical trials.", "qas": [{"question": "Which is the target protein of the drug nivolumab?", "answers": ["programmed death receptor-1"], "qid": "78f0c50b8c6849b2859237d4e919f8cd", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["protein", 20], ["of", 28], ["the", 31], ["drug", 35], ["nivolumab", 40], ["?", 49]], "detected_answers": [{"text": "programmed death receptor-1", "token_spans": [[8, 10]], "char_spans": [[47, 73]]}]}], "context_tokens": [["On", 0], ["the", 3], ["basis", 7], ["of", 13], ["remarkable", 16], ["antitumor", 27], ["activity", 37], [",", 45], ["programmed", 47], ["death", 58], ["receptor-1", 64], ["(", 75], ["PD-1", 76], [")", 80], ["inhibitors", 82], ["pembrolizumab", 93], ["and", 107], ["nivolumab", 111], ["were", 121], ["approved", 126], ["for", 135], ["the", 139], ["treatment", 143], ["of", 153], ["advanced", 156], ["melanoma", 165], ["in", 174], ["the", 177], ["second", 181], ["-", 187], ["line", 188], ["setting", 193], ["following", 201], ["progression", 211], ["on", 223], ["either", 226], ["CTLA-4", 233], ["inhibitor", 240], ["ipilimumab", 250], ["or", 261], ["BRAF", 264], ["/", 268], ["MEK", 269], ["inhibitors", 273], ["(", 284], ["for", 285], ["BRAF", 289], ["mutated", 294], ["melanoma", 302], [")", 310], [".", 311], ["Given", 313], ["hypothesized", 319], ["risk", 332], ["of", 337], ["triggering", 340], ["exacerbations", 351], ["of", 365], ["autoimmune", 368], ["diseases", 379], ["and/or", 388], ["chronic", 395], ["viral", 403], ["infections", 409], [",", 419], ["clinical", 421], ["trials", 430], ["(", 437], ["including", 438], ["regulatory", 448], ["studies", 459], [")", 466], ["evaluating", 468], ["checkpoint", 479], ["blocking", 490], ["antibodies", 499], ["PD-1", 510], ["and", 515], ["CTLA-4", 519], ["have", 526], ["excluded", 531], ["patients", 540], ["with", 549], ["autoimmune", 554], ["diseases", 565], [",", 573], ["chronic", 575], ["hepatitis", 583], ["B", 593], ["/", 594], ["C", 595], ["virus", 597], ["(", 603], ["HBV", 604], ["/", 607], ["HCV", 608], [")", 611], [",", 612], ["and/or", 614], ["human", 621], ["immunodeficiency", 627], ["virus", 644], ["(", 650], ["HIV", 651], [")", 654], ["infections", 656], [".", 666], ["Herein", 668], [",", 674], ["we", 676], ["describe", 679], ["two", 688], ["patients", 692], ["with", 701], ["advanced", 706], ["melanoma", 715], ["and", 724], ["concomitant", 728], ["HCV", 740], ["/", 743], ["HIV", 744], ["infections", 748], ["treated", 759], ["with", 767], ["PD-1", 772], ["inhibitor", 777], ["pembrolizumab", 787], [".", 800], ["Patient", 802], ["2", 810], ["with", 812], ["HIV", 817], ["/", 820], ["HCV", 821], ["coinfection", 825], ["progressed", 837], ["after", 848], ["2", 854], ["doses", 856], ["of", 862], ["pembrolizumab", 865], [".", 878], ["Patient", 880], ["1", 888], ["who", 890], ["had", 894], ["HCV", 898], ["alone", 902], ["was", 908], ["treated", 912], ["with", 920], ["pembrolizumab", 925], ["with", 939], ["initial", 944], ["partial", 952], ["response", 960], [".", 968], ["HCV", 970], ["viral", 974], ["load", 980], ["remained", 985], ["stable", 994], ["after", 1001], ["9", 1007], ["cycles", 1009], ["of", 1016], ["pembrolizumab", 1019], ["following", 1033], ["which", 1043], ["12-week", 1049], ["course", 1057], ["of", 1064], ["HCV", 1067], ["-", 1070], ["directed", 1071], ["therapy", 1080], ["was", 1088], ["commenced", 1092], [",", 1101], ["resulting", 1103], ["in", 1113], ["prompt", 1116], ["reduction", 1123], ["of", 1133], ["HCV", 1136], ["viral", 1140], ["load", 1146], ["below", 1151], ["detectable", 1157], ["levels", 1168], [".", 1174], ["Response", 1176], ["is", 1185], ["ongoing", 1188], ["and", 1196], ["HCV", 1200], ["viral", 1204], ["load", 1210], ["remains", 1215], ["undetectable", 1223], [".", 1235], ["In", 1237], ["both", 1240], ["patients", 1245], [",", 1253], ["no", 1255], ["significant", 1258], ["toxicities", 1270], ["were", 1281], ["observed", 1286], ["when", 1295], ["pembrolizumab", 1300], ["was", 1314], ["initiated", 1318], [".", 1327], ["We", 1329], ["argue", 1332], ["for", 1338], ["the", 1342], ["further", 1346], ["investigation", 1354], ["of", 1368], ["checkpoint", 1371], ["inhibition", 1382], ["in", 1393], ["cancer", 1396], ["patients", 1403], ["with", 1412], ["underlying", 1417], ["chronic", 1428], ["viral", 1436], ["infections", 1442], ["in", 1453], ["the", 1456], ["context", 1460], ["of", 1468], ["carefully", 1471], ["designed", 1481], ["clinical", 1490], ["trials", 1499], [".", 1505]]}
{"context": "Neuroacanthocytosis syndromes are mainly comprised of two diseases: chorea-acanthocytosis (ChAc) and McLeod syndrome (MLS). There is a high incidence of psychiatric disorders such as mood disorder and schizophrenia among neuroacanthocytosis patients. We hypothesized that neuroacanthocytosis-related-genes might be associated with susceptibility to these psychiatric disorders. We performed a comprehensive mutation screen of VPS13A and XK, the gene responsible for ChAc and MLS, respectively, in 85 mood disorder subjects and XK in 86 schizophrenia subjects and compared the variants to 100 or more control alleles. We also performed copy number variation (CNV) analysis in 72 mood disorder subjects and 86 schizophrenia subjects. We identified three non-synonymous, two synonymous and six intron variants in mood disorder subjects and a novel GAT triplet repeat polymorphism in VPS13A. By CNV analysis, we identified a heterozygous exon 60-61 deletion in VPS13A in one mood disorder subject. We identified one non-synonymous and one intron variant in mood disorder and schizophrenia subjects, respectively, in XK. The presence of a pathogenic mutation or a potentially functional variant in mood disorder or schizophrenia subjects suggests that neuroacanthocytosis-related-genes might be involved in the pathogenesis of these psychiatric disorders.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "363dd52c30bd4c8b98c0e42bbe9d8ce1", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[188, 188], [67, 67], [85, 85]], "char_spans": [[1112, 1113], [437, 438], [527, 528]]}]}], "context_tokens": [["Neuroacanthocytosis", 0], ["syndromes", 20], ["are", 30], ["mainly", 34], ["comprised", 41], ["of", 51], ["two", 54], ["diseases", 58], [":", 66], ["chorea", 68], ["-", 74], ["acanthocytosis", 75], ["(", 90], ["ChAc", 91], [")", 95], ["and", 97], ["McLeod", 101], ["syndrome", 108], ["(", 117], ["MLS", 118], [")", 121], [".", 122], ["There", 124], ["is", 130], ["a", 133], ["high", 135], ["incidence", 140], ["of", 150], ["psychiatric", 153], ["disorders", 165], ["such", 175], ["as", 180], ["mood", 183], ["disorder", 188], ["and", 197], ["schizophrenia", 201], ["among", 215], ["neuroacanthocytosis", 221], ["patients", 241], [".", 249], ["We", 251], ["hypothesized", 254], ["that", 267], ["neuroacanthocytosis", 272], ["-", 291], ["related", 292], ["-", 299], ["genes", 300], ["might", 306], ["be", 312], ["associated", 315], ["with", 326], ["susceptibility", 331], ["to", 346], ["these", 349], ["psychiatric", 355], ["disorders", 367], [".", 376], ["We", 378], ["performed", 381], ["a", 391], ["comprehensive", 393], ["mutation", 407], ["screen", 416], ["of", 423], ["VPS13A", 426], ["and", 433], ["XK", 437], [",", 439], ["the", 441], ["gene", 445], ["responsible", 450], ["for", 462], ["ChAc", 466], ["and", 471], ["MLS", 475], [",", 478], ["respectively", 480], [",", 492], ["in", 494], ["85", 497], ["mood", 500], ["disorder", 505], ["subjects", 514], ["and", 523], ["XK", 527], ["in", 530], ["86", 533], ["schizophrenia", 536], ["subjects", 550], ["and", 559], ["compared", 563], ["the", 572], ["variants", 576], ["to", 585], ["100", 588], ["or", 592], ["more", 595], ["control", 600], ["alleles", 608], [".", 615], ["We", 617], ["also", 620], ["performed", 625], ["copy", 635], ["number", 640], ["variation", 647], ["(", 657], ["CNV", 658], [")", 661], ["analysis", 663], ["in", 672], ["72", 675], ["mood", 678], ["disorder", 683], ["subjects", 692], ["and", 701], ["86", 705], ["schizophrenia", 708], ["subjects", 722], [".", 730], ["We", 732], ["identified", 735], ["three", 746], ["non", 752], ["-", 755], ["synonymous", 756], [",", 766], ["two", 768], ["synonymous", 772], ["and", 783], ["six", 787], ["intron", 791], ["variants", 798], ["in", 807], ["mood", 810], ["disorder", 815], ["subjects", 824], ["and", 833], ["a", 837], ["novel", 839], ["GAT", 845], ["triplet", 849], ["repeat", 857], ["polymorphism", 864], ["in", 877], ["VPS13A.", 880], ["By", 888], ["CNV", 891], ["analysis", 895], [",", 903], ["we", 905], ["identified", 908], ["a", 919], ["heterozygous", 921], ["exon", 934], ["60", 939], ["-", 941], ["61", 942], ["deletion", 945], ["in", 954], ["VPS13A", 957], ["in", 964], ["one", 967], ["mood", 971], ["disorder", 976], ["subject", 985], [".", 992], ["We", 994], ["identified", 997], ["one", 1008], ["non", 1012], ["-", 1015], ["synonymous", 1016], ["and", 1027], ["one", 1031], ["intron", 1035], ["variant", 1042], ["in", 1050], ["mood", 1053], ["disorder", 1058], ["and", 1067], ["schizophrenia", 1071], ["subjects", 1085], [",", 1093], ["respectively", 1095], [",", 1107], ["in", 1109], ["XK", 1112], [".", 1114], ["The", 1116], ["presence", 1120], ["of", 1129], ["a", 1132], ["pathogenic", 1134], ["mutation", 1145], ["or", 1154], ["a", 1157], ["potentially", 1159], ["functional", 1171], ["variant", 1182], ["in", 1190], ["mood", 1193], ["disorder", 1198], ["or", 1207], ["schizophrenia", 1210], ["subjects", 1224], ["suggests", 1233], ["that", 1242], ["neuroacanthocytosis", 1247], ["-", 1266], ["related", 1267], ["-", 1274], ["genes", 1275], ["might", 1281], ["be", 1287], ["involved", 1290], ["in", 1299], ["the", 1302], ["pathogenesis", 1306], ["of", 1319], ["these", 1322], ["psychiatric", 1328], ["disorders", 1340], [".", 1349]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two new genes, BCR-ABL on the 22q- (Ph chromosome) and the reciprocal ABL-BCR on 9q-. The BCR-ABL gene encodes for a 210-kD protein with deregulated tyrosine kinase (TK) activity, which is crucial for malignant transformation in CML. The recognition of the BCR-ABL gene and corresponding protein led to the synthesis of small-molecule drugs, designed to interfere with BCR-ABL tyrosine kinase activation by competitive binding at the ATP-binding site. The first tyrosine kinase inhibitor (TKI), introduced into clinical practice in 1998, was imatinib mesylate. Imatinib became the first choice drug in chronic phase CML, because of its high efficacy, low toxicity and ability to maintain durable hematological and cytogenetic responses. However, approximately 20-25% of patients initially treated with imatinib will need alternative therapy, due to drug resistance, which is often caused by the appearance of clones expressing mutant forms of BCR-ABL. Second-generation TKIs have provided new therapeutic option for the patients resistant to imatinib. Dasatinib is the first, second-generation TKI, approved in the US and European Union for the treatment of CML patients with imatinib resistance or intolerance. This drug is a dual SRC-ABL kinase inhibitor, active in most clinically relevant BCR-ABL mutations, except highly resistant T315I. Other second-generation TKIs include nilotinib, bosutinib and INNO 406. Apart from TKIs, the promising group of molecules is inhibitors of Aurora family of serine-threonine kinases. One of these molecules, MK0457, has entered clinical trials, and initial reports indicate that this compound could be active in disease associated with T315I mutation. Thus, wide spectrum of new agents, with different mode of action, is currently in clinical development for CML. It is likely that combination therapy will be the best therapeutic strategy in the future.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4287f637557a460287055045f9eb49ab", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[65, 67], [45, 47], [117, 119], [218, 220], [96, 98], [283, 285]], "char_spans": [[332, 338], [257, 263], [611, 617], [1185, 1191], [499, 505], [1535, 1541]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["presence", 55], ["of", 64], ["the", 67], ["Philadelphia", 71], ["(", 84], ["Ph", 85], [")", 87], ["chromosome", 89], [",", 99], ["which", 101], ["results", 107], ["from", 115], ["a", 120], ["reciprocal", 122], ["translocation", 133], ["between", 147], ["the", 155], ["long", 159], ["arms", 164], ["of", 169], ["the", 172], ["chromosomes", 176], ["9", 188], ["and", 190], ["22", 194], ["t(9;22)(q34;q11", 197], [")", 212], [".", 213], ["This", 215], ["translocation", 220], ["creates", 234], ["two", 242], ["new", 246], ["genes", 250], [",", 255], ["BCR", 257], ["-", 260], ["ABL", 261], ["on", 265], ["the", 268], ["22q-", 272], ["(", 277], ["Ph", 278], ["chromosome", 281], [")", 291], ["and", 293], ["the", 297], ["reciprocal", 301], ["ABL", 312], ["-", 315], ["BCR", 316], ["on", 320], ["9q-", 323], [".", 326], ["The", 328], ["BCR", 332], ["-", 335], ["ABL", 336], ["gene", 340], ["encodes", 345], ["for", 353], ["a", 357], ["210-kD", 359], ["protein", 366], ["with", 374], ["deregulated", 379], ["tyrosine", 391], ["kinase", 400], ["(", 407], ["TK", 408], [")", 410], ["activity", 412], [",", 420], ["which", 422], ["is", 428], ["crucial", 431], ["for", 439], ["malignant", 443], ["transformation", 453], ["in", 468], ["CML", 471], [".", 474], ["The", 476], ["recognition", 480], ["of", 492], ["the", 495], ["BCR", 499], ["-", 502], ["ABL", 503], ["gene", 507], ["and", 512], ["corresponding", 516], ["protein", 530], ["led", 538], ["to", 542], ["the", 545], ["synthesis", 549], ["of", 559], ["small", 562], ["-", 567], ["molecule", 568], ["drugs", 577], [",", 582], ["designed", 584], ["to", 593], ["interfere", 596], ["with", 606], ["BCR", 611], ["-", 614], ["ABL", 615], ["tyrosine", 619], ["kinase", 628], ["activation", 635], ["by", 646], ["competitive", 649], ["binding", 661], ["at", 669], ["the", 672], ["ATP", 676], ["-", 679], ["binding", 680], ["site", 688], [".", 692], ["The", 694], ["first", 698], ["tyrosine", 704], ["kinase", 713], ["inhibitor", 720], ["(", 730], ["TKI", 731], [")", 734], [",", 735], ["introduced", 737], ["into", 748], ["clinical", 753], ["practice", 762], ["in", 771], ["1998", 774], [",", 778], ["was", 780], ["imatinib", 784], ["mesylate", 793], [".", 801], ["Imatinib", 803], ["became", 812], ["the", 819], ["first", 823], ["choice", 829], ["drug", 836], ["in", 841], ["chronic", 844], ["phase", 852], ["CML", 858], [",", 861], ["because", 863], ["of", 871], ["its", 874], ["high", 878], ["efficacy", 883], [",", 891], ["low", 893], ["toxicity", 897], ["and", 906], ["ability", 910], ["to", 918], ["maintain", 921], ["durable", 930], ["hematological", 938], ["and", 952], ["cytogenetic", 956], ["responses", 968], [".", 977], ["However", 979], [",", 986], ["approximately", 988], ["20", 1002], ["-", 1004], ["25", 1005], ["%", 1007], ["of", 1009], ["patients", 1012], ["initially", 1021], ["treated", 1031], ["with", 1039], ["imatinib", 1044], ["will", 1053], ["need", 1058], ["alternative", 1063], ["therapy", 1075], [",", 1082], ["due", 1084], ["to", 1088], ["drug", 1091], ["resistance", 1096], [",", 1106], ["which", 1108], ["is", 1114], ["often", 1117], ["caused", 1123], ["by", 1130], ["the", 1133], ["appearance", 1137], ["of", 1148], ["clones", 1151], ["expressing", 1158], ["mutant", 1169], ["forms", 1176], ["of", 1182], ["BCR", 1185], ["-", 1188], ["ABL", 1189], [".", 1192], ["Second", 1194], ["-", 1200], ["generation", 1201], ["TKIs", 1212], ["have", 1217], ["provided", 1222], ["new", 1231], ["therapeutic", 1235], ["option", 1247], ["for", 1254], ["the", 1258], ["patients", 1262], ["resistant", 1271], ["to", 1281], ["imatinib", 1284], [".", 1292], ["Dasatinib", 1294], ["is", 1304], ["the", 1307], ["first", 1311], [",", 1316], ["second", 1318], ["-", 1324], ["generation", 1325], ["TKI", 1336], [",", 1339], ["approved", 1341], ["in", 1350], ["the", 1353], ["US", 1357], ["and", 1360], ["European", 1364], ["Union", 1373], ["for", 1379], ["the", 1383], ["treatment", 1387], ["of", 1397], ["CML", 1400], ["patients", 1404], ["with", 1413], ["imatinib", 1418], ["resistance", 1427], ["or", 1438], ["intolerance", 1441], [".", 1452], ["This", 1454], ["drug", 1459], ["is", 1464], ["a", 1467], ["dual", 1469], ["SRC", 1474], ["-", 1477], ["ABL", 1478], ["kinase", 1482], ["inhibitor", 1489], [",", 1498], ["active", 1500], ["in", 1507], ["most", 1510], ["clinically", 1515], ["relevant", 1526], ["BCR", 1535], ["-", 1538], ["ABL", 1539], ["mutations", 1543], [",", 1552], ["except", 1554], ["highly", 1561], ["resistant", 1568], ["T315I.", 1578], ["Other", 1585], ["second", 1591], ["-", 1597], ["generation", 1598], ["TKIs", 1609], ["include", 1614], ["nilotinib", 1622], [",", 1631], ["bosutinib", 1633], ["and", 1643], ["INNO", 1647], ["406", 1652], [".", 1655], ["Apart", 1657], ["from", 1663], ["TKIs", 1668], [",", 1672], ["the", 1674], ["promising", 1678], ["group", 1688], ["of", 1694], ["molecules", 1697], ["is", 1707], ["inhibitors", 1710], ["of", 1721], ["Aurora", 1724], ["family", 1731], ["of", 1738], ["serine", 1741], ["-", 1747], ["threonine", 1748], ["kinases", 1758], [".", 1765], ["One", 1767], ["of", 1771], ["these", 1774], ["molecules", 1780], [",", 1789], ["MK0457", 1791], [",", 1797], ["has", 1799], ["entered", 1803], ["clinical", 1811], ["trials", 1820], [",", 1826], ["and", 1828], ["initial", 1832], ["reports", 1840], ["indicate", 1848], ["that", 1857], ["this", 1862], ["compound", 1867], ["could", 1876], ["be", 1882], ["active", 1885], ["in", 1892], ["disease", 1895], ["associated", 1903], ["with", 1914], ["T315I", 1919], ["mutation", 1925], [".", 1933], ["Thus", 1935], [",", 1939], ["wide", 1941], ["spectrum", 1946], ["of", 1955], ["new", 1958], ["agents", 1962], [",", 1968], ["with", 1970], ["different", 1975], ["mode", 1985], ["of", 1990], ["action", 1993], [",", 1999], ["is", 2001], ["currently", 2004], ["in", 2014], ["clinical", 2017], ["development", 2026], ["for", 2038], ["CML", 2042], [".", 2045], ["It", 2047], ["is", 2050], ["likely", 2053], ["that", 2060], ["combination", 2065], ["therapy", 2077], ["will", 2085], ["be", 2090], ["the", 2093], ["best", 2097], ["therapeutic", 2102], ["strategy", 2114], ["in", 2123], ["the", 2126], ["future", 2130], [".", 2136]]}
{"context": "Imatinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML). Indication was based on the STI571 0109 study, in which imatinib favorably compared to historical treatments in patients failing prior therapies. The relevance of these results to currently newly diagnosed AP-CML patients remains unknown. We evaluated the benefit of imatinib in 42 newly diagnosed AP-CML patients. In all, 16 patients had hematological acceleration without chromosomal abnormalities in addition to the Philadelphia chromosome (ACAs; HEM-AP), 16 solely had ACAs (ACA-AP) and 10 had hematological acceleration plus ACAs (HEM-AP + ACA). Major cytogenetic responses were achieved in 93.7% of HEM-AP patients, 75% of patients with ACA-AP (P=NS) and 40% of patients with HEM-AP + ACA (P=0.0053). The 24-month failure-free survival rate was 87.5% in HEM-AP patients, 43.8% in ACA-AP patients and 15% in HEM-AP + ACA patients (P=0.022). The 24-month estimate of progression-free survival was 100% in HEM-AP patients, 92.8% in ACA-AP patients and 58.3% in HEM-AP + ACA patients (P=0.0052). In conclusion, frontline imatinib allows favorable outcomes in HEM-AP and ACA-AP patients but appears insufficient for patients with HEM-AP + ACA. Broader-target and/or more potent BCR-ABL tyrosine kinase inhibitors alone or in combination may be considered in this setting.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f00ef1233f084ed28b6eacd36aca14d6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7], [286, 288]], "char_spans": [[30, 36], [1334, 1340]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["the", 21], ["sole", 25], ["BCR", 30], ["-", 33], ["ABL", 34], ["tyrosine", 38], ["kinase", 47], ["inhibitor", 54], ["approved", 64], ["as", 73], ["first", 76], ["-", 81], ["line", 82], ["treatment", 87], ["of", 97], ["accelerated", 100], ["-", 111], ["phase", 112], ["(", 118], ["AP", 119], [")", 121], ["chronic", 123], ["myeloid", 131], ["leukemia", 139], ["(", 148], ["CML", 149], [")", 152], [".", 153], ["Indication", 155], ["was", 166], ["based", 170], ["on", 176], ["the", 179], ["STI571", 183], ["0109", 190], ["study", 195], [",", 200], ["in", 202], ["which", 205], ["imatinib", 211], ["favorably", 220], ["compared", 230], ["to", 239], ["historical", 242], ["treatments", 253], ["in", 264], ["patients", 267], ["failing", 276], ["prior", 284], ["therapies", 290], [".", 299], ["The", 301], ["relevance", 305], ["of", 315], ["these", 318], ["results", 324], ["to", 332], ["currently", 335], ["newly", 345], ["diagnosed", 351], ["AP", 361], ["-", 363], ["CML", 364], ["patients", 368], ["remains", 377], ["unknown", 385], [".", 392], ["We", 394], ["evaluated", 397], ["the", 407], ["benefit", 411], ["of", 419], ["imatinib", 422], ["in", 431], ["42", 434], ["newly", 437], ["diagnosed", 443], ["AP", 453], ["-", 455], ["CML", 456], ["patients", 460], [".", 468], ["In", 470], ["all", 473], [",", 476], ["16", 478], ["patients", 481], ["had", 490], ["hematological", 494], ["acceleration", 508], ["without", 521], ["chromosomal", 529], ["abnormalities", 541], ["in", 555], ["addition", 558], ["to", 567], ["the", 570], ["Philadelphia", 574], ["chromosome", 587], ["(", 598], ["ACAs", 599], [";", 603], ["HEM", 605], ["-", 608], ["AP", 609], [")", 611], [",", 612], ["16", 614], ["solely", 617], ["had", 624], ["ACAs", 628], ["(", 633], ["ACA", 634], ["-", 637], ["AP", 638], [")", 640], ["and", 642], ["10", 646], ["had", 649], ["hematological", 653], ["acceleration", 667], ["plus", 680], ["ACAs", 685], ["(", 690], ["HEM", 691], ["-", 694], ["AP", 695], ["+", 698], ["ACA", 700], [")", 703], [".", 704], ["Major", 706], ["cytogenetic", 712], ["responses", 724], ["were", 734], ["achieved", 739], ["in", 748], ["93.7", 751], ["%", 755], ["of", 757], ["HEM", 760], ["-", 763], ["AP", 764], ["patients", 767], [",", 775], ["75", 777], ["%", 779], ["of", 781], ["patients", 784], ["with", 793], ["ACA", 798], ["-", 801], ["AP", 802], ["(", 805], ["P", 806], ["=", 807], ["NS", 808], [")", 810], ["and", 812], ["40", 816], ["%", 818], ["of", 820], ["patients", 823], ["with", 832], ["HEM", 837], ["-", 840], ["AP", 841], ["+", 844], ["ACA", 846], ["(", 850], ["P=0.0053", 851], [")", 859], [".", 860], ["The", 862], ["24-month", 866], ["failure", 875], ["-", 882], ["free", 883], ["survival", 888], ["rate", 897], ["was", 902], ["87.5", 906], ["%", 910], ["in", 912], ["HEM", 915], ["-", 918], ["AP", 919], ["patients", 922], [",", 930], ["43.8", 932], ["%", 936], ["in", 938], ["ACA", 941], ["-", 944], ["AP", 945], ["patients", 948], ["and", 957], ["15", 961], ["%", 963], ["in", 965], ["HEM", 968], ["-", 971], ["AP", 972], ["+", 975], ["ACA", 977], ["patients", 981], ["(", 990], ["P=0.022", 991], [")", 998], [".", 999], ["The", 1001], ["24-month", 1005], ["estimate", 1014], ["of", 1023], ["progression", 1026], ["-", 1037], ["free", 1038], ["survival", 1043], ["was", 1052], ["100", 1056], ["%", 1059], ["in", 1061], ["HEM", 1064], ["-", 1067], ["AP", 1068], ["patients", 1071], [",", 1079], ["92.8", 1081], ["%", 1085], ["in", 1087], ["ACA", 1090], ["-", 1093], ["AP", 1094], ["patients", 1097], ["and", 1106], ["58.3", 1110], ["%", 1114], ["in", 1116], ["HEM", 1119], ["-", 1122], ["AP", 1123], ["+", 1126], ["ACA", 1128], ["patients", 1132], ["(", 1141], ["P=0.0052", 1142], [")", 1150], [".", 1151], ["In", 1153], ["conclusion", 1156], [",", 1166], ["frontline", 1168], ["imatinib", 1178], ["allows", 1187], ["favorable", 1194], ["outcomes", 1204], ["in", 1213], ["HEM", 1216], ["-", 1219], ["AP", 1220], ["and", 1223], ["ACA", 1227], ["-", 1230], ["AP", 1231], ["patients", 1234], ["but", 1243], ["appears", 1247], ["insufficient", 1255], ["for", 1268], ["patients", 1272], ["with", 1281], ["HEM", 1286], ["-", 1289], ["AP", 1290], ["+", 1293], ["ACA", 1295], [".", 1298], ["Broader", 1300], ["-", 1307], ["target", 1308], ["and/or", 1315], ["more", 1322], ["potent", 1327], ["BCR", 1334], ["-", 1337], ["ABL", 1338], ["tyrosine", 1342], ["kinase", 1351], ["inhibitors", 1358], ["alone", 1369], ["or", 1375], ["in", 1378], ["combination", 1381], ["may", 1393], ["be", 1397], ["considered", 1400], ["in", 1411], ["this", 1414], ["setting", 1419], [".", 1426]]}
{"context": "A 29-year-old man presented with sudden left-sided pleuritic chest pain on a background of sore throat during the preceding week. On examination he had tender cervical lymphadenopathy, he was tachycardic and had a 24 mm Hg blood pressure difference between the left and right arms. Bloods revealed deranged liver function tests and a lymphocytosis. His D-dimer was raised, hence he was treated for presumed pulmonary embolism before imaging was available. Monospot test was positive. He subsequently had both a CT pulmonary angiogram and a CT angiogram of the aorta to exclude pulmonary embolism and aortic dissection. The CT revealed splenomegaly with a large subdiaphragmatic haematoma secondary to splenic rupture. This had likely caused referred pain through diaphragmatic irritation. He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "647cf5ef073243d2bf27e3c5ec738617", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[156, 159]], "char_spans": [[945, 962]]}]}], "context_tokens": [["A", 0], ["29-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["sudden", 33], ["left", 40], ["-", 44], ["sided", 45], ["pleuritic", 51], ["chest", 61], ["pain", 67], ["on", 72], ["a", 75], ["background", 77], ["of", 88], ["sore", 91], ["throat", 96], ["during", 103], ["the", 110], ["preceding", 114], ["week", 124], [".", 128], ["On", 130], ["examination", 133], ["he", 145], ["had", 148], ["tender", 152], ["cervical", 159], ["lymphadenopathy", 168], [",", 183], ["he", 185], ["was", 188], ["tachycardic", 192], ["and", 204], ["had", 208], ["a", 212], ["24", 214], ["mm", 217], ["Hg", 220], ["blood", 223], ["pressure", 229], ["difference", 238], ["between", 249], ["the", 257], ["left", 261], ["and", 266], ["right", 270], ["arms", 276], [".", 280], ["Bloods", 282], ["revealed", 289], ["deranged", 298], ["liver", 307], ["function", 313], ["tests", 322], ["and", 328], ["a", 332], ["lymphocytosis", 334], [".", 347], ["His", 349], ["D", 353], ["-", 354], ["dimer", 355], ["was", 361], ["raised", 365], [",", 371], ["hence", 373], ["he", 379], ["was", 382], ["treated", 386], ["for", 394], ["presumed", 398], ["pulmonary", 407], ["embolism", 417], ["before", 426], ["imaging", 433], ["was", 441], ["available", 445], [".", 454], ["Monospot", 456], ["test", 465], ["was", 470], ["positive", 474], [".", 482], ["He", 484], ["subsequently", 487], ["had", 500], ["both", 504], ["a", 509], ["CT", 511], ["pulmonary", 514], ["angiogram", 524], ["and", 534], ["a", 538], ["CT", 540], ["angiogram", 543], ["of", 553], ["the", 556], ["aorta", 560], ["to", 566], ["exclude", 569], ["pulmonary", 577], ["embolism", 587], ["and", 596], ["aortic", 600], ["dissection", 607], [".", 617], ["The", 619], ["CT", 623], ["revealed", 626], ["splenomegaly", 635], ["with", 648], ["a", 653], ["large", 655], ["subdiaphragmatic", 661], ["haematoma", 678], ["secondary", 688], ["to", 698], ["splenic", 701], ["rupture", 709], [".", 716], ["This", 718], ["had", 723], ["likely", 727], ["caused", 734], ["referred", 741], ["pain", 750], ["through", 755], ["diaphragmatic", 763], ["irritation", 777], [".", 787], ["He", 789], ["was", 792], ["taken", 796], ["to", 802], ["theatre", 805], ["for", 813], ["urgent", 817], ["splenectomy", 824], [".", 835], ["The", 837], ["unifying", 841], ["diagnosis", 850], ["was", 860], ["infectious", 864], ["mononucleosis", 875], ["complicated", 889], ["by", 901], ["spontaneous", 904], ["splenic", 916], ["rupture", 924], ["secondary", 932], ["to", 942], ["Epstein", 945], ["-", 952], ["Barr", 953], ["virus", 958], ["infection", 964], [".", 973]]}
{"context": "Sickle cell anemia (SCA) is an autosomal recessive disease caused by the HBB:c.20A>T mutation that leads to hemoglobin S synthesis. The disease presents with high clinical heterogeneity characterized by chronic hemolysis, recurrent episodes of vaso-oclusion and infection. This work aimed to characterize by in silico studies some genetic modulators of severe hemolysis and stroke risk in children with SCA, and understand their consequences at the hemorheological level.Association studies were performed between hemolysis biomarkers as well as the degree of cerebral vasculopathy and the inheritance of several polymorphic regions in genes related with vascular cell adhesion and vascular tonus in pediatric SCA patients. In silico tools (e.g. MatInspector) were applied to investigate the main variant consequences.Variants in vascular adhesion molecule-1 (VCAM1) gene promoter and endothelial nitric oxide synthase (NOS3) gene were significantly associated with higher degree of hemolysis and stroke events. They potentially modify transcription factor binding sites (e.g. VCAM1 rs1409419_T allele may lead to an EVI1 gain) or disturb the corresponding protein structure/function. Our findings emphasize the relevance of genetic variation in modulating the disease severity due to their effect on gene expression or modification of protein biological activities related with sickled erythrocyte/endothelial interactions and consequent hemorheological abnormalities.", "qas": [{"question": "What gene is mutated in Sickle Cell Anemia?", "answers": ["HBB"], "qid": "b76c8191ad4145ff85301d09427f3538", "question_tokens": [["What", 0], ["gene", 5], ["is", 10], ["mutated", 13], ["in", 21], ["Sickle", 24], ["Cell", 31], ["Anemia", 36], ["?", 42]], "detected_answers": [{"text": "HBB", "token_spans": [[14, 14]], "char_spans": [[73, 75]]}]}], "context_tokens": [["Sickle", 0], ["cell", 7], ["anemia", 12], ["(", 19], ["SCA", 20], [")", 23], ["is", 25], ["an", 28], ["autosomal", 31], ["recessive", 41], ["disease", 51], ["caused", 59], ["by", 66], ["the", 69], ["HBB", 73], [":", 76], ["c.20A", 77], [">", 82], ["T", 83], ["mutation", 85], ["that", 94], ["leads", 99], ["to", 105], ["hemoglobin", 108], ["S", 119], ["synthesis", 121], [".", 130], ["The", 132], ["disease", 136], ["presents", 144], ["with", 153], ["high", 158], ["clinical", 163], ["heterogeneity", 172], ["characterized", 186], ["by", 200], ["chronic", 203], ["hemolysis", 211], [",", 220], ["recurrent", 222], ["episodes", 232], ["of", 241], ["vaso", 244], ["-", 248], ["oclusion", 249], ["and", 258], ["infection", 262], [".", 271], ["This", 273], ["work", 278], ["aimed", 283], ["to", 289], ["characterize", 292], ["by", 305], ["in", 308], ["silico", 311], ["studies", 318], ["some", 326], ["genetic", 331], ["modulators", 339], ["of", 350], ["severe", 353], ["hemolysis", 360], ["and", 370], ["stroke", 374], ["risk", 381], ["in", 386], ["children", 389], ["with", 398], ["SCA", 403], [",", 406], ["and", 408], ["understand", 412], ["their", 423], ["consequences", 429], ["at", 442], ["the", 445], ["hemorheological", 449], ["level", 465], [".", 470], ["Association", 471], ["studies", 483], ["were", 491], ["performed", 496], ["between", 506], ["hemolysis", 514], ["biomarkers", 524], ["as", 535], ["well", 538], ["as", 543], ["the", 546], ["degree", 550], ["of", 557], ["cerebral", 560], ["vasculopathy", 569], ["and", 582], ["the", 586], ["inheritance", 590], ["of", 602], ["several", 605], ["polymorphic", 613], ["regions", 625], ["in", 633], ["genes", 636], ["related", 642], ["with", 650], ["vascular", 655], ["cell", 664], ["adhesion", 669], ["and", 678], ["vascular", 682], ["tonus", 691], ["in", 697], ["pediatric", 700], ["SCA", 710], ["patients", 714], [".", 722], ["In", 724], ["silico", 727], ["tools", 734], ["(", 740], ["e.g.", 741], ["MatInspector", 746], [")", 758], ["were", 760], ["applied", 765], ["to", 773], ["investigate", 776], ["the", 788], ["main", 792], ["variant", 797], ["consequences", 805], [".", 817], ["Variants", 818], ["in", 827], ["vascular", 830], ["adhesion", 839], ["molecule-1", 848], ["(", 859], ["VCAM1", 860], [")", 865], ["gene", 867], ["promoter", 872], ["and", 881], ["endothelial", 885], ["nitric", 897], ["oxide", 904], ["synthase", 910], ["(", 919], ["NOS3", 920], [")", 924], ["gene", 926], ["were", 931], ["significantly", 936], ["associated", 950], ["with", 961], ["higher", 966], ["degree", 973], ["of", 980], ["hemolysis", 983], ["and", 993], ["stroke", 997], ["events", 1004], [".", 1010], ["They", 1012], ["potentially", 1017], ["modify", 1029], ["transcription", 1036], ["factor", 1050], ["binding", 1057], ["sites", 1065], ["(", 1071], ["e.g.", 1072], ["VCAM1", 1077], ["rs1409419_T", 1083], ["allele", 1095], ["may", 1102], ["lead", 1106], ["to", 1111], ["an", 1114], ["EVI1", 1117], ["gain", 1122], [")", 1126], ["or", 1128], ["disturb", 1131], ["the", 1139], ["corresponding", 1143], ["protein", 1157], ["structure", 1165], ["/", 1174], ["function", 1175], [".", 1183], ["Our", 1185], ["findings", 1189], ["emphasize", 1198], ["the", 1208], ["relevance", 1212], ["of", 1222], ["genetic", 1225], ["variation", 1233], ["in", 1243], ["modulating", 1246], ["the", 1257], ["disease", 1261], ["severity", 1269], ["due", 1278], ["to", 1282], ["their", 1285], ["effect", 1291], ["on", 1298], ["gene", 1301], ["expression", 1306], ["or", 1317], ["modification", 1320], ["of", 1333], ["protein", 1336], ["biological", 1344], ["activities", 1355], ["related", 1366], ["with", 1374], ["sickled", 1379], ["erythrocyte", 1387], ["/", 1398], ["endothelial", 1399], ["interactions", 1411], ["and", 1424], ["consequent", 1428], ["hemorheological", 1439], ["abnormalities", 1455], [".", 1468]]}
{"context": "Evaluate efficacy and safety of tanezumab, a humanized monoclonal antibody against nerve growth factor, in neuropathic pain. Two randomized controlled trials. Patients with pain due to diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN). In the DPN study, patients received subcutaneous tanezumab 20 mg or placebo on Day 1 and Week 8. Evaluations included change from baseline in average DPN pain (primary endpoint), Patient's Global Assessment of DPN, and safety (including neuropathy assessments). Due to a partial clinical hold limiting enrollment and treatment duration, the prespecified landmark analysis was modified post hoc from Week 16 to Week 8. In the PHN study, patients received intravenous tanezumab 50 \u03bcg/kg, tanezumab 200 \u03bcg/kg, or placebo on Day 1. Evaluations included change from baseline in average daily pain (primary endpoint), Brief Pain Inventory-short form, Patient's Global Assessment of pain from PHN, and safety. Mean DPN pain reduction from baseline to Week 8 was greater with tanezumab vs placebo (P = 0.009); differences in Patient's Global Assessment of DPN were not significant (P > 0.05). Neither tanezumab dose resulted in significant differences vs placebo in efficacy in PHN (P > 0.05), although tanezumab 200 \u03bcg/kg provided some benefit. Neuropathy assessments showed no meaningful changes. Tanezumab provided effective pain reduction in DPN. In PHN, only the highest tanezumab dose reduced pain; treatment differences were not significant. No new safety concerns were observed despite preexisting neuropathy.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "75cf86f198b54282922a9737923ac9a6", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[12, 14]], "char_spans": [[83, 101]]}]}], "context_tokens": [["Evaluate", 0], ["efficacy", 9], ["and", 18], ["safety", 22], ["of", 29], ["tanezumab", 32], [",", 41], ["a", 43], ["humanized", 45], ["monoclonal", 55], ["antibody", 66], ["against", 75], ["nerve", 83], ["growth", 89], ["factor", 96], [",", 102], ["in", 104], ["neuropathic", 107], ["pain", 119], [".", 123], ["Two", 125], ["randomized", 129], ["controlled", 140], ["trials", 151], [".", 157], ["Patients", 159], ["with", 168], ["pain", 173], ["due", 178], ["to", 182], ["diabetic", 185], ["peripheral", 194], ["neuropathy", 205], ["(", 216], ["DPN", 217], [")", 220], ["or", 222], ["postherpetic", 225], ["neuralgia", 238], ["(", 248], ["PHN", 249], [")", 252], [".", 253], ["In", 255], ["the", 258], ["DPN", 262], ["study", 266], [",", 271], ["patients", 273], ["received", 282], ["subcutaneous", 291], ["tanezumab", 304], ["20", 314], ["mg", 317], ["or", 320], ["placebo", 323], ["on", 331], ["Day", 334], ["1", 338], ["and", 340], ["Week", 344], ["8", 349], [".", 350], ["Evaluations", 352], ["included", 364], ["change", 373], ["from", 380], ["baseline", 385], ["in", 394], ["average", 397], ["DPN", 405], ["pain", 409], ["(", 414], ["primary", 415], ["endpoint", 423], [")", 431], [",", 432], ["Patient", 434], ["'s", 441], ["Global", 444], ["Assessment", 451], ["of", 462], ["DPN", 465], [",", 468], ["and", 470], ["safety", 474], ["(", 481], ["including", 482], ["neuropathy", 492], ["assessments", 503], [")", 514], [".", 515], ["Due", 517], ["to", 521], ["a", 524], ["partial", 526], ["clinical", 534], ["hold", 543], ["limiting", 548], ["enrollment", 557], ["and", 568], ["treatment", 572], ["duration", 582], [",", 590], ["the", 592], ["prespecified", 596], ["landmark", 609], ["analysis", 618], ["was", 627], ["modified", 631], ["post", 640], ["hoc", 645], ["from", 649], ["Week", 654], ["16", 659], ["to", 662], ["Week", 665], ["8", 670], [".", 671], ["In", 673], ["the", 676], ["PHN", 680], ["study", 684], [",", 689], ["patients", 691], ["received", 700], ["intravenous", 709], ["tanezumab", 721], ["50", 731], ["\u03bcg", 734], ["/", 736], ["kg", 737], [",", 739], ["tanezumab", 741], ["200", 751], ["\u03bcg", 755], ["/", 757], ["kg", 758], [",", 760], ["or", 762], ["placebo", 765], ["on", 773], ["Day", 776], ["1", 780], [".", 781], ["Evaluations", 783], ["included", 795], ["change", 804], ["from", 811], ["baseline", 816], ["in", 825], ["average", 828], ["daily", 836], ["pain", 842], ["(", 847], ["primary", 848], ["endpoint", 856], [")", 864], [",", 865], ["Brief", 867], ["Pain", 873], ["Inventory", 878], ["-", 887], ["short", 888], ["form", 894], [",", 898], ["Patient", 900], ["'s", 907], ["Global", 910], ["Assessment", 917], ["of", 928], ["pain", 931], ["from", 936], ["PHN", 941], [",", 944], ["and", 946], ["safety", 950], [".", 956], ["Mean", 958], ["DPN", 963], ["pain", 967], ["reduction", 972], ["from", 982], ["baseline", 987], ["to", 996], ["Week", 999], ["8", 1004], ["was", 1006], ["greater", 1010], ["with", 1018], ["tanezumab", 1023], ["vs", 1033], ["placebo", 1036], ["(", 1044], ["P", 1045], ["=", 1047], ["0.009", 1049], [")", 1054], [";", 1055], ["differences", 1057], ["in", 1069], ["Patient", 1072], ["'s", 1079], ["Global", 1082], ["Assessment", 1089], ["of", 1100], ["DPN", 1103], ["were", 1107], ["not", 1112], ["significant", 1116], ["(", 1128], ["P", 1129], [">", 1131], ["0.05", 1133], [")", 1137], [".", 1138], ["Neither", 1140], ["tanezumab", 1148], ["dose", 1158], ["resulted", 1163], ["in", 1172], ["significant", 1175], ["differences", 1187], ["vs", 1199], ["placebo", 1202], ["in", 1210], ["efficacy", 1213], ["in", 1222], ["PHN", 1225], ["(", 1229], ["P", 1230], [">", 1232], ["0.05", 1234], [")", 1238], [",", 1239], ["although", 1241], ["tanezumab", 1250], ["200", 1260], ["\u03bcg", 1264], ["/", 1266], ["kg", 1267], ["provided", 1270], ["some", 1279], ["benefit", 1284], [".", 1291], ["Neuropathy", 1293], ["assessments", 1304], ["showed", 1316], ["no", 1323], ["meaningful", 1326], ["changes", 1337], [".", 1344], ["Tanezumab", 1346], ["provided", 1356], ["effective", 1365], ["pain", 1375], ["reduction", 1380], ["in", 1390], ["DPN", 1393], [".", 1396], ["In", 1398], ["PHN", 1401], [",", 1404], ["only", 1406], ["the", 1411], ["highest", 1415], ["tanezumab", 1423], ["dose", 1433], ["reduced", 1438], ["pain", 1446], [";", 1450], ["treatment", 1452], ["differences", 1462], ["were", 1474], ["not", 1479], ["significant", 1483], [".", 1494], ["No", 1496], ["new", 1499], ["safety", 1503], ["concerns", 1510], ["were", 1519], ["observed", 1524], ["despite", 1533], ["preexisting", 1541], ["neuropathy", 1553], [".", 1563]]}
{"context": "During brain development, excess neurons that are formed die by apoptosis. cln3 was recently identified as the gene defective in juvenile Batten disease, an inherited neurodegenerative disease of childhood. In this disease, neurons die by apoptosis. Overexpression of this gene increases survival of human NT2 neuronal precursor cells. We, therefore, hypothesized that cln3 may be present in developing neurons and may play an important role in regulating the developmental process. NT2 neuronal cells were induced to develop into mature neurons. We evaluated cln3 expression by reverse transcription PCR and immunohistochemistry over a 7-wk period of differentiation. Also, cln3 expression was characterized in neonatal rat brain during the first week of life (P-1, P0, P4, and P8) and at P30. cln3 was differentially expressed during neuronal development into nondividing post-mitotic neurons. The greatest expression was noted during wk 6 and then dropped to predifferentiation levels during wk 7. cln3 expression was detected in all the rat brain developmental stages evaluated. The greatest expression was seen at P0 and was double compared with the other stages. We conclude that cln3 is present during critical periods of neuronal cell differentiation and brain development. As cln3 is antiapoptotic, we hypothesize that cln3 plays an important role in regulating brain development. These findings may have implications for identifying strategies aimed at neuroprotection and neuronal survival during development.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "4a7fcf0ca992473da095fa4ba3f4fffa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[23, 24]], "char_spans": [[138, 151]]}]}], "context_tokens": [["During", 0], ["brain", 7], ["development", 13], [",", 24], ["excess", 26], ["neurons", 33], ["that", 41], ["are", 46], ["formed", 50], ["die", 57], ["by", 61], ["apoptosis", 64], [".", 73], ["cln3", 75], ["was", 80], ["recently", 84], ["identified", 93], ["as", 104], ["the", 107], ["gene", 111], ["defective", 116], ["in", 126], ["juvenile", 129], ["Batten", 138], ["disease", 145], [",", 152], ["an", 154], ["inherited", 157], ["neurodegenerative", 167], ["disease", 185], ["of", 193], ["childhood", 196], [".", 205], ["In", 207], ["this", 210], ["disease", 215], [",", 222], ["neurons", 224], ["die", 232], ["by", 236], ["apoptosis", 239], [".", 248], ["Overexpression", 250], ["of", 265], ["this", 268], ["gene", 273], ["increases", 278], ["survival", 288], ["of", 297], ["human", 300], ["NT2", 306], ["neuronal", 310], ["precursor", 319], ["cells", 329], [".", 334], ["We", 336], [",", 338], ["therefore", 340], [",", 349], ["hypothesized", 351], ["that", 364], ["cln3", 369], ["may", 374], ["be", 378], ["present", 381], ["in", 389], ["developing", 392], ["neurons", 403], ["and", 411], ["may", 415], ["play", 419], ["an", 424], ["important", 427], ["role", 437], ["in", 442], ["regulating", 445], ["the", 456], ["developmental", 460], ["process", 474], [".", 481], ["NT2", 483], ["neuronal", 487], ["cells", 496], ["were", 502], ["induced", 507], ["to", 515], ["develop", 518], ["into", 526], ["mature", 531], ["neurons", 538], [".", 545], ["We", 547], ["evaluated", 550], ["cln3", 560], ["expression", 565], ["by", 576], ["reverse", 579], ["transcription", 587], ["PCR", 601], ["and", 605], ["immunohistochemistry", 609], ["over", 630], ["a", 635], ["7-wk", 637], ["period", 642], ["of", 649], ["differentiation", 652], [".", 667], ["Also", 669], [",", 673], ["cln3", 675], ["expression", 680], ["was", 691], ["characterized", 695], ["in", 709], ["neonatal", 712], ["rat", 721], ["brain", 725], ["during", 731], ["the", 738], ["first", 742], ["week", 748], ["of", 753], ["life", 756], ["(", 761], ["P-1", 762], [",", 765], ["P0", 767], [",", 769], ["P4", 771], [",", 773], ["and", 775], ["P8", 779], [")", 781], ["and", 783], ["at", 787], ["P30", 790], [".", 793], ["cln3", 795], ["was", 800], ["differentially", 804], ["expressed", 819], ["during", 829], ["neuronal", 836], ["development", 845], ["into", 857], ["nondividing", 862], ["post", 874], ["-", 878], ["mitotic", 879], ["neurons", 887], [".", 894], ["The", 896], ["greatest", 900], ["expression", 909], ["was", 920], ["noted", 924], ["during", 930], ["wk", 937], ["6", 940], ["and", 942], ["then", 946], ["dropped", 951], ["to", 959], ["predifferentiation", 962], ["levels", 981], ["during", 988], ["wk", 995], ["7", 998], [".", 999], ["cln3", 1001], ["expression", 1006], ["was", 1017], ["detected", 1021], ["in", 1030], ["all", 1033], ["the", 1037], ["rat", 1041], ["brain", 1045], ["developmental", 1051], ["stages", 1065], ["evaluated", 1072], [".", 1081], ["The", 1083], ["greatest", 1087], ["expression", 1096], ["was", 1107], ["seen", 1111], ["at", 1116], ["P0", 1119], ["and", 1122], ["was", 1126], ["double", 1130], ["compared", 1137], ["with", 1146], ["the", 1151], ["other", 1155], ["stages", 1161], [".", 1167], ["We", 1169], ["conclude", 1172], ["that", 1181], ["cln3", 1186], ["is", 1191], ["present", 1194], ["during", 1202], ["critical", 1209], ["periods", 1218], ["of", 1226], ["neuronal", 1229], ["cell", 1238], ["differentiation", 1243], ["and", 1259], ["brain", 1263], ["development", 1269], [".", 1280], ["As", 1282], ["cln3", 1285], ["is", 1290], ["antiapoptotic", 1293], [",", 1306], ["we", 1308], ["hypothesize", 1311], ["that", 1323], ["cln3", 1328], ["plays", 1333], ["an", 1339], ["important", 1342], ["role", 1352], ["in", 1357], ["regulating", 1360], ["brain", 1371], ["development", 1377], [".", 1388], ["These", 1390], ["findings", 1396], ["may", 1405], ["have", 1409], ["implications", 1414], ["for", 1427], ["identifying", 1431], ["strategies", 1443], ["aimed", 1454], ["at", 1460], ["neuroprotection", 1463], ["and", 1479], ["neuronal", 1483], ["survival", 1492], ["during", 1501], ["development", 1508], [".", 1519]]}
{"context": "Current therapies for Alzheimer's disease only treat the symptoms of the disease. We have previously developed a novel monoclonal antibody, 2B3, which binds to the \u03b2-secretase cleavage site in amyloid precursor protein (APP) and reduces the production of amyloid-\u03b2 (A\u03b2) in human cell lines. To determine whether the antibody was likely to be effective in mouse models of amyloid pathology in vivo, we investigated whether 2B3 could also bind to APP in mouse primary cortical neurones. Primary cortical neurones were produced from E15.5-17.5 C57Bl/6 wild-type and transgenic APP/V717I (London mutation) embryos. The percentage of the neuronal population was determined by immunocytochemistry. Cells were treated with 10 \u03bcg/ml 2B3 or an irrelevant IgG for 48 h and A\u03b240 levels determined by ELISA. The population of cells was found to contain over 75% neurones and 2B3 bound effectively to these cells. No differences in A\u03b240 were detected between wild-type and transgenic cells. Importantly, 2B3 significantly inhibited the production of A\u03b240 by 75.15\u00b11.37% of the media control, whereas an irrelevant IgG only significantly reduced A\u03b240 levels by 23.35\u00b15.55% of the media control. The reduction in A\u03b240 produced by 2B3 was significantly greater than that caused by the IgG. These data indicate that 2B3 binds to APP in mouse neurones and can inhibit A\u03b240, similar to our previous findings. The antibody is probably therefore acting by steric hindrance of \u03b2-secretase and these data suggest that it will be effective in mice in vivo and could be an alternative potential therapy for Alzheimer's disease.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "f0957846c2644cfea2237b83f75706a6", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[289, 291], [3, 5]], "char_spans": [[1582, 1600], [22, 40]]}]}], "context_tokens": [["Current", 0], ["therapies", 8], ["for", 18], ["Alzheimer", 22], ["'s", 31], ["disease", 34], ["only", 42], ["treat", 47], ["the", 53], ["symptoms", 57], ["of", 66], ["the", 69], ["disease", 73], [".", 80], ["We", 82], ["have", 85], ["previously", 90], ["developed", 101], ["a", 111], ["novel", 113], ["monoclonal", 119], ["antibody", 130], [",", 138], ["2B3", 140], [",", 143], ["which", 145], ["binds", 151], ["to", 157], ["the", 160], ["\u03b2", 164], ["-", 165], ["secretase", 166], ["cleavage", 176], ["site", 185], ["in", 190], ["amyloid", 193], ["precursor", 201], ["protein", 211], ["(", 219], ["APP", 220], [")", 223], ["and", 225], ["reduces", 229], ["the", 237], ["production", 241], ["of", 252], ["amyloid", 255], ["-", 262], ["\u03b2", 263], ["(", 265], ["A\u03b2", 266], [")", 268], ["in", 270], ["human", 273], ["cell", 279], ["lines", 284], [".", 289], ["To", 291], ["determine", 294], ["whether", 304], ["the", 312], ["antibody", 316], ["was", 325], ["likely", 329], ["to", 336], ["be", 339], ["effective", 342], ["in", 352], ["mouse", 355], ["models", 361], ["of", 368], ["amyloid", 371], ["pathology", 379], ["in", 389], ["vivo", 392], [",", 396], ["we", 398], ["investigated", 401], ["whether", 414], ["2B3", 422], ["could", 426], ["also", 432], ["bind", 437], ["to", 442], ["APP", 445], ["in", 449], ["mouse", 452], ["primary", 458], ["cortical", 466], ["neurones", 475], [".", 483], ["Primary", 485], ["cortical", 493], ["neurones", 502], ["were", 511], ["produced", 516], ["from", 525], ["E15.5", 530], ["-", 535], ["17.5", 536], ["C57Bl/6", 541], ["wild", 549], ["-", 553], ["type", 554], ["and", 559], ["transgenic", 563], ["APP", 574], ["/", 577], ["V717I", 578], ["(", 584], ["London", 585], ["mutation", 592], [")", 600], ["embryos", 602], [".", 609], ["The", 611], ["percentage", 615], ["of", 626], ["the", 629], ["neuronal", 633], ["population", 642], ["was", 653], ["determined", 657], ["by", 668], ["immunocytochemistry", 671], [".", 690], ["Cells", 692], ["were", 698], ["treated", 703], ["with", 711], ["10", 716], ["\u03bcg", 719], ["/", 721], ["ml", 722], ["2B3", 725], ["or", 729], ["an", 732], ["irrelevant", 735], ["IgG", 746], ["for", 750], ["48", 754], ["h", 757], ["and", 759], ["A\u03b240", 763], ["levels", 768], ["determined", 775], ["by", 786], ["ELISA", 789], [".", 794], ["The", 796], ["population", 800], ["of", 811], ["cells", 814], ["was", 820], ["found", 824], ["to", 830], ["contain", 833], ["over", 841], ["75", 846], ["%", 848], ["neurones", 850], ["and", 859], ["2B3", 863], ["bound", 867], ["effectively", 873], ["to", 885], ["these", 888], ["cells", 894], [".", 899], ["No", 901], ["differences", 904], ["in", 916], ["A\u03b240", 919], ["were", 924], ["detected", 929], ["between", 938], ["wild", 946], ["-", 950], ["type", 951], ["and", 956], ["transgenic", 960], ["cells", 971], [".", 976], ["Importantly", 978], [",", 989], ["2B3", 991], ["significantly", 995], ["inhibited", 1009], ["the", 1019], ["production", 1023], ["of", 1034], ["A\u03b240", 1037], ["by", 1042], ["75.15\u00b11.37", 1045], ["%", 1055], ["of", 1057], ["the", 1060], ["media", 1064], ["control", 1070], [",", 1077], ["whereas", 1079], ["an", 1087], ["irrelevant", 1090], ["IgG", 1101], ["only", 1105], ["significantly", 1110], ["reduced", 1124], ["A\u03b240", 1132], ["levels", 1137], ["by", 1144], ["23.35\u00b15.55", 1147], ["%", 1157], ["of", 1159], ["the", 1162], ["media", 1166], ["control", 1172], [".", 1179], ["The", 1181], ["reduction", 1185], ["in", 1195], ["A\u03b240", 1198], ["produced", 1203], ["by", 1212], ["2B3", 1215], ["was", 1219], ["significantly", 1223], ["greater", 1237], ["than", 1245], ["that", 1250], ["caused", 1255], ["by", 1262], ["the", 1265], ["IgG.", 1269], ["These", 1274], ["data", 1280], ["indicate", 1285], ["that", 1294], ["2B3", 1299], ["binds", 1303], ["to", 1309], ["APP", 1312], ["in", 1316], ["mouse", 1319], ["neurones", 1325], ["and", 1334], ["can", 1338], ["inhibit", 1342], ["A\u03b240", 1350], [",", 1354], ["similar", 1356], ["to", 1364], ["our", 1367], ["previous", 1371], ["findings", 1380], [".", 1388], ["The", 1390], ["antibody", 1394], ["is", 1403], ["probably", 1406], ["therefore", 1415], ["acting", 1425], ["by", 1432], ["steric", 1435], ["hindrance", 1442], ["of", 1452], ["\u03b2", 1455], ["-", 1456], ["secretase", 1457], ["and", 1467], ["these", 1471], ["data", 1477], ["suggest", 1482], ["that", 1490], ["it", 1495], ["will", 1498], ["be", 1503], ["effective", 1506], ["in", 1516], ["mice", 1519], ["in", 1524], ["vivo", 1527], ["and", 1532], ["could", 1536], ["be", 1542], ["an", 1545], ["alternative", 1548], ["potential", 1560], ["therapy", 1570], ["for", 1578], ["Alzheimer", 1582], ["'s", 1591], ["disease", 1594], [".", 1601]]}
{"context": "Myotonic dystrophy type 2 (DM2) is an autosomal dominant, multisystem disorder caused by a CCTG tetranucleotide repeat expansion located in intron 1 of the zinc finger protein 9 gene (ZNF9 gene) on chromosome 3q 21.3. To describe the clinical, electrophysiologic and pathologic findings in patients with myotonic dystrophy 2. We evaluated 10 patients genetically, clinically and electrophysiologically during the years 2007 to 2008. All patients were of Jewish European ancestry. Among affected individuals, eight patients had symptoms of proximal muscle weakness, two had muscle pain, and two exhibited myotonia. On physical examination six patients had severe weakness of hip flexor muscles. Seven individuals underwent cataract surgery, and cardiac involvement was seen in one case. On the initial electromyographic (EMG) examination five patients demonstrated myotonic discharges; repeated studies showed these discharges in nine cases. Six muscle biopsies showed non-specific pathological changes. Seven patients had an affected first-degree relative with either a diagnosed or an undiagnosed muscular disorder consistent with an autosomal dominant trait. DM2 may often present with proximal muscle weakness without myotonia. EMG may initially fail to show myotonic discharges, but these discharges may eventually show in most cases on repeated EMG. Thus, DM2 may be underdiagnosed and should be included in the differential diagnosis of adult patients of Jewish European ancestry presenting with proximal lower limb weakness.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "2129b866927d4b40aa157a6635c07254", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10], [186, 187]], "char_spans": [[38, 55], [1135, 1152]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["type", 19], ["2", 24], ["(", 26], ["DM2", 27], [")", 30], ["is", 32], ["an", 35], ["autosomal", 38], ["dominant", 48], [",", 56], ["multisystem", 58], ["disorder", 70], ["caused", 79], ["by", 86], ["a", 89], ["CCTG", 91], ["tetranucleotide", 96], ["repeat", 112], ["expansion", 119], ["located", 129], ["in", 137], ["intron", 140], ["1", 147], ["of", 149], ["the", 152], ["zinc", 156], ["finger", 161], ["protein", 168], ["9", 176], ["gene", 178], ["(", 183], ["ZNF9", 184], ["gene", 189], [")", 193], ["on", 195], ["chromosome", 198], ["3q", 209], ["21.3", 212], [".", 216], ["To", 218], ["describe", 221], ["the", 230], ["clinical", 234], [",", 242], ["electrophysiologic", 244], ["and", 263], ["pathologic", 267], ["findings", 278], ["in", 287], ["patients", 290], ["with", 299], ["myotonic", 304], ["dystrophy", 313], ["2", 323], [".", 324], ["We", 326], ["evaluated", 329], ["10", 339], ["patients", 342], ["genetically", 351], [",", 362], ["clinically", 364], ["and", 375], ["electrophysiologically", 379], ["during", 402], ["the", 409], ["years", 413], ["2007", 419], ["to", 424], ["2008", 427], [".", 431], ["All", 433], ["patients", 437], ["were", 446], ["of", 451], ["Jewish", 454], ["European", 461], ["ancestry", 470], [".", 478], ["Among", 480], ["affected", 486], ["individuals", 495], [",", 506], ["eight", 508], ["patients", 514], ["had", 523], ["symptoms", 527], ["of", 536], ["proximal", 539], ["muscle", 548], ["weakness", 555], [",", 563], ["two", 565], ["had", 569], ["muscle", 573], ["pain", 580], [",", 584], ["and", 586], ["two", 590], ["exhibited", 594], ["myotonia", 604], [".", 612], ["On", 614], ["physical", 617], ["examination", 626], ["six", 638], ["patients", 642], ["had", 651], ["severe", 655], ["weakness", 662], ["of", 671], ["hip", 674], ["flexor", 678], ["muscles", 685], [".", 692], ["Seven", 694], ["individuals", 700], ["underwent", 712], ["cataract", 722], ["surgery", 731], [",", 738], ["and", 740], ["cardiac", 744], ["involvement", 752], ["was", 764], ["seen", 768], ["in", 773], ["one", 776], ["case", 780], [".", 784], ["On", 786], ["the", 789], ["initial", 793], ["electromyographic", 801], ["(", 819], ["EMG", 820], [")", 823], ["examination", 825], ["five", 837], ["patients", 842], ["demonstrated", 851], ["myotonic", 864], ["discharges", 873], [";", 883], ["repeated", 885], ["studies", 894], ["showed", 902], ["these", 909], ["discharges", 915], ["in", 926], ["nine", 929], ["cases", 934], [".", 939], ["Six", 941], ["muscle", 945], ["biopsies", 952], ["showed", 961], ["non", 968], ["-", 971], ["specific", 972], ["pathological", 981], ["changes", 994], [".", 1001], ["Seven", 1003], ["patients", 1009], ["had", 1018], ["an", 1022], ["affected", 1025], ["first", 1034], ["-", 1039], ["degree", 1040], ["relative", 1047], ["with", 1056], ["either", 1061], ["a", 1068], ["diagnosed", 1070], ["or", 1080], ["an", 1083], ["undiagnosed", 1086], ["muscular", 1098], ["disorder", 1107], ["consistent", 1116], ["with", 1127], ["an", 1132], ["autosomal", 1135], ["dominant", 1145], ["trait", 1154], [".", 1159], ["DM2", 1161], ["may", 1165], ["often", 1169], ["present", 1175], ["with", 1183], ["proximal", 1188], ["muscle", 1197], ["weakness", 1204], ["without", 1213], ["myotonia", 1221], [".", 1229], ["EMG", 1231], ["may", 1235], ["initially", 1239], ["fail", 1249], ["to", 1254], ["show", 1257], ["myotonic", 1262], ["discharges", 1271], [",", 1281], ["but", 1283], ["these", 1287], ["discharges", 1293], ["may", 1304], ["eventually", 1308], ["show", 1319], ["in", 1324], ["most", 1327], ["cases", 1332], ["on", 1338], ["repeated", 1341], ["EMG", 1350], [".", 1353], ["Thus", 1355], [",", 1359], ["DM2", 1361], ["may", 1365], ["be", 1369], ["underdiagnosed", 1372], ["and", 1387], ["should", 1391], ["be", 1398], ["included", 1401], ["in", 1410], ["the", 1413], ["differential", 1417], ["diagnosis", 1430], ["of", 1440], ["adult", 1443], ["patients", 1449], ["of", 1458], ["Jewish", 1461], ["European", 1468], ["ancestry", 1477], ["presenting", 1486], ["with", 1497], ["proximal", 1502], ["lower", 1511], ["limb", 1517], ["weakness", 1522], [".", 1530]]}
{"context": "Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the overproduction of granulocytes, which leads to high white blood cell counts and splenomegaly in patients. Based on clinical symptoms and laboratory findings, CML is classified into three clinical phases, often starting with a chronic phase, progressing to an accelerated phase and ultimately ending in a terminal phase called blast crisis. Blast crisis phase of CML is clinically similar to an acute leukemia; in particular, B-cell acute lymphoblastic leukemia (B-ALL) is a severe form of acute leukemia in blast crisis, and there is no effective therapy for it yet. CML is induced by the BCR-ABL oncogene, whose gene product is a BCR-ABL tyrosine kinase. Currently, inhibition of BCR-ABL kinase activity by its kinase inhibitor such as imatinib mesylate (Gleevec) is a major therapeutic strategy for CML. However, the inability of BCR-ABL kinase inhibitors to completely kill leukemia stem cells (LSCs) indicates that these kinase inhibitors are unlikely to cure CML. In addition, drug resistance due to the development of BCRABL mutations occurs before and during treatment of CML with kinase inhibitors. A critical issue to resolve this problem is to fully understand the biology of LSCs, and to identify key genes that play significant roles in survival and self-renewal of LSCs. In this review, we will focus on LSCs in CML by summarizing and discussing available experimental results, including the original studies from our own laboratory.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "eb81aaa1e4b44724821213505ab1015b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[142, 144], [132, 134], [122, 124], [171, 173]], "char_spans": [[765, 771], [715, 721], [673, 679], [916, 922]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["myeloproliferative", 36], ["disease", 55], ["characterized", 63], ["by", 77], ["the", 80], ["overproduction", 84], ["of", 99], ["granulocytes", 102], [",", 114], ["which", 116], ["leads", 122], ["to", 128], ["high", 131], ["white", 136], ["blood", 142], ["cell", 148], ["counts", 153], ["and", 160], ["splenomegaly", 164], ["in", 177], ["patients", 180], [".", 188], ["Based", 190], ["on", 196], ["clinical", 199], ["symptoms", 208], ["and", 217], ["laboratory", 221], ["findings", 232], [",", 240], ["CML", 242], ["is", 246], ["classified", 249], ["into", 260], ["three", 265], ["clinical", 271], ["phases", 280], [",", 286], ["often", 288], ["starting", 294], ["with", 303], ["a", 308], ["chronic", 310], ["phase", 318], [",", 323], ["progressing", 325], ["to", 337], ["an", 340], ["accelerated", 343], ["phase", 355], ["and", 361], ["ultimately", 365], ["ending", 376], ["in", 383], ["a", 386], ["terminal", 388], ["phase", 397], ["called", 403], ["blast", 410], ["crisis", 416], [".", 422], ["Blast", 424], ["crisis", 430], ["phase", 437], ["of", 443], ["CML", 446], ["is", 450], ["clinically", 453], ["similar", 464], ["to", 472], ["an", 475], ["acute", 478], ["leukemia", 484], [";", 492], ["in", 494], ["particular", 497], [",", 507], ["B", 509], ["-", 510], ["cell", 511], ["acute", 516], ["lymphoblastic", 522], ["leukemia", 536], ["(", 545], ["B", 546], ["-", 547], ["ALL", 548], [")", 551], ["is", 553], ["a", 556], ["severe", 558], ["form", 565], ["of", 570], ["acute", 573], ["leukemia", 579], ["in", 588], ["blast", 591], ["crisis", 597], [",", 603], ["and", 605], ["there", 609], ["is", 615], ["no", 618], ["effective", 621], ["therapy", 631], ["for", 639], ["it", 643], ["yet", 646], [".", 649], ["CML", 651], ["is", 655], ["induced", 658], ["by", 666], ["the", 669], ["BCR", 673], ["-", 676], ["ABL", 677], ["oncogene", 681], [",", 689], ["whose", 691], ["gene", 697], ["product", 702], ["is", 710], ["a", 713], ["BCR", 715], ["-", 718], ["ABL", 719], ["tyrosine", 723], ["kinase", 732], [".", 738], ["Currently", 740], [",", 749], ["inhibition", 751], ["of", 762], ["BCR", 765], ["-", 768], ["ABL", 769], ["kinase", 773], ["activity", 780], ["by", 789], ["its", 792], ["kinase", 796], ["inhibitor", 803], ["such", 813], ["as", 818], ["imatinib", 821], ["mesylate", 830], ["(", 839], ["Gleevec", 840], [")", 847], ["is", 849], ["a", 852], ["major", 854], ["therapeutic", 860], ["strategy", 872], ["for", 881], ["CML", 885], [".", 888], ["However", 890], [",", 897], ["the", 899], ["inability", 903], ["of", 913], ["BCR", 916], ["-", 919], ["ABL", 920], ["kinase", 924], ["inhibitors", 931], ["to", 942], ["completely", 945], ["kill", 956], ["leukemia", 961], ["stem", 970], ["cells", 975], ["(", 981], ["LSCs", 982], [")", 986], ["indicates", 988], ["that", 998], ["these", 1003], ["kinase", 1009], ["inhibitors", 1016], ["are", 1027], ["unlikely", 1031], ["to", 1040], ["cure", 1043], ["CML", 1048], [".", 1051], ["In", 1053], ["addition", 1056], [",", 1064], ["drug", 1066], ["resistance", 1071], ["due", 1082], ["to", 1086], ["the", 1089], ["development", 1093], ["of", 1105], ["BCRABL", 1108], ["mutations", 1115], ["occurs", 1125], ["before", 1132], ["and", 1139], ["during", 1143], ["treatment", 1150], ["of", 1160], ["CML", 1163], ["with", 1167], ["kinase", 1172], ["inhibitors", 1179], [".", 1189], ["A", 1191], ["critical", 1193], ["issue", 1202], ["to", 1208], ["resolve", 1211], ["this", 1219], ["problem", 1224], ["is", 1232], ["to", 1235], ["fully", 1238], ["understand", 1244], ["the", 1255], ["biology", 1259], ["of", 1267], ["LSCs", 1270], [",", 1274], ["and", 1276], ["to", 1280], ["identify", 1283], ["key", 1292], ["genes", 1296], ["that", 1302], ["play", 1307], ["significant", 1312], ["roles", 1324], ["in", 1330], ["survival", 1333], ["and", 1342], ["self", 1346], ["-", 1350], ["renewal", 1351], ["of", 1359], ["LSCs", 1362], [".", 1366], ["In", 1368], ["this", 1371], ["review", 1376], [",", 1382], ["we", 1384], ["will", 1387], ["focus", 1392], ["on", 1398], ["LSCs", 1401], ["in", 1406], ["CML", 1409], ["by", 1413], ["summarizing", 1416], ["and", 1428], ["discussing", 1432], ["available", 1443], ["experimental", 1453], ["results", 1466], [",", 1473], ["including", 1475], ["the", 1485], ["original", 1489], ["studies", 1498], ["from", 1506], ["our", 1511], ["own", 1515], ["laboratory", 1519], [".", 1529]]}
{"context": "Mutations of SLC9A6 may cause an X-linked clinical syndrome first described by Christianson in 1999 in which affected males exhibited profound intellectual disability, autism, drug-resistant epilepsy, ophthalmoplegia, mild craniofacial dysmorphism, microcephaly, and ataxia. We describe a child with an SLC9A6 mutation and an electroencephalographic pattern consistent with electrographic status epilepticus of sleep. Our patient's electrographic status epilepticus of sleep resolved after treatment with felbamate. Following treatment, he remained seizure-free but did not make significant or lasting gains in language. Our report extends the clinical epilepsy phenotype in children with SLC9A6 mutations to include electrographic status epilepticus of sleep. In addition, felbamate was an effective treatment for electrographic status epilepticus of sleep in our patient.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "215553b82687403fb1ece277d1cece01", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[50, 50], [107, 107], [2, 2]], "char_spans": [[303, 308], [689, 694], [13, 18]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["SLC9A6", 13], ["may", 20], ["cause", 24], ["an", 30], ["X", 33], ["-", 34], ["linked", 35], ["clinical", 42], ["syndrome", 51], ["first", 60], ["described", 66], ["by", 76], ["Christianson", 79], ["in", 92], ["1999", 95], ["in", 100], ["which", 103], ["affected", 109], ["males", 118], ["exhibited", 124], ["profound", 134], ["intellectual", 143], ["disability", 156], [",", 166], ["autism", 168], [",", 174], ["drug", 176], ["-", 180], ["resistant", 181], ["epilepsy", 191], [",", 199], ["ophthalmoplegia", 201], [",", 216], ["mild", 218], ["craniofacial", 223], ["dysmorphism", 236], [",", 247], ["microcephaly", 249], [",", 261], ["and", 263], ["ataxia", 267], [".", 273], ["We", 275], ["describe", 278], ["a", 287], ["child", 289], ["with", 295], ["an", 300], ["SLC9A6", 303], ["mutation", 310], ["and", 319], ["an", 323], ["electroencephalographic", 326], ["pattern", 350], ["consistent", 358], ["with", 369], ["electrographic", 374], ["status", 389], ["epilepticus", 396], ["of", 408], ["sleep", 411], [".", 416], ["Our", 418], ["patient", 422], ["'s", 429], ["electrographic", 432], ["status", 447], ["epilepticus", 454], ["of", 466], ["sleep", 469], ["resolved", 475], ["after", 484], ["treatment", 490], ["with", 500], ["felbamate", 505], [".", 514], ["Following", 516], ["treatment", 526], [",", 535], ["he", 537], ["remained", 540], ["seizure", 549], ["-", 556], ["free", 557], ["but", 562], ["did", 566], ["not", 570], ["make", 574], ["significant", 579], ["or", 591], ["lasting", 594], ["gains", 602], ["in", 608], ["language", 611], [".", 619], ["Our", 621], ["report", 625], ["extends", 632], ["the", 640], ["clinical", 644], ["epilepsy", 653], ["phenotype", 662], ["in", 672], ["children", 675], ["with", 684], ["SLC9A6", 689], ["mutations", 696], ["to", 706], ["include", 709], ["electrographic", 717], ["status", 732], ["epilepticus", 739], ["of", 751], ["sleep", 754], [".", 759], ["In", 761], ["addition", 764], [",", 772], ["felbamate", 774], ["was", 784], ["an", 788], ["effective", 791], ["treatment", 801], ["for", 811], ["electrographic", 815], ["status", 830], ["epilepticus", 837], ["of", 849], ["sleep", 852], ["in", 858], ["our", 861], ["patient", 865], [".", 872]]}
{"context": "The ubiquitin-proteasome pathway regulates many basic cellular processes and has been proven to be a promising target for cancer therapy. Bortezomib is the first U.S. Food and Drug Administration (FDA) approved proteasome inhibitor used in the treatment of newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and mantle cell lymphoma. The anti-cancer mechanisms of bortezomib elucidated by preclinical studies include: upregulation of proapoptotic proteins (e.g., Noxa, I\u03baB), inhibition of NF\u03baB and its anti-apoptotic target genes, suppression of several anti-apoptotic proteins (e.g., Bcl-XL, Bcl-2, and STAT-3), down-regulation of expression of several proteins involved in DNA repair pathways, and induction of endoplasmic reticulum (ER) stress and pro-apoptotic Unfolded Protein Response (UPR). Bortezomib has potent chemo-/radio-sensitizing effects and can overcome traditional drug resistance in tumors when used in combination with potential chemotherapies. Although bortezomib has been successful in improving clinical outcomes when used in hematological malignancies, relapse may occur in those patients who responded initially. Furthermore, some cytotoxicities (such as peripheral neuropathy) were found to be associated with bortezomib treatment. These observations have encouraged researchers to search for the next generation proteasome inhibitors (including carfilzomib and marizomib) that could overcome bortezomib resistance and have improved properties, reduced toxicities, and broader anticancer activities, based on the lessons learned from the mechanisms and use of bortezomib. This review summarizes the current status of bortezomib as well as several other proteasome inhibitors that are currently under clinical and preclinical investigation.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "0ed20ead469f4406ac6977afdfa3ba6e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[1, 4]], "char_spans": [[4, 31]]}]}], "context_tokens": [["The", 0], ["ubiquitin", 4], ["-", 13], ["proteasome", 14], ["pathway", 25], ["regulates", 33], ["many", 43], ["basic", 48], ["cellular", 54], ["processes", 63], ["and", 73], ["has", 77], ["been", 81], ["proven", 86], ["to", 93], ["be", 96], ["a", 99], ["promising", 101], ["target", 111], ["for", 118], ["cancer", 122], ["therapy", 129], [".", 136], ["Bortezomib", 138], ["is", 149], ["the", 152], ["first", 156], ["U.S.", 162], ["Food", 167], ["and", 172], ["Drug", 176], ["Administration", 181], ["(", 196], ["FDA", 197], [")", 200], ["approved", 202], ["proteasome", 211], ["inhibitor", 222], ["used", 232], ["in", 237], ["the", 240], ["treatment", 244], ["of", 254], ["newly", 257], ["diagnosed", 263], ["multiple", 273], ["myeloma", 282], [",", 289], ["relapsed", 291], ["/", 299], ["refractory", 300], ["multiple", 311], ["myeloma", 320], [",", 327], ["and", 329], ["mantle", 333], ["cell", 340], ["lymphoma", 345], [".", 353], ["The", 355], ["anti", 359], ["-", 363], ["cancer", 364], ["mechanisms", 371], ["of", 382], ["bortezomib", 385], ["elucidated", 396], ["by", 407], ["preclinical", 410], ["studies", 422], ["include", 430], [":", 437], ["upregulation", 439], ["of", 452], ["proapoptotic", 455], ["proteins", 468], ["(", 477], ["e.g.", 478], [",", 482], ["Noxa", 484], [",", 488], ["I\u03baB", 490], [")", 493], [",", 494], ["inhibition", 496], ["of", 507], ["NF\u03baB", 510], ["and", 515], ["its", 519], ["anti", 523], ["-", 527], ["apoptotic", 528], ["target", 538], ["genes", 545], [",", 550], ["suppression", 552], ["of", 564], ["several", 567], ["anti", 575], ["-", 579], ["apoptotic", 580], ["proteins", 590], ["(", 599], ["e.g.", 600], [",", 604], ["Bcl", 606], ["-", 609], ["XL", 610], [",", 612], ["Bcl-2", 614], [",", 619], ["and", 621], ["STAT-3", 625], [")", 631], [",", 632], ["down", 634], ["-", 638], ["regulation", 639], ["of", 650], ["expression", 653], ["of", 664], ["several", 667], ["proteins", 675], ["involved", 684], ["in", 693], ["DNA", 696], ["repair", 700], ["pathways", 707], [",", 715], ["and", 717], ["induction", 721], ["of", 731], ["endoplasmic", 734], ["reticulum", 746], ["(", 756], ["ER", 757], [")", 759], ["stress", 761], ["and", 768], ["pro", 772], ["-", 775], ["apoptotic", 776], ["Unfolded", 786], ["Protein", 795], ["Response", 803], ["(", 812], ["UPR", 813], [")", 816], [".", 817], ["Bortezomib", 819], ["has", 830], ["potent", 834], ["chemo-/radio", 841], ["-", 853], ["sensitizing", 854], ["effects", 866], ["and", 874], ["can", 878], ["overcome", 882], ["traditional", 891], ["drug", 903], ["resistance", 908], ["in", 919], ["tumors", 922], ["when", 929], ["used", 934], ["in", 939], ["combination", 942], ["with", 954], ["potential", 959], ["chemotherapies", 969], [".", 983], ["Although", 985], ["bortezomib", 994], ["has", 1005], ["been", 1009], ["successful", 1014], ["in", 1025], ["improving", 1028], ["clinical", 1038], ["outcomes", 1047], ["when", 1056], ["used", 1061], ["in", 1066], ["hematological", 1069], ["malignancies", 1083], [",", 1095], ["relapse", 1097], ["may", 1105], ["occur", 1109], ["in", 1115], ["those", 1118], ["patients", 1124], ["who", 1133], ["responded", 1137], ["initially", 1147], [".", 1156], ["Furthermore", 1158], [",", 1169], ["some", 1171], ["cytotoxicities", 1176], ["(", 1191], ["such", 1192], ["as", 1197], ["peripheral", 1200], ["neuropathy", 1211], [")", 1221], ["were", 1223], ["found", 1228], ["to", 1234], ["be", 1237], ["associated", 1240], ["with", 1251], ["bortezomib", 1256], ["treatment", 1267], [".", 1276], ["These", 1278], ["observations", 1284], ["have", 1297], ["encouraged", 1302], ["researchers", 1313], ["to", 1325], ["search", 1328], ["for", 1335], ["the", 1339], ["next", 1343], ["generation", 1348], ["proteasome", 1359], ["inhibitors", 1370], ["(", 1381], ["including", 1382], ["carfilzomib", 1392], ["and", 1404], ["marizomib", 1408], [")", 1417], ["that", 1419], ["could", 1424], ["overcome", 1430], ["bortezomib", 1439], ["resistance", 1450], ["and", 1461], ["have", 1465], ["improved", 1470], ["properties", 1479], [",", 1489], ["reduced", 1491], ["toxicities", 1499], [",", 1509], ["and", 1511], ["broader", 1515], ["anticancer", 1523], ["activities", 1534], [",", 1544], ["based", 1546], ["on", 1552], ["the", 1555], ["lessons", 1559], ["learned", 1567], ["from", 1575], ["the", 1580], ["mechanisms", 1584], ["and", 1595], ["use", 1599], ["of", 1603], ["bortezomib", 1606], [".", 1616], ["This", 1618], ["review", 1623], ["summarizes", 1630], ["the", 1641], ["current", 1645], ["status", 1653], ["of", 1660], ["bortezomib", 1663], ["as", 1674], ["well", 1677], ["as", 1682], ["several", 1685], ["other", 1693], ["proteasome", 1699], ["inhibitors", 1710], ["that", 1721], ["are", 1726], ["currently", 1730], ["under", 1740], ["clinical", 1746], ["and", 1755], ["preclinical", 1759], ["investigation", 1771], [".", 1784]]}
{"context": "There may be a relationship between proton pump inhibitors (PPIs) and iron absorption. PPIs may decrease the amount of iron absorbed gastrointestinally specifically due to alteration of the pH in the duodenum. Restless legs syndrome (RLS) is a sensorimotor disorder that includes an urge to move legs, accompanied or caused by uncomfortable and unpleasant sensations in the legs; the urge to move begins or worsens during periods of rest or inactivity, the urge to move is partially or totally relieved by movement, and the urge is worse or only occurs at night. In the majority of the restless leg syndrome population, the sensation is deep seated, often described as being in the shin bones, and most commonly felt between the knee and ankle. It may be described as a creepy, shock-like, tense, electric, buzzing, itchy, or even numb sensation. A subpopulation of this restless leg syndrome patient population experiences restless leg syndrome associated pain (RLSAP) that has been described as a deep \"achy pain.\" This pain has not been found to be relieved by many of the typical over the counter analgesics. Often, constant movement of the legs appears to be the only remedy, as these sensations usually appear during periods of rest. Furthermore, there appears to be an association between iron deficiency and those suffering from Restless Leg Syndrome (RLS). The authors theorize that there may be a possible correlation between PPIs and the symptoms (e.g. pain) associated with RLS. The authors propose that PPIs, such as omeprazole, may interfere with iron absorption in certain patients and that a subpopulation of patients who develop significant iron deficiency characterized by low serum ferritin levels while on PPIs may also develop RLS-like symptoms (including RLSAP). While there is no robust direct evidence to support any associations of PPIs and iron deficiency or PPIs associated with RLS-like symptoms (including RLSAP), it is hoped that this manuscript may spark research efforts on this issue.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "98b6b16cb95a49bd915989305b3d7d4c", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[245, 245], [13, 13], [294, 294], [22, 22], [308, 308], [345, 345]], "char_spans": [[1296, 1299], [70, 73], [1561, 1564], [119, 122], [1658, 1661], [1866, 1869]]}]}], "context_tokens": [["There", 0], ["may", 6], ["be", 10], ["a", 13], ["relationship", 15], ["between", 28], ["proton", 36], ["pump", 43], ["inhibitors", 48], ["(", 59], ["PPIs", 60], [")", 64], ["and", 66], ["iron", 70], ["absorption", 75], [".", 85], ["PPIs", 87], ["may", 92], ["decrease", 96], ["the", 105], ["amount", 109], ["of", 116], ["iron", 119], ["absorbed", 124], ["gastrointestinally", 133], ["specifically", 152], ["due", 165], ["to", 169], ["alteration", 172], ["of", 183], ["the", 186], ["pH", 190], ["in", 193], ["the", 196], ["duodenum", 200], [".", 208], ["Restless", 210], ["legs", 219], ["syndrome", 224], ["(", 233], ["RLS", 234], [")", 237], ["is", 239], ["a", 242], ["sensorimotor", 244], ["disorder", 257], ["that", 266], ["includes", 271], ["an", 280], ["urge", 283], ["to", 288], ["move", 291], ["legs", 296], [",", 300], ["accompanied", 302], ["or", 314], ["caused", 317], ["by", 324], ["uncomfortable", 327], ["and", 341], ["unpleasant", 345], ["sensations", 356], ["in", 367], ["the", 370], ["legs", 374], [";", 378], ["the", 380], ["urge", 384], ["to", 389], ["move", 392], ["begins", 397], ["or", 404], ["worsens", 407], ["during", 415], ["periods", 422], ["of", 430], ["rest", 433], ["or", 438], ["inactivity", 441], [",", 451], ["the", 453], ["urge", 457], ["to", 462], ["move", 465], ["is", 470], ["partially", 473], ["or", 483], ["totally", 486], ["relieved", 494], ["by", 503], ["movement", 506], [",", 514], ["and", 516], ["the", 520], ["urge", 524], ["is", 529], ["worse", 532], ["or", 538], ["only", 541], ["occurs", 546], ["at", 553], ["night", 556], [".", 561], ["In", 563], ["the", 566], ["majority", 570], ["of", 579], ["the", 582], ["restless", 586], ["leg", 595], ["syndrome", 599], ["population", 608], [",", 618], ["the", 620], ["sensation", 624], ["is", 634], ["deep", 637], ["seated", 642], [",", 648], ["often", 650], ["described", 656], ["as", 666], ["being", 669], ["in", 675], ["the", 678], ["shin", 682], ["bones", 687], [",", 692], ["and", 694], ["most", 698], ["commonly", 703], ["felt", 712], ["between", 717], ["the", 725], ["knee", 729], ["and", 734], ["ankle", 738], [".", 743], ["It", 745], ["may", 748], ["be", 752], ["described", 755], ["as", 765], ["a", 768], ["creepy", 770], [",", 776], ["shock", 778], ["-", 783], ["like", 784], [",", 788], ["tense", 790], [",", 795], ["electric", 797], [",", 805], ["buzzing", 807], [",", 814], ["itchy", 816], [",", 821], ["or", 823], ["even", 826], ["numb", 831], ["sensation", 836], [".", 845], ["A", 847], ["subpopulation", 849], ["of", 863], ["this", 866], ["restless", 871], ["leg", 880], ["syndrome", 884], ["patient", 893], ["population", 901], ["experiences", 912], ["restless", 924], ["leg", 933], ["syndrome", 937], ["associated", 946], ["pain", 957], ["(", 962], ["RLSAP", 963], [")", 968], ["that", 970], ["has", 975], ["been", 979], ["described", 984], ["as", 994], ["a", 997], ["deep", 999], ["\"", 1004], ["achy", 1005], ["pain", 1010], [".", 1014], ["\"", 1015], ["This", 1017], ["pain", 1022], ["has", 1027], ["not", 1031], ["been", 1035], ["found", 1040], ["to", 1046], ["be", 1049], ["relieved", 1052], ["by", 1061], ["many", 1064], ["of", 1069], ["the", 1072], ["typical", 1076], ["over", 1084], ["the", 1089], ["counter", 1093], ["analgesics", 1101], [".", 1111], ["Often", 1113], [",", 1118], ["constant", 1120], ["movement", 1129], ["of", 1138], ["the", 1141], ["legs", 1145], ["appears", 1150], ["to", 1158], ["be", 1161], ["the", 1164], ["only", 1168], ["remedy", 1173], [",", 1179], ["as", 1181], ["these", 1184], ["sensations", 1190], ["usually", 1201], ["appear", 1209], ["during", 1216], ["periods", 1223], ["of", 1231], ["rest", 1234], [".", 1238], ["Furthermore", 1240], [",", 1251], ["there", 1253], ["appears", 1259], ["to", 1267], ["be", 1270], ["an", 1273], ["association", 1276], ["between", 1288], ["iron", 1296], ["deficiency", 1301], ["and", 1312], ["those", 1316], ["suffering", 1322], ["from", 1332], ["Restless", 1337], ["Leg", 1346], ["Syndrome", 1350], ["(", 1359], ["RLS", 1360], [")", 1363], [".", 1364], ["The", 1366], ["authors", 1370], ["theorize", 1378], ["that", 1387], ["there", 1392], ["may", 1398], ["be", 1402], ["a", 1405], ["possible", 1407], ["correlation", 1416], ["between", 1428], ["PPIs", 1436], ["and", 1441], ["the", 1445], ["symptoms", 1449], ["(", 1458], ["e.g.", 1459], ["pain", 1464], [")", 1468], ["associated", 1470], ["with", 1481], ["RLS", 1486], [".", 1489], ["The", 1491], ["authors", 1495], ["propose", 1503], ["that", 1511], ["PPIs", 1516], [",", 1520], ["such", 1522], ["as", 1527], ["omeprazole", 1530], [",", 1540], ["may", 1542], ["interfere", 1546], ["with", 1556], ["iron", 1561], ["absorption", 1566], ["in", 1577], ["certain", 1580], ["patients", 1588], ["and", 1597], ["that", 1601], ["a", 1606], ["subpopulation", 1608], ["of", 1622], ["patients", 1625], ["who", 1634], ["develop", 1638], ["significant", 1646], ["iron", 1658], ["deficiency", 1663], ["characterized", 1674], ["by", 1688], ["low", 1691], ["serum", 1695], ["ferritin", 1701], ["levels", 1710], ["while", 1717], ["on", 1723], ["PPIs", 1726], ["may", 1731], ["also", 1735], ["develop", 1740], ["RLS", 1748], ["-", 1751], ["like", 1752], ["symptoms", 1757], ["(", 1766], ["including", 1767], ["RLSAP", 1777], [")", 1782], [".", 1783], ["While", 1785], ["there", 1791], ["is", 1797], ["no", 1800], ["robust", 1803], ["direct", 1810], ["evidence", 1817], ["to", 1826], ["support", 1829], ["any", 1837], ["associations", 1841], ["of", 1854], ["PPIs", 1857], ["and", 1862], ["iron", 1866], ["deficiency", 1871], ["or", 1882], ["PPIs", 1885], ["associated", 1890], ["with", 1901], ["RLS", 1906], ["-", 1909], ["like", 1910], ["symptoms", 1915], ["(", 1924], ["including", 1925], ["RLSAP", 1935], [")", 1940], [",", 1941], ["it", 1943], ["is", 1946], ["hoped", 1949], ["that", 1955], ["this", 1960], ["manuscript", 1965], ["may", 1976], ["spark", 1980], ["research", 1986], ["efforts", 1995], ["on", 2003], ["this", 2006], ["issue", 2011], [".", 2016]]}
{"context": "The Ehlers-Danlos syndromes (EDS) are a group of heritable connective tissue disorders that share the common features of skin hyperextensibility, articular hypermobility, and tissue fragility. Considerable clinical and genetic heterogeneity exists, and more than nine separate forms have been recognized. Recent advances in the molecular analysis of EDS have identify defects responsible for EDS VI (homozygous and compound heterozygous mutations in the lysyl-hydroxylase gene), EDS VIIA and EDS VIIB (mutations in the type I collagene genes), EDS VIIC (deficiency of procollagen N-proteinase), EDS IX (mutations in the MNK gene), and EDS IV (mutations in the type III collagen gene). Of the various types of Ehlers-Danlos syndrome the most severe is type IV (EDS IV). Early studies showed that fibroblasts from EDS IV patients secreted lower than normal amounts of type III procollagen (Pope et al., 1975). Later, the disease was linked to COL3A1, the gene encoding this protein. More recently, with the publication of full length cDNA and partial characterisation of the gene structure, detailed analysis of mutations in EDS IV patients has become possible. Nineteen different mutations in the type III procollagen gene have been reported in different families with EDS IV. Recent results support the hypothesis that in EDS IV, dominant inheritance should be assumed, in sporadic cases also, unless proven otherwise. Very little is known about the genetics or biochemicals defects responsible for the others EDS subtypes, but with the applications of the tools of molecular biology, analysis of these defects if now within reach.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "0fd48e8ecbbf4547af93df0c4d6ecfe0", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[59, 75]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["are", 34], ["a", 38], ["group", 40], ["of", 46], ["heritable", 49], ["connective", 59], ["tissue", 70], ["disorders", 77], ["that", 87], ["share", 92], ["the", 98], ["common", 102], ["features", 109], ["of", 118], ["skin", 121], ["hyperextensibility", 126], [",", 144], ["articular", 146], ["hypermobility", 156], [",", 169], ["and", 171], ["tissue", 175], ["fragility", 182], [".", 191], ["Considerable", 193], ["clinical", 206], ["and", 215], ["genetic", 219], ["heterogeneity", 227], ["exists", 241], [",", 247], ["and", 249], ["more", 253], ["than", 258], ["nine", 263], ["separate", 268], ["forms", 277], ["have", 283], ["been", 288], ["recognized", 293], [".", 303], ["Recent", 305], ["advances", 312], ["in", 321], ["the", 324], ["molecular", 328], ["analysis", 338], ["of", 347], ["EDS", 350], ["have", 354], ["identify", 359], ["defects", 368], ["responsible", 376], ["for", 388], ["EDS", 392], ["VI", 396], ["(", 399], ["homozygous", 400], ["and", 411], ["compound", 415], ["heterozygous", 424], ["mutations", 437], ["in", 447], ["the", 450], ["lysyl", 454], ["-", 459], ["hydroxylase", 460], ["gene", 472], [")", 476], [",", 477], ["EDS", 479], ["VIIA", 483], ["and", 488], ["EDS", 492], ["VIIB", 496], ["(", 501], ["mutations", 502], ["in", 512], ["the", 515], ["type", 519], ["I", 524], ["collagene", 526], ["genes", 536], [")", 541], [",", 542], ["EDS", 544], ["VIIC", 548], ["(", 553], ["deficiency", 554], ["of", 565], ["procollagen", 568], ["N", 580], ["-", 581], ["proteinase", 582], [")", 592], [",", 593], ["EDS", 595], ["IX", 599], ["(", 602], ["mutations", 603], ["in", 613], ["the", 616], ["MNK", 620], ["gene", 624], [")", 628], [",", 629], ["and", 631], ["EDS", 635], ["IV", 639], ["(", 642], ["mutations", 643], ["in", 653], ["the", 656], ["type", 660], ["III", 665], ["collagen", 669], ["gene", 678], [")", 682], [".", 683], ["Of", 685], ["the", 688], ["various", 692], ["types", 700], ["of", 706], ["Ehlers", 709], ["-", 715], ["Danlos", 716], ["syndrome", 723], ["the", 732], ["most", 736], ["severe", 741], ["is", 748], ["type", 751], ["IV", 756], ["(", 759], ["EDS", 760], ["IV", 764], [")", 766], [".", 767], ["Early", 769], ["studies", 775], ["showed", 783], ["that", 790], ["fibroblasts", 795], ["from", 807], ["EDS", 812], ["IV", 816], ["patients", 819], ["secreted", 828], ["lower", 837], ["than", 843], ["normal", 848], ["amounts", 855], ["of", 863], ["type", 866], ["III", 871], ["procollagen", 875], ["(", 887], ["Pope", 888], ["et", 893], ["al", 896], [".", 898], [",", 899], ["1975", 901], [")", 905], [".", 906], ["Later", 908], [",", 913], ["the", 915], ["disease", 919], ["was", 927], ["linked", 931], ["to", 938], ["COL3A1", 941], [",", 947], ["the", 949], ["gene", 953], ["encoding", 958], ["this", 967], ["protein", 972], [".", 979], ["More", 981], ["recently", 986], [",", 994], ["with", 996], ["the", 1001], ["publication", 1005], ["of", 1017], ["full", 1020], ["length", 1025], ["cDNA", 1032], ["and", 1037], ["partial", 1041], ["characterisation", 1049], ["of", 1066], ["the", 1069], ["gene", 1073], ["structure", 1078], [",", 1087], ["detailed", 1089], ["analysis", 1098], ["of", 1107], ["mutations", 1110], ["in", 1120], ["EDS", 1123], ["IV", 1127], ["patients", 1130], ["has", 1139], ["become", 1143], ["possible", 1150], [".", 1158], ["Nineteen", 1160], ["different", 1169], ["mutations", 1179], ["in", 1189], ["the", 1192], ["type", 1196], ["III", 1201], ["procollagen", 1205], ["gene", 1217], ["have", 1222], ["been", 1227], ["reported", 1232], ["in", 1241], ["different", 1244], ["families", 1254], ["with", 1263], ["EDS", 1268], ["IV", 1272], [".", 1274], ["Recent", 1276], ["results", 1283], ["support", 1291], ["the", 1299], ["hypothesis", 1303], ["that", 1314], ["in", 1319], ["EDS", 1322], ["IV", 1326], [",", 1328], ["dominant", 1330], ["inheritance", 1339], ["should", 1351], ["be", 1358], ["assumed", 1361], [",", 1368], ["in", 1370], ["sporadic", 1373], ["cases", 1382], ["also", 1388], [",", 1392], ["unless", 1394], ["proven", 1401], ["otherwise", 1408], [".", 1417], ["Very", 1419], ["little", 1424], ["is", 1431], ["known", 1434], ["about", 1440], ["the", 1446], ["genetics", 1450], ["or", 1459], ["biochemicals", 1462], ["defects", 1475], ["responsible", 1483], ["for", 1495], ["the", 1499], ["others", 1503], ["EDS", 1510], ["subtypes", 1514], [",", 1522], ["but", 1524], ["with", 1528], ["the", 1533], ["applications", 1537], ["of", 1550], ["the", 1553], ["tools", 1557], ["of", 1563], ["molecular", 1566], ["biology", 1576], [",", 1583], ["analysis", 1585], ["of", 1594], ["these", 1597], ["defects", 1603], ["if", 1611], ["now", 1614], ["within", 1618], ["reach", 1625], [".", 1630]]}
{"context": "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodies. Several groups have studied the role of phosphorylation at the S129 in \u03b1-synuclein in a rat model for Parkinson's disease using recombinant adeno-associated viral (rAAV) vectors. The results obtained are inconsistent and accordingly the role of S129 phosphorylation in \u03b1-synuclein toxicity remains unclear. This prompted us to re-examine the neuropathological and behavioral effects of the S129 modified \u03b1-synuclein species in vivo. For this purpose, we used two mutated forms of human \u03b1-synuclein in which the S129 was replaced either with an alanine (S129A), to block phosphorylation, or with an aspartate (S129D), to mimic phosphorylation, and compared them with the wild type \u03b1-synuclein. This approach was similar in design to previous studies, however our investigation of dopaminergic degeneration also included performing a detailed study of the \u03b1-synuclein induced pathology in the striatum and the analysis of motor deficits. Our results showed that overexpressing S129D or wild type \u03b1-synuclein resulted in an accelerated dopaminergic fiber loss as compared with S129A \u03b1-synuclein. Furthermore, the motor deficit seen in the group treated with the mutant S129D \u03b1-synuclein appeared earlier than the other two forms of \u03b1-synuclein. Conversely, S129A \u03b1-synuclein showed significantly larger pathological \u03b1-synuclein-positive inclusions, and slower dopaminergic fiber loss, when compared to the other two forms of \u03b1-synuclein, suggesting a neuroprotective effect of the mutation. When examined at long-term, all three \u03b1-synuclein forms resulted in pathological accumulations of \u03b1-synuclein in striatal fibers and dopaminergic cell death in the substantia nigra. Our data show that changes in the S129 residue of \u03b1-synuclein influence the rate of pathology and neurodegeneration, with an overall deleterious effect of exchanging S129 to a residue mimicking its phosphorylated state.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "440cb51fb1df468ebee4c3925fef9da6", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[5, 6]], "char_spans": [[34, 43]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["phosphorylated", 16], ["at", 31], ["serine", 34], ["129", 41], ["(", 45], ["S129", 46], [")", 50], ["is", 52], ["highly", 55], ["elevated", 62], ["in", 71], ["Parkinson", 74], ["'s", 83], ["disease", 86], ["patients", 94], ["where", 103], ["it", 109], ["mainly", 112], ["accumulates", 119], ["in", 131], ["the", 134], ["Lewy", 138], ["bodies", 143], [".", 149], ["Several", 151], ["groups", 159], ["have", 166], ["studied", 171], ["the", 179], ["role", 183], ["of", 188], ["phosphorylation", 191], ["at", 207], ["the", 210], ["S129", 214], ["in", 219], ["\u03b1", 222], ["-", 223], ["synuclein", 224], ["in", 234], ["a", 237], ["rat", 239], ["model", 243], ["for", 249], ["Parkinson", 253], ["'s", 262], ["disease", 265], ["using", 273], ["recombinant", 279], ["adeno", 291], ["-", 296], ["associated", 297], ["viral", 308], ["(", 314], ["rAAV", 315], [")", 319], ["vectors", 321], [".", 328], ["The", 330], ["results", 334], ["obtained", 342], ["are", 351], ["inconsistent", 355], ["and", 368], ["accordingly", 372], ["the", 384], ["role", 388], ["of", 393], ["S129", 396], ["phosphorylation", 401], ["in", 417], ["\u03b1", 420], ["-", 421], ["synuclein", 422], ["toxicity", 432], ["remains", 441], ["unclear", 449], [".", 456], ["This", 458], ["prompted", 463], ["us", 472], ["to", 475], ["re", 478], ["-", 480], ["examine", 481], ["the", 489], ["neuropathological", 493], ["and", 511], ["behavioral", 515], ["effects", 526], ["of", 534], ["the", 537], ["S129", 541], ["modified", 546], ["\u03b1", 555], ["-", 556], ["synuclein", 557], ["species", 567], ["in", 575], ["vivo", 578], [".", 582], ["For", 584], ["this", 588], ["purpose", 593], [",", 600], ["we", 602], ["used", 605], ["two", 610], ["mutated", 614], ["forms", 622], ["of", 628], ["human", 631], ["\u03b1", 637], ["-", 638], ["synuclein", 639], ["in", 649], ["which", 652], ["the", 658], ["S129", 662], ["was", 667], ["replaced", 671], ["either", 680], ["with", 687], ["an", 692], ["alanine", 695], ["(", 703], ["S129A", 704], [")", 709], [",", 710], ["to", 712], ["block", 715], ["phosphorylation", 721], [",", 736], ["or", 738], ["with", 741], ["an", 746], ["aspartate", 749], ["(", 759], ["S129D", 760], [")", 765], [",", 766], ["to", 768], ["mimic", 771], ["phosphorylation", 777], [",", 792], ["and", 794], ["compared", 798], ["them", 807], ["with", 812], ["the", 817], ["wild", 821], ["type", 826], ["\u03b1", 831], ["-", 832], ["synuclein", 833], [".", 842], ["This", 844], ["approach", 849], ["was", 858], ["similar", 862], ["in", 870], ["design", 873], ["to", 880], ["previous", 883], ["studies", 892], [",", 899], ["however", 901], ["our", 909], ["investigation", 913], ["of", 927], ["dopaminergic", 930], ["degeneration", 943], ["also", 956], ["included", 961], ["performing", 970], ["a", 981], ["detailed", 983], ["study", 992], ["of", 998], ["the", 1001], ["\u03b1", 1005], ["-", 1006], ["synuclein", 1007], ["induced", 1017], ["pathology", 1025], ["in", 1035], ["the", 1038], ["striatum", 1042], ["and", 1051], ["the", 1055], ["analysis", 1059], ["of", 1068], ["motor", 1071], ["deficits", 1077], [".", 1085], ["Our", 1087], ["results", 1091], ["showed", 1099], ["that", 1106], ["overexpressing", 1111], ["S129D", 1126], ["or", 1132], ["wild", 1135], ["type", 1140], ["\u03b1", 1145], ["-", 1146], ["synuclein", 1147], ["resulted", 1157], ["in", 1166], ["an", 1169], ["accelerated", 1172], ["dopaminergic", 1184], ["fiber", 1197], ["loss", 1203], ["as", 1208], ["compared", 1211], ["with", 1220], ["S129A", 1225], ["\u03b1", 1231], ["-", 1232], ["synuclein", 1233], [".", 1242], ["Furthermore", 1244], [",", 1255], ["the", 1257], ["motor", 1261], ["deficit", 1267], ["seen", 1275], ["in", 1280], ["the", 1283], ["group", 1287], ["treated", 1293], ["with", 1301], ["the", 1306], ["mutant", 1310], ["S129D", 1317], ["\u03b1", 1323], ["-", 1324], ["synuclein", 1325], ["appeared", 1335], ["earlier", 1344], ["than", 1352], ["the", 1357], ["other", 1361], ["two", 1367], ["forms", 1371], ["of", 1377], ["\u03b1", 1380], ["-", 1381], ["synuclein", 1382], [".", 1391], ["Conversely", 1393], [",", 1403], ["S129A", 1405], ["\u03b1", 1411], ["-", 1412], ["synuclein", 1413], ["showed", 1423], ["significantly", 1430], ["larger", 1444], ["pathological", 1451], ["\u03b1", 1464], ["-", 1465], ["synuclein", 1466], ["-", 1475], ["positive", 1476], ["inclusions", 1485], [",", 1495], ["and", 1497], ["slower", 1501], ["dopaminergic", 1508], ["fiber", 1521], ["loss", 1527], [",", 1531], ["when", 1533], ["compared", 1538], ["to", 1547], ["the", 1550], ["other", 1554], ["two", 1560], ["forms", 1564], ["of", 1570], ["\u03b1", 1573], ["-", 1574], ["synuclein", 1575], [",", 1584], ["suggesting", 1586], ["a", 1597], ["neuroprotective", 1599], ["effect", 1615], ["of", 1622], ["the", 1625], ["mutation", 1629], [".", 1637], ["When", 1639], ["examined", 1644], ["at", 1653], ["long", 1656], ["-", 1660], ["term", 1661], [",", 1665], ["all", 1667], ["three", 1671], ["\u03b1", 1677], ["-", 1678], ["synuclein", 1679], ["forms", 1689], ["resulted", 1695], ["in", 1704], ["pathological", 1707], ["accumulations", 1720], ["of", 1734], ["\u03b1", 1737], ["-", 1738], ["synuclein", 1739], ["in", 1749], ["striatal", 1752], ["fibers", 1761], ["and", 1768], ["dopaminergic", 1772], ["cell", 1785], ["death", 1790], ["in", 1796], ["the", 1799], ["substantia", 1803], ["nigra", 1814], [".", 1819], ["Our", 1821], ["data", 1825], ["show", 1830], ["that", 1835], ["changes", 1840], ["in", 1848], ["the", 1851], ["S129", 1855], ["residue", 1860], ["of", 1868], ["\u03b1", 1871], ["-", 1872], ["synuclein", 1873], ["influence", 1883], ["the", 1893], ["rate", 1897], ["of", 1902], ["pathology", 1905], ["and", 1915], ["neurodegeneration", 1919], [",", 1936], ["with", 1938], ["an", 1943], ["overall", 1946], ["deleterious", 1954], ["effect", 1966], ["of", 1973], ["exchanging", 1976], ["S129", 1987], ["to", 1992], ["a", 1995], ["residue", 1997], ["mimicking", 2005], ["its", 2015], ["phosphorylated", 2019], ["state", 2034], [".", 2039]]}
{"context": "Determine effects of evidence-based clinical decision support (CDS) on the use and yield of computed tomographic pulmonary angiography for suspected pulmonary embolism (CTPE) in Emergency Department (ED) patients. This multi-site prospective quality improvement intervention conducted in three urban EDs used a pre/post design. For ED patients aged 18+years with suspected PE, CTPE use and yield were compared 19months pre- and 32months post-implementation of CDS intervention based on the Wells criteria, provided at the time of CTPE order, deployed in April 2012. Primary outcome was the yield (percentage of studies positive for acute PE). Secondary outcome was utilization (number of studies/100 ED visits) of CTPE. Chi-square and statistical process control chart assessed pre- and post-intervention differences. An interrupted time series analysis was also performed. Of 558,795 patients presenting October 2010-December 2014, 7987 (1.4%) underwent CTPE (mean age 52\u00b117.5years, 66% female, 60.1% black); 34.7% of patients presented pre- and 65.3% post-CDS implementation. Overall CTPE diagnostic yield was 9.8% (779/7987 studies positive for PE). Yield increased a relative 30.8% after CDS implementation (8.1% vs. 10.6%; p=0.0003). There was no statistically significant change in CTPE utilization (1.4% pre- vs. 1.4% post-implementation; p=0.25). A statistical process control chart demonstrated immediate and sustained improvement in CTPE yield post-implementation. Interrupted time series analysis demonstrated the slope of PE findings versus time to be unchanged before and after the intervention (p=0.9). However, there was a trend that the intervention was associated with a 50% increased probability of PE finding (p=0.08), suggesting an immediate rather than gradual change after the intervention. Implementing evidence-based CDS in the ED was associated with an immediate, significant and sustained increase in CTPE yield without a measurable decrease in CTPE utilization. Further studies will be needed to assess whether stronger interventions could further improve appropriate use of CTPE.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "0bf17a3982cf449e9c3c7f52a98650c2", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[24, 25]], "char_spans": [[149, 166]]}]}], "context_tokens": [["Determine", 0], ["effects", 10], ["of", 18], ["evidence", 21], ["-", 29], ["based", 30], ["clinical", 36], ["decision", 45], ["support", 54], ["(", 62], ["CDS", 63], [")", 66], ["on", 68], ["the", 71], ["use", 75], ["and", 79], ["yield", 83], ["of", 89], ["computed", 92], ["tomographic", 101], ["pulmonary", 113], ["angiography", 123], ["for", 135], ["suspected", 139], ["pulmonary", 149], ["embolism", 159], ["(", 168], ["CTPE", 169], [")", 173], ["in", 175], ["Emergency", 178], ["Department", 188], ["(", 199], ["ED", 200], [")", 202], ["patients", 204], [".", 212], ["This", 214], ["multi", 219], ["-", 224], ["site", 225], ["prospective", 230], ["quality", 242], ["improvement", 250], ["intervention", 262], ["conducted", 275], ["in", 285], ["three", 288], ["urban", 294], ["EDs", 300], ["used", 304], ["a", 309], ["pre", 311], ["/", 314], ["post", 315], ["design", 320], [".", 326], ["For", 328], ["ED", 332], ["patients", 335], ["aged", 344], ["18+years", 349], ["with", 358], ["suspected", 363], ["PE", 373], [",", 375], ["CTPE", 377], ["use", 382], ["and", 386], ["yield", 390], ["were", 396], ["compared", 401], ["19months", 410], ["pre-", 419], ["and", 424], ["32months", 428], ["post", 437], ["-", 441], ["implementation", 442], ["of", 457], ["CDS", 460], ["intervention", 464], ["based", 477], ["on", 483], ["the", 486], ["Wells", 490], ["criteria", 496], [",", 504], ["provided", 506], ["at", 515], ["the", 518], ["time", 522], ["of", 527], ["CTPE", 530], ["order", 535], [",", 540], ["deployed", 542], ["in", 551], ["April", 554], ["2012", 560], [".", 564], ["Primary", 566], ["outcome", 574], ["was", 582], ["the", 586], ["yield", 590], ["(", 596], ["percentage", 597], ["of", 608], ["studies", 611], ["positive", 619], ["for", 628], ["acute", 632], ["PE", 638], [")", 640], [".", 641], ["Secondary", 643], ["outcome", 653], ["was", 661], ["utilization", 665], ["(", 677], ["number", 678], ["of", 685], ["studies/100", 688], ["ED", 700], ["visits", 703], [")", 709], ["of", 711], ["CTPE", 714], [".", 718], ["Chi", 720], ["-", 723], ["square", 724], ["and", 731], ["statistical", 735], ["process", 747], ["control", 755], ["chart", 763], ["assessed", 769], ["pre-", 778], ["and", 783], ["post", 787], ["-", 791], ["intervention", 792], ["differences", 805], [".", 816], ["An", 818], ["interrupted", 821], ["time", 833], ["series", 838], ["analysis", 845], ["was", 854], ["also", 858], ["performed", 863], [".", 872], ["Of", 874], ["558,795", 877], ["patients", 885], ["presenting", 894], ["October", 905], ["2010-December", 913], ["2014", 927], [",", 931], ["7987", 933], ["(", 938], ["1.4", 939], ["%", 942], [")", 943], ["underwent", 945], ["CTPE", 955], ["(", 960], ["mean", 961], ["age", 966], ["52\u00b117.5years", 970], [",", 982], ["66", 984], ["%", 986], ["female", 988], [",", 994], ["60.1", 996], ["%", 1000], ["black", 1002], [")", 1007], [";", 1008], ["34.7", 1010], ["%", 1014], ["of", 1016], ["patients", 1019], ["presented", 1028], ["pre-", 1038], ["and", 1043], ["65.3", 1047], ["%", 1051], ["post", 1053], ["-", 1057], ["CDS", 1058], ["implementation", 1062], [".", 1076], ["Overall", 1078], ["CTPE", 1086], ["diagnostic", 1091], ["yield", 1102], ["was", 1108], ["9.8", 1112], ["%", 1115], ["(", 1117], ["779/7987", 1118], ["studies", 1127], ["positive", 1135], ["for", 1144], ["PE", 1148], [")", 1150], [".", 1151], ["Yield", 1153], ["increased", 1159], ["a", 1169], ["relative", 1171], ["30.8", 1180], ["%", 1184], ["after", 1186], ["CDS", 1192], ["implementation", 1196], ["(", 1211], ["8.1", 1212], ["%", 1215], ["vs.", 1217], ["10.6", 1221], ["%", 1225], [";", 1226], ["p=0.0003", 1228], [")", 1236], [".", 1237], ["There", 1239], ["was", 1245], ["no", 1249], ["statistically", 1252], ["significant", 1266], ["change", 1278], ["in", 1285], ["CTPE", 1288], ["utilization", 1293], ["(", 1305], ["1.4", 1306], ["%", 1309], ["pre-", 1311], ["vs.", 1316], ["1.4", 1320], ["%", 1323], ["post", 1325], ["-", 1329], ["implementation", 1330], [";", 1344], ["p=0.25", 1346], [")", 1352], [".", 1353], ["A", 1355], ["statistical", 1357], ["process", 1369], ["control", 1377], ["chart", 1385], ["demonstrated", 1391], ["immediate", 1404], ["and", 1414], ["sustained", 1418], ["improvement", 1428], ["in", 1440], ["CTPE", 1443], ["yield", 1448], ["post", 1454], ["-", 1458], ["implementation", 1459], [".", 1473], ["Interrupted", 1475], ["time", 1487], ["series", 1492], ["analysis", 1499], ["demonstrated", 1508], ["the", 1521], ["slope", 1525], ["of", 1531], ["PE", 1534], ["findings", 1537], ["versus", 1546], ["time", 1553], ["to", 1558], ["be", 1561], ["unchanged", 1564], ["before", 1574], ["and", 1581], ["after", 1585], ["the", 1591], ["intervention", 1595], ["(", 1608], ["p=0.9", 1609], [")", 1614], [".", 1615], ["However", 1617], [",", 1624], ["there", 1626], ["was", 1632], ["a", 1636], ["trend", 1638], ["that", 1644], ["the", 1649], ["intervention", 1653], ["was", 1666], ["associated", 1670], ["with", 1681], ["a", 1686], ["50", 1688], ["%", 1690], ["increased", 1692], ["probability", 1702], ["of", 1714], ["PE", 1717], ["finding", 1720], ["(", 1728], ["p=0.08", 1729], [")", 1735], [",", 1736], ["suggesting", 1738], ["an", 1749], ["immediate", 1752], ["rather", 1762], ["than", 1769], ["gradual", 1774], ["change", 1782], ["after", 1789], ["the", 1795], ["intervention", 1799], [".", 1811], ["Implementing", 1813], ["evidence", 1826], ["-", 1834], ["based", 1835], ["CDS", 1841], ["in", 1845], ["the", 1848], ["ED", 1852], ["was", 1855], ["associated", 1859], ["with", 1870], ["an", 1875], ["immediate", 1878], [",", 1887], ["significant", 1889], ["and", 1901], ["sustained", 1905], ["increase", 1915], ["in", 1924], ["CTPE", 1927], ["yield", 1932], ["without", 1938], ["a", 1946], ["measurable", 1948], ["decrease", 1959], ["in", 1968], ["CTPE", 1971], ["utilization", 1976], [".", 1987], ["Further", 1989], ["studies", 1997], ["will", 2005], ["be", 2010], ["needed", 2013], ["to", 2020], ["assess", 2023], ["whether", 2030], ["stronger", 2038], ["interventions", 2047], ["could", 2061], ["further", 2067], ["improve", 2075], ["appropriate", 2083], ["use", 2095], ["of", 2099], ["CTPE", 2102], [".", 2106]]}
{"context": "We show that overexpression of Polo-like kinase 4 (Plk4) in human cells induces centrosome amplification through the simultaneous generation of multiple procentrioles adjoining each parental centriole. This provided an opportunity for dissecting centriole assembly and characterizing assembly intermediates. Critical components were identified and ordered into an assembly pathway through siRNA and localized through immunoelectron microscopy. Plk4, hSas-6, CPAP, Cep135, gamma-tubulin, and CP110 were required at different stages of procentriole formation and in association with different centriolar structures. Remarkably, hSas-6 associated only transiently with nascent procentrioles, whereas Cep135 and CPAP formed a core structure within the proximal lumen of both parental and nascent centrioles. Finally, CP110 was recruited early and then associated with the growing distal tips, indicating that centrioles elongate through insertion of alpha-/beta-tubulin underneath a CP110 cap. Collectively, these data afford a comprehensive view of the assembly pathway underlying centriole biogenesis in human cells.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "6e490d79b45145a1a5f718e029813107", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[17, 17]], "char_spans": [[80, 89]]}]}], "context_tokens": [["We", 0], ["show", 3], ["that", 8], ["overexpression", 13], ["of", 28], ["Polo", 31], ["-", 35], ["like", 36], ["kinase", 41], ["4", 48], ["(", 50], ["Plk4", 51], [")", 55], ["in", 57], ["human", 60], ["cells", 66], ["induces", 72], ["centrosome", 80], ["amplification", 91], ["through", 105], ["the", 113], ["simultaneous", 117], ["generation", 130], ["of", 141], ["multiple", 144], ["procentrioles", 153], ["adjoining", 167], ["each", 177], ["parental", 182], ["centriole", 191], [".", 200], ["This", 202], ["provided", 207], ["an", 216], ["opportunity", 219], ["for", 231], ["dissecting", 235], ["centriole", 246], ["assembly", 256], ["and", 265], ["characterizing", 269], ["assembly", 284], ["intermediates", 293], [".", 306], ["Critical", 308], ["components", 317], ["were", 328], ["identified", 333], ["and", 344], ["ordered", 348], ["into", 356], ["an", 361], ["assembly", 364], ["pathway", 373], ["through", 381], ["siRNA", 389], ["and", 395], ["localized", 399], ["through", 409], ["immunoelectron", 417], ["microscopy", 432], [".", 442], ["Plk4", 444], [",", 448], ["hSas-6", 450], [",", 456], ["CPAP", 458], [",", 462], ["Cep135", 464], [",", 470], ["gamma", 472], ["-", 477], ["tubulin", 478], [",", 485], ["and", 487], ["CP110", 491], ["were", 497], ["required", 502], ["at", 511], ["different", 514], ["stages", 524], ["of", 531], ["procentriole", 534], ["formation", 547], ["and", 557], ["in", 561], ["association", 564], ["with", 576], ["different", 581], ["centriolar", 591], ["structures", 602], [".", 612], ["Remarkably", 614], [",", 624], ["hSas-6", 626], ["associated", 633], ["only", 644], ["transiently", 649], ["with", 661], ["nascent", 666], ["procentrioles", 674], [",", 687], ["whereas", 689], ["Cep135", 697], ["and", 704], ["CPAP", 708], ["formed", 713], ["a", 720], ["core", 722], ["structure", 727], ["within", 737], ["the", 744], ["proximal", 748], ["lumen", 757], ["of", 763], ["both", 766], ["parental", 771], ["and", 780], ["nascent", 784], ["centrioles", 792], [".", 802], ["Finally", 804], [",", 811], ["CP110", 813], ["was", 819], ["recruited", 823], ["early", 833], ["and", 839], ["then", 843], ["associated", 848], ["with", 859], ["the", 864], ["growing", 868], ["distal", 876], ["tips", 883], [",", 887], ["indicating", 889], ["that", 900], ["centrioles", 905], ["elongate", 916], ["through", 925], ["insertion", 933], ["of", 943], ["alpha-/beta", 946], ["-", 957], ["tubulin", 958], ["underneath", 966], ["a", 977], ["CP110", 979], ["cap", 985], [".", 988], ["Collectively", 990], [",", 1002], ["these", 1004], ["data", 1010], ["afford", 1015], ["a", 1022], ["comprehensive", 1024], ["view", 1038], ["of", 1043], ["the", 1046], ["assembly", 1050], ["pathway", 1059], ["underlying", 1067], ["centriole", 1078], ["biogenesis", 1088], ["in", 1099], ["human", 1102], ["cells", 1108], [".", 1113]]}
{"context": "Extrapolating the figures from a previous study on FSHD in a province of The Netherlands to the entire Dutch population suggests that at present a nearly complete overview is obtained of all symptomatic kindred. In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. A mutation frequency of 9.6% was calculated. Mental retardation and severe retinal vasculopathy were reported in low frequencies (1%). Early onset was seen more frequently in sporadic cases. Chromosome 4 linkage appeared excluded in 3 of 22 autosomal-dominant families. The clinical pictures in the linked and nonlinked families were identical.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "9c3b896a35634a75b5d535c858119572", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[108, 110]], "char_spans": [[610, 627]]}]}], "context_tokens": [["Extrapolating", 0], ["the", 14], ["figures", 18], ["from", 26], ["a", 31], ["previous", 33], ["study", 42], ["on", 48], ["FSHD", 51], ["in", 56], ["a", 59], ["province", 61], ["of", 70], ["The", 73], ["Netherlands", 77], ["to", 89], ["the", 92], ["entire", 96], ["Dutch", 103], ["population", 109], ["suggests", 120], ["that", 129], ["at", 134], ["present", 137], ["a", 145], ["nearly", 147], ["complete", 154], ["overview", 163], ["is", 172], ["obtained", 175], ["of", 184], ["all", 187], ["symptomatic", 191], ["kindred", 203], [".", 210], ["In", 212], ["139", 215], ["families", 219], [",", 227], ["dominant", 229], ["inheritance", 238], ["was", 250], ["observed", 254], ["in", 263], ["97", 266], [",", 268], ["a", 270], ["pattern", 272], ["compatible", 280], ["with", 291], ["germline", 296], ["mosaicism", 305], ["in", 315], ["6", 318], [",", 319], ["while", 321], ["sporadic", 327], ["cases", 336], ["were", 342], ["found", 347], ["in", 353], ["36", 356], ["families", 359], [".", 367], ["A", 369], ["mutation", 371], ["frequency", 380], ["of", 390], ["9.6", 393], ["%", 396], ["was", 398], ["calculated", 402], [".", 412], ["Mental", 414], ["retardation", 421], ["and", 433], ["severe", 437], ["retinal", 444], ["vasculopathy", 452], ["were", 465], ["reported", 470], ["in", 479], ["low", 482], ["frequencies", 486], ["(", 498], ["1", 499], ["%", 500], [")", 501], [".", 502], ["Early", 504], ["onset", 510], ["was", 516], ["seen", 520], ["more", 525], ["frequently", 530], ["in", 541], ["sporadic", 544], ["cases", 553], [".", 558], ["Chromosome", 560], ["4", 571], ["linkage", 573], ["appeared", 581], ["excluded", 590], ["in", 599], ["3", 602], ["of", 604], ["22", 607], ["autosomal", 610], ["-", 619], ["dominant", 620], ["families", 629], [".", 637], ["The", 639], ["clinical", 643], ["pictures", 652], ["in", 661], ["the", 664], ["linked", 668], ["and", 675], ["nonlinked", 679], ["families", 689], ["were", 698], ["identical", 703], [".", 712]]}
{"context": "Drosophila melanogaster has a single Adar gene encoding a protein related to mammalian ADAR2 that edits transcripts encoding glutamate receptor subunits. We describe the structure of the Drosophila Adar locus and use ModENCODE information to supplement published data on Adar gene transcription, and splicing. We discuss the roles of ADAR in Drosophila in terms of the two main types of RNA molecules edited and roles of ADARs as RNA-binding proteins. Site-specific RNA editing events in transcripts encoding ion channel subunits were initially found serendipitously and subsequent directed searches for editing sites and transcriptome sequencing have now led to 972 edited sites being identified in 597 transcripts. Four percent of D. melanogaster transcripts are site-specifically edited and these encode a wide range of largely membrane-associated proteins expressed particularly in CNS. Electrophysiological studies on the effects of specific RNA editing events on ion channel subunits do not suggest that loss of RNA editing events in ion channels consistently produce a particular outcome such as making Adar mutant neurons more excitable. This possibility would have been consistent with neurodegeneration seen in Adar mutant fly brains. A further set of ADAR targets are dsRNA intermediates in siRNA generation, derived from transposons and from structured RNA loci. Transcripts with convergent overlapping 3' ends are also edited and the first discovered instance of RNA editing in Drosophila, in the Rnp4F transcript, is an example. There is no evidence yet to show that Adar antagonizes RNA interference in Drosophila. Evidence has been obtained that catalytically inactive ADAR proteins exert effects on microRNA generation and RNA interference. Whether all effects of inactive ADARs are due to RNA-binding or to even further roles of these proteins remains to be determined.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "9bb16ae9ce384988b2c0a173f93c5be4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[272, 272], [29, 29], [5, 5], [202, 202], [52, 52], [40, 40], [258, 258], [193, 193], [177, 177]], "char_spans": [[1685, 1688], [198, 201], [37, 40], [1262, 1265], [334, 337], [271, 274], [1581, 1584], [1221, 1224], [1110, 1113]]}]}], "context_tokens": [["Drosophila", 0], ["melanogaster", 11], ["has", 24], ["a", 28], ["single", 30], ["Adar", 37], ["gene", 42], ["encoding", 47], ["a", 56], ["protein", 58], ["related", 66], ["to", 74], ["mammalian", 77], ["ADAR2", 87], ["that", 93], ["edits", 98], ["transcripts", 104], ["encoding", 116], ["glutamate", 125], ["receptor", 135], ["subunits", 144], [".", 152], ["We", 154], ["describe", 157], ["the", 166], ["structure", 170], ["of", 180], ["the", 183], ["Drosophila", 187], ["Adar", 198], ["locus", 203], ["and", 209], ["use", 213], ["ModENCODE", 217], ["information", 227], ["to", 239], ["supplement", 242], ["published", 253], ["data", 263], ["on", 268], ["Adar", 271], ["gene", 276], ["transcription", 281], [",", 294], ["and", 296], ["splicing", 300], [".", 308], ["We", 310], ["discuss", 313], ["the", 321], ["roles", 325], ["of", 331], ["ADAR", 334], ["in", 339], ["Drosophila", 342], ["in", 353], ["terms", 356], ["of", 362], ["the", 365], ["two", 369], ["main", 373], ["types", 378], ["of", 384], ["RNA", 387], ["molecules", 391], ["edited", 401], ["and", 408], ["roles", 412], ["of", 418], ["ADARs", 421], ["as", 427], ["RNA", 430], ["-", 433], ["binding", 434], ["proteins", 442], [".", 450], ["Site", 452], ["-", 456], ["specific", 457], ["RNA", 466], ["editing", 470], ["events", 478], ["in", 485], ["transcripts", 488], ["encoding", 500], ["ion", 509], ["channel", 513], ["subunits", 521], ["were", 530], ["initially", 535], ["found", 545], ["serendipitously", 551], ["and", 567], ["subsequent", 571], ["directed", 582], ["searches", 591], ["for", 600], ["editing", 604], ["sites", 612], ["and", 618], ["transcriptome", 622], ["sequencing", 636], ["have", 647], ["now", 652], ["led", 656], ["to", 660], ["972", 663], ["edited", 667], ["sites", 674], ["being", 680], ["identified", 686], ["in", 697], ["597", 700], ["transcripts", 704], [".", 715], ["Four", 717], ["percent", 722], ["of", 730], ["D.", 733], ["melanogaster", 736], ["transcripts", 749], ["are", 761], ["site", 765], ["-", 769], ["specifically", 770], ["edited", 783], ["and", 790], ["these", 794], ["encode", 800], ["a", 807], ["wide", 809], ["range", 814], ["of", 820], ["largely", 823], ["membrane", 831], ["-", 839], ["associated", 840], ["proteins", 851], ["expressed", 860], ["particularly", 870], ["in", 883], ["CNS", 886], [".", 889], ["Electrophysiological", 891], ["studies", 912], ["on", 920], ["the", 923], ["effects", 927], ["of", 935], ["specific", 938], ["RNA", 947], ["editing", 951], ["events", 959], ["on", 966], ["ion", 969], ["channel", 973], ["subunits", 981], ["do", 990], ["not", 993], ["suggest", 997], ["that", 1005], ["loss", 1010], ["of", 1015], ["RNA", 1018], ["editing", 1022], ["events", 1030], ["in", 1037], ["ion", 1040], ["channels", 1044], ["consistently", 1053], ["produce", 1066], ["a", 1074], ["particular", 1076], ["outcome", 1087], ["such", 1095], ["as", 1100], ["making", 1103], ["Adar", 1110], ["mutant", 1115], ["neurons", 1122], ["more", 1130], ["excitable", 1135], [".", 1144], ["This", 1146], ["possibility", 1151], ["would", 1163], ["have", 1169], ["been", 1174], ["consistent", 1179], ["with", 1190], ["neurodegeneration", 1195], ["seen", 1213], ["in", 1218], ["Adar", 1221], ["mutant", 1226], ["fly", 1233], ["brains", 1237], [".", 1243], ["A", 1245], ["further", 1247], ["set", 1255], ["of", 1259], ["ADAR", 1262], ["targets", 1267], ["are", 1275], ["dsRNA", 1279], ["intermediates", 1285], ["in", 1299], ["siRNA", 1302], ["generation", 1308], [",", 1318], ["derived", 1320], ["from", 1328], ["transposons", 1333], ["and", 1345], ["from", 1349], ["structured", 1354], ["RNA", 1365], ["loci", 1369], [".", 1373], ["Transcripts", 1375], ["with", 1387], ["convergent", 1392], ["overlapping", 1403], ["3", 1415], ["'", 1416], ["ends", 1418], ["are", 1423], ["also", 1427], ["edited", 1432], ["and", 1439], ["the", 1443], ["first", 1447], ["discovered", 1453], ["instance", 1464], ["of", 1473], ["RNA", 1476], ["editing", 1480], ["in", 1488], ["Drosophila", 1491], [",", 1501], ["in", 1503], ["the", 1506], ["Rnp4F", 1510], ["transcript", 1516], [",", 1526], ["is", 1528], ["an", 1531], ["example", 1534], [".", 1541], ["There", 1543], ["is", 1549], ["no", 1552], ["evidence", 1555], ["yet", 1564], ["to", 1568], ["show", 1571], ["that", 1576], ["Adar", 1581], ["antagonizes", 1586], ["RNA", 1598], ["interference", 1602], ["in", 1615], ["Drosophila", 1618], [".", 1628], ["Evidence", 1630], ["has", 1639], ["been", 1643], ["obtained", 1648], ["that", 1657], ["catalytically", 1662], ["inactive", 1676], ["ADAR", 1685], ["proteins", 1690], ["exert", 1699], ["effects", 1705], ["on", 1713], ["microRNA", 1716], ["generation", 1725], ["and", 1736], ["RNA", 1740], ["interference", 1744], [".", 1756], ["Whether", 1758], ["all", 1766], ["effects", 1770], ["of", 1778], ["inactive", 1781], ["ADARs", 1790], ["are", 1796], ["due", 1800], ["to", 1804], ["RNA", 1807], ["-", 1810], ["binding", 1811], ["or", 1819], ["to", 1822], ["even", 1825], ["further", 1830], ["roles", 1838], ["of", 1844], ["these", 1847], ["proteins", 1853], ["remains", 1862], ["to", 1870], ["be", 1873], ["determined", 1876], [".", 1886]]}
{"context": "Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "785d411170fb461891f9aaf5794d8c28", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[6, 6]], "char_spans": [[31, 39]]}]}], "context_tokens": [["Duavee", 0], [",", 6], ["an", 8], ["oral", 11], ["contraceptive", 16], [";", 29], ["riociguat", 31], ["(", 41], ["Adempas", 42], [")", 49], ["for", 51], ["two", 55], ["types", 59], ["of", 65], ["pulmonary", 68], ["hypertension", 78], [";", 90], ["and", 92], ["macitentan", 96], ["(", 107], ["Opsumit", 108], [")", 115], ["for", 117], ["pulmonary", 121], ["arterial", 131], ["hypertension", 140], [".", 152]]}
{"context": "McLeod syndrome is a rare X-linked neuroacanthocytosis syndrome with hematologic, muscular, and neurologic manifestations. McLeod syndrome is caused by mutations in the XK gene whose product is expressed at the red blood cell (RBC) surface but whose function is currently unknown. A variety of XK mutations has been reported but no clear phenotype-genotype correlation has been found, especially for the point mutations affecting splicing sites. A man suspected of neuroacanthocytosis was evaluated by neurologic examination, electromyography, muscle biopsy, muscle computed tomography, and cerebral magnetic resonance imaging. The McLeod RBC phenotype was disclosed by blood smear and immunohematology analyses and then confirmed at the biochemical level by Western blot analysis. The responsible XK mutation was characterized at the mRNA level by reverse transcription-polymerase chain reaction (PCR), identified by genomic DNA sequencing, and verified by allele-specific PCR. A novel XK splice site mutation (IVS1-1G>A) has been identified in a McLeod patient who has developed hematologic, neuromuscular, and neurologic symptoms. This is the first reported example of a XK point mutation affecting the 3' acceptor splice site of Intron 1, and it was demonstrated that this mutation indeed induces aberrant splicing of XK RNA and lack of XK protein at the RBC membrane. The detailed characterization at the molecular biology level of this novel XK splice site mutation associated with the clinical description of the patient contributes to a better understanding of the phenotype-genotype correlation in the McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "301ef4187543422199ccbb4addc1483d", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[27, 27], [227, 227], [250, 250], [164, 164], [52, 52], [201, 201], [232, 232], [129, 129]], "char_spans": [[169, 170], [1322, 1323], [1448, 1449], [987, 988], [294, 295], [1174, 1175], [1341, 1342], [798, 799]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["rare", 21], ["X", 26], ["-", 27], ["linked", 28], ["neuroacanthocytosis", 35], ["syndrome", 55], ["with", 64], ["hematologic", 69], [",", 80], ["muscular", 82], [",", 90], ["and", 92], ["neurologic", 96], ["manifestations", 107], [".", 121], ["McLeod", 123], ["syndrome", 130], ["is", 139], ["caused", 142], ["by", 149], ["mutations", 152], ["in", 162], ["the", 165], ["XK", 169], ["gene", 172], ["whose", 177], ["product", 183], ["is", 191], ["expressed", 194], ["at", 204], ["the", 207], ["red", 211], ["blood", 215], ["cell", 221], ["(", 226], ["RBC", 227], [")", 230], ["surface", 232], ["but", 240], ["whose", 244], ["function", 250], ["is", 259], ["currently", 262], ["unknown", 272], [".", 279], ["A", 281], ["variety", 283], ["of", 291], ["XK", 294], ["mutations", 297], ["has", 307], ["been", 311], ["reported", 316], ["but", 325], ["no", 329], ["clear", 332], ["phenotype", 338], ["-", 347], ["genotype", 348], ["correlation", 357], ["has", 369], ["been", 373], ["found", 378], [",", 383], ["especially", 385], ["for", 396], ["the", 400], ["point", 404], ["mutations", 410], ["affecting", 420], ["splicing", 430], ["sites", 439], [".", 444], ["A", 446], ["man", 448], ["suspected", 452], ["of", 462], ["neuroacanthocytosis", 465], ["was", 485], ["evaluated", 489], ["by", 499], ["neurologic", 502], ["examination", 513], [",", 524], ["electromyography", 526], [",", 542], ["muscle", 544], ["biopsy", 551], [",", 557], ["muscle", 559], ["computed", 566], ["tomography", 575], [",", 585], ["and", 587], ["cerebral", 591], ["magnetic", 600], ["resonance", 609], ["imaging", 619], [".", 626], ["The", 628], ["McLeod", 632], ["RBC", 639], ["phenotype", 643], ["was", 653], ["disclosed", 657], ["by", 667], ["blood", 670], ["smear", 676], ["and", 682], ["immunohematology", 686], ["analyses", 703], ["and", 712], ["then", 716], ["confirmed", 721], ["at", 731], ["the", 734], ["biochemical", 738], ["level", 750], ["by", 756], ["Western", 759], ["blot", 767], ["analysis", 772], [".", 780], ["The", 782], ["responsible", 786], ["XK", 798], ["mutation", 801], ["was", 810], ["characterized", 814], ["at", 828], ["the", 831], ["mRNA", 835], ["level", 840], ["by", 846], ["reverse", 849], ["transcription", 857], ["-", 870], ["polymerase", 871], ["chain", 882], ["reaction", 888], ["(", 897], ["PCR", 898], [")", 901], [",", 902], ["identified", 904], ["by", 915], ["genomic", 918], ["DNA", 926], ["sequencing", 930], [",", 940], ["and", 942], ["verified", 946], ["by", 955], ["allele", 958], ["-", 964], ["specific", 965], ["PCR", 974], [".", 977], ["A", 979], ["novel", 981], ["XK", 987], ["splice", 990], ["site", 997], ["mutation", 1002], ["(", 1011], ["IVS1", 1012], ["-", 1016], ["1G", 1017], [">", 1019], ["A", 1020], [")", 1021], ["has", 1023], ["been", 1027], ["identified", 1032], ["in", 1043], ["a", 1046], ["McLeod", 1048], ["patient", 1055], ["who", 1063], ["has", 1067], ["developed", 1071], ["hematologic", 1081], [",", 1092], ["neuromuscular", 1094], [",", 1107], ["and", 1109], ["neurologic", 1113], ["symptoms", 1124], [".", 1132], ["This", 1134], ["is", 1139], ["the", 1142], ["first", 1146], ["reported", 1152], ["example", 1161], ["of", 1169], ["a", 1172], ["XK", 1174], ["point", 1177], ["mutation", 1183], ["affecting", 1192], ["the", 1202], ["3", 1206], ["'", 1207], ["acceptor", 1209], ["splice", 1218], ["site", 1225], ["of", 1230], ["Intron", 1233], ["1", 1240], [",", 1241], ["and", 1243], ["it", 1247], ["was", 1250], ["demonstrated", 1254], ["that", 1267], ["this", 1272], ["mutation", 1277], ["indeed", 1286], ["induces", 1293], ["aberrant", 1301], ["splicing", 1310], ["of", 1319], ["XK", 1322], ["RNA", 1325], ["and", 1329], ["lack", 1333], ["of", 1338], ["XK", 1341], ["protein", 1344], ["at", 1352], ["the", 1355], ["RBC", 1359], ["membrane", 1363], [".", 1371], ["The", 1373], ["detailed", 1377], ["characterization", 1386], ["at", 1403], ["the", 1406], ["molecular", 1410], ["biology", 1420], ["level", 1428], ["of", 1434], ["this", 1437], ["novel", 1442], ["XK", 1448], ["splice", 1451], ["site", 1458], ["mutation", 1463], ["associated", 1472], ["with", 1483], ["the", 1488], ["clinical", 1492], ["description", 1501], ["of", 1513], ["the", 1516], ["patient", 1520], ["contributes", 1528], ["to", 1540], ["a", 1543], ["better", 1545], ["understanding", 1552], ["of", 1566], ["the", 1569], ["phenotype", 1573], ["-", 1582], ["genotype", 1583], ["correlation", 1592], ["in", 1604], ["the", 1607], ["McLeod", 1611], ["syndrome", 1618], [".", 1626]]}
{"context": "The phagocyte NADPH oxidase is dormant in resting cells but becomes activated during phagocytosis to produce superoxide, a precursor of microbicidal oxidants, thereby playing a crucial role in host defence. The catalytic core of this enzyme comprises the two membranous subunits gp91phox/Nox2 and p22phox. The oxidase activation requires the small GTPase Rac and the SH3 domain-containing proteins p47phox and p67phox; they normally exist in the cytoplasm and translocate upon cell stimulation to the membrane. The translocation depends on a stimulus-induced conformational change of p47phox, which leads to the SH3 domain-mediated interaction with p22phox, a binding required for the gp91phox/Nox2-dependent superoxide production. Activation of Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Noxa1, respectively. Noxo1 and Noxa1, both expressed abundantly in the colon, are capable of constitutively activating Nox1. The constitutive activation may be due to the property of Noxo1: in contrast with p47phox, Noxo1 seems to normally associate with p22phox, which is required for the Nox1 activation. We will also describe the mechanism underlying regulation of the third oxidase Nox3, which exits in fetal kidney and inner ears.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "305e48f06a854133811be7ee3e983da5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[201, 201], [169, 169], [122, 122]], "char_spans": [[1187, 1190], [1016, 1019], [746, 749]]}]}], "context_tokens": [["The", 0], ["phagocyte", 4], ["NADPH", 14], ["oxidase", 20], ["is", 28], ["dormant", 31], ["in", 39], ["resting", 42], ["cells", 50], ["but", 56], ["becomes", 60], ["activated", 68], ["during", 78], ["phagocytosis", 85], ["to", 98], ["produce", 101], ["superoxide", 109], [",", 119], ["a", 121], ["precursor", 123], ["of", 133], ["microbicidal", 136], ["oxidants", 149], [",", 157], ["thereby", 159], ["playing", 167], ["a", 175], ["crucial", 177], ["role", 185], ["in", 190], ["host", 193], ["defence", 198], [".", 205], ["The", 207], ["catalytic", 211], ["core", 221], ["of", 226], ["this", 229], ["enzyme", 234], ["comprises", 241], ["the", 251], ["two", 255], ["membranous", 259], ["subunits", 270], ["gp91phox", 279], ["/", 287], ["Nox2", 288], ["and", 293], ["p22phox", 297], [".", 304], ["The", 306], ["oxidase", 310], ["activation", 318], ["requires", 329], ["the", 338], ["small", 342], ["GTPase", 348], ["Rac", 355], ["and", 359], ["the", 363], ["SH3", 367], ["domain", 371], ["-", 377], ["containing", 378], ["proteins", 389], ["p47phox", 398], ["and", 406], ["p67phox", 410], [";", 417], ["they", 419], ["normally", 424], ["exist", 433], ["in", 439], ["the", 442], ["cytoplasm", 446], ["and", 456], ["translocate", 460], ["upon", 472], ["cell", 477], ["stimulation", 482], ["to", 494], ["the", 497], ["membrane", 501], [".", 509], ["The", 511], ["translocation", 515], ["depends", 529], ["on", 537], ["a", 540], ["stimulus", 542], ["-", 550], ["induced", 551], ["conformational", 559], ["change", 574], ["of", 581], ["p47phox", 584], [",", 591], ["which", 593], ["leads", 599], ["to", 605], ["the", 608], ["SH3", 612], ["domain", 616], ["-", 622], ["mediated", 623], ["interaction", 632], ["with", 644], ["p22phox", 649], [",", 656], ["a", 658], ["binding", 660], ["required", 668], ["for", 677], ["the", 681], ["gp91phox", 685], ["/", 693], ["Nox2-dependent", 694], ["superoxide", 709], ["production", 720], [".", 730], ["Activation", 732], ["of", 743], ["Nox1", 746], [",", 750], ["an", 752], ["oxidase", 755], ["that", 763], ["is", 768], ["likely", 771], ["involved", 778], ["in", 787], ["host", 790], ["defence", 795], ["at", 803], ["the", 806], ["colon", 810], [",", 815], ["requires", 817], ["novel", 826], ["proteins", 832], ["homologous", 841], ["to", 852], ["p47phox", 855], ["and", 863], ["p67phox", 867], [",", 874], ["designated", 876], ["Noxo1", 887], ["and", 893], ["Noxa1", 897], [",", 902], ["respectively", 904], [".", 916], ["Noxo1", 918], ["and", 924], ["Noxa1", 928], [",", 933], ["both", 935], ["expressed", 940], ["abundantly", 950], ["in", 961], ["the", 964], ["colon", 968], [",", 973], ["are", 975], ["capable", 979], ["of", 987], ["constitutively", 990], ["activating", 1005], ["Nox1", 1016], [".", 1020], ["The", 1022], ["constitutive", 1026], ["activation", 1039], ["may", 1050], ["be", 1054], ["due", 1057], ["to", 1061], ["the", 1064], ["property", 1068], ["of", 1077], ["Noxo1", 1080], [":", 1085], ["in", 1087], ["contrast", 1090], ["with", 1099], ["p47phox", 1104], [",", 1111], ["Noxo1", 1113], ["seems", 1119], ["to", 1125], ["normally", 1128], ["associate", 1137], ["with", 1147], ["p22phox", 1152], [",", 1159], ["which", 1161], ["is", 1167], ["required", 1170], ["for", 1179], ["the", 1183], ["Nox1", 1187], ["activation", 1192], [".", 1202], ["We", 1204], ["will", 1207], ["also", 1212], ["describe", 1217], ["the", 1226], ["mechanism", 1230], ["underlying", 1240], ["regulation", 1251], ["of", 1262], ["the", 1265], ["third", 1269], ["oxidase", 1275], ["Nox3", 1283], [",", 1287], ["which", 1289], ["exits", 1295], ["in", 1301], ["fetal", 1304], ["kidney", 1310], ["and", 1317], ["inner", 1321], ["ears", 1327], [".", 1331]]}
{"context": "A common challenge in pathogen discovery by deep sequencing approaches is to recognize viral or subviral pathogens in samples of diseased tissue that share no significant homology with a known pathogen. Here we report a homology-independent approach for discovering viroids, a distinct class of free circular RNA subviral pathogens that encode no protein and are known to infect plants only. Our approach involves analyzing the sequences of the total small RNAs of the infected plants obtained by deep sequencing with a unique computational algorithm, progressive filtering of overlapping small RNAs (PFOR). Viroid infection triggers production of viroid-derived overlapping siRNAs that cover the entire genome with high densities. PFOR retains viroid-specific siRNAs for genome assembly by progressively eliminating nonoverlapping small RNAs and those that overlap but cannot be assembled into a direct repeat RNA, which is synthesized from circular or multimeric repeated-sequence templates during viroid replication. We show that viroids from the two known families are readily identified and their full-length sequences assembled by PFOR from small RNAs sequenced from infected plants. PFOR analysis of a grapevine library further identified a viroid-like circular RNA 375 nt long that shared no significant sequence homology with known molecules and encoded active hammerhead ribozymes in RNAs of both plus and minus polarities, which presumably self-cleave to release monomer from multimeric replicative intermediates. A potential application of the homology-independent approach for viroid discovery in plant and animal species where RNA replication triggers the biogenesis of siRNAs is discussed.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "f248d3aef85c4155a94ef1ebba8c6769", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[167, 167], [42, 42]], "char_spans": [[1033, 1039], [266, 272]]}]}], "context_tokens": [["A", 0], ["common", 2], ["challenge", 9], ["in", 19], ["pathogen", 22], ["discovery", 31], ["by", 41], ["deep", 44], ["sequencing", 49], ["approaches", 60], ["is", 71], ["to", 74], ["recognize", 77], ["viral", 87], ["or", 93], ["subviral", 96], ["pathogens", 105], ["in", 115], ["samples", 118], ["of", 126], ["diseased", 129], ["tissue", 138], ["that", 145], ["share", 150], ["no", 156], ["significant", 159], ["homology", 171], ["with", 180], ["a", 185], ["known", 187], ["pathogen", 193], [".", 201], ["Here", 203], ["we", 208], ["report", 211], ["a", 218], ["homology", 220], ["-", 228], ["independent", 229], ["approach", 241], ["for", 250], ["discovering", 254], ["viroids", 266], [",", 273], ["a", 275], ["distinct", 277], ["class", 286], ["of", 292], ["free", 295], ["circular", 300], ["RNA", 309], ["subviral", 313], ["pathogens", 322], ["that", 332], ["encode", 337], ["no", 344], ["protein", 347], ["and", 355], ["are", 359], ["known", 363], ["to", 369], ["infect", 372], ["plants", 379], ["only", 386], [".", 390], ["Our", 392], ["approach", 396], ["involves", 405], ["analyzing", 414], ["the", 424], ["sequences", 428], ["of", 438], ["the", 441], ["total", 445], ["small", 451], ["RNAs", 457], ["of", 462], ["the", 465], ["infected", 469], ["plants", 478], ["obtained", 485], ["by", 494], ["deep", 497], ["sequencing", 502], ["with", 513], ["a", 518], ["unique", 520], ["computational", 527], ["algorithm", 541], [",", 550], ["progressive", 552], ["filtering", 564], ["of", 574], ["overlapping", 577], ["small", 589], ["RNAs", 595], ["(", 600], ["PFOR", 601], [")", 605], [".", 606], ["Viroid", 608], ["infection", 615], ["triggers", 625], ["production", 634], ["of", 645], ["viroid", 648], ["-", 654], ["derived", 655], ["overlapping", 663], ["siRNAs", 675], ["that", 682], ["cover", 687], ["the", 693], ["entire", 697], ["genome", 704], ["with", 711], ["high", 716], ["densities", 721], [".", 730], ["PFOR", 732], ["retains", 737], ["viroid", 745], ["-", 751], ["specific", 752], ["siRNAs", 761], ["for", 768], ["genome", 772], ["assembly", 779], ["by", 788], ["progressively", 791], ["eliminating", 805], ["nonoverlapping", 817], ["small", 832], ["RNAs", 838], ["and", 843], ["those", 847], ["that", 853], ["overlap", 858], ["but", 866], ["can", 870], ["not", 873], ["be", 877], ["assembled", 880], ["into", 890], ["a", 895], ["direct", 897], ["repeat", 904], ["RNA", 911], [",", 914], ["which", 916], ["is", 922], ["synthesized", 925], ["from", 937], ["circular", 942], ["or", 951], ["multimeric", 954], ["repeated", 965], ["-", 973], ["sequence", 974], ["templates", 983], ["during", 993], ["viroid", 1000], ["replication", 1007], [".", 1018], ["We", 1020], ["show", 1023], ["that", 1028], ["viroids", 1033], ["from", 1041], ["the", 1046], ["two", 1050], ["known", 1054], ["families", 1060], ["are", 1069], ["readily", 1073], ["identified", 1081], ["and", 1092], ["their", 1096], ["full", 1102], ["-", 1106], ["length", 1107], ["sequences", 1114], ["assembled", 1124], ["by", 1134], ["PFOR", 1137], ["from", 1142], ["small", 1147], ["RNAs", 1153], ["sequenced", 1158], ["from", 1168], ["infected", 1173], ["plants", 1182], [".", 1188], ["PFOR", 1190], ["analysis", 1195], ["of", 1204], ["a", 1207], ["grapevine", 1209], ["library", 1219], ["further", 1227], ["identified", 1235], ["a", 1246], ["viroid", 1248], ["-", 1254], ["like", 1255], ["circular", 1260], ["RNA", 1269], ["375", 1273], ["nt", 1277], ["long", 1280], ["that", 1285], ["shared", 1290], ["no", 1297], ["significant", 1300], ["sequence", 1312], ["homology", 1321], ["with", 1330], ["known", 1335], ["molecules", 1341], ["and", 1351], ["encoded", 1355], ["active", 1363], ["hammerhead", 1370], ["ribozymes", 1381], ["in", 1391], ["RNAs", 1394], ["of", 1399], ["both", 1402], ["plus", 1407], ["and", 1412], ["minus", 1416], ["polarities", 1422], [",", 1432], ["which", 1434], ["presumably", 1440], ["self", 1451], ["-", 1455], ["cleave", 1456], ["to", 1463], ["release", 1466], ["monomer", 1474], ["from", 1482], ["multimeric", 1487], ["replicative", 1498], ["intermediates", 1510], [".", 1523], ["A", 1525], ["potential", 1527], ["application", 1537], ["of", 1549], ["the", 1552], ["homology", 1556], ["-", 1564], ["independent", 1565], ["approach", 1577], ["for", 1586], ["viroid", 1590], ["discovery", 1597], ["in", 1607], ["plant", 1610], ["and", 1616], ["animal", 1620], ["species", 1627], ["where", 1635], ["RNA", 1641], ["replication", 1645], ["triggers", 1657], ["the", 1666], ["biogenesis", 1670], ["of", 1681], ["siRNAs", 1684], ["is", 1691], ["discussed", 1694], [".", 1703]]}
{"context": "(i) evaluate the performance of MR-pro-ADM in reflecting the outcome and risk for CAP patients in the emergency department, and (ii) compare the prognostic performance of MR-pro-ADM with that of clinical scores PSI and CURB65. Observational prospective, single-center study in patients with suspected community acquired pneumonia (CAP). Eighty one patients underwent full clinical and laboratory assessment as by protocol, and were followed up a 28 days. Primary endpoints measured were: death, death at 14 days, non-invasive mechanical ventilation (NIMV), endotracheal intubation (EI), ICU admission, overall hospital stay >10 days, emergency department stay >4 days. The discriminative performance of MR-pro-ADM and clinical scores was assessed by AUROC analysis. The distribution for MR-pro-ADM followed an upward trend, increasing with the increase of both PSI (p<0.001) and CURB65 (p<0.001) classes. However, the difference between MRproADM values and score classes was significant only in the case of CURB65 classes 0 and 1 (p = 0.046), 2 (p = 0.013), and 3 (p = 0.011); and with PSI classes 5, 3 (p = 0.044), and 1 (p = 0.020). As to the differences among variables for the six end-points, MR-pro-ADM values in the two groups selected for each considered end-point differed in a statistically significant manner for all endpoints. Both PSI and CURB65 differed significantly for all end-points, except for stay in the ED longer than 4 days and the hospital stay longer than 10 days and endotracheal intubation (only PSI classes differed with statistical significance). ROC analyses evidenced that MR-pro-ADM values gave the greatest AUC for the prediction of death, endotracheal intubation, hospital stay >10 days and DE stay >4 days, compared to the PSI and CURB (though difference not statistically significant). For each endpoint measured, the best thresholds values for Mr-pro-ADM were: 1.6 (specificity 76.5%; sensitivity 77.8%) for death; 2.5 (specificity 88.9%; sensitivity 80.0%) for death at 14 days; 1.5 (specificity 77.0%; sensitivity 87.5%) for NIMV; 2.4 (specificity 88.7%; sensitivity 83.3%) for endotracheal intubation; 0.9 (specificity 53.5%; sensitivity 70.6%) for DE stay greater than 4 days; 1.9 (specificity 82.1%; sensitivity 55.3%) for hospital stay greater than 10 days. The AUC for the combination of MR-pro-ADM and PSI was 81.29% [63.41%-99.17%], but not in a statistically significant manner compared to the AUCs of the single predictors. Conversely, the AUC for the combination of MR-pro-ADM and CURB65 was 87.58% [75.54%-99.62%], which was significantly greater than the AUC of CURB65 (p = 0.047) or PSI (p = 0.017) alone. The present study confirms that assessment of MR-pro-ADM levels in CAP patients in addition to CURB scores increases the prognostic accuracy of CURB alone and may help rule out discrepancies arising from flawed clinical severity classification. With particular reference to patients scoring in the upper classes of CURB and PSI, MR-pro-ADM values provided additional information towards a better risk stratification of those patients. In particular, our results pointed towards two MR-pro-ADM threshold values that appear to predict with a good degree of accuracy the patient's need for non-invasive mechanical ventilation, endotracheal intubation, or intensive care. This aspect, however, deserves further investigation.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "4a5e280ba4534d708cd9a706f914288a", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[62, 62]], "char_spans": [[320, 328]]}]}], "context_tokens": [["(", 0], ["i", 1], [")", 2], ["evaluate", 4], ["the", 13], ["performance", 17], ["of", 29], ["MR", 32], ["-", 34], ["pro", 35], ["-", 38], ["ADM", 39], ["in", 43], ["reflecting", 46], ["the", 57], ["outcome", 61], ["and", 69], ["risk", 73], ["for", 78], ["CAP", 82], ["patients", 86], ["in", 95], ["the", 98], ["emergency", 102], ["department", 112], [",", 122], ["and", 124], ["(", 128], ["ii", 129], [")", 131], ["compare", 133], ["the", 141], ["prognostic", 145], ["performance", 156], ["of", 168], ["MR", 171], ["-", 173], ["pro", 174], ["-", 177], ["ADM", 178], ["with", 182], ["that", 187], ["of", 192], ["clinical", 195], ["scores", 204], ["PSI", 211], ["and", 215], ["CURB65", 219], [".", 225], ["Observational", 227], ["prospective", 241], [",", 252], ["single", 254], ["-", 260], ["center", 261], ["study", 268], ["in", 274], ["patients", 277], ["with", 286], ["suspected", 291], ["community", 301], ["acquired", 311], ["pneumonia", 320], ["(", 330], ["CAP", 331], [")", 334], [".", 335], ["Eighty", 337], ["one", 344], ["patients", 348], ["underwent", 357], ["full", 367], ["clinical", 372], ["and", 381], ["laboratory", 385], ["assessment", 396], ["as", 407], ["by", 410], ["protocol", 413], [",", 421], ["and", 423], ["were", 427], ["followed", 432], ["up", 441], ["a", 444], ["28", 446], ["days", 449], [".", 453], ["Primary", 455], ["endpoints", 463], ["measured", 473], ["were", 482], [":", 486], ["death", 488], [",", 493], ["death", 495], ["at", 501], ["14", 504], ["days", 507], [",", 511], ["non", 513], ["-", 516], ["invasive", 517], ["mechanical", 526], ["ventilation", 537], ["(", 549], ["NIMV", 550], [")", 554], [",", 555], ["endotracheal", 557], ["intubation", 570], ["(", 581], ["EI", 582], [")", 584], [",", 585], ["ICU", 587], ["admission", 591], [",", 600], ["overall", 602], ["hospital", 610], ["stay", 619], [">", 624], ["10", 625], ["days", 628], [",", 632], ["emergency", 634], ["department", 644], ["stay", 655], [">", 660], ["4", 661], ["days", 663], [".", 667], ["The", 669], ["discriminative", 673], ["performance", 688], ["of", 700], ["MR", 703], ["-", 705], ["pro", 706], ["-", 709], ["ADM", 710], ["and", 714], ["clinical", 718], ["scores", 727], ["was", 734], ["assessed", 738], ["by", 747], ["AUROC", 750], ["analysis", 756], [".", 764], ["The", 766], ["distribution", 770], ["for", 783], ["MR", 787], ["-", 789], ["pro", 790], ["-", 793], ["ADM", 794], ["followed", 798], ["an", 807], ["upward", 810], ["trend", 817], [",", 822], ["increasing", 824], ["with", 835], ["the", 840], ["increase", 844], ["of", 853], ["both", 856], ["PSI", 861], ["(", 865], ["p<0.001", 866], [")", 873], ["and", 875], ["CURB65", 879], ["(", 886], ["p<0.001", 887], [")", 894], ["classes", 896], [".", 903], ["However", 905], [",", 912], ["the", 914], ["difference", 918], ["between", 929], ["MRproADM", 937], ["values", 946], ["and", 953], ["score", 957], ["classes", 963], ["was", 971], ["significant", 975], ["only", 987], ["in", 992], ["the", 995], ["case", 999], ["of", 1004], ["CURB65", 1007], ["classes", 1014], ["0", 1022], ["and", 1024], ["1", 1028], ["(", 1030], ["p", 1031], ["=", 1033], ["0.046", 1035], [")", 1040], [",", 1041], ["2", 1043], ["(", 1045], ["p", 1046], ["=", 1048], ["0.013", 1050], [")", 1055], [",", 1056], ["and", 1058], ["3", 1062], ["(", 1064], ["p", 1065], ["=", 1067], ["0.011", 1069], [")", 1074], [";", 1075], ["and", 1077], ["with", 1081], ["PSI", 1086], ["classes", 1090], ["5", 1098], [",", 1099], ["3", 1101], ["(", 1103], ["p", 1104], ["=", 1106], ["0.044", 1108], [")", 1113], [",", 1114], ["and", 1116], ["1", 1120], ["(", 1122], ["p", 1123], ["=", 1125], ["0.020", 1127], [")", 1132], [".", 1133], ["As", 1135], ["to", 1138], ["the", 1141], ["differences", 1145], ["among", 1157], ["variables", 1163], ["for", 1173], ["the", 1177], ["six", 1181], ["end", 1185], ["-", 1188], ["points", 1189], [",", 1195], ["MR", 1197], ["-", 1199], ["pro", 1200], ["-", 1203], ["ADM", 1204], ["values", 1208], ["in", 1215], ["the", 1218], ["two", 1222], ["groups", 1226], ["selected", 1233], ["for", 1242], ["each", 1246], ["considered", 1251], ["end", 1262], ["-", 1265], ["point", 1266], ["differed", 1272], ["in", 1281], ["a", 1284], ["statistically", 1286], ["significant", 1300], ["manner", 1312], ["for", 1319], ["all", 1323], ["endpoints", 1327], [".", 1336], ["Both", 1338], ["PSI", 1343], ["and", 1347], ["CURB65", 1351], ["differed", 1358], ["significantly", 1367], ["for", 1381], ["all", 1385], ["end", 1389], ["-", 1392], ["points", 1393], [",", 1399], ["except", 1401], ["for", 1408], ["stay", 1412], ["in", 1417], ["the", 1420], ["ED", 1424], ["longer", 1427], ["than", 1434], ["4", 1439], ["days", 1441], ["and", 1446], ["the", 1450], ["hospital", 1454], ["stay", 1463], ["longer", 1468], ["than", 1475], ["10", 1480], ["days", 1483], ["and", 1488], ["endotracheal", 1492], ["intubation", 1505], ["(", 1516], ["only", 1517], ["PSI", 1522], ["classes", 1526], ["differed", 1534], ["with", 1543], ["statistical", 1548], ["significance", 1560], [")", 1572], [".", 1573], ["ROC", 1575], ["analyses", 1579], ["evidenced", 1588], ["that", 1598], ["MR", 1603], ["-", 1605], ["pro", 1606], ["-", 1609], ["ADM", 1610], ["values", 1614], ["gave", 1621], ["the", 1626], ["greatest", 1630], ["AUC", 1639], ["for", 1643], ["the", 1647], ["prediction", 1651], ["of", 1662], ["death", 1665], [",", 1670], ["endotracheal", 1672], ["intubation", 1685], [",", 1695], ["hospital", 1697], ["stay", 1706], [">", 1711], ["10", 1712], ["days", 1715], ["and", 1720], ["DE", 1724], ["stay", 1727], [">", 1732], ["4", 1733], ["days", 1735], [",", 1739], ["compared", 1741], ["to", 1750], ["the", 1753], ["PSI", 1757], ["and", 1761], ["CURB", 1765], ["(", 1770], ["though", 1771], ["difference", 1778], ["not", 1789], ["statistically", 1793], ["significant", 1807], [")", 1818], [".", 1819], ["For", 1821], ["each", 1825], ["endpoint", 1830], ["measured", 1839], [",", 1847], ["the", 1849], ["best", 1853], ["thresholds", 1858], ["values", 1869], ["for", 1876], ["Mr", 1880], ["-", 1882], ["pro", 1883], ["-", 1886], ["ADM", 1887], ["were", 1891], [":", 1895], ["1.6", 1897], ["(", 1901], ["specificity", 1902], ["76.5", 1914], ["%", 1918], [";", 1919], ["sensitivity", 1921], ["77.8", 1933], ["%", 1937], [")", 1938], ["for", 1940], ["death", 1944], [";", 1949], ["2.5", 1951], ["(", 1955], ["specificity", 1956], ["88.9", 1968], ["%", 1972], [";", 1973], ["sensitivity", 1975], ["80.0", 1987], ["%", 1991], [")", 1992], ["for", 1994], ["death", 1998], ["at", 2004], ["14", 2007], ["days", 2010], [";", 2014], ["1.5", 2016], ["(", 2020], ["specificity", 2021], ["77.0", 2033], ["%", 2037], [";", 2038], ["sensitivity", 2040], ["87.5", 2052], ["%", 2056], [")", 2057], ["for", 2059], ["NIMV", 2063], [";", 2067], ["2.4", 2069], ["(", 2073], ["specificity", 2074], ["88.7", 2086], ["%", 2090], [";", 2091], ["sensitivity", 2093], ["83.3", 2105], ["%", 2109], [")", 2110], ["for", 2112], ["endotracheal", 2116], ["intubation", 2129], [";", 2139], ["0.9", 2141], ["(", 2145], ["specificity", 2146], ["53.5", 2158], ["%", 2162], [";", 2163], ["sensitivity", 2165], ["70.6", 2177], ["%", 2181], [")", 2182], ["for", 2184], ["DE", 2188], ["stay", 2191], ["greater", 2196], ["than", 2204], ["4", 2209], ["days", 2211], [";", 2215], ["1.9", 2217], ["(", 2221], ["specificity", 2222], ["82.1", 2234], ["%", 2238], [";", 2239], ["sensitivity", 2241], ["55.3", 2253], ["%", 2257], [")", 2258], ["for", 2260], ["hospital", 2264], ["stay", 2273], ["greater", 2278], ["than", 2286], ["10", 2291], ["days", 2294], [".", 2298], ["The", 2300], ["AUC", 2304], ["for", 2308], ["the", 2312], ["combination", 2316], ["of", 2328], ["MR", 2331], ["-", 2333], ["pro", 2334], ["-", 2337], ["ADM", 2338], ["and", 2342], ["PSI", 2346], ["was", 2350], ["81.29", 2354], ["%", 2359], ["[", 2361], ["63.41%-99.17", 2362], ["%", 2374], ["]", 2375], [",", 2376], ["but", 2378], ["not", 2382], ["in", 2386], ["a", 2389], ["statistically", 2391], ["significant", 2405], ["manner", 2417], ["compared", 2424], ["to", 2433], ["the", 2436], ["AUCs", 2440], ["of", 2445], ["the", 2448], ["single", 2452], ["predictors", 2459], [".", 2469], ["Conversely", 2471], [",", 2481], ["the", 2483], ["AUC", 2487], ["for", 2491], ["the", 2495], ["combination", 2499], ["of", 2511], ["MR", 2514], ["-", 2516], ["pro", 2517], ["-", 2520], ["ADM", 2521], ["and", 2525], ["CURB65", 2529], ["was", 2536], ["87.58", 2540], ["%", 2545], ["[", 2547], ["75.54%-99.62", 2548], ["%", 2560], ["]", 2561], [",", 2562], ["which", 2564], ["was", 2570], ["significantly", 2574], ["greater", 2588], ["than", 2596], ["the", 2601], ["AUC", 2605], ["of", 2609], ["CURB65", 2612], ["(", 2619], ["p", 2620], ["=", 2622], ["0.047", 2624], [")", 2629], ["or", 2631], ["PSI", 2634], ["(", 2638], ["p", 2639], ["=", 2641], ["0.017", 2643], [")", 2648], ["alone", 2650], [".", 2655], ["The", 2657], ["present", 2661], ["study", 2669], ["confirms", 2675], ["that", 2684], ["assessment", 2689], ["of", 2700], ["MR", 2703], ["-", 2705], ["pro", 2706], ["-", 2709], ["ADM", 2710], ["levels", 2714], ["in", 2721], ["CAP", 2724], ["patients", 2728], ["in", 2737], ["addition", 2740], ["to", 2749], ["CURB", 2752], ["scores", 2757], ["increases", 2764], ["the", 2774], ["prognostic", 2778], ["accuracy", 2789], ["of", 2798], ["CURB", 2801], ["alone", 2806], ["and", 2812], ["may", 2816], ["help", 2820], ["rule", 2825], ["out", 2830], ["discrepancies", 2834], ["arising", 2848], ["from", 2856], ["flawed", 2861], ["clinical", 2868], ["severity", 2877], ["classification", 2886], [".", 2900], ["With", 2902], ["particular", 2907], ["reference", 2918], ["to", 2928], ["patients", 2931], ["scoring", 2940], ["in", 2948], ["the", 2951], ["upper", 2955], ["classes", 2961], ["of", 2969], ["CURB", 2972], ["and", 2977], ["PSI", 2981], [",", 2984], ["MR", 2986], ["-", 2988], ["pro", 2989], ["-", 2992], ["ADM", 2993], ["values", 2997], ["provided", 3004], ["additional", 3013], ["information", 3024], ["towards", 3036], ["a", 3044], ["better", 3046], ["risk", 3053], ["stratification", 3058], ["of", 3073], ["those", 3076], ["patients", 3082], [".", 3090], ["In", 3092], ["particular", 3095], [",", 3105], ["our", 3107], ["results", 3111], ["pointed", 3119], ["towards", 3127], ["two", 3135], ["MR", 3139], ["-", 3141], ["pro", 3142], ["-", 3145], ["ADM", 3146], ["threshold", 3150], ["values", 3160], ["that", 3167], ["appear", 3172], ["to", 3179], ["predict", 3182], ["with", 3190], ["a", 3195], ["good", 3197], ["degree", 3202], ["of", 3209], ["accuracy", 3212], ["the", 3221], ["patient", 3225], ["'s", 3232], ["need", 3235], ["for", 3240], ["non", 3244], ["-", 3247], ["invasive", 3248], ["mechanical", 3257], ["ventilation", 3268], [",", 3279], ["endotracheal", 3281], ["intubation", 3294], [",", 3304], ["or", 3306], ["intensive", 3309], ["care", 3319], [".", 3323], ["This", 3325], ["aspect", 3330], [",", 3336], ["however", 3338], [",", 3345], ["deserves", 3347], ["further", 3356], ["investigation", 3364], [".", 3377]]}
{"context": "Precursor cells have been shown to be affected by oxidative stress, in vivo and vitro, but little is known about the expression of antioxidant mechanisms in neuronal/glial differentiation. We have characterized the expression of Cu/Zn superoxide dismutase (Cu/Zn SOD), one of the main antioxidant proteins involved in the breakdown of superoxide, in the immature rat dorsolateral subventricular zone (SVZ), rostral migratory stream (RMS) and hippocampal subgranular zone (SGZ). Progenitor cells were identified immunohistochemically on cryostat sections by 5'Bromodeoxyuridine (BrdU) incorporation and expressing cells were further characterized using double labeling for progenitor markers. In the SVZ, only a subpopulation of BrdU+ cells, mostly found in the medial SVZ, expressed Cu/Zn SOD. These cells were mostly nestin+ and some were also vimentin+. In contrast, in the lateral SVZ few Cu/Zn SOD+/BrdU+ cells were found. These were primarily nestin+, vimentin-, showed some PSA-NCAM expression, but only a few were NG2+. In the RMS and SGZ virtually all BrdU+ progenitors were Cu/Zn SOD+ and expressed nestin and vimentin. Some RMS cells were also PSA-NCAM+. These findings show a heterogeneous expression of Cu/Zn SOD in restricted cell types in the germinative zones and suggest a role for antioxidant Cu/Zn SOD in progenitor cells of the immature rat brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "9bbe9aa6979c41d589172404e634acc1", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[144, 144], [205, 205], [170, 170]], "char_spans": [[818, 824], [1108, 1113], [948, 954]]}]}], "context_tokens": [["Precursor", 0], ["cells", 10], ["have", 16], ["been", 21], ["shown", 26], ["to", 32], ["be", 35], ["affected", 38], ["by", 47], ["oxidative", 50], ["stress", 60], [",", 66], ["in", 68], ["vivo", 71], ["and", 76], ["vitro", 80], [",", 85], ["but", 87], ["little", 91], ["is", 98], ["known", 101], ["about", 107], ["the", 113], ["expression", 117], ["of", 128], ["antioxidant", 131], ["mechanisms", 143], ["in", 154], ["neuronal", 157], ["/", 165], ["glial", 166], ["differentiation", 172], [".", 187], ["We", 189], ["have", 192], ["characterized", 197], ["the", 211], ["expression", 215], ["of", 226], ["Cu", 229], ["/", 231], ["Zn", 232], ["superoxide", 235], ["dismutase", 246], ["(", 256], ["Cu", 257], ["/", 259], ["Zn", 260], ["SOD", 263], [")", 266], [",", 267], ["one", 269], ["of", 273], ["the", 276], ["main", 280], ["antioxidant", 285], ["proteins", 297], ["involved", 306], ["in", 315], ["the", 318], ["breakdown", 322], ["of", 332], ["superoxide", 335], [",", 345], ["in", 347], ["the", 350], ["immature", 354], ["rat", 363], ["dorsolateral", 367], ["subventricular", 380], ["zone", 395], ["(", 400], ["SVZ", 401], [")", 404], [",", 405], ["rostral", 407], ["migratory", 415], ["stream", 425], ["(", 432], ["RMS", 433], [")", 436], ["and", 438], ["hippocampal", 442], ["subgranular", 454], ["zone", 466], ["(", 471], ["SGZ", 472], [")", 475], [".", 476], ["Progenitor", 478], ["cells", 489], ["were", 495], ["identified", 500], ["immunohistochemically", 511], ["on", 533], ["cryostat", 536], ["sections", 545], ["by", 554], ["5'Bromodeoxyuridine", 557], ["(", 577], ["BrdU", 578], [")", 582], ["incorporation", 584], ["and", 598], ["expressing", 602], ["cells", 613], ["were", 619], ["further", 624], ["characterized", 632], ["using", 646], ["double", 652], ["labeling", 659], ["for", 668], ["progenitor", 672], ["markers", 683], [".", 690], ["In", 692], ["the", 695], ["SVZ", 699], [",", 702], ["only", 704], ["a", 709], ["subpopulation", 711], ["of", 725], ["BrdU+", 728], ["cells", 734], [",", 739], ["mostly", 741], ["found", 748], ["in", 754], ["the", 757], ["medial", 761], ["SVZ", 768], [",", 771], ["expressed", 773], ["Cu", 783], ["/", 785], ["Zn", 786], ["SOD", 789], [".", 792], ["These", 794], ["cells", 800], ["were", 806], ["mostly", 811], ["nestin+", 818], ["and", 826], ["some", 830], ["were", 835], ["also", 840], ["vimentin+", 845], [".", 854], ["In", 856], ["contrast", 859], [",", 867], ["in", 869], ["the", 872], ["lateral", 876], ["SVZ", 884], ["few", 888], ["Cu", 892], ["/", 894], ["Zn", 895], ["SOD+/BrdU+", 898], ["cells", 909], ["were", 915], ["found", 920], [".", 925], ["These", 927], ["were", 933], ["primarily", 938], ["nestin+", 948], [",", 955], ["vimentin-", 957], [",", 966], ["showed", 968], ["some", 975], ["PSA", 980], ["-", 983], ["NCAM", 984], ["expression", 989], [",", 999], ["but", 1001], ["only", 1005], ["a", 1010], ["few", 1012], ["were", 1016], ["NG2", 1021], ["+", 1024], [".", 1025], ["In", 1027], ["the", 1030], ["RMS", 1034], ["and", 1038], ["SGZ", 1042], ["virtually", 1046], ["all", 1056], ["BrdU+", 1060], ["progenitors", 1066], ["were", 1078], ["Cu", 1083], ["/", 1085], ["Zn", 1086], ["SOD+", 1089], ["and", 1094], ["expressed", 1098], ["nestin", 1108], ["and", 1115], ["vimentin", 1119], [".", 1127], ["Some", 1129], ["RMS", 1134], ["cells", 1138], ["were", 1144], ["also", 1149], ["PSA", 1154], ["-", 1157], ["NCAM+", 1158], [".", 1163], ["These", 1165], ["findings", 1171], ["show", 1180], ["a", 1185], ["heterogeneous", 1187], ["expression", 1201], ["of", 1212], ["Cu", 1215], ["/", 1217], ["Zn", 1218], ["SOD", 1221], ["in", 1225], ["restricted", 1228], ["cell", 1239], ["types", 1244], ["in", 1250], ["the", 1253], ["germinative", 1257], ["zones", 1269], ["and", 1275], ["suggest", 1279], ["a", 1287], ["role", 1289], ["for", 1294], ["antioxidant", 1298], ["Cu", 1310], ["/", 1312], ["Zn", 1313], ["SOD", 1316], ["in", 1320], ["progenitor", 1323], ["cells", 1334], ["of", 1340], ["the", 1343], ["immature", 1347], ["rat", 1356], ["brain", 1360], [".", 1365]]}
{"context": "Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation. Throughout its development, increasingly more effective adjuvants have been key in improving the potency of the vaccine. RTS,S-based vaccine formulations have been demonstrated to be safe, well tolerated, immunogenic, and to confer partial efficacy in both malaria-naive and -experienced adults as well as children. Further research to optimize and improve vaccine efficacy is ongoing.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e20b24502922481885eab94b612f374d", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[99, 99], [0, 0], [19, 19], [50, 50]], "char_spans": [[586, 592], [0, 6], [114, 120], [300, 306]]}]}], "context_tokens": [["Malaria", 0], ["continues", 8], ["to", 18], ["be", 21], ["a", 24], ["worldwide", 26], ["leading", 36], ["cause", 44], ["of", 50], ["morbidity", 53], ["and", 63], ["mortality", 67], [",", 76], ["and", 78], ["the", 82], ["development", 86], ["of", 98], ["an", 101], ["effective", 104], ["malaria", 114], ["vaccine", 122], ["remains", 130], ["a", 138], ["research", 140], ["imperative", 149], [".", 159], ["Of", 161], ["the", 164], ["multiple", 168], ["approaches", 177], ["that", 188], ["have", 193], ["been", 198], ["pursued", 203], [",", 210], ["the", 212], ["RTS", 216], [",", 219], ["S", 220], ["/", 221], ["AS01", 222], ["vaccine", 227], ["candidate", 235], ["represents", 245], ["the", 256], ["most", 260], ["developed", 265], ["and", 275], ["clinically", 279], ["validated", 290], ["malaria", 300], ["vaccine", 308], ["formulation", 316], [".", 327], ["Throughout", 329], ["its", 340], ["development", 344], [",", 355], ["increasingly", 357], ["more", 370], ["effective", 375], ["adjuvants", 385], ["have", 395], ["been", 400], ["key", 405], ["in", 409], ["improving", 412], ["the", 422], ["potency", 426], ["of", 434], ["the", 437], ["vaccine", 441], [".", 448], ["RTS", 450], [",", 453], ["S", 454], ["-", 455], ["based", 456], ["vaccine", 462], ["formulations", 470], ["have", 483], ["been", 488], ["demonstrated", 493], ["to", 506], ["be", 509], ["safe", 512], [",", 516], ["well", 518], ["tolerated", 523], [",", 532], ["immunogenic", 534], [",", 545], ["and", 547], ["to", 551], ["confer", 554], ["partial", 561], ["efficacy", 569], ["in", 578], ["both", 581], ["malaria", 586], ["-", 593], ["naive", 594], ["and", 600], ["-experienced", 604], ["adults", 617], ["as", 624], ["well", 627], ["as", 632], ["children", 635], [".", 643], ["Further", 645], ["research", 653], ["to", 662], ["optimize", 665], ["and", 674], ["improve", 678], ["vaccine", 686], ["efficacy", 694], ["is", 703], ["ongoing", 706], [".", 713]]}
{"context": "Type I interferons play an outstanding role in innate and adaptive immunity by enhancing functions of dendritic cells, inducing differentiation of monocytes, promoting immunoglobulin class switching in B cells and stimulating effector functions of T cells. The increased production of IFN\u03b1/\u03b2 by plasmacytoid dendritic cells could be responsible for not only efficient antiviral defence, but it also may be a pathological factor in the development of various autoimmune disorders. The first evidence of a genetic link between type I interferons and autoimmune diseases was the observation that elevated IFN\u03b1 activity is frequently detected in the sera of patients with systemic lupus erythematosus, and that this trait shows high heritability and familial aggregation in their first-degree healthy relatives. To date, a number of genes involved in interferon signalling have been associated with various autoimmune diseases. Patients with systemic lupus erythematosus, Sj\u00f6gren's syndrome, dermatomyositis, psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature. Here, in an attempt to understand the role of type I interferons in the pathogenesis of autoimmunity, we review the recent advances in the genetics of autoimmune diseases focusing on the association of genes involved in type I interferon pathways.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "255dd5946c024c9287665ddcd2830180", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Interferon signature", "token_spans": [[185, 186]], "char_spans": [[1169, 1188]]}]}], "context_tokens": [["Type", 0], ["I", 5], ["interferons", 7], ["play", 19], ["an", 24], ["outstanding", 27], ["role", 39], ["in", 44], ["innate", 47], ["and", 54], ["adaptive", 58], ["immunity", 67], ["by", 76], ["enhancing", 79], ["functions", 89], ["of", 99], ["dendritic", 102], ["cells", 112], [",", 117], ["inducing", 119], ["differentiation", 128], ["of", 144], ["monocytes", 147], [",", 156], ["promoting", 158], ["immunoglobulin", 168], ["class", 183], ["switching", 189], ["in", 199], ["B", 202], ["cells", 204], ["and", 210], ["stimulating", 214], ["effector", 226], ["functions", 235], ["of", 245], ["T", 248], ["cells", 250], [".", 255], ["The", 257], ["increased", 261], ["production", 271], ["of", 282], ["IFN\u03b1", 285], ["/", 289], ["\u03b2", 290], ["by", 292], ["plasmacytoid", 295], ["dendritic", 308], ["cells", 318], ["could", 324], ["be", 330], ["responsible", 333], ["for", 345], ["not", 349], ["only", 353], ["efficient", 358], ["antiviral", 368], ["defence", 378], [",", 385], ["but", 387], ["it", 391], ["also", 394], ["may", 399], ["be", 403], ["a", 406], ["pathological", 408], ["factor", 421], ["in", 428], ["the", 431], ["development", 435], ["of", 447], ["various", 450], ["autoimmune", 458], ["disorders", 469], [".", 478], ["The", 480], ["first", 484], ["evidence", 490], ["of", 499], ["a", 502], ["genetic", 504], ["link", 512], ["between", 517], ["type", 525], ["I", 530], ["interferons", 532], ["and", 544], ["autoimmune", 548], ["diseases", 559], ["was", 568], ["the", 572], ["observation", 576], ["that", 588], ["elevated", 593], ["IFN\u03b1", 602], ["activity", 607], ["is", 616], ["frequently", 619], ["detected", 630], ["in", 639], ["the", 642], ["sera", 646], ["of", 651], ["patients", 654], ["with", 663], ["systemic", 668], ["lupus", 677], ["erythematosus", 683], [",", 696], ["and", 698], ["that", 702], ["this", 707], ["trait", 712], ["shows", 718], ["high", 724], ["heritability", 729], ["and", 742], ["familial", 746], ["aggregation", 755], ["in", 767], ["their", 770], ["first", 776], ["-", 781], ["degree", 782], ["healthy", 789], ["relatives", 797], [".", 806], ["To", 808], ["date", 811], [",", 815], ["a", 817], ["number", 819], ["of", 826], ["genes", 829], ["involved", 835], ["in", 844], ["interferon", 847], ["signalling", 858], ["have", 869], ["been", 874], ["associated", 879], ["with", 890], ["various", 895], ["autoimmune", 903], ["diseases", 914], [".", 922], ["Patients", 924], ["with", 933], ["systemic", 938], ["lupus", 947], ["erythematosus", 953], [",", 966], ["Sj\u00f6gren", 968], ["'s", 975], ["syndrome", 978], [",", 986], ["dermatomyositis", 988], [",", 1003], ["psoriasis", 1005], [",", 1014], ["and", 1016], ["a", 1020], ["fraction", 1022], ["of", 1031], ["patients", 1034], ["with", 1043], ["rheumatoid", 1048], ["arthritis", 1059], ["display", 1069], ["a", 1077], ["specific", 1079], ["expression", 1088], ["pattern", 1099], ["of", 1107], ["interferon", 1110], ["-", 1120], ["dependent", 1121], ["genes", 1131], ["in", 1137], ["their", 1140], ["leukocytes", 1146], [",", 1156], ["termed", 1158], ["the", 1165], ["interferon", 1169], ["signature", 1180], [".", 1189], ["Here", 1191], [",", 1195], ["in", 1197], ["an", 1200], ["attempt", 1203], ["to", 1211], ["understand", 1214], ["the", 1225], ["role", 1229], ["of", 1234], ["type", 1237], ["I", 1242], ["interferons", 1244], ["in", 1256], ["the", 1259], ["pathogenesis", 1263], ["of", 1276], ["autoimmunity", 1279], [",", 1291], ["we", 1293], ["review", 1296], ["the", 1303], ["recent", 1307], ["advances", 1314], ["in", 1323], ["the", 1326], ["genetics", 1330], ["of", 1339], ["autoimmune", 1342], ["diseases", 1353], ["focusing", 1362], ["on", 1371], ["the", 1374], ["association", 1378], ["of", 1390], ["genes", 1393], ["involved", 1399], ["in", 1408], ["type", 1411], ["I", 1416], ["interferon", 1418], ["pathways", 1429], [".", 1437]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a major challenge in health care, yet the limited heterogeneity within this group hinders molecular investigations of related outbreaks. Pulsed-field gel electrophoresis (PFGE) has been the gold standard approach but is impractical for many clinical laboratories and is often replaced with PCR-based methods. Regardless, both approaches can prove problematic for identifying subclonal outbreaks. Here, we explore the use of whole-genome sequencing for clinical laboratory investigations of MRSA molecular epidemiology. We examine the relationships of 44 MRSA isolates collected over a period of 3 years by using whole-genome sequencing and two PCR-based methods, multilocus variable-number tandem-repeat analysis (MLVA) and spa typing. We find that MLVA offers higher resolution than spa typing, as it resolved 17 versus 12 discrete isolate groups, respectively. In contrast, whole-genome sequencing reproducibly cataloged genomic variants (131,424 different single nucleotide polymorphisms and indels across the strain collection) that uniquely identified each MRSA clone, recapitulating those groups but enabling higher-resolution phylogenetic inferences of the epidemiological relationships. Importantly, whole-genome sequencing detected a significant number of variants, thereby distinguishing between groups that were considered identical by both spa typing (minimum, 1,124 polymorphisms) and MLVA (minimum, 193 polymorphisms); this suggests that these more conventional approaches can lead to false-positive identification of outbreaks due to inappropriate grouping of genetically distinct strains. An analysis of the distribution of variants across the MRSA genome reveals 47 mutational hot spots (comprising \u223c 2.5% of the genome) that account for 23.5% of the observed polymorphisms, and the use of this selected data set successfully recapitulates most epidemiological relationships in this pathogen group.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e9f8a67168b34db5ab3343fb3e9136ae", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[90, 90], [6, 6], [188, 188], [100, 100], [280, 280]], "char_spans": [[557, 560], [45, 48], [1129, 1132], [621, 624], [1727, 1730]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["infections", 51], ["pose", 62], ["a", 67], ["major", 69], ["challenge", 75], ["in", 85], ["health", 88], ["care", 95], [",", 99], ["yet", 101], ["the", 105], ["limited", 109], ["heterogeneity", 117], ["within", 131], ["this", 138], ["group", 143], ["hinders", 149], ["molecular", 157], ["investigations", 167], ["of", 182], ["related", 185], ["outbreaks", 193], [".", 202], ["Pulsed", 204], ["-", 210], ["field", 211], ["gel", 217], ["electrophoresis", 221], ["(", 237], ["PFGE", 238], [")", 242], ["has", 244], ["been", 248], ["the", 253], ["gold", 257], ["standard", 262], ["approach", 271], ["but", 280], ["is", 284], ["impractical", 287], ["for", 299], ["many", 303], ["clinical", 308], ["laboratories", 317], ["and", 330], ["is", 334], ["often", 337], ["replaced", 343], ["with", 352], ["PCR", 357], ["-", 360], ["based", 361], ["methods", 367], [".", 374], ["Regardless", 376], [",", 386], ["both", 388], ["approaches", 393], ["can", 404], ["prove", 408], ["problematic", 414], ["for", 426], ["identifying", 430], ["subclonal", 442], ["outbreaks", 452], [".", 461], ["Here", 463], [",", 467], ["we", 469], ["explore", 472], ["the", 480], ["use", 484], ["of", 488], ["whole", 491], ["-", 496], ["genome", 497], ["sequencing", 504], ["for", 515], ["clinical", 519], ["laboratory", 528], ["investigations", 539], ["of", 554], ["MRSA", 557], ["molecular", 562], ["epidemiology", 572], [".", 584], ["We", 586], ["examine", 589], ["the", 597], ["relationships", 601], ["of", 615], ["44", 618], ["MRSA", 621], ["isolates", 626], ["collected", 635], ["over", 645], ["a", 650], ["period", 652], ["of", 659], ["3", 662], ["years", 664], ["by", 670], ["using", 673], ["whole", 679], ["-", 684], ["genome", 685], ["sequencing", 692], ["and", 703], ["two", 707], ["PCR", 711], ["-", 714], ["based", 715], ["methods", 721], [",", 728], ["multilocus", 730], ["variable", 741], ["-", 749], ["number", 750], ["tandem", 757], ["-", 763], ["repeat", 764], ["analysis", 771], ["(", 780], ["MLVA", 781], [")", 785], ["and", 787], ["spa", 791], ["typing", 795], [".", 801], ["We", 803], ["find", 806], ["that", 811], ["MLVA", 816], ["offers", 821], ["higher", 828], ["resolution", 835], ["than", 846], ["spa", 851], ["typing", 855], [",", 861], ["as", 863], ["it", 866], ["resolved", 869], ["17", 878], ["versus", 881], ["12", 888], ["discrete", 891], ["isolate", 900], ["groups", 908], [",", 914], ["respectively", 916], [".", 928], ["In", 930], ["contrast", 933], [",", 941], ["whole", 943], ["-", 948], ["genome", 949], ["sequencing", 956], ["reproducibly", 967], ["cataloged", 980], ["genomic", 990], ["variants", 998], ["(", 1007], ["131,424", 1008], ["different", 1016], ["single", 1026], ["nucleotide", 1033], ["polymorphisms", 1044], ["and", 1058], ["indels", 1062], ["across", 1069], ["the", 1076], ["strain", 1080], ["collection", 1087], [")", 1097], ["that", 1099], ["uniquely", 1104], ["identified", 1113], ["each", 1124], ["MRSA", 1129], ["clone", 1134], [",", 1139], ["recapitulating", 1141], ["those", 1156], ["groups", 1162], ["but", 1169], ["enabling", 1173], ["higher", 1182], ["-", 1188], ["resolution", 1189], ["phylogenetic", 1200], ["inferences", 1213], ["of", 1224], ["the", 1227], ["epidemiological", 1231], ["relationships", 1247], [".", 1260], ["Importantly", 1262], [",", 1273], ["whole", 1275], ["-", 1280], ["genome", 1281], ["sequencing", 1288], ["detected", 1299], ["a", 1308], ["significant", 1310], ["number", 1322], ["of", 1329], ["variants", 1332], [",", 1340], ["thereby", 1342], ["distinguishing", 1350], ["between", 1365], ["groups", 1373], ["that", 1380], ["were", 1385], ["considered", 1390], ["identical", 1401], ["by", 1411], ["both", 1414], ["spa", 1419], ["typing", 1423], ["(", 1430], ["minimum", 1431], [",", 1438], ["1,124", 1440], ["polymorphisms", 1446], [")", 1459], ["and", 1461], ["MLVA", 1465], ["(", 1470], ["minimum", 1471], [",", 1478], ["193", 1480], ["polymorphisms", 1484], [")", 1497], [";", 1498], ["this", 1500], ["suggests", 1505], ["that", 1514], ["these", 1519], ["more", 1525], ["conventional", 1530], ["approaches", 1543], ["can", 1554], ["lead", 1558], ["to", 1563], ["false", 1566], ["-", 1571], ["positive", 1572], ["identification", 1581], ["of", 1596], ["outbreaks", 1599], ["due", 1609], ["to", 1613], ["inappropriate", 1616], ["grouping", 1630], ["of", 1639], ["genetically", 1642], ["distinct", 1654], ["strains", 1663], [".", 1670], ["An", 1672], ["analysis", 1675], ["of", 1684], ["the", 1687], ["distribution", 1691], ["of", 1704], ["variants", 1707], ["across", 1716], ["the", 1723], ["MRSA", 1727], ["genome", 1732], ["reveals", 1739], ["47", 1747], ["mutational", 1750], ["hot", 1761], ["spots", 1765], ["(", 1771], ["comprising", 1772], ["\u223c", 1783], ["2.5", 1785], ["%", 1788], ["of", 1790], ["the", 1793], ["genome", 1797], [")", 1803], ["that", 1805], ["account", 1810], ["for", 1818], ["23.5", 1822], ["%", 1826], ["of", 1828], ["the", 1831], ["observed", 1835], ["polymorphisms", 1844], [",", 1857], ["and", 1859], ["the", 1863], ["use", 1867], ["of", 1871], ["this", 1874], ["selected", 1879], ["data", 1888], ["set", 1893], ["successfully", 1897], ["recapitulates", 1910], ["most", 1924], ["epidemiological", 1929], ["relationships", 1945], ["in", 1959], ["this", 1962], ["pathogen", 1967], ["group", 1976], [".", 1981]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant muscular disorder associated with a short (<35 kb) EcoRI/BlnI fragment resulting from deletion of an integral number of units of a 3.3-kb repeat located at 4q35. In this study, we determined fragment sizes separated by pulsed-field gel electrophoresis in a patient with an apparently sporadic case of FSHD and in his healthy family members. A 38-kb fragment was detected in the proband, in his older brother, and in their father. This finding prompted a clinical reevaluation of the father and brother. A subclinical phenotype restricted to abdominal muscle weakness was detected, and serum creatine kinase values were found to be elevated in both. The proband's brother also showed evidence of an independently occurring subtelomeric rearrangement of 4q35, which normally occurs in about 20% of the population. The identification of a \"borderline\" 38-kb EcoRI/BlnI fragment in an affected subject and his very mildly affected relatives extends the size range of disease alleles and expands existing data on the variable intrafamilial expressivity of FSHD. This study highlights the importance of a careful molecular and clinical analysis extended to family members of apparently sporadic cases with larger EcoRI/BlnI fragments for accurate diagnosis and appropriate genetic counseling in FSHD.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "59d3efb511ad4c1d90d9b4c980a562c2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[7, 9]], "char_spans": [[43, 60]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["an", 40], ["autosomal", 43], ["-", 52], ["dominant", 53], ["muscular", 62], ["disorder", 71], ["associated", 80], ["with", 91], ["a", 96], ["short", 98], ["(", 104], ["<", 105], ["35", 106], ["kb", 109], [")", 111], ["EcoRI", 113], ["/", 118], ["BlnI", 119], ["fragment", 124], ["resulting", 133], ["from", 143], ["deletion", 148], ["of", 157], ["an", 160], ["integral", 163], ["number", 172], ["of", 179], ["units", 182], ["of", 188], ["a", 191], ["3.3-kb", 193], ["repeat", 200], ["located", 207], ["at", 215], ["4q35", 218], [".", 222], ["In", 224], ["this", 227], ["study", 232], [",", 237], ["we", 239], ["determined", 242], ["fragment", 253], ["sizes", 262], ["separated", 268], ["by", 278], ["pulsed", 281], ["-", 287], ["field", 288], ["gel", 294], ["electrophoresis", 298], ["in", 314], ["a", 317], ["patient", 319], ["with", 327], ["an", 332], ["apparently", 335], ["sporadic", 346], ["case", 355], ["of", 360], ["FSHD", 363], ["and", 368], ["in", 372], ["his", 375], ["healthy", 379], ["family", 387], ["members", 394], [".", 401], ["A", 403], ["38-kb", 405], ["fragment", 411], ["was", 420], ["detected", 424], ["in", 433], ["the", 436], ["proband", 440], [",", 447], ["in", 449], ["his", 452], ["older", 456], ["brother", 462], [",", 469], ["and", 471], ["in", 475], ["their", 478], ["father", 484], [".", 490], ["This", 492], ["finding", 497], ["prompted", 505], ["a", 514], ["clinical", 516], ["reevaluation", 525], ["of", 538], ["the", 541], ["father", 545], ["and", 552], ["brother", 556], [".", 563], ["A", 565], ["subclinical", 567], ["phenotype", 579], ["restricted", 589], ["to", 600], ["abdominal", 603], ["muscle", 613], ["weakness", 620], ["was", 629], ["detected", 633], [",", 641], ["and", 643], ["serum", 647], ["creatine", 653], ["kinase", 662], ["values", 669], ["were", 676], ["found", 681], ["to", 687], ["be", 690], ["elevated", 693], ["in", 702], ["both", 705], [".", 709], ["The", 711], ["proband", 715], ["'s", 722], ["brother", 725], ["also", 733], ["showed", 738], ["evidence", 745], ["of", 754], ["an", 757], ["independently", 760], ["occurring", 774], ["subtelomeric", 784], ["rearrangement", 797], ["of", 811], ["4q35", 814], [",", 818], ["which", 820], ["normally", 826], ["occurs", 835], ["in", 842], ["about", 845], ["20", 851], ["%", 853], ["of", 855], ["the", 858], ["population", 862], [".", 872], ["The", 874], ["identification", 878], ["of", 893], ["a", 896], ["\"", 898], ["borderline", 899], ["\"", 909], ["38-kb", 911], ["EcoRI", 917], ["/", 922], ["BlnI", 923], ["fragment", 928], ["in", 937], ["an", 940], ["affected", 943], ["subject", 952], ["and", 960], ["his", 964], ["very", 968], ["mildly", 973], ["affected", 980], ["relatives", 989], ["extends", 999], ["the", 1007], ["size", 1011], ["range", 1016], ["of", 1022], ["disease", 1025], ["alleles", 1033], ["and", 1041], ["expands", 1045], ["existing", 1053], ["data", 1062], ["on", 1067], ["the", 1070], ["variable", 1074], ["intrafamilial", 1083], ["expressivity", 1097], ["of", 1110], ["FSHD", 1113], [".", 1117], ["This", 1119], ["study", 1124], ["highlights", 1130], ["the", 1141], ["importance", 1145], ["of", 1156], ["a", 1159], ["careful", 1161], ["molecular", 1169], ["and", 1179], ["clinical", 1183], ["analysis", 1192], ["extended", 1201], ["to", 1210], ["family", 1213], ["members", 1220], ["of", 1228], ["apparently", 1231], ["sporadic", 1242], ["cases", 1251], ["with", 1257], ["larger", 1262], ["EcoRI", 1269], ["/", 1274], ["BlnI", 1275], ["fragments", 1280], ["for", 1290], ["accurate", 1294], ["diagnosis", 1303], ["and", 1313], ["appropriate", 1317], ["genetic", 1329], ["counseling", 1337], ["in", 1348], ["FSHD", 1351], [".", 1355]]}
{"context": "Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy characterized by Parkinsonism, vertical gaze palsy, and early falls. Lewy bodies (LBs) are detected in approximately 10% of PSP cases, but there is little information on the relationship of LBs to tau pathology. We determined the frequency of LBs in a large series of autopsy-confirmed cases of PSP and studied the density and distribution of LBs, including Parkinson disease stage, in cases with LBs (PSP/LBD). PSP/LBD was compared with pure LB disease (LBD), including assessment of neuronal loss in key brainstem nuclei. Immunohistochemistry for alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%). One case had multiple system atrophy in addition to PSP and was excluded from further study along with 2 PSP/LBD cases with concurrent Alzheimer disease. The 29 cases of PSP/LBD were compared with 30 cases of PSP and 24 cases of LBD. The age, sex, brain weight, Braak neurofibrillary tangle (NFT) stage, as well as counts of NFTs and senile plaques were not different among PSP, LBD, and PSP/LBD, but disease duration was longer in LBD. The Parkinson disease stage was similar, but the density of LBs in most subcortical nuclei tended to be greater in LBD than in PSP/LBD. In contrast, substantia nigra neuronal loss was greater in PSP/LBD than both PSP and LBD. Double immunostaining demonstrated alpha-synuclein and tau in different neurons with few exceptions. The findings suggest that LBs in PSP are similar in distribution to those in LBD and independent of tau pathology. The greater density of LBs in LBD compared with PSP/LBD may be the result of longer disease duration in LBD, whereas greater neuronal loss in the substantia nigra in PSP/LBD may be the result of vulnerability of this brain region to both disease processes.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "2a5f33eb024e41f39c9afc6c4409b13a", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[277, 279], [117, 119]], "char_spans": [[1376, 1390], [619, 633]]}]}], "context_tokens": [["Progressive", 0], ["supranuclear", 12], ["palsy", 25], ["(", 31], ["PSP", 32], [")", 35], ["is", 37], ["a", 40], ["neurodegenerative", 42], ["tauopathy", 60], ["characterized", 70], ["by", 84], ["Parkinsonism", 87], [",", 99], ["vertical", 101], ["gaze", 110], ["palsy", 115], [",", 120], ["and", 122], ["early", 126], ["falls", 132], [".", 137], ["Lewy", 139], ["bodies", 144], ["(", 151], ["LBs", 152], [")", 155], ["are", 157], ["detected", 161], ["in", 170], ["approximately", 173], ["10", 187], ["%", 189], ["of", 191], ["PSP", 194], ["cases", 198], [",", 203], ["but", 205], ["there", 209], ["is", 215], ["little", 218], ["information", 225], ["on", 237], ["the", 240], ["relationship", 244], ["of", 257], ["LBs", 260], ["to", 264], ["tau", 267], ["pathology", 271], [".", 280], ["We", 282], ["determined", 285], ["the", 296], ["frequency", 300], ["of", 310], ["LBs", 313], ["in", 317], ["a", 320], ["large", 322], ["series", 328], ["of", 335], ["autopsy", 338], ["-", 345], ["confirmed", 346], ["cases", 356], ["of", 362], ["PSP", 365], ["and", 369], ["studied", 373], ["the", 381], ["density", 385], ["and", 393], ["distribution", 397], ["of", 410], ["LBs", 413], [",", 416], ["including", 418], ["Parkinson", 428], ["disease", 438], ["stage", 446], [",", 451], ["in", 453], ["cases", 456], ["with", 462], ["LBs", 467], ["(", 471], ["PSP", 472], ["/", 475], ["LBD", 476], [")", 479], [".", 480], ["PSP", 482], ["/", 485], ["LBD", 486], ["was", 490], ["compared", 494], ["with", 503], ["pure", 508], ["LB", 513], ["disease", 516], ["(", 524], ["LBD", 525], [")", 528], [",", 529], ["including", 531], ["assessment", 541], ["of", 552], ["neuronal", 555], ["loss", 564], ["in", 569], ["key", 572], ["brainstem", 576], ["nuclei", 586], [".", 592], ["Immunohistochemistry", 594], ["for", 615], ["alpha", 619], ["-", 624], ["synuclein", 625], ["revealed", 635], ["LBs", 644], ["in", 648], ["31", 651], ["of", 654], ["290", 657], ["PSP", 661], ["cases", 665], ["(", 671], ["11", 672], ["%", 674], [")", 675], [".", 676], ["One", 678], ["case", 682], ["had", 687], ["multiple", 691], ["system", 700], ["atrophy", 707], ["in", 715], ["addition", 718], ["to", 727], ["PSP", 730], ["and", 734], ["was", 738], ["excluded", 742], ["from", 751], ["further", 756], ["study", 764], ["along", 770], ["with", 776], ["2", 781], ["PSP", 783], ["/", 786], ["LBD", 787], ["cases", 791], ["with", 797], ["concurrent", 802], ["Alzheimer", 813], ["disease", 823], [".", 830], ["The", 832], ["29", 836], ["cases", 839], ["of", 845], ["PSP", 848], ["/", 851], ["LBD", 852], ["were", 856], ["compared", 861], ["with", 870], ["30", 875], ["cases", 878], ["of", 884], ["PSP", 887], ["and", 891], ["24", 895], ["cases", 898], ["of", 904], ["LBD", 907], [".", 910], ["The", 912], ["age", 916], [",", 919], ["sex", 921], [",", 924], ["brain", 926], ["weight", 932], [",", 938], ["Braak", 940], ["neurofibrillary", 946], ["tangle", 962], ["(", 969], ["NFT", 970], [")", 973], ["stage", 975], [",", 980], ["as", 982], ["well", 985], ["as", 990], ["counts", 993], ["of", 1000], ["NFTs", 1003], ["and", 1008], ["senile", 1012], ["plaques", 1019], ["were", 1027], ["not", 1032], ["different", 1036], ["among", 1046], ["PSP", 1052], [",", 1055], ["LBD", 1057], [",", 1060], ["and", 1062], ["PSP", 1066], ["/", 1069], ["LBD", 1070], [",", 1073], ["but", 1075], ["disease", 1079], ["duration", 1087], ["was", 1096], ["longer", 1100], ["in", 1107], ["LBD", 1110], [".", 1113], ["The", 1115], ["Parkinson", 1119], ["disease", 1129], ["stage", 1137], ["was", 1143], ["similar", 1147], [",", 1154], ["but", 1156], ["the", 1160], ["density", 1164], ["of", 1172], ["LBs", 1175], ["in", 1179], ["most", 1182], ["subcortical", 1187], ["nuclei", 1199], ["tended", 1206], ["to", 1213], ["be", 1216], ["greater", 1219], ["in", 1227], ["LBD", 1230], ["than", 1234], ["in", 1239], ["PSP", 1242], ["/", 1245], ["LBD", 1246], [".", 1249], ["In", 1251], ["contrast", 1254], [",", 1262], ["substantia", 1264], ["nigra", 1275], ["neuronal", 1281], ["loss", 1290], ["was", 1295], ["greater", 1299], ["in", 1307], ["PSP", 1310], ["/", 1313], ["LBD", 1314], ["than", 1318], ["both", 1323], ["PSP", 1328], ["and", 1332], ["LBD", 1336], [".", 1339], ["Double", 1341], ["immunostaining", 1348], ["demonstrated", 1363], ["alpha", 1376], ["-", 1381], ["synuclein", 1382], ["and", 1392], ["tau", 1396], ["in", 1400], ["different", 1403], ["neurons", 1413], ["with", 1421], ["few", 1426], ["exceptions", 1430], [".", 1440], ["The", 1442], ["findings", 1446], ["suggest", 1455], ["that", 1463], ["LBs", 1468], ["in", 1472], ["PSP", 1475], ["are", 1479], ["similar", 1483], ["in", 1491], ["distribution", 1494], ["to", 1507], ["those", 1510], ["in", 1516], ["LBD", 1519], ["and", 1523], ["independent", 1527], ["of", 1539], ["tau", 1542], ["pathology", 1546], [".", 1555], ["The", 1557], ["greater", 1561], ["density", 1569], ["of", 1577], ["LBs", 1580], ["in", 1584], ["LBD", 1587], ["compared", 1591], ["with", 1600], ["PSP", 1605], ["/", 1608], ["LBD", 1609], ["may", 1613], ["be", 1617], ["the", 1620], ["result", 1624], ["of", 1631], ["longer", 1634], ["disease", 1641], ["duration", 1649], ["in", 1658], ["LBD", 1661], [",", 1664], ["whereas", 1666], ["greater", 1674], ["neuronal", 1682], ["loss", 1691], ["in", 1696], ["the", 1699], ["substantia", 1703], ["nigra", 1714], ["in", 1720], ["PSP", 1723], ["/", 1726], ["LBD", 1727], ["may", 1731], ["be", 1735], ["the", 1738], ["result", 1742], ["of", 1749], ["vulnerability", 1752], ["of", 1766], ["this", 1769], ["brain", 1774], ["region", 1780], ["to", 1787], ["both", 1790], ["disease", 1795], ["processes", 1803], [".", 1812]]}
{"context": "NFAT (nuclear factor of activated T cell) proteins are expressed in most immune system cells and regulate the transcription of cytokine genes critical for the immune response. The activity of NFAT proteins is tightly regulated by the Ca(2+)/calmodulin-dependent protein phosphatase 2B/calcineurin (CaN). Dephosphorylation of NFAT by CaN is required for NFAT nuclear localization. Current immunosuppressive drugs such as cyclosporin A and FK506 block CaN activity thus inhibiting nuclear translocation of NFAT and consequent cytokine gene transcription. The inhibition of CaN in cells outside of the immune system may contribute to the toxicities associated with cyclosporin A therapy. In a search for safer immunosuppressive drugs, we identified a series of 3,5-bistrifluoromethyl pyrazole (BTP) derivatives that block Th1 and Th2 cytokine gene transcription. The BTP compounds block the activation-dependent nuclear localization of NFAT as determined by electrophoretic mobility shift assays. Confocal microscopy of cells expressing fluorescent-tagged NFAT confirmed that the BTP compounds block calcium-induced movement of NFAT from the cytosol to the nucleus. Inhibition of NFAT was selective because the BTP compounds did not affect the activation of NF-kappaB and AP-1 transcription factors. Treatment of intact T cells with the BTP compounds prior to calcium ionophore-induced activation of CaN caused NFAT to remain in a highly phosphorylated state. However, the BTP compounds did not directly inhibit the dephosphorylation of NFAT by CaN in vitro, nor did the drugs block the dephosphorylation of other CaN substrates including the type II regulatory subunit of protein kinase A and the transcription factor Elk-1. The data suggest that the BTP compounds cause NFAT to be maintained in the cytosol in a phosphorylated state and block the nuclear import of NFAT and, hence, NFAT-dependent cytokine gene transcription by a mechanism other than direct inhibition of CaN phosphatase activity. The novel inhibitors described herein will be useful in better defining the cellular regulation of NFAT activation and may lead to identification of new therapeutic targets for the treatment of autoimmune disease and transplant rejection.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "da7f2fd5258442938f8496ff49ace9a0", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[47, 47]], "char_spans": [[285, 295]]}, {"text": "CaN", "token_spans": [[91, 91], [251, 251], [74, 74], [326, 326], [56, 56], [264, 264], [226, 226], [49, 49]], "char_spans": [[571, 573], [1542, 1544], [450, 452], [1971, 1973], [333, 335], [1611, 1613], [1397, 1399], [298, 300]]}, {"text": "phosphatase 2b", "token_spans": [[44, 45]], "char_spans": [[270, 283]]}]}], "context_tokens": [["NFAT", 0], ["(", 5], ["nuclear", 6], ["factor", 14], ["of", 21], ["activated", 24], ["T", 34], ["cell", 36], [")", 40], ["proteins", 42], ["are", 51], ["expressed", 55], ["in", 65], ["most", 68], ["immune", 73], ["system", 80], ["cells", 87], ["and", 93], ["regulate", 97], ["the", 106], ["transcription", 110], ["of", 124], ["cytokine", 127], ["genes", 136], ["critical", 142], ["for", 151], ["the", 155], ["immune", 159], ["response", 166], [".", 174], ["The", 176], ["activity", 180], ["of", 189], ["NFAT", 192], ["proteins", 197], ["is", 206], ["tightly", 209], ["regulated", 217], ["by", 227], ["the", 230], ["Ca(2+)/calmodulin", 234], ["-", 251], ["dependent", 252], ["protein", 262], ["phosphatase", 270], ["2B", 282], ["/", 284], ["calcineurin", 285], ["(", 297], ["CaN", 298], [")", 301], [".", 302], ["Dephosphorylation", 304], ["of", 322], ["NFAT", 325], ["by", 330], ["CaN", 333], ["is", 337], ["required", 340], ["for", 349], ["NFAT", 353], ["nuclear", 358], ["localization", 366], [".", 378], ["Current", 380], ["immunosuppressive", 388], ["drugs", 406], ["such", 412], ["as", 417], ["cyclosporin", 420], ["A", 432], ["and", 434], ["FK506", 438], ["block", 444], ["CaN", 450], ["activity", 454], ["thus", 463], ["inhibiting", 468], ["nuclear", 479], ["translocation", 487], ["of", 501], ["NFAT", 504], ["and", 509], ["consequent", 513], ["cytokine", 524], ["gene", 533], ["transcription", 538], [".", 551], ["The", 553], ["inhibition", 557], ["of", 568], ["CaN", 571], ["in", 575], ["cells", 578], ["outside", 584], ["of", 592], ["the", 595], ["immune", 599], ["system", 606], ["may", 613], ["contribute", 617], ["to", 628], ["the", 631], ["toxicities", 635], ["associated", 646], ["with", 657], ["cyclosporin", 662], ["A", 674], ["therapy", 676], [".", 683], ["In", 685], ["a", 688], ["search", 690], ["for", 697], ["safer", 701], ["immunosuppressive", 707], ["drugs", 725], [",", 730], ["we", 732], ["identified", 735], ["a", 746], ["series", 748], ["of", 755], ["3,5-bistrifluoromethyl", 758], ["pyrazole", 781], ["(", 790], ["BTP", 791], [")", 794], ["derivatives", 796], ["that", 808], ["block", 813], ["Th1", 819], ["and", 823], ["Th2", 827], ["cytokine", 831], ["gene", 840], ["transcription", 845], [".", 858], ["The", 860], ["BTP", 864], ["compounds", 868], ["block", 878], ["the", 884], ["activation", 888], ["-", 898], ["dependent", 899], ["nuclear", 909], ["localization", 917], ["of", 930], ["NFAT", 933], ["as", 938], ["determined", 941], ["by", 952], ["electrophoretic", 955], ["mobility", 971], ["shift", 980], ["assays", 986], [".", 992], ["Confocal", 994], ["microscopy", 1003], ["of", 1014], ["cells", 1017], ["expressing", 1023], ["fluorescent", 1034], ["-", 1045], ["tagged", 1046], ["NFAT", 1053], ["confirmed", 1058], ["that", 1068], ["the", 1073], ["BTP", 1077], ["compounds", 1081], ["block", 1091], ["calcium", 1097], ["-", 1104], ["induced", 1105], ["movement", 1113], ["of", 1122], ["NFAT", 1125], ["from", 1130], ["the", 1135], ["cytosol", 1139], ["to", 1147], ["the", 1150], ["nucleus", 1154], [".", 1161], ["Inhibition", 1163], ["of", 1174], ["NFAT", 1177], ["was", 1182], ["selective", 1186], ["because", 1196], ["the", 1204], ["BTP", 1208], ["compounds", 1212], ["did", 1222], ["not", 1226], ["affect", 1230], ["the", 1237], ["activation", 1241], ["of", 1252], ["NF", 1255], ["-", 1257], ["kappaB", 1258], ["and", 1265], ["AP-1", 1269], ["transcription", 1274], ["factors", 1288], [".", 1295], ["Treatment", 1297], ["of", 1307], ["intact", 1310], ["T", 1317], ["cells", 1319], ["with", 1325], ["the", 1330], ["BTP", 1334], ["compounds", 1338], ["prior", 1348], ["to", 1354], ["calcium", 1357], ["ionophore", 1365], ["-", 1374], ["induced", 1375], ["activation", 1383], ["of", 1394], ["CaN", 1397], ["caused", 1401], ["NFAT", 1408], ["to", 1413], ["remain", 1416], ["in", 1423], ["a", 1426], ["highly", 1428], ["phosphorylated", 1435], ["state", 1450], [".", 1455], ["However", 1457], [",", 1464], ["the", 1466], ["BTP", 1470], ["compounds", 1474], ["did", 1484], ["not", 1488], ["directly", 1492], ["inhibit", 1501], ["the", 1509], ["dephosphorylation", 1513], ["of", 1531], ["NFAT", 1534], ["by", 1539], ["CaN", 1542], ["in", 1546], ["vitro", 1549], [",", 1554], ["nor", 1556], ["did", 1560], ["the", 1564], ["drugs", 1568], ["block", 1574], ["the", 1580], ["dephosphorylation", 1584], ["of", 1602], ["other", 1605], ["CaN", 1611], ["substrates", 1615], ["including", 1626], ["the", 1636], ["type", 1640], ["II", 1645], ["regulatory", 1648], ["subunit", 1659], ["of", 1667], ["protein", 1670], ["kinase", 1678], ["A", 1685], ["and", 1687], ["the", 1691], ["transcription", 1695], ["factor", 1709], ["Elk-1", 1716], [".", 1721], ["The", 1723], ["data", 1727], ["suggest", 1732], ["that", 1740], ["the", 1745], ["BTP", 1749], ["compounds", 1753], ["cause", 1763], ["NFAT", 1769], ["to", 1774], ["be", 1777], ["maintained", 1780], ["in", 1791], ["the", 1794], ["cytosol", 1798], ["in", 1806], ["a", 1809], ["phosphorylated", 1811], ["state", 1826], ["and", 1832], ["block", 1836], ["the", 1842], ["nuclear", 1846], ["import", 1854], ["of", 1861], ["NFAT", 1864], ["and", 1869], [",", 1872], ["hence", 1874], [",", 1879], ["NFAT", 1881], ["-", 1885], ["dependent", 1886], ["cytokine", 1896], ["gene", 1905], ["transcription", 1910], ["by", 1924], ["a", 1927], ["mechanism", 1929], ["other", 1939], ["than", 1945], ["direct", 1950], ["inhibition", 1957], ["of", 1968], ["CaN", 1971], ["phosphatase", 1975], ["activity", 1987], [".", 1995], ["The", 1997], ["novel", 2001], ["inhibitors", 2007], ["described", 2018], ["herein", 2028], ["will", 2035], ["be", 2040], ["useful", 2043], ["in", 2050], ["better", 2053], ["defining", 2060], ["the", 2069], ["cellular", 2073], ["regulation", 2082], ["of", 2093], ["NFAT", 2096], ["activation", 2101], ["and", 2112], ["may", 2116], ["lead", 2120], ["to", 2125], ["identification", 2128], ["of", 2143], ["new", 2146], ["therapeutic", 2150], ["targets", 2162], ["for", 2170], ["the", 2174], ["treatment", 2178], ["of", 2188], ["autoimmune", 2191], ["disease", 2202], ["and", 2210], ["transplant", 2214], ["rejection", 2225], [".", 2234]]}
{"context": "Prior studies published in the cardiothoracic, orthopedic and gastrointestinal surgery have identified the importance of nasal (methicillin-resistant Staphylococcus aureus) MRSA screening and subsequent decolonization to reduce MRSA surgical site infection (SSI). This is the first study to date correlating nasal MRSA colonization with postoperative spinal MRSA SSI. To assess the significance of nasal MRSA colonization in the setting of MRSA SSI. A retrospective electronic chart review of patients from year 2011 to June 2013 was conducted for patients with both nasal MRSA colonization within 30 days prior to spinal surgery. Patients who tested positive for MRSA were put on contact isolation protocol. None of these patients received topical antibiotics for decolonization of nasal MRSA. A total of 519 patients were identified; 384 negative (74%), 110 MSSA-positive (21.2%), and 25 (4.8%) MRSA-positive. Culture positive surgical site infection (SSI) was identified in 27 (5.2%) cases and was higher in MRSA-positive group than in MRSA-negative and MSSA-positive groups (12% vs. 5.73% vs. 1.82%; p=0.01). The MRSA SSI rate was 0.96% (n=5). MRSA SSI developed in 8% of the MRSA-positive group as compared to only in 0.61% of MRSA-negative group, with a calculated odds ratio of 14.23 (p=0.02). In the presence of SSI, nasal MRSA colonization was associated with MRSA-positive wound culture (66.67 vs. 12.5%; p<0.0001). Preoperative nasal MRSA colonization is associated with postoperative spinal MRSA SSI. Preoperative screening and subsequent decolonization using topical antibiotics may help in decreasing the incidence of MRSA SSI after spine surgery. Nasal MRSA+ patients undergoing spinal surgery should be informed regarding their increased risk of developing surgical site infection.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f9b282fbb19a4becb10efa8009e39d88", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[53, 53], [309, 309], [268, 268], [263, 263], [125, 125], [68, 68], [188, 188], [316, 316], [62, 62], [48, 48], [240, 240], [24, 24], [91, 91], [157, 157], [106, 106], [182, 182], [291, 291], [220, 220], [228, 228], [284, 284], [210, 210], [31, 31]], "char_spans": [[358, 361], [1632, 1635], [1369, 1372], [1331, 1334], [789, 792], [440, 443], [1039, 1042], [1668, 1672], [404, 407], [314, 317], [1232, 1235], [173, 176], [573, 576], [897, 900], [664, 667], [1011, 1014], [1503, 1506], [1148, 1151], [1180, 1183], [1445, 1448], [1117, 1120], [228, 231]]}]}], "context_tokens": [["Prior", 0], ["studies", 6], ["published", 14], ["in", 24], ["the", 27], ["cardiothoracic", 31], [",", 45], ["orthopedic", 47], ["and", 58], ["gastrointestinal", 62], ["surgery", 79], ["have", 87], ["identified", 92], ["the", 103], ["importance", 107], ["of", 118], ["nasal", 121], ["(", 127], ["methicillin", 128], ["-", 139], ["resistant", 140], ["Staphylococcus", 150], ["aureus", 165], [")", 171], ["MRSA", 173], ["screening", 178], ["and", 188], ["subsequent", 192], ["decolonization", 203], ["to", 218], ["reduce", 221], ["MRSA", 228], ["surgical", 233], ["site", 242], ["infection", 247], ["(", 257], ["SSI", 258], [")", 261], [".", 262], ["This", 264], ["is", 269], ["the", 272], ["first", 276], ["study", 282], ["to", 288], ["date", 291], ["correlating", 296], ["nasal", 308], ["MRSA", 314], ["colonization", 319], ["with", 332], ["postoperative", 337], ["spinal", 351], ["MRSA", 358], ["SSI", 363], [".", 366], ["To", 368], ["assess", 371], ["the", 378], ["significance", 382], ["of", 395], ["nasal", 398], ["MRSA", 404], ["colonization", 409], ["in", 422], ["the", 425], ["setting", 429], ["of", 437], ["MRSA", 440], ["SSI", 445], [".", 448], ["A", 450], ["retrospective", 452], ["electronic", 466], ["chart", 477], ["review", 483], ["of", 490], ["patients", 493], ["from", 502], ["year", 507], ["2011", 512], ["to", 517], ["June", 520], ["2013", 525], ["was", 530], ["conducted", 534], ["for", 544], ["patients", 548], ["with", 557], ["both", 562], ["nasal", 567], ["MRSA", 573], ["colonization", 578], ["within", 591], ["30", 598], ["days", 601], ["prior", 606], ["to", 612], ["spinal", 615], ["surgery", 622], [".", 629], ["Patients", 631], ["who", 640], ["tested", 644], ["positive", 651], ["for", 660], ["MRSA", 664], ["were", 669], ["put", 674], ["on", 678], ["contact", 681], ["isolation", 689], ["protocol", 699], [".", 707], ["None", 709], ["of", 714], ["these", 717], ["patients", 723], ["received", 732], ["topical", 741], ["antibiotics", 749], ["for", 761], ["decolonization", 765], ["of", 780], ["nasal", 783], ["MRSA", 789], [".", 793], ["A", 795], ["total", 797], ["of", 803], ["519", 806], ["patients", 810], ["were", 819], ["identified", 824], [";", 834], ["384", 836], ["negative", 840], ["(", 849], ["74", 850], ["%", 852], [")", 853], [",", 854], ["110", 856], ["MSSA", 860], ["-", 864], ["positive", 865], ["(", 874], ["21.2", 875], ["%", 879], [")", 880], [",", 881], ["and", 883], ["25", 887], ["(", 890], ["4.8", 891], ["%", 894], [")", 895], ["MRSA", 897], ["-", 901], ["positive", 902], [".", 910], ["Culture", 912], ["positive", 920], ["surgical", 929], ["site", 938], ["infection", 943], ["(", 953], ["SSI", 954], [")", 957], ["was", 959], ["identified", 963], ["in", 974], ["27", 977], ["(", 980], ["5.2", 981], ["%", 984], [")", 985], ["cases", 987], ["and", 993], ["was", 997], ["higher", 1001], ["in", 1008], ["MRSA", 1011], ["-", 1015], ["positive", 1016], ["group", 1025], ["than", 1031], ["in", 1036], ["MRSA", 1039], ["-", 1043], ["negative", 1044], ["and", 1053], ["MSSA", 1057], ["-", 1061], ["positive", 1062], ["groups", 1071], ["(", 1078], ["12", 1079], ["%", 1081], ["vs.", 1083], ["5.73", 1087], ["%", 1091], ["vs.", 1093], ["1.82", 1097], ["%", 1101], [";", 1102], ["p=0.01", 1104], [")", 1110], [".", 1111], ["The", 1113], ["MRSA", 1117], ["SSI", 1122], ["rate", 1126], ["was", 1131], ["0.96", 1135], ["%", 1139], ["(", 1141], ["n=5", 1142], [")", 1145], [".", 1146], ["MRSA", 1148], ["SSI", 1153], ["developed", 1157], ["in", 1167], ["8", 1170], ["%", 1171], ["of", 1173], ["the", 1176], ["MRSA", 1180], ["-", 1184], ["positive", 1185], ["group", 1194], ["as", 1200], ["compared", 1203], ["to", 1212], ["only", 1215], ["in", 1220], ["0.61", 1223], ["%", 1227], ["of", 1229], ["MRSA", 1232], ["-", 1236], ["negative", 1237], ["group", 1246], [",", 1251], ["with", 1253], ["a", 1258], ["calculated", 1260], ["odds", 1271], ["ratio", 1276], ["of", 1282], ["14.23", 1285], ["(", 1291], ["p=0.02", 1292], [")", 1298], [".", 1299], ["In", 1301], ["the", 1304], ["presence", 1308], ["of", 1317], ["SSI", 1320], [",", 1323], ["nasal", 1325], ["MRSA", 1331], ["colonization", 1336], ["was", 1349], ["associated", 1353], ["with", 1364], ["MRSA", 1369], ["-", 1373], ["positive", 1374], ["wound", 1383], ["culture", 1389], ["(", 1397], ["66.67", 1398], ["vs.", 1404], ["12.5", 1408], ["%", 1412], [";", 1413], ["p<0.0001", 1415], [")", 1423], [".", 1424], ["Preoperative", 1426], ["nasal", 1439], ["MRSA", 1445], ["colonization", 1450], ["is", 1463], ["associated", 1466], ["with", 1477], ["postoperative", 1482], ["spinal", 1496], ["MRSA", 1503], ["SSI", 1508], [".", 1511], ["Preoperative", 1513], ["screening", 1526], ["and", 1536], ["subsequent", 1540], ["decolonization", 1551], ["using", 1566], ["topical", 1572], ["antibiotics", 1580], ["may", 1592], ["help", 1596], ["in", 1601], ["decreasing", 1604], ["the", 1615], ["incidence", 1619], ["of", 1629], ["MRSA", 1632], ["SSI", 1637], ["after", 1641], ["spine", 1647], ["surgery", 1653], [".", 1660], ["Nasal", 1662], ["MRSA+", 1668], ["patients", 1674], ["undergoing", 1683], ["spinal", 1694], ["surgery", 1701], ["should", 1709], ["be", 1716], ["informed", 1719], ["regarding", 1728], ["their", 1738], ["increased", 1744], ["risk", 1754], ["of", 1759], ["developing", 1762], ["surgical", 1773], ["site", 1782], ["infection", 1787], [".", 1796]]}
{"context": "Turner syndrome (TS) is a chromosomal disorder caused by complete or partial X chromosome monosomy that manifests various clinical features depending on the karyotype and on the genetic background of affected girls. This study aimed to systematically investigate the key clinical features of TS in relationship to karyotype in a large pediatric Turkish patient population. Our retrospective study included 842 karyotype-proven TS patients aged 0-18 years who were evaluated in 35 different centers in Turkey in the years 2013-2014. The most common karyotype was 45,X (50.7%), followed by 45,X/46,XX (10.8%), 46,X,i(Xq) (10.1%) and 45,X/46,X,i(Xq) (9.5%). Mean age at diagnosis was 10.2\u00b14.4 years. The most common presenting complaints were short stature and delayed puberty. Among patients diagnosed before age one year, the ratio of karyotype 45,X was significantly higher than that of other karyotype groups. Cardiac defects (bicuspid aortic valve, coarctation of the aorta and aortic stenosis) were the most common congenital anomalies, occurring in 25% of the TS cases. This was followed by urinary system anomalies (horseshoe kidney, double collector duct system and renal rotation) detected in 16.3%. Hashimoto's thyroiditis was found in 11.1% of patients, gastrointestinal abnormalities in 8.9%, ear nose and throat problems in 22.6%, dermatologic problems in 21.8% and osteoporosis in 15.3%. Learning difficulties and/or psychosocial problems were encountered in 39.1%. Insulin resistance and impaired fasting glucose were detected in 3.4% and 2.2%, respectively. Dyslipidemia prevalence was 11.4%. This comprehensive study systematically evaluated the largest group of karyotype-proven TS girls to date. The karyotype distribution, congenital anomaly and comorbidity profile closely parallel that from other countries and support the need for close medical surveillance of these complex patients throughout their lifespan.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "a6c94ff890694dde8583eedd2e670526", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[14, 14]], "char_spans": [[77, 77]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["(", 16], ["TS", 17], [")", 19], ["is", 21], ["a", 24], ["chromosomal", 26], ["disorder", 38], ["caused", 47], ["by", 54], ["complete", 57], ["or", 66], ["partial", 69], ["X", 77], ["chromosome", 79], ["monosomy", 90], ["that", 99], ["manifests", 104], ["various", 114], ["clinical", 122], ["features", 131], ["depending", 140], ["on", 150], ["the", 153], ["karyotype", 157], ["and", 167], ["on", 171], ["the", 174], ["genetic", 178], ["background", 186], ["of", 197], ["affected", 200], ["girls", 209], [".", 214], ["This", 216], ["study", 221], ["aimed", 227], ["to", 233], ["systematically", 236], ["investigate", 251], ["the", 263], ["key", 267], ["clinical", 271], ["features", 280], ["of", 289], ["TS", 292], ["in", 295], ["relationship", 298], ["to", 311], ["karyotype", 314], ["in", 324], ["a", 327], ["large", 329], ["pediatric", 335], ["Turkish", 345], ["patient", 353], ["population", 361], [".", 371], ["Our", 373], ["retrospective", 377], ["study", 391], ["included", 397], ["842", 406], ["karyotype", 410], ["-", 419], ["proven", 420], ["TS", 427], ["patients", 430], ["aged", 439], ["0", 444], ["-", 445], ["18", 446], ["years", 449], ["who", 455], ["were", 459], ["evaluated", 464], ["in", 474], ["35", 477], ["different", 480], ["centers", 490], ["in", 498], ["Turkey", 501], ["in", 508], ["the", 511], ["years", 515], ["2013", 521], ["-", 525], ["2014", 526], [".", 530], ["The", 532], ["most", 536], ["common", 541], ["karyotype", 548], ["was", 558], ["45,X", 562], ["(", 567], ["50.7", 568], ["%", 572], [")", 573], [",", 574], ["followed", 576], ["by", 585], ["45,X/46,XX", 588], ["(", 599], ["10.8", 600], ["%", 604], [")", 605], [",", 606], ["46,X", 608], [",", 612], ["i(Xq", 613], [")", 617], ["(", 619], ["10.1", 620], ["%", 624], [")", 625], ["and", 627], ["45,X/46,X", 631], [",", 640], ["i(Xq", 641], [")", 645], ["(", 647], ["9.5", 648], ["%", 651], [")", 652], [".", 653], ["Mean", 655], ["age", 660], ["at", 664], ["diagnosis", 667], ["was", 677], ["10.2\u00b14.4", 681], ["years", 690], [".", 695], ["The", 697], ["most", 701], ["common", 706], ["presenting", 713], ["complaints", 724], ["were", 735], ["short", 740], ["stature", 746], ["and", 754], ["delayed", 758], ["puberty", 766], [".", 773], ["Among", 775], ["patients", 781], ["diagnosed", 790], ["before", 800], ["age", 807], ["one", 811], ["year", 815], [",", 819], ["the", 821], ["ratio", 825], ["of", 831], ["karyotype", 834], ["45,X", 844], ["was", 849], ["significantly", 853], ["higher", 867], ["than", 874], ["that", 879], ["of", 884], ["other", 887], ["karyotype", 893], ["groups", 903], [".", 909], ["Cardiac", 911], ["defects", 919], ["(", 927], ["bicuspid", 928], ["aortic", 937], ["valve", 944], [",", 949], ["coarctation", 951], ["of", 963], ["the", 966], ["aorta", 970], ["and", 976], ["aortic", 980], ["stenosis", 987], [")", 995], ["were", 997], ["the", 1002], ["most", 1006], ["common", 1011], ["congenital", 1018], ["anomalies", 1029], [",", 1038], ["occurring", 1040], ["in", 1050], ["25", 1053], ["%", 1055], ["of", 1057], ["the", 1060], ["TS", 1064], ["cases", 1067], [".", 1072], ["This", 1074], ["was", 1079], ["followed", 1083], ["by", 1092], ["urinary", 1095], ["system", 1103], ["anomalies", 1110], ["(", 1120], ["horseshoe", 1121], ["kidney", 1131], [",", 1137], ["double", 1139], ["collector", 1146], ["duct", 1156], ["system", 1161], ["and", 1168], ["renal", 1172], ["rotation", 1178], [")", 1186], ["detected", 1188], ["in", 1197], ["16.3", 1200], ["%", 1204], [".", 1205], ["Hashimoto", 1207], ["'s", 1216], ["thyroiditis", 1219], ["was", 1231], ["found", 1235], ["in", 1241], ["11.1", 1244], ["%", 1248], ["of", 1250], ["patients", 1253], [",", 1261], ["gastrointestinal", 1263], ["abnormalities", 1280], ["in", 1294], ["8.9", 1297], ["%", 1300], [",", 1301], ["ear", 1303], ["nose", 1307], ["and", 1312], ["throat", 1316], ["problems", 1323], ["in", 1332], ["22.6", 1335], ["%", 1339], [",", 1340], ["dermatologic", 1342], ["problems", 1355], ["in", 1364], ["21.8", 1367], ["%", 1371], ["and", 1373], ["osteoporosis", 1377], ["in", 1390], ["15.3", 1393], ["%", 1397], [".", 1398], ["Learning", 1400], ["difficulties", 1409], ["and/or", 1422], ["psychosocial", 1429], ["problems", 1442], ["were", 1451], ["encountered", 1456], ["in", 1468], ["39.1", 1471], ["%", 1475], [".", 1476], ["Insulin", 1478], ["resistance", 1486], ["and", 1497], ["impaired", 1501], ["fasting", 1510], ["glucose", 1518], ["were", 1526], ["detected", 1531], ["in", 1540], ["3.4", 1543], ["%", 1546], ["and", 1548], ["2.2", 1552], ["%", 1555], [",", 1556], ["respectively", 1558], [".", 1570], ["Dyslipidemia", 1572], ["prevalence", 1585], ["was", 1596], ["11.4", 1600], ["%", 1604], [".", 1605], ["This", 1607], ["comprehensive", 1612], ["study", 1626], ["systematically", 1632], ["evaluated", 1647], ["the", 1657], ["largest", 1661], ["group", 1669], ["of", 1675], ["karyotype", 1678], ["-", 1687], ["proven", 1688], ["TS", 1695], ["girls", 1698], ["to", 1704], ["date", 1707], [".", 1711], ["The", 1713], ["karyotype", 1717], ["distribution", 1727], [",", 1739], ["congenital", 1741], ["anomaly", 1752], ["and", 1760], ["comorbidity", 1764], ["profile", 1776], ["closely", 1784], ["parallel", 1792], ["that", 1801], ["from", 1806], ["other", 1811], ["countries", 1817], ["and", 1827], ["support", 1831], ["the", 1839], ["need", 1843], ["for", 1848], ["close", 1852], ["medical", 1858], ["surveillance", 1866], ["of", 1879], ["these", 1882], ["complex", 1888], ["patients", 1896], ["throughout", 1905], ["their", 1916], ["lifespan", 1922], [".", 1930]]}
{"context": "Highly repetitive DNA sequences account for more than 50% of the human genome. The L1 and Alu families harbor the most common mammalian long (LINEs) and short (SINEs) interspersed elements. Alu elements are each a dimer of similar, but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA gene. Each element contains a bipartite promoter for RNA polymerase III, a poly(A) tract located between the monomers, a 3'-terminal poly(A) tract, and numerous CpG islands, and is flanked by short direct repeats. Alu repeats comprise more than 10% of the human genome and are capable of retroposition. Possibly, these elements played an important part in genome evolution. Insertion of an Alu element into a functionally important genome region or other Alu-dependent alterations of gene functions cause various hereditary disorders and are probably associated with carcinogenesis. In total, 14 Alu families differing in diagnostic mutations are known. Some of these, which are present in the human genome, are polymorphic and relatively recently inserted into new loci. Alu copies transposed during ethnic divergence of the human population are useful markers for evolutionary genetic studies.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "7aee0395db2b4a49bbecaa0dd253b366", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[62, 63]], "char_spans": [[312, 318]]}]}], "context_tokens": [["Highly", 0], ["repetitive", 7], ["DNA", 18], ["sequences", 22], ["account", 32], ["for", 40], ["more", 44], ["than", 49], ["50", 54], ["%", 56], ["of", 58], ["the", 61], ["human", 65], ["genome", 71], [".", 77], ["The", 79], ["L1", 83], ["and", 86], ["Alu", 90], ["families", 94], ["harbor", 103], ["the", 110], ["most", 114], ["common", 119], ["mammalian", 126], ["long", 136], ["(", 141], ["LINEs", 142], [")", 147], ["and", 149], ["short", 153], ["(", 159], ["SINEs", 160], [")", 165], ["interspersed", 167], ["elements", 180], [".", 188], ["Alu", 190], ["elements", 194], ["are", 203], ["each", 207], ["a", 212], ["dimer", 214], ["of", 220], ["similar", 223], [",", 230], ["but", 232], ["not", 236], ["identical", 240], [",", 249], ["fragments", 251], ["of", 261], ["total", 264], ["size", 270], ["about", 275], ["300", 281], ["bp", 285], [",", 287], ["and", 289], ["originate", 293], ["from", 303], ["the", 308], ["7SL", 312], ["RNA", 316], ["gene", 320], [".", 324], ["Each", 326], ["element", 331], ["contains", 339], ["a", 348], ["bipartite", 350], ["promoter", 360], ["for", 369], ["RNA", 373], ["polymerase", 377], ["III", 388], [",", 391], ["a", 393], ["poly(A", 395], [")", 401], ["tract", 403], ["located", 409], ["between", 417], ["the", 425], ["monomers", 429], [",", 437], ["a", 439], ["3'-terminal", 441], ["poly(A", 453], [")", 459], ["tract", 461], [",", 466], ["and", 468], ["numerous", 472], ["CpG", 481], ["islands", 485], [",", 492], ["and", 494], ["is", 498], ["flanked", 501], ["by", 509], ["short", 512], ["direct", 518], ["repeats", 525], [".", 532], ["Alu", 534], ["repeats", 538], ["comprise", 546], ["more", 555], ["than", 560], ["10", 565], ["%", 567], ["of", 569], ["the", 572], ["human", 576], ["genome", 582], ["and", 589], ["are", 593], ["capable", 597], ["of", 605], ["retroposition", 608], [".", 621], ["Possibly", 623], [",", 631], ["these", 633], ["elements", 639], ["played", 648], ["an", 655], ["important", 658], ["part", 668], ["in", 673], ["genome", 676], ["evolution", 683], [".", 692], ["Insertion", 694], ["of", 704], ["an", 707], ["Alu", 710], ["element", 714], ["into", 722], ["a", 727], ["functionally", 729], ["important", 742], ["genome", 752], ["region", 759], ["or", 766], ["other", 769], ["Alu", 775], ["-", 778], ["dependent", 779], ["alterations", 789], ["of", 801], ["gene", 804], ["functions", 809], ["cause", 819], ["various", 825], ["hereditary", 833], ["disorders", 844], ["and", 854], ["are", 858], ["probably", 862], ["associated", 871], ["with", 882], ["carcinogenesis", 887], [".", 901], ["In", 903], ["total", 906], [",", 911], ["14", 913], ["Alu", 916], ["families", 920], ["differing", 929], ["in", 939], ["diagnostic", 942], ["mutations", 953], ["are", 963], ["known", 967], [".", 972], ["Some", 974], ["of", 979], ["these", 982], [",", 987], ["which", 989], ["are", 995], ["present", 999], ["in", 1007], ["the", 1010], ["human", 1014], ["genome", 1020], [",", 1026], ["are", 1028], ["polymorphic", 1032], ["and", 1044], ["relatively", 1048], ["recently", 1059], ["inserted", 1068], ["into", 1077], ["new", 1082], ["loci", 1086], [".", 1090], ["Alu", 1092], ["copies", 1096], ["transposed", 1103], ["during", 1114], ["ethnic", 1121], ["divergence", 1128], ["of", 1139], ["the", 1142], ["human", 1146], ["population", 1152], ["are", 1163], ["useful", 1167], ["markers", 1174], ["for", 1182], ["evolutionary", 1186], ["genetic", 1199], ["studies", 1207], [".", 1214]]}
{"context": "Mutations in genes for any of the six subunits of NADPH oxidase cause chronic granulomatous disease (CGD), but almost 2/3 of CGD cases are caused by mutations in the X-linked CYBB gene, also known as NAD (P) H oxidase 2. Approximately 260 patients with CGD have been reported in Japan, of whom 92 were shown to have mutations of the CYBB gene and 16 to have chromosomal deletions. However, there has been very little detailed analysis of the range of the deletion or close understanding of the disease based on this. We therefore analyzed genomic rearrangements in X-linked CGD using array comparative genomic hybridization analysis, revealing the extent and the types of the deletion genes. The subjects were five Japanese X-linked CGD patients estimated to have large base deletions of 1 kb or more in the CYBB gene (four male patients, one female patient) and the mothers of four of those patients. The five Japanese patients were found to range from a patient exhibiting deletions only of the CYBB gene to a female patient exhibiting an extensive DNA deletion and the DMD and CGD phenotype manifested. Of the other three patients, two exhibited CYBB, XK, and DYNLT3 gene deletions. The remaining patient exhibited both a deletion encompassing DNA subsequent to the CYBB region following intron 2 and the DYNLT3 gene and a complex copy number variation involving the insertion of an inverted duplication of a region from the centromere side of DYNLT3 into the deleted region.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e472df4a59ae4903a88c41fd0f454190", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[220, 220]], "char_spans": [[1155, 1156]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["genes", 13], ["for", 19], ["any", 23], ["of", 27], ["the", 30], ["six", 34], ["subunits", 38], ["of", 47], ["NADPH", 50], ["oxidase", 56], ["cause", 64], ["chronic", 70], ["granulomatous", 78], ["disease", 92], ["(", 100], ["CGD", 101], [")", 104], [",", 105], ["but", 107], ["almost", 111], ["2/3", 118], ["of", 122], ["CGD", 125], ["cases", 129], ["are", 135], ["caused", 139], ["by", 146], ["mutations", 149], ["in", 159], ["the", 162], ["X", 166], ["-", 167], ["linked", 168], ["CYBB", 175], ["gene", 180], [",", 184], ["also", 186], ["known", 191], ["as", 197], ["NAD", 200], ["(", 204], ["P", 205], [")", 206], ["H", 208], ["oxidase", 210], ["2", 218], [".", 219], ["Approximately", 221], ["260", 235], ["patients", 239], ["with", 248], ["CGD", 253], ["have", 257], ["been", 262], ["reported", 267], ["in", 276], ["Japan", 279], [",", 284], ["of", 286], ["whom", 289], ["92", 294], ["were", 297], ["shown", 302], ["to", 308], ["have", 311], ["mutations", 316], ["of", 326], ["the", 329], ["CYBB", 333], ["gene", 338], ["and", 343], ["16", 347], ["to", 350], ["have", 353], ["chromosomal", 358], ["deletions", 370], [".", 379], ["However", 381], [",", 388], ["there", 390], ["has", 396], ["been", 400], ["very", 405], ["little", 410], ["detailed", 417], ["analysis", 426], ["of", 435], ["the", 438], ["range", 442], ["of", 448], ["the", 451], ["deletion", 455], ["or", 464], ["close", 467], ["understanding", 473], ["of", 487], ["the", 490], ["disease", 494], ["based", 502], ["on", 508], ["this", 511], [".", 515], ["We", 517], ["therefore", 520], ["analyzed", 530], ["genomic", 539], ["rearrangements", 547], ["in", 562], ["X", 565], ["-", 566], ["linked", 567], ["CGD", 574], ["using", 578], ["array", 584], ["comparative", 590], ["genomic", 602], ["hybridization", 610], ["analysis", 624], [",", 632], ["revealing", 634], ["the", 644], ["extent", 648], ["and", 655], ["the", 659], ["types", 663], ["of", 669], ["the", 672], ["deletion", 676], ["genes", 685], [".", 690], ["The", 692], ["subjects", 696], ["were", 705], ["five", 710], ["Japanese", 715], ["X", 724], ["-", 725], ["linked", 726], ["CGD", 733], ["patients", 737], ["estimated", 746], ["to", 756], ["have", 759], ["large", 764], ["base", 770], ["deletions", 775], ["of", 785], ["1", 788], ["kb", 790], ["or", 793], ["more", 796], ["in", 801], ["the", 804], ["CYBB", 808], ["gene", 813], ["(", 818], ["four", 819], ["male", 824], ["patients", 829], [",", 837], ["one", 839], ["female", 843], ["patient", 850], [")", 857], ["and", 859], ["the", 863], ["mothers", 867], ["of", 875], ["four", 878], ["of", 883], ["those", 886], ["patients", 892], [".", 900], ["The", 902], ["five", 906], ["Japanese", 911], ["patients", 920], ["were", 929], ["found", 934], ["to", 940], ["range", 943], ["from", 949], ["a", 954], ["patient", 956], ["exhibiting", 964], ["deletions", 975], ["only", 985], ["of", 990], ["the", 993], ["CYBB", 997], ["gene", 1002], ["to", 1007], ["a", 1010], ["female", 1012], ["patient", 1019], ["exhibiting", 1027], ["an", 1038], ["extensive", 1041], ["DNA", 1051], ["deletion", 1055], ["and", 1064], ["the", 1068], ["DMD", 1072], ["and", 1076], ["CGD", 1080], ["phenotype", 1084], ["manifested", 1094], [".", 1104], ["Of", 1106], ["the", 1109], ["other", 1113], ["three", 1119], ["patients", 1125], [",", 1133], ["two", 1135], ["exhibited", 1139], ["CYBB", 1149], [",", 1153], ["XK", 1155], [",", 1157], ["and", 1159], ["DYNLT3", 1163], ["gene", 1170], ["deletions", 1175], [".", 1184], ["The", 1186], ["remaining", 1190], ["patient", 1200], ["exhibited", 1208], ["both", 1218], ["a", 1223], ["deletion", 1225], ["encompassing", 1234], ["DNA", 1247], ["subsequent", 1251], ["to", 1262], ["the", 1265], ["CYBB", 1269], ["region", 1274], ["following", 1281], ["intron", 1291], ["2", 1298], ["and", 1300], ["the", 1304], ["DYNLT3", 1308], ["gene", 1315], ["and", 1320], ["a", 1324], ["complex", 1326], ["copy", 1334], ["number", 1339], ["variation", 1346], ["involving", 1356], ["the", 1366], ["insertion", 1370], ["of", 1380], ["an", 1383], ["inverted", 1386], ["duplication", 1395], ["of", 1407], ["a", 1410], ["region", 1412], ["from", 1419], ["the", 1424], ["centromere", 1428], ["side", 1439], ["of", 1444], ["DYNLT3", 1447], ["into", 1454], ["the", 1459], ["deleted", 1463], ["region", 1471], [".", 1477]]}
{"context": "LHCII, the largest plant photosynthetic pigment-protein complex of photosystem II, is a most abundant membrane protein in living organisms and comprises approximately half of the pool of chlorophyll molecules in the biosphere. The principal role of this pigment-protein complex is to collect sunlight quanta and transfer electronic excitations toward the reaction centers, where the primary photosynthetic electric charge separation reactions take place. The LHCII protein, as a major protein component of the photosynthetic membranes, modulates also the structural and dynamic properties of the lipid phase of the membranes. According to the recent concepts, one of the physiological roles of LHCII is also a protection of the photosynthetic apparatus against oxidative damage caused by illumination with high intensity light. Detailed examination of all those physiological functions of LHCII, in relation to the complex structure, was possible owing to the application of several molecular spectroscopy techniques. Some examples of such studies are presented in this chapter. The examples of application of steady-state and time-resolved fluorescence spectroscopy, Fourier-transform infrared absorption spectroscopy, and resonance Raman scattering spectroscopy are presented and discussed.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "25f0f26d8d674227bd9950f0a956f541", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[140, 140], [0, 0], [72, 72], [112, 112]], "char_spans": [[889, 893], [0, 4], [459, 463], [694, 698]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["largest", 11], ["plant", 19], ["photosynthetic", 25], ["pigment", 40], ["-", 47], ["protein", 48], ["complex", 56], ["of", 64], ["photosystem", 67], ["II", 79], [",", 81], ["is", 83], ["a", 86], ["most", 88], ["abundant", 93], ["membrane", 102], ["protein", 111], ["in", 119], ["living", 122], ["organisms", 129], ["and", 139], ["comprises", 143], ["approximately", 153], ["half", 167], ["of", 172], ["the", 175], ["pool", 179], ["of", 184], ["chlorophyll", 187], ["molecules", 199], ["in", 209], ["the", 212], ["biosphere", 216], [".", 225], ["The", 227], ["principal", 231], ["role", 241], ["of", 246], ["this", 249], ["pigment", 254], ["-", 261], ["protein", 262], ["complex", 270], ["is", 278], ["to", 281], ["collect", 284], ["sunlight", 292], ["quanta", 301], ["and", 308], ["transfer", 312], ["electronic", 321], ["excitations", 332], ["toward", 344], ["the", 351], ["reaction", 355], ["centers", 364], [",", 371], ["where", 373], ["the", 379], ["primary", 383], ["photosynthetic", 391], ["electric", 406], ["charge", 415], ["separation", 422], ["reactions", 433], ["take", 443], ["place", 448], [".", 453], ["The", 455], ["LHCII", 459], ["protein", 465], [",", 472], ["as", 474], ["a", 477], ["major", 479], ["protein", 485], ["component", 493], ["of", 503], ["the", 506], ["photosynthetic", 510], ["membranes", 525], [",", 534], ["modulates", 536], ["also", 546], ["the", 551], ["structural", 555], ["and", 566], ["dynamic", 570], ["properties", 578], ["of", 589], ["the", 592], ["lipid", 596], ["phase", 602], ["of", 608], ["the", 611], ["membranes", 615], [".", 624], ["According", 626], ["to", 636], ["the", 639], ["recent", 643], ["concepts", 650], [",", 658], ["one", 660], ["of", 664], ["the", 667], ["physiological", 671], ["roles", 685], ["of", 691], ["LHCII", 694], ["is", 700], ["also", 703], ["a", 708], ["protection", 710], ["of", 721], ["the", 724], ["photosynthetic", 728], ["apparatus", 743], ["against", 753], ["oxidative", 761], ["damage", 771], ["caused", 778], ["by", 785], ["illumination", 788], ["with", 801], ["high", 806], ["intensity", 811], ["light", 821], [".", 826], ["Detailed", 828], ["examination", 837], ["of", 849], ["all", 852], ["those", 856], ["physiological", 862], ["functions", 876], ["of", 886], ["LHCII", 889], [",", 894], ["in", 896], ["relation", 899], ["to", 908], ["the", 911], ["complex", 915], ["structure", 923], [",", 932], ["was", 934], ["possible", 938], ["owing", 947], ["to", 953], ["the", 956], ["application", 960], ["of", 972], ["several", 975], ["molecular", 983], ["spectroscopy", 993], ["techniques", 1006], [".", 1016], ["Some", 1018], ["examples", 1023], ["of", 1032], ["such", 1035], ["studies", 1040], ["are", 1048], ["presented", 1052], ["in", 1062], ["this", 1065], ["chapter", 1070], [".", 1077], ["The", 1079], ["examples", 1083], ["of", 1092], ["application", 1095], ["of", 1107], ["steady", 1110], ["-", 1116], ["state", 1117], ["and", 1123], ["time", 1127], ["-", 1131], ["resolved", 1132], ["fluorescence", 1141], ["spectroscopy", 1154], [",", 1166], ["Fourier", 1168], ["-", 1175], ["transform", 1176], ["infrared", 1186], ["absorption", 1195], ["spectroscopy", 1206], [",", 1218], ["and", 1220], ["resonance", 1224], ["Raman", 1234], ["scattering", 1240], ["spectroscopy", 1251], ["are", 1264], ["presented", 1268], ["and", 1278], ["discussed", 1282], [".", 1291]]}
{"context": "Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL transcript levels by RT-qPCR has become always more important to assess minimal residual disease. Recently, recommendations for harmonizing current methodologies for detecting and measuring BCR-ABL transcripts in CML patients have been suggested. Studies of imatinib-treated patients have determined that the BCR-ABL levels measured early in therapy may predict durable cytogenetic remission and in turn prolonged progression free-survival or acquisition of resistance. The major mechanism of imatinib resistance is clonal expansion of leukaemia cells with mutations in the Bcr-Abl fusion tyrosine kinase. The early reduction of such mutations may allow timely treatment intervention to prevent or overcome resistance. We review current trends in the management of chronic myeloid leukaemia patients undergoing treatment with tyrosine kinase inhibitors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "07eb57f9a700412681dd07f3b615a303", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[81, 83], [102, 104], [9, 11], [144, 146], [50, 52]], "char_spans": [[506, 512], [625, 631], [59, 65], [890, 896], [308, 314]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["binding", 19], ["to", 27], ["the", 30], ["inactive", 34], ["conformation", 43], ["of", 56], ["Bcr", 59], ["-", 62], ["Abl", 63], ["tyrosine", 67], ["kinase", 76], ["and", 83], ["suppressing", 87], ["the", 99], ["Ph", 103], ["chromosome", 106], ["positive", 117], ["clone", 126], [",", 131], ["has", 133], ["revolutionized", 137], ["the", 152], ["treatment", 156], ["of", 166], ["chronic", 169], ["myeloid", 177], ["leukaemia", 185], ["(", 195], ["CML", 196], [")", 199], ["patients", 201], [".", 209], ["Given", 211], ["the", 217], ["high", 221], ["rates", 226], ["of", 232], ["clinical", 235], ["and", 244], ["cytogenetic", 248], ["remission", 260], ["achieved", 270], [",", 278], ["the", 280], ["molecular", 284], ["monitoring", 294], ["of", 305], ["BCR", 308], ["-", 311], ["ABL", 312], ["transcript", 316], ["levels", 327], ["by", 334], ["RT", 337], ["-", 339], ["qPCR", 340], ["has", 345], ["become", 349], ["always", 356], ["more", 363], ["important", 368], ["to", 378], ["assess", 381], ["minimal", 388], ["residual", 396], ["disease", 405], [".", 412], ["Recently", 414], [",", 422], ["recommendations", 424], ["for", 440], ["harmonizing", 444], ["current", 456], ["methodologies", 464], ["for", 478], ["detecting", 482], ["and", 492], ["measuring", 496], ["BCR", 506], ["-", 509], ["ABL", 510], ["transcripts", 514], ["in", 526], ["CML", 529], ["patients", 533], ["have", 542], ["been", 547], ["suggested", 552], [".", 561], ["Studies", 563], ["of", 571], ["imatinib", 574], ["-", 582], ["treated", 583], ["patients", 591], ["have", 600], ["determined", 605], ["that", 616], ["the", 621], ["BCR", 625], ["-", 628], ["ABL", 629], ["levels", 633], ["measured", 640], ["early", 649], ["in", 655], ["therapy", 658], ["may", 666], ["predict", 670], ["durable", 678], ["cytogenetic", 686], ["remission", 698], ["and", 708], ["in", 712], ["turn", 715], ["prolonged", 720], ["progression", 730], ["free", 742], ["-", 746], ["survival", 747], ["or", 756], ["acquisition", 759], ["of", 771], ["resistance", 774], [".", 784], ["The", 786], ["major", 790], ["mechanism", 796], ["of", 806], ["imatinib", 809], ["resistance", 818], ["is", 829], ["clonal", 832], ["expansion", 839], ["of", 849], ["leukaemia", 852], ["cells", 862], ["with", 868], ["mutations", 873], ["in", 883], ["the", 886], ["Bcr", 890], ["-", 893], ["Abl", 894], ["fusion", 898], ["tyrosine", 905], ["kinase", 914], [".", 920], ["The", 922], ["early", 926], ["reduction", 932], ["of", 942], ["such", 945], ["mutations", 950], ["may", 960], ["allow", 964], ["timely", 970], ["treatment", 977], ["intervention", 987], ["to", 1000], ["prevent", 1003], ["or", 1011], ["overcome", 1014], ["resistance", 1023], [".", 1033], ["We", 1035], ["review", 1038], ["current", 1045], ["trends", 1053], ["in", 1060], ["the", 1063], ["management", 1067], ["of", 1078], ["chronic", 1081], ["myeloid", 1089], ["leukaemia", 1097], ["patients", 1107], ["undergoing", 1116], ["treatment", 1127], ["with", 1137], ["tyrosine", 1142], ["kinase", 1151], ["inhibitors", 1158], [".", 1168]]}
{"context": "Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the determination at a central laboratory of the dilute thrombin time or ecarin clotting time. A key secondary end point was the restoration of hemostasis. This interim analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B). Among 68 patients with an elevated dilute thrombin time and 81 with an elevated ecarin clotting time at baseline, the median maximum percentage reversal was 100% (95% confidence interval, 100 to 100). Idarucizumab normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes. Concentrations of unbound dabigatran remained below 20 ng per milliliter at 24 hours in 79% of the patients. Among 35 patients in group A who could be assessed, hemostasis, as determined by local investigators, was restored at a median of 11.4 hours. Among 36 patients in group B who underwent a procedure, normal intraoperative hemostasis was reported in 33, and mildly or moderately abnormal hemostasis was reported in 2 patients and 1 patient, respectively. One thrombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoagulants had not been reinitiated. Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.).", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "34511ff99544417f936dc6f115803c07", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[326, 326], [90, 90], [28, 28], [217, 217], [55, 55]], "char_spans": [[1870, 1879], [538, 547], [177, 186], [1232, 1241], [348, 357]]}]}], "context_tokens": [["Specific", 0], ["reversal", 9], ["agents", 18], ["for", 25], ["non", 29], ["-", 32], ["vitamin", 33], ["K", 41], ["antagonist", 43], ["oral", 54], ["anticoagulants", 59], ["are", 74], ["lacking", 78], [".", 85], ["Idarucizumab", 87], [",", 99], ["an", 101], ["antibody", 104], ["fragment", 113], [",", 121], ["was", 123], ["developed", 127], ["to", 137], ["reverse", 140], ["the", 148], ["anticoagulant", 152], ["effects", 166], ["of", 174], ["dabigatran", 177], [".", 187], ["We", 189], ["undertook", 192], ["this", 202], ["prospective", 207], ["cohort", 219], ["study", 226], ["to", 232], ["determine", 235], ["the", 245], ["safety", 249], ["of", 256], ["5", 259], ["g", 261], ["of", 263], ["intravenous", 266], ["idarucizumab", 278], ["and", 291], ["its", 295], ["capacity", 299], ["to", 308], ["reverse", 311], ["the", 319], ["anticoagulant", 323], ["effects", 337], ["of", 345], ["dabigatran", 348], ["in", 359], ["patients", 362], ["who", 371], ["had", 375], ["serious", 379], ["bleeding", 387], ["(", 396], ["group", 397], ["A", 403], [")", 404], ["or", 406], ["required", 409], ["an", 418], ["urgent", 421], ["procedure", 428], ["(", 438], ["group", 439], ["B", 445], [")", 446], [".", 447], ["The", 449], ["primary", 453], ["end", 461], ["point", 465], ["was", 471], ["the", 475], ["maximum", 479], ["percentage", 487], ["reversal", 498], ["of", 507], ["the", 510], ["anticoagulant", 514], ["effect", 528], ["of", 535], ["dabigatran", 538], ["within", 549], ["4", 556], ["hours", 558], ["after", 564], ["the", 570], ["administration", 574], ["of", 589], ["idarucizumab", 592], [",", 604], ["on", 606], ["the", 609], ["basis", 613], ["of", 619], ["the", 622], ["determination", 626], ["at", 640], ["a", 643], ["central", 645], ["laboratory", 653], ["of", 664], ["the", 667], ["dilute", 671], ["thrombin", 678], ["time", 687], ["or", 692], ["ecarin", 695], ["clotting", 702], ["time", 711], [".", 715], ["A", 717], ["key", 719], ["secondary", 723], ["end", 733], ["point", 737], ["was", 743], ["the", 747], ["restoration", 751], ["of", 763], ["hemostasis", 766], [".", 776], ["This", 778], ["interim", 783], ["analysis", 791], ["included", 800], ["90", 809], ["patients", 812], ["who", 821], ["received", 825], ["idarucizumab", 834], ["(", 847], ["51", 848], ["patients", 851], ["in", 860], ["group", 863], ["A", 869], ["and", 871], ["39", 875], ["in", 878], ["group", 881], ["B", 887], [")", 888], [".", 889], ["Among", 891], ["68", 897], ["patients", 900], ["with", 909], ["an", 914], ["elevated", 917], ["dilute", 926], ["thrombin", 933], ["time", 942], ["and", 947], ["81", 951], ["with", 954], ["an", 959], ["elevated", 962], ["ecarin", 971], ["clotting", 978], ["time", 987], ["at", 992], ["baseline", 995], [",", 1003], ["the", 1005], ["median", 1009], ["maximum", 1016], ["percentage", 1024], ["reversal", 1035], ["was", 1044], ["100", 1048], ["%", 1051], ["(", 1053], ["95", 1054], ["%", 1056], ["confidence", 1058], ["interval", 1069], [",", 1077], ["100", 1079], ["to", 1083], ["100", 1086], [")", 1089], [".", 1090], ["Idarucizumab", 1092], ["normalized", 1105], ["the", 1116], ["test", 1120], ["results", 1125], ["in", 1133], ["88", 1136], ["to", 1139], ["98", 1142], ["%", 1144], ["of", 1146], ["the", 1149], ["patients", 1153], [",", 1161], ["an", 1163], ["effect", 1166], ["that", 1173], ["was", 1178], ["evident", 1182], ["within", 1190], ["minutes", 1197], [".", 1204], ["Concentrations", 1206], ["of", 1221], ["unbound", 1224], ["dabigatran", 1232], ["remained", 1243], ["below", 1252], ["20", 1258], ["ng", 1261], ["per", 1264], ["milliliter", 1268], ["at", 1279], ["24", 1282], ["hours", 1285], ["in", 1291], ["79", 1294], ["%", 1296], ["of", 1298], ["the", 1301], ["patients", 1305], [".", 1313], ["Among", 1315], ["35", 1321], ["patients", 1324], ["in", 1333], ["group", 1336], ["A", 1342], ["who", 1344], ["could", 1348], ["be", 1354], ["assessed", 1357], [",", 1365], ["hemostasis", 1367], [",", 1377], ["as", 1379], ["determined", 1382], ["by", 1393], ["local", 1396], ["investigators", 1402], [",", 1415], ["was", 1417], ["restored", 1421], ["at", 1430], ["a", 1433], ["median", 1435], ["of", 1442], ["11.4", 1445], ["hours", 1450], [".", 1455], ["Among", 1457], ["36", 1463], ["patients", 1466], ["in", 1475], ["group", 1478], ["B", 1484], ["who", 1486], ["underwent", 1490], ["a", 1500], ["procedure", 1502], [",", 1511], ["normal", 1513], ["intraoperative", 1520], ["hemostasis", 1535], ["was", 1546], ["reported", 1550], ["in", 1559], ["33", 1562], [",", 1564], ["and", 1566], ["mildly", 1570], ["or", 1577], ["moderately", 1580], ["abnormal", 1591], ["hemostasis", 1600], ["was", 1611], ["reported", 1615], ["in", 1624], ["2", 1627], ["patients", 1629], ["and", 1638], ["1", 1642], ["patient", 1644], [",", 1651], ["respectively", 1653], [".", 1665], ["One", 1667], ["thrombotic", 1671], ["event", 1682], ["occurred", 1688], ["within", 1697], ["72", 1704], ["hours", 1707], ["after", 1713], ["idarucizumab", 1719], ["administration", 1732], ["in", 1747], ["a", 1750], ["patient", 1752], ["in", 1760], ["whom", 1763], ["anticoagulants", 1768], ["had", 1783], ["not", 1787], ["been", 1791], ["reinitiated", 1796], [".", 1807], ["Idarucizumab", 1809], ["completely", 1822], ["reversed", 1833], ["the", 1842], ["anticoagulant", 1846], ["effect", 1860], ["of", 1867], ["dabigatran", 1870], ["within", 1881], ["minutes", 1888], [".", 1895], ["(", 1897], ["Funded", 1898], ["by", 1905], ["Boehringer", 1908], ["Ingelheim", 1919], [";", 1928], ["RE", 1930], ["-", 1932], ["VERSE", 1933], ["AD", 1939], ["ClinicalTrials.gov", 1942], ["number", 1961], [",", 1967], ["NCT02104947", 1969], [".", 1980], [")", 1981], [".", 1982]]}
{"context": "Estrogens and progesterones are major drivers of breast development but also promote carcinogenesis in this organ. Yet, their respective roles and the mechanisms underlying their action in the human breast are unclear. Receptor activator of nuclear factor \u03baB ligand (RANKL) has been identified as a pivotal paracrine mediator of progesterone function in mouse mammary gland development and mammary carcinogenesis. Whether the factor has the same role in humans is of clinical interest because an inhibitor for RANKL, denosumab, is already used for the treatment of bone disease and might benefit breast cancer patients. We show that progesterone receptor (PR) signaling failed to induce RANKL in PR(+) breast cancer cell lines and in dissociated, cultured breast epithelial cells. In clinical specimens from healthy donors and intact breast tissue microstructures, hormone response was maintained and RANKL expression was under progesterone control, which increased RNA stability. RANKL was sufficient to trigger cell proliferation and was required for progesterone-induced proliferation. The findings were validated in vivo where RANKL protein expression in the breast epithelium correlated with serum progesterone levels and the protein was expressed in a subset of luminal cells that express PR. Thus, important hormonal control mechanisms are conserved across species, making RANKL a potential target in breast cancer treatment and prevention.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "7396c54d3c39402c9b7c126ac3529764", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[160, 160], [43, 43], [82, 82], [148, 148], [183, 183], [222, 222], [114, 114]], "char_spans": [[981, 985], [267, 271], [510, 514], [901, 905], [1131, 1135], [1380, 1384], [687, 691]]}]}], "context_tokens": [["Estrogens", 0], ["and", 10], ["progesterones", 14], ["are", 28], ["major", 32], ["drivers", 38], ["of", 46], ["breast", 49], ["development", 56], ["but", 68], ["also", 72], ["promote", 77], ["carcinogenesis", 85], ["in", 100], ["this", 103], ["organ", 108], [".", 113], ["Yet", 115], [",", 118], ["their", 120], ["respective", 126], ["roles", 137], ["and", 143], ["the", 147], ["mechanisms", 151], ["underlying", 162], ["their", 173], ["action", 179], ["in", 186], ["the", 189], ["human", 193], ["breast", 199], ["are", 206], ["unclear", 210], [".", 217], ["Receptor", 219], ["activator", 228], ["of", 238], ["nuclear", 241], ["factor", 249], ["\u03baB", 256], ["ligand", 259], ["(", 266], ["RANKL", 267], [")", 272], ["has", 274], ["been", 278], ["identified", 283], ["as", 294], ["a", 297], ["pivotal", 299], ["paracrine", 307], ["mediator", 317], ["of", 326], ["progesterone", 329], ["function", 342], ["in", 351], ["mouse", 354], ["mammary", 360], ["gland", 368], ["development", 374], ["and", 386], ["mammary", 390], ["carcinogenesis", 398], [".", 412], ["Whether", 414], ["the", 422], ["factor", 426], ["has", 433], ["the", 437], ["same", 441], ["role", 446], ["in", 451], ["humans", 454], ["is", 461], ["of", 464], ["clinical", 467], ["interest", 476], ["because", 485], ["an", 493], ["inhibitor", 496], ["for", 506], ["RANKL", 510], [",", 515], ["denosumab", 517], [",", 526], ["is", 528], ["already", 531], ["used", 539], ["for", 544], ["the", 548], ["treatment", 552], ["of", 562], ["bone", 565], ["disease", 570], ["and", 578], ["might", 582], ["benefit", 588], ["breast", 596], ["cancer", 603], ["patients", 610], [".", 618], ["We", 620], ["show", 623], ["that", 628], ["progesterone", 633], ["receptor", 646], ["(", 655], ["PR", 656], [")", 658], ["signaling", 660], ["failed", 670], ["to", 677], ["induce", 680], ["RANKL", 687], ["in", 693], ["PR(+", 696], [")", 700], ["breast", 702], ["cancer", 709], ["cell", 716], ["lines", 721], ["and", 727], ["in", 731], ["dissociated", 734], [",", 745], ["cultured", 747], ["breast", 756], ["epithelial", 763], ["cells", 774], [".", 779], ["In", 781], ["clinical", 784], ["specimens", 793], ["from", 803], ["healthy", 808], ["donors", 816], ["and", 823], ["intact", 827], ["breast", 834], ["tissue", 841], ["microstructures", 848], [",", 863], ["hormone", 865], ["response", 873], ["was", 882], ["maintained", 886], ["and", 897], ["RANKL", 901], ["expression", 907], ["was", 918], ["under", 922], ["progesterone", 928], ["control", 941], [",", 948], ["which", 950], ["increased", 956], ["RNA", 966], ["stability", 970], [".", 979], ["RANKL", 981], ["was", 987], ["sufficient", 991], ["to", 1002], ["trigger", 1005], ["cell", 1013], ["proliferation", 1018], ["and", 1032], ["was", 1036], ["required", 1040], ["for", 1049], ["progesterone", 1053], ["-", 1065], ["induced", 1066], ["proliferation", 1074], [".", 1087], ["The", 1089], ["findings", 1093], ["were", 1102], ["validated", 1107], ["in", 1117], ["vivo", 1120], ["where", 1125], ["RANKL", 1131], ["protein", 1137], ["expression", 1145], ["in", 1156], ["the", 1159], ["breast", 1163], ["epithelium", 1170], ["correlated", 1181], ["with", 1192], ["serum", 1197], ["progesterone", 1203], ["levels", 1216], ["and", 1223], ["the", 1227], ["protein", 1231], ["was", 1239], ["expressed", 1243], ["in", 1253], ["a", 1256], ["subset", 1258], ["of", 1265], ["luminal", 1268], ["cells", 1276], ["that", 1282], ["express", 1287], ["PR", 1295], [".", 1297], ["Thus", 1299], [",", 1303], ["important", 1305], ["hormonal", 1315], ["control", 1324], ["mechanisms", 1332], ["are", 1343], ["conserved", 1347], ["across", 1357], ["species", 1364], [",", 1371], ["making", 1373], ["RANKL", 1380], ["a", 1386], ["potential", 1388], ["target", 1398], ["in", 1405], ["breast", 1408], ["cancer", 1415], ["treatment", 1422], ["and", 1432], ["prevention", 1436], [".", 1446]]}
{"context": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents. Heterophile antibody tests, including the Monospot test, are red cell or latex agglutination assays, which detect antired cell antibodies produced as part of a polyclonal antibody response occurring during EBV infection. Heterophile antibody tests are rapid, cheap and specific tests that can be performed from the onset of symptoms of infectious mononucleosis. In adolescents, heterophile antibody tests have high specificity and sensitivity in the diagnosis of primary acute EBV infection. However, the tests have low sensitivity and low negative predictive value in young children and are not useful under the age of 4. Heterophile tests may be positive in other viral infections, autoimmune disease and haematological malignancies, but do not appear to be positive in primary bacterial infection. Virus-specific serology is required in children under the age of 4 or if an older child is heterophile negative. Virus-specific serology allows diagnosis and the pattern of positivity and negativity enables the clinician to stage the EBV infection. Virus-specific serology appears to have better sensitivity in young children, but there is cross-reaction with other herpesvirus infections, a longer turnaround time and it is more expensive to perform. Further research is needed to establish which children benefit from and hence require testing for heterophile antibodies, the cost-effectiveness of EBV investigations and whether heterophile titres have predictive value for the severity of infection and the likelihood of complications.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "57dcf6f202754ad999100460e1b5d6c0", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[0, 3]], "char_spans": [[0, 17]]}]}], "context_tokens": [["Epstein", 0], ["-", 7], ["Barr", 8], ["virus", 13], ["(", 19], ["EBV", 20], [")", 23], ["is", 25], ["a", 28], ["highly", 30], ["prevalent", 37], ["virus", 47], [",", 52], ["transmitted", 54], ["via", 66], ["saliva", 70], [",", 76], ["which", 78], ["often", 84], ["causes", 90], ["asymptomatic", 97], ["infection", 110], ["in", 120], ["children", 123], ["but", 132], ["frequently", 136], ["results", 147], ["in", 155], ["infectious", 158], ["mononucleosis", 169], ["in", 183], ["adolescents", 186], [".", 197], ["Heterophile", 199], ["antibody", 211], ["tests", 220], [",", 225], ["including", 227], ["the", 237], ["Monospot", 241], ["test", 250], [",", 254], ["are", 256], ["red", 260], ["cell", 264], ["or", 269], ["latex", 272], ["agglutination", 278], ["assays", 292], [",", 298], ["which", 300], ["detect", 306], ["antired", 313], ["cell", 321], ["antibodies", 326], ["produced", 337], ["as", 346], ["part", 349], ["of", 354], ["a", 357], ["polyclonal", 359], ["antibody", 370], ["response", 379], ["occurring", 388], ["during", 398], ["EBV", 405], ["infection", 409], [".", 418], ["Heterophile", 420], ["antibody", 432], ["tests", 441], ["are", 447], ["rapid", 451], [",", 456], ["cheap", 458], ["and", 464], ["specific", 468], ["tests", 477], ["that", 483], ["can", 488], ["be", 492], ["performed", 495], ["from", 505], ["the", 510], ["onset", 514], ["of", 520], ["symptoms", 523], ["of", 532], ["infectious", 535], ["mononucleosis", 546], [".", 559], ["In", 561], ["adolescents", 564], [",", 575], ["heterophile", 577], ["antibody", 589], ["tests", 598], ["have", 604], ["high", 609], ["specificity", 614], ["and", 626], ["sensitivity", 630], ["in", 642], ["the", 645], ["diagnosis", 649], ["of", 659], ["primary", 662], ["acute", 670], ["EBV", 676], ["infection", 680], [".", 689], ["However", 691], [",", 698], ["the", 700], ["tests", 704], ["have", 710], ["low", 715], ["sensitivity", 719], ["and", 731], ["low", 735], ["negative", 739], ["predictive", 748], ["value", 759], ["in", 765], ["young", 768], ["children", 774], ["and", 783], ["are", 787], ["not", 791], ["useful", 795], ["under", 802], ["the", 808], ["age", 812], ["of", 816], ["4", 819], [".", 820], ["Heterophile", 822], ["tests", 834], ["may", 840], ["be", 844], ["positive", 847], ["in", 856], ["other", 859], ["viral", 865], ["infections", 871], [",", 881], ["autoimmune", 883], ["disease", 894], ["and", 902], ["haematological", 906], ["malignancies", 921], [",", 933], ["but", 935], ["do", 939], ["not", 942], ["appear", 946], ["to", 953], ["be", 956], ["positive", 959], ["in", 968], ["primary", 971], ["bacterial", 979], ["infection", 989], [".", 998], ["Virus", 1000], ["-", 1005], ["specific", 1006], ["serology", 1015], ["is", 1024], ["required", 1027], ["in", 1036], ["children", 1039], ["under", 1048], ["the", 1054], ["age", 1058], ["of", 1062], ["4", 1065], ["or", 1067], ["if", 1070], ["an", 1073], ["older", 1076], ["child", 1082], ["is", 1088], ["heterophile", 1091], ["negative", 1103], [".", 1111], ["Virus", 1113], ["-", 1118], ["specific", 1119], ["serology", 1128], ["allows", 1137], ["diagnosis", 1144], ["and", 1154], ["the", 1158], ["pattern", 1162], ["of", 1170], ["positivity", 1173], ["and", 1184], ["negativity", 1188], ["enables", 1199], ["the", 1207], ["clinician", 1211], ["to", 1221], ["stage", 1224], ["the", 1230], ["EBV", 1234], ["infection", 1238], [".", 1247], ["Virus", 1249], ["-", 1254], ["specific", 1255], ["serology", 1264], ["appears", 1273], ["to", 1281], ["have", 1284], ["better", 1289], ["sensitivity", 1296], ["in", 1308], ["young", 1311], ["children", 1317], [",", 1325], ["but", 1327], ["there", 1331], ["is", 1337], ["cross", 1340], ["-", 1345], ["reaction", 1346], ["with", 1355], ["other", 1360], ["herpesvirus", 1366], ["infections", 1378], [",", 1388], ["a", 1390], ["longer", 1392], ["turnaround", 1399], ["time", 1410], ["and", 1415], ["it", 1419], ["is", 1422], ["more", 1425], ["expensive", 1430], ["to", 1440], ["perform", 1443], [".", 1450], ["Further", 1452], ["research", 1460], ["is", 1469], ["needed", 1472], ["to", 1479], ["establish", 1482], ["which", 1492], ["children", 1498], ["benefit", 1507], ["from", 1515], ["and", 1520], ["hence", 1524], ["require", 1530], ["testing", 1538], ["for", 1546], ["heterophile", 1550], ["antibodies", 1562], [",", 1572], ["the", 1574], ["cost", 1578], ["-", 1582], ["effectiveness", 1583], ["of", 1597], ["EBV", 1600], ["investigations", 1604], ["and", 1619], ["whether", 1623], ["heterophile", 1631], ["titres", 1643], ["have", 1650], ["predictive", 1655], ["value", 1666], ["for", 1672], ["the", 1676], ["severity", 1680], ["of", 1689], ["infection", 1692], ["and", 1702], ["the", 1706], ["likelihood", 1710], ["of", 1721], ["complications", 1724], [".", 1737]]}
{"context": "Sodium/glucose cotransporter 2 (SGLT2) inhibitors are oral hypoglycemic agents used to treat patients with diabetes mellitus. SGLT2 inhibitors block reabsorption of filtered glucose by inhibiting SGLT2, the primary glucose transporter in the proximal tubular cell (PTC), leading to glycosuria and lowering of serum glucose. We examined the renoprotective effects of the SGLT2 inhibitor empagliflozin to determine whether blocking glucose entry into the kidney PTCs reduced the inflammatory and fibrotic responses of the cell to high glucose. We used an in vitro model of human PTCs. HK2 cells (human kidney PTC line) were exposed to control 5 mM, high glucose (HG) 30 mM or the profibrotic cytokine transforming growth factor beta (TGF\u03b21; 0.5 ng/ml) in the presence and absence of empagliflozin for up to 72 h. SGLT1 and 2 expression and various inflammatory/fibrotic markers were assessed. A chromatin immunoprecipitation assay was used to determine the binding of phosphorylated smad3 to the promoter region of the SGLT2 gene. Our data showed that TGF\u03b21 but not HG increased SGLT2 expression and this occurred via phosphorylated smad3. HG induced expression of Toll-like receptor-4, increased nuclear deoxyribonucleic acid binding for nuclear factor kappa B (NF-\u03baB) and activator protein 1, induced collagen IV expression as well as interleukin-6 secretion all of which were attenuated with empagliflozin. Empagliflozin did not reduce high mobility group box protein 1 induced NF-\u03baB suggesting that its effect is specifically related to a reduction in glycotoxicity. SGLT1 and GLUT2 expression was not significantly altered with HG or empagliflozin. In conclusion, empagliflozin reduces HG induced inflammatory and fibrotic markers by blocking glucose transport and did not induce a compensatory increase in SGLT1/GLUT2 expression. Although HG itself does not regulate SGLT2 expression in our model, TGF\u03b2 increases SGLT2 expression through phosphorylated smad3.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "5cd8e8a3b0244a109179dd5aad4fab3b", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[179, 179], [21, 21], [61, 61], [6, 6], [326, 326], [318, 318], [30, 30], [191, 191]], "char_spans": [[1017, 1021], [126, 130], [370, 374], [32, 36], [1917, 1921], [1871, 1875], [196, 200], [1077, 1081]]}]}], "context_tokens": [["Sodium", 0], ["/", 6], ["glucose", 7], ["cotransporter", 15], ["2", 29], ["(", 31], ["SGLT2", 32], [")", 37], ["inhibitors", 39], ["are", 50], ["oral", 54], ["hypoglycemic", 59], ["agents", 72], ["used", 79], ["to", 84], ["treat", 87], ["patients", 93], ["with", 102], ["diabetes", 107], ["mellitus", 116], [".", 124], ["SGLT2", 126], ["inhibitors", 132], ["block", 143], ["reabsorption", 149], ["of", 162], ["filtered", 165], ["glucose", 174], ["by", 182], ["inhibiting", 185], ["SGLT2", 196], [",", 201], ["the", 203], ["primary", 207], ["glucose", 215], ["transporter", 223], ["in", 235], ["the", 238], ["proximal", 242], ["tubular", 251], ["cell", 259], ["(", 264], ["PTC", 265], [")", 268], [",", 269], ["leading", 271], ["to", 279], ["glycosuria", 282], ["and", 293], ["lowering", 297], ["of", 306], ["serum", 309], ["glucose", 315], [".", 322], ["We", 324], ["examined", 327], ["the", 336], ["renoprotective", 340], ["effects", 355], ["of", 363], ["the", 366], ["SGLT2", 370], ["inhibitor", 376], ["empagliflozin", 386], ["to", 400], ["determine", 403], ["whether", 413], ["blocking", 421], ["glucose", 430], ["entry", 438], ["into", 444], ["the", 449], ["kidney", 453], ["PTCs", 460], ["reduced", 465], ["the", 473], ["inflammatory", 477], ["and", 490], ["fibrotic", 494], ["responses", 503], ["of", 513], ["the", 516], ["cell", 520], ["to", 525], ["high", 528], ["glucose", 533], [".", 540], ["We", 542], ["used", 545], ["an", 550], ["in", 553], ["vitro", 556], ["model", 562], ["of", 568], ["human", 571], ["PTCs", 577], [".", 581], ["HK2", 583], ["cells", 587], ["(", 593], ["human", 594], ["kidney", 600], ["PTC", 607], ["line", 611], [")", 615], ["were", 617], ["exposed", 622], ["to", 630], ["control", 633], ["5", 641], ["mM", 643], [",", 645], ["high", 647], ["glucose", 652], ["(", 660], ["HG", 661], [")", 663], ["30", 665], ["mM", 668], ["or", 671], ["the", 674], ["profibrotic", 678], ["cytokine", 690], ["transforming", 699], ["growth", 712], ["factor", 719], ["beta", 726], ["(", 731], ["TGF\u03b21", 732], [";", 737], ["0.5", 739], ["ng", 743], ["/", 745], ["ml", 746], [")", 748], ["in", 750], ["the", 753], ["presence", 757], ["and", 766], ["absence", 770], ["of", 778], ["empagliflozin", 781], ["for", 795], ["up", 799], ["to", 802], ["72", 805], ["h.", 808], ["SGLT1", 811], ["and", 817], ["2", 821], ["expression", 823], ["and", 834], ["various", 838], ["inflammatory", 846], ["/", 858], ["fibrotic", 859], ["markers", 868], ["were", 876], ["assessed", 881], [".", 889], ["A", 891], ["chromatin", 893], ["immunoprecipitation", 903], ["assay", 923], ["was", 929], ["used", 933], ["to", 938], ["determine", 941], ["the", 951], ["binding", 955], ["of", 963], ["phosphorylated", 966], ["smad3", 981], ["to", 987], ["the", 990], ["promoter", 994], ["region", 1003], ["of", 1010], ["the", 1013], ["SGLT2", 1017], ["gene", 1023], [".", 1027], ["Our", 1029], ["data", 1033], ["showed", 1038], ["that", 1045], ["TGF\u03b21", 1050], ["but", 1056], ["not", 1060], ["HG", 1064], ["increased", 1067], ["SGLT2", 1077], ["expression", 1083], ["and", 1094], ["this", 1098], ["occurred", 1103], ["via", 1112], ["phosphorylated", 1116], ["smad3", 1131], [".", 1136], ["HG", 1138], ["induced", 1141], ["expression", 1149], ["of", 1160], ["Toll", 1163], ["-", 1167], ["like", 1168], ["receptor-4", 1173], [",", 1183], ["increased", 1185], ["nuclear", 1195], ["deoxyribonucleic", 1203], ["acid", 1220], ["binding", 1225], ["for", 1233], ["nuclear", 1237], ["factor", 1245], ["kappa", 1252], ["B", 1258], ["(", 1260], ["NF", 1261], ["-", 1263], ["\u03baB", 1264], [")", 1266], ["and", 1268], ["activator", 1272], ["protein", 1282], ["1", 1290], [",", 1291], ["induced", 1293], ["collagen", 1301], ["IV", 1310], ["expression", 1313], ["as", 1324], ["well", 1327], ["as", 1332], ["interleukin-6", 1335], ["secretion", 1349], ["all", 1359], ["of", 1363], ["which", 1366], ["were", 1372], ["attenuated", 1377], ["with", 1388], ["empagliflozin", 1393], [".", 1406], ["Empagliflozin", 1408], ["did", 1422], ["not", 1426], ["reduce", 1430], ["high", 1437], ["mobility", 1442], ["group", 1451], ["box", 1457], ["protein", 1461], ["1", 1469], ["induced", 1471], ["NF", 1479], ["-", 1481], ["\u03baB", 1482], ["suggesting", 1485], ["that", 1496], ["its", 1501], ["effect", 1505], ["is", 1512], ["specifically", 1515], ["related", 1528], ["to", 1536], ["a", 1539], ["reduction", 1541], ["in", 1551], ["glycotoxicity", 1554], [".", 1567], ["SGLT1", 1569], ["and", 1575], ["GLUT2", 1579], ["expression", 1585], ["was", 1596], ["not", 1600], ["significantly", 1604], ["altered", 1618], ["with", 1626], ["HG", 1631], ["or", 1634], ["empagliflozin", 1637], [".", 1650], ["In", 1652], ["conclusion", 1655], [",", 1665], ["empagliflozin", 1667], ["reduces", 1681], ["HG", 1689], ["induced", 1692], ["inflammatory", 1700], ["and", 1713], ["fibrotic", 1717], ["markers", 1726], ["by", 1734], ["blocking", 1737], ["glucose", 1746], ["transport", 1754], ["and", 1764], ["did", 1768], ["not", 1772], ["induce", 1776], ["a", 1783], ["compensatory", 1785], ["increase", 1798], ["in", 1807], ["SGLT1/GLUT2", 1810], ["expression", 1822], [".", 1832], ["Although", 1834], ["HG", 1843], ["itself", 1846], ["does", 1853], ["not", 1858], ["regulate", 1862], ["SGLT2", 1871], ["expression", 1877], ["in", 1888], ["our", 1891], ["model", 1895], [",", 1900], ["TGF\u03b2", 1902], ["increases", 1907], ["SGLT2", 1917], ["expression", 1923], ["through", 1934], ["phosphorylated", 1942], ["smad3", 1957], [".", 1962]]}
{"context": "Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is a potent and promising anti-HIV molecule. It is currently being investigated for use as a vaginal microbicide in two dosage forms, a semi-solid gel and a silicone elastomer ring. Quick-dissolving films are promising and attractive dosage forms that may provide an alternative platform for the vaginal delivery of microbicide drug candidates. Vaginal films may provide advantages such as discreet use, no product leakage during use, lack of requirement for an applicator for insertion, rapid drug release and minimal packaging and reduced wastage. Within this study the in vitro bioactivity of dapivirine as compared to the NNRTI UC781 was further established and a quick dissolve film was developed for vaginal application of dapivirine for prevention of HIV infection. The developed film was characterized with respect to its physical and chemical attributes including water content, mechanical strength, drug release profile, permeability, compatibility with lactobacilli and bioactivity. The anti-HIV activity of the formulated dapivirine film was confirmed in in vitro and ex vivo models. Importantly the physical and chemical properties of the film as well as its bioactivity were maintained for a period of 18 months. In conclusion, a vaginal film containing dapivirine was developed and characterized. The film was shown to prevent HIV-1 infection in vitro and ex vivo and have acceptable characteristics which make this film a promising candidate for testing as vaginal microbicide.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "74501bd3f1354fecae7e54e935faa3e9", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[140, 140], [17, 17], [178, 178]], "char_spans": [[820, 822], [93, 95], [1065, 1067]]}]}], "context_tokens": [["Dapivirine", 0], [",", 10], ["a", 12], ["non", 14], ["-", 17], ["nucleoside", 18], ["reverse", 29], ["transcriptase", 37], ["inhibitor", 51], [",", 60], ["is", 62], ["a", 65], ["potent", 67], ["and", 74], ["promising", 78], ["anti", 88], ["-", 92], ["HIV", 93], ["molecule", 97], [".", 105], ["It", 107], ["is", 110], ["currently", 113], ["being", 123], ["investigated", 129], ["for", 142], ["use", 146], ["as", 150], ["a", 153], ["vaginal", 155], ["microbicide", 163], ["in", 175], ["two", 178], ["dosage", 182], ["forms", 189], [",", 194], ["a", 196], ["semi", 198], ["-", 202], ["solid", 203], ["gel", 209], ["and", 213], ["a", 217], ["silicone", 219], ["elastomer", 228], ["ring", 238], [".", 242], ["Quick", 244], ["-", 249], ["dissolving", 250], ["films", 261], ["are", 267], ["promising", 271], ["and", 281], ["attractive", 285], ["dosage", 296], ["forms", 303], ["that", 309], ["may", 314], ["provide", 318], ["an", 326], ["alternative", 329], ["platform", 341], ["for", 350], ["the", 354], ["vaginal", 358], ["delivery", 366], ["of", 375], ["microbicide", 378], ["drug", 390], ["candidates", 395], [".", 405], ["Vaginal", 407], ["films", 415], ["may", 421], ["provide", 425], ["advantages", 433], ["such", 444], ["as", 449], ["discreet", 452], ["use", 461], [",", 464], ["no", 466], ["product", 469], ["leakage", 477], ["during", 485], ["use", 492], [",", 495], ["lack", 497], ["of", 502], ["requirement", 505], ["for", 517], ["an", 521], ["applicator", 524], ["for", 535], ["insertion", 539], [",", 548], ["rapid", 550], ["drug", 556], ["release", 561], ["and", 569], ["minimal", 573], ["packaging", 581], ["and", 591], ["reduced", 595], ["wastage", 603], [".", 610], ["Within", 612], ["this", 619], ["study", 624], ["the", 630], ["in", 634], ["vitro", 637], ["bioactivity", 643], ["of", 655], ["dapivirine", 658], ["as", 669], ["compared", 672], ["to", 681], ["the", 684], ["NNRTI", 688], ["UC781", 694], ["was", 700], ["further", 704], ["established", 712], ["and", 724], ["a", 728], ["quick", 730], ["dissolve", 736], ["film", 745], ["was", 750], ["developed", 754], ["for", 764], ["vaginal", 768], ["application", 776], ["of", 788], ["dapivirine", 791], ["for", 802], ["prevention", 806], ["of", 817], ["HIV", 820], ["infection", 824], [".", 833], ["The", 835], ["developed", 839], ["film", 849], ["was", 854], ["characterized", 858], ["with", 872], ["respect", 877], ["to", 885], ["its", 888], ["physical", 892], ["and", 901], ["chemical", 905], ["attributes", 914], ["including", 925], ["water", 935], ["content", 941], [",", 948], ["mechanical", 950], ["strength", 961], [",", 969], ["drug", 971], ["release", 976], ["profile", 984], [",", 991], ["permeability", 993], [",", 1005], ["compatibility", 1007], ["with", 1021], ["lactobacilli", 1026], ["and", 1039], ["bioactivity", 1043], [".", 1054], ["The", 1056], ["anti", 1060], ["-", 1064], ["HIV", 1065], ["activity", 1069], ["of", 1078], ["the", 1081], ["formulated", 1085], ["dapivirine", 1096], ["film", 1107], ["was", 1112], ["confirmed", 1116], ["in", 1126], ["in", 1129], ["vitro", 1132], ["and", 1138], ["ex", 1142], ["vivo", 1145], ["models", 1150], [".", 1156], ["Importantly", 1158], ["the", 1170], ["physical", 1174], ["and", 1183], ["chemical", 1187], ["properties", 1196], ["of", 1207], ["the", 1210], ["film", 1214], ["as", 1219], ["well", 1222], ["as", 1227], ["its", 1230], ["bioactivity", 1234], ["were", 1246], ["maintained", 1251], ["for", 1262], ["a", 1266], ["period", 1268], ["of", 1275], ["18", 1278], ["months", 1281], [".", 1287], ["In", 1289], ["conclusion", 1292], [",", 1302], ["a", 1304], ["vaginal", 1306], ["film", 1314], ["containing", 1319], ["dapivirine", 1330], ["was", 1341], ["developed", 1345], ["and", 1355], ["characterized", 1359], [".", 1372], ["The", 1374], ["film", 1378], ["was", 1383], ["shown", 1387], ["to", 1393], ["prevent", 1396], ["HIV-1", 1404], ["infection", 1410], ["in", 1420], ["vitro", 1423], ["and", 1429], ["ex", 1433], ["vivo", 1436], ["and", 1441], ["have", 1445], ["acceptable", 1450], ["characteristics", 1461], ["which", 1477], ["make", 1483], ["this", 1488], ["film", 1493], ["a", 1498], ["promising", 1500], ["candidate", 1510], ["for", 1520], ["testing", 1524], ["as", 1532], ["vaginal", 1535], ["microbicide", 1543], [".", 1554]]}
{"context": "One of the challenges faced by Mycobacterium tuberculosis (M. tuberculosis) in dormancy is hypoxia. DosR/DevR of M. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes. In this study, we have used DosR regulon proteins of M. tuberculosis H37Rv as the query set and performed a comprehensive homology search against the non-redundant database. Homologs were found in environmental mycobacteria, environmental bacteria and archaebacteria. Analysis of genomic context of DosR regulon revealed that they are distributed as nine blocks in the genome of M. tuberculosis with many transposases and integrases in their vicinity. Further, we classified DosR regulon proteins into eight functional categories. One of the hypothetical proteins Rv1998c could probably be a methylisocitrate lyase or a phosphonomutase. Another hypothetical protein, Rv0572 was found only in mycobacteria. Insights gained in this study can potentially aid in the development of novel therapeutic interventions.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "88146ec6149e4c6ea96cd35e52672e06", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[36, 37]], "char_spans": [[217, 224]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["challenges", 11], ["faced", 22], ["by", 28], ["Mycobacterium", 31], ["tuberculosis", 45], ["(", 58], ["M.", 59], ["tuberculosis", 62], [")", 74], ["in", 76], ["dormancy", 79], ["is", 88], ["hypoxia", 91], [".", 98], ["DosR", 100], ["/", 104], ["DevR", 105], ["of", 110], ["M.", 113], ["tuberculosis", 116], ["is", 129], ["a", 132], ["two", 134], ["component", 138], ["dormancy", 148], ["survival", 157], ["response", 166], ["regulator", 175], ["which", 185], ["induces", 191], ["the", 199], ["expression", 203], ["of", 214], ["48", 217], ["genes", 220], [".", 225], ["In", 227], ["this", 230], ["study", 235], [",", 240], ["we", 242], ["have", 245], ["used", 250], ["DosR", 255], ["regulon", 260], ["proteins", 268], ["of", 277], ["M.", 280], ["tuberculosis", 283], ["H37Rv", 296], ["as", 302], ["the", 305], ["query", 309], ["set", 315], ["and", 319], ["performed", 323], ["a", 333], ["comprehensive", 335], ["homology", 349], ["search", 358], ["against", 365], ["the", 373], ["non", 377], ["-", 380], ["redundant", 381], ["database", 391], [".", 399], ["Homologs", 401], ["were", 410], ["found", 415], ["in", 421], ["environmental", 424], ["mycobacteria", 438], [",", 450], ["environmental", 452], ["bacteria", 466], ["and", 475], ["archaebacteria", 479], [".", 493], ["Analysis", 495], ["of", 504], ["genomic", 507], ["context", 515], ["of", 523], ["DosR", 526], ["regulon", 531], ["revealed", 539], ["that", 548], ["they", 553], ["are", 558], ["distributed", 562], ["as", 574], ["nine", 577], ["blocks", 582], ["in", 589], ["the", 592], ["genome", 596], ["of", 603], ["M.", 606], ["tuberculosis", 609], ["with", 622], ["many", 627], ["transposases", 632], ["and", 645], ["integrases", 649], ["in", 660], ["their", 663], ["vicinity", 669], [".", 677], ["Further", 679], [",", 686], ["we", 688], ["classified", 691], ["DosR", 702], ["regulon", 707], ["proteins", 715], ["into", 724], ["eight", 729], ["functional", 735], ["categories", 746], [".", 756], ["One", 758], ["of", 762], ["the", 765], ["hypothetical", 769], ["proteins", 782], ["Rv1998c", 791], ["could", 799], ["probably", 805], ["be", 814], ["a", 817], ["methylisocitrate", 819], ["lyase", 836], ["or", 842], ["a", 845], ["phosphonomutase", 847], [".", 862], ["Another", 864], ["hypothetical", 872], ["protein", 885], [",", 892], ["Rv0572", 894], ["was", 901], ["found", 905], ["only", 911], ["in", 916], ["mycobacteria", 919], [".", 931], ["Insights", 933], ["gained", 942], ["in", 949], ["this", 952], ["study", 957], ["can", 963], ["potentially", 967], ["aid", 979], ["in", 983], ["the", 986], ["development", 990], ["of", 1002], ["novel", 1005], ["therapeutic", 1011], ["interventions", 1023], [".", 1036]]}
{"context": "It is well established that growth-factor-induced reactive oxygen species (ROS) act as second messengers in cell signaling. We have previously reported that betaPix, a guanine nucleotide exchange factor for Rac, interacts with NADPH oxidase 1 (Nox1) leading to EGF-induced ROS generation. Here, we report the identification of the domains of Nox1 and betaPix responsible for the interaction between the two proteins. GST pull-down assays show that the PH domain of betaPix binds to the FAD-binding region of Nox1. We also show that overexpression of the PH domain of betaPix results in inhibition of superoxide anion generation in response to EGF. Additionally, NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1. These results suggest that the formation of the complex consisting of Nox1, betaPix, and NoxO1 is likely to be a critical step in EGF-induced ROS generation.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "adf08b78ff7f4b26bfe31413163ae9d5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[41, 43]], "char_spans": [[227, 241]]}, {"text": "NOX1", "token_spans": [[155, 155], [45, 45], [97, 97], [142, 142], [65, 65]], "char_spans": [[826, 829], [244, 247], [508, 511], [750, 753], [342, 345]]}]}], "context_tokens": [["It", 0], ["is", 3], ["well", 6], ["established", 11], ["that", 23], ["growth", 28], ["-", 34], ["factor", 35], ["-", 41], ["induced", 42], ["reactive", 50], ["oxygen", 59], ["species", 66], ["(", 74], ["ROS", 75], [")", 78], ["act", 80], ["as", 84], ["second", 87], ["messengers", 94], ["in", 105], ["cell", 108], ["signaling", 113], [".", 122], ["We", 124], ["have", 127], ["previously", 132], ["reported", 143], ["that", 152], ["betaPix", 157], [",", 164], ["a", 166], ["guanine", 168], ["nucleotide", 176], ["exchange", 187], ["factor", 196], ["for", 203], ["Rac", 207], [",", 210], ["interacts", 212], ["with", 222], ["NADPH", 227], ["oxidase", 233], ["1", 241], ["(", 243], ["Nox1", 244], [")", 248], ["leading", 250], ["to", 258], ["EGF", 261], ["-", 264], ["induced", 265], ["ROS", 273], ["generation", 277], [".", 287], ["Here", 289], [",", 293], ["we", 295], ["report", 298], ["the", 305], ["identification", 309], ["of", 324], ["the", 327], ["domains", 331], ["of", 339], ["Nox1", 342], ["and", 347], ["betaPix", 351], ["responsible", 359], ["for", 371], ["the", 375], ["interaction", 379], ["between", 391], ["the", 399], ["two", 403], ["proteins", 407], [".", 415], ["GST", 417], ["pull", 421], ["-", 425], ["down", 426], ["assays", 431], ["show", 438], ["that", 443], ["the", 448], ["PH", 452], ["domain", 455], ["of", 462], ["betaPix", 465], ["binds", 473], ["to", 479], ["the", 482], ["FAD", 486], ["-", 489], ["binding", 490], ["region", 498], ["of", 505], ["Nox1", 508], [".", 512], ["We", 514], ["also", 517], ["show", 522], ["that", 527], ["overexpression", 532], ["of", 547], ["the", 550], ["PH", 554], ["domain", 557], ["of", 564], ["betaPix", 567], ["results", 575], ["in", 583], ["inhibition", 586], ["of", 597], ["superoxide", 600], ["anion", 611], ["generation", 617], ["in", 628], ["response", 631], ["to", 640], ["EGF", 643], [".", 646], ["Additionally", 648], [",", 660], ["NADPH", 662], ["oxidase", 668], ["Organizer", 676], ["1", 686], ["(", 688], ["NoxO1", 689], [")", 694], ["is", 696], ["shown", 699], ["to", 705], ["interact", 708], ["with", 717], ["the", 722], ["NADPH", 726], ["-", 731], ["binding", 732], ["region", 740], ["of", 747], ["Nox1", 750], [".", 754], ["These", 756], ["results", 762], ["suggest", 770], ["that", 778], ["the", 783], ["formation", 787], ["of", 797], ["the", 800], ["complex", 804], ["consisting", 812], ["of", 823], ["Nox1", 826], [",", 830], ["betaPix", 832], [",", 839], ["and", 841], ["NoxO1", 845], ["is", 851], ["likely", 854], ["to", 861], ["be", 864], ["a", 867], ["critical", 869], ["step", 878], ["in", 883], ["EGF", 886], ["-", 889], ["induced", 890], ["ROS", 898], ["generation", 902], [".", 912]]}
{"context": "Selenium (Se) is an essential trace element for several organisms and is present in proteins as selenocysteine (Sec or U), an amino acid that is chemically distinct from serine and cysteine by a single atom (Se instead of O or S, respectively). Sec is incorporated into selenoproteins at an in-frame UGA codon specified by an mRNA stem-loop structure called the selenocysteine incorporating sequence (SECIS) presented in selenoprotein mRNA and specific selenocysteine synthesis and incorporation machinery. Selenoproteins are presented in all domains but are not found in all organisms. Although several functions have been attributed to this class, the majority of the proteins are involved in oxidative stress defense. Here, we discuss the kinetoplastid selenocysteine pathway and how selenium supplementation is able to alter the infection course of trypanosomatids in detail. These organisms possess the canonical elements required for selenoprotein production such as phosphoseryl tRNA kinase (PSTK), selenocysteine synthase (SepSecS), selenophosphase synthase (SelD or SPS), and elongation factor EFSec (SelB), whereas other important factors presented in mammal cells, such as SECIS binding protein 2 (SBP) and SecP 43, are absent. The selenoproteome of trypanosomatids is small, as is the selenoproteome of others parasites, which is in contrast to the large number of selenoproteins found in bacteria, aquatic organisms and higher eukaryotes. Trypanosoma and Leishmania are sensitive to auranofin, a potent selenoprotein inhibitor; however, the probable drug mechanism is not related to selenoproteins in kinetoplastids. Selenium supplementation decreases the parasitemia of various Trypanosome infections and reduces important parameters associated with diseases such as anemia and parasite-induced organ damage. New experiments are necessary to determine how selenium acts, but evidence suggests that immune response modulation and increased host defense against oxidative stress contribute to control of the parasite infection.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "c974d3fb68c64a29b1b191a9eb7f8eec", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[203, 203], [77, 77]], "char_spans": [[1184, 1188], [401, 405]]}]}], "context_tokens": [["Selenium", 0], ["(", 9], ["Se", 10], [")", 12], ["is", 14], ["an", 17], ["essential", 20], ["trace", 30], ["element", 36], ["for", 44], ["several", 48], ["organisms", 56], ["and", 66], ["is", 70], ["present", 73], ["in", 81], ["proteins", 84], ["as", 93], ["selenocysteine", 96], ["(", 111], ["Sec", 112], ["or", 116], ["U", 119], [")", 120], [",", 121], ["an", 123], ["amino", 126], ["acid", 132], ["that", 137], ["is", 142], ["chemically", 145], ["distinct", 156], ["from", 165], ["serine", 170], ["and", 177], ["cysteine", 181], ["by", 190], ["a", 193], ["single", 195], ["atom", 202], ["(", 207], ["Se", 208], ["instead", 211], ["of", 219], ["O", 222], ["or", 224], ["S", 227], [",", 228], ["respectively", 230], [")", 242], [".", 243], ["Sec", 245], ["is", 249], ["incorporated", 252], ["into", 265], ["selenoproteins", 270], ["at", 285], ["an", 288], ["in", 291], ["-", 293], ["frame", 294], ["UGA", 300], ["codon", 304], ["specified", 310], ["by", 320], ["an", 323], ["mRNA", 326], ["stem", 331], ["-", 335], ["loop", 336], ["structure", 341], ["called", 351], ["the", 358], ["selenocysteine", 362], ["incorporating", 377], ["sequence", 391], ["(", 400], ["SECIS", 401], [")", 406], ["presented", 408], ["in", 418], ["selenoprotein", 421], ["mRNA", 435], ["and", 440], ["specific", 444], ["selenocysteine", 453], ["synthesis", 468], ["and", 478], ["incorporation", 482], ["machinery", 496], [".", 505], ["Selenoproteins", 507], ["are", 522], ["presented", 526], ["in", 536], ["all", 539], ["domains", 543], ["but", 551], ["are", 555], ["not", 559], ["found", 563], ["in", 569], ["all", 572], ["organisms", 576], [".", 585], ["Although", 587], ["several", 596], ["functions", 604], ["have", 614], ["been", 619], ["attributed", 624], ["to", 635], ["this", 638], ["class", 643], [",", 648], ["the", 650], ["majority", 654], ["of", 663], ["the", 666], ["proteins", 670], ["are", 679], ["involved", 683], ["in", 692], ["oxidative", 695], ["stress", 705], ["defense", 712], [".", 719], ["Here", 721], [",", 725], ["we", 727], ["discuss", 730], ["the", 738], ["kinetoplastid", 742], ["selenocysteine", 756], ["pathway", 771], ["and", 779], ["how", 783], ["selenium", 787], ["supplementation", 796], ["is", 812], ["able", 815], ["to", 820], ["alter", 823], ["the", 829], ["infection", 833], ["course", 843], ["of", 850], ["trypanosomatids", 853], ["in", 869], ["detail", 872], [".", 878], ["These", 880], ["organisms", 886], ["possess", 896], ["the", 904], ["canonical", 908], ["elements", 918], ["required", 927], ["for", 936], ["selenoprotein", 940], ["production", 954], ["such", 965], ["as", 970], ["phosphoseryl", 973], ["tRNA", 986], ["kinase", 991], ["(", 998], ["PSTK", 999], [")", 1003], [",", 1004], ["selenocysteine", 1006], ["synthase", 1021], ["(", 1030], ["SepSecS", 1031], [")", 1038], [",", 1039], ["selenophosphase", 1041], ["synthase", 1057], ["(", 1066], ["SelD", 1067], ["or", 1072], ["SPS", 1075], [")", 1078], [",", 1079], ["and", 1081], ["elongation", 1085], ["factor", 1096], ["EFSec", 1103], ["(", 1109], ["SelB", 1110], [")", 1114], [",", 1115], ["whereas", 1117], ["other", 1125], ["important", 1131], ["factors", 1141], ["presented", 1149], ["in", 1159], ["mammal", 1162], ["cells", 1169], [",", 1174], ["such", 1176], ["as", 1181], ["SECIS", 1184], ["binding", 1190], ["protein", 1198], ["2", 1206], ["(", 1208], ["SBP", 1209], [")", 1212], ["and", 1214], ["SecP", 1218], ["43", 1223], [",", 1225], ["are", 1227], ["absent", 1231], [".", 1237], ["The", 1239], ["selenoproteome", 1243], ["of", 1258], ["trypanosomatids", 1261], ["is", 1277], ["small", 1280], [",", 1285], ["as", 1287], ["is", 1290], ["the", 1293], ["selenoproteome", 1297], ["of", 1312], ["others", 1315], ["parasites", 1322], [",", 1331], ["which", 1333], ["is", 1339], ["in", 1342], ["contrast", 1345], ["to", 1354], ["the", 1357], ["large", 1361], ["number", 1367], ["of", 1374], ["selenoproteins", 1377], ["found", 1392], ["in", 1398], ["bacteria", 1401], [",", 1409], ["aquatic", 1411], ["organisms", 1419], ["and", 1429], ["higher", 1433], ["eukaryotes", 1440], [".", 1450], ["Trypanosoma", 1452], ["and", 1464], ["Leishmania", 1468], ["are", 1479], ["sensitive", 1483], ["to", 1493], ["auranofin", 1496], [",", 1505], ["a", 1507], ["potent", 1509], ["selenoprotein", 1516], ["inhibitor", 1530], [";", 1539], ["however", 1541], [",", 1548], ["the", 1550], ["probable", 1554], ["drug", 1563], ["mechanism", 1568], ["is", 1578], ["not", 1581], ["related", 1585], ["to", 1593], ["selenoproteins", 1596], ["in", 1611], ["kinetoplastids", 1614], [".", 1628], ["Selenium", 1630], ["supplementation", 1639], ["decreases", 1655], ["the", 1665], ["parasitemia", 1669], ["of", 1681], ["various", 1684], ["Trypanosome", 1692], ["infections", 1704], ["and", 1715], ["reduces", 1719], ["important", 1727], ["parameters", 1737], ["associated", 1748], ["with", 1759], ["diseases", 1764], ["such", 1773], ["as", 1778], ["anemia", 1781], ["and", 1788], ["parasite", 1792], ["-", 1800], ["induced", 1801], ["organ", 1809], ["damage", 1815], [".", 1821], ["New", 1823], ["experiments", 1827], ["are", 1839], ["necessary", 1843], ["to", 1853], ["determine", 1856], ["how", 1866], ["selenium", 1870], ["acts", 1879], [",", 1883], ["but", 1885], ["evidence", 1889], ["suggests", 1898], ["that", 1907], ["immune", 1912], ["response", 1919], ["modulation", 1928], ["and", 1939], ["increased", 1943], ["host", 1953], ["defense", 1958], ["against", 1966], ["oxidative", 1974], ["stress", 1984], ["contribute", 1991], ["to", 2002], ["control", 2005], ["of", 2013], ["the", 2016], ["parasite", 2020], ["infection", 2029], [".", 2038]]}
{"context": "Scientists have been aware for many years of genetic programs that get activated under stress and produce genetic variants in cells that escape non-proliferating conditions. These programs are well conserved in all organisms and expand our view of evolution. They mediate genome instability, create diversity in antibody formation, expand metabolism and increase fitness of pathogens within host environments. Error-prone DNA replication and repair are genetic variability-causing agents that get stimulated by the onset of cellular stresses. Embedded in these programs is the ability to limit mutagenesis to defined genomic regions and times, ensuring integrity of most of the genome. Recent evidence suggests that factors involved in RNA polymerase (RNAP) processivity or transcriptional derepression contribute to the generation of stress-induced mutations. In Bacillus subtilis, transcription-associated mutagenesis has been shown to be independent of recombination-dependent repair and, in some cases, of the Y DNA polymerases. Central to stationary-phase mutagenesis in B. subtilis is the requirement for Mfd, transcription coupling repair factor, which suggests a novel mechanism from those described in other model systems.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1126a2a0c1ae4863844e2b5cc811f042", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[172, 174]], "char_spans": [[1044, 1059]]}]}], "context_tokens": [["Scientists", 0], ["have", 11], ["been", 16], ["aware", 21], ["for", 27], ["many", 31], ["years", 36], ["of", 42], ["genetic", 45], ["programs", 53], ["that", 62], ["get", 67], ["activated", 71], ["under", 81], ["stress", 87], ["and", 94], ["produce", 98], ["genetic", 106], ["variants", 114], ["in", 123], ["cells", 126], ["that", 132], ["escape", 137], ["non", 144], ["-", 147], ["proliferating", 148], ["conditions", 162], [".", 172], ["These", 174], ["programs", 180], ["are", 189], ["well", 193], ["conserved", 198], ["in", 208], ["all", 211], ["organisms", 215], ["and", 225], ["expand", 229], ["our", 236], ["view", 240], ["of", 245], ["evolution", 248], [".", 257], ["They", 259], ["mediate", 264], ["genome", 272], ["instability", 279], [",", 290], ["create", 292], ["diversity", 299], ["in", 309], ["antibody", 312], ["formation", 321], [",", 330], ["expand", 332], ["metabolism", 339], ["and", 350], ["increase", 354], ["fitness", 363], ["of", 371], ["pathogens", 374], ["within", 384], ["host", 391], ["environments", 396], [".", 408], ["Error", 410], ["-", 415], ["prone", 416], ["DNA", 422], ["replication", 426], ["and", 438], ["repair", 442], ["are", 449], ["genetic", 453], ["variability", 461], ["-", 472], ["causing", 473], ["agents", 481], ["that", 488], ["get", 493], ["stimulated", 497], ["by", 508], ["the", 511], ["onset", 515], ["of", 521], ["cellular", 524], ["stresses", 533], [".", 541], ["Embedded", 543], ["in", 552], ["these", 555], ["programs", 561], ["is", 570], ["the", 573], ["ability", 577], ["to", 585], ["limit", 588], ["mutagenesis", 594], ["to", 606], ["defined", 609], ["genomic", 617], ["regions", 625], ["and", 633], ["times", 637], [",", 642], ["ensuring", 644], ["integrity", 653], ["of", 663], ["most", 666], ["of", 671], ["the", 674], ["genome", 678], [".", 684], ["Recent", 686], ["evidence", 693], ["suggests", 702], ["that", 711], ["factors", 716], ["involved", 724], ["in", 733], ["RNA", 736], ["polymerase", 740], ["(", 751], ["RNAP", 752], [")", 756], ["processivity", 758], ["or", 771], ["transcriptional", 774], ["derepression", 790], ["contribute", 803], ["to", 814], ["the", 817], ["generation", 821], ["of", 832], ["stress", 835], ["-", 841], ["induced", 842], ["mutations", 850], [".", 859], ["In", 861], ["Bacillus", 864], ["subtilis", 873], [",", 881], ["transcription", 883], ["-", 896], ["associated", 897], ["mutagenesis", 908], ["has", 920], ["been", 924], ["shown", 929], ["to", 935], ["be", 938], ["independent", 941], ["of", 953], ["recombination", 956], ["-", 969], ["dependent", 970], ["repair", 980], ["and", 987], [",", 990], ["in", 992], ["some", 995], ["cases", 1000], [",", 1005], ["of", 1007], ["the", 1010], ["Y", 1014], ["DNA", 1016], ["polymerases", 1020], [".", 1031], ["Central", 1033], ["to", 1041], ["stationary", 1044], ["-", 1054], ["phase", 1055], ["mutagenesis", 1061], ["in", 1073], ["B.", 1076], ["subtilis", 1079], ["is", 1088], ["the", 1091], ["requirement", 1095], ["for", 1107], ["Mfd", 1111], [",", 1114], ["transcription", 1116], ["coupling", 1130], ["repair", 1139], ["factor", 1146], [",", 1152], ["which", 1154], ["suggests", 1160], ["a", 1169], ["novel", 1171], ["mechanism", 1177], ["from", 1187], ["those", 1192], ["described", 1198], ["in", 1208], ["other", 1211], ["model", 1217], ["systems", 1223], [".", 1230]]}
{"context": "Telomeres may regulate human disease by at least two independent mechanisms. First, replicative senescence occurs once short telomeres generate DNA-damage signals that produce a barrier to tumor progression. Second, telomere position effects (TPE) could change gene expression at intermediate telomere lengths in cultured human cells. Here we report that telomere length may contribute to the pathogenesis of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a late-onset disease genetically residing only 25-60 kilobases from the end of chromosome 4q. We used a floxable telomerase to generate isogenic clones with different telomere lengths from affected patients and their unaffected siblings. DUX4, the primary candidate for FSHD pathogenesis, is upregulated over ten-fold in FSHD myoblasts and myotubes with short telomeres, and its expression is inversely proportional to telomere length. FSHD may be the first known human disease in which TPE contributes to age-related phenotype.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "874766ca4acd487abe5fd450dda756cd", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[131, 131], [149, 149], [70, 70], [73, 73], [121, 121]], "char_spans": [[785, 788], [900, 903], [449, 452], [456, 459], [734, 737]]}]}], "context_tokens": [["Telomeres", 0], ["may", 10], ["regulate", 14], ["human", 23], ["disease", 29], ["by", 37], ["at", 40], ["least", 43], ["two", 49], ["independent", 53], ["mechanisms", 65], [".", 75], ["First", 77], [",", 82], ["replicative", 84], ["senescence", 96], ["occurs", 107], ["once", 114], ["short", 119], ["telomeres", 125], ["generate", 135], ["DNA", 144], ["-", 147], ["damage", 148], ["signals", 155], ["that", 163], ["produce", 168], ["a", 176], ["barrier", 178], ["to", 186], ["tumor", 189], ["progression", 195], [".", 206], ["Second", 208], [",", 214], ["telomere", 216], ["position", 225], ["effects", 234], ["(", 242], ["TPE", 243], [")", 246], ["could", 248], ["change", 254], ["gene", 261], ["expression", 266], ["at", 277], ["intermediate", 280], ["telomere", 293], ["lengths", 302], ["in", 310], ["cultured", 313], ["human", 322], ["cells", 328], [".", 333], ["Here", 335], ["we", 340], ["report", 343], ["that", 350], ["telomere", 355], ["length", 364], ["may", 371], ["contribute", 375], ["to", 386], ["the", 389], ["pathogenesis", 393], ["of", 406], ["facioscapulohumeral", 409], ["muscular", 429], ["dystrophy", 438], ["(", 448], ["FSHD", 449], [")", 453], [".", 454], ["FSHD", 456], ["is", 461], ["a", 464], ["late", 466], ["-", 470], ["onset", 471], ["disease", 477], ["genetically", 485], ["residing", 497], ["only", 506], ["25", 511], ["-", 513], ["60", 514], ["kilobases", 517], ["from", 527], ["the", 532], ["end", 536], ["of", 540], ["chromosome", 543], ["4q", 554], [".", 556], ["We", 558], ["used", 561], ["a", 566], ["floxable", 568], ["telomerase", 577], ["to", 588], ["generate", 591], ["isogenic", 600], ["clones", 609], ["with", 616], ["different", 621], ["telomere", 631], ["lengths", 640], ["from", 648], ["affected", 653], ["patients", 662], ["and", 671], ["their", 675], ["unaffected", 681], ["siblings", 692], [".", 700], ["DUX4", 702], [",", 706], ["the", 708], ["primary", 712], ["candidate", 720], ["for", 730], ["FSHD", 734], ["pathogenesis", 739], [",", 751], ["is", 753], ["upregulated", 756], ["over", 768], ["ten", 773], ["-", 776], ["fold", 777], ["in", 782], ["FSHD", 785], ["myoblasts", 790], ["and", 800], ["myotubes", 804], ["with", 813], ["short", 818], ["telomeres", 824], [",", 833], ["and", 835], ["its", 839], ["expression", 843], ["is", 854], ["inversely", 857], ["proportional", 867], ["to", 880], ["telomere", 883], ["length", 892], [".", 898], ["FSHD", 900], ["may", 905], ["be", 909], ["the", 912], ["first", 916], ["known", 922], ["human", 928], ["disease", 934], ["in", 942], ["which", 945], ["TPE", 951], ["contributes", 955], ["to", 967], ["age", 970], ["-", 973], ["related", 974], ["phenotype", 982], [".", 991]]}
{"context": "The Romano Ward long QT syndrome (LQTS) has an autosomal dominant mode of inheritance. Patients suffer from syncopal attacks often resulting in sudden cardiac death. The main diagnostic parameter is a prolonged QT(c) interval as judged by electro-cardiographic investigation. LQTS is a genetically heterogeneous disease with four loci having been identified to date: chromosome 11p15.5 (LQT1), 7q35-36 (LQT2), 3p21-24 (LQT3) and 4q25-26 (LQT4). The corresponding genes code for potassium channels KVLQT1 (LQT1) and HERG (LQT2) and the sodium channel SCN5A (LQT3). The KVLQT1 gene is characterized by six transmembrane domains (S1-S6), a pore region situated between the S5 and S6 domains and a C-terminal domain accounting for approximately 60% of the channel. This domain is thought to be co-associated with another protein, viz. minK (minimal potassium channel). We have studied a Romano Ward family with several affected individuals showing a severe LQTS phenotype (syncopes and occurrence of sudden death). Most affected individuals had considerable prolongations of QT(c). By using haplotyping with a set of markers covering the four LQT loci, strong linkage was established to the LQT1 locus, whereas the other loci (LQT2, LQT3 and LQT4) could be excluded. Single-strand conformation polymorphism analysis and direct sequencing were used to screen the KVLQT1 gene for mutations in the S1-S6 region, including the pore domain. We identified a Gly-216-Arg substitution in the S6 transmembrane domain of KVLQT1. The mutation was present in all affected family members but absent in normal control individuals, providing evidence that the mutated KVLQT1-gene product indeed caused LQTS in this family. The mutated KVLQT1-gene product thus probably results in a dominant negative suppression of channel activity.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "c68098a2b69d435d846e9305f82a5432", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[11, 12]], "char_spans": [[47, 64]]}]}], "context_tokens": [["The", 0], ["Romano", 4], ["Ward", 11], ["long", 16], ["QT", 21], ["syndrome", 24], ["(", 33], ["LQTS", 34], [")", 38], ["has", 40], ["an", 44], ["autosomal", 47], ["dominant", 57], ["mode", 66], ["of", 71], ["inheritance", 74], [".", 85], ["Patients", 87], ["suffer", 96], ["from", 103], ["syncopal", 108], ["attacks", 117], ["often", 125], ["resulting", 131], ["in", 141], ["sudden", 144], ["cardiac", 151], ["death", 159], [".", 164], ["The", 166], ["main", 170], ["diagnostic", 175], ["parameter", 186], ["is", 196], ["a", 199], ["prolonged", 201], ["QT(c", 211], [")", 215], ["interval", 217], ["as", 226], ["judged", 229], ["by", 236], ["electro", 239], ["-", 246], ["cardiographic", 247], ["investigation", 261], [".", 274], ["LQTS", 276], ["is", 281], ["a", 284], ["genetically", 286], ["heterogeneous", 298], ["disease", 312], ["with", 320], ["four", 325], ["loci", 330], ["having", 335], ["been", 342], ["identified", 347], ["to", 358], ["date", 361], [":", 365], ["chromosome", 367], ["11p15.5", 378], ["(", 386], ["LQT1", 387], [")", 391], [",", 392], ["7q35", 394], ["-", 398], ["36", 399], ["(", 402], ["LQT2", 403], [")", 407], [",", 408], ["3p21", 410], ["-", 414], ["24", 415], ["(", 418], ["LQT3", 419], [")", 423], ["and", 425], ["4q25", 429], ["-", 433], ["26", 434], ["(", 437], ["LQT4", 438], [")", 442], [".", 443], ["The", 445], ["corresponding", 449], ["genes", 463], ["code", 469], ["for", 474], ["potassium", 478], ["channels", 488], ["KVLQT1", 497], ["(", 504], ["LQT1", 505], [")", 509], ["and", 511], ["HERG", 515], ["(", 520], ["LQT2", 521], [")", 525], ["and", 527], ["the", 531], ["sodium", 535], ["channel", 542], ["SCN5A", 550], ["(", 556], ["LQT3", 557], [")", 561], [".", 562], ["The", 564], ["KVLQT1", 568], ["gene", 575], ["is", 580], ["characterized", 583], ["by", 597], ["six", 600], ["transmembrane", 604], ["domains", 618], ["(", 626], ["S1-S6", 627], [")", 632], [",", 633], ["a", 635], ["pore", 637], ["region", 642], ["situated", 649], ["between", 658], ["the", 666], ["S5", 670], ["and", 673], ["S6", 677], ["domains", 680], ["and", 688], ["a", 692], ["C", 694], ["-", 695], ["terminal", 696], ["domain", 705], ["accounting", 712], ["for", 723], ["approximately", 727], ["60", 741], ["%", 743], ["of", 745], ["the", 748], ["channel", 752], [".", 759], ["This", 761], ["domain", 766], ["is", 773], ["thought", 776], ["to", 784], ["be", 787], ["co", 790], ["-", 792], ["associated", 793], ["with", 804], ["another", 809], ["protein", 817], [",", 824], ["viz", 826], [".", 829], ["minK", 831], ["(", 836], ["minimal", 837], ["potassium", 845], ["channel", 855], [")", 862], [".", 863], ["We", 865], ["have", 868], ["studied", 873], ["a", 881], ["Romano", 883], ["Ward", 890], ["family", 895], ["with", 902], ["several", 907], ["affected", 915], ["individuals", 924], ["showing", 936], ["a", 944], ["severe", 946], ["LQTS", 953], ["phenotype", 958], ["(", 968], ["syncopes", 969], ["and", 978], ["occurrence", 982], ["of", 993], ["sudden", 996], ["death", 1003], [")", 1008], [".", 1009], ["Most", 1011], ["affected", 1016], ["individuals", 1025], ["had", 1037], ["considerable", 1041], ["prolongations", 1054], ["of", 1068], ["QT(c", 1071], [")", 1075], [".", 1076], ["By", 1078], ["using", 1081], ["haplotyping", 1087], ["with", 1099], ["a", 1104], ["set", 1106], ["of", 1110], ["markers", 1113], ["covering", 1121], ["the", 1130], ["four", 1134], ["LQT", 1139], ["loci", 1143], [",", 1147], ["strong", 1149], ["linkage", 1156], ["was", 1164], ["established", 1168], ["to", 1180], ["the", 1183], ["LQT1", 1187], ["locus", 1192], [",", 1197], ["whereas", 1199], ["the", 1207], ["other", 1211], ["loci", 1217], ["(", 1222], ["LQT2", 1223], [",", 1227], ["LQT3", 1229], ["and", 1234], ["LQT4", 1238], [")", 1242], ["could", 1244], ["be", 1250], ["excluded", 1253], [".", 1261], ["Single", 1263], ["-", 1269], ["strand", 1270], ["conformation", 1277], ["polymorphism", 1290], ["analysis", 1303], ["and", 1312], ["direct", 1316], ["sequencing", 1323], ["were", 1334], ["used", 1339], ["to", 1344], ["screen", 1347], ["the", 1354], ["KVLQT1", 1358], ["gene", 1365], ["for", 1370], ["mutations", 1374], ["in", 1384], ["the", 1387], ["S1-S6", 1391], ["region", 1397], [",", 1403], ["including", 1405], ["the", 1415], ["pore", 1419], ["domain", 1424], [".", 1430], ["We", 1432], ["identified", 1435], ["a", 1446], ["Gly-216-Arg", 1448], ["substitution", 1460], ["in", 1473], ["the", 1476], ["S6", 1480], ["transmembrane", 1483], ["domain", 1497], ["of", 1504], ["KVLQT1", 1507], [".", 1513], ["The", 1515], ["mutation", 1519], ["was", 1528], ["present", 1532], ["in", 1540], ["all", 1543], ["affected", 1547], ["family", 1556], ["members", 1563], ["but", 1571], ["absent", 1575], ["in", 1582], ["normal", 1585], ["control", 1592], ["individuals", 1600], [",", 1611], ["providing", 1613], ["evidence", 1623], ["that", 1632], ["the", 1637], ["mutated", 1641], ["KVLQT1-gene", 1649], ["product", 1661], ["indeed", 1669], ["caused", 1676], ["LQTS", 1683], ["in", 1688], ["this", 1691], ["family", 1696], [".", 1702], ["The", 1704], ["mutated", 1708], ["KVLQT1-gene", 1716], ["product", 1728], ["thus", 1736], ["probably", 1741], ["results", 1750], ["in", 1758], ["a", 1761], ["dominant", 1763], ["negative", 1772], ["suppression", 1781], ["of", 1793], ["channel", 1796], ["activity", 1804], [".", 1812]]}
{"context": "One of the colors of mink is Aleutian (aa)-a specific gun-metal gray pigmentation of the fur-commonly used in combination with other color loci to generate popular colors such as Violet (aammpp) and Sapphire (aapp). The Aleutian color allele is a manifestation of mink Ch\u00e9diak-Higashi syndrome (CHS), which has been described in humans and several other species. As with forms of CHS in other species, we report that the mink CHS is linked to the lysosomal trafficking regulator ( LYST ) gene. Furthermore, we have identified a base deletion (c.9468delC) in exon 40 of LYST, which causes a frameshift and virtually terminates the LYST product prematurely (p.Leu3156Phefs*37). We investigated the blood parameters of three wild-type mink and three CHS mink. No difference in the platelet number between the two groups was observed, but an accumulation of platelets between the groups appears different when collagen is used as a coagulant. Microscopic analysis of peripheral blood indicates giant inclusions in the neutrophils of the Aleutian mink types. Molecular findings at the LYST locus enable the development of genetic tests for analyzing the color selection in American mink.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "a03dcd828ad547288622933b68946271", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[95, 97]], "char_spans": [[481, 491]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["colors", 11], ["of", 18], ["mink", 21], ["is", 26], ["Aleutian", 29], ["(", 38], ["aa)-a", 39], ["specific", 45], ["gun", 54], ["-", 57], ["metal", 58], ["gray", 64], ["pigmentation", 69], ["of", 82], ["the", 85], ["fur", 89], ["-", 92], ["commonly", 93], ["used", 102], ["in", 107], ["combination", 110], ["with", 122], ["other", 127], ["color", 133], ["loci", 139], ["to", 144], ["generate", 147], ["popular", 156], ["colors", 164], ["such", 171], ["as", 176], ["Violet", 179], ["(", 186], ["aammpp", 187], [")", 193], ["and", 195], ["Sapphire", 199], ["(", 208], ["aapp", 209], [")", 213], [".", 214], ["The", 216], ["Aleutian", 220], ["color", 229], ["allele", 235], ["is", 242], ["a", 245], ["manifestation", 247], ["of", 261], ["mink", 264], ["Ch\u00e9diak", 269], ["-", 276], ["Higashi", 277], ["syndrome", 285], ["(", 294], ["CHS", 295], [")", 298], [",", 299], ["which", 301], ["has", 307], ["been", 311], ["described", 316], ["in", 326], ["humans", 329], ["and", 336], ["several", 340], ["other", 348], ["species", 354], [".", 361], ["As", 363], ["with", 366], ["forms", 371], ["of", 377], ["CHS", 380], ["in", 384], ["other", 387], ["species", 393], [",", 400], ["we", 402], ["report", 405], ["that", 412], ["the", 417], ["mink", 421], ["CHS", 426], ["is", 430], ["linked", 433], ["to", 440], ["the", 443], ["lysosomal", 447], ["trafficking", 457], ["regulator", 469], ["(", 479], ["LYST", 481], [")", 486], ["gene", 488], [".", 492], ["Furthermore", 494], [",", 505], ["we", 507], ["have", 510], ["identified", 515], ["a", 526], ["base", 528], ["deletion", 533], ["(", 542], ["c.9468delC", 543], [")", 553], ["in", 555], ["exon", 558], ["40", 563], ["of", 566], ["LYST", 569], [",", 573], ["which", 575], ["causes", 581], ["a", 588], ["frameshift", 590], ["and", 601], ["virtually", 605], ["terminates", 615], ["the", 626], ["LYST", 630], ["product", 635], ["prematurely", 643], ["(", 655], ["p", 656], [".", 657], ["Leu3156Phefs*37", 658], [")", 673], [".", 674], ["We", 676], ["investigated", 679], ["the", 692], ["blood", 696], ["parameters", 702], ["of", 713], ["three", 716], ["wild", 722], ["-", 726], ["type", 727], ["mink", 732], ["and", 737], ["three", 741], ["CHS", 747], ["mink", 751], [".", 755], ["No", 757], ["difference", 760], ["in", 771], ["the", 774], ["platelet", 778], ["number", 787], ["between", 794], ["the", 802], ["two", 806], ["groups", 810], ["was", 817], ["observed", 821], [",", 829], ["but", 831], ["an", 835], ["accumulation", 838], ["of", 851], ["platelets", 854], ["between", 864], ["the", 872], ["groups", 876], ["appears", 883], ["different", 891], ["when", 901], ["collagen", 906], ["is", 915], ["used", 918], ["as", 923], ["a", 926], ["coagulant", 928], [".", 937], ["Microscopic", 939], ["analysis", 951], ["of", 960], ["peripheral", 963], ["blood", 974], ["indicates", 980], ["giant", 990], ["inclusions", 996], ["in", 1007], ["the", 1010], ["neutrophils", 1014], ["of", 1026], ["the", 1029], ["Aleutian", 1033], ["mink", 1042], ["types", 1047], [".", 1052], ["Molecular", 1054], ["findings", 1064], ["at", 1073], ["the", 1076], ["LYST", 1080], ["locus", 1085], ["enable", 1091], ["the", 1098], ["development", 1102], ["of", 1114], ["genetic", 1117], ["tests", 1125], ["for", 1131], ["analyzing", 1135], ["the", 1145], ["color", 1149], ["selection", 1155], ["in", 1165], ["American", 1168], ["mink", 1177], [".", 1181]]}
{"context": "Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis. We describe our experience with idarucizumab in a 71-year-old male patient pretreated with dabigatran etexilate. The patient arrived with a hemiparesis, central facial palsy, and dysarthria. Dabigatran etexilate was antagonized with idarucizumab, approximately 2.5 hours after the patient's last dose. Immediately after the infusion of idarucizumab, the patient received thrombolytic therapy. The hemiparesis and the central facial palsy were fully remitted 3 days after the onset of symptoms, and the dysarthria was remitted 2 days afterwards. Non-vitamin K oral anticoagulants (NOACs) are widely used for the prevention of embolic stroke in patients with atrial fibrillation. Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab. Idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity. Reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "8f221782cbec411ab44ab1376d453c6e", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[69, 69], [173, 173], [150, 150], [6, 6], [182, 182], [52, 52], [15, 15]], "char_spans": [[432, 441], [1069, 1078], [919, 928], [37, 46], [1132, 1141], [332, 341], [102, 111]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["reversal", 18], ["agent", 27], ["for", 33], ["dabigatran", 37], ["etexilate", 48], [".", 57], ["By", 59], ["reversing", 62], ["the", 72], ["anticoagulating", 76], ["effect", 92], ["of", 99], ["dabigatran", 102], ["etexilate", 113], ["with", 123], ["idarucizumab", 128], ["(", 141], ["Praxbind", 142], [")", 150], [",", 151], ["patients", 153], ["presenting", 162], ["with", 173], ["an", 178], ["acute", 181], ["ischemic", 187], ["stroke", 196], ["can", 203], ["now", 207], ["be", 211], ["eligible", 214], ["for", 223], ["thrombolysis", 227], [".", 239], ["We", 241], ["describe", 244], ["our", 253], ["experience", 257], ["with", 268], ["idarucizumab", 273], ["in", 286], ["a", 289], ["71-year", 291], ["-", 298], ["old", 299], ["male", 303], ["patient", 308], ["pretreated", 316], ["with", 327], ["dabigatran", 332], ["etexilate", 343], [".", 352], ["The", 354], ["patient", 358], ["arrived", 366], ["with", 374], ["a", 379], ["hemiparesis", 381], [",", 392], ["central", 394], ["facial", 402], ["palsy", 409], [",", 414], ["and", 416], ["dysarthria", 420], [".", 430], ["Dabigatran", 432], ["etexilate", 443], ["was", 453], ["antagonized", 457], ["with", 469], ["idarucizumab", 474], [",", 486], ["approximately", 488], ["2.5", 502], ["hours", 506], ["after", 512], ["the", 518], ["patient", 522], ["'s", 529], ["last", 532], ["dose", 537], [".", 541], ["Immediately", 543], ["after", 555], ["the", 561], ["infusion", 565], ["of", 574], ["idarucizumab", 577], [",", 589], ["the", 591], ["patient", 595], ["received", 603], ["thrombolytic", 612], ["therapy", 625], [".", 632], ["The", 634], ["hemiparesis", 638], ["and", 650], ["the", 654], ["central", 658], ["facial", 666], ["palsy", 673], ["were", 679], ["fully", 684], ["remitted", 690], ["3", 699], ["days", 701], ["after", 706], ["the", 712], ["onset", 716], ["of", 722], ["symptoms", 725], [",", 733], ["and", 735], ["the", 739], ["dysarthria", 743], ["was", 754], ["remitted", 758], ["2", 767], ["days", 769], ["afterwards", 774], [".", 784], ["Non", 786], ["-", 789], ["vitamin", 790], ["K", 798], ["oral", 800], ["anticoagulants", 805], ["(", 820], ["NOACs", 821], [")", 826], ["are", 828], ["widely", 832], ["used", 839], ["for", 844], ["the", 848], ["prevention", 852], ["of", 863], ["embolic", 866], ["stroke", 874], ["in", 881], ["patients", 884], ["with", 893], ["atrial", 898], ["fibrillation", 905], [".", 917], ["Dabigatran", 919], ["etexilate", 930], ["is", 940], ["an", 943], ["oral", 946], ["thrombin", 951], ["inhibitor", 960], ["that", 970], ["can", 975], ["be", 979], ["reversed", 982], ["by", 991], ["idarucizumab", 994], [".", 1006], ["Idarucizumab", 1008], [",", 1020], ["a", 1022], ["monoclonal", 1024], ["antibody", 1035], ["fragment", 1044], [",", 1052], ["directly", 1054], ["binds", 1063], ["dabigatran", 1069], ["etexilate", 1080], ["and", 1090], ["neutralizes", 1094], ["its", 1106], ["activity", 1110], [".", 1118], ["Reversal", 1120], ["of", 1129], ["dabigatran", 1132], ["etexilate", 1143], ["using", 1153], ["idarucizumab", 1159], ["was", 1172], ["safe", 1176], ["and", 1181], ["successful", 1185], ["with", 1196], ["no", 1201], ["recombinant", 1204], ["tissue", 1216], ["plasminogen", 1223], ["activator", 1235], ["interactions", 1245], [".", 1257]]}
{"context": "Christianson syndrome (OMIM 300243), caused by mutations in the X-linked SLC9A6 gene, is characterized by severe global developmental delay and intellectual disability, developmental regression, epilepsy, microcephaly and impaired ocular movements. It shares many common features with Angelman syndrome. Carrier females have been described as having learning difficulties with mild to moderate intellectual disability, behavioural issues and psychiatric illnesses. There is little literature on the carrier female phenotype of Christianson syndrome. We describe a large extended family with three affected males, four carrier females, one presumed carrier female and one obligate carrier female with a c.190G>T, p.E64X mutation known to cause a premature stop codon in SLC9A6. We characterize and expand the clinical phenotype of female SLC9A6 mutation carriers by comparing our described family with female carriers previously discussed in the literature. In particular, we highlight the neurodevelopmental and psychiatric phenotypes observed in our family and previous reports.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "141c4f0d6d4d4916a34c9dae06adcc8a", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[137, 137], [15, 15], [126, 126]], "char_spans": [[837, 842], [73, 78], [769, 774]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["OMIM", 23], ["300243", 28], [")", 34], [",", 35], ["caused", 37], ["by", 44], ["mutations", 47], ["in", 57], ["the", 60], ["X", 64], ["-", 65], ["linked", 66], ["SLC9A6", 73], ["gene", 80], [",", 84], ["is", 86], ["characterized", 89], ["by", 103], ["severe", 106], ["global", 113], ["developmental", 120], ["delay", 134], ["and", 140], ["intellectual", 144], ["disability", 157], [",", 167], ["developmental", 169], ["regression", 183], [",", 193], ["epilepsy", 195], [",", 203], ["microcephaly", 205], ["and", 218], ["impaired", 222], ["ocular", 231], ["movements", 238], [".", 247], ["It", 249], ["shares", 252], ["many", 259], ["common", 264], ["features", 271], ["with", 280], ["Angelman", 285], ["syndrome", 294], [".", 302], ["Carrier", 304], ["females", 312], ["have", 320], ["been", 325], ["described", 330], ["as", 340], ["having", 343], ["learning", 350], ["difficulties", 359], ["with", 372], ["mild", 377], ["to", 382], ["moderate", 385], ["intellectual", 394], ["disability", 407], [",", 417], ["behavioural", 419], ["issues", 431], ["and", 438], ["psychiatric", 442], ["illnesses", 454], [".", 463], ["There", 465], ["is", 471], ["little", 474], ["literature", 481], ["on", 492], ["the", 495], ["carrier", 499], ["female", 507], ["phenotype", 514], ["of", 524], ["Christianson", 527], ["syndrome", 540], [".", 548], ["We", 550], ["describe", 553], ["a", 562], ["large", 564], ["extended", 570], ["family", 579], ["with", 586], ["three", 591], ["affected", 597], ["males", 606], [",", 611], ["four", 613], ["carrier", 618], ["females", 626], [",", 633], ["one", 635], ["presumed", 639], ["carrier", 648], ["female", 656], ["and", 663], ["one", 667], ["obligate", 671], ["carrier", 680], ["female", 688], ["with", 695], ["a", 700], ["c.190G", 702], [">", 708], ["T", 709], [",", 710], ["p", 712], [".", 713], ["E64X", 714], ["mutation", 719], ["known", 728], ["to", 734], ["cause", 737], ["a", 743], ["premature", 745], ["stop", 755], ["codon", 760], ["in", 766], ["SLC9A6", 769], [".", 775], ["We", 777], ["characterize", 780], ["and", 793], ["expand", 797], ["the", 804], ["clinical", 808], ["phenotype", 817], ["of", 827], ["female", 830], ["SLC9A6", 837], ["mutation", 844], ["carriers", 853], ["by", 862], ["comparing", 865], ["our", 875], ["described", 879], ["family", 889], ["with", 896], ["female", 901], ["carriers", 908], ["previously", 917], ["discussed", 928], ["in", 938], ["the", 941], ["literature", 945], [".", 955], ["In", 957], ["particular", 960], [",", 970], ["we", 972], ["highlight", 975], ["the", 985], ["neurodevelopmental", 989], ["and", 1008], ["psychiatric", 1012], ["phenotypes", 1024], ["observed", 1035], ["in", 1044], ["our", 1047], ["family", 1051], ["and", 1058], ["previous", 1062], ["reports", 1071], [".", 1078]]}
{"context": "Replicating circular RNAs are independent plant pathogens known as viroids, or act to modulate the pathogenesis of plant and animal viruses as their satellite RNAs. The rate of discovery of these subviral pathogens was low over the past 40 years because the classical approaches are technical demanding and time-consuming. We previously described an approach for homology-independent discovery of replicating circular RNAs by analysing the total small RNA populations from samples of diseased tissues with a computational program known as progressive filtering of overlapping small RNAs (PFOR). However, PFOR written in PERL language is extremely slow and is unable to discover those subviral pathogens that do not trigger in vivo accumulation of extensively overlapping small RNAs. Moreover, PFOR is yet to identify a new viroid capable of initiating independent infection. Here we report the development of PFOR2 that adopted parallel programming in the C++ language and was 3 to 8 times faster than PFOR. A new computational program was further developed and incorporated into PFOR2 to allow the identification of circular RNAs by deep sequencing of long RNAs instead of small RNAs. PFOR2 analysis of the small RNA libraries from grapevine and apple plants led to the discovery of Grapevine latent viroid (GLVd) and Apple hammerhead viroid-like RNA (AHVd-like RNA), respectively. GLVd was proposed as a new species in the genus Apscaviroid, because it contained the typical structural elements found in this group of viroids and initiated independent infection in grapevine seedlings. AHVd-like RNA encoded a biologically active hammerhead ribozyme in both polarities, and was not specifically associated with any of the viruses found in apple plants. We propose that these computational algorithms have the potential to discover novel circular RNAs in plants, invertebrates and vertebrates regardless of whether they replicate and/or induce the in vivo accumulation of small RNAs.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "a1eb48cd8fd248b298836e6dfdebb1a5", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[260, 260], [9, 9]], "char_spans": [[1520, 1526], [67, 73]]}]}], "context_tokens": [["Replicating", 0], ["circular", 12], ["RNAs", 21], ["are", 26], ["independent", 30], ["plant", 42], ["pathogens", 48], ["known", 58], ["as", 64], ["viroids", 67], [",", 74], ["or", 76], ["act", 79], ["to", 83], ["modulate", 86], ["the", 95], ["pathogenesis", 99], ["of", 112], ["plant", 115], ["and", 121], ["animal", 125], ["viruses", 132], ["as", 140], ["their", 143], ["satellite", 149], ["RNAs", 159], [".", 163], ["The", 165], ["rate", 169], ["of", 174], ["discovery", 177], ["of", 187], ["these", 190], ["subviral", 196], ["pathogens", 205], ["was", 215], ["low", 219], ["over", 223], ["the", 228], ["past", 232], ["40", 237], ["years", 240], ["because", 246], ["the", 254], ["classical", 258], ["approaches", 268], ["are", 279], ["technical", 283], ["demanding", 293], ["and", 303], ["time", 307], ["-", 311], ["consuming", 312], [".", 321], ["We", 323], ["previously", 326], ["described", 337], ["an", 347], ["approach", 350], ["for", 359], ["homology", 363], ["-", 371], ["independent", 372], ["discovery", 384], ["of", 394], ["replicating", 397], ["circular", 409], ["RNAs", 418], ["by", 423], ["analysing", 426], ["the", 436], ["total", 440], ["small", 446], ["RNA", 452], ["populations", 456], ["from", 468], ["samples", 473], ["of", 481], ["diseased", 484], ["tissues", 493], ["with", 501], ["a", 506], ["computational", 508], ["program", 522], ["known", 530], ["as", 536], ["progressive", 539], ["filtering", 551], ["of", 561], ["overlapping", 564], ["small", 576], ["RNAs", 582], ["(", 587], ["PFOR", 588], [")", 592], [".", 593], ["However", 595], [",", 602], ["PFOR", 604], ["written", 609], ["in", 617], ["PERL", 620], ["language", 625], ["is", 634], ["extremely", 637], ["slow", 647], ["and", 652], ["is", 656], ["unable", 659], ["to", 666], ["discover", 669], ["those", 678], ["subviral", 684], ["pathogens", 693], ["that", 703], ["do", 708], ["not", 711], ["trigger", 715], ["in", 723], ["vivo", 726], ["accumulation", 731], ["of", 744], ["extensively", 747], ["overlapping", 759], ["small", 771], ["RNAs", 777], [".", 781], ["Moreover", 783], [",", 791], ["PFOR", 793], ["is", 798], ["yet", 801], ["to", 805], ["identify", 808], ["a", 817], ["new", 819], ["viroid", 823], ["capable", 830], ["of", 838], ["initiating", 841], ["independent", 852], ["infection", 864], [".", 873], ["Here", 875], ["we", 880], ["report", 883], ["the", 890], ["development", 894], ["of", 906], ["PFOR2", 909], ["that", 915], ["adopted", 920], ["parallel", 928], ["programming", 937], ["in", 949], ["the", 952], ["C++", 956], ["language", 960], ["and", 969], ["was", 973], ["3", 977], ["to", 979], ["8", 982], ["times", 984], ["faster", 990], ["than", 997], ["PFOR", 1002], [".", 1006], ["A", 1008], ["new", 1010], ["computational", 1014], ["program", 1028], ["was", 1036], ["further", 1040], ["developed", 1048], ["and", 1058], ["incorporated", 1062], ["into", 1075], ["PFOR2", 1080], ["to", 1086], ["allow", 1089], ["the", 1095], ["identification", 1099], ["of", 1114], ["circular", 1117], ["RNAs", 1126], ["by", 1131], ["deep", 1134], ["sequencing", 1139], ["of", 1150], ["long", 1153], ["RNAs", 1158], ["instead", 1163], ["of", 1171], ["small", 1174], ["RNAs", 1180], [".", 1184], ["PFOR2", 1186], ["analysis", 1192], ["of", 1201], ["the", 1204], ["small", 1208], ["RNA", 1214], ["libraries", 1218], ["from", 1228], ["grapevine", 1233], ["and", 1243], ["apple", 1247], ["plants", 1253], ["led", 1260], ["to", 1264], ["the", 1267], ["discovery", 1271], ["of", 1281], ["Grapevine", 1284], ["latent", 1294], ["viroid", 1301], ["(", 1308], ["GLVd", 1309], [")", 1313], ["and", 1315], ["Apple", 1319], ["hammerhead", 1325], ["viroid", 1336], ["-", 1342], ["like", 1343], ["RNA", 1348], ["(", 1352], ["AHVd", 1353], ["-", 1357], ["like", 1358], ["RNA", 1363], [")", 1366], [",", 1367], ["respectively", 1369], [".", 1381], ["GLVd", 1383], ["was", 1388], ["proposed", 1392], ["as", 1401], ["a", 1404], ["new", 1406], ["species", 1410], ["in", 1418], ["the", 1421], ["genus", 1425], ["Apscaviroid", 1431], [",", 1442], ["because", 1444], ["it", 1452], ["contained", 1455], ["the", 1465], ["typical", 1469], ["structural", 1477], ["elements", 1488], ["found", 1497], ["in", 1503], ["this", 1506], ["group", 1511], ["of", 1517], ["viroids", 1520], ["and", 1528], ["initiated", 1532], ["independent", 1542], ["infection", 1554], ["in", 1564], ["grapevine", 1567], ["seedlings", 1577], [".", 1586], ["AHVd", 1588], ["-", 1592], ["like", 1593], ["RNA", 1598], ["encoded", 1602], ["a", 1610], ["biologically", 1612], ["active", 1625], ["hammerhead", 1632], ["ribozyme", 1643], ["in", 1652], ["both", 1655], ["polarities", 1660], [",", 1670], ["and", 1672], ["was", 1676], ["not", 1680], ["specifically", 1684], ["associated", 1697], ["with", 1708], ["any", 1713], ["of", 1717], ["the", 1720], ["viruses", 1724], ["found", 1732], ["in", 1738], ["apple", 1741], ["plants", 1747], [".", 1753], ["We", 1755], ["propose", 1758], ["that", 1766], ["these", 1771], ["computational", 1777], ["algorithms", 1791], ["have", 1802], ["the", 1807], ["potential", 1811], ["to", 1821], ["discover", 1824], ["novel", 1833], ["circular", 1839], ["RNAs", 1848], ["in", 1853], ["plants", 1856], [",", 1862], ["invertebrates", 1864], ["and", 1878], ["vertebrates", 1882], ["regardless", 1894], ["of", 1905], ["whether", 1908], ["they", 1916], ["replicate", 1921], ["and/or", 1931], ["induce", 1938], ["the", 1945], ["in", 1949], ["vivo", 1952], ["accumulation", 1957], ["of", 1970], ["small", 1973], ["RNAs", 1979], [".", 1983]]}
{"context": "The mechanism of L-DOPA for antinociception was investigated. Nociceptive behaviors in mice after an intrathecal (i.t.) administration of substance P were evaluated. L-DOPA (i.t.) dose-dependently attenuated the substance P-induced nociceptive behaviors. Co-administration of benserazide (i.t.), a DOPA decarboxylase inhibitor, abolished the antinociceptive effect of L-DOPA. The L-DOPA-induced antinociception was antagonized by sulpiride, a D2 blocker, but not by SCH 23390, a D1 blocker. These results suggest that L-DOPA relieves pain after conversion to dopamine, with the dopamine sedating pain transmission by way of the dopamine D2 receptor.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "b8c8036eed1c449eb5db1160c25e2ed4", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[102, 104], [68, 70], [29, 31], [73, 75], [3, 5]], "char_spans": [[518, 523], [368, 373], [166, 171], [380, 385], [17, 22]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["L", 17], ["-", 18], ["DOPA", 19], ["for", 24], ["antinociception", 28], ["was", 44], ["investigated", 48], [".", 60], ["Nociceptive", 62], ["behaviors", 74], ["in", 84], ["mice", 87], ["after", 92], ["an", 98], ["intrathecal", 101], ["(", 113], ["i.t", 114], [".", 117], [")", 118], ["administration", 120], ["of", 135], ["substance", 138], ["P", 148], ["were", 150], ["evaluated", 155], [".", 164], ["L", 166], ["-", 167], ["DOPA", 168], ["(", 173], ["i.t", 174], [".", 177], [")", 178], ["dose", 180], ["-", 184], ["dependently", 185], ["attenuated", 197], ["the", 208], ["substance", 212], ["P", 222], ["-", 223], ["induced", 224], ["nociceptive", 232], ["behaviors", 244], [".", 253], ["Co", 255], ["-", 257], ["administration", 258], ["of", 273], ["benserazide", 276], ["(", 288], ["i.t", 289], [".", 292], [")", 293], [",", 294], ["a", 296], ["DOPA", 298], ["decarboxylase", 303], ["inhibitor", 317], [",", 326], ["abolished", 328], ["the", 338], ["antinociceptive", 342], ["effect", 358], ["of", 365], ["L", 368], ["-", 369], ["DOPA", 370], [".", 374], ["The", 376], ["L", 380], ["-", 381], ["DOPA", 382], ["-", 386], ["induced", 387], ["antinociception", 395], ["was", 411], ["antagonized", 415], ["by", 427], ["sulpiride", 430], [",", 439], ["a", 441], ["D2", 443], ["blocker", 446], [",", 453], ["but", 455], ["not", 459], ["by", 463], ["SCH", 466], ["23390", 470], [",", 475], ["a", 477], ["D1", 479], ["blocker", 482], [".", 489], ["These", 491], ["results", 497], ["suggest", 505], ["that", 513], ["L", 518], ["-", 519], ["DOPA", 520], ["relieves", 525], ["pain", 534], ["after", 539], ["conversion", 545], ["to", 556], ["dopamine", 559], [",", 567], ["with", 569], ["the", 574], ["dopamine", 578], ["sedating", 587], ["pain", 596], ["transmission", 601], ["by", 614], ["way", 617], ["of", 621], ["the", 624], ["dopamine", 628], ["D2", 637], ["receptor", 640], [".", 648]]}
{"context": "We report the first case of McLeod syndrome (MLS) in a 47-year-old Chinese man who presented with progressive limb weakness, chorea of feet, red blood cell acanthocytosis, absence of Kx red blood cell antigen and weak expression of Kell antigens. The diagnosis of MLS was confirmed by genetic testing showing a hemizygous mutation of XK gene. We review literature on neuroacanthocytosis in the Chinese population.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "2a7364668d534661a202c2f541df1621", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[334, 335]]}]}], "context_tokens": [["We", 0], ["report", 3], ["the", 10], ["first", 14], ["case", 20], ["of", 25], ["McLeod", 28], ["syndrome", 35], ["(", 44], ["MLS", 45], [")", 48], ["in", 50], ["a", 53], ["47-year", 55], ["-", 62], ["old", 63], ["Chinese", 67], ["man", 75], ["who", 79], ["presented", 83], ["with", 93], ["progressive", 98], ["limb", 110], ["weakness", 115], [",", 123], ["chorea", 125], ["of", 132], ["feet", 135], [",", 139], ["red", 141], ["blood", 145], ["cell", 151], ["acanthocytosis", 156], [",", 170], ["absence", 172], ["of", 180], ["Kx", 183], ["red", 186], ["blood", 190], ["cell", 196], ["antigen", 201], ["and", 209], ["weak", 213], ["expression", 218], ["of", 229], ["Kell", 232], ["antigens", 237], [".", 245], ["The", 247], ["diagnosis", 251], ["of", 261], ["MLS", 264], ["was", 268], ["confirmed", 272], ["by", 282], ["genetic", 285], ["testing", 293], ["showing", 301], ["a", 309], ["hemizygous", 311], ["mutation", 322], ["of", 331], ["XK", 334], ["gene", 337], [".", 341], ["We", 343], ["review", 346], ["literature", 353], ["on", 364], ["neuroacanthocytosis", 367], ["in", 387], ["the", 390], ["Chinese", 394], ["population", 402], [".", 412]]}
{"context": "The aim of the study was to exclude neurovascular damage due to prosthetic mini-invasive surgery using transobturator tape (TOT) by pre- and postoperative electromyography (EMG) of the striated urethral sphincter and a color Doppler ultrasonography evaluation of clitoral blood flow. A total of 25 women affected by clinical stress urinary incontinence (SUI) were enrolled. After undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, Q-tip test, and stress test, each subject underwent color Doppler ultrasonography to record clitoral blood flow and EMG of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery. A single urogynecologist performed the TOT surgical technique for the treatment of all patients. Urogynecologic examination, EMG, and color Doppler ultrasound follow-up were performed at 1 and 6 months after surgery. At the urogynecologic examination performed 1 and 6 months after the TOT approach the stress test was negative, urethral hypermobility was reduced, and sling exposure was not observed for each patient. There was no statistically significant difference in electromyographic values (p > 0.05) in both the follow-ups with regard to baseline values. Pulsatility index (PI), resistance index (RI), and peak systolic velocity (PSV) values increased during the first follow-up (p < 0.01); PI and RI values increased during the second follow-up with respect to baseline values (p < 0.01) TOT prosthesis surgery, avoiding denervation and devascularization of pelvic structures, does not damage the urethral sphincter.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "810e979286e64a7eac73389457ab5f2c", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[55, 57]], "char_spans": [[325, 351]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["study", 15], ["was", 21], ["to", 25], ["exclude", 28], ["neurovascular", 36], ["damage", 50], ["due", 57], ["to", 61], ["prosthetic", 64], ["mini", 75], ["-", 79], ["invasive", 80], ["surgery", 89], ["using", 97], ["transobturator", 103], ["tape", 118], ["(", 123], ["TOT", 124], [")", 127], ["by", 129], ["pre-", 132], ["and", 137], ["postoperative", 141], ["electromyography", 155], ["(", 172], ["EMG", 173], [")", 176], ["of", 178], ["the", 181], ["striated", 185], ["urethral", 194], ["sphincter", 203], ["and", 213], ["a", 217], ["color", 219], ["Doppler", 225], ["ultrasonography", 233], ["evaluation", 249], ["of", 260], ["clitoral", 263], ["blood", 272], ["flow", 278], [".", 282], ["A", 284], ["total", 286], ["of", 292], ["25", 295], ["women", 298], ["affected", 304], ["by", 313], ["clinical", 316], ["stress", 325], ["urinary", 332], ["incontinence", 340], ["(", 353], ["SUI", 354], [")", 357], ["were", 359], ["enrolled", 364], [".", 372], ["After", 374], ["undergoing", 380], ["urodynamic", 391], ["assessment", 402], [",", 412], ["pelvic", 414], ["organ", 421], ["prolapse", 427], ["quantification", 436], [",", 450], ["urine", 452], ["culture", 458], [",", 465], ["Q", 467], ["-", 468], ["tip", 469], ["test", 473], [",", 477], ["and", 479], ["stress", 483], ["test", 490], [",", 494], ["each", 496], ["subject", 501], ["underwent", 509], ["color", 519], ["Doppler", 525], ["ultrasonography", 533], ["to", 549], ["record", 552], ["clitoral", 559], ["blood", 568], ["flow", 574], ["and", 579], ["EMG", 583], ["of", 587], ["the", 590], ["urethral", 594], ["sphincter", 603], ["with", 613], ["a", 618], ["needle", 620], ["electrode", 627], ["inserted", 637], ["through", 646], ["the", 654], ["mucosa", 658], ["into", 665], ["the", 670], ["muscle", 674], ["tissue", 681], ["before", 688], ["surgery", 695], [".", 702], ["A", 704], ["single", 706], ["urogynecologist", 713], ["performed", 729], ["the", 739], ["TOT", 743], ["surgical", 747], ["technique", 756], ["for", 766], ["the", 770], ["treatment", 774], ["of", 784], ["all", 787], ["patients", 791], [".", 799], ["Urogynecologic", 801], ["examination", 816], [",", 827], ["EMG", 829], [",", 832], ["and", 834], ["color", 838], ["Doppler", 844], ["ultrasound", 852], ["follow", 863], ["-", 869], ["up", 870], ["were", 873], ["performed", 878], ["at", 888], ["1", 891], ["and", 893], ["6", 897], ["months", 899], ["after", 906], ["surgery", 912], [".", 919], ["At", 921], ["the", 924], ["urogynecologic", 928], ["examination", 943], ["performed", 955], ["1", 965], ["and", 967], ["6", 971], ["months", 973], ["after", 980], ["the", 986], ["TOT", 990], ["approach", 994], ["the", 1003], ["stress", 1007], ["test", 1014], ["was", 1019], ["negative", 1023], [",", 1031], ["urethral", 1033], ["hypermobility", 1042], ["was", 1056], ["reduced", 1060], [",", 1067], ["and", 1069], ["sling", 1073], ["exposure", 1079], ["was", 1088], ["not", 1092], ["observed", 1096], ["for", 1105], ["each", 1109], ["patient", 1114], [".", 1121], ["There", 1123], ["was", 1129], ["no", 1133], ["statistically", 1136], ["significant", 1150], ["difference", 1162], ["in", 1173], ["electromyographic", 1176], ["values", 1194], ["(", 1201], ["p", 1202], [">", 1204], ["0.05", 1206], [")", 1210], ["in", 1212], ["both", 1215], ["the", 1220], ["follow", 1224], ["-", 1230], ["ups", 1231], ["with", 1235], ["regard", 1240], ["to", 1247], ["baseline", 1250], ["values", 1259], [".", 1265], ["Pulsatility", 1267], ["index", 1279], ["(", 1285], ["PI", 1286], [")", 1288], [",", 1289], ["resistance", 1291], ["index", 1302], ["(", 1308], ["RI", 1309], [")", 1311], [",", 1312], ["and", 1314], ["peak", 1318], ["systolic", 1323], ["velocity", 1332], ["(", 1341], ["PSV", 1342], [")", 1345], ["values", 1347], ["increased", 1354], ["during", 1364], ["the", 1371], ["first", 1375], ["follow", 1381], ["-", 1387], ["up", 1388], ["(", 1391], ["p", 1392], ["<", 1394], ["0.01", 1396], [")", 1400], [";", 1401], ["PI", 1403], ["and", 1406], ["RI", 1410], ["values", 1413], ["increased", 1420], ["during", 1430], ["the", 1437], ["second", 1441], ["follow", 1448], ["-", 1454], ["up", 1455], ["with", 1458], ["respect", 1463], ["to", 1471], ["baseline", 1474], ["values", 1483], ["(", 1490], ["p", 1491], ["<", 1493], ["0.01", 1495], [")", 1499], ["TOT", 1501], ["prosthesis", 1505], ["surgery", 1516], [",", 1523], ["avoiding", 1525], ["denervation", 1534], ["and", 1546], ["devascularization", 1550], ["of", 1568], ["pelvic", 1571], ["structures", 1578], [",", 1588], ["does", 1590], ["not", 1595], ["damage", 1599], ["the", 1606], ["urethral", 1610], ["sphincter", 1619], [".", 1628]]}
{"context": "Turner's syndrome, also known as 'monosomy X', is a genetic disorder that occurs in 1/2,500 female births and is hypothesized to result from haploinsufficiency of certain genes expressed from both sex chromosomes that escape X inactivation. While the classic karyotype related to Turner's syndrome is 45,X, the majority of those affected actually have a mosaic chromosomal complement, most often with a second normal cell line (46,XX). The resulting phenotype is variable and related to the underlying chromosomal pattern, but it is characterized by three cardinal features: short stature (around 100%), ovarian failure (>90%) and congenital lymphedema (>80%). In this paper we report a molecular and cytogenetic investigation of a 26-year-old female with non-mosaic 45,X karyotype, who has a stature of 170 cm without GH treatment, and whose only apparent Turner feature is gonadal dysgenesis. The only possible explanation for the absence of Turner phenotype is the hidden mosaicism combined with an untreated gonadal dysgenesis. Our results support the theory that significant ascertainment bias exists in our understanding of Turner's syndrome.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f936edc724e441e3aee4d610eb000a14", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[39, 39], [9, 9]], "char_spans": [[225, 225], [43, 43]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], [",", 17], ["also", 19], ["known", 24], ["as", 30], ["'", 33], ["monosomy", 34], ["X", 43], ["'", 44], [",", 45], ["is", 47], ["a", 50], ["genetic", 52], ["disorder", 60], ["that", 69], ["occurs", 74], ["in", 81], ["1/2,500", 84], ["female", 92], ["births", 99], ["and", 106], ["is", 110], ["hypothesized", 113], ["to", 126], ["result", 129], ["from", 136], ["haploinsufficiency", 141], ["of", 160], ["certain", 163], ["genes", 171], ["expressed", 177], ["from", 187], ["both", 192], ["sex", 197], ["chromosomes", 201], ["that", 213], ["escape", 218], ["X", 225], ["inactivation", 227], [".", 239], ["While", 241], ["the", 247], ["classic", 251], ["karyotype", 259], ["related", 269], ["to", 277], ["Turner", 280], ["'s", 286], ["syndrome", 289], ["is", 298], ["45,X", 301], [",", 305], ["the", 307], ["majority", 311], ["of", 320], ["those", 323], ["affected", 329], ["actually", 338], ["have", 347], ["a", 352], ["mosaic", 354], ["chromosomal", 361], ["complement", 373], [",", 383], ["most", 385], ["often", 390], ["with", 396], ["a", 401], ["second", 403], ["normal", 410], ["cell", 417], ["line", 422], ["(", 427], ["46,XX", 428], [")", 433], [".", 434], ["The", 436], ["resulting", 440], ["phenotype", 450], ["is", 460], ["variable", 463], ["and", 472], ["related", 476], ["to", 484], ["the", 487], ["underlying", 491], ["chromosomal", 502], ["pattern", 514], [",", 521], ["but", 523], ["it", 527], ["is", 530], ["characterized", 533], ["by", 547], ["three", 550], ["cardinal", 556], ["features", 565], [":", 573], ["short", 575], ["stature", 581], ["(", 589], ["around", 590], ["100", 597], ["%", 600], [")", 601], [",", 602], ["ovarian", 604], ["failure", 612], ["(", 620], [">", 621], ["90", 622], ["%", 624], [")", 625], ["and", 627], ["congenital", 631], ["lymphedema", 642], ["(", 653], [">", 654], ["80", 655], ["%", 657], [")", 658], [".", 659], ["In", 661], ["this", 664], ["paper", 669], ["we", 675], ["report", 678], ["a", 685], ["molecular", 687], ["and", 697], ["cytogenetic", 701], ["investigation", 713], ["of", 727], ["a", 730], ["26-year", 732], ["-", 739], ["old", 740], ["female", 744], ["with", 751], ["non", 756], ["-", 759], ["mosaic", 760], ["45,X", 767], ["karyotype", 772], [",", 781], ["who", 783], ["has", 787], ["a", 791], ["stature", 793], ["of", 801], ["170", 804], ["cm", 808], ["without", 811], ["GH", 819], ["treatment", 822], [",", 831], ["and", 833], ["whose", 837], ["only", 843], ["apparent", 848], ["Turner", 857], ["feature", 864], ["is", 872], ["gonadal", 875], ["dysgenesis", 883], [".", 893], ["The", 895], ["only", 899], ["possible", 904], ["explanation", 913], ["for", 925], ["the", 929], ["absence", 933], ["of", 941], ["Turner", 944], ["phenotype", 951], ["is", 961], ["the", 964], ["hidden", 968], ["mosaicism", 975], ["combined", 985], ["with", 994], ["an", 999], ["untreated", 1002], ["gonadal", 1012], ["dysgenesis", 1020], [".", 1030], ["Our", 1032], ["results", 1036], ["support", 1044], ["the", 1052], ["theory", 1056], ["that", 1063], ["significant", 1068], ["ascertainment", 1080], ["bias", 1094], ["exists", 1099], ["in", 1106], ["our", 1109], ["understanding", 1113], ["of", 1127], ["Turner", 1130], ["'s", 1136], ["syndrome", 1139], [".", 1147]]}
{"context": "Adjuvant System AS01 is a liposome-based vaccine adjuvant containing 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21. AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III). Given the known immunostimulatory properties of MPL and QS-21, the objective of this study was to describe the early immune response parameters after immunization with an AS01-adjuvanted vaccine and to identify relationships with the vaccine-specific adaptive immune response. Cytokine production and innate immune cell recruitment occurred rapidly and transiently at the muscle injection site and draining lymph node postinjection, consistent with the rapid drainage of the vaccine components to the draining lymph node. The induction of Ag-specific Ab and T cell responses was dependent on the Ag being injected at the same time or within 24 h after AS01, suggesting that the early events occurring postinjection were required for these elevated adaptive responses. In the draining lymph node, after 24 h, the numbers of activated and Ag-loaded monocytes and MHCII(high) dendritic cells were higher after the injection of the AS01-adjuvanted vaccine than after Ag alone. However, only MHCII(high) dendritic cells appeared efficient at and necessary for direct Ag presentation to T cells. These data suggest that the ability of AS01 to improve adaptive immune responses, as has been demonstrated in clinical trials, is linked to a transient stimulation of the innate immune system leading to the generation of high number of efficient Ag-presenting dendritic cells.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "1363ed9604ca4b6e86e3a335d50b1bb3", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[38, 38]], "char_spans": [[232, 238]]}]}], "context_tokens": [["Adjuvant", 0], ["System", 9], ["AS01", 16], ["is", 21], ["a", 24], ["liposome", 26], ["-", 34], ["based", 35], ["vaccine", 41], ["adjuvant", 49], ["containing", 58], ["3-O", 69], ["-", 72], ["desacyl-4'-monophosphoryl", 73], ["lipid", 99], ["A", 105], ["and", 107], ["the", 111], ["saponin", 115], ["QS-21", 123], [".", 128], ["AS01", 130], ["has", 135], ["been", 139], ["selected", 144], ["for", 153], ["the", 157], ["clinical", 161], ["development", 170], ["of", 182], ["several", 185], ["candidate", 193], ["vaccines", 203], ["including", 212], ["the", 222], ["RTS", 226], [",", 229], ["S", 230], ["malaria", 232], ["vaccine", 240], ["and", 248], ["the", 252], ["subunit", 256], ["glycoprotein", 264], ["E", 277], ["varicella", 279], ["zoster", 289], ["vaccine", 296], ["(", 304], ["both", 305], ["currently", 310], ["in", 320], ["phase", 323], ["III", 329], [")", 332], [".", 333], ["Given", 335], ["the", 341], ["known", 345], ["immunostimulatory", 351], ["properties", 369], ["of", 380], ["MPL", 383], ["and", 387], ["QS-21", 391], [",", 396], ["the", 398], ["objective", 402], ["of", 412], ["this", 415], ["study", 420], ["was", 426], ["to", 430], ["describe", 433], ["the", 442], ["early", 446], ["immune", 452], ["response", 459], ["parameters", 468], ["after", 479], ["immunization", 485], ["with", 498], ["an", 503], ["AS01-adjuvanted", 506], ["vaccine", 522], ["and", 530], ["to", 534], ["identify", 537], ["relationships", 546], ["with", 560], ["the", 565], ["vaccine", 569], ["-", 576], ["specific", 577], ["adaptive", 586], ["immune", 595], ["response", 602], [".", 610], ["Cytokine", 612], ["production", 621], ["and", 632], ["innate", 636], ["immune", 643], ["cell", 650], ["recruitment", 655], ["occurred", 667], ["rapidly", 676], ["and", 684], ["transiently", 688], ["at", 700], ["the", 703], ["muscle", 707], ["injection", 714], ["site", 724], ["and", 729], ["draining", 733], ["lymph", 742], ["node", 748], ["postinjection", 753], [",", 766], ["consistent", 768], ["with", 779], ["the", 784], ["rapid", 788], ["drainage", 794], ["of", 803], ["the", 806], ["vaccine", 810], ["components", 818], ["to", 829], ["the", 832], ["draining", 836], ["lymph", 845], ["node", 851], [".", 855], ["The", 857], ["induction", 861], ["of", 871], ["Ag", 874], ["-", 876], ["specific", 877], ["Ab", 886], ["and", 889], ["T", 893], ["cell", 895], ["responses", 900], ["was", 910], ["dependent", 914], ["on", 924], ["the", 927], ["Ag", 931], ["being", 934], ["injected", 940], ["at", 949], ["the", 952], ["same", 956], ["time", 961], ["or", 966], ["within", 969], ["24", 976], ["h", 979], ["after", 981], ["AS01", 987], [",", 991], ["suggesting", 993], ["that", 1004], ["the", 1009], ["early", 1013], ["events", 1019], ["occurring", 1026], ["postinjection", 1036], ["were", 1050], ["required", 1055], ["for", 1064], ["these", 1068], ["elevated", 1074], ["adaptive", 1083], ["responses", 1092], [".", 1101], ["In", 1103], ["the", 1106], ["draining", 1110], ["lymph", 1119], ["node", 1125], [",", 1129], ["after", 1131], ["24", 1137], ["h", 1140], [",", 1141], ["the", 1143], ["numbers", 1147], ["of", 1155], ["activated", 1158], ["and", 1168], ["Ag", 1172], ["-", 1174], ["loaded", 1175], ["monocytes", 1182], ["and", 1192], ["MHCII(high", 1196], [")", 1206], ["dendritic", 1208], ["cells", 1218], ["were", 1224], ["higher", 1229], ["after", 1236], ["the", 1242], ["injection", 1246], ["of", 1256], ["the", 1259], ["AS01-adjuvanted", 1263], ["vaccine", 1279], ["than", 1287], ["after", 1292], ["Ag", 1298], ["alone", 1301], [".", 1306], ["However", 1308], [",", 1315], ["only", 1317], ["MHCII(high", 1322], [")", 1332], ["dendritic", 1334], ["cells", 1344], ["appeared", 1350], ["efficient", 1359], ["at", 1369], ["and", 1372], ["necessary", 1376], ["for", 1386], ["direct", 1390], ["Ag", 1397], ["presentation", 1400], ["to", 1413], ["T", 1416], ["cells", 1418], [".", 1423], ["These", 1425], ["data", 1431], ["suggest", 1436], ["that", 1444], ["the", 1449], ["ability", 1453], ["of", 1461], ["AS01", 1464], ["to", 1469], ["improve", 1472], ["adaptive", 1480], ["immune", 1489], ["responses", 1496], [",", 1505], ["as", 1507], ["has", 1510], ["been", 1514], ["demonstrated", 1519], ["in", 1532], ["clinical", 1535], ["trials", 1544], [",", 1550], ["is", 1552], ["linked", 1555], ["to", 1562], ["a", 1565], ["transient", 1567], ["stimulation", 1577], ["of", 1589], ["the", 1592], ["innate", 1596], ["immune", 1603], ["system", 1610], ["leading", 1617], ["to", 1625], ["the", 1628], ["generation", 1632], ["of", 1643], ["high", 1646], ["number", 1651], ["of", 1658], ["efficient", 1661], ["Ag", 1671], ["-", 1673], ["presenting", 1674], ["dendritic", 1685], ["cells", 1695], [".", 1700]]}
{"context": "Viroids, subviral pathogens of plants, are composed of a single-stranded circular RNA of 246-399 nucleotides. Within the 27 viroids sequenced, avocado sunblotch, peach latent mosaic and chrysanthemum chlorotic mottle viroids (ASBVd, PLMVd and CChMVd, respectively) can form hammerhead structures in both of their polarity strands. These ribozymes mediate self-cleavage of the oligomeric RNAs generated in the replication through a rolling circle mechanism, whose two other steps are catalyzed by an RNA polymerase and an RNA ligase. ASBVd, and presumably PLMVd and CChMVd, replicate and accumulate in the chloroplast, whereas typical viroids replicate and accumulate in the nucleus. PLMVd and CChMVd do not adopt a rod-like or quasi rod-like secondary structure as typical viroids do but have a highly branched conformation. A pathogenicity determinant has been mapped in a defined region of the CChMVd molecule.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "023fcaa40e9a45319ee26a33d98fb40f", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[0, 0], [138, 138], [38, 38], [25, 25], [111, 111]], "char_spans": [[0, 6], [773, 779], [217, 223], [124, 130], [634, 640]]}]}], "context_tokens": [["Viroids", 0], [",", 7], ["subviral", 9], ["pathogens", 18], ["of", 28], ["plants", 31], [",", 37], ["are", 39], ["composed", 43], ["of", 52], ["a", 55], ["single", 57], ["-", 63], ["stranded", 64], ["circular", 73], ["RNA", 82], ["of", 86], ["246", 89], ["-", 92], ["399", 93], ["nucleotides", 97], [".", 108], ["Within", 110], ["the", 117], ["27", 121], ["viroids", 124], ["sequenced", 132], [",", 141], ["avocado", 143], ["sunblotch", 151], [",", 160], ["peach", 162], ["latent", 168], ["mosaic", 175], ["and", 182], ["chrysanthemum", 186], ["chlorotic", 200], ["mottle", 210], ["viroids", 217], ["(", 225], ["ASBVd", 226], [",", 231], ["PLMVd", 233], ["and", 239], ["CChMVd", 243], [",", 249], ["respectively", 251], [")", 263], ["can", 265], ["form", 269], ["hammerhead", 274], ["structures", 285], ["in", 296], ["both", 299], ["of", 304], ["their", 307], ["polarity", 313], ["strands", 322], [".", 329], ["These", 331], ["ribozymes", 337], ["mediate", 347], ["self", 355], ["-", 359], ["cleavage", 360], ["of", 369], ["the", 372], ["oligomeric", 376], ["RNAs", 387], ["generated", 392], ["in", 402], ["the", 405], ["replication", 409], ["through", 421], ["a", 429], ["rolling", 431], ["circle", 439], ["mechanism", 446], [",", 455], ["whose", 457], ["two", 463], ["other", 467], ["steps", 473], ["are", 479], ["catalyzed", 483], ["by", 493], ["an", 496], ["RNA", 499], ["polymerase", 503], ["and", 514], ["an", 518], ["RNA", 521], ["ligase", 525], [".", 531], ["ASBVd", 533], [",", 538], ["and", 540], ["presumably", 544], ["PLMVd", 555], ["and", 561], ["CChMVd", 565], [",", 571], ["replicate", 573], ["and", 583], ["accumulate", 587], ["in", 598], ["the", 601], ["chloroplast", 605], [",", 616], ["whereas", 618], ["typical", 626], ["viroids", 634], ["replicate", 642], ["and", 652], ["accumulate", 656], ["in", 667], ["the", 670], ["nucleus", 674], [".", 681], ["PLMVd", 683], ["and", 689], ["CChMVd", 693], ["do", 700], ["not", 703], ["adopt", 707], ["a", 713], ["rod", 715], ["-", 718], ["like", 719], ["or", 724], ["quasi", 727], ["rod", 733], ["-", 736], ["like", 737], ["secondary", 742], ["structure", 752], ["as", 762], ["typical", 765], ["viroids", 773], ["do", 781], ["but", 784], ["have", 788], ["a", 793], ["highly", 795], ["branched", 802], ["conformation", 811], [".", 823], ["A", 825], ["pathogenicity", 827], ["determinant", 841], ["has", 853], ["been", 857], ["mapped", 862], ["in", 869], ["a", 872], ["defined", 874], ["region", 882], ["of", 889], ["the", 892], ["CChMVd", 896], ["molecule", 903], [".", 911]]}
{"context": "The Ehlers-Danlos syndrome encompasses a group of hereditary disorders of the connective tissue, characterized by hyperextensible skin, joint hypermobility; and varying degrees of vessel and tissue fragility. The main forms are classical, hypermobile, vascular, kyphoscoliotic A/B, arthrochalasis A/B and dermatosparaxis types. We report our experience in diagnosis and classification of Ehlers-Danlos-syndrome, especially with the combination of clinical and morphological criteria, at the Department of Dermatology of the University of Heidelberg with more than 600 patients between 1984 and 2004. We classified those types of EDS which are characterized by regular and characteristic ultrastructural changes in the dermal components, primarily collagen, including the classical, hypermobile and vascular types as well as the less-common arthrochalasis and dermatosparaxis types. The combination of clinical and morphologic features facilitates the selection of candidate genes for molecular genetic investigation. Besides the skin, skeleton and vessels, many other organ systems such as eyes and intestine, can be affected in Ehlers-Danlos syndrome. Accordingly, interdisciplinary cooperation (pediatrics, surgery, orthopedics, rheumatology, neurology, genetics) is necessary. As the connective tissue of the skin is accessible for biopsy and diagnostic investigation, dermatologists should be trained in the diagnostic approach and classification of this syndrome.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "93c9b82b1f4f4d52ac7e695d7d49694e", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [211, 212]], "char_spans": [[78, 94], [1287, 1303]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["encompasses", 27], ["a", 39], ["group", 41], ["of", 47], ["hereditary", 50], ["disorders", 61], ["of", 71], ["the", 74], ["connective", 78], ["tissue", 89], [",", 95], ["characterized", 97], ["by", 111], ["hyperextensible", 114], ["skin", 130], [",", 134], ["joint", 136], ["hypermobility", 142], [";", 155], ["and", 157], ["varying", 161], ["degrees", 169], ["of", 177], ["vessel", 180], ["and", 187], ["tissue", 191], ["fragility", 198], [".", 207], ["The", 209], ["main", 213], ["forms", 218], ["are", 224], ["classical", 228], [",", 237], ["hypermobile", 239], [",", 250], ["vascular", 252], [",", 260], ["kyphoscoliotic", 262], ["A", 277], ["/", 278], ["B", 279], [",", 280], ["arthrochalasis", 282], ["A", 297], ["/", 298], ["B", 299], ["and", 301], ["dermatosparaxis", 305], ["types", 321], [".", 326], ["We", 328], ["report", 331], ["our", 338], ["experience", 342], ["in", 353], ["diagnosis", 356], ["and", 366], ["classification", 370], ["of", 385], ["Ehlers", 388], ["-", 394], ["Danlos", 395], ["-", 401], ["syndrome", 402], [",", 410], ["especially", 412], ["with", 423], ["the", 428], ["combination", 432], ["of", 444], ["clinical", 447], ["and", 456], ["morphological", 460], ["criteria", 474], [",", 482], ["at", 484], ["the", 487], ["Department", 491], ["of", 502], ["Dermatology", 505], ["of", 517], ["the", 520], ["University", 524], ["of", 535], ["Heidelberg", 538], ["with", 549], ["more", 554], ["than", 559], ["600", 564], ["patients", 568], ["between", 577], ["1984", 585], ["and", 590], ["2004", 594], [".", 598], ["We", 600], ["classified", 603], ["those", 614], ["types", 620], ["of", 626], ["EDS", 629], ["which", 633], ["are", 639], ["characterized", 643], ["by", 657], ["regular", 660], ["and", 668], ["characteristic", 672], ["ultrastructural", 687], ["changes", 703], ["in", 711], ["the", 714], ["dermal", 718], ["components", 725], [",", 735], ["primarily", 737], ["collagen", 747], [",", 755], ["including", 757], ["the", 767], ["classical", 771], [",", 780], ["hypermobile", 782], ["and", 794], ["vascular", 798], ["types", 807], ["as", 813], ["well", 816], ["as", 821], ["the", 824], ["less", 828], ["-", 832], ["common", 833], ["arthrochalasis", 840], ["and", 855], ["dermatosparaxis", 859], ["types", 875], [".", 880], ["The", 882], ["combination", 886], ["of", 898], ["clinical", 901], ["and", 910], ["morphologic", 914], ["features", 926], ["facilitates", 935], ["the", 947], ["selection", 951], ["of", 961], ["candidate", 964], ["genes", 974], ["for", 980], ["molecular", 984], ["genetic", 994], ["investigation", 1002], [".", 1015], ["Besides", 1017], ["the", 1025], ["skin", 1029], [",", 1033], ["skeleton", 1035], ["and", 1044], ["vessels", 1048], [",", 1055], ["many", 1057], ["other", 1062], ["organ", 1068], ["systems", 1074], ["such", 1082], ["as", 1087], ["eyes", 1090], ["and", 1095], ["intestine", 1099], [",", 1108], ["can", 1110], ["be", 1114], ["affected", 1117], ["in", 1126], ["Ehlers", 1129], ["-", 1135], ["Danlos", 1136], ["syndrome", 1143], [".", 1151], ["Accordingly", 1153], [",", 1164], ["interdisciplinary", 1166], ["cooperation", 1184], ["(", 1196], ["pediatrics", 1197], [",", 1207], ["surgery", 1209], [",", 1216], ["orthopedics", 1218], [",", 1229], ["rheumatology", 1231], [",", 1243], ["neurology", 1245], [",", 1254], ["genetics", 1256], [")", 1264], ["is", 1266], ["necessary", 1269], [".", 1278], ["As", 1280], ["the", 1283], ["connective", 1287], ["tissue", 1298], ["of", 1305], ["the", 1308], ["skin", 1312], ["is", 1317], ["accessible", 1320], ["for", 1331], ["biopsy", 1335], ["and", 1342], ["diagnostic", 1346], ["investigation", 1357], [",", 1370], ["dermatologists", 1372], ["should", 1387], ["be", 1394], ["trained", 1397], ["in", 1405], ["the", 1408], ["diagnostic", 1412], ["approach", 1423], ["and", 1432], ["classification", 1436], ["of", 1451], ["this", 1454], ["syndrome", 1459], [".", 1467]]}
{"context": "Flumazenil is indicated for reversal of sedation from benzodiazepines administered during therapeutic or diagnostic procedures and during induction or maintenance of general anesthesia, as well as for benzodiazepine overdose. Bolus doses of flumazenil are usually adequate to achieve reversal; however, when medical conditions may lead to a prolonged half-life of the benzodiazepine involved, continuous infusion may be warranted. A 67-year-old man with chlordiazepoxide toxicity required a 9-day infusion of flumazenil to prevent resedation and respiratory insufficiency; he initially was admitted to the hospital for alcohol detoxification. Concomitant medical conditions and the metabolism characteristics of each benzodiazepine must dictate the agent of choice. When measures are required to ensure adequate recovery of a patient's respiratory function and mental awareness, such as in patients with benzodiazepine toxicity, consideration of continuous-infusion flumazenil is warranted.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "f432b5bc07f54ef7aca42e75d115e658", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [79, 79], [146, 146], [34, 34]], "char_spans": [[0, 9], [509, 518], [966, 975], [241, 250]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["indicated", 14], ["for", 24], ["reversal", 28], ["of", 37], ["sedation", 40], ["from", 49], ["benzodiazepines", 54], ["administered", 70], ["during", 83], ["therapeutic", 90], ["or", 102], ["diagnostic", 105], ["procedures", 116], ["and", 127], ["during", 131], ["induction", 138], ["or", 148], ["maintenance", 151], ["of", 163], ["general", 166], ["anesthesia", 174], [",", 184], ["as", 186], ["well", 189], ["as", 194], ["for", 197], ["benzodiazepine", 201], ["overdose", 216], [".", 224], ["Bolus", 226], ["doses", 232], ["of", 238], ["flumazenil", 241], ["are", 252], ["usually", 256], ["adequate", 264], ["to", 273], ["achieve", 276], ["reversal", 284], [";", 292], ["however", 294], [",", 301], ["when", 303], ["medical", 308], ["conditions", 316], ["may", 327], ["lead", 331], ["to", 336], ["a", 339], ["prolonged", 341], ["half", 351], ["-", 355], ["life", 356], ["of", 361], ["the", 364], ["benzodiazepine", 368], ["involved", 383], [",", 391], ["continuous", 393], ["infusion", 404], ["may", 413], ["be", 417], ["warranted", 420], [".", 429], ["A", 431], ["67-year", 433], ["-", 440], ["old", 441], ["man", 445], ["with", 449], ["chlordiazepoxide", 454], ["toxicity", 471], ["required", 480], ["a", 489], ["9-day", 491], ["infusion", 497], ["of", 506], ["flumazenil", 509], ["to", 520], ["prevent", 523], ["resedation", 531], ["and", 542], ["respiratory", 546], ["insufficiency", 558], [";", 571], ["he", 573], ["initially", 576], ["was", 586], ["admitted", 590], ["to", 599], ["the", 602], ["hospital", 606], ["for", 615], ["alcohol", 619], ["detoxification", 627], [".", 641], ["Concomitant", 643], ["medical", 655], ["conditions", 663], ["and", 674], ["the", 678], ["metabolism", 682], ["characteristics", 693], ["of", 709], ["each", 712], ["benzodiazepine", 717], ["must", 732], ["dictate", 737], ["the", 745], ["agent", 749], ["of", 755], ["choice", 758], [".", 764], ["When", 766], ["measures", 771], ["are", 780], ["required", 784], ["to", 793], ["ensure", 796], ["adequate", 803], ["recovery", 812], ["of", 821], ["a", 824], ["patient", 826], ["'s", 833], ["respiratory", 836], ["function", 848], ["and", 857], ["mental", 861], ["awareness", 868], [",", 877], ["such", 879], ["as", 884], ["in", 887], ["patients", 890], ["with", 899], ["benzodiazepine", 904], ["toxicity", 919], [",", 927], ["consideration", 929], ["of", 943], ["continuous", 946], ["-", 956], ["infusion", 957], ["flumazenil", 966], ["is", 977], ["warranted", 980], [".", 989]]}
{"context": "PECAM-1 (CD31) is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing             surface glycoprotein expressed on various hematopoietic cells as well as on endothelial             cells. PECAM-1 has been shown to play roles in regulation of adhesion, migration             and apoptosis. The BCR/ABL fusion tyrosine kinase is expressed in chronic myeloid             leukemia and Philadelphia-positive (Ph+) acute lymphoblastic leukemia cells, and             its inhibition by the clinically used tyrosine kinase inhibitors imatinib or dasatinib             induces apoptosis of these cells. In the present study, we demonstrate that PECAM-1             is tyrosine phospho-rylated in its ITIM motifs in various BCR/ABL-expressing cells             including primary leukemia cells. Studies using imatinib and dasatinib as well             as transient expression experiments in 293T cells revealed that PECAM-1 was phosphorylated             directly by BCR/ABL, which was enhanced by the imatinib-resistant E255K and T315I             mutations, or partly by the Src family tyrosine kinases, including Lyn, which             were activated dependently or independently on BCR/ABL. We also demonstrate by             using a substrate trapping mutant of SHP2 that tyrosine phosphorylated PECAM-1             binds SHP2 and is a major substrate for this tyrosine phosphatase in BCR/ABL-expressing             cells. Overexpression of PECAM-1 in BCR/ABL-expressing cells, including K562 human             leukemia cells, enhanced cell adhesion and partially inhibited imatinib-induced             apoptosis involving mitochondria depolarization and caspase-3 cleavage, at least             partly, in an ITIM-independent manner. These data suggest that PECAM-1 may play             a role in regulation of apoptosis as well as adhesion of BCR/ABL-expressing cells             to modulate their imatinib sensitivity and would be a possible candidate for therapeutic             target in Ph+ leukemias.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4fa3e89a79474c9aa77b1afb5c01d09e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[209, 211], [108, 110], [220, 222], [141, 143], [45, 47], [178, 180], [279, 281]], "char_spans": [[1397, 1403], [731, 737], [1464, 1470], [974, 980], [310, 316], [1193, 1199], [1857, 1863]]}]}], "context_tokens": [["PECAM-1", 0], ["(", 8], ["CD31", 9], [")", 13], ["is", 15], ["an", 18], ["immunoreceptor", 21], ["tyrosine", 36], ["-", 44], ["based", 45], ["inhibitory", 51], ["motif", 62], ["(", 68], ["ITIM)-containing", 69], ["surface", 98], ["glycoprotein", 106], ["expressed", 119], ["on", 129], ["various", 132], ["hematopoietic", 140], ["cells", 154], ["as", 160], ["well", 163], ["as", 168], ["on", 171], ["endothelial", 174], ["cells", 198], [".", 203], ["PECAM-1", 205], ["has", 213], ["been", 217], ["shown", 222], ["to", 228], ["play", 231], ["roles", 236], ["in", 242], ["regulation", 245], ["of", 256], ["adhesion", 259], [",", 267], ["migration", 269], ["and", 291], ["apoptosis", 295], [".", 304], ["The", 306], ["BCR", 310], ["/", 313], ["ABL", 314], ["fusion", 318], ["tyrosine", 325], ["kinase", 334], ["is", 341], ["expressed", 344], ["in", 354], ["chronic", 357], ["myeloid", 365], ["leukemia", 385], ["and", 394], ["Philadelphia", 398], ["-", 410], ["positive", 411], ["(", 420], ["Ph+", 421], [")", 424], ["acute", 426], ["lymphoblastic", 432], ["leukemia", 446], ["cells", 455], [",", 460], ["and", 462], ["its", 478], ["inhibition", 482], ["by", 493], ["the", 496], ["clinically", 500], ["used", 511], ["tyrosine", 516], ["kinase", 525], ["inhibitors", 532], ["imatinib", 543], ["or", 552], ["dasatinib", 555], ["induces", 577], ["apoptosis", 585], ["of", 595], ["these", 598], ["cells", 604], [".", 609], ["In", 611], ["the", 614], ["present", 618], ["study", 626], [",", 631], ["we", 633], ["demonstrate", 636], ["that", 648], ["PECAM-1", 653], ["is", 673], ["tyrosine", 676], ["phospho", 685], ["-", 692], ["rylated", 693], ["in", 701], ["its", 704], ["ITIM", 708], ["motifs", 713], ["in", 720], ["various", 723], ["BCR", 731], ["/", 734], ["ABL", 735], ["-", 738], ["expressing", 739], ["cells", 750], ["including", 768], ["primary", 778], ["leukemia", 786], ["cells", 795], [".", 800], ["Studies", 802], ["using", 810], ["imatinib", 816], ["and", 825], ["dasatinib", 829], ["as", 839], ["well", 842], ["as", 859], ["transient", 862], ["expression", 872], ["experiments", 883], ["in", 895], ["293", 898], ["T", 901], ["cells", 903], ["revealed", 909], ["that", 918], ["PECAM-1", 923], ["was", 931], ["phosphorylated", 935], ["directly", 962], ["by", 971], ["BCR", 974], ["/", 977], ["ABL", 978], [",", 981], ["which", 983], ["was", 989], ["enhanced", 993], ["by", 1002], ["the", 1005], ["imatinib", 1009], ["-", 1017], ["resistant", 1018], ["E255", 1028], ["K", 1032], ["and", 1034], ["T315I", 1038], ["mutations", 1056], [",", 1065], ["or", 1067], ["partly", 1070], ["by", 1077], ["the", 1080], ["Src", 1084], ["family", 1088], ["tyrosine", 1095], ["kinases", 1104], [",", 1111], ["including", 1113], ["Lyn", 1123], [",", 1126], ["which", 1128], ["were", 1146], ["activated", 1151], ["dependently", 1161], ["or", 1173], ["independently", 1176], ["on", 1190], ["BCR", 1193], ["/", 1196], ["ABL", 1197], [".", 1200], ["We", 1202], ["also", 1205], ["demonstrate", 1210], ["by", 1222], ["using", 1237], ["a", 1243], ["substrate", 1245], ["trapping", 1255], ["mutant", 1264], ["of", 1271], ["SHP2", 1274], ["that", 1279], ["tyrosine", 1284], ["phosphorylated", 1293], ["PECAM-1", 1308], ["binds", 1328], ["SHP2", 1334], ["and", 1339], ["is", 1343], ["a", 1346], ["major", 1348], ["substrate", 1354], ["for", 1364], ["this", 1368], ["tyrosine", 1373], ["phosphatase", 1382], ["in", 1394], ["BCR", 1397], ["/", 1400], ["ABL", 1401], ["-", 1404], ["expressing", 1405], ["cells", 1428], [".", 1433], ["Overexpression", 1435], ["of", 1450], ["PECAM-1", 1453], ["in", 1461], ["BCR", 1464], ["/", 1467], ["ABL", 1468], ["-", 1471], ["expressing", 1472], ["cells", 1483], [",", 1488], ["including", 1490], ["K562", 1500], ["human", 1505], ["leukemia", 1523], ["cells", 1532], [",", 1537], ["enhanced", 1539], ["cell", 1548], ["adhesion", 1553], ["and", 1562], ["partially", 1566], ["inhibited", 1576], ["imatinib", 1586], ["-", 1594], ["induced", 1595], ["apoptosis", 1615], ["involving", 1625], ["mitochondria", 1635], ["depolarization", 1648], ["and", 1663], ["caspase-3", 1667], ["cleavage", 1677], [",", 1685], ["at", 1687], ["least", 1690], ["partly", 1708], [",", 1714], ["in", 1716], ["an", 1719], ["ITIM", 1722], ["-", 1726], ["independent", 1727], ["manner", 1739], [".", 1745], ["These", 1747], ["data", 1753], ["suggest", 1758], ["that", 1766], ["PECAM-1", 1771], ["may", 1779], ["play", 1783], ["a", 1800], ["role", 1802], ["in", 1807], ["regulation", 1810], ["of", 1821], ["apoptosis", 1824], ["as", 1834], ["well", 1837], ["as", 1842], ["adhesion", 1845], ["of", 1854], ["BCR", 1857], ["/", 1860], ["ABL", 1861], ["-", 1864], ["expressing", 1865], ["cells", 1876], ["to", 1894], ["modulate", 1897], ["their", 1906], ["imatinib", 1912], ["sensitivity", 1921], ["and", 1933], ["would", 1937], ["be", 1943], ["a", 1946], ["possible", 1948], ["candidate", 1957], ["for", 1967], ["therapeutic", 1971], ["target", 1995], ["in", 2002], ["Ph+", 2005], ["leukemias", 2009], [".", 2018]]}
{"context": "Diagnosis of tuberculosis (TB) is difficult, since symptoms are often very unspecific or lacking. However active, prompt and accurate diagnosis is the key element in the public health response to tuberculosis and the cornerstone of tuberculosis control. Different diagnostic methods for an assured diagnosis of TB are necessary. Chest radiography is a useful keystone to identify tuberculosis, but diagnosis of tuberculosis cannot be established by radiography alone. CT scanning is used in patients without pathological chest radiography but clinically suspected active TB and to differentiate TB from other diseases. Radiological appearance is primarily determined by the immune status of patients and caverns and disseminated disease foci are often observed. Laboratory diagnostic methods include microscopic identification of acid-fast mycobacteria from any body fluid (especially sputum), as well as isolation and characterisation of mycobacteria in culture. It is then possible to type the pathogens by the shape of their colony, their growth behavior and their biochemical characteristics. These methods are regarded as the gold standard in diagnosis of active TB. In patients who are highly suspected of having TB, but whose sputum specimens tested negative for mycobacteria, a nucleic acid amplification test is additionally performed. Moreover, sensitivity testing with first and second line antitubercular drugs is applied as standard. Laboratory diagnostic testing of cellular immunity against pathogenic mycobacteria employs the tuberculin skin test (TST, Mantoux tuberculin test) or the more specific interferon \u03b3 test to determine \u03b3 interferon released by T lymphocytes stimulated in vitro. The new ELISA and ELISPOT procedures exhibit higher test specificity and less cross reactivity to NTM (non-tuberculosis mycobacteria), are independent of BCG-vaccination status and correlate better with the degree of exposure than does the TST.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "271142dba562457da03647b4042bff41", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[35, 35], [68, 68], [292, 292], [40, 40], [2, 2], [63, 63]], "char_spans": [[196, 207], [411, 422], [1813, 1824], [232, 243], [13, 24], [380, 391]]}]}], "context_tokens": [["Diagnosis", 0], ["of", 10], ["tuberculosis", 13], ["(", 26], ["TB", 27], [")", 29], ["is", 31], ["difficult", 34], [",", 43], ["since", 45], ["symptoms", 51], ["are", 60], ["often", 64], ["very", 70], ["unspecific", 75], ["or", 86], ["lacking", 89], [".", 96], ["However", 98], ["active", 106], [",", 112], ["prompt", 114], ["and", 121], ["accurate", 125], ["diagnosis", 134], ["is", 144], ["the", 147], ["key", 151], ["element", 155], ["in", 163], ["the", 166], ["public", 170], ["health", 177], ["response", 184], ["to", 193], ["tuberculosis", 196], ["and", 209], ["the", 213], ["cornerstone", 217], ["of", 229], ["tuberculosis", 232], ["control", 245], [".", 252], ["Different", 254], ["diagnostic", 264], ["methods", 275], ["for", 283], ["an", 287], ["assured", 290], ["diagnosis", 298], ["of", 308], ["TB", 311], ["are", 314], ["necessary", 318], [".", 327], ["Chest", 329], ["radiography", 335], ["is", 347], ["a", 350], ["useful", 352], ["keystone", 359], ["to", 368], ["identify", 371], ["tuberculosis", 380], [",", 392], ["but", 394], ["diagnosis", 398], ["of", 408], ["tuberculosis", 411], ["can", 424], ["not", 427], ["be", 431], ["established", 434], ["by", 446], ["radiography", 449], ["alone", 461], [".", 466], ["CT", 468], ["scanning", 471], ["is", 480], ["used", 483], ["in", 488], ["patients", 491], ["without", 500], ["pathological", 508], ["chest", 521], ["radiography", 527], ["but", 539], ["clinically", 543], ["suspected", 554], ["active", 564], ["TB", 571], ["and", 574], ["to", 578], ["differentiate", 581], ["TB", 595], ["from", 598], ["other", 603], ["diseases", 609], [".", 617], ["Radiological", 619], ["appearance", 632], ["is", 643], ["primarily", 646], ["determined", 656], ["by", 667], ["the", 670], ["immune", 674], ["status", 681], ["of", 688], ["patients", 691], ["and", 700], ["caverns", 704], ["and", 712], ["disseminated", 716], ["disease", 729], ["foci", 737], ["are", 742], ["often", 746], ["observed", 752], [".", 760], ["Laboratory", 762], ["diagnostic", 773], ["methods", 784], ["include", 792], ["microscopic", 800], ["identification", 812], ["of", 827], ["acid", 830], ["-", 834], ["fast", 835], ["mycobacteria", 840], ["from", 853], ["any", 858], ["body", 862], ["fluid", 867], ["(", 873], ["especially", 874], ["sputum", 885], [")", 891], [",", 892], ["as", 894], ["well", 897], ["as", 902], ["isolation", 905], ["and", 915], ["characterisation", 919], ["of", 936], ["mycobacteria", 939], ["in", 952], ["culture", 955], [".", 962], ["It", 964], ["is", 967], ["then", 970], ["possible", 975], ["to", 984], ["type", 987], ["the", 992], ["pathogens", 996], ["by", 1006], ["the", 1009], ["shape", 1013], ["of", 1019], ["their", 1022], ["colony", 1028], [",", 1034], ["their", 1036], ["growth", 1042], ["behavior", 1049], ["and", 1058], ["their", 1062], ["biochemical", 1068], ["characteristics", 1080], [".", 1095], ["These", 1097], ["methods", 1103], ["are", 1111], ["regarded", 1115], ["as", 1124], ["the", 1127], ["gold", 1131], ["standard", 1136], ["in", 1145], ["diagnosis", 1148], ["of", 1158], ["active", 1161], ["TB", 1168], [".", 1170], ["In", 1172], ["patients", 1175], ["who", 1184], ["are", 1188], ["highly", 1192], ["suspected", 1199], ["of", 1209], ["having", 1212], ["TB", 1219], [",", 1221], ["but", 1223], ["whose", 1227], ["sputum", 1233], ["specimens", 1240], ["tested", 1250], ["negative", 1257], ["for", 1266], ["mycobacteria", 1270], [",", 1282], ["a", 1284], ["nucleic", 1286], ["acid", 1294], ["amplification", 1299], ["test", 1313], ["is", 1318], ["additionally", 1321], ["performed", 1334], [".", 1343], ["Moreover", 1345], [",", 1353], ["sensitivity", 1355], ["testing", 1367], ["with", 1375], ["first", 1380], ["and", 1386], ["second", 1390], ["line", 1397], ["antitubercular", 1402], ["drugs", 1417], ["is", 1423], ["applied", 1426], ["as", 1434], ["standard", 1437], [".", 1445], ["Laboratory", 1447], ["diagnostic", 1458], ["testing", 1469], ["of", 1477], ["cellular", 1480], ["immunity", 1489], ["against", 1498], ["pathogenic", 1506], ["mycobacteria", 1517], ["employs", 1530], ["the", 1538], ["tuberculin", 1542], ["skin", 1553], ["test", 1558], ["(", 1563], ["TST", 1564], [",", 1567], ["Mantoux", 1569], ["tuberculin", 1577], ["test", 1588], [")", 1592], ["or", 1594], ["the", 1597], ["more", 1601], ["specific", 1606], ["interferon", 1615], ["\u03b3", 1626], ["test", 1628], ["to", 1633], ["determine", 1636], ["\u03b3", 1646], ["interferon", 1648], ["released", 1659], ["by", 1668], ["T", 1671], ["lymphocytes", 1673], ["stimulated", 1685], ["in", 1696], ["vitro", 1699], [".", 1704], ["The", 1706], ["new", 1710], ["ELISA", 1714], ["and", 1720], ["ELISPOT", 1724], ["procedures", 1732], ["exhibit", 1743], ["higher", 1751], ["test", 1758], ["specificity", 1763], ["and", 1775], ["less", 1779], ["cross", 1784], ["reactivity", 1790], ["to", 1801], ["NTM", 1804], ["(", 1808], ["non", 1809], ["-", 1812], ["tuberculosis", 1813], ["mycobacteria", 1826], [")", 1838], [",", 1839], ["are", 1841], ["independent", 1845], ["of", 1857], ["BCG", 1860], ["-", 1863], ["vaccination", 1864], ["status", 1876], ["and", 1883], ["correlate", 1887], ["better", 1897], ["with", 1904], ["the", 1909], ["degree", 1913], ["of", 1920], ["exposure", 1923], ["than", 1932], ["does", 1937], ["the", 1942], ["TST", 1946], [".", 1949]]}
{"context": "Compelling evidence indicates that the CRISPR-Cas system protects prokaryotes from viruses and other potential genome invaders. This adaptive prokaryotic immune system arises from the clustered regularly interspaced short palindromic repeats (CRISPRs) found in prokaryotic genomes, which harbor short invader-derived sequences, and the CRISPR-associated (Cas) protein-coding genes. Here, we have identified a CRISPR-Cas effector complex that is comprised of small invader-targeting RNAs from the CRISPR loci (termed prokaryotic silencing (psi)RNAs) and the RAMP module (or Cmr) Cas proteins. The psiRNA-Cmr protein complexes cleave complementary target RNAs at a fixed distance from the 3' end of the integral psiRNAs. In Pyrococcus furiosus, psiRNAs occur in two size forms that share a common 5' sequence tag but have distinct 3' ends that direct cleavage of a given target RNA at two distinct sites. Our results indicate that prokaryotes possess a unique RNA silencing system that functions by homology-dependent cleavage of invader RNAs.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "34c1938371614922aa43c41ab4146049", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[5, 7], [68, 70]], "char_spans": [[39, 48], [409, 418]]}]}], "context_tokens": [["Compelling", 0], ["evidence", 11], ["indicates", 20], ["that", 30], ["the", 35], ["CRISPR", 39], ["-", 45], ["Cas", 46], ["system", 50], ["protects", 57], ["prokaryotes", 66], ["from", 78], ["viruses", 83], ["and", 91], ["other", 95], ["potential", 101], ["genome", 111], ["invaders", 118], [".", 126], ["This", 128], ["adaptive", 133], ["prokaryotic", 142], ["immune", 154], ["system", 161], ["arises", 168], ["from", 175], ["the", 180], ["clustered", 184], ["regularly", 194], ["interspaced", 204], ["short", 216], ["palindromic", 222], ["repeats", 234], ["(", 242], ["CRISPRs", 243], [")", 250], ["found", 252], ["in", 258], ["prokaryotic", 261], ["genomes", 273], [",", 280], ["which", 282], ["harbor", 288], ["short", 295], ["invader", 301], ["-", 308], ["derived", 309], ["sequences", 317], [",", 326], ["and", 328], ["the", 332], ["CRISPR", 336], ["-", 342], ["associated", 343], ["(", 354], ["Cas", 355], [")", 358], ["protein", 360], ["-", 367], ["coding", 368], ["genes", 375], [".", 380], ["Here", 382], [",", 386], ["we", 388], ["have", 391], ["identified", 396], ["a", 407], ["CRISPR", 409], ["-", 415], ["Cas", 416], ["effector", 420], ["complex", 429], ["that", 437], ["is", 442], ["comprised", 445], ["of", 455], ["small", 458], ["invader", 464], ["-", 471], ["targeting", 472], ["RNAs", 482], ["from", 487], ["the", 492], ["CRISPR", 496], ["loci", 503], ["(", 508], ["termed", 509], ["prokaryotic", 516], ["silencing", 528], ["(", 538], ["psi)RNAs", 539], [")", 547], ["and", 549], ["the", 553], ["RAMP", 557], ["module", 562], ["(", 569], ["or", 570], ["Cmr", 573], [")", 576], ["Cas", 578], ["proteins", 582], [".", 590], ["The", 592], ["psiRNA", 596], ["-", 602], ["Cmr", 603], ["protein", 607], ["complexes", 615], ["cleave", 625], ["complementary", 632], ["target", 646], ["RNAs", 653], ["at", 658], ["a", 661], ["fixed", 663], ["distance", 669], ["from", 678], ["the", 683], ["3", 687], ["'", 688], ["end", 690], ["of", 694], ["the", 697], ["integral", 701], ["psiRNAs", 710], [".", 717], ["In", 719], ["Pyrococcus", 722], ["furiosus", 733], [",", 741], ["psiRNAs", 743], ["occur", 751], ["in", 757], ["two", 760], ["size", 764], ["forms", 769], ["that", 775], ["share", 780], ["a", 786], ["common", 788], ["5", 795], ["'", 796], ["sequence", 798], ["tag", 807], ["but", 811], ["have", 815], ["distinct", 820], ["3", 829], ["'", 830], ["ends", 832], ["that", 837], ["direct", 842], ["cleavage", 849], ["of", 858], ["a", 861], ["given", 863], ["target", 869], ["RNA", 876], ["at", 880], ["two", 883], ["distinct", 887], ["sites", 896], [".", 901], ["Our", 903], ["results", 907], ["indicate", 915], ["that", 924], ["prokaryotes", 929], ["possess", 941], ["a", 949], ["unique", 951], ["RNA", 958], ["silencing", 962], ["system", 972], ["that", 979], ["functions", 984], ["by", 994], ["homology", 997], ["-", 1005], ["dependent", 1006], ["cleavage", 1016], ["of", 1025], ["invader", 1028], ["RNAs", 1036], [".", 1040]]}
{"context": "There are few more compelling questions in clinical microbiology today than the issue of whether or not to screen for the presence of methicillin-resistant Staphylococcus aureus (MRSA), with the results being used to institute infection control interventions aimed at preventing transmission of MRSA in health care environments. Numerous different matters must be addressed when considering a screening program. Who is to be screened, what method is to be employed to detect MRSA, and what sites should be sampled? When and how often should the screening be performed? Who is going to pay for the screening, and, finally and perhaps most importantly, how are screening results to be communicated to health care providers and what kind of interventions are best undertaken based on the results? Numerous governmental agencies have mandated MRSA screening programs, and yet several authorities in infection control organizations have questioned the appropriateness of mandated screening. In this Point-Counterpoint feature, Dr. Lance Peterson of Evanston Hospital (Evanston, IL) offers his perspective on why screening for MRSA is to be encouraged. Dr. Daniel Diekema of the University of Iowa Carver College of Medicine (Iowa City, IA) offers an opposing view.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "072774d22d1943ada30195f317483bf3", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[144, 144], [189, 189], [29, 29], [79, 79], [47, 47]], "char_spans": [[839, 842], [1121, 1124], [179, 182], [475, 478], [295, 298]]}]}], "context_tokens": [["There", 0], ["are", 6], ["few", 10], ["more", 14], ["compelling", 19], ["questions", 30], ["in", 40], ["clinical", 43], ["microbiology", 52], ["today", 65], ["than", 71], ["the", 76], ["issue", 80], ["of", 86], ["whether", 89], ["or", 97], ["not", 100], ["to", 104], ["screen", 107], ["for", 114], ["the", 118], ["presence", 122], ["of", 131], ["methicillin", 134], ["-", 145], ["resistant", 146], ["Staphylococcus", 156], ["aureus", 171], ["(", 178], ["MRSA", 179], [")", 183], [",", 184], ["with", 186], ["the", 191], ["results", 195], ["being", 203], ["used", 209], ["to", 214], ["institute", 217], ["infection", 227], ["control", 237], ["interventions", 245], ["aimed", 259], ["at", 265], ["preventing", 268], ["transmission", 279], ["of", 292], ["MRSA", 295], ["in", 300], ["health", 303], ["care", 310], ["environments", 315], [".", 327], ["Numerous", 329], ["different", 338], ["matters", 348], ["must", 356], ["be", 361], ["addressed", 364], ["when", 374], ["considering", 379], ["a", 391], ["screening", 393], ["program", 403], [".", 410], ["Who", 412], ["is", 416], ["to", 419], ["be", 422], ["screened", 425], [",", 433], ["what", 435], ["method", 440], ["is", 447], ["to", 450], ["be", 453], ["employed", 456], ["to", 465], ["detect", 468], ["MRSA", 475], [",", 479], ["and", 481], ["what", 485], ["sites", 490], ["should", 496], ["be", 503], ["sampled", 506], ["?", 513], ["When", 515], ["and", 520], ["how", 524], ["often", 528], ["should", 534], ["the", 541], ["screening", 545], ["be", 555], ["performed", 558], ["?", 567], ["Who", 569], ["is", 573], ["going", 576], ["to", 582], ["pay", 585], ["for", 589], ["the", 593], ["screening", 597], [",", 606], ["and", 608], [",", 611], ["finally", 613], ["and", 621], ["perhaps", 625], ["most", 633], ["importantly", 638], [",", 649], ["how", 651], ["are", 655], ["screening", 659], ["results", 669], ["to", 677], ["be", 680], ["communicated", 683], ["to", 696], ["health", 699], ["care", 706], ["providers", 711], ["and", 721], ["what", 725], ["kind", 730], ["of", 735], ["interventions", 738], ["are", 752], ["best", 756], ["undertaken", 761], ["based", 772], ["on", 778], ["the", 781], ["results", 785], ["?", 792], ["Numerous", 794], ["governmental", 803], ["agencies", 816], ["have", 825], ["mandated", 830], ["MRSA", 839], ["screening", 844], ["programs", 854], [",", 862], ["and", 864], ["yet", 868], ["several", 872], ["authorities", 880], ["in", 892], ["infection", 895], ["control", 905], ["organizations", 913], ["have", 927], ["questioned", 932], ["the", 943], ["appropriateness", 947], ["of", 963], ["mandated", 966], ["screening", 975], [".", 984], ["In", 986], ["this", 989], ["Point", 994], ["-", 999], ["Counterpoint", 1000], ["feature", 1013], [",", 1020], ["Dr.", 1022], ["Lance", 1026], ["Peterson", 1032], ["of", 1041], ["Evanston", 1044], ["Hospital", 1053], ["(", 1062], ["Evanston", 1063], [",", 1071], ["IL", 1073], [")", 1075], ["offers", 1077], ["his", 1084], ["perspective", 1088], ["on", 1100], ["why", 1103], ["screening", 1107], ["for", 1117], ["MRSA", 1121], ["is", 1126], ["to", 1129], ["be", 1132], ["encouraged", 1135], [".", 1145], ["Dr.", 1147], ["Daniel", 1151], ["Diekema", 1158], ["of", 1166], ["the", 1169], ["University", 1173], ["of", 1184], ["Iowa", 1187], ["Carver", 1192], ["College", 1199], ["of", 1207], ["Medicine", 1210], ["(", 1219], ["Iowa", 1220], ["City", 1225], [",", 1229], ["IA", 1231], [")", 1233], ["offers", 1235], ["an", 1242], ["opposing", 1245], ["view", 1254], [".", 1258]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare, autosomal, recessive lysosomal disorder with hematological and immunologic abnormalities; however, stem-cell transplantation from a matched or related donor may be curative. Many mutations of the CHS1/LYST gene have been reported to date. We report a novel nonsense mutation of the CHS1/LYST gene in 3 Omani patients. Three patients from 2 different families presented with clinical and laboratory features of CHS and a history of death of a previous sibling because of a severe illness, suggestive of the accelerated phase of CHS. Giant granules were present in the myeloid cell lines. Before the stem-cell transplant, the first patient underwent gene sequencing of all exons of the lysosome trafficking regulator (CHS1/LYST) gene and revealed a nonsense mutation in exon 5 (c.925C>T, p.R309X). Subsequently, upon presentation, the second and third patients' direct gene sequencing of exon 5 revealed the same mutation. We report a nonsense mutation in exon 5 (c.925C>T, p.R309X). This supports the allelic heterogeneity of CHS and is in line with most reported mutation types that lead to a truncated protein. Identification of the mutation type will facilitate timely diagnosis, management, and family counseling for those with affected children in Oman.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "0a6e92fd38084c6080d63bdcfc202f5b", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], [",", 40], ["autosomal", 42], [",", 51], ["recessive", 53], ["lysosomal", 63], ["disorder", 73], ["with", 82], ["hematological", 87], ["and", 101], ["immunologic", 105], ["abnormalities", 117], [";", 130], ["however", 132], [",", 139], ["stem", 141], ["-", 145], ["cell", 146], ["transplantation", 151], ["from", 167], ["a", 172], ["matched", 174], ["or", 182], ["related", 185], ["donor", 193], ["may", 199], ["be", 203], ["curative", 206], [".", 214], ["Many", 216], ["mutations", 221], ["of", 231], ["the", 234], ["CHS1/LYST", 238], ["gene", 248], ["have", 253], ["been", 258], ["reported", 263], ["to", 272], ["date", 275], [".", 279], ["We", 281], ["report", 284], ["a", 291], ["novel", 293], ["nonsense", 299], ["mutation", 308], ["of", 317], ["the", 320], ["CHS1/LYST", 324], ["gene", 334], ["in", 339], ["3", 342], ["Omani", 344], ["patients", 350], [".", 358], ["Three", 360], ["patients", 366], ["from", 375], ["2", 380], ["different", 382], ["families", 392], ["presented", 401], ["with", 411], ["clinical", 416], ["and", 425], ["laboratory", 429], ["features", 440], ["of", 449], ["CHS", 452], ["and", 456], ["a", 460], ["history", 462], ["of", 470], ["death", 473], ["of", 479], ["a", 482], ["previous", 484], ["sibling", 493], ["because", 501], ["of", 509], ["a", 512], ["severe", 514], ["illness", 521], [",", 528], ["suggestive", 530], ["of", 541], ["the", 544], ["accelerated", 548], ["phase", 560], ["of", 566], ["CHS", 569], [".", 572], ["Giant", 574], ["granules", 580], ["were", 589], ["present", 594], ["in", 602], ["the", 605], ["myeloid", 609], ["cell", 617], ["lines", 622], [".", 627], ["Before", 629], ["the", 636], ["stem", 640], ["-", 644], ["cell", 645], ["transplant", 650], [",", 660], ["the", 662], ["first", 666], ["patient", 672], ["underwent", 680], ["gene", 690], ["sequencing", 695], ["of", 706], ["all", 709], ["exons", 713], ["of", 719], ["the", 722], ["lysosome", 726], ["trafficking", 735], ["regulator", 747], ["(", 757], ["CHS1/LYST", 758], [")", 767], ["gene", 769], ["and", 774], ["revealed", 778], ["a", 787], ["nonsense", 789], ["mutation", 798], ["in", 807], ["exon", 810], ["5", 815], ["(", 817], ["c.925C", 818], [">", 824], ["T", 825], [",", 826], ["p", 828], [".", 829], ["R309X", 830], [")", 835], [".", 836], ["Subsequently", 838], [",", 850], ["upon", 852], ["presentation", 857], [",", 869], ["the", 871], ["second", 875], ["and", 882], ["third", 886], ["patients", 892], ["'", 900], ["direct", 902], ["gene", 909], ["sequencing", 914], ["of", 925], ["exon", 928], ["5", 933], ["revealed", 935], ["the", 944], ["same", 948], ["mutation", 953], [".", 961], ["We", 963], ["report", 966], ["a", 973], ["nonsense", 975], ["mutation", 984], ["in", 993], ["exon", 996], ["5", 1001], ["(", 1003], ["c.925C", 1004], [">", 1010], ["T", 1011], [",", 1012], ["p", 1014], [".", 1015], ["R309X", 1016], [")", 1021], [".", 1022], ["This", 1024], ["supports", 1029], ["the", 1038], ["allelic", 1042], ["heterogeneity", 1050], ["of", 1064], ["CHS", 1067], ["and", 1071], ["is", 1075], ["in", 1078], ["line", 1081], ["with", 1086], ["most", 1091], ["reported", 1096], ["mutation", 1105], ["types", 1114], ["that", 1120], ["lead", 1125], ["to", 1130], ["a", 1133], ["truncated", 1135], ["protein", 1145], [".", 1152], ["Identification", 1154], ["of", 1169], ["the", 1172], ["mutation", 1176], ["type", 1185], ["will", 1190], ["facilitate", 1195], ["timely", 1206], ["diagnosis", 1213], [",", 1222], ["management", 1224], [",", 1234], ["and", 1236], ["family", 1240], ["counseling", 1247], ["for", 1258], ["those", 1262], ["with", 1268], ["affected", 1273], ["children", 1282], ["in", 1291], ["Oman", 1294], [".", 1298]]}
{"context": "Because the neural differentiation capacity of bone marrow stromal cells (BMSCs) is still a matter of controversial debate, we performed a thorough investigation into the differentiation capacity of human BMSCs and examined their therapeutic potency. BMSCs were isolated from the femur and kept in cell cultures with various cultivation protocols being applied. In standard culture conditions using a fetal calf serum-enriched medium, while not exhibiting a neural phenotype, the majority of cells expressed a variety of neuronal marker proteins as well as the astrocyte marker GFAP. Only a minority of stem cells expressed nestin, a marker for neural precursor cells. Cultivation in serum-free medium supplemented with specific growth factors resulted in a markedly higher percentage of nestin-positive cells. To establish the therapeutic potency of bone marrow-derived cells, the synthesis of neurotrophic factors such as NGF, BDNF and GDNF was analyzed under non-stimulating standard culture conditions as well as after a neural selection procedure. The therapeutic potency of BMSCs was further examined with regard to their migratory potential in vitro and after transplantation in vivo. After stereotactic engraftment into the lateral ventricle of adult rats, mesenchymal stem cells were seen to adhere to the ependymocytes and cells of the choroids plexus. Afterwards grafted cells passed through the ependymal barrier, locating in the subventricular space. Their BMSCs took up a close host graft interaction without any degenerative influence on the host cells. Furthermore, there was morphological as well as immunohistochemical evidence for a transdifferentiation within the host tissue. In addition, BMSCs could be efficiently transduced using a third-generation adenoviral vector, indicating their potential feasibility for a gene-therapeutic option.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "d35038567c084610981eef4ef2010504", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[103, 103], [130, 130]], "char_spans": [[624, 629], [788, 793]]}]}], "context_tokens": [["Because", 0], ["the", 8], ["neural", 12], ["differentiation", 19], ["capacity", 35], ["of", 44], ["bone", 47], ["marrow", 52], ["stromal", 59], ["cells", 67], ["(", 73], ["BMSCs", 74], [")", 79], ["is", 81], ["still", 84], ["a", 90], ["matter", 92], ["of", 99], ["controversial", 102], ["debate", 116], [",", 122], ["we", 124], ["performed", 127], ["a", 137], ["thorough", 139], ["investigation", 148], ["into", 162], ["the", 167], ["differentiation", 171], ["capacity", 187], ["of", 196], ["human", 199], ["BMSCs", 205], ["and", 211], ["examined", 215], ["their", 224], ["therapeutic", 230], ["potency", 242], [".", 249], ["BMSCs", 251], ["were", 257], ["isolated", 262], ["from", 271], ["the", 276], ["femur", 280], ["and", 286], ["kept", 290], ["in", 295], ["cell", 298], ["cultures", 303], ["with", 312], ["various", 317], ["cultivation", 325], ["protocols", 337], ["being", 347], ["applied", 353], [".", 360], ["In", 362], ["standard", 365], ["culture", 374], ["conditions", 382], ["using", 393], ["a", 399], ["fetal", 401], ["calf", 407], ["serum", 412], ["-", 417], ["enriched", 418], ["medium", 427], [",", 433], ["while", 435], ["not", 441], ["exhibiting", 445], ["a", 456], ["neural", 458], ["phenotype", 465], [",", 474], ["the", 476], ["majority", 480], ["of", 489], ["cells", 492], ["expressed", 498], ["a", 508], ["variety", 510], ["of", 518], ["neuronal", 521], ["marker", 530], ["proteins", 537], ["as", 546], ["well", 549], ["as", 554], ["the", 557], ["astrocyte", 561], ["marker", 571], ["GFAP", 578], [".", 582], ["Only", 584], ["a", 589], ["minority", 591], ["of", 600], ["stem", 603], ["cells", 608], ["expressed", 614], ["nestin", 624], [",", 630], ["a", 632], ["marker", 634], ["for", 641], ["neural", 645], ["precursor", 652], ["cells", 662], [".", 667], ["Cultivation", 669], ["in", 681], ["serum", 684], ["-", 689], ["free", 690], ["medium", 695], ["supplemented", 702], ["with", 715], ["specific", 720], ["growth", 729], ["factors", 736], ["resulted", 744], ["in", 753], ["a", 756], ["markedly", 758], ["higher", 767], ["percentage", 774], ["of", 785], ["nestin", 788], ["-", 794], ["positive", 795], ["cells", 804], [".", 809], ["To", 811], ["establish", 814], ["the", 824], ["therapeutic", 828], ["potency", 840], ["of", 848], ["bone", 851], ["marrow", 856], ["-", 862], ["derived", 863], ["cells", 871], [",", 876], ["the", 878], ["synthesis", 882], ["of", 892], ["neurotrophic", 895], ["factors", 908], ["such", 916], ["as", 921], ["NGF", 924], [",", 927], ["BDNF", 929], ["and", 934], ["GDNF", 938], ["was", 943], ["analyzed", 947], ["under", 956], ["non", 962], ["-", 965], ["stimulating", 966], ["standard", 978], ["culture", 987], ["conditions", 995], ["as", 1006], ["well", 1009], ["as", 1014], ["after", 1017], ["a", 1023], ["neural", 1025], ["selection", 1032], ["procedure", 1042], [".", 1051], ["The", 1053], ["therapeutic", 1057], ["potency", 1069], ["of", 1077], ["BMSCs", 1080], ["was", 1086], ["further", 1090], ["examined", 1098], ["with", 1107], ["regard", 1112], ["to", 1119], ["their", 1122], ["migratory", 1128], ["potential", 1138], ["in", 1148], ["vitro", 1151], ["and", 1157], ["after", 1161], ["transplantation", 1167], ["in", 1183], ["vivo", 1186], [".", 1190], ["After", 1192], ["stereotactic", 1198], ["engraftment", 1211], ["into", 1223], ["the", 1228], ["lateral", 1232], ["ventricle", 1240], ["of", 1250], ["adult", 1253], ["rats", 1259], [",", 1263], ["mesenchymal", 1265], ["stem", 1277], ["cells", 1282], ["were", 1288], ["seen", 1293], ["to", 1298], ["adhere", 1301], ["to", 1308], ["the", 1311], ["ependymocytes", 1315], ["and", 1329], ["cells", 1333], ["of", 1339], ["the", 1342], ["choroids", 1346], ["plexus", 1355], [".", 1361], ["Afterwards", 1363], ["grafted", 1374], ["cells", 1382], ["passed", 1388], ["through", 1395], ["the", 1403], ["ependymal", 1407], ["barrier", 1417], [",", 1424], ["locating", 1426], ["in", 1435], ["the", 1438], ["subventricular", 1442], ["space", 1457], [".", 1462], ["Their", 1464], ["BMSCs", 1470], ["took", 1476], ["up", 1481], ["a", 1484], ["close", 1486], ["host", 1492], ["graft", 1497], ["interaction", 1503], ["without", 1515], ["any", 1523], ["degenerative", 1527], ["influence", 1540], ["on", 1550], ["the", 1553], ["host", 1557], ["cells", 1562], [".", 1567], ["Furthermore", 1569], [",", 1580], ["there", 1582], ["was", 1588], ["morphological", 1592], ["as", 1606], ["well", 1609], ["as", 1614], ["immunohistochemical", 1617], ["evidence", 1637], ["for", 1646], ["a", 1650], ["transdifferentiation", 1652], ["within", 1673], ["the", 1680], ["host", 1684], ["tissue", 1689], [".", 1695], ["In", 1697], ["addition", 1700], [",", 1708], ["BMSCs", 1710], ["could", 1716], ["be", 1722], ["efficiently", 1725], ["transduced", 1737], ["using", 1748], ["a", 1754], ["third", 1756], ["-", 1761], ["generation", 1762], ["adenoviral", 1773], ["vector", 1784], [",", 1790], ["indicating", 1792], ["their", 1803], ["potential", 1809], ["feasibility", 1819], ["for", 1831], ["a", 1835], ["gene", 1837], ["-", 1841], ["therapeutic", 1842], ["option", 1854], [".", 1860]]}
{"context": "The SET domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)3-9, E(z), and Trithorax], is recognized as a signature motif for histone methyltransferases that are involved in epigenetic processes. The SUV39H family of SET domain proteins methylate specifically the residue lysine 9 of histone H3, creating a code for gene silencing. This family of proteins contain at their C termini a unique catalytic domain consisting of pre-SET, SET, and post-SET domains. Sequence homology-based searches identified 15 Arabidopsis, 14 maize, and 12 rice proteins that can be assigned to the SUV39H family. These high numbers in plants are in marked contrast to the situation in animals, in which each species appears to contain only two to three proteins of this family. Our phylogenetic analyses revealed that plant proteins can be classified into seven orthology groups. Representative members of each group can be found in single plant species, suggesting that different group members are evolutionarily conserved to perform specific functions.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "6e30dde1ec814c99a87bb332ce35af0c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[1, 2], [48, 49]], "char_spans": [[4, 13], [264, 273]]}]}], "context_tokens": [["The", 0], ["SET", 4], ["domain", 8], [",", 14], ["first", 16], ["identified", 22], ["within", 33], ["and", 40], ["named", 44], ["after", 50], ["proteins", 56], ["encoded", 65], ["by", 73], ["three", 76], ["Drosophila", 82], ["genes", 93], ["[", 99], ["Su(var)3", 100], ["-", 108], ["9", 109], [",", 110], ["E(z", 112], [")", 115], [",", 116], ["and", 118], ["Trithorax", 122], ["]", 131], [",", 132], ["is", 134], ["recognized", 137], ["as", 148], ["a", 151], ["signature", 153], ["motif", 163], ["for", 169], ["histone", 173], ["methyltransferases", 181], ["that", 200], ["are", 205], ["involved", 209], ["in", 218], ["epigenetic", 221], ["processes", 232], [".", 241], ["The", 243], ["SUV39H", 247], ["family", 254], ["of", 261], ["SET", 264], ["domain", 268], ["proteins", 275], ["methylate", 284], ["specifically", 294], ["the", 307], ["residue", 311], ["lysine", 319], ["9", 326], ["of", 328], ["histone", 331], ["H3", 339], [",", 341], ["creating", 343], ["a", 352], ["code", 354], ["for", 359], ["gene", 363], ["silencing", 368], [".", 377], ["This", 379], ["family", 384], ["of", 391], ["proteins", 394], ["contain", 403], ["at", 411], ["their", 414], ["C", 420], ["termini", 422], ["a", 430], ["unique", 432], ["catalytic", 439], ["domain", 449], ["consisting", 456], ["of", 467], ["pre", 470], ["-", 473], ["SET", 474], [",", 477], ["SET", 479], [",", 482], ["and", 484], ["post", 488], ["-", 492], ["SET", 493], ["domains", 497], [".", 504], ["Sequence", 506], ["homology", 515], ["-", 523], ["based", 524], ["searches", 530], ["identified", 539], ["15", 550], ["Arabidopsis", 553], [",", 564], ["14", 566], ["maize", 569], [",", 574], ["and", 576], ["12", 580], ["rice", 583], ["proteins", 588], ["that", 597], ["can", 602], ["be", 606], ["assigned", 609], ["to", 618], ["the", 621], ["SUV39H", 625], ["family", 632], [".", 638], ["These", 640], ["high", 646], ["numbers", 651], ["in", 659], ["plants", 662], ["are", 669], ["in", 673], ["marked", 676], ["contrast", 683], ["to", 692], ["the", 695], ["situation", 699], ["in", 709], ["animals", 712], [",", 719], ["in", 721], ["which", 724], ["each", 730], ["species", 735], ["appears", 743], ["to", 751], ["contain", 754], ["only", 762], ["two", 767], ["to", 771], ["three", 774], ["proteins", 780], ["of", 789], ["this", 792], ["family", 797], [".", 803], ["Our", 805], ["phylogenetic", 809], ["analyses", 822], ["revealed", 831], ["that", 840], ["plant", 845], ["proteins", 851], ["can", 860], ["be", 864], ["classified", 867], ["into", 878], ["seven", 883], ["orthology", 889], ["groups", 899], [".", 905], ["Representative", 907], ["members", 922], ["of", 930], ["each", 933], ["group", 938], ["can", 944], ["be", 948], ["found", 951], ["in", 957], ["single", 960], ["plant", 967], ["species", 973], [",", 980], ["suggesting", 982], ["that", 993], ["different", 998], ["group", 1008], ["members", 1014], ["are", 1022], ["evolutionarily", 1026], ["conserved", 1041], ["to", 1051], ["perform", 1054], ["specific", 1062], ["functions", 1071], [".", 1080]]}
{"context": "In this issue of Molecular Cell, Zhang et al. report the structure of a ternary complex between the SET domain histone methyltransferase DIM-5, its cofactor, and a histone H3 peptide. The insight gained from analysis of a key amino acid provides an exciting opportunity to dissect the possible functional meaning of mono-, di-, and trimethylation of histone lysine residues in vivo that will complement existing approaches in the quest to crack the histone methylation code.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "abd10770670a4418a7c6b4d3caab167b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[20, 21]], "char_spans": [[100, 109]]}]}], "context_tokens": [["In", 0], ["this", 3], ["issue", 8], ["of", 14], ["Molecular", 17], ["Cell", 27], [",", 31], ["Zhang", 33], ["et", 39], ["al", 42], [".", 44], ["report", 46], ["the", 53], ["structure", 57], ["of", 67], ["a", 70], ["ternary", 72], ["complex", 80], ["between", 88], ["the", 96], ["SET", 100], ["domain", 104], ["histone", 111], ["methyltransferase", 119], ["DIM-5", 137], [",", 142], ["its", 144], ["cofactor", 148], [",", 156], ["and", 158], ["a", 162], ["histone", 164], ["H3", 172], ["peptide", 175], [".", 182], ["The", 184], ["insight", 188], ["gained", 196], ["from", 203], ["analysis", 208], ["of", 217], ["a", 220], ["key", 222], ["amino", 226], ["acid", 232], ["provides", 237], ["an", 246], ["exciting", 249], ["opportunity", 258], ["to", 270], ["dissect", 273], ["the", 281], ["possible", 285], ["functional", 294], ["meaning", 305], ["of", 313], ["mono-", 316], [",", 321], ["di-", 323], [",", 326], ["and", 328], ["trimethylation", 332], ["of", 347], ["histone", 350], ["lysine", 358], ["residues", 365], ["in", 374], ["vivo", 377], ["that", 382], ["will", 387], ["complement", 392], ["existing", 403], ["approaches", 412], ["in", 423], ["the", 426], ["quest", 430], ["to", 436], ["crack", 439], ["the", 445], ["histone", 449], ["methylation", 457], ["code", 469], [".", 473]]}
{"context": "Clinical and experimental evidence suggest that interleukin-17A (IL-17A; also known as IL-17) is an attractive therapeutic target in rheumatoid arthritis (RA). Rheumatoid synovial tissue produces IL-17A, which causes cartilage and bone degradation in synovial and bone explants. Overexpression of IL-17A induces synovial inflammation and joint destruction in animal RA models. These effects are attenuated in IL-17A-deficient animals and by agents that block IL-17A. Serum IL-17A levels and, to a greater extent, synovial fluid IL-17A levels are elevated in many patients with RA. In some RA cohorts, higher IL-17A levels have been associated with a more severe clinical course. Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials. Of these, secukinumab is the most advanced with respect to clinical evaluation in RA, with phase III trials ongoing in patients on background methotrexate who had inadequate responses to previous tumor necrosis factor blocker therapy.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "b4470440346c4d9faa342aaaeb739017", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[6, 6]], "char_spans": [[48, 62]]}]}], "context_tokens": [["Clinical", 0], ["and", 9], ["experimental", 13], ["evidence", 26], ["suggest", 35], ["that", 43], ["interleukin-17A", 48], ["(", 64], ["IL-17A", 65], [";", 71], ["also", 73], ["known", 78], ["as", 84], ["IL-17", 87], [")", 92], ["is", 94], ["an", 97], ["attractive", 100], ["therapeutic", 111], ["target", 123], ["in", 130], ["rheumatoid", 133], ["arthritis", 144], ["(", 154], ["RA", 155], [")", 157], [".", 158], ["Rheumatoid", 160], ["synovial", 171], ["tissue", 180], ["produces", 187], ["IL-17A", 196], [",", 202], ["which", 204], ["causes", 210], ["cartilage", 217], ["and", 227], ["bone", 231], ["degradation", 236], ["in", 248], ["synovial", 251], ["and", 260], ["bone", 264], ["explants", 269], [".", 277], ["Overexpression", 279], ["of", 294], ["IL-17A", 297], ["induces", 304], ["synovial", 312], ["inflammation", 321], ["and", 334], ["joint", 338], ["destruction", 344], ["in", 356], ["animal", 359], ["RA", 366], ["models", 369], [".", 375], ["These", 377], ["effects", 383], ["are", 391], ["attenuated", 395], ["in", 406], ["IL-17A", 409], ["-", 415], ["deficient", 416], ["animals", 426], ["and", 434], ["by", 438], ["agents", 441], ["that", 448], ["block", 453], ["IL-17A.", 459], ["Serum", 467], ["IL-17A", 473], ["levels", 480], ["and", 487], [",", 490], ["to", 492], ["a", 495], ["greater", 497], ["extent", 505], [",", 511], ["synovial", 513], ["fluid", 522], ["IL-17A", 528], ["levels", 535], ["are", 542], ["elevated", 546], ["in", 555], ["many", 558], ["patients", 563], ["with", 572], ["RA", 577], [".", 579], ["In", 581], ["some", 584], ["RA", 589], ["cohorts", 592], [",", 599], ["higher", 601], ["IL-17A", 608], ["levels", 615], ["have", 622], ["been", 627], ["associated", 632], ["with", 643], ["a", 648], ["more", 650], ["severe", 655], ["clinical", 662], ["course", 671], [".", 677], ["Several", 679], ["IL-17A", 687], ["blockers", 694], [",", 702], ["including", 704], ["the", 714], ["anti", 718], ["-", 722], ["IL-17A", 723], ["monoclonal", 730], ["antibodies", 741], ["secukinumab", 752], ["and", 764], ["ixekizumab", 768], [",", 778], ["and", 780], ["the", 784], ["anti", 788], ["-", 792], ["IL-17", 793], ["receptor", 799], ["subunit", 808], ["A", 816], ["monoclonal", 818], ["antibody", 829], ["brodalumab", 838], ["have", 849], ["been", 854], ["evaluated", 859], ["in", 869], ["phase", 872], ["II", 878], ["clinical", 881], ["trials", 890], [".", 896], ["Of", 898], ["these", 901], [",", 906], ["secukinumab", 908], ["is", 920], ["the", 923], ["most", 927], ["advanced", 932], ["with", 941], ["respect", 946], ["to", 954], ["clinical", 957], ["evaluation", 966], ["in", 977], ["RA", 980], [",", 982], ["with", 984], ["phase", 989], ["III", 995], ["trials", 999], ["ongoing", 1006], ["in", 1014], ["patients", 1017], ["on", 1026], ["background", 1029], ["methotrexate", 1040], ["who", 1053], ["had", 1057], ["inadequate", 1061], ["responses", 1072], ["to", 1082], ["previous", 1085], ["tumor", 1094], ["necrosis", 1100], ["factor", 1109], ["blocker", 1116], ["therapy", 1124], [".", 1131]]}
